Nampt and Rock Inhibitors

Abstract
Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.
Description
FIELD OF THE INVENTION

This invention pertains to compounds which inhibit the activity of NAMPT, compositions containing the compounds, and methods of treating diseases during which NAMPT is expressed. This invention also pertains to compounds which inhibit the activity of ROCK, compositions containing the compounds, and methods of treating diseases during which ROCK is expressed.


BACKGROUND OF THE INVENTION

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that plays a critical role in many physiologically essential processes (Ziegkel, M. Eur. J. Biochem. 267, 1550-1564, 2000). NAD is necessary for several signaling pathways including among others poly ADP-ribosylation in DNA repair, mono-ADP-ribosylation in both the immune system and G-protein-coupled signaling, and NAD is also required by sirtuins for their deacetylase activity (Garten, A. et al Trends in Endocrinology and Metabolism, 20, 130-138, 2008).


NAMPT (also known as pre-B-cell-colony-enhancing factor (PBEF) and visfatin) is an enzyme that catalyzes the phosphoribosylation of nicotinamide and is the rate-limiting enzyme in one of two pathways that salvage NAD.




embedded image


Increasing evidence suggests that NAMPT inhibitors have potential as anticancer agents. Cancer cells have a higher basal turnover of NAD and also display higher energy requirements compared with normal cells. Additionally, increased NAMPT expression has been reported in colorectal cancer (Van Beijnum, J. R. et al Int. J. Cancer 101, 118-127, 2002) and NAMPT is involved in angiogenesis (Kim, S. R. et al. Biochem. Biophys. Res. Commun. 357, 150-156, 2007). Small-molecule inhibitors of NAMPT have been shown to cause depletion of intracellular NAD+ levels and ultimately induce tumor cell death (Hansen, C M et al. Anticancer Res. 20, 42111-4220, 2000) as well as inhibit tumor growth in xenograft models (Olese, U. H. et al. Mol Cancer Ther. 9, 1609-1617, 2010).


NAMPT inhibitors also have potential as therapeutic agents in inflammatory and metabolic disorders (Galli, M. et al Cancer Res. 70, 8-11, 2010). For example, NAMPT is the predominant enzyme in T and B lymphocytes. Selective inhibition of NAMPT leads to NAD+ depletion in lymphocytes blocking the expansion that accompanies autoimmune disease progression whereas cell types expressing the other NAD+ generating pathways might be spared. A small molecule NAMPT inhibitor (FK866) has been shown to selectively block proliferation and induce apoptosis of activated T cells and was efficacious in animal models of arthritis (collagen induced arthritis) (Busso, N. et al. Plos One 3, e2267, 2008). FK866 ameliorated the manifestations of experimental autoimmune encephalomyelitis (EAE), a model of T-cell mediated autoimmune disorders. (Bruzzone, S et al. Plos One 4, e7897, 2009). NaMPT activity increases NF-kB transcriptional activity in human vascular endothelial cell, resulting in MMP-2 and MMP-9 activation, suggesting a role for NAMPT inhibitors in the prevention of inflammatory mediated complications of obesity and type 2 diabetes (Adya, R. et. Al. Diabetes Care, 31, 758-760, 2008).


Rho kinases (ROCKs), the first Rho effectors to be described, are serine/threonine kinases that are important in fundamental processes of cell migration, cell proliferation and cell survival. Abnormal activation of the Rho/ROCK pathway has been observed in various disorders. Examples of disease states in which compounds with ROCK inhibition have potentially beneficial therapeutic effects due to their anti vasospasm activity includes cardiovascular diseases such as hypertension, chronic and congestive heart failure, cardiac hypertrophy, restenosis, chronic renal failure, cerebral vasospasm after subarachnoid bleeding, pulmonary hypertension and atherosclerosis. This muscle relaxing property is also beneficial for treating asthma, male erectile dysfunctions, female sexual dysfunction, and over-active bladder syndrome. Injury to the adult vertebrate brain and spinal cord activates ROCKs, thereby inhibiting neurite growth and sprouting Inhibition of ROCKs results in induction of new axonal growth, axonal rewiring across lesions within the CNS, accelerated regeneration and enhanced functional recovery after acute neuronal injury in mammals (spinal-cord injury, traumatic brain injury). Inhibition of the Rho/ROCK pathway has also proved to be efficacious in other animal models of neurodegeneration like stroke, inflammatory and demyelinating diseases, Alzheimer's disease as well as for the treatment of pain. Rho/ROCK pathway inhibitors therefore have potential for preventing neurodegeneration and stimulating neuroregeneration in various neurological disorders, including spinal-cord injury, Alzheimer's disease, stroke, multiple sclerosis, amyotrophic lateral sclerosis, as well as for the treatment of pain. ROCK inhibitors have been shown to possess anti-inflammatory properties. Thus, compounds of the invention can be used as treatment for neuroinflammatory diseases such as stroke, multiple sclerosis, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, and inflammatory pain, as well as other diseases such as rheumatoid arthritis, osteoarthritis, asthma, irritable bowel syndrome, Crohn's disease, psoriasis, ulcerative colitis, Lupus, and inflammatory bowel disease. Since ROCK inhibitors reduce cell proliferation and cell migration, they could be useful in treating cancer and tumor metastasis. Further more, there is evidence suggesting that ROCK inhibitors suppress cytoskeletal rearrangement upon virus invasion, thus they also have potential therapeutic value in anti-viral and anti-bacterial applications. ROCK inhibitors are also useful for the treatment of insulin resistance and diabetes. Further, ROCK inhibitors have been shown to ameliorate progression of cystic fibrosis (Abstract S02.3, 8th World Congress on Inflammation, Copenhagen, Denmark, Jun. 16-20, 2007).


In addition, Rho-associated coiled-coil forming protein kinases (ROCK)-1 and -2, have been shown to enhance myosin light chain (MLC) phosphorylation by inhibiting MLC phosphatase as well as phosphorylating MLC. This results in the regulation of actin-myosin contraction. Recent reports have demonstrated that inhibition of ROCK results in disruption of inflammatory cell chemotaxis as well as inhibition of smooth muscle contraction in models of pulmonary inflammation associated with asthma. Therefore, the inhibitors of the Rho/ROCK pathway may be useful for the treatment of asthma.


SUMMARY OF THE INVENTION

One embodiment of this invention, therefore, pertains to compounds and pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT or ROCK, the compounds having Formula (Ic)




embedded image


wherein


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R2 is alkyl, alkenyl, alkynyl, phenyl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R2 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, CO(O)R4, OC(O)R4, OC(O)OR4, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R2 phenyl is optionally substituted at the para position with one independently selected R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, Br or I; wherein each R2 phenyl is optionally additionally substituted with one F; wherein each R2 heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R3, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R4, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, cycloalkyl, or heterocyclyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R4 aryl and heterocycyl is optionally substituted with one, two, three or four independently selected R8, ORB, SR8, S(O)R8, SO2R8, C(O)R8, CO(O)R8, OC(O)R8, OC(O)OR8, NH2, NHR8, NHC(O)R8, NR8C(O)R8, NHS(O)2R8, NR8S(O)2R8, NHC(O)OR8, NR8C(O)OR8, NHC(O)NH2, NHC(O)NHR8, NHC(O)N(R8)2, NR8C(O)NHR8, NR8C(O)N(R8)2, C(O)NH2, C(O)NHR8, C(O)N(R8)2, C(O)NHOH, C(O)NHOR8, C(O)NHSO2R8, C(O)NR8SO2R8, SO2NH2, SO2NHR8, SO2N(R8)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R7, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R7 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R11, OR11, SR11, S(O)R11, SO2R11, NHR11, N(R11)2, C(O)R11, C(O)NH2, C(O)NHR11, C(O)N(R11)2, NHC(O)R11, NR11C(O)R11, NHSO2R11, NHC(O)OR11, SO2NH2, SO2NHR11, SO2N(R11)2, NHC(O)NH2, NHC(O)NHR11, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R8, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R8 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R12, OR12, SR12, S(O)R12, SO2R12, NHR12, N(R12)2, C(O)R12, C(O)NH2, C(O)NHR12, C(O)N(R12)2, NHC(O)R12, NR12C(O)R12, NHSO2R12, NHC(O)OR12, SO2NH2, SO2NHR12, SO2N(R12)2, NHC(O)NH2, NHC(O)NHR12, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R10, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


R11, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


R12, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R12 alkyl, alkenyl, and alkynyl is optionally substituted with one or more alkoxy;


wherein the cyclic moieties represented by R3, R5, R6, R7, R8, R9, R10, R11, and R12 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I; wherein the R16 alkyl is optionally substituted with one, two, three or four alkoxy;


R15, at each occurrence, is independently selected alkyl; wherein the R15 alkyl is optionally substituted with one, two, three or four alkoxy;


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four alkoxy;


with the proviso that when X1, X2, and X3 are CH and R2 is phenyl; R5 is not methyl;


with the proviso that when X1, X2, and X3 are CH, and R2 is phenyl substituted with OR5; R5 is not methyl;


with the proviso that when R2 is unsubstituted alkyl or optionally substituted alkyl; R2 is C4-C6-alkyl;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


Another embodiment pertains to compounds having Formula (Vc), and pharmaceutically acceptable salts thereof




embedded image


wherein


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R3, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R10, OR10, Se, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R16, NR16C(O)R16, NHSO2R16, NHC(O)OR16, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R10, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;

    • wherein the cyclic moieties represented by R3, R5, R6, R9, and R10 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I;


R15, at each occurrence, is independently selected alkyl, wherein the R15 alkyl is optionally substituted with one, two, three or four alkoxy; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four alkoxy;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


Another embodiment pertains to compounds having Formula (Ic) or Formula (Vc), and pharmaceutically acceptable salts thereof; wherein X1, X2, and X3 are CH, or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1.


Another embodiment pertains to compounds having Formula (Ic) or Formula (Vc), and pharmaceutically acceptable salts thereof; wherein X1 and X3 are CH; and X2 is N; or X2 is CH; and X1 and X3 are N; X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N.


Another embodiment pertains to compounds having Formula (Ic), and pharmaceutically acceptable salts thereof, wherein R2 is phenyl which is substituted at the para position with R5; and R5 is phthalazin-1(2H)-onyl, isoquinolinyl, isoquinolin-1(2H)-onyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, 5-fluorophthalazin-1(2H)-onyl, (Z)-3H-benzo[d][1,2]diazepin-4(5H)-onyl, 5-(trifluoromethyl)phthalazin-1(2H)-onyl, pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one, or isoindolin-1-onyl.


Still another embodiment pertains to compounds of Formula (Ic), which are

  • N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(aminomethyl)benzyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(furo[3,2-c]pyridin-4-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(pyridin-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(benzylcarbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(thieno[3,2-c]pyridin-4-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,3-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(pyridazin-3-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,3-dihydro-1,4-benzodioxin-5-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(3-methylbutyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-fluorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-5-methyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(4-cyanophenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-fluorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,5-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,2-dimethylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(2-oxopyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethoxy)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-fluoro-5-(trifluoromethyl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-chlorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4,5-trimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-nitro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(4-fluorophenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-ethyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-benzyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-methoxyphenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(3-methoxyphenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(4-acetylphenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,3-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyridin-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(2-thienyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3-methylbutyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(6-aminohexyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-thienyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1,3-benzodioxol-5-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridin-3-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(benzylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridazin-3-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyrimidin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(3-fluorophenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-butoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,4-dihydroxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-propoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-furylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-cyanophenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxy-2-methylphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)carbamoyl]phenyl}-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methyl-1H-indazol-5-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-ethoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,5-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4[(1-benzyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 5-({4[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}amino)-1H-indazole-3-carboxylate;
  • N-(4-{[2-(2-oxopyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(5-chloropyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-indol-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethyl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,5-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,3-dihydro-1,4-benzodioxin-6-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-fluorobenzoyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(5-methoxy-1H-indol-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-chlorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-propoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-isobutoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridin-4-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4,5-trimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methylpiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[4-(dimethylamino)phenyl]ethyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(trifluoromethoxy)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-3-hydroxy-1-phenylpropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-cyanophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluoro-4-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,3-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-fluorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(isobutylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1,3-benzodioxol-5-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-isopropoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-isopropoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-fluorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,4-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N2-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N-{4-[(2-phenoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-hydroxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3-fluorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({1-[(3S)-tetrahydrofuran-3-yl]-1H-pyrazol-4-yl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-phenylethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(methylthio)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-ethoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-fluorophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(pyridin-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[(trifluoromethyl)thio]benzyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(2-fluorophenyl)pyrrolidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3-chlorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(hydroxymethyl)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3-benzodioxol-5-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-isopropyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-hydroxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-ethyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,5-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[methyl(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(thiomorpholin-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-furoyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-benzylpiperidin-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(5-acetamido-2-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,5-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[3-(trifluoromethyl)phenyl]ethyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylbutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-imidazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-1-(3-cyanophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[benzyl(2-hydroxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-cyanophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-chlorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyanomethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclohexylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[butyl(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(dimethylamino)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,3-dihydro-1H-indol-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(phenylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-fluorophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(diethylamino)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-hydroxy-2-phenylethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-aminophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl(1-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}piperidin-4-yl)carbamate;
  • N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(cyclohexylmethyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3-chlorobenzyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(diethylcarbamoyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-hydroxy-6-methylphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(5-fluoropyridin-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopropylmethyl)(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-methoxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3,4,9-tetrahydro-2H-beta-carbolin-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tert-butylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-difluoropyrrolidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylpiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-1-benzylpyrrolidin-3-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-hydroxypiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluorophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclopentylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-carbamoylpiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclopropylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(methylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pentan-2-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pentan-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclobutylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1,3-dioxolan-2-ylmethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(4-fluorophenyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-hydroxy-2-methylpropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-phenyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[4-(trifluoromethyl)phenyl]ethyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxyethyl)(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(sec-butylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(trifluoromethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[bis(2-ethoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[butyl(ethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(morpholin-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[isobutyl(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylpiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-carbamoylphenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylpyrrolidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[ethyl(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,6-dimethylmorpholin-4-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-hydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,5-dimethylpyrrolidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(prop-2-yn-1-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[isopropyl(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[isopropyl(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-cyanoethyl)(cyclopropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[ethyl(isopropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluoropyrrolidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}-N-isopropyl-beta-alanine;
  • N-{4-[methyl(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5,6-dimethoxy-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(4-chlorophenoxy)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethoxy)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenyl-1,3-thiazol-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 2-{[4-(propylcarbamoyl)phenyl]carbamoyl}isoindoline-5-carboxylate;
  • 2-{[4-(propylcarbamoyl)phenyl]carbamoyl}isoindoline-5-carboxylic acid;
  • 5-amino-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(aminomethyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(2-hydroxy-2-methylpropanoyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-acetamido-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(N,N-dimethylglycyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-5-(1H-pyrazol-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-5-(1H-pyrazol-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(methoxyacetyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(methylsulfonyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-bromo-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,5-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-chlorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4,4,4-trifluorobutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-ethoxypropanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenylbutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methylpentanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(benzyloxy)acetyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-phenylpropanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-phenoxypropanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[N-(2-furoyl)glycyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-thienyl)butanoyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-oxo-4-phenylbutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(N-benzoylglycyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenoxybutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propionylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pentanoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(hexanoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(heptanoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pent-4-enoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(ethoxyacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2-methoxyethoxy)acetyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopropylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(4-methylpiperazin-1-yl)propanoyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 2-({4-[(cyclopentylacetyl)amino]phenyl}carbamoyl)isoindoline-5-carboxylate;
  • 2-({4-[(cyclopentylacetyl)amino]phenyl}carbamoyl)isoindoline-5-carboxylic acid;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-cyclopentylethyl)amino]phenyl}-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}-3,6-dihydropyridine-1(2H)-carboxylate;
  • N-[4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methylbutyl)-1H-pyrazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1E)-5-phenylpent-1-en-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-propyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[6-(1-propyl-1H-pyrazol-4-yl)pyridin-3-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-phenylpentyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[2-fluoro-4-(1-propyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{2-fluoro-4-[1-(3-methylbutyl)-1H-pyrazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-butyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(isopropylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1′-isobutyryl-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1′-benzoyl-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-benzoylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(isopropylsulfonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(phenylsulfonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[3-(benzoylamino)pyrrolidin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[3-(butyrylamino)pyrrolidin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}piperazine-1-carboxylate;
  • N-[4-(4-propionylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(2-butyryl-2,3-dihydro-1H-isoindol-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(2-isobutyryl-2,3-dihydro-1H-isoindol-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(2-benzoyl-2,3-dihydro-1H-isoindol-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[2-(3-methylbutyl)-2,3-dihydro-1H-isoindol-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(hexyloxy)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridin-3-ylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[6-(4-chlorophenoxy)hexyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(piperidin-4-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N,N′-hexane-1,6-diylbis(1,3-dihydro-2H-isoindole-2-carboxamide);
  • N-(4-phenylbutyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • ethyl 6-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]hexanoate;
  • N-hexyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-octyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(1-methyl-1H-pyrazol-4-yl)amino]-6-oxohexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[6-(methylamino)-6-oxohexyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-oxo-6-[(3-phenylpropyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-methylbutyl)amino]-6-oxohexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(5-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}pyridin-2-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(3-phenylpropyl)carbamoyl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(3-methylbutyl)carbamoyl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(3-phenylpropyl)carbamoyl]-1,3-thiazol-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(3-methylbutyl)carbamoyl]-1,3-thiazol-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(isoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(8-fluoro-4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(morpholin-4-ylmethyl)-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(4-methylpiperazin-1-yl)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-chloro-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-4,5-dihydro-3H-2,3-benzodiazepin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-oxo-8-(trifluoromethyl)-3,4-dihydrophthalazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(dimethylamino)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(di ethylamino)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(4-methylpiperazin-1-yl)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(dimethylamino)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(di ethylamino)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-oxo-8-(trifluoromethyl)-3,4-dihydrophthalazin-1-yl]phenyl}-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(1-methylpiperidin-4-yl)oxy]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-{[(3R)-3-fluoropyrrolidin-1-yl]methyl}-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-{[(3S)-3-fluoropyrrolidin-1-yl]methyl}-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(azetidin-1-ylmethyl)-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydropyrrolo[1,2-d][1,2,4]triazin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydropyrrolo[1,2-d][1,2,4]triazin-4-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}piperidine-1-carboxylate;
  • N-[4-(5-propyl-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(piperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(tetrahydrofuran-3-ylmethyl)carbamoyl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-butyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[5-(3-methylbutyl)-1,2,4-oxadiazol-3-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-benzyl-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3R)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(5-chloropyridin-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxy-4-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,4-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-oxopyrrolidin-1-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-hydroxycyclopropyl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl 4-{6-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]-1H-benzimidazol-2-yl}piperazine-1-carboxylate;
  • N-[2-(piperazin-1-yl)-1H-benzimidazol-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-5-vinyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-benzoylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[5-(tetrahydrofuran-3-yl)-1,2,4-oxadiazol-3-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3-methylbutyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide;
  • N-(4-{[(3-phenylpropyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide;
  • N-{4-[1-(4-methylbenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(tetrahydrofuran-3-ylmethyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-({[(2S)-tetrahydrofuran-2-ylmethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-({[(2R)-tetrahydrofuran-2-ylmethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(1S)-2-hydroxy-1-phenylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(2-methoxyethyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-(2-hydroxyethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(propylamino)carbonyl]phenyl}-5-pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(propylamino)carbonyl]phenyl}-5-pyridin-4-yl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N5-(2-methoxyethyl)-N2-{4-[(propylamino)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N-(4-cyanophenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(trifluoromethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(1S)-2-hydroxy-1-pyridin-2-ylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3-methylbutyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(tetrahydrofuran-3-ylmethyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-pyridin-2-ylpiperazin-1-yl)carbonyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-({[(1S)-2-hydroxy-1-pyridin-2-ylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(1,2-dihydroxyethyl)-N-{4-[(propylamino)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoylpiperidin-4-yl)butyl]-5-cyano-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1′-butyryl-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1′-isobutyryl-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(tetrahydrofuran-3-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide; and
  • N-[2-(4-acetylpiperazin-1-yl)-1H-benzimidazol-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(5-oxo-L-prolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(5-oxo-D-prolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-propionyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-ethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(methoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(ethoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(cyclopropylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(cyclopentylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-methylbenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methylbenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-methoxybenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methoxybenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(4-methoxybenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-fluorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-fluorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(4-fluorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(4-chlorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[3-(dimethylamino)benzoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[4-(dimethylamino)benzoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-furoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-thienylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1H-pyrrol-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2,5-dimethyl-1H-pyrrol-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1,3-thiazol-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1H-pyrazol-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(3,5-dimethyl-1,2-oxazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridin-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridin-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isonicotinoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridazin-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyrazin-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyrimidin-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[3-(piperidin-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1′-benzoyl-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[6-(benzoylamino)hexyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[(benzoylamino)methyl]benzyl}carbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(5-oxo-L-prolyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(5-oxo-D-prolyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(1-acetylpiperidin-4-yl)carbonyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-acetamidobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[4-(methylsulfonyl)benzoyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-butyrylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-isobutyrylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-methylbutanoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3,3,3-trifluoropropanoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(methoxyacetyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(tetrahydrofuran-3-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(cyclopentylacetyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(cyclohexylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-methoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3-methoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(4-methoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3-fluorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-chlorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(4-chlorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3-cyanobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(4-cyanobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[3-(dimethylamino)benzoyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[4-(dimethylamino)benzoyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3,5-dimethoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(3,4-dimethoxyphenyl)acetyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-furoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3-furoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(1H-pyrrol-2-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(1H-pyrazol-5-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyridin-2-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-isonicotinoylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyridazin-3-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyrazin-2-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyrimidin-4-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(N,N-dimethyl-beta-alanyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-acetylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-fluorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(4-fluorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(phenylacetyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(1,3-thiazol-4-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(morpholin-4-ylacetyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-phenylbutyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-butyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-benzoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-oxo-2,3-dihydro-1H-isoindol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)cyclohex-3-en-1-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)cyclohex-3-en-1-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)cyclohex-3-en-1-yl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-1,3-dihydro-2H-isoindole-2-carboxamide; N-[1-(2-phenylethyl)-1H-pyrazol-4-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N5-[2-(dimethylamino)ethyl]-N2-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • 5-(morpholin-4-ylcarbonyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{benzyl[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(isobutoxycarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide; 5-bromo-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 4-{[(5-cyano-1,3-dihydro-2H-isoindol-2-yl)carbonyl]amino}benzoate;
  • N-(4-{(E)-[(benzyloxy)imino]methyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1S)-2-hydroxy-1-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3-aminopyrrolidin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-methylbutyl)carbamoyl]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-phenylpropyl)carbamoyl]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(tetrahydrofuran-3-ylmethyl)carbamoyl]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N2-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N-[4-({benzyl[3-(morpholin-4-yl)propyl]amino}methyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(1H-pyrazol-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(1-methyl-1H-pyrazol-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N2-{4-[(cyclopentylacetyl)amino]phenyl}-N5-(2-methoxyethyl)-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N2-{4-[(cyclopentylacetyl)amino]phenyl}-N5-(2-hydroxyethyl)-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • 5-(aminomethyl)-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;


N-(4-{[(2S)-1-hydroxy-4-(methylthio)butan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;


N-(4-{[(2S,3S)-1-hydroxy-3-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;

  • N-(4-{[(2S)-1-hydroxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S,3R)-1,3-dihydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxyhexan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxypentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S,2S)-2-hydroxycyclopentyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S,2R)-2-hydroxycyclopentyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-cyclohexyl-3-hydroxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({(2R)-1-hydroxy-3-[(4-methylbenzyl)thio]propan-2-yl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-(4-tert-butylphenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-methoxy-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[6-(benzoylamino)hexyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(pyridin-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(cyclopentylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[1′-(tetrahydrofuran-3-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{1′-[(2-methoxyethoxy)acetyl]-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-(4-phenylbutyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(3-methylbutyl)carbamoyl]pyrazin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-acetamidohexyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{(1E)-3-[benzyl(methyl)amino]prop-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-phenoxypiperidin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3-phenoxyazetidin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[benzyl(methyl)amino]methyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3R)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4[(4-hydroxypiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-hydroxy-2-methylpropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-benzyl-1H-1,2,3-triazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methylbutyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylmethyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1H-1,2,3-triazol-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1-benzylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[4-(morpholin-4-yl)benzyl]-1H-1,2,3-triazol-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyl-1H-1,2,3-triazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(cyclopentylmethyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methoxypropyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(tetrahydrofuran-3-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-(4-{[(2-methoxyethoxy)acetyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1′-isobutyryl-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(1′-benzoyl-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(tetrahydrofuran-3-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{1′-[(2-methoxyethoxy)acetyl]-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(6-{[4-(methylsulfonyl)benzoyl]amino}hexyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(ethoxyacetyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(cyclopentylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(2-hydroxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-hydroxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(4-hydroxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(2-methoxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-methoxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(4-methoxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(2-fluorobenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-fluorobenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(4-fluorobenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(2-chlorobenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-chlorobenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(4-chlorobenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-cyanobenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(4-cyanobenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[3-(dimethylamino)benzoyl]amino}hexyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[4-(dimethylamino)benzoyl]amino}hexyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[3-(trifluoromethyl)benzoyl]amino}hexyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[4-(trifluoromethyl)benzoyl]amino}hexyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[3-(trifluoromethoxy)benzoyl]amino}hexyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(2,3-dimethoxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(2,4-dimethoxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(2,5-dimethoxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(phenylacetyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[(3-fluorophenyl)acetyl]amino}hexyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(tetrahydrofuran-2-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(ethoxyacetyl)amino]phenyl}-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(tetrahydro-2H-pyran-4-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(morpholin-4-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(morpholin-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[6-(benzoylamino)hexyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 4-fluoro-N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-cyano-N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-chloro-N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(pyridin-2-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(tetrahydrofuran-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(tetrahydro-2H-pyran-4-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(1,4-dioxan-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{1′-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(2-hydroxy-2-methylpropanoyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(tetrahydrofuran-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(tetrahydro-2H-pyran-4-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(1,4-dioxan-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{1′-[(1-methylpyrrolidin-3-yl)carbonyl]-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{1′-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyrrolidin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(7-oxo-7-{[(3R)-tetrahydrofuran-3-ylmethyl]amino}heptyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{7-oxo-7-[(tetrahydro-2H-pyran-4-ylmethyl)amino]heptyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-isopropoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(azetidin-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[methyl(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(isobutylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cyclopentylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-isopropoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[benzyl(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(6-methoxypyridin-3-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-isobutoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(trifluoromethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[5-(morpholin-4-ylmethyl)-1,2,4-oxadiazol-3-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{5-[(4-methylpiperazin-1-yl)methyl]-1,2,4-oxadiazol-3-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-{[(3-methylbutyl)amino]methyl}-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{5-[(4-hydroxypiperidin-1-yl)methyl]-1,2,4-oxadiazol-3-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(2-hydroxy-2-methylpropanoyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(tetrahydrofuran-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(tetrahydro-2H-pyran-4-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(1,4-dioxan-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{1′-[(1-methylpyrrolidin-3-yl)carbonyl]-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{1′-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(2-hydroxy-2-methylpropanoyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(2-aminoethyl)-1H-imidazol-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyrimidin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(pyridin-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-methoxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[3-(hydroxymethyl)oxetan-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2-{benzyl[3-(morpholin-4-yl)propyl]amino}-2-oxoethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3-{benzyl[3-(morpholin-4-yl)propyl]amino}-3-oxopropyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2R)-butan-2-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-cyano-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-methyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-chloro-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide; N-[4-(6-bromo-2-oxoquinolin-1(2H)-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[6-(3-acetylphenyl)-2-oxoquinolin-1(2H)-yl]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(morpholin-4-ylacetyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(morpholin-4-ylacetyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(2-{(4-fluorobenzyl)[4-(pyridin-3-yl)benzyl]amino}-1,3-thiazol-5-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2-benzyl-1,3-thiazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(7-{benzyl[3-(morpholin-4-yl)propyl]amino}-7-oxoheptyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(1,3-thiazol-5-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1R)-3-hydroxy-1-phenylpropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[2-hydroxy-1-(4-methylphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(1,3-dihydroxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2R)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(3-furylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[4-(2-furoyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[4-(ethylsulfonyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1R)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2S)-1-hydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(2,3-dihydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[2-hydroxy-1-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(1-hydroxy-4-methylpentan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(5-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}pyridin-2-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.3]hept-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.4]oct-6-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.4]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,8-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3,9-diazaspiro[5.5]undec-3-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,9-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,8-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[5.5]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.6]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-oxa-9-azaspiro[5.5]undec-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxa-4,8-diazaspiro[5.5]undec-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,6-diazaspiro[3.5]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,5-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-oxa-2-azaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(6-oxa-2-azaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(hexahydro-5H-furo[2,3-c]pyrrol-5-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(hexahydrofuro[3,4-c]pyridin-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-{benzyl[3-(morpholin-4-yl)propyl]amino}-4-oxobutyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-phenylbutyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2-{benzyl[3-(morpholin-4-yl)propyl]amino}ethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-acetyl-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[(3-methylbutyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)sulfamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(1-hydroxyethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(butyrylamino)phenyl]-5-cyano-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyrrolidin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-pyrrolidin-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3-methoxybenzyl)sulfonyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.4]oct-6-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-1-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,8-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-7-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,8-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[5.5]undec-8-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.6]undec-8-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(1-oxa-4,8-diazaspiro[5.5]undec-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-1-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-8-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.4]oct-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,6-diazaspiro[3.5]non-1-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,5-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(5-oxa-2-azaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(6-oxa-2-azaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(2-oxa-7-azaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(hexahydro-5H-furo[2,3-c]pyrrol-5-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(tetrahydro-1H-furo[3,4-c]pyrrol-5 (3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(hexahydrofuro[3,4-c]pyridin-5 (3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[6-(3-acetylphenyl)-4-(3-hydroxypropyl)-2-oxoquinolin-1(2H)-yl]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-(acetamidomethyl)-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[2-(2-chlorobenzyl)-1,3-thiazol-4-yl]-2-thienyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-fluorophenyl)butyl]-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(3R)-1-isobutyrylpyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[(3R)-1-benzoylpyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[1-(methylsulfonyl)pyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-isobutyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylmethyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylmethyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-isobutylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylmethyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylmethyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(2-hydroxypropan-2-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl {4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzyl}carbamate;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(methoxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-{[(tetrahydrofuran-2-ylmethyl)amino]methyl}-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{5-[(4-methoxypiperidin-1-yl)methyl]-1,2,4-oxadiazol-3-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-{[4-(2-methoxyethyl)piperazin-1-yl]methyl}-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[1-(morpholin-4-yl)cyclopentyl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-pentanoylpiperidin-4-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-butyrylpiperidin-4-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{6-[(1-acetylpiperidin-4-yl)oxy]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(1-isobutyrylpiperidin-4-yl)oxy]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(methoxyacetyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclopropylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclobutylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclopentylacetyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl(2-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}ethyl)carbamate;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-1-(4-fluorophenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[3-(hydroxymethyl)oxetan-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-1-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)sulfamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydrofuran-3-ylmethyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-(4-fluorophenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3,3,3-trifluoropropanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(4,4,4-trifluorobutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-phenylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(phenylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4-methoxyphenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(methoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-benzoylpyrrolidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-ethoxypropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2-methylcyclopropyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(1-methylcyclopropyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-acetylpyrrolidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(4,4,4-trifluorobutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(ethoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1-methylpiperidin-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[1-(2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl[(1-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}azetidin-3-yl)methyl]carbamate;
  • N-(4-{4-[(tetrahydrofuran-3-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydro-2H-pyran-4-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(morpholin-4-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(2-methoxyethoxy)acetyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(2,3-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(cyclohexylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(morpholin-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(morpholin-4-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2,2-dimethylpropanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3,3-dimethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tricyclo[3.3.1.1˜3,7˜]dec-1-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4-methoxycyclohexyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[4-(acetylamino)phenyl]sulfonyl}amino)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(propylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(4-propylphenyl)sulfonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(butylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[({[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl}sulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(ethylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(benzylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(4-fluorophenyl)sulfonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(thiophen-2-ylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,6-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,9-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,8-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[5.5]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.6]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-oxa-9-azaspiro[5.5]undec-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-oxa-4,8-diazaspiro[5.5]undec-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,6-diazaspiro[3.5]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,5-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(5-oxa-2-azaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(6-oxa-2-azaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(hexahydro-5H-furo[2,3-c]pyrrol-5-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(hexahydrofuro[3,4-c]pyridin-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(N,N-dimethylglycyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydrofuran-2-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydrofuran-3-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(cyclohexylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(4,4-difluorocyclohexyl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-hydroxy-2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydrofuran-2-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(piperidin-1-ylsulfonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(1,3-thiazol-2-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4[(4,4-difluorocyclohexyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-methyl-2-(morpholin-4-yl)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(2-methyl-1,3-thiazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-methyl-1-(morpholin-4-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • Nalpha-(4-{[(5-fluoro-1,3-dihydro-2H-isoindol-2-yl)carbonyl]amino}benzoyl)-D-phenylalaninamide;
  • N-(4-{[2-(acetylamino)phenyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(furan-2-yl)-2-(pyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-amino-1-oxohexan-2-yl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • Nalpha-(4-{[(5-fluoro-1,3-dihydro-2H-isoindol-2-yl)carbonyl]amino}benzoyl)-L-phenylalaninamide;
  • N-(4-{[(2R)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(methylcarbamoyl)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-amino-2-oxo-1-phenylethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-tert-butoxypropyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-2-amino-2-oxo-1-phenylethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-methyl-2-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3S)-1-methyl-2-oxoazepan-3-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(5-methyl-1H-pyrazol-1-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(4-chloro-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)butyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-carbamoylbenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-amino-1-oxohexan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • Nalpha-{4-[(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-ylcarbonyl)amino]benzoyl}-L-phenylalaninamide;
  • N-(4-{[(2R)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-tert-butoxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(3S)-1-methyl-2-oxoazepan-3-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(4,5,6,7-tetrahydro-1H-indazol-5-ylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • 5-fluoro-N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethylbutyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(furan-2-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3-methyl-1,2-oxazol-5-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-cyanobutan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2R)-butan-2-ylcarbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(ethylamino)-1-oxopropan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methoxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(1-methoxybutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-ethoxypropyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[benzyl(methyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(5-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(3-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(1-methylcyclopropyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(thiophen-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(4-methoxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(5-methyl-1,3-oxazol-2-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(tetrahydro-2H-pyran-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-1-methoxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethyl-2-oxobutyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1-methyl-1H-pyrrol-2-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(propan-2-yloxy)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-amino-1-oxobutan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(tetrahydro-2H-pyran-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(1H-pyrrol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclopentylcarbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2R)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-2-methylbutyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(tetrahydro-2H-pyran-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-cyanoethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(5-methyl-1,2-oxazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3,3-dimethylbutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(furan-2-yl)propan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(3-methyl-1,2-oxazol-5-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2R)-1-cyanobutan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methoxybutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(1,3-thiazol-2-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(1-methyl-1H-pyrazol-4-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-methoxybutan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-aminobenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-ethoxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(6-methoxypyridin-3-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-cyanocyclopropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(5-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(4-methyl-1,3-thiazol-2-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(1-methylcyclopropyl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(thiophen-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-methoxybutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(tetrahydro-2H-pyran-3-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2S)-1-methoxypropan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3,3-dimethyl-2-oxobutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrrol-2-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(propan-2-yloxy)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(tetrahydro-2H-pyran-3-ylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(1H-pyrrol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2R)-3-methylbutan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-cyanoethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methoxy-2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[methyl(propyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • methyl 1-{4-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]phenyl}azetidine-3-carboxylate;
  • N-(4-{3-[(3-methylbutyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(tetrahydrofuran-2-ylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[3-(benzylcarbamoyl)azetidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[3-(cyclopentylcarbamoyl)azetidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(cyclopentylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(2-methoxyethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopentylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-2-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(pyrrolidin-1-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(pyrazin-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4,4-difluorocyclohexyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-cyanobutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(ethylamino)-1-oxopropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(tetrahydro-2H-pyran-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(5-methyl-1,3-oxazol-2-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[(dimethylamino)methyl]benzyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-2-amino-2-oxo-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3-oxazol-2-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tetrahydro-2H-pyran-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(1-methylcyclopropyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(furan-2-yl)-2-(pyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[1-(2-hydroxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[1-(morpholin-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-fluorobenzyl)(3-methylbutanoyl)amino]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(9-chloro-5-oxo-2,3,3a,4,4a,5-hexahydro-6H-furo[2′,3′:2,3]cyclobuta[1,2-c]quinolin-6-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[7-chloro-1-(2-hydroxyethyl)-3-oxo-1,3-dihydrocyclobuta[c]quinolin-4(2H)-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(6-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(cyclopropylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4[(1-acetylpiperidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-butanoylpiperidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-methylbutanoyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(methoxyacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutanoyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-2-ylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(3,5-dimethyl-1H-pyrazol-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-1-methyl-2-oxoazepan-3-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(1,3-thiazol-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(furan-2-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(1-methyl-1H-pyrazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,2-difluoroethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(tetrahydro-2H-pyran-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(5-methyl-1,2-oxazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrazol-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • Nalpha-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}-L-phenylalaninamide;
  • N-(4-{[2-(2-methyl-1,3-thiazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(thiophen-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(5-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethyl-2-oxobutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(acetylamino)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-methoxybutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tetrahydro-2H-pyran-4-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pyrimidin-4-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-pyrrol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-methylbutyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-amino-1-oxohexan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-amino-2-oxo-1-phenylethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-tert-butoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(methylcarbamoyl)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-methyl-1-(morpholin-4-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(5-oxo-L-prolyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-ethoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylacetyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylacetyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(4,4-difluorocyclohexyl)carbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(propan-2-yloxy)acetyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-ethoxypropanoyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-acetylpiperidin-4-yl)carbonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(ethoxyacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-2-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{7-oxo-7-[(3-phenylpropyl)amino]heptyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(bicyclo[2.2.1]hept-2-ylacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1,3-thiazol-5-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(4-oxo-4,5,6,7-tetrahydro-1-benzofuran-3-yl)carbonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{2-[(3-methylbutanoyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(4-methylpentanoyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(ethoxyacetyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2-{[(2-methoxyethoxy)acetyl]amino}ethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(tetrahydrofuran-2-ylcarbonyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(cyclopentylcarbonyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(cyclopentylacetyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[2-(benzoylamino)ethyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(tetrahydro-2H-pyran-4-ylcarbonyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(tetrahydro-2H-pyran-4-ylacetyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(tetrahydrofuran-3-ylacetyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(5-oxo-L-prolyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-propanoylazetidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2,2-dimethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-ethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pent-4-ynoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(furan-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(furan-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(thiophen-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(1H-pyrrol-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyrimidin-4-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(5-methylpyrazin-2-yl)carbonyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(N,N-dimethylglycyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(N,N-dimethyl-beta-alanyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyrrolidin-1-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(pyrrolidin-1-yl)propanoyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(piperidin-1-yl)propanoyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4-methylpiperazin-1-yl)acetyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(4-methylpiperazin-1-yl)propanoyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-cyclopropylethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-cyclopentylethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3,3-dimethylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-methylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylpropyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(butylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(phenylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4-fluorophenyl)sulfonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(ethylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(propan-2-ylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(benzylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(propylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(thiophen-2-ylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4,4-difluoro cyclohexyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(5-oxo-D-prolyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylpentanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-ethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(1H-pyrrol-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(1,2-oxazol-5-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyridin-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyridazin-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyrazin-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide; N-(4-{[1-(pyrimidin-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(5-methylpyrazin-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(piperidin-1-yl)propanoyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(morpholin-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(4-methylpiperazin-1-yl)propanoyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • benzyl trans-3-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]cyclobutanecarboxylate;
  • N-[4-(4-{[(4-methylpiperazin-1-yl)acetyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydro-2H-pyran-4-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(benzoylamino)cyclohex-1-en-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(1-methylpiperidin-4-yl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(3R)-tetrahydrofuran-3-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(3S)-tetrahydrofuran-3-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(2S)-2-methylbutanoyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(3-methylbutanoyl)amino]oxetan-3-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • tert-butyl 4-({4-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]phenyl}sulfonyl)piperidine-1-carboxylate;
  • N-{4-[4-(propylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-methoxyethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(cyclopentylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(1,4-dioxan-2-ylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(cyclopentylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(tetrahydro-2H-pyran-4-ylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(morpholin-4-ylcarbonyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(cyclopropylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(butan-2-ylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{(4R)-4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{(4S)-4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-benzoylazetidin-3-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoylazetidin-3-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[trans-3-(benzylcarbamoyl)cyclobutyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{trans-3-[(2-phenylethyl)carbamoyl]cyclobutyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{trans-3-[(3-phenylpropyl)carbamoyl]cyclobutyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methyl-1,3-oxazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(furan-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2E)-3-(furan-2-yl)prop-2-enoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1,3-oxazol-5-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3,3,3-trifluoropropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,5-dimethyl-1H-pyrazol-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(4-methoxycyclohexyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2,3-dimethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2,2-difluorocyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1H-pyrazol-5-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tert-butoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[3-(1H-1,2,4-triazol-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3-ethoxypropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3-hydroxy-3-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[3-(1H-pyrrol-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methylcyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methylpropoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1-methylprolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-hydroxycyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopropylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopentylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-{[1-(methoxymethyl)cyclopropyl]carbonyl}-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(methylsulfonyl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methyl-1H-pyrazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopropylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-ethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(5-oxo-L-prolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2E)-4-methylpent-2-enoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-methoxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopent-1-en-1-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(thiophen-3-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclohexylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-propanoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2,2-dimethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(methoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2,2-dimethylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(4-methylhexanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2,2-dimethylcyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclobutylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(piperidin-1-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[2-(pyrrolidin-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,3-dimethyl-1H-pyrazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cis-4-{[(2-methoxyethoxy)acetyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(trans-4-{[(2-methoxyethoxy)acetyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cis-4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(trans-4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cis-4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(trans-4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(6-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3R)-1-(cyclobutylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({(3R)-1-[(2R)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({(3R)-1-[(2S)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3R)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-1-(cyclobutylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({(3S)-1-[(2R)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({(3S)-1-[(2S)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(6-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{6-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{6-[(cyclopentylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{6-[(tetrahydrofuran-3-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{6-[(bicyclo[2.2.1]hept-2-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{trans-4-[(2-methylpropanoyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{cis-4-[(2-methylpropanoyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{cis-4-[(cyclohexylcarbonyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{trans-4-[(cyclohexylcarbonyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{trans-4-[(cyclopropylacetyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{cis-4-[(cyclopropylacetyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(cyclopentylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(cyclopropylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(2-hydroxy-2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(tetrahydro-2H-pyran-4-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(cyclohexylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide; and pharmaceutically acceptable salts thereof.


Still another embodiment pertains to compounds of Formula (Ic), which are

  • N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-fluoro-N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide; and pharmaceutically acceptable salts thereof.


Still another embodiment pertains to compounds of Formula (Ic), which are

  • N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide; and pharmaceutically acceptable salts thereof.


Another embodiment pertains to a composition for treating hypertension, chronic and congestive heart failure, cardiac hypertrophy, restenosis, chronic renal failure, cerebral vasospasm after subarachnoid bleeding, pulmonary hypertension, atherosclerosis, asthma, male erectile dysfunctions, female sexual dysfunction, over-active bladder syndrome, spinal-cord injury, traumatic brain injury, stroke, inflammatory and demyelinating diseases, Alzheimer's disease, pain, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, inflammatory pain, rheumatoid arthritis, osteoarthritis, irritable bowel syndrome, Crohn's disease, psoriasis, ulcerative colitis, lupus, inflammatory bowel disease, cancer, tumor metastasis, viral infections, bacterial infections, insulin resistance, diabetes, ocular hypertension, preterm labor, atherosclerosis, spinal muscular atrophy, encephalomyelitis, osteoporosis, HIV-1, encephalitis, ischemic CNS disorders, vascular or AD type dementia, glaucoma, retinopathy, benign prostatic hypertrophy, psychiatric disorders, in particular depression, schizophrenia, obsessive compulsive disorder and bipolar disorder, epilepsy and seizure disorders, for decreasing ischemia-reperfusion injury, myocardial infarct size and myocardial fibrosis, for the prevention of graft failure, and cystic fibrosis, said composition comprising an excipient and a therapeutically effective amount of a compound of Formula (Ic), or pharmaceutically acceptable salts thereof.


Another embodiment pertains to a composition for treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia, said composition comprising an excipient and a therapeutically effective amount of a compound of Formula (Ic), or pharmaceutically acceptable salts thereof.


Another embodiment pertains to a method of treating hypertension, chronic and congestive heart failure, cardiac hypertrophy, restenosis, chronic renal failure, cerebral vasospasm after subarachnoid bleeding, pulmonary hypertension, atherosclerosis, asthma, male erectile dysfunctions, female sexual dysfunction, over-active bladder syndrome, spinal-cord injury, traumatic brain injury, stroke, inflammatory and demyelinating diseases, Alzheimer's disease, pain, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, inflammatory pain, rheumatoid arthritis, osteoarthritis, irritable bowel syndrome, Crohn's disease, psoriasis, ulcerative colitis, lupus, inflammatory bowel disease, cancer, tumor metastasis, viral infections, bacterial infections, insulin resistance, diabetes, ocular hypertension, preterm labor, atherosclerosis, spinal muscular atrophy, encephalomyelitis, osteoporosis, HIV-1, encephalitis, ischemic CNS disorders, vascular or AD type dementia, glaucoma, retinopathy, benign prostatic hypertrophy, psychiatric disorders, in particular depression, schizophrenia, obsessive compulsive disorder and bipolar disorder, epilepsy and seizure disorders, for decreasing ischemia-reperfusion injury, myocardial infarct size and myocardial fibrosis, for the prevention of graft failure, and cystic fibrosis, in a patient, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula (Ic), or pharmaceutically acceptable salts thereof.


Another embodiment pertains to a method of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia in a patient, said method comprising administering to the patient a therapeutically effective amount of a compound of Formula (Ic), or pharmaceutically acceptable salts thereof.


Another embodiment pertains to a method of treating hypertension, chronic and congestive heart failure, cardiac hypertrophy, restenosis, chronic renal failure, cerebral vasospasm after subarachnoid bleeding, pulmonary hypertension, atherosclerosis, asthma, male erectile dysfunctions, female sexual dysfunction, over-active bladder syndrome, spinal-cord injury, traumatic brain injury, stroke, inflammatory and demyelinating diseases, Alzheimer's disease, pain, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, inflammatory pain, rheumatoid arthritis, osteoarthritis, irritable bowel syndrome, Crohn's disease, psoriasis, ulcerative colitis, lupus, inflammatory bowel disease, cancer, tumor metastasis, viral infections, bacterial infections, insulin resistance, diabetes, ocular hypertension, preterm labor, atherosclerosis, spinal muscular atrophy, encephalomyelitis, osteoporosis, HIV-1, encephalitis, ischemic CNS disorders, vascular or AD type dementia, glaucoma, retinopathy, benign prostatic hypertrophy, psychiatric disorders, in particular depression, schizophrenia, obsessive compulsive disorder and bipolar disorder, epilepsy and seizure disorders, for decreasing ischemia-reperfusion injury, myocardial infarct size and myocardial fibrosis, for the prevention of graft failure, and cystic fibrosis in a patient, said method comprising administering to the patient therapeutically effective amount of the compound of Formula (Ic), or pharmaceutically acceptable salts thereof; and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.


Another embodiment pertains to a method of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia or spleen cancer in a patient, said method comprising administering to the patient therapeutically effective amount of the compound of Formula (Ic), or pharmaceutically acceptable salts thereof; and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.







DETAILED DESCRIPTION OF THE INVENTION

This detailed description is intended only to acquaint others skilled in the art with Applicants' invention, its principles, and its practical application so that others skilled in the art may adapt and apply the invention in its numerous forms, as they may be best suited to the requirements of a particular use. This description and its specific examples are intended for purposes of illustration only. This invention, therefore, is not limited to the embodiments described in this patent application, and may be variously modified.


ABBREVIATIONS AND DEFINITIONS

Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. The meaning and scope of the terms should be clear, however, in the event of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. In this application, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including”, as well as other forms, such as “includes” and “included”, is not limiting. With reference to the use of the words “comprise” or “comprises” or “comprising” in this patent application (including the claims), Applicants note that unless the context requires otherwise, those words are used on the basis and clear understanding that they are to be interpreted inclusively, rather than exclusively, and that Applicants intend each of those words to be so interpreted in construing this patent application, including the claims below. For a variable that occurs more than one time in any substituent or in the compound of the invention or any other formulae herein, its definition on each occurrence is independent of its definition at every other occurrence. Combinations of substituents are permissible only if such combinations result in stable compounds. Stable compounds are compounds which can be isolated in a useful degree of purity from a reaction mixture.


It is meant to be understood that proper valences are maintained for all combinations herein, that monovalent moieties having more than one atom are attached through their left ends, and that divalent moieties are drawn from left to right.


As used in the specification and the appended claims, unless specified to the contrary, the following terms have the meaning indicated:


The term “alkyl” (alone or in combination with another term(s)) means a straight- or branched-chain saturated hydrocarbyl substituent typically containing from 1 to about 10 carbon atoms; or in another embodiment, from 1 to about 8 carbon atoms; in another embodiment, from 1 to about 6 carbon atoms; and in another embodiment, from 1 to about 4 carbon atoms. Examples of such substituents include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, and hexyl and the like.


The term “alkenyl” (alone or in combination with another term(s)) means a straight- or branched-chain hydrocarbyl substituent containing one or more double bonds and typically from 2 to about 10 carbon atoms; or in another embodiment, from 2 to about 8 carbon atoms; in another embodiment, from 2 to about 6 carbon atoms; and in another embodiment, from 2 to about 4 carbon atoms. Examples of such substituents include ethenyl (vinyl), 2-propenyl, 3-propenyl, 1,4-pentadienyl, 1,4-butadienyl, 1-butenyl, 2-butenyl, and 3-butenyl and the like.


The term “alkynyl” (alone or in combination with another term(s)) means a straight- or branched-chain hydrocarbyl substituent containing one or more triple bonds and typically from 2 to about 10 carbon atoms; or in another embodiment, from 2 to about 8 carbon atoms; in another embodiment, from 2 to about 6 carbon atoms; and in another embodiment, from 2 to about 4 carbon atoms. Examples of such substituents include ethynyl, 2-propynyl, 3-propynyl, 2-butynyl, and 3-butynyl and the like.


The term “carbocyclyl” (alone or in combination with another term(s)) means a saturated cyclic (i.e., “cycloalkyl”), partially saturated cyclic (i.e., “cycloalkenyl”), or completely unsaturated (i.e., “aryl”) hydrocarbyl substituent containing from 3 to 14 carbon ring atoms (“ring atoms” are the atoms bound together to form the ring or rings of a cyclic substituent). A carbocyclyl may be a single-ring (monocyclic) or polycyclic ring structure.


A carbocyclyl may be a single ring structure, which typically contains from 3 to 8 ring atoms, more typically from 3 to 6 ring atoms, and even more typically 5 to 6 ring atoms. Examples of such single-ring carbocyclyls include cyclopropyl (cyclopropanyl), cyclobutyl (cyclobutanyl), cyclopentyl (cyclopentanyl), cyclopentenyl, cyclopentadienyl, cyclohexyl (cyclohexanyl), cyclohexenyl, cyclohexadienyl, and phenyl. A carbocyclyl may alternatively be polycyclic (i.e., may contain more than one ring). Examples of polycyclic carbocyclyls include bridged, fused, and spirocyclic carbocyclyls. In a spirocyclic carbocyclyl, one atom is common to two different rings. An example of a spirocyclic carbocyclyl is spiropentanyl. In a bridged carbocyclyl, the rings share at least two common non-adjacent atoms. Examples of bridged carbocyclyls include bicyclo[2.2.1]heptanyl, bicyclo[2.2.1]hept-2-enyl, and adamantanyl. In a fused-ring carbocyclyl system, two or more rings may be fused together, such that two rings share one common bond. Examples of two- or three-fused ring carbocyclyls include naphthalenyl, tetrahydronaphthalenyl (tetralinyl), indenyl, indanyl (dihydroindenyl), anthracenyl, phenanthrenyl, and decalinyl.


The term “cycloalkyl” (alone or in combination with another term(s)) means a saturated cyclic hydrocarbyl substituent containing from 3 to 14 carbon ring atoms. A cycloalkyl may be a single carbon ring, which typically contains from 3 to 8 carbon ring atoms and more typically from 3 to 6 ring atoms. Examples of single-ring cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. A cycloalkyl may alternatively be polycyclic or contain more than one ring. Examples of polycyclic cycloalkyls include bridged, fused, and spirocyclic carbocyclyls. In a bridged cycloalkyl, the rings share at least two common non-adjacent atoms. Examples of bridged cycloalkyls include bicyclo[2.2.1]heptanyl and adamantanyl.


The term “aryl” (alone or in combination with another term(s)) means an aromatic carbocyclyl containing from 6 to 14 carbon ring atoms. An aryl may be monocyclic or polycyclic (i.e., may contain more than one ring). In the case of polycyclic aromatic rings, only one ring in the polycyclic system is required to be unsaturated while the remaining ring(s) may be saturated, partially saturated or unsaturated. Examples of aryls include phenyl, naphthalenyl, indenyl, 2,3-dihydroindenyl, indanyl, and tetrahydronapthyl.


In some instances, the number of carbon atoms in a hydrocarbyl substituent (e.g., alkyl, alkenyl, alkynyl, or cycloalkyl) is indicated by the prefix “Cx-Cy-”, wherein x is the minimum and y is the maximum number of carbon atoms in the substituent. Thus, for example, “C1-C6-alkyl” refers to an alkyl substituent containing from 1 to 6 carbon atoms. Illustrating further, C3-C8-cycloalkyl means a saturated hydrocarbyl ring containing from 3 to 8 carbon ring atoms.


The term “hydrogen” (alone or in combination with another term(s)) means a hydrogen radical, and may be depicted as —H.


The term “hydroxy” (alone or in combination with another term(s)) means —OH.


The term “carboxy” (alone or in combination with another term(s)) means —C(O)—OH.


The term “amino” (alone or in combination with another term(s)) means —NH2.


The term “halogen” or “halo” (alone or in combination with another term(s)) means a fluorine radical (which may be depicted as —F), chlorine radical (which may be depicted as —Cl), bromine radical (which may be depicted as —Br), or iodine radical (which may be depicted as —I).


If a substituent is described as being “substituted”, a non-hydrogen radical is in the place of hydrogen radical on a carbon or nitrogen of the substituent. Thus, for example, a substituted alkyl substituent is an alkyl substituent in which at least one non-hydrogen radical is in the place of a hydrogen radical on the alkyl substituent. To illustrate, monofluoroalkyl is alkyl substituted with a fluoro radical, and difluoroalkyl is alkyl substituted with two fluoro radicals. It should be recognized that if there are more than one substitution on a substituent, each non-hydrogen radical may be identical or different (unless otherwise stated).


If a substituent is described as being “optionally substituted”, the substituent may be either (1) not substituted or (2) substituted. If a substituent is described as being optionally substituted with up to a particular number of non-hydrogen radicals, that substituent may be either (1) not substituted; or (2) substituted by up to that particular number of non-hydrogen radicals or by up to the maximum number of substitutable positions on the substituent, whichever is less. Thus, for example, if a substituent is described as a heteroaryl optionally substituted with up to 3 non-hydrogen radicals, then any heteroaryl with less than 3 substitutable positions would be optionally substituted by up to only as many non-hydrogen radicals as the heteroaryl has substitutable positions. To illustrate, tetrazolyl (which has only one substitutable position) would be optionally substituted with up to one non-hydrogen radical. To illustrate further, if an amino nitrogen is described as being optionally substituted with up to 2 non-hydrogen radicals, then a primary amino nitrogen will be optionally substituted with up to 2 non-hydrogen radicals, whereas a secondary amino nitrogen will be optionally substituted with up to only 1 non-hydrogen radical.


This patent application uses the terms “substituent” and “radical” interchangeably.


The prefix “halo” indicates that the substituent to which the prefix is attached is substituted with one or more independently selected halogen radicals. For example, haloalkyl means an alkyl substituent in which at least one hydrogen radical is replaced with a halogen radical. Examples of haloalkyls include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, and 1,1,1-trifluoroethyl. It should be recognized that if a substituent is substituted by more than one halogen radical, those halogen radicals may be identical or different (unless otherwise stated).


The prefix “perhalo” indicates that every hydrogen radical on the substituent to which the prefix is attached is replaced with independently selected halogen radicals, i.e., each hydrogen radical on the substituent is replaced with a halogen radical. If all the halogen radicals are identical, the prefix typically will identify the halogen radical. Thus, for example, the term “perfluoro” means that every hydrogen radical on the substituent to which the prefix is attached is substituted with a fluorine radical. To illustrate, the term “perfluoroalkyl” means an alkyl substituent wherein a fluorine radical is in the place of each hydrogen radical.


The term “carbonyl” (alone or in combination with another term(s)) means —C(O)—.


The term “aminocarbonyl” (alone or in combination with another term(s)) means —C(O)—NH2.


The term “oxo” (alone or in combination with another term(s)) means (═O).


The term “oxy” (alone or in combination with another term(s)) means an ether substituent, and may be depicted as —O—.


The term “alkylhydroxy” (alone or in combination with another term(s)) means alkyl-OH.


The term “alkylamino” (alone or in combination with another term(s)) means alkyl-NH2.


The term “alkyloxy” (alone or in combination with another term(s)) means an alkylether substituent, i.e., —O-alkyl. Examples of such a substituent include methoxy (—O—CH3), ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, and tert-butoxy.


The term “alkylcarbonyl” (alone or in combination with another term(s)) means —C(O)-alkyl.


The term “aminoalkylcarbonyl” (alone or in combination with another term(s)) means —C(O)-alkyl-NH2.


The term “alkyloxycarbonyl” (alone or in combination with another term(s)) means —C(O)—O-alkyl.


The term “carbocyclylcarbonyl” (alone or in combination with another term(s)) means —C(O)-carbocyclyl.


Similarly, the term “heterocyclylcarbonyl” (alone or in combination with another term(s)) means —C(O)-heterocyclyl.


The term “carbocyclylalkylcarbonyl” (alone or in combination with another term(s)) means —C(O)-alkyl-carbocyclyl.


Similarly, the term “heterocyclylalkylcarbonyl” (alone or in combination with another term(s)) means —C(O)-alkyl-heterocyclyl.


The term “carbocyclyloxycarbonyl” (alone or in combination with another term(s)) means —C(O)—O-carbocyclyl.


The term “carbocyclylalkyloxycarbonyl” (alone or in combination with another term(s)) means —C(O)—O-alkyl-carbocyclyl.


The term “thio” or “thia” (alone or in combination with another term(s)) means a thiaether substituent, i.e., an ether substituent wherein a divalent sulfur atom is in the place of the ether oxygen atom. Such a substituent may be depicted as —S—. This, for example, “alkyl-thio-alkyl” means alkyl-S-alkyl (alkyl-sulfanyl-alkyl).


The term “thiol” or “sulfhydryl” (alone or in combination with another term(s)) means a sulfhydryl substituent, and may be depicted as —SH.


The term “(thiocarbonyl)” (alone or in combination with another term(s)) means a carbonyl wherein the oxygen atom has been replaced with a sulfur. Such a substituent may be depicted as —C(S)—.


The term “sulfonyl” (alone or in combination with another term(s)) means —S(O)2—.


The term “aminosulfonyl” (alone or in combination with another term(s)) means —S(O)2—NH2.


The term “sulfinyl” or “sulfoxido” (alone or in combination with another term(s)) means —S(O)—.


The term “heterocyclyl” (alone or in combination with another term(s)) means a saturated (i.e., “heterocycloalkyl”), partially saturated (i.e., “heterocycloalkenyl”), or completely unsaturated (i.e., “heteroaryl”) ring structure containing a total of 3 to 20 ring atoms. At least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen, and sulfur. A heterocyclyl may be a single-ring (monocyclic) or polycyclic ring structure.


A heterocyclyl may be a single ring, which typically contains from 3 to 7 ring atoms, more typically from 3 to 6 ring atoms, and even more typically 5 to 6 ring atoms. Examples of single-ring heterocyclyls include 1,2,3,6-tetrahydropyridine, thiomorpholinyl, tetrahydropyranyl, furanyl, dihydrofuranyl, tetrahydrofuranyl, thiophenyl (thiofuranyl), dihydrothiophenyl, tetrahydrothiophenyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrrolidin-2-onyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, triazolyl, tetrazolyl, oxazolyl, oxazolidinyl, isoxazolidinyl, isoxazolyl, thiazolyl, isothiazolyl, thiazolinyl, isothiazolinyl, thiazolidinyl, isothiazolidinyl, thiodiazolyl, oxadiazolyl (including 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl(furazanyl), or 1,3,4-oxadiazolyl), oxatriazolyl (including 1,2,3,4-oxatriazolyl or 1,2,3,5-oxatriazolyl), dioxazolyl (including 1,2,3-dioxazolyl, 1,2,4-dioxazolyl, 1,3,2-dioxazolyl, or 1,3,4-dioxazolyl), oxathiazolyl, oxathiolyl, oxathiolanyl, pyranyl, dihydropyranyl, thiopyranyl, tetrahydrothiopyranyl, pyridinyl (azinyl), piperidinyl, diazinyl (including pyridazinyl (1,2-diazinyl), pyrimidinyl (1,3-diazinyl), or pyrazinyl (1,4-diazinyl)), piperazinyl, pyrrolidin-2-only, triazinyl (including 1,3,5-triazinyl, 1,2,4-triazinyl, and 1,2,3-triazinyl)), oxazinyl (including 1,2-oxazinyl, 1,3-oxazinyl, or 1,4-oxazinyl)), oxathiazinyl (including 1,2,3-oxathiazinyl, 1,2,4-oxathiazinyl, 1,2,5-oxathiazinyl, or 1,2,6-oxathiazinyl)), oxadiazinyl (including 1,2,3-oxadiazinyl, 1,2,4-oxadiazinyl, 1,4,2-oxadiazinyl, or 1,3,5-oxadiazinyl)), morpholinyl, azepinyl, oxepinyl, thiepinyl, diazepinyl, thiomorpholinyl, tetrahydrothiophenyl 1,1-dioxidyl, tetrahydro-2H-thiopyranyl, 1,1-dioxidyl, oxetanyl, azetidinyl, thiazolyl, azepanyl, azepan-2-onyl, and dioxolayl (including 1,3-dioxolanyl).


A heterocyclyl may alternatively be polycyclic (i.e., may contain more than one ring). Examples of polycyclic heterocyclyls include bridged, fused, and spirocyclic heterocyclyls. In a spirocyclic heterocyclyl, one atom is common to two different rings. In a bridged heterocyclyl, the rings share at least two common non-adjacent atoms. In a fused-ring heterocyclyl, two or more rings may be fused together, such that two rings share one common bond. Examples of fused ring heterocyclyls containing two, three or four rings include hexahydro-furo[3,4-c]pyrrole, hexahydro-furo[3,4-b]pyrrole, octahydro-pyrrolo[3,4-b]pyridine, octahydro-pyrrolo[3,4-c]pyridine, (3aR,6aR)-5-methyl-octahydro-pyrrolo[3,4-b]pyrrole, (3aR,6aR)-octahydro-pyrrolo[3,4-b]pyrrole, 6-methyl-2,6-diazabicyclo[3.2.0]heptane, (3aS,6aR)-2-methyl-octahydro-pyrrolo[3,4-c]pyrrole, decahydro-[1,5]naphthyridine, 2,3-dihydrobenzofuranyl, 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indolyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, isoindolin-1-onyl, phthalazin-1(2H)-onyl, isoquinolinyl, isoquinolin-1(2H)-onyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, fluorophthalazin-1(2H)-onyl, (Z)-3H-benzo[d][1,2]diazepin-4(5H)-onyl, (trifluoromethyl)phthalazin-1(2H)-onyl, pyrrolo[1,2-d][1,2,4]triazin-1(2H)-onyl, 1,2,3,4-tetrahydroisoquinolinyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, indolizinyl, pyranopyrrolyl, 4H-quinolizinyl, purinyl, naphthyridinyl, pyridopyridinyl (including pyrido[3,4-b]-pyridinyl, pyrido[3,2-b]-pyridinyl, or pyrido[4,3-b]-pyridinyl), pteridinyl, 4,5,6,7-tetrahydro-indolyl, 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazinyl, 6,7-dihydropyrrolo[3,4-d]pyrimidinyl, 6,7-dihydropyrrolo[3,4-b]pyridinyl, 2,3-dihydropyrrolo[3,4-c]pyridinyl, 6,7-dihydrobenzofuran-4(5H)-onyl, indolinyl, benzo[d][1,3]dioxolyl, isoquinolinyl, indolyl, quinolin-2(1H)-onyl, benzo[d]imidazolyl, 1,2,3,4-tetrahydrocyclobuta[c]quinolinyl, 1,2-dihydrocyclobuta[c]quinolin-3(4H)-onyl, and 3,3a,4,4a-tetrahydro-2H-furo[2′,3′:2,3]cyclobuta[1,2-c]quinolin-5(6H)-onyl. Other examples of fused-ring heterocyclyls include benzo-fused heterocyclyls, such as benzimidazolyl, benzo[d][1,3]dioxolyl, indolyl, isoindolyl (isobenzazolyl, pseudoisoindolyl), indoleninyl (pseudoindolyl), isoindazolyl (benzpyrazolyl), benzazinyl (including quinolinyl (1-benzazinyl) or isoquinolinyl (2-benzazinyl)), phthalazinyl, quinoxalinyl, quinazolinyl, benzodiazinyl (including cinnolinyl (1,2-benzodiazinyl) or quinazolinyl (1,3-benzodiazinyl)), benzopyranyl (including chromanyl or isochromanyl), benzoxazinyl (including 1,3,2-benzoxazinyl, 1,4,2-benzoxazinyl, 2,3,1-benzoxazinyl, or 3,1,4-benzoxazinyl), benzisoxazinyl (including 1,2-benzisoxazinyl or 1,4-benzisoxazinyl), isoindolin-1-onyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, 1,2,3,4-tetrahydroisoquinolinyl, quinolin-2(1H)-onyl, benzo[d]imidazolyl, 2,3,4,9-tetrahydro-pyrido[3,4-b]indolyl, 1,2,3,4-tetrahydrocyclobuta[c]quinolinyl, 1,2-dihydrocyclobuta[c]quinolin-3(4H)-onyl, and 3,3a,4,4a-tetrahydro-2H-furo[2′,3′:2,3]cyclobuta[1,2-c]quinolin-5(6H)-onyl. Examples of spirocyclic heterocyclyls include 1,4-dioxa-8-azaspiro[4.5]decanyl, 2-oxa-6-aza-spiro[3.3]heptanyl, bicyclo[2.2.1]heptan-2-only, 6-oxa-1-aza-spiro[3.3]heptanyl, 2-oxa-7-aza-spiro[3.5]nonanyl, 2-oxa-6-aza-spiro[3.5]nonanyl, 2-oxa-5-aza-spiro[3.5]nonanyl, 2-oxa-6-aza-spiro[3.4]octanyl, 2-oxa-5-aza-spiro[3.4]octanyl, 2,7-diazaspiro[3.5]nonane, 1,4-dioxa-8-azaspiro[4.5]decanyl, 2-oxa-9-azaspiro[5.5]undecanyl, 2,9-diazaspiro[5.5]undecanyl, 2,8-diazaspiro[5.5]undecanyl, 1-oxa-8-azaspiro[5.5]undecanyl, 1,8-diazaspiro[5.5]undecanyl, 3,9-diazaspiro[5.5]undecanyl, 1-oxa-4,8-diazaspiro[5.5]undecanyl, 1,8-diazaspiro[4.6]undecanyl, 1-oxa-8-azaspiro[4.5]decanyl, 2,7-diazaspiro[4.5]decanyl, 1,8-diazaspiro[4.5]decanyl, 2,8-diazaspiro[4.5]decanyl, 2,6-diazaspiro[4.5]decanyl, 1,4-dioxaspiro[4.5]decanyl, 1,7-diazaspiro[4.4]nonanyl, 2,7-diazaspiro[4.4]nonanyl, 2,5-diazaspiro[3.5]nonanyl, 2,6-diazaspiro[3.5]nonanyl, 1,7-diazaspiro[3.5]nonanyl, 6-oxa-2-azaspiro[3.5]nonanyl, 1,6-diazaspiro[3.5]nonanyl, 2,6-diazaspiro[3.4]octanyl, 6-oxa-2-azaspiro[3.4]octanyl, 5-oxa-2-azaspiro[3.4]octanyl, and 2,6-diazaspiro[3.3]heptanyl.


The term “heterocycloalkyl” (alone or in combination with another term(s)) means a saturated heterocyclyl. Examples of heterocycloalkyls include piperidine, tetrahydropyranyl, piperazinyl, morpholinyl, azepan-2-oneyl, pyrrolidinyl, 1,3-dioxolanyl, tetrahydrofuranyl, pyrrolidin-2-onyl, oxetanyl, azetidinyl, 2-oxa-9-azaspiro[5.5]undecanyl, 2,9-diazaspiro[5.5]undecanyl, 2,8-diazaspiro[5.5]undecanyl, 1-oxa-8-azaspiro[5.5]undecanyl, 1,8-diazaspiro[5.5]undecanyl, 3,9-diazaspiro[5.5]undecanyl, 1-oxa-4,8-diazaspiro[5.5]undecanyl, 1,8-diazaspiro[4.6]undecanyl, 1-oxa-8-azaspiro[4.5]decanyl, 2,7-diazaspiro[4.5]decanyl, 1,8-diazaspiro[4.5]decanyl, 2,8-diazaspiro[4.5]decanyl, 2,6-diazaspiro[4.5]decanyl, 1,4-dioxaspiro[4.5]decanyl, 1,7-diazaspiro[4.4]nonanyl, 2,7-diazaspiro[4.4]nonanyl, 2,5-diazaspiro[3.5]nonanyl, 2,6-diazaspiro[3.5]nonanyl, 1,7-diazaspiro[3.5]nonanyl, 6-oxa-2-azaspiro[3.5]nonanyl, 1,6-diazaspiro[3.5]nonanyl, 2,6-diazaspiro[3.4]octanyl, 6-oxa-2-azaspiro[3.4]octanyl, 5-oxa-2-azaspiro[3.4]octanyl, bicyclo[2.2.1]heptan-2-onyl, 1,4-dioxa-8-azaspiro[4.5]decanyl, 2,7-diazaspiro[3.5]nonanyl and 2,6-diazaspiro[3.3]heptanyl.


The term “heteroaryl” (alone or in combination with another term(s)) means an aromatic heterocyclyl containing from 5 to 14 ring atoms. A heteroaryl may be monocyclic or polycyclic (i.e., may contain more than one ring). In the case of a polycyclic heteroaryl, only one heterocyclyl ring in the polycyclic system is required to be unsaturated while the remaining ring(s) may be saturated, partially saturated or unsaturated. Examples of heteroaryl substituents include: 6-membered ring substituents such as pyridyl, pyrazyl, pyrrolyl, isoxazolyl, 1,2,3-triazolyl, pyrimidinyl, pyridazinyl, and 1,3,5-, 1,2,4- or 1,2,3-triazinyl; 5-membered ring substituents such as imidazyl, furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,3-, 1,2,4-, 1,2,5-, and 1,3,4-, oxadiazolyl and isothiazolyl; 6/5-membered fused ring substituents such as indolyl, benzothiofuranyl, benzisoxazolyl, benzoxazolyl, purinyl, 4,5,6,7-tetrahydro-indolyl, furo[3,2-c]pyridinyl, pyrrolo[1,2-d][1,2,4]triazin-1(2H)-onyl, thieno[3,2-c]pyridinyl, 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazinyl, benzo[d]imidazolyl, 6,7-dihydro-pyrrolo[3,4-d]pyrimidinyl, 6,7-dihydro-pyrrolo[3,4-b]pyridinyl, 2,3-dihydro-pyrrolo[3,4-c]pyridinyl, 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazinyl, 6,7-dihydrobenzofuran-4(5H)-onyl, 6,7-dihydrobenzofuran-4(5H)-onyl, and indolyl; 6/6-membered fused rings such as benzopyranyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, benzoxazinyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, phthalazin-1(2H)-onyl, isoquinolin-1(2H)-onyl, and quinolin-2(1H)-onyl; 6/5/6 membered rings such as 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indolyl, and 1,2-dihydrocyclobuta[c]quinolin-3(4H)-onyl; and 6/6/4/5 membered rings such as 2,3,4,9-tetrahydro-pyrido[3,4-b]indolyl.


A prefix attached to a multi-component substituent only applies to the first component. To illustrate, the term “alkylcycloalkyl” contains two components: alkyl and cycloalkyl. Thus, the C1-C6— prefix on C1-C6-alkylcycloalkyl means that the alkyl component of the alkylcycloalkyl contains from 1 to 6 carbon atoms; the C1-C6-prefix does not describe the cycloalkyl component. To illustrate further, the prefix “halo” on haloalkyloxyalkyl indicates that only the alkyloxy component of the alkyloxyalkyl substituent is substituted with one or more halogen radicals. If halogen substitution may alternatively or additionally occur on the alkyl component, the substituent would instead be described as “halogen-substituted alkyloxyalkyl” rather than “haloalkyloxyalkyl.” And finally, if the halogen substitution may only occur on the alkyl component, the substituent would instead be described as “alkyloxyhaloalkyl.”


The terms “treat”, “treating” and “treatment” refer to a method of alleviating or abrogating a disease and/or its attendant symptoms.


The terms “prevent”, “preventing” and “prevention” refer to a method of preventing the onset of a disease and/or its attendant symptoms or barring a subject from acquiring a disease. As used herein, “prevent”, “preventing” and “prevention” also include delaying the onset of a disease and/or its attendant symptoms and reducing a subject's risk of acquiring a disease.


The term “therapeutically effective amount” refers to that amount of the compound being administered sufficient to prevent development of or alleviate to some extent one or more of the symptoms of the condition or disorder being treated.


The term “modulate” refers to the ability of a compound to increase or decrease the function, or activity, of a kinase. “Modulation”, as used herein in its various forms, is intended to encompass antagonism, agonism, partial antagonism and/or partial agonism of the activity associated with kinase. Kinase inhibitors are compounds that, e.g., bind to, partially or totally block stimulation, decrease, prevent, delay activation, inactivate, desensitize, or down regulate signal transduction. Kinase activators are compounds that, e.g., bind to, stimulate, increase, open, activate, facilitate, enhance activation, sensitize or up regulate signal transduction.


The term “composition” as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By “pharmaceutically acceptable” it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.


The “subject” is defined herein to include animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In preferred embodiments, the subject is a human.


Isotope Enriched or Labeled Compounds

Compounds of the invention can exist in isotope-labeled or -enriched form containing one or more atoms having an atomic mass or mass number different from the atomic mass or mass number most abundantly found in nature. Isotopes can be radioactive or non-radioactive isotopes. Isotopes of atoms such as hydrogen, carbon, phosphorous, sulfur, fluorine, chlorine, and iodine include, but are not limited to, 2H, 3H, 13C, 14C, 15N, 18O, 32P, 35S, 36Cl, and 125I. Compounds that contain other isotopes of these and/or other atoms are within the scope of this invention.


In another embodiment, the isotope-labeled compounds contain deuterium (2H), tritium (3H) or 14C isotopes. Isotope-labeled compounds of this invention can be prepared by the general methods well known to persons having ordinary skill in the art. Such isotope-labeled compounds can be conveniently prepared by carrying out the procedures disclosed in the Examples disclosed herein and Schemes by substituting a readily available isotope-labeled reagent for a non-labeled reagent. In some instances, compounds may be treated with isotope-labeled reagents to exchange a normal atom with its isotope, for example, hydrogen for deuterium can be exchanged by the action of a deuteric acid such as D2SO4/D2O. In addition to the above, relevant procedures and intermediates are disclosed, for instance, in Lizondo, J et al., Drugs Fut, 21(11), 1116 (1996); Brickner, S J et al., J Med Chem, 39(3), 673 (1996); Mallesham, B et al., Org Lett, 5(7), 963 (2003); PCT publications WO1997010223, WO2005099353, WO1995007271, WO2006008754; U.S. Pat. Nos. 7,538,189; 7,534,814; 7,531,685; 7,528,131; 7,521,421; 7,514,068; 7,511,013; and US Patent Application Publication Nos. 20090137457; 20090131485; 20090131363; 20090118238; 20090111840; 20090105338; 20090105307; 20090105147; 20090093422; 20090088416; and 20090082471, the methods are hereby incorporated by reference.


The isotope-labeled compounds of the invention may be used as standards to determine the effectiveness of Bcl-2 inhibitors in binding assays. Isotope containing compounds have been used in pharmaceutical research to investigate the in vivo metabolic fate of the compounds by evaluation of the mechanism of action and metabolic pathway of the nonisotope-labeled parent compound (Blake et al. J. Pharm. Sci. 64, 3, 367-391 (1975)). Such metabolic studies are important in the design of safe, effective therapeutic drugs, either because the in vivo active compound administered to the patient or because the metabolites produced from the parent compound prove to be toxic or carcinogenic (Foster et al., Advances in Drug Research Vol. 14, pp. 2-36, Academic press, London, 1985; Kato et al., J. Labelled Comp. Radiopharmaceut., 36(10):927-932 (1995); Kushner et al., Can. J. Physiol. Pharmacol., 77, 79-88 (1999).


In addition, non-radio active isotope containing drugs, such as deuterated drugs called “heavy drugs,” can be used for the treatment of diseases and conditions related to Bcl-2 activity. Increasing the amount of an isotope present in a compound above its natural abundance is called enrichment. Examples of the amount of enrichment include from about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 21, 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71, 75, 79, 84, 88, 92, 96, to about 100 mol %. Replacement of up to about 15% of normal atom with a heavy isotope has been effected and maintained for a period of days to weeks in mammals, including rodents and dogs, with minimal observed adverse effects (Czajka D M and Finkel A J, Ann. N.Y. Acad. Sci. 1960 84: 770; Thomson J F, Ann. New York Acad. Sci 1960 84: 736; Czakja D M et al., Am. J. Physiol. 1961 201: 357). Acute replacement of as high as 15%-23% in human fluids with deuterium was found not to cause toxicity (Blagojevic N et al. in “Dosimetry & Treatment Planning for Neutron Capture Therapy”, Zamenhof R, Solares G and Harling 0 Eds. 1994. Advanced Medical Publishing, Madison Wis. pp. 125-134; Diabetes Metab. 23: 251 (1997)).


Stable isotope labeling of a drug can alter its physico-chemical properties such as pKa and lipid solubility. These effects and alterations can affect the pharmacodynamic response of the drug molecule if the isotopic substitution affects a region involved in a ligand-receptor interaction. While some of the physical properties of a stable isotope-labeled molecule are different from those of the unlabeled one, the chemical and biological properties are the same, with one important exception: because of the increased mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than the same bond between the light isotope and that atom. Accordingly, the incorporation of an isotope at a site of metabolism or enzymatic transformation will slow said reactions potentially altering the pharmacokinetic profile or efficacy relative to the non-isotopic compound.


Compounds

Suitable groups for X1, X2, X3, and R2 in compounds of Formula (I) are independently selected. The described embodiments of the present invention may be combined. Such combination is contemplated and within the scope of the present invention. For example, it is contemplated that embodiments for any of X1, X2, X3, and R2 can be combined with embodiments defined for any other of X1, X2, X3, and R2.


Embodiments of Formula (I)

One embodiment of this invention, therefore, pertains to compounds or pharmaceutically acceptable salts, which are useful as inhibitors of NAMPT, the compounds having Formula (I)




embedded image


wherein


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R2 is alkyl, alkenyl, alkynyl, phenyl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, CO(O)R4, OC(O)R4, OC(O)OR4, NH2, NHR4, N(R4)2, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each phenyl is optionally substituted at the para position with one independently selected R5, OCH2CH2CH2CH2CH2CH3, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, Br or I; wherein each phenyl is optionally substituted with one F; wherein each heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more independently selected R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein R2 is not 4-methylphenyl;


R3 is alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R4 is alkyl, alkenyl, alkynyl, aryl or heterocyclyl; wherein each alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, CO(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, N(R7)2, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each aryl and heterocycyl is optionally substituted with one or more independently selected R8, ORB, SR8, S(O)R8, SO2R8, C(O)R8, CO(O)R8, OC(O)R8, OC(O)OR8, NH2, NHR8, N(R8)2, NHC(O)R8, NR8C(O)R8, NHS(O)2R8, NR8S(O)2R8, NHC(O)OR8, NR8C(O)OR8, NHC(O)NH2, NHC(O)NHR8, NHC(O)N(R8)2, NR8C(O)NHR8, NR8C(O)N(R8)2, C(O)NH2, C(O)NHR8, C(O)N(R8)2, C(O)NHOH, C(O)NHOR8, C(O)NHSO2R8, C(O)NR8SO2R8, SO2NH2, SO2NHR8, SO2N(R8)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R7 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R11, OR11, SR11, S(O)R11, SO2R11, NHR11, N(R11)2, C(O)R11, C(O)NH2, C(O)NHR11, SO2N(R11)2, NHC(O)NH2, NHC(O)NHR11, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R8 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R12, OR12, SR12, S(O)R12, SO2R12, NHR12, N(R12)2, C(O)R12, C(O)NH2, C(O)NHR12, C(O)N(R12)2, NHC(O)R12, NR12C(O)R12, NHSO2R12, NHC(O)OR12, SO2NH2, SO2NHR12, SO2N(R12)2, NHC(O)NH2, NHC(O)NHR12, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected OCH3, or aryl;


R10 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


R11 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


R12 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R5, R6, R7, R8, R9, R19, R11, and R12 are optionally substituted with one or more independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13 is alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, cycloalkyl, or cycloalkenyl; wherein each alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, CO(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; and


R15 is alkyl.


In one embodiment of Formula (I), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N. In another embodiment of Formula (I), X1, X2, and X3 are CH. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (I), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is N.


In another embodiment of Formula (I), R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (I), R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), R1 is C(O)NH2. In another embodiment of Formula (I), R1 is F. In another embodiment of Formula (I), R1 is Cl. In another embodiment of Formula (I), R1 is Br. In another embodiment of Formula (I), R1 is CN. In another embodiment of Formula (I), R1 is NH2. In another embodiment of Formula (I), R1 is NO2. In another embodiment of Formula (I), R1 is CF3. In another embodiment of Formula (I), R1 is C(O)OH.


In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (I), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH.


In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (I), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH.


In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (I), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH.


In one embodiment of Formula (I),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N;


R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH;


R2 is alkyl, phenyl, heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R4, OR4, C(O)R4, CO(O)R4, NHC(O)R4, C(O)NHR4, F, Cl, Br or I; each phenyl is optionally substituted at the para position with one independently selected R5, OCH2CH2CH2CH2CH2CH3, C(O)R5, NHR5, NHC(O)R5, C(O)NH2, C(O)NHR5, C(O)N(R5)2, or CF3; wherein each phenyl is optionally substituted with one F; wherein each heterocyclyl is optionally substituted with one or more independently selected R5, C(O)R5, NHC(O)R5, C(O)NHR5, F, Cl, Br or I; wherein R2 is not 4-methylphenyl;


R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, OH, F, Cl, Br or I;


R4 is alkyl, aryl or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R7, F, Cl, Br or I; wherein each aryl and heterocycyl is optionally substituted with one or more independently selected R8, C(O)R8, F, Cl, Br or I;


R5 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, or cycloalkyl; wherein each alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R9, OR9, SR9, C(O)R9, NH2, N(R9)2, NHC(O)R9, C(O)NH2, C(O)OH, OH, CN, CF3, F, Cl, Br or I;


R6 is alkyl or heterocyclyl;


R7 is aryl;


R8 is alkyl, aryl, or heterocyclyl;


R9 is alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each alkyl is optionally substituted with one or more independently selected OCH3, or aryl;


wherein the cyclic moieties represented by R3, R5, R6, R7, R8, and R9 are optionally substituted with one or more independently selected R13, OR13SO2R13, C(O)R13, CO(O)R13, NH2, N(R13)2, NHC(O)R13, NHC(O)OR13, C(O)NH2, C(O)N(R13)2, OH, CN, CF3, OCF3, SCF3, F, Cl, Br or I;


R13 is alkyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, or pyrrolidin-2-onyl, wherein each alkyl is optionally substituted with one or more independently selected R14, OR14, NH2, OH, F, Cl, Br or I; wherein each aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more independently selected R15, OR15, C(O)R15, CN, CF3, F, Cl, Br or I;


R14 is alkyl, aryl, or cycloalkyl; wherein each alkyl is optionally substituted with one or more independently selected OH, F, Cl, Br or I; and


R15 is alkyl.


Still another embodiment pertains to compounds having Formula (I), which include Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, and pharmaceutically acceptable salts thereof.


Embodiments of Formula (II)

In another aspect, the present invention provides compounds of Formula (II)




embedded image


or pharmaceutically acceptable salts thereof; wherein X1, X2, X3, are as described herein for Formula (I); and R2 is phenyl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein the phenyl, heterocyclyl, cycloalkyl, and cycloalkenyl are optionally substituted as described herein for Formula (I).


In one embodiment of Formula (II), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N. In another embodiment of Formula (II), X1, X2, and X3 are CH. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (II), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is N.


In another embodiment of Formula (II), R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (II), R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), R1 is C(O)NH2. In another embodiment of Formula (II), R1 is F. In another embodiment of Formula (II), R1 is Cl. In another embodiment of Formula (II), R1 is Br. In another embodiment of Formula (II), R1 is CN. In another embodiment of Formula (II), R1 is NH2. In another embodiment of Formula (II), R1 is NO2. In another embodiment of Formula (II), R1 is CF3. In another embodiment of Formula (II), R1 is C(O)OH.


In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (II), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH.


In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (II), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH.


In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (II), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH.


In one embodiment of Formula (II),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N;


R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH;


R2 is phenyl, or heterocyclyl; wherein each phenyl is optionally substituted at the para position with one independently selected R5, OCH2CH2CH2CH2CH2CH3, C(O)R5, NHR5, NHC(O)R5, C(O)NH2, C(O)NHR5, C(O)N(R5)2, or CF3; wherein each phenyl is optionally substituted with one F; wherein each heterocyclyl is optionally substituted with one or more independently selected R5, C(O)R5, NHC(O)R5, C(O)NHR5, F, Cl, Br or I; wherein R2 is not 4-methylphenyl;


R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, OH, F, Cl, Br or I;


R5 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, or cycloalkyl; wherein each alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R9, OR9, SR9, C(O)R9, NH2, N(R9)2, NHC(O)R9, C(O)NH2, C(O)OH, OH, CN, CF3, F, Cl, Br or I;


R6 is alkyl or heterocyclyl;


R9 is alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each alkyl is optionally substituted with one or more independently selected OCH3, or aryl;


wherein the cyclic moieties represented by R3, R5, R6, and R9 are optionally substituted with one or more independently selected R13, OR13SO2R13, C(O)R13, CO(O)R13, NH2, N(R13)2, NHC(O)R13, NHC(O)OR13, C(O)NH2, C(O)N(R13)2, OH, CN, CF3, OCF3, SCF3, F, Cl, Br or I;


R13 is alkyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, or pyrrolidin-2-onyl, wherein each alkyl is optionally substituted with one or more independently selected R14, OR14, NH2, OH, F, Cl, Br or I; wherein each aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more independently selected R15, OR15, C(O)R15, CN, CF3, F, Cl, Br or I;


R14 is alkyl, aryl, or cycloalkyl; wherein each alkyl is optionally substituted with one or more independently selected OH, F, Cl, Br or I; and


R15 is alkyl.


Still another embodiment pertains to compounds having Formula (II), which include Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 452, 453, 454, 455, and pharmaceutically acceptable salts thereof.


Embodiments of Formula (III)

In another aspect, the present invention provides compounds of Formula (III)




embedded image


or pharmaceutically acceptable salts thereof; wherein X1, X2, X3, are as described herein for Formula (I); and Rx is as described herein for Formula (I) when R2 is phenyl.


In one embodiment of Formula (III), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N. In another embodiment of Formula (III), X1, X2, and X3 are CH. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (III), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is N.


In another embodiment of Formula (III), R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (III), R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), R1 is C(O)NH2. In another embodiment of Formula (III), R1 is F. In another embodiment of Formula (III), R1 is Cl. In another embodiment of Formula (III), R1 is Br. In another embodiment of Formula (III), R1 is CN. In another embodiment of Formula (III), R1 is NH2. In another embodiment of Formula (III), R1 is NO2. In another embodiment of Formula (III), R1 is CF3. In another embodiment of Formula (III), R1 is C(O)OH.


In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (III), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH.


In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (III), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH.


In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (III), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH.


In another embodiment of Formula (III), Rx is phthalazin-1(2H)-onyl, isoquinolinyl, isoquinolin-1(2H)-onyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, 5-fluorophthalazin-1(2H)-onyl, (Z)-3H-benzo[d][1,2]diazepin-4(5H)-onyl, 5-(trifluoromethyl)phthalazin-1(2H)-onyl, or pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one.


In one embodiment of Formula (III),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N;


R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH;


Rx is R5, OCH2CH2CH2CH2CH2CH3, C(O)R5, NHR5, NHC(O)R5, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CF3 or F;


R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, OH, F, Cl, Br or I;


R5 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, or cycloalkyl; wherein each alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R9, OR9, SR9, C(O)R9, NH2, N(R9)2, NHC(O)R9, C(O)NH2, C(O)OH, OH, CN, CF3, F, Cl, Br or I;


R6 is alkyl or heterocyclyl;


R9 is alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each alkyl is optionally substituted with one or more independently selected OCH3, or aryl;


wherein the cyclic moieties represented by R3, R5, R6, and R9 are optionally substituted with one or more independently selected R13, OR13SO2R13, C(O)R13, CO(O)R13, NH2, N(R13)2, NHC(O)R13, NHC(O)OR13, C(O)NH2, C(O)N(R13)2, OH, CN, CF3, OCF3, SCF3, F, Cl, Br or I;


R13 is alkyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, or pyrrolidin-2-onyl, wherein each alkyl is optionally substituted with one or more independently selected R14, OR14, NH2, OH, F, Cl, Br or I; wherein each aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more independently selected R15, OR15, C(O)R15, CN, CF3, F, Cl, Br or I;


R14 is alkyl, aryl, or cycloalkyl; wherein each alkyl is optionally substituted with one or more independently selected OH, F, Cl, Br or I; and


R15 is alkyl.


Still another embodiment pertains to compounds having Formula (III), which include Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 330, 331, 332, 333, 336, 337, 338, 339, 340, 341, 342, 343, 348, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 547, 548, 549, 550, 551, 552, and pharmaceutically acceptable salts thereof.


Embodiments of Formula (IV)

In another aspect, the present invention provides compounds of Formula (IV)




embedded image


or pharmaceutically acceptable salts thereof; wherein X1, X2, X3, and R5 are as described herein for Formula (I).


In one embodiment of Formula (IV), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N. In another embodiment of Formula (IV), X1, X2, and X3 are CH. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (IV), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is N.


In another embodiment of Formula (IV), R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IV), R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), R1 is C(O)NH2. In another embodiment of Formula (IV), R1 is F. In another embodiment of Formula (IV), R1 is Cl. In another embodiment of Formula (IV), R1 is Br. In another embodiment of Formula (IV), R1 is CN. In another embodiment of Formula (IV), R1 is NH2. In another embodiment of Formula (IV), R1 is NO2. In another embodiment of Formula (IV), R1 is CF3. In another embodiment of Formula (IV), R1 is C(O)OH.


In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (IV), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH.


In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (IV), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH.


In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (IV), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH.


In one embodiment of Formula (IV),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N;


R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH;


R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, OH, F, Cl, Br or I;


R5 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, or cycloalkyl; wherein each alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R9, OR9, SR9, C(O)R9, NH2, N(R9)2, NHC(O)R9, C(O)NH2, C(O)OH, OH, CN, CF3, F, Cl, Br or I;


R6 is alkyl or heterocyclyl;


R9 is alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each alkyl is optionally substituted with one or more independently selected OCH3, or aryl;


wherein the cyclic moieties represented by R3, R5, R6, and R9 are optionally substituted with one or more independently selected R13, OR13SO2R13, C(O)R13, CO(O)R13, NH2, N(R13)2, NHC(O)R13, NHC(O)OR13, C(O)NH2, C(O)N(R13)2, OH, CN, CF3, OCF3, SCF3, F, Cl, Br or I;


R13 is alkyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, or pyrrolidin-2-onyl, wherein each alkyl is optionally substituted with one or more independently selected R14, OR14, NH2, OH, F, Cl, Br or I; wherein each aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more independently selected R15, OR15, C(O)R15, CN, CF3, F, Cl, Br or I;


R14 is alkyl, aryl, or cycloalkyl; wherein each alkyl is optionally substituted with one or more independently selected OH, F, Cl, Br or I; and


R15 is alkyl.


Still another embodiment pertains to compounds having Formula (IV), which include Examples 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, and pharmaceutically acceptable salts thereof.


Embodiments of Formula (V)

In another aspect, the present invention provides compounds of Formula (V)




embedded image


or pharmaceutically acceptable salts thereof; wherein X1, X2, X3, and R5 are as described herein for Formula (I).


In one embodiment of Formula (V), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N. In another embodiment of Formula (V), X1, X2, and X3 are CH. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (V), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is N.


In another embodiment of Formula (V), R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (V), R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), R1 is C(O)NH2. In another embodiment of Formula (V), R1 is F. In another embodiment of Formula (V), R1 is Cl. In another embodiment of Formula (V), R1 is Br. In another embodiment of Formula (V), R1 is CN. In another embodiment of Formula (V), R1 is NH2. In another embodiment of Formula (V), R1 is NO2. In another embodiment of Formula (V), R1 is CF3. In another embodiment of Formula (V), R1 is C(O)OH.


In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (V), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH.


In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (V), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH.


In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (V), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH.


In one embodiment of Formula (V),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N;


R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH;


R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, OH, F, Cl, Br or I;


R5 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, or cycloalkyl; wherein each alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R9, OR9, SR9, C(O)R9, NH2, N(R9)2, NHC(O)R9, C(O)NH2, C(O)OH, OH, CN, CF3, F, Cl, Br or I;


R6 is alkyl or heterocyclyl;


R9 is alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each alkyl is optionally substituted with one or more independently selected OCH3, or aryl;


wherein the cyclic moieties represented by R3, R5, R6, and R9 are optionally substituted with one or more independently selected R13, OR13SO2R13, C(O)R13, CO(O)R13, NH2, N(R13)2, NHC(O)R13, NHC(O)OR13, C(O)NH2, C(O)N(R13)2, OH, CN, CF3, OCF3, SCF3, F, Cl, Br or I;


R13 is alkyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, or pyrrolidin-2-onyl, wherein each alkyl is optionally substituted with one or more independently selected R14, OR14, NH2, OH, F, Cl, Br or I; wherein each aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more independently selected R15, OR15, C(O)R15, CN, CF3, F, Cl, Br or I;


R14 is alkyl, aryl, or cycloalkyl; wherein each alkyl is optionally substituted with one or more independently selected OH, F, Cl, Br or I; and


R15 is alkyl.


Still another embodiment pertains to compounds having Formula (V), which include Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 176, 177, 178, 179, 180, 181, 182, 184, 185, 186, 187, 188, 189, 190, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 209, 210, 211, 213, 214, 215, 216, 217, 218, 219, 220, 221, 223, 224, 225, 226, 227, 228, 230, 231, 232, 234, 235, 236, 237, 239, 240, 243, 245, 246, 248, 249, 250, 251, 252, 253, 254, 256, 257, 258, 259, 260, 265, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 373, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 424, 425, 426, 427, 430, 431, 434, 435, 436, 437, 438, 439, 440, 441, 442, 445, 449, 450, and pharmaceutically acceptable salts thereof.


Embodiments of Formula (Ia)

One embodiment of this invention, therefore, pertains to compounds or pharmaceutically acceptable salts, which are useful as inhibitors of NAMPT, the compounds having Formula (Ia)




embedded image


wherein


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R2 is alkyl, alkenyl, alkynyl, phenyl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R2 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, CO(O)R4, OC(O)R4, OC(O)OR4, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R2 phenyl is optionally substituted at the para position with one independently selected R5, OCH2CH2CH2CH2CH2CH3, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, Br or I; wherein each R2 phenyl is optionally additionally substituted with one F; wherein each R2 heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more independently selected R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein R2 is not 4-methylphenyl;


R3 is alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R4 is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, or heterocyclyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R4 aryl and heterocycyl is optionally substituted with one or more independently selected R8, ORB, SR8, S(O)R8, SO2R8, C(O)R8, CO(O)R8, OC(O)R8, OC(O)OR8, NH2, NHR8, NHC(O)R8, NR8C(O)R8, NHS(O)2R8, NR8S(O)2R8, NHC(O)OR8, NR8C(O)OR8, NHC(O)NH2, NHC(O)NHR8, NHC(O)N(R8)2, NR8C(O)NHR8, NR8C(O)N(R8)2, C(O)NH2, C(O)NHR8, C(O)N(R8)2, C(O)NHOH, C(O)NHOR8, C(O)NHSO2R8, C(O)NR8SO2R8, SO2NH2, SO2NHR8, SO2N(R8)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R7 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R7 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R11, OR11, SR11, S(O)R11, SO2R11, NHR11, N(R11)2, C(O)R11, C(O)NH2, C(O)NHR11, C(O)N(R11)2, NHC(O)R11, NR11C(O)R11, NHSO2R11, NHC(O)OR11, SO2NH2, SO2NHR11, SO2N(R11)2, NHC(O)NH2, NHC(O)NHR11, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R8 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R8 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R12, OR12, SR12, S(O)R12, SO2R12, NHR12, N(R12)2, C(O)R12, C(O)NH2, C(O)NHR12, C(O)N(R12)2, NHC(O)R12, NR12C(O)R12, NHSO2R12, NHC(O)OR12, SO2NH2, SO2NHR12, SO2N(R12)2, NHC(O)NH2, NHC(O)NHR12, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected OCH3, OH, aryl, or heterocyclyl;


R10 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


R11 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


R12 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R5, R6, R7, R8, R9, R10, R11, and R12 are optionally substituted with one or more independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13 is alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolyl, thienyl, furanyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolyl, thienyl, furanyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected OCH3, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, or cycloalkenyl is optionally substituted with one or more independently selected alkyl, or OCH3; and


R15 is alkyl;


with the proviso that when R2 is unsubstituted alkyl or optionally substituted alkyl; R2 is C4-C6-alkyl.


In one embodiment of Formula (Ia), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (Ia), X1, X2, and X3 are CH. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (Ia), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (Ia), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (Ia), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (Ia), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (Ia), X1 is N; X2 is CR1; and X3 is N.


In another embodiment of Formula (Ia), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Ia), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), R1 is C(O)NH2. In another embodiment of Formula (Ia), R1 is F. In another embodiment of Formula (Ia), R1 is Cl. In another embodiment of Formula (Ia), R1 is Br. In another embodiment of Formula (Ia), R1 is CN. In another embodiment of Formula (Ia), R1 is NH2. In another embodiment of Formula (Ia), R1 is NO2. In another embodiment of Formula (Ia), R1 is CF3. In another embodiment of Formula (Ia), R1 is C(O)OH. In another embodiment of Formula (Ia), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (Ia), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (Ia), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (Ia), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In one embodiment of Formula (Ia),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N;


R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH;


R2 is alkyl, phenyl, heterocyclyl, wherein each R2 alkyl is optionally substituted with one or more independently selected R4, OR4, C(O)R4, CO(O)R4, NHC(O)R4, C(O)NHR4, or F, Cl, Br or I; wherein each R2 phenyl is optionally substituted at the para position with one independently selected R5, OCH2CH2CH2CH2CH2CH3, C(O)R5, CO(O)R5, NHR5, NHC(O)R5, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOR5, CF3, Br or I; wherein each R2 phenyl is optionally additionally substituted with one F; wherein each R2 heterocyclyl is optionally substituted with one or more independently selected R5, C(O)R5, NHC(O)R5, C(O)NHR5, F, Cl, Br or I; wherein R2 is not 4-methylphenyl;


R3 is alkyl, alkenyl, or heterocyclyl; wherein each R3 alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, OH, F, Cl, Br or I;


R4 is alkyl, aryl, cycloalkyl, or heterocyclyl; wherein each R4 alkyl is optionally substituted with one or more independently selected R7, F, Cl, Br or I; wherein each R4 aryl and heterocycyl is optionally substituted with one or more independently selected R8, C(O)R8, F, Cl, Br or I;


R5 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, or cycloalkyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R9, OR9, SR9, C(O)R9, NH2, N(R9)2, NHC(O)R9, C(O)NH2, C(O)OH, OH, CN, CF3, F, Cl, Br or I;


R6 is alkyl, or heterocyclyl;


R7 is aryl;


R8 is alkyl, aryl, or heterocyclyl;


R9 is alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R9 alkyl is optionally substituted with one or more independently selected OCH3, OH, aryl, or heterocyclyl;


wherein the cyclic moieties represented by R3, R5, R6, R7, R8, and R9, are optionally substituted with one or more independently selected R13, OR13, SO2R13, C(O)R13, CO(O)R13, NH2, N(R13)2, NHC(O)R13, NHC(O)OR13, C(O)NH2, C(O)N(R13)2, OH, CN, CF3, OCF3, SCF3, F, Cl, Br or I;


R13 is alkyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolyl, thienyl, furanyl, or cycloalkyl; wherein each R13 alkyl is optionally substituted with one or more independently selected R14, OR14, NH2, N(R14)2, NHC(O)R14, OH, CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolyl, thienyl, furanyl, and cycloalkyl is optionally substituted with one or more independently selected R15, OR15, SO2R15, C(O)R15, N(R15)2, NHC(O)R15, CN, CF3, F, Cl, Br or I;


R14 is alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R14 alkyl is optionally substituted with one or more independently selected OCH3, OH, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, or cycloalkenyl is optionally substituted with one or more independently selected alkyl, or OCH3; and


R15 is alkyl;


with the proviso that when R2 is unsubstituted alkyl or optionally substituted alkyl; R2 is C4-C6-alkyl.


In another embodiment of Formula (Ia),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N;


R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, CN, NH2, NO2, CF3, or C(O)OH;


R2 is alkyl, phenyl, heterocyclyl, wherein each R2 alkyl is optionally substituted with one or more independently selected R4, OR4, C(O)R4, CO(O)R4, NHC(O)R4, C(O)NHR4, or F, Cl, Br or I; wherein each R2 phenyl is optionally substituted at the para position with one independently selected R5, OCH2CH2CH2CH2CH2CH3, C(O)R5, CO(O)R5, NHR5, NHC(O)R5, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOR5, or CF3; wherein each R2 phenyl is optionally additionally substituted with one F; wherein each R2 heterocyclyl is optionally substituted with one or more independently selected R5, C(O)R5, NHC(O)R5, or C(O)NHR5; wherein R2 is not 4-methylphenyl;


R3 is alkyl, alkenyl, or heterocyclyl; wherein each R3 alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH;


R4 is alkyl, aryl, cycloalkyl, or heterocyclyl; wherein each R4 alkyl is optionally substituted with one or more R7; wherein each R4 aryl and heterocycyl is optionally substituted with one or more independently selected R8, C(O)R8, or Cl;


R5 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, or cycloalkyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R9, OR9, SR9, C(O)R9, NH2, N(R9)2, NHC(O)R9, C(O)NH2, C(O)OH, OH, CN, or CF3;


R6 is alkyl, or heterocyclyl;


R7 is aryl;


R8 is alkyl, aryl, or heterocyclyl;


R9 is alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R9 alkyl is optionally substituted with one or more independently selected OCH3, OH, aryl, or heterocyclyl;


wherein the cyclic moieties represented by R3, R5, R6, R7, R8, and R9, are optionally substituted with one or more independently selected R13, OR13, SO2R13, C(O)R13, CO(O)R13, NH2, N(R13)2, NHC(O)R13, NHC(O)OR13, C(O)NH2, C(O)N(R13)2, OH, CN, CF3, OCF3, SCF3, F, or Cl;


R13 is alkyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolyl, thienyl, furanyl, or cycloalkyl; wherein each R13 alkyl is optionally substituted with one or more independently selected R14, OR14, NH2, N(R14)2, NHC(O)R14, OH, or CF3; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolyl, thienyl, furanyl, and cycloalkyl is optionally substituted with one or more independently selected R15, OR15, SO2R15, C(O)R15, N(R15)2, NHC(O)R15, CN, CF3, F, or Cl;


R14 is alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R14 alkyl is optionally substituted with one or more independently selected OCH3, or OH; wherein each R14 aryl, heterocyclyl, cycloalkyl, or cycloalkenyl is optionally substituted with one or more independently selected alkyl, or OCH3; and


R15 is alkyl;


with the proviso that when R2 is unsubstituted alkyl or optionally substituted alkyl; R2 is C4-C6-alkyl.


Still another embodiment pertains to compounds having Formula (Ia), which include Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 358, 359, 360, 361, 362, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, and pharmaceutically acceptable salts thereof.


Embodiments of Formula (IIa)

In another aspect, the present invention provides compounds of Formula (IIa)




embedded image


or pharmaceutically acceptable salts thereof; wherein X1, X2, X3, are as described herein for Formula (Ia); and R2 is phenyl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein the R2 phenyl, heterocyclyl, cycloalkyl, and cycloalkenyl are optionally substituted as described herein for substituents on R2 in Formula (Ia).


In one embodiment of formula (Ha),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R2 is phenyl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R2 phenyl is optionally substituted at the para position with one independently selected R5, OCH2CH2CH2CH2CH2CH3, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, Br or I; wherein each R2 phenyl is optionally additionally substituted with one F; wherein each R2 heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more independently selected R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein R2 is not 4-methylphenyl;


R3 is alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected OCH3, OH, aryl, or heterocyclyl;


R10 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R5, R6, R9, and R10, are optionally substituted with one or more independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13 is alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolyl, thienyl, furanyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolyl, thienyl, furanyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected OCH3, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, or cycloalkenyl is optionally substituted with one or more independently selected alkyl, or OCH3; and


R15 is alkyl.


In one embodiment of Formula (IIa), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (Ha), X1, X2, and X3 are CH. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (IIa), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (IIa), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (IIa), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (IIa), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (IIa), X1 is N; X2 is CR1; and X3 is N.


In another embodiment of Formula (IIa), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIa), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (BO, R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (BO, R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ha), R1 is C(O)NH2. In another embodiment of Formula (IIa), R1 is F. In another embodiment of Formula (IIa), R1 is Cl. In another embodiment of Formula (BO, R1 is Br. In another embodiment of Formula (IIa), R1 is CN. In another embodiment of Formula (IIa), R1 is NH2. In another embodiment of Formula (IIa), R1 is NO2. In another embodiment of Formula (IIa), R1 is CF3. In another embodiment of Formula (BO, R1 is C(O)OH. In another embodiment of Formula (IIa), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ha), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IIa), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IIa), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (IIa), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


Still another embodiment pertains to compounds having Formula (IIa), which include Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 607, 608, 613, 614, 615, 617, 618, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 682, 683, 684, 685, 686, 687, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, and pharmaceutically acceptable salts thereof.


Embodiments of Formula (IIIa)

In another aspect, the present invention provides compounds of Formula (IIIa)




embedded image


or pharmaceutically acceptable salts thereof; wherein X1, X2, X3, are as described herein for Formula (Ia); and Rx is as described herein for substituents at the para position in Formula (Ia) when R2 is phenyl.


In one embodiment of formula (IIIa),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


Rx is R5, OCH2CH2CH2CH2CH2CH3, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, Br or I; wherein Rx is not 4-methyl;


R3 is alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected OCH3, OH, aryl, or heterocyclyl;


R10 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R5, R6, R9, and R10, are optionally substituted with one or more independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13 is alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolyl, thienyl, furanyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolyl, thienyl, furanyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected OCH3, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, or cycloalkenyl is optionally substituted with one or more independently selected alkyl, or OCH3; and


R15 is alkyl.


In one embodiment of Formula (IIIa), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (IIIa), X1, X2, and X3 are CH. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (IIIa), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (IIIa), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (IIIa), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (IIIa), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (IIIa), X1 is N; X2 is CR1; and X3 is N.


In another embodiment of Formula (IIIa), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIIa), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), R1 is C(O)NH2. In another embodiment of Formula (IIIa), R1 is F. In another embodiment of Formula (IIIa), R1 is Cl. In another embodiment of Formula (IIIa), R1 is Br. In another embodiment of Formula (IIIa), R1 is CN. In another embodiment of Formula (IIIa), R1 is NH2. In another embodiment of Formula (IIIa), R1 is NO2. In another embodiment of Formula (IIIa), R1 is CF3. In another embodiment of Formula (IIIa), R1 is C(O)OH. In another embodiment of Formula (IIIa), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IIIa), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IIIa), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (IIIa), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In one embodiment of formula (IIIa), Rx is R5, OCH2CH2CH2CH2CH2CH3, C(O)R5, CO(O)R5, NHR5, NHC(O)R5, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOR5, or CF3; wherein Rx is not 4-methyl. In another embodiment of formula (IIIa), Rx is R5, NHC(O)R5, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, or C(O)NHOR5; wherein Rx is not 4-methyl. In another embodiment of formula (IIIa), Rx is R5, and R5 is heterocyclyl, which is optionally substituted as described in embodiments herein.


In another embodiment of Formula (III), Rx is phthalazin-1(2H)-onyl, isoquinolinyl, isoquinolin-1(2H)-onyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, 5-fluorophthalazin-1(2H)-onyl, (Z)-3H-benzo[d][1,2]diazepin-4(5H)-onyl, 5-(trifluoromethyl)phthalazin-1(2H)-onyl, pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one, isoindolin-1-onyl, or 1,2,3,6-tetrahydropyridinyl. In another embodiment of Formula (III), Rx is phthalazin-1(2H)-onyl, isoquinolinyl, isoquinolin-1(2H)-onyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, 5-fluorophthalazin-1(2H)-onyl, (Z)-3H-benzo[d][1,2]diazepin-4(5H)-onyl, 5-(trifluoromethyl)phthalazin-1(2H)-onyl, isoindolin-1-onyl, or pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one; which are optionally substituted as defined herein. In another embodiment of Formula (III), Rx is, 2,3,6-tetrahydropyridinyl; which is optionally substituted as defined herein.


Still another embodiment pertains to compounds having Formula (IIIa), which include Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 327, 330, 331, 332, 333, 336, 337, 338, 339, 340, 341, 342, 343, 348, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 543, 544, 545, 546, 547, 548, 549, 553, 554, 555, 556, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 607, 608, 613, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 649, 650, 682, 683, 684, 685, 686, 687, 705, 706, 707, 708, 709, 710, 716, 717, and pharmaceutically acceptable salts thereof.


Still another embodiment pertains to compounds having Formula (IIIa), which include Examples 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 547, 548, 549, 550, 551, 552, and pharmaceutically acceptable salts thereof.


Embodiments of Formula (IVa)

In another aspect, the present invention provides compounds of Formula (IVa)




embedded image


or pharmaceutically acceptable salts thereof; wherein X1, X2, X3, and R5 are as described herein for Formula (Ia).


In one embodiment of formula (IVa),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R3 is alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected OCH3, OH, aryl, or heterocyclyl;


R10 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R5, R6, R9, and R10, are optionally substituted with one or more independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13 is alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolyl, thienyl, furanyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolyl, thienyl, furanyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected OCH3, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, or cycloalkenyl is optionally substituted with one or more independently selected alkyl, or OCH3; and


R15 is alkyl;


with the proviso that when R2 is unsubstituted alkyl or optionally substituted alkyl; R2 is C4-C6-alkyl.


In one embodiment of Formula (IVa), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (IVa), X1, X2, and X3 are CH. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (IVa), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (IVa), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (IVa), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (IVa), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (IVa), X1 is N; X2 is CR1; and X3 is N.


In another embodiment of Formula (IVa), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IVa), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), R1 is C(O)NH2. In another embodiment of Formula (IVa), R1 is F. In another embodiment of Formula (IVa), R1 is Cl. In another embodiment of Formula (IVa), R1 is Br. In another embodiment of Formula (IVa), R1 is CN. In another embodiment of Formula (IVa), R1 is NH2. In another embodiment of Formula (IVa), R1 is NO2. In another embodiment of Formula (IVa), R1 is CF3. In another embodiment of Formula (IVa), R1 is C(O)OH. In another embodiment of Formula (IVa), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IVa), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IVa), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (IVa), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


Still another embodiment pertains to compounds having Formula (IVa), which include Examples 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 563, 564, 577, 579, 580, 581, 582, 583, 584, 596, 607, 649, 650, 682, 683, 684, 685, and pharmaceutically acceptable salts thereof.


Embodiments of Formula (Va)

In another aspect, the present invention provides compounds of Formula (Va)




embedded image


or pharmaceutically acceptable salts thereof; wherein X1, X2, X3, and R5 are as described herein for Formula (Ia).


In one embodiment of formula (Va),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R3 is alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R10, OR10, Se, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R16)2, NHC(O)R16, NR16C(O)R16, NHSO2R10, NHC(O)OR16, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected OCH3, OH, aryl, or heterocyclyl;


R10 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R5, R6, R9, and R10, are optionally substituted with one or more independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13 is alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolyl, thienyl, furanyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolyl, thienyl, furanyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected OCH3, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, or cycloalkenyl is optionally substituted with one or more independently selected alkyl, or OCH3; and


R15 is alkyl.


In one embodiment of Formula (Va), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (Va), X1, X2, and X3 are CH. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (Va), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (Va), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (Va), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (Va), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (Va), X1 is N; X2 is CR1; and X3 is N.


In another embodiment of Formula (Va), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Va), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), R1 is C(O)NH2. In another embodiment of Formula (Va), R1 is F. In another embodiment of Formula (Va), R1 is Cl. In another embodiment of Formula (Va), R1 is Br. In another embodiment of Formula (Va), R1 is CN. In another embodiment of Formula (Va), R1 is NH2. In another embodiment of Formula (Va), R1 is NO2. In another embodiment of Formula (Va), R1 is CF3. In another embodiment of Formula (Va), R1 is C(O)OH. In another embodiment of Formula (Va), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (Va), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (Va), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (Va), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


Still another embodiment pertains to compounds having Formula (Va), which include Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 373, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 424, 425, 426, 427, 430, 431, 434, 435, 436, 437, 438, 439, 440, 441, 442, 445, 446, 447, 448, 449, 450, 496, 497, 553, 554, 555, 556, 559, 560, 561, 562, 565, 567, 568, 569, 570, 571, 572, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 597, 598, 599, 600, 601, 602, 603, 604, 608, 613, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 686, 687, 716, 717, and pharmaceutically acceptable salts thereof.


Embodiments of Formula (VIa)

In another aspect, the present invention provides compounds of Formula (VIa)




embedded image


or pharmaceutically acceptable salts thereof; wherein R1 and R5 are as described herein for Formula (Ia); and n is 0 or 1.


In one embodiment of formula (VIa),


n is 0 or 1;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R3 is alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R10, OR10, Se, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R16)2, NHC(O)R16, NR16C(O)R16, NHSO2R10, NHC(O)OR16, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected OCH3, OH, aryl, or heterocyclyl;


R10 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R5, R6, R9, and R10, are optionally substituted with one or more independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13 is alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolyl, thienyl, furanyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolyl, thienyl, furanyl, cycloalkyl, and cycloalkenyl is optionally substituted with one or more independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14 is alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one or more independently selected OCH3, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, or cycloalkenyl is optionally substituted with one or more independently selected alkyl, or OCH3; and


R15 is alkyl.


In another embodiment of Formula (VIa), n is 0. In another embodiment of Formula (VIa), n is 1. In another embodiment of Formula (VIa), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (VIa), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIa), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIa), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIa), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIa), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIa), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIa), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIa), R1 is C(O)NH2. In another embodiment of Formula (VIa), R1 is F. In another embodiment of Formula (VIa), R1 is Cl. In another embodiment of Formula (VIa), R1 is Br. In another embodiment of Formula (VIa), R1 is CN. In another embodiment of Formula (VIa), R1 is NH2. In another embodiment of Formula (VIa), R1 is NO2. In another embodiment of Formula (VIa), R1 is CF3. In another embodiment of Formula (VIa), R1 is C(O)OH. In another embodiment of Formula (VIa), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


Still another embodiment pertains to compounds having Formula (VIa), which include Examples 285, 286, 287, 288, 289, 290, 426, 427, 437, 445, 553, 554, 555, 556, 599, 627, 628, 629, 630, 631, 632, 633, 634, 635, 686, 687, and pharmaceutically acceptable salts thereof.


Embodiments of Formula (Ib)

One embodiment of this invention, therefore, pertains to compounds or pharmaceutically acceptable salts, which are useful as inhibitors of NAMPT, the compounds having Formula (Ib)




embedded image


wherein


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R2 is alkyl, alkenyl, alkynyl, phenyl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R2 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, CO(O)R4, OC(O)R4, OC(O)OR4, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R2 phenyl is optionally substituted at the para position with one independently selected R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, Br or I; wherein each R2 phenyl is optionally additionally substituted with one F; wherein each R2 heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R3, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R4, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, cycloalkyl, or heterocyclyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R4 aryl and heterocycyl is optionally substituted with one, two, three or four independently selected R8, ORB, SR8, S(O)R8, SO2R8, C(O)R8, CO(O)R8, OC(O)R8, OC(O)OR8, NH2, NHR8, NHC(O)R8, NR8C(O)R8, NHS(O)2R8, NR8S(O)2R8, NHC(O)OR8, NR8C(O)OR8, NHC(O)NH2, NHC(O)NHR8, NHC(O)N(R8)2, NR8C(O)NHR8, NR8C(O)N(R8)2, C(O)NH2, C(O)NHR8, C(O)N(R8)2, C(O)NHOH, C(O)NHOR8, C(O)NHSO2R8, C(O)NR8SO2R8, SO2NH2, SO2NHR8, SO2N(R8)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R10, OR10, Se, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R16, NR16C(O)R16, NHSO2R16, NHC(O)OR16, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R7, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R7 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R11, OR11, SR11, S(O)R11, SO2R11, NHR11, N(R11)2, C(O)R11, C(O)NH2, C(O)NHR11, C(O)N(R11)2, NHC(O)R11, NR11C(O)R11, NHSO2R11, NHC(O)OR11, SO2NH2, SO2NHR11, SO2N(R11)2, NHC(O)NH2, NHC(O)NHR11, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R8, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R8 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R12, OR12, SR12, S(O)R12, SO2R12, NHR12, N(R12)2, C(O)R12, C(O)NH2, C(O)NHR12, C(O)N(R12)2, NHC(O)R12, NR12C(O)R12, NHSO2R12, NHC(O)OR12, SO2NH2, SO2NHR12, SO2N(R12)2, NHC(O)NH2, NHC(O)NHR12, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R10, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


R11, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


R12, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R12 alkyl, alkenyl, and alkynyl is optionally substituted with one or more alkoxy;


wherein the cyclic moieties represented by R3, R5, R6, R7, R8, R9, R10, R11, and R12 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I;


R15, at each occurrence, is independently selected alkyl; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four independently selected alkoxy;


with the proviso that when X1, X2, and X3 are CH and R2 is phenyl; R5 is not methyl;


with the proviso that when X1, X2, and X3 are CH, and R2 is phenyl substituted with OR5; R5 is not methyl;


with the proviso that when R2 is unsubstituted alkyl or optionally substituted alkyl; R2 is C4-C6-alkyl;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


In one embodiment of Formula (Ib), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (Ib), X1, X2, and X3 are CH. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (Ib), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (Ib), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (Ib), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (Ib), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (Ib), X1 is N; X2 is CR1; and X3 is N.


In another embodiment of Formula (Ib), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Ib), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), R1 is C(O)NH2. In another embodiment of Formula (Ib), R1 is F. In another embodiment of Formula (Ib), R1 is Cl. In another embodiment of Formula (Ib), R1 is Br. In another embodiment of Formula (Ib), R1 is CN. In another embodiment of Formula (Ib), R1 is NH2. In another embodiment of Formula (Ib), R1 is NO2. In another embodiment of Formula (Ib), R1 is CF3. In another embodiment of Formula (Ib), R1 is C(O)OH. In another embodiment of Formula (Ib), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (Ib), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (Ib), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (Ib), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In one embodiment of Formula (Ib), R2 is phenyl which is substituted at the para position with R5; and R5 is phthalazin-1(2H)-onyl, isoquinolinyl, isoquinolin-1(2H)-onyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, 5-fluorophthalazin-1(2H)-onyl, (Z)-3H-benzo[d][1,2]diazepin-4(5H)-onyl, 5-(trifluoromethyl)phthalazin-1(2H)-onyl, pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one, or isoindolin-1-onyl.


In one embodiment of Formula (Ib),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH;


R2 is alkyl, phenyl, heterocyclyl; wherein each R2 alkyl is optionally substituted with one, two, three or four independently selected R4, OR4, C(O)R4, CO(O)R4NHC(O)R4, NR4C(O)R4, C(O)NHR4, or C(O)N(R4)2; wherein each R2 phenyl is optionally substituted at the para position with one independently selected R5, OR5, SO2R5, C(O)R5, CO(O)R5, NHR5, NHC(O)R5, NHS(O)2R5, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOR5, SO2NHR5, CF3, Br or I; wherein each R2 phenyl is optionally additionally substituted with one F; wherein each R2 heterocyclyl is optionally substituted with one, two, three or four independently selected R5, OR5, C(O)R5, N(R5)2, NHC(O)R5, C(O)NHR5, F, Cl, Br or I;


R3, at each occurrence, is independently selected alkyl, alkenyl, or heterocyclyl; wherein each R3 alkyl is optionally substituted with one, two, three or four independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, OH, F, Cl, Br or I;


R4, at each occurrence, is independently selected alkyl, aryl, cycloalkyl, or heterocyclyl; wherein each R4 alkyl is optionally substituted with one, two, three or four independently selected R7, F, Cl, Br or I; wherein each R4 aryl cycloalkyl, and heterocycyl is optionally substituted with one, two, three or four independently selected R8, C(O)R8, CO(O)R8, F, Cl, Br or I;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, C(O)R9, NH2, N(R9)2, NHC(O)R9, NR9C(O)OR9, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)OH, OH, CN, CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl or heterocyclyl; wherein each R6 alkyl is optionally substituted with one, two, three or four independently selected F, Cl, Br or I;


R7, at each occurrence, is independently selected aryl, or heterocyclyl;


R8, at each occurrence, is independently selected alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R8 alkyl is optionally substituted with one, two, three or four independently selected R12, OR12OH, CF3, F, Cl, Br or I;


R9, at each occurrence, is independently selected alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R9 alkyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R12, at each occurrence, is independently selected alkyl, heterocyclyl, or cycloalkyl; wherein each R12 alkyl is optionally substituted with one or more alkoxy;


wherein the cyclic moieties represented by R3, R5, R6, R7, R8, R9, R10, R11 and R12 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SO2R13, C(O)R13, CO(O)R13, NH2, N(R13)2, NHC(O)R13, NHC(O)OR13, C(O)NH2, C(O)NHR13, C(O)N(R13)2, OH, CN, CF3, OCF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, or cycloalkyl; wherein each R13 alkyl and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NHC(O)OR14, OH, CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, and cycloalkyl is optionally substituted with one, two, three or four independently selected R15, OR15, SO2R15, C(O)R15, N(R15)2, NHC(O)R15, CN, CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R14 alkyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, OH, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, and cycloalkyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I;


R15, at each occurrence, is independently selected alkyl; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four independently selected alkoxy;


with the proviso that when X1, X2, and X3 are CH and R2 is phenyl; R5 is not methyl;


with the proviso that when X1, X2, and X3 are CH, and R2 is phenyl substituted with OR5; R5 is not methyl;


with the proviso that when R2 is unsubstituted alkyl or optionally substituted alkyl; R2 is C4-C6-alkyl;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


In another embodiment of Formula (Ib),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH;


R2 is alkyl, phenyl, heterocyclyl; wherein each R2 alkyl is optionally substituted with one, two, three or four independently selected R4, OR4, C(O)R4, CO(O)R4NHC(O)R4, NR4C(O)R4, C(O)NHR4, or C(O)N(R4)2; wherein each R2 phenyl is optionally substituted at the para position with one independently selected R5, OR5, SO2R5, C(O)R5, CO(O)R5, NHR5, NHC(O)R5, NHS(O)2R5, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOR5, SO2NHR5, or CF3; wherein each R2 phenyl is optionally additionally substituted with one F; wherein each R2 heterocyclyl is optionally substituted with one, two, three or four independently selected R5, OR5, C(O)R5, N(R5)2, NHC(O)R5, or C(O)NHR5;


R3, at each occurrence, is independently selected alkyl, alkenyl, or heterocyclyl; wherein each R3 alkyl is optionally substituted with one, two, three or four independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH;


R4, at each occurrence, is independently selected alkyl, aryl, cycloalkyl, or heterocyclyl; wherein each R4 alkyl is optionally substituted with one, two, three or four independently selected R7; wherein each R4 aryl cycloalkyl, and heterocycyl is optionally substituted with one, two, three or four independently selected R8, C(O)R8, CO(O)R8, F, Cl, or Br;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, C(O)R9, NH2, N(R9)2, NHC(O)R9, NR9C(O)OR9, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)OH, OH, CN, CF3, or F;


R6, at each occurrence, is independently selected alkyl or heterocyclyl;


R7, at each occurrence, is independently selected aryl, or heterocyclyl;


R8, at each occurrence, is independently selected alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R8 alkyl is optionally substituted with one, two, three or four independently selected R12, OR12OH, or CF3;


R9, at each occurrence, is independently selected alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R9 alkyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R12, at each occurrence, is independently selected alkyl, heterocyclyl, or cycloalkyl; wherein each R12 alkyl is optionally substituted with one or more alkoxy;


wherein the cyclic moieties represented by R3, R5, R6, R7, R8, R9, R10, R11, and R12 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SO2R13, C(O)R13, CO(O)R13, NH2, N(R13)2, NHC(O)R13, NHC(O)OR13, C(O)NH2, C(O)NHR13, C(O)N(R13)2, OH, CN, CF3, OCF3, SCF3, F, or Cl;


R13, at each occurrence, is independently selected alkyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, or cycloalkyl; wherein each R13 alkyl and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NHC(O)OR14, OH, or CF3; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, and cycloalkyl is optionally substituted with one, two, three or four independently selected R15, OR15, SO2R15, C(O)R15, N(R15)2, NHC(O)R15, CN, CF3, F, or Cl;


R14, at each occurrence, is independently selected alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R14 alkyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, or OH; wherein each R14 aryl, heterocyclyl, and cycloalkyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, or Cl;


R15, at each occurrence, is independently selected alkyl; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four independently selected alkoxy;


with the proviso that when X1, X2, and X3 are CH and R2 is phenyl; R5 is not methyl;


with the proviso that when X1, X2, and X3 are CH, and R2 is phenyl substituted with OR5; R5 is not methyl;


with the proviso that when R2 is unsubstituted alkyl or optionally substituted alkyl; R2 is C4-C6-alkyl;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


Still another embodiment pertains to compounds having Formula (Ib), which include Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 358, 359, 360, 361, 362, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 796, 797, 798, 799, 800, 801, 802, 803, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000, 1001, 1002, 1003, 1004, 1005, 1006, 1007, 1008, 1009, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1037, 1038, 1039, 1040, 1041, 1042, 1043, 1044, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 1059, 1060, 1061, 1062, 1063, 1064, 1065, 1066, 1067, 1068, 1069, 1070, 1071, 1072, 1073, 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 1082, 1083, 1084, 1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092, 1093, 1094, 1095, 1096, 1097, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106, 1107, 1108, 1109, 1110, 1111, 1112, 1113, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 1121, 1122, 1123, 1124, 1125, 1126, 1127, 1128, 1129, 1130, 1131, 1132, 1133, 1134, 1135, 1136, 1137, 1138, 1139, 1140, 1141, 1142, 1143, 1144, 1145, 1146, 1147, 1148, 1149, 1150, 1151, 1152, 1153, 1154, 1155, 1156, 1157, 1158, 1159, 1160, 1161, 1162, 1163, 1164, 1165, 1166, 1167, 1168, 1169, 1170, 1171, 1172, 1173, 1174, 1175, 1176, 1177, 1178, 1179, 1180, 1181, 1182, 1183, 1184, 1185, 1186, 1187, 1188, 1189, 1190, 1191, 1192, 1193, 1194, 1195, 1196, 1197, 1198, 1199, 1200, 1201, 1202, 1203, 1204, 1205, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1213, 1214, 1215, 1216, 1217, 1218, 1219, 1220, 1221, 1222, 1223, 1224, 1225, 1226, 1227, 1228, 1229, 1230, 1231, 1232, 1233, 1234, 1235, 1236, 1237, 1238, 1239, 1240, 1241, 1242, 1243, 1244, 1245, 1246, 1247, 1248, 1249, 1250, 1251, 1252, 1253, 1254, 1255, 1256, 1257, 1258, 1259, 1260, 1261, 1262, 1263, 1264, 1265, 1266, 1267, 1269, 1270, 1271, 1272, 1273, 1274, 1275, 1276, 1277, 1278, 1279, 1280, 1281, 1282, 1283, 1284, 1285, 1286, 1287, 1288, 1289, 1292, 1293, 1294, 1295, 1296, 1297, 1298, 1299, 1300, 1301, 1302, 1303, 1304, 1305, 1306, 1307, 1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1320, 1321, 1322, 1323, 1324, 1325, 1326, 1327, 1328, 1329, 1330, 1331, 1332, 1333, 1334, 1335, 1336, 1337, 1338, 1339, 1340, 1341, 1342, 1343, 1344, 1345, 1346, 1347, 1348, 1349, 1350, 1351, 1352, 1353, 1354, 1355, 1356, 1357, 1358, 1359, 1360, 1361, 1362, 1363, 1364, 1365, 1366, 1367, 1368, 1369, 1370, 1371, 1372, 1373, 1374, 1375, 1376, 1377, 1378, 1379, 1380, 1381, 1382, 1383, 1384, 1385, 1386, 1387, 1388, 1389, 1390, 1391, 1392, 1393, 1394, 1395, 1396, 1397, 1398, 1399, 1400, 1401, 1402, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, or pharmaceutically acceptable salts thereof.


Embodiments of Formula (IIb)

In another aspect, the present invention provides compounds of Formula (IIb)




embedded image


or pharmaceutically acceptable salts thereof; wherein X1, X2, X3, are as described herein for Formula (Ib); and R2 is phenyl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein the R2 phenyl, heterocyclyl, cycloalkyl, and cycloalkenyl are optionally substituted as described herein for substituents on R2 in Formula (Ib).


In one embodiment of formula (IIb),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R2 is phenyl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R2 phenyl is optionally substituted at the para position with one independently selected R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, Br or I; wherein each R2 phenyl is optionally additionally substituted with one F; wherein each R2 heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R3, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R10, OR10, Se, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R16, NR16C(O)R16, NHSO2R16, NHC(O)OR16, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R10, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R5, R6, R9, and R10 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I;


R15, at each occurrence, is independently selected alkyl; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four independently selected alkoxy;


with the proviso that when X1, X2, and X3 are CH and R2 is phenyl; R5 is not methyl;


with the proviso that when X1, X2, and X3 are CH, and R2 is phenyl substituted with OR5; R5 is not methyl;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


In one embodiment of Formula (IIb), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (IIb), X1, X2, and X3 are CH. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (IIb), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (IIb), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (IIb), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (IIb), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (IIb), X1 is N; X2 is CR1; and X3 is N.


In another embodiment of Formula (IIb), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIb), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), R1 is C(O)NH2. In another embodiment of Formula (IIb), R1 is F. In another embodiment of Formula (IIb), R1 is Cl. In another embodiment of Formula (IIb), R1 is Br. In another embodiment of Formula (IIb), R1 is CN. In another embodiment of Formula (IIb), R1 is NH2. In another embodiment of Formula (IIb), R1 is NO2. In another embodiment of Formula (IIb), R1 is CF3. In another embodiment of Formula (IIb), R1 is C(O)OH. In another embodiment of Formula (IIb), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Bb), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IIb), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IIb), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (IIb), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


Still another embodiment pertains to compounds having Formula (IIb), which include Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 607, 608, 613, 614, 615, 617, 618, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 682, 683, 684, 685, 686, 687, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 796, 799, 800, 801, 802, 803, 805, 806, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000, 1001, 1002, 1003, 1004, 1005, 1006, 1007, 1008, 1009, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1037, 1038, 1039, 1040, 1041, 1042, 1043, 1044, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 1059, 1060, 1061, 1062, 1063, 1064, 1065, 1066, 1067, 1068, 1069, 1070, 1071, 1072, 1073, 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 1082, 1083, 1084, 1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092, 1093, 1094, 1095, 1096, 1097, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106, 1107, 1108, 1109, 1110, 1111, 1112, 1113, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 1121, 1122, 1123, 1124, 1125, 1126, 1127, 1128, 1129, 1130, 1131, 1132, 1133, 1134, 1135, 1136, 1137, 1138, 1139, 1140, 1141, 1142, 1143, 1144, 1145, 1146, 1147, 1148, 1149, 1150, 1151, 1152, 1153, 1154, 1155, 1156, 1157, 1158, 1159, 1160, 1161, 1162, 1163, 1164, 1165, 1166, 1167, 1168, 1169, 1170, 1171, 1172, 1173, 1174, 1175, 1176, 1177, 1178, 1179, 1180, 1181, 1182, 1183, 1184, 1185, 1186, 1187, 1188, 1189, 1190, 1191, 1192, 1193, 1194, 1195, 1196, 1197, 1198, 1199, 1200, 1201, 1202, 1203, 1204, 1205, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1213, 1214, 1215, 1216, 1217, 1218, 1219, 1220, 1221, 1222, 1223, 1224, 1225, 1226, 1227, 1228, 1229, 1230, 1231, 1232, 1233, 1234, 1235, 1236, 1237, 1238, 1239, 1240, 1241, 1242, 1243, 1244, 1245, 1246, 1247, 1248, 1249, 1250, 1251, 1252, 1253, 1254, 1255, 1256, 1257, 1258, 1259, 1260, 1261, 1262, 1263, 1264, 1265, 1266, 1267, 1269, 1270, 1271, 1272, 1273, 1274, 1275, 1276, 1277, 1278, 1279, 1280, 1281, 1282, 1283, 1284, 1288, 1289, 1292, 1293, 1294, 1295, 1296, 1297, 1298, 1299, 1300, 1301, 1302, 1303, 1304, 1305, 1306, 1307, 1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1320, 1321, 1322, 1323, 1324, 1325, 1326, 1327, 1328, 1329, 1330, 1331, 1332, 1333, 1334, 1335, 1336, 1337, 1338, 1339, 1340, 1341, 1342, 1343, 1344, 1345, 1346, 1347, 1348, 1349, 1363, 1364, 1365, 1366, 1367, 1368, 1370, 1371, 1372, 1373, 1374, 1375, 1376, 1377, 1378, 1379, 1380, 1381, 1382, 1383, 1384, 1385, 1386, 1387, 1388, 1389, 1390, 1391, 1392, 1393, 1394, 1395, 1396, 1397, 1398, 1399, 1400, 1401, 1402, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, or pharmaceutically acceptable salts thereof.


Embodiments of Formula (IIIb)

In another aspect, the present invention provides compounds of Formula (IIIb)




embedded image


or pharmaceutically acceptable salts thereof; wherein X1, X2, X3, are as described herein for Formula (Ib); and Rx is as described herein for substituents at the para position in Formula (Ib) when R2 is phenyl.


In one embodiment of formula (Mb),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


Rx is R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, Br or I;


R3, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R1)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R10, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R5, R6, R9, and R19 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I;


R15, at each occurrence, is independently selected alkyl; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four independently selected alkoxy;


with the proviso that when X1, X2, and X3 are CH; Rx is not methyl;


with the proviso that when X1, X2, and X3 are CH; Rx is not methoxy;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


In one embodiment of Formula (IIIb), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (IIIb), X1, X2, and X3 are CH. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (IIIb), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (IIIb), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (IIIb), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (IIIb), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (IIIb), X1 is N; X2 is CR1; and X3 is N.


In another embodiment of Formula (IIIb), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIIb), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), R1 is C(O)NH2. In another embodiment of Formula (IIIb), R1 is F. In another embodiment of Formula (IIIb), R1 is Cl. In another embodiment of Formula (IIIb), R1 is Br. In another embodiment of Formula (IIIb), R1 is CN. In another embodiment of Formula (IIIb), R1 is NH2. In another embodiment of Formula (IIIb), R1 is NO2. In another embodiment of Formula (IIIb), R1 is CF3. In another embodiment of Formula (IIIb), R1 is C(O)OH. In another embodiment of Formula (IIIb), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IIIb), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IIIb), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (IIIb), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In one embodiment of formula (TIN, Rx is R5, OR5, SO2R5, C(O)R5, CO(O)R5, NHR5, NHC(O)R5, NHS(O)2R5, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOR5, SO2NHR5 or CF3. In another embodiment of formula (IIIb), Rx is R5, and R5 is heterocyclyl, which is optionally substituted as described in embodiments herein.


In another embodiment of Formula (IIIb), Rx is phthalazin-1(2H)-onyl, isoquinolinyl, isoquinolin-1(2H)-onyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, 5-fluorophthalazin-1(2H)-onyl, (Z)-3H-benzo[d][1,2]diazepin-4(5H)-onyl, 5-(trifluoromethyl)phthalazin-1(2H)-onyl, pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one, isoindolin-1-onyl, or 1,2,3,6-tetrahydropyridinyl. In another embodiment of Formula (IIIb), Rx is phthalazin-1(2H)-onyl, isoquinolinyl, isoquinolin-1(2H)-onyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, 5-fluorophthalazin-1(2H)-onyl, (Z)-3H-benzo[d][1,2]diazepin-4(5H)-onyl, 5-(trifluoromethyl)phthalazin-1(2H)-onyl, isoindolin-1-onyl, or pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one; which are optionally substituted as defined herein. In another embodiment of Formula (IIIb), Rx is, 2,3,6-tetrahydropyridinyl; which is optionally substituted as defined herein.


Still another embodiment pertains to compounds having Formula (IIIb), which include Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 327, 330, 331, 332, 333, 336, 337, 338, 339, 340, 341, 342, 343, 348, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 543, 544, 545, 546, 547, 548, 549, 553, 554, 555, 556, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 607, 608, 613, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 649, 650, 682, 683, 684, 685, 686, 687, 705, 706, 707, 708, 709, 710, 716, 717, 718, 719, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 759, 760, 761, 762, 763, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 796, 799, 802, 803, 806, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000, 1001, 1002, 1003, 1004, 1005, 1006, 1007, 1008, 1009, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1037, 1038, 1039, 1040, 1041, 1042, 1043, 1044, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 1059, 1060, 1061, 1062, 1063, 1064, 1065, 1066, 1067, 1068, 1069, 1070, 1071, 1072, 1073, 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 1082, 1083, 1084, 1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092, 1093, 1094, 1095, 1096, 1097, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106, 1107, 1108, 1109, 1110, 1111, 1112, 1113, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 1121, 1122, 1123, 1124, 1125, 1126, 1127, 1128, 1129, 1130, 1131, 1132, 1133, 1134, 1135, 1136, 1137, 1138, 1139, 1140, 1141, 1142, 1143, 1144, 1145, 1146, 1147, 1148, 1149, 1150, 1151, 1152, 1153, 1154, 1155, 1156, 1157, 1158, 1159, 1160, 1161, 1162, 1163, 1164, 1165, 1166, 1167, 1168, 1169, 1170, 1171, 1172, 1173, 1174, 1175, 1176, 1177, 1178, 1179, 1180, 1181, 1182, 1183, 1184, 1185, 1186, 1187, 1188, 1189, 1190, 1191, 1192, 1193, 1194, 1195, 1196, 1197, 1198, 1199, 1200, 1201, 1202, 1203, 1204, 1205, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1213, 1214, 1215, 1216, 1217, 1218, 1219, 1220, 1221, 1222, 1223, 1224, 1225, 1226, 1227, 1228, 1229, 1230, 1231, 1232, 1233, 1234, 1235, 1236, 1237, 1238, 1239, 1240, 1241, 1242, 1243, 1244, 1245, 1246, 1247, 1248, 1249, 1250, 1251, 1252, 1253, 1254, 1255, 1256, 1257, 1258, 1259, 1260, 1261, 1262, 1263, 1264, 1265, 1266, 1267, 1269, 1270, 1271, 1272, 1273, 1274, 1275, 1276, 1277, 1278, 1279, 1280, 1281, 1282, 1283, 1284, 1288, 1289, 1292, 1293, 1294, 1295, 1296, 1297, 1298, 1299, 1300, 1301, 1302, 1303, 1304, 1305, 1306, 1307, 1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1320, 1321, 1322, 1323, 1324, 1325, 1326, 1327, 1328, 1329, 1330, 1331, 1332, 1333, 1334, 1335, 1336, 1337, 1338, 1339, 1340, 1341, 1342, 1343, 1344, 1345, 1346, 1347, 1348, 1349, 1363, 1364, 1365, 1366, 1367, 1368, 1370, 1371, 1372, 1373, 1374, 1375, 1376, 1377, 1378, 1379, 1380, 1381, 1382, 1383, 1384, 1385, 1386, 1387, 1388, 1389, 1390, 1391, 1392, 1393, 1394, 1395, 1396, 1397, 1398, 1399, 1400, 1401, 1402, 1403, 1404, 1405, 1406, 1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418, 1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, or pharmaceutically acceptable salts thereof.


Still another embodiment pertains to compounds having Formula (IIIb), which include 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 547, 548, 549, 550, 551, 552, and pharmaceutically acceptable salts thereof.


Embodiments of Formula (IVb)

In another aspect, the present invention provides compounds of Formula (IVb)




embedded image


or pharmaceutically acceptable salts thereof; wherein X1, X2, X3, and R5 are as described herein for Formula (Ib).


In one embodiment of formula (IVb),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R3, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R10, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R5, R6, R9, and R10 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I;


R15, at each occurrence, is independently selected alkyl; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four independently selected alkoxy;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


In one embodiment of Formula (IVb), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (IVb), X1, X2, and X3 are CH. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (IVb), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (IVb), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (IVb), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (IVb), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (IVb), X1 is N; X2 is CR1; and X3 is N.


In another embodiment of Formula (IVb), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IVb), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), R1 is C(O)NH2. In another embodiment of Formula (IVb), R1 is F. In another embodiment of Formula (IVb), R1 is Cl. In another embodiment of Formula (IVb), R1 is Br. In another embodiment of Formula (IVb), R1 is CN. In another embodiment of Formula (IVb), R1 is NH2. In another embodiment of Formula (IVb), R1 is NO2. In another embodiment of Formula (IVb), R1 is CF3. In another embodiment of Formula (IVb), R1 is C(O)OH. In another embodiment of Formula (IVb), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IVb), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IVb), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (IVb), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


Still another embodiment pertains to compounds having Formula (IVb), which include Examples 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 563, 564, 577, 579, 580, 581, 582, 583, 584, 596, 607, 649, 650, 682, 683, 684, 685, 789, 791, 792, 793, 794, 796, 874, 878, 879, 919, 932, 934, 935, 1363, 1364, 1365, 1366, 1367, 1368, 1370, 1371, 1372, or pharmaceutically acceptable salts thereof.


Embodiments of Formula (Vb)

In another aspect, the present invention provides compounds of Formula (Vb)




embedded image


or pharmaceutically acceptable salts thereof; wherein X1, X2, X3, and R5 are as described herein for Formula (Ib).


In one embodiment of formula (Vb),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R3, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R10, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R5, R6, R9, and R10 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I;


R15, at each occurrence, is independently selected alkyl; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four independently selected alkoxy;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


In one embodiment of Formula (Vb), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (Vb), X1, X2, and X3 are CH. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (Vb), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (Vb), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (Vb), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (Vb), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (Vb), X1 is N; X2 is CR1; and X3 is N.


In another embodiment of Formula (Vb), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Vb), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), R1 is C(O)NH2. In another embodiment of Formula (Vb), R1 is F. In another embodiment of Formula (Vb), R1 is Cl. In another embodiment of Formula (Vb), R1 is Br. In another embodiment of Formula (Vb), R1 is CN. In another embodiment of Formula (Vb), R1 is NH2. In another embodiment of Formula (Vb), R1 is NO2. In another embodiment of Formula (Vb), R1 is CF3. In another embodiment of Formula (Vb), R1 is C(O)OH. In another embodiment of Formula (Vb), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (Vb), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (Vb), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (Vb), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


Still another embodiment pertains to compounds having Formula (Vb), which include Examples 1, 2, 3, 4, 5, 8, 9, 10, 13, 14, 16, 17, 18, 20, 21, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33, 34, 36, 37, 38, 39, 40, 42, 43, 45, 46, 48, 49, 53, 54, 57, 58, 59, 60, 61, 62, 63, 66, 67, 68, 70, 71, 73, 75, 77, 79, 80, 81, 82, 83, 85, 86, 87, 88, 90, 91, 92, 93, 94, 95, 97, 98, 99, 100, 101, 103, 104, 105, 106, 107, 108, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 139, 140, 141, 142, 143, 144, 145, 146, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 159, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 176, 177, 178, 179, 180, 181, 182, 184, 188, 189, 190, 192, 193, 194, 196, 199, 201, 203, 204, 205, 209, 210, 211, 213, 215, 217, 220, 223, 224, 226, 227, 228, 230, 231, 232, 234, 235, 236, 237, 239, 243, 245, 252, 253, 256, 258, 260, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 288, 289, 290, 373, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 424, 426, 427, 430, 431, 435, 436, 437, 440, 441, 442, 445, 446, 447, 449, 450, 496, 497, 553, 554, 555, 556, 559, 560, 562, 567, 568, 569, 570, 571, 572, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 597, 598, 599, 600, 601, 602, 603, 604, 608, 613, 625, 626, 628, 629, 630, 631, 632, 633, 634, 687, 716, 717, 718, 719, 723, 728, 729, 731, 732, 733, 734, 735, 737, 738, 739, 741, 743, 744, 745, 747, 748, 752, 770, 771, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 790, 802, 803, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 826, 827, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 856, 857, 858, 875, 880, 881, 882, 884, 894, 895, 922, 923, 924, 925, 939, 969, 970, 971, 972, 976, 977, 978, 1063, 1064, 1065, 1089, 1090, 1091, 1092, 1093, 1094, 1095, 1096, 1097, 1098, 1100, 1102, 1103, 1104, 1105, 1106, 1108, 1109, 1110, 1111, 1112, 1113, 1114, 1115, 1116, 1117, 1118, 1119, 1120, 1121, 1122, 1123, 1124, 1125, 1127, 1129, 1130, 1132, 1133, 1135, 1136, 1137, 1138, 1139, 1140, 1141, 1142, 1143, 1144, 1145, 1146, 1147, 1148, 1149, 1150, 1152, 1153, 1154, 1155, 1156, 1157, 1158, 1160, 1161, 1162, 1163, 1164, 1165, 1166, 1167, 1168, 1169, 1170, 1171, 1172, 1173, 1174, 1175, 1176, 1177, 1178, 1179, 1180, 1181, 1182, 1183, 1184, 1185, 1186, 1187, 1188, 1189, 1192, 1193, 1194, 1195, 1196, 1197, 1198, 1199, 1201, 1202, 1203, 1204, 1205, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1213, 1214, 1215, 1216, 1217, 1218, 1219, 1220, 1221, 1222, 1223, 1224, 1225, 1226, 1227, 1228, 1229, 1230, 1231, 1232, 1233, 1234, 1235, 1236, 1239, 1240, 1241, 1242, 1243, 1245, 1260, 1261, 1262, 1263, 1264, 1266, 1267, 1268, 1269, 1270, 1271, 1272, 1273, 1274, 1275, 1276, 1277, 1278, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1320, 1321, 1322, 1323, 1324, 1325, 1326, 1327, 1328, 1329, 1330, 1331, 1332, 1333, 1334, 1335, 1336, 1337, 1338, 1339, 1340, 1341, 1342, 1343, 1344, 1345, 1346, 1348, 1349, or pharmaceutically acceptable salts thereof.


Embodiments of Formula (VIb)

In another aspect, the present invention provides compounds of Formula (VIb)




embedded image


or pharmaceutically acceptable salts thereof; wherein R1 and R5 are as described herein for Formula (Ia); and n is 0 or 1.


In one embodiment of formula (VIb),


n is 0 or 1;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R3, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R10, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R5, R6, R9, and R10 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I;


R15, at each occurrence, is independently selected alkyl; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four independently selected alkoxy;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl.


In another embodiment of Formula (VIb), n is 0. In another embodiment of Formula (VIb), n is 1. In another embodiment of Formula (VIb), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (VIb), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIb), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIb), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIb), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIb), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIb), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIb), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIb), R1 is C(O)NH2. In another embodiment of Formula (VIb), R1 is F. In another embodiment of Formula (VIb), R1 is Cl. In another embodiment of Formula (VIb), R1 is Br. In another embodiment of Formula (VIb), R1 is CN. In another embodiment of Formula (VIb), R1 is NH2. In another embodiment of Formula (VIb), R1 is NO2. In another embodiment of Formula (VIb), R1 is CF3. In another embodiment of Formula (VIb), R1 is C(O)OH. In another embodiment of Formula (VIb), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


Still another embodiment pertains to compounds having Formula (VIb), which include Examples 285, 286, 288, 289, 290, 426, 427, 437, 445, 553, 554, 555, 556, 599, 627, 628, 629, 630, 631, 632, 633, 634, 635, 686, 687, 718, 723, 725, 726, 727, 728, 729, 731, 732, 733, 734, 735, 737, 738, 739, 741, 743, 744, 745, 747, 748, 749, 750, 751, 752, 770, 771, 773, 774, 775, 776, 777, 778, 779, 780, 803, 875, 880, 881, 882, 884, 922, 923, 924, 925, 939, 969, 970, 971, 972, 1055, 1056, 1057, 1058, 1059, 1060, 1061, 1062, 1063, 1064, 1065, 1066, 1067, 1068, 1069, 1070, 1071, 1072, 1073, 1074, 1075, 1076, or pharmaceutically acceptable salts thereof.


Embodiments of Formula (VIIb)

In another aspect, the present invention provides compounds of Formula (VIIb)




embedded image


or pharmaceutically acceptable salts thereof; wherein X1, X2, X3, and R13 are as described herein for Formula (Ib), and custom-character indicates a single or a double bond.


In one embodiment of formula (VIIb),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R3, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R10, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R6, and R10 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I;


R15, at each occurrence, is independently selected alkyl; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four independently selected alkoxy;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


In one embodiment of Formula (VIIb), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (VIIb), X1, X2, and X3 are CH. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (VIIb), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (VIIb), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (VIIb), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (VIIb), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (VIIb), X1 is N; X2 is CR1; and X3 is N.


In another embodiment of Formula (VIIb), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (VIIb), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), R1 is C(O)NH2. In another embodiment of Formula (VIIb), R1 is F. In another embodiment of Formula (VIIb), R1 is Cl. In another embodiment of Formula (VIIb), R1 is Br. In another embodiment of Formula (VIIb), R1 is CN. In another embodiment of Formula (VIIb), R1 is NH2. In another embodiment of Formula (VIIb), R1 is NO2. In another embodiment of Formula (VIIb), R1 is CF3. In another embodiment of Formula (VIIb), R1 is C(O)OH. In another embodiment of Formula (VIIb), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (VIIb), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (VIIb), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (VIIb), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


Still another embodiment pertains to compounds having Formula (VIIb), which include Examples 317, 330, 331, 332, 401, 405, 406, 407, 432, 456, 457, 458, 459, 460, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 543, 544, 545, 546, 620, 646, 647, 705, 706, 707, 708, 709, 710, 759, 760, 761, 762, 763, 799, 910, 911, 912, 913, 914, 915, 916, 917, 918, 967, 968, 979, 980, 981, 982, 983, 984, 985, 986, 1014, 1015, 1016, 1017, 1019, 1077, 1078, 1079, 1080, 1254, 1255, 1256, 1257, 1258, 1259, 1279, 1280, 1281, 1282, 1283, 1284, 1384, 1385, or pharmaceutically acceptable salts thereof.


Embodiments of Formula (Ic)

One embodiment of this invention, therefore, pertains to compounds or pharmaceutically acceptable salts, which are useful as inhibitors of NAMPT, the compounds having Formula (Ic)




embedded image


wherein


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R2 is alkyl, alkenyl, alkynyl, phenyl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R2 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R4, OR4, SR4, S(O)R4, SO2R4, C(O)R4, CO(O)R4, OC(O)R4, OC(O)OR4, NHC(O)R4, NR4C(O)R4, NHS(O)2R4, NR4S(O)2R4, NHC(O)OR4, NR4C(O)OR4, NHC(O)NH2, NHC(O)NHR4, NHC(O)N(R4)2, NR4C(O)NHR4, NR4C(O)N(R4)2, C(O)NH2, C(O)NHR4, C(O)N(R4)2, C(O)NHOH, C(O)NHOR4, C(O)NHSO2R4, C(O)NR4SO2R4, SO2NH2, SO2NHR4, SO2N(R4)2, C(O)H, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R2 phenyl is optionally substituted at the para position with one independently selected R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, Br or I; wherein each R2 phenyl is optionally additionally substituted with one F; wherein each R2 heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R3, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R4, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, cycloalkyl, or heterocyclyl; wherein each R4 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R7, OR7, SR7, S(O)R7, SO2R7, C(O)R7, OC(O)R7, OC(O)OR7, NH2, NHR7, NHC(O)R7, NR7C(O)R7, NHS(O)2R7, NR7S(O)2R7, NHC(O)OR7, NR7C(O)OR7, NHC(O)NH2, NHC(O)NHR7, NHC(O)N(R7)2, NR7C(O)NHR7, NR7C(O)N(R7)2, C(O)NH2, C(O)NHR7, C(O)N(R7)2, C(O)NHOH, C(O)NHOR7, C(O)NHSO2R7, C(O)NR7SO2R7, SO2NH2, SO2NHR7, SO2N(R7)2, C(O)H, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R4 aryl and heterocycyl is optionally substituted with one, two, three or four independently selected R8, ORB, SR8, S(O)R8, SO2R8, C(O)R8, CO(O)R8, OC(O)R8, OC(O)OR8, NH2, NHR8, NHC(O)R8, NR8C(O)R8, NHS(O)2R8, NR8S(O)2R8, NHC(O)OR8, NR8C(O)OR8, NHC(O)NH2, NHC(O)NHR8, NHC(O)N(R8)2, NR8C(O)NHR8, NR8C(O)N(R8)2, C(O)NH2, C(O)NHR8, C(O)N(R8)2, C(O)NHOH, C(O)NHOR8, C(O)NHSO2R8, C(O)NR8SO2R8, SO2NH2, SO2NHR8, SO2N(R8)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R1)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R7, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R7 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R11, OR11, SR11, S(O)R11, SO2R11, NHR11, N(R11)2, C(O)R11, C(O)NH2, C(O)NHR11, C(O)N(R11)2, NHC(O)R11, NR11C(O)R11, NHSO2R11, NHC(O)OR11, SO2NH2, SO2NHR11, SO2N(R11)2, NHC(O)NH2, NHC(O)NHR11, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R8, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R8 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R12, OR12, SR12, S(O)R12, SO2R12, NHR12, N(R12)2, C(O)R12, C(O)NH2, C(O)NHR12, C(O)N(R12)2, NHC(O)R12, NR12C(O)R12, NHSO2R12, NHC(O)OR12, SO2NH2, SO2NHR12, SO2N(R12)2, NHC(O)NH2, NHC(O)NHR12, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I; R9, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R10, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


R11, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


R12, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R12 alkyl, alkenyl, and alkynyl is optionally substituted with one or more alkoxy;


wherein the cyclic moieties represented by R3, R5, R6, R7, R8, R9, R19, R11, and R12 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I; wherein the R16 alkyl is optionally substituted with one, two, three or four alkoxy;


R15, at each occurrence, is independently selected alkyl; wherein the R15 alkyl is optionally substituted with one, two, three or four alkoxy;


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four alkoxy;


with the proviso that when X1, X2, and X3 are CH and R2 is phenyl; R5 is not methyl;


with the proviso that when X1, X2, and X3 are CH, and R2 is phenyl substituted with OR5; R5 is not methyl;


with the proviso that when R2 is unsubstituted alkyl or optionally substituted alkyl; R2 is C4-C6-alkyl;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


In one embodiment of Formula (Ic), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (Ic), X1, X2, and X3 are CH. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (Ic), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (Ic), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (Ic), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (Ic), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (Ic), X1 is N; X2 is CR1; and X3 is N.


In another embodiment of Formula (Ic), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Ic), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), R1 is C(O)NH2. In another embodiment of Formula (Ic), R1 is F. In another embodiment of Formula (Ic), R1 is Cl. In another embodiment of Formula (Ic), R1 is Br. In another embodiment of Formula (Ic), R1 is CN. In another embodiment of Formula (Ic), R1 is NH2. In another embodiment of Formula (Ic), R1 is NO2. In another embodiment of Formula (Ic), R1 is CF3. In another embodiment of Formula (Ic), R1 is C(O)OH. In another embodiment of Formula (Ic), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (Ic), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (Ic), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (Ic), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In one embodiment of Formula (Ic), R2 is phenyl which is substituted at the para position with R5; and R5 is phthalazin-1(2H)-onyl, isoquinolinyl, isoquinolin-1(2H)-onyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, 5-fluorophthalazin-1(2H)-onyl, (Z)-3H-benzo[d][1,2]diazepin-4(5H)-onyl, 5-(trifluoromethyl)phthalazin-1(2H)-onyl, pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one, or isoindolin-1-onyl.


In one embodiment of Formula (Ic),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH;


R2 is alkyl, phenyl, cycloalkyl, or heterocyclyl; wherein each R2 alkyl is optionally substituted with one, two, three or four independently selected R4, OR4, C(O)R4, CO(O)R4NHC(O)R4, NR4C(O)R4, C(O)NHR4, or C(O)N(R4)2; wherein each R2 phenyl is optionally substituted at the para position with one independently selected R5, OR5, SO2R5, C(O)R5, CO(O)R5, NHR5, NHC(O)R5, NHS(O)2R5, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOR5, SO2NHR5, CF3, Br or I; wherein each R2 phenyl is optionally additionally substituted with one F; wherein each R2 heterocyclyl and cycloalkyl are optionally substituted with one, two, three or four independently selected R5, OR5, C(O)R5, C(O)OR5, N(R5)2, NHC(O)R5, C(O)NHR5, F, Cl, Br or I;


R3, at each occurrence, is independently selected alkyl, alkenyl, or heterocyclyl; wherein each R3 alkyl is optionally substituted with one, two, three or four independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, OH, F, Cl, Br or I;


R4, at each occurrence, is independently selected alkyl, aryl, cycloalkyl, or heterocyclyl; wherein each R4 alkyl is optionally substituted with one, two, three or four independently selected R7, F, Cl, Br or I; wherein each R4 aryl cycloalkyl, and heterocycyl is optionally substituted with one, two, three or four independently selected R8, C(O)R8, CO(O)R8, F, Cl, Br or I;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, C(O)R9, NH2, N(R9)2, NHC(O)R9, NR9C(O)OR9, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)OH, OH, CN, CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl or heterocyclyl; wherein each R6 alkyl is optionally substituted with one, two, three or four independently selected F, Cl, Br or I;


R7, at each occurrence, is independently selected aryl, or heterocyclyl;


R8, at each occurrence, is independently selected alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R8 alkyl is optionally substituted with one, two, three or four independently selected R12, OR12OH, CF3, F, Cl, Br or I;


R9, at each occurrence, is independently selected alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R9 alkyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R12, at each occurrence, is independently selected alkyl, heterocyclyl, or cycloalkyl; wherein each R12 alkyl is optionally substituted with one or more alkoxy;


wherein the cyclic moieties represented by R3, R5, R6, R7, R8, R9, R10, R11 and R12 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SO2R13, C(O)R13, CO(O)R13, NH2, N(R13)2, NHC(O)R13, NHC(O)OR13, C(O)NH2, C(O)NHR13, C(O)N(R13)2, OH, CN, CF3, OCF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SO2R14, NH2, NHR14, N(R14)2, NHC(O)R14, NHC(O)OR14, OH, CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, or cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SO2R15, C(O)R15, N(R15)2, NHC(O)R15, OH, CN, CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R14 alkyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, OH, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, and cycloalkyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I;


R15, at each occurrence, is independently selected alkyl; wherein the R15 alkyl is optionally substituted with one, two, three or four alkoxy; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four alkoxy;


with the proviso that when X1, X2, and X3 are CH and R2 is phenyl; R5 is not methyl;


with the proviso that when X1, X2, and X3 are CH, and R2 is phenyl substituted with OR5; R5 is not methyl;


with the proviso that when R2 is unsubstituted alkyl or optionally substituted alkyl; R2 is C4-C6-alkyl;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


In another embodiment of Formula (Ic),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH;


R2 is alkyl, phenyl, cycloalkyl, or heterocyclyl; wherein each R2 alkyl is optionally substituted with one, two, three or four independently selected R4, OR4, C(O)R4, CO(O)R4NHC(O)R4, NR4C(O)R4, C(O)NHR4, or C(O)N(R4)2; wherein each R2 phenyl is optionally substituted at the para position with one independently selected R5, OR5, SO2R5, C(O)R5, CO(O)R5, NHR5, NHC(O)R5, NHS(O)2R5, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOR5, SO2NHR5, or CF3; wherein each R2 phenyl is optionally additionally substituted with one F; wherein each R2 heterocyclyl and cycloalkyl are optionally substituted with one, two, three or four independently selected R5, OR5, C(O)R5, C(O)OR5, N(R5)2, NHC(O)R5, or C(O)NHR5;


R3, at each occurrence, is independently selected alkyl, alkenyl, or heterocyclyl; wherein each R3 alkyl is optionally substituted with one, two, three or four independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH;


R4, at each occurrence, is independently selected alkyl, aryl, cycloalkyl, or heterocyclyl; wherein each R4 alkyl is optionally substituted with one, two, three or four independently selected R7; wherein each R4 aryl cycloalkyl, and heterocycyl is optionally substituted with one, two, three or four independently selected R8, C(O)R8, CO(O)R8, F, Cl, or Br;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, C(O)R9, NH2, N(R9)2, NHC(O)R9, NR9C(O)OR9, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)OH, OH, CN, CF3, or F;


R6, at each occurrence, is independently selected alkyl or heterocyclyl;


R7, at each occurrence, is independently selected aryl, or heterocyclyl;


R8, at each occurrence, is independently selected alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R8 alkyl is optionally substituted with one, two, three or four independently selected R12, OR12OH, or CF3;


R9, at each occurrence, is independently selected alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R9 alkyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R12, at each occurrence, is independently selected alkyl, heterocyclyl, or cycloalkyl; wherein each R12 alkyl is optionally substituted with one or more alkoxy;


wherein the cyclic moieties represented by R3, R5, R6, R7, R8, R9, R10, R11, and R12 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SO2R13, C(O)R13, CO(O)R13, NH2, N(R13)2, NHC(O)R13, NHC(O)OR13, C(O)NH2, C(O)NHR13, C(O)N(R13)2, OH, CN, CF3, OCF3, SCF3, F, or Cl;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SO2R14, NH2, NHR14, N(R14)2, NHC(O)R14, NHC(O)OR14, OH, or CF3; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SO2R15, C(O)R15, N(R15)2, NHC(O)R15, CN, OH, CF3, F, or Cl;


R14, at each occurrence, is independently selected alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R14 alkyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, or OH; wherein each R14 aryl, heterocyclyl, and cycloalkyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, or Cl;


R15, at each occurrence, is independently selected alkyl; wherein the R15 alkyl is optionally substituted with one, two, three or four alkoxy; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four independently selected alkoxy;


with the proviso that when X1, X2, and X3 are CH and R2 is phenyl; R5 is not methyl;


with the proviso that when X1, X2, and X3 are CH, and R2 is phenyl substituted with OR5; R5 is not methyl;


with the proviso that when R2 is unsubstituted alkyl or optionally substituted alkyl; R2 is C4-C6-alkyl;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


Still another embodiment pertains to compounds having Formula (Ic), which include

  • N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(aminomethyl)benzyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(furo[3,2-c]pyridin-4-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(pyridin-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(benzylcarbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(thieno[3,2-c]pyridin-4-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,3-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(pyridazin-3-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,3-dihydro-1,4-benzodioxin-5-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(3-methylbutyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-fluorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-5-methyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(4-cyanophenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-fluorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,5-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,2-dimethylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(2-oxopyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethoxy)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-fluoro-5-(trifluoromethyl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-chlorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4,5-trimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-nitro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(4-fluorophenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-ethyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-benzyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-methoxyphenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(3-methoxyphenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(4-acetylphenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,3-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyridin-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(2-thienyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3-methylbutyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(6-aminohexyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-thienyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1,3-benzodioxol-5-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridin-3-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(benzylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridazin-3-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyrimidin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(3-fluorophenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-butoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,4-dihydroxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-propoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-furylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-cyanophenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxy-2-methylphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)carbamoyl]phenyl}-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methyl-1H-indazol-5-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-ethoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,5-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4[(1-benzyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 5-({4[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}amino)-1H-indazole-3-carboxylate;
  • N-(4-{[2-(2-oxopyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(5-chloropyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-indol-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethyl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,5-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,3-dihydro-1,4-benzodioxin-6-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-fluorobenzoyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(5-methoxy-1H-indol-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-chlorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-propoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-isobutoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridin-4-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4,5-trimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methylpiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[4-(dimethylamino)phenyl]ethyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(trifluoromethoxy)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-3-hydroxy-1-phenylpropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-cyanophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluoro-4-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,3-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-fluorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(isobutylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1,3-benzodioxol-5-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-isopropoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-isopropoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-fluorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,4-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N2-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N-{4-[(2-phenoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-hydroxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3-fluorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({1-[(3S)-tetrahydrofuran-3-yl]-1H-pyrazol-4-yl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-phenylethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(methylthio)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-ethoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-fluorophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(pyridin-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[(trifluoromethyl)thio]benzyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(2-fluorophenyl)pyrrolidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3-chlorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(hydroxymethyl)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3-benzodioxol-5-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-isopropyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-hydroxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-ethyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,5-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[methyl(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(thiomorpholin-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-furoyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-benzylpiperidin-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(5-acetamido-2-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,5-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[3-(trifluoromethyl)phenyl]ethyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylbutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-imidazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-1-(3-cyanophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[benzyl(2-hydroxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-cyanophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-chlorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyanomethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclohexylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[butyl(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(dimethylamino)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,3-dihydro-1H-indol-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(phenylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-fluorophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(diethylamino)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-hydroxy-2-phenylethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-aminophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl (1-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}piperidin-4-yl)carbamate;
  • N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(cyclohexylmethyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3-chlorobenzyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(diethylcarbamoyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-hydroxy-6-methylphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(5-fluoropyridin-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopropylmethyl)(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-methoxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3,4,9-tetrahydro-2H-beta-carbolin-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tert-butylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-difluoropyrrolidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylpiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-1-benzylpyrrolidin-3-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-hydroxypiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluorophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclopentylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-carbamoylpiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclopropylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(methylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pentan-2-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pentan-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclobutylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1,3-dioxolan-2-ylmethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(4-fluorophenyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-hydroxy-2-methylpropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-phenyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[4-(trifluoromethyl)phenyl]ethyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxyethyl)(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(sec-butylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(trifluoromethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[bis(2-ethoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[butyl(ethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(morpholin-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[isobutyl(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylpiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-carbamoylphenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylpyrrolidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[ethyl(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,6-dimethylmorpholin-4-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-hydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,5-dimethylpyrrolidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(prop-2-yn-1-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[isopropyl(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[isopropyl(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-cyanoethyl)(cyclopropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[ethyl(isopropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluoropyrrolidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}-N-isopropyl-beta-alanine;
  • N-{4-[methyl(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5,6-dimethoxy-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(4-chlorophenoxy)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethoxy)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenyl-1,3-thiazol-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 2-{[4-(propylcarbamoyl)phenyl]carbamoyl}isoindoline-5-carboxylate;
  • 2-{[4-(propylcarbamoyl)phenyl]carbamoyl}isoindoline-5-carboxylic acid;
  • 5-amino-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(aminomethyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(2-hydroxy-2-methylpropanoyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-acetamido-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(N,N-dimethylglycyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-5-(1H-pyrazol-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-5-(1H-pyrazol-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(methoxyacetyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(methylsulfonyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-bromo-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,5-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-chlorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4,4,4-trifluorobutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-ethoxypropanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenylbutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methylpentanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(benzyloxy)acetyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-phenylpropanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-phenoxypropanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[N-(2-furoyl)glycyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-thienyl)butanoyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-oxo-4-phenylbutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(N-benzoylglycyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenoxybutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propionylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pentanoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(hexanoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(heptanoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pent-4-enoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(ethoxyacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2-methoxyethoxy)acetyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopropylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(4-methylpiperazin-1-yl)propanoyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 2-({4-[(cyclopentylacetyl)amino]phenyl}carbamoyl)isoindoline-5-carboxylate;
  • 2-({4-[(cyclopentylacetyl)amino]phenyl}carbamoyl)isoindoline-5-carboxylic acid;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-cyclopentylethyl)amino]phenyl}-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}-3,6-dihydropyridine-1(2H)-carboxylate;
  • N-[4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methylbutyl)-1H-pyrazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1E)-5-phenylpent-1-en-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-propyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[6-(1-propyl-1H-pyrazol-4-yl)pyridin-3-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-phenylpentyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[2-fluoro-4-(1-propyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{2-fluoro-4-[1-(3-methylbutyl)-1H-pyrazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-butyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(isopropylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1 ‘-isobutyryl-1’,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1 ‘-benzoyl-1’,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-benzoylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(isopropylsulfonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(phenylsulfonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[3-(benzoylamino)pyrrolidin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[3-(butyrylamino)pyrrolidin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}piperazine-1-carboxylate;
  • N-[4-(4-propionylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(2-butyryl-2,3-dihydro-1H-isoindol-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(2-isobutyryl-2,3-dihydro-1H-isoindol-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(2-benzoyl-2,3-dihydro-1H-isoindol-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[2-(3-methylbutyl)-2,3-dihydro-1H-isoindol-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(hexyloxy)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridin-3-ylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[6-(4-chlorophenoxy)hexyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(piperidin-4-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N,N′-hexane-1,6-diylbis(1,3-dihydro-2H-isoindole-2-carboxamide);
  • N-(4-phenylbutyl)-1,3-dihydro-2H-isoindole-2-carboxamide; ethyl 6-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]hexanoate;
  • N-hexyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-octyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(1-methyl-1H-pyrazol-4-yl)amino]-6-oxohexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[6-(methylamino)-6-oxohexyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-oxo-6-[(3-phenylpropyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-methylbutyl)amino]-6-oxohexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(5-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}pyridin-2-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(3-phenylpropyl)carbamoyl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(3-methylbutyl)carbamoyl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(3-phenylpropyl)carbamoyl]-1,3-thiazol-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(3-methylbutyl)carbamoyl]-1,3-thiazol-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(isoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(8-fluoro-4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(morpholin-4-ylmethyl)-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(4-methylpiperazin-1-yl)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-chloro-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-4,5-dihydro-3H-2,3-benzodiazepin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-oxo-8-(trifluoromethyl)-3,4-dihydrophthalazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(dimethylamino)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(di ethylamino)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(4-methylpiperazin-1-yl)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(dimethylamino)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(di ethylamino)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-oxo-8-(trifluoromethyl)-3,4-dihydrophthalazin-1-yl]phenyl}-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(1-methylpiperidin-4-yl)oxy]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-{[(3R)-3-fluoropyrrolidin-1-yl]methyl}-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-{[(3S)-3-fluoropyrrolidin-1-yl]methyl}-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(azetidin-1-ylmethyl)-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydropyrrolo[1,2-d][1,2,4]triazin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydropyrrolo[1,2-d][1,2,4]triazin-4-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}piperidine-1-carboxylate;
  • N-[4-(5-propyl-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(piperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(tetrahydrofuran-3-ylmethyl)carbamoyl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-butyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[5-(3-methylbutyl)-1,2,4-oxadiazol-3-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-benzyl-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3R)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(5-chloropyridin-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxy-4-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,4-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-oxopyrrolidin-1-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-hydroxycyclopropyl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl 4-{6-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]-1H-benzimidazol-2-yl}piperazine-1-carboxylate;
  • N-[2-(piperazin-1-yl)-1H-benzimidazol-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-5-vinyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-benzoylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[5-(tetrahydrofuran-3-yl)-1,2,4-oxadiazol-3-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3-methylbutyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide;
  • N-(4-{[(3-phenylpropyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide;
  • N-{4-[1-(4-methylbenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(tetrahydrofuran-3-ylmethyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-({[(2S)-tetrahydrofuran-2-ylmethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-({[(2R)-tetrahydrofuran-2-ylmethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(1S)-2-hydroxy-1-phenylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(2-methoxyethyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-(2-hydroxyethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(propylamino)carbonyl]phenyl}-5-pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(propylamino)carbonyl]phenyl}-5-pyridin-4-yl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N5-(2-methoxyethyl)-N2-{4-[(propylamino)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N-(4-cyanophenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(trifluoromethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(1S)-2-hydroxy-1-pyridin-2-ylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3-methylbutyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(tetrahydrofuran-3-ylmethyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-pyridin-2-ylpiperazin-1-yl)carbonyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-({[(1S)-2-hydroxy-1-pyridin-2-ylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(1,2-dihydroxyethyl)-N-{4-[(propylamino)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoylpiperidin-4-yl)butyl]-5-cyano-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1′-butyryl-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1′-isobutyryl-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(tetrahydrofuran-3-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide; and
  • N-[2-(4-acetylpiperazin-1-yl)-1H-benzimidazol-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(5-oxo-L-prolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(5-oxo-D-prolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-propionyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-ethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(methoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(ethoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(cyclopropylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(cyclopentylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-methylbenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methylbenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-methoxybenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methoxybenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(4-methoxybenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-fluorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-fluorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(4-fluorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(4-chlorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[3-(dimethylamino)benzoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[4-(dimethylamino)benzoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-furoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-thienylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1H-pyrrol-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2,5-dimethyl-1H-pyrrol-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1,3-thiazol-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1H-pyrazol-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(3,5-dimethyl-1,2-oxazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridin-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridin-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isonicotinoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridazin-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyrazin-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyrimidin-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[3-(piperidin-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1′-benzoyl-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[6-(benzoylamino)hexyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[(benzoylamino)methyl]benzyl}carbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(5-oxo-L-prolyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(5-oxo-D-prolyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(1-acetylpiperidin-4-yl)carbonyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-acetamidobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[4-(methylsulfonyl)benzoyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-butyrylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-isobutyrylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-methylbutanoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3,3,3-trifluoropropanoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(methoxyacetyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(tetrahydrofuran-3-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(cyclopentylacetyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(cyclohexylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-methoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3-methoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(4-methoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3-fluorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-chlorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(4-chlorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3-cyanobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(4-cyanobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[3-(dimethylamino)benzoyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[4-(dimethylamino)benzoyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3,5-dimethoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(3,4-dimethoxyphenyl)acetyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-furoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3-furoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(1H-pyrrol-2-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(1H-pyrazol-5-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyridin-2-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-isonicotinoylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyridazin-3-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyrazin-2-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyrimidin-4-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(N,N-dimethyl-beta-alanyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-acetylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-fluorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(4-fluorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(phenylacetyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(1,3-thiazol-4-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(morpholin-4-ylacetyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-phenylbutyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-butyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-benzoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-oxo-2,3-dihydro-1H-isoindol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)cyclohex-3-en-1-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)cyclohex-3-en-1-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)cyclohex-3-en-1-yl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1-(2-phenylethyl)-1H-pyrazol-4-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N5-[2-(dimethylamino)ethyl]-N2-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • 5-(morpholin-4-ylcarbonyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{benzyl[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(isobutoxycarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-bromo-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 4-{[(5-cyano-1,3-dihydro-2H-isoindol-2-yl)carbonyl]amino}benzoate;
  • N-(4-{(E)-[(benzyloxy)imino]methyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1S)-2-hydroxy-1-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3-aminopyrrolidin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-methylbutyl)carbamoyl]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-phenylpropyl)carbamoyl]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(tetrahydrofuran-3-ylmethyl)carbamoyl]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N2-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N-[4-({benzyl[3-(morpholin-4-yl)propyl]amino}methyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(1H-pyrazol-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(1-methyl-1H-pyrazol-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N2-{4-[(cyclopentylacetyl)amino]phenyl}-N5-(2-methoxyethyl)-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N2-{4-[(cyclopentylacetyl)amino]phenyl}-N5-(2-hydroxyethyl)-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • 5-(aminomethyl)-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-(methylthio)butan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S,3S)-1-hydroxy-3-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S,3R)-1,3-dihydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxyhexan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxypentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S,2S)-2-hydroxycyclopentyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S,2R)-2-hydroxycyclopentyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-cyclohexyl-3-hydroxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({(2R)-1-hydroxy-3-[(4-methylbenzyl)thio]propan-2-yl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-(4-tert-butylphenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-methoxy-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide; N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[6-(benzoylamino)hexyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(pyridin-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(cyclopentylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[1′-(tetrahydrofuran-3-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{1′-[(2-methoxyethoxy)acetyl]-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-(4-phenylbutyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(3-methylbutyl)carbamoyl]pyrazin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-acetamidohexyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{(1E)-3-[benzyl(methyl)amino]prop-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-phenoxypiperidin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3-phenoxyazetidin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[benzyl(methyl)amino]methyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3R)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-hydroxypiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-hydroxy-2-methylpropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-benzyl-1H-1,2,3-triazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methylbutyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylmethyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1H-1,2,3-triazol-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1-benzylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[4-(morpholin-4-yl)benzyl]-1H-1,2,3-triazol-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyl-1H-1,2,3-triazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(cyclopentylmethyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methoxypropyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(tetrahydrofuran-3-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-(4-{[(2-methoxyethoxy)acetyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1′-isobutyryl-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(1′-benzoyl-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(tetrahydrofuran-3-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{1′-[(2-methoxyethoxy)acetyl]-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(6-{[4-(methylsulfonyl)benzoyl]amino}hexyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(ethoxyacetyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(cyclopentylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(2-hydroxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-hydroxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(4-hydroxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(2-methoxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-methoxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(4-methoxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(2-fluorobenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-fluorobenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(4-fluorobenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(2-chlorobenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-chlorobenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(4-chlorobenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-cyanobenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(4-cyanobenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[3-(dimethylamino)benzoyl]amino}hexyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[4-(dimethylamino)benzoyl]amino}hexyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[3-(trifluoromethyl)benzoyl]amino}hexyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[4-(trifluoromethyl)benzoyl]amino}hexyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[3-(trifluoromethoxy)benzoyl]amino}hexyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(2,3-dimethoxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(2,4-dimethoxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(2,5-dimethoxybenzoyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(phenylacetyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[(3-fluorophenyl)acetyl]amino}hexyl)-1,3-dihydro-2H-isoindole-2-carboxamide;


5-(hydroxymethyl)-N-{4-[(tetrahydrofuran-2-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;

  • N-{4-[(ethoxyacetyl)amino]phenyl}-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(tetrahydro-2H-pyran-4-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(morpholin-4-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(morpholin-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[6-(benzoylamino)hexyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 4-fluoro-N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-cyano-N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-chloro-N-{6-[(pyridin-3-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(pyridin-2-ylcarbonyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(tetrahydrofuran-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(tetrahydro-2H-pyran-4-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(1,4-dioxan-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{1′-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(2-hydroxy-2-methylpropanoyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(tetrahydrofuran-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(tetrahydro-2H-pyran-4-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(1,4-dioxan-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{1′-[(1-methylpyrrolidin-3-yl)carbonyl]-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{1′-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyrrolidin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(7-oxo-7-{[(3R)-tetrahydrofuran-3-ylmethyl]amino}heptyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{7-oxo-7-[(tetrahydro-2H-pyran-4-ylmethyl)amino]heptyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-isopropoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(azetidin-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[methyl(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(isobutylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cyclopentylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-isopropoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[benzyl(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(6-methoxypyridin-3-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-isobutoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(trifluoromethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[5-(morpholin-4-ylmethyl)-1,2,4-oxadiazol-3-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{5-[(4-methylpiperazin-1-yl)methyl]-1,2,4-oxadiazol-3-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-{[(3-methylbutyl)amino]methyl}-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{5-[(4-hydroxypiperidin-1-yl)methyl]-1,2,4-oxadiazol-3-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(2-hydroxy-2-methylpropanoyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(tetrahydrofuran-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(tetrahydro-2H-pyran-4-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(1,4-dioxan-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{1′-[(1-methylpyrrolidin-3-yl)carbonyl]-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{1′-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(2-hydroxy-2-methylpropanoyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(2-aminoethyl)-1H-imidazol-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyrimidin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(pyridin-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-methoxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[3-(hydroxymethyl)oxetan-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2-{benzyl[3-(morpholin-4-yl)propyl]amino}-2-oxoethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3-{benzyl[3-(morpholin-4-yl)propyl]amino}-3-oxopropyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2R)-butan-2-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-cyano-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-methyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-chloro-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(6-bromo-2-oxoquinolin-1(2H)-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[6-(3-acetylphenyl)-2-oxoquinolin-1(2H)-yl]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(morpholin-4-ylacetyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(morpholin-4-ylacetyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(2-{(4-fluorobenzyl)[4-(pyridin-3-yl)benzyl]amino}-1,3-thiazol-5-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2-benzyl-1,3-thiazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(7-{benzyl[3-(morpholin-4-yl)propyl]amino}-7-oxoheptyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(1,3-thiazol-5-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1R)-3-hydroxy-1-phenylpropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[2-hydroxy-1-(4-methylphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(1,3-dihydroxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2R)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(3-furylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[4-(2-furoyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[4-(ethylsulfonyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1R)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2S)-1-hydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(2,3-dihydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[2-hydroxy-1-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(1-hydroxy-4-methylpentan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(5-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}pyridin-2-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.3]hept-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.4]oct-6-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.4]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,8-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3,9-diazaspiro[5.5]undec-3-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,9-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,8-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[5.5]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.6]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-oxa-9-azaspiro[5.5]undec-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxa-4,8-diazaspiro[5.5]undec-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,6-diazaspiro[3.5]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,5-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-oxa-2-azaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(6-oxa-2-azaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(hexahydro-5H-furo[2,3-c]pyrrol-5-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tetrahydro-1H-furo[3,4-c]pyrrol-5 (3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(hexahydrofuro[3,4-c]pyridin-5 (3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-{benzyl[3-(morpholin-4-yl)propyl]amino}-4-oxobutyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-phenylbutyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2-{benzyl[3-(morpholin-4-yl)propyl]amino}ethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-acetyl-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[(3-methylbutyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)sulfamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(1-hydroxyethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(butyrylamino)phenyl]-5-cyano-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyrrolidin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-pyrrolidin-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3-methoxybenzyl)sulfonyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.4]oct-6-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-1-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,8-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-7-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,8-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[5.5]undec-8-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.6]undec-8-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(1-oxa-4,8-diazaspiro[5.5]undec-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-1-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-8-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.4]oct-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,6-diazaspiro[3.5]non-1-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,5-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(5-oxa-2-azaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(6-oxa-2-azaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(2-oxa-7-azaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(hexahydro-5H-furo[2,3-c]pyrrol-5-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(hexahydrofuro[3,4-c]pyridin-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[6-(3-acetylphenyl)-4-(3-hydroxypropyl)-2-oxoquinolin-1(2H)-yl]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-(acetamidomethyl)-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[2-(2-chlorobenzyl)-1,3-thiazol-4-yl]-2-thienyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-fluorophenyl)butyl]-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(3R)-1-isobutyrylpyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[(3R)-1-benzoylpyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[1-(methylsulfonyl)pyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-isobutyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylmethyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylmethyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-isobutylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylmethyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylmethyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(2-hydroxypropan-2-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl {4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzyl}carbamate;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(methoxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-{[(tetrahydrofuran-2-ylmethyl)amino]methyl}-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{5-[(4-methoxypiperidin-1-yl)methyl]-1,2,4-oxadiazol-3-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-{[4-(2-methoxyethyl)piperazin-1-yl]methyl}-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[1-(morpholin-4-yl)cyclopentyl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-pentanoylpiperidin-4-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-butyrylpiperidin-4-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{6-[(1-acetylpiperidin-4-yl)oxy]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(1-isobutyrylpiperidin-4-yl)oxy]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(methoxyacetyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclopropylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclobutylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclopentylacetyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl (2-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}ethyl)carbamate;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-1-(4-fluorophenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[3-(hydroxymethyl)oxetan-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-1-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)sulfamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydrofuran-3-ylmethyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-(4-fluorophenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3,3,3-trifluoropropanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(4,4,4-trifluorobutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-phenylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(phenylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4-methoxyphenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(methoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-benzoylpyrrolidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-ethoxypropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2-methylcyclopropyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(1-methylcyclopropyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-acetylpyrrolidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(4,4,4-trifluorobutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(ethoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1-methylpiperidin-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[1-(2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl[(1-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}azetidin-3-yl)methyl]carbamate;
  • N-(4-{4-[(tetrahydrofuran-3-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydro-2H-pyran-4-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(morpholin-4-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(2-methoxyethoxy)acetyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(2,3-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(cyclohexylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(morpholin-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(morpholin-4-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2,2-dimethylpropanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3,3-dimethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tricyclo[3.3.1.1˜3,7˜]dec-1-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4-methoxycyclohexyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[4-(acetylamino)phenyl]sulfonyl}amino)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(propylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(4-propylphenyl)sulfonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(butylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[({[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl}sulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(ethylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(benzylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(4-fluorophenyl)sulfonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(thiophen-2-ylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,6-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,9-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,8-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[5.5]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.6]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-oxa-9-azaspiro[5.5]undec-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-oxa-4,8-diazaspiro[5.5]undec-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,6-diazaspiro[3.5]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,5-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(5-oxa-2-azaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(6-oxa-2-azaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(hexahydro-5H-furo[2,3-c]pyrrol-5-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(hexahydrofuro[3,4-c]pyridin-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(N,N-dimethylglycyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydrofuran-2-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydrofuran-3-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(cyclohexylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(4,4-difluorocyclohexyl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-hydroxy-2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydrofuran-2-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(piperidin-1-ylsulfonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(1,3-thiazol-2-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4,4-difluorocyclohexyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;


5-fluoro-N-(4-{[2-methyl-2-(morpholin-4-yl)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;


5-fluoro-N-(4-{[2-(2-methyl-1,3-thiazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;

  • 5-fluoro-N-(4-{[2-methyl-1-(morpholin-4-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • Nalpha-(4-{[(5-fluoro-1,3-dihydro-2H-isoindol-2-yl)carbonyl]amino}benzoyl)-D-phenylalaninamide;
  • N-(4-{[2-(acetylamino)phenyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(furan-2-yl)-2-(pyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-amino-1-oxohexan-2-yl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • Nalpha-(4-{[(5-fluoro-1,3-dihydro-2H-isoindol-2-yl)carbonyl]amino}benzoyl)-L-phenylalaninamide;
  • N-(4-{[(2R)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(methylcarbamoyl)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-amino-2-oxo-1-phenylethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-tert-butoxypropyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-2-amino-2-oxo-1-phenylethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-methyl-2-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3S)-1-methyl-2-oxoazepan-3-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(5-methyl-1H-pyrazol-1-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(4-chloro-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)butyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-carbamoylbenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-amino-1-oxohexan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • Nalpha-{4-[(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-ylcarbonyl)amino]benzoyl}-L-phenylalaninamide;
  • N-(4-{[(2R)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-tert-butoxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(3S)-1-methyl-2-oxoazepan-3-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(4,5,6,7-tetrahydro-1H-indazol-5-ylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • 5-fluoro-N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethylbutyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(furan-2-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3-methyl-1,2-oxazol-5-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-cyanobutan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2R)-butan-2-ylcarbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(ethylamino)-1-oxopropan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methoxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(1-methoxybutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-ethoxypropyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[benzyl(methyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(5-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(3-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(1-methylcyclopropyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(thiophen-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(4-methoxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(5-methyl-1,3-oxazol-2-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(tetrahydro-2H-pyran-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-1-methoxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethyl-2-oxobutyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1-methyl-1H-pyrrol-2-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(propan-2-yloxy)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-amino-1-oxobutan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(tetrahydro-2H-pyran-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(1H-pyrrol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclopentylcarbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2R)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-2-methylbutyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(tetrahydro-2H-pyran-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-cyanoethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(5-methyl-1,2-oxazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3,3-dimethylbutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(furan-2-yl)propan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(3-methyl-1,2-oxazol-5-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2R)-1-cyanobutan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methoxybutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(1,3-thiazol-2-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(1-methyl-1H-pyrazol-4-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-methoxybutan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-aminobenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-ethoxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(6-methoxypyridin-3-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-cyanocyclopropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(5-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(4-methyl-1,3-thiazol-2-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(1-methylcyclopropyl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(thiophen-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-methoxybutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(tetrahydro-2H-pyran-3-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2S)-1-methoxypropan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3,3-dimethyl-2-oxobutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrrol-2-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(propan-2-yloxy)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(tetrahydro-2H-pyran-3-ylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(1H-pyrrol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2R)-3-methylbutan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-cyanoethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methoxy-2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[methyl(propyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • methyl 1-{4-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]phenyl}azetidine-3-carboxylate;
  • N-(4-{3-[(3-methylbutyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(tetrahydrofuran-2-ylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[3-(benzylcarbamoyl)azetidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[3-(cyclopentylcarbamoyl)azetidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(cyclopentylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(2-methoxyethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopentylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-2-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(pyrrolidin-1-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(pyrazin-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4,4-difluorocyclohexyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-cyanobutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(ethylamino)-1-oxopropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(tetrahydro-2H-pyran-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(5-methyl-1,3-oxazol-2-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[(dimethylamino)methyl]benzyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-2-amino-2-oxo-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3-oxazol-2-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tetrahydro-2H-pyran-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(1-methylcyclopropyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(furan-2-yl)-2-(pyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[1-(2-hydroxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[1-(morpholin-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-fluorobenzyl)(3-methylbutanoyl)amino]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(9-chloro-5-oxo-2,3,3a,4,4a,5-hexahydro-6H-furo[2′,3′:2,3]cyclobuta[1,2-c]quinolin-6-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[7-chloro-1-(2-hydroxyethyl)-3-oxo-1,3-dihydrocyclobuta[c]quinolin-4(2H)-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(6-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(cyclopropylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-acetylpiperidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-butanoylpiperidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-methylbutanoyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(methoxyacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutanoyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-2-ylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(3,5-dimethyl-1H-pyrazol-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-1-methyl-2-oxoazepan-3-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(1,3-thiazol-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(furan-2-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(1-methyl-1H-pyrazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,2-difluoroethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(tetrahydro-2H-pyran-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(5-methyl-1,2-oxazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrazol-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • Nalpha-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}-L-phenylalaninamide;
  • N-(4-{[2(2-methyl-1,3-thiazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(thiophen-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(5-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethyl-2-oxobutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(acetylamino)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-methoxybutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tetrahydro-2H-pyran-4-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pyrimidin-4-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-pyrrol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-methylbutyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-amino-1-oxohexan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-amino-2-oxo-1-phenylethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-tert-butoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(methylcarbamoyl)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-methyl-1-(morpholin-4-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(5-oxo-L-prolyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-ethoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylacetyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylacetyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(4,4-difluorocyclohexyl)carbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(propan-2-yloxy)acetyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-ethoxypropanoyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-acetylpiperidin-4-yl)carbonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(ethoxyacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-2-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{7-oxo-7-[(3-phenylpropyl)amino]heptyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(bicyclo[2.2.1]hept-2-ylacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1,3-thiazol-5-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(4-oxo-4,5,6,7-tetrahydro-1-benzofuran-3-yl)carbonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{2-[(3-methylbutanoyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(4-methylpentanoyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(ethoxyacetyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2-{[(2-methoxyethoxy)acetyl]amino}ethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(tetrahydrofuran-2-ylcarbonyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(cyclopentylcarbonyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(cyclopentylacetyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[2-(benzoylamino)ethyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(tetrahydro-2H-pyran-4-ylcarbonyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(tetrahydro-2H-pyran-4-ylacetyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(tetrahydrofuran-3-ylacetyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(5-oxo-L-prolyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-propanoylazetidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2,2-dimethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-ethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(p ent-4-ynoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(furan-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(furan-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(thiophen-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(1H-pyrrol-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyrimidin-4-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(5-methylpyrazin-2-yl)carbonyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(N,N-dimethylglycyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(N,N-dimethyl-beta-alanyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyrrolidin-1-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(pyrrolidin-1-yl)propanoyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(piperidin-1-yl)propanoyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4-methylpiperazin-1-yl)acetyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(4-methylpiperazin-1-yl)propanoyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-cyclopropylethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-cyclopentylethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3,3-dimethylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-methylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylpropyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(butylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(phenylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4-fluorophenyl)sulfonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(ethylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(propan-2-ylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(benzylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(propylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(thiophen-2-ylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4,4-difluoro cyclohexyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(5-oxo-D-prolyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylpentanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-ethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(1H-pyrrol-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(1,2-oxazol-5-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyridin-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyridazin-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyrazin-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyrimidin-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(5-methylpyrazin-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(piperidin-1-yl)propanoyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(morpholin-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(4-methylpiperazin-1-yl)propanoyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • benzyl trans-3-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]cyclobutanecarboxylate;
  • N-[4-(4-{[(4-methylpiperazin-1-yl)acetyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydro-2H-pyran-4-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(benzoylamino)cyclohex-1-en-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(1-methylpiperidin-4-yl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(3R)-tetrahydrofuran-3-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(3S)-tetrahydrofuran-3-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(2S)-2-methylbutanoyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(3-methylbutanoyl)amino]oxetan-3-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • tert-butyl 4-({4-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]phenyl}sulfonyl)piperidine-1-carboxylate;
  • N-{4-[4-(propylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-methoxyethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(cyclopentylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(1,4-dioxan-2-ylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(cyclopentylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(tetrahydro-2H-pyran-4-ylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(morpholin-4-ylcarbonyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(cyclopropylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(butan-2-ylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{(4R)-4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{(4S)-4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-benzoylazetidin-3-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoylazetidin-3-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[trans-3-(benzylcarbamoyl)cyclobutyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{trans-3-[(2-phenylethyl)carbamoyl]cyclobutyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{trans-3-[(3-phenylpropyl)carbamoyl]cyclobutyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methyl-1,3-oxazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(furan-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2E)-3-(furan-2-yl)prop-2-enoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1,3-oxazol-5-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3,3,3-trifluoropropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,5-dimethyl-1H-pyrazol-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(4-methoxycyclohexyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2,3-dimethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2,2-difluorocyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1H-pyrazol-5-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tert-butoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[3-(1H-1,2,4-triazol-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3-ethoxypropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3-hydroxy-3-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[3-(1H-pyrrol-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methylcyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methylpropoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1-methylprolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-hydroxycyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopropylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopentylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-{[1-(methoxymethyl)cyclopropyl]carbonyl}-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(methylsulfonyl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methyl-1H-pyrazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopropylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-ethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(5-oxo-L-prolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2E)-4-methylpent-2-enoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-methoxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopent-1-en-1-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(thiophen-3-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclohexylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-propanoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2,2-dimethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(methoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2,2-dimethylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(4-methylhexanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2,2-dimethylcyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclobutylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(piperidin-1-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[2-(pyrrolidin-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,3-dimethyl-1H-pyrazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cis-4-{[(2-methoxyethoxy)acetyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(trans-4-{[(2-methoxyethoxy)acetyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cis-4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(trans-4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cis-4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(trans-4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(6-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3R)-1-(cyclobutylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({(3R)-1-[(2R)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({(3R)-1-[(2S)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3R)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-1-(cyclobutylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({(3S)-1-[(2R)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({(3S)-1-[(2S)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(6-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{6-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{6-[(cyclopentylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{6-[(tetrahydrofuran-3-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{6-[(bicyclo[2.2.1]hept-2-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{trans-4-[(2-methylpropanoyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{cis-4-[(2-methylpropanoyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{cis-4-[(cyclohexylcarbonyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{trans-4-[(cyclohexylcarbonyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{trans-4-[(cyclopropylacetyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{cis-4-[(cyclopropylacetyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(cyclopentylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(cyclopropylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(2-hydroxy-2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(tetrahydro-2H-pyran-4-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(cyclohexylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide; and pharmaceutically acceptable salts thereof.


Still another embodiment pertains to compounds of Formula (Ic), which are

  • N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-fluoro-N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide; and pharmaceutically acceptable salts thereof.


Still another embodiment pertains to compounds of Formula (Ic), which are

  • N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide; and pharmaceutically acceptable salts thereof.


Embodiments of Formula (IIc)

In another aspect, the present invention provides compounds of Formula (IIc)




embedded image


and pharmaceutically acceptable salts thereof; wherein X1, X2, X3, are as described herein for Formula (Ic); and R2 is phenyl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein the R2 phenyl, heterocyclyl, cycloalkyl, and cycloalkenyl are optionally substituted as described herein for substituents on R2 in Formula (Ic).


In one embodiment of formula (IIc),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R2 is phenyl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R2 phenyl is optionally substituted at the para position with one independently selected R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, Br or I; wherein each R2 phenyl is optionally additionally substituted with one F; wherein each R2 heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R3, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R10, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R5, R6, R9, and R10 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I;


R15, at each occurrence, is independently selected alkyl; wherein the R15 alkyl is optionally substituted with one, two, three or four alkoxy; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four alkoxy;


with the proviso that when X1, X2, and X3 are CH and R2 is phenyl; R5 is not methyl;


with the proviso that when X1, X2, and X3 are CH, and R2 is phenyl substituted with OR5; R5 is not methyl;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


In one embodiment of Formula (IIc), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (IIc), X1, X2, and X3 are CH. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (IIc), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (IIc), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (IIc), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (IIc), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (IIc), X1 is N; X2 is CR1; and X3 is N.


In another embodiment of Formula (IIc), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIc), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), R1 is C(O)NH2. In another embodiment of Formula (IIc), R1 is F. In another embodiment of Formula (IIc), R1 is Cl. In another embodiment of Formula (IIc), R1 is Br. In another embodiment of Formula (IIc), R1 is CN. In another embodiment of Formula (IIc), R1 is NH2. In another embodiment of Formula (IIc), R1 is NO2. In another embodiment of Formula (IIc), R1 is CF3. In another embodiment of Formula (IIc), R1 is C(O)OH. In another embodiment of Formula (IIc), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IIc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IIc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (IIc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


Still another embodiment pertains to compounds having Formula (IIc), which include

  • N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(aminomethyl)benzyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(furo[3,2-c]pyridin-4-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(pyridin-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(benzylcarbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(thieno[3,2-c]pyridin-4-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,3-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(pyridazin-3-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,3-dihydro-1,4-benzodioxin-5-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(3-methylbutyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-fluorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-5-methyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(4-cyanophenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-fluorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,5-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,2-dimethylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(2-oxopyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethoxy)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-fluoro-5-(trifluoromethyl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-chlorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4,5-trimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-nitro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(4-fluorophenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-ethyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-benzyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-methoxyphenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(3-methoxyphenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(4-acetylphenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,3-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyridin-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(2-thienyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3-methylbutyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(6-aminohexyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-thienyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1,3-benzodioxol-5-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridin-3-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(benzylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridazin-3-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyrimidin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(3-fluorophenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-butoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,4-dihydroxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-propoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-furylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-cyanophenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxy-2-methylphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)carbamoyl]phenyl}-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methyl-1H-indazol-5-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-ethoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,5-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4[(1-benzyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 5-({4[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}amino)-1H-indazole-3-carboxylate;
  • N-(4-{[2-(2-oxopyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(5-chloropyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-indol-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethyl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,5-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,3-dihydro-1,4-benzodioxin-6-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-fluorobenzoyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(5-methoxy-1H-indol-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-chlorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-propoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-isobutoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridin-4-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4,5-trimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methylpiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[4-(dimethylamino)phenyl]ethyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(trifluoromethoxy)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-3-hydroxy-1-phenylpropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-cyanophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluoro-4-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,3-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-fluorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(isobutylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1,3-benzodioxol-5-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-isopropoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-isopropoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-fluorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,4-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N2-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N-{4-[(2-phenoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-hydroxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3-fluorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({1-[(3S)-tetrahydrofuran-3-yl]-1H-pyrazol-4-yl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-phenylethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(methylthio)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-ethoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-fluorophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(pyridin-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[(trifluoromethyl)thio]benzyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(2-fluorophenyl)pyrrolidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3-chlorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(hydroxymethyl)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3-benzodioxol-5-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-isopropyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-hydroxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-ethyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,5-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[methyl(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(thiomorpholin-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-furoyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-benzylpiperidin-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(5-acetamido-2-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,5-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[3-(trifluoromethyl)phenyl]ethyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylbutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-imidazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-1-(3-cyanophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[benzyl(2-hydroxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-cyanophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-chlorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyanomethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclohexylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[butyl(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(dimethylamino)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,3-dihydro-1H-indol-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(phenylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-fluorophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(diethylamino)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-hydroxy-2-phenylethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-aminophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl (1-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}piperidin-4-yl)carbamate;
  • N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(cyclohexylmethyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3-chlorobenzyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(diethylcarbamoyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-hydroxy-6-methylphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(5-fluoropyridin-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopropylmethyl)(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-methoxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3,4,9-tetrahydro-2H-beta-carbolin-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tert-butylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-difluoropyrrolidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylpiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-1-benzylpyrrolidin-3-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-hydroxypiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluorophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclopentylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-carbamoylpiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclopropylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(methylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pentan-2-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pentan-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclobutylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1,3-dioxolan-2-ylmethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(4-fluorophenyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-hydroxy-2-methylpropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-phenyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[4-(trifluoromethyl)phenyl]ethyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxyethyl)(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(sec-butylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(trifluoromethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[bis(2-ethoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[butyl(ethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(morpholin-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[isobutyl(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylpiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-carbamoylphenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylpyrrolidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[ethyl(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,6-dimethylmorpholin-4-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-hydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,5-dimethylpyrrolidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(prop-2-yn-1-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[isopropyl(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[isopropyl(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-cyanoethyl)(cyclopropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[ethyl(isopropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluoropyrrolidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}-N-isopropyl-beta-alanine;
  • N-{4-[methyl(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5,6-dimethoxy-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(4-chlorophenoxy)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethoxy)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenyl-1,3-thiazol-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 2-{[4-(propylcarbamoyl)phenyl]carbamoyl}isoindoline-5-carboxylate; 2-{[4-(propylcarbamoyl)phenyl]carbamoyl}isoindoline-5-carboxylic acid;
  • 5-amino-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(aminomethyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(2-hydroxy-2-methylpropanoyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-acetamido-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(N,N-dimethylglycyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-5-(1H-pyrazol-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-5-(1H-pyrazol-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(methoxyacetyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(methylsulfonyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-bromo-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,5-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-chlorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4,4,4-trifluorobutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-ethoxypropanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenylbutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methylpentanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(benzyloxy)acetyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-phenylpropanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-phenoxypropanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[N-(2-furoyl)glycyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-thienyl)butanoyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-oxo-4-phenylbutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(N-benzoylglycyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenoxybutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propionylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pentanoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(hexanoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(heptanoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pent-4-enoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(ethoxyacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2-methoxyethoxy)acetyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopropylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(4-methylpiperazin-1-yl)propanoyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 2-({4-[(cyclopentylacetyl)amino]phenyl}carbamoyl)isoindoline-5-carboxylate;
  • 2-({4-[(cyclopentylacetyl)amino]phenyl}carbamoyl)isoindoline-5-carboxylic acid;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-cyclopentylethyl)amino]phenyl}-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}-3,6-dihydropyridine-1(2H)-carboxylate;
  • N-[4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methylbutyl)-1H-pyrazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1E)-5-phenylpent-1-en-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-propyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[6-(1-propyl-1H-pyrazol-4-yl)pyridin-3-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-phenylpentyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[2-fluoro-4-(1-propyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{2-fluoro-4-[1-(3-methylbutyl)-1H-pyrazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-butyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(isopropylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1′-isobutyryl-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1′-benzoyl-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-benzoylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(isopropylsulfonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(phenylsulfonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[3-(benzoylamino)pyrrolidin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[3-(butyrylamino)pyrrolidin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}piperazine-1-carboxylate;
  • N-[4-(4-propionylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(2-butyryl-2,3-dihydro-1H-isoindol-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(2-isobutyryl-2,3-dihydro-1H-isoindol-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(2-benzoyl-2,3-dihydro-1H-isoindol-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[2-(3-methylbutyl)-2,3-dihydro-1H-isoindol-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(hexyloxy)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(5-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}pyridin-2-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(3-phenylpropyl)carbamoyl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(3-methylbutyl)carbamoyl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(3-phenylpropyl)carbamoyl]-1,3-thiazol-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(3-methylbutyl)carbamoyl]-1,3-thiazol-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(isoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(8-fluoro-4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(morpholin-4-ylmethyl)-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(4-methylpiperazin-1-yl)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-chloro-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-4,5-dihydro-3H-2,3-benzodiazepin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-oxo-8-(trifluoromethyl)-3,4-dihydrophthalazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(dimethylamino)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(di ethylamino)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(4-methylpiperazin-1-yl)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(dimethylamino)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(di ethylamino)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-oxo-8-(trifluoromethyl)-3,4-dihydrophthalazin-1-yl]phenyl}-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(1-methylpiperidin-4-yl)oxy]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-{[(3R)-3-fluoropyrrolidin-1-yl]methyl}-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-{[(3S)-3-fluoropyrrolidin-1-yl]methyl}-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(azetidin-1-ylmethyl)-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydropyrrolo[1,2-d][1,2,4]triazin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydropyrrolo[1,2-d][1,2,4]triazin-4-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}piperidine-1-carboxylate;
  • N-[4-(5-propyl-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(piperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(tetrahydrofuran-3-ylmethyl)carbamoyl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-butyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[5-(3-methylbutyl)-1,2,4-oxadiazol-3-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-benzyl-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3R)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(5-chloropyridin-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxy-4-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,4-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-oxopyrrolidin-1-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-hydroxycyclopropyl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl 4-{6-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]-1H-benzimidazol-2-yl}piperazine-1-carboxylate;
  • N-[2-(piperazin-1-yl)-1H-benzimidazol-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-5-vinyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-benzoylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[5-(tetrahydrofuran-3-yl)-1,2,4-oxadiazol-3-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3-methylbutyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide;
  • N-(4-{[(3-phenylpropyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide;
  • N-{4-[1-(4-methylbenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(tetrahydrofuran-3-ylmethyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-({[(2S)-tetrahydrofuran-2-ylmethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-({[(2R)-tetrahydrofuran-2-ylmethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(1S)-2-hydroxy-1-phenylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(2-methoxyethyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-(2-hydroxyethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(propylamino)carbonyl]phenyl}-5-pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(propylamino)carbonyl]phenyl}-5-pyridin-4-yl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N5-(2-methoxyethyl)-N2-{4-[(propylamino)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N-(4-cyanophenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(trifluoromethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(1S)-2-hydroxy-1-pyridin-2-ylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3-methylbutyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(tetrahydrofuran-3-ylmethyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-pyridin-2-ylpiperazin-1-yl)carbonyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-({[(1S)-2-hydroxy-1-pyridin-2-ylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(1,2-dihydroxyethyl)-N-{4-[(propylamino)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1′-butyryl-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1′-isobutyryl-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(tetrahydrofuran-3-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide; and
  • N-[2-(4-acetylpiperazin-1-yl)-1H-benzimidazol-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(5-oxo-L-prolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(5-oxo-D-prolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-propionyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-ethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(methoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(ethoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(cyclopropylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(cyclopentylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-methylbenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methylbenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-methoxybenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methoxybenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(4-methoxybenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-fluorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-fluorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(4-fluorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(4-chlorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[3-(dimethylamino)benzoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[4-(dimethylamino)benzoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-furoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-thienylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1H-pyrrol-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2,5-dimethyl-1H-pyrrol-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1,3-thiazol-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1H-pyrazol-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(3,5-dimethyl-1,2-oxazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridin-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridin-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isonicotinoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridazin-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyrazin-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyrimidin-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[3-(piperidin-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1′-benzoyl-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[6-(benzoylamino)hexyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[(benzoylamino)methyl]benzyl}carbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(5-oxo-L-prolyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(5-oxo-D-prolyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(1-acetylpiperidin-4-yl)carbonyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-acetamidobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[4-(methylsulfonyl)benzoyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-butyrylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-isobutyrylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-methylbutanoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3,3,3-trifluoropropanoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(methoxyacetyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(tetrahydrofuran-3-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(cyclopentylacetyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(cyclohexylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-methoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3-methoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(4-methoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3-fluorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-chlorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(4-chlorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3-cyanobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(4-cyanobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[3-(dimethylamino)benzoyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[4-(dimethylamino)benzoyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3,5-dimethoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(3,4-dimethoxyphenyl)acetyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-furoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3-furoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(1H-pyrrol-2-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(1H-pyrazol-5-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyridin-2-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-isonicotinoylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyridazin-3-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyrazin-2-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyrimidin-4-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(N,N-dimethyl-beta-alanyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-acetylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-fluorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(4-fluorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(phenylacetyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(1,3-thiazol-4-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(morpholin-4-ylacetyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-butyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-benzoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-oxo-2,3-dihydro-1H-isoindol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)cyclohex-3-en-1-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)cyclohex-3-en-1-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)cyclohex-3-en-1-yl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1-(2-phenylethyl)-1H-pyrazol-4-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N5-[2-(dimethylamino)ethyl]-N2-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • 5-(morpholin-4-ylcarbonyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{benzyl[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(isobutoxycarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-bromo-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 4-{[(5-cyano-1,3-dihydro-2H-isoindol-2-yl)carbonyl]amino}benzoate;
  • N-(4-{(E)-[(benzyloxy)imino]methyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1S)-2-hydroxy-1-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3-aminopyrrolidin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-methylbutyl)carbamoyl]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(3-phenylpropyl)carbamoyl]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(tetrahydrofuran-3-ylmethyl)carbamoyl]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N2-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N-[4-({benzyl[3-(morpholin-4-yl)propyl]amino}methyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(1H-pyrazol-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(1-methyl-1H-pyrazol-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N2-{4-[(cyclopentylacetyl)amino]phenyl}-N5-(2-methoxyethyl)-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N2-{4-[(cyclopentylacetyl)amino]phenyl}-N5-(2-hydroxyethyl)-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • 5-(aminomethyl)-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-(methylthio)butan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S,3S)-1-hydroxy-3-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S,3R)-1,3-dihydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxyhexan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxypentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S,2S)-2-hydroxycyclopentyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S,2R)-2-hydroxycyclopentyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-cyclohexyl-3-hydroxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({(2R)-1-hydroxy-3-[(4-methylbenzyl)thio]propan-2-yl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-(4-tert-butylphenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-methoxy-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(pyridin-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(cyclopentylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[1′-(tetrahydrofuran-3-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{1′-[(2-methoxyethoxy)acetyl]-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[(3-methylbutyl)carbamoyl]pyrazin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{(1E)-3-[benzyl(methyl)amino]prop-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-phenoxypiperidin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3-phenoxyazetidin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[benzyl(methyl)amino]methyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3R)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-hydroxypiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-hydroxy-2-methylpropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-benzyl-1H-1,2,3-triazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methylbutyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylmethyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1H-1,2,3-triazol-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1-benzylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[4-(morpholin-4-yl)benzyl]-1H-1,2,3-triazol-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyl-1H-1,2,3-triazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(cyclopentylmethyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methoxypropyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(tetrahydrofuran-3-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-(4-{[(2-methoxyethoxy)acetyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(1′-isobutyryl-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(1′-benzoyl-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(tetrahydrofuran-3-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{1′-[(2-methoxyethoxy)acetyl]-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(tetrahydrofuran-2-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(ethoxyacetyl)amino]phenyl}-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(tetrahydro-2H-pyran-4-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(morpholin-4-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(morpholin-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(tetrahydrofuran-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(tetrahydro-2H-pyran-4-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(1,4-dioxan-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{1′-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(2-hydroxy-2-methylpropanoyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(tetrahydrofuran-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(tetrahydro-2H-pyran-4-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(1,4-dioxan-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{1′-[(1-methylpyrrolidin-3-yl)carbonyl]-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{1′-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyrrolidin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-isopropoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(azetidin-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[methyl(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(isobutylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cyclopentylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-isopropoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[benzyl(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(6-methoxypyridin-3-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-isobutoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(trifluoromethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[5-(morpholin-4-ylmethyl)-1,2,4-oxadiazol-3-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{5-[(4-methylpiperazin-1-yl)methyl]-1,2,4-oxadiazol-3-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-{[(3-methylbutyl)amino]methyl}-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{5-[(4-hydroxypiperidin-1-yl)methyl]-1,2,4-oxadiazol-3-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(2-hydroxy-2-methylpropanoyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(tetrahydrofuran-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(tetrahydro-2H-pyran-4-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(1,4-dioxan-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{1′-[(1-methylpyrrolidin-3-yl)carbonyl]-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{1′-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(2-hydroxy-2-methylpropanoyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(2-aminoethyl)-1H-imidazol-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyrimidin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(pyridin-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-methoxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[3-(hydroxymethyl)oxetan-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2-{benzyl[3-(morpholin-4-yl)propyl]amino}-2-oxoethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3-{benzyl[3-(morpholin-4-yl)propyl]amino}-3-oxopropyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2R)-butan-2-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-cyano-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-methyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-chloro-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[1′-(morpholin-4-ylacetyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[1′-(morpholin-4-ylacetyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(2-{(4-fluorobenzyl)[4-(pyridin-3-yl)benzyl]amino}-1,3-thiazol-5-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2-benzyl-1,3-thiazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(1,3-thiazol-5-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1R)-3-hydroxy-1-phenylpropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[2-hydroxy-1-(4-methylphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(1,3-dihydroxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2R)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(3-furylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[4-(2-furoyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[4-(ethylsulfonyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1R)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2S)-1-hydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(2,3-dihydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[2-hydroxy-1-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(1-hydroxy-4-methylpentan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(5-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}pyridin-2-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.3]hept-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.4]oct-6-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.4]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,8-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3,9-diazaspiro[5.5]undec-3-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,9-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,8-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[5.5]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.6]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-oxa-9-azaspiro[5.5]undec-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxa-4,8-diazaspiro[5.5]undec-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,6-diazaspiro[3.5]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,5-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-oxa-2-azaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(6-oxa-2-azaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(hexahydro-5H-furo[2,3-c]pyrrol-5-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(hexahydrofuro[3,4-c]pyridin-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-{benzyl[3-(morpholin-4-yl)propyl]amino}-4-oxobutyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2-{benzyl[3-(morpholin-4-yl)propyl]amino}ethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-acetyl-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[(3-methylbutyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)sulfamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(1-hydroxyethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(butyrylamino)phenyl]-5-cyano-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyrrolidin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-pyrrolidin-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3-methoxybenzyl)sulfonyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.4]oct-6-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-1-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,8-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-7-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,8-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[5.5]undec-8-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.6]undec-8-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(1-oxa-4,8-diazaspiro[5.5]undec-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-1-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-8-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.4]oct-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,6-diazaspiro[3.5]non-1-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,5-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(5-oxa-2-azaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(6-oxa-2-azaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(2-oxa-7-azaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(hexahydro-5H-furo[2,3-c]pyrrol-5-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(hexahydrofuro[3,4-c]pyridin-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-(acetamidomethyl)-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{5-[2-(2-chlorobenzyl)-1,3-thiazol-4-yl]-2-thienyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(3R)-1-isobutyrylpyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[(3R)-1-benzoylpyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[1-(methylsulfonyl)pyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-isobutyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylmethyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylmethyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-isobutylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylmethyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylmethyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(2-hydroxypropan-2-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl {4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzyl}carbamate;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(methoxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-{[(tetrahydrofuran-2-ylmethyl)amino]methyl}-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{5-[(4-methoxypiperidin-1-yl)methyl]-1,2,4-oxadiazol-3-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-{[4-(2-methoxyethyl)piperazin-1-yl]methyl}-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[1-(morpholin-4-yl)cyclopentyl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-pentanoylpiperidin-4-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-butyrylpiperidin-4-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{6-[(1-acetylpiperidin-4-yl)oxy]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{6-[(1-isobutyrylpiperidin-4-yl)oxy]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(methoxyacetyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclopropylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclobutylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclopentylacetyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl (2-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}ethyl)carbamate;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-1-(4-fluorophenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[3-(hydroxymethyl)oxetan-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-1-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)sulfamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydrofuran-3-ylmethyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-(4-fluorophenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3,3,3-trifluoropropanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(4,4,4-trifluorobutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-phenylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(phenylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4-methoxyphenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(methoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-benzoylpyrrolidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-ethoxypropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2-methylcyclopropyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(1-methylcyclopropyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-acetylpyrrolidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(4,4,4-trifluorobutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(ethoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1-methylpiperidin-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[1-(2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl[(1-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}azetidin-3-yl)methyl]carbamate;
  • N-(4-{4-[(tetrahydrofuran-3-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydro-2H-pyran-4-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(morpholin-4-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(2-methoxyethoxy)acetyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(2,3-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(cyclohexylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(morpholin-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(morpholin-4-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2,2-dimethylpropanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3,3-dimethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tricyclo[3.3.1.1˜3,7˜]dec-1-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4-methoxycyclohexyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[4-(acetylamino)phenyl]sulfonyl}amino)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(propylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(4-propylphenyl)sulfonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(butylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[({[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl}sulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(ethylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(benzylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(4-fluorophenyl)sulfonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(thiophen-2-ylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,6-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,9-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,8-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[5.5]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.6]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-oxa-9-azaspiro[5.5]undec-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-oxa-4,8-diazaspiro[5.5]undec-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,6-diazaspiro[3.5]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,5-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(5-oxa-2-azaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(6-oxa-2-azaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(hexahydro-5H-furo[2,3-c]pyrrol-5-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(hexahydrofuro[3,4-c]pyridin-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(N,N-dimethylglycyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydrofuran-2-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydrofuran-3-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(cyclohexylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(4,4-difluoro cyclohexyl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-hydroxy-2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydrofuran-2-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(piperidin-1-ylsulfonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(1,3-thiazol-2-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4,4-difluorocyclohexyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-methyl-2-(morpholin-4-yl)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(2-methyl-1,3-thiazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-methyl-1-(morpholin-4-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • Nalpha-(4-{[(5-fluoro-1,3-dihydro-2H-isoindol-2-yl)carbonyl]amino}benzoyl)-D-phenylalaninamide;
  • N-(4-{[2-(acetylamino)phenyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(furan-2-yl)-2-(pyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-amino-1-oxohexan-2-yl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • Nalpha-(4-{[(5-fluoro-1,3-dihydro-2H-isoindol-2-yl)carbonyl]amino}benzoyl)-L-phenylalaninamide;
  • N-(4-{[(2R)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(methylcarbamoyl)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-amino-2-oxo-1-phenylethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-tert-butoxypropyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-2-amino-2-oxo-1-phenylethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-methyl-2-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3S)-1-methyl-2-oxoazepan-3-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(5-methyl-1H-pyrazol-1-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(4-chloro-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)butyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-carbamoylbenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-amino-1-oxohexan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide; Nalpha-{4-[(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-ylcarbonyl)amino]benzoyl}-L-phenylalaninamide;
  • N-(4-{[(2R)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-tert-butoxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(3S)-1-methyl-2-oxoazepan-3-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(4,5,6,7-tetrahydro-1H-indazol-5-ylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • 5-fluoro-N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethylbutyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(furan-2-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3-methyl-1,2-oxazol-5-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-cyanobutan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2R)-butan-2-ylcarbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(ethylamino)-1-oxopropan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methoxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(1-methoxybutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-ethoxypropyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[benzyl(methyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(5-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(3-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(1-methylcyclopropyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(thiophen-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(4-methoxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(5-methyl-1,3-oxazol-2-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(tetrahydro-2H-pyran-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-1-methoxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethyl-2-oxobutyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1-methyl-1H-pyrrol-2-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(propan-2-yloxy)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-amino-1-oxobutan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(tetrahydro-2H-pyran-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(1H-pyrrol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclopentylcarbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2R)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-2-methylbutyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(tetrahydro-2H-pyran-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-cyanoethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(5-methyl-1,2-oxazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3,3-dimethylbutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(furan-2-yl)propan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(3-methyl-1,2-oxazol-5-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2R)-1-cyanobutan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methoxybutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(1,3-thiazol-2-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(1-methyl-1H-pyrazol-4-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-methoxybutan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-aminobenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-ethoxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(6-methoxypyridin-3-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-cyanocyclopropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(5-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(4-methyl-1,3-thiazol-2-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(1-methylcyclopropyl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(thiophen-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-methoxybutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(tetrahydro-2H-pyran-3-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2S)-1-methoxypropan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3,3-dimethyl-2-oxobutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrrol-2-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(propan-2-yloxy)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(tetrahydro-2H-pyran-3-ylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(1H-pyrrol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2R)-3-methylbutan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-cyanoethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methoxy-2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[methyl(propyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • methyl 1-{4-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]phenyl}azetidine-3-carboxylate;
  • N-(4-{3-[(3-methylbutyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(tetrahydrofuran-2-ylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[3-(benzylcarbamoyl)azetidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[3-(cyclopentylcarbamoyl)azetidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(cyclopentylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(2-methoxyethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopentylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-2-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(pyrrolidin-1-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(pyrazin-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4,4-difluorocyclohexyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-cyanobutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(ethylamino)-1-oxopropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(6-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(tetrahydro-2H-pyran-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(5-methyl-1,3-oxazol-2-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[(dimethylamino)methyl]benzyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-2-amino-2-oxo-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3-oxazol-2-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tetrahydro-2H-pyran-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(1-methylcyclopropyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(furan-2-yl)-2-(pyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[1-(2-hydroxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[1-(morpholin-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(6-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(cyclopropylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-acetylpiperidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-butanoylpiperidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-methylbutanoyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(methoxyacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutanoyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-2-ylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(3,5-dimethyl-1H-pyrazol-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-1-methyl-2-oxoazepan-3-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(1,3-thiazol-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(furan-2-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(1-methyl-1H-pyrazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,2-difluoroethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(tetrahydro-2H-pyran-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(5-methyl-1,2-oxazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrazol-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • Nalpha-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}-L-phenylalaninamide;
  • N-(4-{[2-(2-methyl-1,3-thiazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(thiophen-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(5-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethyl-2-oxobutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(acetylamino)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-methoxybutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tetrahydro-2H-pyran-4-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pyrimidin-4-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-pyrrol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-methylbutyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-amino-1-oxohexan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-amino-2-oxo-1-phenylethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-tert-butoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(methylcarbamoyl)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-methyl-1-(morpholin-4-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(5-oxo-L-prolyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-ethoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-ethoxypropanoyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-acetylpiperidin-4-yl)carbonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(ethoxyacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-2-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(bicyclo[2.2.1]hept-2-ylacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1,3-thiazol-5-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(4-oxo-4,5,6,7-tetrahydro-1-benzofuran-3-yl)carbonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{2-[(3-methylbutanoyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(4-methylpentanoyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(ethoxyacetyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2-{[(2-methoxyethoxy)acetyl]amino}ethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(tetrahydrofuran-2-ylcarbonyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(cyclopentylcarbonyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(cyclopentylacetyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[2-(benzoylamino)ethyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(tetrahydro-2H-pyran-4-ylcarbonyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(tetrahydro-2H-pyran-4-ylacetyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(tetrahydrofuran-3-ylacetyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(5-oxo-L-prolyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-propanoylazetidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2,2-dimethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-ethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(p ent-4-ynoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(furan-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(furan-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(thiophen-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(1H-pyrrol-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyrimidin-4-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(5-methylpyrazin-2-yl)carbonyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(N,N-dimethylglycyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(N,N-dimethyl-beta-alanyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyrrolidin-1-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(pyrrolidin-1-yl)propanoyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(piperidin-1-yl)propanoyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4-methylpiperazin-1-yl)acetyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(4-methylpiperazin-1-yl)propanoyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-cyclopropylethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-cyclopentylethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3,3-dimethylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-methylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylpropyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(butylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(phenylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4-fluorophenyl)sulfonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(ethylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(propan-2-ylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(benzylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(propylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(thiophen-2-ylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4,4-difluoro cyclohexyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(5-oxo-D-prolyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylpentanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-ethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(1H-pyrrol-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(1,2-oxazol-5-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyridin-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyridazin-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyrazin-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyrimidin-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(5-methylpyrazin-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(piperidin-1-yl)propanoyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(morpholin-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(4-methylpiperazin-1-yl)propanoyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • benzyl trans-3-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]cyclobutanecarboxylate;
  • N-[4-(4-{[(4-methylpiperazin-1-yl)acetyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydro-2H-pyran-4-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(benzoylamino)cyclohex-1-en-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(1-methylpiperidin-4-yl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(3R)-tetrahydrofuran-3-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(3S)-tetrahydrofuran-3-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(2S)-2-methylbutanoyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(3-methylbutanoyl)amino]oxetan-3-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • tert-butyl 4-({4-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]phenyl}sulfonyl)piperidine-1-carboxylate;
  • N-{4-[4-(propylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-methoxyethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(cyclopentylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(1,4-dioxan-2-ylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(cyclopentylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(tetrahydro-2H-pyran-4-ylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(morpholin-4-ylcarbonyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(cyclopropylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(butan-2-ylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{(4R)-4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{(4S)-4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[trans-3-(benzylcarbamoyl)cyclobutyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{trans-3-[(2-phenylethyl)carbamoyl]cyclobutyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{trans-3-[(3-phenylpropyl)carbamoyl]cyclobutyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methyl-1,3-oxazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(furan-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2E)-3-(furan-2-yl)prop-2-enoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1,3-oxazol-5-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3,3,3-trifluoropropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,5-dimethyl-1H-pyrazol-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(4-methoxycyclohexyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2,3-dimethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2,2-difluorocyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1H-pyrazol-5-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tert-butoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[3-(1H-1,2,4-triazol-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3-ethoxypropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3-hydroxy-3-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[3-(1H-pyrrol-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methylcyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methylpropoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1-methylprolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-hydroxycyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopropylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopentylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-{[1-(methoxymethyl)cyclopropyl]carbonyl}-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(methylsulfonyl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methyl-1H-pyrazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopropylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-ethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(5-oxo-L-prolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2E)-4-methylpent-2-enoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-methoxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopent-1-en-1-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(thiophen-3-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclohexylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-propanoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2,2-dimethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(methoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2,2-dimethylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(4-methylhexanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2,2-dimethylcyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclobutylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(piperidin-1-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[2-(pyrrolidin-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,3-dimethyl-1H-pyrazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cis-4-{[(2-methoxyethoxy)acetyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(trans-4-{[(2-methoxyethoxy)acetyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cis-4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(trans-4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cis-4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(trans-4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(6-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3R)-1-(cyclobutylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({(3R)-1-[(2R)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({(3R)-1-[(2S)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3R)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-1-(cyclobutylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({(3S)-1-[(2R)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({(3S)-1-[(2S)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(6-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{6-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{6-[(cyclopentylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{6-[(tetrahydrofuran-3-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{6-[(bicyclo[2.2.1]hept-2-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{trans-4-[(2-methylpropanoyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{cis-4-[(2-methylpropanoyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{cis-4-[(cyclohexylcarbonyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{trans-4-[(cyclohexylcarbonyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{trans-4-[(cyclopropylacetyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{cis-4-[(cyclopropylacetyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(cyclopentylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(cyclopropylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(2-hydroxy-2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(tetrahydro-2H-pyran-4-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(cyclohexylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide; and pharmaceutically acceptable salts thereof.


Embodiments of Formula (IIIc)

In another aspect, the present invention provides compounds of Formula (IIIc)




embedded image


and pharmaceutically acceptable salts thereof; wherein X1, X2, X3, are as described herein for Formula (Ic); and Rx is as described herein for substituents at the para position in Formula (Ic) when R2 is phenyl.


In one embodiment of formula (IIIc),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


Rx is R5, OR5, SR5, S(O)R5, SO2R5, C(O)R5, CO(O)R5, OC(O)R5, OC(O)OR5, NH2, NHR5, N(R5)2, NHC(O)R5, NR5C(O)R5, NHS(O)2R5, NR5S(O)2R5, NHC(O)OR5, NR5C(O)OR5, NHC(O)NH2, NHC(O)NHR5, NHC(O)N(R5)2, NR5C(O)NHR5, NR5C(O)N(R5)2, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOH, C(O)NHOR5, C(O)NHSO2R5, C(O)NR5SO2R5, SO2NH2, SO2NHR5, SO2N(R5)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, Br or I;


R3, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R10, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R5, R6, R9, and R10 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I;


R15, at each occurrence, is independently selected alkyl, wherein the R15 alkyl is optionally substituted with one, two, three or four alkoxy; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four alkoxy;


with the proviso that when X1, X2, and X3 are CH; Rx is not methyl;


with the proviso that when X1, X2, and X3 are CH; Rx is not methoxy;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


In one embodiment of Formula (IIIc), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (IIIc), X1, X2, and X3 are CH. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (IIIc), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (IIIc), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (IIIc), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (IIIc), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (IIIc), X1 is N; X2 is CR1; and X3 is N.


In another embodiment of Formula (IIIc), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIIc), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), R1 is C(O)NH2. In another embodiment of Formula (IIIc), R1 is F. In another embodiment of Formula (IIIc), R1 is Cl. In another embodiment of Formula (IIIc), R1 is Br. In another embodiment of Formula (IIIc), R1 is CN. In another embodiment of Formula (IIIc), R1 is NH2. In another embodiment of Formula (IIIc), R1 is NO2. In another embodiment of Formula (IIIc), R1 is CF3. In another embodiment of Formula (IIIc), R1 is C(O)OH. In another embodiment of Formula (IIIc), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IIIc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IIIc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (IIIc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In one embodiment of formula (IIIc), Rx is R5, OR5, SO2R5, C(O)R5, CO(O)R5, NHR5, NHC(O)R5, NHS(O)2R5, C(O)NH2, C(O)NHR5, C(O)N(R5)2, CHNOR5, C(O)NHOR5, SO2NHR5 or CF3. In another embodiment of formula (IIIc), Rx is R5, and R5 is heterocyclyl, which is optionally substituted as described in embodiments herein.


In another embodiment of Formula (IIIc), Rx is phthalazin-1(2H)-onyl, isoquinolinyl, isoquinolin-1(2H)-onyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, 5-fluorophthalazin-1(2H)-onyl, (Z)-3H-benzo[d][1,2]diazepin-4(5H)-onyl, 5-(trifluoromethyl)phthalazin-1(2H)-onyl, pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one, isoindolin-1-onyl, or 1,2,3,6-tetrahydropyridinyl. In another embodiment of Formula (IIIc), Rx is phthalazin-1(2H)-onyl, isoquinolinyl, isoquinolin-1(2H)-onyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, 5-fluorophthalazin-1(2H)-onyl, (Z)-3H-benzo[d][1,2]diazepin-4(5H)-onyl, 5-(trifluoromethyl)phthalazin-1(2H)-onyl, isoindolin-1-onyl, or pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one; which are optionally substituted as defined herein. In another embodiment of Formula (IIIc), Rx is, 2,3,6-tetrahydropyridinyl; which is optionally substituted as defined herein.


Still another embodiment pertains to compounds having Formula (IIIc), which include

  • N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(aminomethyl)benzyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(furo[3,2-c]pyridin-4-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(pyridin-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(benzylcarbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(thieno[3,2-c]pyridin-4-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,3-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(pyridazin-3-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,3-dihydro-1,4-benzodioxin-5-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(3-methylbutyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-fluorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-5-methyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(4-cyanophenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-fluorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,5-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,2-dimethylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(2-oxopyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethoxy)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-fluoro-5-(trifluoromethyl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-chlorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4,5-trimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-nitro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(4-fluorophenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-ethyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-benzyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-methoxyphenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(3-methoxyphenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(4-acetylphenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,3-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyridin-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(2-thienyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3-methylbutyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(6-aminohexyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-thienyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1,3-benzodioxol-5-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridin-3-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(benzylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridazin-3-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyrimidin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(3-fluorophenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-butoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,4-dihydroxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-propoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-furylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-cyanophenyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxy-2-methylphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)carbamoyl]phenyl}-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methyl-1H-indazol-5-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-ethoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,5-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4[(1-benzyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 5-({4[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}amino)-1H-indazole-3-carboxylate;
  • N-(4-{[2-(2-oxopyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(5-chloropyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-indol-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethyl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,5-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,3-dihydro-1,4-benzodioxin-6-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-fluorobenzoyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(5-methoxy-1H-indol-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-chlorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-propoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-isobutoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(pyridin-4-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4,5-trimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methylpiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[4-(dimethylamino)phenyl]ethyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(trifluoromethoxy)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-3-hydroxy-1-phenylpropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-cyanophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluoro-4-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,3-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-fluorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(isobutylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1,3-benzodioxol-5-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-isopropoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-isopropoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-fluorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,4-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N2-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N-{4-[(2-phenoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-hydroxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3-fluorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({1-[(3S)-tetrahydrofuran-3-yl]-1H-pyrazol-4-yl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-phenylethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(methylthio)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-ethoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-fluorophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(pyridin-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[(trifluoromethyl)thio]benzyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(2-fluorophenyl)pyrrolidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3-chlorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(hydroxymethyl)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3-benzodioxol-5-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-isopropyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-hydroxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-ethyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,5-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[methyl(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(thiomorpholin-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-furoyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-benzylpiperidin-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(5-acetamido-2-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,5-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[3-(trifluoromethyl)phenyl]ethyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylbutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-imidazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-1-(3-cyanophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[benzyl(2-hydroxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-cyanophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-chlorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyanomethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclohexylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[butyl(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(dimethylamino)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3-dihydro-2H-isoindol-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,3-dihydro-1H-indol-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(phenylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-fluorophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(diethylamino)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-hydroxy-2-phenylethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-aminophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl (1-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}piperidin-4-yl)carbamate;
  • N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(cyclohexylmethyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3-chlorobenzyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(diethylcarbamoyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-hydroxy-6-methylphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(5-fluoropyridin-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopropylmethyl)(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-methoxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3,4,9-tetrahydro-2H-beta-carbolin-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tert-butylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-difluoropyrrolidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylpiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-1-benzylpyrrolidin-3-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-hydroxypiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluorophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclopentylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-carbamoylpiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclopropylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(methylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pentan-2-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pentan-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclobutylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1,3-dioxolan-2-ylmethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(4-fluorophenyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-hydroxy-2-methylpropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-phenyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[4-(trifluoromethyl)phenyl]ethyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxyethyl)(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(sec-butylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(trifluoromethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[bis(2-ethoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[butyl(ethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(morpholin-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[isobutyl(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylpiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-carbamoylphenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylpyrrolidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[ethyl(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,6-dimethylmorpholin-4-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-hydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,5-dimethylpyrrolidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(prop-2-yn-1-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[isopropyl(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[isopropyl(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-cyanoethyl)(cyclopropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[ethyl(isopropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluoropyrrolidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}-N-isopropyl-beta-alanine;
  • N-{4-[methyl(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide; 5,6-dimethoxy-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(4-chlorophenoxy)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethoxy)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenyl-1,3-thiazol-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 2-{[4-(propylcarbamoyl)phenyl]carbamoyl}isoindoline-5-carboxylate; 2-{[4-(propylcarbamoyl)phenyl]carbamoyl}isoindoline-5-carboxylic acid;
  • 5-amino-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(aminomethyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(2-hydroxy-2-methylpropanoyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-acetamido-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(N,N-dimethylglycyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-5-(1H-pyrazol-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-5-(1H-pyrazol-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(methoxyacetyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(methylsulfonyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-bromo-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,5-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-chlorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4,4,4-trifluorobutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-ethoxypropanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenylbutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methylpentanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(benzyloxy)acetyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-phenylpropanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-phenoxypropanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[N-(2-furoyl)glycyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-thienyl)butanoyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-oxo-4-phenylbutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(N-benzoylglycyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenoxybutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propionylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pentanoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(hexanoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(heptanoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pent-4-enoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(ethoxyacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2-methoxyethoxy)acetyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopropylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(4-methylpiperazin-1-yl)propanoyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 2-({4-[(cyclopentylacetyl)amino]phenyl}carbamoyl)isoindoline-5-carboxylate;
  • 2-({4-[(cyclopentylacetyl)amino]phenyl}carbamoyl)isoindoline-5-carboxylic acid;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-cyclopentylethyl)amino]phenyl}-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}-3,6-dihydropyridine-1(2H)-carboxylate;
  • N-[4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methylbutyl)-1H-pyrazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1E)-5-phenylpent-1-en-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-propyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-phenylpentyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-butyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(isopropylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-benzoylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(isopropylsulfonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(phenylsulfonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[3-(benzoylamino)pyrrolidin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[3-(butyrylamino)pyrrolidin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}piperazine-1-carboxylate;
  • N-[4-(4-propionylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(hexyloxy)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(isoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(8-fluoro-4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(morpholin-4-ylmethyl)-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(4-methylpiperazin-1-yl)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-chloro-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-4,5-dihydro-3H-2,3-benzodiazepin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-oxo-8-(trifluoromethyl)-3,4-dihydrophthalazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(dimethylamino)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(di ethylamino)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(4-methylpiperazin-1-yl)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(dimethylamino)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(di ethylamino)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-oxo-8-(trifluoromethyl)-3,4-dihydrophthalazin-1-yl]phenyl}-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(1-methylpiperidin-4-yl)oxy]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-{[(3R)-3-fluoropyrrolidin-1-yl]methyl}-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-{[(3S)-3-fluoropyrrolidin-1-yl]methyl}-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(azetidin-1-ylmethyl)-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydropyrrolo[1,2-d][1,2,4]triazin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydropyrrolo[1,2-d][1,2,4]triazin-4-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}piperidine-1-carboxylate;
  • N-[4-(5-propyl-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(piperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-butyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[5-(3-methylbutyl)-1,2,4-oxadiazol-3-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-benzyl-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3R)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(5-chloropyridin-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxy-4-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,4-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-oxopyrrolidin-1-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-hydroxycyclopropyl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-5-vinyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-benzoylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[5-(tetrahydrofuran-3-yl)-1,2,4-oxadiazol-3-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3-methylbutyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide;
  • N-(4-{[(3-phenylpropyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide;
  • N-{4-[1-(4-methylbenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(tetrahydrofuran-3-ylmethyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-({[(2S)-tetrahydrofuran-2-ylmethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-({[(2R)-tetrahydrofuran-2-ylmethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(1S)-2-hydroxy-1-phenylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(2-methoxyethyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-(2-hydroxyethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(propylamino)carbonyl]phenyl}-5-pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(propylamino)carbonyl]phenyl}-5-pyridin-4-yl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N5-(2-methoxyethyl)-N2-{4-[(propylamino)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N-(4-cyanophenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(trifluoromethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(1S)-2-hydroxy-1-pyridin-2-ylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3-methylbutyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(tetrahydrofuran-3-ylmethyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-pyridin-2-ylpiperazin-1-yl)carbonyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-({[(1S)-2-hydroxy-1-pyridin-2-ylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(1,2-dihydroxyethyl)-N-{4-[(propylamino)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(5-oxo-L-prolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(5-oxo-D-prolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-propionyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-ethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(methoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(ethoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(cyclopropylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(cyclopentylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-methylbenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methylbenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-methoxybenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methoxybenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(4-methoxybenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-fluorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-fluorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(4-fluorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(4-chlorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[3-(dimethylamino)benzoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[4-(dimethylamino)benzoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-furoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-thienylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1H-pyrrol-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2,5-dimethyl-1H-pyrrol-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1,3-thiazol-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1H-pyrazol-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(3,5-dimethyl-1,2-oxazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridin-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridin-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isonicotinoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridazin-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyrazin-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyrimidin-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[3-(piperidin-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[6-(benzoylamino)hexyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[(benzoylamino)methyl]benzyl}carbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(5-oxo-L-prolyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(5-oxo-D-prolyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(1-acetylpiperidin-4-yl)carbonyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-acetamidobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[4-(methylsulfonyl)benzoyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-butyrylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-isobutyrylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-methylbutanoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3,3,3-trifluoropropanoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(methoxyacetyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(tetrahydrofuran-3-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(cyclopentylacetyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(cyclohexylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-methoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3-methoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(4-methoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3-fluorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-chlorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(4-chlorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3-cyanobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(4-cyanobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[3-(dimethylamino)benzoyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[4-(dimethylamino)benzoyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3,5-dimethoxybenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(3,4-dimethoxyphenyl)acetyl]piperazin-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-furoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(3-furoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(1H-pyrrol-2-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(1H-pyrazol-5-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyridin-2-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyridin-3-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-isonicotinoylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyridazin-3-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyrazin-2-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(pyrimidin-4-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(N,N-dimethyl-beta-alanyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-acetylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(2-fluorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(4-fluorobenzoyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(phenylacetyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(1,3-thiazol-4-ylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-(morpholin-4-ylacetyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-butyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-benzoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-oxo-2,3-dihydro-1H-isoindol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N5-[2-(dimethylamino)ethyl]-N2-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • 5-(morpholin-4-ylcarbonyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{benzyl[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(isobutoxycarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-bromo-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 4-{[(5-cyano-1,3-dihydro-2H-isoindol-2-yl)carbonyl]amino}benzoate;
  • N-(4-{(E)-[(benzyloxy)imino]methyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1S)-2-hydroxy-1-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3-aminopyrrolidin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N2-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N-[4-({benzyl[3-(morpholin-4-yl)propyl]amino}methyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(1H-pyrazol-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(1-methyl-1H-pyrazol-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N2-{4-[(cyclopentylacetyl)amino]phenyl}-N5-(2-methoxyethyl)-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N2-{4-[(cyclopentylacetyl)amino]phenyl}-N5-(2-hydroxyethyl)-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • 5-(aminomethyl)-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-(methylthio)butan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S,3S)-1-hydroxy-3-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S,3R)-1,3-dihydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxyhexan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxypentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S,2S)-2-hydroxycyclopentyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S,2R)-2-hydroxycyclopentyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-cyclohexyl-3-hydroxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({(2R)-1-hydroxy-3-[(4-methylbenzyl)thio]propan-2-yl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-(4-tert-butylphenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-methoxy-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide; N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(pyridin-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{(1E)-3-[benzyl(methyl)amino]prop-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-phenoxypiperidin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3-phenoxyazetidin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[benzyl(methyl)amino]methyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3R)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4[(4-hydroxypiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-hydroxy-2-methylpropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-benzyl-1H-1,2,3-triazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methylbutyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylmethyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1H-1,2,3-triazol-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1-benzylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[4-(morpholin-4-yl)benzyl]-1H-1,2,3-triazol-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyl-1H-1,2,3-triazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(cyclopentylmethyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methoxypropyl)-1H-1,2,3-triazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(tetrahydrofuran-3-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-(4-{[(2-methoxyethoxy)acetyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(tetrahydrofuran-2-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(ethoxyacetyl)amino]phenyl}-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(tetrahydro-2H-pyran-4-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(morpholin-4-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(morpholin-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyrrolidin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-isopropoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(azetidin-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[methyl(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(isobutylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cyclopentylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-isopropoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[benzyl(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(6-methoxypyridin-3-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-isobutoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(trifluoromethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[5-(morpholin-4-ylmethyl)-1,2,4-oxadiazol-3-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{5-[(4-methylpiperazin-1-yl)methyl]-1,2,4-oxadiazol-3-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-{[(3-methylbutyl)amino]methyl}-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{5-[(4-hydroxypiperidin-1-yl)methyl]-1,2,4-oxadiazol-3-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(2-aminoethyl)-1H-imidazol-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyrimidin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(pyridin-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-methoxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[3-(hydroxymethyl)oxetan-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2-{benzyl[3-(morpholin-4-yl)propyl]amino}-2-oxoethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3-{benzyl[3-(morpholin-4-yl)propyl]amino}-3-oxopropyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2R)-butan-2-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-cyano-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-methyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-chloro-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2-benzyl-1,3-thiazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(1,3-thiazol-5-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1R)-3-hydroxy-1-phenylpropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[2-hydroxy-1-(4-methylphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(1,3-dihydroxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2R)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(3-furylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[4-(2-furoyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[4-(ethylsulfonyl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1R)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2S)-1-hydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(2,3-dihydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[2-hydroxy-1-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(1-hydroxy-4-methylpentan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.3]hept-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.4]oct-6-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.4]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,8-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(3,9-diazaspiro[5.5]undec-3-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,9-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,8-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[5.5]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.6]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-oxa-9-azaspiro[5.5]undec-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxa-4,8-diazaspiro[5.5]undec-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,6-diazaspiro[3.5]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,5-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-oxa-2-azaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(6-oxa-2-azaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(hexahydro-5H-furo[2,3-c]pyrrol-5-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(hexahydrofuro[3,4-c]pyridin-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-{benzyl[3-(morpholin-4-yl)propyl]amino}-4-oxobutyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2-{benzyl[3-(morpholin-4-yl)propyl]amino}ethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-acetyl-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[(3-methylbutyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)sulfamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(1-hydroxyethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(butyrylamino)phenyl]-5-cyano-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyrrolidin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-pyrrolidin-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3-methoxybenzyl)sulfonyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.4]oct-6-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-1-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,8-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-7-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,8-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[5.5]undec-8-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.6]undec-8-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(1-oxa-4,8-diazaspiro[5.5]undec-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-1-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-8-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.4]oct-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,6-diazaspiro[3.5]non-1-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,5-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(5-oxa-2-azaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(6-oxa-2-azaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(2-oxa-7-azaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(hexahydro-5H-furo[2,3-c]pyrrol-5-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(hexahydrofuro[3,4-c]pyridin-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-(acetamidomethyl)-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(3R)-1-isobutyrylpyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[(3R)-1-benzoylpyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[1-(methylsulfonyl)pyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-isobutyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylmethyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylmethyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-isobutylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylmethyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylmethyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(2-hydroxypropan-2-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl {4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzyl}carbamate;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(methoxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-{[(tetrahydrofuran-2-ylmethyl)amino]methyl}-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{5-[(4-methoxypiperidin-1-yl)methyl]-1,2,4-oxadiazol-3-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(5-{[4-(2-methoxyethyl)piperazin-1-yl]methyl}-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[1-(morpholin-4-yl)cyclopentyl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-pentanoylpiperidin-4-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4[(1-acetylpiperidin-4-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-butyrylpiperidin-4-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • tert-butyl (2-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}ethyl)carbamate;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-1-(4-fluorophenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[3-(hydroxymethyl)oxetan-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-1-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)sulfamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydrofuran-3-ylmethyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-(4-fluorophenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3,3,3-trifluoropropanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(4,4,4-trifluorobutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-phenylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(phenylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4-methoxyphenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(methoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-benzoylpyrrolidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-ethoxypropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2-methylcyclopropyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(1-methylcyclopropyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-acetylpyrrolidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(4,4,4-trifluorobutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(ethoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1-methylpiperidin-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[1-(2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl[(1-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}azetidin-3-yl)methyl]carbamate;
  • N-(4-{4-[(tetrahydrofuran-3-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydro-2H-pyran-4-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(morpholin-4-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(2-methoxyethoxy)acetyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(2,3-dimethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(cyclohexylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(morpholin-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(morpholin-4-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2,2-dimethylpropanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3,3-dimethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tricyclo[3.3.1.1˜3,7˜]dec-1-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4-methoxycyclohexyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[4-(acetylamino)phenyl]sulfonyl}amino)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(propylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(4-propylphenyl)sulfonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(butylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[({[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl}sulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(ethylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(benzylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(4-fluorophenyl)sulfonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(thiophen-2-ylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,6-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,9-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,8-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[5.5]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.6]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-oxa-9-azaspiro[5.5]undec-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-oxa-4,8-diazaspiro[5.5]undec-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,6-diazaspiro[3.5]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,5-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(5-oxa-2-azaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(6-oxa-2-azaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(hexahydro-5H-furo[2,3-c]pyrrol-5-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(hexahydrofuro[3,4-c]pyridin-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(N,N-dimethylglycyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydrofuran-2-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydrofuran-3-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(cyclohexylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(4,4-difluorocyclohexyl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-hydroxy-2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydrofuran-2-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(piperidin-1-ylsulfonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(1,3-thiazol-2-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4,4-difluorocyclohexyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-methyl-2-(morpholin-4-yl)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(2-methyl-1,3-thiazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-methyl-1-(morpholin-4-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • Nalpha-(4-{[(5-fluoro-1,3-dihydro-2H-isoindol-2-yl)carbonyl]amino}benzoyl)-D-phenylalaninamide;
  • N-(4-{[2-(acetylamino)phenyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(furan-2-yl)-2-(pyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-amino-1-oxohexan-2-yl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • Nalpha-(4-{[(5-fluoro-1,3-dihydro-2H-isoindol-2-yl)carbonyl]amino}benzoyl)-L-phenylalaninamide;
  • N-(4-{[(2R)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(methylcarbamoyl)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-amino-2-oxo-1-phenylethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-tert-butoxypropyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-2-amino-2-oxo-1-phenylethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-methyl-2-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3S)-1-methyl-2-oxoazepan-3-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(5-methyl-1H-pyrazol-1-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(4-chloro-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)butyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-carbamoylbenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-amino-1-oxohexan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • Nalpha-{4-[(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-ylcarbonyl)amino]benzoyl}-L-phenylalaninamide;
  • N-(4-{[(2R)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-tert-butoxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(3S)-1-methyl-2-oxoazepan-3-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(4,5,6,7-tetrahydro-1H-indazol-5-ylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • 5-fluoro-N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethylbutyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(furan-2-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3-methyl-1,2-oxazol-5-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-cyanobutan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2R)-butan-2-ylcarbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(ethylamino)-1-oxopropan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methoxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(1-methoxybutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-ethoxypropyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[benzyl(methyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(5-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(3-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4[(2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(1-methylcyclopropyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(thiophen-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(4-methoxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(5-methyl-1,3-oxazol-2-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(tetrahydro-2H-pyran-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-1-methoxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethyl-2-oxobutyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1-methyl-1H-pyrrol-2-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(propan-2-yloxy)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-amino-1-oxobutan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(tetrahydro-2H-pyran-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(1H-pyrrol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclopentylcarbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2R)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-2-methylbutyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(tetrahydro-2H-pyran-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-cyanoethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(5-methyl-1,2-oxazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3,3-dimethylbutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(furan-2-yl)propan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(3-methyl-1,2-oxazol-5-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2R)-1-cyanobutan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methoxybutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(1,3-thiazol-2-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(1-methyl-1H-pyrazol-4-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-methoxybutan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-aminobenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-ethoxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(6-methoxypyridin-3-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-cyanocyclopropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(5-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(4-methyl-1,3-thiazol-2-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(1-methylcyclopropyl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(thiophen-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-methoxybutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(tetrahydro-2H-pyran-3-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2S)-1-methoxypropan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3,3-dimethyl-2-oxobutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrrol-2-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(propan-2-yloxy)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(tetrahydro-2H-pyran-3-ylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(1H-pyrrol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2R)-3-methylbutan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-cyanoethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methoxy-2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[methyl(propyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • methyl 1-{4-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]phenyl}azetidine-3-carboxylate;
  • N-(4-{3-[(3-methylbutyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(tetrahydrofuran-2-ylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[3-(benzylcarbamoyl)azetidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[3-(cyclopentylcarbamoyl)azetidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(cyclopentylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(2-methoxyethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopentylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-2-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(pyrrolidin-1-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(pyrazin-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4,4-difluorocyclohexyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-cyanobutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(ethylamino)-1-oxopropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(tetrahydro-2H-pyran-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(5-methyl-1,3-oxazol-2-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[(dimethylamino)methyl]benzyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-2-amino-2-oxo-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3-oxazol-2-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tetrahydro-2H-pyran-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(1-methylcyclopropyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(furan-2-yl)-2-(pyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[1-(2-hydroxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[1-(morpholin-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(6-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(cyclopropylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-acetylpiperidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-butanoylpiperidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-methylbutanoyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(methoxyacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutanoyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclobutylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-2-ylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(3,5-dimethyl-1H-pyrazol-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-1-methyl-2-oxoazepan-3-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(1,3-thiazol-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(furan-2-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(1-methyl-1H-pyrazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,2-difluoroethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(tetrahydro-2H-pyran-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(5-methyl-1,2-oxazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrazol-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide; Nalpha-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}-L-phenylalaninamide;
  • N-(4-{[2(2-methyl-1,3-thiazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(thiophen-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(5-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethyl-2-oxobutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(acetylamino)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-methoxybutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tetrahydro-2H-pyran-4-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pyrimidin-4-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-pyrrol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-methylbutyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-amino-1-oxohexan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-amino-2-oxo-1-phenylethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-tert-butoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(methylcarbamoyl)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-methyl-1-(morpholin-4-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(5-oxo-L-prolyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-ethoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-ethoxypropanoyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-acetylpiperidin-4-yl)carbonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(ethoxyacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-2-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(bicyclo[2.2.1]hept-2-ylacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1,3-thiazol-5-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(4-oxo-4,5,6,7-tetrahydro-1-benzofuran-3-yl)carbonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{2-[(3-methylbutanoyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(4-methylpentanoyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(ethoxyacetyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2-{[(2-methoxyethoxy)acetyl]amino}ethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(tetrahydrofuran-2-ylcarbonyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(cyclopentylcarbonyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(cyclopentylacetyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[2-(benzoylamino)ethyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(tetrahydro-2H-pyran-4-ylcarbonyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(tetrahydro-2H-pyran-4-ylacetyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{2-[(tetrahydrofuran-3-ylacetyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(5-oxo-L-prolyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-propanoylazetidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2,2-dimethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-ethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(p ent-4-ynoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(furan-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(furan-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(thiophen-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(1H-pyrrol-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyrimidin-4-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(5-methylpyrazin-2-yl)carbonyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(N,N-dimethylglycyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(N,N-dimethyl-beta-alanyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyrrolidin-1-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(pyrrolidin-1-yl)propanoyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(piperidin-1-yl)propanoyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4-methylpiperazin-1-yl)acetyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(4-methylpiperazin-1-yl)propanoyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-cyclopropylethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-cyclopentylethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-3-ylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3,3-dimethylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclohexylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(3-methylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopentylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(tetrahydrofuran-2-ylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylpropyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(butylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(cyclopropylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(phenylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4-fluorophenyl)sulfonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(ethylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(propan-2-ylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(benzylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(propylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(thiophen-2-ylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(4,4-difluorocyclohexyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(5-oxo-D-prolyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-methylpentanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(2-ethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(1H-pyrrol-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(1,2-oxazol-5-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyridin-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyridazin-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyrazin-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(pyrimidin-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[(5-methylpyrazin-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(piperidin-1-yl)propanoyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[1-(morpholin-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({1-[3-(4-methylpiperazin-1-yl)propanoyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(4-methylpiperazin-1-yl)acetyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydro-2H-pyran-4-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(benzoylamino)cyclohex-1-en-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(1-methylpiperidin-4-yl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(3R)-tetrahydrofuran-3-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(3S)-tetrahydrofuran-3-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-{[(2S)-2-methylbutanoyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{3-[(3-methylbutanoyl)amino]oxetan-3-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • tert-butyl 4-({4-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]phenyl}sulfonyl)piperidine-1-carboxylate;
  • N-{4-[4-(propylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-methoxyethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(cyclopentylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(1,4-dioxan-2-ylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(cyclopentylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(tetrahydro-2H-pyran-4-ylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(morpholin-4-ylcarbonyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(cyclopropylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[4-(butan-2-ylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{(4R)-4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{(4S)-4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methyl-1,3-oxazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(furan-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2E)-3-(furan-2-yl)prop-2-enoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1,3-oxazol-5-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3,3,3-trifluoropropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,5-dimethyl-1H-pyrazol-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(4-methoxycyclohexyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2,3-dimethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2,2-difluorocyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1H-pyrazol-5-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tert-butoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[3-(1H-1,2,4-triazol-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3-ethoxypropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3-hydroxy-3-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[3-(1H-pyrrol-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methylcyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methylpropoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1-methylprolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-hydroxycyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopropylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopentylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-{[1-(methoxymethyl)cyclopropyl]carbonyl}-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(methylsulfonyl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methyl-1H-pyrazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopropylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-ethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(5-oxo-L-prolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2E)-4-methylpent-2-enoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-methoxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopent-1-en-1-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(thiophen-3-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclohexylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-propanoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2,2-dimethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(methoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2,2-dimethylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(4-methylhexanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2,2-dimethylcyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclobutylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(piperidin-1-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[2-(pyrrolidin-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,3-dimethyl-1H-pyrazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cis-4-{[(2-methoxyethoxy)acetyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(trans-4-{[(2-methoxyethoxy)acetyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cis-4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(trans-4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cis-4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(trans-4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3R)-1-(cyclobutylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({(3R)-1-[(2R)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({(3R)-1-[(2S)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3R)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-1-(cyclobutylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({(3S)-1-[(2R)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({(3S)-1-[(2S)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{trans-4-[(2-methylpropanoyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{cis-4-[(2-methylpropanoyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{cis-4-[(cyclohexylcarbonyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{trans-4-[(cyclohexylcarbonyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{trans-4-[(cyclopropylacetyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{cis-4-[(cyclopropylacetyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(cyclopentylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(cyclopropylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(2-hydroxy-2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(tetrahydro-2H-pyran-4-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{4-[(cyclohexylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide; and pharmaceutically acceptable salts thereof.


Still another embodiment pertains to compounds having Formula (IIIc), which include

  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(isoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(8-fluoro-4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(morpholin-4-ylmethyl)-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(4-methylpiperazin-1-yl)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-chloro-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-4,5-dihydro-3H-2,3-benzodiazepin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-oxo-8-(trifluoromethyl)-3,4-dihydrophthalazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(dimethylamino)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(di ethylamino)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(4-methylpiperazin-1-yl)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(dimethylamino)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(di ethylamino)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[4-oxo-8-(trifluoromethyl)-3,4-dihydrophthalazin-1-yl]phenyl}-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(1-methylpiperidin-4-yl)oxy]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-{[(3R)-3-fluoropyrrolidin-1-yl]methyl}-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-{[(3S)-3-fluoropyrrolidin-1-yl]methyl}-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(azetidin-1-ylmethyl)-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-1,2-dihydropyrrolo[1,2-d][1,2,4]triazin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide; and
  • N-[4-(1-oxo-1,2-dihydropyrrolo[1,2-d][1,2,4]triazin-4-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxo-2,3-dihydro-1H-isoindol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)cyclohex-3-en-1-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)cyclohex-3-en-1-yl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)cyclohex-3-en-1-yl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide; and pharmaceutically acceptable salts thereof.


Embodiments of Formula (IVc)

In another aspect, the present invention provides compounds of Formula (IVc)




embedded image


and pharmaceutically acceptable salts thereof; wherein X1, X2, X3, and R5 are as described herein for Formula (Ic).


In one embodiment of formula (IVc),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R3, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R10, OR10, Se, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R10, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R5, R6, R9, and R10 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I;


R15, at each occurrence, is independently selected alkyl; wherein the R15 alkyl is optionally substituted with one, two, three or four alkoxy; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four alkoxy;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


In one embodiment of Formula (IVc), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (IVc), X1, X2, and X3 are CH. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (IVc), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (IVc), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (IVc), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (IVc), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (IVc), X1 is N; X2 is CR1; and X3 is N.


In another embodiment of Formula (IVc), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IVc), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), R1 is C(O)NH2. In another embodiment of Formula (IVc), R1 is F. In another embodiment of Formula (IVc), R1 is Cl. In another embodiment of Formula (IVc), R1 is Br. In another embodiment of Formula (IVc), R1 is CN. In another embodiment of Formula (IVc), R1 is NH2. In another embodiment of Formula (IVc), R1 is NO2. In another embodiment of Formula (IVc), R1 is CF3. In another embodiment of Formula (IVc), R1 is C(O)OH. In another embodiment of Formula (IVc), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IVc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (IVc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (IVc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


Still another embodiment pertains to compounds having Formula (IVc), which include

  • N-{4-[(4,4,4-trifluorobutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-ethoxypropanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenylbutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methylpentanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(benzyloxy)acetyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-phenylpropanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-phenoxypropanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[N-(2-furoyl)glycyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-thienyl)butanoyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-oxo-4-phenylbutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(N-benzoylglycyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenoxybutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propionylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pentanoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(hexanoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(heptanoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pent-4-enoylamino)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(ethoxyacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2-methoxyethoxy)acetyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopropylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(4-methylpiperazin-1-yl)propanoyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 2-({4-[(cyclopentylacetyl)amino]phenyl}carbamoyl)isoindoline-5-carboxylate;
  • 2-({4-[(cyclopentylacetyl)amino]phenyl}carbamoyl)isoindoline-5-carboxylic acid;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-bromo-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N2-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(1H-pyrazol-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(1-methyl-1H-pyrazol-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N2-{4-[(cyclopentylacetyl)amino]phenyl}-N5-(2-methoxyethyl)-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N2-{4-[(cyclopentylacetyl)amino]phenyl}-N5-(2-hydroxyethyl)-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • 5-(aminomethyl)-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-methoxy-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(pyridin-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(tetrahydrofuran-3-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-(4-{[(2-methoxyethoxy)acetyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(tetrahydrofuran-2-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(ethoxyacetyl)amino]phenyl}-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(tetrahydro-2H-pyran-4-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(morpholin-4-ylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-cyano-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-methyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-chloro-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-acetyl-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(1-hydroxyethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(butyrylamino)phenyl]-5-cyano-1,3-dihydro-2H-isoindole-2-carboxamide;
  • -4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-(acetamidomethyl)-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(2-hydroxypropan-2-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(methoxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-ethoxypropanoyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-acetylpiperidin-4-yl)carbonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(ethoxyacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-2-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(bicyclo[2.2.1]hept-2-ylacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1,3-thiazol-5-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(4-oxo-4,5,6,7-tetrahydro-1-benzofuran-3-yl)carbonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide; and pharmaceutically acceptable salts thereof.


Embodiments of Formula (Vc)

In another aspect, the present invention provides compounds of Formula (Vc)




embedded image


and pharmaceutically acceptable salts thereof; wherein X1, X2, X3, and R5 are as described herein for Formula (Ic).


In one embodiment of formula (Vc),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R3, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R10, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R5, R6, R9, and R10 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I;


R15, at each occurrence, is independently selected alkyl, wherein the R15 alkyl is optionally substituted with one, two, three or four alkoxy; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four alkoxy;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


In one embodiment of Formula (Vc), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (Vc), X1, X2, and X3 are CH. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (Vc), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (Vc), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (Vc), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (Vc), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (Vc), X1 is N; X2 is CR1; and X3 is N.


In another embodiment of Formula (Vc), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Vc), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), R1 is C(O)NH2. In another embodiment of Formula (Vc), R1 is F. In another embodiment of Formula (Vc), R1 is Cl. In another embodiment of Formula (Vc), R1 is Br. In another embodiment of Formula (Vc), R1 is CN. In another embodiment of Formula (Vc), R1 is NH2. In another embodiment of Formula (Vc), R1 is NO2. In another embodiment of Formula (Vc), R1 is CF3. In another embodiment of Formula (Vc), R1 is C(O)OH. In another embodiment of Formula (Vc), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (Vc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (Vc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (Vc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


Still another embodiment pertains to compounds having Formula (Vc), which include

  • N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(aminomethyl)benzyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(pyridin-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(benzylcarbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,3-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,3-dihydro-1,4-benzodioxin-5-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(3-methylbutyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-fluorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-5-methyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-fluorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,5-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,2-dimethylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(2-oxopyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethoxy)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-fluoro-5-(trifluoromethyl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-chlorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4,5-trimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-nitro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-ethyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-benzyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,3-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyridin-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(2-thienyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3-methylbutyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(6-aminohexyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide; 4-chloro-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-thienyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1,3-benzodioxol-5-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(benzylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyrimidin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-butoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,4-dihydroxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-propoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-furylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxy-2-methylphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutyl)carbamoyl]phenyl}-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methyl-1H-indazol-5-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-ethoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,5-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4[(1-benzyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 5-({4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}amino)-1H-indazole-3-carboxylate;
  • N-(4-{[2-(2-oxopyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-indol-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethyl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,5-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(2,3-dihydro-1,4-benzodioxin-6-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(5-methoxy-1H-indol-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-chlorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-propoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-isobutoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4,5-trimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methylpiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[4-(dimethylamino)phenyl]ethyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(trifluoromethoxy)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-3-hydroxy-1-phenylpropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-cyanophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluoro-4-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,3-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-fluorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(isobutylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1,3-benzodioxol-5-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-isopropoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-isopropoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 4-chloro-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-fluorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,4-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N2-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N-{4-[(2-phenoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-hydroxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3-fluorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({1-[(3S)-tetrahydrofuran-3-yl]-1H-pyrazol-4-yl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-phenylethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(methylthio)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-ethoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-fluorophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(pyridin-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[(trifluoromethyl)thio]benzyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,4-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(1H-imidazol-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3-chlorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-5-(trifluoromethyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(hydroxymethyl)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3-benzodioxol-5-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-isopropyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-hydroxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-ethyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,5-dimethoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-benzylpiperidin-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(5-acetamido-2-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,5-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[3-(trifluoromethyl)phenyl]ethyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methylbutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-imidazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-1-(3-cyanophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-cyanophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-chlorophenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(cyanomethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide; N-[4-(cyclohexylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(dimethylamino)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(phenylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-fluorophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(diethylamino)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-aminophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3-chlorobenzyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-hydroxy-6-methylphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(5-fluoropyridin-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-methoxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tert-butylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methylbutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-1-benzylpyrrolidin-3-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-fluorophenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclopentylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclopropylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(methylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pentan-2-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pentan-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclobutylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(4-fluorophenyl)-1H-pyrazol-4-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-hydroxy-2-methylpropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-phenyl-1H-pyrazol-4-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[4-(trifluoromethyl)phenyl]ethyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(sec-butylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-hydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(prop-2-yn-1-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5,6-dimethoxy-N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(4-chlorophenoxy)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(trifluoromethoxy)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4-phenyl-1,3-thiazol-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • methyl 2-{[4-(propylcarbamoyl)phenyl]carbamoyl}isoindoline-5-carboxylate; 2-{[4-(propylcarbamoyl)phenyl]carbamoyl}isoindoline-5-carboxylic acid;
  • 5-amino-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(hydroxymethyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(aminomethyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(2-hydroxy-2-methylpropanoyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-acetamido-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(N,N-dimethylglycyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-5-(1H-pyrazol-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-5-(1H-pyrazol-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(methoxyacetyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-[(methylsulfonyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-bromo-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,5-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-chlorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-fluoro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3R)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(5-chloropyridin-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-hydroxy-4-methoxyphenyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,4-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(2-oxopyrrolidin-1-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-hydroxycyclopropyl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-5-vinyl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3-methylbutyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide;
  • N-(4-{[(3-phenylpropyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide;
  • 5-fluoro-N-[4-({[(2S)-tetrahydrofuran-2-ylmethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-({[(2R)-tetrahydrofuran-2-ylmethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(1S)-2-hydroxy-1-phenylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(propylamino)carbonyl]phenyl}-5-pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(propylamino)carbonyl]phenyl}-5-pyridin-4-yl-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N5-(2-methoxyethyl)-N2-{4-[(propylamino)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • N-[4-({[(1S)-2-hydroxy-1-pyridin-2-ylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3-methylbutyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(tetrahydrofuran-3-ylmethyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-({[(1S)-2-hydroxy-1-pyridin-2-ylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-(1,2-dihydroxyethyl)-N-{4-[(propylamino)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[6-(benzoylamino)hexyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({4-[(benzoylamino)methyl]benzyl}carbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N5-[2-(dimethylamino)ethyl]-N2-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2,5-dicarboxamide;
  • 5-(morpholin-4-ylcarbonyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(isobutoxycarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1S)-2-hydroxy-1-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-(methylthio)butan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S,3S)-1-hydroxy-3-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S,3R)-1,3-dihydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxyhexan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxypentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S,2S)-2-hydroxycyclopentyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S,2R)-2-hydroxycyclopentyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-cyclohexyl-3-hydroxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({(2R)-1-hydroxy-3-[(4-methylbenzyl)thio]propan-2-yl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-(4-tert-butylphenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methoxy-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-methyl-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • 5-(hydroxymethyl)-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • 5-fluoro-N-(4-{[(3R)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-hydroxy-2-methylpropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(pyrrolidin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-isopropoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(isobutylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cyclopentylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-isopropoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(6-methoxypyridin-3-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-isobutoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyrimidin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(pyridin-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-methoxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[3-(hydroxymethyl)oxetan-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2R)-butan-2-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(1,3-thiazol-5-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1R)-3-hydroxy-1-phenylpropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[2-hydroxy-1-(4-methylphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(1,3-dihydroxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2R)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(3-furylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1R)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(2S)-1-hydroxybutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(2,3-dihydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[2-hydroxy-1-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(1-hydroxy-4-methylpentan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-oxa-9-azaspiro[5.5]undec-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyrrolidin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-pyrrolidin-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-fluoro-N-{4[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({[(3R)-1-isobutyrylpyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[(3R)-1-benzoylpyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[1-(methylsulfonyl)pyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[1-(morpholin-4-yl)cyclopentyl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-1-(4-fluorophenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[3-(hydroxymethyl)oxetan-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-1-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-1-(4-fluorophenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-oxa-9-azaspiro[5.5]undec-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(1,3-thiazol-2-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4,4-difluorocyclohexyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-methyl-2-(morpholin-4-yl)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(2-methyl-1,3-thiazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-methyl-1-(morpholin-4-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • Nalpha-(4-{[(5-fluoro-1,3-dihydro-2H-isoindol-2-yl)carbonyl]amino}benzoyl)-D-phenylalaninamide;
  • N-(4-{[2-(acetylamino)phenyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(furan-2-yl)-2-(pyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-amino-1-oxohexan-2-yl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • Nalpha-(4-{[(5-fluoro-1,3-dihydro-2H-isoindol-2-yl)carbonyl]amino}benzoyl)-L-phenylalaninamide;
  • N-(4-{[(2R)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(methylcarbamoyl)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-amino-2-oxo-1-phenylethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-tert-butoxypropyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-2-amino-2-oxo-1-phenylethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-methyl-2-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3S)-1-methyl-2-oxoazepan-3-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(5-methyl-1H-pyrazol-1-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(4-chloro-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)butyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-carbamoylbenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-amino-1-oxohexan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • Nalpha-{4-[(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-ylcarbonyl)amino]benzoyl}-L-phenylalaninamide;
  • N-(4-{[(2R)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-tert-butoxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(3S)-1-methyl-2-oxoazepan-3-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(4,5,6,7-tetrahydro-1H-indazol-5-ylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • 5-fluoro-N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethylbutyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(furan-2-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(3-methyl-1,2-oxazol-5-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-cyanobutan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2R)-butan-2-ylcarbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(ethylamino)-1-oxopropan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methoxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(1-methoxybutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-ethoxypropyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(5-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(3-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[1-(1-methylcyclopropyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(thiophen-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(4-methoxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(5-methyl-1,3-oxazol-2-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(tetrahydro-2H-pyran-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-1-methoxypropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethyl-2-oxobutyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(1-methyl-1H-pyrrol-2-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(propan-2-yloxy)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-1-amino-1-oxobutan-2-yl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-[4-(tetrahydro-2H-pyran-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(1H-pyrrol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(cyclopentylcarbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2R)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(2S)-2-methylbutyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[2-(tetrahydro-2H-pyran-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-cyanoethyl)carbamoyl]phenyl}-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-(4-{[(5-methyl-1,2-oxazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-fluoro-N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3,3-dimethylbutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(furan-2-yl)propan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(3-methyl-1,2-oxazol-5-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2R)-1-cyanobutan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methoxybutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(1,3-thiazol-2-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(1-methyl-1H-pyrazol-4-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-methoxybutan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-aminobenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-ethoxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(6-methoxypyridin-3-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-cyanocyclopropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(5-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(4-methyl-1,3-thiazol-2-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[1-(1-methylcyclopropyl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(thiophen-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(4-methoxybutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(tetrahydro-2H-pyran-3-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2S)-1-methoxypropan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3,3-dimethyl-2-oxobutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrrol-2-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(propan-2-yloxy)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(tetrahydro-2H-pyran-3-ylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[2-(1H-pyrrol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-(4-{[(2R)-3-methylbutan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(1-cyanoethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(2-methoxy-2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;
  • N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(4,4-difluorocyclohexyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-cyanobutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(ethylamino)-1-oxopropan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(tetrahydro-2H-pyran-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(5-methyl-1,3-oxazol-2-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-({2-[(dimethylamino)methyl]benzyl}carbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1R)-2-amino-2-oxo-1-phenylethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1,3-oxazol-2-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tetrahydro-2H-pyran-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(1-methylcyclopropyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(furan-2-yl)-2-(pyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(3,5-dimethyl-1H-pyrazol-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(3S)-1-methyl-2-oxoazepan-3-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(1,3-thiazol-2-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(furan-2-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(1-methyl-1H-pyrazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2,2-difluoroethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(tetrahydro-2H-pyran-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-methoxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(5-methyl-1,2-oxazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrazol-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide; Nalpha-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzoyl}-L-phenylalaninamide;
  • N-(4-{[2-(2-methyl-1,3-thiazol-4-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(thiophen-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(5-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(3-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3,3-dimethyl-2-oxobutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(acetylamino)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-methoxybutan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(tetrahydro-2H-pyran-4-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(pyrimidin-4-ylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-(1H-pyrrol-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-2-methylbutyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(1-amino-1-oxohexan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-amino-2-oxo-1-phenylethyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(3-tert-butoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[3-(methylcarbamoyl)phenyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2R)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[(2S)-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-methyl-1-(morpholin-4-yl)propan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{[2-methyl-2-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[(2-ethoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide; and pharmaceutically acceptable salts thereof.


Embodiments of Formula (VIc)

In another aspect, the present invention provides compounds of Formula (VIc)




embedded image


and pharmaceutically acceptable salts thereof; wherein R1 and R5 are as described herein for Formula (Ic); and n is 0 or 1.


In one embodiment of formula (VIc),


n is 0 or 1;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R3, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R5, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R5 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R9, OR9, SR9, S(O)R9, SO2R9, C(O)R9, CO(O)R9, OC(O)R9, OC(O)OR9, NH2, NHR9, N(R9)2, NHC(O)R9, NR9C(O)R9, NHS(O)2R9, NR9S(O)2R9, NHC(O)OR9, NR9C(O)OR9, NHC(O)NH2, NHC(O)NHR9, NHC(O)N(R9)2, NR9C(O)NHR9, NR9C(O)N(R9)2, C(O)NH2, C(O)NHR9, C(O)N(R9)2, C(O)NHOH, C(O)NHOR9, C(O)NHSO2R9, C(O)NR9SO2R9, SO2NH2, SO2NHR9, SO2N(R9)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR19, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R9, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R9 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected alkoxy, OH, cycloalkyl, aryl, or heterocyclyl;


R10, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R5, R6, R9, and R10 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I;


R15, at each occurrence, is independently selected alkyl, wherein the R15 alkyl is optionally substituted with one, two, three or four alkoxy; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four independently selected alkoxy;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl.


In another embodiment of Formula (VIc), n is 0. In another embodiment of Formula (VIc), n is 1. In another embodiment of Formula (VIc), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (VIc), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIc), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIc), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIc), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIc), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIc), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIc), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIc), R1 is C(O)NH2. In another embodiment of Formula (VIc), R1 is F. In another embodiment of Formula (VIc), R1 is Cl. In another embodiment of Formula (VIc), R1 is Br. In another embodiment of Formula (VIc), R1 is CN. In another embodiment of Formula (VIc), R1 is NH2. In another embodiment of Formula (VIc), R1 is NO2. In another embodiment of Formula (VIc), R1 is CF3. In another embodiment of Formula (VIc), R1 is C(O)OH. In another embodiment of Formula (VIc), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


Still another embodiment pertains to compounds having Formula (VIc), which include

  • N-{4-[(3,5-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-chlorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-([(1S)-2-hydroxy-1-phenylethyl]amino carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-([(1S)-2-hydroxy-1-pyridin-2-ylethyl]amino carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4[(4-hydroxypiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-hydroxy-2-methylpropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(morpholin-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-isopropoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(azetidin-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,6-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(isobutylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(butylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(cyclopentylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-isopropoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(6-methoxypyridin-3-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-isobutoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(trifluoromethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyrimidin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(pyridin-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(pyrrolidin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(3S)-pyrrolidin-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[(3R)-1-isobutyrylpyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[(3R)-1-benzoylpyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[1-(methylsulfonyl)pyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[1-(morpholin-4-yl)cyclopentyl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-1-(4-fluorophenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-2-hydroxy-1-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-({[3-(hydroxymethyl)oxetan-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{[(1S)-1-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,7-diazaspiro[4.4]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,6-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,7-diazaspiro[4.5]dec-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,9-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,8-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[5.5]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.6]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[(2-oxa-9-azaspiro[5.5]undec-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-oxa-4,8-diazaspiro[5.5]undec-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,8-diazaspiro[4.5]dec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1,6-diazaspiro[3.5]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(2,5-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(5-oxa-2-azaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(6-oxa-2-azaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(hexahydro-5H-furo[2,3-c]pyrrol-5-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(hexahydrofuro[3,4-c]pyridin-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide; and pharmaceutically acceptable salts thereof.


Embodiments of Formula (VIIc)

In another aspect, the present invention provides compounds of Formula (VIIc)




embedded image


and pharmaceutically acceptable salts thereof; wherein X1, X2, X3, and R13 are as described herein for Formula (Ic), and custom-character indicates a single or a double bond.


In one embodiment of formula (VIIc),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;



custom-character indicates a single or double bond;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R3, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R1)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R10, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


wherein the cyclic moieties represented by R3, R6, and R10 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I;


R15, at each occurrence, is independently selected alkyl, wherein the R15 alkyl is optionally substituted with one, two, three or four alkoxy; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four alkoxy;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


In one embodiment of Formula (VIIc), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (VIIc), X1, X2, and X3 are CH. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (VIIc), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (VIIc), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (VIIc), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (VIIc), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (VIIc), X1 is N; X2 is CR1; and X3 is N.


In one embodiment of Formula (VIIc), custom-character is a single bond. In another embodiment of Formula (VIIc), custom-character is a double bond.


In another embodiment of Formula (VIIc), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (VIIc), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), R1 is C(O)NH2. In another embodiment of Formula (VIIc), R1 is F. In another embodiment of Formula (VIIc), R1 is Cl. In another embodiment of Formula (VIIc), R1 is Br. In another embodiment of Formula (VIIc), R1 is CN. In another embodiment of Formula (VIIc), R1 is NH2. In another embodiment of Formula (VIIc), R1 is NO2. In another embodiment of Formula (VIIc), R1 is CF3. In another embodiment of Formula (VIIc), R1 is C(O)OH. In another embodiment of Formula (VIIc), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (VIIc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (VIIc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (VIIc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


Still another embodiment pertains to compounds having Formula (VIIc), which include

  • tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}-3,6-dihydropyridine-1(2H)-carboxylate;
  • N-[4-(1-butyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}piperidine-1-carboxylate;
  • N-[4-(1-butyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(4-methylbenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(5-oxo-L-prolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(5-oxo-D-prolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-propionyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-ethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(ethoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(cyclopropylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(cyclopentylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-methylbenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methylbenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-methoxybenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-methoxybenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(4-methoxybenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-fluorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-fluorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(4-fluorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(4-chlorobenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[3-(dimethylamino)benzoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[4-(dimethylamino)benzoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(3-thienylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1H-pyrrol-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2,5-dimethyl-1H-pyrrol-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1,3-thiazol-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1H-pyrazol-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(3,5-dimethyl-1,2-oxazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridin-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridin-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-isonicotinoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridazin-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyrazin-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyrimidin-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[3-(piperidin-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-butyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-benzoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(1,4-dioxan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1-methylpiperidin-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[1-(2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(N,N-dimethylglycyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopentylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydro-2H-pyran-2-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(pyrrolidin-1-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(pyrazin-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • 5-cyano-N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[1-(2-hydroxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • 5-cyano-N-{4-[1-(morpholin-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-(4-{1-[(2-methyl-1,3-oxazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(furan-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2E)-3-(furan-2-yl)prop-2-enoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1,3-oxazol-5-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3,3,3-trifluoropropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,5-dimethyl-1H-pyrazol-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(4-methoxycyclohexyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2,3-dimethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2,2-difluorocyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1H-pyrazol-5-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tert-butoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[3-(1H-1,2,4-triazol-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3-ethoxypropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(3-hydroxy-3-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[3-(1H-pyrrol-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methylcyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methylpropoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(1-methylprolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-hydroxycyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopropylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopentylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-{[1-(methoxymethyl)cyclopropyl]carbonyl}-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(methylsulfonyl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methyl-1H-pyrazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopropylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-ethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(5-oxo-L-prolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2E)-4-methylpent-2-enoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-methoxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopent-1-en-1-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(thiophen-3-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclohexylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-[4-(1-propanoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2,2-dimethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(methoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2,2-dimethylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(4-methylhexanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2,2-dimethylcyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclobutylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(piperidin-1-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[2-(pyrrolidin-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,3-dimethyl-1H-pyrazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide; and pharmaceutically acceptable salts thereof.


Embodiments of Formula (VIIIc)

One embodiment of this invention, therefore, pertains to compounds or pharmaceutically acceptable salts thereof, which are useful as inhibitors of NAMPT, the compounds having Formula (VIIIc)




embedded image


wherein


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


X1 is CH; X2 is N; and X3 is CR1; or


X1 is CR1; X2 is N; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is CH; or


X1 is N; X2 is CR1; and X3 is N;


R1 is R3, OR3, SR3, S(O)R3, SO2R3, C(O)R3, C(O)OR3, OC(O)R3, NHR3, N(R3)2, C(O)NH2, C(O)NHR3, C(O)N(R3)2, NHC(O)R3, NR3C(O)R3, NHC(O)OR3, NR3C(O)OR3, SO2NH2, SO2NHR3, SO2N(R3)2, NHSO2R3, NR3SO2R3, NHSO2NHR3, NHSO2N(R3)2, NR3SO2NHR3, NR3SO2N(R3)2, C(O)NHSO2R3, NHSO2NHR3, F, Cl, Br, I, CN, NH2, NO2, N3, OH, C(O)H, CF3, C(O)OH, or C(O)NH2;


R3, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, or heterocyclyl; wherein each R3 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R6, OR6, SR6, S(O)R6, SO2R6, C(O)R6, CO(O)R6, OC(O)R6, OC(O)OR6, NH2, NHR6, N(R6)2, NHC(O)R6, NR6C(O)R6, NHS(O)2R6, NR6S(O)2R6, NHC(O)OR6, NR6C(O)OR6, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)NHR6, NR6C(O)N(R6)2, C(O)NH2, C(O)NHR6, C(O)N(R6)2, C(O)NHOH, C(O)NHOR6, C(O)NHSO2R6, C(O)NR6SO2R6, SO2NH2, SO2NHR6, SO2N(R6)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R6 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R10, OR10, SR10, S(O)R10, SO2R10, NHR10, N(R10)2, C(O)R10, C(O)NH2, C(O)NHR10, C(O)N(R10)2, NHC(O)R10, NR10C(O)R10, NHSO2R10, NHC(O)OR10, SO2NH2, SO2NHR10, SO2N(R10)2, NHC(O)NH2, NHC(O)NHR10, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R8, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R8 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R12, OR12, SR12, S(O)R12, SO2R12, NHR12, N(R12)2, C(O)R12, C(O)NH2, C(O)NHR12, C(O)N(R12)2, NHC(O)R12, NR12C(O)R12, NHSO2R12, NHC(O)OR12, SO2NH2, SO2NHR12, SO2N(R12)2, NHC(O)NH2, NHC(O)NHR12, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;


R10, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl;


R12, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R12 alkyl, alkenyl, and alkynyl is optionally substituted with one or more alkoxy;


wherein the cyclic moieties represented by R3, R6, R8, R10, and R12 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SR13, S(O)R13, SO2R13, C(O)R13, CO(O)R13, OC(O)R13, OC(O)OR13, NH2, NHR13, N(R13)2, NHC(O)R13, NR13C(O)R13, NHS(O)2R13, NR13S(O)2R13, NHC(O)OR13, NR13C(O)OR13, NHC(O)NH2, NHC(O)NHR13, NHC(O)N(R13)2, NR13C(O)NHR13, NR13C(O)N(R13)2, C(O)NH2, C(O)NHR13, C(O)N(R13)2, C(O)NHOH, C(O)NHOR13, C(O)NHSO2R13, C(O)NR13SO2R13, SO2NH2, SO2NHR13, SO2N(R13)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SR14, S(O)R14, SO2R14, C(O)R14, OC(O)R14, OC(O)OR14, NH2, NHR14, N(R14)2, NHC(O)R14, NR14C(O)R14, NHS(O)2R14, NR14S(O)2R14, NHC(O)OR14, NR14C(O)OR14, NHC(O)NH2, NHC(O)NHR14, NHC(O)N(R14)2, NR14C(O)NHR14, NR14C(O)N(R14)2, C(O)NH2, C(O)NHR14, C(O)N(R14)2, C(O)NHOH, C(O)NHOR14, C(O)NHSO2R14, C(O)NR14SO2R14, SO2NH2, SO2NHR14, SO2N(R14)2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, CO(O)R15, OC(O)R15, OC(O)OR15, NH2, NHR15, N(R15)2, NHC(O)R15, NR15C(O)R15, NHS(O)2R15, NR15S(O)2R15, NHC(O)OR15, NR15C(O)OR15, NHC(O)NH2, NHC(O)NHR15, NHC(O)N(R15)2, NR15C(O)NHR15, NR15C(O)N(R15)2, C(O)NH2, C(O)NHR15, C(O)N(R15)2, C(O)NHOH, C(O)NHOR15, C(O)NHSO2R15, C(O)NR15SO2R15, SO2NH2, SO2NHR15, SO2N(R15)2, C(O)H, C(O)OH, OH, CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, or cycloalkenyl; wherein each R14 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, NH2, SO2NH2, C(O)H, C(O)OH, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I; wherein the R16 alkyl is optionally substituted with one, two, three or four alkoxy;


R15, at each occurrence, is independently selected alkyl; wherein the R15 alkyl is optionally substituted with one, two, three or four alkoxy;


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four alkoxy;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


In one embodiment of Formula (VIIIc), X1, X2, and X3 are CH; or X1 and X3 are CH; and X2 is N; or X1 and X3 are CH; and X2 is CR1; or X2 and X3 are CH; and X1 is CR1; or X1 is CH; and X2 and X3 are CR1; or X2 is CH; and X1 and X3 are N; or X2 and X3 are CH; and X1 is N; or X1 is CH; X2 is N; and X3 is CR1; or X1 is CR1; X2 is N; and X3 is CH; or X1 is N; X2 is CR1; and X3 is CH; or X1 is N; X2 is CR1; and X3 is N. In another embodiment of Formula (VIIIc), X1, X2, and X3 are CH. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is N. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1. In another embodiment of Formula (VIIIc), X2 is CH; and X1 and X3 are N. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is N. In another embodiment of Formula (VIIIc), X1 is CH; X2 is N; and X3 is CR1. In another embodiment of Formula (VIIIc), X1 is CR1; X2 is N; and X3 is CH. In another embodiment of Formula (VIIIc), X1 is N; X2 is CR1; and X3 is CH. In another embodiment of Formula (VIIIc), X1 is N; X2 is CR1; and X3 is N.


In another embodiment of Formula (VIIIc), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (VIIIc), R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), R1 is C(O)NH2. In another embodiment of Formula (VIIIc), R1 is F. In another embodiment of Formula (VIIIc), R1 is Cl. In another embodiment of Formula (VIIIc), R1 is Br. In another embodiment of Formula (VIIIc), R1 is CN. In another embodiment of Formula (VIIIc), R1 is NH2. In another embodiment of Formula (VIIIc), R1 is NO2. In another embodiment of Formula (VIIIc), R1 is CF3. In another embodiment of Formula (VIIIc), R1 is C(O)OH. In another embodiment of Formula (VIIIc), R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl.


In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; and R1 is F. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; and R1 is Cl. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; and R1 is Br. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; and R1 is CN. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; and R1 is NH2. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; and R1 is NO2. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; and R1 is CF3. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; and R1 is C(O)OH. In another embodiment of Formula (VIIIc), X1 and X3 are CH; and X2 is CR1; R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)NH2. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; and R1 is F. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; and R1 is Cl. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; and R1 is Br. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; and R1 is CN. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; and R1 is NH2. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; and R1 is NO2. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; and R1 is CF3. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)OH. In another embodiment of Formula (VIIIc), X2 and X3 are CH; and X1 is CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; and R1 is R3, OR3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; R1 is R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; R1 is OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; R1 is C(O)OR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; R1 is C(O)NHR3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; R1 is NHC(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; R1 is NHSO2R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; wherein R6 is alkyl or heterocyclyl. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)NH2. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; and R1 is F. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; and R1 is Cl. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; and R1 is Br. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; and R1 is CN. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; and R1 is NH2. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; and R1 is NO2. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; and R1 is CF3. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)OH. In another embodiment of Formula (VIIIc), X1 is CH; and X2 and X3 are CR1; and R1 is C(O)R3; wherein R3 is alkyl, alkenyl, or heterocyclyl; wherein each alkyl is optionally substituted with one or more independently selected R6, OR6, NH2, NHC(O)R6, N(R6)2, or OH; and R6 is alkyl or heterocyclyl.


In one embodiment of Formula (VIIIc),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH;


R3, at each occurrence, is independently selected alkyl, alkenyl, or heterocyclyl; wherein each R3 alkyl is optionally substituted with one, two, three or four independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, OH, F, Cl, Br or I;


R6, at each occurrence, is independently selected alkyl or heterocyclyl; wherein each R6 alkyl is optionally substituted with one, two, three or four independently selected F, Cl, Br or I;


R8, at each occurrence, is independently selected alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R8 alkyl is optionally substituted with one, two, three or four independently selected R12, OR12OH, CF3, F, Cl, Br or I;


R12, at each occurrence, is independently selected alkyl, heterocyclyl, or cycloalkyl; wherein each R12 alkyl is optionally substituted with one or more alkoxy;


wherein the cyclic moieties represented by R3, R6, R8, and R12 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SO2R13, C(O)R13, CO(O)R13, NH2, N(R13)2, NHC(O)R13, NHC(O)OR13, C(O)NH2, C(O)NHR13, C(O)N(R13)2, OH, CN, CF3, OCF3, SCF3, F, Cl, Br or I;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl, alkenyl, and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SO2R14, NH2, NHR14, N(R14)2, NHC(O)R14, NHC(O)OR14, OH, CF3, F, Cl, Br or I; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, or cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SO2R15, C(O)R15, N(R15)2, NHC(O)R15, OH, CN, CF3, F, Cl, Br or I;


R14, at each occurrence, is independently selected alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R14 alkyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, OH, F, Cl, Br or I; wherein each R14 aryl, heterocyclyl, and cycloalkyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, F, Cl, Br, or I;


R15, at each occurrence, is independently selected alkyl; wherein the R15 alkyl is optionally substituted with one, two, three or four alkoxy; and R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four alkoxy;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


In another embodiment of Formula (VIIIc),


X1, X2, and X3 are CH; or


X1 and X3 are CH; and X2 is N; or


X1 and X3 are CH; and X2 is CR1; or


X2 and X3 are CH; and X1 is CR1; or


X1 is CH; and X2 and X3 are CR1; or


X2 is CH; and X1 and X3 are N; or


X2 and X3 are CH; and X1 is N; or


R1 is R3, OR3, C(O)R3, C(O)OR3, C(O)NH2, C(O)NHR3, NHC(O)R3, NHSO2R3, F, Cl, Br, I, CN, NH2, NO2, CF3, or C(O)OH;


R3, at each occurrence, is independently selected alkyl, alkenyl, or heterocyclyl; wherein each R3 alkyl is optionally substituted with one, two, three or four independently selected R6, OR6, NH2, N(R6)2, NHC(O)R6, or OH;


R6, at each occurrence, is independently selected alkyl or heterocyclyl; R8, at each occurrence, is independently selected alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R8 alkyl is optionally substituted with one, two, three or four independently selected R12, OR12OH, or CF3;


R12, at each occurrence, is independently selected alkyl, heterocyclyl, or cycloalkyl; wherein each R12 alkyl is optionally substituted with one or more alkoxy;


wherein the cyclic moieties represented by R3, R6, R8, and R12 are optionally substituted with one, two, three, four, five, or six independently selected R13, OR13, SO2R13, C(O)R13, CO(O)R13, NH2, N(R13)2, NHC(O)R13, NHC(O)OR13, C(O)NH2, C(O)NHR13, C(O)N(R13)2, OH, CN, CF3, OCF3, SCF3, F, or Cl;


R13, at each occurrence, is independently selected alkyl, alkenyl, alkynyl, aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, or cycloalkenyl; wherein each R13 alkyl and alkynyl is optionally substituted with one, two, three or four independently selected R14, OR14, SO2R14, NH2, NHR14, N(R14)2), NHC(O)R14, NHC(O)OR14, OH, or CF3; wherein each R13 aryl, tetrahydrofuranyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyridinyl, thieno[3,2-c]pyridinyl, furo[3,2-c]pyridinyl, pyrrolidin-2-onyl, 1,1-dioxidotetrahydrothien-3-yl, 1,1-dioxidotetrahydro-2H-thiopyran-3-yl, dioxanyl, tetrahydropyranyl, piperidinyl, pyrimidinyl, oxazolyl, pyrazolyl, thiazolyl, pyrrolidinyl, pyrrolyl, thienyl, furanyl, morpholinyl, isooxazolyl, cycloalkyl, and cycloalkenyl is optionally substituted with one, two, three or four independently selected R15, OR15, SO2R15, C(O)R15, N(R15)2, NHC(O)R15, CN, OH, CF3, F, or Cl;


R14, at each occurrence, is independently selected alkyl, aryl, heterocyclyl, or cycloalkyl; wherein each R14 alkyl is optionally substituted with one, two, three or four independently selected heterocyclyl, alkoxy, or OH; wherein each R14 aryl, heterocyclyl, and cycloalkyl is optionally substituted with one, two, three or four independently selected R16, OR16, OH, or Cl;


R15, at each occurrence, is independently selected alkyl; wherein the R15 alkyl is optionally substituted with one, two, three or four alkoxy; and


R16, at each occurrence, is independently selected alkyl, wherein the R16 alkyl is optionally substituted with one, two, three or four independently selected alkoxy;


with the proviso that when R13 is piperidinyl, it is substituted piperidinyl; and


with the proviso that when R13 is pyrrolinyl, at least one of X1, X2, and X3 is N.


Still another embodiment pertains to compounds having Formula (VIIIc), which include

  • N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridin-3-ylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoylpiperidin-4-yl)butyl]-5-cyano-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-{4-[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide;
  • N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-2-ylacetyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylacetyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(4,4-difluorocyclohexyl)carbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-(4-{1-[(propan-2-yloxy)acetyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;
  • N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide; and pharmaceutically acceptable salts thereof.


Pharmaceutical Compositions, Combination Therapies, Methods of Treatment, and Administration

Another embodiment comprises pharmaceutical compositions comprising a compound having Formula (I) and an excipient.


Still another embodiment comprises methods of treating cancer in a mammal comprising administering thereto a therapeutically acceptable amount of a compound having Formula (I).


Still another embodiment pertains to compositions for treating diseases during which NAMPT is expressed, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I).


Still another embodiment pertains to compositions for treating diseases during which ROCK is expressed, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I).


Still another embodiment pertains to methods of treating disease in a patient during which NAMPT is expressed, said methods comprising administering to the patient a therapeutically effective amount of a compound having Formula (I).


Still another embodiment pertains to methods of treating disease in a patient during which ROCK is expressed, said methods comprising administering to the patient a therapeutically effective amount of a compound having Formula (I).


Still another embodiment pertains to compositions for treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I).


Still another embodiment pertains to compositions for treating hypertension, chronic and congestive heart failure, cardiac hypertrophy, restenosis, chronic renal failure, cerebral vasospasm after subarachnoid bleeding, pulmonary hypertension, atherosclerosis, asthma, male erectile dysfunctions, female sexual dysfunction, over-active bladder syndrome, spinal-cord injury, traumatic brain injury, stroke, inflammatory and demyelinating diseases, Alzheimer's disease, pain, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, inflammatory pain, rheumatoid arthritis, osteoarthritis, irritable bowel syndrome, Crohn's disease, psoriasis, ulcerative colitis, lupus, inflammatory bowel disease, cancer, tumor metastasis, viral infections, bacterial infections, insulin resistance, diabetes, ocular hypertension, preterm labor, atherosclerosis, spinal muscular atrophy, encephalomyelitis, osteoporosis, HIV-1, encephalitis, ischemic CNS disorders, vascular or AD type dementia, glaucoma, retinopathy, benign prostatic hypertrophy, psychiatric disorders, in particular depression, schizophrenia, obsessive compulsive disorder and bipolar disorder, epilepsy and seizure disorders, for decreasing ischemia-reperfusion injury, myocardial infarct size and myocardial fibrosis, for the prevention of graft failure, and cystic fibrosis, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I).


Still another embodiment pertains to methods of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia in a patient, said methods comprising administering to the patient a therapeutically effective amount of a compound having Formula (I).


Still another embodiment pertains to methods of treating hypertension, chronic and congestive heart failure, cardiac hypertrophy, restenosis, chronic renal failure, cerebral vasospasm after subarachnoid bleeding, pulmonary hypertension, atherosclerosis, asthma, male erectile dysfunctions, female sexual dysfunction, over-active bladder syndrome, spinal-cord injury, traumatic brain injury, stroke, inflammatory and demyelinating diseases, Alzheimer's disease, pain, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, inflammatory pain, rheumatoid arthritis, osteoarthritis, irritable bowel syndrome, Crohn's disease, psoriasis, ulcerative colitis, lupus, inflammatory bowel disease, cancer, tumor metastasis, viral infections, bacterial infections, insulin resistance, diabetes, ocular hypertension, preterm labor, atherosclerosis, spinal muscular atrophy, encephalomyelitis, osteoporosis, HIV-1, encephalitis, ischemic CNS disorders, vascular or AD type dementia, glaucoma, retinopathy, benign prostatic hypertrophy, psychiatric disorders, in particular depression, schizophrenia, obsessive compulsive disorder and bipolar disorder, epilepsy and seizure disorders, for decreasing ischemia-reperfusion injury, myocardial infarct size and myocardial fibrosis, for the prevention of graft failure, and cystic fibrosis, said methods comprising administering to the patient a therapeutically effective amount of a compound having Formula (I).


Still another embodiment pertains to compositions for treating diseases during which NAMPT is expressed, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.


Still another embodiment pertains to compositions for treating diseases during which ROCK is expressed, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.


Still another embodiment pertains to methods of treating disease in a patient during which NAMPT is expressed, said methods comprising administering to the patient a therapeutically effective amount of a compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.


Still another embodiment pertains to methods of treating disease in a patient during which ROCK is expressed, said methods comprising administering to the patient a therapeutically effective amount of a compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.


Still another embodiment pertains to compositions for treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.


Still another embodiment pertains to compositions for treating hypertension, chronic and congestive heart failure, cardiac hypertrophy, restenosis, chronic renal failure, cerebral vasospasm after subarachnoid bleeding, pulmonary hypertension, atherosclerosis, asthma, male erectile dysfunctions, female sexual dysfunction, over-active bladder syndrome, spinal-cord injury, traumatic brain injury, stroke, inflammatory and demyelinating diseases, Alzheimer's disease, pain, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, inflammatory pain, rheumatoid arthritis, osteoarthritis, irritable bowel syndrome, Crohn's disease, psoriasis, ulcerative colitis, lupus, inflammatory bowel disease, cancer, tumor metastasis, viral infections, bacterial infections, insulin resistance, diabetes, ocular hypertension, preterm labor, atherosclerosis, spinal muscular atrophy, encephalomyelitis, osteoporosis, HIV-1, encephalitis, ischemic CNS disorders, vascular or AD type dementia, glaucoma, retinopathy, benign prostatic hypertrophy, psychiatric disorders, in particular depression, schizophrenia, obsessive compulsive disorder and bipolar disorder, epilepsy and seizure disorders, for decreasing ischemia-reperfusion injury, myocardial infarct size and myocardial fibrosis, for the prevention of graft failure, and cystic fibrosis, said compositions comprising an excipient and a therapeutically effective amount of the compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.


Still another embodiment pertains to methods of treating inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia in a patient, said methods comprising administering to the patient a therapeutically effective amount of the compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.


Still another embodiment pertains to methods of treating hypertension, chronic and congestive heart failure, cardiac hypertrophy, restenosis, chronic renal failure, cerebral vasospasm after subarachnoid bleeding, pulmonary hypertension, atherosclerosis, asthma, male erectile dysfunctions, female sexual dysfunction, over-active bladder syndrome, spinal-cord injury, traumatic brain injury, stroke, inflammatory and demyelinating diseases, Alzheimer's disease, pain, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, inflammatory pain, rheumatoid arthritis, osteoarthritis, irritable bowel syndrome, Crohn's disease, psoriasis, ulcerative colitis, lupus, inflammatory bowel disease, cancer, tumor metastasis, viral infections, bacterial infections, insulin resistance, diabetes, ocular hypertension, preterm labor, atherosclerosis, spinal muscular atrophy, encephalomyelitis, osteoporosis, HIV-1, encephalitis, ischemic CNS disorders, vascular or AD type dementia, glaucoma, retinopathy, benign prostatic hypertrophy, psychiatric disorders, in particular depression, schizophrenia, obsessive compulsive disorder and bipolar disorder, epilepsy and seizure disorders, for decreasing ischemia-reperfusion injury, myocardial infarct size and myocardial fibrosis, for the prevention of graft failure, and cystic fibrosis in a patient, said methods comprising administering to the patient a therapeutically effective amount of the compound having Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.


Metabolites of compounds having Formula (I), produced by in vitro or in vivo metabolic processes, may also have utility for treating diseases associated with NAMPT.


Metabolites of compounds having Formula (I), produced by in vitro or in vivo metabolic processes, may also have utility for treating diseases associated with ROCK.


Certain precursor compounds which may be metabolized in vitro or in vivo to form compounds having Formula (I) may also have utility for treating diseases associated with NAMPT.


Certain precursor compounds which may be metabolized in vitro or in vivo to form compounds having Formula (I) may also have utility for treating diseases associated with ROCK.


Compounds having Formula (I) may exist as acid addition salts, basic addition salts or zwitterions. Salts of the compounds are prepared during isolation or following purification of the compounds. Acid addition salts of the compounds are those derived from the reaction of the compounds with an acid. For example, the acetate, adipate, alginate, bicarbonate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsufonate, digluconate, formate, fumarate, glycerophosphate, glutamate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactobionate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, phosphate, picrate, propionate, succinate, tartrate, thiocyanate, trichloroacetic, trifluoroacetic, para-toluenesulfonate, and undecanoate salts of the compounds are contemplated as being embraced by this invention. Basic addition salts of the compounds are those derived from the reaction of the compounds with the hydroxide, carbonate or bicarbonate of cations such as lithium, sodium, potassium, calcium, and magnesium.


The compounds having Formula (I) may be administered, for example, bucally, ophthalmically, orally, osmotically, parenterally (intramuscularly, intraperitoneally intrasternally, intravenously, subcutaneously), rectally, topically, transdermally or vaginally.


Therapeutically effective amounts of compounds having Formula (I) depend on the recipient of the treatment, the disorder being treated and the severity thereof, the composition containing the compound, the time of administration, the route of administration, the duration of treatment, the compound potency, its rate of clearance and whether or not another drug is co-administered. The amount of a compound of this invention having Formula (I) used to make a composition to be administered daily to a patient in a single dose or in divided doses is from about 0.03 to about 200 mg/kg body weight. Single dose compositions contain these amounts or a combination of submultiples thereof.


Compounds having Formula (I) may be administered with or without an excipient. Excipients include, for example, encapsulating materials or additives such as absorption accelerators, antioxidants, binders, buffers, coating agents, coloring agents, diluents, disintegrating agents, emulsifiers, extenders, fillers, flavoring agents, humectants, lubricants, perfumes, preservatives, propellants, releasing agents, sterilizing agents, sweeteners, solubilizers, wetting agents and mixtures thereof.


Excipients for preparation of compositions comprising a compound having Formula (I) to be administered orally in solid dosage form include, for example, agar, alginic acid, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1,3-butylene glycol, carbomers, castor oil, cellulose, cellulose acetate, cocoa butter, corn starch, corn oil, cottonseed oil, cross-povidone, diglycerides, ethanol, ethyl cellulose, ethyl laureate, ethyl oleate, fatty acid esters, gelatin, germ oil, glucose, glycerol, groundnut oil, hydroxypropylmethyl cellulose, isopropanol, isotonic saline, lactose, magnesium hydroxide, magnesium stearate, malt, mannitol, monoglycerides, olive oil, peanut oil, potassium phosphate salts, potato starch, povidone, propylene glycol, Ringer's solution, safflower oil, sesame oil, sodium carboxymethyl cellulose, sodium phosphate salts, sodium lauryl sulfate, sodium sorbitol, soybean oil, stearic acids, stearyl fumarate, sucrose, surfactants, talc, tragacanth, tetrahydrofurfuryl alcohol, triglycerides, water, and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered ophthalmically or orally in liquid dosage forms include, for example, 1,3-butylene glycol, castor oil, corn oil, cottonseed oil, ethanol, fatty acid esters of sorbitan, germ oil, groundnut oil, glycerol, isopropanol, olive oil, polyethylene glycols, propylene glycol, sesame oil, water and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered osmotically include, for example, chlorofluorohydrocarbons, ethanol, water and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered parenterally include, for example, 1,3-butanediol, castor oil, corn oil, cottonseed oil, dextrose, germ oil, groundnut oil, liposomes, oleic acid, olive oil, peanut oil, Ringer's solution, safflower oil, sesame oil, soybean oil, U.S.P. or isotonic sodium chloride solution, water and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having Formula (I) to be administered rectally or vaginally include, for example, cocoa butter, polyethylene glycol, wax and mixtures thereof.


Compounds having Formula (I) are expected to be useful when used with alkylating agents, angiogenesis inhibitors, antibodies, antimetabolites, antimitotics, antiproliferatives, antivirals, aurora kinase inhibitors, apoptosis promoters (for example, Bcl-xL, Bcl-w and Bfl-1) inhibitors, activators of death receptor pathway, Bcr-Abl kinase inhibitors, BiTE (Bi-Specific T cell Engager) antibodies, antibody drug conjugates, biologic response modifiers, cyclin-dependent kinase inhibitors, cell cycle inhibitors, cyclooxygenase-2 inhibitors, DVDs, leukemia viral oncogene homolog (ErbB2) receptor inhibitors, growth factor inhibitors, heat shock protein (HSP)-90 inhibitors, histone deacetylase (HDAC) inhibitors, hormonal therapies, immunologicals, inhibitors of inhibitors of apoptosis proteins (IAPs), intercalating antibiotics, kinase inhibitors, kinesin inhibitors, Jak2 inhibitors, mammalian target of rapamycin inhibitors, microRNA's, mitogen-activated extracellular signal-regulated kinase inhibitors, multivalent binding proteins, non-steroidal anti-inflammatory drugs (NSAIDs), poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitors, platinum chemotherapeutics, polo-like kinase (Plk) inhibitors, phosphoinositide-3 kinase (PI3K) inhibitors, proteosome inhibitors, purine analogs, pyrimidine analogs, receptor tyrosine kinase inhibitors, retinoids/deltoids plant alkaloids, small inhibitory ribonucleic acids (siRNAs), topoisomerase inhibitors, ubiquitin ligase inhibitors, and the like, and in combination with one or more of these agents.


BiTE antibodies are bi-specific antibodies that direct T-cells to attack cancer cells by simultaneously binding the two cells. The T-cell then attacks the target cancer cell. Examples of BiTE antibodies include adecatumumab (Micromet MT201), blinatumomab (Micromet MT103) and the like. Without being limited by theory, one of the mechanisms by which T-cells elicit apoptosis of the target cancer cell is by exocytosis of cytolytic granule components, which include perforin and granzyme B. In this regard, Bcl-2 has been shown to attenuate the induction of apoptosis by both perforin and granzyme B. These data suggest that inhibition of Bcl-2 could enhance the cytotoxic effects elicited by T-cells when targeted to cancer cells (V. R. Sutton, D. L. Vaux and J. A. Trapani, J. of Immunology 1997, 158 (12), 5783).


SiRNAs are molecules having endogenous RNA bases or chemically modified nucleotides. The modifications do not abolish cellular activity, but rather impart increased stability and/or increased cellular potency. Examples of chemical modifications include phosphorothioate groups, 2′-deoxynucleotide, 2′-OCH3-containing ribonucleotides, 2′-F-ribonucleotides, 2′-methoxyethyl ribonucleotides, combinations thereof and the like. The siRNA can have varying lengths (e.g., 10-200 bps) and structures (e.g., hairpins, single/double strands, bulges, nicks/gaps, mismatches) and are processed in cells to provide active gene silencing. A double-stranded siRNA (dsRNA) can have the same number of nucleotides on each strand (blunt ends) or asymmetric ends (overhangs). The overhang of 1-2 nucleotides can be present on the sense and/or the antisense strand, as well as present on the 5′- and/or the 3′-ends of a given strand.


Multivalent binding proteins are binding proteins comprising two or more antigen binding sites. Multivalent binding proteins are engineered to have the three or more antigen binding sites and are generally not naturally occurring antibodies. The term “multispecific binding protein” means a binding protein capable of binding two or more related or unrelated targets. Dual variable domain (DVD) binding proteins are tetravalent or multivalent binding proteins binding proteins comprising two or more antigen binding sites. Such DVDs may be monospecific (i.e., capable of binding one antigen) or multispecific (i.e., capable of binding two or more antigens). DVD binding proteins comprising two heavy chain DVD polypeptides and two light chain DVD polypeptides are referred to as DVD Ig's. Each half of a DVD Ig comprises a heavy chain DVD polypeptide, a light chain DVD polypeptide, and two antigen binding sites. Each binding site comprises a heavy chain variable domain and a light chain variable domain with a total of 6 CDRs involved in antigen binding per antigen binding site.


Alkylating agents include altretamine, AMD-473, AP-5280, apaziquone, bendamustine, brostallicin, busulfan, carboquone, carmustine (BCNU), chlorambucil, CLORETAZINE® (laromustine, VNP 40101M), cyclophosphamide, decarbazine, estramustine, fotemustine, glufosfamide, ifosfamide, KW-2170, lomustine (CCNU), mafosfamide, melphalan, mitobronitol, mitolactol, nimustine, nitrogen mustard N-oxide, ranimustine, temozolomide, thiotepa, TREANDA® (bendamustine), treosulfan, trofosfamide and the like.


Angiogenesis inhibitors include endothelial-specific receptor tyrosine kinase (Tie-2) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, insulin growth factor-2 receptor (IGFR-2) inhibitors, matrix metalloproteinase-2 (MMP-2) inhibitors, matrix metalloproteinase-9 (MMP-9) inhibitors, platelet-derived growth factor receptor (PDGFR) inhibitors, thrombospondin analogs, vascular endothelial growth factor receptor tyrosine kinase (VEGFR) inhibitors and the like.


Antimetabolites include ALIMTA® (pemetrexed disodium, LY231514, MTA), 5-azacitidine, XELODA® (capecitabine), carmofur, LEUSTAT® (cladribine), clofarabine, cytarabine, cytarabine ocfosfate, cytosine arabinoside, decitabine, deferoxamine, doxifluridine, eflornithine, EICAR (5-ethynyl-1-(3-D-ribofuranosylimidazole-4-carboxamide), enocitabine, ethnylcytidine, fludarabine, 5-fluorouracil alone or in combination with leucovorin, GEMZAR® (gemcitabine), hydroxyurea, ALKERAN®(melphalan), mercaptopurine, 6-mercaptopurine riboside, methotrexate, mycophenolic acid, nelarabine, nolatrexed, ocfosfate, pelitrexol, pentostatin, raltitrexed, Ribavirin, triapine, trimetrexate, S-1, tiazofurin, tegafur, TS-1, vidarabine, UFT and the like.


Antivirals include ritonavir, hydroxychloroquine and the like.


Aurora kinase inhibitors include ABT-348, AZD-1152, MLN-8054, VX-680, Aurora A-specific kinase inhibitors, Aurora B-specific kinase inhibitors and pan-Aurora kinase inhibitors and the like.


Bcl-2 protein inhibitors include AT-101 ((−)gossypol), GENASENSE® (G3139 or oblimersen (Bcl-2-targeting antisense oligonucleotide)), IPI-194, IPI-565, N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide) (ABT-737), N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide (ABT-263), GX-070 (obatoclax) and the like.


Bcr-Abl kinase inhibitors include DASATINIB® (BMS-354825), GLEEVEC® (imatinib) and the like.


CDK inhibitors include AZD-5438, BMI-1040, BMS-032, BMS-387, CVT-2584, flavopyridol, GPC-286199, MCS-5A, PD0332991, PHA-690509, seliciclib (CYC-202, R-roscovitine), ZK-304709 and the like.


COX-2 inhibitors include ABT-963, ARCOXIA® (etoricoxib), BEXTRA® (valdecoxib), BMS347070, CELEBREX® (celecoxib), COX-189 (lumiracoxib), CT-3, DERAMAXX® (deracoxib), JTE-522, 4-methyl-2-(3,4-dimethylphenyl)-1-(4-sulfamoylphenyl-1H-pyrrole), MK-663 (etoricoxib), NS-398, parecoxib, RS-57067, SC-58125, SD-8381, SVT-2016, S-2474, T-614, VIOXX® (rofecoxib) and the like.


EGFR inhibitors include ABX-EGF, anti-EGFR immunoliposomes, EGF-vaccine, EMD-7200, ERBITUX® (cetuximab), HR3, IgA antibodies, IRESSA® (gefitinib), TARCEVA® (erlotinib or OSI-774), TP-38, EGFR fusion protein, TYKERB® (lapatinib) and the like.


ErbB2 receptor inhibitors include CP-724-714, CI-1033 (canertinib), HERCEPTIN® (trastuzumab), TYKERB® (lapatinib), OMNITARG® (2C4, petuzumab), TAK-165, GW-572016 (ionafarnib), GW-282974, EKB-569, PI-166, dHER2 (HER2 vaccine), APC-8024 (HER-2 vaccine), anti-HER/2neu bispecific antibody, B7.her2IgG3, AS HER2 trifunctional bispecfic antibodies, mAB AR-209, mAB 2B-1 and the like.


Histone deacetylase inhibitors include depsipeptide, LAQ-824, MS-275, trapoxin, suberoylanilide hydroxamic acid (SAHA), TSA, valproic acid and the like.


HSP-90 inhibitors include 17-AAG-nab, 17-AAG, CNF-101, CNF-1010, CNF-2024, 17-DMAG, geldanamycin, IPI-504, KOS-953, MYCOGRAB® (human recombinant antibody to HSP-90), NCS-683664, PU24FCl, PU-3, radicicol, SNX-2112, STA-9090 VER49009 and the like.


Inhibitors of inhibitors of apoptosis proteins include HGS1029, GDC-0145, GDC-0152, LCL-161, LBW-242 and the like.


Antibody drug conjugates include anti-CD22-MC-MMAF, anti-CD22-MC-MMAE, anti-CD22-MCC-DM1, CR-011-vcMMAE, PSMA-ADC, MEDI-547, SGN-19Am SGN-35, SGN-75 and the like.


Activators of death receptor pathway include TRAIL, antibodies or other agents that target TRAIL or death receptors (e.g., DR4 and DR5) such as Apomab, conatumumab, ETR2-ST01, GDC0145 (lexatumumab), HGS-1029, LBY-135, PRO-1762 and trastuzumab.


Kinesin inhibitors include Eg5 inhibitors such as AZD4877, ARRY-520; CENPE inhibitors such as GSK923295A and the like.


JAK-2 inhibitors include CEP-701 (lesaurtinib), XL019 and INCB018424 and the like.


MEK inhibitors include ARRY-142886, ARRY-438162 PD-325901, PD-98059 and the like.


mTOR inhibitors include AP-23573, CCI-779, everolimus, RAD-001, rapamycin, temsirolimus, ATP-competitive TORC1/TORC2 inhibitors, including PI-103, PP242, PP30, Torin 1 and the like.


Non-steroidal anti-inflammatory drugs include AMIGESIC® (salsalate), DOLOBID® (diflunisal), MOTRIN® (ibuprofen), ORUDIS® (ketoprofen), RELAFEN® (nabumetone), FELDENE® (piroxicam), ibuprofen cream, ALEVE® (naproxen) and NAPROSYN® (naproxen), VOLTAREN® (diclofenac), INDOCIN® (indomethacin), CLINORIL® (sulindac), TOLECTIN® (tolmetin), LODINE® (etodolac), TORADOL® (ketorolac), DAYPRO® (oxaprozin) and the like.


PDGFR inhibitors include C-451, CP-673, CP-868596 and the like.


Platinum chemotherapeutics include cisplatin, ELOXATIN® (oxaliplatin) eptaplatin, lobaplatin, nedaplatin, PARAPLATIN® (carboplatin), satraplatin, picoplatin and the like.


Polo-like kinase inhibitors include BI-2536 and the like.


Phosphoinositide-3 kinase (PI3K) inhibitors include wortmannin, LY294002, XL-147, CAL-120, ONC-21, AEZS-127, ETP-45658, PX-866, GDC-0941, BGT226, BEZ235, XL765 and the like.


Thrombospondin analogs include ABT-510, ABT-567, ABT-898, TSP-1 and the like.


VEGFR inhibitors include AVASTIN® (bevacizumab), ABT-869, AEE-788, ANGIOZYME™ (a ribozyme that inhibits angiogenesis (Ribozyme Pharmaceuticals (Boulder, Colo.) and Chiron, (Emeryville, Calif.)), axitinib (AG-13736), AZD-2171, CP-547,632, IM-862, MACUGEN (pegaptamib), NEXAVAR® (sorafenib, BAY43-9006), pazopanib (GW-786034), vatalanib (PTK-787, ZK-222584), SUTENT® (sunitinib, SU-11248), VEGF trap, ZACTIMA™ (vandetanib, ZD-6474) and the like.


Antibiotics include intercalating antibiotics aclarubicin, actinomycin D, amrubicin, annamycin, adriamycin, BLENOXANE® (bleomycin), daunorubicin, CAELYX® or MYOCET® (liposomal doxorubicin), elsamitrucin, epirbucin, glarbuicin, ZAVEDOS® (idarubicin), mitomycin C, nemorubicin, neocarzinostatin, peplomycin, pirarubicin, rebeccamycin, stimalamer, streptozocin, VALSTAR® (vahrubicin), zinostatin and the like.


Topoisomerase inhibitors include aclarubicin, 9-aminocamptothecin, amonafide, amsacrine, becatecarin, belotecan, BN-80915, CAMPTOSAR® (irinotecan hydrochloride), camptothecin, CARDIOXANE® (dexrazoxine), diflomotecan, edotecarin, ELLENCE® or PHARMORUBICIN® (epirubicin), etoposide, exatecan, 10-hydroxycamptothecin, gimatecan, lurtotecan, mitoxantrone, orathecin, pirarbucin, pixantrone, rubitecan, sobuzoxane, SN-38, tafluposide, topotecan and the like.


Antibodies include AVASTIN® (bevacizumab), CD40-specific antibodies, chTNT-1/B, denosumab, ERBITUX® (cetuximab), HUMAX-CD4® (zanolimumab), IGF1R-specific antibodies, lintuzumab, PANOREX® (edrecolomab), RENCAREX® (WX G250), RITUXAN® (rituximab), ticilimumab, trastuzimab, CD20 antibodies types I and II and the like.


Hormonal therapies include ARIMIDEX® (anastrozole), AROMASIN® (exemestane), arzoxifene, CASODEX® (bicalutamide), CETROTIDE® (cetrorelix), degarelix, deslorelin, DESOPAN® (trilostane), dexamethasone, DROGENIL® (flutamide), EVISTA® (raloxifene), AFEMA™ (fadrozole), FARESTON® (toremifene), FASLODEX® (fulvestrant), FEMARA® (letrozole), formestane, glucocorticoids, HECTOROL® (doxercalciferol), RENAGEL® (sevelamer carbonate), lasofoxifene, leuprolide acetate, MEGACE® (megesterol), MIFEPREX® (mifepristone), NILANDRON™ (nilutamide), NOLVADEX® (tamoxifen citrate), PLENAXIS™ (abarelix), prednisone, PROPECIA® (finasteride), rilostane, SUPREFACT® (buserelin), TRELSTAR® (luteinizing hormone releasing hormone (LHRH)), VANTAS® (Histrelin implant), VETORYL® (trilostane or modrastane), ZOLADEX® (fosrelin, goserelin) and the like.


Deltoids and retinoids include seocalcitol (EB1089, CB1093), lexacalcitrol (KH1060), fenretinide, PANRETIN® (aliretinoin), ATRAGEN® (liposomal tretinoin), TARGRETIN® (bexarotene), LGD-1550 and the like.


PARP inhibitors include ABT-888 (veliparib), olaparib, KU-59436, AZD-2281, AG-014699, BSI-201, BGP-15, INO-1001, ONO-2231 and the like.


Plant alkaloids include, but are not limited to, vincristine, vinblastine, vindesine, vinorelbine and the like.


Proteasome inhibitors include VELCADE® (bortezomib), MG132, NPI-0052, PR-171 and the like.


Examples of immunologicals include interferons and other immune-enhancing agents. Interferons include interferon alpha, interferon alpha-2a, interferon alpha-2b, interferon beta, interferon gamma-la, ACTIMMUNE® (interferon gamma-1b) or interferon gamma-n1, combinations thereof and the like. Other agents include ALFAFERONE®, (IFN-α), BAM-002 (oxidized glutathione), BEROMUN® (tasonermin), BEXXAR® (tositumomab), CAMPATH® (alemtuzumab), CTLA4 (cytotoxic lymphocyte antigen 4), decarbazine, denileukin, epratuzumab, GRANOCYTE® (lenograstim), lentinan, leukocyte alpha interferon, imiquimod, MDX-010 (anti-CTLA-4), melanoma vaccine, mitumomab, molgramostim, MYLOTARG™ (gemtuzumab ozogamicin), NEUPOGEN® (filgrastim), OncoVAC-CL, OVAREX® (oregovomab), pemtumomab (Y-muHMFG1), PROVENGE® (sipuleucel-T), sargaramostim, sizofilan, teceleukin, THERACYS® (Bacillus Calmette-Guerin), ubenimex, VIRULIZIN® (immunotherapeutic, Lorus Pharmaceuticals), Z-100 (Specific Substance of Maruyama (SSM)), WF-10 (Tetrachlorodecaoxide (TCDO)), PROLEUKIN® (aldesleukin), ZADAXIN® (thymalfasin), ZENAPAX® (daclizumab), ZEVALIN® (90Y-Ibritumomab tiuxetan) and the like.


Biological response modifiers are agents that modify defense mechanisms of living organisms or biological responses, such as survival, growth or differentiation of tissue cells to direct them to have anti-tumor activity and include krestin, lentinan, sizofiran, picibanil PF-3512676 (CpG-8954), ubenimex and the like.


Pyrimidine analogs include cytarabine (ara C or Arabinoside C), cytosine arabinoside, doxifluridine, FLUDARA® (fludarabine), 5-FU (5-fluorouracil), floxuridine, GEMZAR® (gemcitabine), TOMUDEX® (ratitrexed), TROXATYL™ (triacetyluridine troxacitabine) and the like.


Purine analogs include LANVIS® (thioguanine) and PURI-NETHOL® (mercaptopurine).


Antimitotic agents include batabulin, epothilone D (KOS-862), N-(24(4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide, ixabepilone (BMS 247550), paclitaxel, TAXOTERE® (docetaxel), PNU100940 (109881), patupilone, XRP-9881 (larotaxel), vinflunine, ZK-EPO (synthetic epothilone) and the like.


Ubiquitin ligase inhibitors include MDM2 inhibitors, such as nutlins, NEDD8 inhibitors such as MLN4924 and the like.


Compounds of this invention can also be used as radiosensitizers that enhance the efficacy of radiotherapy. Examples of radiotherapy include external beam radiotherapy, teletherapy, brachytherapy and sealed, unsealed source radiotherapy and the like.


Additionally, compounds having Formula (I) may be combined with other chemotherapeutic agents such as ABRAXANE™ (ABI-007), ABT-100 (farnesyl transferase inhibitor), ADVEXIN® (Ad5CMV-p53 vaccine), ALTOCOR® or MEVACOR® (lovastatin), AMPLIGEN® (poly I:poly C12U, a synthetic RNA), APTOSYN® (exisulind), AREDIA® (pamidronic acid), arglabin, L-asparaginase, atamestane (1-methyl-3,17-dione-androsta-1,4-diene), AVAGE® (tazarotene), AVE-8062 (combreastatin derivative) BEC2 (mitumomab), cachectin or cachexin (tumor necrosis factor), canvaxin (vaccine), CEAVAC® (cancer vaccine), CELEUK® (celmoleukin), CEPLENE® (histamine dihydrochloride), CERVARIX® (human papillomavirus vaccine), CHOP® (C: CYTOXAN® (cyclophosphamide); H: ADRIAMYCIN® (hydroxydoxorubicin); 0: Vincristine (ONCOVIN®); P: prednisone), CYPAT™ (cyproterone acetate), combrestatin A4P, DAB(389)EGF (catalytic and translocation domains of diphtheria toxin fused via a His-Ala linker to human epidermal growth factor) or TransMID-107R™ (diphtheria toxins), dacarbazine, dactinomycin, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), eniluracil, EVIZON™ (squalamine lactate), DIMERICINE® (T4N5 liposome lotion), discodermolide, DX-8951f (exatecan mesylate), enzastaurin, EP0906 (epithilone B), GARDASIL® (quadrivalent human papillomavirus (Types 6, 11, 16, 18) recombinant vaccine), GASTRIMMUNE®, GENASENSE®, GMK (ganglioside conjugate vaccine), GVAX® (prostate cancer vaccine), halofuginone, histerelin, hydroxycarbamide, ibandronic acid, IGN-101, IL-13-PE38, IL-13-PE38QQR (cintredekin besudotox), IL-13-pseudomonas exotoxin, interferon-α, interferon-γ, JUNOVAN™ or MEPACT™ (mifamurtide), lonafarnib, 5,10-methylenetetrahydrofolate, miltefosine (hexadecylphosphocholine), NEOVASTAT®(AE-941), NEUTREXIN® (trimetrexate glucuronate), NIPENT® (pentostatin), ONCONASE® (a ribonuclease enzyme), ONCOPHAGE® (melanoma vaccine treatment), ONCOVAX® (IL-2 Vaccine), ORATHECIN™ (rubitecan), OSIDEM® (antibody-based cell drug), OVAREX® MAb (murine monoclonal antibody), paclitaxel, PANDIMEX™ (aglycone saponins from ginseng comprising 20(S)protopanaxadiol (aPPD) and 20(S)protopanaxatriol (aPPT)), panitumumab, PANVAC®-VF (investigational cancer vaccine), pegaspargase, PEG Interferon A, phenoxodiol, procarbazine, rebimastat, REMOVAB® (catumaxomab), REVLIMID® (lenalidomide), RSR13 (efaproxiral), SOMATULINE® LA (lanreotide), SORIATANE® (acitretin), staurosporine (Streptomyces staurospores), talabostat (PT100), TARGRETIN® (bexarotene), TAXOPREXIN® (DHA-paclitaxel), TELCYTA® (canfosfamide, TLK286), temilifene, TEMODAR® (temozolomide), tesmilifene, thalidomide, THERATOPE® (STn-KLH), thymitaq (2-amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)quinazoline dihydrochloride), TNFERADE™ (adenovector: DNA carrier containing the gene for tumor necrosis factor-α), TRACLEER® or ZAVESCA® (bosentan), tretinoin (Retin-A), tetrandrine, TRISENOX® (arsenic trioxide), VIRULIZIN®, ukrain (derivative of alkaloids from the greater celandine plant), vitaxin (anti-alphavbeta3 antibody), XCYTRIN® (motexafin gadolinium), XINLAY™ (atrasentan), XYOTAX™ (paclitaxel poliglumex), YONDELIS® (trabectedin), ZD-6126, ZINECARD® (dexrazoxane), ZOMETA® (zolendronic acid), zorubicin and the like.


Data

Determination of the utility of compounds having Formula (I) as binders to and inhibitors of NAMPT was performed using a Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) binding assay.


Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Binding Assay of NAMPT

The assay was carried out in 18 uL low volume plates (Owens Corning) in reaction buffer (50 mM HEPES (NaOH), pH 7.5, 100 mM NaCl, 10 mM MgCl2, 1 mM DTT, 1% Glycerol) using 6.8 nM recombinant, human, C-terminally-His tagged NAMPT, 1 nM Tb-anti-His antibody (Invitrogen, Cat # PV5895), and 200 nM probe (Oregon Green 488-conjugated AP0866; A-1251667.0 (probe 1) or A-1287128.0 (probe 2)). Plates were covered, and reactions were carried out for 2-3 hours. Plates were read with Envision (Laser Lantha low volume protocol) after 2 to 3 hours. Excitation was carried out at 337 nm, and the ratio of emission of Oregon Green (520 nm) to terbium (492 nm) was determined and used to calculate IC50 values of test compounds.


TABLE 1 shows the utility of compounds having Formula I to functionally inhibit NAMPT.










TABLE 1






TR-FRET Binding IC50 (μM)


Example
probe 1, probe 2
















1
0.0125, nd


2
0.00278, nd


3
0.00309, 0.00252


4
0.00371, nd


5
0.00692, 0.00832


6
0.00425, nd


7
0.0046, nd


8
0.00488, nd


9
0.00502, nd


10
0.00525, nd


11
0.00618, nd


12
0.00656, nd


13
0.00807, nd


14
0.00888, nd


15
0.00991, nd


16
0.0101, nd


17
0.0105, nd


18
0.011, nd


19
0.011, nd


20
0.011, nd


21
0.0112, nd


22
0.0116, nd


23
0.0119, nd


24
0.0123, nd


25
0.008, 0.00299


26
0.0126, nd


27
0.0138, nd


28
0.0141, nd


29
0.0145, nd


30
0.0146, nd


31
0.0149, nd


32
0.015, nd


33
0.015, nd


34
0.0151, nd


35
0.0152, nd


36
0.0157, nd


37
0.0161, nd


38
0.0164, nd


39
0.0166, nd


40
0.0171, nd


41
0.0174, nd


42
0.0174, 0.0173


43
0.0178, nd


44
0.018, nd


45
0.0181, nd


46
0.0183, nd


47
0.0185, nd


48
0.0186, nd


49
0.0186, nd


50
nd, nd


51
0.0191, nd


52
0.0197, nd


53
0.0197, nd


54
0.0201, nd


55
0.0202, nd


56
0.0203, nd


57
0.0211, nd


58
0.0212, nd


59
0.0229, 0.0154


60
0.0224, nd


61
0.0225, nd


62
0.0231, nd


63
0.0236, nd


64
0.0237, nd


65
0.0238, nd


66
0.024, nd


67
0.0241, nd


68
0.0247, nd


69
0.0248, nd


70
0.0248, nd


71
0.0256, nd


72
0.0258, nd


73
0.0267, nd


74
0.0273, nd


75
0.0274, nd


76
0.0278, nd


77
0.0284, nd


78
0.0293, nd


79
0.0295, nd


80
0.0299, nd


81
0.0301, nd


82
0.0301, nd


83
0.0306, nd


84
0.0308, nd


85
0.0313, nd


86
0.0319, nd


87
0.0326, nd


88
0.033, nd


89
0.0334, nd


90
0.0335, nd


91
0.0342, nd


92
0.0346, nd


93
0.0351, nd


94
0.0354, nd


95
nd, nd


96
0.0365, nd


97
0.037, nd


98
0.0381, nd


99
0.0382, nd


100
nd, nd


101
0.0393, nd


102
0.0395, nd


103
0.0395, nd


104
0.0395, nd


105
0.0397, nd


106
0.0263, nd


107
0.0408, nd


108
0.0408, nd


109
0.0412, nd


110
0.0422, nd


111
0.044, nd


112
0.0445, nd


113
0.0445, nd


114
0.0461, nd


115
0.0465, nd


116
0.0465, nd


117
0.0481, nd


118
0.0481, nd


119
0.0484, nd


120
0.049, nd


121
0.0493, nd


122
0.0511, nd


123
0.0515, nd


124
0.0517, nd


125
0.0518, nd


126
0.0537, nd


127
0.0539, nd


128
0.0553, nd


129
0.0567, nd


130
0.0567, nd


131
0.0573, nd


132
0.0581, nd


133
0.0582, nd


134
0.0613, nd


135
0.0615, nd


136
0.0616, nd


137
0.0629, nd


138
0.0632, nd


139
0.0638, nd


140
0.0655, nd


141
0.0656, nd


142
0.0664, nd


143
0.0665, nd


144
0.0666, nd


145
0.0692, nd


146
0.0694, nd


147
0.0701, nd


148
0.0702, nd


149
0.0717, nd


150
0.0728, nd


151
0.0733, nd


152
0.0759, nd


153
0.0799, nd


154
0.0813, nd


155
0.0834, nd


156
0.0836, nd


157
0.0846, nd


158
0.0857, nd


159
0.0858, nd


160
0.0861, nd


161
0.0876, nd


162
0.0882, nd


163
0.0893, nd


164
0.0907, nd


165
0.0931, nd


166
0.0999, nd


167
0.101, nd


168
0.105, nd


169
0.108, nd


170
0.108, nd


171
0.11, nd


172
0.111, nd


173
0.115, nd


174
0.12, nd


175
0.12, nd


176
0.12, nd


177
0.123, nd


178
nd, nd


179
0.128, nd


180
0.131, nd


181
0.133, nd


182
0.136, nd


183
0.14, nd


184
0.141, nd


185
0.142, nd


186
0.145, nd


187
0.146, nd


188
0.148, nd


189
0.149, nd


190
0.15, nd


191
0.154, nd


192
0.155, nd


193
0.164, nd


194
0.164, nd


195
0.172, nd


196
0.176, nd


197
0.178, nd


198
0.179, nd


199
0.179, nd


200
0.186, nd


201
0.189, nd


202
0.192, nd


203
0.198, nd


204
0.20, nd


205
0.203, nd


206
0.216, nd


207
0.219, nd


208
0.223, nd


209
0.146, 0.258


210
0.235, Nd


211
0.241, nd


212
0.252, nd


213
0.255, nd


214
0.265, nd


215
0.267, nd


216
0.271, nd


217
0.274, nd


218
0.279, nd


219
0.284, nd


220
0.293, nd


221
0.295, nd


222
0.297, nd


223
0.302, nd


224
0.317, nd


225
0.333, nd


226
0.339, nd


227
0.359, nd


228
0.359, nd


229
0.361, nd


230
0.369, nd


231
0.414, nd


232
0.42, nd


233
0.43, nd


234
0.43, nd


235
0.455, nd


236
0.457, nd


237
0.46, nd


238
0.504, nd


239
0.519, nd


240
0.52, nd


241
0.523, nd


242
0.524, nd


243
0.543, nd


244
0.574, nd


245
0.585, nd


246
0.618, nd


247
0.624, nd


248
0.738, nd


249
0.778, nd


250
0.78, nd


251
0.83, nd


252
0.837, nd


253
0.852, nd


254
0.877, nd


255
0.969, nd


256
1.23, nd


257
1.36, nd


258
1.52, nd


259
1.54, nd


260
1.57, 0.152


261
1.63, nd


262
1.66, nd


263
1.66, nd


264
1.92, nd


265
2.24, nd


266
2.29, nd


267
2.75, nd


268
2.85, nd


269
3.62, nd


270
4.7, nd


271
11.1, nd


272
0.0816, nd


273
1.0, nd


274
1.03, nd


275
0.197, nd


276
0.298, nd


277
1.02, nd


278
0.385, nd


279
1.91, nd


280
0.04453, 0.0612


281
0.0383, nd


282
0.14, nd


283
0.387, nd


284
0.0333, 0.0344


285
0.00192, 0.00259


286
0.00206, nd


287
0.00435, nd


288
0.00447, nd


289
0.00743, nd


290
0.0104, nd


291
0.0277, nd


292
0.0361, nd


293
0.00877, nd


294
0.00814, nd


295
0.0141, nd


296
0.0247, nd


297
0.012, nd


298
0.097, nd


299
0.00673, nd


300
0.0103, nd


301
0.0546, nd


302
0.0157, nd


303
0.251, nd


304
0.0133, nd


305
0.0121, nd


306
0.0133, nd


307
0.0254, nd


308
0.0808, nd


309
0.0634, nd


310
0.0368, nd


311
0.00524, nd


312
0.114, nd


313
0.00541, 0.00587


314
0.021, nd


315
0.00762, nd


316
0.287, nd


317
0.0421, nd


318
0.249, nd


319
0.0319, nd


320
0.272, nd


321
0.203, nd


322
0.0255, nd


323
0.0988, nd


324
0.333, nd


325
0.0987, nd


326
0.0743, nd


327
0.223, nd


328
0.331, nd


329
2.02, nd


330
0.00618, nd


331
0.00611, nd


332
0.0042, nd


333
0.00315, nd


334
0.0223, nd


335
0.00669, nd


336
0.0259, nd


337
0.0261, nd


338
0.0785, nd


339
0.315, nd


340
0.783, nd


341
0.101, nd


342
0.103, nd


343
0.0791, nd


344
0.216, nd


345
0.84, nd


346
0.0498, nd


347
0.297, nd


348
1.56, nd


349
0.0022, nd


350
0.00825, nd


351
0.064, nd


352
1.19, nd


353
0.00763, nd


354
0.0405, nd


355
0.124, nd


356
0.404, nd


357
9.88, nd


358
0.0711, nd


359
0.0881, nd


360
0.239, nd


361
0.436, nd


362
0.578, nd


363
2.04, nd


364
6.48, nd


365
11.2, nd


366
3.34, nd


367
4.84, nd


368
0.00373, nd


369
0.00656, nd


370
0.0075, nd


371
0.0395, nd


372
0.0535, nd


373
0.0234, nd


374
nd, nd


375
0.595, nd


376
nd, nd


377
0.105, nd


378
0.492, 0.377


379
0.0511, 0.0404


380
nd, 0.201


381
0.547, nd


382
0.257, nd


383
1.99, 1.34


384
0.00974, 0.00889


385
0.040, 0.0484


386
0.0707, nd


387
0.17, nd


388
5.7, 4.55


389
0.266, nd


390
0.727, 0.616


391
0.0465, 1.41


392
0.282, 0.288


393
0.415, 0.281


394
2.07, 1.45


395
1.84, 1.67


396
0.474, 0.278


397
0.405, 0.353


398
0.346, 0.272


399
0.0903, 0.0736


400
1.89, 2.35


401
0.072, nd


402
0.183, nd


403
0.606, nd


404
0.0277, nd


405
0.012, nd


406
0.011, nd


407
0.00145, nd


408
0.372, nd


409
1.02, nd


410
0.0295, nd


411
0.0197, nd


412
0.168, 0.109


413
2.01, nd


414
0.032, nd


415
0.0121, nd


416
0.041, nd


417
4.91, nd


418
0.506, 0.0514


419
0.010, nd


420
0.0182, nd


421
0.0404, nd


422
3.94, nd


423
12.5, nd


424
0.0826, nd


425
0.0814, nd


426
0.0104, nd


427
0.0154, nd


428
0.0327, nd


429
0.179, nd


430
0.191, nd


431
0.0607, nd


432
0.00874, nd


433
0.00807, nd


434
0.0507, nd


435
0.00589, nd


436
0.00933, nd


437
0.0080, nd


438
0.60, nd


439
1.69, nd


440
0.0355, nd


441
0.0237, 0.015


442
0.0492, nd


443
0.365, nd


444
0.281, nd


445
0.0141, nd


446
0.011, nd


447
0.0466, nd


448
0.021, nd


449
0.0257, nd


450
1.03, nd


451
0.000946, 0.00124


452
0.0512, nd


453
0.0527, nd


454
0.0803, nd


455
12.2, nd


456
0.0598, 0.0475


457
0.0756, nd


458
nd, nd


459
0.00362, nd


460
0.0193, nd


461
nd, 0.00815


462
0.00694, nd


463
0.0215, 0.013


464
0.0166, 0.0272


465
0.00823, 0.0238


466
nd, nd


467
0.0165, 0.047


468
0.00339, 0.00726


469
0.00597, 0.00947


470
0.00445, 0.0080


471
0.00811, 0.019


472
0.0149, 0.0107


473
0.00321, 0.00381


474
0.00389, 0.00775


475
0.0090, 0.0139


476
0.0125, 0.0468


477
0.00996, nd


478
0.015, 0.386


479
nd, 0.00399


480
0.00571, 0.0676


481
nd, nd


482
0.00511, nd


483
0.00479, 0.00937


484
nd, nd


485
0.00557, 0.0118


486
0.0047, 0.00497


487
0.00884, 0.0573


488
0.00825, 0.0211


489
0.0123, nd


490
0.0212, 0.028


491
0.00455, 0.0113


492
0.0396, 0.0417


493
0.0336, 0.013


494
0.016, 0.021


495
0.0516, 0.0607


496
0.0139, 0.0257


497
0.00331, 0.0048


498
0.307, nd


499
0.806, nd


500
0.182, nd


501
0.0459, 0.018


502
0.157, nd


503
0.0786, nd


504
0.0766, 0.0563


505
0.0204, 0.0182


506
0.0332, 0.0227


507
0.186, nd


508
0.184, nd


509
0.211, nd


510
0.0337, 0.0221


511
0.0176, 0.0275


512
0.0436, 0.0443


513
0.0539, 0.0681


514
0.0481, 0.0673


515
0.0723, 0.0666


516
0.0106, 0.00847


517
0.0758, nd


518
0.266, nd


519
0.0968, nd


520
0.0488, nd


521
0.0601, 0.0631


522
0.0296, 0.0611


523
0.187, nd


524
0.115, nd


525
0.0375, 0.060


526
0.076, 0.0644


527
0.0168, 0.0243


528
0.0521, 0.0454


529
0.103, nd


530
0.124, nd


531
0.159, nd


532
0.488, nd


533
0.294, nd


534
0.14, nd


535
0.743, nd


536
0.187, nd


537
0.0132, 0.0106


538
0.072, 0.0829


539
0.072, 0.0417


540
0.137, nd


541
0.225, nd


542
0.00277, 0.0026


543
0.00213, 0.00302


544
0.00302, 0.00305


545
0.00278, 0.0020


546
0.00332, 0.00322


547
nd, nd


548
nd, nd


549
nd, nd


550
nd, nd


551
nd, nd


552
nd, nd


553
0.00755, 0.00582


554
0.00401, 0.00519


555
0.0196, 0.0114


556
0.0145, 0.0102


557
0.862, 1.98


558
1.84, 5.63


559
1.98, nd


560
5.02, nd


561
0.268, nd


562
0.0189, 0.0177


563
0.00166, 0.00361


564
0.00196, 0.00159


565
0.0083, 0.00737


566
0.193, nd


567
0.00675, 0.00624


568
0.00412, 0.00501


569
0.00808, 0.0085


570
0.00913, 0.00995


571
0.0138, 0.0104


572
0.00845, 0.00972


573
1.26, nd


574
0.0794, 0.0621


575
0.0538, 0.0378


576
0.0902, 0.0507


577
0.00439, 0.00297


578
0.060, 0.0707


579
0.00314, 0.00247


580
0.00239, 0.00201


581
0.0040, 0.00338


582
0.00205, 0.00169


583
0.00282, 0.0027


584
0.0147, 0.0117


585
nd, 0.0271


586
nd, 0.0338


587
nd, 0.444


588
nd, 0.739


589
nd, 0.044


590
nd, 0.0428


591
nd, 0.661


592
nd, 0.0884


593
nd, 0.0269


594
nd, 0.021


595
nd, 0.0651


596
nd, 0.00448


597
nd, 0.0631


598
nd, 0.0322


599
nd, 0.0582


600
nd, 0.0385


601
nd, 0.0326


602
nd, 0.0392


603
nd, 0.056


604
nd, 0.0224


605
nd, 0.00759


606
nd, 0.0139


607
nd, 0.00159


608
nd, 0.00985


609
nd, 0.196


610
nd, 1.3


611
nd, 0.328


612
nd, 0.365


613
nd, 0.119


614
nd, 0.0482


615
nd, 0.0842


616
nd, 0.097


617
nd, 1.13


618
nd, 0.00755


619
nd, 0.0827


620
nd, 0.00755


621
nd, 0.0118


622
nd, 0.0595


623
nd, 1.48


624
nd, 0.046


625
nd, 0.0107


626
nd, 0.00759


627
nd, 0.164


628
nd, 0.0234


629
nd, 0.0335


630
nd, 0.0725


631
nd, 0.0506


632
nd, 0.104


633
nd, 0.0873


634
nd, 0.0361


635
nd, 0.129


636
nd, 1.21


637
nd, 0.0542


638
nd, 0.102


639
nd, 0.0882


640
nd, 0.135


641
nd, 0.163


642
nd, 0.507


643
nd, 0.0633


644
nd, 0.0594


645
nd, 0.125


646
nd, 0.00568


647
nd, 0.0385


648
nd, 0.845


649
nd, 0.0445


650
nd, 0.106


651
nd, 0.0207


652
nd, 0.00488


653
nd, 0.0144


654
nd, 0.0256


655
nd, 0.0224


656
nd, 0.116


657
nd, 0.0533


658
nd, 0.00549


659
nd, 0.00585


660
nd, 0.0221


661
nd, 0.00253


662
nd, 0.00977


663
nd, 0.0136


664
nd, 0.00412


665
nd, 0.00814


666
nd, 0.0111


667
nd, 0.00905


668
nd, 0.00698


669
nd, 0.0136


670
nd, 0.0183


671
nd, 0.0238


672
nd, 0.011


673
nd, 0.0248


674
nd, 0.00839


675
nd, 0.0414


676
nd, 0.0165


677
nd, 0.0126


678
nd, 0.00265


679
nd, 0.00461


680
nd, 0.126


681
nd, 0.0603


682
nd, 0.019


683
nd, 0.0669


684
nd, 0.0153


685
nd, 0.0205


686
nd, 0.653


687
nd, 0.0238


688
nd, 0.00303


689
nd, 0.0123


690
nd, 0.00616


691
nd, 0.0392


692
nd, 0.0247


693
nd, 0.0264


694
nd, 0.0359


695
nd, 0.027


696
nd, 0.00223


697
nd, 0.0049


698
nd, 0.0327


699
nd, 0.00558


700
nd, 0.0204


701
nd, 0.0227


702
nd, 0.0232


703
nd, 0.0829


704
nd, 0.0126


705
nd, 0.00742


706
nd, 0.00581


707
nd, 0.00573


708
nd, 0.00997


709
nd, 0.00601


710
nd, 0.00336


711
nd, 0.0462


712
nd, 0.0453


713
nd, 0.0529


714
nd, 0.121


715
nd, 0.136


716
nd, 0.102


717
nd, 0.0718


718
nd, 0.012


719
nd, 0.0347


720
nd, 0.164


721
nd, 0.14


722
nd, 0.00157


723
nd, 0.0209


724
nd, 0.0851


725
nd, 0.477


726
nd, 0.577


727
nd, 1.22


728
nd, 0.00752


729
nd, 0.0445


730
nd, 0.45


731
nd, 0.0183


732
nd, 0.0241


733
nd, 0.0598


734
nd, 0.0845


735
nd, 0.126


736
nd, 0.281


737
nd, 0.186


738
nd, 0.00417


739
nd, 0.0049


740
nd, 0.204


741
nd, 0.0165


742
nd, 0.0331


743
nd, 0.00971


744
nd, 0.00446


745
nd, 0.00868


746
nd, 0.0768


747
nd, 0.00434


748
nd, 0.00455


749
nd, 0.0161


750
nd, 0.0118


751
nd, 0.229


752
nd, 0.0108


753
nd, 0.0655


754
nd, 0.0683


755
nd, 0.0407


756
nd, 0.0488


757
nd, 0.00201


758
nd, 0.0293


759
nd, 0.00581


760
nd, 0.00483


761
nd, 0.0131


762
nd, 0.0173


763
nd, 0.00528


764
nd, 0.0581


765
nd, 0.0532


766
nd, 0.0468


767
nd, 0.169


768
nd, 0.13


769
nd, 0.0695


770
nd, 0.135


771
nd, 0.0893


772
nd, 0.0534


773
nd, 0.297


774
nd, 0.0826


775
nd, 0.0951


776
nd, 0.00746


777
nd, 0.00625


778
nd, 0.0259


779
nd, 0.0385


780
nd, 0.109


781
nd, 0.0158


782
nd, 0.0296


783
nd, 0.029


784
nd, 0.0224


785
nd, 0.0262


786
nd, 0.0262


787
nd, 0.13


788
nd, 0.0785


789
nd, 0.00318


790
nd, 0.159


791
nd, 0.00977


792
nd, 0.0217


793
nd, 0.0118


794
nd, 0.017


795
nd, 0.991


796
nd, 0.00322


797
nd, 0.00295


798
nd, 0.00221


799
nd, 0.00361


800
nd, 0.0821


801
nd, 0.30


802
nd, 0.0258


803
nd, 0.0132


804
nd, 0.0373


805
nd, 0.0287


806
nd, 0.286


807
nd, 0.0417


808
nd, 0.696


809
nd, 0.00207


810
nd, nd


811
nd, 0.00359


812
nd, 0.00679


813
nd, 0.0446


814
nd, 0.00713


815
nd, 0.00287


816
nd, 0.0243


817
nd, 0.00251


818
nd, 0.0128


819
nd, 0.00428


820
nd, 0.00631


821
nd, 0.012


822
nd, 0.00207


823
nd, 0.00176


824
nd, 0.0066


825
nd, 0.0107


826
nd, 0.00918


827
nd, 0.00311


828
nd, 0.00737


829
nd, 0.00359


830
nd, nd


831
nd, 0.00918


832
nd, 0.00888


833
nd, 0.0034


834
nd, 0.00358


835
nd, 0.00353


836
nd, 0.00454


837
nd, 0.00367


838
nd, 0.00203


839
nd, 0.0191


840
nd, 0.725


841
nd, 1.61


842
nd, 0.0746


843
nd, 0.704


844
nd, 2.62


845
nd, 5.64


846
nd, 2.99


847
nd, 0.24


848
nd, 1.19


849
nd, 5.71


850
nd, 2.1


851
nd, 0.277


852
nd, 5.48


853
nd, 12.5


854
nd, 5.66


855
nd, 0.839


856
nd, 0.00913


857
nd, 0.061


858
nd, 0.0082


859
nd, 2.14


860
nd, 12.5


861
nd, 3.15


862
nd, 0.599


863
nd, 0.143


864
nd, 0.122


865
nd, 1.56


866
nd, 0.14


867
nd, 0.0593


868
nd, 0.128


869
nd, 0.229


870
nd, 0.12


871
nd, 0.036


872
nd, 0.00746


873
nd, 0.00465


874
nd, 0.00231


875
nd, 0.00419


876
nd, 0.0022


877
nd, 0.00882


878
nd, 0.0525


879
nd, 0.00298


880
nd, 0.0517


881
nd, 0.0463


882
nd, 0.0377


883
nd, 0.0156


884
nd, 0.0154


885
nd, 0.466


886
nd, 0.0246


887
nd, 0.826


888
nd, 0.0934


889
nd, 1.47


890
nd, 1.38


891
nd, 1.72


892
nd, 1.84


893
nd, 0.154


894
nd, 0.00302


895
nd, 0.0261


896
nd, 0.444


897
nd, 0.969


898
nd, 0.288


899
nd, 0.19


900
nd, 0.0437


901
nd, 0.0676


902
nd, 0.35


903
nd, 0.0491


904
nd, 0.0351


905
nd, 0.0383


906
nd, 0.0569


907
nd, 0.0711


908
nd, 0.0334


909
nd, 0.0019


910
nd, 0.00638


911
nd, 0.0133


912
nd, 0.00832


913
nd, 0.0074


914
nd, 0.00486


915
nd, 0.0188


916
nd, 0.0221


917
nd, 0.00207


918
nd, 0.0128


919
nd, 0.00708


920
nd, 0.548


921
nd, 0.0602


922
nd, 0.00567


923
nd, 0.00395


924
nd, 0.00277


925
nd, 0.00683


926
nd, 0.0508


927
nd, 0.0406


928
nd, 0.0725


929
nd, 0.21


930
nd, 0.146


931
nd, 0.0981


932
nd, 1.31


933
nd, 0.206


934
nd, 0.00168


935
nd, 0.00584


936
nd, 0.121


937
nd, 0.0398


938
nd, 0.0877


939
nd, 0.0105


940
nd, 0.0168


941
nd, 0.136


942
nd, 0.0238


943
nd, 0.0090


944
nd, 0.0328


945
nd, 0.0433


946
nd, 0.0172


947
nd, 0.0459


948
nd, 0.0192


949
nd, 0.0309


950
nd, 0.0198


951
nd, 0.00968


952
nd, 0.0128


953
nd, 0.426


954
nd, 0.341


955
nd, 0.222


956
nd, 0.346


957
nd, 0.374


958
nd, 0.148


959
nd, 0.307


960
nd, 0.22


961
nd, 0.161


962
nd, 0.201


963
nd, 0.198


964
nd, 0.128


965
nd, 0.17


966
nd, 0.223


967
nd, 0.0047


968
nd, 0.00259


969
nd, 0.0234


970
nd, 0.0213


971
nd, 0.0205


972
nd, 0.00919


973
nd, 0.0435


974
nd, 0.034


975
nd, 0.0115


976
nd, 0.0225


977
nd, 0.0214


978
nd, 0.0236


979
nd, 0.0365


980
nd, 0.0173


981
nd, 0.034


982
nd, 0.0144


983
nd, 0.0296


984
nd, 0.0689


985
nd, 0.00963


986
nd, 0.0407


987
nd, 0.111


988
nd, nd


989
nd, 0.0269


990
nd, 0.031


991
nd, 0.0408


992
nd, 0.0168


993
nd, 0.00941


994
nd, 0.00802


995
nd, 0.0285


996
nd, 0.101


997
nd, 0.175


998
nd, 0.0277


999
nd, 0.0166


1000
nd, 0.0391


1001
nd, 0.00157


1002
nd, 0.0426


1003
nd, 0.0489


1004
nd, 0.0461


1005
nd, 0.0385


1006
nd, 0.0252


1007
nd, 0.0598


1008
nd, 0.0349


1009
nd, 0.0266


1010
nd, 0.114


1011
nd, 0.0264


1012
nd, 0.0923


1013
nd, 0.389


1014
nd, 0.00661


1015
nd, 0.00631


1016
nd, 0.00375


1017
nd, 0.00201


1018
nd, 0.0244


1019
nd, 0.00144


1020
nd, 10.0


1021
nd, 1.17


1022
nd, 0.0135


1023
nd, 0.0127


1024
nd, 0.0921


1025
nd, 0.00795


1026
nd, 0.035


1027
nd, 0.0842


1028
nd, 0.0519


1029
nd, 0.035


1030
nd, 0.0116


1031
nd, 0.0251


1032
nd, 0.156


1033
nd, 0.113


1034
nd, 0.164


1035
nd, 0.376


1036
nd, 0.20


1037
nd, 0.048


1038
nd, 0.0248


1039
nd, 0.105


1040
nd, 0.0163


1041
nd, 0.0128


1042
nd, 0.00968


1043
nd, 0.00489


1044
nd, 0.00621


1045
nd, 0.00924


1046
nd, 0.0469


1047
nd, 0.0542


1048
nd, 0.0345


1049
nd, 0.0398


1050
nd, 0.102


1051
nd, 0.0626


1052
nd, 0.0318


1053
nd, 0.0764


1054
nd, 0.0563


1055
nd, 1.55


1056
nd, 0.335


1057
nd, 2.32


1058
nd, 1.12


1059
nd, 0.394


1060
nd, 1.57


1061
nd, 1.78


1062
nd, 0.222


1063
nd, 0.00988


1064
nd, 0.0621


1065
nd, 0.00445


1066
nd, 0.318


1067
nd, 0.738


1068
nd, 0.365


1069
nd, 0.122


1070
nd, 0.332


1071
nd, 0.993


1072
nd, 0.117


1073
nd, 0.0659


1074
nd, 0.0674


1075
nd, 0.0931


1076
nd, 0.0389


1077
nd, 0.0069


1078
nd, 0.00347


1079
nd, 0.0259


1080
nd, 0.00297


1081
nd, 0.00682


1082
nd, 0.0195


1083
nd, 0.0117


1084
nd, 0.0296


1085
nd, 0.029


1086
nd, 0.0152


1087
nd, 0.00733


1088
nd, 0.0155


1089
nd, 0.0771


1090
nd, 0.0493


1091
nd, 0.0289


1092
nd, 0.0192


1093
nd, 0.0117


1094
nd, 0.044


1095
nd, 0.0118


1096
nd, 0.028


1097
nd, 0.0756


1098
nd, 0.0111


1099
nd, 0.145


1100
nd, 0.0263


1101
nd, 0.0448


1102
nd, 0.108


1103
nd, 0.00784


1104
nd, 1.69


1105
nd, 0.0619


1106
nd, 0.364


1107
nd, 0.152


1108
nd, 0.0061


1109
nd, 0.048


1110
nd, 0.0151


1111
nd, 0.0139


1112
nd, 0.0498


1113
nd, 0.00326


1114
nd, 0.0281


1115
nd, 0.0188


1116
nd, 0.0419


1117
nd, 0.0332


1118
nd, 0.00548


1119
nd, 0.0224


1120
nd, 0.0227


1121
nd, 0.0302


1122
nd, 0.162


1123
nd, 0.0309


1124
nd, 0.0143


1125
nd, 0.0764


1126
nd, 0.311


1127
nd, 0.00569


1128
nd, 0.199


1129
nd, 0.546


1130
nd, 0.0354


1131
nd, 0.0414


1132
nd, 0.201


1133
nd, 0.703


1134
nd, 0.175


1135
nd, 0.121


1136
nd, 0.0498


1137
nd, 0.0119


1138
nd, 0.0874


1139
nd, 0.333


1140
nd, 0.138


1141
nd, 0.0099


1142
nd, 0.136


1143
nd, 0.328


1144
nd, 0.00515


1145
nd, 0.00619


1146
nd, 0.0148


1147
nd, 0.00824


1148
nd, 0.0409


1149
nd, 0.0824


1150
nd, 0.0132


1151
nd, 0.048


1152
nd, 0.233


1153
nd, 0.00492


1154
nd, 0.00962


1155
nd, 0.033


1156
nd, 0.216


1157
nd, 0.0725


1158
nd, 0.0125


1159
nd, 0.0179


1160
nd, 0.237


1161
nd, 0.0044


1162
nd, 0.00954


1163
nd, 0.0174


1164
nd, 0.00544


1165
nd, nd


1166
nd, 0.0562


1167
nd, 0.0298


1168
nd, nd


1169
nd, 0.239


1170
nd, 0.0214


1171
nd, 0.0105


1172
nd, 0.00867


1173
nd, 0.0437


1174
nd, 0.0156


1175
nd, 0.00662


1176
nd, 0.00915


1177
nd, 0.0496


1178
nd, 0.112


1179
nd, 0.0791


1180
nd, 0.0102


1181
nd, 0.128


1182
nd, nd


1183
nd, 0.0404


1184
nd, 0.109


1185
nd, 0.0503


1186
nd, 0.0106


1187
nd, 0.00878


1188
nd, 0.00494


1189
nd, 0.0291


1190
nd, 0.0843


1191
nd, 0.0607


1192
nd, 0.17


1193
nd, 0.00776


1194
nd, 0.171


1195
nd, 0.0205


1196
nd, 0.0102


1197
nd, 0.101


1198
nd, nd


1199
nd, 0.165


1200
nd, nd


1201
nd, 0.0422


1202
nd, 0.0227


1203
nd, 0.378


1204
nd, 0.0772


1205
nd, 0.345


1206
nd, 0.394


1207
nd, 0.283


1208
nd, 0.028


1209
nd, 0.0387


1210
nd, 0.0192


1211
nd, 0.879


1212
nd, 0.144


1213
nd, nd


1214
nd, 0.035


1215
nd, 0.133


1216
nd, 0.054


1217
nd, 0.0316


1218
nd, 0.158


1219
nd, 0.0613


1220
nd, 0.0181


1221
nd, 1.13


1222
nd, 0.0513


1223
nd, 0.0192


1224
nd, 0.497


1225
nd, 0.0767


1226
nd, 0.0116


1227
nd, 0.0534


1228
nd, 0.418


1229
nd, 0.393


1230
nd, 0.0674


1231
nd, 0.576


1232
nd, 0.0248


1233
nd, 0.351


1234
nd, 0.0174


1235
nd, 0.0668


1236
nd, 0.078


1237
nd, 0.561


1238
nd, 0.748


1239
nd, 0.328


1240
nd, 0.592


1241
nd, 0.0122


1242
nd, 0.0488


1243
nd, 0.142


1244
nd, 2.23


1245
nd, 0.0214


1246
nd, 0.803


1247
nd, 0.212


1248
nd, 0.373


1249
nd, 0.17


1250
nd, 0.335


1251
nd, 0.111


1252
nd, 0.125


1253
nd, 0.669


1254
nd, 0.00222


1255
nd, 0.00211


1256
nd, 0.00328


1257
nd, 0.00482


1258
nd, 0.00831


1259
nd, 0.00191


1260
nd, 0.00491


1261
nd, 0.0583


1262
nd, 0.109


1263
nd, 0.0116


1264
nd, 0.309


1265
nd, 0.0393


1266
nd, 0.113


1267
nd, 0.285


1268
nd, 0.932


1269
nd, 0.216


1270
nd, 0.0109


1271
nd, 0.0627


1272
nd, 0.0224


1273
nd, 0.132


1274
nd, 0.199


1275
nd, 0.097


1276
nd, 0.0269


1277
nd, 0.0429


1278
nd, 0.0136


1279
nd, 0.00784


1280
nd, 0.00438


1281
nd, 0.00122


1282
nd, 0.00134


1283
nd, 0.00151


1284
nd, 0.00172


1285
nd, 0.0432


1286
nd, 0.00323


1287
nd, 0.00325


1288
nd, 0.0228


1289
nd, 0.0267


1290
nd, 0.409


1291
nd, 0.00847


1292
nd, 0.0252


1293
nd, 0.0165


1294
nd, 0.0327


1295
nd, 0.0607


1296
nd, 0.0175


1297
nd, 0.0238


1298
nd, 0.032


1299
nd, 0.0424


1300
nd, 0.0111


1301
nd, 0.0197


1302
nd, 0.0734


1303
nd, 0.209


1304
nd, 0.204


1305
nd, 0.431


1306
nd, 0.224


1307
nd, 0.401


1308
nd, 0.139


1309
nd, 0.0767


1310
nd, nd


1311
nd, 0.0917


1312
nd, 0.0265


1313
nd, 0.0783


1314
nd, 0.0247


1315
nd, 0.214


1316
nd, 0.379


1317
nd, 0.074


1318
nd, 0.0456


1319
nd, 0.0147


1320
nd, 0.0163


1321
nd, 0.0148


1322
nd, nd


1323
nd, nd


1324
nd, 0.0779


1325
nd, 0.0903


1326
nd, 0.0216


1327
nd, 1.46


1328
nd, 0.147


1329
nd, 0.0143


1330
nd, 0.0179


1331
nd, 0.206


1332
nd, 0.0414


1333
nd, 0.0195


1334
nd, nd


1335
nd, 0.0855


1336
nd, 0.0746


1337
nd, 0.105


1338
nd, 0.0244


1339
nd, 0.0202


1340
nd, 0.257


1341
nd, 0.195


1342
nd, 0.0269


1343
nd, 0.0114


1344
nd, 0.0821


1345
nd, 0.183


1346
nd, 0.275


1347
nd, 0.0292


1348
nd, 0.0565


1349
nd, 0.029


1350
nd, 0.0149


1351
nd, 0.0184


1352
nd, 0.0113


1353
nd, 0.00584


1354
nd, 0.00438


1355
nd, 0.00307


1356
nd, 0.00784


1357
nd, 0.0082


1358
nd, 0.013


1359
nd, 0.0129


1360
nd, 0.00654


1361
nd, 0.00515


1362
nd, 0.0055


1363
nd, 0.00534


1364
nd, 0.0149


1365
nd, 0.0119


1366
nd, 0.0476


1367
nd, 0.0291


1368
nd, 0.0151


1369
nd, 0.056


1370
nd, 0.00237


1371
nd, 0.0176


1372
nd, 0.0106


1373
nd, 0.0937


1374
nd, nd


1375
nd, 0.436


1376
nd, 0.381


1377
nd, 0.275


1378
nd, nd


1379
nd, 0.0867


1380
nd, 0.0936


1381
nd, 0.189


1382
nd, 0.237


1383
nd, 0.225


1384
nd, 0.0123


1385
nd, 0.00676


1386
nd, 0.0815


1387
nd, 0.0275


1388
nd, 0.00403


1389
nd, 0.00592


1390
nd, 0.0148


1391
nd, 0.00956


1392
nd, nd


1393
nd, 0.0129


1394
nd, nd


1395
nd, 0.0176


1396
nd, 0.00585


1397
nd, nd


1398
nd, 0.0559


1399
nd, 0.179


1400
nd, 0.0241


1401
nd, 0.018


1402
nd, 0.0412


1403
nd, 0.0322


1404
nd, 0.0561


1405
nd, 0.127


1406
nd, 0.194


1407
nd, 0.227


1408
nd, 0.222


1409
nd, 0.0823


1410
nd, 0.0722


1411
nd, 0.135


1412
nd, nd


1413
nd, 0.364


1414
nd, 0.00826


1415
nd, 0.0111


1416
nd, 0.00622


1417
nd, 0.0125


1418
nd, 0.0113


1419
nd, 0.0116


1420
nd, nd


1421
nd, 0.00753


1422
nd, 0.0069


1423
nd, 0.00831


1424
nd, 0.0135


1425
nd, 0.035


1426
nd, 0.0267


1427
nd, 0.033


1428
nd, 0.0184


1429
nd, 0.0069


1430
nd, 0.266


1431
nd, 0.011


1432
nd, nd


1433
nd, 0.0587


1434
nd, 0.0574


1435
nd, 0.0266


1436
nd, 0.0484


1437
nd, 0.0738


1438
nd, 0.0276


1439
nd, nd


1440
nd, nd


1441
nd, 0.032


1442
nd, 0.0136


1443
nd, 0.0148


1444
nd, 0.00577


1445
nd, 0.0128


1446
nd, 0.0113


1447
nd, 0.0105


1448
nd, 0.0223


1449
nd, 0.0186


1450
nd, 0.0154


1451
nd, 0.0139


1452
nd, 0.00765


1453
nd, 0.0617


1454
nd, 0.0678


1455
nd, 0.124


1456
nd, 0.0422


1457
nd, 0.0715


1458
nd, 0.0764


1459
nd, 0.0669


1460
nd, 0.126


1461
nd, 0.0487


1462
nd, 0.0694


1463
nd, 0.0779


1464
nd, 0.109


1465
nd, 0.101


1466
nd, 0.0125


1467
nd, 0.0164


1468
nd, 0.00486


1469
nd, 0.0138


1470
nd, 0.00221


1471
nd, 0.0109


1472
nd, 0.0125


1473
nd, 0.00872


1474
nd, 0.00888


1475
nd, 0.00744


1476
nd, 0.21


1477
nd, 0.0452


1478
nd, 0.0682


1479
nd, 0.0015


1480
nd, 0.00425


1481
nd, 0.00416


1482
nd, 0.00488


1483
nd, nd


1484
nd, 0.00149


1485
nd, 0.00323


1486
nd, 0.00137


1487
nd, 0.00234


1488
nd, 0.00844


1489
nd, 0.00656


1490
nd, nd


1491
nd, nd


1492
nd, 0.00153


1493
nd, 0.00295


1494
nd, 0.00202


1495
nd, 0.00877


1496
nd, 0.00844


1497
nd, 0.00135


1498
nd, 0.00228


1499
nd, 0.00152


1500
nd, 0.00415


1501
nd, 0.00264


1502
nd, 0.0101


1503
nd, 0.0067


1504
nd, 0.0101


1505
nd, nd


1506
nd, 0.00219


1507
nd, nd


1508
nd, 0.00244


1509
nd, 0.00397


1510
nd, 0.00326


1511
nd, 0.00664


1512
nd, nd


1513
nd, 0.0028


1514
nd, 0.00183


1515
nd, 0.00159


1516
nd, 0.00457


1517
nd, 0.00103


1518
nd, 0.00155


1519
nd, 0.00168


1520
nd, 0.00203


1521
nd, 0.0019


1522
nd, 0.0316


1523
nd, 0.0134


1524
nd, 0.00324


1525
nd, 0.0063


1526
nd, 0.00714


1527
nd, 0.0026


1528
nd, 0.00881


1529
nd, 0.00174


1530
nd, 0.00389


1531
nd, 0.124


1532
nd, 0.00541


1533
nd, 0.0102


1534
nd, 0.0213


1535
nd, 0.0201


1536
nd, 0.0114


1537
nd, 0.0118


1538
nd, 0.0257


1539
nd, 0.0611


1540
nd, 0.0644


1541
nd, 0.031


1542
nd, 0.762


1543
nd, 0.20


1544
nd, 0.193


1545
nd, 0.774


1546
nd, 0.0241


1547
nd, 0.00501


1548
nd, 0.000973


1549
nd, 0.00471


1550
nd, 0.0112


1551
nd, 0.00472


1552
nd, 0.00086


1553
nd, 0.0216


1554
nd, 0.0385


1555
nd, 0.0104


1556
nd, 0.0488


1557
nd, 0.0058


1558
nd, 0.0165


1559
nd, 0.0447


1560
nd, 0.0655





nd = not determined






ROCK2 Kinase Activity Assays

[33P]-ATP Assay:


ROCK2 activity was initially determined using a radioactive FlashPlate-based assay. In a 96-well format, biotinylated peptide substrates (2 μM final; S6-short for ROCK2), γ-[33P]-ATP (5 μM, 2 mCi/μmol), compounds (0.1-10000 nM in 2% DMSO), and ROCK2 (0.2 nM; Upstate) catalytic domains.


HTRF Assay:


This assay used the CisBio HTRF KinEASE kit (kit 62ST2PEZ) and the kinase reaction containing 0.2 μM biotinylated substrate peptide (S2, CisBio), 5 μM, 100 μM or 1 mM of ATP, inhibitors (0.1-10,000 nM in 2% DMSO) and enzymes as in the 33P-ATP assay above.


TABLE 2 shows the results of the HTRF assay and the utility of compounds having Formula I to functionally inhibit ROCK2.












TABLE 2








ROCK2




HTRF




Binding



Example
Ki (μM)



















374
0.0036



375
4.06



376
0.00526



377
0.0195



378
0.00237



379
0.0024



380
0.0023



381
0.00412



382
0.00614



383
0.00361



384
0.00424



385
0.00651



386
10



387
0.00139



388
0.0112



389
0.00174



390
0.00245



391
0.00049



392
nd



393
nd



394
0.0093



395
0.0321



396
0.182



397
0.138



398
0.0022



399
nd



400
0.0251



547
0.179



548
0.014



549
0.0031



550
0.0154



551
0.0184



552
3.27







nd = not determined






Compounds which inhibit NAMPT are useful for treating diseases in which activation of NF-KB is implicated. Such methods are useful in the treatment of a variety of diseases including inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, particularly wherein the cancer is selected from breast, prostate, lung, colon, cervix, ovary, skin, CNS, bladder, pancreas, leukaemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia.


Involvement of NAMPT in the treatment of cancer is described in WO 97/48696. Involvement of NAMPT in immuno-supression is described in WO 97/48397. Involvement of NAMPT for the treatment of diseases involving angiogenesis is described in WO 2003/80054. Involvement of NAMPT for the treatment of rheumatoid arthritis and septic shock is described in WO 2008/025857. Involvement of NAMPT for the prophlaxis and treatment of ischaemia is described in WO 2009/109610.


Cancers include, but are not limited to, hematologic and solid tumor types such as acoustic neuroma, acute leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute t-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer (including estrogen-receptor positive breast cancer), bronchogenic carcinoma, Burkitt's lymphoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, gastric carcinoma, germ cell testicular cancer, gestational trophobalstic disease, glioblastoma, head and neck cancer, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, liposarcoma, lung cancer (including small cell lung cancer and non-small cell lung cancer), lymphangioendothelio-sarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, leukemia, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, peripheral T-cell lymphoma, pinealoma, polycythemia vera, prostate cancer (including hormone-insensitive (refractory) prostate cancer), rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, testicular cancer (including germ cell testicular cancer), thyroid cancer, Waldenstrm's macroglobulinemia, testicular tumors, uterine cancer, Wilms' tumor and the like.


Abnormal activation of the Rho/ROCK pathway has been observed in various disorders (Wettschureck, N., Offermanns, S., Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J. Mol. Med. 80, 2002, 629-638; Miller, B. K., Mack, H., Teusch, N., Rho kinase, a promising drug target for neurological discorders. Nat. Drug Discov. Rev. 4, 2005, 387-398; Hu, E, Lee, D., ROCK inhibitors as potential therapeutic agents for cardiovascular diseases. Curr. Opin. Investig. Drugs. 4, 2003, 1065-1075). As already mentioned, ROCKs phosphorylate the myosin binding subunit of myosin light chain (MLC) phosphatase (MLCP), resulting in increased myosin phosphorylation and actin-myosin contraction (Somlyo, A. P., Somlyo, A. V., Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol. Rev. 83, 2003, 1325-1358). Examples of disease states related with abnormal Rho/ROCK activity, in particular with vasospasm activity, include cardiovascular diseases such as hypertension (Satoh S., Kreutz R., Wilm C., Ganten D., Pfitzer G., Augmented agonist-induced Ca2+-sensitization of coronary artery contraction in genetically hypertensive rats. Evidence for altered signal transduction in the coronary smooth muscle cells. J. Clin. Invest. 94, 1994, 1397-1403; Mukai, Y., Shimokawa, H., Matoba, T., Kandabashi, T., Satoh, S., Hiroki, J., Kaibuchi, K., Takeshita, A., Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 15, 2001, 1062-1064; Uehata, M., Ishizaki, T., Satoh, H., Ono, T., Kawahara, T., Morishita, T., Tamakawa, H., Yamagami, K., Inui, J., Maekawa, M., Narumiya, S., Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 1997, 990-994; Masumoto, A., Hirooka, Y., Shimokawa, H., Hironaga, K., Setoguchi, S., Takeshita, A., Possible involvement of Rhokinase in the pathogenesis of hypertension in humans. Hypertension 38, 2001, 1307-1310), chronic and congestive heart failure (Fuster, V., Badimon, L., Badimon, J J, Chesebro, J H, The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 326, 1992, 310-318; Shimokawa, H., Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models. Jpn Circ J 64, 2000, 1-12; Shimokawa, H., Morishige, K., Miyata, K., Kandabashi, T., Eto, Y., Ikegaki, I., Asano, T., Kaibuchi, K., Takeshita, A., Longterm inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res 51, 2001, 169-177; Utsunomiya, T., Satoh, S., Ikegaki, I., Toshima, Y., Asano, T., Shimokawa, H., Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina. Br J Pharmacol 134, 201, 1724-1730), cardiac hypertrophy (Hoshijima, M., Sah, V. P., Wang, Y., Chien, K. R., Brown, J. H., The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho kinase. J Biol Chem 273, 1998, 7725-77230; Sah, V. P., Hoshijima, M., Chien, K. R., Brown, J. H., Rho is required for Galphaq and alpha1-adrenergic receptor signal-637 ing in cardiomyocytes. Dissociation of Ras and Rho pathways. J Biol Chem 271, 1996, 31185-1190; Kuwahara, K., Saito, Y., Nakagawa, O., Kishimoto, I., Harada, M., Ogawa, E., Miyamoto, Y., Hamanaka, I., Kajiyama, N., Takahashi, N., Izumi, T., Kawakami, R., Tamura, N., Ogawa, Y., Nakao, K., The effects of the selective ROCK inhibitor, Y27632, on ET-1-induced hypertrophic response in neonatal rat cardiacmyocytes-possible involvement of Rho/ROCK pathway in cardiac muscle cell hypertrophy. FEBS Lett 452, 1999, 314-318), chronic renal failure (Sharpe, C. C., Hendry, B., M. Signaling: focus on Rho in renal disease. J. Am. Soc. Nephrol. 14, 2003, 261-264), cerebral vasospasm after subarachnoid bleeding (Shibuya, M., Suzuki, Y., Sugita, K., Saito, I., Sasaki, T., Takakura, K., Okamoto, S., Kikuchi, H., Takemae, T., Hidaka, H., Dose escalation trial of a novel calcium antagonist, AT877, in patients 636 with aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien) 107, 1990, 11-15; Shibuya, M., Suzuki, Y., Sugita, K., Saito, I., Sasaki, T., Takakura, K., Nagata, I., Kikuchi, H., Takemae, T., Hidaka, H., et. al, Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 76, 1992, 571-577; Sato, M., Tani, E., Fujikawa, H., Kaibuchi, K., Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res 87, 2000, 195-200; Miyagi, Y., Carpenter, R. C., Meguro, T., Parent, A. D., Zhang, J. H., Upregulation of rho A and rho kinase messenger RNAs in the basilar artery of a rat model of subarachnoid hemorrhage. J Neurosurg 93, 2000, 471-476; Tachibana, E., Harada, T., Shibuya, M. Saito, K., Takayasu, M., Suzuki, Y., Yoshida, J., Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien) 141, 1999, 13-19), pulmonary hypertension (Sylvester, J. T., Am. J. Physiol. Lung Cell. Mol. Physiol. 287, 2004, L624-L630) and ocular hypertension (Honjo, M., Inatani, M., Kido, N., Sawamura, T., Yue, B. Y., Honda, Y., Tanihara, H., Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes. Arch Ophthalmol 119, 2001, 1171-1178; Rao, P. V., Deng, P. F., Kumar, J. Epstein, D. L., Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci 42, 2001, 1029-1037). Further diseases related to abnormal Rho/ROCK activity are cancer (Aznar, S., Fernandez-Valeron, P., Espina, C., Lacal, J. C., Rho GTPases: potential candidates for anticancer therapy. Cancer Lett. 206, 2004, 181-191; Yin, L. et al., Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther 5, 2007, 1517-25; Itoh, K., Yoshioka, K., Akedo, H., Uehata, M., Ishizaki, T., Narumiya, S., An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 5, 1999, 221-225; Genda, T. Sakamoto, M., Ichida, T., Asakura, H., Kojiro, M., Narumiya, S., Hirohashi, S., Cell motility mediated by rho and Rho-associated protein kinase plays a critical role inintrahepatic metastasis of human hepatocellular carcinoma. Hepatology 30, 1999, 1027-1036; Somlyo, A. V., Bradshaw, D., Ramos, S., Murphy, C., Myers, C. E., Somlyo, A. P., Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 269, 2000, 652-659), asthma (Roberts, J. A., Raeburn, D., Rodger, I. W., Thomson, N. C., Comparison of in vivo airway responsiveness and in vitro smooth muscle sensitivity to methacholine in man. Thorax 39; 1984, 837-843; Chiba, Y., Misawa, M., Characteristics of muscarinic cholinoceptors in airways of antigen-induced airway hyperresponsive rats. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 111, 1995, 351-357; Chiba, Y., Takada, Y., Miyamoto, S., MitsuiSaito, M., Karaki, H., Misawa, M., Augmented acetylcholine-induced, Rho mediated Ca2+ sensitization of bronchial smooth muscle contraction in antigen-induced airway hyperresponsive rats. Br J Pharmacol 127, 1999, 597-600; Chiba, Y., Sakai, H. Misawa, M., Augmented acetylcholine-induced translocation of RhoA in bronchial smooth muscle from antigen-induced airway hyperresponsive rats. Br J Pharmacol 133, 2001, 886-890; Iizuka, K., Shimizu, Y., Tsukagoshi, H., Yoshii, A., Harada, T. Dobashi, K., Murozono, T., Nakazawa, T., Mori, M., Evaluation of Y-27632, a rho-kinase inhibitor, as a bronchodilator in guinea pigs. Eur J Pharmacol 406, 2000, 273-279), male erectile dysfunctions (Andersson, K. E., Hedlund, P., New directions for erectile dysfunction therapies. Int. J. Impot. Res. 14 (Suppl. 1), 2002, S82S92; Chitaley, K., Wingard, C. J., Clinton Webb, R., Branam, H., Stopper, V. S., Lewis, R. W., Mills, T. M., Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxideindependent pathway. Nat Med 7, 2001, 119-122; Mills, T. M., Chitaley, K., Wingard, C. J., Lewis, R. W., Webb, R. C., Effect of Rho-kinase inhibition on vasoconstriction in the penile circulation. J Appl Physiol 91, 2001, 1269-1273), female sexual dysfunction, over-active bladder syndrome (Peters, S. L. et al., Rho kinase: a target for treating urinary bladder dysfunction. Trends Pharmacol Sci. 27, 2006, 492-7) and preterm labor (Niiro, N., Nishimura, J., Sakihara, C., Nakano, H., Kanaide, H., Up-regulation of rho A and rho-kinase mRNAs in the rat myometrium during pregnancy. Biochem Biophys Res Commun 230, 1997, 356-359; Tahara, M., Morishige, K., Sawada, K., Ikebuchi, Y., Kawagishi, R., Tasaka, K., Murata, Y., RhoA/Rho-kinase cascade is involved in oxytocin-induced rat uterine contraction. Endocrinology 143, 2002, 920-929; Kupittayanant, S., Burdyga, T., Wray, S., The effects of inhibiting Rho-associated kinase with Y-27632 on force and intracellular calcium in human myometrium. Pflugers Arch. 443, 2001, 112-114).


Inhibitors of ROCKs have been suggested for use in the treatments of a variety of diseases. They include cardiovascular diseases such as hypertension (Satoh S., Kreutz R., Wilm C., Ganten D., Pfitzer G., Augmented agonist-induced Ca2+-sensitization of coronary artery contraction in genetically hypertensive rats. Evidence for altered signal transduction in the coronary smooth muscle cells. J. Clin. Invest. 94, 1994, 1397-1403; Mukai, Y., Shimokawa, H., Matoba, T., Kandabashi, T., Satoh, S., Hiroki, J., Kaibuchi, K., Takeshita, A., Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 15, 2001, 1062-1064; Uehata, M., Ishizaki, T., Satoh, H., Ono, T., Kawahara, T., Morishita, T., Tamakawa, H., Yamagami, K., Inui, J., Maekawa, M., Narumiya, S., Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 1997, 990-994; and Masumoto, A., Hirooka, Y., Shimokawa, H., Hironaga, K., Setoguchi, S., Takeshita, A., Possible involvement of Rhokinase in the pathogenesis of hypertension in humans. Hypertension 38, 2001, 1307-1310), chronic and congestive heart failure (Fuster, V., Badimon, L., Badimon, J J, Chesebro, J H, The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 326, 1992, 310-318; Shimokawa, H., Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models. Jpn Circ J 64, 2000, 1-12; Shimokawa, H., Morishige, K., Miyata, K., Kandabashi, T., Eto, Y., Ikegaki, I., Asano, T., Kaibuchi, K., Takeshita, A., Longterm inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res 51, 2001, 169-177; Utsunomiya, T., Satoh, S., Ikegaki, I., Toshima, Y., Asano, T., Shimokawa, H., Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina. Br J Pharmacol 134, 201, 1724-1730), cardiac hypertrophy), and cardiac hypertrophy (Hoshijima, M., Sah, V. P., Wang, Y., Chien, K. R., Brown, J. H., The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho kinase. J Biol Chem 273, 1998, 7725-77230; Sah, V. P., Hoshijima, M., Chien, K. R., Brown, J. H., Rho is required for Galphaq and alpha1-adrenergic receptor signal-637 ing in cardiomyocytes. Dissociation of Ras and Rho pathways. J Biol Chem 271, 1996, 31185-1190; Kuwahara, K., Saito, Y., Nakagawa, O., Kishimoto, I., Harada, M., Ogawa, E., Miyamoto, Y., Hamanaka, I., Kajiyama, N., Takahashi, N., Izumi, T., Kawakami, R., Tamura, N., Ogawa, Y., Nakao, K., The effects of the selective ROCK inhibitor, Y27632, on ET-1-induced hypertrophic response in neonatal rat cardiacmyocytes-possible involvement of Rho/ROCK pathway in cardiac muscle cell hypertrophy. FEBS Lett 452, 1999, 314-318), chronic renal failure), chronic renal failure (Sharpe, C. C., Hendry, B., M. Signaling: focus on Rho in renal disease. J. Am. Soc. Nephrol. 14, 2003, 261-264), furthermore cerebral vasospasm after subarachnoid bleeding (Shibuya, M., Suzuki, Y., Sugita, K., Saito, I., Sasaki, T., Takakura, K., Okamoto, S., Kikuchi, H., Takemae, T., Hidaka, H., Dose escalation trial of a novel calcium antagonist, AT877, in patients 636 with aneurysmal subarachnoid haemorrhage. (Acta Neurochir (Wien) 107, 1990, 11-15; Shibuya, M., Suzuki, Y., Sugita, K., Saito, I., Sasaki, T., Takakura, K., Nagata, I., Kikuchi, H., Takemae, T., Hidaka, H., et. al, Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 76, 1992, 571-577; Sato, M., Tani, E., Fujikawa, H., Kaibuchi, K., Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res 87, 2000, 195-200; Miyagi, Y., Carpenter, R. C., Meguro, T., Parent, A. D., Zhang, J. H., Upregulation of rho A and rho kinase messenger RNAs in the basilar artery of a rat model of subarachnoid hemorrhage. J Neurosurg 93, 2000, 471-476; Tachibana, E., Harada, T., Shibuya, M. Saito, K., Takayasu, M., Suzuki, Y., Yoshida, J., Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien) 141, 1999, 13-19), pulmonary hypertension (Sylvester, J. T., Am. J. Physiol. Lung Cell. Mol. Physiol. 287, 2004, L624-L630) and ocular hypertension (Honjo, M., Inatani, M., Kido, N., Sawamura, T., Yue, B. Y., Honda, Y., Tanihara, H., Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes. Arch Ophthalmol 119, 2001, 1171-1178; Rao, P. V., Deng, P. F., Kumar, J. Epstein, D. L., Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci 42, 2001, 1029-1037). In addition, because of their muscle relaxing properties, they are also suitable for asthma (Roberts, J. A., Raeburn, D., Rodger, I. W., Thomson, N. C., Comparison of in vivo airway responsiveness and in vitro smooth muscle sensitivity to methacholine in man. Thorax 39; 1984, 837-843; Chiba, Y., Misawa, M., Characteristics of muscarinic cholinoceptors in airways of antigen-induced airway hyperresponsive rats. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 111, 1995, 351-357; Chiba, Y., Takada, Y., Miyamoto, S., MitsuiSaito, M., Karaki, H., Misawa, M., Augmented acetylcholine-induced, Rho mediated Ca2+ sensitization of bronchial smooth muscle contraction in antigen-induced airway hyperresponsive rats. Br J Pharmacol 127, 1999, 597-600; Chiba, Y., Sakai, H. Misawa, M., Augmented acetylcholine-induced translocation of RhoA in bronchial smooth muscle from antigen-induced airway hyperresponsive rats. Br J Pharmacol 133, 2001, 886-890; fizuka, K., Shimizu, Y., Tsukagoshi, H., Yoshii, A., Harada, T. Dobashi, K., Murozono, T., Nakazawa, T., Mori, M., Evaluation of Y-27632, a rho-kinase inhibitor, as a bronchodilator in guinea pigs. Eur J Pharmacol 406, 2000, 273-279), male erectile dysfunctions (Andersson, K. E., Hedlund, P., New directions for erectile dysfunction therapies. Int. J. Impot. Res. 14 (Suppl. 1), 2002, S82-S92; Chitaley, K., Wingard, C. J., Clinton Webb, R., Branam, H., Stopper, V. S., Lewis, R. W., Mills, T. M., Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxideindependent pathway. Nat Med 7, 2001, 119-122; Mills, T. M., Chitaley, K., Wingard, C. J., Lewis, R. W., Webb, R. C., Effect of Rho-kinase inhibition on vasoconstriction in the penile circulation. J Appl Physiol 91, 2001, 1269-1273), female sexual dysfunction and over-active bladder syndrome (Peters, S. L. et al., Rho kinase: a target for treating urinary bladder dysfunction. Trends Pharmacol Sci. 27, 2006, 492-7) and preterm labor (Niiro, N., Nishimura, J., Sakihara, C., Nakano, H., Kanaide, H., Up-regulation of rho A and rho-kinase mRNAs in the rat myometrium during pregnancy. Biochem Biophys Res Commun 230, 1997, 356-359; Tahara, M., Morishige, K., Sawada, K., Ikebuchi, Y., Kawagishi, R., Tasaka, K., Murata, Y., RhoA/Rho-kinase cascade is involved in oxytocin-induced rat uterine contraction. Endocrinology 143, 2002, 920-929; Kupittayanant, S., Burdyga, T., Wray, S., The effects of inhibiting Rho-associated kinase with Y-27632 on force and intracellular calcium in human myometrium. Pflugers Arch. 443, 2001, 112-114). Several recent studies have reported the beneficial effects of ROCK inhibitors in ischemia-reperfusion and myocardial infarction. In these studies, the ROCK inhibitors Y-27632 and fasudil were shown to decrease ischemia-reperfusion injury, myocardial infarct size, and myocardial fibrosis in response to experimental myocardial infarction (MI) and in a rat model of chronic hypertension induced congestive heart failure (see above (Fuster, V., Badimon, L., Badimon, J J, Chesebro, J H, The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 326, 1992, 310-318; Shimokawa, H., Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models. Jpn Circ J 64, 2000, 1-12; Shimokawa, H., Morishige, K., Miyata, K., Kandabashi, T., Eto, Y., Ikegaki, I., Asano, T., Kaibuchi, K., Takeshita, A., Longterm inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res 51, 2001, 169-177; Utsunomiya, T., Satoh, S., Ikegaki, I., Toshima, Y., Asano, T., Shimokawa, H., Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina. Br J Pharmacol 134, 201, 1724-1730), cardiac hypertrophy) and Masumoto, A., Mohri, M., Shimokaw, a H., Urakami, L., Usui, M., Takeshita, A., Suppression of coronary artery spasm by the rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105, 2002, 1545-1547; Shimokawa, H., linuma, H., Kishida, H., et al., Antianginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study (abstract). Circulation 104[Suppl II], 2001, 11691; Morishige K, Shimokawa H, Eto Y, Kandabashi T, Miyata K, Matsumoto Y, Hoshijima M, Kaibuchi K, Takeshita A, Adenovirus-mediated transfer of dominant-negative rho-kinase induces a regression of coronary arteriosclerosis in pigs in vivo. Arterioscler Thromb Vasc Biol 21, 2001, 548-554; Kandabashi T, Shimokawa H, Mukai Y, Matoba T, Kunihiro I, Morikawa K, Ito M, Takahashi S, Kaibuchi K, Takeshita A, Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. Arterioscler Thromb Vasc Biol 22, 2002, 243-248; Liu M W, Roubin G S, King S B 3rd, Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 79, 1989, 1374-1387; Shibata R, Kai H, Seki Y, Kato S, Morimatsu M, Kaibuchi K, Imaizumi T, Role of Rho-associated kinase in neointima formation after vascular injury. Circulation 103, 2001, 284-289).


Additionally, ROCKs can interact with other signalling pathways resulting in inhibition of phosphoinositide-3 kinase (PI-3K), endothelial nitric oxide synthase (eNOS) pathways, and activation of plasminogen activator inhibitor-1 (PAI-1) which may contribute to endothelial dysfunction like restenosis and atherosclerosis. Thus ROCK inhibitors have been suggested for the treatment of restenosis and atherosclerosis (see above (Morishige K, Shimokawa H, Eto Y, Kandabashi T, Miyata K, Matsumoto Y, Hoshijima M, Kaibuchi K, Takeshita A, Adenovirus-mediated transfer of dominant-negative rho-kinase induces a regression of coronary arteriosclerosis in pigs in vivo. Arterioscler Thromb Vasc Biol 21, 2001, 548-554; Kandabashi T, Shimokawa H, Mukai Y, Matoba T, Kunihiro I, Morikawa K, Ito M, Takahashi S, Kaibuchi K, Takeshita A, Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. Arterioscler Thromb Vasc Biol 22, 2002, 243-248; Liu M W, Roubin G S, King S B 3rd, Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 79, 1989, 1374-1387; Shibata R, Kai H, Seki Y, Kato S, Morimatsu M, Kaibuchi K, Imaizumi T, Role of Rho-associated kinase in neointima formation after vascular injury. Circulation 103, 2001, 284-289) and Iwasaki, H. et al., High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-kappaB activation in bovine aortic endothelial cells. Atherosclerosis, 2007, Jan. 31).


Vascular intimal thickening in vein grafts after surgery is the major cause of late graft failure. In a study with the ROCK inhibitor fasudil, the intimal thickening and vascular smooth muscle cell (VSMC) proliferation was significantly suppressed, whereas VSMC apoptosis was enhanced in the weeks following the procedure, suggesting that ROCK inhibitors can be used as a therapeutic agent for the prevention of graft (Morishige K, Shimokawa H, Eto Y, Kandabashi T, Miyata K, Matsumoto Y, Hoshijima M, Kaibuchi K, Takeshita A, Adenovirus-mediated transfer of dominant-negative rho-kinase induces a regression of coronary arteriosclerosis in pigs in vivo. Arterioscler Thromb Vasc Biol 21, 2001, 548-554; Kandabashi T, Shimokawa H, Mukai Y, Matoba T, Kunihiro I, Morikawa K, Ito M, Takahashi S, Kaibuchi K, Takeshita A, Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. Arterioscler Thromb Vasc Biol 22, 2002, 243-248; Liu M W, Roubin G S, King S B 3rd, Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 79, 1989, 1374-1387; Shibata R, Kai H, Seki Y, Kato S, Morimatsu M, Kaibuchi K, Imaizumi T, Role of Rho-associated kinase in neointima formation after vascular injury. Circulation 103, 2001, 284-289).


Injury to the adult vertebrate brain and spinal cord activates ROCKs, thereby causing neurodegeneration and inhibition of neuroregeneration like neurite growth and sprouting (Bito, H., Furuyashiki, T., Ishihara, H., Shibasaki, Y., Ohashi, K., Mizuno, K., Maekawa, M., Ishizaki, T., Narumiya, S., A critical role for a Rho-associated kinase, p160ROCK, in determining axon outgrowth in mammalian CNS neurons. Neuron 26, 2000, 431-441). Inhibition of ROCKs results in induction of new axonal growth, axonal rewiring across lesions within the CNS, accelerated regeneration and enhanced functional recovery after acute neuronal injury in mammals (spinal-cord injury, traumatic brain injury) (see above (Peters, S. L. et al., Rho kinase: a target for treating urinary bladder dysfunction. Trends Pharmacol Sci. 27, 2006, 492-7) and Hara, M. et al., Protein kinase inhibition by fasudil hydrochloride promotes neurological recovery after spinal cord injury in rats. J. Neurosurg. Spine 93, 94-101; Fournier, A. E., Takizawa, B. T. & Strittmatter, S. M., ROCK inhibition enhances axonal regeneration in the injured CNS. J. Neurosci. 23, 2003, 1416-1423; Sung, J. K. et al., A possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat. Brain Res. 959, 2003, 29-38; Tanaka, H. et al., Cytoplasmic p21(Cip1/WAF1) enhances axonal regeneration and functional recovery after spinal cord injury in rats. Neuroscience 127, 2004, 155-164). ROCK inhibitors are therefore likely to be useful for regenerative (recovery) treatment of CNS disorders such as spinal cord injury, acute neuronal injury (stroke, traumatic brain injury) (Okamura N et al., Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats. J Ocul Pharmacol Ther. 23, 2007, 207-12; Yagita Y et al., Rho-kinase activation in endothelial cells contributes to expansion of infarction after focal cerebral ischemia. J Neurosci Res. 85, 2007, 2460-9), Parkinson's disease, Alzheimer disease (Pedrini S et al., Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med. 2, 2005, 18; Burton A., NSAIDS and Alzheimer's disease: it's only Rock and Rho. Lancet Neurol. 3(1), 2004, 6) and other neurodegenerative disorders. Other neurodegenetarive disorders for which ROCK inhibitors are expected to be useful are Huntington's disease (Shao J, Welch W J, Diprospero N A, Diamond M I. Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol Cell Biol. 2008 September; 28(17):5196-208; Shao J, Welch W J, Diamond M I. ROCK and PRK-2 mediate the inhibitory effect of Y-27632 on polyglutamine aggregation. FEBS Lett. 2008 May 28; 582(12):1637-42), spinal muscular atrophy (Bowerman M, Shafey D, Kothary R., Smn depletion alters profilin II expression and leads to upregulation of the RhoA/ROCK pathway and defects in neuronal integrity. J Mol Neurosci. 2007; 32(2):120-31) and amyotrophic lateral sclerosis. Inhibition of the Rho/ROCK pathway has also proved to be efficacious in other animal models of neurodegeneration like stroke (Okamura N et al., Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats. J Ocul Pharmacol Ther. 23, 2007, 207-12; Yagita Y et al., Rho-kinase activation in endothelial cells contributes to expansion of infarction after focal cerebral ischemia. J Neurosci Res. 85, 2007, 2460-9) and in inflammatory and demyelinating diseases like multiple sclerosis (Sun X et al., The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. J Neuroimmunol. 180, 2006, 126-34), acute and chronic pain (Inoue, M. et al., Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nature Med. 10, 2004, 712-718; Ramer, L. M., Borisoff, J. F. & Ramer, M. S., Rho-kinase inhibition enhances axonal plasticity and attenuates cold hyperalgesia after dorsal rhizotomy. J Neurosci. 24, 2004, 10796-10805; Tatsumi, S. et al., Involvement of Rho-kinase in inflammatory and neuropathic pain through phosphorylation of myristoylated alanine-rich C-kinase substrate (MARCKS). Neuroscience 131,2005, 491-498).


ROCK inhibitors have been shown to possess anti-inflammatory properties by decreased cytokine release, e.g. TNFα. Thus they can be used as treatment for neuroinflammatory diseases such as stroke, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and inflammatory pain, as well as other inflammatory diseases such as rheumatoid arthritis, osteoarthritis, osteoporosis, asthma, irritable bowel syndrome, or inflammatory bowel disease (Segain J. P., Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology. 124(5), 2003, 1180-7). In addition, recent reports have demonstrated that inhibition of ROCK results in disruption of inflammatory cell chemotaxis as well as inhibition of smooth muscle contraction in models of pulmonary inflammation associated with asthma. Therefore, the inhibitors of the Rho/ROCK pathway should be useful for the treatment of asthma (see above (Sun X et al., The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. J Neuroimmunol. 180, 2006, 126-34) and Kawaguchi A, Ohmori M, Harada K, Tsuruoka S, Sugimoto K, Fujimura A., The effect of a Rho kinase inhibitor Y-27632 on superoxide production, aggregation and adhesion inhuman polymorphonuclear leukocytes. Eur J Pharmacol 403, 2000, 203-208; Lou Z, Billadeau D D, Savoy D N, Schoon R A, Leibson P. J., A role for a RhoA/ROCK/LIM-kinase pathway in the regulation of cytotoxic lymphocytes. J Immunol 167, 2001, 5749-5757; Vicente-Manzanares M, Cabrero J R, Rey M, Perez-Martinez M, Ursa A, Itoh K, Sanchez-Madrid F., A role for the Rho-p160 Rho coiled-coil kinase axis in the chemokine stromal cell-derived factor-1alpha-induced lymphocyte actomyosinand microtubular organization and chemotaxis. J Immunol 168, 2002, 400-410; Thorlacius K et al., Protective effect of fasudil, a Rho-kinase inhibitor, on chemokine expression, leukocyte recruitment, and hepatocellular apoptosis in septic liver injury. J Leukoc Biol. 79, 2006, 923-31).


Since ROCK inhibitors reduce cell proliferation and cell migration, they could be useful in treating cancer and tumor metastasis (Aznar, S., Fernandez-Valeron, P., Espina, C., Lacal, J. C., Rho GTPases: potential candidates for anticancer therapy. Cancer Lett. 206, 2004, 181-191; Yin, L. et al., Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther 5, 2007, 1517-25. Itoh, K., Yoshioka, K., Akedo, H., Uehata, M., Ishizaki, T., Narumiya, S., An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 5, 1999, 221-225; Genda, T. Sakamoto, M., Ichida, T., Asakura, H., Kojiro, M., Narumiya, S., Hirohashi, S., Cell motility mediated by rho and Rho-associated protein kinase plays a critical role inintrahepatic metastasis of human hepatocellular carcinoma. Hepatology 30, 1999, 1027-1036; Somlyo, A. V., Bradshaw, D., Ramos, S., Murphy, C., Myers, C. E., Somlyo, A. P., Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 269, 2000, 652-659). ROCK inhibitors can also be beneficial in diseases with impaired blood brain barrier function, e.g. HIV-1 encephalitis (Persidski Y et al., Rho-mediated regulation of tight junctions during monocyte migration across the blood-brain barrier in HIV-1 encephalitis (HIVE). Blood. 107, 2006, 4770-4780) and Alzheimer's disease (Man S-M et al., Peripheral T cells overexpress MIP-1a to enhance its transendothelial migration in Alzheimer's disease. Neurobiol. Of Aging 28, 2007, 485-496).


Furthermore, there is evidence suggesting that ROCK inhibitors suppress cytoskeletal rearrangement upon virus invasion, thus they also have potential therapeutic value in anti-viral and anti-bacterial applications (Favoreel H W, Cytoskeletal rearrangements and cell extensions induced by the US3 kinase of an alphaherpesvirus are associated with enhanced spread. Proc Natl Acad Sci USA. 102(25), 2006, 8990-5).


ROCKs have been reported to interfere with insulin signalling through serine phosphorylation of insulin receptor substrate-1 (IRS-1), in cultured VSMC. Activation of RhoA/ROCK was observed in skeletal muscles and aortic tissues of Zucker obese rats. Inhibition of ROCK, by fasudil for 4 weeks, reduced blood pressure, corrected glucose and lipid metabolism, improved insulin signalling and endothelial dysfunction. In another experiment administration of high dose fasudil completely suppressed the development of diabetes, obesity, and dyslipidemia and increased serum adiponectin levels in OLETF rats. ROCK inhibitors may therefore be useful for the treatment of insulin resistance and diabetes (Nakamura Y et al., Marked increase of insulin gene transcription by suppression of the Rho/Rho-kinase pathway. Biochem Biophys Res Commun 350(1), 2006, 68-73; Kikuchi Y et al., A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol. 192(3), 2007, 595-603; Goyo A et al., The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol. 568(1-3), 2007, 242-7).


The ROCK inhibitor Fasudil increased cerebral blood flow and was neuroprotective under CNS ischemic conditions. ROCK inhibitors are expected to be useful for the treatment of ischemic CNS disorders and may therefore improve functional outcome in patients suffering from stroke, vascular or AD type dementia (Okamura N et al., Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats. J Ocul Pharmacol Ther. 23, 2007, 207-12; Yagita Y et al., Rho-kinase activation in endothelial cells contributes to expansion of infarction after focal cerebral ischemia. J Neurosci Res. 85, 2007, 2460-9).


Due to the efficacy of Y-27632 and fasudil in animal models of epileptogenesis, ROCK inhibitors have been suggested for the use in the treatments of epilepsy and seizure disorders (Inan S Y, Büyükafsar K. Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice. Br. J. Pharmacol. advance online publication, 9 Jun. 2008; doi:10.1038/bjp.2008.225)


ROCK inhibitors are also expected to be useful for the treatment of glaucoma (Honjo, M., Inatani, M., Kido, N., Sawamura, T., Yue, B. Y., Honda, Y., Tanihara, H., Effects of protein kinase inhibitor, HAI 077, on intraocular pressure and outflow facility in rabbit eyes. Arch Ophthalmol 119, 2001, 1171-1178; Rao, P. V., Deng, P. F., Kumar, J. Epstein, D. L., Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci 42, 2001, 1029-1037), psoriasis, retinopathy and benign prostatic hypertrophy.


Furthermore, there is evidence suggesting that ROCK inhibitors suppress cytoskeletal rearrangement upon virus invasion, thus they also have potential therapeutic value in anti-viral and anti-bacterial applications.


As ROCKs have been implicated in neuronal morphogenesis, connectivity, and plasticity in general, they are expected to be useful for the treatment of psychiatric disorders, e.g. depression, schizophrenia, obsessive compulsive disorder and bipolar disorders.


ROCK inhibitors have been described in e.g. WO 2007/026920, WO 2005/074643, and WO 2004/016597. However, their affinity and selectivity or their pharmacological profile is not yet satisfactory.


SCHEMES AND EXPERIMENTALS

The following abbreviations have the meanings indicated. ADDP means 1,1′-(azodicarbonyl)dipiperidine; AD-mix-β means a mixture of (DHQD)2PHAL, K3Fe(CN)6, K2CO3, and K2SO4; 9-BBN means 9-borabicyclo(3.3.1)nonane; Boc means tert-butoxycarbonyl; (DHQD)2PHAL means hydroquinidine 1,4-phthalazinediyl diethyl ether; DBU means 1,8-diazabicyclo[5.4.0]undec-7-ene; DIBAL means diisobutylaluminum hydride; DIEA means diisopropylethylamine; DMAP means N,N-dimethylaminopyridine; DMF means N,N-dimethylformamide; dmpe means 1,2-bis(dimethylphosphino)ethane; DMSO means dimethylsulfoxide; dppb means 1,4-bis(diphenylphosphino)-butane; dppe means 1,2-bis(diphenylphosphino)ethane; dppf means 1,1′-bis(diphenylphosphino)ferrocene; dppm means 1,1-bis(diphenylphosphino)methane; EDACHC1 means 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; Fmoc means fluorenylmethoxycarbonyl; HATU means O-(7-azabenzotriazol-1-yl)-N,N′N′N′-tetramethyluronium hexafluorophosphate; HMPA means hexamethylphosphoramide; IPA means isopropyl alcohol; MP-BH3 means macroporous triethylammonium methylpolystyrene cyanoborohydride; TEA means triethylamine; TFA means trifluoroacetic acid; tetrahydrofuran means tetrahydrofuran; NCS means N-chlorosuccinimide; NMM means N-methylmorpholine; NMP means N-methylpyrrolidine; PPh3 means triphenylphosphine.


The following schemes are presented to provide what is believed to be the most useful and readily understood description of procedures and conceptual aspects of this invention. Compounds of this invention may be made by synthetic chemical processes, examples of which are shown herein. It is meant to be understood that the order of the steps in the processes may be varied, that reagents, solvents and reaction conditions may be substituted for those specifically mentioned, and that vulnerable moieties may be protected and deprotected, as necessary.


SCHEMES



embedded image


As shown in Scheme 1, compounds of formula (1), wherein X1, X2, and X3 are as described herein, can be reacted with methyl 4-isocyanatobenzoate to provide compounds of formula (2). The reaction is typically performed in a solvent such as but not limited to tetrahydrofuran. The methyl 4-isocyanatobenzoate is typically added at low temperature followed by stirring at room temperature. Compounds of formula (3) can be prepared by reacting compounds of formula (2) with aqueous lithium hydroxide. The reaction is typically performed in a solvent such as but not limited to tetrahydrofuran, methanol, or mixtures thereof. Compounds of formula (3) can be reacted with amine of formula (3A), wherein R5 is hydrogen or is as described herein, using coupling conditions known to those skilled in the art and readily available in the literature to provide compounds of formula (4), which are representative of the compounds of this invention.




embedded image


As shown in Scheme 2, compounds of formula (1), wherein X1, X2, and X3 are as described herein, can be reacted with 4-nitrophenylisocyanate to provide compounds of formula (5). The reaction is typically performed in a solvent such as but not limited to tetrahydrofuran. Compounds of formula (5) can be treated with a hydrogen balloon in the presence of 10% Pd on carbon to provide compounds of formula (6). The reaction is typically performed at ambient temperature in a solvent such as but not limited to dimethylformamide. Compounds of formula (6) can be reacted with acid of formula (6A), wherein R5 is as described herein, using coupling conditions known to those skilled in the art and readily available in the literature to provide compounds of formula (7), which are representative of the compounds of this invention.




embedded image


As shown in Scheme 3, compounds of formula (1), wherein X1, X2, and X3 are as described herein, can be reacted with 4-bromophenyl isocyanate to provide compounds of formula (8). The reaction is typically performed in a solvent such as but not limited to tetrahydrofuran. Compounds of formula (8) can be reacted with a boronic acid of formula (9A) (or an appropriate boronate ester), wherein R5 is as described herein, using Suzuki Coupling conditions known to those skilled in the art and readily available in the literature to provide compounds of formula (9), which are representative of the compounds of this invention.




embedded image


As shown in Scheme 4, compounds of formula (8), wherein X1, X2, and X3 are as described herein, can be reacted with tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate under Suzuki coupling conditions known to those skilled in the art and widely available in the literature to provide compounds of formula (10). Compounds of formula (11) can be prepared by treating compounds of formula (10) with an acid such as but not limited to trifluoroacetic acid. The reaction is typically performed at room temperature in a solvent such as but not limited to dichloromethane. Compounds of formula (11) can be reacted with compounds of formula (12A) wherein R13 is as described herein, in the presence of a carboxyl activating agent such as but not limited to N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, and a coupling agent such but not limited to 1-hydroxybenzotriazole hydrate, to provide compounds of formula (12). The reaction is typically performed at room temperature in a solvent such as but not limited to N,N-dimethylformamide.


Alternatively, compounds of formula (12) can be treated with hydrogen in the presence of palladium on carbon to provide compounds of formula (13). The reaction is typically performed under pressure in a solvent such as but not limited to tetrahydrofuran or N,N-dimethylformamide. Compounds of formula (13) can be reacted with compounds of formula (12A) wherein R13 is as described herein, in the presence of a carboxyl activating agent such as but not limited to N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, and a coupling agent such but not limited to 1-hydroxybenzotriazole hydrate, to provide compounds of formula (14). The reaction is typically performed at room temperature in a solvent such as but not limited to N,N-dimethylformamide.




embedded image


Aqueous potassium hydroxide and a phase transfer catalyst such as but not limited to tetrabutylammonium bromide can be added to a mixture of 4-hydroxy-1-piperidine-1-carboxylic acid tert-butyl ester and 1-fluoro-4-nitrobenzene to provide tert-butyl 4-(4-nitrophenoxy)piperidine-1-carboxylate. tert-Butyl 4-(4-aminophenoxy)piperidine-1-carboxylate can be prepared by reacting tert-butyl 4-(4-nitrophenoxy)piperidine-1-carboxylate with hydrogen in the presence of palladium on carbon. The reaction is typically performed under pressure in a solvent such as but not limited to tetrahydrofuran or N,N-dimethylformamide. tert-Butyl 4-(4-aminophenoxy)piperidine-1-carboxylate can be reacted with bis(2,5-dioxopyrrolidin-1-yl) carbonate and pyridine in acetonitrile, followed by the addition of a base such as but not limited to diisopropylethylamine and compounds of formula (15A) to provide compounds of formula (15). The reaction is typically performed at room temperature. Compounds of formula (16) can be prepared by treating compounds of formula (15) with an acid such as but not limited to trifluoroacetic acid. The reaction is typically performed at room temperature in a solvent such as but not limited to dichloromethane. Compounds of formula (16) can be reacted with compounds of formula (12A) wherein R13 is as described herein, in the presence of a carboxyl activating agent such as but not limited to N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, and a coupling agent such but not limited to 1-hydroxybenzotriazole hydrate, to provide compounds of formula (17). The reaction is typically performed at room temperature in a solvent such as but not limited to N,N-dimethylformamide.


The following examples are presented to provide what is believed to be the most useful and readily understood description of procedures and conceptual aspects of this invention. The exemplified compounds were named using ACD/ChemSketch Version 12.01 (13 May 2009), Advanced Chemistry Development Inc., Toronto, Ontario), or ChemDraw® Ver. 9.0.5 (CambridgeSoft, Cambridge, Mass.). Intermediates were named using ChemDraw® Ver. 9.0.5 (CambridgeSoft, Cambridge, Mass.).


EXPERIMENTALS
Example 1
N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 1A
Methyl 4-(isoindoline-2-carboxamido)benzoate

Isoindoline (1.693 ml, 14.47 mmol) was dissolved in tetrahydrofuran (20 ml) and cooled to 0° C.; and methyl 4-isocyanatobenzoate (2.18 g, 12.06 mmol) was added by syringe and the resulting mixture was warmed to ambient temperature, and then stirred overnight. The solution was concentrated to a slurry, diluted with ether, and filtered to provide the title compound.


Example 1B
4-(isoindoline-2-carboxamido)benzoic acid

Methyl 4-(isoindoline-2-carboxamido)benzoate (1.65 g, 5.57 mmol) was dissolved in tetrahydrofuran (30 ml) and methanol (15.00 ml) followed by the addition of lithium hydroxide (11.14 ml, 22.27 mmol) and the mixture was allowed to stir at ambient temperature over the weekend. The organic solvent was removed under vacuum, the aqueous layer was adjusted to pH 3 with 2N aqueous HCl, and the resulting solid was filtered with water washes to provide the title compound after drying.


Example 1C
N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

4-(Isoindoline-2-carboxamido)benzoic acid (150 mg, 0.531 mmol) and 1-hydroxybenzotriazole hydrate (122 mg, 0.797 mmol) were dissolved in dimethylformamide (3 ml) followed by addition of 3-phenylpropan-1-amine (110 mg, 0.797 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (153 mg, 0.797 mmol). The homogeneous solution was stirred at ambient temperature overnight. The solution was diluted with water to give a precipitate which was filtered, washed with cold ethyl acetate then ether and dried under vacuum to provide the title compound. 1H NMR (400 MHz, DMSO-d6, Temp=90° C.) δ ppm 8.27-8.34 (bs, 1H), 7.93-7.98 (m, 1H), 7.73-7.76 (m, 2H), 7.61-7.64 (m, 2H), 7.32-7.36 (m, 2H), 7.27-7.32 (m, 2H), 7.24-7.28 (m, 2H), 7.19-7.24 (m, 2H), 7.13-7.18 (m, 1H), 4.79 (s, 4H), 3.30 (q, J=6.5 Hz, 2H), 2.65 (t, J=7.6 Hz, 2H), 1.86 (p, J=7.3 Hz, 2H); MS (ESI(+)) m/e 400 (M+H)+.


Example 2
N-(4-{[4-(aminomethyl)benzyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide
Example 2A
methyl 4-(5-fluoroisoindoline-2-carboxamido)benzoate

The title compound was prepared as described in Example 1A, substituting 5-fluoroisoindoline for isoindoline.


Example 2B
4-(5-fluoroisoindoline-2-carboxamido)benzoic acid

The title compound was prepared as described in Example 1B, substituting methyl 4-(5-fluoroisoindoline-2-carboxamido)benzoate for methyl 4-(isoindoline-2-carboxamido)benzoate.


Example 2C
tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate

The title compound was prepared as described in Example 1C, substituting 4-(5-fluoroisoindoline-2-carboxamido)benzoic acid for 4-(isoindoline-2-carboxamido)benzoic acid and tert-butyl 4-(aminomethyl)benzylcarbamate for 3-phenylpropan-1-amine.


Example 2D
N-(4-{[4-(aminomethyl)benzyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide

tert-Butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate (392 mg, 0.756 mmol) was dissolved in dichloromethane, treated with trifluoroacetic acid (582 μl, 7.56 mmol), stirred for 3 hours at ambient temperature and then concentrated to dryness. The resulting solid was triturated with ether, collected and dried under vacuum to provide the title compound. 1H NMR (400 MHz, DMSO-d6) δ ppm 4.01 (q, J=5.6 Hz, 2H), 4.46 (d, J=6.0 Hz, 2H), 4.76 (d, J=7.9 Hz, 4H), 7.08-7.29 (m, 2H), 7.32-7.44 (m, 5H), 7.67 (d, J=8.7 Hz, 2H), 7.76-7.86 (m, 2H), 8.12 (s, 2H), 8.63 (s, 1H), 8.91 (t, J=6.2 Hz, 1H); MS (ESI(+)) m/e 419 (M+H)+.









TABLE 3







The following Examples were prepared essentially as described in Example 1, substituting the appropriate


substituted isoindoline for isoindoline in Example 1A and the appropriate amine for 3-phenylpropan-


1-amine in Example 1C. Some products were purified by flash chromatography while others were purified


by reverse-phase HPLC; some compounds also required Boc-deprotection after amide coupling as described


in Example 2D. Accordingly, some Examples were isolated as trifluoroacetic acid salts.










Ex
Name

1H NMR

MS













3
5-cyano-N-{4-[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.65

(ESI(+))



phenylpropyl)carbamoyl]phenyl}-
(s, 1H), 8.29 (t, J = 5.6 Hz, 1H), 7.89 (s, 1H),
m/e 425



1,3-dihydro-2H-
7.75-7.81 (m, 3H), 7.63-7.68 (m, 2H), 7.59
(M + H)+



isoindole-2-
(d, J = 8.0 Hz, 1H), 7.15-7.32 (m, 5H), 4.82-



carboxamide
4.86 (m, 4H), 3.22-3.30 (m, 2H), 2.63 (t, J =




7.6 Hz, 2H), 1.82 (p, J = 7.4 Hz, 2H)


4
N-

1H NMR (400 MHz, DMSO-d6) δ 1.16-

(ESI(+))



{4[(cyclopentylmeth-
1.33 (m, 2 H), 1.41-1.75 (m, 6 H), 2.04-
m/e 382



yl)carbamoyl]phenyl}-
2.23 (m, 1 H), 3.11-3.22 (m, 2 H), 4.76 (d,
(M + H)+



5-fluoro-1,3-
J = 7.9 Hz, 4 H), 7.08-7.19 (m, 1 H), 7.24



dihydro-2H-
(dd, J = 9.12, 2.4 Hz, 1 H), 7.39 (dd, J = 8.3,



isoindole-2-
5.16 Hz, 1 H), 7.60-7.68 (m, 2 H), 7.72-



carboxamide
7.82 (m, 2 H), 8.27 (t, J = 5.8 Hz, 1 H), 8.58




(s, 1 H)


5
5-cyano-N-[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.65

(ESI(+))



(propylcarbamoyl)phenyl]-
(s, 1H), 8.26 (t, J = 5.7 Hz, 1H), 7.89 (s, 1H),
m/e 349



1,3-dihydro-
7.79 (dd, J = 8.0, 1.7 Hz, 1H), 7.74-7.79 (m,
(M + H)+



2H-isoindole-2-
2H), 7.62-7.67 (m, 2H), 7.59 (d, J = 7.9 Hz,



carboxamide
1H), 4.84 (d, J = 7.5 Hz, 4H), 3.14-3.27 (m,




2H), 1.46-1.59 (m, 2H), 0.89 (t, J = 7.4 Hz,




3H)


6
N-(4-{[4-(furo[3,2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.65

(ESI(+))



c]pyridin-4-
(s, 1H), 8.26 (t, J = 5.7 Hz, 1H), 7.89 (s, 1H),
m/e 468



yl)piperazin-1-
7.79 (dd, J = 8.0, 1.7 Hz, 1H), 7.74-7.79 (m,
(M + H)+



yl]carbonyl}phenyl)-
2H), 7.62-7.67 (m, 2H), 7.59 (d, J = 7.9 Hz,



1,3-dihydro-2H-
1H), 4.84 (d, J = 7.5 Hz, 4H), 3.14-3.27 (m,



isoindole-2-
2H), 1.46-1.59 (m, 2H), 0.89 (t, J = 7.4 Hz,



carboxamide
3H)


7
5-cyano-N-(4-{[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.64

(ESI(−))



(pyridin-2-
(s, 1H), 8.13 (dd, J = 5.0, 1.9 Hz, 1H), 7.89
m/e 451



yl)piperazin-1-
(s, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.64-7.68
(M − H)



yl]carbonyl}phenyl)-
(m, 2H), 7.51-7.61 (m, 2H), 7.36-7.40 (m,



1,3-dihydro-2H-
2H), 6.85 (d, J = 8.6 Hz, 1H), 6.65-6.69 (m,



isoindole-2-
1H), 4.82-4.85 (bs, 4H), 3.48-3.69 (m, 8H)



carboxamide


8
5-fluoro-N-{4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.93

(ESI(+))



[(pyridin-2-
(t, J = 6.0 Hz, 1H), 8.63 (s, 1H), 8.51 (ddd, J =
m/e 391



ylmethyl)carbamoyl]
4.8, 1.8, 0.9 Hz, 1H), 7.83-7.87 (m, 2H),
(M + H)+



phenyl}-1,3-dihydro-
7.75 (td, J = 7.7, 1.8 Hz, 1H), 7.66-7.70 (m,



2H-isoindole-2-
2H), 7.40 (dd, J = 8.4, 5.2 Hz, 1H), 7.22-



carboxamide
7.33 (m, 3H), 7.15 (td, J = 8.9, 2.5 Hz, 1H),




4.75-4.80 (m, 4H), 4.55 (d, J = 5.8 Hz, 2H)


9
N-[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.86

(ESI(+))



(benzylcarbamoyl)phenyl]-
(t, J = 6.0 Hz, 1H), 8.61 (s, 1H), 7.80-7.85
m/e 390



5-fluoro-1,3-
(m, 2H), 7.64-7.70 (m, 2H), 7.39 (dd, J =
(M + H)+



dihydro-2H-
8.7, 5.2 Hz, 1H), 7.29-7.35 (m, 4H), 7.20-



isoindole-2-
7.28 (m, 2H), 7.15 (ddd, J = 9.4, 8.5, 2.5 Hz,



carboxamide
1H), 4.74-4.79 (m, 4H), 4.47 (d, J = 5.9 Hz,




2H)


10
N-{4-[(3,4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(−))



dimethoxybenzyl)carbamoyl]phenyl}-
Oxide) δ ppm 7.80-7.82 (m, 2H), 7.64-7.67
m/e 430



1,3-dihydro-2H-
(m, 2H), 7.36-7.41 (m, 2H), 7.32-7.35 (m,
(M − H)



isoindole-2-
2H), 6.96 (d, J = 1.9 Hz, 1H), 6.91 (d, J =



carboxamide
8.2 Hz, 1H), 6.86 (dd, J = 8.2, 2.0 Hz, 1H),




4.79 (s, 4H), 4.39-4.40 (bs, 2H), 3.78 (s, 3H)


11
5-methyl-N-(4-{[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.54

(ESI(+))



(pyridin-2-
(s, 1H), 8.13 (ddd, J = 4.9, 2.0, 0.8 Hz, 1H),
m/e 442



yl)piperazin-1-
7.65-7.68 (m, 2H), 7.55 (ddd, J = 8.6, 7.1,
(M + H)+



yl]carbonyl}phenyl)-
2.0 Hz, 1H), 7.35-7.39 (m, 2H), 7.25 (d, J =



1,3-dihydro-2H-
7.7 Hz, 1H), 7.17-7.19 (m, 1H), 7.13 (d, J =



isoindole-2-
7.8 Hz, 1H), 6.85 (dt, J = 8.6, 0.8 Hz, 1H),



carboxamide
6.67 (ddd, J = 7.1, 4.9, 0.8 Hz, 1H), 4.73-




4.75 (bs, 4H), 3.48-3.68 (m, 8H), 2.33 (s,




3H)


12
N-(4-{[4-(thieno[3,2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.56

(ESI(+))



c]pyridin-4-
(s, 1H), 8.03 (d, J = 5.6 Hz, 1H), 7.78 (d, J =
m/e 484



yl)piperazin-1-
5.5 Hz, 1H), 7.64-7.71 (m, 2H), 7.58 (t, J =
(M + H)+



yl]carbonyl}phenyl)-
5.3 Hz, 2H), 7.30-7.41 (m, 6H), 4.79 (s, 4H),



1,3-dihydro-2H-
3.61-3.94 (m, 4H), 3.39-3.63 (m, 4H)



isoindole-2-



carboxamide


13
N-{4-[(2,3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



dimethoxybenzyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.30-8.37 (bs, 1H), 8.27-
m/e 432



1,3-dihydro-2H-
8.31 (m, 1H), 8.13-8.16 (m, 2H), 7.91-7.93
(M + H)+



isoindole-2-
(m, 2H), 7.19-7.24 (m, 2H), 7.16-7.18 (m,



carboxamide
2H), 7.16-7.17 (m, 1H), 6.98 (t, J = 7.8 Hz,




1H), 6.86 (dd, J = 8.1, 1.5 Hz, 1H), 4.91 (d, J =




5.7 Hz, 2H), 4.83-4.85 (m, 4H), 3.85 (s,




3H), 3.71 (s, 3H)


14
5-fluoro-N-{4-[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.59

(ESI(+))



phenylpropyl)carbamoyl]phenyl}-
(s, 1H), 8.29 (t, J = 5.5 Hz, 1H), 7.75-7.78
m/e 418



1,3-dihydro-2H-
(m, 2H), 7.63-7.67 (m, 2H), 7.39 (dd, J =
(M + H)+



isoindole-2-
8.5, 5.1 Hz, 1H), 7.11-7.32 (m, 7H), 4.74-



carboxamide
4.78 (m, 4H), 3.22-3.31 (m, 2H), 2.63 (t, J =




7.6 Hz, 2H), 1.82 (p, J = 7.4 Hz, 2H)


15
5-fluoro-N-(4-{[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.58-

(ESI(+))



(pyridazin-3-
8.59 (m, 1H), 8.57-8.60 (m, 1H), 7.65-7.69
m/e 447



yl)piperazin-1-
(m, 2H), 7.37-7.44 (m, 4H), 7.22-7.29 (m,
(M + H)+



yl]carbonyl}phenyl)-
2H), 7.15 (td, J = 8.9, 2.5 Hz, 1H), 4.77 (d, J =



1,3-dihydro-2H-
8.3 Hz, 4H), 3.49-3.81 (m, 8H)



isoindole-2-



carboxamide


16
N-{4-[(2,3-dihydro-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



1,4-benzodioxin-5-
Temp = 90° C.) δ ppm 8.33 (d, J = 1.8 Hz, 1H),
m/e 430



ylmethyl)carbamoyl]
8.28-8.29 (bs, 1H), 8.13-8.16 (m, 2H), 7.91-
(M + H)+



phenyl}-1,3-dihydro-
7.93 (m, 2H), 7.19-7.23 (m, 2H), 7.15-7.19



2H-isoindole-2-
(m, 2H), 7.10-7.13 (m, 1H), 6.86 (dd, J =



carboxamide
8.1, 1.8 Hz, 1H), 6.80 (dd, J = 8.1, 7.4 Hz,




1H), 4.87 (d, J = 5.7 Hz, 2H), 4.84 (s, 4H),




4.03-4.10 (m, 4H)


17
5-fluoro-N-(4-{[1-(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 10.22

(ESI(−))



methylbutyl)-1H-
(s, 1H), 8.65 (s, 1H), 8.03 (s, 1H), 7.85-7.89
m/e 434



pyrazol-4-
(m, 2H), 7.69-7.73 (m, 2H), 7.56 (d, J = 0.7
(M − H)



yl]carbamoyl}phenyl)-
Hz, 1H), 7.40 (dd, J = 8.4, 5.2 Hz, 1H), 7.25



1,3-dihydro-2H-
(dd, J = 9.1, 2.4 Hz, 1H), 7.15 (td, J = 8.9,



isoindole-2-
2.5 Hz, 1H), 4.73-4.85 (m, 4H), 4.06-4.14



carboxamide
(m, 2H), 1.65 (q, J = 7.0 Hz, 2H), 1.40-1.54




(m, 1H), 0.90 (d, J = 6.6 Hz, 6H)


18
N-{4-[(2-

1H NMR (500 MHz, DMSO-d6/Deuterium

(APCI+)



fluorobenzyl)carbamoyl]phenyl}-
Oxide) δ ppm 8.92 (t, J = 5.9 Hz, 1H), 8.67
m/e 390



1,3-dihydro-2H-
(s, 1H), 7.81-7.84 (m, 2H), 7.66-7.68 (m,
(M + H)+



isoindole-2-
2H), 7.30-7.40 (m, 6H), 7.18 (d, J = 7.2 Hz,



carboxamide
1H), 7.16-7.20 (m, 1H), 4.79-4.80 (bs, 4H),




4.52 (d, J = 5.2 Hz, 2H)


19
5-fluoro-N-(4-{[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.58

(ESI(+))



(pyrimidin-2-
(s, 1H), 8.37-8.40 (m, 2H), 7.64-7.68 (m,
m/e 447



yl)piperazin-1-
2H), 7.36-7.43 (m, 3H), 7.24 (dd, J = 9.1, 2.4
(M + H)+



yl]carbonyl}phenyl)-
Hz, 1H), 7.15 (td, J = 8.9, 2.5 Hz, 1H), 6.67



1,3-dihydro-2H-
(t, J = 4.7 Hz, 1H), 4.75-4.79 (m, 4H), 3.70-



isoindole-2-
3.85 (m, 4H), 3.49-3.69 (m, 4H)



carboxamide


20
5-fluoro-N-{4-[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.58

(ESI(+))



methylbutyl)carbamoyl]phenyl}-
(s, 1H), 8.22 (t, J = 5.6 Hz, 1H), 7.73-7.77
m/e 370



1,3-dihydro-2H-
(m, 2H), 7.62-7.66 (m, 2H), 7.39 (dd, J =
(M + H)+



isoindole-2-
8.4, 5.2 Hz, 1H), 7.24 (dd, J = 9.1, 2.5 Hz,



carboxamide
1H), 7.15 (td, J = 8.9, 2.5 Hz, 1H), 4.74-4.78




(m, 4H), 3.21-3.32 (m, 2H), 1.61 (dp, J =




13.3, 6.6 Hz, 1H), 1.37-1.45 (m, 2H), 0.90




(d, J = 6.6 Hz, 6H)


21
N-{4-[(2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90°

(APCI+)



methoxybenzyl)carbamoyl]phenyl}-
C.) δ ppm 8.27-8.29 (bs, 2H), 8.12-8.14 (m,
m/e 402



1,3-dihydro-2H-
2H), 7.90-7.93 (m, 2H), 7.52-7.55 (m, 1H),
(M + H)+



isoindole-2-
7.19-7.24 (m, 2H), 7.14-7.19 (m, 2H), 6.91



carboxamide
(td, J = 7.4, 1.0 Hz, 1H), 6.85 (dd, J = 8.2,




1.1 Hz, 1H), 4.89 (d, J = 5.7 Hz, 2H), 4.83




(s, 4H), 3.65 (s, 3H)


22
5-fluoro-N-(4-{[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.59

(ESI(+))



(pyridin-2-
(s, 1H), 8.10 (dd, J = 5.5, 1.8 Hz, 1H), 7.74-
m/e 446



yl)piperazin-1-
7.81 (m, 1H), 7.65-7.69 (m, 2H), 7.37-7.43
(M + H)+



yl]carbonyl}phenyl)-
(m, 3H), 7.24 (dd, J = 9.1, 2.4 Hz, 1H), 7.07-



1,3-dihydro-2H-
7.19 (m, 2H), 6.82 (t, J = 6.2 Hz, 1H), 4.77



isoindole-2-
(d, J = 7.9 Hz, 4H), 3.61-3.69 (bs, 8H)



carboxamide


23
N-{4-[(3-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



fluorobenzyl)carbamoyl]phenyl}-
Oxide) δ ppm 8.99 (t, J = 6.0 Hz, 1H), 7.81-
m/e 390



1,3-dihydro-2H-
7.84 (m, 2H), 7.66-7.69 (m, 2H), 7.36-7.46
(M + H)+



isoindole-2-
(m, 3H), 7.32-7.35 (m, 2H), 7.17 (d, J = 7.7



carboxamide
Hz, 1H), 7.12 (dd, J = 10.3, 2.6 Hz, 1H),




7.07 (td, J = 8.5, 2.8 Hz, 1H), 4.79-4.80 (bs,




4H), 4.48 (d, J = 5.8 Hz, 2H)


24
5-fluoro-N-(4-{[3-(2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.59

(ESI(+))



oxopyrrolidin-1-
(s, 1H), 8.26 (t, J = 5.6 Hz, 1H), 7.74-7.78
m/e 425



yl)propyl]carbamoyl}phenyl)-
(m, 2H), 7.63-7.67 (m, 2H), 7.39 (dd, J =
(M + H)+



1,3-dihydro-2H-
8.4, 5.2 Hz, 1H), 7.24 (dd, J = 9.1, 2.8 Hz,



isoindole-2-
1H), 7.15 (ddd, J = 9.4, 8.5, 2.6 Hz, 1H),



carboxamide
4.74-4.79 (m, 4H), 3.33-3.38 (m, 2H), 3.16-




3.27 (m, 4H), 2.22 (t, J = 8.0 Hz, 2H), 1.93




(p, J = 7.5 Hz, 2H), 1.69 (p, J = 7.0 Hz, 2H)


25
5-cyano-N-{4-[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.65

(ESI(+))



methylbutyl)carbamoyl]phenyl}-
(s, 1H), 8.22 (t, J = 5.6 Hz, 1H), 7.89 (s, 1H),
m/e 377



1,3-dihydro-2H-
7.79 (dd, J = 7.9, 1.6 Hz, 1H), 7.73-7.78 (m,
(M + H)+



isoindole-2-
2H), 7.62-7.67 (m, 2H), 7.59 (d, J = 7.9 Hz,



carboxamide
1H), 4.77-4.91 (m, 4H), 3.22-3.32 (m, 2H),




1.53-1.70 (m, 1H), 1.37-1.45 (m, 2H), 0.90




(d, J = 6.6 Hz, 6H)


26
N-{4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.54

(ESI(+))



[(cyclopentylmethyl)
(s, 1H), 8.26 (t, J = 5.7 Hz, 1H), 7.73-7.78
m/e 378



carbamoyl]phenyl}-
(m, 2H), 7.63-7.67 (m, 2H), 7.24 (d, J = 7.7
(M + H)+



5-methyl-1,3-
Hz, 1H), 7.17 (s, 1H), 7.11-7.14 (m, 1H),



dihydro-2H-
4.73-4.74 (bs, 4H), 3.14-3.19 (m, 2H), 2.33



isoindole-2-
(s, 3H), 2.07-2.21 (m, 1H), 1.42-1.75 (m,



carboxamide
6H), 1.16-1.34 (m, 2H)


27
N-(4-{[4-(4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



cyanophenyl)piperazin-1-
Temp = 90° C.) δ ppm 8.34-8.35 (bs, 1H), 7.93-
m/e 452



yl]carbonyl}phenyl)-
7.96 (m, 2H), 7.56-7.59 (m, 2H), 7.49-7.52
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.20-7.24 (m, 2H), 7.16-7.19 (m,



isoindole-2-
2H), 6.84-6.86 (m, 2H), 4.87 (s, 4H), 3.71-



carboxamide
3.74 (m, 4H), 3.24-3.29 (m, 4H)


28
N-{4-[(4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



fluorobenzyl)carbamoyl]phenyl}-
Oxide) δ ppm 8.95 (t, J = 6.0 Hz, 1H), 7.80-
m/e 390



1,3-dihydro-2H-
7.82 (m, 2H), 7.65-7.68 (m, 2H), 7.32-7.40
(M + H)+



isoindole-2-
(m, 6H), 7.13-7.17 (m, 2H), 4.79-4.80 (bs,



carboxamide
4H), 4.45 (d, J = 5.7 Hz, 2H)


29
N-{4-[(3,5-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



dimethoxybenzyl)carbamoyl]phenyl}-
Oxide) δ ppm 7.80-7.83 (m, 2H), 7.66-7.69
m/e 492



1,3-dihydro-2H-
(m, 2H), 7.36-7.41 (m, 2H), 7.31-7.36 (m,
(M + H)+



isoindole-2-
2H), 6.49 (d, J = 2.3 Hz, 2H), 6.38 (t, J = 2.3



carboxamide
Hz, 1H), 4.79-4.80 (bs, 4H), 4.40-4.41 (m,




2H), 3.72 (s, 6H)


30
5-fluoro-N-{4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.60

(ESI(+))



[(tetrahydrofuran-3-
(s, 1H), 8.39 (t, J = 5.7 Hz, 1H), 7.75-7.79
m/e 383



ylmethyl)carbamoyl]
(m, 2H), 7.63-7.68 (m, 2H), 7.40 (dd, J =
(M + H)+



phenyl}-1,3-dihydro-
8.4, 5.2 Hz, 1H), 7.24 (dd, J = 9.1, 2.5 Hz,



2H-isoindole-2-
1H), 7.15 (td, J = 8.9, 2.5 Hz, 1H), 4.75-4.79



carboxamide
(m, 4H), 3.57-3.78 (m, 3H), 3.48 (dd, J =




8.5, 5.2 Hz, 1H), 3.16-3.30 (m, 2H), 2.40-




2.51 (m, 1H), 1.87-1.99 (m, 1H), 1.54-1.66




(m, 1H)


31
N-{4-[(2,2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



dimethylpropyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.28-8.30 (bs, 1H), 8.08-
m/e 352



1,3-dihydro-2H-
8.11 (m, 2H), 7.90-7.93 (m, 2H), 7.66-7.71
(M + H)+



isoindole-2-
(bs, 1H), 7.19-7.23 (m, 2H), 7.15-7.18 (m,



carboxamide
2H), 4.84 (s, 4H), 3.41 (d, J = 6.3 Hz, 2H),




0.98 (s, 9H)


32
5-fluoro-N-(4-{[2-(2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.59

(ESI(+))



oxopyrrolidin-1-
(s, 1H), 8.31-8.34 (m, 1H), 7.71-7.75 (m,
m/e 411



yl)ethyl]carbamoyl}phenyl)-
2H), 7.62-7.66 (m, 2H), 7.39 (dd, J = 8.4, 5.1
(M + H)+



1,3-dihydro-
Hz, 1H), 7.24 (dd, J = 9.0, 2.4 Hz, 1H), 7.15



2H-isoindole-2-
(td, J = 8.9, 2.5 Hz, 1H), 4.74-4.79 (m, 4H),



carboxamide
3.34-3.46 (m, 6H), 2.17 (t, J = 8.0 Hz, 2H),




1.91 (p, J = 7.4 Hz, 2H)


33
N-(4-{[4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



(trifluoromethoxy)ben-
Oxide) δ ppm 7.81-7.83 (m, 2H), 7.66-7.68
m/e 456



zyl]carbamoyl}phenyl)-
(m, 2H), 7.43-7.47 (m, 2H), 7.37-7.40 (m,
(M + H)+



1,3-dihydro-2H-
2H), 7.31-7.35 (m, 4H), 4.79 (s, 4H), 4.49 (s,



isoindole-2-
2H)



carboxamide


34
N-(4-{[3-fluoro-5-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



(trifluoromethyl)ben-
Oxide) δ ppm 9.07 (t, J = 6.0 Hz, 1H), 7.81-
m/e 458



zyl]carbamoyl}phenyl)-
7.83 (m, 2H), 7.67-7.70 (m, 2H), 7.53-7.56
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.45-7.48 (m, 1H), 7.36-7.41 (m,



isoindole-2-
2H), 7.31-7.36 (m, 2H), 4.80 (s, 4H), 4.56 (d,



carboxamide
J = 5.4 Hz, 2H)


35
5-fluoro-N-(4-{[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.59

(ESI(+))



(pyrazin-2-
(s, 1H), 8.34 (d, J = 1.5 Hz, 1H), 8.10 (dd, J =
m/e 447



yl)piperazin-1-
2.6, 1.4 Hz, 1H), 7.87 (d, J = 2.6 Hz, 1H),
(M + H)+



yl]carbonyl}phenyl)-
7.64-7.68 (m, 2H), 7.36-7.43 (m, 3H), 7.24



1,3-dihydro-2H-
(dd, J = 9.1, 2.4 Hz, 1H), 7.11-7.19 (m, 1H),



isoindole-2-
4.75-4.79 (m, 4H), 3.58-3.69 (bs, 8H)



carboxamide


36
N-{4-[(3-

1H NMR (400 MHz, DMSO-d6,

(ESI(+))



methylbutyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.31 (s, 1H), 7.86-7.89
m/e 352



1,3-dihydro-2H-
(m, 1H), 7.72-7.75 (m, 2H), 7.60-7.64 (m,
(M + H)+



isoindole-2-
2H), 7.28-7.36 (m, 4H), 4.79 (s, 4H), 3.28 (q,



carboxamide
J = 6.7 Hz, 2H), 1.58-1.71 (m, 1H), 1.45 (q,




J = 7.1 Hz, 2H), 0.92 (d, J = 6.6 Hz, 6H)


37
5-methoxy-N-{4-[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.55

(ESI(+))



phenylpropyl)carbamoyl]phenyl}-
(s, 1H), 8.29 (t, J = 5.6 Hz, 1H), 7.74-7.79
m/e 429



1,3-dihydro-2H-
(m, 2H), 7.63-7.67 (m, 2H), 7.15-7.32 (m,
(M + H)+



isoindole-2-
6H), 6.94 (d, J = 2.3 Hz, 1H), 6.88 (dd, J =



carboxamide
8.3, 2.4 Hz, 1H), 4.65-4.79 (m, 4H), 3.77 (s,




3H), 3.22-3.31 (m, 2H), 2.60-2.68 (m, 2H),




1.77-1.88 (m, 2H)


38
N-{4-[(4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



chlorobenzyl)carbamoyl]phenyl}-
Oxide) δ ppm 8.97 (t, J = 6.0 Hz, 1H), 8.67
m/e 406



1,3-dihydro-2H-
(s, 1H), 7.80-7.83 (m, 2H), 7.66-7.68 (m,
(M + H)+



isoindole-2-
2H), 7.32-7.40 (m, 8H), 4.79-4.80 (bs, 4H),



carboxamide
4.45 (d, J = 5.4 Hz, 2H)


39
N-{4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90

(ESI(+))



[(cyclopentylmethyl)
C.) δ ppm 8.28-8.29 (bs, 1H), 8.09-8.12 (m,
m/e 364



carbamoyl]phenyl}-
2H), 7.90-7.94 (m, 2H), 7.84-7.91 (m, 1H),
(M + H)+



1,3-dihydro-2H-
7.19-7.24 (m, 2H), 7.14-7.18 (m, 2H), 4.84



isoindole-2-
(s, 4H), 3.51 (dd, J = 7.2, 5.8 Hz, 2H), 2.20-



carboxamide
2.32 (m, 1H), 1.67-1.76 (m, 2H), 1.51-1.62




(m, 2H), 1.40-1.51 (m, 2H), 1.27-1.38 (m,




2H)


40
N-{4-[(3,4,5-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



trimethoxybenzyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.59-8.64 (m, 1H), 8.29-
m/e 462



1,3-dihydro-2H-
8.32 (m, 1H), 8.17-8.19 (m, 2H), 7.92-7.94
(M + H)+



isoindole-2-
(m, 2H), 7.19-7.24 (m, 2H), 7.15-7.18 (m,



carboxamide
2H), 6.82 (s, 2H), 4.84 (s, 4H), 4.77 (d, J =




5.8 Hz, 2H), 3.85 (s, 3H), 3.69 (s, 6H)


41
N-(4-{[4-(pyrimidin-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.56

(ESI(+))



2-yl)piperazin-1-
(s, 1H), 8.37-8.40 (m, 2H), 7.66-7.69 (m,
m/e 429



yl]carbonyl}phenyl)-
2H), 7.30-7.40 (m, 6H), 6.67 (t, J = 4.7 Hz,
(M + H)+



1,3-dihydro-2H-
1H), 4.79 (s, 4H), 3.77-3.81 (m, 4H), 3.58 (s,



isoindole-2-
4H)



carboxamide


42
5-nitro-N-[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.68

(ESI(+))



(propylcarbamoyl)phenyl]-
(s, 1H), 8.23-8.30 (m, 2H), 8.21 (dd, J = 8.3,
m/e 369



1,3-dihydro-
2.4 Hz, 1H), 7.75-7.79 (m, 2H), 7.63-7.67
(M + H)+



2H-isoindole-2-
(m, 3H), 4.88-4.91 (m, 4H), 3.16-3.23 (m,



carboxamide
2H), 1.46-1.59 (m, 2H), 0.89 (t, J = 7.4 Hz,




3H)


43
5-methyl-N-{4-[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.54

(ESI(+))



methylbutyl)carbamoyl]phenyl}-
(s, 1H), 8.21 (t, J = 5.6 Hz, 1H), 7.73-7.77
m/e 366



1,3-dihydro-2H-
(m, 2H), 7.63-7.67 (m, 2H), 7.24 (d, J = 7.7
(M + H)+



isoindole-2-
Hz, 1H), 7.17 (s, 1H), 7.11-7.14 (m, 1H),



carboxamide
4.72-4.74 (bs, 4H), 3.22-3.31 (m, 2H), 2.33




(s, 3H), 1.61 (dp, J = 13.3, 6.6 Hz, 1H), 1.37-




1.45 (m, 2H), 0.90 (d, J = 6.6 Hz, 6H)


44
N-(4-{[4-(4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.56

(ESI(+))



fluorophenyl)piperazin-1-
(s, 1H), 7.65-7.69 (m, 2H), 7.30-7.39 (m,
m/e 445



yl]carbonyl}phenyl)-
6H), 6.96-7.14 (m, 4H), 4.78-4.80 (bs, 4H),
(M + H)+



1,3-dihydro-2H-
3.52-3.77 (m, 4H), 3.03-3.20 (m, 4H)



isoindole-2-



carboxamide


45
N-{4-[(4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methoxybenzyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.46-8.51 (bs, 1H), 8.27-
m/e 402



1,3-dihydro-2H-
8.29 (bs, 1H), 8.14-8.16 (m, 2H), 7.91-7.93
(M + H)+



isoindole-2-
(m, 2H), 7.36-7.39 (m, 2H), 7.19-7.23 (m,



carboxamide
2H), 7.16-7.18 (m, 2H), 6.88-6.90 (m, 2H),




4.84 (s, 4H), 4.74 (d, J = 5.8 Hz, 2H), 3.65




(s, 3H)


46
N-{4-[(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



thienylmethyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.73-8.79 (m, 1H), 8.30
m/e 378



1,3-dihydro-2H-
(d, J = 2.1 Hz, 1H), 8.11-8.14 (m, 2H), 7.90-
(M + H)+



isoindole-2-
7.93 (m, 2H), 7.19-7.24 (m, 2H), 7.20-7.21



carboxamide
(m, 1H), 7.15-7.18 (m, 2H), 7.05-7.07 (m,




1H), 6.90 (dd, J = 5.0, 3.5 Hz, 1H), 4.94 (d, J =




5.8 Hz, 2H), 4.84 (s, 4H)


47
N-(4-{[4-(pyrimidin-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.64

(ESI(+))



2-yl)piperazin-1-
(s, 1H), 8.37-8.40 (m, 2H), 7.77 (s, 1H),
m/e 497



yl]carbonyl}phenyl)-
7.66-7.71 (m, 1H), 7.64-7.69 (m, 2H), 7.61
(M + H)+



5-(trifluoromethyl)-
(d, J = 8.1 Hz, 1H), 7.37-7.40 (m, 2H), 6.67



1,3-dihydro-2H-
(t, J = 4.7 Hz, 1H), 4.85-4.88 (bs, 4H), 3.73-



isoindole-2-
3.87 (m, 4H), 3.50-3.69 (m, 4H)



carboxamide


48
N-{4-[(1-ethyl-1H-

1H NMR (300 MHz, DMSO-d6) δ ppm 10.22

(ESI(+))



pyrazol-4-
(s, 1H), 8.65 (s, 1H), 8.03 (s, 1H), 7.85-7.89
m/e 394



yl)carbamoyl]phenyl}-
(m, 2H), 7.68-7.75 (m, 2H), 7.57 (d, J = 0.7
(M + H)+



5-fluoro-1,3-
Hz, 1H), 7.40 (dd, J = 8.4, 5.2 Hz, 1H), 7.25



dihydro-2H-
(dd, J = 9.1, 2.5 Hz, 1H), 7.15 (td, J = 8.9,



isoindole-2-
2.5 Hz, 1H), 4.71-4.80 (m, 4H), 4.11 (q, J =



carboxamide
7.2 Hz, 2H), 1.36 (t, J = 7.2 Hz, 3H)


49
N-{4-[(1-benzyl-1H-

1H NMR (300 MHz, DMSO-d6) δ ppm 10.26

(ESI(+))



pyrazol-4-
(s, 1H), 8.65 (s, 1H), 8.11 (d, J = 0.7 Hz,
m/e 456



yl)carbamoyl]phenyl}-
1H), 7.84-7.88 (m, 2H), 7.68-7.73 (m, 2H),
(M + H)+



5-fluoro-1,3-
7.61 (d, J = 0.7 Hz, 1H), 7.38-7.43 (m, 1H),



dihydro-2H-
7.28-7.38 (m, 3H), 7.22-7.27 (m, 3H), 7.11-



isoindole-2-
7.19 (m, 1H), 5.31 (s, 2H), 4.70-4.85 (m, 4H)



carboxamide


50
N-(4-{[4-(pyridin-2-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



yl)piperazin-1-
Oxide, Temp = 90° C.) δ ppm 8.08 (ddd, J =
m/e 428



yl]carbonyl}phenyl)-
5.4, 1.9, 0.8 Hz, 1H), 7.77 (ddd, J = 8.9, 7.0,
(M + H)+



1,3-dihydro-2H-
1.9 Hz, 1H), 7.65-7.68 (m, 2H), 7.38-7.42



isoindole-2-
(m, 2H), 7.32-7.39 (m, 4H), 7.03-7.06 (m,



carboxamide
1H), 6.83 (ddd, J = 7.0, 5.4, 0.8 Hz, 1H),




4.82 (s, 4H), 3.64-3.72 (m, 8H)


51
N-(4-{[4-(pyrazin-2-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



yl)piperazin-1-
Oxide) δ ppm 8.33-8.34 (bs, 1H), 8.13-8.14
m/e 429



yl]carbonyl}phenyl)-
(bs, 1H), 7.88-7.89 (bs, 1H), 7.65-7.67 (m,
(M + H)+



1,3-dihydro-2H-
2H), 7.38-7.42 (m, 2H), 7.37-7.40 (m, 2H),



isoindole-2-
7.31-7.36 (m, 2H), 4.79-4.80 (bs, 4H), 3.52-



carboxamide
3.75 (m, 8H)


52
N-(4-{[4-(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methoxyphenyl)piperazin-1-
Temp = 90° C.) δ ppm 8.30-8.32 (bs, 1H), 7.92-
m/e 457



yl]carbonyl}phenyl)-
7.96 (m, 2H), 7.56-7.59 (m, 2H), 7.20-7.23
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.16-7.19 (m, 2H), 6.97-7.03 (m,



isoindole-2-
1H), 6.90-6.96 (m, 3H), 4.86 (s, 4H), 3.78-



carboxamide
3.81 (m, 4H), 3.75 (s, 3H), 3.04-3.07 (m, 4H)


53
N-{4-[(3,3-

1H NMR (500 MHz, DMSO-d6) δ ppm 8.56

(ESI(+))



dimethylbutyl)carbamoyl]phenyl}-
(s, 1H), 8.20 (t, J = 5.7 Hz, 1H), 7.74-7.76
m/e 366



1,3-dihydro-2H-
(m, 2H), 7.64-7.66 (m, 2H), 7.34-7.40 (m,
(M + H)+



isoindole-2-
2H), 7.29-7.34 (m, 2H), 4.78-4.79 (bs, 4H),



carboxamide
3.24-3.28 (m, 2H), 1.43-1.46 (m, 2H), 0.93




(s, 9H)


54
N-(4-{[(2R)-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



tetrahydrofuran-2-
Temp = 90° C.) δ ppm 8.33 (d, J = 8.7 Hz, 1H),
m/e 366



ylmethyl]carbamoyl}
8.08-8.10 (m, 2H), 7.90-7.96 (bs, 1H), 7.89-
(M + H)+



phenyl)-1,3-dihydro-
7.93 (m, 2H), 7.19-7.24 (m, 2H), 7.14-7.18



2H-isoindole-2-
(m, 2H), 4.84 (s, 4H), 4.10-4.19 (m, 1H),



carboxamide
3.74-3.83 (m, 2H), 3.56-3.67 (m, 2H), 1.79-




1.91 (m, 1H), 1.56-1.80 (m, 3H)


55
N-(4-{[4-(3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methoxyphenyl)piperazin-1-
Temp = 90° C.) δ ppm 8.32-8.33 (bs, 1H), 7.93-
m/e 457



yl]carbonyl}phenyl)-
7.96 (m, 2H), 7.55-7.58 (m, 2H), 7.15-7.27
(M + H)+



1,3-dihydro-2H-
(m, 5H), 6.63 (t, J = 2.3 Hz, 1H), 6.60 (ddd,



isoindole-2-
J = 8.2, 2.4, 0.8 Hz, 1H), 6.54 (ddd, J = 8.1,



carboxamide
2.3, 0.8 Hz, 1H), 4.86 (s, 4H), 3.72-3.76 (m,




4H), 3.71 (s, 3H), 3.14-3.17 (m, 4H)


56
N-(4-{[4-(4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



acetylphenyl)piperazin-1-
Temp = 90° C.) δ ppm 8.34 (d, J = 2.2 Hz, 1H),
m/e 469



yl]carbonyl}phenyl)-
7.98-8.02 (m, 2H), 7.93-7.96 (m, 2H), 7.56-
(M + H)+



1,3-dihydro-2H-
7.60 (m, 2H), 7.20-7.26 (m, 2H), 7.15-7.20



isoindole-2-
(m, 2H), 6.89-6.93 (m, 2H), 4.87 (s, 4H),



carboxamide
3.73-3.76 (m, 4H), 3.26-3.32 (m, 4H), 2.47




(s, 3H)


57
N-(4-{[2-(2,3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



dimethoxyphenyl)eth-
Temp = 90° C.) δ ppm 8.25-8.26 (bs, 1H), 8.08-
m/e 446



yl]carbamoyl}phenyl)-
8.13 (bs, 1H), 8.07-8.11 (m, 2H), 7.89-7.92
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.19-7.23 (m, 2H), 7.17-7.19 (m,



isoindole-2-
2H), 6.93-6.97 (m, 1H), 6.91 (dd, J = 7.6, 2.0



carboxamide
Hz, 1H), 6.82 (dd, J = 7.7, 1.9 Hz, 1H), 4.84




(s, 4H), 3.85-3.89 (m, 2H), 3.83 (s, 3H), 3.70




(s, 3H), 3.11 (t, J = 7.2 Hz, 2H)


58
N-{4-[(3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



thienylmethyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.54-8.60 (m, 1H), 8.27-
m/e 378



1,3-dihydro-2H-
8.31 (bs, 1H), 8.12-8.14 (m, 2H), 7.90-7.93
(M + H)+



isoindole-2-
(m, 2H), 7.26-7.30 (m, 2H), 7.19-7.23 (m,



carboxamide
2H), 7.16-7.19 (m, 3H), 4.84 (s, 4H), 4.77 (d,




J = 5.8 Hz, 2H)


59
5-methoxy-N-{4-[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.55

(ESI(+))



methylbutyl)carbamoyl]phenyl}-
(s, 1H), 8.22 (t, J = 5.6 Hz, 1H), 7.73-7.78
m/e 382



1,3-dihydro-2H-
(m, 2H), 7.62-7.67 (m, 2H), 7.26 (d, J = 8.3
(M + H)+



isoindole-2-
Hz, 1H), 6.94 (d, J = 2.0 Hz, 1H), 6.89 (dd, J =



carboxamide
8.3, 2.4 Hz, 1H), 4.70-4.75 (m, 4H), 3.77




(s, 3H), 3.22-3.30 (m, 2H), 1.53-1.69 (m,




1H), 1.37-1.45 (m, 2H), 0.91 (d, J = 6.6 Hz,




6H)


60
N-{4-[(pyridin-2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.93

(ESI(+))



ylmethyl)carbamoyl]
(t, J = 6.0 Hz, 1H), 8.61 (s, 1H), 8.51 (ddd, J =
m/e 372



phenyl}-1,3-dihydro-
4.8, 1.8, 0.9 Hz, 1H), 7.83-7.87 (m, 2H),
(M + H)+



2H-isoindole-2-
7.75 (td, J = 7.7, 1.8 Hz, 1H), 7.67-7.72 (m,



carboxamide
2H), 7.29-7.40 (m, 5H), 7.26 (ddd, J = 7.5,




4.8, 1.1 Hz, 1H), 4.80 (s, 4H), 4.56 (d, J =




5.8 Hz, 2H)


61
5-fluoro-N-(4-{[2-(2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.60

(ESI(+))



thienyl)ethyl]carbamoyl}phenyl)-
(s, 1H), 8.45 (t, J = 5.6 Hz, 1H), 7.74-7.78
m/e 410



1,3-dihydro-2H-
(m, 2H), 7.63-7.67 (m, 2H), 7.40 (dd, J =
(M + H)+



isoindole-2-
8.4, 5.2 Hz, 1H), 7.33 (dd, J = 5.0, 1.3 Hz,



carboxamide
1H), 7.24 (dd, J = 9.1, 2.3 Hz, 1H), 7.10-




7.19 (m, 1H), 6.96 (dd, J = 5.0, 3.4 Hz, 1H),




6.90-6.93 (m, 1H), 4.71-4.84 (m, 4H), 3.44-




3.53 (m, 2H), 3.06 (t, J = 7.2 Hz, 2H)


62
N-(4-{[(2S)-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



tetrahydrofuran-2-
Temp = 90° C.) δ ppm 8.27-8.31 (bs, 1H), 8.06-
m/e 366



ylmethyl]carbamoyl}
8.12 (m, 2H), 7.89-7.93 (m, 2H), 7.89-7.92
(M + H)+



phenyl)-1,3-dihydro-
(m, 1H), 7.18-7.25 (m, 2H), 7.14-7.19 (m,



2H-isoindole-2-
2H), 4.84 (s, 4H), 4.14 (qd, J = 6.7, 4.5 Hz,



carboxamide
1H), 3.73-3.83 (m, 2H), 3.55-3.68 (m, 2H),




1.80-1.91 (m, 1H), 1.56-1.79 (m, 3H)


63
N-(4-{[1-(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 10.21

(ESI(+))



methylbutyl)-1H-
(s, 1H), 8.63 (s, 1H), 8.03 (d, J = 0.7 Hz,
m/e 418



pyrazol-4-
1H), 7.85-7.89 (m, 2H), 7.70-7.74 (m, 2H),
(M + H)+



yl]carbamoyl}phenyl)-
7.56 (d, J = 0.7 Hz, 1H), 7.30-7.40 (m, 4H),



1,3-dihydro-2H-
4.80 (s, 4H), 4.10 (t, J = 7.1 Hz, 2H), 1.65



isoindole-2-
(q, J = 7.0 Hz, 2H), 1.40-1.56 (m, 1H), 0.90



carboxamide
(d, J = 6.6 Hz, 6H)


64
4-chloro-N-(4-{[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.66

(ESI(+))



(pyridin-2-
(s, 1H), 8.13 (dd, J = 4.9, 1.9 Hz, 1H), 7.64-
m/e 462



yl)piperazin-1-
7.71 (m, 2H), 7.56 (ddd, J = 8.7, 7.0, 1.9 Hz,
(M + H)+



yl]carbonyl}phenyl)-
1H), 7.34-7.41 (m, 5H), 6.85 (d, J = 8.6 Hz,



1,3-dihydro-2H-
1H), 6.67 (dd, J = 6.9, 4.8 Hz, 1H), 4.76-



isoindole-2-
4.92 (m, 4H), 3.45-3.74 (m, 8H)



carboxamide


65
N-{4-[(4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.56

(ESI(+))



phenylpiperazin-1-
(s, 1H), 7.65-7.69 (m, 2H), 7.29-7.41 (m,
m/e 427



yl)carbonyl]phenyl}-
6H), 7.18-7.27 (m, 2H), 6.94-6.98 (m, 2H),
(M + H)+



1,3-dihydro-2H-
6.81 (t, J = 7.3 Hz, 1H), 4.79-4.80 (bs, 4H),



isoindole-2-
3.58-3.74 (m, 4H), 3.14-3.22 (m, 4H)



carboxamide


66
N-{4-[(6-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.58

(ESI(+))



aminohexyl)carbamoyl]phenyl}-
(s, 1H), 8.26 (t, J = 5.6 Hz, 1H), 7.73-7.80
m/e 381



1,3-dihydro-2H-
(m, 2H), 7.64-7.68 (m, 2H), 7.61-7.69 (m,
(M + H)+



isoindole-2-
2H), 7.30-7.39 (m, 4H), 4.79 (s, 4H), 3.21-



carboxamide
3.26 (m, 2H), 2.72-2.84 (m, 2H), 1.48-1.57




(m, 4H), 1.31-1.35 (m, 4H)


67
4-chloro-N-{4-[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.66

(ESI(+))



methylbutyl)carbamoyl]phenyl}-
(s, 1H), 8.22 (t, J = 5.6 Hz, 1H), 7.74-7.78
m/e 386



1,3-dihydro-2H-
(m, 2H), 7.63-7.68 (m, 2H), 7.35-7.42 (m,
(M + H)+



isoindole-2-
3H), 4.76-4.92 (m, 4H), 3.22-3.30 (m, 2H),



carboxamide
1.54-1.68 (m, 1H), 1.37-1.45 (m, 2H), 0.91




(d, J = 6.6 Hz, 6H)


68
N-(4-{[2-(2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.58

(ESI(+))



thienyl)ethyl]carbamoyl}phenyl)-
(s, 1H), 8.45 (t, J = 5.6 Hz, 1H), 7.75-7.78
m/e 390



1,3-dihydro-2H-
(m, 2H), 7.65-7.68 (m, 2H), 7.25-7.44 (m,
(M + H)+



isoindole-2-
5H), 6.96 (dd, J = 5.1, 3.4 Hz, 1H), 6.90-



carboxamide
6.93 (m, 1H), 4.78-4.79 (bs, 4H), 3.45-3.52




(m, 2H), 3.06 (t, J = 7.2 Hz, 2H)


69
5-methoxy-N-(4-{[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.56

(ESI(+))



(pyridin-2-
(s, 1H), 8.10 (dd, J = 5.5, 1.8 Hz, 1H), 7.75-
m/e 458



yl)piperazin-1-
7.82 (m, 1H), 7.65-7.69 (m, 2H), 7.37-7.41
(M + H)+



yl]carbonyl}phenyl)-
(m, 2H), 7.27 (d, J = 8.3 Hz, 1H), 7.08-7.12



1,3-dihydro-2H-
(m, 1H), 6.95 (d, J = 2.3 Hz, 1H), 6.89 (dd, J =



isoindole-2-
8.3, 2.4 Hz, 1H), 6.82 (t, J = 6.2 Hz, 1H),



carboxamide
4.71-4.75 (m, 4H), 3.95-4.67 (m, 8H), 3.77




(s, 3H)


70
N-{4-[(1,3-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



benzodioxol-5-
Oxide) δ ppm 7.79-7.81 (m, 2H), 7.65-7.67
m/e 416



ylmethyl)carbamoyl]
(m, 2H), 7.32-7.39 (m, 4H), 6.89 (d, J = 1.6
(M + H)+



phenyl}-1,3-dihydro-
Hz, 1H), 6.86 (d, J = 7.9 Hz, 1H), 6.81 (dd, J =



2H-isoindole-2-
8.0, 1.4 Hz, 1H), 5.97 (s, 2H), 4.79 (s, 4H),



carboxamide
4.37(d, J = 5.2 Hz, 2H)


71
N-{4-[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.83

(ESI(+))



methoxybenzyl)carbamoyl]phenyl}-
(t, J = 6.0 Hz, 1 H), 8.59 (s, 1 H), 7.77-7.87
m/e 402



1,3-dihydro-2H-
(m, 2 H), 7.68 (d, J = 8.7 Hz, 2 H), 7.28-7.42
(M + H)+



isoindole-2-
(m, 4 H), 7.24 (t, J = 8.1 Hz, 1 H), 6.75-6.94



carboxamide
(m, 3 H), 4.79 (s, 4 H), 4.43 (d, J = 6.0 Hz, 2




H), 3.73 (s, 3 H)


72
N-(4-{[4-(pyridin-3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.56

(ESI(+))



yl)piperazin-1-
(s, 1H), 8.33 (d, J = 2.9 Hz, 1H), 8.03 (dd, J =
m/e 428



yl]carbonyl}phenyl)-
4.5, 1.3 Hz, 1H), 7.66-7.69 (m, 2H), 7.30-
(M + H)+



1,3-dihydro-2H-
7.41 (m, 7H), 7.24 (dd, J = 8.4, 4.5 Hz, 1H),



isoindole-2-
4.79 (s, 4H), 3.64-3.67 (m, 4H), 3.21-3.29



carboxamide
(m, 4H)


73
N-[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.86

(ESI(+))



(benzylcarbamoyl)phenyl]-
(t, J = 6.0 Hz, 1H), 8.59 (s, 1H), 7.80-7.84
m/e 372



1,3-dihydro-
(m, 2H), 7.66-7.70 (m, 2H), 7.31-7.36 (m,
(M + H)+



2H-isoindole-2-
9H), 4.79 (s, 4H), 4.47 (d, J = 5.9 Hz, 2H)



carboxamide


74
N-(4-{[4-(pyridazin-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.56-

(ESI(−))



3-yl)piperazin-1-
8.60 (m, 1H), 8.57-8.58 (m, 1H), 7.64-7.72
m/e 427



yl]carbonyl}phenyl)-
(m, 2H), 7.24-7.45 (m, 8H), 4.80 (s, 4H),
(M − H)



1,3-dihydro-2H-
3.60-3.70 (m, 8H)



isoindole-2-



carboxamide


75
N-{4-[(pyrimidin-4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



ylmethyl)carbamoyl]
Temp = 90° C.) δ ppm 9.21 (d, J = 1.4 Hz, 1H),
m/e 372



phenyl}-1,3-dihydro-
8.86-8.90 (m, 1H), 8.61 (d, J = 5.1 Hz, 1H),
(M − H)



2H-isoindole-2-
8.34-8.36 (bs, 1H), 8.17-8.20 (m, 2H), 7.95-



carboxamide
7.97 (m, 2H), 7.41-7.43 (m, 1H), 7.20-7.23




(m, 2H), 7.15-7.19 (m, 2H), 4.87 (d, J = 5.8




Hz, 2H), 4.85 (s, 4H)


76
N-(4-{[4-(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.56

(ESI(−))



fluorophenyl)piperazin-1-
(s, 1H), 7.65-7.69 (m, 2H), 7.15-7.46 (m,
m/e 443



yl]carbonyl}phenyl)-
7H), 6.70-6.84 (m, 2H), 6.54-6.61 (m, 1H),
(M − H)



1,3-dihydro-2H-
4.79-4.80 (bs, 4H), 3.54-3.75 (m, 4H), 3.12-



isoindole-2-
3.28 (m, 4H)



carboxamide


77
N-{4-[(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methylbutyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.28-8.30 (bs, 1H), 8.09-
m/e 352



1,3-dihydro-2H-
8.12 (m, 2H), 7.90-7.93 (m, 2H), 7.84 (d, J =
(M + H)+



isoindole-2-
6.2 Hz, 1H), 7.16-7.26 (m, 4H), 4.84 (s, 4H),



carboxamide
3.51 (dt, J = 13.2, 6.1 Hz, 1H), 3.39 (ddd, J =




13.2, 7.1, 6.0 Hz, 1H), 1.71-1.83 (m, 1H),




1.42-1.53 (m, 1H), 1.08-1.24 (m, 1H), 0.93




(d, J = 6.7 Hz, 3H), 0.86 (t, J = 7.4 Hz, 3H)


78
N-(4-{[4-(pyridin-2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.65

(ESI(+))



yl)piperazin-1-
(s, 1H), 8.10 (dd, J = 5.5, 1.8 Hz, 1H), 7.46-
m/e 496



yl]carbonyl}phenyl)-
7.82 (m, 6H), 7.38-7.42 (m, 2H), 7.06-7.10
(M + H)+



5-(trifluoromethyl)-
(m, 1H), 6.81 (t, J = 6.2 Hz, 1H), 4.85-4.88



1,3-dihydro-2H-
(bs, 4H), 3.56-3.73 (bs, 8H)



isoindole-2-



carboxamide


79
N-{4-[(3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



butoxypropyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.27-8.29 (bs, 1H), 8.07-
m/e 394



1,3-dihydro-2H-
8.10 (m, 2H), 7.93-7.98 (m, 1H), 7.90-7.94
(M − H)



isoindole-2-
(m, 2H), 7.19-7.23 (m, 2H), 7.16-7.18 (m,



carboxamide
2H), 4.84 (s, 4H), 3.69 (td, J = 6.7, 5.6 Hz,




2H), 3.51 (t, J = 6.1 Hz, 2H), 3.36 (t, J = 6.5




Hz, 2H), 1.95 (p, J = 6.4 Hz, 2H), 1.44-1.60




(m, 2H), 1.25-1.42 (m, 2H), 0.85 (t, J = 7.3




Hz, 3H)


80
N-(4-{[(1S)-2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



hydroxy-1-
Temp = 90° C.) δ ppm 8.28-8.30 (bs, 1H), 8.14-
m/e 402



phenylethyl]carbamoyl}phenyl)-
8.18 (m, 1H), 8.07-8.11 (m, 2H), 7.87-7.89
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.60-7.65 (m, 2H), 7.26-7.32 (m,



isoindole-2-
2H), 7.20-7.23 (m, 3H), 7.14-7.18 (m, 3H),



carboxamide
5.67-5.73 (m, 1H), 4.83 (s, 4H), 4.21-4.25




(m, 2H)


81
N-(4-{[2-(3,4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



dihydroxyphenyl)eth-
Oxide) δ ppm 7.74-7.76 (m, 2H), 7.64-7.67
m/e 418



yl]carbamoyl}phenyl)-
(m, 2H), 7.32-7.40 (m, 4H), 6.66 (d, J = 10.7
(M + H)+



1,3-dihydro-2H-
Hz, 1H), 6.66 (d, J = 2.4 Hz, 1H), 6.51 (dd, J =



isoindole-2-
8.0, 2.1 Hz, 1H), 4.79-4.80 (bs, 4H), 3.39



carboxamide
(t, J = 7.5 Hz, 2H), 2.66 (t, J = 7.5 Hz, 2H)


82
N-{4-[(3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



propoxypropyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.28-8.30 (bs, 1H), 8.07-
m/e 380



1,3-dihydro-2H-
8.10 (m, 2H), 7.93-8.00 (m, 1H), 7.90-7.94
(M − H)



isoindole-2-
(m, 2H), 7.19-7.24 (m, 2H), 7.15-7.18 (m,



carboxamide
2H), 4.84 (s, 4H), 3.66-3.71 (m, 2H), 3.51 (t,




J = 6.1 Hz, 2H), 3.30 (t, J = 6.5 Hz, 2H),




1.94 (p, J = 6.4 Hz, 2H), 1.48-1.57 (m, 2H),




0.85 (t, J = 7.4 Hz, 3H)


83
N-{4-[(3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



furylmethyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.37-8.53 (m, 1H), 8.28-
m/e 362



1,3-dihydro-2H-
8.31 (bs, 1H), 8.10-8.13 (m, 2H), 7.90-7.93
(M + H)+



isoindole-2-
(m, 2H), 7.52-7.54 (m, 1H), 7.41 (t, J = 1.7



carboxamide
Hz, 1H), 7.19-7.23 (m, 2H), 7.15-7.18 (m,




2H), 6.51-6.53 (m, 1H), 4.84 (s, 4H), 4.60-




4.62 (m, 2H)


84
N-(4-{[4-(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



cyanophenyl)piperazin-1-
Temp = 90° C.) δ ppm 8.32-8.33 (bs, 1H), 7.92-
m/e 452



yl]carbonyl}phenyl)-
7.95 (m, 2H), 7.55-7.58 (m, 1H), 7.53-7.59
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.39-7.44 (m, 1H), 7.20-7.25 (m,



isoindole-2-
2H), 7.15-7.20 (m, 2H), 6.93-6.99 (m, 2H),



carboxamide
4.80-4.87 (m, 4H), 3.80-3.83 (m, 4H), 3.15-




3.17 (m, 4H)


85
N-{4-[(3-hydroxy-2-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(−))



methylphenyl)carbamoyl]phenyl}-
Oxide) δ ppm 7.89-7.92 (m, 2H), 7.69-7.72
m/e 386



1,3-dihydro-2H-
(m, 2H), 7.38-7.41 (m, 2H), 7.33-7.36 (m,
(M − H)



isoindole-2-
2H), 7.02 (t, J = 7.9 Hz, 1H), 6.79 (d, J = 7.8



carboxamide
Hz, 1H), 6.74 (d, J = 8.0 Hz, 1H), 4.80-4.82




(bs, 4H), 2.02 (s, 3H)


86
N-{4-[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.64

(ESI(+))



methylbutyl)carbamoyl]phenyl}-
(s, 1H), 8.21 (t, J = 5.6 Hz, 1H), 7.74-7.78
m/e 420



5-(trifluoromethyl)-1,3-
(m, 3H), 7.56-7.70 (m, 4H), 4.85-4.87 (bs,
(M + H)+



dihydro-2H-
4H), 3.22-3.30 (m, 2H), 1.51-1.72 (m, 1H),



isoindole-2-
1.37-1.45 (m, 2H), 0.91 (d, J = 6.6 Hz, 6H)



carboxamide


87
N-{4-[(3-methyl-1H-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



indazol-5-
Temp = 90° C.) δ ppm 10.02-10.04 (bs, 1H),
m/e 412



yl)carbamoyl]phenyl}-
8.41-8.42 (m, 1H), 8.33-8.35 (bs, 1H), 8.23-
(M + H)+



1,3-dihydro-2H-
8.26 (m, 2H), 7.95-7.98 (m, 2H), 7.86 (dd, J =



isoindole-2-
8.8, 1.9 Hz, 1H), 7.48-7.53 (m, 1H), 7.20-



carboxamide
7.25 (m, 2H), 7.15-7.19 (m, 2H), 4.86 (s,




4H), 2.58 (s, 3H)


88
N-{4-[(3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



ethoxypropyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.27-8.28 (bs, 1H), 8.07-
m/e 368



1,3-dihydro-2H-
8.10 (m, 2H), 7.94-7.99 (m, 1H), 7.89-7.94
(M + H)+



isoindole-2-
(m, 2H), 7.19-7.23 (m, 2H), 7.15-7.19 (m,



carboxamide
2H), 4.84 (s, 4H), 3.68 (td, J = 6.7, 5.7 Hz,




2H), 3.49 (t, J = 6.1 Hz, 2H), 3.38 (q, J = 6.9




Hz, 2H), 1.93 (p, J = 6.4 Hz, 2H), 1.10 (t, J =




6.9 Hz, 3H)


89
N-(4-{[4-(pyrazin-2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.65

(ESI(−))



yl)piperazin-1-
(s, 1H), 8.34 (s, 1H), 8.09-8.12 (bs, 1H), 7.87
m/e 495



yl]carbonyl}phenyl)-
(d, J = 2.6 Hz, 1H), 7.76-7.78 (bs, 1H), 7.64-
(M − H)



5-(trifluoromethyl)-
7.73 (m, 3H), 7.58-7.64 (m, 1H), 7.37-7.41



1,3-dihydro-2H-
(m, 2H), 4.85-4.88 (bs, 4H), 3.62-3.65 (m,



isoindole-2-
8H)



carboxamide


90
N-(4-{[2-(2,5-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(−))



dimethoxyphenyl)eth-
Oxide) δ ppm 7.73-7.75 (m, 2H), 7.62-7.65
m/e 444



yl]carbamoyl}phenyl)-
(m, 2H), 7.37-7.40 (m, 2H), 7.32-7.35 (m,
(M − H)



1,3-dihydro-2H-
2H), 6.90 (d, J = 8.6 Hz, 1H), 6.76-6.78 (m,



isoindole-2-
2H), 4.78-4.80 (bs, 4H), 3.78 (s, 3H), 3.44 (t,



carboxamide
J = 7.3 Hz, 2H), 2.81 (t, J = 7.2 Hz, 2H)


91
N-{4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.58

(ESI(+))



[(tetrahydrofuran-3-
(s, 1H), 8.39 (t, J = 5.7 Hz, 1H), 7.75-7.79
m/e 366



ylmethyl)carbamoyl]
(m, 2H), 7.65-7.68 (m, 2H), 7.30-7.39 (m,
(M + H)+



phenyl}-1,3-dihydro-
4H), 4.79 (s, 4H), 3.57-3.78 (m, 3H), 3.48



2H-isoindole-2-
(dd, J = 8.5, 5.2 Hz, 1H), 3.17-3.28 (m, 2H),



carboxamide
2.41-2.51 (m, 1H), 1.93 (dtd, J = 12.2, 8.0,




5.7 Hz, 1H), 1.54-1.66 (m, 1H)


92
N-{4-[(1-benzyl-1H-

1H NMR (300 MHz, DMSO-d6) δ ppm 10.25

(ESI(+))



pyrazol-4-
(s, 1H), 8.63 (s, 1H), 8.11 (s, 1H), 7.84-7.88
m/e 438



yl)carbamoyl]phenyl}-
(m, 2H), 7.70-7.74 (m, 2H), 7.61 (d, J = 0.7
(M + H)+



1,3-dihydro-2H-
Hz, 1H), 7.23-7.40 (m, 9H), 5.31 (s, 2H),



isoindole-2-
4.79-4.80 (bs, 4H)



carboxamide


93
methyl 5-({4-[(1,3-

1H NMR (400 MHz, Pyridine-d5,

(APCI(+))



dihydro-2H-isoindol-
Temp = 90° C.) δ ppm 10.25-10.26 (bs, 1H),
m/e 456



2-ylcarbonyl)amino]ben-
8.92 (d, J = 1.9 Hz, 1H), 8.34-8.36 (bs, 1H),
(M + H)+



zoyl}amino)-1H-
8.23-8.25 (m, 2H), 8.17 (dd, J = 8.9, 2.0 Hz,



indazole-3-
1H), 7.95-7.98 (m, 2H), 7.64 (d, J = 8.9 Hz,



carboxylate
1H), 7.20-7.24 (m, 2H), 7.15-7.20 (m, 2H),




4.86 (s, 4H), 3.90 (s, 3H)


94
N-(4-{[2-(2-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



oxopyrrolidin-1-
Oxide, Temp = 90° C.) δ ppm 7.73-7.75 (m,
m/e 393



yl)ethyl]carbamoyl}phenyl)-
2H), 7.62-7.65 (m, 2H), 7.32-7.40 (m, 4H),
(M + H)+



1,3-dihydro-
4.82 (s, 4H), 3.38-3.47 (m, 6H), 2.23 (t, J =



2H-isoindole-2-
8.0 Hz, 2H), 1.91-1.99 (m, 2H)



carboxamide


95
N-{4-[(pyridin-4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



ylmethyl)carbamoyl]
Temp = 90° C.) δ ppm 8.81-8.88 (m, 1H), 8.57-
m/e 373



phenyl}-1,3-dihydro-
8.60 (m, 2H), 8.34-8.37 (bs, 1H), 8.16-8.19
(M + H)+



2H-isoindole-2-
(m, 2H), 7.94-7.98 (m, 2H), 7.30-7.32 (m,



carboxamide
2H), 7.19-7.23 (m, 2H), 7.17-7.19 (m, 2H),




4.85 (s, 4H), 4.74 (d, J = 6.0 Hz, 2H)


96
N-(4-{[4-(5-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.56

(ESI(+))



chloropyridin-2-
(s, 1H), 8.13 (d, J = 2.7 Hz, 1H), 7.64-7.70
m/e 462



yl)piperazin-1-
(m, 2H), 7.63 (dd, J = 9.2, 2.7 Hz, 1H), 7.30-
(M + H)+



yl]carbonyl}phenyl)-
7.39 (m, 6H), 6.90 (d, J = 9.1 Hz, 1H), 4.79-



1,3-dihydro-2H-
4.80 (bs, 4H), 3.47-3.72 (m, 8H)



isoindole-2-



carboxamide


97
N-(4-{[2-(1H-indol-3-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



yl)ethyl]carbamoyl}phenyl)-
Oxide, Temp = 90° C.) δ ppm 7.75-7.78 (m,
m/e 425



1,3-dihydro-
2H), 7.63-7.66 (m, 2H), 7.59-7.63 (m, 1H),
(M + H)+



2H-isoindole-2-
7.32-7.40 (m, 5H), 7.17 (s, 1H), 7.10 (ddd, J =



carboxamide
8.1, 6.9, 1.2 Hz, 1H), 7.01 (ddd, J = 7.9,




6.9, 1.0 Hz, 1H), 4.82 (s, 4H), 3.60 (t, J = 7.4




Hz, 2H), 3.01 (t, J = 7.4 Hz, 2H)


98
N-(4-{[4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



(trifluoromethyl)ben-
Oxide) δ ppm 9.05 (t, J = 6.0 Hz, 1H), 7.81-
m/e 440



zyl]carbamoyl}phenyl)-
7.84 (m, 2H), 7.66-7.71 (m, 4H), 7.53-7.55
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.36-7.41 (m, 2H), 7.32-7.36 (m,



isoindole-2-
2H), 4.79-4.80 (bs, 4H), 4.54-4.56 (m, 2H)



carboxamide


99
N-{4-[(3,5-

1H NMR (500 MHz, DMSO-d6/Deuterium

(APCI(+))



dimethoxyphenyl)carbamoyl]phenyl}-
Oxide) δ ppm 7.88-7.91 (m, 2H), 7.71-7.74
m/e 418



1,3-dihydro-2H-
(m, 2H), 7.38-7.41 (m, 2H), 7.33-7.36 (m,
(M + H)+



isoindole-2-
2H), 7.06-7.07 (m, 2H), 6.27 (t, J = 2.2 Hz,



carboxamide
1H), 4.80-4.81 (bs, 4H), 3.78 (s, 6H)


100
N-{4-[(pyridin-3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



ylmethyl)carbamoyl]
Temp = 90° C.) δ ppm 8.81 (d, J = 2.3 Hz, 1H),
m/e 373



phenyl}-1,3-dihydro-
8.75-8.80 (m, 1H), 8.53 (dd, J = 4.7, 1.6 Hz,
(M + H)+



2H-isoindole-2-
1H), 8.31-8.33 (bs, 1H), 8.12-8.15 (m, 2H),



carboxamide
7.91-7.94 (m, 2H), 7.71-7.75 (m, 1H), 7.19-




7.23 (m, 2H), 7.16-7.18 (m, 2H), 7.10-7.14




(m, 1H), 4.84 (s, 4H), 4.75 (d, J = 5.8 Hz,




2H)


101
N-[4-(2,3-dihydro-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



1,4-benzodioxin-6-
Temp = 90° C.) δ ppm 9.88-9.89 (bs, 1H), 8.30
m/e 416



ylcarbamoyl)phenyl]-
(d, J = 2.0 Hz, 1H), 8.13-8.16 (m, 2H), 7.89-
(M + H)+



1,3-dihydro-2H-
7.92 (m, 2H), 7.77 (d, J = 2.5 Hz, 1H), 7.41



isoindole-2-
(dd, J = 8.6, 2.5 Hz, 1H), 7.19-7.23 (m, 2H),



carboxamide
7.17-7.19 (m, 2H), 6.93 (d, J = 8.6 Hz, 1H),




4.84 (s, 4H), 4.07-4.10 (m, 4H)


102
N-(4-{[4-(2-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



fluorobenzoyl)piperazin-1-
Oxide) δ ppm 7.63-7.65 (m, 2H), 7.50-7.57
m/e 473



yl]carbonyl}phenyl)-
(m, 1H), 7.42-7.46 (m, 1H), 7.35-7.41 (m,
(M + H)+



1,3-dihydro-2H-
4H), 7.28-7.35 (m, 4H), 4.78-4.79 (bs, 4H),



isoindole-2-
3.71-3.76 (m, 2H), 3.51-3.62 (m, 4H), 3.30-



carboxamide
3.33 (m, 2H)


103
N-(4-{[2-(5-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



methoxy-1H-indol-3-
Oxide, Temp = 90° C.) δ ppm 7.75-7.78 (m,
m/e 455



yl)ethyl]carbamoyl}phenyl)-
2H), 7.62-7.65 (m, 2H), 7.36-7.41 (m, 2H),
(M + H)+



1,3-dihydro-
7.31-7.36 (m, 2H), 7.27 (dd, J = 8.7, 0.6 Hz,



2H-isoindole-2-
1H), 7.14 (q, J = 0.7 Hz, 1H), 7.11 (dd, J =



carboxamide
2.4, 0.5 Hz, 1H), 6.76 (dd, J = 8.6, 2.4 Hz,




1H), 4.82 (s, 4H), 3.78 (s, 3H), 3.58 (t, J =




7.3 Hz, 2H), 2.97 (t, J = 7.3 Hz, 2H)


104
N-{4-[(3-

1H NMR (400 MHz, Pyridine-d5,

(APCI(+))



aminobenzyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.39-8.43 (m, 1H), 8.30-
m/e 387



1,3-dihydro-2H-
8.32 (bs, 1H), 8.11-8.14 (m, 2H), 7.90-7.93
(M + H)+



isoindole-2-
(m, 2H), 7.20-7.24 (m, 2H), 7.17-7.19 (m,



carboxamide
2H), 7.09 (t, J = 7.7 Hz, 1H), 6.92 (t, J = 1.9




Hz, 1H), 6.80 (dd, J = 7.5, 1.4 Hz, 1H), 6.67-




6.70 (m, 1H), 4.85 (s, 4H), 4.73 (d, J = 5.8




Hz, 2H)


105
N-(4-{[2-(2-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



chlorophenyl)ethyl]carbamoyl}phenyl)-
Oxide) δ ppm 8.49 (t, J = 5.6 Hz, 1H), 7.73-
m/e 420



1,3-dihydro-2H-
7.75 (m, 2H), 7.63-7.65 (m, 2H), 7.43 (dd, J =
(M + H)+



isoindole-2-
7.4, 1.9 Hz, 1H), 7.36-7.40 (m, 2H), 7.35-



carboxamide
7.37 (m, 1H), 7.32-7.36 (m, 2H), 7.24-7.31




(m, 1H), 4.78-4.80 (bs, 4H), 3.49-3.54 (m,




2H), 2.98 (t, J = 7.2 Hz, 2H)


106
N-(4-{[(2R)-1-

1H NMR (300 MHz, DMSO-d6) d ppm 8.56

(ESI(+))



hydroxy-4-
(s, 1 H) 7.71-7.86 (m, 3 H) 7.59-7.71 (m,
m/e 382



methylpentan-2-
2 H) 7.20-7.45 (m, 4 H) 4.79 (s, 4 H) 4.64
(M + H)+



yl]carbamoyl}phenyl)-
(t, J = 5.8 Hz, 1 H) 3.90-4.16 (m, 1 H) 3.21-



1,3-dihydro-2H-
3.52 (m, 2 H) 1.54-1.72 (m, 1 H) 1.28-



isoindole-2-
1.53 (m, 2 H) 0.88 (t, J = 6.7 Hz, 6 H)



carboxamide


107
N-{4-[(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



propoxyethyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.26-8.28 (bs, 1H), 8.08-
m/e 368



1,3-dihydro-2H-
8.11 (m, 2H), 7.99-8.06 (m, 1H), 7.89-7.92
(M + H)+



isoindole-2-
(m, 2H), 7.19-7.23 (m, 2H), 7.16-7.18 (m,



carboxamide
2H), 4.84 (s, 4H), 3.77 (q, J = 5.7 Hz, 2H),




3.65 (t, J = 5.7 Hz, 2H), 3.35 (t, J = 6.5 Hz,




2H), 1.43-1.59 (m, 2H), 0.84 (t, J = 7.4 Hz,




3H)


108
N-{4-[(3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



isobutoxypropyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.27-8.29 (bs, 1H), 8.08-
m/e 396



1,3-dihydro-2H-
8.10 (m, 2H), 7.92-7.98 (m, 1H), 7.90-7.94
(M + H)+



isoindole-2-
(m, 2H), 7.19-7.23 (m, 2H), 7.16-7.19 (m,



carboxamide
2H), 4.84 (s, 4H), 3.66-3.72 (m, 2H), 3.51 (t,




J = 6.1 Hz, 2H), 3.13 (d, J = 6.4 Hz, 2H),




1.95 (p, J = 6.4 Hz, 2H), 1.75-1.87 (m, 1H),




0.87 (d, J = 6.7 Hz, 6H)


109
N-(4-{[4-(pyridin-4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.57

(ESI(+))



yl)piperazin-1-
(s, 1H), 8.16-8.20 (m, 2H), 7.65-7.69 (m,
m/e 428



yl]carbonyl}phenyl)-
2H), 7.30-7.40 (m, 6H), 6.81-6.85 (m, 2H),
(M + H)+



1,3-dihydro-2H-
4.79-4.80 (bs, 4H), 3.60-3.64 (m, 4H)



isoindole-2-



carboxamide


110
N-[4-({4-[5-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(−))



(trifluoromethyl)pyridin-
Oxide) δ ppm 8.42-8.43 (m, 1H), 7.83 (dd, J =
m/e 494



2-yl]piperazin-1-
9.1, 2.6 Hz, 1H), 7.65-7.67 (m, 2H), 7.38-
(M − H)



yl}carbonyl)phenyl]-
7.43 (m, 2H), 7.36-7.41 (m, 2H), 7.32-7.36



1,3-dihydro-2H-
(m, 2H), 6.98 (d, J = 9.1 Hz, 1H), 4.79-4.80



isoindole-2-
(bs, 4H), 3.50-3.74 (m, 8H)



carboxamide


111
N-{4-[(3,4,5-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



trimethoxyphenyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 9.91-9.93 (bs, 1H), 8.33-
m/e 446



1,3-dihydro-2H-
8.35 (bs, 1H), 8.17-8.20 (m, 2H), 7.92-7.95
(M − H)



isoindole-2-
(m, 2H), 7.43 (s, 2H), 7.20-7.25 (m, 2H),



carboxamide
7.15-7.19 (m, 2H), 4.84 (s, 4H), 3.87 (d, J =




0.4 Hz, 3H), 3.74 (s, 6H)


112
N-{4-[(4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methylpiperidin-1-
Temp = 90° C.) δ ppm 8.26-8.28 (bs, 1H), 7.90-
m/e 364



yl)carbonyl]phenyl}-
7.92 (m, 2H), 7.51-7.54 (m, 2H), 7.19-7.25
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.15-7.19 (m, 2H), 4.85 (s, 4H),



isoindole-2-
4.21-4.27 (m, 2H), 2.82 (ddd, J = 13.2, 12.1,



carboxamide
2.7 Hz, 2H), 1.44-1.50 (m, 3H), 1.01-1.12




(m, 2H), 0.83 (d, J = 6.1 Hz, 3H)


113
N-[4-({2-[4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(APCI(+))



(dimethylamino)phe-
Oxide) δ ppm 7.73-7.76 (m, 2H), 7.64-7.66
m/e 429



nyl]ethyl}carbamoyl)phenyl]-
(m, 2H), 7.36-7.41 (m, 2H), 7.30-7.36 (m,
(M + H)+



1,3-dihydro-
4H), 7.21-7.25 (m, 2H), 4.78-4.80 (bs, 4H),



2H-isoindole-2-
3.47 (t, J = 7.3 Hz, 2H), 3.05 (s, 6H), 2.83-



carboxamide
2.88 (m, 2H)


114
N-(4-{[3-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



(trifluoromethoxy)ben-
Oxide) δ ppm 9.03 (t, J = 6.0 Hz, 1H), 8.67-
m/e 456



zyl]carbamoyl}phenyl)-
8.69 (bs, 1H), 7.81-7.83 (m, 2H), 7.67-7.69
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.48 (t, J = 7.9 Hz, 1H), 7.36-7.41



isoindole-2-
(m, 2H), 7.34-7.37 (m, 1H), 7.31-7.35 (m,



carboxamide
2H), 7.28-7.29 (bs, 1H), 7.24 (dd, J = 8.2,




2.2 Hz, 1H), 4.79-4.80 (bs, 4H), 4.51 (d, J =




5.6 Hz, 2H)


115
N-(4-{[(1R)-3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



hydroxy-1-
Temp = 90° C.) δ ppm 8.45-8.49 (m, 1H), 8.28-
m/e 414



phenylpropyl]carbamoyl}phenyl)-
8.29 (bs, 1H), 8.08-8.12 (m, 2H), 7.87-7.90
(M − H)



1,3-dihydro-2H-
(m, 2H), 7.55-7.59 (m, 2H), 7.26-7.33 (m,



isoindole-2-
2H), 7.19-7.23 (m, 3H), 7.16-7.18 (m, 2H),



carboxamide
5.79 (td, J = 7.9, 5.4 Hz, 1H), 4.82 (s, 4H),




3.88-3.99 (m, 2H), 2.19-2.43 (m, 2H)


116
N-{4-[(3-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(−))



cyanophenyl)carbamoyl]phenyl}-
Oxide) δ ppm 8.23 (t, J = 1.8 Hz, 1H), 8.04
m/e 381



1,3-dihydro-2H-
(ddd, J = 8.0, 2.3, 1.5 Hz, 1H), 7.91-7.94 (m,
(M − H)



isoindole-2-
2H), 7.71-7.78 (m, 2H), 7.59 (t, J = 7.9 Hz,



carboxamide
1H), 7.56 (dt, J = 7.6, 1.5 Hz, 1H), 7.38-7.41




(m, 2H), 7.33-7.36 (m, 2H), 4.75-4.87 (m,




4H)


117
N-{4-[(3-fluoro-4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



methoxyphenyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 10.07-10.09 (bs, 1H),
m/e 404



1,3-dihydro-2H-
8.33-8.34 (bs, 1H), 8.13-8.16 (m, 2H), 8.01
(M − H)



isoindole-2-
(dd, J = 13.5, 2.5 Hz, 1H), 7.91-7.93 (m,



carboxamide
2H), 7.57-7.60 (m, 1H), 7.20-7.23 (m, 2H),




7.15-7.19 (m, 2H), 6.98 (t, J = 9.1 Hz, 1H),




4.84 (s, 4H), 3.73 (s, 3H)


118
N-{4-[(2,3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



dimethoxyphenyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 9.11-9.13 (bs, 1H), 8.40-
m/e 418



1,3-dihydro-2H-
8.44 (m, 1H), 8.37 (dd, J = 8.4, 1.3 Hz, 1H),
(M + H)+



isoindole-2-
8.08-8.11 (m, 2H), 7.96-7.99 (m, 2H), 7.21-



carboxamide
7.23 (m, 2H), 7.17-7.19 (m, 2H), 7.06 (t, J =




8.3 Hz, 1H), 6.74 (dd, J = 8.3, 1.3 Hz, 1H),




4.85 (s, 4H), 3.88 (s, 3H), 3.74 (s, 3H)


119
N-(4-{[2-(2-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(−))



fluorophenyl)ethyl]carbamoyl}phenyl)-
Oxide) δ ppm 8.64-8.65 (bs, 1H), 8.48 (t, J =
m/e 402



1,3-dihydro-2H-
5.7 Hz, 1H), 7.72-7.74 (m, 2H), 7.62-7.66
(M − H)



isoindole-2-
(m, 2H), 7.36-7.42 (m, 2H), 7.31-7.36 (m,



carboxamide
2H), 7.25-7.32 (m, 2H), 7.12-7.17 (m, 2H),




4.79-4.88 (m, 4H), 3.47-3.51 (m, 2H), 2.89




(t, J = 7.2 Hz, 2H)


120
N-[4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



(isobutylcarbamoyl)phenyl]-
Temp = 90° C.) δ ppm 8.27-8.29 (bs, 1H), 8.09-
m/e 338



1,3-dihydro-
8.12 (m, 2H), 7.90-7.93 (m, 2H), 7.84-7.90
(M + H)+



2H-isoindole-2-
(m, 1H), 7.19-7.23 (m, 2H), 7.14-7.19 (m,



carboxamide
2H), 4.84 (s, 4H), 3.39 (dd, J = 6.8, 6.0 Hz,




2H), 1.91-2.03 (m, 1H), 0.93 (d, J = 6.7 Hz,




6H)


121
N-(4-{[2-(1,3-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



benzodioxol-5-
Oxide) δ ppm 8.64-8.66 (bs, 1H), 8.42 (t, J =
m/e 430



yl)ethyl]carbamoyl}phenyl)-
5.6 Hz, 1H), 7.73-7.75 (m, 2H), 7.63-7.67
(M + H)+



1,3-dihydro-
(m, 2H), 7.36-7.41 (m, 2H), 7.31-7.36 (m,



2H-isoindole-2-
2H), 6.81-6.84 (m, 2H), 6.71 (dd, J = 7.8, 1.7



carboxamide
Hz, 1H), 5.95 (s, 2H), 4.78-4.79 (bs, 4H),




3.41-3.46 (m, 2H), 2.73-2.78 (m, 2H)


122
N-(4-{[2-(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methoxyphenyl)eth-
Temp = 90° C.) δ ppm 8.25-8.27 (bs, 1H), 8.05-
m/e 416



yl]carbamoyl}phenyl)-
8.08 (m, 2H), 7.98-8.02 (bs, 1H), 7.89-7.92
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.19-7.25 (m, 3H), 7.14-7.19 (m,



isoindole-2-
3H), 6.83-6.90 (m, 2H), 4.84 (s, 4H), 3.83-



carboxamide
3.88 (m, 2H), 3.66 (s, 3H), 3.09 (t, J = 7.1




Hz, 2H)


123
N-[4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



(butylcarbamoyl)phenyl]-
Temp = 90° C.) δ ppm 8.27-8.28 (bs, 1H), 8.09-
m/e 338



1,3-dihydro-2H-
8.12 (m, 2H), 7.89-7.93 (m, 2H), 7.86-7.92
(M + H)+



isoindole-2-
(m, 1H), 7.19-7.23 (m, 2H), 7.15-7.18 (m,



carboxamide
2H), 4.84 (s, 4H), 3.48-3.61 (m, 2H), 1.62 (p,




J = 7.2 Hz, 2H), 1.26-1.44 (m, 2H), 0.85 (t, J =




7.3 Hz, 3H)


124
N-{4-[(2-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(−))



isopropoxyethyl)carbamoyl]phenyl}-
Oxide, Temp = 90° C.) δ ppm 7.75-7.78 (m,
m/e 366



1,3-dihydro-2H-
2H), 7.63-7.66 (m, 2H), 7.26-7.40 (m, 4H),
(M − H)



isoindole-2-
4.82 (s, 4H), 3.58-3.68 (m, 1H), 3.52-3.56



carboxamide
(m, 2H), 3.42 (t, J = 6.2 Hz, 2H), 1.12 (d, J =




6.1 Hz, 6H)


125
N-{4-[(3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



isopropoxypropyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.28-8.30 (bs, 1H), 8.07-
m/e 382



1,3-dihydro-2H-
8.10 (m, 2H), 7.93-7.97 (m, 1H), 7.90-7.94
(M + H)+



isoindole-2-
(m, 2H), 7.19-7.23 (m, 2H), 7.14-7.19 (m,



carboxamide
2H), 4.85 (s, 4H), 3.62-3.74 (m, 2H), 3.42-




3.55 (m, 3H), 1.92 (p, J = 6.4 Hz, 2H), 1.08




(d, J = 6.1 Hz, 6H)


126
4-chloro-N-{4-[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.66

(ESI(+))



phenylpropyl)carbamoyl]phenyl}-
(s, 1H), 8.29 (t, J = 5.6 Hz, 1H), 7.75-7.79
m/e 434



1,3-dihydro-2H-
(m, 2H), 7.64-7.68 (m, 2H), 7.33-7.41 (m,
(M + H)+



isoindole-2-
3H), 7.13-7.32 (m, 5H), 4.77-4.89 (m, 4H),



carboxamide
3.19-3.31 (m, 2H), 2.58-2.68 (m, 2H), 1.76-




1.89 (m, 2H)


127
N-(4-{[2-(4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



methoxyphenyl)eth-
Oxide) δ ppm 8.64-8.66 (bs, 1H), 8.43 (t, J =
m/e 416



yl]carbamoyl}phenyl)-
5.6 Hz, 1H), 7.73-7.76 (m, 2H), 7.63-7.65
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.36-7.41 (m, 2H), 7.31-7.35 (m,



isoindole-2-
2H), 7.16-7.19 (m, 2H), 6.86-6.88 (m, 2H),



carboxamide
4.78-4.80 (bs, 4H), 3.72 (s, 3H), 3.42-3.51




(m, 2H), 2.78 (t, J = 7.4 Hz, 2H)


128
N-{4-[(3-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



methoxypropyl)carbamoyl]phenyl}-
Oxide) δ ppm 7.75-7.78 (m, 2H), 7.60-7.69
m/e 354



1,3-dihydro-2H-
(m, 2H), 7.37-7.40 (m, 2H), 7.32-7.35 (m,
(M + H)+



isoindole-2-
2H), 4.79-4.80 (bs, 4H), 3.39 (t, J = 6.3 Hz,



carboxamide
2H), 3.30 (t, J = 7.0 Hz, 2H), 3.25 (s, 3H),




1.76 (p, J = 6.7 Hz, 2H)


129
N-(4-{[2-(4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



fluorophenyl)ethyl]carbamoyl}phenyl)-
Oxide) δ ppm 8.64-8.66 (bs, 1H), 8.45 (t, J =
m/e 404



1,3-dihydro-2H-
5.6 Hz, 1H), 7.73-7.75 (m, 2H), 7.63-7.66
(M + H)+



isoindole-2-
(m, 2H), 7.36-7.41 (m, 2H), 7.31-7.35 (m,



carboxamide
2H), 7.27-7.31 (m, 2H), 7.09-7.13 (m, 2H),




4.78-4.80 (bs, 4H), 3.47 (t, J = 7.3 Hz, 2H),




2.84 (t, J = 7.3 Hz, 2H)


130
N-(4-{[3-(2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.58

(ESI(+))



oxopyrrolidin-1-
(s, 1H), 8.27 (t, J = 5.7 Hz, 1H), 7.74-7.78
m/e 407



yl)propyl]carbamoyl}phenyl)-
(m, 2H), 7.64-7.69 (m, 2H), 7.30-7.39 (m,
(M + H)+



1,3-dihydro-2H-
4H), 4.78-4.79 (bs, 4H), 3.32-3.39 (m, 2H),



isoindole-2-
3.17-3.26 (m, 4H), 2.22 (t, J = 8.0 Hz, 2H),



carboxamide
1.87-1.97 (m, 2H), 1.69 (p, J = 7.0 Hz, 2H)


131
N-{4-[(2,4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



dimethoxyphenyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.89-8.91 (bs, 1H), 8.53
m/e 418



1,3-dihydro-2H-
(d, J = 8.7 Hz, 1H), 8.36-8.37 (bs, 1H), 8.10-
(M + H)+



isoindole-2-
8.13 (m, 2H), 7.95-7.98 (m, 2H), 7.19-7.24



carboxamide
(m, 2H), 7.15-7.19 (m, 2H), 6.67 (d, J = 2.6




Hz, 1H), 6.61 (dd, J = 8.7, 2.7 Hz, 1H), 4.85




(s, 4H), 3.72 (s, 3H), 3.69 (s, 3H)


133
N-{4-[(2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.59

(ESI(+))



phenoxyethyl)carbamoyl]phenyl}-
(s, 1H), 8.52 (t, J = 5.5 Hz, 1H), 7.77-7.81
m/e 402



1,3-dihydro-2H-
(m, 2H), 7.65-7.69 (m, 2H), 7.26-7.39 (m,
(M + H)+



isoindole-2-
6H), 6.90-6.99 (m, 3H), 4.79 (s, 4H), 4.10 (t,



carboxamide
J = 5.9 Hz, 2H), 3.62 (q, J = 5.7 Hz, 2H)


134
N-(4-{[2-(4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



hydroxyphenyl)eth-
Oxide) δ ppm 7.73-7.76 (m, 2H), 7.63-7.66
m/e 402



yl]carbamoyl}phenyl)-
(m, 2H), 7.36-7.41 (m, 2H), 7.31-7.36 (m,
(M + H)+



1,3-dihydro-2H-
2H), 7.04-7.07 (m, 2H), 6.69-6.71 (m, 2H),



isoindole-2-
4.79-4.80 (bs, 4H), 3.41 (dd, J = 8.5, 6.5 Hz,



carboxamide
2H), 2.73 (t, J = 7.5 Hz, 2H)


135
N-(4-{[2-(3-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



fluorophenyl)ethyl]carbamoyl}phenyl)-
Oxide) δ ppm 8.64-8.66 (bs, 1H), 8.46 (t, J =
m/e 404



1,3-dihydro-2H-
5.6 Hz, 1H), 7.72-7.75 (m, 2H), 7.63-7.66
(M + H)+



isoindole-2-
(m, 2H), 7.36-7.41 (m, 2H), 7.31-7.35 (m,



carboxamide
3H), 7.08-7.11 (m, 2H), 7.00-7.05 (m, 1H),




4.78-4.79 (bs, 4H), 3.50 (t, J = 6.9 Hz, 2H),




2.88 (t, J = 7.2 Hz, 2H)


136
N-[4-({1-[(3S)-

1H NMR (300 MHz, DMSO-d6) δ ppm 10.25

(ESI(+))



tetrahydrofuran-3-
(s, 1H), 8.64 (s, 1H), 8.08 (s, 1H), 7.85-7.89
m/e 418



yl]-1H-pyrazol-4-
(m, 2H), 7.70-7.75 (m, 2H), 7.61 (s, 1H),
(M + H)+



yl}carbamoyl)phenyl]-
7.29-7.41 (m, 4H), 4.94-5.06 (m, 1H), 4.80-



1,3-dihydro-2H-
4.81 (bs, 4H), 3.93-4.01 (m, 2H), 3.78-3.89



isoindole-2-
(m, 2H), 2.30-2.46 (m, 1H), 2.14-2.30 (m, 1H)



carboxamide


137
5-methyl-N-{4-[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.55

(ESI(+))



phenylpropyl)carbamoyl]phenyl}-
(s, 1H), 8.29 (t, J = 5.6 Hz, 1H), 7.74-7.79
m/e 414



1,3-dihydro-2H-
(m, 2H), 7.63-7.68 (m, 2H), 7.11-7.34 (m,
(M + H)+



isoindole-2-
8H), 4.73-4.74 (bs, 4H), 3.20-3.30 (m, 2H),



carboxamide
2.63 (t, J = 7.6 Hz, 2H), 2.33 (s, 3H), 1.82




(p, J = 7.4 Hz, 2H)


138
N-[4-(1,4-dioxa-8-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



azaspiro[4.5]dec-8-
Temp = 90° C.) δ ppm 8.27-8.28 (bs, 1H), 7.89-
m/e 408



ylcarbonyl)phenyl]-
7.92 (m, 2H), 7.52-7.55 (m, 2H), 7.19-7.23
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.16-7.18 (m, 2H), 4.85 (s, 4H),



isoindole-2-
3.84 (s, 4H), 3.73-3.76 (m, 4H), 1.71-1.75



carboxamide
(m, 4H)


139
N-{4-[(2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.57

(ESI(+))



phenylethyl)carbamoyl]phenyl}-
(s, 1H), 8.38 (t, J = 5.6 Hz, 1H), 7.73-7.77
m/e 386



1,3-dihydro-2H-
(m, 2H), 7.64-7.67 (m, 2H), 7.20-7.39 (m,
(M + H)+



isoindole-2-
9H), 4.79 (s, 4H), 3.43-3.50 (m, 2H), 2.80-



carboxamide
2.88 (m, 2H)


140
N-(4-{[2-(2,4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



dimethoxyphenyl)eth-
Temp = 90° C.) δ ppm 8.25-8.26 (bs, 1H), 8.07-
m/e 446



yl]carbamoyl}phenyl)-
8.09 (m, 2H), 7.95-8.02 (m, 1H), 7.88-7.93
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.19-7.24 (m, 2H), 7.13-7.19 (m,



isoindole-2-
2H), 6.57 (d, J = 2.4 Hz, 1H), 6.49 (dd, J =



carboxamide
8.1, 2.4 Hz, 1H), 4.84 (s, 4H), 3.81-3.85 (m,




2H), 3.68 (s, 3H), 3.66 (s, 3H), 3.04 (t, J =




7.0 Hz, 2H)


141
N-(4-{[3-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



(methylthio)propyl]carbamoyl}phenyl)-
Oxide, Temp = 90° C.) δ ppm 7.76-7.78 (m,
m/e 370



1,3-dihydro-2H-
2H), 7.63-7.65 (m, 2H), 7.32-7.40 (m, 4H),
(M + H)+



isoindole-2-
4.82 (s, 4H), 3.37 (t, J = 6.9 Hz, 2H), 2.53-



carboxamide
2.57 (m, 2H), 2.09 (s, 3H), 1.85 (p, J = 7.1




Hz, 2H)


142
N-{4-[(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



ethoxyethyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.28-8.34 (m, 1H), 8.07-
m/e 354



1,3-dihydro-2H-
8.12 (m, 2H), 8.01-8.08 (m, 1H), 7.89-7.92
(M + H)+



isoindole-2-
(m, 2H), 7.19-7.24 (m, 2H), 7.14-7.18 (m,



carboxamide
2H), 4.84 (s, 4H), 3.76 (q, J = 5.7 Hz, 2H),




3.63 (t, J = 5.7 Hz, 2H), 3.43 (q, J = 6.9 Hz,




2H), 1.09 (t, J = 6.9 Hz, 3H)


143
N-{4-[(2-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(−))



fluorophenyl)carbamoyl]phenyl}-
Oxide) δ ppm 7.91-7.93 (m, 2H), 7.72-7.75
m/e 374



1,3-dihydro-2H-
(m, 2H), 7.56-7.65 (m, 1H), 7.37-7.42 (m,
(M − H)



isoindole-2-
2H), 7.32-7.37 (m, 2H), 7.26-7.31 (m, 2H),



carboxamide
7.21-7.26 (m, 1H), 4.78-4.82 (m, 4H)


144
N-(4-{[2-(pyridin-3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.57

(ESI(+))



yl)ethyl]carbamoyl}phenyl)-
(s, 1H), 8.45 (d, J = 2.2 Hz, 1H), 8.41 (dd, J =
m/e 387



1,3-dihydro-
4.7, 1.6 Hz, 1H), 8.38 (d, J = 5.5 Hz, 1H),
(M + H)+



2H-isoindole-2-
7.71-7.75 (m, 2H), 7.63-7.68 (m, 3H), 7.29-



carboxamide
7.39 (m, 5H), 4.79 (s, 4H), 3.46-3.53 (m,




2H), 2.87 (t, J = 7.1 Hz, 2H)


145
N-[4-({4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



[(trifluoromethyl)thio]ben-
Oxide) δ ppm 9.03 (t, J = 6.0 Hz, 1H), 8.67-
m/e 472



zyl}carbamoyl)phenyl]-
8.70 (bs, 1H), 7.82-7.84 (m, 2H), 7.66-7.70
(M + H)+



1,3-dihydro-
(m, 4H), 7.47-7.49 (m, 2H), 7.36-7.41 (m,



2H-isoindole-2-
2H), 7.31-7.36 (m, 2H), 4.79-4.80 (bs, 4H),



carboxamide
4.53 (d, J = 5.3 Hz, 2H)


146
N-{4-[(3,4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



dimethoxyphenyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 9.90-9.92 (bs, 1H), 8.32-
m/e 418



1,3-dihydro-2H-
8.33 (bs, 1H), 8.17-8.19 (m, 2H), 7.92-7.94
(M + H)+



isoindole-2-
(m, 2H), 7.77 (d, J = 2.4 Hz, 1H), 7.49-7.53



carboxamide
(m, 1H), 7.20-7.23 (m, 2H), 7.14-7.19 (m,




2H), 6.94 (d, J = 8.6 Hz, 1H), 4.84 (s, 4H),




3.74 (s, 6H)


147
N-(4-{[3-(2-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



fluorophenyl)pyrrolidin-1-
Oxide) δ ppm 7.60-7.67 (m, 2H), 7.47-7.55
m/e 430



yl]carbonyl}phenyl)-
(m, 2H), 7.26-7.45 (m, 6H), 7.12-7.25 (m,
(M + H)+



1,3-dihydro-2H-
2H), 4.77-4.82 (m, 4H), 3.83-3.97 (m, 1H),



isoindole-2-
3.47-3.64 (m, 4H), 2.19-2.36 (m, 1H), 1.98-



carboxamide
2.18 (m, 1H)


148
N-(4-{[3-(1H-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



imidazol-1-
Temp = 90° C.) δ ppm 8.36-8.38 (bs, 1H), 8.24-
m/e 390



yl)propyl]carbamoyl}phenyl)-
8.31 (m, 1H), 8.08-8.12 (m, 2H), 8.00-8.05
(M + H)+



1,3-dihydro-2H-
(bs, 1H), 7.91-7.97 (m, 2H), 7.25-7.31 (bs,



isoindole-2-
1H), 7.19-7.24 (m, 2H), 7.16-7.19 (m, 2H),



carboxamide
4.86 (s, 4H), 4.06 (t, J = 7.0 Hz, 2H), 3.55




(q, J = 6.4 Hz, 2H), 2.11 (p, J = 6.9 Hz, 2H)


149
N-(4-{[2-(3-

1H NMR (500 MHz, DMSO-d6/Deuterium

(APCI(+))



chlorophenyl)ethyl]carbamoyl}phenyl)-
Oxide) δ ppm 8.64-8.66 (bs, 1H), 8.45 (t, J =
m/e 420



1,3-dihydro-2H-
5.6 Hz, 1H), 7.72-7.75 (m, 2H), 7.63-7.66
(M + H)+



isoindole-2-
(m, 2H), 7.36-7.41 (m, 2H), 7.31-7.36 (m,



carboxamide
4H), 7.25-7.29 (m, 1H), 7.21-7.24 (m, 1H),




4.76-4.81 (bs, 4H), 3.47-3.51 (m, 2H), 2.86




(t, J = 7.2 Hz, 2H)


150
N-{4-[(4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



hydroxybutyl)carbamoyl]phenyl}-
Oxide, Temp = 90° C.) δ ppm 7.75-7.78 (m,
m/e 354



1,3-dihydro-2H-
2H), 7.62-7.65 (m, 2H), 7.32-7.40 (m, 4H),
(M + H)+



isoindole-2-
4.81 (s, 4H), 3.48 (t, J = 6.3 Hz, 2H), 3.28-



carboxamide
3.32 (m, 2H), 1.49-1.65 (m, 4H)


151
N-{4-[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.65

(ESI(+))



phenylpropyl)carbamoyl]phenyl}-
(s, 1H), 8.30 (t, J = 5.6 Hz, 1H), 7.74-7.81
m/e 468



5-(trifluoromethyl)-1,3-
(m, 3H), 7.57-7.73 (m, 4H), 7.15-7.32 (m,
(M + H)+



dihydro-2H-
5H), 4.85-4.87 (bs, 4H), 3.27 (q, J = 6.6 Hz,



isoindole-2-
2H), 2.63 (t, J = 7.6 Hz, 2H), 1.83 (p, J = 7.4



carboxamide
Hz, 2H)


152
N-(4-{[4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(APCI(+))



(hydroxymethyl)phe-
Oxide) δ ppm 7.90-7.92 (m, 2H), 7.68-7.74
m/e 388



nyl]carbamoyl}phenyl)-
(m, 4H), 7.38-7.41 (m, 2H), 7.33-7.36 (m,
(M + H)+



1,3-dihydro-2H-
2H), 7.29-7.32 (m, 2H), 4.78-4.84 (m, 4H),



isoindole-2-
4.47 (s, 2H)



carboxamide


153
N-[4-(1,3-

1H NMR (400 MHz, Pyridine-d5,

(APCI(+))



benzodioxol-5-
Temp = 90° C.) δ ppm 9.95-9.97 (bs, 1H), 8.28-
m/e 402



ylcarbamoyl)phenyl]-
8.36 (m, 1H), 8.13-8.15 (m, 2H), 7.90-7.93
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.76 (d, J = 2.1 Hz, 1H), 7.32 (dd, J =



isoindole-2-
8.3, 2.1 Hz, 1H), 7.19-7.23 (m, 2H), 7.15-



carboxamide
7.19 (m, 2H), 6.82 (d, J = 8.3 Hz, 1H), 5.86




(s, 2H), 4.84 (s, 4H)


154
N-{4-[(1-isopropyl-

1H NMR (300 MHz, DMSO-d6) δ ppm 10.21

(ESI(+))



1H-pyrazol-4-
(s, 1H), 8.64 (s, 1H), 8.03 (d, J = 0.7 Hz,
m/e 390



yl)carbamoyl]phenyl}-
1H), 7.85-7.89 (m, 2H), 7.70-7.74 (m, 2H),
(M + H)+



1,3-dihydro-2H-
7.57 (d, J = 0.7 Hz, 1H), 7.30-7.40 (m, 4H),



isoindole-2-
4.80-4.81 (bs, 4H), 4.41-4.55 (m, 1H), 1.41



carboxamide
(d, J = 6.7 Hz, 6H)


155
N-{4-[(4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



hydroxyphenyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 9.83-9.85 (bs, 1H), 8.29-
m/e 374



1,3-dihydro-2H-
8.33 (bs, 1H), 8.16-8.18 (m, 2H), 7.91-7.93
(M + H)+



isoindole-2-
(m, 2H), 7.86-7.89 (m, 2H), 7.19-7.23 (m,



carboxamide
2H), 7.17-7.19 (m, 3H), 7.10-7.12 (m, 2H),




4.84 (s, 4H)


156
N-{4-[(1-ethyl-1H-

1H NMR (300 MHz, DMSO-d6) δ ppm 10.22

(ESI(+))



pyrazol-4-
(s, 1H), 8.64 (s, 1H), 8.03 (s, 1H), 7.85-7.90
m/e 376



yl)carbamoyl]phenyl}-
(m, 2H), 7.70-7.74 (m, 2H), 7.57 (s, 1H),
(M + H)+



1,3-dihydro-2H-
7.30-7.40 (m, 4H), 4.80-4.81 (bs, 4H), 4.11



isoindole-2-
(q, J = 7.2 Hz, 2H), 1.36 (t, J = 7.2 Hz, 3H)



carboxamide


157
N-{4-[(2,5-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



dimethoxyphenyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.97-8.99 (bs, 1H), 8.56
m/e 418



1,3-dihydro-2H-
(d, J = 3.0 Hz, 1H), 8.40-8.42 (bs, 1H), 8.07-
(M + H)+



isoindole-2-
8.10 (m, 2H), 7.96-7.98 (m, 2H), 7.21-7.24



carboxamide
(m, 2H), 7.16-7.19 (m, 2H), 6.88 (d, J = 8.8




Hz, 1H), 6.69 (dd, J = 8.8, 3.0 Hz, 1H), 4.85




(s, 4H), 3.72 (s, 3H), 3.71 (s, 3H)


158
N-{4-[methyl(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.51

(ESI(+))



phenylpropyl)carbamoyl]phenyl}-
(s, 1H), 7.60-7.64 (m, 2H), 7.11-7.44 (m,
m/e 414



1,3-dihydro-2H-
11H), 4.78-4.79 (bs, 4H), 3.26-3.52 (m, 2H),
(M + H)+



isoindole-2-
2.94 (s, 3H), 2.34-2.70 (m, 2H), 1.82-1.91



carboxamide
(m, 2H)


159
N-{4-[(2-hydroxy-2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



methylpropyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.30-8.32 (bs, 1H), 8.06-
m/e 352



1,3-dihydro-2H-
8.09 (m, 2H), 7.89-7.95 (m, 1H), 7.89-7.92
(M − H)



isoindole-2-
(m, 2H), 7.19-7.23 (m, 2H), 7.15-7.19 (m,



carboxamide
2H), 4.84 (s, 4H), 3.70 (d, J = 5.9 Hz, 2H),




1.38 (s, 6H)


160
N-(4-{[4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



(trifluoromethyl)piperidin-1-
Temp = 90° C.) δ ppm 8.31-8.33 (bs, 1H), 7.91-
m/e 416



yl]carbonyl}phenyl)-
7.94 (m, 2H), 7.50-7.55 (m, 2H), 7.19-7.24
(M − H)



1,3-dihydro-2H-
(m, 2H), 7.15-7.19 (m, 2H), 4.86 (s, 4H),



isoindole-2-
4.34-4.39 (m, 2H), 2.83 (td, J = 12.9, 2.8 Hz,



carboxamide
2H), 2.24-2.43 (m, 1H), 1.73-1.77 (m, 2H),




1.50 (qd, J = 12.5, 4.4 Hz, 2H)


161
N-[4-(thiomorpholin-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



4-ylcarbonyl)phenyl]-
Temp = 90° C.) δ ppm 8.29-8.31 (bs, 1H), 7.90-
m/e 368



1,3-dihydro-2H-
7.92 (m, 2H), 7.47-7.50 (m, 2H), 7.20-7.23
(M + H)+



isoindole-2-
(m, 2H), 7.15-7.19 (m, 2H), 4.85 (s, 4H),



carboxamide
3.81-3.84 (m, 4H), 2.54-2.58 (m, 4H)


162
N-[4-(5,6-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.59

(ESI(+))



dihydroimidazo[1,5-
(s, 1H), 7.67-7.71 (m, 2H), 7.60-7.62 (bs,
m/e 388



a]pyrazin-7(8H)-
1H), 7.30-7.43 (m, 6H), 6.72-6.77 (bs, 1H),
(M + H)+



ylcarbonyl)phenyl]-
4.79-4.80 (bs, 4H), 4.73-4.75 (bs, 2H), 4.06-



1,3-dihydro-2H-
4.18 (m, 2H), 3.81-3.88 (m, 2H)



isoindole-2-



carboxamide


163
N-(4-{[4-(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



furoyl)piperazin-1-
Temp = 90° C.) δ ppm 8.31-8.34 (m, 1H), 7.92-
m/e 443



yl]carbonyl}phenyl)-
7.95 (m, 2H), 7.57-7.59 (m, 1H), 7.53-7.57
(M − H)



1,3-dihydro-2H-
(m, 2H), 7.20-7.24 (m, 2H), 7.16-7.19 (m,



isoindole-2-
2H), 7.08-7.09 (m, 1H), 6.45 (dd, J = 3.4, 1.7



carboxamide
Hz, 1H), 4.86 (s, 4H), 3.75-3.80 (m, 4H),




3.64-3.70 (m, 4H)


164
N-{4-[(1-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



benzylpiperidin-4-
Oxide, Temp = 90° C.) δ ppm 7.77-7.80 (m,
m/e 455



yl)carbamoyl]phenyl}-
2H), 7.65-7.67 (m, 2H), 7.49-7.56 (m, 5H),
(M + H)+



1,3-dihydro-2H-
7.37-7.43 (m, 2H), 7.32-7.36 (m, 2H), 4.82



isoindole-2-
(s, 4H), 4.31-4.32 (bs, 2H), 4.03-4.10 (m,



carboxamide
1H), 3.39-3.44 (m, 2H), 3.12-3.19 (m, 2H),




2.08-2.14 (m, 2H), 1.88-1.99 (m, 2H)


165
N-{4-[(4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methoxyphenyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 9.91-9.93 (bs, 1H), 8.33-
m/e 388



1,3-dihydro-2H-
8.34 (bs, 1H), 8.16-8.18 (m, 2H), 7.86-7.98
(M + H)+



isoindole-2-
(m, 4H), 7.20-7.23 (m, 2H), 7.15-7.19 (m,



carboxamide
2H), 6.95-6.98 (m, 2H), 4.85 (s, 4H), 3.67 (s,




3H)


166
N-{4-[(3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methoxyphenyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 9.99-10.01 (m, 1H),
m/e 388



1,3-dihydro-2H-
8.34-8.35 (bs, 1H), 8.10-8.20 (m, 2H), 7.91-
(M + H)+



isoindole-2-
7.94 (m, 2H), 7.82 (t, J = 2.2 Hz, 1H), 7.57-



carboxamide
7.60 (m, 1H), 7.21-7.24 (m, 2H), 7.14-7.19




(m, 2H), 6.75 (dd, J = 8.2, 2.5 Hz, 1H), 4.84




(s, 4H), 3.68 (s, 3H)


167
N-{4-[(5-acetamido-2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methoxyphenyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 9.89-9.92 (bs, 1H), 8.93-
m/e 445



1,3-dihydro-2H-
8.97 (m, 2H), 8.38-8.39 (bs, 1H), 8.04-8.07
(M + H)+



isoindole-2-
(m, 2H), 7.93-7.96 (m, 2H), 7.87-7.93 (m,



carboxamide
1H), 7.20-7.25 (m, 2H), 7.15-7.19 (m, 2H),




6.91 (d, J = 8.8 Hz, 1H), 4.85 (s, 4H), 3.71




(d, J = 1.1 Hz, 3H), 2.14 (d, J = 0.9 Hz, 3H)


168
N-(4-{[2-(3,5-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



dimethoxyphenyl)eth-
Temp = 90° C.) δ ppm 8.25-8.28 (bs, 1H), 8.08-
m/e 444



yl]carbamoyl}phenyl)-
8.13 (m, 1H), 8.07-8.11 (m, 2H), 7.87-7.92
(M − H)



1,3-dihydro-2H-
(m, 2H), 7.19-7.24 (m, 2H), 7.14-7.19 (m,



isoindole-2-
2H), 6.56-6.59 (m, 2H), 6.47-6.50 (m, 1H),



carboxamide
4.84 (s, 4H), 3.82-3.88 (m, 2H), 3.65 (s, 6H),




3.00 (t, J = 7.2 Hz, 2H)


169
N-[4-({2-[3-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



(trifluoromethyl)phe-
Oxide) δ ppm 8.63-8.66 (bs, 1H), 8.45 (t, J =
m/e 454



nyl]ethyl}carbamoyl)phenyl]-
5.6 Hz, 1H), 7.70-7.73 (m, 2H), 7.62-7.65
(M + H)+



1,3-dihydro-
(m, 2H), 7.53-7.61 (m, 4H), 7.37-7.40 (m,



2H-isoindole-2-
2H), 7.32-7.35 (m, 2H), 4.78-4.79 (bs, 4H),



carboxamide
3.50-3.56 (m, 2H), 2.96 (t, J = 7.1 Hz, 2H)


170
N-{4-[(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methylbutan-2-
Temp = 90° C.) δ ppm 8.26-8.28 (bs, 1H), 7.96-
m/e 352



yl)carbamoyl]phenyl}-
7.99 (m, 2H), 7.86-7.88 (m, 2H), 7.18-7.24
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.14-7.19 (m, 2H), 6.76-6.79 (bs,



isoindole-2-
1H), 4.83 (s, 4H), 1.94 (q, J = 7.5 Hz, 2H),



carboxamide
1.47 (s, 6H), 0.90 (t, J = 7.4 Hz, 3H)


171
N-(4-{[2-(1H-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



imidazol-4-
Temp = 90° C.) δ ppm 8.48-8.52 (bs, 1H), 8.32-
m/e 376



yl)ethyl]carbamoyl}phenyl)-
8.34 (bs, 1H), 8.27 (s, 1H), 8.09-8.12 (m,
(M + H)+



1,3-dihydro-
2H), 7.90-7.93 (m, 2H), 7.19-7.23 (m, 2H),



2H-isoindole-2-
7.16-7.19 (m, 2H), 4.84 (s, 4H), 3.90-3.96



carboxamide
(m, 2H), 3.13 (t, J = 6.7 Hz, 2H)


172
N-(4-{[(2S)-2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



hydroxypropyl]carbamoyl}phenyl)-
Temp = 90° C.) δ ppm 8.28-8.30 (bs, 1H), 8.06-
m/e 338



1,3-dihydro-2H-
8.10 (m, 2H), 8.03-8.09 (m, 1H), 7.88-7.91
(M − H)



isoindole-2-
(m, 2H), 7.19-7.23 (m, 2H), 7.15-7.19 (m,



carboxamide
2H), 4.84 (s, 4H), 4.25 (dddd, J = 12.4, 7.0,




6.3, 4.2 Hz, 1H), 3.78 (ddd, J = 13.4, 6.1, 4.3




Hz, 1H), 3.61 (ddd, J = 13.4, 6.9, 5.4 Hz,




1H), 1.31 (d, J = 6.2 Hz, 3H)


173
N-(4-{[(1R)-1-(3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



cyanophenyl)ethyl]carbamoyl}phenyl)-
Temp = 90° C.) δ ppm 8.32-8.37 (m, 1H), 8.28-
m/e 411



1,3-dihydro-2H-
8.32 (bs, 1H), 8.09-8.12 (m, 2H), 7.88-7.90
(M + H)+



isoindole-2-
(m, 2H), 7.83 (s, 1H), 7.69-7.72 (m, 1H),



carboxamide
7.43-7.47 (m, 1H), 7.30 (t, J = 7.8 Hz, 1H),




7.19-7.24 (m, 2H), 7.14-7.18 (m, 2H), 5.55




(p, J = 7.1 Hz, 1H), 4.83 (s, 4H), 1.56 (d, J =




7.0 Hz, 3H)


174
N-(4-{[(2S)-1-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



hydroxy-3-
Temp = 90° C.) δ ppm 8.29-8.31 (bs, 1H), 8.05-
m/e 366



methylbutan-2-
8.08 (m, 2H), 7.87-7.90 (m, 2H), 7.46-7.53
(M + H)+



yl]carbamoyl}phenyl)-
(bs, 1H), 7.19-7.24 (m, 2H), 7.14-7.18 (m,



1,3-dihydro-2H-
2H), 4.84 (s, 4H), 4.29-4.36 (m, 1H), 3.99 (d,



isoindole-2-
J = 4.8 Hz, 2H), 2.17-2.28 (m, 1H), 1.00-



carboxamide
1.10 (m, 6H)


175
N-{4-[benzyl(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



hydroxyethyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.20-8.21 (bs, 1H), 7.85-
m/e 414



1,3-dihydro-2H-
7.88 (m, 2H), 7.61-7.64 (m, 2H), 7.37-7.43
(M − H)



isoindole-2-
(m, 2H), 7.29-7.34 (m, 2H), 7.20-7.27 (m,



carboxamide
3H), 7.14-7.19 (m, 2H), 4.94-4.94 (bs, 2H),




4.84 (s, 4H), 3.94-3.97 (m, 2H), 3.73 (t, J =




6.0 Hz, 2H)


176
N-{4-[(4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(−))



cyanophenyl)carbamoyl]phenyl}-
Oxide) δ ppm 7.97-7.99 (m, 2H), 7.91-7.93
m/e 381



1,3-dihydro-2H-
(m, 2H), 7.80-7.83 (m, 2H), 7.72-7.77 (m,
(M − H)



isoindole-2-
2H), 7.38-7.41 (m, 2H), 7.33-7.36 (m, 2H),



carboxamide
4.81 (s, 4H)


177
N-(4-{[2-(4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



chlorophenyl)ethyl]carbamoyl}phenyl)-
Oxide) δ ppm 8.66 (s, 1H), 8.45 (t, J = 5.6
m/e 420



1,3-dihydro-2H-
Hz, 1H), 7.72-7.74 (m, 2H), 7.64 (dd, J =
(M + H)+



isoindole-2-
8.7, 2.3 Hz, 2H), 7.37-7.40 (m, 2H), 7.32-



carboxamide
7.36 (m, 4H), 7.27-7.30 (m, 2H), 4.78-4.79




(bs, 4H), 3.45-3.50 (m, 2H), 2.84 (t, J = 7.2




Hz, 2H)


178
N-(4-{[2-(4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methylpiperazin-1-
Temp = 90° C.) δ ppm 8.34-8.35 (bs, 1H), 8.08-
m/e 408



yl)ethyl]carbamoyl}phenyl)-
8.12 (m, 2H), 8.06-8.10 (m, 1H), 7.92-7.94
(M + H)+



1,3-dihydro-
(m, 2H), 7.19-7.23 (m, 2H), 7.17-7.19 (m,



2H-isoindole-2-
2H), 4.85 (s, 4H), 3.71 (q, J = 5.9 Hz, 2H),



carboxamide
2.85-2.90 (m, 4H), 2.81-2.85 (m, 4H), 2.76




(t, J = 6.3 Hz, 2H), 2.48 (s, 3H)


179
N-(4-{[2-(pyridin-2-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



yl)ethyl]carbamoyl}phenyl)-
Oxide) δ ppm 8.77 (dd, J = 5.8, 1.6 Hz, 1H),
m/e 387



1,3-dihydro-
8.45 (td, J = 7.8, 1.6 Hz, 1H), 7.92 (d, J = 8.0
(M + H)+



2H-isoindole-2-
Hz, 1H), 7.88 (ddd, J = 7.5, 6.0, 1.3 Hz, 1H),



carboxamide
7.66-7.69 (m, 2H), 7.62-7.65 (m, 2H), 7.36-




7.39 (m, 2H), 7.32-7.35 (m, 2H), 4.78-4.79




(bs, 4H), 3.68-3.72 (m, 2H), 3.25 (t, J = 6.4




Hz, 2H)


180
N-{4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(APCI(+))



[(cyanomethyl)carbamoyl]phenyl}-
Oxide, Temp = 90° C.) δ ppm 7.79-7.81 (m,
m/e 321



1,3-dihydro-2H-
2H), 7.68-7.71 (m, 2H), 7.36-7.41 (m, 2H),
(M + H)+



isoindole-2-
7.31-7.36 (m, 2H), 4.82 (s, 4H), 4.28 (s, 2H)



carboxamide


181
N-[4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



(cyclohexylcarbamoyl)phenyl]-
Temp = 90° C.) δ ppm 8.26-8.28 (bs, 1H), 8.05-
m/e 364



1,3-dihydro-2H-
8.08 (m, 2H), 7.88-7.90 (m, 2H), 7.40-7.47
(M + H)+



isoindole-2-
(m, 1H), 7.19-7.24 (m, 2H), 7.14-7.19 (m,



carboxamide
2H), 4.84 (s, 4H), 4.13-4.20 (m, 1H), 2.05-




2.08 (m, 2H), 1.63-1.67 (m, 2H), 1.47-1.54




(m, 1H), 1.28-1.41 (m, 4H), 1.04-1.17 (m,




1H)


182
N-{4-[(3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



hydroxyphenyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 9.93-9.94 (m, 1H), 8.30-
m/e 374



1,3-dihydro-2H-
8.32 (m, 1H), 8.10-8.14 (m, 2H), 8.01 (t, J =
(M + H)+



isoindole-2-
2.2 Hz, 1H), 7.87-7.92 (m, 2H), 7.48 (ddd, J =



carboxamide
8.0, 2.0, 0.9 Hz, 1H), 7.25 (t, J = 8.0 Hz,




1H), 7.19-7.25 (m, 2H), 7.13-7.18 (m, 2H),




6.90 (ddd, J = 8.0, 2.4, 1.0 Hz, 1H), 4.83 (s,




4H)


183
N-{4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



[butyl(methyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.24-8.26 (bs, 1H), 7.89-
m/e 350



1,3-dihydro-2H-
7.92 (m, 2H), 7.49-7.52 (m, 2H), 7.19-7.24
(M + H)+



isoindole-2-
(m, 2H), 7.15-7.19 (m, 2H), 4.85 (s, 4H),



carboxamide
3.41 (t, J = 7.3 Hz, 2H), 2.95 (s, 3H), 1.52




(p, J = 7.3 Hz, 2H), 1.15-1.33 (m, 2H), 0.82




(t, J = 7.3 Hz, 3H)


184
N-(4-{[4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



(dimethylamino)phe-
Temp = 90° C.) δ ppm 9.76-9.77 (bs, 1H), 8.30-
m/e 399



nyl]carbamoyl}phenyl)-
8.32 (bs, 1H), 8.16-8.19 (m, 2H), 7.91-7.95
(M − H)



1,3-dihydro-2H-
(m, 2H), 7.84-7.86 (m, 2H), 7.20-7.23 (m,



isoindole-2-
2H), 7.15-7.19 (m, 2H), 6.73-6.81 (m, 2H),



carboxamide
4.85 (s, 4H), 2.77 (s, 6H)


185
N-[4-(3,4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



dihydroisoquinolin-
Temp = 90° C.) δ ppm 8.29-8.30 (bs, 1H), 7.91-
m/e 398



2(1H)-
7.94 (m, 2H), 7.54-7.60 (m, 2H), 7.19-7.26
(M + H)+



ylcarbonyl)phenyl]-
(m, 2H), 7.15-7.19 (m, 2H), 7.11-7.15 (m,



1,3-dihydro-2H-
2H), 7.05-7.11 (m, 1H), 6.98-7.04 (m, 1H),



isoindole-2-
4.86 (s, 4H), 4.80-4.81 (bs, 2H), 3.75 (t, J =



carboxamide
5.9 Hz, 2H), 2.78 (t, J = 6.0 Hz, 2H)


186
N-[4-(1,3-dihydro-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



2H-isoindol-2-
Temp = 90° C.) δ ppm 8.34-8.36 (bs, 1H), 7.96-
m/e 384



ylcarbonyl)phenyl]-
7.98 (m, 2H), 7.72-7.75 (m, 2H), 7.20-7.24
(M + H)+



1,3-dihydro-2H-
(m, 4H), 7.16-7.20 (m, 4H), 4.87-4.90 (bs,



isoindole-2-
4H), 4.88 (s, 4H)



carboxamide


187
N-[4-(2,3-dihydro-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



1H-indol-1-
Temp = 90° C.) δ ppm 8.36-8.38 (m, 1H), 7.96-
m/e 384



ylcarbonyl)phenyl]-
8.00 (m, 1H), 7.93-7.97 (m, 2H), 7.63-7.65
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.20-7.24 (m, 2H), 7.15-7.20 (m,



isoindole-2-
2H), 7.11-7.15 (m, 2H), 6.96-7.00 (m, 1H),



carboxamide
4.87 (s, 4H), 3.94-3.99 (m, 2H), 2.89 (t, J =




8.3 Hz, 2H)


188
N-[4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(−))



(phenylcarbamoyl)phenyl]-
Oxide) δ ppm 7.90-7.92 (m, 2H), 7.72-7.77
m/e 356



1,3-dihydro-
(m, 4H), 7.33-7.40 (m, 6H), 7.12 (t, J = 7.3
(M − H)



2H-isoindole-2-
Hz, 1H), 4.80-4.82 (bs, 4H)



carboxamide


189
N-{4-[(4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



fluorophenyl)carbamoyl]phenyl}-
Oxide) δ ppm 10.17-10.19 (bs, 1H), 8.72-
m/e 376



1,3-dihydro-2H-
8.74 (bs, 1H), 7.89-7.91 (m, 2H), 7.74-7.79
(M + H)+



isoindole-2-
(m, 2H), 7.71-7.75 (m, 2H), 7.37-7.41 (m,



carboxamide
2H), 7.33-7.36 (m, 2H), 7.18-7.22 (m, 2H),




4.80-4.81 (bs, 4H)


190
N-(4-{[2-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



(diethylamino)ethyl]
Oxide, Temp = 90° C.) δ ppm 7.78-7.81 (m,
m/e 381



carbamoyl}phenyl)-
2H), 7.67-7.70 (m, 2H), 7.37-7.41 (m, 2H),
(M + H)+



1,3-dihydro-2H-
7.32-7.36 (m, 2H), 4.82 (s, 4H), 3.66 (t, J =



isoindole-2-
6.4 Hz, 2H), 3.29-3.33 (m, 2H), 3.24 (q, J =



carboxamide
7.5 Hz, 4H), 1.24-1.33 (m, 6H)


191
N-{4-[2-hydroxy-2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



phenylethyl)(methyl)
Temp = 90° C.) δ ppm 8.21 (d, J = 1.6 Hz, 1H),
m/e 416



carbamoyl]phenyl}-
7.85-7.88 (m, 2H), 7.56-7.59 (m, 2H), 7.51-
(M + H)+



1,3-dihydro-2H-
7.54 (m, 2H), 7.29-7.35 (m, 2H), 7.20-7.24



isoindole-2-
(m, 3H), 7.14-7.19 (m, 2H), 5.29-5.35 (m,



carboxamide
1H), 4.84 (s, 4H), 3.11 (s, 3H)


192
N-{4-[(2-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(−))



aminophenyl)carbamoyl]phenyl}-
Oxide) δ ppm 7.91-7.93 (m, 2H), 7.69-7.72
m/e 371



1,3-dihydro-2H-
(m, 2H), 7.38-7.43 (m, 2H), 7.33-7.36 (m,
(M − H)



isoindole-2-
2H), 7.15-7.18 (m, 1H), 7.01 (ddd, J = 8.0,



carboxamide
7.3, 1.5 Hz, 1H), 6.82 (dd, J = 8.0, 1.4 Hz,




1H), 6.66 (td, J = 7.5, 1.5 Hz, 1H), 4.81 (s,




4H)


193
N-(4-{[(2R)-2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



hydroxypropyl]carbamoyl}phenyl)-
Temp = 90° C.) δ ppm 8.28-8.30 (bs, 1H), 8.05-
m/e 340



1,3-dihydro-2H-
8.10 (m, 2H), 8.04-8.09 (m, 1H), 7.88-7.91
(M + H)+



isoindole-2-
(m, 2H), 7.19-7.23 (m, 2H), 7.16-7.18 (m,



carboxamide
2H), 4.84 (s, 4H), 4.25 (dqd, J = 6.9, 6.2, 4.2




Hz, 1H), 3.78 (ddd, J = 13.4, 6.1, 4.2 Hz,




1H), 3.61 (ddd, J = 13.4, 6.9, 5.4 Hz, 1H),




1.31 (d, J = 6.2 Hz, 3H)


194
N-(4-{[(2S)-1-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(−))



amino-4-methyl-1-
Oxide, Temp = 90° C.) δ ppm 7.80-7.83 (m,
m/e 393



oxopentan-2-
2H), 7.65-7.68 (m, 2H), 7.36-7.41 (m, 2H),
(M − H)



yl]carbamoyl}phenyl)-
7.31-7.36 (m, 2H), 4.82 (s, 4H), 4.50 (dd, J =



1,3-dihydro-2H-
9.1, 5.0 Hz, 1H), 1.60-1.77 (m, 3H), 0.94



isoindole-2-
(dd, J = 11.0, 6.1 Hz, 6H)



carboxamide


195
tert-butyl(1-{4-

1H NMR (400 MHz, pyridine-d5) δ ppm 1.49-

(ESI(+))



[(1,3-dihydro-2H-
1.51 (m, 9 H), 1.51-1.61 (m, 1 H), 1.88-
m/e 465



isoindol-2-
2.00 (m, 1 H), 2.98-3.11 (m, 2 H), 3.75-
(M + H)+



ylcarbonyl)amino]ben-
3.90 (m, 1 H), 4.21 (d, J = 13.4 Hz, 1 H), 4.85



zoyl}piperidin-4-
(s, 4 H), 6.59 (d, J = 6.1 Hz, 1 H), 7.10-7.25



yl)carbamate
(m, 5 H), 7.45-7.55 (m, 4 H), 7.89 (d, J = 8.5




Hz, 2 H), 8.26 (s, 1 H) 8.64 (s, 1 H)


196
N-(4-{[3-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



(morpholin-4-
Oxide, Temp = 90° C.) δ ppm 7.75-7.78 (m,
m/e 409



yl)propyl]carbamoyl}phenyl)-
2H), 7.63-7.66 (m, 2H), 7.26-7.42 (m, 4H),
(M + H)+



1,3-dihydro-2H-
4.79 (s, 4H), 3.82-3.86 (m, 4H), 3.37 (t, J =



isoindole-2-
6.6 Hz, 2H), 3.20-3.26 (m, 4H), 3.12-3.18



carboxamide
(m, 2H), 1.89-2.03 (m, 2H)


197
N-[4-({4-[3-chloro-5-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.57-

(ESI(+))



(trifluoromethyl)pyridin-
8.59 (m, 1H), 8.55-8.57 (bs, 1H), 8.23 (d, J =
m/e 530



2-yl]piperazin-1-
2.2 Hz, 1H), 7.65-7.69 (m, 2H), 7.37-7.41
(M + H)+



yl}carbonyl)phenyl]-
(m, 2H), 7.29-7.38 (m, 4H), 4.79-4.80 (bs,



1,3-dihydro-2H-
4H), 3.59-3.84 (m, 4H), 3.45-3.58 (m, 4H)



isoindole-2-



carboxamide


198
N-(4-{[4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



(cyclohexylmethyl)piperazin-
Temp = 90° C.) δ ppm 8.31-8.33 (bs, 1H), 7.91-
m/e 445



1yl]carbony1}phenyl)-
7.95 (m, 2H), 7.50-7.57 (m, 2H), 7.20-7.23
(M − H)



1,3-dihydro-2H-
(m, 2H), 7.15-7.19 (m, 2H), 4.86 (s, 4H),



isoindole-2-
3.63-3.74 (m, 4H), 2.40-2.43 (m, 4H), 2.16



carboxamide
(d, J = 7.0 Hz, 2H), 1.75-1.81 (m, 2H), 1.56-




1.70 (m, 3H), 1.43-1.56 (m, 1H), 1.09-1.29




(m, 3H), 0.82-0.97 (m, 2H)


199
N-(4-{[1-(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 10.28

(ESI(−))



chlorobenzyl)-1H-
(s, 1H), 8.64 (s, 1H), 8.18 (s, 1H), 7.85-7.89
m/e 470



pyrazol-4-
(m, 2H), 7.70-7.74 (m, 2H), 7.63 (s, 1H),
(M − H)



yl]carbamoyl}phenyl)-
7.28-7.42 (m, 7H), 7.18-7.23 (m, 1H), 5.33-



1,3-dihydro-2H-
5.34 (bs, 2H), 4.79-4.81 (bs, 4H)



isoindole-2-



carboxamide


200
N-(4-{[3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



(diethylcarbamoyl)piperidin-1-
Temp = 90° C.) δ ppm 8.27-8.29 (bs, 1H), 7.89-
m/e 447



yl]carbonyl}phenyl)-
7.92 (m, 2H), 7.52-7.56 (m, 2H), 7.19-7.24
(M − H)



1,3-dihydro-2H-
(m, 2H), 7.15-7.19 (m, 2H), 4.85 (s, 4H),



isoindole-2-
4.17-4.21 (m, 1H), 3.19-3.43 (m, 5H), 2.94



carboxamide
(ddd, J = 13.0, 12.1, 3.3 Hz, 0H), 2.84 (tt, J =




10.6, 4.1 Hz, 1H), 1.89-2.07 (m, 2H), 1.58-




1.66 (m, 1H), 1.43-1.58 (m, 1H), 1.04 (t, J =




7.1 Hz, 6H)


201
N-(4-{[3-(piperidin-1-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



yl)propyl]carbamoyl}phenyl)-
Temp = 90° C.) δ ppm 8.45-8.51 (m, 1H), 8.32-
m/e 407



1,3-dihydro-2H-
8.36 (bs, 1H), 8.16-8.18 (m, 2H), 7.93-7.96
(M + H)+



isoindole-2-
(m, 2H), 7.19-7.24 (m, 2H), 7.15-7.19 (m,



carboxamide
2H), 4.85 (s, 4H), 3.61 (q, J = 6.1 Hz, 2H),




3.00-3.05 (m, 2H), 2.88-2.91 (m, 4H), 2.08-




2.16 (m, 2H), 1.66-1.76 (m, 4H), 1.32-1.41




(m, 2H)


202
N-(4-{[4-(2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.53

(ESI(+))



hydroxyethyl)piperazin-1-
(s, 1H), 7.62-7.66 (m, 2H), 7.24-7.43 (m,
m/e 395



yl]carbonyl}phenyl)-
6H), 4.78-4.79 (bs, 4H), 4.39-4.44 (m, 1H),
(M + H)+



1,3-dihydro-2H-
3.39-3.58 (m, 6H), 2.34-2.45 (m, 6H)



isoindole-2-



carboxamide


203
N-{4-[(2-hydroxy-6-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methylphenyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 9.59-9.61 (bs, 1H), 8.38-
m/e 388



1,3-dihydro-2H-
8.40 (bs, 1H), 8.22-8.25 (m, 2H), 7.95-7.98
(M + H)+



isoindole-2-
(m, 2H), 7.20-7.23 (m, 2H), 7.16-7.19 (m,



carboxamide
2H), 7.08 (d, J = 7.1 Hz, 1H), 7.06 (d, J =




2.0 Hz, 1H), 6.82 (dd, J = 7.0, 1.8 Hz, 1H),




4.85 (s, 4H), 2.43 (s, 3H)


204
N-(4-{[4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



(dimethylamino)bu-
Oxide, Temp = 90° C.) δ ppm 7.76-7.79 (m,
m/e 381



tyl]carbamoyl}phenyl)-
2H), 7.64-7.67 (m, 2H), 7.37-7.42 (m, 2H),
(M + H)+



1,3-dihydro-2H-
7.32-7.36 (m, 2H), 4.82 (s, 4H), 3.32-3.37



isoindole-2-
(m, 2H), 3.10-3.15 (m, 2H), 2.81 (s, 6H),



carboxamide
1.68-1.79 (m, 2H), 1.59-1.67 (m, 2H)


205
N-{4-[(3-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



hydroxypropyl)carbamoyl]phenyl}-
Oxide, Temp = 90° C.) δ ppm 7.75-7.77 (m,
m/e 340



1,3-dihydro-2H-
2H), 7.63-7.65 (m, 2H), 7.36-7.41 (m, 2H),
(M + H)+



isoindole-2-
7.31-7.36 (m, 2H), 4.82 (s, 4H), 3.53 (t, J =



carboxamide
6.3 Hz, 2H), 3.36 (t, J = 6.9 Hz, 2H), 1.74 (p,




J = 6.6 Hz, 2H)


206
N-{4-[(4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



cyclohexylpiperazin-
Temp = 90° C.) δ ppm 8.31-8.33 (bs, 1H), 7.91-
m/e 433



1-
7.94 (m, 2H), 7.52-7.56 (m, 2H), 7.20-7.25
(M + H)+



yl)carbonyl]phenyl}-
(m, 2H), 7.15-7.20 (m, 2H), 4.86 (s, 4H),



1,3-dihydro-2H-
3.72-3.80 (m, 4H), 2.62-2.65 (m, 4H), 2.36-



isoindole-2-
2.44 (m, 1H), 1.80-1.84 (m, 2H), 1.67-1.72



carboxamide
(m, 2H), 1.48-1.54 (m, 1H), 1.01-1.28 (m,




5H)


207
N-[4-(5,6-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.61

(ESI(+))



dihydro[1,2,4]triazolo[4,3-
(s, 1H), 8.51 (s, 1H), 7.72 (s, 1H), 7.68-7.70
m/e 389



a]pyrazin-7(8H)-
(m, 1H), 7.41-7.47 (m, 2H), 7.35-7.40 (m,
(M + H)+



ylcarbonyl)phenyl]-
2H), 7.29-7.35 (m, 2H), 4.86 (s, 2H), 4.79-



1,3-dihydro-2H-
4.80 (bs, 4H), 4.15 (t, J = 5.3 Hz, 2H), 3.83-



isoindole-2-
3.95 (m, 2H)



carboxamide


208
N-{4-[methyl(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.49-

(ESI(+))



methylbutyl)carbamoyl]phenyl}-
8.53 (bs, 1H), 7.60-7.67 (m, 2H), 7.26-7.40
m/e 366



1,3-dihydro-2H-
(m, 6H), 4.78 (s, 4H), 3.16-3.49 (m, 2H),
(M + H)+



isoindole-2-
2.92 (s, 3H), 1.13-1.79 (m, 3H), 0.48-1.12



carboxamide
(m, 6H)


209
N-[4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



(propylcarbamoyl)phenyl]-
Oxide, Temp = 90° C.) δ ppm 7.75-7.78 (m,
m/e 324



1,3-dihydro-
2H), 7.62-7.65 (m, 2H), 7.32-7.40 (m, 4H),
(M + H)+



2H-isoindole-2-
4.82 (s, 4H), 3.22-3.30 (m, 2H), 1.53-1.63



carboxamide
(m, 2H), 0.93 (t, J = 7.4 Hz, 3H)


210
N-(4-{[(2S)-1-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



hydroxybutan-2-
Temp = 90° C.) δ ppm 8.28-8.29 (bs, 1H), 8.06-
m/e 354



yl]carbamoyl}phenyl)-
8.08 (m, 2H), 7.87-7.90 (m, 2H), 7.57-7.61
(M + H)+



1,3-dihydro-2H-
(m, 1H), 7.19-7.23 (m, 2H), 7.15-7.19 (m,



isoindole-2-
2H), 4.84 (s, 4H), 4.37-4.47 (m, 1H), 3.91-



carboxamide
3.99 (m, 2H), 1.84-1.96 (m, 1H), 1.71-1.85




(m, 1H), 1.03 (t, J = 7.5 Hz, 3H)


211
N-{4-[(5-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



fluoropyridin-2-
Temp = 90° C.) δ ppm 10.45-10.47 (bs, 1H),
m/e 377



yl)carbamoyl]phenyl}-
8.58 (dd, J = 9.1, 4.2 Hz, 1H), 8.42-8.44 (bs,
(M + H)+



1,3-dihydro-2H-
1H), 8.24 (d, J = 3.0 Hz, 1H), 8.18-8.20 (m,



isoindole-2-
2H), 7.98-8.00 (m, 2H), 7.45 (ddd, J = 9.0,



carboxamide
8.1, 3.1 Hz, 1H), 7.20-7.24 (m, 2H), 7.15-




7.20 (m, 2H), 4.86 (s, 4H)


212
N-{4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



[(cyclopropylmethyl)
Temp = 90° C.) δ ppm 8.23-8.24 (bs, 1H), 7.90-
m/e 378



(propyl)carbamoyl]phenyl}-
7.92 (m, 2H), 7.48-7.52 (m, 2H), 7.19-7.24
(M + H)+



1,3-dihydro-
(m, 2H), 7.15-7.19 (m, 2H), 4.85 (s, 4H),



2H-isoindole-2-
3.49-3.53 (m, 2H), 3.35 (d, J = 6.7 Hz, 2H),



carboxamide
1.58-1.66 (m, 2H), 0.96-1.07 (m, 1H), 0.81




(t, J = 7.4 Hz, 3H), 0.42-0.47 (m, 2H), 0.15-




0.19 (m, 2H)


213
N-(4-{[(2S)-1-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methoxypropan-2-
Temp = 90° C.) δ ppm 8.28-8.34 (m, 1H), 8.05-
m/e 354



yl]carbamoyl}phenyl)-
8.08 (m, 2H), 7.88-7.90 (m, 2H), 7.54-7.63
(M + H)+



1,3-dihydro-2H-
(m, 1H), 7.18-7.24 (m, 2H), 7.15-7.18 (m,



isoindole-2-
2H), 4.83 (s, 4H), 4.54-4.64 (m, 1H), 3.53



carboxamide
(dd, J = 9.5, 5.2 Hz, 1H), 3.45 (dd, J = 9.5,




5.5 Hz, 1H), 3.27 (s, 3H), 1.30 (d, J = 6.8




Hz, 3H)


214
N-[4-(1,3,4,9-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



tetrahydro-2H-beta-
Temp = 90° C.) δ ppm 11.10-11.13 (bs, 1H),
m/e 437



carbolin-2-
8.29-8.30 (bs, 1H), 7.91-7.94 (m, 2H), 7.57-
(M + H)+



ylcarbonyl)phenyl]-
7.61 (m, 2H), 7.57-7.60 (m, 1H), 7.45-7.48



1,3-dihydro-2H-
(m, 1H), 7.16-7.25 (m, 6H), 4.96-4.97 (bs,



isoindole-2-
2H), 4.87 (s, 4H), 3.86-3.92 (m, 2H), 2.85 (t,



carboxamide
J = 5.7 Hz, 2H)


215
N-[4-(tert-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



butylcarbamoyl)phenyl]-
Temp = 90° C.) δ ppm 8.24-8.26 (bs, 1H), 7.96-
m/e 338



1,3-dihydro-2H-
7.99 (m, 2H), 7.85-7.88 (m, 2H), 7.19-7.23
(M + H)+



isoindole-2-
(m, 2H), 7.14-7.19 (m, 2H), 6.93-6.96 (bs,



carboxamide
1H), 4.83 (s, 4H), 1.52 (s, 9H)


216
N-[4-({4-[4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



(trifluoromethyl)phe-
Oxide) δ ppm 7.64-7.67 (m, 2H), 7.53-7.55
m/e 495



nyl]piperazin-1-
(m, 2H), 7.36-7.42 (m, 4H), 7.31-7.36 (m,
(M + H)+



yl}carbonyl)phenyl]-
2H), 7.09-7.11 (m, 2H), 4.79-4.80 (bs, 4H),



1,3-dihydro-2H-
3.55-3.76 (m, 4H), 3.26-3.43 (m, 4H)



isoindole-2-



carboxamide


217
N-{4-[(3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methylbutan-2-
Temp = 90° C.) δ ppm 8.28-8.29 (bs, 1H), 8.06-
m/e 352



yl)carbamoyl]phenyl}-
8.09 (m, 2H), 7.88-7.92 (m, 2H), 7.30-7.35
(M + H)+



1,3-dihydro-2H-
(bs, 1H), 7.19-7.24 (m, 2H), 7.14-7.18 (m,



isoindole-2-
2H), 4.84 (s, 4H), 4.22-4.32 (m, 1H), 1.82-



carboxamide
1.91 (m, 1H), 1.19 (d, J = 6.8 Hz, 3H), 0.97




(d, J = 6.7 Hz, 3H), 0.93 (d, J = 6.7 Hz, 3H)


218
N-{4-[(3,3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



difluoropyrrolidin-1-
Temp = 90° C.) δ ppm 8.34-8.36 (bs, 1H), 7.91-
m/e 370



yl)carbonyl]phenyl}-
7.94 (m, 2H), 7.61-7.65 (m, 2H), 7.20-7.24
(M − H)



1,3-dihydro-2H-
(m, 2H), 7.15-7.19 (m, 2H), 4.86 (s, 4H),



isoindole-2-
3.96-4.04 (m, 2H), 3.76 (t, J = 7.4 Hz, 2H),



carboxamide
2.21-2.35 (m, 2H)


219
N-{4-[(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methylpiperidin-1-
Temp = 90° C.) δ ppm 8.26-8.28 (bs, 1H), 7.90-
m/e 364



yl)carbonyl]phenyl}-
7.92 (m, 2H), 7.47-7.51 (m, 2H), 7.19-7.23
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.14-7.19 (m, 2H), 4.85 (s, 4H),



isoindole-2-
4.62-4.67 (m, 1H), 4.02-4.17 (m, 1H), 2.93



carboxamide
(td, J = 12.9, 3.1 Hz, 1H), 1.30-1.65 (m, 6H),




1.14 (d, J = 6.9 Hz, 3H)


220
N-(4-{[(3S)-1-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



benzylpyrrolidin-3-
Temp = 90° C.) δ ppm 8.26-8.31 (bs, 1H), 8.20-
m/e 439



yl]carbamoyl}phenyl)-
8.26 (m, 1H), 8.09-8.12 (m, 2H), 7.89-7.92
(M − H)



1,3-dihydro-2H-
(m, 2H), 7.41-7.48 (m, 2H), 7.23-7.33 (m,



isoindole-2-
3H), 7.19-7.24 (m, 2H), 7.14-7.19 (m, 2H),



carboxamide
4.90-5.00 (m, 1H), 4.84 (s, 4H), 3.91 (s, 2H),




3.09-3.17 (m, 3H), 2.68-2.75 (m, 1H), 2.30-




2.43 (m, 1H), 2.02 (dtd, J = 13.1, 7.8, 5.2




Hz, 1H)


221
N-{4-[(4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



hydroxypiperidin-1-
Temp = 90° C.) δ ppm 8.26-8.28 (bs, 1H), 7.89-
m/e 366



yl)carbonyl]phenyl}-
7.92 (m, 2H), 7.52-7.56 (m, 2H), 7.19-7.23
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.16-7.19 (m, 2H), 4.85 (s, 4H),



isoindole-2-
3.99-4.12 (m, 3H), 3.35 (ddd, J = 13.2, 9.1,



carboxamide
3.8 Hz, 2H), 1.82-1.98 (m, 2H), 1.59-1.75




(m, 2H)


222
N-{4-[bis(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methoxyethyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.22-8.24 (bs, 1H), 7.88-
m/e 398



1,3-dihydro-2H-
7.92 (m, 2H), 7.54-7.57 (m, 2H), 7.19-7.23
(M + H)+



isoindole-2-
(m, 2H), 7.16-7.18 (m, 2H), 4.84 (s, 4H),



carboxamide
3.75 (t, J = 5.8 Hz, 4H), 3.57 (t, J = 5.8 Hz,




4H), 3.23 (s, 6H)


223
N-{4-[(3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



fluorophenyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 10.17-10.23 (m, 1H),
m/e 376



1,3-dihydro-2H-
8.35-8.36 (bs, 1H), 8.12-8.14 (m, 2H), 8.04
(M + H)+



isoindole-2-
(dt, J = 11.5, 2.3 Hz, 1H), 7.90-7.93 (m, 2H),



carboxamide
7.66 (ddd, J = 8.1, 2.0, 1.0 Hz, 1H), 7.20-




7.31 (m, 3H), 7.15-7.19 (m, 2H), 6.83 (tdd, J =




8.4, 2.6, 0.9 Hz, 1H), 4.84 (s, 4H)


224
N-[4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



(cyclopentylcarbamoyl)phenyl]-
Oxide) δ ppm 7.76-7.78 (m, 2H), 7.60-7.68
m/e 350



1,3-dihydro-2H-
(m, 2H), 7.37-7.42 (m, 2H), 7.32-7.35 (m,
(M + H)+



isoindole-2-
2H), 4.76-4.82 (m, 4H), 4.17-4.25 (m, 1H),



carboxamide
1.86-1.93 (m, 2H), 1.66-1.71 (m, 2H), 1.50-




1.59 (m, 4H)


225
N-{4-[(4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(−))



carbamoylpiperidin-1-
Oxide, Temp = 90° C.) δ ppm 7.62-7.64 (m,
m/e 393



yl)carbonyl]phenyl}-
2H), 7.30-7.40 (m, 6H), 4.81 (s, 4H), 4.01-
(M − H)



1,3-dihydro-2H-
4.09 (m, 2H), 2.96-3.04 (m, 2H), 2.42-2.50



isoindole-2-
(m, 1H), 1.76-1.82 (m, 2H), 1.51-1.62 (m,



carboxamide
2H)


226
N-[4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(−))



(cyclopropylcarbamoyl)phenyl]-
Oxide) δ ppm 7.73-7.76 (m, 2H), 7.60-7.67
m/e 320



1,3-dihydro-2H-
(m, 2H), 7.36-7.40 (m, 2H), 7.32-7.36 (m,
(M − H)



isoindole-2-
2H), 4.78-4.79 (bs, 4H), 2.79-2.84 (m, 1H),



carboxamide
0.67-0.75 (m, 2H), 0.53-0.60 (m, 2H)


227
N-[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.56

(ESI(+))



(methylcarbamoyl)phenyl]-
(s, 1H), 8.19-8.26 (m, 1H), 7.73-7.77 (m,
m/e 296



1,3-dihydro-
2H), 7.63-7.67 (m, 2H), 7.30-7.39 (m, 4H),
(M + H)+



2H-isoindole-2-
4.79 (s, 4H), 2.76 (d, J = 4.5 Hz, 3H)



carboxamide


228
N-(4-{[3-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



(dimethylamino)pro-
Oxide, Temp = 90° C.) δ ppm 7.77-7.80 (m,
m/e 367



pyl]carbamoyl}phenyl)-
2H), 7.65-7.68 (m, 2H), 7.37-7.44 (m, 2H),
(M + H)+



1,3-dihydro-2H-
7.32-7.36 (m, 2H), 4.82 (s, 4H), 3.39 (t, J =



isoindole-2-
6.7 Hz, 2H), 3.09-3.19 (m, 2H), 2.83 (s, 6H),



carboxamide
1.89-2.03 (m, 2H)


229
N-{4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



[methyl(tetrahydrofuran-2-
Temp = 90° C.) δ ppm 8.24-8.26 (bs, 1H), 7.89-
m/e 380



ylmethyl)carbamoyl]
7.91 (m, 2H), 7.52-7.56 (m, 2H), 7.19-7.24
(M + H)+



phenyl}-1,3-dihydro-
(m, 2H), 7.14-7.19 (m, 2H), 4.85 (s, 4H),



2H-isoindole-2-
4.09-4.20 (m, 1H), 3.72-3.78 (m, 1H), 3.59-



carboxamide
3.71 (m, 2H), 3.46-3.52 (m, 1H), 3.10 (s,




3H), 1.74-1.86 (m, 1H), 1.62-1.72 (m, 2H),




1.39-1.50 (m, 1H)


230
N-[4-(pentan-2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



ylcarbamoyl)phenyl]-
Temp = 90° C.) δ ppm 8.26-8.28 (bs, 1H), 8.07-
m/e 352



1,3-dihydro-2H-
8.10 (m, 2H), 7.88-7.91 (m, 2H), 7.44 (d, J =
(M + H)+



isoindole-2-
7.0 Hz, 1H), 7.19-7.23 (m, 2H), 7.14-7.18



carboxamide
(m, 2H), 4.84 (s, 4H), 4.35-4.45 (m, 1H),




1.58-1.67 (m, 1H), 1.34-1.56 (m, 3H), 1.24




(d, J = 6.6 Hz, 3H), 0.88 (t, J = 7.2 Hz, 3H)


231
N-[4-(pentan-3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



ylcarbamoyl)phenyl]-
Temp = 90° C.) δ ppm 8.27-8.29 (bs, 1H), 8.08-
m/e 352



1,3-dihydro-2H-
8.11 (m, 2H), 7.89-7.91 (m, 2H), 7.31-7.37
(M + H)+



isoindole-2-
(m, 1H), 7.19-7.23 (m, 2H), 7.14-7.18 (m,



carboxamide
2H), 4.84 (s, 4H), 4.15-4.24 (m, 1H), 1.42-




1.72 (m, 4H), 0.96 (t, J = 7.4 Hz, 6H)


232
N-[4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



(cyclobutylcarbamoyl)phenyl]-
Temp = 90° C.) δ ppm 8.25-8.27 (m, 1H), 8.06-
m/e 336



1,3-dihydro-2H-
8.10 (m, 2H), 7.92-8.00 (m, 1H), 7.88-7.90
(M + H)+



isoindole-2-
(m, 2H), 7.19-7.23 (m, 2H), 7.14-7.18 (m,



carboxamide
2H), 4.84 (s, 4H), 4.71-4.80 (m, 1H), 2.27-




2.46 (m, 2H), 1.99-2.17 (m, 2H), 1.53-1.74




(m, 2H)


233
N-{4-[(1,3-dioxolan-2-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(−))



ylmethyl)(methyl)carbamoyl]phenyl}-
Oxide, Temp = 90° C.) δ ppm 7.61-7.64 (m,
m/e 280



1,3-dihydro-2H-
2H), 7.31-7.45 (m, 6H), 5.04 (t, J = 4.3 Hz,
(M − H)



isoindole-2-
1H), 4.81 (s, 4H), 3.88-3.94 (m, 2H), 3.82-



carboxamide
3.86 (m, 2H), 3.54 (d, J = 4.3 Hz, 2H), 3.04




(s, 3H)


234
N-(4-{[1-(4-

1H NMR (300 MHz, DMSO-d6) δ ppm 10.45

(ESI(+))



fluorophenyl)-1H-
(s, 1H), 8.65-8.68 (m, 2H), 7.82-7.94 (m,
m/e 442



pyrazol-4-
5H), 7.74-7.78 (m, 2H), 7.31-7.40 (m, 6H),
(M + H)+



yl]carbamoyl}phenyl)-
4.80-4.82 (bs, 4H)



1,3-dihydro-2H-



isoindole-2-



carboxamide


235
N-{4-[(1-hydroxy-2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



methylpropan-2-
Temp = 90° C.) δ ppm 8.23-8.34 (m, 1H), 7.95-
m/e 352



yl)carbamoyl]phenyl}-
7.97 (m, 2H), 7.84-7.88 (m, 2H), 7.19-7.24
(M − H)



1,3-dihydro-2H-
(m, 2H), 7.15-7.18 (m, 2H), 4.83 (s, 4H),



isoindole-2-
3.91 (s, 2H), 1.59 (s, 6H)



carboxamide


236
N-{4-[(1-phenyl-1H-

1H NMR (300 MHz, DMSO-d6) δ ppm 10.45

(ESI(+))



pyrazol-4-
(s, 1H), 8.67 (s, 2H), 7.90-7.95 (m, 3H),
m/e 424



yl)carbamoyl]phenyl}-
7.80-7.84 (m, 2H), 7.74-7.78 (m, 2H), 7.47-
(M + H)+



1,3-dihydro-2H-
7.53 (m, 2H), 7.27-7.40 (m, 5H), 4.80-4.82



isoindole-2-
(bs, 4H)



carboxamide


237
N-[4-({2-[4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(−))



(trifluoromethyl)phe-
Oxide) δ ppm 7.72-7.74 (m, 2H), 7.63-7.67
m/e 452



nyl]ethyl}carbamoyl)
(m, 4H), 7.48-7.50 (m, 2H), 7.36-7.41 (m,
(M − H)



phenyl]-1,3-dihydro-
2H), 7.31-7.36 (m, 2H), 4.78-4.79 (bs, 4H),



2H-isoindole-2-
3.52 (t, J = 7.0 Hz, 2H), 2.95 (t, J = 7.2 Hz,



carboxamide
2H)


238
N-{4-[(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



methoxyethyl)(pro-
Temp = 90° C.) δ ppm 8.24-8.26 (bs, 1H), 7.89-
m/e 380



pyl)carbamoyl]phenyl}-
7.92 (m, 2H), 7.49-7.53 (m, 2H), 7.19-7.23
(M − H)



1,3-dihydro-2H-
(m, 2H), 7.15-7.19 (m, 2H), 4.85 (s, 4H),



isoindole-2-
3.65 (t, J = 5.7 Hz, 2H), 3.56 (t, J = 5.7 Hz,



carboxamide
2H), 3.46 (t, J = 7.3 Hz, 2H), 3.24 (s, 3H),




1.53-1.67 (m, 2H), 0.78 (t, J = 7.4 Hz, 3H)


239
N-[4-(sec-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



butylcarbamoyl)phenyl]-
Temp = 90° C.) δ ppm 8.26-8.28 (bs, 1H), 8.06-
m/e 338



1,3-dihydro-2H-
8.10 (m, 2H), 7.88-7.91 (m, 2H), 7.42-7.46
(M + H)+



isoindole-2-
(m, 1H), 7.19-7.23 (m, 2H), 7.15-7.18 (m,



carboxamide
2H), 4.84 (s, 4H), 4.21-4.36 (m, 1H), 1.42-




1.75 (m, 2H), 1.23 (d, J = 6.6 Hz, 3H), 0.93




(t, J = 7.4 Hz, 3H)


240
N-(4-{[3-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(−))



(trifluoromethyl)piperidin-1-
Oxide) δ ppm 8.61-8.63 (bs, 1H), 7.63-7.65
m/e 416



yl]carbonyl}phenyl)-
(m, 2H), 7.36-7.41 (m, 2H), 7.31-7.36 (m,
(M − H)



1,3-dihydro-2H-
4H), 4.78-4.79 (bs, 4H), 3.94-4.64 (m, 2H),



isoindole-2-
2.97-3.12 (m, 2H), 1.97-2.02 (m, 1H), 1.64-



carboxamide
1.83 (m, 1H), 1.55-1.66 (m, 1H), 1.42-1.55




(m, 1H)


241
N-{4-[bis(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



ethoxyethyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.20-8.22 (bs, 1H), 7.89-
m/e 424



1,3-dihydro-2H-
7.92 (m, 2H), 7.57-7.60 (m, 2H), 7.19-7.23
(M − H)



isoindole-2-
(m, 2H), 7.14-7.19 (m, 2H), 4.84 (s, 4H),



carboxamide
3.77 (t, J = 5.8 Hz, 4H), 3.62-3.65 (m, 4H),




3.42 (q, J = 7.0 Hz, 4H), 1.11 (t, J = 7.0 Hz,




6H)


242
N-{4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



[butyl(ethyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.23-8.25 (bs, 1H), 7.89-
m/e 366



1,3-dihydro-2H-
7.93 (m, 2H), 7.48-7.51 (m, 2H), 7.19-7.23
(M + H)+



isoindole-2-
(m, 2H), 7.15-7.19 (m, 2H), 4.85 (s, 4H),



carboxamide
3.35-3.47 (m, 4H), 1.56 (p, J = 7.3 Hz, 2H),




1.19-1.32 (m, 2H), 1.10 (t, J = 7.1 Hz, 3H),




0.83 (t, J = 7.3 Hz, 3H)


243
N-{4-[(1-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methoxypropan-2-
Temp = 90° C.) δ ppm 8.28-8.32 (m, 1H), 8.05-
m/e 354



yl)carbamoyl]phenyl}-
8.08 (m, 2H), 7.88-7.90 (m, 2H), 7.56-7.60
(M + H)+



1,3-dihydro-2H-
(m, 1H), 7.19-7.24 (m, 2H), 7.15-7.19 (m,



isoindole-2-
2H), 4.84 (s, 4H), 4.54-4.64 (m, 1H), 3.53



carboxamide
(dd, J = 9.6, 5.2 Hz, 1H), 3.45 (dd, J = 9.5,




5.5 Hz, 1H), 3.27 (s, 3H), 1.30 (d, J = 6.7




Hz, 3H)


244
N-{4-[(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methoxyethyl)(meth-
Temp = 90° C.) δ ppm 8.23-8.28 (bs, 1H), 7.88-
m/e 354



yl)carbamoyl]phenyl}-
7.91 (m, 2H), 7.51-7.56 (m, 2H), 7.19-7.25
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.15-7.19 (m, 2H), 4.85 (s, 4H),



isoindole-2-
3.63 (t, J = 5.6 Hz, 2H), 3.53 (t, J = 5.6 Hz,



carboxamide
2H), 3.23 (s, 3H), 3.04 (s, 3H)


245
N-{4-[(3R)-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



tetrahydrofuran-3-
Temp = 90° C.) δ ppm 8.29-8.31 (bs, 1H), 8.04-
m/e 350



ylcarbamoyl]phenyl}-
8.09 (m, 2H), 7.97-8.04 (m, 1H), 7.88-7.90
(M − H)



1,3-dihydro-2H-
(m, 2H), 7.19-7.24 (m, 2H), 7.14-7.19 (m,



isoindole-2-
2H), 4.80-4.87 (m, 1H), 4.80-4.87 (m, 4H),



carboxamide
4.02 (dd, J = 9.0, 6.1 Hz, 1H), 3.85-3.93 (m,




2H), 3.72 (td, J = 8.2, 6.1 Hz, 1H), 2.21 (tdd,




J = 7.9, 12.7, 6.4 Hz, 1H), 1.93-2.02 (m, 1H)


246
N-[4-(morpholin-4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(−))



ylcarbonyl)phenyl]-
Oxide, Temp = 90° C.) δ ppm 7.62-7.65 (m,
m/e 350



1,3-dihydro-2H-
2H), 7.31-7.41 (m, 6H), 4.81 (s, 4H), 3.63-
(M − H)



isoindole-2-
3.65 (m, 4H), 3.50-3.58 (m, 4H)



carboxamide


247
N-{4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



[isobutyl(methyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.24-8.26 (bs, 1H), 7.89-
m/e 352



1,3-dihydro-2H-
7.92 (m, 2H), 7.48-7.52 (m, 2H), 7.19-7.24
(M + H)+



isoindole-2-
(m, 2H), 7.15-7.19 (m, 2H), 4.85 (s, 4H),



carboxamide
3.30 (d, J = 7.3 Hz, 2H), 2.94 (s, 3H), 1.91-




2.07 (m, 1H), 0.83 (d, J = 6.6 Hz, 6H)


248
N-[4-({4-[2-(2-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



hydroxyethoxy)ethyl]piperazin-1-
Oxide, Temp = 90° C.) δ ppm 7.66-7.69 (m,
m/e 439



yl}carbonyl)phenyl]-
2H), 7.39-7.43 (m, 2H), 7.36-7.40 (m, 2H),
(M + H)+



1,3-dihydro-2H-
7.32-7.36 (m, 2H), 4.82 (s, 4H), 3.79-3.83



isoindole-2-
(m, 2H), 3.71-3.90 (m, 4H), 3.58-3.63 (m,



carboxamide
2H), 3.53-3.58 (m, 2H), 3.32-3.35 (m, 2H),




3.22 (s, 4H)


249
N-{4-[(3-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methylpiperidin-1-
Temp = 90° C.) δ ppm 8.25-8.27 (bs, 1H), 7.90-
m/e 364



yl)carbonyl]phenyl}-
7.92 (m, 2H), 7.51-7.55 (m, 2H), 7.19-7.23
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.15-7.19 (m, 2H), 4.85 (s, 4H),



isoindole-2-
4.09-4.19 (m, 2H), 2.88 (ddd, J = 13.1, 11.1,



carboxamide
3.2 Hz, 1H), 2.57 (dd, J = 12.9, 10.1 Hz,




1H), 1.63-1.69 (m, 1H), 1.47-1.61 (m, 2H),




1.34-1.45 (m, 1H), 1.03 (dddd, J = 13.0,




11.3, 10.6, 4.4 Hz, 1H), 0.75 (d, J = 6.6 Hz, 3H)


250
N-(4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.56

(ESI(+))



carbamoylphenyl)-
(s, 1H), 7.76-7.83 (m, 2H), 7.73-7.85 (bs,
m/e 282



1,3-dihydro-2H-
1H), 7.63-7.67 (m, 2H), 7.30-7.39 (m, 4H),
(M + H)+



isoindole-2-
7.09-7.19 (bs, 1H), 4.79 (s, 4H)



carboxamide


251
N-(4-{[(2S)-2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



(trifluoromethyl)pyrrolidin-1-
Temp = 90° C.) δ ppm 8.34-8.36 (bs, 1H), 7.91-
m/e 402



yl]carbonyl}phenyl)-
7.93 (m, 2H), 7.65-7.68 (m, 2H), 7.20-7.25
(M − H)



1,3-dihydro-2H-
(m, 2H), 7.15-7.19 (m, 2H), 5.25-5.34 (m,



isoindole-2-
1H), 4.85 (s, 4H), 3.50-3.56 (m, 2H), 1.95-



carboxamide
2.02 (m, 2H), 1.80-1.89 (m, 1H), 1.58-1.70




(m, 1H)


252
N-(4-{[(2S)-1-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



hydroxy-4-
Temp = 90° C.) δ ppm 8.29-8.30 (bs, 1H), 8.06-
m/e 382



methylpentan-2-
8.11 (m, 2H), 7.88-7.90 (m, 2H), 7.62 (d, J =
(M + H)+



yl]carbamoyl}phenyl)-
8.0 Hz, 1H), 7.19-7.24 (m, 2H), 7.14-7.18



1,3-dihydro-2H-
(m, 2H), 4.84 (s, 4H), 4.58-4.67 (m, 1H),



isoindole-2-
3.95 (d, J = 4.9 Hz, 3H), 1.82-1.93 (m, 1H),



carboxamide
1.73 (ddd, J = 14.0, 8.6, 5.5 Hz, 1H), 1.68




(ddd, J = 13.7, 8.2, 5.5 Hz, 1H), 0.99 (d, J =




6.6 Hz, 3H), 0.93 (d, J = 6.6 Hz, 3H)


253
N-(4-{[(1R)-2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



hydroxy-1-
Temp = 90° C.) δ ppm 8.29-8.30 (bs, 1H), 8.15-
m/e 402



phenylethyl]carbamoyl}phenyl)-
8.18 (m, 1H), 8.08-8.11 (m, 2H), 7.87-7.90
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.61-7.64 (m, 2H), 7.27-7.33 (m,



isoindole-2-
2H), 7.19-7.24 (m, 3H), 7.15-7.19 (m, 2H),



carboxamide
5.68-5.73 (m, 1H), 4.83 (s, 4H), 4.23 (d, J =




5.6 Hz, 2H)


254
N-{4-[(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methylpyrrolidin-1-
Temp = 90° C.) δ ppm 8.26-8.28 (bs, 1H), 7.89-
m/e 350



yl)carbonyl]phenyl}-
7.92 (m, 2H), 7.60-7.65 (m, 2H), 7.20-7.24
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.15-7.19 (m, 2H), 4.86 (s, 4H),



isoindole-2-
4.26-4.36 (m, 1H), 3.47 (t, J = 6.8 Hz, 2H),



carboxamide
1.92 (dq, J = 12.2, 7.1 Hz, 1H), 1.67-1.78




(m, 1H), 1.52-1.63 (m, 1H), 1.41 (dtd, J =




12.2, 6.9, 5.2 Hz, 1H), 1.22 (d, J = 6.2 Hz,




3H)


255
N-{4-[ethyl(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



methoxyethyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.24-8.26 (bs, 1H), 7.89-
m/e 368



1,3-dihydro-2H-
7.91 (m, 2H), 7.49-7.53 (m, 2H), 7.19-7.24
(M + H)+



isoindole-2-
(m, 2H), 7.15-7.19 (m, 2H), 4.85 (s, 4H),



carboxamide
3.62-3.66 (m, 2H), 3.53-3.58 (m, 2H), 3.50




(q, J = 7.1 Hz, 2H), 3.24 (s, 3H), 1.11 (t, J =




7.1 Hz, 3H)


256
N-(4-{[(2R)-1-

1H NMR (400 MHz, Pyridine-d5, Temp = 90

(ESI(+))



hydroxy-3-
C.) δ ppm 8.29-8.30 (bs, 1H), 8.05-8.08 (m,
m/e 368



methylbutan-2-
2H), 7.87-7.90 (m, 2H), 7.46-7.53 (m, 1H),
(M + H)+



yl]carbamoyl}phenyl)-
7.19-7.24 (m, 2H), 7.15-7.19 (m, 2H), 4.84



1,3-dihydro-2H-
(s, 4H), 4.29-4.36 (m, 1H), 3.99 (d, J = 4.8



isoindole-2-
Hz, 2H), 2.19-2.28 (m, 1H), 1.08 (d, J = 2.3



carboxamide
Hz, 3H), 1.06 (d, J = 2.4 Hz, 3H)


257
N-{4-[(2,6-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



dimethylmorpholin-4-
Temp = 90° C.) δ ppm 8.33-8.40 (m, 1H), 7.92-
m/e 380



yl)carbonyl]phenyl}-
7.96 (m, 2H), 7.54-7.58 (m, 2H), 7.19-7.25
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.15-7.19 (m, 2H), 4.86 (s, 4H),



isoindole-2-
4.14-4.22 (m, 1H), 3.93-4.01 (m, 1H), 3.70



carboxamide
(dd, J = 13.0, 3.4 Hz, 1H), 3.51-3.61 (m,




1H), 3.32 (dd, J = 13.0, 6.3 Hz, 1H), 2.64




(dd, J = 13.1, 10.5 Hz, 1H), 1.02-1.15 (m,




6H)


258
N-(4-{[(2R)-1-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



hydroxybutan-2-
Temp = 90° C.) δ ppm 8.25-8.31 (m, 1H), 8.05-
m/e 354



yl]carbamoyl}phenyl)-
8.08 (m, 2H), 7.87-7.90 (m, 2H), 7.58 (d, J =
(M + H)+



1,3-dihydro-2H-
7.5 Hz, 1H), 7.19-7.24 (m, 2H), 7.14-7.19



isoindole-2-
(m, 2H), 4.84 (s, 4H), 4.36-4.47 (m, 1H),



carboxamide
3.95 (d, J = 4.9 Hz, 2H), 1.85-1.96 (m, 1H),




1.72-1.84 (m, 1H), 1.02 (t, J = 7.4 Hz, 3H)


259
N-{4-[(2,5-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



dimethylpyrrolidin-1-
Temp = 90° C.) δ ppm 8.23-8.25 (bs, 1H), 7.90-
m/e 364



yl)carbonyl]phenyl}-
7.92 (m, 2H), 7.53-7.62 (m, 2H), 7.19-7.23
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.15-7.19 (m, 2H), 4.85 (s, 4H),



isoindole-2-
4.11-4.39 (m, 2H), 1.78-2.11 (m, 2H), 1.35-



carboxamide
1.59 (m, 2H), 0.95-1.27 (m, 6H)


260
N-[4-(prop-2-yn-1-

1H NMR (400 MHz, DMSO-d6,

(ESI(+))



ylcarbamoyl)phenyl]-
Temp = 90° C.) δ ppm 3.10 (t, J = 2.38 Hz, 1 H),
m/e 320



1,3-dihydro-2H-
4.03 (dd, J = 5.55, 2.78 Hz, 2 H), 4.79 (s, 4
(M + H)+



isoindole-2-
H), 7.28-7.42 (m, 4 H), 7.64-7.82 (m, 4



carboxamide
H), 8.60 (s, 1 H), 8.73 (t, J = 5.55 Hz, 1 H)


261
N-{4-[isopropyl(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(−))



methoxyethyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.26-8.28 (bs, 1H), 7.90-
m/e 380



1,3-dihydro-2H-
7.93 (m, 2H), 7.48-7.50 (m, 2H), 7.19-7.23
(M − H)



isoindole-2-
(m, 2H), 7.15-7.18 (m, 2H), 4.85 (s, 4H),



carboxamide
4.18-4.32 (m, 1H), 3.56-3.68 (m, 4H), 3.26




(s, 3H), 1.13 (d, J = 6.7 Hz, 6H)


262
N-{4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



[isopropyl(propyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.24-8.26 (bs, 1H), 7.90-
m/e 366



1,3-dihydro-2H-
7.92 (m, 2H), 7.46-7.48 (m, 2H), 7.19-7.23
(M + H)+



isoindole-2-
(m, 2H), 7.16-7.18 (m, 2H), 4.85 (s, 4H),



carboxamide
4.20-4.32 (m, 1H), 3.25-3.30 (m, 2H), 1.59-




1.77 (m, 2H), 1.12-1.17 (m, 6H), 0.82 (t, J =




7.4 Hz, 3H)


263
N-{4-[(2-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



cyanoethyl)(cyclopro-
Temp = 90° C.) δ ppm 8.27-8.29 (bs, 1H), 7.90-
m/e 375



pyl)carbamoyl]phenyl}-
7.93 (m, 2H), 7.65-7.68 (m, 2H), 7.20-7.23
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.15-7.19 (m, 2H), 4.85 (s, 4H),



isoindole-2-
3.81 (t, J = 6.6 Hz, 2H), 2.90-2.96 (m, 1H),



carboxamide
2.83 (t, J = 6.6 Hz, 2H), 0.54-0.61 (m, 2H),




0.45-0.52 (m, 2H)


264
N-{4-

1H NMR (400 MHz, Pyridine-d5,

(ESI(+))



[ethyl(isopropyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 8.23-8.25 (bs, 1H), 7.89-
m/e 352



1,3-dihydro-2H-
7.92 (m, 2H), 7.45-7.48 (m, 2H), 7.19-7.23
(M + H)+



isoindole-2-
(m, 2H), 7.15-7.18 (m, 2H), 4.85 (s, 4H),



carboxamide
4.27 (p, J = 6.7 Hz, 1H), 3.36 (q, J = 7.0 Hz,




2H), 1.18 (t, J = 6.9 Hz, 3H), 1.11 (d, J = 6.7




Hz, 6H)


265
N-{4-[(3-

1H NMR (500 MHz, DMSO-d6/Deuterium

(APCI(+))



fluoropyrrolidin-1-
Oxide) δ ppm 7.63-7.66 (m, 2H), 7.36-7.41
m/e 354



yl)carbonyl]phenyl}-
(m, 2H), 7.33-7.36 (m, 2H), 7.31-7.35 (m,
(M + H)+



1,3-dihydro-2H-
2H), 5.21-5.48 (m, 1H), 4.79 (s, 4H), 3.53-



isoindole-2-
3.79 (m, 4H), 1.98-2.25 (m, 2H)



carboxamide


266
N-{4-[(1,3-dihydro-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



2H-isoindol-2-
Oxide) δ ppm 7.59-7.62 (m, 2H), 7.37-7.40
m/e 396



ylcarbonyl)amino]benzoyl}-
(m, 2H), 7.31-7.36 (m, 2H), 7.24-7.27 (m,
(M + H)+



N-isopropyl-
2H), 4.78-4.79 (bs, 4H), 1.00-1.27 (m, 6H)



beta-alanine


267
N-{4-

1H NMR (400 MHz, DMSO-d6,

(ESI(+))



[methyl(propyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 0.82 (t, J = 7.32 Hz, 3 H),
m/e 338



1,3-dihydro-2H-
1.49-1.62 (m, 2 H), 2.92 (s, 3 H), 3.27-
(M + H)+



isoindole-2-
3.34 (m, 2 H), 4.78 (s, 4 H), 7.23-7.37 (m, 6



carboxamide
H), 7.58-7.63 (m, 2 H), 8.26 (s, 1 H)


268
5,6-dimethoxy-N-{4-[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.54

(ESI(+))



phenylpropyl)carbamoyl]phenyl}-
(s, 1H), 8.29 (t, J = 5.6 Hz, 1H), 7.75-7.78
m/e 460



1,3-dihydro-2H-
(m, 2H), 7.61-7.68 (m, 2H), 7.15-7.32 (m,
(M + H)+



isoindole-2-
5H), 6.95 (s, 2H), 4.69-4.70 (bs, 4H), 3.32 (s,



carboxamide
6H), 3.21-3.30 (m, 2H), 2.59-2.68 (m, 2H),




1.76-1.90 (m, 2H)


269
N-(4-{[3-(4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.57

(ESI(+))



chlorophenoxy)pro-
(s, 1H), 8.36 (t, J = 5.6 Hz, 1H), 7.75-7.79
m/e 450



pyl]carbamoyl}phenyl)-
(m, 2H), 7.64-7.68 (m, 2H), 7.29-7.39 (m,
(M + H)+



1,3-dihydro-2H-
6H), 6.94-6.98 (m, 2H), 4.79 (s, 4H), 4.03 (t,



isoindole-2-
J = 6.1 Hz, 2H), 3.37-3.44 (m, 2H), 1.97 (p,



carboxamide
J = 6.5 Hz, 2H)


270
N-(4-{[4-

1H NMR (500 MHz, DMSO-d6/Deuterium

(ESI(+))



(trifluoromethoxy)phe-
Oxide) δ ppm 7.89-7.93 (m, 2H), 7.85-7.89
m/e 442



nyl]carbamoyl}phenyl)-
(m, 2H), 7.72-7.75 (m, 2H), 7.33-7.41 (m,
(M + H)+



1,3-dihydro-2H-
6H), 4.80-4.82 (bs, 4H)



isoindole-2-



carboxamide


271
N-{4-[(4-phenyl-1,3-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



thiazol-2-
Oxide, Temp = 90° C.) δ ppm 8.06-8.09 (m,
m/e 441



yl)carbamoyl]phenyl}-
2H), 7.94-7.97 (m, 2H), 7.75-7.78 (m, 2H),
(M + H)+



1,3-dihydro-2H-
7.55 (s, 1H), 7.44-7.49 (m, 2H), 7.37-7.41



isoindole-2-
(m, 2H), 7.32-7.37 (m, 3H), 4.84 (s, 4H)



carboxamide


284
5-bromo-N-[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.60

(ESI(+))



(propylcarbamoyl)phenyl]-
(s, 1H), 8.25 (t, J = 5.6 Hz, 1H), 7.74-7.78
m/e 402



1,3-dihydro-
(m, 2H), 7.62-7.67 (m, 2H), 7.59-7.62 (m,
(M + H)+



2H-isoindole-2-
1H), 7.50 (dd, J = 8.1, 1.9 Hz, 1H), 7.34 (d, J =



carboxamide
8.1 Hz, 1H), 4.70-4.82 (m, 4H), 3.15-3.26




(m, 2H), 1.45-1.61 (m, 2H), 0.89 (t, J = 7.4




Hz, 3H)


373
5-fluoro-N-[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.58

(ESI(+))



(propylcarbamoyl)phenyl]-
(s, 1H), 8.25 (t, J = 5.6 Hz, 1H), 7.74-7.78
m/e 342



1,3-dihydro-
(m, 2H), 7.62-7.66 (m, 2H), 7.39 (dd, J =
(M + H)+



2H-isoindole-2-
8.4, 5.2 Hz, 1H), 7.24 (dd, J = 9.1, 2.3 Hz,



carboxamide
1H), 7.10-7.19 (m, 1H), 4.74-4.78 (m, 4H),




3.16-3.21 (m, 2H), 1.46-1.59 (m, 2H), 0.89




(t, J = 7.4 Hz, 3H);


412
N-{4-[(2-

1H NMR (400 MHz, DMSO-d6,

(ESI(+))



methoxyethyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 3.27 (s, 3 H), 3.35-3.49
m/e 340



1,3-dihydro-2H-
(m, 4 H), 4.79 (s, 4 H), 7.25-7.40 (m, 4 H),
(M + H)+



isoindole-2-
7.62-7.69 (m, 2 H), 7.74-7.81 (m, 2 H),



carboxamide
8.31 (t, J = 5.09 Hz, 1 H), 8.57 (s, 1 H)


413
N-{4-[(5-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



chloropyridin-2-
Oxide, Temp = 90° C.) δ ppm 8.37 (d, J = 2.7
m/e 393



yl)carbamoyl]phenyl}-
Hz, 1H), 8.16 (d, J = 8.9 Hz, 1H), 7.94-7.97
(M + H)+



1,3-dihydro-2H-
(m, 2H), 7.89 (dd, J = 8.8, 2.6 Hz, 1H), 7.69-



isoindole-2-
7.72 (m, 2H), 7.35-7.38 (m, 2H), 7.30-7.33



carboxamide
(m, 2H), 4.81 (s, 4H)


414
N-{4-[(3-hydroxy-4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



methoxyphenyl)carbamoyl]phenyl}-
Oxide, Temp = 90° C.) δ ppm 7.85-7.88 (m,
m/e 404



1,3-dihydro-2H-
2H), 7.66-7.69 (m, 2H), 7.34-7.39 (m, 2H),
(M + H)+



isoindole-2-
7.30-7.34 (m, 2H), 7.28-7.30 (m, 1H), 7.09



carboxamide
(dd, J = 8.6, 2.5 Hz, 1H), 6.88 (d, J = 8.6 Hz,




1H), 4.81 (s, 4H), 3.77 (s, 3H)


415
N-{4-[(2,4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



dimethoxybenzyl)carbamoyl]phenyl}-
Oxide, Temp = 90° C.) δ ppm 7.77-7.79 (m,
m/e 432



1,3-dihydro-2H-
2H), 7.61-7.64 (m, 2H), 7.33-7.38 (m, 2H),
(M + H)+



isoindole-2-
7.28-7.34 (m, 2H), 7.14 (d, J = 8.2 Hz, 1H),



carboxamide
6.55 (d, J = 2.4 Hz, 1H), 6.48 (dd, J = 8.2,




2.4 Hz, 1H), 4.79 (s, 4H), 4.38-4.40 (m, 2H),




3.82 (s, 3H), 3.75 (s, 3H)


416
N-(4-{[4-(2-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



oxopyrrolidin-1-
Oxide, Temp = 90° C.) δ ppm 7.78-7.80 (m,
m/e 455



yl)benzyl]carbamoyl}phenyl)-
2H), 7.62-7.68 (m, 2H), 7.54-7.56 (m, 2H),
(M + H)+



1,3-dihydro-2H-
7.29-7.38 (m, 6H), 4.79 (s, 4H), 4.45-4.47



isoindole-2-
(m, 2H), 3.82 (t, J = 7.0 Hz, 2H), 2.45-2.50



carboxamide
(m, 2H), 2.04-2.13 (m, 2H)


417
N-(4-{[(1S,2S)-2-

1H NMR (400 MHz, DMSO-d6,

(ESI(+))



hydroxy-2,3-dihydro-
Temp = 90° C.) δ ppm 2.67-2.83 (m, 1 H),
m/e 414



1H-inden-1-
3.18 (dd, J = 15.47, 7.14 Hz, 1 H), 4.34-4.49
(M + H)+



yl]carbamoyl}phenyl)-
(m, 1 H), 4.79 (s, 4 H), 5.25-5.34 (m, 2 H),



1,3-dihydro-2H-
7.06-7.24 (m, 4 H), 7.30-7.42 (m, 4 H),



isoindole-2-
7.69 (d, J = 8.73 Hz, 2 H), 7.87 (d, J = 9.12 Hz,



carboxamide
2 H), 8.50-8.62 (m, 2 H)


418
N-(4-{[(1-

1H NMR (400 MHz, DMSO-d6,

(ESI(−))



hydroxycyclopropyl)
Temp = 90° C.) δ ppm 0.55 (s, 4 H), 3.42 (d,
m/e 350



methyl]carbamoyl}phenyl)-
J = 5.55 Hz, 2 H), 4.79 (s, 4 H), 5.41 (s, 1 H),
(M + H)+



1,3-dihydro-
7.28-7.41 (m, 4 H), 7.64-7.70 (m, 2 H),



2H-isoindole-2-
7.75-7.84 (m, 2 H), 8.20 (t, J = 5.75 Hz, 1



carboxamide
H), 8.58 (s, 1 H)


419
N-{4-[(tetrahydro-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.57

(ESI(−))



2H-pyran-2-
(s, 1H), 8.29 (t, J = 5.8 Hz, 1H), 7.76-7.80
m/e 378



ylmethyl)carbamoyl]
(m, 2H), 7.64-7.68 (m, 2H), 7.30-7.39 (m,
(M + H)+



phenyl}-1,3-dihydro-
4H), 4.78-4.79 (bs, 4H), 3.84-3.90 (m, 1H),



2H-isoindole-2-
3.32-3.47 (m, 2H), 3.21-3.30 (m, 2H), 1.75-



carboxamide
1.81 (m, 1H), 1.58-1.65 (m, 1H), 1.33-1.54




(m, 3H), 1.06-1.28 (m, 1H)


420
N-{4-[(tetrahydro-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.57

(ESI(+))



2H-pyran-3-
(s, 1H), 8.27 (t, J = 5.8 Hz, 1H), 7.74-7.79
m/e 380



ylmethyl)carbamoyl]
(m, 2H), 7.64-7.68 (m, 2H), 7.30-7.39 (m,
(M + H)+



phenyl}-1,3-dihydro-
4H), 4.78-4.79 (bs, 4H), 3.68-3.80 (m, 2H),



2H-isoindole-2-
3.26-3.36 (m, 1H), 3.06-3.18 (m, 3H), 1.74-



carboxamide
1.82 (m, 2H), 1.38-1.68 (m, 2H), 1.15-1.30




(m, 1H)


421
N-{4-[(tetrahydro-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.56

(ESI(+))



2H-pyran-4-
(s, 1H), 8.28 (t, J = 5.8 Hz, 1H), 7.75-7.79
m/e 380



ylmethyl)carbamoyl]
(m, 2H), 7.64-7.68 (m, 2H), 7.25-7.43 (m,
(M + H)+



phenyl}-1,3-dihydro-
4H), 4.79 (s, 4H), 3.81-3.88 (m, 2H), 3.21-



2H-isoindole-2-
3.31 (m, 2H), 3.14 (t, J = 6.3 Hz, 2H), 1.71-



carboxamide
1.86 (m, 1H), 1.56-1.63 (m, 2H), 1.07-1.30




(m, 2H)


425
N-{4-[(4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.55

(ESI(+))



benzoylpiperazin-1-
(s, 1H), 7.64-7.68 (m, 2H), 7.40-7.50 (m,
m/e 455



yl)carbonyl]phenyl}-
5H), 7.29-7.40 (m, 6H), 4.78-4.79 (bs, 4H),
(M + H)+



1,3-dihydro-2H-
3.33-3.86 (m, 8H)



isoindole-2-



carboxamide


434
N-(4-{[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.54

(ESI(+))



(tetrahydrofuran-3-
(s, 1H), 7.62-7.66 (m, 2H), 7.28-7.39 (m,
m/e 435



ylmethyl)piperazin-1-
6H), 4.78-4.79 (bs, 4H), 3.88-3.95 (m, 1H),
(M + H)+



yl]carbonyl}phenyl)-
3.68-3.77 (m, 1H), 3.55-3.64 (m, 1H), 3.39-



1,3-dihydro-2H-
3.56 (m, 4H), 2.46-2.56 (m, 2H), 2.35-2.47



isoindole-2-
(m, 4H), 1.85-1.99 (m, 1H), 1.66-1.86 (m,



carboxamide
2H), 1.39-1.54 (m, 1H)


435
5-fluoro-N-[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.60

(ESI(+))



({[(2S)-
(s, 1H), 8.33 (t, J = 5.8 Hz, 1H), 7.76-7.80
m/e 384



tetrahydrofuran-2-
(m, 2H), 7.63-7.67 (m, 2H), 7.39 (dd, J =
(M + H)+



ylmethyl]amino}car-
8.4, 5.2 Hz, 1H), 7.24 (dd, J = 9.1, 2.4 Hz,



bonyl)phenyl]-1,3-
1H), 7.15 (td, J = 8.9, 2.5 Hz, 1H), 4.74-4.79



dihydro-2H-
(m, 4H), 3.92-4.03 (m, 1H), 3.74-3.82 (m,



isoindole-2-
1H), 3.58-3.66 (m, 1H), 3.24-3.34 (m, 2H),



carboxamide
1.76-1.96 (m, 3H), 1.52-1.69 (m, 1H)


436
5-fluoro-N-[4-({[(2R)-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.60

(ESI(+))



tetrahydrofuran-2-
(s, 1H), 8.33 (t, J = 5.8 Hz, 1H), 7.76-7.80
m/e 384



ylmethyl]amino}carbonyl)phenyl]-
(m, 2H), 7.63-7.67 (m, 2H), 7.39 (dd, J =
(M + H)+



1,3-dihydro-2H-
8.4, 5.2 Hz, 1H), 7.24 (dd, J = 9.1, 2.5 Hz,



isoindole-2-
1H), 7.15 (td, J = 8.9, 2.5 Hz, 1H), 4.74-4.79



carboxamide
(m, 4H), 3.96 (p, J = 6.3 Hz, 1H), 3.74-3.82




(m, 1H), 3.58-3.66 (m, 1H), 3.22-3.34 (m,




2H), 1.74-1.96 (m, 3H), 1.53-1.64 (m, 1H)


438
N-(4-{[4-(2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.53

(ESI(+))



methoxyethyl)piperazin-1-
(s, 1H), 7.62-7.66 (m, 2H), 7.24-7.43 (m,
m/e 409



yl]carbonyl}phenyl)-
6H), 4.78 (s, 4H), 3.44 (t, J = 5.8 Hz, 6H),
(M + H)+



1,3-dihydro-2H-
3.23 (s, 3H), 2.43 (s, 4H)



isoindole-2-



carboxamide


439
N-(4-{[(2S)-2-(2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.51

(ESI(+))



hydroxyethyl)piperidin-1-
(s, 1H), 7.61-7.65 (m, 2H), 7.25-7.39 (m,
m/e 394



yl]carbonyl}phenyl)-
6H), 4.78-4.79 (bs, 4H), 4.36 (t, J = 5.1 Hz,
(M + H)+



1,3-dihydro-2H-
1H), 3.46-4.87 (m, 2H), 3.31-3.43 (m, 2H),



isoindole-2-
2.78-3.10 (m, 1H), 1.80-1.97 (m, 1H), 1.52-



carboxamide
1.76 (m, 6H), 1.26-1.47 (m, 1H)


449
N-[4-({[(1S)-2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.61

(ESI(−))



hydroxy-1-pyridin-2-
(s, 1H), 8.53 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H),
m/e 401



ylethyl]amino}carbonyl)phenyl]-
8.46 (d, J = 7.8 Hz, 1H), 7.84-7.88 (m, 2H),
(M − H)



1,3-dihydro-2H-
7.75 (td, J = 7.7, 1.8 Hz, 1H), 7.67-7.73 (m,



isoindole-2-
2H), 7.29-7.44 (m, 5H), 7.26 (ddd, J = 7.4,



carboxamide
4.9, 1.1 Hz, 1H), 5.10-5.17 (m, 1H), 4.88-




4.93 (m, 1H), 4.80 (s, 3H), 3.73-3.88 (m, 2H)


562
N-[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 11.42

(ESI(+))



(isobutoxycarbamoyl)phenyl]-
(s, 1H), 8.60 (s, 1H), 7.67 (s, 4H), 7.41-
m/e 354



1,3-dihydro-2H-
7.28 (m, 4H), 4.79 (bs, 4H), 3.65 (d, J = 6.7
(M + H)+



isoindole-2-
Hz, 2H), 2.02-1.85 (m, 1H), 0.94 (d, J =



carboxamide
6.7 Hz, 6H)


567
5-fluoro-N-{4-

1H NMR (300 MHz, DMSO-d6) δ 8.59 (s,

(ESI(+))



[(tetrahydro-2H-
1H), 8.29 (t, J = 5.8 Hz, 1H), 7.81-7.74 (m,
m/e 398



pyran-2-
2H), 7.68-7.61 (m, 2H), 7.40 (dd, J = 8.4,
(M + H)+



ylmethyl)carbamoyl]
5.2 Hz, 1H), 7.24 (dd, J = 9.1, 2.5 Hz, 1H),



phenyl}-1,3-dihydro-
7.15 (td, J = 8.9, 2.5 Hz, 1H), 4.80-4.73



2H-isoindole-2-
(m, 3H), 4.05-3.99 (m, 1H), 3.87 (dd, J =



carboxamide
11.3, 3.0 Hz, 1H), 3.24 (dd, J = 8.8, 4.0 Hz,




2H), 1.80-1.74 (m, 1H), 1.66-1.56 (m,




1H), 1.57-1.33 (m, 3H), 1.28-1.04 (m, 1H)


568
5-fluoro-N-{4-

1H NMR (300 MHz, DMSO-d6) δ 8.59 (s,

(ESI(+))



[(tetrahydro-2H-
1H), 8.28 (t, J = 5.7 Hz, 1H), 7.76 (d, J = 8.8
m/e 398



pyran-3-
Hz, 2H), 7.65 (d, J = 8.8 Hz, 2H), 7.58-
(M + H)+



ylmethyl)carbamoyl]
7.32 (m, 1H), 7.31-7.06 (m, 2H), 4.76 (d, J =



phenyl}-1,3-dihydro-
8.0 Hz, 4H), 3.85-3.62 (m, 2H), 3.23-



2H-isoindole-2-
2.96 (m, 3H), 1.91-1.69 (m, 2H), 1.68-



carboxamide
1.35 (m, 2H), 1.35-1.11 (m, 1H)


569
5-fluoro-N-{4-

1H NMR (300 MHz, DMSO-d6) δ 8.58 (s,

(ESI(+))



[(tetrahydro-2H-
1H), 8.28 (t, J = 5.8 Hz, 1H), 7.80-7.73 (m,
m/e 398



pyran-4-
2H), 7.68-7.61 (m, 2H), 7.39 (dd, J = 8.4,
(M + H)+



ylmethyl)carbamoyl]
5.2 Hz, 1H), 7.24 (dd, J = 9.1, 2.5 Hz, 1H),



phenyl}-1,3-dihydro-
7.14 (td, J = 8.9, 2.5 Hz, 1H), 4.80-4.72



2H-isoindole-2-
(m, 4H), 3.89-3.79 (m, 2H), 3.28-3.20 (m,



carboxamide
1H), 3.14 (t, J = 6.3 Hz, 2H), 1.88-1.69 (m,




1H), 1.64-1.54 (m, 2H), 1.28-1.10 (m, 2H)


570
5-fluoro-N-(4-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s,

(ESI(+))



{[(1S)-2-hydroxy-1-
1H), 8.49 (d, J = 8.0 Hz, 1H), 7.88-7.80
m/e 420



phenylethyl]carbamoyl}phenyl)-
(m, 2H), 7.71-7.64 (m, 2H), 7.44-7.36 (m,
(M + H)+



1,3-dihydro-2H-
3H), 7.36-7.27 (m, 2H), 7.28-7.09 (m,



isoindole-2-
3H), 5.12-5.01 (m, 1H), 4.90 (t, J = 5.8 Hz,



carboxamide
1H), 4.81-4.73 (m, 4H), 3.78-3.59 (m, 2H)


571
5-fluoro-N-(4-

1H NMR (300 MHz, DMSO-d6) δ 8.62 (s,

(ESI(+))



{[(1S)-2-hydroxy-1-
1H), 8.53 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H),
m/e 421



(pyridin-2-
8.46 (d, J = 7.8 Hz, 1H), 7.90-7.82 (m,
(M + H)+



yl)ethyl]carbamoyl}phenyl)-
2H), 7.78-7.71 (m, 1H), 7.69 (t, J = 5.5 Hz,



1,3-dihydro-
2H), 7.44-7.36 (m, 2H), 7.30-7.09 (m,



2H-isoindole-2-
3H), 5.19-5.08 (m, 1H), 4.90 (t, J = 5.9 Hz,



carboxamide
1H), 4.87-4.72 (m, 4H), 3.89-3.72 (m, 2H);)


572
5-fluoro-N-(4-

1H NMR (300 MHz, DMSO-d6) δ 8.59 (s,

(ESI(+))



{[(2S)-1-hydroxy-4-
1H), 7.84-7.75 (m, 3H), 7.68-7.61 (m,
m/e 400



methylpentan-2-
2H), 7.40 (dd, J = 8.4, 5.2 Hz, 1H), 7.24 (dd,
(M + H)+



yl]carbamoyl}phenyl)-
J = 9.1, 2.5 Hz, 1H), 7.15 (td, J = 8.9, 2.5



1,3-dihydro-2H-
Hz, 1H), 4.80-4.73 (m, 4H), 4.65 (t, J = 5.7



isoindole-2-
Hz, 1H), 4.10-3.97 (m, 1H), 3.49-3.35



carboxamide
(m, 1H), 1.74-1.54 (m, 1H), 1.52-1.31 (m,




2H), 0.88 (t, J = 6.8 Hz, 6H)


585
N-(4-{[(2S)-1-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.58

(ESI(+))



hydroxy-4-
(s, 1H), 7.90 (d, J = 8.3 Hz, 1H), 7.79 (m,
m/e 400



(methylthio)butan-2-
2H), 7.67 (m, 2H), 7.40-7.29 (m, 4H), 4.79
(M + H)+



yl]carbamoyl}phenyl)-
(s, 4H), 4.73 (m, 1H), 4.03 (m, 1H), 3.47 (m,



1,3-dihydro-2H-
1H), 3.58 (m, 1H), 2.60-2.40 (m, 2H), 2.04



isoindole-2-
(s, 3H), 1.90 (m, 1H), 1.74 (m, 1H)



carboxamide


586
N-(4-{[(2S,3S)-1-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.57

(ESI(+))



hydroxy-3-
(s, 1H), 7.80 (m, 3H), 7.66 (m, 2H), 7.34 (m,
m/e 382



methylpentan-2-
4H), 4.79 (bs, 4H), 4.52 (t, J = 5.5 Hz, 1H),
(M + H)+



yl]carbamoyl}phenyl)-
3.84 (m, 1H), 3.53 (m, 2H), 1.69 (m, 1H),



1,3-dihydro-2H-
1.49 (m, 1H), 1.10 (m, 1H), 0.91-0.81 (m, 6H)



isoindole-2-



carboxamide


587
N-(4-{[(2S)-1-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.57

(ESI(+))



hydroxypropan-2-
(s, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.78 (m,
m/e 340



yl]carbamoyl}phenyl)-
2H), 7.66 (m, 2H), 7.40-7.29 (m, 4H), 4.79
(M + H)+



1,3-dihydro-2H-
(bs, 4H), 4.70 (t, J = 5.7 Hz, 1H), 4.00 (m,



isoindole-2-
1H), 3.46 (dt, J = 10.8, 3.33 (m, 1H), 5.4 Hz,



carboxamide
1H), 1.13 (d, J = 6.7 Hz, 3H)


588
N-(4-{[(2S,3R)-1,3-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.57

(ESI(+))



dihydroxybutan-2-
(bs, 1H), 7.78 (m, 3H), 7.67 (m, 2H), 7.40-
m/e 370



yl]carbamoyl}phenyl)-
7.29 (m, 4H), 4.79 (bs, 4H), 4.67 (d, J = 5.2
(M + H)+



1,3-dihydro-2H-
Hz, 1H), 4.52 (m, 1H), 3.90-3.72 (m, 2H),



isoindole-2-
3.63 (m, 2H), 1.08 (d, J = 6.12 Hz, 3H)



carboxamide


589
N-(4-{[(2S)-1-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.57

(ESI(+))



hydroxyhexan-2-
(s, 1H), 7.80 (m, 3H), 7.66 (m, 2H), 7.40-
m/e 382



yl]carbamoyl}phenyl)-
7.29 (m, 4H), 4.79 (bs, 4H), 4.65 (t, J = 5.7
(M + H)+



1,3-dihydro-2H-
Hz, 1H), 3.93 (m, 1H), 3.44 (dt, J = 10.8, 5.4



isoindole-2-
Hz, 1H), 3.32 (m, 1H), 1.63 (m, 1H), 1.44



carboxamide
(m, 1H), 1.28 (m, 4H), 0.86 (t, J = 6.3 Hz, 3H)


590
N-(4-{[(2S)-1-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.57

(ESI(+))



hydroxypentan-2-
(s, 1H), 7.80 (m, 3H), 7.66 (m, 2H), 7.40-
m/e 368



yl]carbamoyl}phenyl)-
7.29 (m, 4H), 4.79 (bs, 4H), 4.64 (t, J = 5.7
(M + H)+



1,3-dihydro-2H-
Hz, 1H), 3.95 (m, 1H), 3.44 (dt, J = 10.8, 5.4



isoindole-2-
Hz, 1H), 3.32 (m, 1H), 1.58 (m, 1H), 1.50-



carboxamide
1.22 (m, 3H), 0.88 (t, J = 7.3 Hz, 3H)


591
N-(4-{[(1S,2S)-2-
- 1H NMR (400 MHz, DMSO-d6) δ ppm 8.57
(ESI(+))



hydroxycyclopentyl]
(s, 1H), 8.03 (m, 1H), 7.78 (m, 2H), 7.66 (m,
m/e 366



carbamoyl}phenyl)-
2H), 7.40-7.29 (m, 4H), 4.81 (bs, 4H), 4.75
(M + H)+



1,3-dihydro-2H-
(t, J = 5.7 Hz, 1H), 4.98 (m, 2H), 1.99 (m,



isoindole-2-
1H), 1.86 (m, 1H), 1.65 (m, 2H), 1.47 (m,



carboxamide
2H)


592
N-(4-{[(1S,2R)-2-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.57

(ESI(+))



hydroxycyclopentyl]
(s, 1H), 7.80 (m, 2H), 7.65 (m, 3H), 7.40-
m/e 366



carbamoyl}phenyl)-
7.28 (m, 4H), 4.79 (bs, 4H), 4.71 (d, J = 3.6
(M + H)+



1,3-dihydro-2H-
Hz, 1H), 4.04 (m, 2H), 1.88-1.44 (m, 6H)



isoindole-2-



carboxamide


593
N-(4-{[(2S)-1-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.57

(ESI(+))



cyclohexyl-3-
(s, 1H), 7.81 (m, 3H), 7.67 (m, 2H), 7.43-
m/e 422



hydroxypropan-2-
7.26 (m, 4H), 4.79 (s, 4H), 4.64 (t, J = 5.7
(M + H)+



yl]carbamoyl}phenyl)-
Hz, 1H), 4.06 (m, 1H), 3.42 (m, 1H), 3.30



1,3-dihydro-2H-
(m, 1H), 1.80 (d, J = 12.6 Hz, 1H), 1.62 (m,



isoindole-2-
4H), 1.43 (m, 2H), 1.32 (m, 1H), 1.14 (m,



carboxamide
3H), 0.95 (m, 1H), 0.83 (m, 1H)


594
N-[4-({(2R)-1-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.59

(ESI(+))



hydroxy-3-[(4-
(s, 1H), 7.98 (d, J = 8.2 Hz, 1H), 7.79 (m,
m/e 476



methylbenzyl)thio]propan-2-
2H), 7.68 (m, 2H), 7.40-7.28 (m, 4H), 7.20
(M + H)+



yl}carbamoyl)phenyl]-
(m, 2H), 7.10 (m, 2H), 4.80 (m, 5H), 4.13



1,3-dihydro-2H-
(m, 1H), 3.71 (s, 2H), 3.55 (m, 1H), 3.44 (m,



isoindole-2-
1H), 2.70 (dd, J = 13.3, 5.7 Hz, 1H), 2.55



carboxamide
(m, 1H), 2.27 (s, 3H)


595
N-(4-{[(1S)-1-(4-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.59

(ESI(+))



tert-butylphenyl)-2-
(s, 1H), 8.45 (d, J = 8.0 Hz, 1H), 7.83 (m,
m/e 458



hydroxyethyl]carbamoyl}phenyl)-
2H), 7.68 (m, 2H), 7.40-7.27 (m, 8H), 5.03
(M + H)+



1,3-dihydro-2H-
(m, 1H), 4.87 (t, J = 5.8 Hz, 1H), 4.79 (bs,



isoindole-2-
4H), 3.67 (m, 2H), 1.26 (s, 9H)



carboxamide


597
5-methoxy-N-[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.53

(ESI(+))



(propylcarbamoyl)phenyl]-
(s, 1H), 8.24 (m, 1H), 7.80-7.72 (m, 2H),
m/e 354



1,3-dihydro-
7.67-7.61 (m, 2H), 7.26 (d, J = 8.3 Hz,
(M + H)+



2H-isoindole-2-
1H), 6.98-6.91 (m, 1H), 6.88 (dd, J = 8.3,



carboxamide
2.4 Hz, 1H), 4.72 (m, 4H), 3.77 (s, 3H), 3.25-




3.14 (m, 2H), 1.60-1.44 (m, 2H), 0.89 (t,




J = 7.4 Hz, 3H)


598
5-methyl-N-[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.54

(ESI(+))



(propylcarbamoyl)phenyl]-
(s, 1H), 8.24 (m, 1H), 7.80-7.72 (m, 2H),
m/e 338



1,3-dihydro-
7.69-7.61 (m, 2H), 7.24 (d, J = 7.7 Hz,
(M + H)+



2H-isoindole-2-
1H), 7.17 (bs, 1H), 7.16-7.09 (m, 1H), 4.73



carboxamide
(bs, 4H), 3.23-3.14 (m, 2H), 2.33 (s, 3H),




1.60-1.44 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H)


716
N-(4-{[(1-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s,

(ESI(+))



methylpyrrolidin-3-
1H), 8.40 (t, J = 5.7 Hz, 1H), 7.81-7.73 (m,
m/e 379



yl)methyl]carbamoyl}phenyl)-
2H), 7.71-7.63 (m, 2H), 7.41-7.28 (m,
(M + H)+



1,3-dihydro-2H-
6H), 5.83 (dd, J = 19.3, 15.2 Hz, 1H), 4.79



isoindole-2-
(bs, 4H), 3.30-3.21 (m, 1H), 3.06-2.93



carboxamide
(m, 1H), 2.89-2.69 (m, 1H), 2.60 (dd, J =




17.2, 7.4 Hz, 1H), 2.32 (s, 3H), 2.04-1.85




(m, 1H), 1.58 (tt, J = 13.9, 6.9 Hz, 1H)


719
N-(4-{[(1-

1H NMR (300 MHz, DMSO-d6) δ 8.57 (s,

(ESI(+))



methylpiperidin-4-
1H), 8.27 (t, J = 5.8 Hz, 1H), 7.80-7.73 (m,
m/e 393



yl)methyl]carbamoyl}phenyl)-
2H), 7.69-7.62 (m, 2H), 7.41-7.28 (m,
(M + H)+



1,3-dihydro-2H-
4H), 3.35-3.27 (m, 2H), 3.13 (t, J = 6.2 Hz,



isoindole-2-
2H), 3.03-2.93 (m, 1H), 2.86-2.77 (m,



carboxamide
2H), 2.20 (s, 3H), 2.17 (s, 1H), 2.00-1.82




(m, 2H), 1.70-1.45 (m, 3H), 1.28-1.11 (m,




2H)


781
N-(4-{[(1,1-

1H NMR (300 MHz, DMSO DMSO-d6) δ

(ESI(+))



dioxidotetrahydrothiophen-3-
8.58 (s, 1H), 8.44 (t, J = 5.8 Hz, 1H), 7.81-
m/e 414



yl)methyl]carbamoyl}phenyl)-
7.74 (m, 2H), 7.71-7.64 (m, 2H), 7.41-
(M + H)+



1,3-dihydro-2H-
7.28 (m, 4H), 4.79 (s, 4H), 3.41-3.31 (m,



isoindole-2-
2H), 3.30 (s, 2H), 3.11-2.81 (m, 2H), 2.74-



carboxamide
2.59 (m, 1H), 2.30-2.15 (m, 1H), 1.94-




1.76 (m, 1H)


782
N-(4-{[(2,2-

1H NMR (300 MHz, DMSO-d6) δ 8.58 (s,

(ESI(+))



dimethyl-1,3-
1H), 8.38 (t, J = 5.8 Hz, 1H), 8.01-7.89 (m,
m/e 396



dioxolan-4-
1H), 7.78 (d, J = 8.9 Hz, 2H), 7.67 (d, J =
(M + H)+



yl)methyl]carbamoyl}phenyl)-
8.8 Hz, 2H), 7.44-7.24 (m, 4H), 4.79 (s,



1,3-dihydro-2H-
4H), 4.20 (p, J = 5.9 Hz, 1H), 3.98 (dd, J =



isoindole-2-
8.3, 6.2 Hz, 1H), 3.71 (dd, J = 8.3, 5.8 Hz,



carboxamide
1H), 3.50-3.20 (m, 1H), 1.35 (s, 3H), 1.26




(s, 3H)


783
N-(4-{[(1S)-2-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (d, J =

(ESI(+))



methoxy-1-
8.2 Hz, 2H), 7.87-7.79 (m, 2H), 7.70 (s,
m/e 416



phenylethyl]carbamoyl}phenyl)-
1H), 7.67 (s, 1H), 7.46-7.20 (m, 9H), 5.27
(M + H)+



1,3-dihydro-2H-
(td, J = 8.4, 5.4 Hz, 1H), 4.79 (s, 4H), 3.70



isoindole-2-
(dd, J = 10.0, 8.6 Hz, 1H), 3.55 (dd, J = 10.0,



carboxamide
5.5 Hz, 1H), 3.30 (d, J = 2.9 Hz, 3H)


784
N-[4-({[(4S)-2,2-

1H NMR (300 MHz, DMSO-d6) δ 8.58 (s,

(ESI(+))



dimethyl-1,3-
1H), 8.39 (t, J = 5.8 Hz, 1H), 7.81-7.74 (m,
m/e 396



dioxolan-4-
2H), 7.70-7.63 (m, 2H), 7.41-7.28 (m,
(M + H)+



yl]methyl}carbamoyl)phenyl]-
4H), 4.79 (s, 4H), 4.20 (p, J = 5.9 Hz, 1H),



1,3-dihydro-2H-
3.98 (dd, J = 8.3, 6.2 Hz, 1H), 3.71 (dd, J =



isoindole-2-
8.3, 5.8 Hz, 1H), 3.30 (s, 1H), 1.35 (s, 3H),



carboxamide
1.26 (s, 3H)


785
N-[4-({[(4R)-2,2-

1H NMR (300 MHz, DMSO-d6) δ 8.58 (s,

(ESI(+))



dimethyl-1,3-
1H), 8.39 (t, J = 5.8 Hz, 1H), 7.81-7.74 (m,
m/e 396



dioxolan-4-
2H), 7.70-7.63 (m, 2H), 7.43-7.27 (m,
(M + H)+



yl]methyl}carbamoyl)phenyl]-
4H), 4.79 (s, 4H), 4.20 (p, J = 5.9 Hz, 1H),



1,3-dihydro-2H-
3.98 (dd, J = 8.3, 6.2 Hz, 1H), 3.71 (dd, J =



isoindole-2-
8.3, 5.8 Hz, 1H), 3.38 (ddd, J = 14.9, 12.8,



carboxamide
5.8 Hz, 1H), 1.35 (s, 3H), 1.26 (s, 3H)


786
N-[4-({[3-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s,

(ESI(+))



(hydroxymethyl)oxetan-3-
1H), 8.43 (t, J = 6.1 Hz, 1H), 7.83-7.76 (m,
m/e 382



yl]methyl}carbamoyl)phenyl]-
2H), 7.72-7.65 (m, 2H), 7.41-7.28 (m,
(M + H)+



1,3-dihydro-2H-
4H), 4.89 (t, J = 5.6 Hz, 1H), 4.79 (s, 4H),



isoindole-2-
4.40 (d, J = 5.9 Hz, 2H), 4.29 (d, J = 5.8 Hz,



carboxamide
2H), 3.58 (d, J = 5.6 Hz, 2H), 3.51 (d, J =




6.0 Hz, 2H)


790
N-{4-[(2R)-butan-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



ylcarbamoyl]phenyl}-
δ 7.81-7.71 (m, 2H), 7.71-7.48 (m, 2H),
m/e 338



1,3-dihydro-2H-
7.44-7.23 (m, 4H), 4.79 (s, 4H), 3.92 (h, J =
(M + H)+



isoindole-2-
6.7 Hz, 1H), 1.62-1.44 (m, 2H), 1.15 (d,



carboxamide
J = 6.6 Hz, 3H), 0.88 (t, J = 7.4 Hz, 3H)


802
N-(4-{[(3-

1H NMR (300 MHz, DMSO-d6) δ 8.59 (s,

(ESI(+))



methyloxetan-3-
1H), 8.43 (t, J = 6.1 Hz, 1H), 7.83-7.76 (m,
m/e 366



yl)methyl]carbamoyl}phenyl)-
2H), 7.71-7.65 (m, 2H), 7.41-7.28 (m,
(M + H)+



1,3-dihydro-2H-
4H), 4.79 (s, 4H), 4.48 (d, J = 5.7 Hz, 2H),



isoindole-2-
4.20 (d, J = 5.7 Hz, 2H), 3.44 (d, J = 6.0 Hz,



carboxamide
2H), 1.25 (s, 3H)


809
5-cyano-N-{4-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



[(cyclopentylmethyl)
Temp = 90° C.) δ ppm 7.79 (s, 1 H) 7.70-7.77
m/e 389



carbamoyl]phenyl}-
(m, 3 H) 7.60-7.63 (m, 1 H) 7.58-7.60 (m,
(M + H)+



1,3-dihydro-2H-
1 H) 7.56 (d, J = 7.93 Hz, 1 H) 4.85 (d,



isoindole-2-
J = 8.24 Hz, 4 H) 3.21 (d, J = 7.02 Hz, 2 H)



carboxamide
2.08-2.25 (m, 1 H) 1.43-1.76 (m, 6 H)




1.19-1.35 (m, 2 H)


810
5-cyano-N-{4-[(1,3-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



thiazol-5-
Temp = 90° C.) δ ppm 7.74-7.81 (m, 4 H)
m/e 404



ylmethyl)carbamoyl]
7.72 (dd, J = 7.93, 1.53 Hz, 1 H) 7.61-7.65
(M + H)+



phenyl}-1,3-dihydro-
(m, 2 H) 7.56 (d, J = 7.93 Hz, 2 H) 4.85 (d,



2H-isoindole-2-
J = 9.77 Hz, 4 H) 4.68 (s, 2 H)



carboxamide


811
5-cyano-N-(4-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



{[(1R)-3-hydroxy-1-
Temp = 90° C.) δ ppm 7.75-7.81 (m, 3 H)
m/e 441



phenylpropyl]carbamoyl}phenyl)-
7.70-7.73 (m, 1 H) 7.60-7.64 (m, 2 H)
(M + H)+



1,3-dihydro-2H-
7.56 (d, J = 7.93 Hz, 1 H) 7.37-7.43 (m, 2 H)



isoindole-2-
7.28-7.35 (m, 2 H) 7.17-7.25 (m, 1 H)



carboxamide
5.11-5.22 (m, 1 H) 4.85 (d, J = 8.24 Hz, 4 H)




3.44-3.52 (m, 2 H) 1.91-2.12 (m, 2 H)


812
5-cyano-N-(4-{[2-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



hydroxy-1-(4-
Temp = 90° C.) δ ppm 7.77-7.82 (m, 3 H)
m/e 441



methylphenyl)ethyl]carbamoyl}phenyl)-
7.72 (dd, J = 7.93, 1.53 Hz, 1 H) 7.59-7.65
(M + H)+



1,3-dihydro-2H-
(m, 2 H) 7.56 (d, J = 7.93 Hz, 1 H) 7.27 (d,



isoindole-2-
J = 8.24 Hz, 2 H) 7.12 (d, J = 7.93 Hz, 2 H)



carboxamide
5.00-5.07 (m, 1 H) 4.85 (d, J = 8.24 Hz, 4 H)




3.67-3.78 (m, 2 H) 2.27 (s, 3 H)


813
5-cyano-N-{4-[(1,3-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



dihydroxypropan-2-
Temp = 90° C.) δ ppm 7.86-8.00 (m, 1 H)
m/e 381



yl)carbamoyl]phenyl}-
7.67-7.81 (m, 4 H) 7.53-7.65 (m, 2 H)
(M + H)+



1,3-dihydro-2H-
4.85 (d, J = 7.02 Hz, 4 H) 4.33-4.52 (m, 1 H)



isoindole-2-
3.93-4.02 (m, 1 H) 3.59-3.84 (m, 1 H)



carboxamide
3.58 (d, J = 5.80 Hz, 2 H)


814
5-cyano-N-(4-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



{[(2R)-2-
Temp = 90° C.) δ ppm 7.68-7.84 (m, 4 H)
m/e 365



hydroxypropyl]carbamoyl}phenyl)-
7.54-7.64 (m, 3 H) 4.85 (d, J = 8.24 Hz, 4 H)
(M + H)+



1,3-dihydro-2H-
3.77-3.88 (m, 1 H) 3.15-3.26 (m, 2 H)



isoindole-2-
1.10 (d, J = 6.10 Hz, 3H)



carboxamide


815
5-cyano-N-{4-[(2-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



hydroxy-2-
Temp = 90° C.) δ ppm 7.69-7.81 (m, 4 H)
m/e 379



methylpropyl)carbamoyl]phenyl}-
7.54-7.65 (m, 3 H) 4.85 (d, J = 8.24 Hz, 4 H)
(M + H)+



1,3-dihydro-2H-
3.28 (s, 2 H) 1.14 (s, 6 H)



isoindole-2-



carboxamide


816
5-cyano-N-(4-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



{[(2R)-1-hydroxy-3-
Temp = 90° C.) δ ppm 7.69-7.81 (m, 4 H)
m/e 393



methylbutan-2-
7.55-7.64 (m, 3 H) 4.85 (d, J = 8.24 Hz, 4 H)
(M + H)+



yl]carbamoyl}phenyl)-
3.76-3.84 (m, 1 H) 3.56 (d, J = 5.19 Hz, 2 H)



1,3-dihydro-2H-
1.87-2.00 (m, 1 H) 0.92 (dd, J = 11.75, 6.87



isoindole-2-
Hz, 6 H)



carboxamide


817
5-cyano-N-(4-{[(2S)-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



tetrahydrofuran-2-
Temp = 90° C.) δ ppm 7.69-7.81 (m, 4 H)
m/e 391



ylmethyl]carbamoyl}
7.54-7.63 (m, 3 H) 4.85 (d, J = 8.24 Hz, 4 H)
(M + H)+



phenyl)-1,3-dihydro-
3.95-4.05 (m, 1 H) 3.75-3.84 (m, 1 H)



2H-isoindole-2-
3.60-3.68 (m, 1 H) 3.34 (d, J = 5.80 Hz, 2 H)



carboxamide
1.75-1.98 (m, 3 H) 1.54-1.66 (m, 1 H)


818
5-cyano-N-(4-{[2-(4-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



methylpiperazin-1-
Temp = 90° C.) δ ppm 7.70-7.81 (m, 4 H)
m/e 433



yl)ethyl]carbamoyl}phenyl)-
7.60-7.66 (m, 2 H) 7.57 (d, J = 7.93 Hz, 1 H)
(M + H)+



1,3-dihydro-
4.85 (d, J = 8.85 Hz, 4 H) 3.50 (t, J = 6.41 Hz,



2H-isoindole-2-
2 H) 3.22-3.26 (m, 4 H) 3.04 (d, J = 4.88 Hz,



carboxamide
4 H) 2.90 (t, J = 6.41 Hz, 2 H) 2.78 (s, 3 H)


819
5-cyano-N-(4-{[(1S)

1H NMR (400 MHz, DMSO-D2O, Temp = 90°

(ESI(+))



2-hydroxy-1-
C.) δ ppm 7.78-7.85 (m, 3 H) 7.70-7.74
m/e 427



phenylethyl]carbamoyl}phenyl)-
(m, 1 H) 7.60-7.66 (m, 2 H) 7.56 (d, J = 8.24
(M + H)+



1,3-dihydro-2H-
Hz, 1 H) 7.38-7.43 (m, 2 H) 7.28-7.34 (m,



isoindole-2-
2 H) 7.19-7.26 (m, 1 H) 5.03-5.13 (m, 1



carboxamide
H) 4.85 (d, J = 8.24 Hz, 4 H) 3.68-3.79 (m, 2 H)


820
5-cyano-N-{4-[(4-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



hydroxybutyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 7.79 (s, 1 H) 7.70-7.76
m/e 377



1,3-dihydro-2H-
(m, 3 H) 7.58-7.64 (m, 2 H) 7.56 (d, J = 8.24
(M + H)+



isoindole-2-
Hz, 1 H) 4.85 (d, J = 8.24 Hz, 4 H) 4.44 (t,



carboxamide
J = 6.41 Hz, 1 H) 3.45 (t, J = 6.41 Hz, 1 H)




3.27-3.34 (m, 2 H) 1.46-1.81 (m, 4 H)


821
5-cyano-N-(4-{[(2S)-2-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



hydroxypropyl]carbamoyl}phenyl)-
Temp = 90° C.) δ ppm 7.69-7.82 (m, 4 H)
m/e 365



1,3-dihydro-2H-isoindole-2-
7.53-7.64 (m, 3 H) 4.85 (d, J = 8.24 Hz, 4 H)
(M + H)+



carboxamide
3.79-3.87 (m, 1 H) 3.17-3.26 (m, 2 H)




1.10 (d, J = 6.10 Hz, 3H)


822
5-cyano-N-{4-[(3-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



furylmethyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 7.79 (s, 1 H) 7.74-7.78
m/e 387



1,3-dihydro-2H-
(m, 2 H) 7.72 (d, J = 7.93 Hz, 1 H) 7.59-7.65
(M + H)+



isoindole-2-
(m, 2 H) 7.54-7.58 (m, 1 H) 7.50-7.53 (m,



carboxamide
1 H) 7.25 (d, J = 8.54 Hz, 1 H) 6.46 (s, 1 H)




4.85 (d, J = 8.85 Hz, 4 H) 4.31 (s, 2 H)


823
5-cyano-N-{4-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



[(tetrahydrofuran-2-
Temp = 90° C.) δ ppm 7.70-7.81 (m, 4 H)
m/e 391



ylmethyl)carbamoyl]
7.55-7.64 (m, 3 H) 4.85 (d, J = 8.24 Hz, 4 H)
(M + H)+



phenyl}-1,3-dihydro-
3.95-4.04 (m, 1 H) 3.75-3.83 (m, 1 H)



2H-isoindole-2-
3.61-3.68 (m, 1 H) 3.34 (d, J = 5.80 Hz, 2 H)



carboxamide
1.75-1.98 (m, 3 H) 1.54-1.65 (m, 1 H)


824
5-cyano-N-(4-{[4-(2-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



furoyl)piperazin-1-
Temp = 90° C.) δ ppm 7.79 (s, 1 H) 7.73-7.75
m/e 470



yl]carbonyl}phenyl)-
(m, 1 H) 7.71 (d, J = 1.53 Hz, 1 H) 7.60-7.65
(M + H)+



1,3-dihydro-2H-
(m, 2 H) 7.57 (d, J = 8.54 Hz, 1 H) 7.34-7.40



isoindole-2-
(m, 2 H) 7.00 (d, J = 2.75 Hz, 1 H) 6.59 (dd,



carboxamide
J = 3.51, 1.68 Hz, 1H) 4.85 (d, J = 8.54 Hz, 4




H) 3.71-3.77 (m, 4 H) 3.54-3.65 (m, 4 H)


825
5-cyano-N-(4-{[4-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



(tetrahydrofuran-2-
Temp = 90° C.) δ ppm 7.79 (s, 1 H) 7.72 (dd,
m/e 474



ylcarbonyl)piperazin-1-
J = 7.93, 1.53 Hz, 1 H) 7.59-7.64 (m, 2 H)
(M + H)+



yl]carbonyl}phenyl)-
7.57 (d, J = 7.93 Hz, 1 H) 7.33-7.37 (m, 2 H)



1,3-dihydro-2H-
4.85 (d, J = 8.24 Hz, 4 H) 4.64 (dd, J = 7.48,



isoindole-2-
5.95 Hz, 1 H) 3.71-3.86 (m, 2 H) 3.48-



carboxamide
3.61 (m, 8 H) 1.96-2.14 (m, 2 H) 1.75-




1.94 (m, 2 H)


826
5-cyano-N-(4-{[3-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



(piperidin-1-
Temp = 90° C.) δ ppm 7.70-7.81 (m, 4 H)
m/e 432



yl)propyl]carbamoyl}phenyl)-
7.61-7.66 (m, 2 H) 7.57 (d, J = 7.93 Hz, 1 H)
(M + H)+



1,3-dihydro-2H-
4.85 (d, J = 8.24 Hz, 4 H) 3.36 (t, J = 6.71 Hz,



isoindole-2-
4 H) 3.02-3.13 (m, 2 H) 2.90 (s, 2 H) 1.90-



carboxamide
2.18 (m, 2 H) 1.81 (d, J = 84.53 Hz, 6 H)


827
5-cyano-N-(4-{[(2R)-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



tetrahydrofuran-2-
Temp = 90° C.) δ ppm 7.70-7.81 (m, 4 H)
m/e 391



ylmethyl]carbamoyl}
7.55-7.64 (m, 3 H) 4.85 (d, J = 8.54 Hz, 4 H)
(M + H)+



phenyl)-1,3-dihydro-
3.96-4.04 (m, 1 H) 3.76-3.85 (m, 1 H)



2H-isoindole-2-
3.61-3.68 (m, 1 H) 3.34 (d, J = 5.80 Hz, 2 H)



carboxamide
1.75-1.98 (m, 3 H) 1.54-1.67 (m, 1 H)


828
5-cyano-N-(4-{[4-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



(ethylsulfonyl)piperazin-1-
Temp = 90° C.) δ ppm 7.79 (s, 1 H) 7.72 (dd,
m/e 468



yl]carbonyl}phenyl)-
J = 7.93, 1.53 Hz, 1 H) 7.59-7.64 (m, 2 H)
(M + H)+



1,3-dihydro-2H-
7.57 (d, J = 7.63 Hz, 1 H) 7.32-7.37 (m, 2 H)



isoindole-2-
4.85 (d, J = 8.24 Hz, 4 H) 3.56-3.61 (m, 4 H)



carboxamide
3.27 (s, 4 H) 3.07 (q, J = 7.32 Hz, 2 H) 1.24




(t, J = 7.32 Hz, 3 H)


829
5-cyano-N-{4-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



[(tetrahydrofuran-3-
Temp = 90° C.) δ ppm 7.79 (s, 1 H) 7.72-7.77
m/e 391



ylmethyl)carbamoyl]
(m, 2 H) 7.71 (d, J = 1.22 Hz, 1 H) 7.59-7.64
(M + H)+



phenyl}-1,3-dihydro-
(m, 2 H) 7.57 (d, J = 7.93 Hz, 1 H) 4.85 (d,



2H-isoindole-2-
J = 8.24 Hz, 4 H) 3.69-3.80 (m, 2 H) 3.60-



carboxamide
3.67 (m, 1 H) 3.47 (dd, J = 8.54, 5.49 Hz, 1




H) 3.28-3.30 (m, J = 3.36 Hz, 2 H) 2.45-




2.50 (m, 1 H) 1.90-2.01 (m, 1 H) 1.58-




1.68 (m, 1 H)


830
5-cyano-N-(4-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



{[(1R)-2-hydroxy-1-
Temp = 90° C.) δ ppm 7.81-7.83 (m, 1 H)
m/e 427



phenylethyl]carbamoyl}phenyl)-
7.78-7.80 (m, 2 H) 7.72 (dd, J = 7.93, 1.53
(M + H)+



1,3-dihydro-2H-
Hz, 1 H) 7.61-7.64 (m, 2 H) 7.57 (d, J = 8.54



isoindole-2-
Hz, 1 H) 7.39 (d, J = 7.63 Hz, 2 H) 7.28-7.34



carboxamide
(m, 2 H) 7.20-7.25 (m, 1 H) 5.05-5.11 (m,




1 H) 4.83-4.88 (m, 4 H) 3.69-3.79 (m, 2 H)


831
5-cyano-N-(4-{[(2S)-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



1-hydroxybutan-2-
Temp = 90° C.) δ ppm 7.67-7.90 (m, 4 H)
m/e 379



yl]carbamoyl}phenyl)-
7.52-7.65 (m, 3 H) 4.85 (d, J = 8.24 Hz, 4 H)
(M + H)+



1,3-dihydro-2H-
3.79-3.93 (m, 1 H) 3.41-3.55 (m, 2 H)



isoindole-2-
1.41-1.85 (m, 2 H) 0.90 (t, J = 7.48 Hz, 3 H)



carboxamide


832
5-cyano-N-{4-[(2,3-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



dihydroxypropyl)carbamoyl]phenyl}-
Temp = 90° C.) δ ppm 7.70-7.81 (m, 4 H)
m/e 381



1,3-dihydro-2H-
7.54-7.65 (m, 3 H) 4.85 (d, J = 8.24 Hz, 4 H)
(M + H)+



isoindole-2-
3.62-3.73 (m, 1 H) 3.38-3.45 (m, 3 H)



carboxamide
3.29 (d, J = 6.41 Hz, 1 H)


833
5-cyano-N-{4-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



[(tetrahydro-2H-
Temp = 90° C.) δ ppm 7.69-7.84 (m, 4 H)
m/e 405



pyran-4-
7.52-7.64 (m, 3 H) 4.85 (d, J = 8.24 Hz, 4 H)
(M + H)+



ylmethyl)carbamoyl]
3.80-3.89 (m, 2 H) 3.28-3.35 (m, 2 H)



phenyl}-1,3-dihydro-
3.19 (d, J = 7.02 Hz, 2 H) 1.76-1.91 (m, 1 H)



2H-isoindole-2-
1.61 (dd, J = 12.82, 1.83 Hz, 2 H) 1.17-1.32



carboxamide
(m, 2 H)


834
5-cyano-N-(4-{[2-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



hydroxy-1-(pyridin-2-
Temp = 90° C.) δ ppm 8.60 (d, J = 4.27 Hz, 1
m/e 428



yl)ethyl]carbamoyl}phenyl)-
H) 7.96-8.04 (m, 1 H) 7.77-7.86 (m, 3 H)
(M + H)+



1,3-dihydro-
7.73 (d, J = 7.93 Hz, 1 H) 7.61-7.68 (m, 3 H)



2H-isoindole-2-
7.57 (d, J = 7.93 Hz, 1 H) 7.45-7.51 (m, 1 H)



carboxamide
5.21 (t, J = 5.95 Hz, 1 H) 4.86 (d, J = 8.24 Hz,




4H) 3.89 (d, J = 5.80 Hz, 2 H)


835
5-cyano-N-{4-[(1-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



hydroxy-4-
Temp = 90° C.) δ ppm 7.68-7.82 (m, 4 H)
m/e 407



methylpentan-2-
7.52-7.64 (m, 3 H) 4.85 (d, J = 8.24 Hz, 4 H)
(M + H)+



yl)carbamoyl]phenyl}-
4.01-4.09 (m, 1 H) 3.38-3.52 (m, 2 H)



1,3-dihydro-2H-
1.59-1.75 (m, 1 H) 1.37-1.55 (m, 2 H)



isoindole-2-
0.86-0.93 (m, 6 H)



carboxamide


836
5-cyano-N-(4-{[(1-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



methylpyrrolidin-3-
Temp = 90° C.) δ ppm 7.70-7.82 (m, 4 H)
m/e 404



yl)methyl]carbamoyl}phenyl)-
7.59-7.67 (m, 2 H) 7.57 (d, J = 7.63 Hz, 1 H)
(M + H)+



1,3-dihydro-2H-
4.82-4.89 (m, 4 H) 3.41-3.82 (m, 2 H)



isoindole-2-
3.35-3.41 (m, 2 H) 2.94-3.21 (m, 2 H)



carboxamide
2.85 (s, 3 H) 2.60-2.75 (m, 1 H) 1.61-2.34




(m, 2 H)


837
5-cyano-N-(4-{[(1-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



methylpiperidin-4-
Temp = 90° C.) δ ppm 7.67-7.83 (m, 4 H)
m/e 418



yl)methyl]carbamoyl}phenyl)-
7.54-7.65 (m, 3 H) 4.85 (d, J = 8.24 Hz, 4 H)
(M + H)+



1,3-dihydro-2H-
3.36-3.52 (m, 2 H) 3.18-3.25 (m, 2 H)



isoindole-2-
2.92 (s, 2 H) 2.76 (s, 3 H) 1.89 (m, 3 H) 1.29-



carboxamide
1.54 (m, 2H)


838
5-cyano-N-{4-

1H NMR (400 MHz, DMSO-D2O,

(ESI(+))



[(tetrahydro-2H-
Temp = 90° C.) δ ppm 7.68-7.82 (m, 4 H)
m/e 405



pyran-3-
7.52-7.65 (m, 3 H) 4.85 (d, J = 8.54 Hz, 4 H)
(M + H)+



ylmethyl)carbamoyl]
3.65-3.82 (m, 2 H) 3.29-3.40 (m, 1 H)



phenyl}-1,3-dihydro-
3.09-3.20 (m, 3 H) 1.73-1.92 (m, 2 H)



2H-isoindole-2-
1.40-1.69 (m, 2 H) 1.20-1.35 (m, 1 H)



carboxamide


717
N-{4-[(pyrrolidin-3-

1H NMR (300 MHz, DMSO-d6) δ 9.07 (bs,

(ESI(+))



ylmethyl)carbamoyl]
1H), 8.64 (s, 1H), 8.51 (t, J = 5.8 Hz, 1H),
m/e 340



phenyl}-1,3-dihydro-
7.83-7.75 (m, 1H), 7.73-7.65 (m, 2H),
(M + H)+



2H-isoindole-2-
7.42-7.28 (m, 3H), 4.86 (bs, 2H), 4.79 (s,



carboxamide
4H), 3.75-3.64 (m, 1H), 3.53-3.43 (m,




1H), 3.40-3.16 (m, 3H), 3.10 (dt, J = 13.6,




7.7 Hz, 1H), 2.98-2.83 (m, 1H), 2.07-1.92




(m, 1H), 1.84-1.46 (m, 1H)


840
N-[4-(2,6-

1H NMR (400 MHz, DMSO-D2O) δ 7.67-

(ESI(+))



diazaspiro[3.3]hept-2-
7.61 (m, 2H), 7.57-7.51 (m, 2H), 7.40-
m/e 363



ylcarbonyl)phenyl]-
7.26 (m, 4H), 4.79 (s, 4H), 4.36 (bs, 4H),
(M + H)+



1,3-dihydro-2H-
4.20 (s, 4H)



isoindole-2-



carboxamide


841
N-[4-(2,6-

1H NMR (400 MHz, DMSO-D2O) δ 7.70-

(ESI(+))



diazaspiro[3.4]oct-6-
7.56 (m, 2H), 7.48-7.42 (m, 2H), 7.38-
m/e 377



ylcarbonyl)phenyl]-
7.29 (m, 4H), 4.79 (s, 4H), 3.99 (q, J = 10.6
(M + H)+



1,3-dihydro-2H-
Hz, 4H), 3.74 (s, 2H), 3.52 (t, J = 7.0 Hz,



isoindole-2-
2H), 2.18 (t, J = 7.1 Hz, 2H)



carboxamide


842
N-[4-(2,7-

1H NMR (400 MHz, DMSO-D2O) δ 7.73-

(ESI(+))



diazaspiro[3.5]non-7-
7.53 (m, 2H), 7.42-7.31 (m, 4H), 7.31-
m/e 391



ylcarbonyl)phenyl]-
7.25 (m, 2H), 4.79 (s, 4H), 3.81 (d, J = 5.0
(M + H)+



1,3-dihydro-2H-
Hz, 4H), 3.44 (dd, J = 12.2, 6.6 Hz, 4H),



isoindole-2-
1.92-1.53 (m, 4H)



carboxamide


843
N-[4-(2,6-

1H NMR (400 MHz, DMSO-D2O) δ 7.67-

(ESI(+))



diazaspiro[3.5]non-2-
7.61 (m, 2H), 7.58-7.54 (m, 2H), 7.39-
m/e 391



ylcarbonyl)phenyl]-
7.29 (m, 4H), 4.79 (s, 4H), 4.07 (d, J = 7.8
(M + H)+



1,3-dihydro-2H-
Hz, 2H), 3.95 (d, J = 22.6 Hz, 2H), 2.99 (t, J =



isoindole-2-
11.8, 6.0 Hz, 2H), 2.55 (s, 2H), 1.97-1.82



carboxamide
(m, 2H), 1.82-1.59 (m, 2H)


844
N-[4-(1,7-

1H NMR (400 MHz, DMSO-D2O) δ 7.72-

(ESI(+))



diazaspiro[4.4]non-1-
7.57 (m, 2H), 7.50-7.40 (m, 2H), 7.40-
m/e 391



ylcarbonyl)phenyl]-
7.22 (m, 4H), 4.79 (s, 4H), 3.83 (d, J = 12.2
(M + H)+



1,3-dihydro-2H-
Hz, 1H), 3.75-3.63 (m, 1H), 3.57-3.42



isoindole-2-
(m, 2H), 3.17 (t, J = 13.0 Hz, 1H), 2.61 (m, J =



carboxamide
13.5, 9.0 Hz, 1H), 2.27-1.99 (m, 3H),




1.92-1.61 (m, 2H)


845
N-[4-(1,7-

1H NMR (400 MHz, DMSO-D2O) δ 7.77-

(ESI(+))



diazaspiro[4.4]non-7-
7.56 (m, 2H), 7.54-7.42 (m, 2H), 7.41-
m/e 391



ylcarbonyl)phenyl]-
7.22 (m, 4H), 4.79 (s, 4H), 3.88 (d, J = 12.7
(M + H)+



1,3-dihydro-2H-
Hz, 1H), 3.75-3.56 (m, 3H), 2.39-2.25



isoindole-2-
(m, 1H), 2.26-2.11 (m, 1H), 2.10-1.87 (m,



carboxamide
4H)


846
N-[4-(2,7-

1H NMR (400 MHz, DMSO-D2O) δ 7.70-

(ESI(+))



diazaspiro[4.4]non-2-
7.54 (m, 2H), 7.50-7.40 (m, 2H), 7.39-
m/e 391



ylcarbonyl)phenyl]-
7.22 (m, 4H), 4.79 (s, 4H), 3.72-3.42 (m,
(M + H)+



1,3-dihydro-2H-
4H), 3.17 (t, J = 10.1 Hz, 2H), 2.14-1.81



isoindole-2-
(m, 4H)



carboxamide


847
N-[4-(2,8-

1H NMR (400 MHz, DMSO-D2O) δ 7.70-

(ESI(+))



diazaspiro[4.5]dec-2-
7.55 (m, 2H), 7.52-7.40 (m, 2H), 7.38-
m/e 405



ylcarbonyl)phenyl]-
7.16 (m, 4H), 4.79 (s, 4H), 3.57 (t, J = 7.2
(M + H)+



1,3-dihydro-2H-
Hz, 2H), 3.41 (s, 2H), 3.15-2.98 (m, 4H),



isoindole-2-
2.53-2.50 (m, 2H), 1.82 (t, 2H), 1.76-1.60



carboxamide
(m, 4H)


848
N-[4-(2,7-

1H NMR (400 MHz, DMSO-D2O) δ 7.71-

(ESI(+))



diazaspiro[4.5]dec-2-
7.54 (m, 2H), 7.53-7.39 (m, 2H), 7.39-
m/e 405



ylcarbonyl)phenyl]-
7.20 (m, 4H), 4.79 (s, 4H), 3.63-3.55 (m,
(M + H)+



1,3-dihydro-2H-
2H), 3.55-3.47 (m, 1H), 3.46-3.39 (m,



isoindole-2-
1H), 3.07-2.98 (m, 4H), 1.98-1.87 (m,



carboxamide
1H), 1.86-1.77 (m, 1H), 1.77-1.71 (m,




1H), 1.71-1.56 (m, 3H)


849
N-[4-(2,6-

1H NMR (400 MHz, DMSO-D2O) δ 7.76-

(ESI(+))



diazaspiro[4.5]dec-2-
7.55 (m, 2H), 7.55-7.41 (m, 2H), 7.41-
m/e 405



ylcarbonyl)phenyl]-
7.20 (m, 4H), 4.79 (s, 4H), 3.82 (d, J = 12.8
(M + H)+



1,3-dihydro-2H-
Hz, 1H), 3.77-3.66 (m, 1H), 3.66-3.53



isoindole-2-
(m, 2H), 3.17-2.98 (m, 2H), 2.36-2.21 (m,



carboxamide
1H), 2.19-2.06 (m, 1H), 1.87-1.77 (m,




2H), 1.76-1.55 (m, 4H)


850
N-[4-(2,7-

1H NMR (400 MHz, DMSO-D2O) δ 7.76-

(ESI(+))



diazaspiro[4.5]dec-7-
7.55 (m, 2H), 7.45-7.32 (m, 3H), 7.34-
m/e 405



ylcarbonyl)phenyl]-
7.19 (m, 4H), 4.79 (s, 4H), 3.66-3.49 (m,
(M + H)+



1,3-dihydro-2H-
2H), 3.47-3.36 (m, 1H), 3.27-3.12 (m,



isoindole-2-
1H), 3.10-2.90 (m, 2H), 2.00-1.83 (m,



carboxamide
1H), 1.84-1.62 (m, 3H), 1.62-1.46 (m,




2H)


851
N-[4-(3,9-

(ESI(+))



diazaspiro[5.5]undec-3-

m/e XXX



ylcarbonyl)phenyl]-

(M + H)+



1,3-dihydro-2H-



isoindole-2-



carboxamide


852
N-[4-(2,9-

1H NMR (400 MHz, DMSO-D2O) δ 7.78-

(ESI(+))



diazaspiro[5.5]undec-2-
7.54 (m, 2H), 7.46-7.21 (m, 6H), 4.79 (s,
m/e 419



ylcarbonyl)phenyl]-
4H), 3.66 (d, J = 13.3 Hz, 1H), 3.54 (d, J =
(M + H)+



1,3-dihydro-2H-
14.2 Hz, 1H), 3.35 (dd, J = 14.9, 8.0 Hz,



isoindole-2-
2H), 3.09-3.00 (m, 1H), 3.00-2.94 (m,



carboxamide
1H), 2.94-2.85 (m, 2H), 2.54-2.48 (m,




2H), 1.70 (dd, J = 11.6, 5.7 Hz, 2H), 1.63




(dd, J = 16.4, 6.3 Hz, 2H), 1.61-1.50 (m,




4H), 1.50-1.39 (m, 1H)


853
N-[4-(2,8-

1H NMR (400 MHz, DMSO-D2O) δ 7.79-

(ESI(+))



diazaspiro[5.5]undec-2-
7.49 (m, 2H), 7.44-7.13 (m, 6H), 4.79 (s,
m/e 419



ylcarbonyl)phenyl]-
4H), 3.45 (d, J = 9.0 Hz, 4H), 3.17-2.85
(M + H)+



1,3-dihydro-2H-
(m, 4H), 1.59 (dd, J = 12.8, 6.9 Hz, 8H)



isoindole-2-



carboxamide


854
N-[4-(1,8-

1H NMR (400 MHz, DMSO-D2O) δ 7.74-

(ESI(+))



diazaspiro[5.5]undec-8-
7.52 (m, 2H), 7.41-7.24 (m, 6H), 4.79 (s,
m/e 419



ylcarbonyl)phenyl]-
4H), 3.82 (t, J = 14.5 Hz, 1H), 3.70 (d, J =
(M + H)+



1,3-dihydro-2H-
13.7 Hz, 1H), 3.55-3.40 (m, 2H), 3.16-



isoindole-2-
2.88 (m, 2H), 2.01-1.81 (m, 2H), 1.75-



carboxamide
1.53 (m, 8H)


855
N-[4-(1,8-

1H NMR (400 MHz, DMSO-D2O) δ 7.73-

(ESI(+))



diazaspiro[4.6]undec-8-
7.51 (m, 2H), 7.45-7.15 (m, 6H), 4.79 (s,
m/e 419



ylcarbonyl)phenyl]-
4H), 3.77-3.59 (m, 1H), 3.62-3.36 (m,
(M + H)+



1,3-dihydro-2H-
3H), 3.29-3.20 (m, 2H), 2.12-1.95 (m,



isoindole-2-
4H), 1.91-1.66 (m, 5H)



carboxamide


856
N-{4-[(1-oxa-8-

1H NMR (400 MHz, DMSO-D2O) δ 7.78-

(ESI(+))



azaspiro[4.5]dec-2-
7.72 (m, 2H), 7.66-7.61 (m, 2H), 7.39-
m/e 435



ylmethyl)carbamoyl]
7.28 (m, 4H), 4.79 (s, 4H), 4.15 (dd, J =
(M + H)+



phenyl}-1,3-dihydro-
12.2, 6.0 Hz, 1H), 3.38 (qd, J = 13.4, 5.8 Hz,



2H-isoindole-2-
2H), 3.20-3.00 (m, 4H), 2.53-2.50 (m,



carboxamide
3H), 2.18-1.96 (m, 1H), 1.94-1.56 (m, 8H)


857
N-[4-(1-oxa-8-

1H NMR (400 MHz, DMSO-D2O) δ 7.84-

(ESI(+))



azaspiro[4.5]dec-3-
7.70 (m, 2H), 7.70-7.54 (m, 2H), 7.46-
m/e 421



ylcarbamoyl)phenyl]-
7.21 (m, 4H), 4.79 (s, 4H), 4.64-4.44 (m,
(M + H)+



1,3-dihydro-2H-
1H), 4.15-3.95 (m, 1H), 3.73 (dd, J = 9.1,



isoindole-2-
6.1 Hz, 1H), 3.19-2.97 (m, 4H), 2.21 (dd, J =



carboxamide
13.1, 8.3 Hz, 1H), 1.99-1.84 (m, 3H),




1.84-1.70 (m, 2H)


858
N-{4-[(2-oxa-9-

1H NMR (400 MHz, DMSO-D2O) δ 7.87-

(ESI(+))



azaspiro[5.5]undec-3-
7.69 (m, 2H), 7.71-7.53 (m, 2H), 7.45-
m/e 449



ylmethyl)carbamoyl]
7.12 (m, 4H), 4.79 (s, 4H), 3.75 (dd, J =
(M + H)+



phenyl}-1,3-dihydro-
11.5, 2.6 Hz, 1H), 3.55-3.41 (m, 1H), 3.38-



2H-isoindole-2-
3.31 (m, 2H), 3.22-3.12 (m, 1H), 3.11-



carboxamide
2.94 (m, 4H), 1.92-1.66 (m, 3H), 1.62-




1.49 (m, 1H), 1.49-1.24 (m, 4H)


859
N-[4-(1-oxa-4,8-

1H NMR (400 MHz, DMSO-D2O) δ 7.75-

(ESI(+))



diazaspiro[5.5]undec-4-
7.53 (m, 2H), 7.44-7.15 (m, 6H), 4.79 (s,
m/e 421



ylcarbonyl)phenyl]-
4H), 3.82-3.66 (m, 2H), 3.63-3.46 (m,
(M + H)+



1,3-dihydro-2H-
4H), 3.40-3.32 (m, 1H), 3.25-3.14 (m,



isoindole-2-
1H), 2.96-2.77 (m, 2H), 2.08-1.92 (m,



carboxamide
1H), 1.92-1.74 (m, 1H), 1.73-1.58 (m,




1H), 1.59-1.38 (m, 1H)


860
N-[4-(1,8-

1H NMR (400 MHz, DMSO-D2O) δ 7.71-

(ESI(+))



diazaspiro[4.5]dec-1-
7.48 (m, 2H), 7.45-7.18 (m, 6H), 4.79 (s,
m/e 405



ylcarbonyl)phenyl]-
4H), 3.44 (t, J = 6.7 Hz, 2H), 3.36 (dd, J =
(M + H)+



1,3-dihydro-2H-
7.3, 5.1 Hz, 1H), 3.24-3.06 (m, 2H), 3.05-



isoindole-2-
2.85 (m, 2H), 2.05 (t, J = 7.0 Hz, 2H), 1.88-



carboxamide
1.72 (m, 2H), 1.65 (dd, J = 12.7, 1.4 Hz, 2H)


861
N-[4-(1,8-

1H NMR (400 MHz, DMSO-D2O) δ 7.75-

(ESI(+))



diazaspiro[4.5]dec-8-
7.51 (m, 2H), 7.42-7.10 (m, 6H), 4.79 (s,
m/e 405



ylcarbonyl)phenyl]-
4H), 3.92-3.68 (m, 2H), 3.36 (dd, J = 8.1,
(M + H)+



1,3-dihydro-2H-
5.4 Hz, 1H), 3.31-3.21 (m, 2H), 2.14-1.91



isoindole-2-
(m, 4H), 1.91-1.68 (m, 4H)



carboxamide


862
N-[4-(2,6-

1H NMR (400 MHz, DMSO-D2O) δ 7.72-

(ESI(+))



diazaspiro[3.4]oct-2-
7.60 (m, 2H), 7.60-7.49 (m, 2H), 7.42-
m/e 377



ylcarbonyl)phenyl]-
7.21 (m, 4H), 4.79 (s, 4H), 4.20 (dd, J =
(M + H)+



1,3-dihydro-2H-
29.4, 9.1 Hz, 4H), 3.42 (s, 2H), 3.27 (d, J =



isoindole-2-
3.7 Hz, 1H), 3.24 (s, 1H), 2.24 (t, J = 7.4 Hz,



carboxamide
2H)


863
N-[4-(1,7-

1H NMR (400 MHz, DMSO-D2O) δ 7.72-

(ESI(+))



diazaspiro[3.5]non-7-
7.52 (m, 2H), 7.43-7.10 (m, 6H), 5.54 (s,
m/e 390



ylcarbonyl)phenyl]-
1H), 4.79 (s, 4H), 3.99 (d, J = 1 1.5 Hz, 2H),
(M + H)+



1,3-dihydro-2H-
3.68-3.49 (m, 2H), 2.95 (t, J = 7.4 Hz, 2H),



isoindole-2-
2.53-2.51 (m, 1H), 2.41-2.25 (m, 2H),



carboxamide
2.07 (t, J = 31.9 Hz, 2H)


864
N-[4-(1,6-

1H NMR (400 MHz, DMSO-D2O) δ 7.75-

(ESI(+))



diazaspiro[3.5]non-1-
7.61 (m, 2H), 7.60-7.48 (m, 2H), 7.42-
m/e 391



ylcarbonyl)phenyl]-
7.12 (m, 4H), 4.79 (s, 4H), 4.54-4.29 (m,
(M + H)+



1,3-dihydro-2H-
1H), 4.14-3.91 (m, 1H), 3.86-3.55 (m,



isoindole-2-
1H), 3.26-3.18 (m, 1H), 3.12-2.79 (m,



carboxamide
1H), 2.50 (dd, J = 9.4, 1.3 Hz, 1H), 2.43-




2.20 (m, 1H), 2.17-2.01 (m, 1H), 2.01-




1.85 (m, 2H), 1.87-1.52 (m, 1H)


865
N-[4-(2,5-

1H NMR (400 MHz, DMSO-D2O) δ 7.75-

(ESI(+))



diazaspiro[3.5]non-2-
7.62 (m, 2H), 7.62-7.52 (m, 2H), 7.44-
m/e 391



ylcarbonyl)phenyl]-
7.18 (m, 4H), 4.80 (s, 4H), 4.28 (d, J = 10.2
(M + H)+



1,3-dihydro-2H-
Hz, 2H), 4.19 (s, 2H), 3.10 (t, J = 5.3 Hz,



isoindole-2-
2H), 2.01 (t, J = 5.4 Hz, 2H), 1.77-1.35 (m,



carboxamide
4H)


866
N-[4-(5-oxa-2-

1H NMR (400 MHz, DMSO-D2O) δ 7.65-

(ESI(+))



azaspiro[3.4]oct-2-
7.60 (m, 2H), 7.57-7.53 (m, 2H), 7.40-
m/e 378



ylcarbonyl)phenyl]-
6.97 (m, 5H), 4.79 (s, 5H), 4.16 (dd, J =
(M + H)+



1,3-dihydro-2H-
23.4, 9.6 Hz, 4H), 3.77 (t, J = 6.8 Hz, 2H),



isoindole-2-
3.35 (q, J = 7.1 Hz, 1H), 2.07 (dd, J = 8.1,



carboxamide
6.6 Hz, 2H), 1.98-1.74 (m, 2H), 1.11 (t, J =




7.1 Hz, 1H)


867
N-[4-(6-oxa-2-

1H NMR (400 MHz, DMSO-D2O) δ 7.65-

(ESI(+))



azaspiro[3.5]non-2-
7.60 (m, 2H), 7.58-7.54 (m, 2H), 7.38-
m/e 392



ylcarbonyl)phenyl]-
7.28 (m, 4H), 4.79 (s, 4H), 3.95-3.67 (m,
(M + H)+



1,3-dihydro-2H-
4H), 3.59 (s, 2H), 3.55-3.44 (m, 2H), 1.90-



isoindole-2-
1.72 (m, 2H), 1.61-1.39 (m, 2H)



carboxamide


868
N-[4-(hexahydro-5H-

1H NMR (400 MHz, DMSO-D2O) δ 7.75-

(ESI(+))



furo[2,3-c]pyrrol-5-
7.52 (m, 2H), 7.46-7.20 (m, 6H), 4.79 (s,
m/e 378



ylcarbonyl)phenyl]-
4H), 4.49-4.27 (m, 1H), 3.95-3.78 (m,
(M + H)+



1,3-dihydro-2H-
1H), 3.77-3.55 (m, 4H), 3.43 (dd, J = 11.8,



isoindole-2-
5.4 Hz, 1H), 2.98-2.70 (m, 1H), 2.06 (ddd,



carboxamide
J = 15.0, 12.5, 7.7 Hz, 1H), 1.82-1.49 (m,




1H)


869
N-[4-(tetrahydro-1H-

1H NMR (400 MHz, DMSO-D2O) δ 7.69-

(ESI(+))



furo[3,4-c]pyrrol-
7.61 (m, 1H), 7.60 (d, 1H), 7.47-7.07 (m,
m/e 378



5(3H)-
6H), 4.79 (s, 4H) , 3.83-3.59 (m, 4H), 3.58-
(M + H)+



ylcarbonyl)phenyl]-
3.33 (m, 4H), 3.05-2.82 (m, 2H)



1,3-dihydro-2H-



isoindole-2-



carboxamide


870
N-[4-

1H NMR (400 MHz, DMSO-D2O) δ 7.71-

(ESI(+))



(hexahydrofuro[3,4-
7.52 (m, 2H), 7.41-7.12 (m, 6H), 4.79 (s,
m/e 392



c]pyridin-5(3H)-
4H), 3.89-3.65 (m, 2H), 3.67-3.40 (m,
(M + H)+



ylcarbonyl)phenyl]-
5H), 3.39-3.26 (m, 1H), 2.46-2.25 (m,



1,3-dihydro-2H-
2H), 1.88-1.63 (m, 1H), 1.67-1.24 (m, 1H)



isoindole-2-



carboxamide


885
N-[4-(2,6-

1H NMR (400 MHz, DMSO-D2O) δ 7.68-

(ESI(+))



diazaspiro[3.4]oct-6-
7.51 (m, 2H), 7.51-7.28 (m, 3H), 7.24-
m/e 393



ylcarbonyl)phenyl]-
7.00 (m, 1H), 4.77 (d, J = 12.1 Hz, 4H), 3.61
(M + H)+



5-fluoro-1,3-dihydro-
(d, J = 17.1 Hz, 2H), 3.54 (d, J = 8.2 Hz,



2H-isoindole-2-
3H), 3.48 (t, J = 7.0 Hz, 2H), 2.06 (dd, J =



carboxamide
23.6, 16.6 Hz, 2H), 1.89 (s, 1H)


886
N-[4-(2,7-

1H NMR (400 MHz, DMSO-D2O) δ 7.65-

(ESI(+))



diazaspiro[3.5]non-7-
7.53 (m, 2H), 7.37 (dd, J = 8.3, 5.2 Hz, 1H),
m/e 407



ylcarbonyl)phenyl]-
7.31-7.22 (m, 2H), 7.17 (d, J = 9.0 Hz,
(M + H)+



5-fluoro-1,3-dihydro-
1H), 7.15-6.92 (m, 1H), 4.77 (d, J = 12.3



2H-isoindole-2-
Hz, 4H), 3.41 (t, J = 5.5 Hz, 8H), 1.78-1.63



carboxamide
(m, 4H)


887
N-[4-(1,7-

1H NMR (400 MHz, DMSO-D2O) δ 7.65-

(ESI(+))



diazaspiro[4.4]non-1-
7.49 (m, 2H), 7.43-7.32 (m, 3H), 7.22-
m/e 409



ylcarbonyl)phenyl]-
7.03 (m, 2H), 4.76 (d, J = 12.6 Hz, 4H), 3.54-
(M + H)+



5-fluoro-1,3-dihydro-
3.37 (m, 2H), 2.86 (dt, J = 11.3, 7.9 Hz,



2H-isoindole-2-
1H), 2.70 (d, J = 11.7 Hz, 1H), 2.10-1.96



carboxamide
(m, 1H), 1.90 (d, J = 29.4 Hz, 1H), 1.84-




1.67 (m, 2H), 1.25 (s, 1H)


888
N-[4-(2,8-

1H NMR (400 MHz, DMSO-D2O) δ 7.70-

(ESI(+))



diazaspiro[4.5]dec-2-
7.49 (m, 2H), 7.45-7.32 (m, 3H), 7.22-
m/e 423



ylcarbonyl)phenyl]-
7.03 (m, 2H), 4.77 (d, J = 12.4 Hz, 4H), 3.53
(M + H)+



5-fluoro-1,3-dihydro-
(t, J = 7.2 Hz, 2H), 3.33 (s, 2H), 2.79 (dd, J =



2H-isoindole-2-
20.6, 14.7 Hz, 3H), 1.88 (s, 1H), 1.78 (t, J =



carboxamide
7.1 Hz, 2H), 1.50 (s, 4H)


889
N-[4-(2,6-

1H NMR (400 MHz, DMSO-D2O) δ 7.70-

(ESI(+))



diazaspiro[4.5]dec-2-
7.54 (m, 2H), 7.50-7.30 (m, 3H), 7.24-
m/e 423



ylcarbonyl)phenyl]-
7.00 (m, 2H), 4.77 (d, J = 12.5 Hz, 4H), 3.75-
(M + H)+



5-fluoro-1,3-dihydro-
3.54 (m, 1H), 3.57-3.47 (m, 2H), 3.40 (d,



2H-isoindole-2-
J = 11.8 Hz, 1H), 3.20 (d, J = 0.5 Hz, 1H),



carboxamide
2.76 (d, J = 21.5 Hz, 2H), 2.07-1.77 (m,




3H), 1.64-1.40 (m, 6H)


890
N-[4-(2,7-

1H NMR (400 MHz, DMSO-D2O) δ 7.69-

(ESI(+))



diazaspiro[4.5]dec-7-
7.54 (m, 2H), 7.37 (dd, J = 8.4, 5.2 Hz, 1H),
m/e 423



ylcarbonyl)phenyl]-
7.33-7.22 (m, 2H), 7.23-7.02 (m, 2H),
(M + H)+



5-fluoro-1,3-dihydro-
4.77 (d, J = 12.2 Hz, 4H), 3.53-3.31 (m,



2H-isoindole-2-
4H), 3.20 (s, 2H), 2.94-2.79 (m, 2H), 2.64



carboxamide
(dd, J = 42.4, 11.2 Hz, 2H), 1.87 (s, 2H),




1.74-1.32 (m, 6H)


891
N-[4-(2,8-

1H NMR (400 MHz, DMSO-D2O) δ 7.59

(ESI(+))



diazaspiro[5.5]undec-2-
(dd, J = 6.4, 4.5 Hz, 2H), 7.37 (dd, J = 8.4,
m/e 437



ylcarbonyl)phenyl]-
5.1 Hz, 1H), 7.33-7.20 (m, 2H), 7.17 (d, J =
(M + H)+



5-fluoro-1,3-dihydro-
9.0 Hz, 1H), 7.13-7.02 (m, 1H), 4.77 (d,



2H-isoindole-2-
J = 12.4 Hz, 4H), 3.51-3.36 (m, 4H), 3.20



carboxamide
(s, 2H), 2.80-2.65 (m, 2H), 2.64 (s, 2H),




1.85 (s, 2H), 1.52 (s, 4H), 1.37 (t, J = 5.7 Hz,




4H)


892
N-[4-(1,8-

1H NMR (400 MHz, DMSO-D2O) δ 7.65-

(ESI(+))



diazaspiro[5.5]undec-8-
7.51 (m, 2H), 7.37 (dd, J = 8.4, 5.1 Hz, 1H),
m/e 437



ylcarbonyl)phenyl]-
7.34-7.24 (m, 2H), 7.23-7.05 (m, 2H),
(M + H)+



5-fluoro-1,3-dihydro-
4.77 (d, J = 12.5 Hz, 4H), 3.58-3.36 (m,



2H-isoindole-2-
4H), 3.20 (s, 2H), 2.72-2.54 (m, 2H), 1.62-



carboxamide
1.36 (m, 8H)


893
N-[4-(1,8-

1H NMR (400 MHz, DMSO-D2O) δ 7.65-

(ESI(+))



diazaspiro[4.6]undec-8-
7.51 (m, 2H), 7.37 (dd, J = 8.3, 5.2 Hz, 1H),
m/e 437



ylcarbonyl)phenyl]-
7.32-7.23 (m, 2H), 7.19-7.01 (m, 2H),
(M + H)+



5-fluoro-1,3-dihydro-
4.77 (d, J = 12.9 Hz, 4H), 3.49 (d, J = 14.0



2H-isoindole-2-
Hz, 3H), 3.03-2.76 (m, 2H), 1.84-1.59



carboxamide
(m, 8H), 1.25 (s, 6H)


894
5-fluoro-N-{4-[(1-

1H NMR (400 MHz, DMSO-D2O) δ 7.83-

(ESI(+))



oxa-8-
7.68 (m, 2H), 7.68-7.49 (m, 2H), 7.37 (dd,
m/e 453



azaspiro[4.5]dec-2-
J = 8.4, 5.1 Hz, 1H), 7.21-6.93 (m, 2H),
(M + H)+



ylmethyl)carbamoyl]
4.77 (d, J = 12.2 Hz, 4H), 4.10 (t, J = 6.0 Hz,



phenyl}-1,3-dihydro-
1H), 3.44-3.31 (m, 2H), 3.06-2.83 (m,



2H-isoindole-2-
2H), 2.83-2.70 (m, 2H), 2.12-1.92 (m,



carboxamide
1H), 1.81-1.66 (m, 3H), 1.62-1.32 (m, 4H)


895
5-fluoro-N-[4-(1-

1H NMR (400 MHz, DMSO-D2O) δ 7.80-

(ESI(+))



oxa-8-
7.69 (m, 2H), 7.66-7.50 (m, 2H), 7.37 (dd,
m/e 439



azaspiro[4.5]dec-3-
J = 8.2, 5.1 Hz, 1H), 7.27-6.90 (m, 2H),
(M + H)+



ylcarbamoyl)phenyl]-
4.77 (d, J = 12.7 Hz, 4H), 4.61-4.39 (m,



1,3-dihydro-2H-
1H), 4.02 (dd, J = 8.9, 6.8 Hz, 1H), 3.66 (dd,



isoindole-2-
J = 8.9, 6.3 Hz, 1H), 3.01-2.81 (m, 2H),



carboxamide
2.80-2.61 (m, 2H), 2.15 (dd, J = 12.9, 8.3




Hz, 1H), 1.87-1.73 (m, 1H), 1.70 (t, J = 5.7




Hz, 2H), 1.65-1.49 (m, 2H)


896
5-fluoro-N-[4-(1-

1H NMR (400 MHz, DMSO-D2O) δ 7.69-

(ESI(+))



oxa-4,8-
7.54 (m, 2H), 7.37 (dd, J = 8.3, 5.1 Hz, 1H),
m/e 439



diazaspiro[5.5]undec-4-
7.35-7.28 (m, 2H), 7.17 (d, J = 9.0 Hz,
(M + H)+



ylcarbonyl)phenyl]-
1H), 7.14-6.96 (m, 1H), 4.77 (d, J = 12.4



1,3-dihydro-2H-
Hz, 4H), 3.77-3.57 (m, 2H), 3.57-3.36



isoindole-2-
(m, 4H), 2.71 (dd, J = 25.6, 8.7 Hz, 1H),



carboxamide
2.62 (d, J = 13.1 Hz, 3H), 1.90(s, 1H), 1.81-




1.43 (m, 3H), 1.31 (s, 1H)


897
N-[4-(1,8-

1H NMR (400 MHz, DMSO-D2O) δ 7.61-

(ESI(+))



diazaspiro[4.5]dec-1-
7.51 (m, 2H), 7.37 (dd, J = 8.3, 5.2 Hz, 1H),
m/e 423



ylcarbonyl)phenyl]-
7.33-7.25 (m, 2H), 7.16 (d, J = 9.0 Hz,
(M + H)+



5-fluoro-1,3-dihydro-
1H), 7.10 (dd, J = 12.4, 5.4 Hz, 1H), 4.76 (d,



2H-isoindole-2-
J = 13.0 Hz, 4H), 3.39 (t, J = 6.7 Hz, 2H),



carboxamide
3.06 (d, J = 12.4 Hz, 2H), 3.00-2.82 (m,




2H), 2.79-2.61 (m, 2H), 1.99 (t, J = 6.9 Hz,




2H), 1.88 (s, 1H), 1.73 (dd, J = 13.6, 6.9 Hz,




2H), 1.44 (d, J = 13.3 Hz, 2H)


898
N-[4-(1,8-

1H NMR (400 MHz, DMSO-D2O) δ 7.71-

(ESI(+))



diazaspiro[4.5]dec-8-
7.51 (m, 2H), 7.37 (dd, J = 8.4, 5.2 Hz, 1H),
m/e 423



ylcarbonyl)phenyl]-
7.33-7.23 (m, 2H), 7.22-7.12 (m, 1H),
(M + H)+



5-fluoro-1,3-dihydro-
7.09 (dd, J = 13.2, 4.7 Hz, 1H), 4.77 (d, J =



2H-isoindole-2-
12.6 Hz, 4H), 3.62-3.39 (m, 4H), 3.00-



carboxamide
2.75 (m, 2H), 1.86-1.67 (m, 2H), 1.67-




1.43 (m, 6H)


899
N-[4-(2,6-

1H NMR (400 MHz, DMSO-D2O) δ 7.68-

(ESI(+))



diazaspiro[3.4]oct-2-
7.49 (m, 4H), 7.37 (dd, J = 8.5, 5.2 Hz, 1H),
m/e 395



ylcarbonyl)phenyl]-
7.23-7.04 (m, 2H), 4.77 (d, J = 12.3 Hz,
(M + H)+



5-fluoro-1,3-dihydro-
4H), 4.10 (s, 4H), 3.00 (s, 2H), 2.83 (dd, J =



2H-isoindole-2-
46.1, 39.1 Hz, 2H), 1.98 (t, J = 7.1 Hz, 2H)



carboxamide


900
N-[4-(1,7-

1H NMR (400 MHz, DMSO-D2O) δ 7.70-

(ESI(+))



diazaspiro[3.5]non-7-
7.53 (m, 2H), 7.48-7.23 (m, 3H), 7.23-
m/e 409



ylcarbonyl)phenyl]-
7.03 (m, 2H), 5.45 (s, 1H), 4.77 (d, J = 12.2
(M + H)+



5-fluoro-1,3-dihydro-
Hz, 4H), 3.98 (s, 2H), 3.56 (t, J = 5.7 Hz,



2H-isoindole-2-
2H), 2.71 (t, J = 7.1 Hz, 2H), 2.32-2.05 (m,



carboxamide
4H), 1.86 (s, 2H)


901
N-[4-(1,6-

1H NMR (400 MHz, DMSO-D2O) δ 7.69-

(ESI(+))



diazaspiro[3.5]non-1-
7.52 (m, 2H), 7.47 (d, J = 8.6 Hz, 2H), 7.37
m/e 409



ylcarbonyl)phenyl]-
(dd, J = 8.4, 5.1 Hz, 1H), 7.22-7.01 (m,
(M + H)+



5-fluoro-1,3-dihydro-
2H), 4.77 (d, J = 12.9 Hz, 4H), 4.24-3.92



2H-isoindole-2-
(m, 2H), 3.20 (s, 3H), 2.97 (t, J = 18.2 Hz,



carboxamide
1H), 2.75 (t, J = 21.1 Hz, 1H), 2.29-2.11




(m, 1H), 2.10-1.96 (m, 1H), 1.62 (s, 1H),




1.49 (d, J = 11.0 Hz, 1H)


902
N-[4-(2,5-

1H NMR (400 MHz, DMSO-D2O) δ 7.69-

(ESI(+))



diazaspiro[3.5]non-2-
7.50 (m, 4H), 7.37 (dd, J = 8.6, 5.2 Hz, 1H),
m/e 409



ylcarbonyl)phenyl]-
7.22-7.03 (m, 2H), 4.77 (d, J = 13.2 Hz,
(M + H)+



5-fluoro-1,3-dihydro-
4H), 3.92 (s, 4H), 2.66 (dd, J = 10.8, 5.5 Hz,



2H-isoindole-2-
2H), 1.70-1.59 (m, 2H), 1.51 (s, 2H), 1.40



carboxamide
(d, J = 4.6 Hz, 2H)


903
5-fluoro-N-[4-(5-

1H NMR (400 MHz, DMSO-D2O) δ 7.71-

(ESI(+))



oxa-2-
7.47 (m, 4H), 7.37 (dd, J = 8.4, 5.2 Hz, 1H),
m/e 396



azaspiro[3.4]oct-2-
7.22-6.96 (m, 2H), 4.77 (d, J = 12.5 Hz,
(M + H)+



ylcarbonyl)phenyl]-
4H), 4.16 (dd, J = 23.5, 9.7 Hz, 4H), 3.77 (t,



1,3-dihydro-2H-
J = 6.8 Hz, 2H), 2.07 (t, J = 7.3 Hz, 2H),



isoindole-2-
1.94-1.70 (m, 2H)



carboxamide


904
5-fluoro-N-[4-(6-

1H NMR (400 MHz, DMSO-D2O) δ 7.68-

(ESI(+))



oxa-2-
7.51 (m, 2H), 7.5 1-7.33 (m, 1H), 7.36-
m/e 410



azaspiro[3.5]non-2-
7.20 (m, 2H), 7.21-6.92 (m, 2H), 4.77 (d, J =
(M + H)+



ylcarbonyl)phenyl]-
12.5 Hz, 4H), 4.24 (dd, J = 26.5, 6.0 Hz,



1,3-dihydro-2H-
4H), 3.48-3.36 (m, 2H), 1.97-1.75 (m,



isoindole-2-
2H), 1.66-1.25 (m, 4H)



carboxamide


905
5-fluoro-N-[4-(2-

1H NMR (400 MHz, DMSO-D2O) δ 7.65-

(ESI(+))



oxa-7-
7.54 (m, 2H), 7.37 (dd, J = 8.3, 5.2 Hz, 1H),
m/e 410



azaspiro[3.5]non-7-
7.35-7.23 (m, 2H), 7.22-7.03 (m, 2H),
(M + H)+



ylcarbonyl)phenyl]-
4.77 (d, J = 12.4 Hz, 4H), 4.35 (s, 4H), 3.47-



1,3-dihydro-2H-
3.36 (m, 4H), 1.87-1.75 (m, 4H)



isoindole-2-



carboxamide


906
5-fluoro-N-[4-

1H NMR (400 MHz, DMSO-D2O) δ 7.67-

(ESI(+))



(hexahydro-5H-
7.54 (m, 2H), 7.48-7.28 (m, 3H), 7.24-
m/e 396



furo[2,3-c]pyrrol-5-
6.92 (m, 2H), 4.77 (d, J = 12.4 Hz, 4H), 4.52-
(M + H)+



ylcarbonyl)phenyl]-
4.31 (m, 1H), 3.86 (dd, J = 15.5, 7.0 Hz,



1,3-dihydro-2H-
1H), 3.79-3.53 (m, 4H), 3.43 (dd, J = 11.7,



isoindole-2-
5.3 Hz, 1H), 2.97-2.81 (m, 1H), 2.17-1.88



carboxamide
(m, 1H), 1.88-1.59 (m, 1H)


907
5-fluoro-N-[4-

1H NMR (400 MHz, DMSO-D2O) δ 7.65-

(ESI(+))



(tetrahydro-1H-
7.54 (m, 2H), 7.54-7.31 (m, 3H), 7.26-
m/e 396



furo[3,4-c]pyrrol-
7.03 (m, 2H), 4.77 (d, J = 12.2 Hz, 4H), 3.74
(M + H)+



5(3H)-
(ddd, J = 19.7, 10.5, 7.2 Hz, 4H), 3.56-3.34



ylcarbonyl)phenyl]-
(m, 4H), 3.01-2.84 (m, 2H)



1,3-dihydro-2H-



isoindole-2-



carboxamide


908
5-fluoro-N-[4-

1H NMR (400 MHz, DMSO-D2O) δ 7.59 (d,

(ESI(+))



(hexahydrofuro[3,4-
J = 8.7 Hz, 2H), 7.43-7.35 (m, 1H), 7.35-
m/e 410



c]pyridin-5(3H)-
7.24 (m, 2H), 7.22-7.05 (m, 2H), 4.77 (d, J =
(M + H)+



ylcarbonyl)phenyl]-
12.5 Hz, 4H), 3.81-3.67 (m, 2H), 3.62-



1,3-dihydro-2H-
3.40 (m, 4H), 1.76 (s, 1H), 1.62-1.36 (m,



isoindole-2-
1H), 1.28-1.08 (m, 2H)



carboxamide


976
N-(4-{[(1S)-1-(4-

1H NMR (300 MHz, DMSO-d6) δ 8.59 (s,

(ESI(+))



fluorophenyl)-2-
1H), 8.49 (d, J = 8.0 Hz, 1H), 7.87-7.79
m/e 420



hydroxyethyl]carbamoyl}phenyl)-
(m, 2H), 7.72-7.65 (m, 2H), 7.47-7.28 (m,
(M + H)+



1,3-dihydro-2H-
6H), 7.19-7.09 (m, 2H), 5.06 (d, J = 6.7



isoindole-2-
Hz, 1H), 4.95-4.87 (m, 1H), 4.79 (s, 4H),



carboxamide
3.77-3.57 (m, 2H)


977
N-(4-{[(1S)-2-

1H NMR (300 MHz, DMSO-d6) δ 8.58 (d, J =

(ESI(+))



hydroxy-1-(4-
3.8 Hz, 1H), 8.42 (d, J = 8.1 Hz, 1H), 7.86-
m/e 432



methoxyphenyl)eth-
7.76 (m, 3H), 7.69 (s, 1H), 7.69-7.61 (m,
(M + H)+



yl]carbamoyl}phenyl)-
2H), 7.41-7.27 (m, 6H), 6.91-6.84 (m,



1,3-dihydro-2H-
2H), 5.07-4.96 (m, 1H), 3.77-3.59 (m,



isoindole-2-
4H), 3.31 (s, 4H)



carboxamide


978
N-(4-{[(1S)-1-(1,3-

1H NMR (300 MHz, DMSO-d6) δ 8.59 (s,

(ESI(+))



benzodioxol-5-yl)-2-
1H), 8.39 (d, J = 8.1 Hz, 1H), 7.86-7.78
m/e 446



hydroxyethyl]carbamoyl}phenyl)-
(m, 2H), 7.72-7.64 (m, 2H), 7.41-7.28 (m,
(M + H)+



1,3-dihydro-2H-
4H), 6.99 (s, 1H), 6.87-6.82 (m, 2H), 5.97



isoindole-2-
(d, J = 2.3 Hz, 2H), 5.05-4.93 (m, 1H),



carboxamide
4.92-4.82 (m, 1H), 4.81 (d, J = 14.1 Hz,




4H), 3.73-3.53 (m, 2H)


1089
5-fluoro-N-(4-{[1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(1,3-thiazol-2-
δ 7.78-7.64 (m, 2H), 7.64-7.53 (m, 2H),
m/e 425



yl)propan-2-
7.52-7.34 (m, 1H), 7.28-7.16 (m, 1H),
(M + H)+



yl]carbamoyl}phenyl)-
7.17-7.03 (m, 1H), 4.77 (d, J = 12.4 Hz,



1,3-dihydro-2H-
4H), 4.38 (h, J = 6.6 Hz, 1H), 3.41-3.27



isoindole-2-
(m, 2H), 3.24-3.15 (m, 1H), 2.51 (dt, J =



carboxamide
3.7, 1.9 Hz, 2H), 1.25 (t, J = 5.6 Hz, 3H),




1.11 (t, J = 7.1 Hz, 1H)


1090
N-{4-[(4,4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



difluorocyclohexyl)carbamoyl]phe-
δ 7.86-7.70 (m, 2H), 7.67-7.53 (m, 2H),
m/e 418



nyl}-5-fluoro-1,3-dihydro-
7.44-7.29 (m, 1H), 7.24-7.03 (m, 2H),
(M + H)+



2H-isoindole-2-
4.76 (t, J = 10.2 Hz, 4H), 4.08-3.87 (m,



carboxamide
1H), 2.16-1.83 (m, 5H), 1.79-1.54 (m, 2H)


1091
N-(4-{[1-(3,5-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



dimethyl-1H-
δ 7.81-7.65 (m, 2H), 7.65-7.55 (m, 2H),
m/e 436



pyrazol-1-yl)propan-2-
7.41-7.31 (m, 1H), 7.23-6.98 (m, 2H),
(M + H)+



yl]carbamoyl}phenyl)-
4.77 (d, J = 12.4 Hz, 4H), 4.35 (h, J = 6.5



5-fluoro-1,3-
Hz, 1H), 4.17-4.06 (m, 1H), 4.06-3.88



dihydro-2H-
(m, 1H), 3.20 (s, 1H), 2.22 (s, 3H), 2.10 (s,



isoindole-2-
3H), 1.26-1.01 (m, 3H)



carboxamide


1092
5-fluoro-N-(4-{[2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methyl-2-
δ 7.87-7.71 (m, 2H), 7.69-7.58 (m, 2H),
m/e 455



(morpholin-4-
7.46-7.29 (m, 1H), 7.25-7.02 (m, 2H),
(M + H)+



yl)butyl]carbamoyl}
4.89-4.69 (m, 4H), 3.90-3.67 (m, 4H),



phenyl)-1,3-dihydro-
3.61-3.41 (m, 2H), 3.15-2.96 (m, 2H),



2H-isoindole-2-
1.84-1.50 (m, 2H), 1.32-1.06 (m, 3H),



carboxamide
1.07-0.72 (m, 3H)


1093
5-fluoro-N-(4-{[2-(2-

1H NMR (400 MHz, Pyridine-d5) δ 8.59-

(ESI(+))



methyl-1,3-thiazol-4-
8.46 (m, 2H), 7.90 (d, J = 8.6 Hz, 2H), 7.68-
m/e 425



yl)ethyl]carbamoyl}phenyl)-
7.58 (m, 2H), 7.10 (d, J = 5.0 Hz, 1H),
(M + H)+



1,3-dihydro-
4.87 (dd, J = 16.8, 9.9 Hz, 4H), 3.86-3.64



2H-isoindole-2-
(m, 4H), 3.64-3.40 (m, 5H), 2.86-2.58 (m,



carboxamide
2H)


1094
5-fluoro-N-(4-{[2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methyl-1-
δ 7.70 (d, J = 8.7 Hz, 2H), 7.66-7.54 (m,
m/e 425



(morpholin-4-
2H), 7.37 (dd, J = 8.4, 5.1 Hz, 1H), 7.21-
(M + H)+



yl)propan-2-
7.05 (m, 2H), 4.77 (d, J = 12.5 Hz, 4H), 3.65



yl]carbamoyl}phenyl)-
(s, 4H), 2.80 (d, J = 54.6 Hz, 5H), 1.41 (s, 6H)



1,3-dihydro-2H-



isoindole-2-



carboxamide


1095
5-fluoro-N-{4-[(4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methoxybenzyl)carbamoyl]phenyl}-
δ 7.89-7.70 (m, 2H), 7.70-7.52 (m, 2H),
m/e 420



1,3-dihydro-2H-
7.37 (dd, J = 8.3, 5.2 Hz, 1H), 7.26 (d, J =
(M + H)+



isoindole-2-
8.6 Hz, 2H), 7.20-7.04 (m, 2H), 6.93-6.76



carboxamide
(m, 2H), 4.77 (d, J = 12.5 Hz, 4H), 4.41 (s,




2H), 3.74 (s, 3H)


1096
5-fluoro-N-(4-{[3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(morpholin-4-
δ 7.83-7.70 (m, 2H), 7.69-7.55 (m, 2H),
m/e 427



yl)propyl]carbamoyl}phenyl)-
7.37 (dd, J = 8.4, 5.1 Hz, 1H), 7.27-7.03
(M + H)+



1,3-dihydro-2H-
(m, 2H), 4.77 (d, J = 12.4 Hz, 4H), 3.86 (s,



isoindole-2-
4H), 3.36 (dd, J = 17.9, 1 1.2 Hz, 3H), 3.22-



carboxamide
3.09 (m, 3H), 2.09-1.81 (m, 2H)


1097
N-alpha-(4-{[(5-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



fluoro-1,3-dihydro-
δ 7.76-7.64 (m, 2H), 7.64-7.52 (m, 2H),
m/e 447



2H-isoindol-2-
7.44-7.31 (m, 1H), 7.31-7.21 (m, 4H),
(M + H)+



yl)carbonyl]amino}benzoyl)-D-
7.21-7.04 (m, 3H), 4.82-4.73 (m, 4H),



phenylalaninamide
4.73-4.62 (m, 1H), 3.23-3.12 (m, 2H),




3.07-2.93 (m, 2H)


1098
N-(4-{[2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(acetylamino)phenyl]
δ 7.96-7.78 (m, 2H), 7.77-7.64 (m, 3H),
m/e 433



carbamoyl}phenyl)-
7.51-7.42 (m, 1H), 7.42-7.31 (m, 1H),
(M + H)+



5-fluoro-1,3-dihydro-
7.28-7.15 (m, 3H), 7.15-7.03 (m, 1H),



2H-isoindole-2-
4.86-4.70 (m, 4H), 2.09 (s, 3H)



carboxamide


1099
5-fluoro-N-[4-({4-[2-(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



hydroxyethoxy)ethyl]piperazin-
δ 7.71-7.57 (m, 2H), 7.50-7.33 (m, 3H),
m/e 457



1-yl}carbonyl)phenyl]-
7.25-7.01 (m, 2H), 4.77 (d, J = 12.5 Hz,
(M + H)+



1,3-dihydro-2H-
4H), 3.65-3.47 (m, 4H), 3.35 (dd, J = 12.2,



isoindole-2-
7.3 Hz, 6H), 2.52 (dt, J = 3.8, 1.9 Hz, 2H)



carboxamide


1100
5-fluoro-N-(4-{[2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(furan-2-yl)-2-
δ 7.76-7.67 (m, 3H), 7.66-7.53 (m, 2H),
m/e 463



(pyrrolidin-1-
7.37 (dd, J = 8.4, 5.2 Hz, 1H), 7.25-7.02
(M + H)+



yl)ethyl]carbamoyl}phenyl)-
(m, 2H), 6.78 (d, J = 3.3 Hz, 1H), 6.55 (dd, J =



1,3-dihydro-
3.3, 1.9 Hz, 1H), 4.89-4.68 (m, 6H), 4.08-



2H-isoindole-2-
3.94 (m, 1H), 3.87 (dd, J = 14.0, 7.4 Hz,



carboxamide
1H), 3.43 (s, 1H), 2.00-1.78 (m, 4H)


1101
N-{4-[bis(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methoxyethyl)carbamoyl]phenyl}-
δ 7.58 (d, J = 8.6 Hz, 2H), 7.37 (dd, J = 8.3,
m/e 416



5-fluoro-1,3-dihydro-
5.1 Hz, 1H), 7.31-7.22 (m, 2H), 7.17 (d, J =
(M + H)+



2H-isoindole-2-
8.9 Hz, 1H), 7.13-7.03 (m, 1H), 4.76 (d,



carboxamide
J = 12.5 Hz, 4H), 3.60-3.41 (m, 8H), 3.24




(s, 6H)


1102
N-{4-[(1-amino-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



oxohexan-2-
δ 7.87-7.71 (m, 2H), 7.64 (t, J = 10.2 Hz,
m/e 413



yl)carbamoyl]phenyl}-
2H), 7.46-7.31 (m, 1H), 7.23-7.03 (m,
(M + H)+



5-fluoro-1,3-
2H), 4.78 (d, J = 12.5 Hz, 4H), 4.40 (dd, J =



dihydro-2H-
8.6, 5.6 Hz, 1H), 1.90-1.62 (m, 2H), 1.45-



isoindole-2-
1.18 (m, 4H), 0.87 (t, J = 6.9 Hz, 3H)



carboxamide


1103
N-(4-{[2-(3,4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



dimethoxyphenyl)eth-
δ 7.72 (d, J = 8.7 Hz, 2H), 7.60 (d, J = 8.7
m/e 464



yl]carbamoyl}phenyl)-
Hz, 2H), 7.43-7.28 (m, 1H), 7.21-7.04
(M + H)+



5-fluoro-1,3-
(m, 2H), 6.91-6.81 (m, 2H), 6.81-6.69 (m,



dihydro-2H-
1H), 4.77 (d, J = 12.5 Hz, 4H), 3.73 (d, J =



isoindole-2-
2.5 Hz, 6H), 3.58-3.39 (m, 2H), 2.93-2.68



carboxamide
(m, 2H)


1104
N-(4-{[(2S)-3,3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



dimethyl-1-
δ 7.88-7.70 (m, 2H), 7.70-7.57 (m, 2H),
m/e 427



(methylamino)-1-
7.45-7.30 (m, 1H), 7.26-7.01 (m, 2H),
(M + H)+



oxobutan-2-
4.78 (d, J = 12.6 Hz, 4H), 4.41 (d, J = 6.3



yl]carbamoyl}phenyl)-
Hz, 1H), 2.64 (s, 3H), 1.03 (s, 9H)



5-fluoro-1,3-



dihydro-2H-



isoindole-2-



carboxamide


1105
N-alpha-(4-{[(5-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



fluoro-1,3-dihydro-
δ 7.76-7.64 (m, 2H), 7.64-7.54 (m, 2H),
m/e 447



2H-isoindol-2-
7.44-7.33 (m, 1H), 7.32-7.22 (m, 4H),
(M + H)+



yl)carbonyl]amino}benzoyl)-L-
7.25-7.13 (m, 3H), 7.12-6.99 (m, 1H),



phenylalaninamide
4.81-4.71 (m, 4H), 4.71-4.61 (m, 1H),




3.20-3.11 (m, 1H), 3.08-2.93 (m, 1H)


1106
N-(4-{[(2R)-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



amino-4-methyl-1-
δ 7.87-7.72 (m, 2H), 7.70-7.52 (m, 2H),
m/e 413



oxopentan-2-
7.45-7.26 (m, 1H), 7.24-7.03 (m, 2H),
(M + H)+



yl]carbamoyl}phenyl)-
4.78 (d, J = 12.6 Hz, 4H), 4.57-4.38 (m,



5-fluoro-1,3-
1H), 1.90-1.47 (m, 3H), 1.07-0.71 (m,



dihydro-2H-
6H)



isoindole-2-



carboxamide


1107
-{4-[(4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



cyclohexylpiperazin-1-
δ 7.76-7.57 (m, 2H), 7.51-7.32 (m, 3H),
m/e 451



yl)carbonyl]phenyl}-
7.23-7.03 (m, 2H), 4.77 (d, J = 12.4 Hz,
(M + H)+



5-fluoro-1,3-dihydro-
4H), 3.88 (d, J = 76.9 Hz, 4H), 3.22-3.10



2H-isoindole-2-
(m, 2H), 2.08 (d, J = 11.3 Hz, 2H), 1.86 (d, J =



carboxamide
13.1 Hz, 2H), 1.64 (d, J = 12.9 Hz, 1H),




1.54-1.17 (m, 6H), 1.17-1.04 (m, 1H)


1108
5-fluoro-N-(4-{[3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(methylcarbamoyl)phe-
δ 8.16 (t, J = 1.8 Hz, 1H), 7.98-7.80 (m,
m/e 433



nyl]carbamoyl}phenyl)-
3H), 7.74-7.59 (m, 2H), 7.59-7.47 (m,
(M + H)+



1,3-dihydro-2H-
1H), 7.49-7.33 (m, 2H), 7.24-7.05 (m,



isoindole-2-
2H), 4.79 (d, J = 12.5 Hz, 4H), 2.83 (d, J =



carboxamide
3.6 Hz, 3H)


1109
N-{4-[(2-amino-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



oxo-1-
δ 7.90-7.72 (m, 2H), 7.64 (d, J = 8.7 Hz,
m/e 433



phenylethyl)carbamoyl]phenyl}-
2H), 7.50 (d, J = 7.5 Hz, 2H), 7.43-7.26
(M + H)+



5-fluoro-
(m, 4H), 7.20-7.02 (m, 2H), 5.62 (s, 1H),



1,3-dihydro-2H-
4.77 (d, J = 12.5 Hz, 4H)



isoindole-2-



carboxamide


1110
N-{4-[(3-tert-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



butoxypropyl)carbamoyl]phenyl}-
δ 7.79-7.66 (m, 2H), 7.66-7.53 (m, 2H),
m/e 414



5-fluoro-1,3-dihydro-
7.37 (dd, J = 8.4, 5.1 Hz, 1H), 7.27-7.02
(M + H)+



2H-isoindole-2-
(m, 2H), 4.77 (d, J = 12.4 Hz, 4H), 3.44-



carboxamide
3.35 (m, 2H), 3.31 (dd, J = 16.4, 9.5 Hz,




2H), 1.73 (p, J = 6.6 Hz, 2H), 1.15 (s, 9H)


1111
N-(4-{[2-(2,6-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



dimethylmorpholin-
δ 7.86-7.72 (m, 2H), 7.69-7.55 (m, 2H),
m/e 441



4-yl)ethyl]carbamoyl}phenyl)-
7.47-7.32 (m, 1H), 7.24-6.96 (m, 2H),
(M + H)+



5-fluoro-1,3-
4.78 (d, J = 12.5 Hz, 4H), 3.92-3.76 (m,



dihydro-2H-
2H), 3.67 (t, J = 6.2 Hz, 2H), 3.52 (d, J =



isoindole-2-
12.0 Hz, 2H), 3.31 (dd, J = 13.3, 7.0 Hz,



carboxamide
3H), 2.71 (t, J = 11.7 Hz, 2H), 1.17 (d, J =




6.3 Hz, 6H)


1112
N-(4-{[(1R)-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



amino-2-oxo-1-
δ 7.87-7.70 (m, 2H), 7.70-7.56 (m, 2H),
m/e 433



phenylethyl]carbamoyl}phenyl)-
7.51 (dd, J = 11.1, 9.7 Hz, 2H), 7.44-7.25
(M + H)+



5-fluoro-
(m, 4H), 7.22-7.00 (m, 2H), 5.62 (s, 1H),



1,3-dihydro-2H-
4.77 (d, J = 12.5 Hz, 4H)



isoindole-2-



carboxamide-


1113
-fluoro-N-{4-[(3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methoxybenzyl)carbamoyl]phenyl}-
δ 7.89-7.71 (m, 2H), 7.70-7.53 (m, 2H),
m/e 420



1,3-dihydro-2H-
7.43-7.30 (m, 1H), 7.27-7.16 (m, 2H),
(M + H)+



isoindole-2-
7.16-6.97 (m, 1H), 6.97-6.85 (m, 2H),



carboxamide
6.86-6.68 (m, 1H), 4.87-4.65 (m, 4H),




4.54-4.25 (m, 2H), 3.75 (s, 3H)


1114
N-(4-{[2-(3,5-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



dimethyl-1H-
δ 7.78-7.67 (m, 2H), 7.65-7.52 (m, 2H),
m/e 422



pyrazol-1-
7.45-7.29 (m, 1H), 7.25-7.03 (m, 2H),
(M + H)+



yl)ethyl]carbamoyl}phenyl)-
4.79 (dd, J = 15.9, 8.4 Hz, 4H), 4.16 (t, J =



5-fluoro-1,3-
6.4 Hz, 2H), 3.59 (t, J = 6.4 Hz, 2H), 2.21 (s,



dihydro-2H-
3H), 2.14 (s, 3H)



isoindole-2-



carboxamide


1115
5-fluoro-N-(4-{[2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methyl-2-
δ 7.90-7.74 (m, 2H), 7.74-7.56 (m, 2H),
m/e 441



(morpholin-4-
7.48-7.31 (m, 1H), 7.28-7.03 (m, 2H),
(M + H)+



yl)propyl]carbamoyl}phenyl)-
4.78 (d, J = 12.4 Hz, 4H), 4.02-3.80 (m,



1,3-dihydro-2H-
4H), 3.63 (s, 2H), 3.46-3.32 (m, 4H), 1.38



isoindole-2-
(s, 6H)



carboxamide


1116
5-fluoro-N-(4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



{[(3S)-1-methyl-2-
δ 7.83-7.70 (m, 2H), 7.68-7.58 (m, 2H),
m/e 425



oxoazepan-3-
7.37 (dd, J = 8.3, 5.2 Hz, 1H), 7.24-7.03
(M + H)+



yl]carbamoyl}phenyl)-
(m, 2H), 4.82-4.69 (m, 5H), 3.65 (dd, J =



1,3-dihydro-2H-
15.6, 11.3 Hz, 1H), 3.03-2.83 (m, 3H), 2.03-



isoindole-2-
1.80 (m, 2H), 1.81-1.66 (m, 2H), 1.62-



carboxamide
1.33 (m, 2H)


1117
5-fluoro-N-(4-{[2-(4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methylpiperazin-1-
δ 7.81-7.69 (m, 2H), 7.69-7.56 (m, 2H),
m/e 426



yl)ethyl]carbamoyl}phenyl)-
7.37 (dd, J = 8.3, 5.2 Hz, 1H), 7.21-6.98
(M + H)+



1,3-dihydro-
(m, 2H), 4.77 (d, J = 12.3 Hz, 4H), 3.50 (t, J =



2H-isoindole-2-
6.5 Hz, 2H), 3.25-3.16 (m, 4H), 3.08-



carboxamide
2.98 (m, 4H), 2.89 (t, J = 6.5 Hz, 2H), 2.58-




2.46 (m, 3H)


1118
5-fluoro-N-(4-{[4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(morpholin-4-
δ 7.87-7.71 (m, 2H), 7.71-7.52 (m, 2H),
m/e 474



yl)benzyl]carbamoyl}phenyl)-
7.45-7.29 (m, 1H), 7.19 (dq, J = 9.0, 2.5
(M + H)+



1,3-dihydro-2H-
Hz, 3H), 7.14-7.02 (m, 1H), 6.92-6.79



isoindole-2-
(m, 2H), 4.77 (d, J = 12.6 Hz, 4H), 4.38 (s,



carboxamide
2H), 3.83-3.59 (m, 4H), 3.12-2.95 (m,




4H)


1119
5-fluoro-N-(4-{[3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(piperidin-1-
δ 7.84-7.71 (m, 2H), 7.70-7.61 (m, 2H),
m/e 425



yl)propyl]carbamoyl}phenyl)-
7.48-7.32 (m, 1H), 7.27-7.01 (m, 2H),
(M + H)+



1,3-dihydro-2H-
4.77 (d, J = 12.4 Hz, 4H), 3.37 (dd, J = 12.4,



isoindole-2-
5.8 Hz, 5H), 3.16-3.01 (m, 3H), 3.01-2.70



carboxamide
(m, 2H), 2.07-1.90 (m, 3H), 1.77 (d, J =




46.1 Hz, 6H), 1.46(s, 2H)


1144
5-fluoro-N-{4-[(3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methoxy-2,2-
δ 7.76-7.70 (m, 2H), 7.65-7.59 (m, 2H),
m/e 400



dimethylpropyl)carbamoyl]phenyl}-
7.37 (dd, J = 8.4, 5.1 Hz, 1H), 7.17 (dd, J =
(M + H)+



1,3-dihydro-2H-
9.1, 2.5 Hz, 1H), 7.14-7.05 (m, 1H), 4.79



isoindole-2-
(bs, 2H), 4.76 (bs, 2H), 3.15 (s, 2H), 2.99-



carboxamide
2.78 (m, 1H), 0.90 (s, 6H)


1145
N-{4-[(3,3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



dimethylbutyl)carbamoyl]phenyl}-
δ 7.73 (d, J = 8.6 Hz, 2H), 7.68-7.53 (m,
m/e 384



5-fluoro-1,3-dihydro-
2H), 7.48-7.23 (m, 1H), 7.22-7.05 (m,
(M + H)+



2H-isoindole-2-
2H), 4.77 (d, J = 12.7 Hz, 4H), 3.29 (dd, J =



carboxamide
8.6, 6.6 Hz, 2H), 1.66-1.19 (m, 2H), 0.94




(s, 9H)


1146
5-fluoro-N-(4-{[1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(furan-2-yl)propan-2-
δ 7.79-7.66 (m, 2H), 7.62-7.49 (m, 2H),
m/e 408



yl]carbamoyl}phenyl)-
7.45-7.31 (m, 1H), 7.24-6.96 (m, 2H),
(M + H)+



1,3-dihydro-2H-
6.51-6.25 (m, 1H), 6.13 (d, J = 3.2 Hz,



isoindole-2-
1H), 4.77 (d, J = 12.5 Hz, 4H), 4.27 (h, J =



carboxamide
6.7 Hz, 1H), 2.94 (dd, J = 15.0, 6.8 Hz, 2H),




2.87-2.69 (m, 1H), 1.19 (d, J = 6.7 Hz, 3H)


1147
5-fluoro-N-(4-{[(3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methyl-1,2-oxazol-5-
δ 7.86-7.71 (m, 2H), 7.71-7.56 (m, 2H),
m/e 395



yl)methyl]carbamoyl}phenyl)-
7.47-7.24 (m, 1H), 7.22-6.98 (m, 2H),
(M + H)+



1,3-dihydro-2H-
6.16 (s, 1H), 4.88-4.69 (m, 4H), 4.54 (s,



isoindole-2-
2H), 2.20 (s, 3H)



carboxamide


1148
N-(4-{[(2R)-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



cyanobutan-2-
δ 7.86-7.72 (m, 2H), 7.72-7.54 (m, 2H),
m/e 381



yl]carbamoyl}phenyl)-
7.37 (dd, J = 8.4, 5.2 Hz, 1H), 7.27-7.02
(M + H)+



5-fluoro-1,3-
(m, 2H), 4.78 (d, J = 12.4 Hz, 4H), 4.24-



dihydro-2H-
4.01 (m, 1H), 2.90-2.65 (m, 2H), 1.76-



isoindole-2-
1.53 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H)



carboxamide


1149
N-{4-[(2R)-butan-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



ylcarbamoyl]phenyl}-
δ 7.82-7.68 (m, 2H), 7.68-7.52 (m, 2H),
m/e 356



5-fluoro-1,3-
7.44-7.27 (m, 1H), 7.26-7.04 (m, 2H),
(M + H)+



dihydro-2H-
4.77 (d, J = 12.4 Hz, 4H), 4.05-3.76 (m,



isoindole-2-
1H), 1.82-1.38 (m, 2H), 1.16 (t, J = 5.3 Hz,



carboxamide
3H), 0.88 (t, J = 7.4 Hz, 3H)


1150
5-fluoro-N-(4-{[2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(1H-pyrazol-1-
δ 7.78-7.66 (m, 2H), 7.66-7.54 (m, 3H),
m/e 394



yl)ethyl]carbamoyl}phenyl)-
7.48-7.27 (m, 2H), 7.24-7.02 (m, 2H),
(M + H)+



1,3-dihydro-
4.77 (d, J = 12.5 Hz, 4H), 4.31 (t, J = 6.4 Hz,



2H-isoindole-2-
2H), 3.66 (t, J = 6.4 Hz, 2H), 3.04-2.82 (m, 1H)



carboxamide


1151
5-fluoro-N-{4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



[methyl(3-
δ 7.65-7.50 (m, 2H), 7.37 (d, J = 8.4, 5.2
m/e 384



methylbutyl)carbamoyl]phenyl}-
Hz, 1H), 7.32-7.21 (m, 2H), 7.21-7.02
(M + H)+



1,3-dihydro-2H-
(m, 2H), 4.77 (d, J = 12.6 Hz, 4H), 3.44-



isoindole-2-
3.28 (m, 2H), 2.92 (s, 4H), 1.62-1.19 (m,



carboxamide
3H), 0.84 (d, J = 6.3 Hz, 6H)


1152
N-(4-{[1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(ethylamino)-1-
δ 7.87-7.71 (m, 2H), 7.71-7.53 (m, 2H),
m/e 399



oxopropan-2-
7.49-7.24 (m, 1H), 7.25-6.98 (m, 2H),
(M + H)+



yl]carbamoyl}phenyl)-
4.77 (d, J = 12.4 Hz, 4H), 4.55-4.28 (m,



5-fluoro-1,3-
1H), 3.19-3.02 (m, 2H), 3.01-2.74 (m,



dihydro-2H-
3H), 1.96 (s, 1H), 1.34 (d, J = 7.1 Hz, 3H),



isoindole-2-
1.04 (t, J = 7.2 Hz, 2H)



carboxamide


1153
5-fluoro-N-(4-{[(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methyl-1H-pyrazol-3-
δ 7.89-7.69 (m, 2H), 7.69-7.57 (m, 3H),
m/e 394



yl)methyl]carbamoyl}phenyl)-
7.50 (d, J = 2.1 Hz, 1H), 7.42-7.22 (m,
(M + H)+



1,3-dihydro-2H-
2H), 7.25-7.00 (m, 2H), 4.77 (d, J = 12.4



isoindole-2-
Hz, 4H), 4.41 (s, 2H), 3.78 (s, 3H), 2.97 (s,



carboxamide
2H)


1154
5-fluoro-N-{4-[(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methoxybutyl)carbamoyl]phenyl}-
δ 7.78-7.72 (m, 2H), 7.64-7.58 (m, 2H),
m/e 386



1,3-dihydro-2H-
7.37 (dd, J = 8.4, 5.1 Hz, 1H), 7.17 (dd, J =
(M + H)+



isoindole-2-
9.1, 2.4 Hz, 1H), 7.10 (td, J = 8.9, 2.5 Hz,



carboxamide
1H), 4.79 (bs, 3H), 4.76 (bs, 3H), 3.38-3.32




(m, 5H), 3.32 (s, 4H), 1.61-1.39 (m, 2H),




0.90 (t, J = 7.4 Hz, 3H)


1155
N-(4-{[4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(dimethylamino)bu-
δ 7.86-7.69 (m, 2H), 7.70-7.54 (m, 2H),
m/e 399



tyl]carbamoyl}phenyl)-
7.44-7.27 (m, 1H), 7.23-7.00 (m, 2H),
(M + H)+



5-fluoro-1,3-
4.77 (d, J = 12.5 Hz, 4H), 3.31 (dd, J = 13.0,



dihydro-2H-
6.3 Hz, 2H), 3.19-2.99 (m, 3H), 2.79 (s,



isoindole-2-
7H), 1.71-1.50 (m, 4H)



carboxamide


1156
5-fluoro-N-{4-[(3S)-

1H NMR (400 MHz DMSO-d6, Temp = 90° C.)

(ESI(+))



tetrahydrofuran-3-
δ 7.82-7.70 (m, 2H), 7.70-7.54 (m, 2H),
m/e 370



ylcarbamoyl]phenyl}-
7.44-7.28 (m, 1H), 7.23-7.03 (m, 2H),
(M + H)+



1,3-dihydro-2H-
4.77 (d, J = 12.5 Hz, 4H), 4.53-4.35 (m,



isoindole-2-
1H), 3.98-3.81 (m, 2H), 3.77-3.66 (m,



carboxamide
1H), 3.70-3.53 (m, 1H), 3.01-2.87 (m,




1H), 2.32-2.10 (m, 1H), 2.07-1.81 (m,




1H)


1157
5-fluoro-N-{4-[(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methoxybutan-2-
δ 7.78-7.72 (m, 2H), 7.63-7.57 (m, 2H),
m/e 386



yl)carbamoyl]phenyl}-
7.40-7.31 (m, 1H), 7.21-7.04 (m, 2H),
(M + H)+



1,3-dihydro-2H-
4.77 (d, J = 12.4 Hz, 4H), 4.11-3.94 (m,



isoindole-2-
1H), 3.55-3.32 (m, 2H), 3.28 (s, 3H), 1.72-



carboxamide
1.39 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H)


1158
N-{4-[(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



ethoxypropyl)carbamoyl]phenyl}-
δ 7.83-7.70 (m, 2H), 7.69-7.51 (m, 2H),
m/e 386



5-fluoro-1,3-dihydro-
7.48-7.29 (m, 1H), 7.25-7.00 (m, 2H),
(M + H)+



2H-isoindole-2-
4.77 (d, J = 12.5 Hz, 4H), 3.71-3.55 (m,



carboxamide
1H), 3.58-3.40 (m, 2H), 3.40-3.29 (m,




1H), 1.26-0.98 (m, 6H)


1159
N-{4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



[benzyl(methyl)carbamoyl]phenyl}-
δ 7.69-7.53 (m, 2H), 7.42-7.29 (m, 6H),
m/e 404



5-fluoro-1,3-dihydro-
7.28 (dd, J = 13.0, 7.2 Hz, 3H), 7.19-7.01
(M + H)+



2H-isoindole-2-
(m, 2H), 4.76 (d, J = 12.4 Hz, 4H), 4.58 (d, J =



carboxamide
21.5 Hz, 3H), 2.89 (d, J = 3.2 Hz, 3H)


1160
N-{4-[(2S)-butan-2-

1H NMR (400 MHz, DMSO D2O) δ 7.83-

(ESI(+))



ylcarbamoyl]phenyl}-
7.68 (m, 2H), 7.66-7.54 (m, 2H), 7.37 (dd,
m/e 356



5-fluoro-1,3-
J = 8.4, 5.2 Hz, 1H), 7.20-7.12 (m, 1H),
(M + H)+



dihydro-2H-
7.12-7.01 (m, 1H), 4.77 (d, J = 12.5 Hz,



isoindole-2-
4H), 3.92 (h, J = 6.6 Hz, 1H), 1.70-1.41



carboxamide
(m, 2H), 1.15 (d, J = 6.6 Hz, 3H), 0.88 (t, J =




7.4 Hz, 3H)


1161
5-fluoro-N-(4-{[2-(5-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methyl-1H-pyrazol-
δ 7.83-7.68 (m, 2H), 7.66-7.54 (m, 2H),
m/e 408



1-yl)ethyl]carbamoyl}phenyl)-
7.37 (dd, J = 8.4, 5.2 Hz, 1H), 7.20-7.12
(M + H)+



1,3-dihydro-
(m, 1H), 7.12-7.01 (m, 1H), 4.77 (d, J =



2H-isoindole-2-
12.5 Hz, 4H), 3.92 (h, J = 6.6 Hz, 4H), 0.88



carboxamide
(t, J = 7.4 Hz, 3H)


1162
5-fluoro-N-(4-{[2-(3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methyl-1H-pyrazol-1-
δ 7.77-7.66 (m, 2H), 7.66-7.56 (m, 2H),
m/e 408



yl)ethyl]carbamoyl}phenyl)-
7.50 (d, J = 2.1 Hz, 1H), 7.44-7.29 (m,
(M + H)+



1,3-dihydro-
1H), 7.17 (dd, J = 9.0, 2.2 Hz, 1H), 7.14-



2H-isoindole-2-
7.00 (m, 1H), 6.00 (d, J = 2.2 Hz, 1H), 4.77



carboxamide
(d, J = 12.5 Hz, 4H), 4.21 (t, J = 6.4 Hz, 2H),




3.63 (t, J = 6.4 Hz, 2H), 2.89 (d, J = 62.0 Hz,




1H), 2.21 (d, J = 32.8 Hz, 3H)


1163
5-fluoro-N-{4-[(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methylpropyl)carbamoyl]phenyl}-
δ 7.82-7.69 (m, 2H), 7.69-7.54 (m, 2H),
m/e 356



1,3-dihydro-2H-
7.46-7.26 (m, 1H), 7.29-7.01 (m, 2H),
(M + H)+



isoindole-2-
4.77 (d, J = 12.4 Hz, 4H), 3.15-3.05 (m,



carboxamide
2H), 2.98-2.75 (m, 3H), 2.06-1.89 (m,




2H), 1.92-1.78 (m, 1H), 0.90 (d, J = 6.7




Hz, 7H)


1164
5-fluoro-N-{4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



[(pyridin-3-
δ 8.79-8.58 (m, 2H), 8.19 (t, J = 7.0 Hz,
m/e 391



ylmethyl)carbamoyl]
1H), 7.84-7.73 (m, 2H), 7.73-7.66 (m,
(M + H)+



phenyl}-1,3-dihydro-
1H), 7.70-7.55 (m, 2H), 7.50-7.27 (m,



2H-isoindole-2-
1H), 7.27-7.06 (m, 2H), 4.77 (d, J = 12.4



carboxamide
Hz, 4H), 4.59 (s, 2H)


1165
5-fluoro-N-{4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



[(tetrahydrofuran-2-
δ 7.85-7.72 (m, 2H), 7.66-7.53 (m, 2H),
m/e 384



ylmethyl)carbamoyl]
7.46-7.32 (m, 1H), 7.24-7.14 (m, 1H),
(M + H)+



phenyl}-1,3-dihydro-
7.14-7.04 (m, 1H), 4.93-4.61 (m, 4H),



2H-isoindole-2-
4.11-3.90 (m, 1H), 3.87-3.72 (m, 1H),



carboxamide
3.72-3.53 (m, 1H), 3.35 (t, J = 7.5 Hz, 2H),




2.06-1.73 (m, 3H), 1.66-1.52 (m, 1H)


1166
N-(4-{[(1R)-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



cyclopropylethy1]carbamoyl}phenyl)-
δ 7.83-7.72 (m, 2H), 7.68-7.57 (m, 2H),
m/e 368



5-fluoro-1,3-dihydro-
7.37 (dd, J = 8.3, 5.1 Hz, 1H), 7.23-7.02
(M + H)+



2H-isoindole-2-
(m, 2H), 4.77 (d, J = 12.5 Hz, 4H), 3.63-



carboxamide
3.42 (m, 1H), 1.22 (d, J = 6.7 Hz, 3H), 1.15-




0.79 (m, 1H), 0.51-0.24 (m, 3H), 0.24-




0.11 (m, 1H)


1167
5-fluoro-N-(4-{[1-(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methylcyclopropyl)eth-
δ 7.83-7.68 (m, 2H), 7.68-7.54 (m, 2H),
m/e 382



yl]carbamoyl}phenyl)-
7.37 (dd, J = 8.4, 5.1 Hz, 1H), 7.24-7.12
(M + H)+



1,3-dihydro-2H-
(m, 1H), 7.12-7.01 (m, 1H), 4.77 (d, J =



isoindole-2-
12.5 Hz, 4H), 3.72 (q, J = 6.8 Hz, 1H), 1.17



carboxamide
(d, J = 6.9 Hz, 3H), 1.07 (s, 3H), 0.68-0.51




(m, 1H), 0.49-0.27 (m, 1H), 0.32-0.12 (m,




2H)


1168
5-fluoro-N-{4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



[(thiophen-2-
δ 7.89-7.70 (m, 2H), 7.70-7.56 (m, 2H),
m/e 395



ylmethyl)carbamoyl]
7.48-7.26 (m, 2H), 7.24-7.14 (m, 1H),
(M + H)+



phenyl}-1,3-dihydro-
7.14-7.05 (m, 1H), 7.05-6.95 (m, 1H),



2H-isoindole-2-
6.98-6.86 (m, 1H), 4.90-4.67 (m, 4H),



carboxamide
4.63 (d, J = 4.2 Hz, 2H)


1169
-(4-{[(1S)-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



cyclopropylethyl]carbamoyl}phenyl)-
δ 7.85-7.70 (m, 2H), 7.68-7.51 (m, 2H),
m/e 368



5-fluoro-1,3-dihydro-
7.37 (dd, J = 8.4, 5.2 Hz, 1H), 7.21-7.05
(M + H)+



2H-isoindole-2-
(m, 2H), 4.77 (d, J = 12.4 Hz, 4H), 3.64-



carboxamide
3.41 (m, 1H), 1.22 (d, J = 6.7 Hz, 3H), 1.17-




0.94 (m, 1H), 0.51-0.41 (m, 1H), 0.41-




0.34 (m, 1H), 0.34-0.27 (m, 1H), 0.23-




0.11 (m, 1H)


1170
5-fluoro-N-{4-[(4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methoxybutyl)carbamoyl]phenyl}-
δ 7.81-7.67 (m, 2H), 7.67-7.52 (m, 2H),
m/e 386



1,3-dihydro-2H-
7.37 (dd, J = 8.3, 5.2 Hz, 1H), 7.17 (d, J =
(M + H)+



isoindole-2-
9.1 Hz, 1H), 7.14-7.03 (m, 1H), 4.77 (d, J =



carboxamide
12.5 Hz, 4H), 3.42-3.30 (m, 2H), 3.24 (s,




3H), 1.96 (s, 1H), 1.70-1.29 (m, 4H)


1171
5-fluoro-N-(4-{[(5-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methyl-1,3-oxazol-2-
δ 7.93-7.72 (m, 2H), 7.69-7.55 (m, 2H),
m/e 395



yl)methyl]carbamoyl}phenyl)-
7.45-7.29 (m, 1H), 7.17 (dt, J = 5.5, 2.7
(M + H)+



1,3-dihydro-2H-
Hz, 1H), 7.13-7.04 (m, 1H), 6.72 (dd, J =



isoindole-2-
6.4, 1.6 Hz, 1H), 4.77 (d, J = 12.6 Hz, 4H),



carboxamide
4.51 (s, 2H), 2.26 (s, 3H)


1172
5-fluoro-N-(4-{[2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(tetrahydro-2H-
δ 7.74 (dd, J = 9.0, 2.2 Hz, 2H), 7.61 (dd, J =
m/e 412



pyran-3-
9.0, 2.1 Hz, 2H), 7.37 (dd, J = 8.3, 5.2 Hz,
(M + H)+



yl)ethyl]carbamoyl}phenyl)-
1H), 7.17 (dd, J = 9.0, 2.0 Hz, 1H), 7.14-



1,3-dihydro-
6.99 (m, 1H), 4.77 (d, J = 12.5 Hz, 4H), 3.86-



2H-isoindole-2-
3.57 (m, 2H), 3.38-3.28 (m, 2H), 3.17-



carboxamide
2.91 (m, 1H), 1.97-1.73 (m, 1H), 1.74-




1.52 (m, 2H), 1.52-1.34 (m, 3H), 1.33-




1.06 (m, 1H)


1173
5-fluoro-N-(4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



{[(2S)-1-
δ 7.81-7.72 (m, 2H), 7.69-7.51 (m, 2H),
m/e 372



methoxypropan-2-
7.51-7.28 (m, 1H), 7.23-7.14 (m, 1H),
(M + H)+



yl]carbamoyl}phenyl)-
7.14-6.98 (m, 1H), 4.77 (d, J = 12.5 Hz,



1,3-dihydro-2H-
4H), 4.31-4.10 (m, 1H), 3.44 (dd, J = 9.8,



isoindole-2-
6.2 Hz, 1H), 3.35-3.32 (m, 1H), 3.29 (s,



carboxamide
3H), 1.16 (d, J = 6.8 Hz, 3H)


1174
N-{4-[(3,3-dimethyl-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



2-oxobutyl)carbamoyl]
δ 7.89-7.70 (m, 2H), 7.70-7.54 (m, 2H),
m/e 398



phenyl}-5-fluoro-
7.37 (dd, J = 8.4, 5.1 Hz, 1H), 7.17 (dd, J =
(M + H)+



1,3-dihydro-2H-
9.1, 2.2 Hz, 1H), 7.14-6.96 (m, 1H), 4.78



isoindole-2-
(d, J = 12.5 Hz, 4H), 4.30 (d, J = 4.1 Hz,



carboxamide
2H), 1.18 (s, 9H)


1175
5-fluoro-N-(4-{[(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methyl-1H-pyrrol-2-
δ 7.89-7.70 (m, 2H), 7.70-7.54 (m, 2H),
m/e 393



yl)methyl]carbamoyl}phenyl)-
7.37 (dd, J = 8.4, 5.1 Hz, 2H), 7.17 (dd, J =
(M + H)+



1,3-dihydro-2H-
9.1, 2.2 Hz, 1H), 7.14-6.96 (m, 1H), 4.78



isoindole-2-
(d, J = 12.5 Hz, 4H), 4.30 (d, J = 4.1 Hz,



carboxamide
2H), 3.5 (s, 3H)


1176
5-fluoro-N-(4-{[2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(propan-2-
δ 7.87-7.68 (m, 2H), 7.68-7.50 (m, 2H),
m/e 386



yloxy)ethyl]carbamoyl}phenyl)-
7.37 (dd, J = 8.4, 5.2 Hz, 1H), 7.24-7.15
(M + H)+



1,3-dihydro-2H-
(m, 1H), 7.15-7.05 (m, 1H), 4.77 (d, J =



isoindole-2-
12.5 Hz, 4H), 3.83 (p, J = 6.7 Hz, 1H), 1.88-



carboxamide
1.63 (m, 1H), 1.12 (d, J = 6.8 Hz, 3H),




0.90 (dd, J = 6.8, 1.4 Hz, 6H)


1177
N-(4-{[3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(dimethylamino)pro-
δ 7.82-7.70 (m, 2H), 7.70-7.55 (m, 2H),
m/e 385



pyl]carbamoyl}phenyl)-
7.37 (dd, J = 8.4, 5.1 Hz, 1H), 7.17 (dd, J =
(M + H)+



5-fluoro-1,3-
9.0, 2.2 Hz, 1H), 7.15-7.02 (m, 1H), 4.77



dihydro-2H-
(d, J = 12.4 Hz, 4H), 3.39-3.30 (m, 2H),



isoindole-2-
3.23-3.02 (m, 2H), 2.81 (d, J = 4.3 Hz,



carboxamide
6H), 2.02-1.84 (m, 2H)


1178
N-(4-{[(2S)-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



amino-1-oxobutan-2-
δ 7.90-7.73 (m, 2H), 7.73-7.50 (m, 2H),
m/e 385



yl]carbamoyl}phenyl)-
7.50-7.30 (m, 1H), 7.29-7.13 (m, 1H),
(M + H)+



5-fluoro-1,3-
7.13-7.02 (m, 1H), 4.78 (d, J = 12.5 Hz,



dihydro-2H-
4H), 4.46-4.31 (m, 1H), 1.96 (s, 1H), 1.91-



isoindole-2-
1.78 (m, 1H), 1.78-1.66 (m, 1H), 1.04-



carboxamide
0.82 (m, 3H)


1179
5-fluoro-N-[4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(tetrahydro-2H-
δ 7.83-7.69 (m, 2H), 7.68-7.54 (m, 2H),
m/e 384



pyran-3-
7.42-7.28 (m, 1H), 7.22-7.14 (m, 1H),
(M + H)+



ylcarbamoyl)phenyl]-
7.14-7.01 (m, 1H), 4.78 (t, J = 10.5 Hz,



1,3-dihydro-2H-
4H), 3.96-3.86 (m, 1H), 3.85-3.70 (m,



isoindole-2-
2H), 3.41-3.32 (m, 1H), 2.00-1.88 (m,



carboxamide
1H), 1.77-1.65 (m, 1H), 1.65-1.50 (m, 2H)


1180
5-fluoro-N-(4-{[2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(1H-pyrrol-1-
δ 7.76-7.66 (m, 2H), 7.66-7.53 (m, 2H),
m/e 393



yl)ethyl]carbamoyl}phenyl)-
7.46-7.29 (m, 1H), 7.22-7.13 (m, 1H),
(M + H)+



1,3-dihydro-
7.13-6.99 (m, 1H), 6.72 (t, J = 1.9 Hz, 1H),



2H-isoindole-2-
5.99 (t, J = 2.0 Hz, 1H), 4.77 (d, J = 12.5 Hz,



carboxamide
4H), 4.07 (t, J = 6.5 Hz, 2H), 3.57 (t, J = 6.5




Hz, 2H)


1181
5-fluoro-N-{4-[(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methoxypropan-2-
δ 7.78-7.72 (m, 2H), 7.64-7.58 (m, 2H),
m/e 372



yl)carbamoyl]phenyl}-
7.37 (dd, J = 8.4, 5.1 Hz, 1H), 7.17 (dd, J =
(M + H)+



1,3-dihydro-2H-
9.1, 2.4 Hz, 1H), 7.14-7.05 (m, 1H), 4.79



isoindole-2-
(bs, 2H), 4.76 (bs, 2H), 4.18 (h, J = 6.5 Hz,



carboxamide
1H), 3.44 (dd, J = 9.8, 6.2 Hz, 1H), 2.99-




2.78 (m, 1H), 1.16 (d, J = 6.7 Hz, 3H)


1182
5-fluoro-N-{4-[(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methoxyethyl)carbamoyl]phenyl}-
δ 7.78-7.72 (m, 1H), 7.64-7.56 (m, 1H),
m/e 358



1,3-dihydro-2H-
7.41-7.28 (m, 1H), 7.20-7.05 (m, 1H),
(M + H)+



isoindole-2-
4.78 (bs, 1H), 4.75 (bs, 1H), 3.49 (d, J = 5.2



carboxamide
Hz, 1H), 3.48-3.39 (m, 1H), 2.97 (s, 2H),




2.88-2.76 (m, 1H), 1.96 (s, 1H)


1183
N-[4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(cyclopentylcarbamoyl)phenyl]-
δ 7.83-7.68 (m, 2H), 7.68-7.53 (m, 2H),
m/e 368



5-fluoro-
7.51-7.28 (m, 1H), 7.20-7.13 (m, 1H),
(M + H)+



1,3-dihydro-2H-
7.12-7.03 (m, 1H), 4.77 (d, J = 12.4 Hz,



isoindole-2-
4H), 4.33-4.12 (m, 1H), 2.00-1.84 (m,



carboxamide
2H), 1.82-1.66 (m, 2H), 1.66-1.45 (m,




4H)


1184
5-fluoro-N-(4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



{[(2S)-3-
δ 7.85-7.69 (m, 2H), 7.66-7.53 (m, 2H),
m/e 370



methylbutan-2-
7.46-7.31 (m, 1H), 7.23-7.16 (m, 1H),
(M + H)+



yl]carbamoyl}phenyl)-
7.16-7.05 (m, 1H), 4.77 (d, J = 12.5 Hz,



1,3-dihydro-2H-
4H), 3.85-3.79 (m, 1H), 1.89-1.72 (m,



isoindole-2-
1H), 1.11 (t, J = 5.6 Hz, 3H), 0.90 (dd, J =



carboxamide
6.8, 1.1 Hz, 6H)


1185
5-fluoro-N-(4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



{[(2R)-3-
δ 7.87-7.68 (m, 2H), 7.68-7.50 (m, 2H),
m/e 370



methylbutan-2-
7.37 (dd, J = 8.4, 5.2 Hz, 1H), 7.24-7.15
(M + H)+



yl]carbamoyl}phenyl)-
(m, 1H), 7.15-7.05 (m, 1H), 4.77 (d, J =



1,3-dihydro-2H-
12.5 Hz, 4H), 3.83 (p, J = 6.7 Hz, 1H), 1.88-



isoindole-2-
1.63 (m, 1H), 1.12 (d, J = 6.8 Hz, 3H),



carboxamide
0.90 (dd, J = 6.8, 1.4 Hz, 6H)


1186
5-fluoro-N-(4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



{[(2S)-2-
δ 7.84-7.70 (m, 2H), 7.70-7.56 (m, 2H),
m/e 370



methylbutyl]carbamoyl}phenyl)-
7.46-7.27 (m, 1H), 7.25-7.03 (m, 2H),
(M + H)+



1,3-dihydro-2H-
4.77 (d, J = 12.5 Hz, 4H), 3.21 (dd, J = 13.1,



isoindole-2-
6.4 Hz, 1H), 3.15-2.97 (m, 1H), 1.80-1.61



carboxamide
(m, 1H), 1.53-1.30 (m, 1H), 1.28-1.06 (m,




1H), 0.98-0.79 (m, 6H)


1187
5-fluoro-N-{4-[(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



hydroxy-2-
δ 7.81-7.71 (m, 2H), 7.67-7.57 (m, 2H),
m/e 372



methylpropyl)carbamoyl]phenyl}-
7.45-7.27 (m, 1H), 7.21-7.13 (m, 1H),
(M + H)+



1,3-dihydro-2H-
7.13-7.00 (m, 1H), 4.83-4.70 (m, 4H),



isoindole-2-
1.96 (s, 2H), 1.14 (s, 6H)



carboxamide


1188
5-fluoro-N-(4-{[2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(tetrahydro-2H-
δ 7.82-7.67 (m, 2H), 7.69-7.51 (m, 2H),
m/e 412



pyran-4-
7.43-7.32 (m, 1H), 7.21-7.01 (m, 2H),
(M + H)+



yl)ethyl]carbamoyl}phenyl)-
4.78 (t, J = 10.2 Hz, 4H), 3.95-3.70 (m,



1,3-dihydro-
2H), 3.38-3.30 (m, 2H), 1.96 (s, 1H), 1.65-



2H-isoindole-2-
1.55 (m, 2H), 1.57-1.43 (m, 2H), 1.29-



carboxamide
1.09 (m, 2H)


1189
N-[4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(butylcarbamoyl)phenyl]-
δ 7.81-7.69 (m, 2H), 7.68-7.53 (m, 2H),
m/e 356



5-fluoro-1,3-
7.47-7.30 (m, 1H), 7.26-7.13 (m, 1H),
(M + H)+



dihydro-2H-
7.13-7.01 (m, 1H), 4.87-4.67 (m, 4H),



isoindole-2-
3.27 (d, J = 7.1 Hz, 2H), 1.61-1.45 (m,



carboxamide
2H), 1.44-1.26 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H)


1190
5-fluoro-N-{4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



[methyl(tetrahydrofuran-2-
δ 7.69-7.52 (m, 2H), 7.42-7.31 (m, 1H),
m/e 398



ylmethyl)carbamoyl]
7.32-7.24 (m, 2H), 7.20-7.14 (m, 1H),
(M + H)+



phenyl}-1,3-dihydro-
7.14-7.02 (m, 1H), 4.89-4.63 (m, 4H),



2H-isoindole-2-
4.12-3.96 (m, 1H), 3.82-3.58 (m, 2H),



carboxamide
3.59-3.34 (m, 2H), 2.00-1.86 (m, 2H),




1.86-1.72 (m, 2H), 1.61-1.33 (m, 1H)


1191
5-fluoro-N-{4-[(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methoxyethyl)(meth-
δ 7.69-7.53 (m, 2H), 7.43-7.32 (m, 1H),
m/e 372



yl)carbamoyl]phenyl}-
7.32-7.24 (m, 2H), 7.19-7.13 (m, 1H),
(M + H)+



1,3-dihydro-2H-
7.13-7.03 (m, 1H), 4.77 (d, J = 12.4 Hz,



isoindole-2-
4H), 3.52 (s, 3H), 3.03-2.92 (m, 3H)



carboxamide


1192
N-{4-[(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



cyanoethyl)carbamoyl]phenyl}-
δ 7.89-7.74 (m, 2H), 7.74-7.57 (m, 2H),
m/e 353



5-fluoro-
7.37 (dd, J = 8.4, 5.1 Hz, 1H), 7.17 (dd, J =
(M + H)+



1,3-dihydro-2H-
9.0, 2.2 Hz, 1H), 7.13-7.04 (m, 1H), 4.93



isoindole-2-
(q, J = 7.2 Hz, 1H), 4.78 (d, J = 12.4 Hz,



carboxamide
4H), 1.57 (d, J = 7.2 Hz, 3H)


1193
5-fluoro-N-(4-{[(5-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methyl-1,2-oxazol-3-
δ 7.85-7.72 (m, 2H), 7.68-7.56 (m, 2H),
m/e 395



yl)methyl]carbamoyl}phenyl)-
7.42-7.28 (m, 1H), 7.21-7.12 (m, 1H),
(M + H)+



1,3-dihydro-2H-
7.12-7.01 (m, 1H), 6.24-6.00 (m, 1H),



isoindole-2-
4.90-4.68 (m, 4H), 4.55-4.37 (m, 2H),



carboxamide
2.42-2.27 (m, 3H)


1194
5-fluoro-N-{4-[(3R)-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



tetrahydrofuran-3-
δ 7.87-7.72 (m, 2H), 7.66-7.55 (m, 2H),
m/e 370



ylcarbamoyl]phenyl}-
7.45-7.32 (m, 1H), 7.17 (dd, J = 9.0, 2.1
(M + H)+



1,3-dihydro-2H-
Hz, 1H), 7.14-7.01 (m, 1H), 4.77 (d, J =



isoindole-2-
12.4 Hz, 4H), 4.50-4.38 (m, 1H), 3.93-



carboxamide
3.80 (m, 2H), 3.80-3.66 (m, 1H), 3.59 (dd,




J = 8.9, 4.6 Hz, 1H), 2.27-2.09 (m, 1H),




1.99-1.77 (m, 1H)


1260
N-{4-[(3-methoxy-2,2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



dimethylpropyl)carbamoyl]phenyl}-
δ 7.80-7.70 (m, 2H), 7.68-7.52 (m, 2H),
m/e 382



1,3-dihydro-2H-
7.44-7.23 (m, 4H), 4.79 (s, 4H), 3.29 (d, J =
(M + H)+



isoindole-2-
7.7 Hz, 3H), 3.22-3.19 (m, 2H), 3.15 (s,



carboxamide
2H), 0.90 (s, 6H)


1261
N-{4-[(4,4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



difluorocyclohexyl)carbamoyl]phenyl}-
δ 7.86-7.69 (m, 2H), 7.69-7.50 (m, 2H),
m/e 382



1,3-dihydro-2H-
7.38-7.22 (m, 4H), 4.99-4.62 (m, 4H),
(M + H)+



isoindole-2-
3.96 (s, 1H), 2.20-1.82 (m, 6H), 1.70 (t, J =



carboxamide
11.7 Hz, 2H)


1262
N-(4-{[(2R)-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



cyanobutan-2-
δ 7.87-7.70 (m, 2H), 7.73-7.49 (m, 2H),
m/e 362



yl]carbamoyl}phenyl)-
7.45-7.17 (m, 4H), 4.80 (s, 4H), 4.23-3.99
(M + H)+



1,3-dihydro-2H-
(m, 1H), 2.97-2.63 (m, 2H), 1.78-1.56 (m,



isoindole-2-
2H), 0.91 (q, J = 7.2 Hz, 3H)



carboxamide


1263
N-{4-[(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methoxybutyl)carbamoyl]phenyl}-
δ 7.77-7.70 (m, 2H), 7.69-7.52 (m, 2H),
m/e 368



1,3-dihydro-2H-
7.42-7.22 (m, 4H), 4.79 (s, 4H), 3.41-3.31
(M + H)+



isoindole-2-
(m, 5H), 1.65-1.30 (m, 2H), 0.90 (t, J = 7.4



carboxamide
Hz, 3H)


1264
N-(4-{[1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(ethylamino)-1-
δ 7.88-7.73 (m, 2H), 7.69-7.55 (m, 2H),
m/e 381



oxopropan-2-
7.48-7.16 (m, 4H), 4.80 (s, 4H), 4.58-4.35
(M + H)+



yl]carbamoyl}phenyl)-
(m, 1H), 3.13 (q, J = 7.2 Hz, 2H), 1.35 (d, J =



1,3-dihydro-2H-
7.2 Hz, 3H), 1.05 (t, J = 7.2 Hz, 3H)



isoindole-2-



carboxamide


1265
N-(4-{[2-methyl-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(morpholin-4-
δ 7.95-7.77 (m, 2H), 7.70 (t, J = 10.6 Hz,
m/e 437



yl)butyl]carbamoyl}
2H), 7.48-7.20 (m, 4H), 4.80 (s, 4H), 3.95
(M + H)+



phenyl)-1,3-dihydro-
(d, J = 20.8 Hz, 4H), 3.75-3.55 (m, 2H),



2H-isoindole-2-
3.40 (s, 2H), 1.95-1.63 (m, 2H), 1.34 (s,



carboxamide
3H), 1.02 (t, J = 7.4 Hz, 3H)


1266
N-(4-{[(1R)-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



cyclopropylethy1]carbamoyl}phenyl)-
δ 7.86-7.69 (m, 2H), 7.69-7.53 (m, 2H),
m/e 350



1,3-dihydro-2H-
7.49-7.13 (m, 4H), 4.79 (s, 4H), 3.63-3.44
(M + H)+



isoindole-2-
(m, 1H), 1.22 (d, J = 6.7 Hz, 3H), 1.09-



carboxamide
0.90 (m, 1H), 0.57-0.12 (m, 4H)


1267
N-(4-{[(1S)-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



cyclopropylethy1]carbamoyl}phenyl)-
δ 7.84-7.71 (m, 2H), 7.66-7.55 (m, 2H),
m/e 350



1,3-dihydro-2H-
7.40-7.19 (m, 4H), 4.79 (s, 4H), 3.52 (p, J =
(M + H)+



isoindole-2-
6.9 Hz, 1H), 1.22 (d, J = 6.7 Hz, 3H), 1.13-



carboxamide
0.90 (m, 1H), 0.54-0.14 (m, 4H)


1269
N-{4-[(3S)-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



tetrahydrofuran-3-
δ 7.84-7.73 (m, 2H), 7.67-7.53 (m, 2H),
m/e 351



ylcarbamoyl]phenyl}-
7.42-7.19 (m, 4H), 4.80 (d, J = 5.5 Hz,
(M + H)+



1,3-dihydro-2H-
4H), 4.52-4.35 (m, 1H), 3.93-3.78 (m,



isoindole-2-
2H), 3.78-3.67 (m, 1H), 3.63-3.52 (m,



carboxamide
1H), 2.29-2.08 (m, 1H), 2.07-1.79 (m, 1H)


1270
N-(4-{[2-(tetrahydro-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



2H-pyran-3-
δ 7.82-7.69 (m, 2H), 7.65-7.48 (m, 2H),
m/e 394



yl)ethyl]carbamoyl}phenyl)-
7.50-7.14 (m, 4H), 4.79 (s, 4H), 3.93-3.60
(M + H)+



1,3-dihydro-
(m, 2H), 3.41-3.29 (m, 2H), 3.14-2.93 (m,



2H-isoindole-2-
1H), 2.02-1.79 (m, 1H), 1.69-1.43 (m,



carboxamide
4H), 1.29-1.09 (m, 1H)


1271
N-(4-{[(5-methyl-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



1,3-oxazol-2-
δ 7.92-7.71 (m, 2H), 7.72-7.56 (m, 2H),
m/e 377



yl)methyl]carbamoyl}phenyl)-
7.46-7.24 (m, 4H), 4.80 (d, J = 1.4 Hz,
(M + H)+



1,3-dihydro-2H-
4H), 4.63-4.41 (m, 2H), 2.26 (t, J = 2.3 Hz, 3H)



isoindole-2-



carboxamide


1272
N-[4-({2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



[(dimethylamino)meth-
δ 7.85-7.75 (m, 2H), 7.72-7.63 (m, 2H),
m/e 429



yl]benzyl}carbamoyl)phenyl]-
7.59-7.50 (m, 1H), 7.50-7.42 (m, 2H),
(M + H)+



1,3-dihydro-2H-
7.42-7.24 (m, 5H), 4.79 (s, 4H), 4.52 (d, J =



isoindole-2-
16.7 Hz, 4H), 2.88 (s, 6H)



carboxamide


1273
N-(4-{[(1R)-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



amino-2-oxo-1-
δ 7.86-7.76 (m, 2H), 7.70-7.62 (m, 2H),
m/e 415



phenylethyl]carbamoyl}phenyl)-
7.51 (t, J = 6.8 Hz, 2H), 7.40-7.25 (m, 7H),
(M + H)+



1,3-dihydro-2H-
5.63 (s, 1H), 4.79 (s, 4H)



isoindole-2-



carboxamide


1274
N-[4-(1,3-oxazol-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



ylcarbamoyl)phenyl]-
δ 8.03-7.85 (m, 2H), 7.85-7.76 (m, 1H),
m/e 329



1,3-dihydro-2H-
7.76-7.61 (m, 2H), 7.47-7.25 (m, 4H),
(M + H)+



isoindole-2-
7.18-7.03 (m, 1H), 4.92-4.62 (m, 4H)



carboxamide


1275
N-[4-(tetrahydro-2H-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



pyran-3-
δ 7.88-7.65 (m, 2H), 7.69-7.53 (m, 2H),
m/e 366



ylcarbamoyl)phenyl]-
7.46-7.18 (m, 4H), 4.79 (s, 4H), 3.99-3.66
(M + H)+



1,3-dihydro-2H-
(m, 3H), 3.44-3.32 (m, 1H), 2.04-1.86 (m,



isoindole-2-
1H), 1.84-1.50 (m, 3H)



carboxamide


1276
N-(4-{[2-(2,6-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



dimethylmorpholin-
δ 7.85-7.70 (m, 2H), 7.70-7.57 (m, 2H),
m/e 423



4-yl)ethyl]carbamoyl}phenyl)-
7.45-7.22 (m, 4H), 4.80 (s, 4H), 3.94-3.77
(M + H)+



1,3-dihydro-
(m, 2H), 3.67 (t, J = 6.2 Hz, 2H), 3.53 (d, J =



2H-isoindole-2-
12.0 Hz, 2H), 3.32 (dd, J = 12.8, 6.6 Hz,



carboxamide
3H), 2.72 (t, J = 11.7 Hz, 2H), 1.18 (d, J =




6.3 Hz, 6H)


1277
N-(4-{[1-(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methylcyclopropyl)eth-
δ 7.85-7.69 (m, 2H), 7.69-7.53 (m, 2H),
m/e 364



yl]carbamoyl}phenyl)-
7.47-6.99 (m, 4H), 4.79 (s, 4H), 3.82-3.62
(M + H)+



1,3-dihydro-2H-
(m, 1H), 1.17 (d, J = 6.9 Hz, 3H), 1.07 (s,



isoindole-2-
3H), 0.69-0.53 (m, 1H), 0.47-0.35 (m,



carboxamide
1H), 0.29-0.13 (m, 2H)


1278
N-(4-{[2-(furan-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



yl)-2-(pyrrolidin-1-
δ 7.79-7.65 (m, 3H), 7.68-7.54 (m, 2H),
m/e 445



yl)ethyl]carbamoyl}phenyl)-
7.43-7.17 (m, 4H), 6.78 (d, J = 3.3 Hz,
(M + H)+



1,3-dihydro-
1H), 6.64-6.46 (m, 1H), 4.91-4.72 (m,



2H-isoindole-2-
5H), 4.11-3.93 (m, 1H), 3.93-3.77 (m,



carboxamide
1H), 2.01-1.76 (m, 4H)


1310
N-(4-{[3-(3,5-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



dimethyl-1H-
δ 7.80-7.69 (m, 2H), 7.69-7.51 (m, 2H),
m/e 418



pyrazol-1-
7.44-7.25 (m, 4H), 4.79 (s, 4H), 4.03-3.87
(M + H)+



yl)propyl]carbamoyl}phenyl)-
(m, 2H), 2.23-2.15 (m, 3H), 2.10 (s, 3H),



1,3-dihydro-2H-
2.05-1.88 (m, 2H)



isoindole-2-



carboxamide


1311
N-(4-{[(3S)-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methyl-2-oxoazepan-3-
δ 7.92-7.83 (m, 1H), 7.79-7.70 (m, 2H),
m/e 407



yl]carbamoyl}phenyl)-
7.70-7.57 (m, 2H), 7.46-7.13 (m, 5H),
(M + H)+



1,3-dihydro-2H-
6.63-6.61 (m, 1H), 4.90-4.73 (m, 6H),



isoindole-2-
3.76-3.57 (m, 1H), 2.95 (s, 3H), 2.02-1.68



carboxamide
(m, 4H), 1.64-1.32 (m, 2H)


1312
N-(4-{[2-(1H-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



pyrazol-1-
δ 7.74-7.67 (m, 2H), 7.66-7.59 (m, 3H),
m/e 376



yl)ethyl]carbamoyl}phenyl)-
7.39-7.28 (m, 4H), 6.23 (t, J = 2.0 Hz, 1H),
(M + H)+



1,3-dihydro-
4.79 (s, 4H), 4.31 (t, J = 6.4 Hz, 2H), 3.66 (t,



2H-isoindole-2-
J = 6.4 Hz, 2H)



carboxamide


1313
N-(4-{[1-(1,3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



thiazol-2-
δ 7.91-7.75 (m, 2H), 7.74-7.62 (m, 3H),
m/e 393



yl)ethyl]carbamoyl}phenyl)-
7.53 (d, J = 3.3 Hz, 1H), 7.47-7.23 (m,
(M + H)+



1,3-dihydro-
4H), 5.56-5.34 (m, 1H), 4.80 (s, 4H), 1.65



2H-isoindole-2-
(d, J = 7.0 Hz, 3H)



carboxamide


1314
N-(4-{[1-(furan-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



yl)propan-2-
δ 7.77-7.66 (m, 2H), 7.66-7.55 (m, 2H),
m/e 390



yl]carbamoyl}phenyl)-
7.50-7.39 (m, 1H), 7.41-7.19 (m, 4H),
(M + H)+



1,3-dihydro-2H-
6.45-6.23 (m, 1H), 6.13 (d, J = 3.1 Hz,



isoindole-2-
1H), 4.79 (s, 4H), 4.39-4.14 (m, 1H), 3.03-



carboxamide
2.87 (m, 1H), 2.87-2.70 (m, 1H), 1.19 (d,




J = 6.7 Hz, 3H)


1315
N-(4-{[1-(1-methyl-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



1H-pyrazol-4-
δ 7.81-7.68 (m, 2H), 7.70-7.57 (m, 2H),
m/e 390



yl)ethyl]carbamoyl}phenyl)-
7.54 (s, 1H), 7.47-7.20 (m, 4H), 5.14 (q, J =
(M + H)+



1,3-dihydro-
6.9 Hz, 1H), 4.79 (s, 4H), 3.78 (s, 3H),



2H-isoindole-2-
1.47 (d, J = 6.9 Hz, 3H)



carboxamide


1316
N-(4-{[(2R)-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



amino-4-methyl-1-
δ 7.93-7.76 (m, 2H), 7.76-7.52 (m, 2H),
m/e 395



oxopentan-2-
7.46-7.19 (m, 4H), 4.80 (s, 4H), 4.62-4.39
(M + H)+



yl]carbamoyl}phenyl)-
(m, 1H), 1.78-1.50 (m, 3H), 0.92 (dd, J =



1,3-dihydro-2H-
11.0, 6.1 Hz, 6H)



isoindole-2-



carboxamide


1317
N-(4-{[1-(3,5-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



dimethyl-1H-
δ 7.80-7.67 (m, 2H), 7.66-7.56 (m, 2H),
m/e 418



pyrazol-1-yl)propan-2-
7.48-7.09 (m, 4H), 4.79 (s, 4H), 4.38 (h, J =
(M + H)+



yl]carbamoyl}phenyl)-
6.6 Hz, 1H), 4.22-4.00 (m, 2H), 2.25 (s,



1,3-dihydro-2H-
3H), 2.14 (s, 3H), 1.16 (d, J = 6.8 Hz, 3H)



isoindole-2-



carboxamide


1318
N-{4-[(2,2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



difluoroethyl)carbamoyl]phenyl}-
δ 7.93-7.72 (m, 2H), 7.73-7.57 (m, 2H),
m/e 346



1,3-dihydro-2H-
7.44-7.22 (m, 4H), 6.28-5.80 (m, 1H),
(M + H)+



isoindole-2-
4.79 (s, 4H), 3.78-3.55 (m, 2H)



carboxamide


1319
N-(4-{[2-(tetrahydro-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



2H-pyran-4-
δ 7.81-7.68 (m, 2H), 7.68-7.53 (m, 2H),
m/e 394



yl)ethyl]carbamoyl}phenyl)-
7.44-7.25 (m, 4H), 4.79 (s, 4H), 3.93-3.74
(M + H)+



1,3-dihydro-
(m, 2H), 3.34-3.30 (m, 2H), 1.73-1.43 (m,



2H-isoindole-2-
4H), 1.35-1.06 (m, 2H)



carboxamide


1320
N-{4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



[(tetrahydrofuran-2-
δ 7.83-7.72 (m, 2H), 7.67-7.47 (m, 2H),
m/e 366



ylmethyl)carbamoyl]
7.43-7.17 (m, 4H), 4.79 (s, 4H), 4.00 (p, J =
(M + H)+



phenyl}-1,3-dihydro-
6.2 Hz, 1H), 3.88-3.72 (m, 1H), 3.73-



2H-isoindole-2-
3.55 (m, 1H), 3.34 (d, J = 5.9 Hz, 2H), 2.01-



carboxamide
1.76 (m, 3H), 1.71-1.49 (m, 1H)


1321
N-{4-[(2-methoxy-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methylpropyl)carbamoyl]phenyl}-
δ 7.86-7.71 (m, 2H), 7.71-7.58 (m, 2H),
m/e 368



1,3-dihydro-2H-
7.46-7.22 (m, 4H), 4.79 (s, 4H), 3.35 (s,
(M + H)+



isoindole-2-
2H), 3.18 (s, 3H), 1.14 (s, 6H)



carboxamide


1322
N-(4-{[(5-methyl-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



l,2-oxazol-3-
δ 7.81-7.75 (m, 2H), 7.67-7.61 (m, 2H),
m/e 377



yl)methyl]carbamoyl}phenyl)-
7.39-7.28 (m, 4H), 4.83-4.76 (m, 5H),
(M + H)+



1,3-dihydro-2H-
4.46 (s, 2H), 2.36 (d, J = 0.9 Hz, 3H)



isoindole-2-



carboxamide


1323
N-(4-{[(1-methyl-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



1H-pyrazol-4-
δ 7.75 (d, J = 8.7 Hz, 2H), 7.62 (d, J = 8.7
m/e 376



yl)methyl]carbamoyl}phenyl)-
Hz, 2H), 7.54 (s, 1H), 7.39-7.20 (m, 4H),
(M + H)+



1,3-dihydro-2H-
4.79 (s, 4H), 4.30 (s, 2H), 3.78 (s, 3H)



isoindole-2-



carboxamide


1324
N-(4-{[2-(3,5-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



dimethyl-1H-
δ 7.83-7.64 (m, 2H), 7.68-7.53 (m, 2H),
m/e 404



pyrazol-1-
7.46-7.13 (m, 4H), 4.79 (s, 4H), 4.13 (t, J =
(M + H)+



yl)ethyl]carbamoyl}phenyl)-
6.5 Hz, 2H), 3.58 (t, J = 6.5 Hz, 2H), 2.19 (s,



1,3-dihydro-
3H), 2.12 (s, 3H)



2H-isoindole-2-



carboxamide


1325
N-alpha-{4-[(1,3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



dihydro-2H-isoindol-2-
δ 7.70-7.66 (m, 2H), 7.66-7.56 (m, 2H),
m/e 429



ylcarbonyl)amino]benzoyl}-L-
7.39-7.22 (m, 8H), 7.22-7.12 (m, 1H),
(M + H)+



phenylalaninamide
4.79 (s, 4H), 4.72-4.62 (m, 1H), 3.20-3.11




(m, 1H), 3.08-2.91 (m, 1H)


1326
N-(4-{[2-(2-methyl-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



1,3-thiazol-4-
δ 7.74 (dd, J = 6.8, 1.8 Hz, 2H), 7.70-7.57
m/e 477



yl)ethyl]carbamoyl}phenyl)-
(m, 2H), 7.43-7.23 (m, 4H), 7.19-6.98 (m,
(M + H)+



1,3-dihydro-
1H), 4.80 (s, 4H), 3.66-3.41 (m, 2H), 3.05-



2H-isoindole-2-
2.85 (m, 2H), 2.65 (d, J = 5.2 Hz, 3H)



carboxamide


1327
N-(4-{[(2S)-3,3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



dimethyl-1-
δ 7.87-7.69 (m, 2H), 7.69-7.49 (m, 2H),
m/e 409



(methylamino)-1-
7.49-7.24 (m, 4H), 4.80 (s, 4H), 4.45-4.33
(M + H)+



oxobutan-2-
(m, 1H), 2.66 (d, J = 20.0 Hz, 3H), 1.02 (d, J =



yl]carbamoyl}phenyl)-
18.5 Hz, 9H)



1,3-dihydro-2H-



isoindole-2-



carboxamide


1328
N-[4-(thiophen-3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



ylcarbamoyl)phenyl]-
δ 7.97-7.82 (m, 2H), 7.75-7.61 (m, 3H),
m/e 364



1,3-dihydro-2H-
7.46-7.24 (m, 5H), 4.81 (s, 4H)
(M + H)+



isoindole-2-



carboxamide


1329
N-(4-{[2-(5-methyl-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



1H-pyrazol-1-
δ 7.80-7.67 (m, 2H), 7.67-7.55 (m, 2H),
m/e 390



yl)ethyl]carbamoyl}phenyl)-
7.45-7.20 (m, 5H), 6.00 (dd, J = 5.0, 0.7
(M + H)+



1,3-dihydro-
Hz, 1H), 4.79 (s, 4H), 4.21 (t, J = 6.6 Hz,



2H-isoindole-2-
2H), 3.61 (t, J = 6.6 Hz, 2H), 2.25 (s, 3H)



carboxamide


1330
N-(4-{[2-(3-methyl-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



1H-pyrazol-1-
δ 7.76-7.68 (m, 2H), 7.68-7.52 (m, 2H),
m/e 390



yl)ethyl]carbamoyl}phenyl)-
7.56-7.42 (m, 1H), 7.44-7.24 (m, 4H),
(M + H)+



1,3-dihydro-
5.99 (d, J = 2.1 Hz, 1H), 4.79 (s, 4H), 4.21



2H-isoindole-2-
(t, J = 6.4 Hz, 2H), 3.63 (t, J = 6.4 Hz, 2H),



carboxamide
2.21 (d, J = 33.1 Hz, 3H)


1331
N-{4-[(2S)-butan-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



ylcarbamoyl]phenyl}-
δ 7.88-7.68 (m, 2H), 7.66-7.49 (m, 2H),
m/e 338



1,3-dihydro-2H-
7.44-7.19 (m, 4H), 4.79 (s, 4H), 4.01-3.80
(M + H)+



isoindole-2-
(m, 1H), 1.70-1.33 (m, 2H), 1.16 (d, J = 6.6



carboxamide
Hz, 3H), 0.88 (t, J = 7.4 Hz, 3H)


1332
N-{4-[(3,3-dimethyl-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



oxobutyl)carbamoyl]
δ 7.88-7.69 (m, 2H), 7.72-7.54 (m, 2H),
m/e 380



phenyl}-1,3-dihydro-
7.47-7.19 (m, 4H), 4.80 (s, 4H), 4.30 (s,
(M + H)+



2H-isoindole-2-
2H), 1.18 (s, 9H)



carboxamide


1333
N-(4-{[(1-methyl-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



1H-pyrazol-3-
δ 7.83-7.73 (m, 2H), 7.70-7.59 (m, 2H),
m/e 376



yl)methyl]carbamoyl}phenyl)-
7.55-7.46 (m, 1H), 7.41-7.22 (m, 4H),
(M + H)+



1,3-dihydro-2H-
6.15 (d, J = 2.2 Hz, 1H), 4.79 (s, 4H), 4.42



isoindole-2-
(s, 2H)



carboxamide


1334
N-(4-{[2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(acetylamino)phenyl]
δ 7.90-7.79 (m, 2H), 7.76-7.66 (m, 3H),
m/e 415



carbamoyl}phenyl)-
7.51-7.42 (m, 1H), 7.41-7.26 (m, 4H),
(M + H)+



1,3-dihydro-2H-
7.26-7.13 (m, 2H), 4.85-4.77 (m, 4H),



isoindole-2-
2.14-2.05 (m, 3H)



carboxamide


1335
N-{4-[(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methoxybutan-2-
δ 7.83-7.70 (m, 2H), 7.70-7.55 (m, 2H),
m/e 368



yl)carbamoyl]phenyl}-
7.45-7.23 (m, 4H), 4.79 (s, 4H), 4.16-3.89
(M + H)+



1,3-dihydro-2H-
(m, 1H), 3.52-3.33 (m, 2H), 1.75-1.42 (m,



isoindole-2-
2H), 0.90 (t, J = 7.4 Hz, 3H)



carboxamide


1336
N-[4-(tetrahydro-2H-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



pyran-4-
δ 7.85-7.71 (m, 2H), 7.66-7.53 (m, 2H),
m/e 366



ylcarbamoyl)phenyl]-
7.48-7.20 (m, 4H), 4.79 (s, 4H), 4.05-3.82
(M + H)+



1,3-dihydro-2H-
(m, 3H), 3.48-3.31 (m, 2H), 1.93-1.70 (m,



isoindole-2-
2H), 1.70-1.48 (m, 2H)



carboxamide


1337
N-[4-(pyrimidin-4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



ylcarbamoyl)phenyl]-
δ 8.93-8.85 (m, 1H), 8.72-8.62 (m, 1H),
m/e 359



1,3-dihydro-2H-
8.21-8.11 (m, 1H), 8.03-7.91 (m, 2H),
(M + H)+



isoindole-2-
7.77-7.66 (m, 2H), 7.42-7.26 (m, 4H),



carboxamide
4.81 (d, J = 5.2 Hz, 4H)


1338
N-(4-{[2-(1H-pyrrol-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



yl)ethyl]carbamoyl}phenyl)-
δ 7.78-7.66 (m, 2H), 7.66-7.57 (m, 2H),
m/e 375



1,3-dihydro-
7.37-7.26 (m, 4H), 6.87-6.56 (m, 1H),
(M + H)+



2H-isoindole-2-
6.10-5.80 (m, 1H), 4.79 (s, 4H), 4.08 (t, J =



carboxamide
6.5 Hz, 2H), 3.70-3.48 (m, 2H)


1339
N-(4-{[(2S)-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methylbutyl]carbamoyl}phenyl)-
δ 7.83-7.70 (m, 2H), 7.70-7.52 (m, 2H),
m/e 352



1,3-dihydro-2H-
7.45-7.17 (m, 4H), 4.79 (s, 4H), 3.24-3.16
(M + H)+



isoindole-2-
(m, 1H), 3.16-2.98 (m, 1H), 1.77-1.55 (m,



carboxamide
1H), 1.51-1.31 (m, 1H), 1.31-1.01 (m,




1H), 0.90 (dd, J = 13.5, 6.4 Hz, 6H)


1340
N-{4-[(1-amino-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



oxohexan-2-
δ 7.86-7.70 (m, 3H), 7.68-7.47 (m, 3H),
m/e 395



yl)carbamoyl]phenyl}-
7.47-6.53 (m, 6H), 4.84-4.32 (m, 7H),
(M + H)+



1,3-dihydro-2H-
3.27 (s, 73H), 2.61-2.29 (m, 1 1H), 2.04-



isoindole-2-
1.61 (m, 3H), 1.56-0.69 (m, 10H), 0.18-−0.03



carboxamide
(m, 2H)


1341
N-{4-[(2-amino-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



oxo-1-
δ 7.86-7.73 (m, 2H), 7.84-7.78 (m, 2H),
m/e 3 15



phenylethyl)carbamoyl]phenyl}-
7.70-7.57 (m, 2H), 7.68-7.62 (m, 2H),
(M + H)+



1,3-dihydro-2H-
7.53-7.49 (m, 1H), 7.51 (dd, J = 6.8, 5.5



isoindole-2-
Hz, 2H), 7.40-7.26 (m, 7H), 7.36-7.22



carboxamide
(m, 5H), 5.63 (s, 1H), 5.63 (s, 1H), 4.79 (s,




4H), 4.79 (s, 4H)


1342
N-{4-[(3-tert-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



butoxypropyl)carbamoyl]phenyl}-
δ 7.80-7.68 (m, 2H), 7.68-7.53 (m, 2H),
m/e 396



1,3-dihydro-2H-
7.37-7.18 (m, 4H), 4.79 (s, 4H), 3.44-3.29
(M + H)+



isoindole-2-
(m, 4H), 1.81-1.62 (m, 2H), 1.15 (s, 9H)



carboxamide


1343
N-(4-{[3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(methylcarbamoyl)phe-
δ 7.97-7.85 (m, 3H), 7.76-7.65 (m, 2H),
m/e 415



nyl]carbamoyl}phenyl)-
7.45-7.26 (m, 6H), 4.85-4.77 (m, 4H),
(M + H)+



1,3-dihydro-2H-
2.86-2.78 (m, 3H)



isoindole-2-



carboxamide


1344
N-(4-{[(2R)-3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methylbutan-2-
δ 7.90-7.68 (m, 2H), 7.66-7.56 (m, 2H),
m/e 352



yl]carbamoyl}phenyl)-
7.40-7.17 (m, 4H), 4.79 (s, 4H), 4.02-3.72
(M + H)+



1,3-dihydro-2H-
(m, 1H), 1.94-1.65 (m, 1H), 1.12 (d, J = 6.7



isoindole-2-
Hz, 3H), 0.90 (d, J = 6.8 Hz, 6H)



carboxamide


1345
N-(4-{[(2S)-3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



methylbutan-2-
δ 7.85-7.68 (m, 2H), 7.67-7.51 (m, 2H),
m/e 352



yl]carbamoyl}phenyl)-
7.48-7.11 (m, 4H), 4.79 (s, 4H), 3.95-3.74
(M + H)+



1,3-dihydro-2H-
(m, 1H), 1.92-1.64 (m, 1H), 1.12 (d, J = 6.8



isoindole-2-
Hz, 3H), 1.00-0.79 (m, 6H)



carboxamide


1346
N-(4-{[2-methyl-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(morpholin-4-
δ 7.83-7.70 (m, 2H), 7.70-7.52 (m, 2H),
m/e 423



yl)propan-2-
7.45-7.17 (m, 4H), 4.79 (s, 4H), 3.24-3.16
(M + H)+



yl]carbamoyl}phenyl)-
(m, 1H), 3.16-2.98 (m, 1H), 1.77-1.55 (m,



1,3-dihydro-2H-
1H), 1.51-1.31 (m, 1H), 1.31-1.01 (m,



isoindole-2-
1H), 0.90 (dd, J = 13.5, 6.4 Hz, 6H)



carboxamide


1348
N-(4-{[2-methyl-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



(morpholin-4-
δ 7.91-7.75 (m, 2H), 7.75-7.60 (m, 2H),
m/e 423



yl)propyl]carbamoyl}phenyl)-
7.44-7.23 (m, 4H), 4.80 (s, 4H), 4.01-3.86
(M + H)+



1,3-dihydro-2H-
(m, 4H), 3.63 (s, 2H), 3.50-3.35 (m, 4H),



isoindole-2-
1.38 (s, 6H)



carboxamide


1349
N-{4-[(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.)

(ESI(+))



ethoxypropyl)carbamoyl]phenyl}-
δ 7.84-7.70 (m, 2H), 7.70-7.55 (m, 2H),
m/e 368



1,3-dihydro-2H-
7.43-7.24 (m, 4H), 4.79 (s, 4H), 3.72-3.55
(M + H)+



isoindole-2-
(m, 1H), 3.58-3.44 (m, 2H), 3.38-3.31 (m,



carboxamide
1H), 1.20-1.01 (m, 6H)









Example 132
N2-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2,5-dicarboxamide

A solution of 5-cyano-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide (30 mg, 0.9 mmol) in sulfuric acid (0.1 mL) and trifluoroacetic acid (0.3 mL) was stirred at room temperature for 16 hours. The reaction was treated with ice and the suspension was stirred for 10 minutes and filtered. The solid collected was washed with water and dried under vacuum; the solid was purified by reverse-phase HPLC to provide the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.61 (s, 1H), 8.26 (t, J=5.7 Hz, 1H), 7.97-8.00 (bs, 1H), 7.81-7.86 (m, 2H), 7.75-7.79 (m, 2H), 7.63-7.68 (m, 2H), 7.44 (d, J=7.8 Hz, 1H), 7.34-7.39 (bs, 1H), 4.81-4.82 (bs, 4H), 3.16-3.24 (m, 2H), 1.46-1.59 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 367 (M+H)+.


Example 272
methyl 2-{[4-(propylcarbamoyl)phenyl]carbamoyl}isoindoline-5-carboxylate
Example 272A
4-amino-N-propylbenzamide
5-amino-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

A solution of 4-nitro-N-propylbenzamide (800 mg, 0.1 mmol) in 40 ml tetrahydrofuran in the presence of 160 mg of 20% Pd on carbon was treated in a pressure bottle with 30 psi of hydrogen for 30 minutes at room temperature. The suspension was filtered through a nylon membrane and concentrated to provide the title compound.


Example 272B
methyl 2-{[4-(propylcarbamoyl)phenyl]carbamoyl}isoindoline-5-carboxylate

A solution of 4-amino-N-propylbenzamide (390 mg, 2.19 mmol), bis(2,5-dioxopyrrolidin-1-yl) carbonate (700 mg, 2.74 mmol), and pyridine (0.18 mL, 2.19 mmol) in acetonitrile (5 mL) was stirred at ambient temperature for 30 minutes. Diisopropylethylamine (0.85 mL, 6.6 mmol)) was added followed by a suspension of methyl isoindoline-5-carboxylate hydrochloride (538 mg, 2.52 mmol) and diisopropylethylamine (0.46 mL, 4.4 mmol) in 1-methyl-2-pyrrolidinone (8 mL) added dropwise via syringe over 5 minutes. The reaction became a suspension and was stirred 3 hours. The reaction was treated with water (30 mL) and the resulting suspension was stirred 5 minutes and filtered. The solid collected was washed with water and dried under vacuum to provide the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.63 (s, 1H), 8.26 (t, J=5.6 Hz, 1H), 7.94-7.97 (m, 1H), 7.90-7.96 (m, 1H), 7.75-7.78 (m, 2H), 7.63-7.67 (m, 2H), 7.52 (d, J=7.9 Hz, 1H), 4.83-4.86 (m, 4H), 3.87 (s, 3H), 3.16-3.22 (m, 2H), 1.46-1.59 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 382 (M+H)+.


Example 273
2-{[4-(propylcarbamoyl)phenyl]carbamoyl}isoindoline-5-carboxylic acid

The title compound was prepared as described in Example 1B, substituting methyl 2-{[4-(propylcarbamoyl)phenyl]carbamoyl}isoindoline-5-carboxylate for methyl 4-(isoindoline-2-carboxamido)benzoate. 1H NMR (300 MHz, DMSO-d6) δ ppm 12.90-13.07 (bs, 1H), 8.62 (s, 1H), 8.26 (t, J=5.7 Hz, 1H), 7.88-7.93 (m, 2H), 7.75-7.78 (m, 2H), 7.63-7.67 (m, 2H), 7.49 (d, J=7.9 Hz, 1H), 4.83-4.85 (bs, 4H), 3.16-3.24 (m, 2H), 1.46-1.59 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); (ESI(+)) m/e 368 (M+H)+.


Example 274
5-amino-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

A solution of 5-nitro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide (37 mg, 0.1 mmol) in 1 ml dimethylformamide in the presence of 11 mg of 10% Pd on carbon was treated with a hydrogen balloon overnight at room temperature. The suspension was filtered through diatomaceous earth and purified by reverse-phase HPLC to provide the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.51 (s, 1H), 8.24 (t, J=5.6 Hz, 1H), 7.74-7.78 (m, 2H), 7.62-7.66 (m, 2H), 7.19 (d, J=7.9 Hz, 1H), 6.78-6.89 (m, 2H), 4.67-4.71 (m, 4H), 3.15-3.26 (m, 2H), 1.46-1.59 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 339 (M+H)+.


Example 275
5-(hydroxymethyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

A solution of calcium chloride (0.031 g, 0.277 mmol) in ethanol (0.8 mL) was added to a suspension of methyl 2-(4-(propylcarbamoyl)phenylcarbamoyl)isoindoline-5-carboxylate (0.04 g, 0.105 mmol) in tetrahydrofuran (1 mL). Sodium borohydride (0.02 g, 0.524 mmol) was then added in one portion and the suspension stirred at room temperature. After 18 hours, the mixture was concentrated to remove tetrahydrofuran then saturated aqueous sodium bicarbonate and water was added. The suspension was filtered and the solid was flash chromatographed to provide the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.55 (s, 1H), 8.25 (t, J=5.6 Hz, 1H), 7.74-7.78 (m, 2H), 7.64-7.67 (m, 2H), 7.31 (d, J=4.0 Hz, 1H), 7.30 (d, J=2.3 Hz, 1H), 7.26 (d, J=8.0 Hz, 1H), 5.19 (t, J=5.6 Hz, 1H), 4.71-4.78 (m, 4H), 4.52 (d, J=5.4 Hz, 2H), 3.15-3.25 (m, 2H), 1.46-1.59 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 354 (M+H)+.


Example 276
5-(aminomethyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

5-Cyano-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide (0.04 g, 0.115 mmol) and 7M ammonia-methanol/tetrahydrofuran/methanol (4 mL) were added to Ra—Ni 2800, water slurry (0.080 g, 1.363 mmol) in a 50 ml pressure bottle and stirred for 16 hours at 30 psi and room temperature. The mixture was filtered through a nylon membrane, concentrated and purified by reverse-phase HPLC to provide the title compound. 1H NMR (300 MHz, Methanol-d4) δ ppm 7.76-7.79 (m, 2H), 7.60-7.63 (m, 2H), 7.31-7.35 (m, 3H), 4.82 (s, 4H), 3.86 (s, 2H), 3.30-3.33 (m, 2H), 1.53-1.75 (m, 2H), 0.98 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 425 (M+H)+.


Example 277
5-[(2-hydroxy-2-methylpropanoyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and 2-hydroxy-2-methylpropanoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.59 (s, 1H), 8.55 (s, 1H), 8.25 (t, J=5.7 Hz, 1H), 7.81 (s, 1H), 7.74-7.78 (m, 2H), 7.62-7.68 (m, 2H), 7.59-7.64 (m, 1H), 7.28 (d, J=8.3 Hz, 1H), 5.71-5.75 (m, 1H), 4.72-4.80 (m, 4H), 3.16-3.23 (m, 2H), 1.42-1.59 (m, 2H), 1.36 (s, 6H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 425 (M+H)+.


Example 278
5-acetamido-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

A solution of 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide (0.035 g, 0.103 mmol) in dimethylformamide (0.7 mL) was treated with N,N-diisopropylethylamine (0.018 mL, 0.103 mmol) followed by acetyl chloride (0.011 g, 0.134 mmol) and the reaction solution was stirred at room temperature for 16 hours. The reaction was concentrated and purified by reverse-phase HPLC to provide the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.97 (s, 1H), 8.52 (s, 1H), 8.25 (t, J=5.7 Hz, 1H), 7.74-7.78 (m, 2H), 7.65-7.67 (m, 1H), 7.62-7.67 (m, 2H), 7.43 (dd, J=8.2, 1.9 Hz, 1H), 7.27 (d, J=8.2 Hz, 1H), 4.71-4.76 (m, 4H), 3.16-3.21 (m, 2H), 2.04 (s, 3H), 1.46-1.59 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 381 (M+H)+.


Example 279
5-[(N,N-dimethylglycyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and 2-(dimethylamino)acetic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.76 (s, 1H), 8.54 (s, 1H), 8.25 (t, J=5.6 Hz, 1H), 7.74-7.78 (m, 2H), 7.73 (d, J=1.8 Hz, 1H), 7.63-7.67 (m, 2H), 7.54 (dd, J=8.2, 1.9 Hz, 1H), 7.28 (d, J=8.2 Hz, 1H), 4.72-4.76 (m, 4H), 3.16-3.24 (m, 2H), 3.07 (s, 2H), 2.28 (s, 6H), 1.46-1.59 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI(−)) m/e 422 (M−H).


Example 280
N-[4-(propylcarbamoyl)phenyl]-5-(1H-pyrazol-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

In a 4 mL vial, a solution of 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide (50 mg, 0.12 mmol) and 1H-pyrazol-3-ylboronic acid (17 mg, 0.15 mmol) in dimethylformamide was treated with saturated aqueous sodium bicarbonate followed by bis(triphenylphosphine)palladium(II) chloride (7 mg). The vial was capped under nitrogen and the reaction heated at 85° C. for 6 hours. The reaction was cooled to ambient temperature and water was added. The resulting suspension was stirred for 5 minutes and filtered. The solid collected was washed with water and dried under vacuum; the solid was purified by reverse-phase HPLC to provide the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 12.39-13.18 (bs, 1H), 8.59 (s, 1H), 8.24-8.28 (m, 1H), 7.75-7.79 (m, 2H), 7.70-7.80 (m, 3H), 7.62-7.69 (m, 2H), 7.40 (d, J=7.9 Hz, 1H), 6.73 (d, J=2.2 Hz, 1H), 4.79-4.83 (m, 4H), 3.15-3.25 (m, 2H), 1.46-1.57 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 390 (M+H)+.


Example 281
N-[4-(propylcarbamoyl)phenyl]-5-(1H-pyrazol-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1H-pyrazol-3-ylboronic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 10.91-13.69 (bs, 1H), 8.58 (s, 1H), 8.26 (t, J=5.7 Hz, 1H), 8.07-8.08 (bs, 2H), 7.75-7.79 (m, 2H), 7.67 (s, 1H), 7.54-7.65 (m, 2H), 7.57 (d, J=7.8 Hz, 1H), 7.34 (d, J=7.8 Hz, 1H), 4.76-4.79 (m, 4H), 3.15-3.25 (m, 2H), 1.46-1.59 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 390 (M+H)+.


Example 282
5-[(methoxyacetyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting 2-methoxyacetyl chloride for acetyl chloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.80 (s, 1H), 8.54 (s, 1H), 8.25 (t, J=5.7 Hz, 1H), 7.74-7.79 (m, 2H), 7.72-7.74 (m, 1H), 7.63-7.67 (m, 2H), 7.55 (dd, J=8.2, 1.9 Hz, 1H), 7.30 (d, J=8.2 Hz, 1H), 4.72-4.77 (m, 4H), 4.00 (s, 2H), 3.38 (s, 3H), 3.17-3.19 (m, 2H), 1.46-1.59 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 411 (M+H)+.


Example 283
5-[(methylsulfonyl)amino]-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

A solution of 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide (0.035 g, 0.103 mmol), pyridine (0.017 mL, 0.207 mmol) and catalytic N,N-dimethylaminopyridine in dimethylformamide (0.7 mL) was cooled to 0° C. Methanesulfonyl chloride (0.014 g, 0.126 mmol) was added and the reaction solution was allowed to stir at room temperature for 2 hours. The reaction mixture was concentrated and purified by reverse-phase HPLC to provide the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.74 (s, 1H), 8.54 (s, 1H), 8.26 (t, J=5.6 Hz, 1H), 7.74-7.78 (m, 2H), 7.63-7.66 (m, 2H), 7.32 (d, J=8.1 Hz, 1H), 7.14-7.20 (m, 2H), 4.73-4.76 (m, 4H), 3.15-3.25 (m, 2H), 2.98 (s, 3H), 1.45-1.62 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 417 (M+H)+.









TABLE 4







The following Examples were prepared essentially as described in Example 1,


substituting 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine, 5,7-dihydro-6H-pyrrolo[3,4-b]pyridine,


or 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine for isoindoline in Example 1A and using an


appropriate amine as described in Example 1C. Some products were purified by flash


chromatography while others were purified by reverse-phase HPLC; some compounds also


required Boc-deprotection after amide coupling as described in Example 2D. Accordingly,


some Examples were isolated as trifluoroacetic acid salts.










Ex
Name

1H NMR

MS













285
N-{4-[(3,5-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.80 (t, J = 6.0 Hz,

(ESI(+))



dimethoxybenzyl)carbamoyl]phenyl}-
1H), 8.66 (s, 1H), 8.61 (s, 1H), 8.50 (d, J = 5.0 Hz,
m/e 433



1,3-
1H), 7.80-7.84 (m, 2H), 7.65-7.69 (m, 2H), 7.44 (d, J = 5.1 Hz,
(M + H)+



dihydro-2H-
1H), 6.48 (d, J = 2.3 Hz, 2H), 6.37 (t, J = 2.3 Hz,



pyrrolo[3,4-c]pyridine-
1H), 4.81-4.85 (m, 4H), 4.39 (d, J = 5.9 Hz, 2H),



2-carboxamide
3.31 (s, 6H)


286
N-{4-[(4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.88 (t, J = 6.0 Hz,

(ESI(+))



chlorobenzyl)carbamoyl]phenyl}-
1H), 8.66 (s, 1H), 8.61 (s, 1H), 8.50 (d, J = 5.0 Hz,
m/e 407



1,3-
1H), 7.80-7.84 (m, 2H), 7.65-7.69 (m, 2H),
(M + H)+



dihydro-2H-
7.32-7.45 (m, 5H), 4.78-4.88 (m, 4H), 4.44 (d, J = 5.9 Hz, 2H)



pyrrolo[3,4-c]pyridine-



2-carboxamide


287
N-(4-{[4-(pyridin-2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.61-8.64 (m,

(ESI(+))



yl)piperazin-1-
2H), 8.51 (d, J = 5.0 Hz, 1H), 8.13 (ddd, J = 4.9, 2.0,
m/e 429



yl]carbonyl}phenyl)-
0.8 Hz, 1H), 7.64-7.68 (m, 2H), 7.56 (ddd, J = 8.7,
(M + H)+



1,3-dihydro-2H-
7.0, 1.9 Hz, 1H), 7.44 (d, J = 5.1 Hz, 1H),



pyrrolo[3,4-c]pyridine-
7.36-7.40 (m, 2H), 6.85 (d, J = 8.6 Hz, 1H), 6.65-6.69 (m, 1H),



2-carboxamide
4.81-4.85 (m, 4H), 3.53-3.63 (m, 8H)


288
N-{4-[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.61-8.64 (m,

(ESI(+))



phenylpropyl)carbamoyl]phenyl}-
2H), 8.50 (d, J = 5.0 Hz, 1H), 8.27-8.31 (m, 1H),
m/e 401



1,3-
7.75-7.79 (m, 2H), 7.63-7.67 (m, 2H), 7.44 (d, J = 5.1 Hz,
(M + H)+



dihydro-2H-
1H), 7.15-7.31 (m, 5H), 4.76-4.89 (m, 4H),



pyrrolo[3,4-c]pyridine-
3.20-3.32 (m, 2H), 2.63 (t, J = 7.6 Hz, 2H), 1.77-1.88 (m, 2H)



2-carboxamide


289
N-{4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.65 (s, 1H),

(ESI(+))



[(tetrahydrofuran-3-
8.61 (s, 1H), 8.50 (d, J = 5.0 Hz, 1H), 8.39 (t, J = 5.7 Hz,
m/e 367



ylmethyl)carbamoyl]phenyl}-
1H), 7.75-7.79 (m, 2H), 7.63-7.68 (m, 2H),
(M + H)+



1,3-dihydro-
7.44 (d, J = 5.1 Hz, 1H), 4.81-4.84 (m, 4H), 3.57-3.78 (m,



2H-pyrrolo[3,4-
3H), 3.48 (dd, J = 8.5, 5.3 Hz, 1H), 3.14-3.30 (m, 2H),



c]pyridine-2-
2.41-2.51 (m, 1H), 1.87-2.12 (m, 1H), 1.54-1.66 (m,



carboxamide
1H)


290
N-{4-[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.61-8.64 (m,

(ESI(+))



methylbutyl)carbamoyl]phenyl}-
2H), 8.50 (d, J = 5.0 Hz, 1H), 8.21 (t, J = 5.6 Hz, 1H),
m/e 353



1,3-dihydro-
7.74-7.78 (m, 2H), 7.62-7.66 (m, 2H), 7.44 (d, J = 5.1 Hz,
(M + H)+



2H-pyrrolo[3,4-
1H), 4.81-4.84 (m, 4H), 3.20-3.33 (m, 2H),



c]pyridine-2-
1.53-1.69 (m, 1H), 1.37-1.45 (m, 2H), 0.91 (d, J = 6.6 Hz,



carboxamide
6H)


426
N-(4-{[(2S)-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.65 (s, 1H),

(ESI(−))



tetrahydrofuran-2-
8.61 (s, 1H), 8.50 (d, J = 5.0 Hz, 1H), 8.33 (t, J = 5.8 Hz,
m/e 367



ylmethyl]carbamoyl}phenyl)-
1H), 7.76-7.81 (m, 2H), 7.63-7.67 (m, 2H),
(M + H)



1,3-dihydro-
7.44 (d, J = 5.1 Hz, 1H), 4.76-4.89 (m, 4H), 3.96 (p, J = 6.3 Hz,



2H-pyrrolo[3,4-
1H), 3.73-3.82 (m, 1H), 3.58-3.67 (m, 1H),



c]pyridine-2-
3.26-3.35 (m, 2H), 1.73-1.98 (m, 3H), 1.52-1.66 (m, 1H)



carboxamide


427
N-(4-{[(2R)-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.63-8.65 (bs,

(ESI(−))



tetrahydrofuran-2-
1H), 8.61-8.62 (bs, 1H), 8.50 (d, J = 5.0 Hz, 1H),
m/e 411



ylmethyl]carbamoyl}phenyl)-
8.32 (t, J = 5.8 Hz, 1H), 7.76-7.81 (m, 2H), 7.63-7.67 (m,
(M − H)+



1,3-dihydro-
2H), 7.44 (d, J = 5.1 Hz, 1H), 4.81-4.88 (m, 4H),



2H-pyrrolo[3,4-
3.97 (p, J = 6.2 Hz, 1H), 3.74-3.82 (m, 1H), 3.58-3.66 (m,



c]pyridine-2-
1H), 3.26-3.32 (m, 2H), 1.74-1.96 (m, 3H),



carboxamide
1.53-1.64 (m, 1H)


430
N-(4-{[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 9.10-9.12 (bs,

(APCI(+))



methylbutyl)amino]carbonyl}phenyl)-
1H), 8.83 (s, 1H), 8.67 (s, 1H), 8.22 (t, J = 5.6 Hz,
m/e 354



5,7-
1H), 7.75-7.79 (m, 2H), 7.63-7.67 (m, 2H),
(M + H)+



dihydro-6H-
4.81-4.84 (m, 4H), 3.20-3.34 (m, 2H), 1.53-1.69 (m, 1H),



pyrrolo[3,4-
1.37-1.45 (m, 2H), 0.91 (d, J = 6.6 Hz, 6H)



d]pyrimidine-6-



carboxamide


431
N-(4-{[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 9.11 (s, 1H),

(APCI(+))



phenylpropyl)amino]carbonyl}phenyl)-
8.83 (s, 1H), 8.68 (s, 1H), 8.30 (t, J = 5.6 Hz, 1H),
m/e 402



5,7-
7.76-7.80 (m, 2H), 7.64-7.68 (m, 2H), 7.15-7.32 (m,
(M + H)+



dihydro-6H-
5H), 4.77-4.89 (m, 4H), 3.21-3.34 (m, 2H),



pyrrolo[3,4-
2.60-2.74 (m, 2H), 2.29-1.90 (m, 2H)



d]pyrimidine-6-



carboxamide


437
N-[4-({[(1S)-2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.66 (s, 1H),

(ESI(+))



hydroxy-1-
8.61 (s, 1H), 8.51 (d, J = 2.0 Hz, 1H), 8.49 (d, J = 5.2 Hz,
m/e 403



phenylethyl]amino}carbonyl)phenyl]-
1H), 7.82-7.87 (m, 2H), 7.66-7.70 (m, 2H),
(M + H)+



1,3-
7.38-7.45 (m, 3H), 7.29-7.34 (m, 2H), 7.19-7.26 (m, 1H),



dihydro-2H-
5.03-5.10 (m, 1H), 4.90 (t, J = 5.8 Hz, 1H),



pyrrolo[3,4-c]pyridine-
4.79-4.87 (m, 4H), 3.61-3.76 (m, 2H)



2-carboxamide


445
N-[4-({[(1S)-2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.68 (s, 1H),

(ESI(+))



hydroxy-1-pyridin-2-
8.62 (s, 1H), 8.44-8.54 (m, 3H), 7.84-7.89 (m, 2H),
m/e 404



ylethyl]amino}carbonyl)phenyl]-
7.75 (td, J = 7.7, 1.8 Hz, 1H), 7.66-7.72 (m, 2H),
(M + H)+



1,3-dihydro-
7.39-7.45 (m, 2H), 7.26 (ddd, J = 7.5, 4.8, 1.2 Hz, 1H),



2H-pyrrolo[3,4-
5.10-5.17 (m, 1H), 4.90 (t, J = 6.0 Hz, 1H),



c]pyridine-2-
4.79-4.87 (m, 4H), 3.73-3.88 (m, 2H)



carboxamide


446
N-(4-{[(3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.62 (s, 1H),

(ESI(+))



methylbutyl)amino]carbonyl}phenyl)-
8.48 (dd, J = 4.9, 1.5 Hz, 1H), 8.22 (t, J = 5.6 Hz, 1H),
m/e 353



5,7-
7.81 (dd, J = 7.7, 1.5 Hz, 1H), 7.73-7.79 (m, 2H),
(M + H)+



dihydro-6H-
7.64-7.68 (m, 2H), 7.33 (dd, J = 7.7, 4.9 Hz, 1H),



pyrrolo[3,4-b]pyridine-
4.78-4.80 (bs, 4H), 3.21-3.33 (m, 2H), 1.61 (dp, J = 13.3,



6-carboxamide
6.6 Hz, 1H), 1.41 (q, J = 7.1 Hz, 2H), 0.90 (d, J = 6.6 Hz,




6H)


447
N-(4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.63 (s, 1H),

(ESI(+))



{[(tetrahydrofuran-3-
8.48 (dd, J = 4.9, 1.5 Hz, 1H), 8.39 (t, J = 5.7 Hz, 1H),
m/e 367



ylmethyl)amino]carbonyl}phenyl)-
7.76-7.83 (m, 3H), 7.65-7.69 (m, 2H), 7.33 (dd, J = 7.7,
(M + H)+



5,7-
4.9 Hz, 1H), 4.78-4.81 (bs, 4H), 3.57-3.82 (m,



dihydro-6H-
3H), 3.44-3.51 (m, 1H), 3.17-3.28 (m, 2H),



pyrrolo[3,4-b]pyridine-
2.42-2.50 (m, 1H), 1.85-2.02 (m, 1H), 1.54-1.68 (m, 1H)



6-carboxamide


448
N-{4-[(4-pyridin-2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.61 (s, 1H),

(ESI(+))



ylpiperazin-1-
8.49 (dd, J = 4.9, 1.5 Hz, 1H), 8.13 (dd, J = 5.0, 1.9 Hz,
m/e 429



yl)carbonyl]phenyl}-
1H), 7.81 (dd, J = 7.7, 1.5 Hz, 1H), 7.66-7.70 (m,
(M + H)+



5,7-dihydro-6H-
2H), 7.56 (ddd, J = 8.7, 7.0, 1.8 Hz, 1H),



pyrrolo[3,4-b]pyridine-
7.36-7.41 (m, 2H), 7.34 (dd, J = 7.7, 5.0 Hz, 1H), 6.85 (d, J = 8.6 Hz,



6-carboxamide
1H), 6.67 (dd, J = 6.9, 4.8 Hz, 1H),




4.79-4.81 (bs, 4H), 3.43-3.75 (m, 8H)


553
N-{4-[(tetrahydro-2H-

1H NMR (300 MHz, DMSO-d6) δ 8.64 (s, 1H),

(ESI(+))



pyran-2-
8.61 (s, 1H), 8.50 (d, J = 5.0 Hz, 1H), 8.29 (t, J = 5.8 Hz,
m/e 381



ylmethyl)carbamoyl]phenyl}-
1H), 7.82-7.75 (m, 2H), 7.68-7.61 (m, 2H), 7.44 (d,
(M + H)+



1,3-dihydro-
J = 5.1 Hz, 1H), 4.86-4.79 (m, 4H), 3.87 (dd, J = 11.3,



2H-pyrrolo[3,4-
3.0 Hz, 1H), 3.48-3.34 (m, 2H), 3.28-3.17 (m,



c]pyridine-2-
2H), 1.82-1.72 (m, 1H), 1.66-1.56 (m, 1H),



carboxamide
1.56-1.33 (m, 3H), 1.28-1.07 (m, 1H)


554
N-{4-[(tetrahydro-2H-

1H NMR (300 MHz, DMSO-d6) δ 8.63 (d, J = 8.3 Hz,

(ESI(+))



pyran-3-
2H), 8.50 (d, J = 5.0 Hz, 1H), 8.28 (t, J = 5.7 Hz, 1H),
m/e 381



ylmethyl)carbamoyl]phenyl}-
7.77 (d, J = 8.8 Hz, 2H), 7.65 (d, J = 8.8 Hz, 2H),
(M + H)+



1,3-dihydro-
7.44 (d, J = 5.0 Hz, 1H), 4.83 (d, J = 4.3 Hz, 4H),



2H-pyrrolo[3,4-
3.82-3.64 (m, 2H), 3.18-3.04 (m, 3H), 1.78 (dd, J = 6.9,



c]pyridine-2-
3.6 Hz, 2H), 1.58 (dd, J = 10.2, 6.6 Hz, 1H),



carboxamide
1.53-1.36 (m, 1H), 1.31-1.17 (m, 1H)


555
N-{4-[(tetrahydro-2H-

1H NMR (300 MHz, DMSO-d6) δ 8.66-8.59 (m, 2H),

(ESI(+))



pyran-4-
8.50 (d, J = 5.0 Hz, 1H), 8.33-8.25 (m, 1H),
m/e 381



ylmethyl)carbamoyl]phenyl}-
7.81-7.74 (m, 2H), 7.69-7.61 (m, 2H), 7.44 (d, J = 5.0 Hz,
(M + H)+



1,3-dihydro-
1H), 4.82 (bs, 4H), 3.89-3.79 (m, 2H), 3.24 (d, J = 11.6 Hz,



2H-pyrrolo[3,4-
1H), 3.14 (t, J = 6.1 Hz, 2H), 1.86-1.69 (m,



c]pyridine-2-
1H), 1.64-1.54 (m, 2H), 1.27-1.06 (m, 3H)



carboxamide


556
N-(4-{[(2S)-1-

1H NMR (300 MHz, DMSO-d6) δ 8.66-8.59 (m, 2H),

(ESI(+))



hydroxy-4-
8.50 (d, J = 5.0 Hz, 1H), 7.83-7.75 (m, 3H),
m/e 383



methylpentan-2-
7.69-7.61 (m, 2H), 7.44 (d, J = 5.1 Hz, 1H), 4.91-4.80 (m,
(M + H)+



yl]carbamoyl}phenyl)-
4H), 4.64 (t, J = 5.7 Hz, 1H), 4.12-3.99 (m, 1H),



1,3-dihydro-2H-
3.41 (d, J = 5.3 Hz, 1H), 1.69-1.54 (m, 1H),



pyrrolo[3,4-c]pyridine-
1.53-1.31 (m, 2H), 0.88 (t, J = 6.7 Hz, 6H)



2-carboxamide


599
N-[4-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.62 (d, J = 4.9 Hz,

(ESI(+))



(propylcarbamoyl)phenyl]-
2H), 8.50 (d, J = 5.0 Hz, 1H), 8.30-8.20 (m, 1H),
m/e 325



1,3-dihydro-2H-
7.83-7.72 (m, 2H), 7.68-7.59 (m, 2H), 7.44 (d, J = 5.1 Hz,
(M + H)+



pyrrolo[3,4-c]pyridine-
1H), 4.87-4.77 (m, 4H), 3.22-3.13 (m, 2H),



2-carboxamide
1.61-1.45 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H)


600
N-(4-{[(2S)-

1H NMR (300 MHz, DMSO-d6) δ 8.63 (s, 1H),

(ESI(+))



tetrahydrofuran-2-
8.48 (dd, J = 4.9, 1.5 Hz, 1H), 8.34 (t, J = 5.8 Hz, 1H),
m/e 367



ylmethyl]carbamoyl}phenyl)-
7.85-7.75 (m, 3H), 7.70-7.63 (m, 2H), 7.33 (dd, J = 7.7,
(M + H)+



5,7-dihydro-
4.9 Hz, 1H), 4.80 (bs, 4H), 3.97 (p, J = 6.2 Hz, 1H),



6H-pyrrolo[3,4-
3.83-3.72 (m, 1H), 3.68-3.57 (m, 1H), 3.28 (dd, J = 5.9,



b]pyridine-6-
1.7 Hz, 1H), 1.98-1.72 (m, 3H), 1.66-1.51 (m,



carboxamide
1H)


601
N-(4-{[(2R)-

1H NMR (300 MHz, DMSO-d6) δ 8.62 (s, 1H),

(ESI(+))



tetrahydrofuran-2-
8.48 (dd, J = 4.9, 1.5 Hz, 1H), 8.32 (t, J = 5.8 Hz, 1H),
m/e 367



ylmethyl]carbamoyl}phenyl)-
7.85-7.75 (m, 3H), 7.70-7.63 (m, 2H), 7.33 (dd, J = 7.7,
(M + H)+



5,7-dihydro-
4.9 Hz, 1H), 4.80 (bs, 4H), 3.97 (p, J = 6.2 Hz, 1H),



6H-pyrrolo[3,4-
3.83-3.72 (m, 1H), 3.68-3.57 (m, 1H),



b]pyridine-6-
1.98-1.72 (m, 3H), 1.69-1.51 (m, 1H)



carboxamide


602
N-(4-{[(2S)-1-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H),

(ESI(+))



hydroxy-4-
8.48 (dd, J = 4.9, 1.5 Hz, 1H), 7.87-7.71 (m, 4H),
m/e 383



methylpentan-2-
7.70-7.63 (m, 2H), 7.33 (dd, J = 7.7, 4.9 Hz, 1H), 4.79 (bs,
(M + H)+



yl]carbamoyl}phenyl)-
4H), 4.13-3.95 (m, 1H), 3.42 (dd, J = 10.6, 5.4 Hz,



5,7-dihydro-6H-
2H), 1.72-1.54 (m, 1H), 1.53-1.31 (m, 2H), 0.88 (t,



pyrrolo[3,4-b]pyridine-
J = 6.7 Hz, 6H)



6-carboxamide


603
N-(4-{[(1S)-2-

1H NMR (300 MHz, DMSO-d6) δ 8.64 (s, 1H),

(ESI(+))



hydroxy-1-
8.53-8.45 (m, 2H), 7.88-7.78 (m, 3H), 7.73-7.66 (m,
m/e 403



phenylethyl]carbamoyl}phenyl)-
2H), 7.47-7.27 (m, 5H), 7.27-7.18 (m, 1H),
(M + H)+



5,7-dihydro-
5.12-5.01 (m, 1H), 4.90 (t, J = 5.8 Hz, 1H), 4.80 (bs, 4H),



6H-pyrrolo[3,4-
3.78-3.59 (m, 2H)



b]pyridine-6-



carboxamide


604
N-{4-[(tetrahydro-2H-

1H NMR (300 MHz, DMSO-d6) δ 8.62 (s, 1H),

(ESI(+))



pyran-4-
8.48 (dd, J = 4.9, 1.5 Hz, 1H), 8.30 (t, J = 5.8 Hz, 1H),
m/e 381



ylmethyl)carbamoyl]phenyl}-
7.85-7.74 (m, 3H), 7.70-7.63 (m, 2H), 7.33 (dd, J = 7.7,
(M + H)+



5,7-dihydro-
4.9 Hz, 1H), 4.79 (bs, 4H), 3.89-3.79 (m, 2H),



6H-pyrrolo[3,4-
3.28-3.19 (m, 2H), 3.14 (t, J = 6.3 Hz, 2H), 1.87-1.70 (m,



b]pyridine-6-
1H), 1.64-1.54 (m, 2H), 1.29-1.01 (m, 2H)



carboxamide


613
N-(4-{[(1S)-2-

1H NMR (300 MHz, DMSO-d6) δ 8.65 (s, 1H),

(ESI(+))



hydroxy-1-(pyridin-2-
8.55-8.51 (m, 1H), 8.47 (t, J = 6.7 Hz, 2H), 7.87 (d, J = 8.8 Hz,
m/e 404



yl)ethyl]carbamoyl}phenyl)-
2H), 7.84-7.79 (m, 1H), 7.76 (dd, J = 7.7, 1.8 Hz,
(M + H)+



5,7-dihydro-6H-
1H), 7.71 (t, J = 5.4 Hz, 2H), 7.41 (d, J = 7.8 Hz,



pyrrolo[3,4-b]pyridine-
1H), 7.33 (dd, J = 7.7, 4.9 Hz, 1H), 7.29-7.22 (m,



6-carboxamide
1H), 5.19-5.09 (m, 1H), 4.90 (t, J = 5.9 Hz, 1H),




4.80 (bs, 4H), 3.90-3.72 (m, 2H)


627
N-{4-[(4-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (d, J = 5.9 Hz,

(ESI(+))



hydroxypiperidin-1-
2H), 8.50 (d, J = 5.0 Hz, 1H), 7.62 (d, 2H), 7.44 (d, J = 5.1 Hz,
m/e 367



yl)carbonyl]phenyl}-
1H), 7.30 (d, 2H), 4.82 (d, J = 4.3 Hz, 4H),
(M + H)+



1,3-dihydro-2H-
4.76 (d, J = 4.0 Hz, 1H), 3.73 (td, J = 8.3, 4.2 Hz, 2H),



pyrrolo[3,4-c]pyridine-
3.22-3.08 (m, 2H), 1.82-1.65 (m, 2H),



2-carboxamide
1.43-1.26 (m, 2H)


628
N-{4-[(2-hydroxy-2-

1H NMR (300 MHz, DMSO-d6) δ 8.64 (d, J = 12.5 Hz,

(ESI(+))



methylpropyl)carbamoyl]phenyl}-
2H), 8.50 (d, J = 5.0 Hz, 1H), 8.06 (t, J = 6.0 Hz,
m/e 355



1,3-
1H), 7.80 (d, J = 8.8 Hz, 2H), 7.66 (d, J = 8.8 Hz, 2H),
(M + H)+



dihydro-2H-
7.44 (d, J = 5.1 Hz, 1H), 4.83 (d, J = 4.3 Hz, 4H),



pyrrolo[3,4-c]pyridine-
4.56 (s, 1H), 3.24 (d, J = 6.0 Hz, 2H), 2.89 (s, 1H), 1.10 (s,



2-carboxamide
6H)


629
N-{4-[(4-

1H NMR (300 MHz, DMSO-d6) δ 8.62 (d, J = 6.4 Hz,

(ESI(+))



hydroxybutyl)carbamoyl]phenyl}-
1H), 8.50 (d, J = 5.0 Hz, 1H), 8.26 (t, J = 5.6 Hz, 1H),
m/e 355



1,3-
7.76 (d, J = 8.8 Hz, 1H), 7.64 (d, J = 8.8 Hz, 1H),
(M + H)+



dihydro-2H-
7.44 (d, J = 5.1 Hz, 1H), 4.82 (d, J = 4.3 Hz, 1H), 4.39 (t, J = 5.1 Hz,



pyrrolo[3,4-c]pyridine-
1H), 3.41 (q, J = 6.1 Hz, 1H),



2-carboxamide
3.25-3.15 (m, 2H), 1.59-1.38 (m, 4H)


630
N-(4-{[(2S)-1-

1H NMR (300 MHz, DMSO-d6) δ 8.62 (d, J = 6.0 Hz,

(ESI(+))



hydroxy-3-
2H), 8.50 (d, J = 5.0 Hz, 1H), 7.83-7.77 (m, 2H),
m/e 369



methylbutan-2-
7.74 (d, J = 8.9 Hz, 1H), 7.64 (d, J = 1.8 Hz, 1H),
(M + H)+



yl]carbamoyl}phenyl)-
7.44 (d, J = 5.1 Hz, 1H), 4.83 (d, J = 4.3 Hz, 4H), 4.53 (t, J = 5.6 Hz,



1,3-dihydro-2H-
1H), 3.90-3.70 (m, 1H), 3.51 (t, J = 5.8 Hz,



pyrrolo[3,4-c]pyridine-
2H), 1.92 (dq, J = 13.6, 6.8 Hz, 1H), 0.89 (dd, J = 7.9,



2-carboxamide
6.9 Hz, 6H)


631
N-{4-[(1-hydroxy-2-

1H NMR (300 MHz, DMSO-d6) δ 8.62 (d, J = 4.0 Hz,

(ESI(+))



methylpropan-2-
1H), 8.50 (d, J = 5.0 Hz, 1H), 7.73 (d, J = 8.9 Hz, 1H),
m/e 355



yl)carbamoyl]phenyl}-
7.64 (d, J = 8.9 Hz, 1H), 7.44 (d, J = 5.1 Hz, 1H),
(M + H)+



1,3-dihydro-2H-
7.35 (s, 1H), 4.94 (t, J = 5.9 Hz, 1H), 4.82 (d, J = 4.3 Hz,



pyrrolo[3,4-c]pyridine-
1H), 3.49 (d, J = 6.0 Hz, 2H), 1.31 (s, 6H)



2-carboxamide


632
N-(4-{[(2R)-2-

1H NMR (300 MHz, DMSO-d6) δ 8.63 (d, J = 9.3 Hz,

(ESI(+))



hydroxypropyl]carbamoyl}phenyl)-
2H), 8.50 (d, J = 5.0 Hz, 1H), 8.21 (t, J = 5.7 Hz, 1H),
m/e 341



1,3-
7.79 (d, J = 8.8 Hz, 2H), 7.65 (d, J = 8.8 Hz, 2H),
(M + H)+



dihydro-2H-
7.44 (d, J = 5.0 Hz, 1H), 4.83 (d, J = 4.2 Hz, 4H), 4.72 (d, J = 4.7 Hz,



pyrrolo[3,4-c]pyridine-
1H), 3.77 (dt, J = 11.9, 6.1 Hz, 1H),



2-carboxamide
3.24-3.09 (m, 2H), 3.05 (s, 1H), 1.06 (d, J = 6.2 Hz, 3H)


633
N-(4-{[(2S)-2-

1H NMR (300 MHz, DMSO-d6) δ 8.63 (d, J = 8.5 Hz,

(ESI(+))



hydroxypropyl]carbamoyl}phenyl)-
2H), 8.50 (d, J = 5.0 Hz, 1H), 8.20 (t, J = 5.7 Hz, 1H),
m/e 341



1,3-
7.79 (d, J = 8.8 Hz, 1H), 7.65 (d, J = 8.8 Hz, 1H),
(M + H)+



dihydro-2H-
7.44 (d, J = 5.1 Hz, 1H), 4.83 (d, J = 4.3 Hz, 4H), 4.72 (d, J = 4.7 Hz,



pyrrolo[3,4-c]pyridine-
1H), 3.87-3.68 (m, 1H), 3.17 (ddd, J = 15.1,



2-carboxamide
9.4, 3.6 Hz, 2H), 1.06 (d, J = 6.3 Hz, 3H)


634
N-(4-{[3-(piperidin-1-

1H NMR (300 MHz, DMSO-d6) δ 8.63 (d, J = 11.4 Hz,

(ESI(+))



yl)propyl]carbamoyl}phenyl)-
2H), 8.50 (d, J = 5.0 Hz, 1H), 8.35 (t, J = 5.4 Hz,
m/e 408



1,3-dihydro-
1H), 7.76 (d, J = 8.8 Hz, 2H), 7.65 (d, J = 8.8 Hz, 2H),
(M + H)+



2H-pyrrolo[3,4-
7.44 (d, J = 5.0 Hz, 1H), 4.82 (d, J = 4.3 Hz, 4H),



c]pyridine-2-
2.37-2.22 (m, 6H), 1.72-1.59 (m, 10H), 1.54-1.43 (m,



carboxamide
20H), 1.38 (d, J = 4.8 Hz, 10H)


635
N-[4-(5,6-

1H NMR (300 MHz, DMSO-d6) δ 8.64 (d, J = 11.8 Hz,

(ESI(+))



dihydroimidazo[1,5-
2H), 8.51 (d, J = 5.0 Hz, 1H), 7.68 (d, J = 8.6 Hz,
m/e 389



a]pyrazin-7(8H)-
2H), 7.61 (s, 1H), 7.43 (t, J = 6.9 Hz, 3H), 4.83 (d, J = 4.3 Hz,
(M + H)+



ylcarbonyl)phenyl]-
4H), 4.74 (s, 2H), 4.12 (t, J = 5.4 Hz, 2H),



1,3-dihydro-2H-
3.84 (s, 2H)



pyrrolo[3,4-c]pyridine-



2-carboxamide


686
N-[4-(morpholin-4-

1H NMR (500 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



ylcarbonyl)phenyl]-
8.69 (s, 1H), 8.55 (d, J = 3.7, 2H), 7.72 (d, J = 5.6, 1H),
m/e 353



1,3-dihydro-2H-
7.48-7.39 (m, 2H), 7.21-7.11 (m, 2H), 4.76 (d, J = 23.4,
(M + H)+



pyrrolo[3,4-c]pyridine-
4H), 3.40 (s, 8H)



2-carboxamide


687
N-(4-{[3-(2-

1H NMR (500 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



oxopyrrolidin-1-
8.88 (s, 1H), 8.76 (d, J = 5.7, 2H), 8.29 (t, J = 5.7, 1H),
m/e 408



yl)propyl]carbamoyl}phenyl)-
7.91 (d, J = 5.7, 1H), 7.78 (m, 2H), 7.65 (m, 2H),
(M + H)+



1,3-dihydro-
4.98 (bs, 2H), 4.94 (bs, 2H), 3.35 (t, J = 7.0, 2H), 3.22 (m,



2H-pyrrolo[3,4-
4H), 2.22 (t, J = 8.0, 2H), 1.92 (m, 2H), 1.70 (p, J = 7.0,



c]pyridine-2-
2H)



carboxamide


723
N-{4-[(2-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.89 (s, 1 H)

(ESI(+))



isopropoxyethyl)carbamoyl]phenyl}-
8.78 (d, J = 6.10 Hz, 1 H) 8.02 (d, J = 5.80 Hz, 1 H)
m/e 369



1,3-
7.76-7.81 (m, 2 H) 7.62-7.66 (m, 2 H) 5.01 (d, J = 30.82 Hz,
(M + H)+



dihydro-2H-
4 H) 3.54-3.63 (m, 1 H) 3.49 (t, J = 6.10 Hz, 2 H)



pyrrolo[3,4-c]pyridine-
3.38 (t, J = 6.10 Hz, 2 H) 1.09 (d, J = 6.10 Hz, 6 H)



2-carboxamide


724
N-{4-[methyl(3-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.89 (s, 1

(ESI(+))



methylbutyl)carbamoyl]phenyl}-
H) 8.79 (d, J = 6.10 Hz, 1 H) 8.04 (d, J = 5.80 Hz, 1 H)
m/e 367



1,3-dihydro-
7.60 (d, J = 8.54 Hz, 2 H) 7.32 (d, J = 7.63 Hz, 2 H)
(M + H)+



2H-pyrrolo[3,4-
4.95-5.07 (m, 4 H) 3.44 (s, 2 H) 2.89-2.96 (m, 3 H)



c]pyridine-2-
1.44 (s, 3 H) 0.83 (d, J = 107.41 Hz, 6 H)



carboxamide


725
N-[4-(azetidin-1-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.84 (s, 1 H)

(ESI(+))



ylcarbonyl)phenyl]-
8.74 (d, J = 5.80 Hz, 1 H) 7.94 (d, J = 5.80 Hz, 1 H)
m/e 323



1,3-dihydro-2H-
7.60-7.64 (m, 2 H) 7.56-7.59 (m, 2 H) 4.98 (d, J = 24.72 Hz,
(M + H)+



pyrrolo[3,4-c]pyridine-
4 H) 4.34 (s, 2 H) 4.05 (d, J = 6.71 Hz, 2 H)



2-carboxamide
2.22-2.33 (m, 2 H)


726
N-[4-(2,6-



diazaspiro[3.5]non-2-



ylcarbonyl)phenyl]-



1,3-dihydro-2H-



pyrrolo[3,4-c]pyridine-



2-carboxamide


727
N-[4-(1,7-



diazaspiro[4.4]non-1-



ylcarbonyl)phenyl]-



1,3-dihydro-2H-



pyrrolo[3,4-c]pyridine-



2-carboxamide


728
N-(4-{[4-(morpholin-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.90 (s, 1 H)

(ESI(+))



4-
8.80 (d, J = 5.80 Hz, 1 H) 8.05 (d, J = 5.80 Hz, 1 H)
m/e 458



yl)benzyl]carbamoyl}phenyl)-
7.80-7.85 (m, 2 H) 7.61-7.68 (m, 2 H) 7.27 (d, J = 8.54 Hz,
(M + H)+



1,3-dihydro-
2 H) 7.05 (d, J = 8.85 Hz, 2 H) 5.02 (d, J = 33.26 Hz,



2H-pyrrolo[3,4-
4 H) 4.40 (s, 2 H) 3.76-3.81 (m, 4 H)



c]pyridine-2-
3.16-3.19 (m, 4 H)



carboxamide


729
N-{4-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.90 (s, 1 H)

(ESI(+))



[(cyclopropylmethyl)carbamoyl]phenyl}-
8.79 (d, J = 5.80 Hz, 1 H) 8.04 (d, J = 6.10 Hz, 1 H)
m/e 337



1,3-
7.78-7.82 (m, 2 H) 7.62-7.67 (m, 2 H) 5.02 (d, J = 31.73 Hz,
(M + H)+



dihydro-2H-
4 H) 3.14 (d, J = 7.02 Hz, 2 H) 0.99-1.08 (m, 1 H)



pyrrolo[3,4-c]pyridine-
0.40-0.48 (m, 2 H) 0.21-0.26 (m, 2 H)



2-carboxamide


730
N-{4-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.89 (s, 1

(ESI(+))



[methyl(propyl)carbamoyl]phenyl}-
H) 8.79 (d, J = 6.10 Hz, 1 H) 8.04 (d, J = 5.80 Hz, 1 H)
m/e 339



1,3-
7.57-7.64 (m, 2 H) 7.25-7.38 (m, 2 H) 5.01 (d,
(M + H)+



dihydro-2H-
J = 32.04 Hz, 4 H) 3.17-3.45 (m, 2 H) 2.93 (s, 3 H)



pyrrolo[3,4-c]pyridine-
1.53 (d, J = 7.32 Hz, 2 H) 0.64-0.97 (m, 3 H)



2-carboxamide


731
N-[4-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.90 (s, 1 H)

(ESI(+))



(isobutylcarbamoyl)phenyl]-
8.79 (d, J = 5.80 Hz, 1 H) 8.04 (d, J = 5.80 Hz, 1 H)
m/e 339



1,3-dihydro-2H-
7.77-7.81 (m, 2 H) 7.60-7.65 (m, 2 H) 5.02 (d, J = 31.73 Hz,
(M + H)+



pyrrolo[3,4-c]pyridine-
4 H) 3.08 (d, J = 7.02 Hz, 2 H) 1.79-1.89 (m, 1 H)



2-carboxamide
0.89 (d, J = 6.71 Hz, 6 H)


732
N-[4-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.84 (s, 1 H)

(ESI(+))



(butylcarbamoyl)phenyl]-
8.74 (d, J = 5.80 Hz, 1 H) 7.94 (d, J = 5.80 Hz, 1 H)
m/e 339



1,3-dihydro-2H-
7.76-7.79 (m, 2 H) 7.61-7.65 (m, 2 H) 4.98 (d, J = 24.41 Hz,
(M + H)+



pyrrolo[3,4-c]pyridine-
4 H) 3.25 (t, J = 7.02 Hz, 2 H) 1.46-1.55 (m, 2 H)



2-carboxamide
1.28-1.38 (m, 2 H) 0.90 (t, J = 7.32 Hz, 3 H)


733
N-{4-[(2-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.88 (s, 1 H)

(ESI(+))



methoxyethyl)carbamoyl]phenyl}-
8.78 (d, J = 5.80 Hz, 1 H) 8.02 (d, J = 5.80 Hz, 1 H)
m/e 341



1,3-
7.77-7.81 (m, 2 H) 7.60-7.65 (m, 2 H) 5.01 (d, J = 29.90 Hz,
(M + H)+



dihydro-2H-
4 H) 3.40-3.50 (m, 4 H) 3.27 (s, 3 H)



pyrrolo[3,4-c]pyridine-



2-carboxamide


734
N-[4-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.89 (s, 1

(ESI(+))



(cyclopentylcarbamoyl)phenyl]-
H) 8.79 (d, J = 5.80 Hz, 1 H) 8.03 (d, J = 6.10 Hz, 1 H)
m/e 351



1,3-dihydro-
7.77-7.81 (m, 2 H) 7.60-7.65 (m, 2 H) 5.01 (d,
(M + H)+



2H-pyrrolo[3,4-
J = 31.43 Hz, 4 H) 4.14-4.25 (m, 1 H) 1.82-1.99 (m,



c]pyridine-2-
2 H) 1.64-1.78 (m, 2 H) 1.47-1.58 (m, 4 H)



carboxamide


735
N-{4-[(3R)-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.90 (s, 1 H)

(ESI(+))



tetrahydrofuran-3-
8.80 (d, J = 6.10 Hz, 1 H) 8.05 (d, J = 6.10 Hz, 1 H)
m/e 353



ylcarbamoyl]phenyl}-
7.79-7.83 (m, 2 H) 7.61-7.67 (m, 2 H) 5.02 (d, J = 32.65 Hz,
(M + H)+



1,3-dihydro-2H-
4 H) 4.39-4.50 (m, 1 H) 3.85-3.90 (m, 2 H)



pyrrolo[3,4-c]pyridine-
3.70-3.76 (m, 1 H) 3.58 (dd, J = 8.85, 4.27 Hz, 1 H)



2-carboxamide
2.11-2.23 (m, 1 H) 1.89-1.97 (m, 1 H)


736
N-{4-[(2-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.90 (s, 1 H)

(ESI(+))



methoxyethyl)(methyl)carbamoyl]phenyl}-
8.79 (d, J = 6.10 Hz, 1 H) 8.04 (d, J = 5.80 Hz, 1 H)
m/e 355



1,3-dihydro-2H-
7.60 (d, J = 8.54 Hz, 2 H) 7.34 (d, J = 8.54 Hz, 2 H) 5.01 (d,
(M + H)+



pyrrolo[3,4-c]pyridine-
J = 31.73 Hz, 4 H) 3.51 (d, J = 66.52 Hz, 4 H)



2-carboxamide
3.15-3.34 (m, 3 H) 2.94-3.02 (m, 3 H)


737
N-{4-[(1-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.89 (s, 1 H)

(ESI(+))



methoxypropan-2-
8.79 (d, J = 5.49 Hz, 1 H) 8.03 (d, J = 6.10 Hz, 1 H)
m/e 355



yl)carbamoyl]phenyl}-
7.77-7.81 (m, 2 H) 7.61-7.65 (m, 2 H) 5.02 (d, J = 31.12 Hz,
(M + H)+



1,3-dihydro-2H-
4 H) 4.15-4.23 (m, 1 H) 3.42 (dd, J = 9.61, 6.56 Hz,



pyrrolo[3,4-c]pyridine-
1 H) 3.30 (dd, J = 9.61, 5.95 Hz, 1 H) 3.27 (s, 3 H)



2-carboxamide
1.14 (d, J = 6.71 Hz, 3 H)


738
N-{4-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.88 (s, 1 H)

(ESI(+))



[(cyclopentylmethyl)carbamoyl]phenyl}-
8.78 (d, J = 5.80 Hz, 1 H) 8.01 (d, J = 5.80 Hz, 1 H)
m/e 365



1,3-
7.74-7.80 (m, 2 H) 7.60-7.66 (m, 2 H) 5.01 (d, J = 29.29 Hz,
(M + H)+



dihydro-2H-
4 H) 3.18 (d, J = 7.32 Hz, 2 H) 2.08-2.21 (m, 1 H)



pyrrolo[3,4-c]pyridine-
1.45-1.72 (m, 6 H) 1.21-1.29 (m, 2 H)



2-carboxamide


739
N-{4-[(2-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.86 (s, 1 H)

(ESI(+))



thienylmethyl)carbamoyl]phenyl}-
8.76 (d, J = 5.80 Hz, 1 H) 7.98 (d, J = 5.80 Hz, 1 H)
m/e 379



1,3-
7.79-7.85 (m, 2 H) 7.63-7.68 (m, 2 H) 7.37 (dd, J = 5.19,
(M + H)+



dihydro-2H-
1.22 Hz, 1 H) 7.03 (dd, J = 3.36, 1.22 Hz, 1 H)



pyrrolo[3,4-c]pyridine-
6.97 (dd, J = 5.19, 3.36 Hz, 1 H) 5.00 (d, J = 27.16 Hz, 4 H)



2-carboxamide
4.62 (s, 2 H)


740
N-{4-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.89 (s, 1 H)

(ESI(+))



[methyl(tetrahydrofuran-
8.78 (d, J = 5.80 Hz, 1 H) 8.02 (d, J = 5.80 Hz, 1 H)
m/e 381



2-
7.60 (d, J = 8.54 Hz, 2 H) 7.34 (d, J = 4.58 Hz, 2 H) 5.01 (d,
(M + H)+



ylmethyl)carbamoyl]phenyl}-
J = 30.21 Hz, 4 H) 3.93-4.23 (m, 2 H) 3.17-3.72 (m,



1,3-dihydro-
3 H) 3.00 (s, 3 H) 1.18-2.07 (m, 4 H)



2H-pyrrolo[3,4-



c]pyridine-2-



carboxamide


741
N-{4-[(3-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.89 (s, 1 H)

(ESI(+))



isopropoxypropyl)carbamoyl]phenyl}-
8.79 (d, J = 6.10 Hz, 1 H) 8.03 (d, J = 5.80 Hz, 1 H)
m/e 383



1,3-
7.75-7.79 (m, 2 H) 7.61-7.67 (m, 2 H) 5.01 (d, J = 31.43 Hz,
(M + H)+



dihydro-2H-
4 H) 3.50-3.57 (m, 1 H) 3.42 (t, J = 6.26 Hz, 2 H)



pyrrolo[3,4-c]pyridine-
3.31 (t, J = 7.02 Hz, 2 H) 1.69-1.78 (m, 2 H) 1.09 (d,



2-carboxamide
J = 6.10 Hz, 6 H)


742
N-{4-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.89 (s, 1 H)

(ESI(+))



[benzyl(methyl)carbamoyl]phenyl}-
8.78 (d, J = 5.80 Hz, 1 H) 8.03 (d, J = 5.80 Hz, 1 H)
m/e 387



1,3-
7.61 (s, 2 H) 7.12-7.47 (m, 7 H) 5.00 (d, J = 31.12 Hz, 4 H)
(M + H)+



dihydro-2H-
4.49-4.74 (m, 2 H) 2.89 (s, 3 H)



pyrrolo[3,4-c]pyridine-



2-carboxamide


743
N-{4-[(3-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.84 (s, 1

(ESI(+))



aminobenzyl)carbamoyl]phenyl}-
H) 8.73 (d, J = 5.80 Hz, 1 H) 7.92 (d, J = 5.80 Hz, 1 H)
m/e 386



1,3-
7.83-7.86 (m, 2 H) 7.64-7.68 (m, 2 H) 7.43 (t,
(M + H)+



dihydro-2H-
J = 7.78 Hz, 1 H) 7.30 (d, J = 7.93 Hz, 1 H) 7.21 (s, 1 H)



pyrrolo[3,4-c]pyridine-
7.13-7.16 (m, 1 H) 4.98 (d, J = 23.19 Hz, 4 H) 4.49 (s,



2-carboxamide
2 H)


744
N-{4-[(6-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.88 (s, 1 H)

(ESI(+))



methoxypyridin-3-
8.77 (d, J = 5.80 Hz, 1 H) 8.48 (d, J = 2.44 Hz, 1 H)
m/e 390



yl)carbamoyl]phenyl}-
7.98-8.07 (m, 2 H) 7.89-7.95 (m, 2 H) 7.69-7.74 (m, 2
(M + H)+



1,3-dihydro-2H-
H) 6.87 (d, J = 8.85 Hz, 1 H) 5.02 (d, J = 29.29 Hz, 4 H)



pyrrolo[3,4-c]pyridine-
3.83-3.88 (m, 3 H)



2-carboxamide


745
N-{4-[(3-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.87 (s, 1 H)

(ESI(+))



isobutoxypropyl)carbamoyl]phenyl}-
8.76 (d, J = 5.80 Hz, 1 H) 7.99 (d, J = 5.80 Hz, 1 H)
m/e 397



1,3-
7.74-7.80 (m, 2 H) 7.61-7.66 (m, 2 H) 5.00 (d, J = 28.07 Hz,
(M + H)+



dihydro-2H-
4 H) 3.43 (t, J = 6.26 Hz, 2 H) 3.31 (t, J = 7.02 Hz, 2



pyrrolo[3,4-c]pyridine-
H) 3.15 (d, J = 6.71 Hz, 2 H) 1.71-1.81 (m, 3 H)



2-carboxamide
0.86 (d, J = 6.71 Hz, 6 H)


746
N-{4-[bis(2-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.88 (s, 1 H)

(ESI(+))



methoxyethyl)carbamoyl]phenyl}-
8.78 (d, J = 5.80 Hz, 1 H) 8.02 (d, J = 6.10 Hz, 1 H)
m/e 399



1,3-
7.57-7.61 (m, 2 H) 7.29-7.33 (m, 2 H) 5.00 (d, J = 30.82 Hz,
(M + H)+



dihydro-2H-
4 H) 3.34-3.58 (m, 8 H) 3.12-3.32 (m, 6 H)



pyrrolo[3,4-c]pyridine-



2-carboxamide


747
N-{4-[(4-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.84 (s, 1 H)

(ESI(+))



methoxybenzyl)carbamoyl]phenyl}-
8.74 (d, J = 5.80 Hz, 1 H) 7.93 (d, J = 5.80 Hz, 1 H)
m/e 403



1,3-
7.79-7.83 (m, 2 H) 7.62-7.66 (m, 2 H) 7.23-7.30 (m, 2
(M + H)+



dihydro-2H-
H) 6.86-6.93 (m, 2 H) 4.98 (d, J = 24.11 Hz, 4 H)



pyrrolo[3,4-c]pyridine-
4.40 (s, 2 H) 3.73 (s, 3 H)



2-carboxamide


748
N-{4-[(3-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.87 (s, 1 H)

(ESI(+))



methoxybenzyl)carbamoyl]phenyl}-
8.77 (d, J = 5.80 Hz, 1 H) 8.00 (d, J = 6.10 Hz, 1 H)
m/e 403



1,3-
7.81-7.86 (m, 2 H) 7.63-7.68 (m, 2 H) 7.26 (t, J = 7.93 Hz,
(M + H)+



dihydro-2H-
1 H) 6.80-6.92 (m, 3 H) 5.01 (d, J = 28.99 Hz, 4 H)



pyrrolo[3,4-c]pyridine-
4.44 (s, 2 H) 3.74 (s, 3 H)



2-carboxamide


749
N-(4-{[4-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.88 (s, 1 H)

(ESI(+))



(trifluoromethyl)piperidin-
8.78 (d, J = 6.10 Hz, 1 H) 8.02 (d, J = 6.10 Hz, 1 H)
m/e 419



1-
7.59-7.65 (m, 2 H) 7.32-7.38 (m, 2 H) 5.01 (d, J = 30.51 Hz,
(M + H)+



yl]carbonyl}phenyl)-
4 H) 4.55 (d, J = 47.91 Hz, 2 H) 2.75-3.24 (m, 2



1,3-dihydro-2H-
H) 2.59-2.68 (m, 1 H) 1.87 (s, 2 H) 1.34-1.49 (m, 2



pyrrolo[3,4-c]pyridine-
H)



2-carboxamide


750
N-(4-{[4-(pyrazin-2-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.90 (s, 1 H)

(ESI(+))



yl)piperazin-1-
8.79 (d, J = 5.80 Hz, 1 H) 8.32 (d, J = 1.22 Hz, 1 H)
m/e 430



yl]carbonyl}phenyl)-
8.13 (dd, J = 2.59, 1.37 Hz, 1 H) 8.05 (d, J = 5.80 Hz, 1 H)
(M + H)+



1,3-dihydro-2H-
7.88 (d, J = 2.75 Hz, 1 H) 7.61-7.68 (m, 2 H)



pyrrolo[3,4-c]pyridine-
7.38-7.45 (m, 2 H) 5.02 (d, J = 32.34 Hz, 4 H)



2-carboxamide
3.44-3.76 (m, 8 H)


751
N-{4-[(4-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.88 (s, 1 H)

(ESI(+))



cyclohexylpiperazin-1-
8.78 (d, J = 6.10 Hz, 1 H) 8.01 (d, J = 6.10 Hz, 1 H)
m/e 434



yl)carbonyl]phenyl}-
7.57-7.69 (m, 2 H) 7.36-7.49 (m, 2 H) 5.01 (d, J = 29.29 Hz,
(M + H)+



1,3-dihydro-2H-
4 H) 3.96 (s, 1 H) 3.23-3.67 (m, 4 H)



pyrrolo[3,4-c]pyridine-
2.98-3.27 (m, 4 H) 1.04-2.15 (m, 10 H)



2-carboxamide


752
N-(4-{[2-(3,4-

1H NMR (500 MHz, DMSO-D2O) δ ppm 8.88 (s, 1 H)

(ESI(+))



dimethoxyphenyl)ethyl]carbamoyl}phenyl)-
8.77 (d, J = 5.80 Hz, 1 H) 8.01 (d, J = 6.10 Hz, 1 H)
m/e 447



1,3-dihydro-2H-
7.73-7.80 (m, 2 H) 7.58-7.68 (m, 2 H) 6.84-6.89 (m, 2
(M + H)+



pyrrolo[3,4-c]pyridine-
H) 6.77 (dd, J = 8.09, 1.98 Hz, 1 H) 5.01 (d, J = 29.90 Hz,



2-carboxamide
4 H) 3.96 (s, 1 H) 3.70-3.73 (m, 6 H) 3.46 (t,




J = 7.32 Hz, 2 H) 2.78 (t, J = 7.32 Hz, 2 H)


770
N-(4-{[3-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ ppm

(ESI(+))



(dimethylamino)propyl]carbamoyl}phenyl)-
8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H) 7.70-7.78 (m, 2
m/e 368



1,3-dihydro-2H-
H) 7.57-7.65 (m, 2 H) 7.41 (d, J = 4.88 Hz, 1 H)
(M + H)+



pyrrolo[3,4-c]pyridine-
4.80-4.87 (m, 4 H) 3.30-3.34 (m, 2 H) 2.28-2.40 (m, 2 H)



2-carboxamide
2.17-2.21 (m, 6 H) 1.61-1.75 (m, 2 H)


771
N-(4-{[3-(morpholin-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ ppm

(ESI(+))



4-
8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H) 7.69-7.79 (m, 2
m/e 410



yl)propyl]carbamoyl}phenyl)-
H) 7.57-7.64 (m, 2 H) 7.41 (d, J = 5.19 Hz, 1 H)
(M + H)+



1,3-dihydro-
4.80-4.87 (m, 4 H) 3.54-3.62 (m, 4 H) 3.31-3.34 (m, 2 H)



2H-pyrrolo[3,4-
2.34-2.42 (m, 6 H) 1.65-1.76 (m, 2 H)



c]pyridine-2-



carboxamide


772
N-(4-{[4-(2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ ppm

(ESI(+))



aminoethyl)-1H-
8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H) 7.71-7.76 (m, 2
m/e 377



imidazol-1-
H) 7.57-7.66 (m, 2 H) 7.52 (s, 1 H) 7.41 (d, J = 5.19 Hz,
(M + H)+



yl]carbonyl}phenyl)-
1 H) 6.82 (s, 1 H) 4.78-4.86 (m, 4 H) 3.51 (t,



1,3-dihydro-2H-
J = 7.32 Hz, 2 H) 2.80 (t, J = 7.02 Hz, 2 H)



pyrrolo[3,4-c]pyridine-



2-carboxamide


773
N-[4-({4-[2-(2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ ppm

(ESI(+))



hydroxyethoxy)ethyl]piperazin-
8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H) 7.56-7.62 (m, 2
m/e 440



1-
H) 7.41 (d, J = 5.19 Hz, 1 H) 7.27-7.33 (m, 2 H)
(M + H)+



yl}carbonyl)phenyl]-
4.79-4.87 (m, 4 H) 3.40-3.60 (m, 10 H) 2.53-2.57 (m, 2



1,3-dihydro-2H-
H) 2.43-2.50 (m, 4 H)



pyrrolo[3,4-c]pyridine-



2-carboxamide


774
N-{4-[(3-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ ppm

(ESI(+))



hydroxypropyl)carbamoyl]phenyl}-
8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H) 7.71-7.78 (m, 2
m/e 341



1,3-
H) 7.58-7.63 (m, 2 H) 7.41 (d, J = 5.19 Hz, 1 H)
(M + H)+



dihydro-2H-
4.78-4.89 (m, 4 H) 3.51 (t, J = 6.26 Hz, 2 H) 3.34 (t, J = 6.87 Hz,



pyrrolo[3,4-c]pyridine-
2 H) 1.65-1.79 (m, 2 H)



2-carboxamide


775
N-(4-{[4-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ ppm

(ESI(+))



(dimethylamino)butyl]carbamoyl}phenyl)-
8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H) 7.71-7.77 (m, 2
m/e 382



1,3-dihydro-2H-
H) 7.58-7.64 (m, 2 H) 7.42 (d, J = 4.88 Hz, 1 H)
(M + H)+



pyrrolo[3,4-c]pyridine-
4.79-4.88 (m, 4 H) 3.27 (t, J = 6.87 Hz, 2 H) 2.26-2.33 (m,



2-carboxamide
2 H) 2.16 (s, 6 H) 1.41-1.61 (m, 4 H)


776
N-{4-[(pyridin-4-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(ESI(+))



ylmethyl)carbamoyl]phenyl}-
ppm 8.59 (s, 1 H) 8.46-8.50 (m, 3 H) 7.79-7.84 (m,
m/e 374



1,3-dihydro-
2 H) 7.62-7.67 (m, 2 H) 7.42 (d, J = 4.88 Hz, 1 H)
(M + H)+



2H-pyrrolo[3,4-
7.31 (d, J = 6.10 Hz, 2 H) 4.84 (d, J = 7.02 Hz, 4 H)



c]pyridine-2-
4.49 (s, 2 H)



carboxamide


777
N-{4-[(pyridin-3-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ ppm

(ESI(+))



ylmethyl)carbamoyl]phenyl}-
8.58 (s, 1 H) 8.54 (d, J = 1.83 Hz, 1 H) 8.48 (d, J = 5.19 Hz,
m/e 374



1,3-dihydro-
1 H) 8.43 (dd, J = 4.88, 1.53 Hz, 1 H)
(M + H)+



2H-pyrrolo[3,4-
7.77-7.82 (m, 2 H) 7.71-7.75 (m, 1 H) 7.60-7.66 (m, 2 H)



c]pyridine-2-
7.41 (d, J = 5.19 Hz, 1 H) 7.34 (dd, J = 7.93, 5.49 Hz, 1 H)



carboxamide
4.79-4.88 (m, 4 H) 4.44-4.53 (m, 2 H)


778
N-{4-[(pyrimidin-4-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ ppm

(ESI(+))



ylmethyl)carbamoyl]phenyl}-
9.07 (d, J = 1.22 Hz, 1 H) 8.70 (d, J = 5.19 Hz, 1 H)
m/e 375



1,3-dihydro-
8.59 (s, 1 H) 8.49 (d, J = 4.88 Hz, 1 H) 7.79-7.86 (m, 2 H)
(M + H)+



2H-pyrrolo[3,4-
7.63-7.68 (m, 2 H) 7.39-7.45 (m, 2 H)



c]pyridine-2-
4.81-4.87 (m, 4 H) 4.56 (s, 2 H)



carboxamide


779
N-(4-{[2-(pyridin-3-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ ppm

(ESI(+))



yl)ethyl]carbamoyl}phenyl)-
8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H) 8.45 (d, J = 2.14 Hz,
m/e 388



1,3-dihydro-2H-
1 H) 8.39 (dd, J = 4.73, 1.68 Hz, 1 H)
(M + H)+



pyrrolo[3,4-c]pyridine-
7.69-7.73 (m, 2 H) 7.64-7.68 (m, 1 H) 7.58-7.62 (m, 2 H)



2-carboxamide
7.42 (d, J = 4.88 Hz, 1 H) 7.30 (dd, J = 7.93, 4.88 Hz, 1 H)




4.81-4.85 (m, 4 H) 3.52-3.57 (m, 2 H)




2.87-2.92 (m, 2 H)


780
N-(4-{[2-(4-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ ppm

(ESI(+))



methylpiperazin-1-
8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H) 7.71-7.75 (m, 2
m/e 409



yl)ethyl]carbamoyl}phenyl)-
H) 7.58-7.63 (m, 2 H) 7.41 (d, J = 4.88 Hz, 1 H)
(M + H)+



1,3-dihydro-2H-
4.81-4.86 (m, 4 H) 3.38 (t, J = 6.87 Hz, 2 H) 2.44-2.50 (m,



pyrrolo[3,4-c]pyridine-
6 H) 2.33-2.37 (m, 4 H) 2.16 (s, 3 H)



2-carboxamide


803
N-(4-{[(3-

1H NMR (300 MHz, DMSO-d6) δ 8.66 (s, 1H),

(ESI(+))



methyloxetan-3-
8.61 (s, 1H), 8.51 (d, J = 5.0 Hz, 1H), 8.44 (t, J = 6.1 Hz,
m/e 367



yl)methyl]carbamoyl}phenyl)-
1H), 7.84-7.76 (m, 2H), 7.71-7.63 (m, 2H), 7.44 (d,
(M + H)+



1,3-dihydro-
J = 5.1 Hz, 1H), 4.87-4.80 (m, 4H), 4.48 (d, J = 5.7 Hz,



2H-pyrrolo[3,4-
2H), 4.20 (d, J = 5.7 Hz, 2H), 3.49-3.39 (m, 2H),



c]pyridine-2-
1.25 (s, 3H)



carboxamide


875
N-(4-{[(1,1-

1H NMR (300 MHz, DMSO-d6) δ 8.72-8.56 (m, 2H),

(ESI(+))



dioxidotetrahydrothiophen-
8.55-8.37 (m, 2H), 7.78 (d, J = 8.8 Hz, 2H), 7.67 (d,
m/e 415



3-
J = 8.8 Hz, 2H), 7.43 (t, J = 5.6 Hz, 1H), 4.83 (d, J = 4.3 Hz,
(M + H)+



yl)methyl]carbamoyl}phenyl)-
4H), 3.50-3.29 (m, 1H), 3.27-2.99 (m, 3H),



1,3-dihydro-
2.88 (dt, J = 13.1, 7.2 Hz, 1H), 2.78-2.58 (m, 1H),



2H-pyrrolo[3,4-
2.33-2.11 (m, 1H), 1.97-1.72 (m, 1H)



c]pyridine-2-



carboxamide


880
N-{4-[(pyrrolidin-3-

1H NMR (300 MHz, DMSO-d6) δ 9.08 (s, 2H),

(ESI(+))



ylmethyl)carbamoyl]phenyl}-
8.93 (d, J = 15.5 Hz, 2H), 8.82 (d, J = 5.8 Hz, 1H), 8.54 (t,
m/e 366



1,3-dihydro-
J = 5.8 Hz, 1H), 8.02 (d, J = 5.8 Hz, 1H), 7.81 (d, J = 8.6 Hz,
(M + H)+



2H-pyrrolo[3,4-
2H), 7.68 (d, J = 8.6 Hz, 2H), 5.06-4.95 (m,



c]pyridine-2-
4H), 3.73-3.63 (m, 1H), 3.47-3.05 (m, 4H),



carboxamide
3.02-2.80 (m, 1H), 2.07-1.92 (m, 1H), 1.67 (dq, J = 12.8,




8.1 Hz, 1H)


881
N-(4-{[(3S)-

1H NMR (300 MHz, DMSO-d6) δ 9.09 (s, 1H),

(ESI(+))



pyrrolidin-3-
8.93 (d, J = 15.5 Hz, 1H), 8.82 (d, J = 5.8 Hz, 1H), 8.54 (t,
m/e 366



ylmethyl]carbamoyl}phenyl)-
J = 5.8 Hz, 1H), 8.03 (d, J = 5.8 Hz, 1H), 7.81 (d, J = 8.8 Hz,
(M + H)+



1,3-dihydro-
2H), 7.67 (d, J = 8.9 Hz, 2H), 5.00 (d, J = 19.2 Hz,



2H-pyrrolo[3,4-
4H), 3.69 (dq, J = 5.9, 4.4 Hz, 1H),



c]pyridine-2-
3.52-3.44 (m, 1H), 3.35-3.07 (m, 4H), 2.90 (td, J = 13.7, 6.2 Hz,



carboxamide
1H), 2.27 (s, 1H), 2.00 (td, J = 12.8, 7.4 Hz, 1H),




1.66 (dq, J = 16.3, 8.2 Hz, 1H)


882
N-(4-{[(1-

1H NMR (300 MHz, DMSO-d6) δ 9.59 (s, 1H),

(ESI(+))



methylpyrrolidin-3-
8.35 (s, 1H), 7.56-7.49 (m, 2H), 7.41-7.23 (m, 5H),
m/e 380



yl)methyl]carbamoyl}phenyl)-
7.13 (s, 1H), 7.10 (s, 1H), 6.92 (dd, J = 8.3, 2.6 Hz, 1H),
(M + H)+



1,3-dihydro-
6.89-6.79 (m, 2H), 4.76 (s, 4H), 4.36 (s, 2H), 3.73 (s,



2H-pyrrolo[3,4-
3H)



c]pyridine-2-



carboxamide


884
N-(4-{[(1-

1H NMR (300 MHz, DMSO-d6) δ 8.66-8.59 (m, 2H),

(ESI(+))



methylpiperidin-4-
8.50 (d, J = 5.0 Hz, 1H), 8.26 (t, J = 5.8 Hz, 1H),
m/e 394



yl)methyl]carbamoyl}phenyl)-
7.81-7.73 (m, 2H), 7.68-7.61 (m, 2H), 7.44 (d, J = 5.1 Hz,
(M + H)+



1,3-dihydro-
1H), 4.86-4.75 (m, 4H), 3.12 (t, J = 6.2 Hz, 2H),



2H-pyrrolo[3,4-
2.77-2.69 (m, 2H), 2.12 (s, 3H), 1.78 (td, J = 11.5,



c]pyridine-2-
2.4 Hz, 2H), 1.63 (dd, J = 12.5, 2.9 Hz, 2H),



carboxamide
1.54-1.40 (m, 1H), 1.25-1.08 (m, 2H)


922
N-[4-({[(3R)-1-

1H NMR (300 MHz, DMSO-d6) δ 8.66 (s, 1H),

(ESI(+))



isobutyrylpyrrolidin-3-
8.61 (s, 1H), 8.50 (d, J = 5.0 Hz, 1H), 8.41 (t, J = 5.3 Hz,
m/e 436



yl]methyl}carbamoyl)phenyl]-
1H), 7.82-7.74 (m, 2H), 7.70-7.62 (m, 2H), 7.44 (d,
(M + H)+



1,3-dihydro-
J = 5.1 Hz, 1H), 4.84-4.74 (m, 4H), 3.58 (dd, J = 17.0,



2H-pyrrolo[3,4-
9.7 Hz, 1H), 3.44 (dt, J = 22.7, 9.2 Hz, 1H),



c]pyridine-2-
3.28-2.93 (m, 2H), 2.64 (pd, J = 6.7, 3.2 Hz, 1H),



carboxamide
2.08-1.83 (m, 1H), 1.78-1.45 (m, 1H), 1.29-1.24 (m,




3H), 1.08-0.91 (m, 6H)


923
N-[4-({[(3R)-1-

1H NMR (300 MHz, DMSO-d6) δ 8.68-8.59 (m, 2H),

(ESI(+))



benzoylpyrrolidin-3-
8.49 (t, J = 5.1 Hz, 1H), 8.47-8.41 (m, 1H),
m/e 470



yl]methyl}carbamoyl)phenyl]-
8.40-8.28 (m, 1H), 7.85-7.76 (m, 1H), 7.76-7.58 (m,
(M + H)+



1,3-dihydro-
3H), 7.54-7.46 (m, 2H), 7.42 (t, J = 7.6 Hz, 3H),



2H-pyrrolo[3,4-
4.80 (d, J = 15.4 Hz, 4H), 3.68-3.55 (m, 1H),



c]pyridine-2-
3.53-3.36 (m, 1H), 3.20 (ddd, J = 9.8, 7.1, 5.7 Hz, 1H),



carboxamide
2.06-1.87 (m, 2H), 1.76-1.58 (m, 2H), 1.31-1.18 (m,




2H)


924
N-[4-({[1-

1H NMR (300 MHz, DMSO-d6) δ 8.63 (d, J = 12.1 Hz,

(ESI(+))



(tetrahydrofuran-3-
2H), 8.50 (d, J = 5.0 Hz, 1H), 8.41 (s, 1H),
m/e 464



ylcarbonyl)pyrrolidin-
7.78 (d, J = 8.8 Hz, 2H), 7.66 (d, J = 8.1 Hz, 2H), 7.44 (d, J = 5.0 Hz,
(M + H)+



3-
1H), 4.83 (d, J = 4.3 Hz, 4H), 3.88 (t, J = 8.1 Hz,



yl]methyl}carbamoyl)phenyl]-
1H), 3.77-3.59 (m, 4H), 3.52-3.40 (m, 1H),



1,3-dihydro-
3.27-3.06 (m, 2H), 2.40 (dd, J = 13.9, 6.8 Hz, 1H),



2H-pyrrolo[3,4-
2.07-1.90 (m, 3H), 1.78-1.55 (m, 1H), 1.23 (dd, J = 9.7,



c]pyridine-2-
6.6 Hz, 1H)



carboxamide


925
N-[4-({[1-

1H NMR (300 MHz, DMSO-d6) δ 8.66 (s, 1H),

(ESI(+))



(methylsulfonyl)pyrrolidin-
8.62 (s, 1H), 8.51 (d, J = 5.0 Hz, 1H), 8.42 (t, J = 5.7 Hz,
m/e 444



3-
1H), 7.82-7.74 (m, 2H), 7.70-7.63 (m, 2H), 7.44 (d,
(M + H)+



yl]methyl}carbamoyl)phenyl]-
J = 5.1 Hz, 1H), 4.86-4.79 (m, 4H), 3.25-3.11 (m,



1,3-dihydro-
2H), 3.02 (dd, J = 10.0, 6.7 Hz, 1H), 2.90 (s, 3H),



2H-pyrrolo[3,4-
2.06-1.89 (m, 2H), 1.75-1.59 (m, 2H), 1.28-1.20 (m,



c]pyridine-2-
2H)



carboxamide


939
N-[4-({[1-(morpholin-

1H NMR (300 MHz, DMSO-d6) δ 9.35 (s, 1H),

(ESI(+))



4-
8.77 (s, 1H), 8.72 (s, 1H), 8.60 (d, J = 5.3 Hz, 2H), 7.84 (d,
m/e 451



yl)cyclopentyl]methyl}carbamoyl)phenyl]-
J = 8.8 Hz, 2H), 7.71 (d, J = 8.8 Hz, 2H), 7.61 (d, J = 5.2 Hz,
(M + H)+



1,3-dihydro-2H-
1H), 4.88 (s, 4H), 4.03 (d, J = 11.7 Hz, 3H),



pyrrolo[3,4-c]pyridine-
3.79-3.57 (m, 5H), 3.51 (d, J = 11.5 Hz, 2H),



2-carboxamide
3.38 (d, J = 9.6 Hz, 2H), 1.95 (d, J = 6.9 Hz, 4H), 1.74 (s,




4H)


969
N-(4-{[(1S)-1-(4-

1H NMR (300 MHz, DMSO-d6) δ 8.66 (s, 1H),

(ESI(+))



fluorophenyl)-2-
8.62 (s, 1H), 8.50 (d, J = 9.6 Hz, 2H), 7.87-7.80 (m, 2H),
m/e 421



hydroxyethyl]carbamoyl}phenyl)-
7.71-7.64 (m, 2H), 7.47-7.38 (m, 3H), 7.14 (t, J = 8.7 Hz,
(M + H)+



1,3-
2H), 5.12-5.00 (m, 1H), 4.91 (t, J = 5.8 Hz,



dihydro-2H-
1H), 4.83 (d, J = 4.4 Hz, 4H), 3.76-3.57 (m, 2H)



pyrrolo[3,4-c]pyridine-



2-carboxamide


970
N-(4-{[(1S)-2-

1H NMR (300 MHz, DMSO-d6) δ 8.63 (d, J = 10.4 Hz,

(ESI(+))



hydroxy-1-(4-
2H), 8.49 (t, J = 7.8 Hz, 1H), 8.41 (d, J = 8.2 Hz,
m/e 433



methoxyphenyl)ethyl]carbamoyl}phenyl)-
1H), 7.83 (d, J = 8.8 Hz, 2H), 7.67 (d, J = 8.8 Hz, 2H),
(M + H)+



1,3-
7.44 (d, J = 5.1 Hz, 1H), 7.36-7.25 (m, 2H),



dihydro-2H-
6.92-6.82 (m, 2H), 5.01 (dd, J = 13.7, 7.9 Hz, 1H), 4.84 (t, J = 5.7 Hz,



pyrrolo[3,4-c]pyridine-
4H), 3.72 (s, 3H), 3.70-3.57 (m, 3H)



2-carboxamide


971
N-[4-({[3-

1H NMR (300 MHz, DMSO-d6) δ 8.67 (s, 1H),

(ESI(+))



(hydroxymethyl)oxetan-
8.62 (s, 1H), 8.51 (d, J = 5.1 Hz, 1H), 8.49-8.41 (m, 1H),
m/e 383



3-
7.83-7.76 (m, 2H), 7.71-7.64 (m, 2H), 7.44 (d, J = 5.1 Hz,
(M + H)+



yl]methyl}carbamoyl)phenyl]-
1H), 4.93-4.86 (m, 1H), 4.84 (t, J = 7.0 Hz,



1,3-dihydro-
2H), 4.40 (d, J = 5.9 Hz, 2H), 4.29 (d, J = 5.8 Hz, 2H),



2H-pyrrolo[3,4-
3.58 (d, J = 5.6 Hz, 2H), 3.51 (d, J = 6.0 Hz, 2H)



c]pyridine-2-



carboxamide


972
N-(4-{[(1S)-1-(1,3-

1H NMR (300 MHz, DMSO-d6) δ 8.70-8.57 (m, 2H),

(ESI(+))



benzodioxol-5-yl)-2-
8.54-8.46 (m, 1H), 8.43-8.27 (m, 1H),
m/e 447



hydroxyethyl]carbamoyl}phenyl)-
7.87-7.77 (m, 2H), 7.67 (d, J = 8.8 Hz, 2H), 7.49-7.38 (m, 1H),
(M + H)+



1,3-
6.99 (s, 1H), 6.84 (d, J = 0.8 Hz, 2H), 5.96 (dd, J = 2.5,



dihydro-2H-
0.8 Hz, 2H), 5.04-4.94 (m, 1H), 4.89-4.75 (m,



pyrrolo[3,4-c]pyridine-
4H), 3.73-3.53 (m, 2H)



2-carboxamide


1055
N-[4-(1,7-

1H NMR (400 MHz, Pyridine-d5) δ ppm 8.44 (d, J = 20.6 Hz,

(ESI(+))



diazaspiro[4.4]non-7-
1H), 7.88 (t, J = 10.7 Hz, 3H),
m/e 392



ylcarbonyl)phenyl]-
7.69-7.57 (m, 3H), 4.22 (d, J = 12.3 Hz, 1H), 3.93 (dt, J = 11.3,
(M + H)+



1,3-dihydro-2H-
8.0 Hz, 2H), 3.83-3.64 (m, 3H), 3.59-3.46 (m, 3H),



pyrrolo[3,4-c]pyridine-
3.45-3.31 (m, 1H), 2.71-2.46 (m, 1H),



2-carboxamide
2.12-1.80 (m, 8H)


1056
N-[4-(2,7-

1H NMR (400 MHz, Pyridine-d5) δ ppm 8.55 (dd, J = 10.2,

(ESI(+))



diazaspiro[4.5]dec-2-
5.1 Hz, 2H), 7.99-7.83 (m, 2H), 7.70-7.61 (m,
m/e 406



ylcarbonyl)phenyl]-
2H), 7.10 (d, J = 4.9 Hz, 1H), 4.99-4.79 (m, 4H),
(M + H)+



1,3-dihydro-2H-
3.74-3.59 (m, 4H), 3.28-3.10 (m, 4H),



pyrrolo[3,4-c]pyridine-
2.13-1.91 (m, 1H), 1.91-1.72 (m, 2H), 1.71-1.60 (m, 1H),



2-carboxamide
1.64-1.45 (m, 2H)


1057
N-[4-(2,6-

1H NMR (400 MHz, Pyridine-d5) δ ppm

(ESI(+))



diazaspiro[4.5]dec-2-
8.58-8.47 (m, 2H), 7.85 (t, J = 24.8 Hz, 2H), 7.67-7.57 (m,
m/e 406



ylcarbonyl)phenyl]-
2H), 7.10 (d, J = 4.9 Hz, 1H), 4.91-4.74 (m, 4H),
(M + H)+



1,3-dihydro-2H-
4.30 (d, J = 12.6 Hz, 1H), 3.98-3.72 (m, 2H),



pyrrolo[3,4-c]pyridine-
3.68-3.58 (m, 1H), 3.27-3.05 (m, 2H), 2.61-2.45 (m,



2-carboxamide
1H), 2.16-1.92 (m, 1H), 1.92-1.77 (m, 2H),




1.72-1.19 (m, 4H)


1058
N-[4-(2,7-

1H NMR (400 MHz, Pyridine-d5) δ ppm

(ESI(+))



diazaspiro[4.5]dec-7-
8.60-8.49 (m, 2H), 8.09-7.83 (m, 2H), 7.53-7.42 (m, 3H),
m/e 406



ylcarbonyl)phenyl]-
5.06-4.76 (m, 4H), 3.78-3.57 (m, 3H),
(M + H)+



1,3-dihydro-2H-
3.48-3.23 (m, 4H), 2.08-1.91 (m, 1H), 1.91-1.76 (m, 1H),



pyrrolo[3,4-c]pyridine-
1.76-1.65 (m, 1H), 1.61 (dt, J = 23.9, 13.1 Hz, 1H),



2-carboxamide
1.56-1.34 (m, 2H)


1059
N-[4-(2,9-

1H NMR (400 MHz, Pyridine-d5) δ ppm

(ESI(+))



diazaspiro[5.5]undec-
8.62-8.46 (m, 2H), 7.85 (dd, J = 43.4, 8.8 Hz, 2H),
m/e 420



2-ylcarbonyl)phenyl]-
7.52-7.43 (m, 2H), 7.10 (d, J = 4.9 Hz, 1H), 3.90-3.70 (m,
(M + H)+



1,3-dihydro-2H-
1H), 3.60-3.43 (m, 3H), 3.41-3.25 (m, 1H),



pyrrolo[3,4-c]pyridine-
3.24-3.03 (m, 4H), 1.89-1.56 (m, 4H), 1.54-1.31 (m, 4H)



2-carboxamide


1060
N-[4-(2,8-

1H NMR (400 MHz, Pyridine-d5) δ ppm 8.56 (dd, J = 9.9,

(ESI(+))



diazaspiro[5.5]undec-
4.6 Hz, 2H), 8.12-7.80 (m, 2H), 7.52-7.43 (m,
m/e 420



2-ylcarbonyl)phenyl]-
3H), 4.90-4.83 (m, 6H), 3.67-3.55 (m, 2H),
(M + H)+



1,3-dihydro-2H-
3.49-3.37 (m, 2H), 3.41-3.23 (m, 4H), 1.99-1.61 (m,



pyrrolo[3,4-c]pyridine-
4H), 1.47 (d, J = 10.4 Hz, 4H)



2-carboxamide


1061
N-[4-(1,8-

1H NMR (400 MHz, Pyridine-d5) δ ppm

(ESI(+))



diazaspiro[5.5]undec-
8.60-8.44 (m, 2H), 7.86 (t, J = 25.2 Hz, 2H), 7.54 (t, J = 6.9 Hz,
m/e 420



8-ylcarbonyl)phenyl]-
2 H), 7.10 (d, J = 4.9 Hz, 1H), 4.14 (d, J = 13.5 Hz,
(M + H)+



1,3-dihydro-2H-
1H), 4.02 (d, J = 13.5 Hz, 1H), 3.59 (dd, J = 11.5, 6.5 Hz,



pyrrolo[3,4-c]pyridine-
1H), 3.48-3.33 (m, 1H), 3.36-3.13 (m, 2H),



2-carboxamide
2.23 (ddd, J = 13.3, 8.9, 4.3 Hz, 1H), 1.96-1.82 (m,




2H), 1.83-1.65 (m, 4H), 1.69-1.44 (m, 4H)


1062
N-[4-(1,8-

1H NMR (400 MHz, Pyridine-d5) δ ppm 8.50 (dd, J = 43.2,

(ESI(+))



diazaspiro[4.6]undec-
14.6 Hz, 2H), 7.98-7.82 (m, 2H),
m/e 420



8-ylcarbonyl)phenyl]-
7.52-7.41 (m, 2H), 7.10 (d, J = 4.9 Hz, 1H), 3.95-3.75 (m, 1H),
(M + H)+



1,3-dihydro-2H-
3.67 (d, J = 9.3 Hz, 2H), 3.51-3.37 (m, 6H),



pyrrolo[3,4-c]pyridine-
2.52-2.33 (m, 1H), 2.25-2.11 (m, 2H), 2.12-1.99 (m,



2-carboxamide
1H), 2.03-1.83 (m, 6H), 1.66 (d, J = 41.1 Hz, 1H)


1063
N-{4-[(1-oxa-8-

1H NMR (400 MHz, Pyridine-d5) δ ppm

(ESI(+))



azaspiro[4.5]dec-2-
8.61-8.44 (m, 2H), 8.18-8.03 (m, 2H), 7.98-7.81 (m, 2H),
m/e 436



ylmethyl)carbamoyl]phenyl}-
7.10 (d, J = 4.9 Hz, 1H) 4.89-4.79 (m, 6H), 4.28 (dt,
(M + H)+



1,3-dihydro-
J = 12.4, 6.2 Hz, 1H), 3.80-3.64 (m, 2H), 3.51 (s,



2H-pyrrolo[3,4-
1H), 3.45-3.25 (m, 4H), 2.12-1.89 (m, 2H),



c]pyridine-2-
1.87-1.48 (m, 4H)



carboxamide


1064
N-[4-(1-oxa-8-

1H NMR (400 MHz, Pyridine-d5) δ ppm 8.44 (d, J = 20.6 Hz,

(ESI(+))



azaspiro[4.5]dec-3-
1H), 7.88 (t, J = 10.7 Hz, 3H),
m/e 422



ylcarbamoyl)phenyl]-
7.69-7.57 (m, 3H), 4.22 (d, J = 12.3 Hz, 1H), 3.93 (dt, J = 11.3,
(M + H)+



1,3-dihydro-2H-
8.0 Hz, 2H), 3.83-3.64 (m, 3H), 3.59-3.46 (m, 3H),



pyrrolo[3,4-c]pyridine-
3.45-3.31 (m, 1H), 2.71-2.46 (m, 1H),



2-carboxamide
2.12-1.80 (m, 8H)


1065
N-{4-[(2-oxa-9-

1H NMR (400 MHz, Pyridine-d5) δ ppm

(ESI(+))



azaspiro[5.5]undec-3-
8.56-8.44 (m, 2H), 8.26-8.00 (m, 3H), 7.87 (dd, J = 40.3, 8.7 Hz,
m/e 450



ylmethyl)carbamoyl]phenyl}-
2H), 3.99-3.70 (m, 2H), 3.66-3.56 (m, 2H),
(M + H)+



1,3-dihydro-
3.51 (s, 1H), 3.35-3.16 (m, 4H), 3.10 (d, J = 11.5 Hz,



2H-pyrrolo[3,4-
1H), 2.09-1.82 (m, 2H), 1.83-1.68 (m, 1H),



c]pyridine-2-
1.61-1.36 (m, 4H), 1.33-1.05 (m, 1H)



carboxamide


1066
N-[4-(1-oxa-4,8-

1H NMR (400 MHz, Pyridine-d5) δ ppm

(ESI(+))



diazaspiro[5.5]undec-
8.62-8.46 (m, 2H), 7.86 (dd, J = 52.3, 8.6 Hz, 3H), 7.56 (d, J = 15.9 Hz,
m/e 422



4-ylcarbonyl)phenyl]-
2H), 4.94-4.73 (m, 5H), 3.81-3.52 (m,
(M + H)+



1,3-dihydro-2H-
6H), 3.37 (d, J = 12.4 Hz, 1H), 3.17-2.87 (m, 2H),



pyrrolo[3,4-c]pyridine-
2.13-1.83 (m, 2H), 1.63-1.24 (m, 2H)



2-carboxamide


1067
N-[4-(1,8-

1H NMR (400 MHz, Pyridine-d5) δ ppm

(ESI(+))



diazaspiro[4.5]dec-1-
8.59-8.45 (m, 2H), 7.96-7.80 (m, 2H), 7.59-7.52 (m, 2H),
m/e 406



ylcarbonyl)phenyl]-
7.10 (d, J = 4.9 Hz, 1H), 4.87 (d, J = 6.5 Hz, 6H),
(M + H)+



1,3-dihydro-2H-
3.54 (dt, J = 13.2, 4.8 Hz, 4H), 3.41 (dd, J = 9.0, 4.4 Hz,



pyrrolo[3,4-c]pyridine-
2H), 3.28-3.12 (m, 2H), 2.03-1.86 (m, 2H),



2-carboxamide
1.74-1.46 (m, 4H)


1068
N-[4-(1,8-

1H NMR (400 MHz, Pyridine-d5) δ ppm 8.50 (dd, J = 44.5,

(ESI(+))



diazaspiro[4.5]dec-8-
13.2 Hz, 2H), 7.88 (d, J = 8.5 Hz, 2H), 7.50 (d, J = 8.6 Hz,
m/e 406



ylcarbonyl)phenyl]-
2H), 7.10 (d, J = 4.9 Hz, 1H),
(M + H)+



1,3-dihydro-2H-
4.14-3.91 (m, 2H), 3.66-3.34 (m, 6H), 2.43 (s, 1H),



pyrrolo[3,4-c]pyridine-
2.23-2.05 (m, 2H), 2.05-1.66 (m, 8H)



2-carboxamide


1069
N-[4-(1,7-

1H NMR (400 MHz, Pyridine-d5) δ ppm

(ESI(+))



diazaspiro[3.5]non-7-
8.59-8.43 (m, 2H), 7.90 (d, J = 8.5 Hz, 2H), 7.48 (t, J = 13.3 Hz,
m/e 392



ylcarbonyl)phenyl]-
3H), 4.90 (dd, J = 29.4, 12.8 Hz, 4H), 4.01 (d, J = 47.2 Hz,
(M + H)+



1,3-dihydro-2H-
2H), 3.61 (t, J = 5.7 Hz, 2H), 3.51 (s, 2H), 3.37 (t,



pyrrolo[3,4-c]pyridine-
J = 7.4 Hz, 2H), 2.61 (t, J = 7.3 Hz, 2H), 2.10 (s, 2H)



2-carboxamide


1070
N-[4-(1,6-

1H NMR (400 MHz, Pyridine-d5) δ ppm 8.56 (d, J = 6.6 Hz,

(ESI(+))



diazaspiro[3.5]non-1-
2H), 8.05-7.86 (m, 2H), 7.82-7.62 (m, 2H),
m/e 392



ylcarbonyl)phenyl]-
7.10 (d, J = 4.9 Hz, 1H), 4.98-4.75 (m, 4H), 4.27 (td,
(M + H)+



1,3-dihydro-2H-
J = 8.9, 6.8 Hz, 1H), 3.96 (ddd, J = 25.0, 14.5, 9.4 Hz,



pyrrolo[3,4-c]pyridine-
3H), 3.51 (d, J = 6.5 Hz, 1H), 3.44 (t, J = 9.6 Hz, 1H),



2-carboxamide
3.23 (tdd, J = 12.8, 11.1, 4.3 Hz, 2H), 2.58-2.45 (m,




1H), 2.39-2.19 (m, 1H), 1.97 (ddd, J = 11.3, 9.0, 5.2 Hz,




2H), 1.89-1.63 (m, 2H)


1071
N-[4-(2,5-

1H NMR (400 MHz, Pyridine-d5) δ ppm

(ESI(+))



diazaspiro[3.5]non-2-
8.59-8.44 (m, 2H), 7.90 (d, J = 8.7 Hz, 2H), 7.84-7.67 (m, 2H),
m/e 392



ylcarbonyl)phenyl]-
7.10 (d, J = 4.9 Hz, 1H), 4.89 (dd, J = 31.4, 12.8 Hz,
(M + H)+



1,3-dihydro-2H-
4H), 4.38 (d, J = 9.7 Hz, 2H), 4.29-4.03 (m, 2H),



pyrrolo[3,4-c]pyridine-
3.51 (s, 1H), 3.12-2.82 (m, 2H), 2.01-1.69 (m, 2H),



2-carboxamide
1.62-1.22 (m, 4H)


1072
N-[4-(5-oxa-2-

1H NMR (400 MHz, Pyridine-d5) δ ppm

(ESI(+))



azaspiro[3.4]oct-2-
8.60-8.44 (m, 3H), 7.99-7.85 (m, 2H), 7.85-7.74 (m, 2H),
m/e 379



ylcarbonyl)phenyl]-
7.10 (d, J = 4.9 Hz, 1H), 4.98-4.74 (m, 4H),
(M + H)+



1,3-dihydro-2H-
4.41-4.24 (m, 3H), 4.19 (dd, J = 9.6, 1.2 Hz, 2H),



pyrrolo[3,4-c]pyridine-
3.85-3.61 (m, 2H), 1.92 (t, J = 7.3 Hz, 2H), 1.80-1.54 (m,



2-carboxamide
2H)


1073
N-[4-(6-oxa-2-

1H NMR (400 MHz, Pyridine-d5) δ ppm

(ESI(+))



azaspiro[3.5]non-2-
8.58-8.43 (m, 2H), 7.91 (dd, J = 21.0, 8.7 Hz, 2H), 7.85 (t, J = 7.0 Hz,
m/e 393



ylcarbonyl)phenyl]-
2H), 7.11 (d, J = 4.9 Hz, 1H), 4.88 (t, J = 13.2 Hz,
(M + H)+



1,3-dihydro-2H-
4H), 4.04-3.91 (m, 2H), 3.91-3.76 (m, 2H),



pyrrolo[3,4-c]pyridine-
3.62-3.54 (m, 2H), 3.54-3.36 (m, 3H),



2-carboxamide
1.77-1.52 (m, 2H), 1.52-1.27 (m, 2H)


1074
N-[4-(hexahydro-5H-

1H NMR (400 MHz, Pyridine-d5) δ ppm

(ESI(+))



furo[2,3-c]pyrrol-5-
8.57-8.46 (m, 2H), 7.98-7.76 (m, 2H), 7.69-7.57 (m, 2H),
m/e 379



ylcarbonyl)phenyl]-
7.10 (s, 1H), 4.86 (dd, J = 17.1, 10.2 Hz, 4H), 4.39 (t,
(M + H)+



1,3-dihydro-2H-
J = 5.6 Hz, 1H), 3.98-3.81 (m, 2H), 3.74-3.54 (m,



pyrrolo[3,4-c]pyridine-
4H), 3.56-3.41 (m, 1H), 2.78-2.51 (m, 1H),



2-carboxamide
2.07-1.72 (m, 1H), 1.73-1.36 (m, 1H)


1075
N-[4-(tetrahydro-1H-

1H NMR (400 MHz, Pyridine-d5) δ ppm

(ESI(+))



furo[3,4-c]pyrrol-
8.59-8.46 (m, 2H), 7.90 (d, J = 8.6 Hz, 2H), 7.68-7.58 (m, 2H),
m/e 379



5(3H)-
7.10 (d, J = 5.0 Hz, 1H), 4.87 (dd, J = 16.8, 9.9 Hz,
(M + H)+



ylcarbonyl)phenyl]-
4H), 3.86-3.64 (m, 4H), 3.64-3.40 (m, 5H),



1,3-dihydro-2H-
2.86-2.58 (m, 2H)



pyrrolo[3,4-c]pyridine-



2-carboxamide


1076
N-[4-

1H NMR (400 MHz, Pyridine-d5) δ ppm

(ESI(+))



(hexahydrofuro[3,4-
8.62-8.45 (m, 2H), 8.01-7.80 (m, 2H), 7.57-7.52 (m, 2H),
m/e 393



c]pyridin-5(3H)-
7.10 (d, J = 5.1 Hz, 1H), 4.91-4.78 (m, 4H),
(M + H)+



ylcarbonyl)phenyl]-
3.83-3.69 (m, 2H), 3.74-3.55 (m, 6H), 3.45-3.26 (m,



1,3-dihydro-2H-
1H), 2.37-2.17 (m, 2H), 1.72-1.35 (m, 2H)



pyrrolo[3,4-c]pyridine-



2-carboxamide


1120
N-(4-{[3-(5-methyl-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



1H-pyrazol-1-
8.47 (d, J = 4.9 Hz, 1H), 7.80 (d, J = 7.7 Hz, 1H),
m/e 405



yl)propyl]carbamoyl}phenyl)-
7.78-7.70 (m, 2H), 7.70-7.54 (m, 2H), 7.42-7.09 (m,
(M + H)+



5,7-dihydro-
2H), 6.01 (d, J = 0.8 Hz, 1H), 4.81 (d, J = 11.5 Hz,



6H-pyrrolo[3,4-
4H), 4.08 (t, J = 7.0 Hz, 2H), 3.32-3.27 (m, 2H),



b]pyridine-6-
2.25 (s, 3H), 2.12-1.94 (m, 2H)



carboxamide


1121
N-(4-{[2-(4-chloro-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



1H-pyrazol-1-
8.52-8.38 (m, 1H), 7.87-7.76 (m, 2H), 7.73-7.66 (m,
m/e 411



yl)ethyl]carbamoyl}phenyl)-
2H), 7.66-7.55 (m, 2H), 7.54-7.39 (m, 1H),
(M + H)+



5,7-dihydro-6H-
7.38-7.22 (m, 1H), 4.95-4.64 (m, 4H), 4.28 (dd, J = 8.0,



pyrrolo[3,4-b]pyridine-
4.5 Hz, 2H), 3.79-3.50 (m, 2H)



6-carboxamide


1122
N-(4-{[1-(3,5-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ 8.47 (t,

(ESI(+))



dimethyl-1H-pyrazol-
J = 9.6 Hz, 1H), 7.91-7.78 (m, 1H), 7.79-7.68 (m,
m/e 419



1-yl)propan-2-
2H), 7.68-7.57 (m, 2H), 7.38-7.31 (m, 1H), 4.82 (d,
(M + H)+



yl]carbamoyl}phenyl)-
J = 8.8 Hz, 4H), 4.37 (h, J = 6.7 Hz, 1H),



5,7-dihydro-6H-
4.24-3.93 (m, 2H), 2.89-2.68 (m, 1H), 2.63-2.42 (m, 2H),



pyrrolo[3,4-b]pyridine-
2.13 (s, 3H), 1.96 (s, 1H), 1.27-1.02 (m, 3H)



6-carboxamide


1123
N-(4-{[2-methyl-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



(morpholin-4-
8.47 (d, J = 4.8 Hz, 1H), 7.81 (dd, J = 10.0, 8.1 Hz, 3H),
m/e 438



yl)butyl]carbamoyl}phenyl)-
7.75-7.60 (m, 2H), 7.46-7.25 (m, 1H), 4.81 (d, J = 12.8 Hz,
(M + H)+



5,7-dihydro-6H-
4H), 3.92 (s, 4H), 3.40 (s, 3H), 2.85 (dd, J = 84.9,



pyrrolo[3,4-b]pyridine-
29.4 Hz, 2H), 2.57-2.38 (m, 3H), 1.92 (d, J = 35.3 Hz,



6-carboxamide
1H), 1.87-1.66 (m, 2H), 1.02 (t, J = 7.4 Hz,




3H)


1124
N-{4-[(4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methoxybenzyl)carbamoyl]phenyl}-
8.55-8.39 (m, 1H), 7.98-7.71 (m, 3H), 7.67-7.52 (m,
m/e 403



5,7-
2H), 7.36-7.29 (m, 1H), 7.29-7.17 (m, 2H),
(M + H)+



dihydro-6H-
6.98-6.73 (m, 2H), 4.90-4.60 (m, 4H), 4.38 (d, J = 17.5 Hz,



pyrrolo[3,4-b]pyridine-
2H), 3.74 (d, J = 3.2 Hz, 3H)



6-carboxamide


1125
N-(4-{[3-(morpholin-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



4-
8.57-8.35 (m, 1H), 7.89-7.72 (m, 3H), 7.72-7.54 (m,
m/e 410



yl)propyl]carbamoyl}phenyl)-
2H), 7.33 (dd, J = 7.7, 5.0 Hz, 1H), 4.81 (d, J = 11.8 Hz,
(M + H)+



5,7-dihydro-
4H), 3.86 (s, 4H), 3.47-3.34 (m, 2H),



6H-pyrrolo[3,4-
3.24-3.04 (m, 2H), 2.12-1.78 (m, 2H)



b]pyridine-6-



carboxamide


1126
N-[4-({4-[2-(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



hydroxyethoxy)ethyl]piperazin-
8.46 (dd, J = 12.7, 2.9 Hz, 1H), 7.80 (d, J = 7.7 Hz, 1H),
m/e 440



1-
7.73-7.55 (m, 2H), 7.49-7.35 (m, 2H),
(M + H)+



yl}carbonyl)phenyl]-
7.35-7.25 (m, 1H), 4.81 (d, J = 11.4 Hz, 4H), 3.90-3.71 (m,



5,7-dihydro-6H-
6H), 3.66-3.48 (m, 5H), 3.37 (d, J = 5.2 Hz, 5H),



pyrrolo[3,4-b]pyridine-
2.88 (d, J = 53.2 Hz, 4H), 1.96 (s, 2H)



6-carboxamide


1127
N-{4-[(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



carbamoylbenzyl)carbamoyl]phenyl}-
8.46 (d, J = 4.3 Hz, 1H), 7.84-7.73 (m, 3H),
m/e 416



5,7-
7.73-7.59 (m, 2H), 7.48 (d, J = 7.4 Hz, 1H), 7.44-7.37 (m, 2H),
(M + H)+



dihydro-6H-
7.37-7.20 (m, 2H), 4.81 (d, J = 12.6 Hz, 4H), 4.63 (s,



pyrrolo[3,4-b]pyridine-
2H)



6-carboxamide


1128
N-{4-[bis(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methoxyethyl)carbamoyl]phenyl}-
8.65-8.37 (m, 1H), 7.78 (dd, J = 40.2, 6.3 Hz, 1H),
m/e 399



5,7-dihydro-
7.68-7.53 (m, 2H), 7.42-7.31 (m, 1H), 7.32-7.20 (m,
(M + H)+



6H-pyrrolo[3,4-
2H), 4.85 (t, J = 26.3 Hz, 4H), 3.67-3.41 (m, 9H),



b]pyridine-6-
3.28 (t, J = 8.4 Hz, 6H), 3.06-2.71 (m, 2H), 2.01 (d, J = 38.9 Hz,



carboxamide
1H)


1129
N-{4-[(1-amino-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



oxohexan-2-
8.59-8.22 (m, 1H), 7.89-7.75 (m, 3H), 7.70-7.54 (m,
m/e 394



yl)carbamoyl]phenyl}-
2H), 7.37 (dd, J = 7.7, 5.0 Hz, 1H), 4.83 (d, J = 8.7 Hz,
(M + H)+



5,7-dihydro-6H-
4H), 4.41 (dd, J = 8.6, 5.5 Hz, 1H),



pyrrolo[3,4-b]pyridine-
3.11-2.72 (m, 1H), 2.53-2.31 (m, 1H), 1.90-1.56 (m, 2H),



6-carboxamide
1.48-1.22 (m, 4H), 1.11-0.77 (m, 3H)


1130
N-(4-{[2-(3,4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



dimethoxyphenyl)ethyl]carbamoyl}phenyl)-
8.55-8.34 (m, 1H), 7.87-7.75 (m, 1H), 7.76-7.67 (m,
m/e 447



5,7-dihydro-6H-
2H), 7.67-7.52 (m, 2H), 7.45-7.26 (m, 1H),
(M + H)+



pyrrolo[3,4-b]pyridine-
6.94-6.79 (m, 2H), 6.77 (dd, J = 8.1, 2.0 Hz, 1H),



6-carboxamide
4.90-4.61 (m, 4H), 3.73 (d, J = 2.9 Hz, 6H), 3.63-3.35 (m,




2H), 2.87-2.66 (m, 2H)


1131
N-(4-{[4-(pyrazin-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



yl)piperazin-1-
8.31-8.22 (m, 1H), 8.12-8.04 (m, 1H), 7.90-7.59 (m,
m/e 430



yl]carbonyl}phenyl)-
4H), 7.43-7.30 (m, 3H), 4.87-4.75 (m, 4H),
(M + H)+



5,7-dihydro-6H-
3.69-3.60 (m, 8H)



pyrrolo[3,4-b]pyridine-



6-carboxamide


1132
Nalpha-{4-[(5,7-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



dihydro-6H-
8.57-8.27 (m, 1H), 7.83-7.74 (m, 1H), 7.74-7.64 (m,
m/e 430



pyrrolo[3,4-b]pyridin-
2H), 7.64-7.54 (m, 2H), 7.39-7.20 (m, 5H),
(M + H)+



6-
7.20-7.09 (m, 1H), 4.88-4.73 (m, 4H), 4.73-4.58 (m,



ylcarbonyl)amino]benzoyl}-
1H), 3.22-3.11 (m, 1H), 3.11-2.92 (m, 1H)



L-



phenylalaninamide


1133
N-(4-{[(2R)-1-amino-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



4-methyl-1-oxopentan-
8.61-8.35 (m, 1H), 7.96-7.73 (m, 3H), 7.71-7.53 (m,
m/e 396



2-
2H), 7.47-7.28 (m, 1H), 4.94-4.67 (m, 4H),
(M + H)+



yl]carbamoyl}phenyl)-
4.61-4.34 (m, 1H), 3.08-2.71 (m, 1H), 1.93-1.49 (m,



5,7-dihydro-6H-
2H), 1.00-0.70 (m, 6H)



pyrrolo[3,4-b]pyridine-



6-carboxamide


1134
N-{4-[(4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



cyclohexylpiperazin-1-
8.48 (d, J = 4.6 Hz, 1H), 7.91-7.76 (m, 1H),
m/e 434



yl)carbonyl]phenyl}-
7.75-7.57 (m, 2H), 7.50-7.27 (m, 3H), 4.86 (t, J = 26.6 Hz,
(M + H)+



5,7-dihydro-6H-
4H), 3.80 (s, 3H), 3.28-3.13 (m, 2H), 3.05-2.73 (m,



pyrrolo[3,4-b]pyridine-
3H), 2.70-2.43 (m, 1H), 2.09 (d, J = 11.0 Hz, 2H),



6-carboxamide
1.84 (t, J = 13.9 Hz, 2H), 1.64 (d, J = 12.9 Hz, 1H),




1.48-1.22 (m, 4H), 1.22-1.04 (m, 1H)


1135
N-{4-[(3-tert-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



butoxypropyl)carbamoyl]phenyl}-
8.48 (d, J = 4.4 Hz, 1H), 7.80 (t, J = 17.2 Hz, 1H),
m/e 394



5,7-
7.76-7.65 (m, 2H), 7.68-7.52 (m, 2H), 7.36 (dd, J = 7.7,
(M + H)+



dihydro-6H-
5.0 Hz, 1H), 4.82 (d, J = 9.6 Hz, 4H), 3.48-3.33 (m,



pyrrolo[3,4-b]pyridine-
3H), 1.73 (p, J = 6.5 Hz, 2H), 1.15 (s, 9H)



6-carboxamide


1136
N-(4-{[2-(2,6-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



dimethylmorpholin-4-
8.47 (d, J = 5.0 Hz, 1H), 7.89-7.72 (m, 3H),
m/e 424



yl)ethyl]carbamoyl}phenyl)-
7.70-7.53 (m, 2H), 7.48-7.18 (m, 1H), 4.87 (dd, J = 42.6, 12.8 Hz,
(M + H)+



5,7-dihydro-6H-
4H), 3.97-3.75 (m, 2H), 3.75-3.58 (m, 2H),



pyrrolo[3,4-b]pyridine-
3.53 (d, J = 12.0 Hz, 2H), 3.00-2.80 (m, 1H), 2.73 (t,



6-carboxamide
J = 11.7 Hz, 2H), 2.51 (dt, J = 3.7, 1.8 Hz, 2H),




1.18 (d, J = 6.3 Hz, 6H)


1137
N-{4-[(3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methoxybenzyl)carbamoyl]phenyl}-
8.52-8.30 (m, 1H), 7.89-7.70 (m, 3H), 7.70-7.48 (m,
m/e 403



5,7-
2H), 7.34 (dd, J = 7.7, 5.0 Hz, 1H), 7.23 (t, J = 8.0 Hz,
(M + H)+



dihydro-6H-
1H), 6.99-6.84 (m, 2H), 6.86-6.69 (m, 1H), 4.82 (d,



pyrrolo[3,4-b]pyridine-
J = 10.4 Hz, 4H), 4.45 (s, 2H), 3.75 (s, 3H), 1.96 (s,



6-carboxamide
1H)


1138
N-(4-{[2-methyl-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ 8.45 (t,

(ESI(+))



(morpholin-4-
J = 21.3 Hz, 1H), 7.89-7.74 (m, 3H), 7.80-7.58 (m,
m/e 424



yl)propyl]carbamoyl}phenyl)-
2H), 7.34 (dd, J = 7.7, 5.0 Hz, 1H), 4.82 (d, J = 11.1 Hz,
(M + H)+



5,7-dihydro-
4H), 3.92 (s, 4H), 3.64 (s, 2H), 3.39 (s, 3H),



6H-pyrrolo[3,4-
1.39 (s, 6H)



b]pyridine-6-



carboxamide


1139
N-(4-{[(3S)-1-methyl-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



2-oxoazepan-3-
8.64-8.35 (m, 1H), 7.87-7.78 (m, 1H), 7.78-7.71 (m,
m/e 408



yl]carbamoyl}phenyl)-
1H), 7.71-7.59 (m, 2H), 7.47-7.28 (m, 1H),
(M + H)+



5,7-dihydro-6H-
4.99-4.68 (m, 4H), 3.74-3.58 (m, 1H), 3.06-2.86 (m,



pyrrolo[3,4-b]pyridine-
3H), 2.90-2.71 (m, 1H), 2.03-1.74 (m, 4H),



6-carboxamide
1.59-1.28 (m, 2H)


1140
N-(4-{[2-(4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methylpiperazin-1-
8.48 (d, J = 4.4 Hz, 1H), 7.86-7.72 (m, 3H),
m/e 409



yl)ethyl]carbamoyl}phenyl)-
7.72-7.58 (m, 2H), 7.35 (dd, J = 7.7, 5.0 Hz, 1H), 4.82 (d, J = 10.5 Hz,
(M + H)+



5,7-dihydro-6H-
4H), 3.53 (t, J = 6.4 Hz, 2H), 3.32-3.22 (m,



pyrrolo[3,4-b]pyridine-
4H), 3.20-3.02 (m, 4H), 2.97 (t, J = 6.4 Hz, 3H),



6-carboxamide
2.80 (s, 4H)


1141
N-(4-{[4-(morpholin-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



4-
8.60-8.40 (m, 1H), 7.93-7.71 (m, 3H), 7.73-7.49 (m,
m/e 457



yl)benzyl]carbamoyl}phenyl)-
2H), 7.42-7.26 (m, 1H), 7.29-7.02 (m, 2H),
(M + H)+



5,7-dihydro-
6.98-6.81 (m, 2H), 4.81 (d, J = 11.8 Hz, 4H), 4.37 (d, J = 16.6 Hz,



6H-pyrrolo[3,4-
2H), 3.89-3.61 (m, 4H), 3.18-2.93 (m,



b]pyridine-6-
4H), 2.98-2.74 (m, 1H)



carboxamide


1142
N-(4-{[3-(piperidin-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



yl)propyl]carbamoyl}phenyl)-
8.47 (d, J = 4.2 Hz, 1H), 7.89-7.70 (m, 3H),
m/e 408



5,7-dihydro-
7.73-7.51 (m, 2H), 7.33 (dd, J = 7.7, 5.0 Hz, 1H), 4.81 (d, J = 11.5 Hz,
(M + H)+



6H-pyrrolo[3,4-
4H), 3.38 (dd, J = 18.6, 12.0 Hz, 4H),



b]pyridine-6-
3.21-3.00 (m, 2H), 2.92 (d, J = 19.7 Hz, 2H), 1.95 (tt, J = 33.3,



carboxamide
15.0 Hz, 3H), 1.77 (d, J = 48.7 Hz, 6H)


1143
N-[4-(4,5,6,7-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



tetrahydro-1H-indazol-
8.45 (d, J = 7.5 Hz, 1H), 7.84-7.74 (m, 2H), 7.65 (dd, J = 18.3,
m/e 403



5-
8.7 Hz, 2H), 7.56 (d, J = 8.7 Hz, 1H),
(M + H)+



ylcarbamoyl)phenyl]-
7.41-7.19 (m, 2H), 4.90 (s, 1H), 4.81 (d, J = 14.4 Hz, 4H),



5,7-dihydro-6H-
2.87 (dd, J = 33.4, 22.8 Hz, 6H)



pyrrolo[3,4-b]pyridine-



6-carboxamide


1195
N-{4-[(3-methoxy-2,2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ 8.47 (t,

(ESI(+))



dimethylpropyl)carbamoyl]phenyl}-
J = 12.9 Hz, 1H), 7.85 (d, J = 7.7 Hz, 1H),
m/e 388



5,7-
7.79-7.69 (m, 2H), 7.69-7.57 (m, 2H), 7.38 (dd, J = 7.7, 5.0 Hz,
(M + H)+



dihydro-6H-
1H), 4.83 (d, J = 8.0 Hz, 4H), 3.30 (s, 3H), 3.21 (s,



pyrrolo[3,4-b]pyridine-
2H), 3.15 (s, 2H), 0.90 (s, 6H)



6-carboxamide


1196
N-{4-[(3,3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



dimethylbutyl)carbamoyl]phenyl}-
8.48 (d, J = 4.4 Hz, 1H), 7.82 (d, J = 7.7 Hz, 1H),
m/e 367



5,7-
7.78-7.69 (m, 2H), 7.69-7.57 (m, 2H), 7.35 (dd, J = 7.7,
(M + H)+



dihydro-6H-
5.0 Hz, 1H), 4.82 (d, J = 10.1 Hz, 4H), 3.31 (d, J = 4.0 Hz,



pyrrolo[3,4-b]pyridine-
1H), 3.28 (s, 1H), 1.60-1.24 (m, 2H), 0.94 (s,



6-carboxamide
9H)


1197
N-(4-{[1-(furan-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



yl)propan-2-
8.63-8.39 (m, 1H), 7.89-7.79 (m, 1H), 7.79-7.67 (m,
m/e 391



yl]carbamoyl}phenyl)-
2H), 7.67-7.51 (m, 2H), 7.51-7.27 (m, 1H),
(M + H)+



5,7-dihydro-6H-
6.32 (dd, J = 3.1, 1.9 Hz, 1H), 6.13 (dd, J = 3.2, 0.7 Hz,



pyrrolo[3,4-b]pyridine-
1H), 4.86 (t, J = 25.1 Hz, 4H), 4.28 (h, J = 6.7 Hz,



6-carboxamide
1H), 3.06-2.73 (m, 4H), 1.96 (s, 1H), 1.19 (t, J = 5.9 Hz,




3H)


1198
N-(4-{[(3-methyl-1,2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



oxazol-5-
8.59-8.37 (m, 1H), 7.87-7.70 (m, 3H), 7.71-7.52 (m,
m/e 378



yl)methyl]carbamoyl}phenyl)-
2H), 7.42-7.20 (m, 1H), 6.24-6.02 (m, 1H),
(M + H)+



5,7-dihydro-
4.93-4.69 (m, 4H), 4.64-4.44 (m, 2H), 2.20 (s, 3H)



6H-pyrrolo[3,4-



b]pyridine-6-



carboxamide


1199
N-(4-{[(2R)-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ 8.49 (t,

(ESI(+))



cyanobutan-2-
J = 7.9 Hz, 1H), 7.96-7.83 (m, 1H), 7.83-7.73 (m,
m/e 364



yl]carbamoyl}phenyl)-
2H), 7.71-7.54 (m, 2H), 7.39 (dd, J = 7.7, 5.1 Hz,
(M + H)+



5,7-dihydro-6H-
1H), 4.83 (d, J = 7.3 Hz, 4H), 4.27-3.97 (m, 1H),



pyrrolo[3,4-b]pyridine-
2.89-2.62 (m, 3H), 1.97 (s, 1H), 1.68 (p, J = 7.3 Hz,



6-carboxamide
2H), 0.93 (t, J = 7.4 Hz, 3H)


1200
N-{4-[methyl(3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methylbutyl)carbamoyl]phenyl}-
8.48 (dd, J = 5.4, 4.9 Hz, 1H), 7.84 (dd, J = 7.7, 0.7 Hz,
m/e 367



5,7-dihydro-
1H), 7.72-7.50 (m, 2H), 7.47-7.32 (m, 1H),
(M + H)+



6H-pyrrolo[3,4-
7.34-7.16 (m, 2H), 4.86 (t, J = 25.0 Hz, 4H), 3.37 (dd, J = 14.4,



b]pyridine-6-
6.9 Hz, 2H), 2.97-2.84 (m, 4H), 1.97 (s, 2H),



carboxamide
1.66-1.33 (m, 3H), 1.06-0.63 (m, 6H)


1201
N-(4-{[(1-methyl-1H-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



pyrazol-3-
8.47 (d, J = 4.9 Hz, 1H), 7.84-7.70 (m, 3H),
m/e 377



yl)methyl]carbamoyl}phenyl)-
7.70-7.55 (m, 2H), 7.51 (t, J = 5.0 Hz, 1H), 7.32 (dd, J = 7.7, 4.9 Hz,
(M + H)+



5,7-dihydro-
1H), 6.15 (d, J = 2.2 Hz, 1H), 4.85 (t, J = 28.9 Hz,



6H-pyrrolo[3,4-
4H), 4.59-4.31 (m, 2H), 3.78 (d, J = 4.5 Hz, 3H)



b]pyridine-6-



carboxamide


1202
N-{4-[(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methoxybutyl)carbamoyl]phenyl}-
8.49 (d, J = 4.9 Hz, 1H), 7.85 (t, J = 10.7 Hz, 1H),
m/e 369



5,7-
7.78-7.69 (m, 2H), 7.68-7.49 (m, 2H), 7.43-7.30 (m,
(M + H)+



dihydro-6H-
1H), 4.86 (t, J = 25.0 Hz, 4H), 3.35 (d, J = 4.6 Hz,



pyrrolo[3,4-b]pyridine-
2H), 3.32 (d, J = 2.7 Hz, 3H), 1.71-1.34 (m, 2H),



6-carboxamide
0.90 (t, J = 7.4 Hz, 3H)


1203
N-(4-{[4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



(dimethylamino)butyl]carbamoyl}phenyl)-
8.57-8.41 (m, 1H), 7.88-7.73 (m, 3H), 7.68-7.55 (m,
m/e 382



5,7-dihydro-6H-
2H), 7.46-7.02 (m, 1H), 4.81 (d, J = 11.6 Hz, 4H),
(M + H)+



pyrrolo[3,4-b]pyridine-
3.17-3.00 (m, 2H), 2.87-2.67 (m, 8H), 1.96 (s, 1H),



6-carboxamide
1.78-1.55 (m, 4H)


1204
N-(4-{[1-(1,3-thiazol-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ 8.49 (t,

(ESI(+))



2-
J = 5.3 Hz, 1H), 7.83 (d, J = 8.7 Hz, 3H), 7.67 (dt, J = 17.6,
m/e 394



yl)ethyl]carbamoyl}phenyl)-
9.5 Hz, 3H), 7.61-7.47 (m, 1H), 7.34 (dt, J = 35.5,
(M + H)+



5,7-dihydro-6H-
17.8 Hz, 1H), 5.46 (q, J = 7.0 Hz, 1H), 4.83 (d, J = 9.3 Hz,



pyrrolo[3,4-b]pyridine-
4H), 1.65 (d, J = 7.0 Hz, 3H)



6-carboxamide


1205
N-(4-{[1-(1-methyl-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



1H-pyrazol-4-
8.58-8.41 (m, 1H), 7.91-7.81 (m, 1H), 7.79-7.66 (m,
m/e 391



yl)ethyl]carbamoyl}phenyl)-
2H), 7.70-7.58 (m, 2H), 7.58-7.51 (m, 1H),
(M + H)+



5,7-dihydro-6H-
7.37 (dd, J = 7.5, 5.2 Hz, 2H), 5.15 (q, J = 6.9 Hz, 1H),



pyrrolo[3,4-b]pyridine-
4.82 (d, J = 8.4 Hz, 4H), 3.78 (s, 3H), 1.47 (t, J = 5.5 Hz,



6-carboxamide
3H)


1206
N-{4-[(3S)-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ 8.46 (t,

(ESI(+))



tetrahydrofuran-3-
J = 11.6 Hz, 1H), 7.87-7.70 (m, 3H), 7.70-7.52 (m,
m/e 353



ylcarbamoyl]phenyl}-
2H), 7.35 (dt, J = 14.6, 7.3 Hz, 1H), 4.82 (d, J = 9.9 Hz,
(M + H)+



5,7-dihydro-6H-
4H), 4.58-4.37 (m, 1H), 3.92-3.81 (m, 2H),



pyrrolo[3,4-b]pyridine-
3.81-3.67 (m, 1H), 3.59 (dd, J = 8.9, 4.6 Hz, 1H),



6-carboxamide
2.31-2.11 (m, 1H), 2.02-1.76 (m, 2H)


1207
N-{4-[(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methoxybutan-2-
8.47 (dd, J = 15.1, 10.9 Hz, 1H), 7.84 (dd, J = 7.7, 1.0 Hz,
m/e 369



yl)carbamoyl]phenyl}-
1H), 7.82-7.70 (m, 2H), 7.70-7.56 (m, 2H),
(M + H)+



5,7-dihydro-6H-
7.36 (dd, J = 7.7, 5.0 Hz, 1H), 4.82 (d, J = 9.1 Hz, 4H),



pyrrolo[3,4-b]pyridine-
4.18-3.96 (m, 1H), 3.50-3.36 (m, 2H),



6-carboxamide
1.75-1.57 (m, 1H), 1.57-1.39 (m, 1H), 0.90 (t, J = 7.4 Hz, 3H)


1208
N-{4-[(4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



aminobenzyl)carbamoyl]phenyl}-
8.47 (d, J = 4.2 Hz, 1H), 7.87-7.73 (m, 3H),
m/e 388



5,7-
7.70-7.53 (m, 2H), 7.33 (dd, J = 8.0, 6.1 Hz, 3H), 7.09 (d, J = 8.3 Hz,
(M + H)+



dihydro-6H-
2H), 4.81 (d, J = 11.4 Hz, 4H), 4.44 (s, 2H)



pyrrolo[3,4-b]pyridine-



6-carboxamide


1209
N-{4-[(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ 8.47 (t,

(ESI(+))



ethoxypropyl)carbamoyl]phenyl}-
J = 11.3 Hz, 1H), 7.87-7.81 (m, 1H), 7.80-7.71 (m,
m/e 369



5,7-
2H), 7.73-7.53 (m, 2H), 7.45-7.08 (m, 1H), 4.82 (d,
(M + H)+



dihydro-6H-
J = 9.2 Hz, 4H), 3.70-3.56 (m, 1H), 3.56-3.41 (m,



pyrrolo[3,4-b]pyridine-
2H), 3.27 (dd, J = 13.4, 5.7 Hz, 1H), 1.18-0.88 (m,



6-carboxamide
6H)


1210
N-{4-[(6-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methoxypyridin-3-
8.58-8.32 (m, 2H), 8.10-7.96 (m, 1H), 7.96-7.85 (m,
m/e 390



yl)carbamoyl]phenyl}-
2H), 7.85-7.74 (m, 1H), 7.74-7.60 (m, 2H),
(M + H)+



5,7-dihydro-6H-
7.40-7.14 (m, 1H), 6.97-6.64 (m, 1H), 5.01-4.62 (m,



pyrrolo[3,4-b]pyridine-
4H), 3.87 (s, 3H)



6-carboxamide


1211
N-{4-[(2S)-butan-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



ylcarbamoyl]phenyl}-
8.49 (d, J = 4.9 Hz, 1H), 7.83 (t, J = 12.3 Hz, 1H),
m/e 339



5,7-dihydro-6H-
7.84-7.69 (m, 2H), 7.73-7.51 (m, 2H), 7.37 (dd, J = 7.7,
(M + H)+



pyrrolo[3,4-b]pyridine-
5.0 Hz, 1H), 4.82 (d, J = 8.6 Hz, 4H), 3.92 (h, J = 6.7 Hz,



6-carboxamide
1H), 1.69-1.44 (m, 2H), 1.16 (d, J = 6.7 Hz, 3H),




0.89 (t, J = 7.4 Hz, 3H)


1212
N-{4-[(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



cyanocyclopropyl)carbamoyl]phenyl}-
8.47 (d, J = 4.7 Hz, 1H), 7.85-7.72 (m, 3H),
m/e 348



5,7-
7.69-7.52 (m, 2H), 7.43-7.15 (m, 1H), 4.81 (d, J = 11.4 Hz,
(M + H)+



dihydro-6H-
4H), 1.61-1.41 (m, 2H), 1.40-1.17 (m, 2H)



pyrrolo[3,4-b]pyridine-



6-carboxamide


1213
N-(4-{[2-(5-methyl-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



1H-pyrazol-1-
8.55-8.36 (m, 1H), 7.87-7.75 (m, 1H), 7.75-7.67 (m,
m/e 391



yl)ethyl]carbamoyl}phenyl)-
2H), 7.68-7.52 (m, 2H), 7.43-7.22 (m, 2H),
(M + H)+



5,7-dihydro-6H-
6.09-5.92 (m, 1H), 4.91-4.64 (m, 4H), 4.36-4.10 (m,



pyrrolo[3,4-b]pyridine-
2H), 3.74-3.47 (m, 2H), 2.30-2.13 (m, 3H)



6-carboxamide


1214
N-(4-{[(4-methyl-1,3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



thiazol-2-
8.59-8.31 (m, 1H), 7.92-7.72 (m, 3H), 7.71-7.58 (m,
m/e 394



yl)methyl]carbamoyl}phenyl)-
2H), 7.48-7.22 (m, 1H), 7.14-6.93 (m, 1H), 4.82 (d,
(M + H)+



5,7-dihydro-
J = 11.0 Hz, 4H), 4.74-4.63 (m, 2H), 2.35 (d, J = 0.6 Hz,



6H-pyrrolo[3,4-
3H)



b]pyridine-6-



carboxamide


1215
N-{4-[(3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



hydroxypropyl)carbamoyl]phenyl}-
8.56-8.38 (m, 1H), 7.88-7.79 (m, 1H), 7.79-7.68 (m,
m/e 341



5,7-
2H), 7.70-7.55 (m, 2H), 7.46-7.23 (m, 1H), 4.82 (d,
(M + H)+



dihydro-6H-
J = 9.5 Hz, 4H), 3.51 (t, J = 6.3 Hz, 2H), 3.3 (t, J = 6.3 Hz,



pyrrolo[3,4-b]pyridine-
2H)1.83-1.60 (m, 2H)



6-carboxamide


1216
N-{4-[(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methylpropyl)carbamoyl]phenyl}-
8.62-8.39 (m, 1H), 7.86-7.81 (m, 1H), 7.81-7.70 (m,
m/e 339



5,7-
2H), 7.70-7.54 (m, 2H), 7.43-7.17 (m, 1H),
(M + H)+



dihydro-6H-
4.84 (dd, J = 30.5, 23.8 Hz, 4H), 3.17-3.01 (m, 2H),



pyrrolo[3,4-b]pyridine-
2.03-1.72 (m, 2H), 0.89 (t, J = 7.9 Hz, 6H)



6-carboxamide


1217
N-{4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



[(tetrahydrofuran-2-
8.57-8.39 (m, 1H), 7.86-7.80 (m, 1H), 7.80-7.69 (m,
m/e 367



ylmethyl)carbamoyl]phenyl}-
2H), 7.69-7.54 (m, 2H), 7.42-7.26 (m, 1H), 4.82 (d,
(M + H)+



5,7-dihydro-
J = 10.1 Hz, 4H), 4.12-3.93 (m, 1H), 3.88-3.75 (m,



6H-pyrrolo[3,4-
1H), 3.74-3.54 (m, 1H), 3.33 (t, J = 5.9 Hz, 2H),



b]pyridine-6-
1.98-1.78 (m, 4H), 1.71-1.51 (m, 1H)



carboxamide


1218
N-(4-{[(1R)-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ 8.49 (t,

(ESI(+))



cyclopropylethyl]carbamoyl}phenyl)-
J = 5.8 Hz, 1H), 7.90-7.80 (m, 1H), 7.80-7.69 (m,
m/e 351



5,7-
2H), 7.68-7.54 (m, 2H), 7.36 (dd, J = 7.7, 5.0 Hz,
(M + H)+



dihydro-6H-
1H), 4.82 (d, J = 9.6 Hz, 4H), 3.64-3.41 (m, 1H),



pyrrolo[3,4-b]pyridine-
1.23 (d, J = 6.7 Hz, 3H), 1.10-0.86 (m, 1H),



6-carboxamide
0.53-0.28 (m, 3H), 0.28-0.11 (m, 1H)


1219
N-(4-{[1-(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methylcyclopropyl)ethyl]carbamoyl}phenyl)-
8.60-8.35 (m, 1H), 7.93-7.79 (m, 1H), 7.79-7.68 (m,
m/e 365



5,7-dihydro-6H-
2H), 7.68-7.53 (m, 2H), 7.49-7.22 (m, 1H), 4.82 (d,
(M + H)+



pyrrolo[3,4-b]pyridine-
J = 9.2 Hz, 4H), 3.72 (q, J = 6.8 Hz, 1H), 1.17 (d, J = 6.8 Hz,



6-carboxamide
3H), 1.08 (s, 3H), 0.67-0.48 (m, 1H),




0.47-0.34 (m, 1H), 0.32-0.12 (m, 2H)


1220
N-{4-[(thiophen-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ 8.45 (t,

(ESI(+))



ylmethyl)carbamoyl]phenyl}-
J = 8.3 Hz, 1H), 7.83-7.71 (m, 3H), 7.68-7.55 (m,
m/e 379



5,7-dihydro-
2H), 7.39-7.21 (m, 1H), 7.08-6.98 (m, 1H),
(M + H)+



6H-pyrrolo[3,4-
6.99-6.90 (m, 1H), 4.80 (d, J = 12.9 Hz, 4H), 4.63 (s, 2H)



b]pyridine-6-



carboxamide


1221
N-(4-{[(1S)-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



cyclopropylethyl]carbamoyl}phenyl)-
8.49 (d, J = 4.9 Hz, 1H), 7.85 (d, J = 7.7 Hz, 1H),
m/e 350



5,7-
7.78-7.69 (m, 2H), 7.72-7.54 (m, 2H), 7.37 (dd, J = 7.7,
(M + H)+



dihydro-6H-
5.0 Hz, 1H), 4.96-4.68 (m, 4H), 3.70-3.42 (m, 1H),



pyrrolo[3,4-b]pyridine-
1.23 (d, J = 6.7 Hz, 3H), 1.15-0.90 (m, 1H),



6-carboxamide
0.58-0.16 (m, 4H)


1222
N-{4-[(4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methoxybutyl)carbamoyl]phenyl}-
8.60-8.35 (m, 1H), 7.90-7.79 (m, 1H), 7.79-7.70 (m,
m/e 369



5,7-
2H), 7.69-7.52 (m, 2H), 7.43-7.29 (m, 1H), 4.86 (t,
(M + H)+



dihydro-6H-
J = 24.4 Hz, 4H), 3.31-3.25 (m, 2H), 2.68-2.34 (m,



pyrrolo[3,4-b]pyridine-
2H), 1.65-1.48 (m, 4H)



6-carboxamide


1223
N-(4-{[2-(tetrahydro-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



2H-pyran-3-
8.55-8.37 (m, 1H), 7.89-7.78 (m, 1H), 7.78-7.68 (m,
m/e 395



yl)ethyl]carbamoyl}phenyl)-
2H), 7.68-7.52 (m, 2H), 7.43-7.02 (m, 1H), 4.86 (t,
(M + H)+



5,7-dihydro-6H-
J = 25.4 Hz, 4H), 3.96-3.57 (m, 2H), 3.12-2.98 (m,



pyrrolo[3,4-b]pyridine-
1H), 2.95-2.78 (m, 2H), 1.91-1.76 (m, 1H),



6-carboxamide
1.63-1.40 (m, 4H), 1.28-1.09 (m, 1H)


1224
N-(4-{[(2S)-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methoxypropan-2-
8.58-8.40 (m, 1H), 7.87-7.81 (m, 1H), 7.80-7.72 (m,
m/e 355



yl]carbamoyl}phenyl)-
2H), 7.69-7.51 (m, 2H), 7.34 (dd, J = 7.7, 5.0 Hz,
(M + H)+



5,7-dihydro-6H-
1H), 4.81 (d, J = 11.0 Hz, 4H), 4.30-4.08 (m, 1H),



pyrrolo[3,4-b]pyridine-
3.49-3.42 (m, 1H), 3.40-3.33 (m, 1H), 3.29 (s, 3H),



6-carboxamide
1.16 (t, J = 5.4 Hz, 3H)


1225
N-{4-[(3,3-dimethyl-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



oxobutyl)carbamoyl]phenyl}-
8.49 (d, J = 4.3 Hz, 1H), 7.89-7.81 (m, 1H),
m/e 391



5,7-dihydro-
7.84-7.73 (m, 2H), 7.74-7.56 (m, 2H), 7.44-7.18 (m, 1H),
(M + H)+



6H-pyrrolo[3,4-
4.83 (d, J = 9.2 Hz, 4H), 4.30 (s, 2H), 1.18 (s, 9H)



b]pyridine-6-



carboxamide


1226
N-(4-{[(1-methyl-1H-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



pyrrol-2-
8.58-8.35 (m, 1H), 7.92-7.71 (m, 3H), 7.70-7.49 (m,
m/e 376



yl)methyl]carbamoyl}phenyl)-
2H), 7.44-7.19 (m, 1H), 4.82 (d, J = 9.5 Hz, 4H),
(M + H)+



5,7-dihydro-
4.44 (s, 2H), 3.59 (s, 3H)



6H-pyrrolo[3,4-



b]pyridine-6-



carboxamide


1227
N-(4-{[2-(propan-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



yloxy)ethyl]carbamoyl}phenyl)-
8.60-8.37 (m, 1H), 7.86-7.72 (m, 3H), 7.71-7.56 (m,
m/e 369



5,7-dihydro-
3H), 7.47-7.19 (m, 1H), 4.87-4.66 (m, 4H),
(M + H)+



6H-pyrrolo[3,4-
3.67-3.48 (m, 3H), 3.42-3.36 (m, 2H), 1.16-1.02 (m, 6H)



b]pyridine-6-



carboxamide


1228
N-(4-{[3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



(dimethylamino)propyl]carbamoyl}phenyl)-
8.59-8.13 (m, 1H), 7.91-7.72 (m, 3H), 7.73-7.58 (m,
m/e 368



5,7-dihydro-6H-
2H), 7.43-7.26 (m, 1H), 4.83 (t, J = 9.4 Hz, 4H),
(M + H)+



pyrrolo[3,4-b]pyridine-
3.37 (d, J = 6.7 Hz, 2H), 3.27-3.07 (m, 2H), 2.81 (d,



6-carboxamide
J = 4.7 Hz, 6H), 1.95 (d, J = 9.3 Hz, 2H)


1229
N-[4-(tetrahydro-2H-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



pyran-3-
8.56-8.35 (m, 1H), 7.90-7.68 (m, 3H), 7.69-7.56 (m,
m/e 367



ylcarbamoyl)phenyl]-
2H), 7.36 (td, J = 7.9, 4.0 Hz, 1H), 4.82 (d, J = 10.2 Hz,
(M + H)+



5,7-dihydro-6H-
4H), 3.99-3.86 (m, 1H), 3.86-3.68 (m, 1H),



pyrrolo[3,4-b]pyridine-
3.41-3.32 (m, 1H), 3.29-3.17 (m, 1H),



6-carboxamide
2.07-1.84 (m, 1H), 1.83-1.50 (m, 3H)


1230
N-(4-{[2-(1H-pyrrol-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



yl)ethyl]carbamoyl}phenyl)-
8.56-8.30 (m, 1H), 7.87-7.76 (m, 1H), 7.76-7.65 (m,
m/e 376



5,7-dihydro-6H-
2H), 7.67-7.50 (m, 2H), 7.41-7.20 (m, 1H), 6.73 (t,
(M + H)+



pyrrolo[3,4-b]pyridine-
J = 2.0 Hz, 1H), 6.17-5.79 (m, 1H), 4.86-4.72 (m,



6-carboxamide
4H), 4.08 (t, J = 6.5 Hz, 2H), 3.57 (t, J = 6.5 Hz, 2H)


1231
N-{4-[(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methoxypropan-2-
8.49 (d, J = 4.8 Hz, 1H), 7.85 (t, J = 8.8 Hz, 1H),
m/e 355



yl)carbamoyl]phenyl}-
7.81-7.70 (m, 2H), 7.70-7.52 (m, 2H), 7.51-7.22 (m,
(M + H)+



5,7-dihydro-6H-
1H), 4.82 (d, J = 9.0 Hz, 4H), 4.19 (h, J = 6.6 Hz, 1H),



pyrrolo[3,4-b]pyridine-
3.59-3.43 (m, 1H), 3.30 (s, 3H), 2.88 (d, J = 50.6 Hz,



6-carboxamide
1H), 1.15 (dd, J = 10.7, 6.7 Hz, 3H)


1232
N-{4-[(3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



aminobenzyl)carbamoyl]phenyl}-
8.48 (d, J = 4.7 Hz, 1H), 7.92-7.76 (m, 3H),
m/e 388



5,7-
7.74-7.51 (m, 2H), 7.32 (ddd, J = 15.4, 7.7, 4.6 Hz, 2H),
(M + H)+



dihydro-6H-
7.18-7.08 (m, 2H), 7.00 (d, J = 7.9 Hz, 1H), 4.82 (d, J = 11.2 Hz,



pyrrolo[3,4-b]pyridine-
4H), 4.47 (s, 2H)



6-carboxamide


1233
N-(4-{[(2R)-3-

1H NMR (400 MHz, DMSO_D2O) δ 8.56-8.39 (m,

(ESI(+))



methylbutan-2-
1H), 7.92-7.80 (m, 1H), 7.80-7.68 (m, 2H),
m/e 353



yl]carbamoyl}phenyl)-
7.68-7.53 (m, 2H), 7.53-6.97 (m, 1H), 4.83 (d, J = 7.2 Hz,
(M + H)+



5,7-dihydro-6H-
4H), 3.99-3.74 (m, 1H), 1.91-1.66 (m, 1H), 1.12 (d,



pyrrolo[3,4-b]pyridine-
J = 6.8 Hz, 3H), 0.99-0.82 (m, 6H)



6-carboxamide


1234
N-{4-[(tetrahydro-2H-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



pyran-3-
8.62-8.38 (m, 1H), 7.91-7.80 (m, 1H), 7.80-7.70 (m,
m/e 381



ylmethyl)carbamoyl]phenyl}-
2H), 7.69-7.45 (m, 2H), 7.48-7.24 (m, 1H), 4.83 (d,
(M + H)+



5,7-dihydro-
J = 8.0 Hz, 4H), 3.87-3.61 (m, 2H), 3.19-3.12 (m,



6H-pyrrolo[3,4-
3H), 1.92 (d, J = 34.0 Hz, 1H), 1.87-1.73 (m, 2H),



b]pyridine-6-
1.67-1.55 (m, 1H), 1.55-1.37 (m, 1H),



carboxamide
1.39-1.14 (m, 1H)


1235
N-{4-[(2-hydroxy-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methylpropyl)carbamoyl]phenyl}-
8.61-8.43 (m, 1H), 7.90-7.71 (m, 3H), 7.71-7.50 (m,
m/e 355



5,7-
2H), 7.42-7.14 (m, 1H), 4.98-4.68 (m, 4H),
(M + H)+



dihydro-6H-
3.04-2.66 (m, 2H), 1.29-1.01 (m, 6H)



pyrrolo[3,4-b]pyridine-



6-carboxamide


1236
N-[4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



(butylcarbamoyl)phenyl]-
8.55-8.42 (m, 1H), 7.85-7.77 (m, 1H), 7.79-7.68 (m,
m/e 339



5,7-dihydro-6H-
2H), 7.68-7.54 (m, 2H), 7.47-6.86 (m, 1H), 4.80 (t,
(M + H)+



pyrrolo[3,4-b]pyridine-
J = 9.0 Hz, 4H), 3.26-3.17 (m, 2H), 1.63-1.49 (m,



6-carboxamide
2H), 1.46-1.27 (m, 2H), 0.92 (dd, J = 9.2, 5.5 Hz,




3H)


1237
N-{4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



[methyl(tetrahydrofuran-
8.57-8.37 (m, 1H), 7.90-7.72 (m, 1H), 7.66-7.52 (m,
m/e 381



2-
2H), 7.45-7.34 (m, 1H), 7.33-7.16 (m, 2H), 4.86 (t,
(M + H)+



ylmethyl)carbamoyl]phenyl}-
J = 24.4 Hz, 4H), 4.21-3.97 (m, 1H), 3.86-3.55 (m,



5,7-dihydro-
2H), 3.57-3.39 (m, 2H), 3.08-2.97 (m, 3H),



6H-pyrrolo[3,4-
1.98-1.88 (m, 2H), 1.85-1.68 (m, 2H), 1.60-1.37 (m, 1H)



b]pyridine-6-



carboxamide


1238
N-{4-[(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ 8.49 (t,

(ESI(+))



methoxyethyl)(methyl)carbamoyl]phenyl}-
J = 5.2 Hz, 1H), 7.95-7.76 (m, 1H), 7.71-7.52 (m,
m/e 355



5,7-dihydro-6H-
2H), 7.38-7.33 (m, 1H), 7.33-7.22 (m, 2H), 4.82 (d,
(M + H)+



pyrrolo[3,4-b]pyridine-
J = 9.0 Hz, 4H), 3.61-3.44 (m, 4H), 3.29-3.19 (m,



6-carboxamide
3H), 2.98 (s, 3H)


1239
N-{4-[(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



cyanoethyl)carbamoyl]phenyl}-
8.59-8.32 (m, 1H), 7.91-7.72 (m, 3H), 7.72-7.59 (m,
m/e 336



5,7-dihydro-
2H), 7.40-7.20 (m, 1H), 5.03-4.86 (m, 1H),
(M + H)+



6H-pyrrolo[3,4-
4.88-4.68 (m, 4H), 1.72-1.43 (m, 3H)



b]pyridine-6-



carboxamide


1240
N-{4-[(3R)-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



tetrahydrofuran-3-
8.48 (d, J = 4.4 Hz, 1H), 7.89-7.74 (m, 3H),
m/e 353



ylcarbamoyl]phenyl}-
7.68-7.48 (m, 2H), 7.45-7.24 (m, 1H), 4.82 (d, J = 9.2 Hz, 4H),
(M + H)+



5,7-dihydro-6H-
4.59-4.28 (m, 1H), 3.94-3.83 (m, 2H),



pyrrolo[3,4-b]pyridine-
3.80-3.64 (m, 1H), 3.65-3.51 (m, 1H), 2.37-2.00 (m, 1H),



6-carboxamide
2.05-1.80 (m, 1H)


1241
N-{4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



[(cyclopentylmethyl)carbamoyl]phenyl}-
8.49 (d, J = 4.8 Hz, 1H), 7.90-7.80 (m, 1H),
m/e 365



5,7-
7.80-7.68 (m, 2H), 7.68-7.49 (m, 2H), 7.47-7.11 (m, 1H),
(M + H)+



dihydro-6H-
4.82 (d, J = 9.0 Hz, 4H), 3.26-3.10 (m, 2H),



pyrrolo[3,4-b]pyridine-
2.36-2.07 (m, 1H), 1.75-1.45 (m, 6H), 1.39-1.18 (m, 2H)



6-carboxamide


1242
N-{4-[(2-methoxy-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methylpropyl)carbamoyl]phenyl}-
8.61-8.36 (m, 1H), 7.88-7.71 (m, 3H), 7.71-7.55 (m,
m/e 369



5,7-
2H), 7.46-7.15 (m, 1H), 4.99-4.66 (m, 4H), 3.35 (d,
(M + H)+



dihydro-6H-
J = 4.5 Hz, 2H), 3.19-3.16 (m, 3H), 1.46-0.84 (m,



pyrrolo[3,4-b]pyridine-
6H)



6-carboxamide


1243
N-{4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



[(cyclopropylmethyl)carbamoyl]phenyl}-
8.60-8.40 (m, 1H), 7.85 (d, J = 7.7 Hz, 1H), 7.82-7.71 (m,
m/e 337



5,7-
2H), 7.71-7.53 (m, 2H), 7.38 (dd, J = 7.7, 5.0 Hz,
(M + H)+



dihydro-6H-
1H), 7.30-7.14 (m, 1H), 5.07-4.65 (m, 4H), 3.16 (t,



pyrrolo[3,4-b]pyridine-
J = 6.6 Hz, 2H), 1.20-0.87 (m, 1H), 0.52-0.37 (m,



6-carboxamide
2H), 0.32-0.06 (m, 2H)


1244
N-{4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



[methyl(propyl)carbamoyl]phenyl}-
8.61-8.38 (m, 1H), 7.93-7.76 (m, 1H), 7.68-7.54 (m,
m/e 339



5,7-
2H), 7.46-7.33 (m, 1H), 7.31-7.17 (m, 2H),
(M + H)+



dihydro-6H-
4.97-4.59 (m, 4H), 2.92 (d, J = 8.0 Hz, 4H), 1.67-1.47 (m,



pyrrolo[3,4-b]pyridine-
2H), 0.96-0.59 (m, 3H)



6-carboxamide


1245
N-{4-[(pyridin-4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



ylmethyl)carbamoyl]phenyl}-
8.83-8.62 (m, 2H), 8.52-8.39 (m, 1H), 7.96-7.77 (m,
m/e 374



5,7-dihydro-
3H), 7.77-7.70 (m, 2H), 7.70-7.59 (m, 2H),
(M + H)+



6H-pyrrolo[3,4-
7.43-7.14 (m, 1H), 4.90-4.72 (m, 4H), 4.74-4.48 (m, 2H)



b]pyridine-6-



carboxamide









Example 293
N-{4-[(4-phenylbutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 293A
N-(4-nitrophenyl)isoindoline-2-carboxamide

A solution of N-(4-aminophenyl)isoindoline-2-carboxamide (100 mg, 0.395 mmol), 4-phenylbutanoic acid (78 mg, 0.474 mmol), 1-hydroxybenzotriazole hydrate (66.5 mg, 0.434 mmol) and N-methylmorpholine (0.109 ml, 0.987 mmol) in N,N-dimethylformamide (1.771 ml) at room temperature was treated with N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (136 mg, 0.711 mmol). The mixture was stirred overnight and diluted with water (10 ml); the resulting suspension was filtered with water washes to give after drying product with an impurity. This solid was suspended in 2% methanol/dichloromethane and filtered to provide the title compound.


Example 293B
N-(4-aminophenyl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 274, substituting N-(4-nitrophenyl)isoindoline-2-carboxamide for 5-nitro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide.


Example 293C
N-{4-[(4-phenylbutanoyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

A solution of N-(4-aminophenyl)isoindoline-2-carboxamide (100 mg, 0.395 mmol), 4-phenylbutanoic acid (78 mg, 0.474 mmol), 1-hydroxybenzotriazole hydrate (66.5 mg, 0.434 mmol) and N-methylmorpholine (0.109 ml, 0.987 mmol) in dimethylformamide (1.771 ml) at room temperature was treated with N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (136 mg, 0.711 mmol). The mixture was stirred overnight and diluted with water (10 ml); the resulting suspension was filtered with water washes to give product with an impurity. This solid was suspended in 2% methanol/methylene chloride and filtered to provide the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.78-2.00 (m, 2H), 2.30 (t, J=7.3 Hz, 2H), 2.62 (t, J=7.5 Hz, 2H), 4.75 (s, 4H), 7.08-7.41 (m, 9H), 7.46 (s, 4H), 8.26 (s, 1H), 9.73 (s, 1H); (ESI(+)) m/e 400 (M+H)+.









TABLE 5







The following Examples were prepared essentially as described in Example 293,


using an appropriate amine in Example 293A and substituting an appropriate carboxylic acid


for 4-phenylbutanoic acid in Example 293C. Some products were purified by flash


chromatography while others were purified by reverse-phase HPLC; accordingly, some


Examples were isolated as trifluoroacetic acid salts.










Ex
Name

1H NMR

MS





291
N-{4-[(4,4,4-

1H NMR (300 MHz, DMSO-d6) δ ppm

(ESI(+))



trifluorobutanoyl)amino]phenyl}-
2.52-2.69 (m, 4 H), 4.75 (s, 4 H), 7.23-7.40 (m, 4 H),
m/e 378



1,3-dihydro-2H-
7.41-7.56 (m, 4 H), 8.28 (s, 1 H), 9.93 (s, 1 H)
(M + H)+



isoindole-2-carboxamide


292
N-{4-[(3-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



ethoxypropanoyl)amino]phenyl}-
Oxide, Temp = 90° C.) δ ppm 7.44 (s, 4H),
m/e 354



1,3-dihydro-2H-
7.32-7.37 (m, 2H), 7.28-7.32 (m, 2H), 4.76 (s, 4H),
(M + H)+



isoindole-2-carboxamide
3.68 (t, J = 6.3 Hz, 2H), 3.47 (q, J = 6.9 Hz, 2H),




2.50-2.55 (m, 2H), 1.11 (t, J = 6.9 Hz, 3H)


294
N-{4-[(4-

1H NMR (300 MHz, DMSO-d6) δ ppm 0.90 (d,

(ESI(+))



methylpentanoyl)amino]phenyl}-
J = 6.4 Hz, 6 H), 1.40-1.63 (m, 3 H),
m/e 352



1,3-dihydro-2H-
2.18-2.39 (m, 2 H), 4.75 (s, 4 H), 7.20-7.41 (m, 4 H,)
(M + H)+



isoindole-2-carboxamide
7.45 (s, 4 H), 8.26 (s, 1 H), 9.72 (s, 1 H)


295
N-(4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



{[(benzyloxy)acetyl]amino}phenyl)-
Oxide, Temp = 90° C.) δ ppm 7.47 (s, 4H),
m/e 402



1,3-dihydro-2H-
7.28-7.43 (m, 9H), 4.76 (s, 4H), 4.64 (s, 2H), 4.07 (s,
(M + H)+



isoindole-2-carboxamide
2H)


296
N-{4-[(3-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(−)) m/e



phenylpropanoyl)amino]phenyl}-
Oxide, Temp = 90° C.) δ ppm 7.42 (s, 4H),
384 (M − H)



1,3-dihydro-2H-
7.22-7.37 (m, 8H), 7.15-7.20 (m, 1H), 4.76 (s, 4H),



isoindole-2-carboxamide
2.93 (t, J = 7.6 Hz, 2H), 2.59-2.63 (m, 2H)


297
N-{4-[(3-

1H NMR (400 MHz, DMSO-d6/Deuterium

(APCI(+))



phenoxypropanoyl)amino]phenyl}-
Oxide, Temp = 90° C.) δ ppm 7.45 (s, 4H),
m/e 402



1,3-dihydro-2H-
7.26-7.36 (m, 6H), 6.92-6.96 (m, 2H), 6.91-6.95 (m,
(M + H)+



isoindole-2-carboxamide
1H), 4.76 (s, 4H), 4.29 (t, J = 6.2 Hz, 2H),




2.76 (t, J = 6.2 Hz, 2H)


298
N-(4-{[N-(2-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



furoyl)glycyl]amino}phenyl)-
Oxide, Temp = 90° C.) δ ppm 7.76 (dd, J = 1.8, 0.8 Hz,
m/e 405



1,3-dihydro-2H-isoindole-2-
1H), 7.42-7.48 (m, 4H), 7.29-7.36 (m, 4H),
(M + H)+



carboxamide
7.12 (dd, J = 3.5, 0.9 Hz, 1H), 6.62 (dd, J = 3.4,




1.7 Hz, 1H), 4.76 (s, 4H), 4.04 (s, 2H)


299
N-(4-{[4-(2-

1H NMR (400 MHz, DMSO-d6/Deuterium

(APCI(+))



thienyl)butanoyl]amino}phenyl)-
Oxide, Temp = 90° C.) δ ppm 7.43 (s, 4H),
m/e 406



1,3-dihydro-2H-
7.32-7.38 (m, 2H), 7.28-7.32 (m, 2H), 7.25 (dd, J = 5.2,
(M + H)+



isoindole-2-carboxamide
1.2 Hz, 1H), 6.94 (dd, J = 5.0, 3.4 Hz, 1H),




6.86 (dq, J = 3.3, 1.1 Hz, 1H), 4.76 (s, 4H),




2.87 (ddd, J = 8.1, 7.1, 1.0 Hz, 2H), 2.37 (t, J = 7.3 Hz,




2H), 1.96 (p, J = 7.4 Hz, 2H)


300
N-{4-[(4-oxo-4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(−)) m/e



phenylbutanoyl)amino]phenyl}-
Oxide, Temp = 90° C.) δ ppm 7.96-7.99 (m, 2H),
412 (M − H)



1,3-dihydro-2H-isoindole-
7.60-7.65 (m, 1H), 7.50-7.56 (m, 2H), 7.43 (s,



2-carboxamide
4H), 7.32-7.37 (m, 2H), 7.28-7.32 (m, 2H),




4.76 (s, 4H), 3.32 (t, J = 6.6 Hz, 2H), 2.72 (t, J = 6.6 Hz,




2H)


301
N-{4-[(N-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



benzoylglycyl)amino]phenyl}-
Oxide, Temp = 90° C.) δ ppm 7.84-7.94 (m, 2H),
m/e 415



1,3-dihydro-2H-isoindole-
7.52-7.57 (m, 1H), 7.48-7.51 (m, 2H), 7.46 (s,
(M + H)+



2-carboxamide
4H), 7.32-7.37 (m, 2H), 7.28-7.32 (m, 2H),




4.76 (s, 4H), 4.08 (s, 2H)


302
N-{4-[(4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(−)) m/e



phenoxybutanoyl)amino]phenyl}-
Oxide, Temp = 90° C.) δ ppm 7.44 (s, 4H),
414 (M − H)



1,3-dihydro-2H-
7.33-7.37 (m, 2H), 7.29-7.32 (m, 2H), 7.24-7.29 (m,



isoindole-2-carboxamide
2H), 6.90-6.94 (m, 3H), 4.76 (s, 4H), 4.04 (t, J = 6.4 Hz,




2H), 2.47 (t, J = 7.3 Hz, 2H),




2.01-2.08 (m, 2H)


303
N-[4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



(propionylamino)phenyl]-
Oxide, Temp = 90° C.) δ ppm 7.43 (s, 4H),
m/e 310



1,3-dihydro-2H-isoindole-2-
7.29-7.36 (m, 4H), 4.76 (s, 4H), 2.30 (q, J = 7.6 Hz,
(M + H)+



carboxamide
2H), 1.11 (t, J = 7.5 Hz, 3H)


304
N-[4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



(pentanoylamino)phenyl]-
Oxide, Temp = 90° C.) δ ppm 7.43 (s, 4H),
m/e 338



1,3-dihydro-2H-isoindole-2-
7.32-7.37 (m, 2H), 7.28-7.32 (m, 2H), 4.76 (s, 4H),
(M + H)+



carboxamide
2.28 (t, J = 7.4 Hz, 2H), 1.56-1.64 (m, 2H),




1.30-1.40 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H)


305
N-[4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



(hexanoylamino)phenyl]-1,3-
Oxide, Temp = 90° C.) δ ppm 7.43 (s, 4H),
m/e 352



dihydro-2H-isoindole-2-
7.29-7.36 (m, 4H), 4.76 (s, 4H), 2.27 (t, J = 7.4 Hz,
(M + H)+



carboxamide
2H), 1.57-1.65 (m, 2H), 1.27-1.37 (m, 4H),




0.86-0.90 (m, 3H)


306
N-[4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



(heptanoylamino)phenyl]-
Oxide, Temp = 90° C.) δ ppm 7.43 (s, 4H),
m/e 366



1,3-dihydro-2H-isoindole-2-
7.29-7.36 (m, 4H), 4.76 (s, 4H), 2.28 (t, J = 7.4 Hz,
(M + H)+



carboxamide
2H), 1.60 (p, J = 7.1 Hz, 2H), 1.25-1.39 (m, 6H),




0.83-0.91 (m, 3H)


307
N-[4-(pent-4-

1H NMR (300 MHz, DMSO-d6) δ ppm

(ESI(+))



enoylamino)phenyl]-1,3-
2.24-2.44 (m, 4 H), 4.75 (s, 4 H), 4.91-5.14 (m, 2 H),
m/e 336



dihydro-2H-isoindole-2-
5.72-5.97 (m, 1 H), 7.25-7.40 (m, 4 H),
(M + H)+



carboxamide
7.46 (s, 4 H), 8.26 (s, 1 H), 9.76 (s, 1 H)


308
N-{4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



[(ethoxyacetyl)amino]phenyl}-
Oxide, Temp = 90° C.) δ ppm 7.47-7.50 (m, 4H),
m/e 340



1,3-dihydro-2H-isoindole-
7.29-7.36 (m, 4H), 4.76 (s, 4H), 3.99 (s, 2H),
(M + H)+



2-carboxamide
3.60 (q, J = 7.0 Hz, 2H), 1.21 (t, J = 6.9 Hz, 3H)


309
N-(4-{[(2-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



methoxyethoxy)acetyl]amino}phenyl)-
Oxide, Temp = 90° C.) δ ppm 7.47 (s, 4H),
m/e 370



1,3-dihydro-2H-
7.29-7.36 (m, 4H), 4.76 (s, 4H), 4.04 (s, 2H),
(M + H)+



isoindole-2-carboxamide
3.68-3.71 (m, 2H), 3.55-3.58 (m, 2H), 3.32 (s, 3H)


310
N-{4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



[(cyclopropylacetyl)amino]phenyl}-
Oxide, Temp = 90° C.) δ ppm 7.44 (s, 4H),
m/e 336



1,3-dihydro-2H-
7.29-7.36 (m, 4H), 4.76 (s, 4H), 2.21 (d, J = 6.9 Hz,
(M + H)+



isoindole-2-carboxamide
2H), 1.00-1.14 (m, 1H), 0.47-0.52 (m, 2H),




0.18-0.23 (m, 2H)


311
N-{4-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(−)) m/e



[(cyclopentylacetyl)amino]phenyl}-
Oxide, Temp = 90° C.) δ ppm 7.43 (s, 4H),
362 (M − H)



1,3-dihydro-2H-
7.29-7.36 (m, 4H), 4.76 (s, 4H), 2.25-2.30 (m, 3H),



isoindole-2-carboxamide
1.73-1.81 (m, 2H), 1.49-1.64 (m, 4H),




1.18-1.27 (m, 2H)


312
N-(4-{[3-(4-methylpiperazin-

1H NMR (400 MHz, DMSO-d6/Deuterium

(ESI(+))



1-
Oxide, Temp = 90° C.) δ ppm 7.42-7.48 (m, 4H),
m/e 408



yl)propanoyl]amino}phenyl)-
7.29-7.36 (m, 4H), 4.76 (s, 4H), 3.22-3.25 (m,
(M + H)+



1,3-dihydro-2H-isoindole-2-
4H), 3.03 (t, J = 6.9 Hz, 2H), 2.97-3.01 (m, 4H),



carboxamide
2.77 (s, 3H), 2.62 (t, J = 6.9 Hz, 2H)


564
5-cyano-N-{4-

1H NMR (300 MHz, DMSO-d6) δ ppm 9.70 (s,

(ESI(+))



[(cyclopentylacetyl)amino]phenyl}-
1H), 8.35 (s, 1H), 7.88 (s, 1H), 7.78 (dd, J = 7.9,
m/e 389



1,3-dihydro-2H-
1.5 Hz, 1H), 7.58 (d, J = 7.9 Hz, 1H),
(M + H)+



isoindole-2-carboxamide
7.51-7.40 (m, 4H), 4.84-4.76 (m, 4H),




2.31-2.15 (m, 3H), 1.81-1.67 (m, 2H), 1.67-1.45 (m,




4H), 1.29-1.11 (m, 2H)


596
N-{4-

1H NMR (300 MHz, DMSO-d6) δ ppm 9.68 (s,

(ESI(+))



[(cyclopentylacetyl)amino]phenyl}-
1H), 8.23 (s, 1H), 7.50-7.38 (m, 4H), 7.25 (d, J = 8.4 Hz,
m/e 394



5-methoxy-1,3-
1H), 6.95-6.91 (m, 1H),
(M + H)+



dihydro-2H-isoindole-2-
6.90-6.83 (m, 1H), 4.68 (m, 4H), 3.76 (s, 3H),



carboxamide
2.31-2.15 (m, 3H), 1.83-1.68 (m, 2H), 1.67-1.40 (m,




4H), 1.29-1.11 (m, 2H)


649
5-(hydroxymethyl)-N-{4-

1H NMR (300 MHz, DMSO-d6) δ ppm 9.80 (s,

(ESI(+))



[(tetrahydrofuran-3-
1H), 8.28 (s, 1H), 7.46 (s, 4H), 7.33-7.28 (m,
m/e 396



ylacetyl)amino]phenyl}-1,3-
2H), 7.27-7.21 (m, 1H), 5.21 (t, J = 5.6 Hz,
(M + H)+



dihydro-2H-isoindole-2-
1H), 4.73 (bs, 4H), 4.51 (d, J = 5.6 Hz, 2H),



carboxamide
3.85-3.70 (m, 2H), 3.64 (q, J = 7.6 Hz, 1H),




2.61-2.52 (m, 2H), 2.42-2.32 (m, 2H),




2.12-1.94 (m, 1H), 1.62-1.47 (m, 1H)


650
5-(hydroxymethyl)-N-(4-

1H NMR (300 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



{[(2-
ppm 9.19 (s, 1H), 8.05 (s, 1H), 7.48 (m, 4H),
m/e 400



methoxyethoxy)acetyl]amino}phenyl)-
7.31-7.19 (m, 3H), 4.86 (bs, 1H), 4.74 (bs, 4H),
(M + H)+



1,3-dihydro-2H-
4.53 (bs, 2H), 4.04 (s, 2H), 3.74-3.66 (m, 2H),



isoindole-2-carboxamide
3.60-3.52 (m, 2H), 3.32 (s, 3H)


682
5-(hydroxymethyl)-N-{4-

1H NMR (300 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



[(tetrahydrofuran-2-
ppm 9.41 (bs, 1H), 8.01 (bs, 1H), 7.45-7.41 (m,
m/e 396



ylacetyl)amino]phenyl}-1,3-
4H), 7.30-7.22 (m, 3H), 4.87 (bs, 1H), 4.73 (bs,
(M + H)+



dihydro-2H-isoindole-2-
4H), 4.52 (bs, 2H), 4.22-4.14 (m, 1H),



carboxamide
3.82-3.75 (m, 1H), 3.66-3.59 (m, 1H), 2.53 (dd, J = 14.1,




7.0 Hz, 1H), 2.40 (dd, J = 14.0, 6.1 Hz,




1H), 2.05-1.94 (m, 1H), 1.92-1.76 (m, 2H),




1.64-1.51 (m, 1H)


683
N-{4-

1H NMR (300 MHz, DMSO-d6) δ ppm 9.52 (s,

(ESI(+))



[(ethoxyacetyl)amino]phenyl}-
1H), 8.29 (s, 1H), 7.56-7.44 (m, 4H),
m/e 370



5-(hydroxymethyl)-1,3-
7.33-7.20 (m, 3H), 5.20 (t, J = 5.6 Hz, 1H), 4.73 (bs,
(M + H)+



dihydro-2H-isoindole-2-
4H), 4.51 (d, J = 5.6 Hz, 2H), 4.00 (s, 2H),



carboxamide
3.56 (q, J = 7.0 Hz, 2H), 1.19 (t, J = 7.0 Hz, 3H)


684
5-(hydroxymethyl)-N-{4-

1H NMR (300 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



[(tetrahydro-2H-pyran-4-
ppm 9.43 (bs, 1H), 8.00 (bs, 1H), 7.44-7.41 (m,
m/e 410



ylacetyl)amino]phenyl}-1,3-
4H), 7.30-7.20 (m, 3H), 4.87 (bs, 1H), 4.73 (bs,
(M + H)+



dihydro-2H-isoindole-2-
4H), 4.52 (bs, 2H), 3.86-3.78 (m, 2H),



carboxamide
3.38-3.26 (m, 2H), 2.23 (d, J = 7.0 Hz, 2H),




2.07-1.94 (m, 1H), 1.66-1.58 (m, 2H),




1.35-1.20 (m, 2H)


685
5-(hydroxymethyl)-N-{4-

1H NMR (300 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



[(morpholin-4-
ppm 9.32 (bs, 1H), 8.04 (bs, 1H), 7.49-7.45 (m,
m/e 411



ylacetyl)amino]phenyl}-1,3-
4H), 7.32-7.22 (m, 3H), 4.89-4.83 (m, 1H),
(M + H)+



dihydro-2H-isoindole-2-
4.74 (bs, 4H), 4.53 (bs, 2H), 3.68-3.62 (m, 4H),



carboxamide
3.10 (s, 2H), 2.57-2.51 (m, 4H)


789
N-{4-

1H NMR (400 MHz, DMSO-d6/D2O,

(ESI(+))



[(cyclopentylacetyl)amino]phenyl}-
Temp = 90° C.) δ ppm 7.39 (m, 4H), 7.16 (dd, J = 9.1,
m/e 382



5-fluoro-1,3-dihydro-
2.6, 1H), 7.09 (m, 1H), 4.75 (bs, 2H),
(M + H)+



2H-isoindole-2-carboxamide
4.72 (bs, 2H), 2.27 (m, 4H), 1.76 (m, 2H), 1.57 (m,




4H), 1.24 (m, 2H)


791
N-{4-

1H NMR (400 MHz, DMSO-d6/D2O,

(ESI(+))



[(cyclopentylacetyl)amino]phenyl}-
Temp = 90° C.) δ 7.70 (s, 1H), 7.64 (dd, J = 8.0,
m/e 432



5-(trifluoromethyl)-
1.6, 1H), 7.58 (d, J = 8.0, 1H), 7.48-7.41 (m,
(M + H)+



1,3-dihydro-2H-isoindole-2-
3H), 4.83 (s, 3H), 2.32-2.25 (m, 3H),



carboxamide
1.81-1.71 (m, 2H), 1.66-1.47 (m, 4H),




1.28-1.16 (m, 2H)


792
4-cyano-N-{4-

1H NMR (400 MHz, DMSO-d6/D2O,

(ESI(+))



[(cyclopentylacetyl)amino]phenyl}-
Temp = 90° C.) δ 7.70 (ddd, J = 12.2, 7.7, 0.8, 2H),
m/e 389



1,3-dihydro-2H-
7.52 (d, J = 7.7, 1H), 7.45 (m, 5H), 4.93 (d, J = 1.3,
(M + H)+



isoindole-2-carboxamide
2H), 4.83 (d, J = 0.7, 2H), 2.28 (m, 4H),




1.77 (m, 2H), 1.57 (m, 4H)


793
N-{4-

1H NMR (400 MHz, DMSO-d6/D2O,

(ESI(+))



[(cyclopentylacetyl)amino]phenyl}-
Temp = 90° C.) δ 7.42 (s, 4H), 7.22 (d, J = 7.8,
m/e 378



5-methyl-1,3-dihydro-
1H), 7.15 (s, 1H), 7.15-7.08 (m, 1H), 4.70 (bs,
(M + H)+



2H-isoindole-2-carboxamide
4H), 2.35-2.23 (m, 4H), 1.82-1.71 (m, 2H),




1.66-1.47 (m, 4H), 1.30-1.16 (m, 2H)


794
4-chloro-N-{4-

1H NMR (400 MHz, DMSO-d6/D2O,

(ESI(+))



[(cyclopentylacetyl)amino]phenyl}-
Temp = 90° C.) δ 7.43 (m, 4H), 7.33 (m, 3H),
m/e 398



1,3-dihydro-2H-
4.83 (m, 2H), 4.78 (m, 2H), 2.28 (m, 3H), 1.77 (m,
(M + H)+



isoindole-2-carboxamide
2H), 1.57 (m, 4H), 1.22 (m, 2H)


796
5-chloro-N-{4-

1H NMR (400 MHz, DMSO-d6/D2O,

(ESI(+))



[(cyclopentylacetyl)amino]phenyl}-
Temp = 90° C.) δ 7.35 (m, 7H), 4.74 (d, J = 6.7,
m/e 398



1,3-dihydro-2H-
4H), 2.27 (m, 3H), 1.78 (m, 2H), 1.57 (m, 4H),
(M + H)+



isoindole-2-carboxamide
1.21 (m, 2H)


874
5-acetyl-N-{4-

1H NMR (300 MHz, DMSO-d6) δ ppm 9.70 (s,

(ESI(+))



[(cyclopentylacetyl)amino]phenyl}-
1H), 8.33 (s, 1H), 7.96-7.88 (m, 2H),
m/e 406



1,3-dihydro-2H-
7.54-7.40 (m, 5H), 4.81 (bs, 4H), 2.60 (s, 3H),
(M + H)+



isoindole-2-carboxamide
2.31-2.18 (m, 3H), 1.81-1.68 (m, 2H),




1.68-1.43 (m, 4H), 1.25-1.10 (m, 2H)


878
N-{4-

1H NMR (300 MHz, DMSO-d6) δ ppm 9.68 (s,

(ESI(+))



[(cyclopentylacetyl)amino]phenyl}-
1H), 8.25 (s, 1H), 7.47-7.44 (m, 4H), 7.32 (s,
m/e 408



5-(1-hydroxyethyl)-
1H), 7.27 (s, 2H), 5.15 (d, J = 4.0 Hz, 1H),
(M + H)+



1,3-dihydro-2H-isoindole-2-
4.78-4.67 (m, 5H), 2.30-2.15 (m, 3H),



carboxamide
1.82-1.68 (m, 2H), 1.67-1.45 (m, 4H), 1.33 (d, J = 6.4 Hz,




3H), 1.26-1.13 (m, 2H)


879
N-[4-(butyrylamino)phenyl]-

1H NMR (500 MHz, DMSO-d6) δ ppm 9.72 (s,

(ESI(+))



5-cyano-1,3-dihydro-2H-
1H), 8.34 (s, 1H), 7.86 (s, 1H), 7.79-7.73 (m,
m/e 349



isoindole-2-carboxamide
1H), 7.59-7.53 (d, J = 7.9 Hz, 1H),
(M + H)+




7.48-7.40 (m, 4H), 4.83-4.75 (m, 4H), 2.24 (t, J = 7.3 Hz,




2H), 1.65-1.53 (m, 2H), 0.90 (t, J = 7.4 Hz,




3H)


919
5-(acetamidomethyl)-N-{4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



[(cyclopentylacetyl)amino]phenyl}-
ppm 9.36 (bs, 1H), 8.04-7.95 (m, 2H),
m/e 435



1,3-dihydro-2H-
7.48-7.39 (m, 4H), 7.30-7.17 (m, 3H), 4.73 (bs, 4H),
(M + H)+



isoindole-2-carboxamide
4.27 (d, J = 5.9 Hz, 2H), 2.33-2.21 (m, 3H),




1.88 (s, 3H), 1.83-1.71 (m, 2H),




1.69-1.47 (m, 4H), 1.29-1.17 (m, 2H)


932
N-{4-

1H NMR (300 MHz, DMSO-d6) δ ppm 9.70 (s,

(ESI(+))



[(cyclopentylacetyl)amino]phenyl}-
1H), 8.25 (s, 1H), 7.50-7.41 (m, 5H),
m/e 422



5-(2-hydroxypropan-2-
7.42-7.36 (m, 1H), 7.29-7.23 (m, 1H), 5.03 (s, 1H),
(M + H)+



yl)-1,3-dihydro-2H-
4.72 (bs, 4H), 2.31-2.16 (m, 3H),



isoindole-2-carboxamide
1.85-1.68 (m, 2H), 1.68-1.46 (m, 4H), 1.43 (s, 6H),




1.26-1.09 (m, 2H)


935
N-{4-

1H NMR (300 MHz, DMSO-d6) δ ppm 9.69 (s,

(ESI(+))



[(cyclopentylacetyl)amino]phenyl}-
1H), 8.27 (s, 1H), 7.51-7.40 (m, 4H),
m/e 408



5-(methoxymethyl)-
7.36-7.22 (m, 3H), 4.74 (bs, 4H), 4.42 (s, 2H), 3.29 (s,
(M + H)+



1,3-dihydro-2H-isoindole-2-
3H), 2.35-2.15 (m, 3H), 1.81-1.68 (m, 2H),



carboxamide
1.68-1.43 (m, 4H), 1.26-1.10 (m, 2H)









Example 313
methyl 2-({4-[(cyclopentylacetyl)amino]phenyl}carbamoyl)isoindoline-5-carboxylate
Example 313A
methyl 2-(4-nitrophenylcarbamoyl)isoindoline-5-carboxylate

The title compound was prepared as described in Example 1A, substituting 4-nitrophenyl isocyanate for methyl 4-isocyanatobenzoate and methyl isoindoline-5-carboxylate hydrochloride for isoindoline.


Example 313B
methyl 2-(4-aminophenylcarbamoyl)isoindoline-5-carboxylate

The title compound was prepared as described in Example 274, substituting methyl 2-(4-nitrophenylcarbamoyl)isoindoline-5-carboxylate for 5-nitro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide.


Example 313C
methyl 2-({4-[(cyclopentylacetyl)amino]phenyl}carbamoyl)isoindoline-5-carboxylate

The title compound was prepared as described in Example 278, substituting methyl 2-(4-aminophenylcarbamoyl)isoindoline-5-carboxylate for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide and 2-cyclopentylacetyl chloride for acetyl chloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.69 (s, 1H), 8.32 (s, 1H), 7.94-7.94 (m, 1H), 7.89-7.96 (m, 1H), 7.51 (d, J=8.1 Hz, 1H), 7.41-7.49 (m, 4H), 4.75-4.82 (m, 4H), 3.87 (s, 3H), 2.24-2.29 (m, 2H), 2.15-2.28 (m, 1H), 1.68-1.81 (m, 2H), 1.44-1.67 (m, 4H), 1.13-1.24 (m, 2H); MS (ESI(+)) m/e 422 (M+H)+.


Example 314
2-({4-[(cyclopentylacetyl)amino]phenyl}carbamoyl)isoindoline-5-carboxylic acid

The title compound was prepared as described in Example 1B, substituting methyl 2-({4-[(cyclopentylacetyl)amino]phenyl}carbamoyl)isoindoline-5-carboxylate for methyl 4-(isoindoline-2-carboxamido)benzoate. 1H NMR (300 MHz, DMSO-d6) δ ppm 12.97 (dd, J=4.1, 2.1 Hz, 1H), 9.70 (s, 1H), 8.32 (s, 1H), 7.88-7.92 (m, 2H), 7.46-7.50 (m, 1H), 7.43-7.48 (m, 4H), 4.79-4.81 (bs, 4H), 2.24-2.30 (m, 2H), 2.16-2.29 (m, 1H), 1.68-1.81 (m, 2H), 1.44-1.67 (m, 4H), 1.10-1.27 (m, 2H); MS (ESI(−)) m/e 406 (M−H).


Example 315
N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide

To a stirring suspension of 2-(4-(2-cyclopentylacetamido)phenylcarbamoyl)isoindoline-5-carboxylic acid (18 mg, 0.044 mmol) in tetrahydrofuran was added 1M borane in tetrahydrofuran (0.18 mL, 0.18 mml) dropwise. The mixture was heated at 60° C. for 1 hour. The reaction was cooled to room temperature and treated with several drops of 4M HCl-dioxane and methanol and then the clear solution was stirred at room temperature for 2 hours. The reaction was concentrated and purified by reverse-phase HPLC to provide the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.69 (s, 1H), 8.26 (s, 1H), 7.45 (s, 4H), 7.28-7.32 (m, 2H), 7.22-7.26 (m, 1H), 5.18-5.22 (m, 1H), 4.72-4.73 (bs, 4H), 4.50-4.53 (bs, 2H), 2.17-2.32 (m, 3H), 1.70-1.80 (m, 2H), 1.44-1.67 (m, 4H), 1.13-1.24 (m, 2H); MS (ESI(+)) m/e 394 (M+H)+.


Example 316
N-{4-[(2-cyclopentylethyl)amino]phenyl}-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide

To a stirring suspension of 2-(4-(2-cyclopentylacetamido)phenylcarbamoyl)isoindoline-5-carboxylic acid (18 mg, 0.044 mmol) in tetrahydrofuran was added 1M borane in tetrahydrofuran (0.18 mL, 0.18 mml) dropwise. The mixture was heated at 60° C. for 1 hour. The reaction was cooled to room temperature and treated with several drops of 4M HCl-dioxane and methanol and then the clear solution was stirred at room temperature for 2 hours. The reaction was concentrated and purified by reverse-phase HPLC to provide the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.92 (s, 1H), 7.27-7.31 (m, 2H), 7.24 (d, J=8.1 Hz, 1H), 7.15-7.20 (m, 2H), 6.45-6.51 (m, 2H), 5.17-5.21 (m, 2H), 4.68-4.69 (bs, 4H), 4.51 (d, J=5.4 Hz, 2H), 2.97 (q, J=6.7 Hz, 2H), 1.70-1.95 (m, 3H), 1.42-1.66 (m, 6H), 1.04-1.20 (m, 2H); MS (ESI(+)) m/e 380 (M+H)+.


Example 317
tert-Butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}-3,6-dihydropyridine-1(2H)-carboxylate
Example 317A
N-(4-bromophenyl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 1A, substituting 4-bromophenyl isocyanate for methyl 4-isocyanatobenzoate.


Example 317B
tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}-3,6-dihydropyridine-1(2H)-carboxylate

The title compound was prepared as described in Example 280, substituting tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate for 1H-pyrazol-3-ylboronic acid and N-(4-bromophenyl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.38 (s, 1H), 7.55-7.57 (m, 2H), 7.26-7.42 (m, 6H), 6.06-6.09 (bs, 1H), 4.76-4.77 (bs, 4H), 3.97-4.00 (m, 2H), 3.51-3.55 (m, 2H), 2.42-2.46 (m, 2H), 1.43 (s, 9H); MS (ESI(−)) m/e 418 (M−H).


Example 318
N-[4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}-3,6-dihydropyridine-1(2H)-carboxylate for tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.44 (s, 1H), 7.58-7.61 (m, 2H), 7.30-7.41 (m, 6H), 6.12-6.14 (bs, 1H), 4.77-4.78 (bs, 4H), 3.70-3.72 (m, 2H), 3.27-3.31 (m, 2H), 2.60-2.64 (m, 2H); MS (ESI(+)) m/e 320 (M+H)+.


Example 319
N-{4-[1-(3-methylbutyl)-1H-pyrazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting 1-isopentyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1H-pyrazol-3-ylboronic acid and N-(4-bromophenyl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 0.91 (d, J=6.4 Hz, 6H), 1.40-1.60 (m, 1H), 1.70 (q, J=6.8 Hz, 2H), 4.11 (t, J=7.1 Hz, 2H), 4.77 (s, 4H), 7.13-7.40 (m, 4H), 7.42-7.50 (m, 2H), 7.50-7.61 (m, 2H), 7.78 (s, 1H), 8.08 (s, 1H), 8.32 (s, 1H); MS (ESI(+)) m/e 375 (M+H)+.


Example 320
N-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1H-pyrazol-3-ylboronic acid and N-(4-bromophenyl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 3.84 (s, 3H), 4.77 (s, 4H), 7.24-7.40 (m, 4H), 7.40-7.49 (m, 2H), 7.50-7.60 (m, 2H), 7.77 (s, 1H), 8.02 (s, 1H), 8.33 (s, 1H); MS (ESI(+)) m/e 319 (M+H)+.


Example 321
N-{4-[(1E)-5-phenylpent-1-en-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting (E)-4,4,5,5-tetramethyl-2-(5-phenylpent-1-enyl)-1,3,2-dioxaborolane for 1H-pyrazol-3-ylboronic acid and N-(4-bromophenyl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.60-1.84 (m, 2H), 2.19 (q, J=7.0 Hz, 2H), 2.55-2.71 (m, 2H), 4.76 (s, 4H), 6.12-6.27 (m, 1H), 6.26-6.43 (m, 1H), 7.09-7.44 (m, 11H), 7.52 (d, J=8.5 Hz, 2H), 8.33 (s, 1H); MS (ESI(+)) m/e 383 (M+H)+.


Example 322
N-[4-(1-propyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting 1-propyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1H-pyrazol-3-ylboronic acid and N-(4-bromophenyl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 0.85 (t, J=7.3 Hz, 3H), 1.69-1.93 (m, 2H), 4.05 (t, J=6.9 Hz, 2H), 4.77 (s, 4H), 7.26-7.40 (m, 4H), 7.42-7.49 (m, 2H), 7.52-7.61 (m, 2H), 7.79 (s, 1H), 8.07 (s, 1H), 8.33 (s, 1H); MS (ESI(+)) m/e 347 (M+H)+.


Example 323
N-[4-(1-benzyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting 1-benzyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1H-pyrazol-3-ylboronic acid and N-(4-bromophenyl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 4.77 (s, 4H), 5.33 (s, 2H), 7.21-7.42 (m, 9H), 7.41-7.51 (m, 2H), 7.51-7.61 (m, 2H), 7.84 (s, 1H), 8.17 (s, 1H), 8.33 (s, 1H); MS (ESI(+)) m/e 395 (M+H)+.


Example 324
N-{4-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)ethanol for 1H-pyrazol-3-ylboronic acid and N-(4-bromophenyl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 3.76 (q, J=5.8 Hz, 2H), 4.14 (t, J=5.6 Hz, 2H), 4.77 (s, 4H), 4.90 (t, J=5.4 Hz, 1H), 7.25-7.41 (m, 4H), 7.41-7.51 (m, 2H), 7.51-7.60 (m, 2H), 7.80 (s, 1H), 8.04 (s, 1H), 8.32 (s, 1H); MS (ESI(+)) m/e 349 (M+H)+.


Example 325
N-[6-(1-propyl-1H-pyrazol-4-yl)pyridin-3-yl]-1,3-dihydro-2H-isoindole-2-carboxamide
Example 325A
N-(6-chloropyridin-3-yl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 1A, substituting 2-chloro-5-isocyanatopyridine for methyl 4-isocyanatobenzoate.


Example 325B
N-[6-(1-propyl-1H-pyrazol-4-yl)pyridin-3-yl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting 1-propyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1H-pyrazol-3-ylboronic acid and N-(6-chloropyridin-3-yl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.90-8.92 (bs, 1H), 8.84 (d, J=2.5 Hz, 1H), 8.39 (s, 1H), 8.25 (dd, J=8.8, 2.5 Hz, 1H), 8.08 (s, 1H), 7.87 (d, J=8.8 Hz, 1H), 7.31-7.41 (m, 4H), 4.79-4.83 (bs, 4H), 4.13 (t, J=6.9 Hz, 2H), 1.77-1.89 (m, 2H), 0.86 (t, J=7.3 Hz, 3H); MS (ESI(+)) m/e 348 (M+H)+.


Example 326
N-{6-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting 1-isopentyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1H-pyrazol-3-ylboronic acid and N-(6-chloropyridin-3-yl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) 0.5 ppm 8.85-8.87 (bs, 1H), 8.81 (d, J=2.5 Hz, 1H), 8.38 (s, 1H), 8.21 (dd, J=8.8, 2.5 Hz, 1H), 8.05 (s, 1H), 7.82 (d, J=8.8 Hz, 1H), 7.31-7.41 (m, 4H), 4.78-4.83 (bs, 4H), 4.19 (t, J=7.1 Hz, 2H), 1.71 (q, J=7.0 Hz, 2H), 1.40-1.59 (m, 1H), 0.92 (d, J=6.6 Hz, 6H); MS (ESI(−)) m/e 374 (M−H).


Example 327
N-[4-(5-phenylpentyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 274, substituting N-{4-[(1E)-5-phenylpent-1-en-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide for 5-nitro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) 0.5 ppm 1.21-1.40 (m, 4H), 1.49-1.67 (m, 4H), 2.45-2.62 (m, 2H), 4.75 (s, 4H), 7.05 (d, J=8.7 Hz, 2H), 7.14-7.40 (m, 9H), 7.44 (d, J=8.3 Hz, 2H), 8.23 (s, 1H); MS (ESI(+)) m/e 385 (M+H)+.


Example 328
N-[2-fluoro-4-(1-propyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
Example 328A
N-(4-bromo-2-fluorophenyl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 1A, substituting 4-bromo-2-fluoro-1-isocyanatobenzene for methyl 4-isocyanatobenzoate.


Example 328B
N-[2-fluoro-4-(1-propyl-1H-pyrazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting 1-propyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1H-pyrazol-3-ylboronic acid and N-(4-bromo-2-fluorophenyl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) 0.5 ppm 8.19 (s, 1H), 8.03 (s, 1H), 7.89 (s, 1H), 7.57 (t, J=8.4 Hz, 1H), 7.46 (dd, J=12.1, 1.9 Hz, 1H), 7.24-7.39 (m, 5H), 4.76-4.78 (bs, 4H), 4.06 (t, J=6.9 Hz, 2H), 1.75-1.88 (m, 2H), 0.86 (t, J=7.3 Hz, 3H); MS (ESI(+)) m/e 365 (M+H)+.


Example 329
N-{2-fluoro-4-[1-(3-methylbutyl)-1H-pyrazol-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting 1-isopentyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1H-pyrazol-3-ylboronic acid and N-(4-bromo-2-fluorophenyl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.21 (s, 1H), 8.04 (s, 1H), 7.88 (s, 1H), 7.56 (t, J=8.4 Hz, 1H), 7.46 (dd, J=12.1, 1.9 Hz, 1H), 7.25-7.41 (m, 5H), 4.76-4.81 (m, 4H), 4.12 (t, J=7.2 Hz, 2H), 1.70 (q, J=7.1 Hz, 2H), 1.40-1.59 (m, 1H), 0.91 (d, J=6.6 Hz, 6H); MS (ESI(+)) m/e 393 (M+H)+.


Example 330
N-[4-(1-butyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting butyryl chloride for acetyl chloride and N-[4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.38 (s, 1H), 7.55-7.58 (m, 2H), 7.27-7.38 (m, 6H), 6.09-6.11 (m, 1H), 4.77 (s, 4H), 4.08-4.14 (m, 2H), 3.58-3.68 (m, 2H), 2.39-2.51 (m, 2H), 2.34 (dt, J=19.8, 7.3 Hz, 2H), 1.46-1.62 (m, 2H), 0.88-0.93 (m, 3H); MS (ESI(+)) m/e 390 (M+H)+.


Example 331
N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting isobutyryl chloride for acetyl chloride and N-[4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.40 (s, 1H), 7.55-7.58 (m, 2H), 7.30-7.38 (m, 6H), 6.11-6.13 (bs, 1H), 4.76-4.77 (bs, 4H), 4.19-4.21 (m, 1H), 4.08-4.09 (m, 1H), 3.65-3.72 (m, 2H), 2.85-3.00 (m, 1H), 2.40-2.56 (m, 2H), 1.00-1.07 (m, 6H); MS (ESI(+)) m/e 390 (M+H)+.


Example 332
N-[4-(1-benzoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting benzoyl chloride for acetyl chloride and N-[4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.39 (s, 1H), 7.56-7.59 (m, 2H), 7.44-7.49 (m, 5H), 7.34-7.40 (m, 4H), 7.29-7.34 (m, 2H), 5.91-6.27 (m, 1H), 4.76-4.77 (bs, 4H), 4.02-4.26 (m, 2H), 3.36-3.59 (m, 2H), 2.51-2.61 (m, 2H); MS (ESI(+)) m/e 424 (M+H)+.


Example 333
N-{4-[1-(isopropylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 283, substituting propane-2-sulfonyl chloride for methanesulfonyl chloride and N-[4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.38-8.40 (m, 1H), 7.56-7.59 (m, 2H), 7.29-7.38 (m, 6H), 6.11-6.14 (m, 1H), 4.76-4.80 (m, 4H), 3.93-3.96 (m, 2H), 3.49 (t, J=5.5 Hz, 2H), 3.35-3.45 (m, 1H), 2.47-2.51 (m, 2H), 1.24 (d, J=6.9 Hz, 6H); MS (ESI(−)) m/e 424 (M−H).


Example 334
N-(1′-isobutyryl-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide
Example 334A
tert-butyl 4-(5-(isoindoline-2-carboxamido)pyridin-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate

The title compound was prepared as described in Example 280, substituting tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate for 1H-pyrazol-3-ylboronic acid and N-(6-chloropyridin-3-yl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide.


Example 334B
N-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridin-3-yl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(5-(isoindoline-2-carboxamido)pyridin-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate for tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 334C
tert-butyl 4-(5-(isoindoline-2-carboxamido)pyridin-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate

The title compound was prepared as described in Example 278, substituting isobutyryl chloride for acetyl chloride and N-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridin-3-yl)isoindoline-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, DMSO-d6, Temp=90° C.) δ ppm 8.70 (d, J=2.6 Hz, 1H), 8.33-8.37 (m, 1H), 7.95 (dd, J=8.6, 2.6 Hz, 1H), 7.44 (d, J=8.6 Hz, 1H), 7.28-7.36 (m, 4H), 6.54-6.56 (m, 1H), 4.79 (s, 4H), 4.16-4.18 (m, 2H), 3.68 (t, J=5.7 Hz, 2H), 2.86-2.97 (m, 1H), 2.54-2.63 (m, 2H), 1.04 (d, J=6.7 Hz, 6H); MS (ESI(−)) m/e 389 (M−H).


Example 335
N-(1′-benzoyl-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting benzoyl chloride for acetyl chloride and N-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridin-3-yl)isoindoline-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.71 (d, J=2.5 Hz, 1H), 8.61 (s, 1H), 8.01 (dd, J=8.6, 2.2 Hz, 1H), 7.42-7.54 (m, 6H), 7.35-7.39 (m, 2H), 7.29-7.35 (m, 2H), 6.46-6.67 (m, 1H), 4.79 (s, 4H), 4.05-4.32 (m, 2H), 3.77-3.94 (m, 1H), 3.47-3.58 (m, 1H), 2.61-2.65 (m, 2H); MS (ESI(+)) m/e 425 (M+H)+.


Example 336
N-[4-(4-benzoylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
Example 336A
N-(4-(piperazin-1-yl)phenyl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(4-(isoindoline-2-carboxamido)phenyl)piperazine-1-carboxylate for tert-butyl 44(4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 336B
N-[4-(4-benzoylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting benzoyl chloride for acetyl chloride and N-(4-(piperazin-1-yl)phenyl)isoindoline-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.14 (s, 1H), 7.38-7.50 (m, 7H), 7.28-7.38 (m, 4H), 6.87-6.91 (m, 2H), 4.74 (s, 4H), 3.39-3.90 (m, 4H), 3.01-3.17 (m, 4H); MS (ESI(+)) m/e 427 (M+H)+.


Example 337
N-{4-[4-(isopropylsulfonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 283, substituting isopropylsulfonyl chloride for methanesulfonyl chloride and N-(4-(piperazin-1-yl)phenyl)isoindoline-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.16 (s, 1H), 7.39-7.45 (m, 2H), 7.27-7.38 (m, 4H), 6.88-6.92 (m, 2H), 4.74 (s, 4H), 3.07-3.12 (m, 4H), 1.25 (d, J=6.8 Hz, 6H); MS (ESI(+)) m/e 429 (M+H)+.


Example 338
N-{4-[4-(phenylsulfonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 283, substituting benzenesulfonyl chloride for methanesulfonyl chloride and N-(4-(piperazin-1-yl)phenyl)isoindoline-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.14 (s, 1H), 7.65-7.80 (m, 5H), 7.35-7.41 (m, 2H), 7.27-7.37 (m, 4H), 6.81-6.85 (m, 2H), 4.72 (s, 4H), 3.09-3.15 (m, 4H), 2.99-3.04 (m, 4H); MS (ESI(−)) m/e 461 (M−H).


Example 339
N-{4-[3-(benzoylamino)pyrrolidin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 339A
tert-butyl 1-(4-nitrophenyl)pyrrolidin-3-ylcarbamate

A solution of 1-fluoro-4-nitrobenzene (508 mg, 3.6 mmol) and tert-butyl pyrrolidin-3-ylcarbamate (671 mg, 3.6 mmol) in N,N-dimethylformamide (7 mL) was heated at 55° C. for 1.5 hours and then stirred overnight at room temperature. The reaction mixture was poured into water and the suspension was filtered with water washes to provide the title compound after drying.


Example 339B
tert-butyl 1-(4-aminophenyl)pyrrolidin-3-ylcarbamate

The title compound was prepared as described in Example 274, substituting (+/−)-tert-butyl 1-(4-nitrophenyl)pyrrolidin-3-ylcarbamate for 5-nitro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide.


Example 339C
tert-butyl 1-(4-(isoindoline-2-carboxamido)phenyl)pyrrolidin-3-ylcarbamate

The title compound was prepared as described in Example 272, substituting (+/−)-tert-butyl 1-(4-aminophenyl)pyrrolidin-3-ylcarbamate for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride in Example 272B.


Example 339D
N-[4-(3-aminopyrrolidin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 2, substituting (+/−)-tert-butyl 1-(4-(isoindoline-2-carboxamido)phenyl)pyrrolidin-3-ylcarbamate for tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate in Example 2D.


Example 339E
N-{4-[(3R)-3-(benzoylamino)pyrrolidin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide and N-{4-[(3S)-3-(benzoylamino)pyrrolidin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compounds were prepared as described in Example 278, substituting benzoyl chloride for acetyl chloride and (+/−)-N-(4-(3-aminopyrrolidin-1-yl)phenyl)isoindoline-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.61 (d, J=6.8 Hz, 1H), 8.01 (s, 1H), 7.85-7.89 (m, 2H), 7.42-7.56 (m, 3H), 7.28-7.37 (m, 6H), 6.50 (d, J=8.7 Hz, 2H), 4.72 (s, 4H), 4.56-4.67 (m, 1H), 3.53-3.59 (m, 1H), 3.36-3.45 (m, 1H), 3.16-3.24 (m, 1H), 2.22-2.31 (m, 1H), 2.03-2.13 (m, 1H); MS (ESI(+)) m/e 427 (M+H)+.


Example 340
N-{4-[(3R)-3-(butyrylamino)pyrrolidin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide and N-{4-[(3S)-3-(butyrylamino)pyrrolidin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compounds were prepared as described in Example 278, substituting butyryl chloride for acetyl chloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.06 (d, J=6.9 Hz, 1H), 7.28-7.37 (m, 6H), 6.47 (d, J=8.7 Hz, 2H), 4.72 (s, 4H), 4.36 (h, J=5.7 Hz, 1H), 3.41-3.47 (m, 1H), 3.17-3.23 (m, 1H), 2.89-3.05 (m, 1H), 2.10-2.28 (m, 1H), 2.05 (t, J=7.3 Hz, 2H), 1.81-1.96 (m, 1H), 1.45-1.58 (m, 2H), 0.85 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 393 (M+H)+.


Example 341
tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}piperazine-1-carboxylate
Example 341A
tert-butyl 4-(4-nitrophenyl)piperazine-1-carboxylate

A solution of 1-fluoro-4-nitrobenzene (500 mg, 3.54 mmol) and tert-butyl piperazine-1-carboxylate (726 mg, 3.9 mmol) in dimethylformamide was treated with potassium carbonate (735 mg, 5.32 mmol) and the suspension was heated at 55° C. for 4 hours and then stirred overnight at room temperature. The reaction was poured into water and the suspension was filtered with water washes to provide the title compound after vacuum drying.


Example 341B
tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate

The title compound was prepared as described in Example 274, substituting tert-butyl 4-(4-nitrophenyl)piperazine-1-carboxylate for 5-nitro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide.


Example 341C
tert-butyl 4-(4-(isoindoline-2-carboxamido)phenyl)piperazine-1-carboxylate

The title compound was prepared as described in Example 272B, substituting tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.14 (s, 1H), 7.38-7.44 (m, 2H), 7.27-7.39 (m, 4H), 6.88-6.90 (m, 1H), 6.86 (s, 1H), 4.73 (s, 4H), 3.40-3.51 (m, 4H), 2.98-3.02 (m, 4H), 1.42 (s, 9H); MS (ESI(−)) m/e 421 (M−H).


Example 342
N-[4-(4-propionylpiperazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting propionyl chloride for acetyl chloride and N-(4-(piperazin-1-yl)phenyl)isoindoline-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.14 (s, 1H), 7.38-7.44 (m, 2H), 7.28-7.39 (m, 4H), 6.87-6.90 (m, 2H), 4.74 (s, 4H), 3.54-3.60 (m, 4H), 2.95-3.10 (m, 4H), 2.36 (q, J=7.4 Hz, 2H), 1.03 (s, 1H), 1.00 (d, J=7.4 Hz, 2H); MS (ESI(+)) m/e 379 (M+H)+.


Example 343
N-{4-[4-(cyclopropylcarbonyl)piperazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting cyclopropanecarbonyl chloride for acetyl chloride and N-(4-(piperazin-1-yl)phenyl)isoindoline-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.15 (s, 1H), 7.38-7.45 (m, 2H), 7.28-7.39 (m, 4H), 6.87-6.93 (m, 2H), 4.74 (s, 4H), 3.73-3.90 (m, 2H), 3.50-3.70 (m, 2H), 3.02-3.18 (m, 4H), 1.98-2.07 (m, 1H), 0.68-0.77 (m, 4H); MS (ESI(−)) m/e 389 (M−H).


Example 344
N-(2-butyryl-2,3-dihydro-1H-isoindol-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide
Example 344A
tert-butyl 5-(isoindoline-2-carboxamido)isoindoline-2-carboxylate

In a 250 mL round bottom flask was mixed at room temperature triphosgene (234 mg, 0.790 mmol) in anhydrous dichloromethane (25 mL). To this solution was added dropwise over 15 minutes, a slurry of tert-butyl 5-aminoisoindoline-2-carboxylate (500 mg, 2.134 mmol) and diisopropylethylamine (0.410 ml, 2.347 mmol) in anhydrous dichloromethane (20 mL). The mixture was stirred overnight at room temperature. A solution of isoindoline (0.242 ml, 2.134 mmol) and diisopropylethylamine (0.410 ml, 2.347 mmol) in anhydrous dichloromethane (20 mL) was added in one portion. The reaction stirred overnight at room temperature. The solvent was removed and the residue was purified by normal phase flash chromatography to provide the title compound.


Example 344B
N-(isoindolin-5-yl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 5-(isoindoline-2-carboxamido)isoindoline-2-carboxylate for tert-butyl 44(4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 344C
N-(2-butyryl-2,3-dihydro-1H-isoindol-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting butyryl chloride for acetyl chloride and N-(isoindolin-5-yl)isoindoline-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, DMSO-d6) 0.3 ppm 8.39 (s, 1H), 7.59-7.61 (bs, 1H), 7.43-7.48 (m, 1H), 7.30-7.41 (m, 4H), 7.22 (t, J=7.7 Hz, 1H), 4.77 (d, J=13.9 Hz, 2H), 4.77 (s, 4H), 4.55-4.60 (m, 2H), 2.33 (td, J=7.3, 3.7 Hz, 2H), 1.54-1.63 (m, 2H), 0.93 (td, J=7.3, 1.4 Hz, 3H); MS (ESI(+)) m/e 350 (M+H)+.


Example 345
N-(2-isobutyryl-2,3-dihydro-1H-isoindol-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting isobutyryl chloride for acetyl chloride and N-(isoindolin-5-yl)isoindoline-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.40 (s, 1H), 7.59-7.61 (bs, 1H), 7.46 (ddd, J=10.8, 8.5, 2.1 Hz, 1H), 7.30-7.38 (m, 4H), 7.20-7.24 (m, 1H), 4.82-4.87 (m, 2H), 4.76-4.77 (bs, 4H), 4.55-4.60 (m, 2H), 2.78 (h, J=6.9 Hz, 1H), 1.07 (d, J=6.7 Hz, 6H); MS (ESI(+)) m/e 350 (M+H)+.


Example 346
N-(2-benzoyl-2,3-dihydro-1H-isoindol-5-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting benzoyl chloride for acetyl chloride and N-(isoindolin-5-yl)isoindoline-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.40 (d, J=8.8 Hz, 1H), 7.59-7.67 (m, 3H), 7.11-7.52 (m, 9H), 4.68-4.84 (m, 8H); MS (ESI(+)) m/e 384 (M+H)+.


Example 347
N-[2-(3-methylbutyl)-2,3-dihydro-1H-isoindol-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 429, substituting 3-methylbutanal for isobutyraldehyde and N-(isoindolin-5-yl)isoindoline-2-carboxamide for N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.28 (s, 1H), 7.47 (s, 1H), 7.29-7.37 (m, 5H), 7.09 (d, J=8.1 Hz, 1H), 4.75 (s, 4H), 3.77-3.79 (m, 2H), 3.74-3.76 (m, 2H), 2.64 (t, J=7.5 Hz, 2H), 1.60-1.71 (m, 1H), 1.37-1.43 (m, 2H), 0.91 (d, J=6.6 Hz, 6H); MS (ESI(+)) m/e 350 (M+H)+.


Example 348
N-[4-(hexyloxy)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1A, substituting 1-(hexyloxy)-4-isocyanatobenzene for methyl 4-isocyanatobenzoate. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.17 (s, 1H), 7.39-7.45 (m, 2H), 7.27-7.39 (m, 4H), 6.81-6.85 (m, 2H), 4.74 (s, 4H), 3.91 (t, J=6.5 Hz, 2H), 1.64-1.73 (m, 2H), 1.35-1.47 (m, 2H), 1.23-1.38 (m, 4H), 0.85-0.91 (m, 3H); MS (ESI(+)) m/e 339 (M+H)+.


Example 349
N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting benzoyl chloride for acetyl chloride and N-[4-(piperidin-4-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.39-7.47 (m, 3H) 7.22-7.40 (m, 6H) 6.27 (t, J=5.43 Hz, 1H) 4.56 (s, 4H) 4.36-4.52 (br s, 1H) 3.52 (br s, 1H) 3.00-3.15 (m, 2H) 2.93 (br s, 1H) 0.93-1.86 (series of br m, 12H); MS (ESI(+)) m/e 406 (M+H)+.


Example 350
N-{4-[1-(pyridin-3-ylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting nicotinoyl chloride hydrochloride for acetyl chloride and N-[4-(piperidin-4-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.58-8.71 (m, 2H) 7.87 (d, J=7.5 Hz, 1H) 7.52 (dd, J=7.5, 4.8 Hz, 1H) 7.22-7.36 (m, 4H) 6.28 (br m, 1H) 4.56 (s, 4H) 4.44 (br m, 1H) 3.38-3.57 (br m, 1H) 2.95-3.15 (br m, 2H) 2.68-2.84 (br m, 1H) 0.95-1.84 (br series of m, 12H); MS (ESI(+)) m/e 407 (M+H)+.


Example 351
N-[6-(4-chlorophenoxy)hexyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 344A, substituting 6-(4-chlorophenoxy)hexan-1-amine for tert-butyl 5-aminoisoindoline-2-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.40 (q, 6H), 1.70 (q, 2H), 3.08 (q, J=6.8 Hz, 2H), 3.95 (t, J=6.4 Hz, 2H), 4.57 (s, 4H), 6.27 (t, J=5.4 Hz, 1H), 6.85-7.01 (m, 2H), 7.21-7.39 (m, 6H); MS (ESI(+)) m/e 373 (M+H)+.


Example 352
N-[4-(piperidin-4-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide
Example 352A
tert-butyl 4-(4-(isoindoline-2-carboxamido)butyl)piperidine-1-carboxylate

The title compound was prepared as described in Example 344, substituting tert-butyl 4-(4-aminobutyl)piperidine-1-carboxylate for tert-butyl 5-aminoisoindoline-2-carboxylate in Example 344A.


Example 352B
N-[4-(piperidin-4-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(4-(isoindoline-2-carboxamido)butyl)piperidine-1-carboxylate for tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.14-1.34 (m, 6H), 1.35-1.57 (m, 3H), 1.76 (d, J=12.30 Hz, 2H), 2.69-2.89 (m, 2H), 3.07 (q, J=6.74 Hz, 2H), 3.21 (d, J=12.70 Hz, 2H), 4.57 (s, 4H), 6.29 (t, J=5.55 Hz, 1H), 7.11-7.41 (m, 4H), 8.31 (s, 1H); MS (ESI(+)) m/e 299 (M+H)+.


Example 353
N,N′-hexane-1,6-diylbis(1,3-dihydro-2H-isoindole-2-carboxamide)

The title compound was prepared as described in Example 1A, substituting 1,6-diisocyanatohexane for methyl 4-isocyanatobenzoate. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.19-7.37 (m, 8H) 6.28 (t, J=5.59 Hz, 2H) 4.57 (s, 8H) 3.07 (q, J=6.8 Hz, 4H) 1.37-1.55 (m, 4H) 1.21-1.37 (m, 4H); MS (ESI(+)) m/e 407 (M+H)+.


Example 354
N-(4-phenylbutyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1A, substituting (4-isocyanatobutyl)benzene for methyl 4-isocyanatobenzoate. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.24-7.33 (m, 6H), 7.13-7.22 (m, 3H), 6.30 (t, J=5.6 Hz, 1H), 4.56 (s, 4H), 3.06-3.13 (m, 2H), 2.59 (t, J=7.4 Hz, 2H), 1.51-1.65 (m, 2H), 1.40-1.53 (m, 2H); MS (ESI(+)) m/e 295 (M+H)+.


Example 355
ethyl 6-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]hexanoate

The title compound was prepared as described in Example 1A, substituting ethyl 6-isocyanatohexanoate for methyl 4-isocyanatobenzoate. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.25-7.33 (m, 4H), 6.29 (t, J=5.6 Hz, 1H), 4.57 (s, 4H), 4.04 (q, J=7.1 Hz, 2H), 3.02-3.09 (m, 2H), 2.28 (t, J=7.3 Hz, 2H), 1.48-1.60 (m, 2H), 1.39-1.50 (m, 2H), 1.23-1.34 (m, 2H), 1.16 (t, J=7.1 Hz, 3H); MS (ESI(+)) m/e 305 (M+H)+.


Example 356
N-hexyl-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1A, substituting 1-isocyanatohexane for methyl 4-isocyanatobenzoate. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.25-7.33 (m, 4H), 6.27 (t, J=5.6 Hz, 1H), 4.57 (s, 4H), 3.02-3.10 (m, 2H), 1.36-1.51 (m, 2H), 1.25-1.30 (m, 6H), 0.81-0.92 (m, 3H); MS (ESI(−)) m/e 245 (M−H).


Example 357
N-(3-phenylpropyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1A, substituting (3-isocyanatopropyl)benzene for methyl 4-isocyanatobenzoate. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.11-7.37 (m, 9H), 6.31 (t, J=5.5 Hz, 1H), 4.57 (s, 4H), 3.07-3.14 (m, 2H), 2.60 (t, J=7.6 Hz, 2H), 1.71-1.81 (m, 2H); MS (ESI(+)) m/e 281 (M+H)+.


Example 358
N-octyl-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1A, substituting 1-isocyanatooctane for methyl 4-isocyanatobenzoate. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.24-7.35 (m, 4H), 6.27 (t, J=5.5 Hz, 1H), 4.57 (s, 4H), 3.02-3.09 (m, 2H), 1.40-1.47 (m, 2H), 1.25-1.27 (m, 10H), 0.81-0.89 (m, 3H); MS (ESI(+)) m/e 275 (M+H)+.


Example 359
N-{6-[(1-methyl-1H-pyrazol-4-yl)amino]-6-oxohexyl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 359A
6-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]hexanoic acid

The title compound was prepared as described in Example 1B, substituting ethyl 6-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]hexanoate for methyl 4-(isoindoline-2-carboxamido)benzoate.


Example 359B
N-{6-[(1-methyl-1H-pyrazol-4-yl)amino]-6-oxohexyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 1-methyl-1H-pyrazol-4-amine for 3-phenylpropan-1-amine and 6-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]hexanoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.81 (s, 1H), 7.82 (s, 1H), 7.34-7.36 (m, 1H), 7.24-7.34 (m, 4H), 6.28 (t, J=5.5 Hz, 1H), 4.56 (s, 4H), 3.75 (s, 3H), 3.03-3.10 (m, 2H), 2.22 (t, J=7.3 Hz, 2H), 1.51-1.64 (m, 2H), 1.40-1.52 (m, 2H), 1.23-1.34 (m, 2H); MS (ESI(+)) m/e 356 (M+H)+.


Example 360
N-[6-(methylamino)-6-oxohexyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting methylamine for 3-phenylpropan-1-amine and 6-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]hexanoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.60-7.72 (m, 1H), 7.25-7.33 (m, 4H), 6.24-6.29 (m, 1H), 4.57 (s, 4H), 2.94-3.09 (m, 2H), 2.54 (d, J=4.6 Hz, 3H), 2.30 (t, J=7.3 Hz, 1H), 2.04 (t, J=7.4 Hz, 1H), 1.37-1.58 (m, 4H), 1.18-1.35 (m, 2H); MS (ESI(+)) m/e 290 (M+H)+.


Example 361
N-{6-oxo-6-[(3-phenylpropyl)amino]hexyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 6-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]hexanoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.75-7.80 (m, 1H), 7.24-7.34 (m, 6H), 7.12-7.22 (m, 3H), 6.27 (t, J=5.5 Hz, 1H), 4.56 (s, 4H), 2.98-3.11 (m, 4H), 2.52-2.58 (m, 2H), 2.06 (t, J=7.3 Hz, 2H), 1.62-1.72 (m, 2H), 1.37-1.58 (m, 4H), 1.12-1.33 (m, 2H); MS (ESI(+)) m/e 394 (M+H)+.


Example 362
N-{6-[(3-methylbutyl)amino]-6-oxohexyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 3-methylbutan-1-amine for 3-phenylpropan-1-amine and 6-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]hexanoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.64-7.69 (m, 1H), 7.24-7.34 (m, 4H), 6.26 (t, J=5.5 Hz, 1H), 4.57 (s, 4H), 2.99-3.10 (m, 4H), 2.03 (t, J=7.3 Hz, 2H), 1.41-1.59 (m, 5H), 1.21-1.30 (m, 4H), 0.84 (d, J=6.6 Hz, 6H); MS (ESI(+)) m/e 346 (M+H)+.


Example 363
N-{3-oxo-3-[(3-phenylpropyl)amino]propyl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 363A
ethyl 3-(isoindoline-2-carboxamido)propanoate

The title compound was prepared as described in Example 1A, substituting ethyl 3-isocyanatopropanoate for methyl 4-isocyanatobenzoate.


Example 363B
3-(isoindoline-2-carboxamido)propanoic acid

The title compound was prepared as described in Example 1B, substituting ethyl 3-(isoindoline-2-carboxamido)propanoate for methyl 4-(isoindoline-2-carboxamido)benzoate.


Example 363C
N-{3-oxo-3-[(3-phenylpropyl)amino]propyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 3-(isoindoline-2-carboxamido)propanoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.87-7.92 (m, 1H), 7.22-7.32 (m, 6H), 7.12-7.19 (m, 3H), 6.36 (t, J=5.5 Hz, 1H), 4.56 (s, 4H), 3.24-3.32 (m, 2H), 3.03-3.10 (m, 2H), 2.52-2.60 (m, 2H), 2.30 (t, J=7.0 Hz, 2H), 1.63-1.74 (m, 2H); MS (ESI(+)) m/e 352 (M+H)+.


Example 364
N-{3-oxo-3-[4-(pyridin-2-yl)piperazin-1-yl]propyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 1-(pyridin-2-yl)piperazine for 3-phenylpropan-1-amine and 3-(isoindoline-2-carboxamido)propanoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.11 (ddd, J=4.9, 2.0, 0.8 Hz, 1H), 7.53 (ddd, J=8.7, 7.0, 1.9 Hz, 1H), 7.25-7.34 (m, 4H), 6.83 (d, J=8.6 Hz, 1H), 6.65 (ddd, J=7.1, 4.9, 0.8 Hz, 1H), 6.37 (t, J=5.6 Hz, 1H), 4.57 (s, 4H), 3.44-3.61 (m, 8H), 3.28-3.37 (m, 2H), 2.54-2.61 (m, 2H); MS (ESI(+)) m/e 380 (M+H)+.


Example 365
N-{3-[(3-methylbutyl)amino]-3-oxopropyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 1 3-methylbutan-1-amine for 3-phenylpropan-1-amine and 3-(isoindoline-2-carboxamido)propanoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.76-7.81 (m, 1H), 7.25-7.34 (m, 4H), 6.31-6.36 (m, 1H), 4.56 (s, 4H), 3.23-3.31 (m, 2H), 3.02-3.09 (m, 2H), 2.27 (t, J=7.0 Hz, 2H), 1.46-1.62 (m, 1H), 1.27 (q, J=7.1 Hz, 2H), 0.84 (d, J=6.6 Hz, 6H); MS (ESI(+)) m/e 304 (M+H)+.


Example 366
N-[4-(1-propyl-1H-pyrazol-4-yl)benzyl]-1,3-dihydro-2H-isoindole-2-carboxamide
Example 366A
N-(4-bromobenzyl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 1A, substituting 1-bromo-4-(isocyanatomethyl)benzene for methyl 4-isocyanatobenzoate.


Example 366B
N-[4-(1-propyl-1H-pyrazol-4-yl)benzyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting 1-propyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1H-pyrazol-3-ylboronic acid and N-(4-bromobenzyl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 0.85 (t, J=7.5 Hz, 3H), 1.70-1.92 (m, 2H), 4.06 (t, J=6.9 Hz, 2H), 4.29 (d, J=6.1 Hz, 2H), 4.63 (s, 4H), 6.91 (t, J=5.9 Hz, 1H), 7.18-7.40 (m, 6H), 7.49 (d, J=8.5 Hz, 2H), 7.82 (s, 1H), 8.12 (s, 1H); MS (ESI(+)) m/e 361 (M+H)+.


Example 367
N-[4-(1-isobutyl-1H-pyrazol-4-yl)benzyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting 1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1H-pyrazol-3-ylboronic acid and N-(4-bromobenzyl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 0.86 (d, J=6.4 Hz, 6H), 2.03-2.21 (m, 1H), 3.91 (d, J=7.1 Hz, 2H), 4.28 (d, J=5.9 Hz, 2H), 4.63 (s, 4H), 6.92 (t, J=5.9 Hz, 1H), 7.25-7.37 (m, 6H), 7.50 (d, J=8.3 Hz, 2H), 7.83 (s, 1H), 8.10 (s, 1H); MS (ESI(+)) m/e 375 (M+H)+.


Example 368
N-(5-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}pyridin-2-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(2-pyridyl)piperazine for 3-phenylpropan-1-amine and 6-(isoindoline-2-carboxamido)nicotinic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.21 (s, 1H), 8.39 (dd, J=2.3, 0.8 Hz, 1H), 8.13 (dd, J=4.9, 1.9 Hz, 1H), 8.00 (dd, J=8.6, 0.8 Hz, 1H), 7.84 (dd, J=8.6, 2.4 Hz, 1H), 7.56 (ddd, J=8.7, 6.9, 1.9 Hz, 1H), 7.34-7.39 (m, 2H), 7.29-7.34 (m, 2H), 6.85 (d, J=8.5 Hz, 1H), 6.67 (dd, J=6.7, 4.9 Hz, 1H), 4.75-4.92 (bs, 4H), 3.47-3.81 (m, 8H); MS (ESI(+)) m/e 429 (M+H)+.


Example 369
N-{5-[(3-phenylpropyl)carbamoyl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 369A
methyl 6-(isoindoline-2-carboxamido)nicotinate

The title compound was prepared as described in Example 344A, substituting methyl 6-aminonicotinate for tert-butyl 5-aminoisoindoline-2-carboxylate.


Example 369B
6-(isoindoline-2-carboxamido)nicotinic acid

The title compound was prepared as described in Example 1B, substituting methyl 6-(isoindoline-2-carboxamido)nicotinate for methyl 4-(isoindoline-2-carboxamido)benzoate.


Example 369C
N-{5-[(3-phenylpropyl)carbamoyl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 6-(isoindoline-2-carboxamido)nicotinic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.25 (s, 1H), 8.74 (d, J=2.4 Hz, 1H), 8.47-8.51 (m, 1H), 8.14 (dd, J=8.8, 2.4 Hz, 1H), 8.00 (d, J=8.7 Hz, 1H), 7.33-7.38 (m, 2H), 7.29-7.33 (m, 2H), 7.26-7.30 (m, 2H), 7.21-7.26 (m, 2H), 7.15-7.21 (m, 1H), 4.74-4.92 (bs, 4H), 3.25-3.32 (m, 2H), 2.64 (t, J=7.6 Hz, 2H), 1.84 (p, J=7.4 Hz, 2H); MS (ESI(+)) m/e 401 (M+H)+.


Example 370
N-{5-[(3-methylbutyl)carbamoyl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 3-methylbutan-1-amine for 3-phenylpropan-1-amine and 6-(isoindoline-2-carboxamido)nicotinic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.24 (s, 1H), 8.73 (d, J=2.4 Hz, 1H), 8.42 (t, J=5.5 Hz, 1H), 8.13 (dd, J=8.8, 2.4 Hz, 1H), 7.99 (d, J=8.7 Hz, 1H), 7.25-7.37 (m, 4H), 4.71-4.95 (bs, 4H), 3.24-3.32 (m, 2H), 1.57-1.68 (m, 1H), 1.43 (q, J=7.1 Hz, 2H), 0.91 (d, J=6.6 Hz, 6H); MS (ESI(+)) m/e 353 (M+H)+.


Example 371
N-{5-[(3-phenylpropyl)carbamoyl]-1,3-thiazol-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 371A
methyl 2-(isoindoline-2-carboxamido)thiazole-5-carboxylate

The title compound was prepared as described in Example 272B, substituting methyl 2-aminothiazole-5-carboxylate for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride.


Example 371B
2-(isoindoline-2-carboxamido)thiazole-5-carboxylic acid

The title compound was prepared as described in Example 1B, substituting methyl 2-(isoindoline-2-carboxamido)thiazole-5-carboxylate for methyl 4-(isoindoline-2-carboxamido)benzoate.


Example 371C
N-{5-[(3-phenylpropyl)carbamoyl]-1,3-thiazol-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 2-(isoindoline-2-carboxamido)thiazole-5-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 11.00-11.19 (bs, 1H), 8.34 (t, J=5.6 Hz, 1H), 7.98 (s, 1H), 7.15-7.37 (m, 9H), 4.70-4.83 (m, 4H), 3.17-3.28 (m, 2H), 2.63 (t, J=7.6 Hz, 2H), 1.81 (p, J=7.4 Hz, 2H); MS (ESI(−)) m/e 405 (M−H).


Example 372
N-{5-[(3-methylbutyl)carbamoyl]-1,3-thiazol-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 3-methylbutan-1-amine for 3-phenylpropan-1-amine and 2-(isoindoline-2-carboxamido)thiazole-5-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 11.01-11.16 (bs, 1H), 8.27 (t, J=5.6 Hz, 1H), 7.96 (s, 1H), 7.29-7.36 (m, 4H), 4.73-4.88 (bs, 4H), 3.18-3.28 (m, 2H), 1.52-1.69 (m, 1H), 1.34-1.44 (m, 2H), 0.90 (d, J=6.6 Hz, 6H); MS (ESI(−)) m/e 357 (M−H).


Example 374
N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
Example 374A
N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isoindoline-2-carboxamide

500 mg (4-Isocyanatophenyl)boronic acid pinacolester (1.979 mmol) and 365 mg isoindoline (2.97 mmol) were dissolved in 10 ml dichloromethane and the resultant mixture was stirred over night at room temperature. After adding water, the mixture was extracted several times with dichloromethane, the combined organic phases were washed with dried over magnesium sulfate and filtered. The solvent was evaporated under reduced pressure. Column chromatography of the residue with dichloromethane resulted in the title compound.


Example 374B
N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

105 mg N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isoindoline-2-carboxamide (0.288 mmol) and 53 mg 4-chloro-1,2-dihydrophthalazin-1-one (0.288 mmol) were dissolved in 2.5 ml dioxane. Cesium carbonate (474 mg, 1.44 mmol) was dissolved in 0.25 ml water and the resulting solution added to the reaction mixture. After the addition of 27.8 mg [1,1′-bis(diphenylphosphino)-ferrocene]dichlorpalladium(II) (0.038 mmol) the reaction mixture was flushed with nitrogen and stirred for 30 minutes in the microwave (Biotage Initiator 2.5) at 110° C. Dioxane was removed under reduced pressure, water and dichloromethane added to the residue and the formed precipitation was filtered. After dissolving the solid matter in a larger amount of dichloromethane/methanol 8:2, silica gel was added and subsequently the solvent was removed under reduced pressure. This residue was was purified by column chromatography using dichloromethane/methanol 95:5. 1H NMR (DMSO-d6, 400 MHz): 0.3 ppm 12.73 (s, 1H), 8.55 (s, 1H), 8.33 (dd, 1H), 7.85-7.92 (m, 2H), 7.73-7.78 (m, 3H), 7.48 (d, 2H), 7.35-7.38 (m, 2H), 7.30-7.33 (m, 2H), 4.81 (s, 4H). MS (ESI(−)) m/e 383.2 (M+H)+.


Example 375
N-[4-(isoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 374B, substituting 4-chloro-1,2-dihydrophthalazin-1-one with 4-bromoisoquinoline. ESI-MS [M+H+]=366.1.


Example 376
N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-aminophenyl)isoquinolin-1(2H)-one. ESI-MS [M+H+]=382.1.


Example 377
N-[4-(4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
Example 377A
2-(4-Amino-benzoyl)-cyclohex-1-enecarboxylic acid

To a suspension of 2.2 g magnesium turnings (83.5 mmol) in 15 ml tetrahydrofuran were added 0.1 mL 1,2-dibromethane to start the Grignard reaction followed by slow addition of 13.0 g 2-(4-bromphenyl)-1,1,1,3,3,3-hexamethyldisilazane (41 mmol) in 70 mL tetrahydrofuran over a period of 20 minutes at room temperature with subsequent stirring for further 30 minutes. The resulting mixture was added dropwise at −78° C. to a solution of 4,5,6,7-tetrahydro-isobenzofuran-1,3-dione (5.6 g) in 70 mL tetrahydrofuran. The reaction mixture was slowly warmed to room temperature. Sulfuric acid (2 mL, 1 M) was added and the solvent was removed under reduced pressure. The residue was added carefully to 20 mL of 0.5 M sulfuric acid solution and the desired product started to precipitate and was extracted with ethyl acetate. Acidification of the water phase and extraction with ethyl acetate was continued until pH-4-5 (at least three times). The combined organic phases were washed with brine, dried over magnesium sulfate, filtered and the solvent was subsequently evaporated under reduced pressure. Purification of the raw material by column chromatography with ethyl acetate/hexane 1:1 and subsequently 100% ethyl acetate resulted in the desired product.


Example 377B
4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one

10.3 g of 2-(4-amino-benzoyl)-cyclohex-1-enecarboxylic acid (42 mmol) were dissolved in 45 mL ethanol, 2.7 g (54 mmol) hydrazine hydrate was added and the mixture was heated under reflux for 30 hours. Precipitation of the product already started several hours after heating. After cooling in the refrigerator overnight the precipitated product was filtered and washed with cold ethanol.


Example 377C
1,3-dihydro-isoindole-2-carboxylicacid [4-(4-oxo-3,4,5,6,7,8-hexahydro-phthalazin-1-yl)-phenyl]-amide

To a solution of 200 mg 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one (0.829 mmol) in 5 ml N,N-dimethylformamide were added 245 mg carbonic acid bis-(2,5-dioxo-pyrrolidin-1-yl) ester (0.912 mmol) and the reaction mixture was stirred overnight. 255 mg of isoindoline were added, the precipitation formed was dissolved by adding 0.8 ml N,N-dimethylformamide, and the reaction mixture was stirred overnight. Water was added, and the formed precipitation was washed with water/methanol and subsequently dried in vacuum to obtain the crude material. The crude material was refluxed in 20 ml ethanol for 2 hours, cooled to room temperature, filtered and dried to obtain the desired product. ESI-MS [M+H+]=387.2.


Example 378
N-[4-(8-fluoro-4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-amino-phenyl)-5-fluoro-2H-phthalazin-1-one. ESI-MS [M+H+]=401.1.


Example 379
5-fluoro-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-amino-phenyl)-2H-phthalazin-1-one and isoindoline with 5-fluoro-2,3-dihydro-1H-isoindole. ESI-MS [M+H+]=401.1.


Example 380
N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-amino-phenyl)-2H-phthalazin-1-one and isoindoline with 5-pyrrolidin-1-ylmethyl-2,3-dihydro-1H-isoindole. ESI-MS [M+H+]=466.2.


Example 381
5-(morpholin-4-ylmethyl)-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-aminophenyl)isoquinolin-1(2H)-one and isoindoline with 5-morpholin-4-ylmethyl-2,3-dihydro-1H-isoindole. ESI-MS [M+H+]=481.3.


Example 382
5-methoxy-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-aminophenyl)isoquinolin-1(2H)-one and isoindoline with 5-methoxy-2,3-dihydro-1H-isoindole. ESI-MS [M+H+]=412.2.


Example 383
5-[(4-methylpiperazin-1-yl)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-amino-phenyl)-2H-phthalazin-1-one and isoindoline with 5-(4-methyl-piperazin-1-ylmethyl)-2,3-dihydro-1H-isoindole. ESI-MS [M+H+]=495.2.


Example 384
5-cyano-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-aminophenyl)isoquinolin-1(2H)-one and isoindoline with 2,3-dihydro-1H-isoindole-5-carbonitrile. ESI-MS [M+H+]=407.1.


Example 385
5-chloro-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-aminophenyl)isoquinolin-1(2H)-one and isoindoline with 5-chloro-2,3-dihydro-1H-isoindole. ESI-MS [M+H+]=416.1.


Example 386
N-[4-(4-oxo-4,5-dihydro-3H-2,3-benzodiazepin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 1-(4-amino-phenyl)-3,5-dihydrobenzo[d][1,2]diazepin-4-one. ESI-MS [M+H+]=397.2.


Example 387
N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-aminophenyl)isoquinolin-1(2H)-one and isoindoline with 5-pyrrolidin-1-ylmethyl-2,3-dihydro-1H-isoindole. ESI-MS [M+H+]=465.2.


Example 388
N-{4-[4-oxo-8-(trifluoromethyl)-3,4-dihydrophthalazin-1-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-amino-phenyl)-5-trifluoromethyl-2H-phthalazin-1-one. ESI-MS [M+H+]=451.1.


Example 389
5-[(dimethylamino)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-aminophenyl)isoquinolin-1(2H)-one and isoindoline with (2,3-dihydro-1H-isoindol-5-ylmethyl)-dimethyl-amine. ESI-MS [M+H+]=439.3.


Example 390
5-[(diethylamino)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-aminophenyl)isoquinolin-1(2H)-one and isoindoline with (2,3-dihydro-1H-isoindol-5-ylmethyl)-diethyl-amine. ESI-MS [M+H+]=467.3.


Example 391
5-[(4-methylpiperazin-1-yl)methyl]-N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-aminophenyl)isoquinolin-1(2H)-one and isoindoline with 5-(4-methyl-piperazin-1-ylmethyl)-2,3-dihydro-1H-isoindole. ESI-MS [M+H+]=494.3.


Example 392
5-[(dimethylamino)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-amino-phenyl)-2H-phthalazin-1-one and isoindoline with (2,3-dihydro-1H-isoindol-5-ylmethyl)-dimethyl-amine. ESI-MS [M+H+]=440.2.


Example 393
5-[(diethylamino)methyl]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-amino-phenyl)-2H-phthalazin-1-one and isoindoline with (2,3-dihydro-1H-isoindol-5-ylmethyl)-diethyl-amine. ESI-MS [M+H+]=468.2.


Example 394
N-{4-[4-oxo-8-(trifluoromethyl)-3,4-dihydrophthalazin-1-yl]phenyl}-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-amino-phenyl)-5-trifluoromethyl-2H-phthalazin-1-one and isoindoline with 5-pyrrolidin-1-ylmethyl-2,3-dihydro-1H-isoindole. ESI-MS [M+H+]=534.2.


Example 395
5-[(1-methylpiperidin-4-yl)oxy]-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-amino-phenyl)-2H-phthalazin-1-one and isoindoline with 5-(1-methyl-piperidin-4-yloxy)-2,3-dihydro-1H-isoindole. ESI-MS [M+H+]=496.2.


Example 396
5-{[(3R)-3-fluoropyrrolidin-1-yl]methyl}-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-amino-phenyl)-2H-phthalazin-1-one and isoindoline with 5-((R)-3-fluoro-pyrrolidin-1-ylmethyl)-2,3-dihydro-1H-isoindole. ESI-MS [M+H+]=484.2.


Example 397
5-{[(3S)-3-fluoropyrrolidin-1-yl]methyl}-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-amino-phenyl)-2H-phthalazin-1-one and isoindoline with 54(S)-3-fluoro-pyrrolidin-1-ylmethyl)-2,3-dihydro-1H-isoindole. ESI-MS [M+H+]=484.2.


Example 398
5-(azetidin-1-ylmethyl)-N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-amino-phenyl)-2H-phthalazin-1-one and isoindoline with 5-azetidin-1-ylmethyl-2,3-dihydro-1H-isoindole. ESI-MS [M+H+]=452.2.


Example 399A
N′-(4-bromobenzoyl)-1H-pyrrole-2-carbohydrazide

To 0.750 g of 1H-pyrrole-2-carbohydrazide (5.99 mmol) in 50 ml tetrahydrofuran was added 1.315 g 4-bromobenzoyl chloride (5.99 mmol) and 1 ml pyridine (11.99 mmol) at room temperature under nitrogen. After one hour of stirring at room temperature, the desired product precipitated. The precipitate was filtered, washed with minimum dichloromethane and methanol and dried to afford the title compound. 1H NMR (400 MHz, DMSO-d6) δ 11.63 (s, 1H), 10.47 (s, 1H), 10.04 (s, 1H), 7.84-7.88 (m, 2H), 7.75 (d, J=8.8, 1H), 7.75 (q, J=4.2, 1H), 6.91-6.95 (m, 2H), 6.33-6.15 (m, 1H).


Example 399B
2-(4-bromophenyl)-5-(1H-pyrrol-2-yl)-1,3,4-oxadiazole

To 1.2 g of N′-(4-bromobenzoyl)-1H-pyrrole-2-carbohydrazide (3.89 mmol) was added 5 ml phosphoryl trichloride (1.65 mmol). The reaction was stirred for 25 minutes at 120° C. The reaction was cooled to 0° C., and ice was added. The resulting solid was filtered, and washed with water, NH4OH, dichloromethane and ethyl acetate. Purification by silica gel chromatography (dichloromethane:methanol=9:1) resulted in the desired product. 1H NMR (400 MHz, DMSO-d6) δ 12.32 (s, 1H), 8.05-8.00 (m, 2H), 7.89-7.83 (m, 2H), 7.18 (td, J=1.5, 2.6, 1H), 6.97 (ddd, J=1.5, 2.4, 3.7, 1H), 6.33 (dt, J=2.4, 3.6, 1H). 13C NMR (400 MHz, DMSO-d6) δ 110.16, 112.49, 115.12, 122.71, 123.96, 125.23, 128.26, 132.49, 159.37, 161.57.


Example 399C
4-(4-bromophenyl)pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one

To 0.469 g sodium ethanolate (6.89 mmol) dissolved in 20 ml ethanol was added 1.0 g 2-(4-bromophenyl)-5-(1H-pyrrol-2-yl)-1,3,4-oxadiazole (3.45 mmol) at room temperature under nitrogen and the mixture was stirred at room temperature for 5 minutes. The reaction was heated at 160° C. for 2 hours in a microwave (Biotage Initiator 2.5). The reaction was monitored by TLC dichloromethane/methanol=9/1. Additional equivalents of sodium ethanolate were added and additional heating was carried out until completion of the reaction according to TLC. The reaction mixture was concentrated under reduced pressure and adsorbed on silica gel. The product was purified by silica gel chromatography (gradient: cyclohexane/ethylacetate=0-100%) to afford the title compound. 1H NMR (400 MHz, DMSO-d6) δ 12.09 (s, 1H), 7.85-7.78 (m, 2H), 7.76-7.69 (m, 2H), 7.39 (dd, J=1.3, 2.9, 1H), 7.16 (dd, J=1.4, 3.8, 1H), 6.77 (dd, J=2.9, 3.8, 1H). 13C NMR (400 MHz, DMSO-d6) δ 154.22, 136.46, 131.98, 130.90, 129.52, 124.07, 124.00, 118.80, 114.42, 111.01.


Example 399D
4-(4-aminophenyl)pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one

To 1.181 g 4-(4-bromophenyl)pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one (4.07 mmol) in toluene (10 ml) was added 0.080 g 2-dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl (0.2004 mmol), 0.063 g tris(dibenzylideneacetone)dipalladium(0) chloroform adduct (0.061 mmol) and 10.58 ml lithium bis(trimethylsilyl)amide 1M in toluene (10.58 mmol) under nitrogen at room temperature and the reaction was subsequently heated at 150° C. for 5 minutes by microwave (Biotage Initiator 2.5). Thin layer chromotography in cyclohexane/ethyl acetate=1/1 showed no starting material. After cooling the reaction mixture, 7 ml of 2N aqueous HCl was added, the mixture stirred for 30 minutes, and the mixture was basified until pH=10 by addition of aqueous NaOH (2N). A precipitate was formed. The solid was filtered and washed with ether and dried overnight to obtain the title compound. LCMS: m/z 227.0 (M+H). The filtrate was extracted with ethyl acetate. The organic phase was combined with the ether from the washing, dried over Na2SO4, filtered, and the solvent was evaporated under reduced pressure. The raw material was adsorbed on silica (dissolved in ethyl acetate), then purified by silica gel chromatography (cyclohexane: ethyl acetate gradient, the product was eluted at 80% of ethyl acetate) to afford additional title compound. 1H NMR (400 MHz, DMSO-d6) δ 11.85 (br. s., 1H), 7.32-7.44 (m, 3H), 7.09 (dd, J=3.8, 1.3 Hz, 1H), 6.66-6.77 (m, 3H), 5.67 (s, 2H). 13C NMR (400 MHz, DMSO-d6) δ 154.15, 150.86, 137.98, 129.55, 123.98, 118.70, 116.65, 113.95, 113.32, 110.58.


Example 399E
[4-(1-Oxo-1,2-dihydro-pyrrolo[1,2-d][1,2,4]triazin-4-yl)-phenyl]-carbamic acid phenyl ester

To a suspension of 50 mg 4-(4-aminophenyl)pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one (0.22 mmol) in 1 ml tetrahydrofuran at room temperature a solution of 0.03 ml pyridine (0.3 mmol) in 0.5 ml of tetrahydrofuran was added over 5 minutes. Subsequently, 0.03 ml phenylchlorformate (0.23 mmol) dissolved in 3 ml of tetrahydrofuran was added over 30 minutes and the reaction was stirred at room temperature overnight. The solvent was evaporated on vacuo and the mixture was directly incorporated on silica by dichloromethane. The mixture was purified by silica gel chromatography (4 g, cyclohexane:ethylacetate gradient) to afford crude material which was purified by column chromatography (cyclohexane:ethylacetate gradient) to afford the title compound.


Example 399F
N-[4-(1-oxo-1,2-dihydropyrrolo[1,2-d][1,2,4]triazin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

40 mg [4-(1-Oxo-1,2-dihydro-pyrrolo[1,2-d][1,2,4]triazin-4-yl)-phenyl]-carbamic acid phenyl ester (0.115 mmol) were dissolved in 0.3 ml DMSO. A mixture of 15 mg isoindoline (0.121 mmol) in 0.2 ml DMSO was added at room temperature and the reaction was stirred at room temperature over night. The reaction mixture was diluted in ethyl acetate and washed with water, aqueous HCl, water, aqueous NaOH, and water. The solvent was evaporated under reduced pressure to afford the title compound.


Example 400
N-[4-(1-oxo-1,2-dihydropyrrolo[1,2-d][1,2,4]triazin-4-yl)phenyl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide
Example 400A
5-pyrrolidin-1-ylmethyl-1,3-dihydro-isoindole-2-carboxylic acid tert-butyl ester

To a solution of 1.25 g 5-hydroxymethyl-1,3-dihydro-isoindole-2-carboxylic acid tert-butyl ester (5.01 mmol) in 14 ml dichloromethane was slowly added 0.781 ml methanesulfonyl chloride (10.03 mmol) at room temperature. Subsequently the mixture was heated for 4 hours at reflux. LCMS control indicted a near complete formation of the corresponding mesylate, which was not isolated. After cooling to room temperature, 1.244 ml pyrrolidine (15.04 mmol) were added and the mixture was stirred at room temperature overnight. The reaction was complete according to LCMS. Water was added to the reaction mixture, the acidic aqueous phase was extracted two times with dichloromethane, and the water phase was basified and extracted three times with ethyl acetate. The combined ethyl acetate solutions were extracted with brine, dried over Na2SO4, filtered, and the organic solvent was removed under reduced pressure to provide the title compound. The dichloromethane phase was extracted two times with diluted NaOH, once with brine and then dried over Na2SO4. Filtration and removal of the organic solvent under reduced pressure provided additional title compound. Both fractions were combined and used in the next step without further purification. LCMS: m/z 303.2 (M+H).


Example 400B
5-pyrrolidin-1-ylmethyl-2,3-dihydro-1H-isoindole

To a solution of 1.90 g 5-pyrrolidin-1-ylmethyl-1,3-dihydro-isoindole-2-carboxylic acid tert-butyl ester (raw material; 4.96 mmol) in 5 ml dichloromethane was added 3.82 ml trifluoroacetic acid (49.6 mmol) and the reaction mixture was stirred at room temperature overnight. The trifluoroacetic acid and dichloromethane were evaporated under reduced pressure, water was added to the residue, the acidic aqueous phase extracted two times with ethyl acetate, the aqueous phase was basified with diluted NaOH and then subsequently extracted three times with dichloromethane. The dichloromethane phase was washed once with brine, dried over Na2SO4, filtered, and the solvent was removed under vacuum. The title compound was used without further purification in the next step. LCMS: m/z 203.2 (M+H).


Example 400C
5-pyrrolidin-1-ylmethyl-1,3-dihydro-isoindole-2-carboxylic acid [4-(1-oxo-1,2-dihydro-pyrrolo[1,2-d][1,2,4]triazin-4-yl)-phenyl]-amide

The title compound was prepared as described in Example 399E and Example 399F, substituting isoindoline with 5-pyrrolidin-1-ylmethyl-2,3-dihydro-1H-isoindole. LCMS: m/z 455.2 (M+H).


Example 401
tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}piperidine-1-carboxylate

The title compound was prepared as described in Example 272A, substituting tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}-3,6-dihydropyridine-1(2H)-carboxylate for 4-nitro-N-propylbenzamide. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.26 (s, 1H), 7.46-7.48 (m, 2H), 7.34-7.39 (m, 2H), 7.28-7.33 (m, 2H), 7.10-7.13 (m, 2H), 4.75 (s, 4H), 4.02-4.08 (m, 2H), 2.71-2.90 (m, 2H), 2.57-2.68 (m, 1H), 1.71-1.76 (m, 2H), 1.40-1.51 (m, 2H), 1.42 (s, 9H); MS (ESI(−)) m/e 420 (M−H).


Example 402
N-[4-(5-propyl-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
Example 402A
N-(4-cyanophenyl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 1A, substituting 4-isocyanatobenzonitrile for methyl 4-isocyanatobenzoate.


Example 402B
(Z)—N-(4-(N′-hydroxycarbamimidoyl)phenyl)isoindoline-2-carboxamide

In a 25 mL pressure tube were mixed N-(4-cyanophenyl)isoindoline-2-carboxamide (500 mg, 1.899 mmol), hydroxylamine hydrochloride (264 mg, 3.80 mmol), and triethylamine (1.323 ml, 9.50 mmol) in ethanol (6 ml)/water (0.5 ml). The reaction vessel was sealed and heated at 80° C. for four hours. The reaction mixture was diluted with water and the solid was filtered off with water washes. HPLC purification provided the title compound.


Example 402C
N-[4-(5-propyl-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

In a 4 mL vial was mixed (Z)—N-(4-(N′-hydroxycarbamimidoyl)phenyl)isoindoline-2-carboxamide (50 mg, 0.169 mmol), butyric acid (0.017 ml, 0.186 mmol), 1-hydroxybenzotriazole hydrate (12.92 mg, 0.084 mmol), and N-methylmorpholine (0.056 ml, 0.506 mmol) in anhydrous dimethylformamide (2 ml). To this solution was added N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (48.5 mg, 0.253 mmol) and the mixture was stirred overnight at ambient temperature. The solution was diluted with ethyl acetate and washed with water, saturated aqueous sodium bicarbonate, and brine. The organic layer was dried with sodium sulfate, decanted, and concentrated. The residue was taken up in anhydrous toluene (1 ml), and the mixture was heated at 110° C. for 2 days. The reaction was diluted with water; and the solids that formed were filtered and washed with water and ether to provide the title compound. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.68 (s, 1H), 7.89-7.91 (m, 2H), 7.78-7.80 (m, 2H), 7.36-7.40 (m, 2H), 7.30-7.34 (m, 2H), 4.76-4.85 (m, 4H), 2.96 (t, J=7.4 Hz, 2H), 1.81 (hex, J=7.4 Hz, 2H), 0.99 (t, J=7.4 Hz, 3H); MS (ESI(−)) m/e347 (M−H).


Example 403
N-[4-(piperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}piperidine-1-carboxylate for tert-butyl 44(4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.28 (s, 1H), 7.46-7.48 (m, 2H), 7.34-7.37 (m, 2H), 7.30-7.33 (m, 2H), 7.09-7.12 (m, 2H), 4.75-4.76 (bs, 4H), 3.09-3.17 (m, 2H), 2.68 (td, J=12.3, 2.6 Hz, 2H), 2.57 (tt, J=12.0, 3.4 Hz, 1H), 1.71-1.75 (m, 2H), 1.56 (qd, J=12.5, 3.9 Hz, 2H); MS (ESI(+)) m/e 322 (M+H)+.


Example 404
N-{5-[((3R)-tetrahydrofuran-3-ylmethyl)carbamoyl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide and N-{5-[((3S)-tetrahydrofuran-3-ylmethyl)carbamoyl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting (tetrahydrofuran-3-yl)methanamine for 3-phenylpropan-1-amine and 6-(isoindoline-2-carboxamido)nicotinic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.26 (s, 1H), 8.74 (d, J=2.4 Hz, 1H), 8.56-8.60 (m, 1H), 8.14 (dd, J=8.8, 2.5 Hz, 1H), 8.00 (d, J=8.8 Hz, 1H), 7.26-7.40 (m, 4H), 4.59-5.02 (m, 4H), 3.75 (td, J=8.0, 5.7 Hz, 1H), 3.69 (dd, J=8.5, 6.9 Hz, 1H), 3.59-3.66 (m, 1H), 3.48 (dd, J=8.5, 5.2 Hz, 1H), 3.18-3.31 (m, 2H), 2.43-2.51 (m, 1H), 1.90-1.99 (m, 1H), 1.56-1.65 (m, 1H); MS (ESI(−)) m/e 365 (M−H).


Example 405
N-[4-(1-butyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting butyryl chloride for acetyl chloride and N-[4-(piperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.27 (s, 1H), 7.46-7.49 (m, 2H), 7.34-7.39 (m, 2H), 7.28-7.33 (m, 2H), 7.11-7.14 (m, 2H), 4.75-4.76 (bs, 4H), 4.52-4.57 (m, 1H), 3.94-4.00 (m, 1H), 3.03-3.11 (m, 1H), 2.64-2.75 (m, 1H), 2.51-2.63 (m, 1H), 2.31 (t, J=7.4 Hz, 2H), 1.73-1.81 (m, 2H), 1.47-1.59 (m, 3H), 1.32-1.47 (m, 1H), 0.85-0.95 (m, 3H); MS (ESI(+)) m/e 392 (M+H)+.


Example 406
N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting isobutyryl chloride for acetyl chloride and N-[4-(piperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.28 (s, 1H), 7.46-7.48 (m, 2H), 7.34-7.39 (m, 2H), 7.29-7.33 (m, 2H), 7.12-7.14 (m, 2H), 4.75-4.76 (bs, 4H), 4.53-4.58 (m, 1H), 4.03-4.07 (m, 1H), 3.06-3.14 (m, 1H), 2.86-2.93 (m, 1H), 2.67-2.74 (m, 1H), 2.53-2.61 (m, 1H), 1.75-1.84 (m, 2H), 1.45-1.56 (m, 1H), 1.33-1.45 (m, 1H), 1.03 (d, J=6.7 Hz, 3H), 1.00 (d, J=6.6 Hz, 3H); MS (ESI(−)) m/e 390 (M−H).


Example 407
N-[4-(1-benzoylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting benzoyl chloride for acetyl chloride and N-[4-(piperidin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.29 (s, 1H), 7.47-7.50 (m, 2H), 7.41-7.47 (m, 5H), 7.34-7.38 (m, 2H), 7.29-7.33 (m, 2H), 7.16-7.18 (m, 2H), 4.75-4.76 (bs, 4H), 4.54-4.64 (m, 1H), 3.57-3.74 (m, 1H), 3.02-3.21 (m, 1H), 2.79-2.93 (m, 1H), 2.75 (tt, J=11.9, 3.4 Hz, 1H), 1.68-1.88 (m, 2H), 1.54-1.63 (m, 2H); MS (ESI(−)) m/e 424 (M−H).


Example 408
N-{4-[5-(3-methylbutyl)-1,2,4-oxadiazol-3-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 402C, substituting 4-methylpentanoic acid for butyric acid. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.69 (s, 1H), 7.89-7.91 (m, 2H), 7.77-7.79 (m, 2H), 7.36-7.39 (m, 2H), 7.31-7.34 (m, 2H), 4.80-4.81 (bs, 4H), 2.96-3.00 (m, 2H), 1.66-1.72 (m, 2H), 1.59-1.67 (m, 1H), 0.93 (d, J=6.4 Hz, 6H); MS (ESI(−)) m/e 375 (M−H).


Example 409
N-[4-(5-benzyl-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 402C, substituting phenylacetic acid for butyric acid. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.69 (s, 1H), 7.87-7.90 (m, 2H), 7.77-7.79 (m, 2H), 7.35-7.42 (m, 6H), 7.29-7.34 (m, 3H), 4.75-4.84 (m, 4H), 4.42 (s, 2H); MS (ESI(+)) m/e 397 (M+H)+.


Example 410
N-(4-{[(3R)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

A racemic mixture of N-(4-{[tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide (250 mg) was dissolved in methanol and separated using SCF-LC with a ChiralPak AD-H 21×250 mm column to provide N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.58 (s, 1H), 8.38 (t, J=5.7 Hz, 1H), 7.75-7.79 (m, 2H), 7.64-7.69 (m, 2H), 7.30-7.41 (m, 4H), 4.78-4.79 (bs, 4H), 3.57-3.78 (m, 3H), 3.48 (dd, J=8.5, 5.2 Hz, 1H), 3.17-3.28 (m, 2H), 2.41-2.50 (m, 1H), 1.87-2.04 (m, 1H), 1.54-1.66 (m, 1H); MS (ESI(+)) m/e 366 (M+H)+.


Example 411
N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

A racemic mixture of N-(4-{[tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide (250 mg) was dissolved in methanol and separated using SCF-LC with a ChiralPak AD-H 21×250 mm column to provide N-(4-{[(3R)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.57 (s, 1H), 8.38 (t, J=5.7 Hz, 1H), 7.75-7.79 (m, 2H), 7.64-7.69 (m, 2H), 7.30-7.39 (m, 4H), 4.78-4.79 (bs, 4H), 3.57-3.78 (m, 3H), 3.48 (dd, J=8.5, 5.3 Hz, 1H), 3.13-3.29 (m, 2H), 2.40-2.50 (m, 1H), 1.87-2.07 (m, 1H), 1.54-1.66 (m, 1H); MS (ESI(+)) m/e 366 (M+H)+.


Example 422
tert-butyl 4-{6-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]-1H-benzimidazol-2-yl}piperazine-1-carboxylate
Example 422A
tert-butyl 4-(5-nitro-1H-benzo[d]imidazol-2-yl)piperazine-1-carboxylate

In a 20 mL sealed tube under nitrogen, a mixture of tert-butyl piperazine-1-carboxylate (0.943 g, 5.06 mmol), 2-chloro-5-nitro-1H-benzo[d]imidazole (0.5 g, 2.53 mmol) and ethanol (9.5 mL) was heated at 135° C. for 2 hours. The reaction was concentrated and the residue was purified by reverse-phase chromatography to provide the title compound.


Example 422B
tert-butyl 4-(5-amino-1H-benzo[d]imidazol-2-yl)piperazine-1-carboxylate

The title compound was prepared as described in Example 274, substituting tert-butyl 4-(5-nitro-1H-benzo[d]imidazol-2-yl)piperazine-1-carboxylate for 5-nitro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide.


Example 422C
tert-butyl 4-{6-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]-1H-benzimidazol-2-yl}piperazine-1-carboxylate

The title compound was prepared as described in Example 272B, substituting tert-butyl 4-(5-amino-1H-benzo[d]imidazol-2-yl)piperazine-1-carboxylate for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (400 MHz, DMSO-d6, Temp=90° C.) δ ppm 10.90-11.08 (bs, 1H), 7.84-7.85 (m, 1H), 7.46-7.48 (m, 1H), 7.27-7.35 (m, 4H), 7.04-7.06 (m, 2H), 4.76 (s, 4H), 3.46 (s, 8H), 1.44 (s, 9H); MS (ESI(+)) m/e 463 (M+H)+.


Example 423
N-[2-(piperazin-1-yl)-1H-benzimidazol-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-{6-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]-1H-benzimidazol-2-yl}piperazine-1-carboxylate for tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate. 1H NMR (300 MHz, DMSO-d6) δ ppm 11.04-11.29 (m, 1H), 8.08-8.12 (bs, 1H), 7.41-7.58 (m, 1H), 7.24-7.39 (m, 4H), 7.04-7.06 (m, 2H), 4.76 (s, 4H), 3.37-3.44 (m, 4H), 2.85-2.89 (m, 4H); MS (ESI(+)) m/e 363 (M+H)+.


Example 424
N-[4-(propylcarbamoyl)phenyl]-5-vinyl-1,3-dihydro-2H-isoindole-2-carboxamide

In a sealed vial under nitrogen, a mixture of potassium vinyltrifluoroborate (100 mg, 0.75 mmol), 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide (150 mg, 0.37 mmol), bis(triphenylphosphine)palladium(II) chloride and saturated aqueous sodium bicarbonate (0.62 ml) in dimethylformamide was heated at 85° C. for 5 hours. The reaction was poured into water, filtered, dried and purified by reverse-phase chromatography to provide the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.57 (s, 1H), 8.25 (t, J=5.7 Hz, 1H), 7.75-7.78 (m, 2H), 7.63-7.67 (m, 2H), 7.47 (s, 1H), 7.42 (dd, J=7.9, 1.5 Hz, 1H), 7.34 (d, J=7.8 Hz, 1H), 6.77 (dd, J=17.6, 10.9 Hz, 1H), 5.85 (dd, J=17.6, 1.0 Hz, 1H), 5.27 (d, J=11.0 Hz, 1H), 4.77-4.78 (bs, 4H), 3.16-3.22 (m, 2H), 1.46-1.59 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 350 (M+H)+.


Example 428
N-{4-[5-(tetrahydrofuran-3-yl)-1,2,4-oxadiazol-3-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 402C, substituting tetrahydrofuran-3-carboxylic acid for butyric acid. 1H NMR (500 MHz, DMSO-d6)6 ppm 8.69 (s, 1H), 7.89-7.92 (m, 2H), 7.78-7.81 (m, 2H), 7.36-7.40 (m, 2H), 7.30-7.34 (m, 2H), 4.80-4.81 (bs, 4H), 4.08 (dd, J=8.6, 7.6 Hz, 1H), 3.97 (dd, J=8.6, 5.4 Hz, 1H), 3.86-3.95 (m, 2H), 3.79-3.85 (m, 1H), 2.40 (dddd, J=12.5, 9.0, 7.6, 5.9 Hz, 1H), 2.26 (ddt, J=7.7, 12.4, 6.2 Hz, 1H); MS (ESI(−)) m/e 375 (M−H).


Example 429
N-[4-(1-isobutyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

In a 4 mL were mixed N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)isoindoline-2-carboxamide (50 mg, 0.157 mmol) and isobutyraldehyde (0.014 ml, 0.157 mmol) in anhydrous dichloroethane (2 ml) at room temperature. Sodium triacetoxyborohydride (46.4 mg, 0.219 mmol) was added, and reaction was stirred overnight. The reaction mixture was diluted with water, ethyl acetate and saturated aqueous sodium bicarbonate. The layers were separated and the organic layer was washed with brine. The organic layer was diluted with methanol, dried with sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography to provide the title compound. 1H NMR (400 MHz, DMSO-d6) 0.5 ppm 8.35 (s, 1H), 7.53-7.55 (m, 2H), 7.30-7.38 (m, 6H), 6.06-6.08 (m, 1H), 4.77 (s, 4H), 3.01-3.03 (m, 2H), 2.57 (t, J=5.6 Hz, 2H), 2.41-2.47 (m, 2H), 2.14 (d, J=7.3 Hz, 2H), 1.77-1.88 (m, 1H), 0.88 (d, J=6.5 Hz, 6H); MS (ESI(−)) m/e 374 (M−H).


Example 432
N-{4-[1-(4-methylbenzoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting 4-methylbenzoyl chloride for acetyl chloride and N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)isoindoline-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, DMSO-d6) 0.5 ppm 8.38 (s, 1H), 7.55-7.58 (m, 2H), 7.20-7.39 (m, 10H), 6.01-6.21 (m, 1H), 4.77 (s, 4H), 3.93-4.36 (m, 2H), 3.43-3.90 (m, 2H), 2.48-2.57 (m, 2H), 2.36 (s, 3H); MS (ESI(+)) m/e 438 (M+H)+.


Example 433
N-[4-(1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 429, substituting benzaldehyde for isobutyraldehyde. 1H NMR (400 MHz, DMSO-d6) 0.5 ppm 8.36 (s, 1H), 7.52-7.55 (m, 2H), 7.20-7.42 (m, 11H), 6.06-6.08 (m, 1H), 4.76-4.77 (bs, 4H), 3.58 (s, 2H), 3.04-3.06 (m, 2H), 2.63 (t, J=5.6 Hz, 2H), 2.42-2.49 (m, 2H); MS (ESI(+)) m/e 410 (M+H)+.


Example 440
N-{4-[(propylamino)carbonyl]phenyl}-5-pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting pyridin-3-ylboronic acid for 1H-pyrazol-3-ylboronic acid and 5-bromo-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.91 (dd, J=2.4, 0.9 Hz, 1H), 8.63 (s, 1H), 8.58 (dd, J=4.7, 1.6 Hz, 1H), 8.27 (t, J=5.6 Hz, 1H), 8.10 (ddd, J=7.9, 2.4, 1.6 Hz, 1H), 7.73-7.79 (m, 3H), 7.65-7.70 (m, 3H), 7.48-7.53 (m, 2H), 4.79-4.91 (m, 4H), 3.15-3.23 (m, 2H), 1.54 (s, 2H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 401 (M+H)+.


Example 441
N-{4-[(propylamino)carbonyl]phenyl}-5-pyridin-4-yl-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting pyridin-4-ylboronic acid for 1H-pyrazol-3-ylboronic acid and 5-bromo-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.62-8.66 (m, 3H), 8.25 (t, J=5.6 Hz, 1H), 7.70-7.81 (m, 6H), 7.64-7.69 (m, 2H), 7.52 (d, J=8.0 Hz, 1H), 4.85-4.92 (m, 4H), 3.16-3.22 (m, 2H), 1.46-1.59 (m, 2H), 0.89 (t, J=7.4 Hz, 3H). MS (ESI(+)) m/e 401 (M+H)+.


Example 442
N5-(2-methoxyethyl)-N2-{4-[(propylamino)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2,5-dicarboxamide

The title compound was prepared as described in Example 1C, substituting 2-methoxyethanamine for 3-phenylpropan-1-amine and 2-{[4-(propylcarbamoyl)phenyl]carbamoyl}isoindoline-5-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.61 (s, 1H), 8.54 (d, J=5.3 Hz, 1H), 8.26 (t, J=5.7 Hz, 1H), 7.79-7.85 (m, 2H), 7.73-7.80 (m, 2H), 7.63-7.67 (m, 2H), 7.45 (d, J=7.8 Hz, 1H), 4.81-4.83 (bs, 4H), 3.39-3.51 (m, 4H), 3.27 (s, 3H), 3.03-3.22 (m, 2H), 1.46-1.59 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 425 (M+H)+.


Example 443
N-(4-cyanophenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1A, substituting 4-isocyanatobenzonitrile for methyl 4-isocyanatobenzoate. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.83 (s, 1H), 7.78-7.82 (m, 2H), 7.69-7.73 (m, 2H), 7.31-7.39 (m, 4H), 4.79-4.81 (bs, 4H); MS (ESI(+)) m/e 264 (M+H)+.


Example 444
N-[4-(trifluoromethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1A, substituting 1-isocyanato-4-(trifluoromethyl)benzene for methyl 4-isocyanatobenzoate. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.74 (s, 1H), 7.80-7.83 (m, 2H), 7.60-7.63 (m, 2H), 7.30-7.39 (m, 4H), 4.79-4.80 (bs, 4H); MS (ESI(+)) m/e 307 (M+H)+.


Example 450
5-(1,2-dihydroxyethyl)-N-{4-[(propylamino)carbonyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

A suspension of N-[4-(propylcarbamoyl)phenyl]-5-vinyl-1,3-dihydro-2H-isoindole-2-carboxamid (0.03 g, 0.086 mmol) in tetrahydrofuran (1 ml) and 2-propanol (0.3 ml) was treated with osmium tetroxide (2.5% wt. % solution in 2-methyl-2-propanol) (0.108 ml, 8.59 μmol). The reaction mixture was treated with N-methylmorpholine-N-oxide (0.030 g, 0.258 mmol). The reaction mixture was allowed to stir at room temperature overnight, quenched with aqueous sodium sulfite solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. Flash chromatography provided the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.55 (s, 1H), 8.25 (t, J=5.7 Hz, 1H), 7.74-7.78 (m, 2H), 7.63-7.68 (m, 2H), 7.27-7.33 (m, 3H), 5.24 (d, J=4.2 Hz, 1H), 4.75-4.77 (bs, 4H), 4.70 (t, J=5.8 Hz, 1H), 4.53-4.59 (m, 1H), 3.43 (t, J=5.8 Hz, 2H), 3.16-3.23 (m, 2H), 1.42-1.63 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 384 (M+H)+.


Example 451
N-[4-(1-benzoylpiperidin-4-yl)butyl]-5-cyano-1,3-dihydro-2H-isoindole-2-carboxamide
Example 451A
tert-butyl 4-(4-(5-cyanoisoindoline-2-carboxamido)butyl)piperidine-1-carboxylate

The title compound was prepared as described in Example 272B, substituting tert-butyl 4-(4-aminobutyl)piperidine-1-carboxylate for 4-amino-N-propylbenzamide and isoindoline-5-carbonitrile for methyl isoindoline-5-carboxylate hydrochloride.


Example 451B
5-cyano-N-(4-(piperidin-4-yl)butyl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(4-(5-cyanoisoindoline-2-carboxamido)butyl)piperidine-1-carboxylate for tert-butyl 44(4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 451C
N-[4-(1-benzoylpiperidin-4-yl)butyl]-5-cyano-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting benzoyl chloride for acetyl chloride and 5-cyano-N-(4-(piperidin-4-yl)butyl)isoindoline-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.83 (s, 1H), 7.75 (dd, J=7.9, 1.5 Hz, 1H), 7.53 (d, J=7.9 Hz, 1H), 7.41-7.44 (m, 3H), 7.31-7.38 (m, 2H), 6.36 (t, J=5.5 Hz, 1H), 4.60-4.64 (m, 4H), 4.30-4.53 (m, 1H), 3.42-3.71 (m, 1H), 3.02-3.10 (m, 2H), 2.64-3.00 (m, 2H), 1.56-1.84 (m, 2H), 1.37-1.54 (m, 3H), 1.24-1.31 (m, 4H), 0.93-1.16 (m, 2H); MS (ESI(+)) m/e 431 (M+H)+.


Example 452
N-(1′-butyryl-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl)-1,3-dihydro-2H-isoindole-2-carboxamide
Example 452A
N-(5-bromopyridin-2-yl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 344A, substituting 5-bromopyridin-2-amine for tert-butyl 5-aminoisoindoline-2-carboxylate.


Example 452B
tert-butyl 4-(6-(isoindoline-2-carboxamido)pyridin-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate

The title compound was prepared as described in Example 280, substituting tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate for 1H-pyrazol-3-ylboronic acid and N-(5-bromopyridin-2-yl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide.


Example 452C
N-(5-(1,2,3,6-tetrahydropyridin-4-yl)pyridin-2-yl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(6-(isoindoline-2-carboxamido)pyridin-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate for tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 452D
N-(1′-butyryl-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting butyryl chloride for acetyl chloride and N-(5-(1,2,3,6-tetrahydropyridin-4-yl)pyridin-2-yl)isoindoline-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.92-8.95 (bs, 1H), 8.32-8.35 (m, 1H), 7.64-7.97 (m, 2H), 6.94-7.38 (m, 4H), 6.16-6.22 (bs, 1H), 4.45-5.02 (m, 4H), 4.08-4.15 (m, 2H), 3.62-3.68 (m, 2H), 2.23-2.65 (m, 4H), 1.46-1.64 (m, 2H), 0.87-0.93 (m, 3H); MS (ESI(+)) m/e 391 (M+H)+.









TABLE 6







The title compound was prepared as described in Example 1C, substituting N-(5-


(1,2,3,6-tetrahydropyridin-4-yl)pyridin-2-yl)isoindoline-2-carboxamide for 3-phenylpropanl-


amine and the appropriate carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid.










Ex
Name

1H NMR

MS





453
N-(1′-isobutyryl-

1H NMR (500 MHz, DMSO-d6) δ ppm 8.91-8.95 (bs,

(ESI(+))



1′,2′,3′,6′-tetrahydro-
1H), 8.33-8.38 (m, 1H), 7.79-7.92 (m, 2H),
m/e 391



3,4′-bipyridin-6-yl)-1,3-
7.27-7.36 (m, 3H), 6.17-6.22 (bs, 1H), 4.76-4.83 (bs, 4H),
(M + H)+



dihydro-2H-isoindole-2-
4.07-4.22 (m, 2H), 3.64-3.73 (m, 1H), 2.84-2.98 (m, 1H),



carboxamide
2.37-2.63 (m, 3H), 0.77-1.20 (m, 6H)


454
N-[1′-((3R)-

1H NMR (500 MHz, DMSO-d6) δ ppm 8.92-8.95 (bs,

(ESI(+))



tetrahydrofuran-3-
1H), 8.32-8.36 (bs, 1H), 7.79-7.92 (m, 2H),
m/e 419



ylcarbonyl)-1′,2′,3′,6′-
7.11-7.51 (m, 4H), 6.17-6.21 (bs, 1H), 4.59-5.04 (m, 4H),
(M + H)+



tetrahydro-3,4′-
4.10-4.22 (m, 2H), 3.82-4.01 (m, 1H), 3.59-3.81 (m, 5H),



bipyridin-6-yl]-1,3-
2.33-2.62 (m, 2H), 1.94-2.15 (m, 2H)



dihydro-2H-isoindole-2-



carboxamide


495
N-(1′-benzoyl-1′,2′,3′,6′-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



tetrahydro-3,4′-
8.51 (bs, 1H), 8.32 (d, J = 2.5 Hz, 1H), 7.90 (d, J = 8.7 Hz,
m/e 425



bipyridin-6-yl)-1,3-
1H), 7.77 (dd, J = 8.7, 2.5 Hz, 1H),
(M + H)+



dihydro-2H-isoindole-2-
7.48-7.39 (m, 5H), 7.36-7.25 (m, 4H), 6.16 (bs, 1H),



carboxamide
4.81 (s, 4H), 4.18 (m, 2H), 3.68 (m, 2H), 2.55 (m, 2H)


764
N-[1′-(tetrahydrofuran-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



2-ylcarbonyl)-1′,2′,3′,6′-
8.52 (bs, 1H), 8.32 (d, J = 2.5 Hz, 1H), 7.91 (m, 1H),
m/e 419



tetrahydro-3,4′-
7.76 (dd, J = 8.7, 2.5 Hz, 1H), 7.37-7.26 (m, 4H),
(M + H)+



bipyridin-6-yl]-1,3-
6.16 (m, 1H), 4.82 (s, 4H), 4.68 (dd, J = 7.6, 5.6 Hz,



dihydro-2H-isoindole-2-
1H), 4.17 (m, 2H), 3.86-3.70 (m, 4H), 2.52 (m, 2H),



carboxamide
2.12 (m, 1H), 2.01 (m, 1H), 1.87 (m, 2H)


765
N-[1′-(tetrahydro-2H-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



pyran-4-ylcarbonyl)-
8.52 (s, 1H), 8.32 (d, J = 2.5 Hz, 1H), 7.91 (d, J = 8.7 Hz,
m/e 433



1′,2′,3′,6′-tetrahydro-
1H), 7.77 (dd, J = 8.7, 2.5 Hz, 1H),
(M + H)+



3,4′-bipyridin-6-yl]-1,3-
7.37-7.26 (m, 4H), 6.16 (m, 1H), 4.82 (s, 4H), 4.17 (m, 2H),



dihydro-2H-isoindole-2-
3.87 (m, 2H), 3.72 (t, J = 5.7 Hz, 2H), 3.43 (td, J = 11.4,



carboxamide
2.6 Hz, 2H), 2.92 (m 1H), 2.52 (m, 2H),




1.74-1.60 (m, 2H), 1.62-1.53 (m, 2H)


766
N-[1′-(1,4-dioxan-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



ylcarbonyl)-1′,2′,3′,6′-
8.52 (s, 1H), 8.32 (d, J = 2.2 Hz, 1H), 7.91 (d, J = 8.8 Hz,
m/e 435



tetrahydro-3,4′-
1H), 7.76 (dd, J = 8.8, 2.5 Hz, 1H),
(M + H)+



bipyridin-6-yl]-1,3-
7.40-7.23 (m, 4H), 6.15 (m, 1H), 4.82 (s, 4H), 4.38 (dd, J = 9.2,



dihydro-2H-isoindole-2-
2.9 Hz, 1H), 4.16 (m, 2H), 3.83-3.61 (m, 7H),



carboxamide
3.53 (m, 1H), 2.53 (m, 2H)


767
N-{1′-[(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



methylpyrrolidin-3-
8.54 (m, 1H), 8.31 (dd, J = 2.5, 0.8 Hz, 1H), 7.90 (dd,
m/e 432



yl)carbonyl]-1′,2′,3′,6′-
J = 8.7, 0.8 Hz, 1H), 7.75 (dd, J = 8.7, 2.5 Hz, 1H),
(M + H)+



tetrahydro-3,4′-
7.36-7.25 (m, 4H), 6.15 (m, 1H), 4.81 (s, 4H),



bipyridin-6-yl}-1,3-
4.13 (m, 2H), 3.69 (t, J = 5.7 Hz, 2H), 3.26 (m, 1H),



dihydro-2H-isoindole-2-
2.77 (t, J = 8.6 Hz, 1H), 2.68-2.53 (m, 4H), 2.38 (m, 1H),



carboxamide
2.24 (s, 3H), 2.13-1.92 (m, 2H)


768
N-{1′-[(1,1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



dioxidotetrahydrothiophen-
8.53 (bs, 1H), 8.33 (d, J = 2.5 Hz, 1H), 7.91 (d, J = 8.7 Hz,
m/e 467



3-yl)carbonyl]-
1H), 7.77 (dd, J = 8.7, 2.5 Hz, 1H),
(M + H)+



1′,2′,3′,6′-tetrahydro-
7.37-7.26 (m, 4H), 6.16 (m, 1H), 4.82 (s, 4H), 4.19 (m,



3,4′-bipyridin-6-yl}-1,3-
2H), 3.74 (m, 3H), 3.33-3.05 (m, 4H), 2.55 (m, 2H),



dihydro-2H-isoindole-2-
2.37 (m, 1H), 2.15 (m, 1H)



carboxamide


769
N-[1′-(2-hydroxy-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



methylpropanoyl)-
8.51 (bs, 1H), 8.31 (d, J = 2.5 Hz, 1H), 7.90 (d, J = 8.7 Hz,
m/e 407



1′,2′,3′,6′-tetrahydro-
1H), 7.76 (dd, J = 8.7, 2.5 Hz, 1H),
(M + H)+



3,4′-bipyridin-6-yl]-1,3-
7.36-7.25 (m, 4H), 6.17 (m, 1H), 5.11 (bs, 1H), 4.81 (s,



dihydro-2H-isoindole-2-
4H), 4.30 (m, 2H), 3.94 (m, 2H), 2.51 (m, 2H),



carboxamide
1.37 (s, 6H)


801
N-[1′-(morpholin-4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



ylacetyl)-1′,2′,3′,6′-
8.51 (s, 1H), 8.32 (d, J = 2.5 Hz, 1H), 7.90 (d, J = 8.7 Hz,
m/e 448



tetrahydro-3,4′-
1H), 7.76 (dd, J = 8.7, 2.5 Hz, 1H),
(M + H)+



bipyridin-6-yl]-1,3-
7.36-7.26 (m, 4H), 6.15 (m, 1H), 4.81 (s, 4H), 4.13 (m, 2H),



dihydro-2H-isoindole-2-
3.73 (m, 2H), 3.58 (m, 4H), 3.21 (s, 2H), 2.48 (m,



carboxamide
2H), 2.45 (m, 4H)









Example 455
N-[2-(4-acetylpiperazin-1-yl)-1H-benzimidazol-5-yl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting N-[2-(piperazin-1-yl)-1H-benzimidazol-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (500 MHz, DMSO-d6, Temp=90° C.) δ ppm 11.01-11.10 (bs, 1H), 7.89-7.91 (bs, 1H), 7.44-7.52 (m, 1H), 7.32-7.35 (m, 2H), 7.27-7.31 (m, 2H), 7.03-7.06 (m, 2H), 4.76 (s, 4H), 3.55-3.62 (m, 4H), 3.46-3.51 (m, 4H), 2.04 (s, 3H); MS (ESI(+)) m/e 405 (M+H)+.









TABLE 7







The following Examples were essentially prepared as described in Example 1C,


substituting the appropriate tetrahdropyridine for 3-phenylpropan-1-amine and the appropriate


carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid.










Ex
Name

1H NMR

MS













456
N-{4-[1-(5-oxo-L-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(−)) m/e



prolyl)-1,2,3,6-
ppm 8.15-8.17 (bs, 1H), 7.85-7.88 (m, 3H),
429 (M − H)



tetrahydropyridin-4-
7.36-7.38 (m, 2H), 7.16-7.25 (m, 4H), 5.97-5.99 (m,



yl]phenyl}-1,3-dihydro-
1H), 4.85-4.88 (m, 4H), 4.60-4.64 (m, 1H),



2H-isoindole-2-
4.09-4.26 (m, 2H), 3.57-3.81 (m, 2H), 2.40-2.50 (m,



carboxamide
3H), 2.25-2.38 (m, 2H), 2.08-2.15 (m, 1H)


457
N-{4-[1-(5-oxo-D-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(−)) m/e



prolyl)-1,2,3,6-
ppm 8.14-8.16 (bs, 1H), 7.85-7.88 (m, 2H),
429 (M − H)



tetrahydropyridin-4-
7.75-7.82 (m, 1H), 7.36-7.38 (m, 2H), 7.20-7.24 (m,



yl]phenyl}-1,3-dihydro-
2H), 7.16-7.20 (m, 2H), 5.97-5.99 (m, 1H),



2H-isoindole-2-
4.83-4.89 (m, 4H), 4.60-4.63 (m, 1H), 3.59-3.79 (m,



carboxamide
2H), 2.40-2.51 (m, 3H), 2.24-2.38 (m, 2H),




2.08-2.15 (m, 1H)


458
N-[4-(1-propionyl-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



1,2,3,6-tetrahydropyridin-
ppm 8.08-8.15 (m, 1H), 7.84-7.87 (m, 2H),
m/e 376



4-yl)phenyl]-1,3-dihydro-
7.37-7.39 (m, 2H), 7.20-7.24 (m, 2H), 7.16-7.19 (m,
(M + H)+



2H-isoindole-2-
2H), 5.99 (t, J = 3.2 Hz, 1H), 4.84-4.87 (m, 4H),



carboxamide
4.08-4.22 (m, 2H), 3.55-3.75 (m, 2H),




2.42-2.49 (m, 2H), 2.31 (q, J = 7.4 Hz, 2H), 1.17 (t, J = 7.5 Hz,




3H)


459
N-{4-[1-(2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



methylbutanoyl)-1,2,3,6-
ppm 8.11-8.12 (bs, 1H), 7.84-7.86 (m, 2H),
m/e 404



tetrahydropyridin-4-
7.38-7.40 (m, 2H), 7.20-7.24 (m, 2H), 7.18 (d, J = 4.1 Hz,
(M + H)+



yl]phenyl}-1,3-dihydro-
1H), 7.15-7.18 (m, 1H), 6.00-6.03 (m, 1H),



2H-isoindole-2-
4.83-4.89 (m, 4H), 4.18-4.27 (m, 2H),



carboxamide
3.67-3.79 (m, 2H), 2.69 (h, J = 6.7 Hz, 1H), 2.48-2.51 (m,




2H), 1.75-1.89 (m, 1H), 1.40-1.53 (m, 1H), 1.15 (d,




J = 6.9 Hz, 3H), 0.90 (t, J = 7.4 Hz, 3H)


460
N-{4-[1-(2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



ethylbutanoyl)-1,2,3,6-
ppm 8.12 (d, J = −1.9 Hz, 1H), 7.84-7.87 (m, 2H),
m/e 418



tetrahydropyridin-4-
7.38-7.41 (m, 2H), 7.21-7.24 (m, 2H),
(M + H)+



yl]phenyl}-1,3-dihydro-
7.15-7.20 (m, 2H), 6.01-6.04 (m, 1H), 4.86 (s, 4H),



2H-isoindole-2-
4.21-4.32 (m, 2H), 3.73-3.84 (m, 2H), 2.57-2.67 (m, 1H),



carboxamide
2.48-2.55 (m, 2H), 1.74-1.88 (m, 2H),




1.45-1.57 (m, 2H), 0.90 (t, J = 7.4 Hz, 6H)


461
N-{4-[1-(methoxyacetyl)-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



1,2,3,6-tetrahydropyridin-
ppm 2.48-2.54 (m, 2 H), 3.32 (s, 3 H), 3.64 (t,
m/e 392



4-yl]phenyl}-1,3-
J = 5.80 Hz, 2 H), 4.06-4.13 (m, 4 H), 4.77 (s, 4 H),
(M + H)+



dihydro-2H-isoindole-2-
6.02-6.09 (m, 1 H), 7.27-7.37 (m, 6 H),



carboxamide
7.51-7.56 (m, 2 H), 8.12 (s, 1 H)


462
N-{4-[1-(ethoxyacetyl)-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



1,2,3,6-tetrahydropyridin-
ppm 8.11-8.12 (bs, 1H), 7.84-7.86 (m, 2H),
m/e 406



4-yl]phenyl}-1,3-
7.36-7.39 (m, 2H), 7.20-7.25 (m, 2H), 7.13-7.20 (m,
(M + H)+



dihydro-2H-isoindole-2-
2H), 5.97-6.00 (m, 1H), 4.84-4.88 (m, 4H), 4.24 (s,



carboxamide
2H), 4.18-4.23 (m, 2H), 3.69-3.74 (m, 2H), 3.57 (q,




J = 6.9 Hz, 2H), 2.46-2.53 (m, 2H), 1.17 (t, J = 6.9 Hz,




3H)


463
N-(4-{1-[(2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



methoxyethoxy)acetyl]-
ppm 8.10-8.13 (bs, 1H), 7.82-7.87 (m, 2H),
m/e 436



1,2,3,6-tetrahydropyridin-
7.35-7.40 (m, 2H), 7.19-7.25 (m, 2H), 7.15-7.20 (m,
(M + H)+



4-yl}phenyl)-1,3-
2H), 5.96-6.00 (m, 1H), 4.84-4.88 (m, 4H),



dihydro-2H-isoindole-2-
4.30-4.34 (m, 2H), 4.17-4.25 (m, 2H), 3.73-3.77 (m,



carboxamide
2H), 3.67-3.76 (m, 2H), 3.54-3.58 (m, 2H), 3.28 (s,




3H), 2.46-2.53 (m, 2H)


464
N-{4-[1-(tetrahydrofuran-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



2-ylcarbonyl)-1,2,3,6-
ppm 8.08-8.14 (bs, 1H), 7.82-7.87 (m, 2H),
m/e 418



tetrahydropyridin-4-
7.34-7.40 (m, 2H), 7.20-7.25 (m, 2H), 7.15-7.20 (m,
(M + H)+



yl]phenyl}-1,3-dihydro-
2H), 5.97-6.01 (m, 1H), 4.83-4.89 (m, 4H),



2H-isoindole-2-
4.69 (dd, J = 7.2, 5.3 Hz, 1H), 4.24-4.31 (m, 2H),



carboxamide
3.87-3.96 (m, 1H), 3.69-3.88 (m, 3H), 2.39-2.60 (m,




3H), 1.84-2.01 (m, 2H), 1.69-1.83 (m, 1H)


465
N-{4-[1-(tetrahydrofuran-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(−)) m/e



3-ylcarbonyl)-1,2,3,6-
ppm 8.12-8.14 (bs, 1H), 7.83-7.89 (m, 2H),
416 (M − H)



tetrahydropyridin-4-
7.38-7.40 (m, 2H), 7.20-7.24 (m, 2H), 7.15-7.20 (m,



yl]phenyl}-1,3-dihydro-
2H), 5.99-6.02 (m, 1H), 4.83-4.89 (m, 4H),



2H-isoindole-2-
4.16-4.24 (m, 2H), 4.04-4.13 (m, 2H), 3.91 (td, J = 7.9,



carboxamide
5.9 Hz, 1H), 3.77-3.83 (m, 1H), 3.60-3.79 (m, 2H),




3.23-3.35 (m, 1H), 2.42-2.49 (m, 2H), 2.29 (ddd, J = 7.6,




12.1, 6.1 Hz, 1H), 1.97-2.06 (m, 1H)


466
N-{4-[1-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



(cyclopropylacetyl)-
ppm 8.11-8.12 (bs, 1H), 7.84-7.87 (m, 2H),
m/e 402



1,2,3,6-tetrahydropyridin-
7.37-7.40 (m, 2H), 7.20-7.23 (m, 2H), 7.15-7.20 (m,
(M + H)+



4-yl]phenyl}-1,3-
2H), 5.99-6.01 (m, 1H), 4.86 (s, 4H), 4.10-4.28 (m,



dihydro-2H-isoindole-2-
2H), 3.55-3.77 (m, 2H), 2.43-2.52 (m, 2H), 2.36 (d,



carboxamide
J = 6.5 Hz, 2H), 1.13-1.24 (m, 1H), 0.48-0.54 (m,




2H), 0.19-0.27 (m, 2H)


467
N-{4-[1-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



(cyclopentylcarbonyl)-
ppm 8.10-8.13 (bs, 1H), 7.83-7.88 (m, 2H),
m/e 416



1,2,3,6-tetrahydropyridin-
7.38-7.41 (m, 2H), 7.21-7.24 (m, 2H), 7.15-7.20 (m,
(M + H)+



4-yl]phenyl}-1,3-
2H), 6.00-6.03 (m, 1H), 4.83-4.87 (m, 4H),



dihydro-2H-isoindole-2-
4.16-4.26 (m, 2H), 3.63-3.83 (m, 2H), 2.96 (s, 1H),



carboxamide
2.44-2.52 (m, 2H), 1.92-2.04 (m, 2H), 1.75-1.87 (m,




2H), 1.65-1.75 (m, 2H), 1.46-1.60 (m, 2H)


468
N-{4-[1-(2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



methylbenzoyl)-1,2,3,6-
ppm 8.12-8.13 (bs, 1H), 7.84-7.87 (m, 3H),
m/e 438



tetrahydropyridin-4-
7.37-7.40 (m, 3H), 7.21-7.30 (m, 5H), 5.94-6.05 (bs,
(M + H)+



yl]phenyl}-1,3-dihydro-
1H), 4.86 (s, 4H), 4.86 (s, 1H), 4.19-4.48 (m, 2H),



2H-isoindole-2-
3.35-3.61 (m, 2H), 2.39-2.59 (m, 2H), 2.32 (s, 3H)



carboxamide


469
N-{4-[1-(3-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



methylbenzoyl)-1,2,3,6-
ppm 8.11-8.13 (bs, 1H), 7.84-7.87 (m, 2H),
m/e 438



tetrahydropyridin-4-
7.34-7.41 (m, 4H), 7.28 (t, J = 7.5 Hz, 1H),
(M + H)+



yl]phenyl}-1,3-dihydro-
7.20-7.24 (m, 2H), 7.17-7.19 (m, 3H), 5.98-6.01 (bs, 1H),



2H-isoindole-2-
4.83-4.90 (m, 4H), 4.26-4.29 (m, 2H),



carboxamide
3.70-3.79 (m, 2H), 2.50-2.54 (m, 2H), 2.26 (s, 3H)


470
N-{4-[1-(2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



methoxybenzoyl)-1,2,3,6-
ppm 8.11-8.12 (bs, 1H), 7.83-7.86 (m, 2H),
m/e 454



tetrahydropyridin-4-
7.37-7.45 (m, 3H), 7.30-7.35 (m, 1H), 7.20-7.23 (m,
(M + H)+



yl]phenyl}-1,3-dihydro-
2H), 7.15-7.19 (m, 2H), 7.00 (t, J = 7.4 Hz, 1H),



2H-isoindole-2-
6.96 (d, J = 8.3 Hz, 1H), 5.89-6.08 (m, 1H), 4.85 (s,



carboxamide
4H), 4.31-4.68 (m, 2H), 3.69 (s, 3H), 3.28-3.62 (m,




2H), 2.34-2.68 (m, 2H)


471
N-{4-[1-(3-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



methoxybenzoyl)-1,2,3,6-
ppm 8.11-8.13 (bs, 1H), 7.84-7.87 (m, 2H),
m/e 454



tetrahydropyridin-4-
7.37-7.40 (m, 2H), 7.30-7.34 (m, 1H), 7.20-7.24 (m,
(M + H)+



yl]phenyl}-1,3-dihydro-
3H), 7.16-7.19 (m, 2H), 7.12-7.15 (m, 1H),



2H-isoindole-2-
7.01 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H), 5.98-6.00 (bs, 1H),



carboxamide
4.84-4.89 (m, 4H), 4.26-4.29 (m, 2H),




3.71-3.78 (m, 2H), 3.69 (s, 3H), 2.49-2.54 (m, 2H)


472
N-{4-[1-(4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



methoxybenzoyl)-1,2,3,6-
ppm 8.11-8.12 (bs, 1H), 7.84-7.87 (m, 2H),
m/e 454



tetrahydropyridin-4-
7.55-7.58 (m, 2H), 7.38-7.41 (m, 2H), 7.20-7.24 (m,
(M + H)+



yl]phenyl}-1,3-dihydro-
2H), 7.16-7.19 (m, 2H), 6.97-6.99 (m, 2H),



2H-isoindole-2-
5.99-6.02 (m, 1H), 4.86 (s, 4H), 4.29 (q, J = 2.9 Hz, 2H),



carboxamide
3.77 (t, J = 5.7 Hz, 2H), 3.71 (s, 3H), 2.49-2.59 (m,




2H)


473
N-{4-[1-(2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



fluorobenzoyl)-1,2,3,6-
ppm 8.11-8.13 (bs, 1H), 7.84-7.87 (m, 2H),
m/e 442



tetrahydropyridin-4-
7.48 (td, J = 7.1, 1.8 Hz, 1H), 7.35-7.38 (m, 2H),
(M + H)+



yl]phenyl}-1,3-dihydro-
7.29-7.34 (m, 1H), 7.20-7.23 (m, 2H), 7.16-7.19 (m,



2H-isoindole-2-
2H), 7.14-7.17 (m, 1H), 7.10-7.12 (m, 1H),



carboxamide
5.89-6.09 (m, 1H), 4.86 (s, 4H), 4.12-4.67 (m, 2H),




3.28-3.76 (m, 2H), 2.39-2.56 (m, 2H)


474
N-{4-[1-(3-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



fluorobenzoyl)-1,2,3,6-
ppm 8.12-8.14 (bs, 1H), 7.85-7.87 (m, 2H),
m/e 442



tetrahydropyridin-4-
7.37-7.40 (m, 2H), 7.29-7.36 (m, 3H), 7.20-7.24 (m,
(M + H)+



yl]phenyl}-1,3-dihydro-
2H), 7.16-7.19 (m, 2H), 7.09-7.13 (m, 1H),



2H-isoindole-2-
5.97-6.00 (bs, 1H), 4.86 (s, 4H), 4.22-4.26 (m, 2H),



carboxamide
3.68-3.73 (m, 2H), 2.49-2.53 (m, 2H)


475
N-{4-[1-(4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



fluorobenzoyl)-1,2,3,6-
ppm 8.12-8.14 (bs, 1H), 7.85-7.87 (m, 2H),
m/e 442



tetrahydropyridin-4-
7.53-7.58 (m, 2H), 7.38-7.41 (m, 2H), 7.20-7.25 (m,
(M + H)+



yl]phenyl}-1,3-dihydro-
2H), 7.16-7.20 (m, 2H), 7.09-7.14 (m, 2H),



2H-isoindole-2-
5.98-6.01 (m, 1H), 4.86 (s, 4H), 4.24-4.26 (m, 2H),



carboxamide
3.70-3.74 (m, 2H), 2.50-2.55 (m, 2H)


476
N-{4-[1-(4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



chlorobenzoyl)-1,2,3,6-
ppm 8.12-8.14 (bs, 1H), 7.85-7.87 (m, 2H),
m/e 458



tetrahydropyridin-4-
7.46-7.50 (m, 2H), 7.38-7.40 (m, 4H), 7.20-7.25 (m,
(M + H)+



yl]phenyl}-1,3-dihydro-
2H), 7.15-7.19 (m, 2H), 5.98-6.01 (m, 1H), 4.86 (s,



2H-isoindole-2-
4H), 4.22-4.25 (m, 2H), 3.68-3.72 (m, 2H),



carboxamide
2.50-2.54 (m, 2H)


477
N-(4-{1-[3-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



(dimethylamino)benzoyl]-
ppm 8.08-8.15 (m, 1H), 7.84-7.86 (m, 2H),
m/e 467



1,2,3,6-
7.38-7.40 (m, 2H), 7.28 (dd, J = 8.2, 7.5 Hz, 1H),
(M + H)+



tetrahydropyridin-4-
7.20-7.24 (m, 2H), 7.15-7.20 (m, 2H), 6.98-6.99 (m,



yl}phenyl)-1,3-dihydro-
1H), 6.90-6.94 (m, 1H), 6.77-6.80 (m, 1H),



2H-isoindole-2-
5.99-6.02 (bs, 1H), 4.86 (s, 4H), 4.29-4.34 (m, 2H),



carboxamide
3.71-3.83 (m, 2H), 2.79 (s, 6H), 2.51-2.54 (m, 2H)


478
N-(4-{1-[4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



(dimethylamino)benzoyl]-
ppm 8.11 (d, J = 2.1 Hz, 1H), 7.84-7.87 (m, 2H),
m/e 467



1,2,3,6-
7.56-7.59 (m, 2H), 7.39-7.41 (m, 2H),
(M + H)+



tetrahydropyridin-4-
7.20-7.25 (m, 2H), 7.15-7.18 (m, 2H), 6.70-6.73 (m, 2H),



yl}phenyl)-1,3-dihydro-
6.00-6.03 (m, 1H), 4.82-4.91 (m, 4H), 4.34 (q, J = 2.9 Hz,



2H-isoindole-2-
2H), 3.82 (t, J = 5.7 Hz, 2H), 2.82 (s, 6H),



carboxamide
2.53-2.60 (m, 2H)


479
N-{4-[1-(3-furoyl)-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



1,2,3,6-tetrahydropyridin-
ppm 2.55 (d, J = 1.83 Hz, 2 H), 3.77 (t, J = 5.80 Hz, 2
m/e 414



4-yl]phenyl}-1,3-
H) 4.23 (q, J = 2.64 Hz, 2 H), 4.77 (s, 4 H), 6.08 (t,
(M + H)+



dihydro-2H-isoindole-2-
J = 3.51 Hz, 1 H), 6.68 (d, J = 1.22 Hz, 1 H),



carboxamide
7.27-7.37 (m, 6 H), 7.54 (d, J = 8.54 Hz, 2 H), 7.67 (t,




J = 1.68 Hz, 1 H), 7.99 (s, 1 H), 8.13 (s, 1 H)


480
N-{4-[1-(3-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



thienylcarbonyl)-1,2,3,6-
ppm 8.11-8.12 (bs, 1H), 7.84-7.87 (m, 2H),
m/e 430



tetrahydropyridin-4-
7.72-7.73 (m, 1H), 7.35-7.42 (m, 4H), 7.21-7.24 (m,
(M + H)+



yl]phenyl}-1,3-dihydro-
2H), 7.17-7.19 (m, 2H), 5.97-5.99 (bs, 1H),



2H-isoindole-2-
4.82-4.89 (m, 4H), 4.29-4.31 (m, 2H), 3.78 (t, J = 5.6 Hz,



carboxamide
2H), 2.49-2.53 (m, 2H)


481
N-{4-[1-(1H-pyrrol-2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



ylcarbonyl)-1,2,3,6-
ppm 11.78-11.92 (m, 1H), 8.09-8.11 (m, 1H),
m/e 413



tetrahydropyridin-4-
7.83-7.86 (m, 2H), 7.37-7.40 (m, 2H), 7.20-7.23 (m,
(M + H)+



yl]phenyl}-1,3-dihydro-
2H), 7.16-7.20 (m, 2H), 7.08-7.10 (m, 1H),



2H-isoindole-2-
6.72-6.74 (m, 1H), 6.35 (dt, J = 3.6, 2.5 Hz, 1H),



carboxamide
5.99-6.02 (m, 1H), 4.86 (s, 4H), 4.46 (q, J = 2.9 Hz, 2H),




3.98 (t, J = 5.7 Hz, 2H), 2.50-2.60 (m, 2H)


482
N-(4-{1-[(2,5-dimethyl-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



1H-pyrrol-3-yl)carbonyl]-
ppm 10.78-10.83 (m, 1H), 8.06-8.14 (m, 1H),
m/e 441



1,2,3,6-tetrahydropyridin-
7.81-7.89 (m, 2H), 7.37-7.44 (m, 2H), 7.20-7.23 (m,
(M + H)+



4-yl}phenyl)-1,3-
2H), 7.16-7.19 (m, 2H), 6.11 (dd, J = 2.7, 1.2 Hz,



dihydro-2H-isoindole-2-
1H), 6.04-6.06 (m, 1H), 4.82-4.91 (m, 4H),



carboxamide
4.41-4.45 (m, 2H), 3.94 (t, J = 5.7 Hz, 2H),




2.54-2.61 (m, 2H), 2.48 (s, 3H), 2.24 (s, 3H)


483
N-{4-[1-(1,3-thiazol-4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



ylcarbonyl)-1,2,3,6-
ppm 8.97 (d, J = 2.1 Hz, 1H), 8.16 (d, J = 2.1 Hz,
m/e 431



tetrahydropyridin-4-
1H), 8.09-8.14 (m, 1H), 7.83-7.86 (m, 2H),
(M + H)+



yl]phenyl}-1,3-dihydro-
7.37-7.40 (m, 2H), 7.20-7.24 (m, 2H), 7.16-7.19 (m,



2H-isoindole-2-
2H), 6.01 (t, J = 3.2 Hz, 1H), 4.86 (s, 4H),



carboxamide
4.48-4.51 (m, 2H), 3.98-4.01 (m, 2H), 2.56-2.62 (m, 2H)


484
N-{4-[1-(1H-pyrazol-4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



ylcarbonyl)-1,2,3,6-
ppm 8.19-8.23 (m, 2H), 8.06-8.15 (m, 1H),
m/e 414



tetrahydropyridin-4-
7.82-7.90 (m, 2H), 7.36-7.42 (m, 2H), 7.19-7.24 (m,
(M + H)+



yl]phenyl}-1,3-dihydro-
2H), 7.16-7.19 (m, 2H), 6.00-6.05 (m, 1H),



2H-isoindole-2-
4.83-4.89 (m, 4H), 4.40-4.44 (m, 2H), 3.92 (t, J = 5.7 Hz,



carboxamide
2H), 2.52-2.59 (m, 2H)


485
N-(4-{1-[(3,5-dimethyl-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(−)) m/e



1,2-oxazol-4-
ppm 8.14-8.16 (bs, 1H), 7.85-7.88 (m, 2H),
441 (M − H)



yl)carbonyl]-1,2,3,6-
7.38-7.42 (m, 2H), 7.20-7.24 (m, 2H), 7.16-7.19 (m,



tetrahydropyridin-4-
2H), 6.00-6.02 (m, 1H), 4.84-4.88 (m, 4H),



yl}phenyl)-1,3-dihydro-
4.19-4.23 (m, 2H), 3.69-3.75 (m, 2H), 2.49-2.58 (m,



2H-isoindole-2-
2H), 2.32 (s, 3H), 2.29 (s, 3H)



carboxamide


486
N-{4-[1-(pyridin-2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



ylcarbonyl)-1,2,3,6-
ppm 8.61 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H),
m/e 425



tetrahydropyridin-4-
8.10-8.11 (bs, 1H), 7.83-7.86 (m, 2H), 7.76 (dt, J = 7.7, 1.1 Hz,
(M + H)+



yl]phenyl}-1,3-dihydro-
1H), 7.68 (td, J = 7.6, 1.8 Hz, 1H),



2H-isoindole-2-
7.36-7.39 (m, 2H), 7.20-7.24 (m, 3H), 7.16-7.19 (m, 2H),



carboxamide
5.89-6.10 (m, 1H), 4.86 (s, 4H), 4.40-4.42 (m, 2H),




3.56-4.22 (m, 2H), 2.52-2.64 (m, 2H)


487
N-{4-[1-(pyridin-3-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



ylcarbonyl)-1,2,3,6-
ppm 8.93 (d, J = 2.2 Hz, 1H), 8.70 (dd, J = 4.8, 1.7 Hz,
m/e 425



tetrahydropyridin-4-
1H), 8.13-8.15 (bs, 1H), 7.85-7.88 (m, 2H),
(M + H)+



yl]phenyl}-1,3-dihydro-
7.80-7.85 (m, 1H), 7.37-7.40 (m, 2H),



2H-isoindole-2-
7.25-7.29 (m, 1H), 7.20-7.24 (m, 2H), 7.16-7.20 (m, 2H),



carboxamide
5.97-5.99 (bs, 1H), 4.86 (s, 4H), 4.22-4.29 (m, 2H),




3.64-3.78 (m, 2H), 2.47-2.56 (m, 2H)


488
N-[4-(1-isonicotinoyl-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



1,2,3,6-tetrahydropyridin-
ppm 8.74-8.76 (m, 2H), 8.14-8.15 (bs, 1H),
m/e 425



4-yl)phenyl]-1,3-dihydro-
7.85-7.88 (m, 2H), 7.36-7.42 (m, 4H), 7.20-7.24 (m,
(M + H)+



2H-isoindole-2-
2H), 7.16-7.19 (m, 2H), 5.97-6.00 (bs, 1H), 4.86 (s,



carboxamide
4H), 4.13-4.32 (m, 2H), 3.57-3.79 (m, 2H),




2.46-2.55 (m, 2H)


489
N-{4-[1-(pyridazin-3-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



ylcarbonyl)-1,2,3,6-
ppm 9.22 (dd, J = 5.0, 1.8 Hz, 1H), 8.10-8.12 (bs,
m/e 426



tetrahydropyridin-4-
1H), 7.90 (dd, J = 8.3, 1.7 Hz, 1H), 7.83-7.86 (m,
(M + H)+



yl]phenyl}-1,3-dihydro-
2H), 7.47-7.50 (m, 1H), 7.34-7.38 (m, 2H),



2H-isoindole-2-
7.20-7.23 (m, 2H), 7.16-7.20 (m, 2H), 5.92-6.05 (m,



carboxamide
1H), 4.86 (s, 4H), 4.36-4.51 (m, 2H), 3.67-3.94 (m,




2H), 2.53-2.64 (m, 2H)


490
N-{4-[1-(pyrazin-2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



ylcarbonyl)-1,2,3,6-
ppm 9.34 (d, J = 1.2 Hz, 1H), 8.86 (d, J = 4.9 Hz,
m/e 426



tetrahydropyridin-4-
1H), 8.12-8.14 (bs, 1H), 7.84-7.87 (m, 2H),
(M + H)+



yl]phenyl}-1,3-dihydro-
7.69 (dd, J = 5.0, 1.5 Hz, 1H), 7.37-7.39 (m, 2H),



2H-isoindole-2-
7.20-7.23 (m, 2H), 7.16-7.19 (m, 2H), 5.92-6.05 (m,



carboxamide
1H), 4.86 (s, 4H), 4.29-4.45 (m, 2H), 3.62-4.00 (m,




2H), 2.53-2.61 (m, 2H)


491
N-{4-[1-(pyrimidin-4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



ylcarbonyl)-1,2,3,6-
ppm 9.13 (d, J = 1.5 Hz, 1H), 8.59 (d, J = 2.5 Hz,
m/e 426



tetrahydropyridin-4-
1H), 8.51 (dd, J = 2.5, 1.3 Hz, 1H), 8.11-8.13 (bs,
(M + H)+



yl]phenyl}-1,3-dihydro-
1H), 7.84-7.87 (m, 2H), 7.37-7.40 (m, 2H),



2H-isoindole-2-
7.20-7.24 (m, 2H), 7.16-7.19 (m, 2H), 5.95-6.05 (m,



carboxamide
1H), 4.86 (s, 4H), 4.32-4.47 (m, 2H), 3.60-3.91 (m,




2H), 2.55-2.61 (m, 2H)


492
N-(4-{1-[3-(piperidin-1-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



yl)propanoyl]-1,2,3,6-
ppm 8.12-8.13 (bs, 1H), 7.84-7.86 (m, 2H),
m/e 459



tetrahydropyridin-4-
7.35-7.38 (m, 2H), 7.21-7.25 (m, 2H), 7.16-7.20 (m,
(M + H)+



yl}phenyl)-1,3-dihydro-
2H), 5.94-5.98 (m, 1H), 4.84-4.89 (m, 4H),



2H-isoindole-2-
4.06-4.29 (m, 2H), 3.53-3.89 (m, 2H), 3.30 (t, J = 7.2 Hz,



carboxamide
2H), 2.95-3.05 (m, 2H), 2.89-2.92 (m, 4H),




2.42-2.48 (m, 2H), 1.65-1.73 (m, 4H),




1.30-1.40 (m, 2H)


493
N-{4-[1-(morpholin-4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



ylacetyl)-1,2,3,6-
ppm 8.13-8.14 (bs, 1H), 7.85-7.88 (m, 2H),
m/e 447



tetrahydropyridin-4-
7.39-7.41 (m, 2H), 7.20-7.24 (m, 2H), 7.16-7.20 (m,
(M + H)+



yl]phenyl}-1,3-dihydro-
2H), 6.01-6.04 (m, 1H), 4.86-4.87 (m, 4H), 4.27 (q,



2H-isoindole-2-
J = 2.9 Hz, 2H), 3.75-3.80 (m, 2H), 3.64-3.72 (m,



carboxamide
4H), 3.29 (s, 2H), 2.54-2.57 (m, 6H)


494
N-(4-{1-[(4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ

(ESI(+))



methylpiperazin-1-
ppm 8.13-8.15 (bs, 1H), 7.85-7.87 (m, 2H),
m/e 460



yl)acetyl]-1,2,3,6-
7.38-7.41 (m, 2H), 7.20-7.25 (m, 2H), 7.19 (d, J = 7.0 Hz,
(M + H)+



tetrahydropyridin-4-
1H), 7.17-7.19 (m, 1H), 6.00-6.02 (m, 1H),



yl}phenyl)-1,3-dihydro-
4.83-4.89 (m, 4H), 4.24-4.26 (m, 2H),



2H-isoindole-2-
3.74-3.77 (m, 2H), 3.33 (s, 2H), 2.73-2.76 (m, 4H),



carboxamide
2.66-2.69 (m, 4H), 2.49-2.54 (m, 2H), 2.36 (s, 3H)


759
N-{4-[1-(tetrahydro-2H-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



pyran-4-ylcarbonyl)-
ppm 8.13 (s, 1H), 7.54 (m, 2H), 7.38-7.23 (m,
m/e 432



1,2,3,6-tetrahydropyridin-
6H), 6.08 (m, 1H), 4.79 (d, J = 13.1 Hz, 4H),
(M + H)+



4-yl]phenyl}-1,3-
4.15 (m, 2H), 3.86 (m, 2H), 3.70 (t, J = 5.7 Hz, 2H),



dihydro-2H-isoindole-2-
3.43 (td, J = 11.4, 2.4 Hz, 2H), 2.90 (m, 1H),



carboxamide
2.50 (m, 2H), 1.76-1.51 (m, 4H)


760
N-{4-[1-(1,4-dioxan-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



ylcarbonyl)-1,2,3,6-
ppm 8.13 (s, 1H), 7.55 (m, 2H), 7.38-7.26 (m,
m/e 434



tetrahydropyridin-4-
6H), 6.07 (m, 1H), 4.79 (m, 4H), 4.37 (dd, J = 9.2,
(M + H)+



yl]phenyl}-1,3-dihydro-
3.0 Hz, 1H), 4.15 (m, 2H), 3.82-3.62 (m, 7H),



2H-isoindole-2-
3.53 (m, 1H), 2.50 (m, 2H)



carboxamide


761
N-(4-{1-[(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methylpyrrolidin-3-
ppm 8.13 (s, 1H), 7.54 (d, J = 8.6 Hz, 2H),
m/e 431



yl)carbonyl]-1,2,3,6-
7.40-7.20 (m, 6H), 6.07 (s, 1H), 4.78 (s, 4H), 4.12 (m,
(M + H)+



tetrahydropyridin-4-
2H), 3.68 (t, J = 5.7 Hz, 2H), 3.27 (m, 1H),



yl}phenyl)-1,3-dihydro-
2.77 (m, 1H), 2.63-2.45 (m, 4H), 2.38 (m, 1H), 2.25 (s,



2H-isoindole-2-
3H), 98 (m, 2H)



carboxamide


762
N-(4-{1-[(1,1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



dioxidotetrahydrothiophen-
ppm 8.14 (s, 1H), 7.55 (m, 2H), 7.38-7.27 (m,
m/e 466



3-yl)carbonyl]-1,2,3,6-
6H), 6.08 (m, 1H), 4.81 (m, 4H), 4.17 (m, 2H),
(M + H)+



tetrahydropyridin-4-
3.74 (m, 3H), 3.33-3.10 (m, 3H), 3.07 (m, 1H),



yl}phenyl)-1,3-dihydro-
2.53 (m, 2H), 2.37 (m, 1H), 2.14 (m, 1H)



2H-isoindole-2-



carboxamide


763
N-{4-[1-(2-hydroxy-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methylpropanoyl)-
ppm 8.13 (s, 1H), 7.54 (m, 2H), 7.38-7.27 (m,
m/e 406



1,2,3,6-tetrahydropyridin-
6H), 6.09 (m, 1H), 5.10 (s, 1H), 4.78 (s, 4H),
(M + H)+



4-yl]phenyl}-1,3-
4.28 (m, 2H), 3.94 (m, 2H), 2.50 (m, 2H), 1.37 (s, 6H)



dihydro-2H-isoindole-2-



carboxamide


1019
5-cyano-N-{4-[1-(2-
-1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ
(ESI(+))



methylpropanoyl)-
ppm 8.20 (m, 1H), 7.80 (m, 1H), 7.70 (m, 1H),
m/e 415



1,2,3,6-tetrahydropyridin-
7.54 (m, 3H), 7.37 (m, 2H), 6.08 (bs, 1H), 4.90 (m, 4H),
(M + H)+



4-yl]phenyl}-1,3-
4.13 (m, 2H), 3.69 (m, 2H), 2.90 (m, 1H), 2.50 (m,



dihydro-2H-isoindole-2-
2H), 1.02 (m, 6H)



carboxamide


1281
5-cyano-N-{4-[1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



(tetrahydrofuran-3-
ppm 8.21 (s, 1H), 7.80 (s, 1H), 7.71 (d, J = 7.9 Hz,
m/e 443



ylcarbonyl)-1,2,3,6-
1H), 7.54 (m, 3H), 7.33 (m, 2H), 6.07 (bs, 1H),
(M + H)+



tetrahydropyridin-4-
4.83 (m, 4H), 4.14 (m, 2H), 3.91 (t, J = 8.1 Hz,



yl]phenyl}-1,3-dihydro-
1H), 3.71 (m, 5H), 3.38 (m, 1H), 2.50 (m, 2H),



2H-isoindole-2-
2.07 (m, 2H)



carboxamide


1282
5-cyano-N-{4-[1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



(tetrahydro-2H-pyran-4-
ppm 8.22 (bs, 1H), 7.80 (s, 1H), 7.72 (d, J = 7.8 Hz,
m/e 457



ylcarbonyl)-1,2,3,6-
1H), 7.54 (m, 3H), 7.33 (m, 2H), 6.08 (bs, 1H),
(M + H)+



tetrahydropyridin-4-
4.82 (m, 4H), 4.14 (m, 2H), 3.86 (m, 2H), 3.70 (t, J = 5.7 Hz,



yl]phenyl}-1,3-dihydro-
2H), 3.42 (td, J = 11.4, 2.5 Hz, 2H),



2H-isoindole-2-
2.90 (m, 1H), 2.50 (m, 2H), 1.77-1.53 (m, 4H)



carboxamide


1283
5-cyano-N-{4-[1-(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



hydroxy-2-
ppm 8.21 (s, 1H), 7.80 (s, 1H), 7.71 (d, J = 7.7 Hz,
m/e 431



methylpropanoyl)-
1H), 7.53 (m, 3H), 7.33 (m, 2H), 6.08 (m, 1H),
(M + H)+



1,2,3,6-tetrahydropyridin-
5.10 (s, 1H), 4.83 (m, 4H), 4.28 (m, 2H), 3.93 (m, 2H),



4-yl]phenyl}-1,3-
2.50 (m, 2H), 1.37 (s, 6H)



dihydro-2H-isoindole-2-



carboxamide


1284
5-cyano-N-{4-[1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



(morpholin-4-ylacetyl)-
ppm 8.21 (s, 1H), 7.80 (s, 1H), 7.72 (d, J = 7.9 Hz,
m/e 472



1,2,3,6-tetrahydropyridin-
1H), 7.51 (m, 3H), 7.33 (m, 2H), 6.07 (m, 1H),
(M + H)+



4-yl]phenyl}-1,3-
4.83 (m, 4H), 4.15 (m, 2H), 3.71 (m, 2H), 3.58 (m, 4H),



dihydro-2H-isoindole-2-
3.21 (s, 2H), 2.50 (m, 2H), 2.45 (m, 4H)



carboxamide









Example 495
N-(1′-benzoyl-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(5-(1,2,3,6-tetrahydropyridin-4-yl)pyridin-2-yl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and benzoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (400 MHz, DMSO-d6, Temp=90° C.) δ ppm 8.51 (bs, 1H), 8.32 (d, J=2.5 Hz, 1H), 7.90 (d, J=8.7 Hz, 1H), 7.77 (dd, J=8.7, 2.5 Hz, 1H), 7.48-7.39 (m, 5H), 7.36-7.25 (m, 4H), 6.16 (bs, 1H), 4.81 (s, 4H), 4.18 (m, 2H), 3.68 (m, 2H), 2.55 (m, 2H); MS (ESI(+)) m/e 425 (M+H)+.


Example 496
N-(4-{[6-(benzoylamino)hexyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting benzoyl chloride for acetyl chloride and N-{4-[(6-aminohexyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.57 (s, 1H), 8.43 (t, J=5.6 Hz, 1H), 8.25 (t, J=5.6 Hz, 1H), 7.81-7.86 (m, 2H), 7.74-7.78 (m, 2H), 7.63-7.67 (m, 2H), 7.41-7.54 (m, 3H), 7.29-7.39 (m, 4H), 4.78-4.79 (bs, 4H), 3.15-3.27 (m, 4H), 1.44-1.64 (m, 4H), 1.19-1.39 (m, 4H); MS (ESI(+)) m/e 485 (M+H)+.


Example 497
N-[4-({4-[(benzoylamino)methyl]benzyl}carbamoyl)phenyl]-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting benzoyl chloride for acetyl chloride and N-(4-{[4-(aminomethyl)benzyl]carbamoyl}phenyl)-5-fluoro-1,3-dihydro-2H-isoindole-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.01 (t, J=6.0 Hz, 1H), 8.83 (t, J=5.9 Hz, 1H), 8.60 (s, 1H), 7.85-7.91 (m, 2H), 7.78-7.83 (m, 2H), 7.63-7.68 (m, 2H), 7.36-7.56 (m, 4H), 7.27 (s, 4H), 7.21-7.26 (m, 1H), 7.10-7.19 (m, 1H), 4.72-4.81 (m, 4H), 4.40-4.48 (m, 4H); MS (ESI(+)) m/e 523 (M+H)+.









TABLE 8







The following Examples were essentially prepared as described in Example 1C,


substituting N-(4-(piperazin-1-yl)phenyl)isoindoline-2-carboxamide for 3-phenylpropan-1-


amine and the appropriate carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid.










Ex
Name

1H NMR

MS





498
N-{4-[4-(5-oxo-L-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



prolyl)piperazin-1-
7.95-7.98 (bs, 1H), 7.81-7.90 (m, 1H), 7.74-7.77 (m,
m/e 434



yl]phenyl}-1,3-
2H), 7.20-7.23 (m, 2H), 7.16-7.20 (m, 2H),
(M + H)+



dihydro-2H-isoindole-
6.92-6.95 (m, 2H), 4.86 (s, 4H), 4.60-4.64 (m, 1H),



2-carboxamide
3.55-3.76 (m, 4H), 3.03-3.06 (m, 4H), 2.38-2.47 (m, 1H),




2.25-2.37 (m, 2H), 2.08-2.15 (m, 1H)


499
N-{4-[4-(5-oxo-D-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



prolyl)piperazin-1-
7.95-7.98 (bs, 1H), 7.80-7.84 (bs, 1H), 7.75-7.77 (m,
m/e 434



yl]phenyl}-1,3-
2H), 7.20-7.23 (m, 2H), 7.16-7.20 (m, 2H),
(M + H)+



dihydro-2H-isoindole-
6.92-6.95 (m, 2H), 4.86 (s, 4H), 4.60-4.64 (m, 1H),



2-carboxamide
3.57-3.76 (m, 4H), 3.02-3.08 (m, 4H), 2.38-2.46 (m, 1H),




2.24-2.37 (m, 2H), 2.08-2.15 (m, 1H)


500
N-(4-{4-[(1-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



acetylpiperidin-4-
7.93-7.95 (bs, 1H), 7.75-7.77 (m, 2H), 7.20-7.23 (m,
m/e 476



yl)carbonyl]piperazin-
2H), 7.19 (d, J = 4.2 Hz, 1H), 7.16 (d, J = 8.2 Hz,
(M + H)+



1-yl}phenyl)-1,3-
1H), 6.94-6.97 (m, 2H), 4.86 (s, 4H), 3.66-3.76 (m,



dihydro-2H-isoindole-
4H), 3.05-3.08 (m, 4H), 2.78-3.03 (m, 3H), 2.01 (s,



2-carboxamide
3H), 1.81-1.92 (m, 2H), 1.68-1.79 (m, 2H)


501
N-{4-[4-(2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



acetamidobenzoyl)piperazin-
9.65 (d, J = 5.2 Hz, 1H), 8.26 (d, J = 8.1 Hz, 1H),
m/e 484



1-yl]phenyl}-
7.92-7.93 (bs, 1H), 7.73-7.76 (m, 2H), 7.34-7.39 (m,
(M + H)+



1,3-dihydro-2H-
2H), 7.20-7.23 (m, 2H), 7.16-7.19 (m, 2H), 7.12 (dd,



isoindole-2-
J = 7.5, 1.2 Hz, 1H), 6.92-6.94 (m, 2H), 4.86 (s, 4H),



carboxamide
3.68-3.83 (m, 4H), 3.07-3.10 (m, 4H), 2.09 (s, 3H)


502
N-(4-{4-[4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



(methylsulfonyl)benzoyl]piperazin-
8.10-8.13 (m, 2H), 7.94-7.96 (bs, 1H), 7.75-7.78 (m,
m/e 505



1-
2H), 7.68-7.71 (m, 2H), 7.20-7.23 (m, 2H),
(M + H)+



yl}phenyl)-1,3-
7.16-7.20 (m, 2H), 6.94-6.98 (m, 2H), 4.86 (s, 4H),



dihydro-2H-isoindole-
3.55-3.78 (m, 4H), 3.17 (s, 3H), 3.08-3.11 (m, 4H)



2-carboxamide


503
N-[4-(4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



butyrylpiperazin-1-
7.91-7.93 (m, 1H), 7.73-7.77 (m, 2H), 7.20-7.23 (m,
m/e 393



yl)phenyl]-1,3-
2H), 7.19 (d, J = 7.3 Hz, 1H), 7.17-7.18 (m, 1H),
(M + H)+



dihydro-2H-isoindole-
6.93-6.96 (m, 2H), 4.86 (s, 4H), 3.48-3.70 (m, 3H),



2-carboxamide
3.02-3.06 (m, 4H), 2.43 (d, J = 0.6 Hz, 1H), 2.31 (t, J = 7.3 Hz,




2H), 1.65-1.81 (m, 2H), 0.95 (t, J = 7.3 Hz,




3H)


504
N-[4-(4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



isobutyrylpiperazin-1-
7.92-7.94 (bs, 1H), 7.74-7.76 (m, 2H), 7.20-7.23 (m,
m/e 393



yl)phenyl]-1,3-
2H), 7.16-7.20 (m, 2H), 6.93-6.96 (m, 2H), 4.86 (s,
(M + H)+



dihydro-2H-isoindole-
4H), 3.65-3.69 (m, 4H), 3.03-3.06 (m, 4H),



2-carboxamide
2.76-2.87 (m, 1H), 1.15 (d, J = 6.7 Hz, 6H)


505
N-{4-[4-(2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



methylbutanoyl)piperazin-
7.92-7.94 (bs, 1H), 7.74-7.77 (m, 2H), 7.20-7.23 (m,
m/e 407



1-yl]phenyl}-1,3-
2H), 7.16-7.20 (m, 2H), 6.94-6.97 (m, 2H), 4.86 (s,
(M + H)+



dihydro-2H-isoindole-
4H), 3.68-3.73 (m, 4H), 3.04-3.07 (m, 4H), 2.68 (h, J = 6.7 Hz,



2-carboxamide
1H), 1.76-1.87 (m, 1H), 1.40-1.51 (m, 1H),




1.15 (d, J = 6.7 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H)


506
N-{4-[4-(3,3,3-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



trifluoropropanoyl)piperazin-
7.93-7.95 (bs, 1H), 7.74-7.76 (m, 2H), 7.20-7.24 (m,
m/e 433



1-yl]phenyl}-
2H), 7.16-7.19 (m, 2H), 6.92-6.95 (m, 2H), 4.86 (s,
(M + H)+



1,3-dihydro-2H-
4H), 3.58-3.78 (m, 4H), 3.57 (q, J = 10.5 Hz, 2H),



isoindole-2-
3.02-3.09 (m, 4H)



carboxamide


507
N-{4-[4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



(methoxyacetyl)piperazin-
7.92-7.96 (bs, 1H), 7.73-7.76 (m, 2H), 7.16-7.24 (m,
m/e 395



1-yl]phenyl}-1,3-
4H), 6.92-6.95 (m, 2H), 4.86 (s, 4H), 4.18 (s, 2H),
(M + H)+



dihydro-2H-isoindole-
3.55-3.78 (m, 4H), 3.39 (s, 3H), 3.03-3.06 (m, 4H)



2-carboxamide


508
N-{4-[4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



(tetrahydrofuran-2-
7.90-7.95 (m, 1H), 7.73-7.75 (m, 2H), 7.19-7.24 (m,
m/e 421



ylcarbonyl)piperazin-
2H), 7.15-7.19 (m, 2H), 6.92-6.95 (m, 2H), 4.86 (s,
(M + H)+



1-yl]phenyl}-1,3-
4H), 4.66 (dd, J = 7.2, 5.4 Hz, 1H), 3.88-3.94 (m,



dihydro-2H-isoindole-
1H), 3.67-3.83 (m, 5H), 2.93-3.15 (m, 4H),



2-carboxamide
2.37-2.48 (m, 1H), 1.84-2.05 (m, 2H), 1.70-1.81 (m, 1H)


509
N-{4-[4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



(tetrahydrofuran-3-
7.93 (d, J = 2.6 Hz, 1H), 7.74-7.77 (m, 2H),
m/e 421



ylcarbonyl)piperazin-
7.20-7.24 (m, 2H), 7.15-7.20 (m, 2H), 6.94-6.97 (m, 2H),
(M + H)+



1-yl]phenyl}-1,3-
4.86 (s, 4H), 4.08 (dd, J = 8.3, 6.5 Hz, 1H), 4.04 (t, J = 8.0 Hz,



dihydro-2H-isoindole-
1H), 3.91 (td, J = 7.9, 5.9 Hz, 1H), 3.74-3.82 (m,



2-carboxamide
1H), 3.58-3.76 (m, 4H), 3.26-3.34 (m, 1H),




3.00-3.10 (m, 4H), 2.24-2.33 (m, 1H), 1.97-2.07 (m, 1H)


510
N-{4-[4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



(cyclopentylacetyl)piperazin-
7.90-7.92 (bs, 1H), 7.73-7.76 (m, 2H), 7.19-7.24 (m,
m/e 433



1-yl]phenyl}-
2H), 7.15-7.19 (m, 2H), 6.94-6.97 (m, 2H), 4.85 (s,
(M + H)+



1,3-dihydro-2H-
4H), 3.46-3.83 (m, 4H), 3.04-3.07 (m, 4H),



isoindole-2-
2.28-2.49 (m, 3H), 1.81-1.96 (m, 2H), 1.41-1.67 (m, 4H),



carboxamide
1.17-1.32 (m, 2H)


511
N-{4-[4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



(cyclohexylcarbonyl)piperazin-
7.90-7.92 (bs, 1H), 7.73-7.76 (m, 2H), 7.20-7.24 (m,
m/e 433



1-yl]phenyl}-
2H), 7.15-7.20 (m, 2H), 6.94-6.97 (m, 2H), 4.86 (s,
(M + H)+



1,3-dihydro-2H-
4H), 3.64-3.77 (m, 4H), 3.04-3.07 (m, 4H), 2.60 (tt, J = 11.0,



isoindole-2-
3.5 Hz, 1H), 1.55-1.85 (m, 7H), 1.14-1.40 (m,



carboxamide
3H)


512
N-{4-[4-(2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



methoxybenzoyl)piperazin-
7.90-7.92 (bs, 1H), 7.73-7.76 (m, 2H), 7.41 (dd, J = 7.4,
m/e 457



1-yl]phenyl}-1,3-
1.8 Hz, 1H), 7.30-7.35 (m, 1H), 7.19-7.24 (m,
(M + H)+



dihydro-2H-isoindole-
2H), 7.15-7.19 (m, 2H), 7.01 (td, J = 7.4, 1.0 Hz, 1H),



2-carboxamide
6.92-6.98 (m, 3H), 4.85 (s, 4H), 3.77-4.30 (m, 2H),




3.70 (s, 3H), 3.51 (s, 2H), 2.79-3.24 (m, 4H)


513
N-{4-[4-(3-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



methoxybenzoyl)piperazin-
7.92 (d, J = 2.1 Hz, 1H), 7.74-7.76 (m, 2H),
m/e 457



1-yl]phenyl}-1,3-
7.30-7.34 (m, 1H), 7.19-7.24 (m, 3H), 7.15-7.19 (m, 2H),
(M + H)+



dihydro-2H-isoindole-
7.11-7.14 (m, 1H), 7.01 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H),



2-carboxamide
6.93-6.96 (m, 2H), 4.86 (s, 4H), 3.67-3.79 (m, 7H),




3.06-3.09 (m, 4H)


514
N-{4-[4-(4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



methoxybenzoyl)piperazin-
7.89-7.92 (m, 1H), 7.74-7.76 (m, 2H), 7.53-7.56 (m,
m/e 457



1-yl]phenyl}-1,3-
2H), 7.20-7.23 (m, 2H), 7.15-7.20 (m, 2H),
(M + H)+



dihydro-2H-isoindole-
6.90-7.01 (m, 4H), 4.86 (s, 4H), 3.73-3.78 (m, 4H), 3.71 (s,



2-carboxamide
3H), 3.08-3.11 (m, 4H)


515
N-{4-[4-(3-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



fluorobenzoyl)piperazin-
7.91-7.93 (bs, 1H), 7.74-7.77 (m, 2H), 7.29-7.41 (m,
m/e 445



1-yl]phenyl}-1,3-
3H), 7.20-7.23 (m, 2H), 7.16-7.20 (m, 2H),
(M + H)+



dihydro-2H-isoindole-
7.09-7.14 (m, 1H), 6.94-6.97 (m, 2H), 4.86 (s, 4H),



2-carboxamide
3.65-3.83 (m, 4H), 3.06-3.09 (m, 4H)


516
N-{4-[4-(2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



chlorobenzoyl)piperazin-
7.91-7.94 (bs, 1H), 7.74-7.76 (m, 2H), 7.34-7.45 (m,
m/e 461



1-yl]phenyl}-1,3-
2H), 7.25-7.29 (m, 2H), 7.19-7.23 (m, 2H),
(M + H)+



dihydro-2H-isoindole-
7.16-7.19 (m, 2H), 6.94-6.96 (m, 2H), 4.85 (s, 4H),



2-carboxamide
3.72-4.17 (m, 2H), 3.26-3.50 (m, 2H), 2.84-3.25 (m, 4H)


517
N-{4-[4-(4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



chlorobenzoyl)piperazin-
7.91-7.93 (bs, 1H), 7.74-7.77 (m, 2H), 7.47-7.49 (m,
m/e 461



1-yl]phenyl}-1,3-
2H), 7.38-7.41 (m, 2H), 7.20-7.23 (m, 2H),
(M + H)+



dihydro-2H-isoindole-
7.16-7.19 (m, 2H), 6.94-6.97 (m, 2H), 4.86 (s, 4H),



2-carboxamide
3.68-3.71 (m, 4H), 3.07-3.10 (m, 4H)


518
N-{4-[4-(3-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(−))



cyanobenzoyl)piperazin-
7.92-7.94 (bs, 1H), 7.88-7.89 (m, 1H), 7.75-7.77 (m,
m/e 450



1-yl]phenyl}-1,3-
2H), 7.71 (dt, J = 7.7, 1.4 Hz, 1H), 7.65 (dt, J = 7.7,
(M − H)



dihydro-2H-isoindole-
1.4 Hz, 1H), 7.44 (t, J = 7.7 Hz, 1H), 7.20-7.23 (m,



2-carboxamide
2H), 7.16-7.20 (m, 2H), 6.94-6.97 (m, 2H), 4.86 (s,




4H), 3.57-3.83 (m, 4H), 3.08-3.11 (m, 4H)


519
N-{4-[4-(4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



cyanobenzoyl)piperazin-
7.93-7.94 (bs, 1H), 7.74-7.77 (m, 2H), 7.65-7.71 (m,
m/e 452



1-yl]phenyl}-1,3-
2H), 7.56-7.61 (m, 2H), 7.20-7.23 (m, 2H),
(M + H)+



dihydro-2H-isoindole-
7.16-7.19 (m, 2H), 6.94-6.97 (m, 2H), 4.86 (s, 4H),



2-carboxamide
3.58-3.77 (m, 4H), 3.08-3.11 (m, 4H)


520
N-(4-{4-[3-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



(dimethylamino)benzoyl]piperazin-
7.91 (d, J = 2.6 Hz, 1H), 7.73-7.76 (m, 2H),
m/e 470



1-
7.26-7.31 (m, 1H), 7.19-7.23 (m, 2H), 7.16-7.19 (m, 2H),
(M + H)+



yl}phenyl)-1,3-
6.96-6.99 (m, 1H), 6.93-6.97 (m, 2H), 6.90 (dt, J = 7.3, 1.1 Hz,



dihydro-2H-isoindole-
1H), 6.78 (ddd, J = 8.4, 2.7, 0.8 Hz, 1H), 4.85 (s,



2-carboxamide
4H), 3.71-3.83 (m, 4H), 3.07-3.10 (m, 4H), 2.80 (s,




6H)


521
N-(4-{4-[4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



(dimethylamino)benzoyl]piperazin-
7.89-7.91 (bs, 1H), 7.73-7.76 (m, 2H), 7.55-7.57 (m,
m/e 470



1-
2H), 7.19-7.23 (m, 2H), 7.16-7.19 (m, 2H),
(M + H)+



yl}phenyl)-1,3-
6.94-6.97 (m, 2H), 6.71-6.73 (m, 2H), 4.86 (s, 4H),



dihydro-2H-isoindole-
3.78-3.81 (m, 4H), 3.09-3.12 (m, 4H), 2.81-2.84 (m, 6H)



2-carboxamide


522
N-{4-[4-(3,4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



dimethoxybenzoyl)piperazin-
7.91-7.93 (bs, 1H), 7.74-7.77 (m, 2H), 7.26 (d, J = 2.0 Hz,
m/e 487



1-yl]phenyl}-
1H), 7.20-7.24 (m, 2H), 7.16-7.19 (m, 3H),
(M + H)+



1,3-dihydro-2H-
6.93-7.00 (m, 3H), 4.86 (s, 4H), 3.77-3.80 (m, 4H),



isoindole-2-
3.77 (s, 3H), 3.77 (s, 3H), 3.07-3.15 (m, 4H)



carboxamide


523
N-{4-[4-(3,5-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



dimethoxybenzoyl)piperazin-
7.91-7.93 (bs, 1H), 7.74-7.76 (m, 2H), 7.20-7.24 (m,
m/e 487



1-yl]phenyl}-
2H), 7.16-7.19 (m, 2H), 6.94-6.96 (m, 2H),
(M + H)+



1,3-dihydro-2H-
6.81-6.82 (m, 2H), 6.67 (t, J = 2.3 Hz, 1H), 4.86 (s, 4H),



isoindole-2-
3.70-3.77 (m, 4H), 3.71 (s, 6H), 3.07-3.10 (m, 4H)



carboxamide


524
N-(4-{4-[(3,4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



dimethoxyphenyl)acetyl]piperazin-
7.88-7.90 (bs, 1H), 7.71-7.74 (m, 2H), 7.19-7.23 (m,
m/e 501



1-
2H), 7.15-7.19 (m, 2H), 7.09 (d, J = 2.0 Hz, 1H),
(M + H)+



yl}phenyl)-1,3-
6.97 (dd, J = 8.1, 2.0 Hz, 1H), 6.88-6.93 (m, 3H), 4.85 (s,



dihydro-2H-isoindole-
4H), 3.81 (s, 2H), 3.74 (s, 3H), 3.73 (s, 3H),



2-carboxamide
3.67-3.78 (m, 4H), 3.00-3.03 (m, 4H)


525
N-{4-[4-(2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



furoyl)piperazin-1-
7.89-7.91 (bs, 1H), 7.73-7.76 (m, 2H), 7.57 (dd, J = 1.8,
m/e 417



yl]phenyl}-1,3-
0.9 Hz, 1H), 7.20-7.23 (m, 2H), 7.16-7.19 (m,
(M + H)+



dihydro-2H-isoindole-
2H), 7.08 (dd, J = 3.4, 0.8 Hz, 1H), 6.93-6.96 (m,



2-carboxamide
2H), 6.45 (dd, J = 3.4, 1.7 Hz, 1H), 4.85 (s, 4H),




3.86-3.89 (m, 4H), 3.09-3.12 (m, 4H)


526
N-{4-[4-(3-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



furoyl)piperazin-1-
7.93 (dd, J = 1.6, 0.8 Hz, 1H), 7.90-7.92 (bs, 1H),
m/e 417



yl]phenyl}-1,3-
7.73-7.76 (m, 2H), 7.52-7.53 (m, 1H), 7.19-7.23 (m,
(M + H)+



dihydro-2H-isoindole-
2H), 7.16-7.19 (m, 2H), 6.93-6.96 (m, 2H), 6.72 (dd,



2-carboxamide
J = 1.8, 0.9 Hz, 1H), 4.85 (s, 4H), 3.77-3.80 (m, 4H),




3.06-3.10 (m, 4H)


527
N-{4-[4-(1H-pyrrol-2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(−))



ylcarbonyl)piperazin-
11.87-11.96 (bs, 1H), 7.88-7.89 (bs, 1H),
m/e 414



1-yl]phenyl}-1,3-
7.72-7.75 (m, 2H), 7.19-7.23 (m, 2H), 7.15-7.19 (m, 2H),
(M − H)



dihydro-2H-isoindole-
7.10 (td, J = 2.7, 1.3 Hz, 1H), 6.92-6.95 (m, 2H),



2-carboxamide
6.68-6.70 (m, 1H), 6.33-6.36 (m, 1H), 4.85 (s, 4H),




3.94-3.97 (m, 4H), 3.09-3.12 (m, 4H)


528
N-{4-[4-(1H-pyrazol-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



5-
7.88 (d, J = 2.5 Hz, 1H), 7.77 (d, J = 2.2 Hz, 1H),
m/e 417



ylcarbonyl)piperazin-
7.71-7.74 (m, 2H), 7.19-7.23 (m, 2H), 7.15-7.19 (m,
(M + H)+



1-yl]phenyl}-1,3-
2H), 6.91-6.95 (m, 3H), 4.85 (s, 4H), 4.06-4.14 (m,



dihydro-2H-isoindole-
4H), 3.07-3.18 (m, 4H)



2-carboxamide


529
N-{4-[4-(pyridin-2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



ylcarbonyl)piperazin-
8.60 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 7.84-7.97 (m,
m/e 428



1-yl]phenyl}-1,3-
1H), 7.76 (dt, J = 7.7, 1.1 Hz, 1H), 7.72-7.75 (m, 2H),
(M + H)+



dihydro-2H-isoindole-
7.69 (td, J = 7.6, 1.8 Hz, 1H), 7.20-7.24 (m, 2H),



2-carboxamide
7.17-7.19 (m, 2H), 6.93-6.96 (m, 2H), 4.85 (s, 4H),




3.73-3.99 (m, 4H), 3.08-3.19 (m, 4H)


530
N-{4-[4-(pyridin-3-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



ylcarbonyl)piperazin-
8.92 (dd, J = 2.2, 0.9 Hz, 1H), 8.70 (dd, J = 4.8, 1.7 Hz,
m/e 428



1-yl]phenyl}-1,3-
1H), 7.90-8.02 (m, 1H), 7.82 (dt, J = 7.8, 2.0 Hz,
(M + H)+



dihydro-2H-isoindole-
1H), 7.74-7.77 (m, 2H), 7.27 (ddd, J = 7.7, 4.8, 0.9 Hz,



2-carboxamide
1H), 7.20-7.23 (m, 2H), 7.16-7.19 (m, 2H),




6.93-6.96 (m, 2H), 4.86 (s, 4H), 3.68-3.72 (m, 4H),




3.06-3.09 (m, 4H)


531
N-[4-(4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



isonicotinoylpiperazin-
8.74-8.76 (m, 2H), 7.95 (d, J = 2.8 Hz, 1H),
m/e 428



1-yl)phenyl]-1,3-
7.75-7.78 (m, 2H), 7.38-7.40 (m, 2H), 7.20-7.23 (m, 2H),
(M + H)+



dihydro-2H-isoindole-
7.16-7.20 (m, 2H), 6.94-6.97 (m, 2H), 4.86 (s, 4H),



2-carboxamide
3.56-3.76 (m, 4H), 3.06-3.09 (m, 4H)


532
N-{4-[4-(pyridazin-3-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



ylcarbonyl)piperazin-
9.22 (dd, J = 5.0, 1.7 Hz, 1H), 7.91 (dd, J = 8.3, 1.8 Hz,
m/e 429



1-yl]phenyl}-1,3-
1H), 7.89-7.92 (bs, 1H), 7.72-7.75 (m, 2H),
(M + H)+



dihydro-2H-isoindole-
7.51 (dd, J = 8.5, 5.1 Hz, 1H), 7.19-7.23 (m, 2H),



2-carboxamide
7.16-7.19 (m, 2H), 6.92-6.95 (m, 2H), 4.85 (s, 4H),




3.60-4.20 (m, 4H), 2.94-3.32 (m, 4H)


533
N-{4-[4-(pyrazin-2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



ylcarbonyl)piperazin-
9.33 (d, J = 1.4 Hz, 1H), 8.87 (d, J = 5.0 Hz, 1H),
m/e 429



1-yl]phenyl}-1,3-
7.91-7.93 (bs, 1H), 7.73-7.76 (m, 2H), 7.70 (dd, J = 5.0,
(M + H)+



dihydro-2H-isoindole-
1.4 Hz, 1H), 7.20-7.23 (m, 2H), 7.18 (t, J = 3.4 Hz,



2-carboxamide
2H), 6.94-6.96 (m, 2H), 4.85 (s, 4H),




3.48-4.06 (m, 4H), 3.12-3.15 (m, 4H)


534
N-{4-[4-(pyrimidin-4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



ylcarbonyl)piperazin-
9.13 (d, J = 1.5 Hz, 1H), 8.59 (d, J = 2.5 Hz, 1H),
m/e 429



1-yl]phenyl}-1,3-
8.50 (dd, J = 2.5, 1.5 Hz, 1H), 7.91 (d, J = 0.8 Hz,
(M + H)+



dihydro-2H-isoindole-
1H), 7.73-7.76 (m, 2H), 7.20-7.23 (m, 2H),



2-carboxamide
7.16-7.18 (m, 2H), 6.94-6.97 (m, 2H), 4.85 (s, 4H),




3.73-3.96 (m, 4H), 3.07-3.22 (m, 4H)


535
N-{4-[4-(N,N-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



dimethyl-beta-
7.90-7.93 (bs, 1H), 7.72-7.75 (m, 2H), 7.20-7.23 (m,
m/e 422



alanyl)piperazin-1-
2H), 7.16-7.19 (m, 2H), 6.90-6.93 (m, 2H), 4.85 (s,
(M + H)+



yl]phenyl}-1,3-
4H), 3.55-3.72 (m, 4H), 3.33 (t, J = 7.2 Hz, 2H),



dihydro-2H-isoindole-
3.00-3.05 (m, 4H), 2.96 (t, J = 7.2 Hz, 2H), 2.64 (s,



2-carboxamide
6H)


536
N-[4-(4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



acetylpiperazin-1-
7.89-7.92 (bs, 1H), 7.73-7.75 (m, 2H), 7.20-7.23 (m,
m/e 365



yl)phenyl]-1,3-
2H), 7.15-7.19 (m, 2H), 6.92-6.95 (m, 2H), 4.85 (s,
(M + H)+



dihydro-2H-isoindole-
4H), 3.48-3.81 (m, 4H), 2.97-3.03 (m, 4H), 2.04 (s,



2-carboxamide
3H)


537
N-{4-[4-(2-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



fluorobenzoyl)piperazin-
7.90-7.92 (bs, 1H), 7.73-7.76 (m, 2H), 7.46-7.51 (m,
m/e 445



1-yl]phenyl}-1,3-
1H), 7.29-7.36 (m, 1H), 7.19-7.23 (m, 2H),
(M + H)+



dihydro-2H-isoindole-
7.16-7.18 (m, 3H), 7.09-7.12 (m, 1H), 6.93-6.95 (m, 2H),



2-carboxamide
4.85 (s, 4H), 3.38-4.02 (m, 4H), 2.90-3.23 (m, 4H)


538
N-{4-[4-(4-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



fluorobenzoyl)piperazin-
7.91-7.93 (bs, 1H), 7.74-7.77 (m, 2H), 7.52-7.58 (m,
m/e 445



1-yl]phenyl}-1,3-
2H), 7.20-7.25 (m, 2H), 7.16-7.20 (m, 2H),
(M + H)+



dihydro-2H-isoindole-
7.09-7.15 (m, 2H), 6.94-6.97 (m, 2H), 4.86 (s, 4H),



2-carboxamide
3.69-3.72 (m, 4H), 3.07-3.10 (m, 4H)


539
N-{4-[4-

1H NMR (400 MHz, Pyridine-d5-D2O, Temp = 90° C.)

(ESI(+))



(phenylacetyl)piperazin-
δ ppm 2.95-3.04 (m, 4 H), 3.68 (s, 4 H), 3.83 (s, 2
m/e 441



1-yl]phenyl}-1,3-
H), 4.85 (s, 4 H), 6.87-6.93 (m, 2 H), 7.15-7.24 (m,
(M + H)+



dihydro-2H-isoindole-
4 H), 7.27-7.33 (m, 2 H), 7.40 (d, J = 7.02 Hz, 2 H),



2-carboxamide
7.68-7.75 (m, 2 H), 7.89 (s, 1 H)


540
N-{4-[4-(1,3-thiazol-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(−))



4-
8.97 (d, J = 2.1 Hz, 1H), 8.17 (d, J = 2.1 Hz, 1H),
m/e 432



ylcarbonyl)piperazin-
7.88-7.89 (bs, 1H), 7.72-7.75 (m, 2H), 7.19-7.23 (m,
(M − H)



1-yl]phenyl}-1,3-
2H), 7.16-7.19 (m, 2H), 6.93-6.96 (m, 2H), 4.85 (s,



dihydro-2H-isoindole-
4H), 3.98-4.01 (m, 4H), 3.13-3.16 (m, 4H)



2-carboxamide


541
N-{4-[4-(morpholin-

1H NMR (400 MHz, Pyridine-d5, Temp = 90° C.) δ ppm

(ESI(+))



4-ylacetyl)piperazin-
7.85-8.03 (m, 1H), 7.74-7.77 (m, 2H), 7.21-7.23 (m,
m/e 450



1-yl]phenyl}-1,3-
2H), 7.16-7.19 (m, 2H), 6.97 (d, J = 7.0 Hz, 1H),
(M + H)+



dihydro-2H-isoindole-
6.95-6.95 (m, 1H), 4.86 (s, 4H), 3.73-3.76 (m, 4H),



2-carboxamide
3.64-3.71 (m, 4H), 3.29 (s, 2H), 3.07-3.10 (m, 4H),




2.54-2.57 (m, 4H)









Example 542
5-cyano-N-(4-phenylbutyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1A, substituting 4-phenylbutyl isocyanate for methyl 4-isocyanatobenzoate and 5-cyanoisoindoline for isoindoline. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.82 (s, 1H), 7.74 (dd, J=7.9, 1.5 Hz, 1H), 7.53 (d, J=7.9 Hz, 1H), 7.24-7.31 (m, 2H), 7.08-7.22 (m, 3H), 6.38 (t, J=5.6 Hz, 1H), 4.59-4.64 (m, 4H), 3.06-3.13 (m, 2H), 2.58 (t, J=7.5 Hz, 2H), 1.53-1.68 (m, 2H), 1.36-1.51 (m, 2H); MS (ESI(+)) m/e 319 (M+H)+.


Example 543
N-[4-(1-butyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
Example 543A
N-(4-bromophenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide

The title compound was prepared as described in Example 1A, substituting 4-bromophenyl isocyanate for methyl 4-isocyanatobenzoate and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine for isoindoline.


Example 543B
tert-butyl 4-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate

The title compound was prepared as described in Example 280, substituting tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate for 1H-pyrazol-3-ylboronic acid and N-(4-bromophenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide.


Example 543C
N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate for tert-butyl 44(4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 543D
N-[4-(1-butyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 278, substituting butyryl chloride for acetyl chloride and N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.61 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.46 (s, 1H), 7.54-7.57 (m, 2H), 7.43 (d, J=5.0 Hz, 1H), 7.32-7.39 (m, 2H), 6.09-6.11 (m, 1H), 4.79-4.82 (m, 4H), 4.08-4.14 (m, 2H), 3.58-3.68 (m, 2H), 2.39-2.55 (m, 2H), 2.34 (dt, J=19.9, 7.4 Hz, 2H), 1.47-1.62 (m, 2H), 0.88-0.93 (m, 3H); MS (ESI(+)) m/e 391 (M+H)+.


Example 544
N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 278, substituting isobutyryl chloride for acetyl chloride and N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.61 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.46 (s, 1H), 7.54-7.57 (m, 2H), 7.43 (d, J=5.1 Hz, 1H), 7.34-7.38 (m, 2H), 6.10-6.13 (bs, 1H), 4.79-4.82 (m, 4H), 4.07-4.21 (m, 2H), 3.67-3.70 (m, 2H), 2.85-3.01 (m, 1H), 2.39-2.55 (m, 2H), 0.97-1.08 (m, 6H); MS (ESI(+)) m/e 391 (M+H)+.


Example 545
N-[4-(1-benzoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 278, substituting benzoyl chloride for acetyl chloride and N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.61 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.46 (s, 1H), 7.55-7.58 (m, 2H), 7.42-7.49 (m, 6H), 7.35-7.41 (m, 2H), 5.98-6.21 (m, 1H), 4.79-4.82 (m, 4H), 3.95-4.39 (m, 2H), 3.79-3.93 (m, 1H), 3.51-3.61 (m, 1H), 2.46-2.60 (m, 2H); MS (ESI(+)) m/e 425 (M+H)+.









TABLE 9







The following Examples were essentially prepared as described in Example 1C,


substituting N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-


carboxamide for 3-phenylpropan-1-amine and the corresponding carboxylic acid for 4-


(isoindoline-2-carboxamido)benzoic acid.










Ex
Name

1H NMR

MS













546
N-{4-[1-(tetrahydrofuran-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.61 (s,

(ESI(+))



3-ylcarbonyl)-1,2,3,6-
1H), 8.50 (d, J = 5.0 Hz, 1H), 8.46 (s, 1H),
m/e 419



tetrahydropyridin-4-
7.54-7.57 (m, 2H), 7.43 (d, J = 5.0 Hz, 1H), 7.36 (dd, J = 8.4,
(M + H)+



yl]phenyl}-1,3-dihydro-
4.2 Hz, 2H), 6.09-6.12 (m, 1H),



2H-pyrrolo[3,4-
4.75-4.87 (m, 4H), 4.10-4.21 (m, 2H), 3.90 (dt, J = 11.3, 8.1 Hz,



c]pyridine-2-carboxamide
1H), 3.66-3.75 (m, 5H), 3.32-3.50 (m, 1H),




2.41-2.57 (m, 2H), 1.95-2.10 (m, 2H)


620
N-(4-{1-[(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methoxyethoxy)acetyl]-
ppm 8.58 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 8.20 (s,
m/e 437



1,2,3,6-tetrahydropyridin-
1H), 7.53 (m, 2H), 7.38 (d, J = 5.0 Hz, 1H),
(M + H)+



4-yl}phenyl)-1,3-
7.32 (m, 2H), 6.06 (m, 1H), 4.80 (d, J = 8.9 Hz, 4H),



dihydro-2H-pyrrolo[3,4-
4.18 (s, 2H), 4.10 (m, 2H), 3.65 (t, J = 5.7 Hz,



c]pyridine-2-carboxamide
2H), 3.60 (m, 2H), 3.49 (m, 2H), 3.27 (s, 3H),




2.50 (m, 2H)


705
N-{4-[1-(tetrahydrofuran-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



2-ylcarbonyl)-1,2,3,6-
ppm 8.58 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 8.20 (s,
m/e 419



tetrahydropyridin-4-
1H), 7.53 (m, 2H), 7.38 (d, J = 5.5 Hz, 1H),
(M + H)+



yl]phenyl}-1,3-dihydro-
7.33 (m, 2H), 6.07 (m, 1H), 4.79 (m, 4H), 4.67 (dd, J = 7.6,



2H-pyrrolo[3,4-
5.6 Hz, 1H), 4.14 (bs, 2H), 3.85-3.64 (m,



c]pyridine-2-carboxamide
4H), 2.50 (m, 2H), 2.11 (m, 1H), 2.00 (m, 1H),




1.85 (m, 2H)


706
N-{4-[1-(tetrahydro-2H-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



pyran-4-ylcarbonyl)-
ppm 8.58 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 8.20 (s,
m/e 433



1,2,3,6-tetrahydropyridin-
1H), 7.53 (m, 2H), 7.38 (d, J = 5.2 Hz, 1H),
(M + H)+



4-yl]phenyl}-1,3-
7.33 (m, 2H), 6.07 (m, 1H), 4.80 (m, 4H), 4.14 (bs,



dihydro-2H-pyrrolo[3,4-
2H), 3.86 (m, 2H), 3.70 (t, J = 5.8 Hz, 2H),



c]pyridine-2-carboxamide
3.42 (td, J = 11.4, 2.5 Hz, 2H), 2.92 (m, 1H), 2.50 (m,




2H), 1.72-1.52 (m, 4H)


707
N-{4-[1-(1,4-dioxan-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



ylcarbonyl)-1,2,3,6-
ppm8.58 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 8.20 (s,
m/e 435



tetrahydropyridin-4-
1H), 7.53 (m, 2H), 7.38 (d, J = 4.9 Hz, 1H),
(M + H)+



yl]phenyl}-1,3-dihydro-
7.32 (m, 2H), 6.06 (m, 1H), 4.80 (m, 4H), 4.36 (dd, J = 9.2,



2H-pyrrolo[3,4-
2.9 Hz, 1H), 4.14 (s, 2H), 3.83-3.60 (m,



c]pyridine-2-carboxamide
7H), 3.52 (m, 1H), 2.50 (m, 2H)


708
N-(4-{1-[(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methylpyrrolidin-3-
ppm 8.58 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 8.20 (s,
m/e 432



yl)carbonyl]-1,2,3,6-
1H), 7.53 (m, 2H), 7.38 (dd, J = 5.0, 1.1 Hz, 1H),
(M + H)+



tetrahydropyridin-4-
7.32 (m, 2H), 6.07 (m, 1H), 4.79 (m, 4H),



yl}phenyl)-1,3-dihydro-
4.12 (m, 2H), 3.68 (t, J = 5.7 Hz, 2H), 3.27 (m, 1H),



2H-pyrrolo[3,4-
2.77 (t, J = 8.6 Hz, 1H), 2.62-2.45 (m, 2H),



c]pyridine-2-carboxamide
2.50 (m, 2H), 2.38 (m, 1H), 2.24 (s, 3H), 1.97 (m, 2H)


709
N-(4-{1-[(1,1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



dioxidotetrahydrothiophen-
ppm 8.58 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 8.21 (s,
m/e 467



3-yl)carbonyl]-1,2,3,6-
1H), 7.53 (m, 2H), 7.38 (d, J = 5.1 Hz, 1H),
(M + H)+



tetrahydropyridin-4-
7.33 (m, 2H), 6.07 (m, 1H), 4.80 (m, 4H), 4.17 (bs,



yl}phenyl)-1,3-dihydro-
2H), 3.72 (m, 3H), 3.31-3.13 (m, 3H), 3.07 (m,



2H-pyrrolo[3,4-
1H), 2.51 (bs, 2H), 2.35 (m, 1H), 2.13 (m, 1H)



c]pyridine-2-carboxamide


710
N-{4-[1-(2-hydroxy-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methylpropanoyl)-
ppm 8.58 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H),
m/e 407



1,2,3,6-tetrahydropyridin-
8.20 (bs, 1H), 7.52 (m, 2H), 7.38 (d, J = 5.0 Hz, 1H),
(M + H)+



4-yl]phenyl}-1,3-
7.33 (m, 2H), 6.08 (bs, 1H), 5.09 (s, 1H), 4.82 (m,



dihydro-2H-pyrrolo[3,4-
4H), 4.28 (m, 2H), 3.93 (m, 2H), 2.51 (m, 2H),



c]pyridine-2-carboxamide
1.36 (s, 6H)


799
N-{4-[1-(morpholin-4-

1H NMR (501 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



ylacetyl)-1,2,3,6-
ppm 8.59 (s, 1H), 8.49 (d, J = 5.0 Hz, 1H),
m/e



tetrahydropyridin-4-
8.25 (bs, 1H), 7.54 (m, 2H), 7.39 (d, J = 5.1 Hz, 1H),
XXX



yl]phenyl}-1,3-dihydro-
7.35 (s, 1H), 7.33 (s, 1H), 6.08 (m, 1H), 4.82 (bs,
(M + H)+



2H-pyrrolo[3,4-
2H), 4.80 (bs, 2H), 4.18 (m, 2H), 3.71 (m, 2H),



c]pyridine-2-carboxamide
3.58 (m, 4H), 3.21 (bs, 2H), 2.52 (m, 2H),




2.45 (m, 4H)


967
N-(4-{1-[(2R)-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



tetrahydrofuran-2-
ppm 8.58 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H),
m/e 419



ylcarbonyl]-1,2,3,6-
8.21 (bs, 1H), 7.53 (m, 2H), 7.38 (d, J = 5.1 Hz, 1H),
(M + H)+



tetrahydropyridin-4-
7.33 (m, 2H), 6.07 (m, 1H), 4.80 (m, 4H), 4.67 (t,



yl}phenyl)-1,3-dihydro-
J = 6.5 Hz, 1H), 4.14 (m, 2H), 3.86-3.64 (m,



2H-pyrrolo[3,4-
4H), 2.50 (m, 2H), 2.11 (m, 1H), 2.00 (m, 1H),



c]pyridine-2-carboxamide
1.86 (m, 2H)


968
N-(4-{1-[(2S)-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



tetrahydrofuran-2-
ppm 8.58 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 8.20 (s,
m/e 419



ylcarbonyl]-1,2,3,6-
1H), 7.53 (m, 2H), 7.38 (d, J = 5.0 Hz, 1H),
(M + H)+



tetrahydropyridin-4-
7.32 (m, 2H), 6.07 (m, 1H), 4.79 (m, 4H), 4.67 (dd, J = 7.5,



yl}phenyl)-1,3-dihydro-
5.6 Hz, 1H), 4.14 (m, 2H), 3.85-3.66 (m,



2H-pyrrolo[3,4-
4H), 2.50 (m, 2H), 2.11 (m, 1H), 2.00 (m, 1H),



c]pyridine-2-carboxamide
1.86 (m, 2H)


1014
N-(4-{1-[(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methylpiperidin-4-
ppm 8.58 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H),
m/e 446



yl)carbonyl]-1,2,3,6-
8.20 (bs, 1H), 7.53 (m, 2H), 7.38 (d, J = 5.0 Hz, 1H),
(M + H)+



tetrahydropyridin-4-
7.32 (m, 2H), 6.07 (bs, 1H), 4.82 (m, 4H),



yl}phenyl)-1,3-dihydro-
4.12 (m, 2H), 3.67 (t, J = 5.7 Hz, 2H), 2.76 (m, 2H),



2H-pyrrolo[3,4-
2.55 (m, 1H), 2.50 (m, 2H), 2.16 (s, 3H), 1.95 (td,



c]pyridine-2-carboxamide
J = 11.2, 3.6 Hz, 2H), 1.62 (m, 4H)


1015
N-(4-{1-[(1,1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



dioxidotetrahydro-2H-
ppm 8.58 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 8.21 (s,
m/e 481



thiopyran-4-yl)carbonyl]-
1H), 7.53 (m, 2H), 7.38 (d, J = 5.0 Hz, 1H),
(M + H)+



1,2,3,6-tetrahydropyridin-
7.33 (m, 2H), 6.08 (m, 1H), 4.82 (m, 4H), 4.15 (m,



4-yl}phenyl)-1,3-
2H), 3.71 (t, J = 5.7 Hz, 2H), 3.24-3.04 (m, 5H),



dihydro-2H-pyrrolo[3,4-
2.50 (m, 2H), 2.06 (m, 4H)



c]pyridine-2-carboxamide


1016
N-(4-{1-[(3R)-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



tetrahydrofuran-3-
ppm 8.58 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 8.21 (s,
m/e 419



ylcarbonyl]-1,2,3,6-
1H), 7.53 (m, 2H), 7.38 (d, J = 5.1 Hz, 1H),
(M + H)+



tetrahydropyridin-4-
7.33 (m, 2H), 6.07 (m, 1H), 4.79 (m, 4H), 4.14 (m,



yl}phenyl)-1,3-dihydro-
2H), 3.91 (t, J = 8.1 Hz, 1H), 3.77-3.67 (m, 5H),



2H-pyrrolo[3,4-
3.38 (m, 1H), 2.50 (m, 2H), 2.05 (m, 2H)



c]pyridine-2-carboxamide


1017
N-(4-{1-[(3S)-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



tetrahydrofuran-3-
ppm 8.58 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 8.20 (s,
m/e 419



ylcarbonyl]-1,2,3,6-
1H), 7.53 (m, 2H), 7.38 (d, J = 5.1 Hz, 1H),
(M + H)+



tetrahydropyridin-4-
7.33 (m, 2H), 6.07 (m, 1H), 4.79 (m, 4H), 4.14 (m,



yl}phenyl)-1,3-dihydro-
2H), 3.91 (t, J = 8.1 Hz, 1H), 3.78-3.64 (m, 5H),



2H-pyrrolo[3,4-
3.38 (m, 1H), 2.50 (m, 2H), 2.05 (m, 2H)



c]pyridine-2-carboxamide


1077
N-{4-[1-(tetrahydrofuran-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



3-ylacetyl)-1,2,3,6-
ppm 8.57 (bs, 1H), 8.48 (d, J = 5.0 Hz, 1H),
m/e 433



tetrahydropyridin-4-
8.20 (s, 1H), 7.53 (m, 2H), 7.37 (m, 1H), 7.32 (m, 2H),
(M + H)+



yl]phenyl}-1,3-dihydro-
6.06 (m, 1H), 4.81 (m, 4H), 4.11 (d, J = 2.8 Hz,



2H-pyrrolo[3,4-
2H), 3.82 (dd, J = 8.4, 6.8 Hz, 1H),



c]pyridine-2-carboxamide
3.76-3.59 (m, 4H), 3.29 (dd, J = 8.4, 6.1 Hz, 1H),




2.58-2.40 (m, 5H), 2.02 (m, 1H), 1.53 (m, 1H)


1078
N-{4-[1-(tetrahydro-2H-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



pyran-4-ylacetyl)-1,2,3,6-
ppm 8.58 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 8.20 (s,
m/e 447



tetrahydropyridin-4-
1H), 7.52 (m, 2H), 7.38 (d, J = 5.1 Hz, 1H),
(M + H)+



yl]phenyl}-1,3-dihydro-
7.32 (m, 2H), 6.07 (m, 1H), 4.80 (m, 4H), 4.11 (m,



2H-pyrrolo[3,4-
2H), 3.81 (m, 2H), 3.67 (t, J = 5.7 Hz, 2H),



c]pyridine-2-carboxamide
3.30 (td, J = 11.5, 2.2 Hz, 2H), 2.50 (m, 2H), 2.31 (d, J = 6.8 Hz,




2H), 2.98 (m, 1H), 1.62 (m, 2H),




1.25 (m, 2H)


1079
N-{4-[1-(N,N-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



dimethylglycyl)-1,2,3,6-
ppm 8.58 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 8.21 (s,
m/e 406



tetrahydropyridin-4-
1H), 7.53 (m, 2H), 7.38 (d, J = 5.1 Hz, 1H),
(M + H)+



yl]phenyl}-1,3-dihydro-
7.33 (m, 2H), 6.07 (m, 1H), 4.80 (m, 4H), 4.15 (m,



2H-pyrrolo[3,4-
2H), 3.70 (t, J = 5.7 Hz, 2H), 3.15 (s, 2H),



c]pyridine-2-carboxamide
2.50 (m, 2H), 2.23 (s, 6H)


1080
N-(4-{1-[(4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methylpiperazin-1-
ppm 8.58 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 8.20 (s,
m/e 461



yl)acetyl]-1,2,3,6-
1H), 7.53 (m, 2H), 7.38 (d, J = 5.1 Hz, 1H),
(M + H)+



tetrahydropyridin-4-
7.32 (m, 2H), 6.06 (m, 1H), 4.80 (m, 4H), 4.15 (m,



yl}phenyl)-1,3-dihydro-
2H), 3.71 (m, 2H), 3.19 (m, 4H), 2.44 (m, 4H),



2H-pyrrolo[3,4-
2.33 (m, 4H), 2.15 (s, 3H)



c]pyridine-2-carboxamide


1254
N-{4-[1-(3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methylbutanoyl)-1,2,3,6-
ppm 8.59 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 8.21 (s,
m/e 405



tetrahydropyridin-4-
1H), 7.53 (m, 2H), 7.39 (d, J = 5.1 Hz, 1H),
(M + H)+



yl]phenyl}-1,3-dihydro-
7.33 (m, 2H), 6.07 (m, 1H), 4.81 (m, 4H), 4.12 (m,



2H-pyrrolo[3,4-
2H), 3.67 (t, J = 5.7 Hz, 2H), 2.50 (m, 2H),



c]pyridine-2-carboxamide
2.25 (d, J = 6.9 Hz, 2H), 2.05 (m, 1H), 0.94 (d, J = 6.6 Hz,




6H)


1255
N-{4-[1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



(cyclopentylacetyl)-
ppm 8.59 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 8.21 (s,
m/e 431



1,2,3,6-tetrahydropyridin-
1H), 7.53 (m, 2H), 7.39 (d, J = 5.1 Hz, 1H),
(M + H)+



4-yl]phenyl}-1,3-
7.33 (m, 2H), 6.07 (m, 1H), 4.82 (m, 4H), 4.11 (m,



dihydro-2H-pyrrolo[3,4-
2H), 3.67 (t, J = 5.7 Hz, 2H), 2.50 (m, 2H),



c]pyridine-2-carboxamide
2.38 (d, J = 7.1 Hz, 2H), 2.21 (m, 1H), 1.77 (m, 2H),




1.66-1.46 (m, 4H), 1.18 (m, 2H)


1256
N-{4-[1-(tetrahydrofuran-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



2-ylacetyl)-1,2,3,6-
ppm 8.59 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 8.21 (s,
m/e 433



tetrahydropyridin-4-
1H), 7.53 (m, 2H), 7.39 (d, J = 5.0 Hz, 1H),
(M + H)+



yl]phenyl}-1,3-dihydro-
7.33 (m, 2H), 6.07 (m, 1H), 4.80 (m, 4H), 4.16 (m,



2H-pyrrolo[3,4-
3H), 3.77 (m, 1H), 3.68 (m, 2H), 3.60 (m, 1H),



c]pyridine-2-carboxamide
2.69 (m, 1H), 2.50 (m, 2H), 2.45 (m, 1H),




2.02 (m, 1H), 1.83 (m, 2H), 1.54 (m, 1H)


1257
N-{4-[1-(tetrahydro-2H-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



pyran-2-ylacetyl)-1,2,3,6-
ppm 8.59 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 8.21 (s,
m/e 447



tetrahydropyridin-4-
1H), 7.53 (m, 2H), 7.39 (d, J = 5.0 Hz, 1H),
(M + H)+



yl]phenyl}-1,3-dihydro-
7.33 (m, 2H), 6.06 (m, 1H), 4.83 (m, 4H), 4.12 (m,



2H-pyrrolo[3,4-
2H), 3.83 (m, 1H), 3.69 (m, 3H), 3.35 (m, 1H),



c]pyridine-2-carboxamide
2.61 (m, 1H), 2.50 (m, 2H), 2.37 (m, 1H),




1.82-1.63 (m, 2H), 1.48 (m, 3H), 1.26 (m, 1H)


1258
N-{4-[1-(pyrrolidin-1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



ylacetyl)-1,2,3,6-
ppm 8.59 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H),
m/e 432



tetrahydropyridin-4-
8.21 (bs, 1H), 7.53 (m, 2H), 7.39 (d, J = 5.0 Hz, 1H),
(M + H)+



yl]phenyl}-1,3-dihydro-
7.33 (m, 2H), 6.07 (bs, 1H), 4.81 (m, 4H),



2H-pyrrolo[3,4-
4.15 (m, 2H), 3.71 (m, 2H), 3.32 (bs, 2H), 2.55 (m,



c]pyridine-2-carboxamide
4H), 2.50 (m, 2H), 1.70 (m, 4H)


1259
N-{4-[1-(pyrazin-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



ylcarbonyl)-1,2,3,6-
ppm 8.85 (d, J = 1.5 Hz, 1H), 8.72 (d, J = 2.5 Hz,
m/e 427



tetrahydropyridin-4-
1H), 8.66 (m, 1H), 8.58 (s, 1H), 8.48 (d, J = 5.0 Hz,
(M + H)+



yl]phenyl}-1,3-dihydro-
1H), 8.22 (s, 1H), 7.53 (m, 2H), 7.38 (d, J = 5.1 Hz,



2H-pyrrolo[3,4-
1H), 7.34 (m, 2H), 6.09 (m, 1H), 4.82 (m,



c]pyridine-2-carboxamide
4H), 4.22 (m, 2H), 3.69 (m, 2H), 2.57 (m, 2H)


1479
N-(4-{1-[(2-methyl-1,3-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



oxazol-4-yl)carbonyl]-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H) 8.25 (s,
m/e 430



1,2,3,6-tetrahydropyridin-
1 H) 7.49-7.54 (m, 2 H) 7.41 (d, J = 4.88 Hz, 1 H)
(M + H)+



4-yl}phenyl)-1,3-
7.33-7.37 (m, 2 H) 6.11 (t, J = 3.51 Hz, 1 H)



dihydro-2H-pyrrolo[3,4-
4.82 (d, J = 7.93 Hz, 4 H) 4.36 (s, 2 H) 3.95 (s, 2 H)



c]pyridine-2-carboxamide
2.53-2.59 (m, 2 H) 2.45-2.47 (m, 3 H)


1480
N-{4-[1-(furan-3-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



ylcarbonyl)-1,2,3,6-
ppm 8.59 (s, 1 H) 8.49 (d, J = 5.19 Hz, 1 H) 7.98 (s,
m/e 415



tetrahydropyridin-4-
1 H) 7.67 (t, J = 1.68 Hz, 1 H) 7.52 (d, J = 8.54 Hz,
(M + H)+



yl]phenyl}-1,3-dihydro-
2 H) 7.43 (d, J = 4.88 Hz, 1 H) 7.35 (d, J = 8.54 Hz,



2H-pyrrolo[3,4-
2 H) 6.69 (s, 1 H) 6.05-6.13 (m, 1 H) 4.82 (d, 4



c]pyridine-2-carboxamide
H) 4.23-4.28 (m, 2 H) 3.79 (t, J = 5.80 Hz, 2 H)




2.53-2.59 (m, 2 H)


1481
N-(4-{1-[(2E)-3-(furan-2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



yl)prop-2-enoyl]-1,2,3,6-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 441



tetrahydropyridin-4-
7.70 (d, J = 1.53 Hz, 1 H) 7.49-7.55 (m, 2 H)
(M + H)+



yl}phenyl)-1,3-dihydro-
7.30-7.44 (m, 4 H) 6.91 (d, J = 15.26 Hz, 1 H) 6.81 (d,



2H-pyrrolo[3,4-
J = 3.36 Hz, 1 H) 6.57 (dd, J = 3.36, 1.83 Hz, 1 H)



c]pyridine-2-carboxamide
6.12 (t, J = 3.51 Hz, 1 H) 4.81 (d, 4 H)




4.24-4.28 (m, 2 H) 3.81 (t, J = 5.65 Hz, 2 H) 2.55 (s, 2 H)


1482
N-{4-[1-(1,3-oxazol-5-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



ylcarbonyl)-1,2,3,6-
ppm 8.59 (s, 1 H) 8.49 (d, J = 4.88 Hz, 1 H) 8.41 (s,
m/e 416



tetrahydropyridin-4-
1 H) 7.67 (s, 1 H) 7.52 (d, J = 8.85 Hz, 2 H)
(M + H)+



yl]phenyl}-1,3-dihydro-
7.44 (d, J = 5.19 Hz, 1 H) 7.36 (d, J = 8.54 Hz, 2 H)



2H-pyrrolo[3,4-
6.09-6.14 (m, 1 H) 4.83 (d, J = 4.88 Hz, 4 H) 4.32 (d,



c]pyridine-2-carboxamide
J = 2.75 Hz, 2 H) 3.87 (t, J = 5.80 Hz, 2 H) 2.60 (m,




2 H)


1483
N-{4-[1-(3,3,3-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



trifluoropropanoyl)-
ppm 8.58 (s, 1 H) 8.48 (d, 1 H) 7.52 (d, J = 8.85 Hz,
m/e 431



1,2,3,6-tetrahydropyridin-
2 H) 7.42 (d, 1 H) 7.35 (d, J = 8.85 Hz, 2 H)
(M + H)+



4-yl]phenyl}-1,3-
6.08 (s, 1 H) 4.81 (d, J = 9.16 Hz, 4 H)



dihydro-2H-pyrrolo[3,4-
4.12-4.16 (m, 2 H) 3.65-3.73 (m, 2 H) 3.51-3.63 (m, 2 H)



c]pyridine-2-carboxamide
2.52-2.58 (m, 2 H)


1484
N-(4-{1-[(1,5-dimethyl-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



1H-pyrazol-3-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H)
m/e 443



yl)carbonyl]-1,2,3,6-
7.51 (d, J = 8.54 Hz, 2 H) 7.41 (d, J = 4.88 Hz, 1 H)
(M + H)+



tetrahydropyridin-4-
7.35 (d, J = 8.54 Hz, 2 H) 6.33 (s, 1 H) 6.07-6.12 (m, 1



yl}phenyl)-1,3-dihydro-
H) 4.81 (d, J = 7.32 Hz, 4 H) 4.36 (s, 2 H) 3.94 (s,



2H-pyrrolo[3,4-
2 H) 3.75-3.78 (m, 3 H) 2.52-2.57 (m, 2 H)



c]pyridine-2-carboxamide
2.26-2.29 (m, 3 H)


1485
N-(4-{1-[(4-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



methoxycyclohexyl)carbonyl]-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 461



1,2,3,6-
7.51 (d, J = 8.85 Hz, 2 H) 7.41 (d, J = 5.19 Hz, 1 H)
(M + H)+



tetrahydropyridin-4-
7.34 (d, J = 8.54 Hz, 2 H) 6.09 (t, J = 3.51 Hz, 1 H)



yl}phenyl)-1,3-dihydro-
4.81 (d, J = 7.63 Hz, 4 H) 4.12 (s, 2 H) 3.68 (t, J = 5.80 Hz,



2H-pyrrolo[3,4-
2 H) 3.37-3.43 (m, 1 H) 3.22 (s, 3 H)



c]pyridine-2-carboxamide
2.61-2.74 (m, 1 H) 2.44-2.50 (m, 2 H) 1.82-1.91 (m,




J = 12.97, 3.81 Hz, 2 H) 1.62-1.75 (m, 2 H)




1.37-1.55 (m, 4 H)


1486
N-{4-[1-(2,3-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



dimethylbutanoyl)-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 419



1,2,3,6-tetrahydropyridin-
7.51 (d, J = 8.85 Hz, 2 H) 7.41 (d, J = 5.19 Hz, 1 H)
(M + H)+



4-yl]phenyl}-1,3-
7.34 (d, J = 8.54 Hz, 2 H) 6.07-6.13 (m, 1 H) 4.81 (d,



dihydro-2H-pyrrolo[3,4-
J = 7.63 Hz, 4 H) 4.15 (s, 2 H) 3.66-3.76 (m, 2 H)



c]pyridine-2-carboxamide
2.56-2.65 (m, 1 H) 2.42-2.50 (m, 2 H)




1.74-1.89 (m, 1 H) 1.00 (d, J = 6.71 Hz, 3 H) 0.87 (dd,




J = 13.58, 6.87 Hz, 6 H)


1487
N-(4-{1-[(2,2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



difluorocyclopropyl)carbonyl]-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 425



1,2,3,6-
7.52 (d, J = 8.85 Hz, 2 H) 7.41 (d, J = 5.19 Hz, 1 H)
(M + H)+



tetrahydropyridin-4-
7.35 (d, J = 8.85 Hz, 2 H) 6.10 (s, 1 H) 4.82 (d, J = 7.32 Hz,



yl}phenyl)-1,3-dihydro-
4 H) 4.19 (s, 2 H) 3.65-3.94 (m, 2 H)



2H-pyrrolo[3,4-
2.94-3.16 (m, J = 7.32 Hz, 1 H) 2.52-2.66 (m, 2 H)



c]pyridine-2-carboxamide
1.91-2.00 (m, 1 H) 1.76-1.88 (m, 1 H)


1488
N-{4-[1-(1H-pyrazol-5-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



ylcarbonyl)-1,2,3,6-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 415



tetrahydropyridin-4-
7.71 (d, J = 2.14 Hz, 1 H) 7.33-7.55 (m, 5 H) 6.59 (d,
(M + H)+



yl]phenyl}-1,3-dihydro-
J = 2.44 Hz, 1 H) 6.11 (s, 1 H) 4.82 (d, J = 6.41 Hz,



2H-pyrrolo[3,4-
4 H) 4.37 (s, 2 H) 3.95 (s, 2 H) 2.53-2.59 (m,



c]pyridine-2-carboxamide
J = 3.05 Hz, 2 H)


1489
N-{4-[1-(tert-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



butoxyacetyl)-1,2,3,6-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H)
m/e 435



tetrahydropyridin-4-
7.51 (d, J = 8.54 Hz, 2 H) 7.41 (d, J = 4.88 Hz, 1 H)
(M + H)+



yl]phenyl}-1,3-dihydro-
7.34 (d, J = 8.54 Hz, 2 H) 6.08 (t, J = 3.36 Hz, 1 H)



2H-pyrrolo[3,4-
4.82 (d, J = 7.93 Hz, 4 H) 4.12 (s, 2 H) 4.05 (s, 2 H)



c]pyridine-2-carboxamide
3.69 (t, J = 5.80 Hz, 2 H) 1.19 (s, 9 H)


1490
N-(4-{1-[3-(1H-1,2,4-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



triazol-1-yl)propanoyl]-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H) 8.39 (s,
m/e 444



1,2,3,6-tetrahydropyridin-
1 H) 7.88 (s, 1 H) 7.48-7.53 (m, 2 H) 7.42 (d,
(M + H)+



4-yl}phenyl)-1,3-
J = 4.88 Hz, 1 H) 7.33 (d, J = 8.54 Hz, 2 H) 6.05 (s,



dihydro-2H-pyrrolo[3,4-
1 H) 4.82 (d, J = 6.41 Hz, 4 H) 4.46 (t, J = 6.71 Hz,



c]pyridine-2-carboxamide
2 H) 4.07-4.12 (m, 2 H) 3.60-3.67 (m, 2 H)




2.98 (t, J = 6.26 Hz, 2 H) 2.42-2.49 (m, 2 H)


1491
N-{4-[1-(3-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



ethoxypropanoyl)-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 421



1,2,3,6-tetrahydropyridin-
7.51 (d, J = 8.54 Hz, 2 H) 7.42 (d, J = 5.19 Hz, 1 H)
(M + H)+



4-yl]phenyl}-1,3-
7.34 (d, J = 8.54 Hz, 2 H) 6.06-6.10 (m, 1 H) 4.82 (d,



dihydro-2H-pyrrolo[3,4-
J = 7.63 Hz, 4 H) 4.13 (s, 2 H) 3.62-3.72 (m, 4 H)



c]pyridine-2-carboxamide
3.44 (q, J = 7.22 Hz, 2 H) 2.57-2.65 (m, 2 H)




1.09 (t, J = 6.87 Hz, 3 H)


1492
N-{4-[1-(3-hydroxy-3-

1H NMR (400 MHz, Solvent) δ ppm 8.58 (s, 1 H)

(ESI(+))



methylbutanoyl)-1,2,3,6-
8.48 (d, J = 5.19 Hz, 1 H) 7.49-7.54 (m, 2 H)
m/e 421



tetrahydropyridin-4-
7.41 (d, J = 4.88 Hz, 1 H) 7.34 (d, J = 8.54 Hz, 2 H)
(M + H)+



yl]phenyl}-1,3-dihydro-
6.08 (s, 1 H) 4.81 (d, J = 7.63 Hz, 4 H) 4.16 (s, 2 H)



2H-pyrrolo[3,4-
3.72 (t, J = 5.80 Hz, 2 H) 2.31-2.50 (m, J = 14.04 Hz,



c]pyridine-2-carboxamide
2 H) 1.12-1.33 (m, 8 H)


1493
N-(4-{1-[3-(1H-pyrrol-1-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



yl)propanoyl]-1,2,3,6-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H)
m/e 442



tetrahydropyridin-4-
7.51 (d, J = 8.85 Hz, 2 H) 7.41 (d, J = 5.19 Hz, 1 H)
(M + H)+



yl}phenyl)-1,3-dihydro-
7.32 (d, J = 8.54 Hz, 2 H) 6.72 (t, J = 1.98 Hz, 2 H)



2H-pyrrolo[3,4-
6.04 (t, 1 H) 5.96 (t, J = 2.14 Hz, 2 H) 4.81 (d, J = 7.93 Hz,



c]pyridine-2-carboxamide
4 H) 4.16 (t, J = 6.87 Hz, 2 H) 4.06 (t, 2 H)




3.63 (s, 2 H) 2.82 (s, 2 H) 2.45 (s, 2 H)


1494
N-(4-{1-[(1-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



methylcyclopropyl)carbonyl]-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 403



1,2,3,6-
7.48-7.54 (m, 2 H) 7.41 (d, J = 4.88 Hz, 1 H)
(M + H)+



tetrahydropyridin-4-
7.32-7.37 (m, 2 H) 6.11 (t, J = 3.51 Hz, 1 H) 4.79-4.85 (m, 4



yl}phenyl)-1,3-dihydro-
H) 4.12-4.20 (m, 2 H) 3.78 (t, J = 5.65 Hz, 2 H)



2H-pyrrolo[3,4-
2.47-2.51 (m, 2 H) 1.26-1.30 (m, 3 H)



c]pyridine-2-carboxamide
0.81-0.86 (m, 2 H) 0.55-0.62 (m, 2 H)


1495
N-(4-{1-[(2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



methylpropoxy)acetyl]-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H)
m/e 435



1,2,3,6-tetrahydropyridin-
7.48-7.53 (m, 2 H) 7.41 (d, J = 4.88 Hz, 1 H)
(M + H)+



4-yl}phenyl)-1,3-
7.31-7.35 (m, 2 H) 6.05-6.09 (m, 1 H) 4.82 (d, J = 7.93 Hz,



dihydro-2H-pyrrolo[3,4-
4 H) 4.07-4.20 (m, 4 H) 3.67 (t, J = 5.65 Hz, 2 H)



c]pyridine-2-carboxamide
3.18-3.24 (m, 2 H) 2.47-2.51 (m, 2 H)




1.76-1.89 (m, 1 H) 0.85-0.91 (m, 6 H)


1496
N-{4-[1-(1-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



methylprolyl)-1,2,3,6-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 432



tetrahydropyridin-4-
7.49-7.54 (m, 2 H) 7.41 (d, J = 5.19 Hz, 1 H) 7.34 (d,
(M + H)+



yl]phenyl}-1,3-dihydro-
J = 8.85 Hz, 2 H) 6.09 (t, J = 3.36 Hz, 1 H)



2H-pyrrolo[3,4-
4.78-4.84 (m, 4 H) 4.19 (s, 2 H) 3.66-3.89 (m, 2 H)



c]pyridine-2-carboxamide
3.30-3.35 (m, 1 H) 2.98-3.06 (m, 1 H)




2.43-2.50 (m, 2 H) 2.29-2.37 (m, 1 H) 2.27 (s, 3 H)




2.05-2.14 (m, 1 H) 1.71-1.86 (m, 3 H)


1497
N-{4-[1-(2-hydroxy-2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



methylbutanoyl)-1,2,3,6-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H)
m/e 421



tetrahydropyridin-4-
7.49-7.53 (m, 2 H) 7.41 (d, J = 5.19 Hz, 1 H) 7.34 (d,
(M + H)+



yl]phenyl}-1,3-dihydro-
J = 8.85 Hz, 2 H) 6.09 (t, J = 3.66 Hz, 1 H) 4.81 (d,



2H-pyrrolo[3,4-
J = 7.02 Hz, 4 H) 4.29 (s, 2 H) 3.85-3.98 (m, 2 H)



c]pyridine-2-carboxamide
2.46-2.51 (m, 2 H) 1.59-1.86 (m, 2 H)




1.32-1.35 (m, 3 H) 0.82 (t, 3 H)


1498
N-(4-{1-[(1-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



hydroxycyclopropyl)carbonyl]-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 405



1,2,3,6-
7.51 (d, J = 8.54 Hz, 2 H) 7.42 (d, J = 5.19 Hz, 1 H)
(M + H)+



tetrahydropyridin-4-
7.33-7.37 (m, 2 H) 6.11 (t, J = 3.36 Hz, 1 H) 4.82 (d,



yl}phenyl)-1,3-dihydro-
J = 6.41 Hz, 4 H) 4.24 (s, 2 H) 3.87 (t, J = 5.65 Hz, 2



2H-pyrrolo[3,4-
H) 2.52-2.57 (m, 2 H) 0.93-0.99 (m, 2 H)



c]pyridine-2-carboxamide
0.80-0.85 (m, 2 H)


1499
N-{4-[1-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



(cyclopropylacetyl)-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 403



1,2,3,6-tetrahydropyridin-
7.51 (d, J = 8.85 Hz, 2 H) 7.42 (d, J = 5.19 Hz, 1 H)
(M + H)+



4-yl]phenyl}-1,3-
7.31-7.37 (m, 2 H) 6.05-6.11 (m, 1 H) 4.82 (d,



dihydro-2H-pyrrolo[3,4-
J = 6.41 Hz, 4 H) 4.09-4.13 (m, J = 3.05 Hz, 2 H)



c]pyridine-2-carboxamide
3.67 (t, J = 5.80 Hz, 2 H) 2.46-2.50 (m, 2 H)




2.33 (d, J = 6.71 Hz, 2 H) 1.00 (s, 1 H) 0.44-0.51 (m, 2




H) 0.16 (q, J = 4.98 Hz, 2 H)


1500
N-{4-[1-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



(cyclopentylcarbonyl)-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 417



1,2,3,6-tetrahydropyridin-
7.49-7.53 (m, 2 H) 7.41 (d, J = 4.88 Hz, 1 H)
(M + H)+



4-yl]phenyl}-1,3-
7.31-7.36 (m, 2 H) 6.04-6.12 (m, 1 H) 4.79-4.84 (m, 4 H)



dihydro-2H-pyrrolo[3,4-
4.14 (s, 2 H) 3.70 (t, J = 5.80 Hz, 2 H) 3.02 (m,



c]pyridine-2-carboxamide
J = 7.63 Hz, 1 H) 2.43-2.49 (m, 2 H)




1.48-1.86 (m, 8 H)


1501
N-[4-(1-{[1-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



(methoxymethyl)cyclopropyl]carbonyl}-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 433



1,2,3,6-
7.48-7.55 (m, 2 H) 7.41 (d, J = 5.19 Hz, 1 H) 7.34 (d,
(M + H)+



tetrahydropyridin-4-
J = 8.85 Hz, 2 H) 6.06-6.12 (m, J = 3.51, 3.51 Hz, 1



yl)phenyl]-1,3-dihydro-
H) 4.79-4.85 (m, 4 H) 4.17 (d, J = 3.05 Hz, 2 H)



2H-pyrrolo[3,4-
3.79 (t, J = 5.80 Hz, 2 H) 3.44 (s, 2 H) 3.25 (s, 3 H)



c]pyridine-2-carboxamide
2.46-2.50 (m, 2 H) 0.85-0.90 (m, 2 H)




0.73-0.80 (m, 2 H)


1502
N-(4-{1-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



[(methylsulfonyl)acetyl]-
ppm 8.59 (s, 1 H) 8.49 (d, J = 5.19 Hz, 1 H)
m/e 441



1,2,3,6-tetrahydropyridin-
7.52 (d, J = 8.85 Hz, 2 H) 7.42 (d, J = 5.49 Hz, 1 H)
(M + H)+



4-yl}phenyl)-1,3-
7.32-7.38 (m, J = 8.85 Hz, 2 H) 6.08 (s, 1 H) 4.82 (d,



dihydro-2H-pyrrolo[3,4-
J = 6.10 Hz, 4 H) 4.35-4.46 (m, 2 H)



c]pyridine-2-carboxamide
4.11-4.26 (m, 2 H) 3.74 (t, J = 5.80 Hz, 2 H) 3.08-3.12 (m, 3




H) 2.53-2.69 (m, 2 H)


1503
N-(4-{1-[(1-methyl-1H-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



pyrazol-4-yl)carbonyl]-
ppm 8.59 (s, 1 H) 8.49 (d, J = 4.88 Hz, 1 H) 8.00 (s,
m/e 429



1,2,3,6-tetrahydropyridin-
1 H) 7.69 (s, 1 H) 7.49-7.54 (m, 2 H) 7.42 (d,
(M + H)+



4-yl}phenyl)-1,3-
J = 5.49 Hz, 1 H) 7.33-7.38 (m, 2 H)



dihydro-2H-pyrrolo[3,4-
6.07-6.12 (m, J = 3.51, 3.51 Hz, 1 H) 4.79-4.85 (m, 4 H)



c]pyridine-2-carboxamide
4.27 (d, J = 3.05 Hz, 2 H) 3.87 (s, 3 H) 3.81 (t,




J = 5.65 Hz, 2 H) 2.54-2.61 (m, J = 3.36 Hz, 2 H)


1504
N-[4-(1-acetyl-1,2,3,6-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



tetrahydropyridin-4-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 363



yl)phenyl]-1,3-dihydro-
7.51 (d, J = 8.85 Hz, 2 H) 7.41 (d, J = 4.88 Hz, 1 H)
(M + H)+



2H-pyrrolo[3,4-
7.34 (d, J = 8.54 Hz, 2 H) 6.08 (t, J = 3.51 Hz, 1 H)



c]pyridine-2-carboxamide
4.82 (d, J = 7.32 Hz, 4 H) 4.10 (s, 2 H) 3.65 (t, J = 5.80 Hz,




2 H) 2.41-2.51 (m, 2 H) 2.06 (s, 3 H)


1505
N-{4-[1-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



(cyclopropylcarbonyl)-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H)
m/e 389



1,2,3,6-tetrahydropyridin-
7.52 (d, J = 8.54 Hz, 2 H) 7.41 (d, J = 4.58 Hz, 1 H)
(M + H)+



4-yl]phenyl}-1,3-
7.35 (d, J = 8.85 Hz, 2 H) 6.10 (s, 1 H) 4.81 (d, J = 8.54 Hz,



dihydro-2H-pyrrolo[3,4-
4 H) 4.22 (s, 2 H) 3.71-3.84 (m, 2 H)



c]pyridine-2-carboxamide
2.37-2.49 (m, 2 H) 1.90-2.01 (m, J = 13.73 Hz, 1 H)




0.71-0.84 (m, 4 H)


1506
N-{4-[1-(2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



ethylbutanoyl)-1,2,3,6-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 419



tetrahydropyridin-4-
7.51 (d, J = 8.85 Hz, 2 H) 7.41 (d, J = 4.88 Hz, 1 H)
(M + H)+



yl]phenyl}-1,3-dihydro-
7.34 (d, J = 8.85 Hz, 2 H) 6.08-6.12 (m, 1 H) 4.81 (d,



2H-pyrrolo[3,4-
J = 7.93 Hz, 4 H) 4.14-4.20 (m, J = 1.83 Hz, 2 H)



c]pyridine-2-carboxamide
3.74 (t, J = 5.80 Hz, 2 H) 2.60-2.71 (m, 1 H)




2.43-2.50 (m, 2 H) 1.37-1.62 (m, 4 H) 0.82 (t,




J = 7.32 Hz, 6 H)


1507
N-{4-[1-(5-oxo-L-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



prolyl)-1,2,3,6-
ppm 8.59 (s, 1 H) 8.49 (d, J = 4.88 Hz, 1 H)
m/e 432



tetrahydropyridin-4-
7.52 (d, J = 8.85 Hz, 2 H) 7.43 (d, J = 4.88 Hz, 1 H)
(M + H)+



yl]phenyl}-1,3-dihydro-
7.35 (d, J = 8.85 Hz, 2 H) 6.09 (s, 1 H) 4.82 (d, J = 6.71 Hz,



2H-pyrrolo[3,4-
4 H) 4.58 (s, 1 H) 4.14 (s, 2 H) 3.70 (t, 2 H)



c]pyridine-2-carboxamide
2.55-2.64 (m, 1 H) 2.29-2.46 (m, 2 H)




2.14-2.22 (m, 2 H) 1.92 (s, 1 H)


1508
N-(4-{1-[(2E)-4-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



methylpent-2-enoyl]-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H)
m/e 417



1,2,3,6-tetrahydropyridin-
7.51 (d, J = 8.85 Hz, 2 H) 7.41 (d, J = 5.19 Hz, 1 H)
(M + H)+



4-yl}phenyl)-1,3-
7.34 (d, J = 8.85 Hz, 2 H) 6.66 (dd, J = 15.26, 6.71 Hz, 1



dihydro-2H-pyrrolo[3,4-
H) 6.34 (d, J = 15.26 Hz, 1 H) 6.06-6.11 (m, 1 H)



c]pyridine-2-carboxamide
4.81 (d, J = 7.32 Hz, 4 H) 4.18 (d, J = 2.75 Hz, 2 H)




3.74 (t, J = 5.80 Hz, 2 H) 2.38-2.50 (m, 3 H)




1.05 (d, J = 6.71 Hz, 6 H)


1509
N-{4-[1-(2-methoxy-2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



methylpropanoyl)-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 421



1,2,3,6-tetrahydropyridin-
7.51 (d, J = 8.54 Hz, 2 H) 7.41 (d, J = 4.58 Hz, 1 H)
(M + H)+



4-yl]phenyl}-1,3-
7.35 (d, J = 8.85 Hz, 2 H) 6.07-6.14 (m, 1 H)



dihydro-2H-pyrrolo[3,4-
4.78-4.84 (m, 4 H) 4.31 (s, 2 H) 3.92 (s, 2 H) 3.16 (s, 3



c]pyridine-2-carboxamide
H) 2.47-2.50 (m, 2 H) 1.35-1.39 (m, 6 H)


1510
N-{4-[1-(cyclopent-1-en-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



1-ylcarbonyl)-1,2,3,6-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 415



tetrahydropyridin-4-
7.51 (d, J = 8.54 Hz, 2 H) 7.41 (d, J = 5.19 Hz, 1 H)
(M + H)+



yl]phenyl}-1,3-dihydro-
7.32-7.37 (m, 2 H) 6.06-6.11 (m, 1 H)



2H-pyrrolo[3,4-
5.92-5.95 (m, 1 H) 4.81 (d, J = 7.63 Hz, 4 H) 4.15 (q, J = 2.64 Hz,



c]pyridine-2-carboxamide
2 H) 3.71 (t, J = 5.80 Hz, 2 H) 2.53-2.57 (m, 2




H) 2.41-2.50 (m, 4 H) 1.85-1.95 (m, 2 H)


1511
N-{4-[1-(thiophen-3-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(ESI(+))



ylacetyl)-1,2,3,6-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H)
m/e 445



tetrahydropyridin-4-
7.50 (d, J = 8.54 Hz, 2 H) 7.39-7.43 (m, J = 4.12, 4.12 Hz,
(M + H)+



yl]phenyl}-1,3-dihydro-
2 H) 7.31 (d, J = 8.85 Hz, 2 H) 7.23 (s, 1 H)



2H-pyrrolo[3,4-
7.02 (d, J = 5.19 Hz, 1 H) 6.06 (s, 1 H) 4.81 (d,



c]pyridine-2-carboxamide
J = 7.32 Hz, 4 H) 4.15 (s, 2 H) 3.77 (s, 2 H) 3.70 (t,




J = 5.80 Hz, 2 H) 2.38-2.48 (m, 2 H)


1512
N-{4-[1-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



(cyclohexylcarbonyl)-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H)
m/e 431



1,2,3,6-tetrahydropyridin-
7.49-7.53 (m, 2 H) 7.41 (d, 1 H) 7.34 (d, J = 8.54 Hz, 2
(M + H)+



4-yl]phenyl}-1,3-
H) 6.09 (s, 1 H) 4.81 (d, 4 H) 4.12 (s, 2 H) 3.68 (t,



dihydro-2H-pyrrolo[3,4-
J = 5.95 Hz, 2 H) 2.38-2.50 (m, 2 H)



c]pyridine-2-carboxamide
1.61-1.78 (m, 5 H) 1.20-1.45 (m, 6 H)


1513
N-[4-(1-propanoyl-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



1,2,3,6-tetrahydropyridin-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H)
m/e 377



4-yl)phenyl]-1,3-dihydro-
7.51 (d, J = 8.54 Hz, 2 H) 7.41 (d, J = 4.88 Hz, 1 H)
(M + H)+



2H-pyrrolo[3,4-
7.32-7.37 (m, 2 H) 6.05-6.11 (m, 1 H) 4.81 (d,



c]pyridine-2-carboxamide
J = 7.02 Hz, 4 H) 4.11 (d, J = 3.05 Hz, 2 H) 3.66 (t,




J = 5.80 Hz, 2 H) 2.45-2.50 (m, 2 H)




2.33-2.41 (m, 2 H) 1.05 (t, J = 7.32 Hz, 3 H)


1514
N-{4-[1-(2,2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(ESI(+))



dimethylbutanoyl)-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 419



1,2,3,6-tetrahydropyridin-
7.48-7.54 (m, 2 H) 7.41 (d, J = 4.88 Hz, 1 H)
(M + H)+



4-yl]phenyl}-1,3-
7.31-7.37 (m, 2 H) 6.07-6.13 (m, 1 H) 4.81 (d, J = 7.02 Hz,



dihydro-2H-pyrrolo[3,4-
4 H) 4.14-4.18 (m, 2 H) 3.75 (t, J = 5.65 Hz, 2 H)



c]pyridine-2-carboxamide
2.45-2.50 (m, J = 1.83 Hz, 2 H) 1.64 (q, J = 7.43 Hz,




2 H) 1.18-1.23 (m, 6 H) 0.81 (t, J = 7.48 Hz, 3




H)


1515
N-(4-{1-[(1-methyl-1H-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



pyrrol-2-yl)carbonyl]-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H)
m/e 428



1,2,3,6-tetrahydropyridin-
7.52 (d, J = 8.85 Hz, 2 H) 7.41 (d, J = 4.88 Hz, 1 H)
(M + H)+



4-yl}phenyl)-1,3-
7.36 (d, J = 8.85 Hz, 2 H) 6.83-6.86 (m, 1 H) 6.37 (dd,



dihydro-2H-pyrrolo[3,4-
J = 3.66, 1.53 Hz, 1 H) 6.04-6.12 (m, 2 H) 4.82 (d,



c]pyridine-2-carboxamide
J = 7.32 Hz, 4 H) 4.24-4.28 (m, 2 H) 3.82 (t,




J = 5.80 Hz, 2 H) 3.67 (s, 3 H) 2.53-2.59 (m,




J = 1.83 Hz, 2 H)


1516
N-{4-[1-(methoxyacetyl)-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



1,2,3,6-tetrahydropyridin-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H)
m/e 393



4-yl]phenyl}-1,3-
7.51 (d, J = 8.54 Hz, 2 H) 7.41 (d, J = 5.19 Hz, 1 H)
(M + H)+



dihydro-2H-pyrrolo[3,4-
7.30-7.37 (m, 2 H) 6.03-6.12 (m, 1 H) 4.81 (d,



c]pyridine-2-carboxamide
J = 7.63 Hz, 4 H) 4.00-4.17 (m, 4 H)




3.57-3.70 (m, J = 5.65, 5.65 Hz, 2 H) 3.31-3.37 (m, 3 H)




2.41-2.50 (m, 2 H)


1517
N-{4-[1-(2,2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



dimethylpropanoyl)-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H)
m/e 405



1,2,3,6-tetrahydropyridin-
7.51 (d, J = 8.85 Hz, 2 H) 7.41 (d, J = 5.19 Hz, 1 H)
(M + H)+



4-yl]phenyl}-1,3-
7.34 (d, J = 8.85 Hz, 2 H) 6.10 (t, J = 3.51 Hz, 1 H)



dihydro-2H-pyrrolo[3,4-
4.81 (d, J = 7.32 Hz, 4 H) 4.16 (d, J = 3.05 Hz, 2 H)



c]pyridine-2-carboxamide
3.76 (t, J = 5.80 Hz, 2 H) 2.46-2.50 (m, J = 1.83 Hz, 2




H) 1.25 (s, 9 H)


1518
N-{4-[1-(4-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



methylhexanoyl)-1,2,3,6-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H)
m/e 433



tetrahydropyridin-4-
7.51 (d, J = 8.54 Hz, 2 H) 7.41 (d, J = 4.88 Hz, 1 H)
(M + H)+



yl]phenyl}-1,3-dihydro-
7.34 (d, J = 8.54 Hz, 2 H) 6.05-6.11 (m, 1 H) 4.82 (d,



2H-pyrrolo[3,4-
J = 7.93 Hz, 4 H) 4.08-4.16 (m, J = 1.53 Hz, 2 H)



c]pyridine-2-carboxamide
3.67 (t, J = 5.80 Hz, 2 H) 2.43-2.50 (m, 2 H)




2.30-2.40 (m, 2 H) 1.50-1.68 (m, 1 H)




1.27-1.45 (m, 3 H) 1.10-1.22 (m, 1 H) 0.80-0.91 (m, 6 H)


1519
N-(4-{1-[(2,2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



dimethylcyclopropyl)carbonyl]-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 417



1,2,3,6-
7.47-7.53 (m, 2 H) 7.41 (d, J = 4.88 Hz, 1 H)
(M + H)+



tetrahydropyridin-4-
7.32-7.37 (m, 2 H) 6.08-6.14 (m, 1 H) 4.81 (d, 4 H) 4.18 (s,



yl}phenyl)-1,3-dihydro-
2 H) 3.85-3.94 (m, 1 H) 3.60 (s, 1 H)



2H-pyrrolo[3,4-
2.39-2.50 (m, 2 H) 1.73 (t, J = 7.32 Hz, 1 H) 1.18-1.23 (m, 3



c]pyridine-2-carboxamide
H) 0.96-1.01 (m, 1 H) 0.96 (s, 3 H) 0.68 (dd,




J = 7.93, 3.97 Hz, 1 H)


1520
N-(4-{1-[(1,3-dimethyl-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



1H-pyrazol-5-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H)
m/e 443



yl)carbonyl]-1,2,3,6-
7.49-7.56 (m, 2 H) 7.41 (d, J = 5.19 Hz, 1 H)
(M + H)+



tetrahydropyridin-4-
7.33-7.38 (m, 2 H) 6.25 (s, 1 H) 6.07-6.12 (m, 1 H) 4.81 (d,



yl}phenyl)-1,3-dihydro-
J = 7.02 Hz, 4 H) 4.18-4.24 (m, J = 2.75 Hz, 2 H)



2H-pyrrolo[3,4-
3.72-3.79 (m, 5 H) 2.53-2.60 (m, 2 H) 2.18 (s, 3



c]pyridine-2-carboxamide
H)


1521
N-{4-[1-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



(cyclobutylacetyl)-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H)
m/e 417



1,2,3,6-tetrahydropyridin-
7.51 (d, J = 8.85 Hz, 2 H) 7.41 (d, J = 4.88 Hz, 1 H)
(M + H)+



4-yl]phenyl}-1,3-
7.34 (d, J = 8.85 Hz, 2 H) 6.08 (t, J = 3.51 Hz, 1 H)



dihydro-2H-pyrrolo[3,4-
4.81 (d, J = 7.63 Hz, 4 H) 4.10 (s, 2 H) 3.62-3.69 (m, 2



c]pyridine-2-carboxamide
H) 2.55-2.72 (m, 2 H) 2.45-2.50 (m, 2 H)




2.30-2.42 (m, 1 H) 2.01-2.13 (m, 2 H) 1.77-1.88 (m,




2 H) 1.61-1.74 (m, 2 H)


1522
N-{4-[1-(piperidin-1-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



ylacetyl)-1,2,3,6-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 446



tetrahydropyridin-4-
7.48-7.55 (m, 2 H) 7.41 (d, J = 4.58 Hz, 1 H)
(M + H)+



yl]phenyl}-1,3-dihydro-
7.31-7.36 (m, 2 H) 6.08 (t, J = 3.36 Hz, 1 H) 4.81 (d, 4 H)



2H-pyrrolo[3,4-
4.14 (s, 2 H) 3.66-3.78 (m, 2 H) 3.16 (s, 2 H)



c]pyridine-2-carboxamide
2.46-2.51 (m, 2 H) 2.36-2.43 (m, 4 H)




1.45-1.59 (m, 4 H) 1.32-1.43 (m, 2 H)


1523
N-(4-{1-[2-(pyrrolidin-1-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



yl)propanoyl]-1,2,3,6-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H)
m/e 446



tetrahydropyridin-4-
7.48-7.53 (m, 2 H) 7.41 (d, J = 4.88 Hz, 1 H)
(M + H)+



yl}phenyl)-1,3-dihydro-
7.31-7.36 (m, 2 H) 6.09 (t, J = 3.51 Hz, 1 H) 4.81 (d, J = 7.02 Hz,



2H-pyrrolo[3,4-
4 H) 4.21 (s, 2 H) 3.69-3.88 (m, 2 H)



c]pyridine-2-carboxamide
3.61-3.70 (m, 1 H) 2.53-2.66 (m, 4 H) 2.43-2.50 (m,




2 H) 1.63-1.73 (m, 4 H) 1.19 (d, J = 6.71 Hz, 3 H)


1524
N-(4-{1-[(1,3-dimethyl-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.)δ

(ESI(+))



1H-pyrazol-4-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H) 7.78 (s,
m/e 443



yl)carbonyl]-1,2,3,6-
1 H) 7.52 (d, J = 8.54 Hz, 2 H) 7.41 (d, J = 4.88 Hz,
(M + H)+



tetrahydropyridin-4-
1 H) 7.35 (d, J = 8.85 Hz, 2 H) 6.07-6.11 (m, 1 H)



yl}phenyl)-1,3-dihydro-
4.81 (d, J = 7.32 Hz, 4 H) 4.19 (d, J = 3.05 Hz, 2 H)



2H-pyrrolo[3,4-
3.77-3.79 (m, 3 H) 3.72-3.77 (m, 2 H)



c]pyridine-2-carboxamide
2.52-2.57 (m, 2 H) 2.16-2.22 (m, 3 H)









Example 547
N-[4-(1-oxo-2,3-dihydro-1H-isoindol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-amino-phenyl)-2,3-dihydro-isoindol-1-one. ESI-MS [M+H+]=370.1.


Example 548
N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 377C, substituting isoindoline with 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine. ESI-MS [M+H+]=384.1.


Example 549
N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide

The title compound was prepared as described in Example 377C, substituting isoindoline with 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine. ESI-MS [M+H+]=384.1.


Example 550
N-[4-(1-oxo-1,2-dihydroisoquinolin-4-yl)cyclohex-3-en-1-yl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-amino-cyclohex-1-enyl)-2H-isoquinolin-1-one. ESI-MS [M+H+]=386.2.


Example 551
N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)cyclohex-3-en-1-yl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-amino-cyclohex-1-enyl)-2H-phthalazin-1-one. ESI-MS [M+H+]=387.2.


Example 552
N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)cyclohex-3-en-1-yl]-5-(pyrrolidin-1-ylmethyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 377C, substituting 4-(4-aminophenyl)-5,6,7,8-tetrahydro-2H-phthalazin-1-one with 4-(4-amino-cyclohex-1-enyl)-2H-phthalazin-1-one and isoindoline with 5-pyrrolidin-1-ylmethyl-2,3-dihydro-1H-isoindole. ESI-MS [M+H+]=470.2.


Example 557
N-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 1-isopentyl-1H-pyrazol-4-amine dihydrochloride for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride in Example 272B. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.39 (s, 1H), 7.74 (s, 1H), 7.39 (s, 1H), 7.38-7.26 (m, 4H), 4.69 (s, 4H), 4.04 (t, J=7.1 Hz, 2H), 1.81-1.57 (m, 2H), 1.52-1.37 (m, 1H), 0.89 (d, J=6.6 Hz, 6H); MS (ESI(+)) m/e 299 (M+H)+.


Example 558
N-[1-(2-phenylethyl)-1H-pyrazol-4-yl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 1-phenethyl-1H-pyrazol-4-amine dihydrochloride for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride in Example 272B. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.39 (s, 1H), 7.68 (s, 1H), 7.42 (s, 1H), 7.39-7.23 (m, 6H), 7.24-7.15 (m, 3H), 4.68 (bs, 4H), 4.27 (t, J=7.3 Hz, 2H), 3.07 (t, J=7.3 Hz, 2H); MS (ESI(+)) m/e 333 (M+H)+.


Example 559
N5-[2-(dimethylamino)ethyl]-N2-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2,5-dicarboxamide

The title compound was prepared as described in Example 1C, substituting N1,N1-dimethylethane-1,2-diamine for 3-phenylpropan-1-amine and 2-{[4-(propylcarbamoyl)phenyl]carbamoyl}isoindoline-5-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.28 (s, 1H), 8.70 (t, J=5.6 Hz, 1H), 8.62 (s, 1H), 8.26 (t, J=5.6 Hz, 1H), 7.86-7.74 (m, 4H), 7.68-7.61 (m, 2H), 7.49 (d, J=7.8 Hz, 1H), 4.84 (bs, 4H), 3.66-3.55 (m, 2H), 3.29-3.12 (m, 4H), 2.90-2.80 (m, 6H), 2.28-1.46 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 438 (M+H)+.


Example 560
5-(morpholin-4-ylcarbonyl)-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting morpholine for 3-phenylpropan-1-amine and 2-{[4-(propylcarbamoyl)phenyl]carbamoyl}isoindoline-5-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.61 (s, 1H), 8.26 (t, J=5.7 Hz, 1H), 7.80-7.73 (m, 2H), 7.69-7.62 (m, 2H), 7.47-7.41 (m, 2H), 7.35 (dd, J=7.7, 1.6 Hz, 1H), 4.82 (bs, 4H), 3.73-3.43 (m, 6H), 3.28-3.12 (m, 4H), 1.60-1.44 (m, 2H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 437 (M+H)+.


Example 561
N-(4-{benzyl[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-benzyl-3-morpholinopropan-1-amine for 3-phenylpropan-1-amine. 1H NMR (400 MHz, DMSO-d6, Temp=90° C.) δ ppm 8.28 (s, 1H), 7.65-7.59 (m, 2H), 7.39-7.25 (m, 11H), 4.79 (bs, 4H), 4.63 (s, 2H), 3.52-3.45 (m, 4H), 3.35-3.27 (m, 2H), 2.27-2.20 (m, 4H), 2.17 (t, 2H), 1.69-1.60 (m, 2H); MS (ESI(+)) m/e 499 (M+H)+.


Example 563
5-bromo-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 563A
2-cyclopentyl-N-(4-nitrophenyl)acetamide

The title compound was prepared as described in Example 278, substituting 2-cyclopentylacetyl chloride for acetyl chloride and 4-nitroaniline for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide.


Example 563B
N-(4-aminophenyl)-2-cyclopentylacetamide

The title compound was prepared as described in Example 274, substituting 2-cyclopentyl-N-(4-nitrophenyl)acetamide for 5-nitro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide.


Example 563C
5-bromo-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 272B, substituting N-(4-aminophenyl)-2-cyclopentylacetamide for 4-amino-N-propylbenzamide and 5-bromoisoindoline for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.68 (s, 1H), 8.29 (s, 1H), 7.65-7.55 (m, 1H), 7.53-7.36 (m, 5H), 7.36-7.26 (m, 1H), 4.79-4.65 (m, 4H), 2.33-2.16 (m, 3H), 1.85-1.68 (m, 2H), 1.68-1.41 (m, 4H), 1.29-1.09 (m, 2H); MS (ESI(+)) m/e 442 (M+H)+.


Example 565
methyl 4-{[(5-cyano-1,3-dihydro-2H-isoindol-2-yl)carbonyl]amino}benzoate

The title compound was prepared as described in Example 1A, substituting 5-cyanoisoindoline for isoindoline. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.81 (s, 1H), 7.91-7.82 (m, 3H), 7.82-7.77 (m, 1H), 7.76-7.69 (m, 2H), 7.59 (d, J=7.9 Hz, 1H), 4.89-4.81 (m, 4H), 3.81 (s, 3H); MS (ESI(+)) m/e 322 (M+H)+.


Example 566
N-(4-{(E)-[(benzyloxy)imino]methyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
Example 566A
N-(4-formylphenyl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 4-aminobenzaldehyde for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride.


Example 566B
N-(4-{(E)-[(benzyloxy)imino]methyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

In a 8 mL sealed vial was mixed N-(4-formylphenyl)isoindoline-2-carboxamide (50 mg, 0.188 mmol) in methanol (1 ml). A solution of O-benzylhydroxylamine hydrochloride (45.0 mg, 0.282 mmol) and sodium acetate (46.0 mg, 0.338 mmol) in water (1.000 ml) was then added and the reaction was stirred overnight at room temperature. The reaction was diluted with water and the product was extracted with dichloromethane. The organic layer was washed with brine, dried with sodium sulfate, decanted, and concentrated. Purification by chromatography provided the title compound. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.55 (s, 1H), 8.21 (s, 1H), 7.65 (m, 2H), 7.50 (m, 2H), 7.44-7.28 (m, 9H), 5.14 (s, 2H), 4.78 (bs, 4H); MS (ESI(+)) m/e 372 (M+H)+.


Example 573
N-[4-(3-aminopyrrolidin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 339D. 1H NMR (400 MHz, DMSO-d6, Temp=90° C.) δ ppm 7.76 (bs, 1H), 7.36-7.31 (m, 2H), 7.31-7.25 (m, 4H), 6.46-6.42 (m, 2H), 4.73 (bs, 4H), 3.56 (p, J=5.8 Hz, 1H), 3.41-3.36 (m, 1H), 3.35-3.28 (m, 1H), 3.24-3.15 (m, 3H), 2.85 (dd, J=9.1, 4.9 Hz, 1H), 2.13-2.05 (m, 1H), 1.73-1.64 (m, 1H); MS (ESI(+)) m/e 323 (M+H)+.


Example 574
N-{6-[(3-methylbutyl)carbamoyl]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 574A
methyl 5-(isoindoline-2-carboxamido)picolinate

The title compound was prepared as described in Example 272B, substituting methyl 5-aminopicolinate for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride.


Example 574B
5-(isoindoline-2-carboxamido)picolinic acid

The title compound was prepared as described in Example 1B, substituting methyl 5-(isoindoline-2-carboxamido)picolinate for methyl 4-(isoindoline-2-carboxamido)benzoate.


Example 574C
N-{6-[(3-methylbutyl)carbamoyl]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 3-methylbutan-1-amine for 3-phenylpropan-1-amine and 5-(isoindoline-2-carboxamido)picolinic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.85 (m, 2H), 8.57 (t, J=6.1 Hz, 1H), 8.17 (dd, J=8.5, 2.4 Hz, 1H), 7.94 (d, J=8.5 Hz, 1H), 7.41-7.29 (m, 4H), 4.79 (m, 4H), 3.35 (m, 2H), 1.59 (m, 1H), 1.42 (q, J=7.1 Hz, 2H), 0.90 (d, J=6.6 Hz, 6H); MS (ESI(+)) m/e 353 (M+H)+.


Example 575
N-{6-[(3-phenylpropyl)carbamoyl]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 5-(isoindoline-2-carboxamido)picolinic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.86 (m, 2H), 8.68 (t, J=6.0 Hz, 1H), 8.18 (dd, J=8.6, 2.5 Hz, 1H), 7.95 (d, J=8.5 Hz, 1H), 7.41-7.14 (m, 9H), 4.81 (bs, 4H), 3.35 (m, 2H), 2.61 (t, J=7.6 Hz, 2H), 1.84 (m, 2H); MS (ESI(+)) m/e 401 (M+H)+.


Example 576
N-{6-[(tetrahydrofuran-3-ylmethyl)carbamoyl]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting (tetrahydrofuran-3-yl)methanamine for 3-phenylpropan-1-amine and 5-(isoindoline-2-carboxamido)picolinic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.87 (m, 2H), 8.78 (t, J=6.1 Hz, 1H), 8.18 (dd, J=8.5, 2.5 Hz, 1H), 7.95 (d, J=8.5 Hz, 1H), 7.42-7.26 (m, 4H), 4.81 (m, 4H), 3.75 (m, 1H), 3.70-3.56 (m, 2H), 3.47 (dd, J=8.5, 5.3 Hz, 1H), 3.27 (m, 2H), 2.53 (m, 1H), 1.91 (m, 1H), 1.61 (m, 1H); MS (ESI(+)) m/e 368 (M+H)+.


Example 577
N2-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2,5-dicarboxamide

The title compound was prepared as described in Example 132 substituting 5-cyano-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide for 5-cyano-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.69 (s, 1H), 8.31 (s, 1H), 7.98 (s, 1H), 7.87-7.78 (m, 2H), 7.53-7.38 (m, 5H), 7.36 (brs, 1H), 4.78 (bs, 4H), 2.32-2.13 (m, 3H), 1.82-1.67 (m, 2H), 1.67-1.42 (m, 4H), 1.27-1.10 (m, 2H); MS (ESI(+)) m/e 407 (M+H)+.


Example 578
N-[4-({benzyl[3-(morpholin-4-yl)propyl]amino}methyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

To a stirring suspension of N-(4-{benzyl[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide (0.028 g, 0.056 mmol) in THF (1.1 ml) was added 1M borane tetrahydrofuran complex (0.225 ml, 0.225 mmol) dropwise. The mixture was heated at 60° C. for 5 hours. Additional borane complex (0.084 mL) was added and reaction was heated at 60° C. for 1 hour. The reaction was cooled to ambient temperature and 0.3 mL of 1.25 M HCl in methanol was added. The quenched reaction was stirred 30 min and concentrated. The title compound was isolated after flash chromatography. 1H NMR (400 MHz, pyridine-d5, Temp=90° C.) δ ppm 8.05 (s, 1H), 7.88-7.82 (m, 2H), 7.47-7.38 (m, 4H), 7.36-7.29 (m, 2H), 7.26-7.15 (m, 5H), 4.85 (bs, 4H), 3.68-3.59 (m, 8H), 3.48-3.35 (m, 1H), 2.59 (t, J=7.0 Hz, 2H), 2.38-2.29 (m, 6H), 1.79-1.65 (m, 3H); MS (ESI(+)) m/e 485 (M+H)+.


Example 579
N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(1H-pyrazol-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting 5-bromo-N-(4-(2-cyclopentylacetamido)phenyl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 13.30 (bs, 0.25H), 12.87 (bs, 0.75H), 9.69 (s, 1H), 8.34-8.23 (m, 1H), 7.83-7.63 (m, 3H), 7.56-7.32 (m, 5H), 6.76-6.68 (m, 1H), 4.81-4.72 (m, 4H), 2.31-2.12 (m, 3H), 1.85-1.67 (m, 2H), 1.67-1.42 (m, 4H), 1.29-1.10 (m, 2H); MS (ESI(+)) m/e 430 (M+H)+.


Example 580
N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(pyridin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting pyridin-3-ylboronic acid for 1H-pyrazol-3-ylboronic acid and 5-bromo-N-(4-(2-cyclopentylacetamido)phenyl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.70 (bs, 1H), 8.93-8.89 (m, 1H), 8.58 (dd, J=4.7, 1.6 Hz, 1H), 8.33 (s, 1H), 8.13-8.05 (m, 1H), 7.72 (bs, 1H), 7.71-7.64 (m, 1H), 7.54-7.44 (m, 6H), 4.81 (bs, 4H), 2.31-2.18 (m, 3H), 1.82-1.68 (m, 2H), 1.68-1.43 (m, 4H), 1.26-1.11 (m, 2H); MS (ESI(+)) m/e 441 (M+H)+.


Example 581
N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(1-methyl-1H-pyrazol-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole for 1H-pyrazol-3-ylboronic acid and 5-bromo-N-(4-(2-cyclopentylacetamido)phenyl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.69 (s, 1H), 8.27 (s, 1H), 8.14 (s, 1H), 7.88-7.85 (m, 1H), 7.55-7.40 (m, 6H), 7.36-7.30 (m, 1H), 4.77-4.69 (m, 4H), 3.86 (s, 3H), 2.31-2.16 (m, 3H), 1.81-1.68 (m, 2H), 1.68-1.42 (m, 4H), 1.28-1.12 (m, 2H); MS (ESI(+)) m/e 444 (M+H)+.


Example 582
N2-{4-[(cyclopentylacetyl)amino]phenyl}-N5-(2-methoxyethyl)-1,3-dihydro-2H-isoindole-2,5-dicarboxamide

The title compound was prepared as described in Example 1C, substituting 2-methoxyethanamine for 3-phenylpropan-1-amine and 2-({4-[(cyclopentylacetyl)amino]phenyl}carbamoyl)isoindoline-5-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.69 (s, 1H), 8.56-8.49 (m, 1H), 8.31 (s, 1H), 7.84-7.77 (m, 2H), 7.50-7.40 (m, 5H), 4.78 (bs, 4H), 3.50-3.39 (m, 4H), 3.27 (s, 3H), 2.31-2.18 (m, 3H), 1.81-1.68 (m, 2H), 1.66-1.43 (m, 4H), 1.26-1.12 (m, 2H); MS (ESI(+)) m/e 465 (M+H)+.


Example 583
N2-{4-[(cyclopentylacetyl)amino]phenyl}-N5-(2-hydroxyethyl)-1,3-dihydro-2H-isoindole-2,5-dicarboxamide

The title compound was prepared as described in Example 1C, substituting 2-aminoethanol for 3-phenylpropan-1-amine and 2-({4-[(cyclopentylacetyl)amino]phenyl}carbamoyl)isoindoline-5-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.70 (s, 1H), 8.51-8.40 (m, 1H), 8.31 (s, 1H), 7.86-7.75 (m, 2H), 7.51-7.36 (m, 5H), 4.78 (bs, 4H), 4.71 (t, J=5.6 Hz, 1H), 3.58-3.46 (m, 2H), 3.39-3.28 (m, 2H), 2.32-2.13 (m, 3H), 1.82-1.68 (m, 2H), 1.67-1.44 (m, 4H), 1.27-1.10 (m, 2H); MS (ESI(+)) m/e 451 (M+H)+.


Example 584
5-(aminomethyl)-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 276, substituting 5-cyano-N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide for 5-cyano-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.35 (bs, 1H), 7.99 (bs, 1H), 7.44-7.41 (m, 4H), 7.31-7.20 (m, 3H), 4.72 (bs, 4H), 3.81-3.68 (m, 2H), 2.29-2.25 (m, 3H), 1.80-1.68 (m, 2H), 1.66-1.48 (m, 6H), 1.29-1.14 (m, 2H); MS (ESI(+)) m/e 393 (M+H)+.


Example 605
N-[6-(benzoylamino)hexyl]-1,3-dihydro-2H-isoindole-2-carboxamide
Example 605A
tert-butyl 6-(isoindoline-2-carboxamido)hexylcarbamate

The title compound was prepared as described in Example 344A, substituting tert-butyl 6-aminohexylcarbamate for tert-butyl 5-aminoisoindoline-2-carboxylate.


Example 605B
N-(6-aminohexyl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 2D, substituting Boc-tert-butyl 6-(isoindoline-2-carboxamido)hexylcarbamate for tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 605C
N-[6-(benzoylamino)hexyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(6-aminohexyl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and benzoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.42 (t, J=5.35 Hz, 1H) 7.76-7.90 (m, 2H) 7.36-7.58 (m, 3H) 7.20-7.36 (m, 4H) 6.28 (t, J=5.55 Hz, 1H) 4.57 (s, 4H) 3.21-3.30 (m, 2H) 3.07 (q, J=6.74 Hz, 2H) 1.24-1.66 (m, 8H); (ESI(+)) m/e 366 (M+H)+.









TABLE 10







The following Examples were prepared as described in Example 1C, substituting


N-(6-aminohexyl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and the


appropriate carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid.










Ex
Name

1H NMR

MS













606
N-{6-[(pyridin-3-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.98 (d,

(ESI(+))



ylcarbonyl)amino]hexyl}-
J = 1.36 Hz, 1 H) 8.68 (dd, J = 4.75, 1.70 Hz, 1 H) 8.62
m/e 367



1,3-dihydro-2H-isoindole-2-
(t, J = 5.43 Hz, 1 H) 8.12-8.21 (m, 1 H) 7.48 (dd,
(M + H)+



carboxamide
J = 8.31, 5.26 Hz, 1 H) 7.20-7.36 (m, 4 H) 6.27 (t,




J = 5.43 Hz, 1 H) 4.57 (s, 4 H) 3.23-3.29 (m, 2 H)




2.99-3.13 (m, 2 H) 1.25-1.60 (m, 9 H)


619
N-(6-acetamidohexyl)-

1H NMR (300 MHz, DMSO-d6) δ ppm 7.77 (s, 1 H)

(ESI(+))



1,3-dihydro-2H-isoindole-2-
7.22-7.38 (m, 4 H) 6.28 (t, J = 5.55 Hz, 1 H) 4.57 (s, 4
m/e 304



carboxamide
H) 2.93-3.14 (m, 4 H) 1.77 (s, 3 H) 1.31-1.61 (m, 4
(M + H)+




H) 1.20-1.31 (m, 4 H)


655
N-(6-{[4-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



(methylsulfonyl)benzoyl]ami-
Temp = 90° C.) δ ppm 1.33-1.40 (m, 4 H), 1.45-1.63
m/e 444



no}hexyl)-1,3-
(m, 4 H), 3.11 (t, J = 7.02 Hz, 2 H), 3.19 (s, 3 H), 3.30
(M + H)+



dihydro-2H-isoindole-2-
(t, J = 7.02 Hz, 2 H), 4.59 (s, 4 H), 7.24-7.33 (m, 4 H),



carboxamide
7.95-8.04 (m, 4 H)


656
N-{6-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



[(ethoxyacetyl)amino]hexyl}-
Temp = 90° C.) δ ppm 1.15 (t, J = 7.02 Hz, 3 H), 1.25-
m/e 348



1,3-dihydro-2H-isoindole-2-
1.36 (m, 4 H), 1.42-1.51 (m, 4 H), 3.11 (q, J = 7.43
(M + H)+



carboxamide
Hz, 4 H), 3.50 (q, J = 7.02 Hz, 2 H), 3.80 (s, 2 H), 4.59




(s, 4 H), 7.24-7.33 (m, 4 H)


657
N-{6-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



[(cyclopentylcarbonyl)ami-
Temp = 90° C.) δ ppm 1.25-1.35 (m, 5 H), 1.38-1.55
m/e 358



no]hexyl}-1,3-
(m, 6 H), 1.56-1.67 (m, 4 H), 1.68-1.81 (m, 2 H),
(M + H)+



dihydro-2H-isoindole-2-
3.00-3.13 (m, 4 H), 4.59 (s, 4 H), 7.20-7.37 (m, 4



carboxamide
H)


658
N-{6-[(2-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



hydroxybenzoyl)amino]
Temp = 90° C.) δ ppm 1.32-1.42 (m, 4 H), 1.45-1.53
m/e 382



hexyl}-1,3-dihydro-2H-
(m, 2 H), 1.53-1.63 (m, 2 H), 3.11 (t, 2 H), 3.31 (t,
(M + H)+



isoindole-2-
J = 7.02 Hz, 2 H), 4.58 (s, 4 H), 6.83-6.90 (m, 2 H),



carboxamide
7.23-7.32 (m, 4 H), 7.34-7.40 (m, 1 H), 7.78 (dd,




J = 7.78, 1.68 Hz, 1 H)


659
N-{6-[(3-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



hydroxybenzoyl)amino]
Temp = 90° C.) δ ppm 1.28-1.41 (m, 4 H), 1.42-1.61
m/e 382



hexyl}-1,3-dihydro-2H-
(m, 4 H), 3.08-3.15 (m, 2 H), 3.22-3.25 (m, 2 H),
(M + H)+



isoindole-2-
4.59 (s, 4 H), 6.86-6.93 (m, 1 H), 7.17-7.34 (m, 7



carboxamide
H)


660
N-{6-[(4-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



hydroxybenzoyl)amino]
Temp = 90° C.) δ ppm 1.30-1.38 (m, 4 H), 1.44-1.60
m/e 382



hexyl}-1,3-dihydro-2H-
(m, 4 H), 3.09-3.13 (m, 2 H), 3.20-3.25 (m, 2 H),
(M + H)+



isoindole-2-
4.59 (s, 4 H), 6.75-6.83 (m, 2 H), 7.23-7.32 (m, 4



carboxamide
H), 7.65-7.71 (m, 2 H)


661
N-{6-[(2-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



methoxybenzoyl)amino]
Temp = 90° C.) δ ppm 1.29-1.43 (m, 4 H), 1.45-1.61
m/e 396



hexyl}-1,3-dihydro-2H-
(m, 4 H), 3.08-3.15 (m, 2 H), 3.30 (t, J = 7.02 Hz, 2
(M + H)+



isoindole-2-
H), 3.89 (s, 3 H), 4.58 (s, 4 H), 6.99-7.04 (m, 1 H),



carboxamide
7.10 (d, J = 8.24 Hz, 1 H), 7.24-7.32 (m, 4 H), 7.41-




7.47 (m, 1 H), 7.74 (dd, J = 7.63, 1.83 Hz, 1 H)


662
N-{6-[(3-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



methoxybenzoyl)amino]
Temp = 90° C.) δ ppm 1.30-1.41 (m, 4 H), 1.44-1.62
m/e 396



hexyl}-1,3-dihydro-2H-
(m, 4 H), 3.09-3.14 (m, 2 H), 3.26-3.31 (m, 2 H),
(M + H)+



isoindole-2-
3.80 (s, 3 H), 4.58 (s, 4 H), 7.03-7.07 (m, 1 H), 7.24-



carboxamide
7.41 (m, 7 H)


663
N-{6-[(4-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



methoxybenzoyl)amino]
Temp = 90° C.) δ ppm 1.31-1.39 (m, 4 H), 1.49 (s, 4
m/e 396



hexyl}-1,3-dihydro-2H-
H), 3.11 (t, J = 7.02 Hz, 2 H), 3.26-3.28 (m, 2 H), 3.80
(M + H)+



isoindole-2-
(s, 3 H), 4.58 (s, 4 H), 6.92-6.97 (m, 2 H), 7.24-7.32



carboxamide
(m, 4 H), 7.75-7.80 (m, 2 H)


664
N-{6-[(2-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



fluorobenzoyl)amino]hexyl}-
Temp = 90° C.) δ ppm 1.27-1.42 (m, 4 H), 1.43-1.64
m/e 384



1,3-dihydro-2H-isoindole-2-
(m, 4 H), 3.11 (t, 2 H), 3.28 (t, J = 7.02 Hz, 2 H), 4.58
(M + H)+



carboxamide
(s, 4 H), 7.17-7.33 (m, 6 H), 7.45-7.52 (m, 1 H),




7.57-7.63 (m, 1 H)


665
N-{6-[(3-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



fluorobenzoyl)amino]hexyl}-
Temp = 90° C.) δ ppm 1.32-1.41 (m, 4 H), 1.44-1.61
m/e 384



1,3-dihydro-2H-isoindole-2-
(m, 4 H), 3.11 (t, 2 H), 3.28 (t, J = 7.02 Hz, 2 H), 4.58
(M + H)+



carboxamide
(s, 4 H), 7.24-7.33 (m, 5 H), 7.44-7.51 (m, 1 H),




7.55-7.60 (m, 1 H), 7.65 (d, J = 8.24 Hz, 1 H)


666
N-{6-[(4-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



fluorobenzoyl)amino]hexyl}-
Temp = 90° C.) δ ppm 1.31-1.38 (m, 4 H), 1.44-1.61
m/e 384



1,3-dihydro-2H-isoindole-2-
(m, 4 H), 3.11 (t, J = 7.02 Hz, 2 H), 3.26 (t, J = 7.02 Hz,
(M + H)+



carboxamide
2 H), 4.58 (s, 4 H), 7.16-7.31 (m, 6 H), 7.84-7.89




(m, 2 H)


667
N-{6-[(2-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



chlorobenzoyl)amino]hexyl}-
Temp = 90° C.) δ ppm 1.30-1.42 (m, 4 H), 1.45-1.63
m/e 400



1,3-dihydro-2H-isoindole-2-
(m, 4 H), 3.12 (t, J = 7.02 Hz, 2 H), 3.26-3.29 (m, 2
(M + H)+



carboxamide
H), 4.59 (s, 4 H), 7.24-7.32 (m, 4 H), 7.33-7.45 (m,




4 H)


668
N-{6-[(3-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



chlorobenzoyl)amino]hexyl}-
Temp = 90° C.) δ ppm 1.29-1.40 (m, 4 H), 1.44-1.62
m/e 400



1,3-dihydro-2H-isoindole-2-
(m, 4 H), 3.11 (t, 2 H), 3.27 (t, 2 H), 4.58 (s, 4 H),
(M + H)+



carboxamide
7.24-7.33 (m, 4 H), 7.46 (t, J = 7.78 Hz, 1 H), 7.51-




7.55 (m, 1 H), 7.75 (dd, J = 7.63, 1.53 Hz, 1 H), 7.82 (t,




J = 1.68 Hz, 1 H)


669
N-{6-[(4-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



chlorobenzoyl)amino]hexyl}-
Temp = 90° C.) δ ppm 1.28-1.40 (m, 4 H), 1.44-1.62
m/e 400



1,3-dihydro-2H-isoindole-2-
(m, 4 H), 3.11 (t, J = 7.02 Hz, 2 H), 3.27 (t, 2 H), 4.58
(M + H)+



carboxamide
(s, 4 H), 7.24-7.32 (m, 4 H), 7.43-7.49 (m, 2 H),




7.78-7.85 (m, 2 H)


670
N-{6-[(3-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



cyanobenzoyl)amino]hexyl}-
Temp = 90° C.) δ ppm 1.28-1.41 (m, 4 H), 1.45-1.63
m/e 391



1,3-dihydro-2H-isoindole-2-
(m, 4 H), 3.11 (t, 2 H), 3.29 (t, J = 7.02 Hz, 2 H), 4.58
(M + H)+



carboxamide
(s, 4 H), 7.24-7.32 (m, 4 H), 7.65 (t, J = 7.78 Hz, 1 H),




7.88-7.92 (m, 1 H), 8.09-8.12 (m, 1 H), 8.18 (t, 1 H)


671
N-{6-[(4-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



cyanobenzoyl)amino]hexyl}-
Temp = 90° C.) δ ppm 1.32-1.39 (m, 4 H), 1.44-1.63
m/e 391



1,3-dihydro-2H-isoindole-2-
(m, 4 H), 3.11 (t, 2 H), 3.29 (t, J = 7.02 Hz, 2 H), 4.58
(M + H)+



carboxamide
(s, 4 H), 7.22-7.33 (m, 4 H), 7.82-7.87 (m, 2 H),




7.92-7.96 (m, 2 H)


672
N-(6-{[3-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



(dimethylamino)benzoyl]ami-
Temp = 90° C.) δ ppm 1.30-1.38 (m, 4 H), 1.45-1.60
m/e 409



no}hexyl)-1,3-
(m, 4 H), 2.96 (s, 6 H), 3.11 (t, 2 H), 3.27 (t, 2 H),
(M + H)+



dihydro-2H-isoindole-2-
4.59 (s, 4 H), 6.93-7.00 (m, 1 H), 7.17-7.21 (m, 1



carboxamide
H), 7.24-7.33 (m, 6 H)


673
N-(6-{[4-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



(dimethylamino)benzoyl]ami-
Temp = 90° C.) δ ppm 1.31-1.37 (m, 4 H), 1.43-1.58
m/e 409



no}hexyl)-1,3-
(m, 4 H), 2.95 (s, 6 H), 3.11 (t, 2 H), 3.24 (t, J = 7.02
(M + H)+



dihydro-2H-isoindole-2-
Hz, 2 H), 4.59 (s, 4 H), 6.68-6.74 (m, 2 H), 7.22-



carboxamide
7.33 (m, 4 H), 7.66-7.70 (m, 2 H)


674
N-(6-{[3-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



(trifluoromethyl)benzoyl]ami-
Temp = 90° C.) δ ppm 1.32-1.41 (m, 4 H), 1.46-1.62
m/e 434



no}hexyl)-1,3-
(m, 4 H), 3.09-3.14 (m, 2 H), 3.30 (t, J = 7.02 Hz, 2
(M + H)+



dihydro-2H-isoindole-2-
H), 4.58 (s, 4 H), 7.24-7.33 (m, 4 H), 7.68 (t, J = 7.78



carboxamide
Hz, 1 H), 7.83 (d, J = 7.63 Hz, 1 H), 8.06-8.14 (m, 2 H)


675
N-(6-{[4-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



(trifluoromethyl)benzoyl]ami-
Temp = 90° C.) δ ppm 1.32-1.41 (m, 4 H), 1.45-1.62
m/e 434



no}hexyl)-1,3-
(m, 4 H), 3.11 (t, 2 H), 3.30 (t, J = 7.17 Hz, 2 H), 4.58
(M + H)+



dihydro-2H-isoindole-2-
(s, 4 H), 7.24-7.33 (m, 4 H), 7.77 (d, J = 7.93 Hz, 2



carboxamide
H), 7.98 (d, J = 7.93 Hz, 2 H)


676
N-(6-{[3-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



(trifluoromethoxy)benzoyl]ami-
Temp = 90° C.) δ ppm 1.30-1.41 (m, 4 H), 1.45-1.61
m/e 450



no}hexyl)-1,3-
(m, 4 H), 3.12 (t, J = 7.02 Hz, 2 H), 3.29 (t, J = 7.17 Hz,
(M + H)+



dihydro-2H-isoindole-2-
2 H), 4.59 (s, 4 H), 7.23-7.32 (m, 4 H), 7.41-7.49



carboxamide
(m, 1 H), 7.58 (t, J = 7.93 Hz, 1 H), 7.73 (s, 1 H), 7.84




(d, J = 7.93 Hz, 1 H)


677
N-{6-[(2,3-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



dimethoxybenzoyl)ami-
Temp = 90° C.) δ ppm 1.33-1.42 (m, 4 H), 1.45-1.61
m/e 426



no]hexyl}-1,3-dihydro-
(m, 4 H), 3.12 (t, J = 7.02 Hz, 2 H), 3.28 (t, J = 7.02 Hz,
(M + H)+



2H-isoindole-2-
2 H), 3.79 (s, 3 H), 3.83 (s, 3 H), 4.58 (s, 4 H), 7.06-



carboxamide
7.20 (m, 3 H), 7.24-7.32 (m, 4 H)


678
N-{6-[(2,4-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



dimethoxybenzoyl)ami-
Temp = 90° C.) δ ppm 1.30-1.41 (m, 4 H), 1.45-1.62
m/e 426



no]hexyl}-1,3-dihydro-
(m, 4 H), 3.11 (t, J = 7.02 Hz, 2 H), 3.29 (t, J = 7.02 Hz,
(M + H)+



2H-isoindole-2-
2 H), 3.81 (s, 3 H), 3.90 (s, 3 H), 4.58 (s, 4 H), 6.56-



carboxamide
6.63 (m, 2 H), 7.22-7.33 (m, 4 H), 7.78 (d, J = 8.54




Hz, 1 H)


679
N-{6-[(2,5-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



dimethoxybenzoyl)ami-
Temp = 90° C.) δ ppm 1.31-1.40 (m, 4 H), 1.44-1.59
m/e 426



no]hexyl}-1,3-dihydro-
(m, 4 H), 3.12 (t, 2 H), 3.30 (t, J = 6.87 Hz, 2 H), 3.73
(M + H)+



2H-isoindole-2-
(s, 3 H), 3.82-3.86 (m, 3 H), 4.58 (s, 4 H), 6.99-7.08



carboxamide
(m, 2 H), 7.23-7.34 (m, 5 H)


680
N-{6-

1H NMR (500 MHz, DMSO-d6, Temp = 90° C.) δ 8.00

(ESI(+))



[(phenylacetyl)amino]hexyl}-
(m, 1H), 7.28 (m, 8H), 7.20 (m, 1H), 6.27 (t, J = 5.5,
m/e 380



1,3-dihydro-2H-isoindole-2-
1H), 4.57 (s, 4H), 3.04 (m, 4H), 1.40 (m, 4H), 1.27
(M + H)+



carboxamide
(m, 4H)


681
N-(6-{[(3-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(ESI(+))



fluorophenyl)acetyl]ami-
Temp = 90° C.) δ ppm 1.22-1.33 (m, 4 H), 1.36-1.53
m/e 398



no}hexyl)-1,3-dihydro-
(m, 4 H), 3.02-3.13 (m, 4 H), 3.43 (s, 2 H), 4.59 (s, 4
(M + H)+



2H-isoindole-2-
H), 6.93-7.12 (m, 3 H), 7.23-7.34 (m, 5 H)



carboxamide


688
N-[6-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.55 (s, 1 H)

(ESI(+))



(benzoylamino)hexyl]-
8.46 (d, J = 4.75 Hz, 1 H) 8.41 (t, J = 5.43 Hz, 1 H) 7.78-
m/e 367



1,3-dihydro-2H-
7.86 (m, 2 H) 7.40-7.55 (m, 3 H) 7.38 (d, J = 5.09
(M + H)+



pyrrolo[3,4-c]pyridine-
Hz, 1 H) 6.36 (t, J = 5.43 Hz, 1 H) 4.60 (d, J = 2.03 Hz,



2-carboxamide
4 H) 3.21-3.29 (m, 2 H) 3.00-3.13 (m, 2 H) 1.25-




1.60 (m, 8H)


689
4-fluoro-N-{6-[(pyridin-3-

1H NMR (500 MHz, DMSO-d6, Temp = 90° C.) δ 9.02

(ESI(+))



ylcarbonyl)amino]hexyl}-
(d, J = 2.2, 1H), 8.71 (m, 2H), 8.26 (dt, J = 7.9, 1.9,
m/e 385



1,3-dihydro-2H-isoindole-2-
1H), 7.58 (ddd, J = 7.9, 4.8, 0.8, 1H), 7.34 (td, J = 7.8,
(M + H)+



carboxamide
5.1, 1H), 7.16 (d, J = 7.5, 1H), 7.10 (t, J = 8.8, 1H),




6.39 (bs, 1H), 4.62 (s, 4H), 3.28 (m, 2H), 3.07 (m,




2H), 1.54 (m, 2H), 1.46 (m, 2H), 1.34 (m, 4H)


690
5-fluoro-N-{6-[(pyridin-

1H NMR (400 MHz, DMSO-d6D2O, Temp = 90° C.) δ

(ESI(+))



3-ylcarbonyl)amino]hexyl}-
8.99 (dd, J = 2.2, 0.9, 1H), 8.71 (m, 1H), 8.26 (m,
m/e 385



1,3-dihydro-2H-isoindole-2-
1H), 7.58 (m, 1H), 7.32 (m, 1H), 7.08 (m, 2H), 4.58
(M + H)+



carboxamide
(d, J = 2.5, 2H), 4.55 (m, 2H), 3.11 (t, J = 7.0, 2H),




1.47 (m, 11H)


691
5-methoxy-N-{6-

1H NMR (400 MHz, DMSO-d6D2O, Temp = 90° C.) δ

(ESI(+))



[(pyridin-3-
9.01 (dd, J = 2.2, 0.9, 1H), 8.73 (dd, J = 5.0, 1.6, 1H),
m/e 397



ylcarbonyl)amino]hexyl}-
8.33 (ddd, J = 7.9, 2.2, 1.6, 1H), 7.63 (ddd, J = 7.9,
(M + H)+



1,3-dihydro-2H-isoindole-2-
5.0, 0.9, 1H), 7.20 (m, 1H), 6.85 (m, 2H), 4.55 (m,



carboxamide
2H), 4.50 (d, J = 2.4, 2H), 3.76 (s, 3H), 3.11 (t, J =




7.0, 2H), 1.58 (t, J = 7.0, 3H), 1.50 (t, J = 6.8, 2H),




1.36 (m, 5H)


692
N-{6-[(pyridin-3-

1H NMR (400 MHz, DMSO-d6D2O, Temp = 90° C.) δ

(ESI(+))



ylcarbonyl)amino]hexyl}-
8.99 (dd, J = 2.2, 0.9, 1H), 8.71 (dd, J = 4.9, 1.6, 1H),
m/e 435



5-(trifluoromethyl)-
8.27 (m, 1H), 7.58 (m, 4H), 4.66 (s, 4H), 3.12 (t, J =
(M + H)+



1,3-dihydro-2H-isoindole-2-
7.0, 2H), 1.54 (m, 5H), 1.37 (m, 5H)



carboxamide


693
4-cyano-N-{6-[(pyridin-

1H NMR (400 MHz, DMSO-d6D2O, Temp = 90° C.) δ

(ESI(+))



3-ylcarbonyl)amino]hexyl}-
8.99 (m, 1H), 8.71 (dd, J = 5.0, 1.6, 1H), 8.28 (ddd,
m/e 392



1,3-dihydro-2H-isoindole-2-
J = 8.0, 2.3, 1.6, 1H), 7.67 (m, 2H), 7.59 (ddd, J = 7.9,
(M + H)+



carboxamide
5.0, 0.9, 1H), 7.48 (t, J = 7.7, 1H), 4.75 (d, J = 2.2,




2H), 4.67 (m, 2H), 3.12 (t, J = 7.0, 2H), 1.56 (m, 5H),




1.37 (m, 5H)


694
5-methyl-N-{6-

1H NMR (400 MHz, DMSO-d6D2O, Temp = 90° C.) δ

(ESI(+))



[(pyridin-3-
9.01 (m, 1H), 8.73 (dd, J = 5.0, 1.6, 1H), 8.32 (ddd,
m/e 381



ylcarbonyl)amino]hexyl}-
J = 7.9, 2.2, 1.6, 1H), 7.62 (ddd, J = 8.0, 5.0, 0.9, 1H),
(M + H)+



1,3-dihydro-2H-isoindole-2-
7.17 (d, J = 7.7, 1H), 7.08 (d, J = 7.8, 2H), 4.54 (bs,



carboxamide
4H), 3.11 (t, J = 7.0, 2H), 2.31 (s, 3H), 1.56 (m, 5H),




1.37 (m, 5H)


695
4-chloro-N-{6-

1H NMR (400 MHz, DMSO-d6D2O, Temp = 90° C.) δ

(ESI(+))



[(pyridin-3-
9.00 (dd, J = 2.2, 0.8, 1H), 8.71 (dd, J = 5.0, 1.6, 1H),
m/e 401



ylcarbonyl)amino]hexyl}-
8.29 (ddd, J = 8.0, 2.2, 1.7, 1H), 7.60 (m, 1H), 7.30
(M + H)+



1,3-dihydro-2H-
(m, 3H), 4.63 (m, 4H), 3.32 (m, 2H), 3.12 (m, 2H),



isoindole-2-
1.54 (m, 5H), 1.36 (m, 5H)



carboxamide


696
5-cyano-N-{6-[(pyridin-

1H NMR (400 MHz, DMSO-d6D2O, Temp = 90° C.) δ

(ESI(+))



3-ylcarbonyl)amino]hexyl}-
8.98 (d, J = 1.7, 1H), 8.70 (dd, J = 4.9, 1.6, 1H), 8.24
m/e 392



1,3-dihydro-2H-isoindole-2-
(m, 1H), 7.68 (m, 2H), 7.54 (m, 2H), 4.65 (m, 4H),
(M + H)+



carboxamide
3.11 (m, 2H), 1.54 (m, 5H), 1.36 (m, 5H)


697
5-chloro-N-{6-

1H NMR (400 MHz, DMSO-d6D2O, Temp = 90° C.) δ

(ESI(+))



[(pyridin-3-
8.99 (dd, J = 2.2, 0.7, 1H), 8.71 (dd, J = 5.0, 1.6, 1H),
m/e 401



ylcarbonyl)amino]hexyl}-
8.27 (ddd, J = 8.0, 2.2, 1.7, 1H), 7.58 (m, 1H), 7.32
(M + H)+



1,3-dihydro-2H-
(m, 3H), 4.57 (dd, J = 8.2, 1.9, 4H), 3.11 (m, 2H),



isoindole-2-
1.54 (m, 5H), 1.37 (m, 5H)



carboxamide


698
N-{6-[(pyridin-2-

1H NMR (300 MHz, DMSO-d6) δ ppm 8.74 (t, J = 5.76

(ESI(+))



ylcarbonyl)amino]hexyl}-
Hz, 1 H) 8.63 (d, J = 4.75 Hz, 1 H) 7.89-8.12 (m, 2 H)
m/e 367



1,3-dihydro-2H-
7.50-7.65 (m, 1 H) 7.19-7.39 (m, 4 H) 6.26 (t,
(M + H)+



isoindole-2-
J = 5.43 Hz, 1 H) 4.57 (s, 4 H) 3.23-3.35 (m, 2 H)



carboxamide
3.06 (q, J = 6.67 Hz, 2 H) 1.22-1.61 (m, 8 H)









Example 607
N-{4-[(cyclopentylacetyl)amino]phenyl}-5-(pyridin-4-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting pyridin-4-ylboronic acid for 1H-pyrazol-3-ylboronic acid and 5-bromo-N-(4-(2-cyclopentylacetamido)phenyl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.70 (s, 1H), 8.69-8.61 (m, 2H), 8.33 (s, 1H), 7.82-7.69 (m, 4H), 7.54-7.41 (m, 5H), 4.81 (bs, 4H), 2.31-2.15 (m, 3H), 1.82-1.68 (m, 2H), 1.68-1.43 (m, 4H), 1.26-1.11 (m, 2H); MS (ESI(+)) m/e 441 (M+H)+.


Example 608
5-(hydroxymethyl)-N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 4-amino-N-isopentylbenzamide for 4-amino-N-propylbenzamide and isoindolin-5-ylmethanol hydrochloride for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.55 (s, 1H), 8.24-8.17 (m, 1H), 7.79-7.72 (m, 2H), 7.68-7.61 (m, 2H), 7.37-7.21 (m, 3H), 5.19 (t, J=5.7 Hz, 1H), 4.76 (bs, 4H), 4.52 (d, J=5.7 Hz, 2H), 3.30-3.21 (m, 2H), 1.70-1.54 (m, 1H), 1.47-1.36 (m, 2H), 0.90 (d, J=6.6 Hz, 6H); MS (ESI(+)) m/e 382 (M+H)+.


Example 609
N-{3-[(1-benzoylpiperidin-4-yl)oxy]propyl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 609A
tert-butyl 4-(3-(isoindoline-2-carboxamido)propoxy)piperidine-1-carboxylate

The title compound was prepared as described in Example 344A, substituting tert-butyl 4-(3-aminopropoxy)piperidine-1-carboxylate for tert-butyl 5-aminoisoindoline-2-carboxylate.


Example 609B
N-(3-(piperidin-4-yloxy)propyl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(3-(isoindoline-2-carboxamido)propoxy)piperidine-1-carboxylate for tert-butyl 44(4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 609C
N-{3-[(1-benzoylpiperidin-4-yl)oxy]propyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting benzoyl chloride for acetyl chloride and N-(3-(piperidin-4-yloxy)propyl)isoindoline-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.21-7.50 (m, 9H) 6.27 (t, J=5.43 Hz, 1H) 4.57 (s, 4H) 3.40-3.58 (m, 6H) 3.07-3.21 (m, 2H) 1.74-1.93 (br m, 2H) 1.62-1.75 (m, 2H) 1.44 (br m, 2H); MS (ESI(+)) m/e 408 (M+H)+.


Example 610
N-(3-{[1-(pyridin-3-ylcarbonyl)piperidin-4-yl]oxy}propyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting nicotinoyl chloride for acetyl chloride and N-(3-(piperidin-4-yloxy)propyl)isoindoline-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.51-8.70 (m, 2H) 7.75-7.88 (m, 1H) 7.46 (dd, J=7.73, 4.96 Hz, 1H) 7.20-7.38 (m, 3H) 6.28 (t, J=5.35 Hz, 1H) 4.57 (s, 4H) 3.83-4.01 (m, 1H) 3.40-3.63 (m, 6H) 3.16 (q, J=6.35 Hz, 2H) 1.35-1.95 (m, 7H); MS (ESI(+)) m/e 409 (M+H)+.









TABLE 11







The following Examples were essentially prepared as described in Example 1C, substituting N-


(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridin-3-yl)isoindoline-2-carboxamide for 3-phenylpropan-


1-amine and the corresponding carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid.










Ex
Name

1H NMR

MS













614
N-[1′-(tetrahydrofuran-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



3-ylcarbonyl)-
8.70 (d, J = 2.6 Hz, 1H), 8.35 (s, 1H), 7.95 (dd, J =
m/e 419



1′,2′,3′,6′-tetrahydro-
8.7, 2.6 Hz, 1H), 7.44 (d, J = 8.7 Hz, 1H), 7.40-
(M + H)+



2,4′-bipyridin-5-yl]-
7.24 (m, 4H), 6.54 (m, 1H), 4.79 (s, 4H), 4.19 (s,



1,3-dihydro-2H-
2H), 3.91 (t, J = 8.1 Hz, 1H), 3.72 (m, 5H), 3.40 (m,



isoindole-2-
1H), 2.60 (s, 2H), 2.05 (m, 2H)



carboxamide


615
N-{1′-[(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



methoxyethoxy)acetyl]-
8.69 (d, J = 2.6 Hz, 1H), 8.35 (s, 1H), 7.95 (dd, J =
m/e 437



1′,2′,3′,6′-tetrahydro-
8.6, 2.6 Hz, 1H), 7.44 (d, J = 8.6 Hz, 1H), 7.38-
(M + H)+



2,4′-bipyridin-5-yl}-
7.27 (m, 4H), 6.54 (m, 1H), 4.79 (s, 4H), 4.19 (s,



1,3-dihydro-2H-
2H), 4.15 (m, 2H), 3.65 (t, J = 5.7 Hz, 2H), 3.60 (m,



isoindole-2-
2H), 3.48 (m, 2H), 3.27 (s, 3H), 2.61 (m, 2H)



carboxamide


711
N-[1′-(tetrahydrofuran-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



2-ylcarbonyl)-
8.69 (d, J = 2.6 Hz, 1H), 8.34 (s, 1H), 7.95 (dd, J =
m/e 419



1′,2′,3′,6′-tetrahydro-
8.7, 2.6 Hz, 1H), 7.43 (d, J = 8.9 Hz, 1H), 7.39-
(M + H)+



2,4′-bipyridin-5-yl]-
7.23 (m, 4H), 6.54 (m, 1H), 4.79 (bs, 4H), 4.68 (dd,



1,3-dihydro-2H-
J = 7.4, 5.8 Hz, 1H), 4.19 (bs, 2H), 3.88-3.62 (m,



isoindole-2-
4H), 2.63 (m, 2H), 2.11 (m, 1H), 2.01 (m, 1H), 1.86



carboxamide
(m, 2H)


712
N-[1′-(tetrahydro-2H-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



pyran-4-ylcarbonyl)-
8.69 (dd, J = 2.6, 0.7 Hz, 1H), 8.34 (s, 1H), 7.95 (dd,
m/e 433



1′,2′,3′,6′-tetrahydro-
J = 8.6, 2.6 Hz, 1H), 7.43 (d, J = 8.9 Hz, 1H), 7.38-
(M + H)+



2,4′-bipyridin-5-yl]-
7.26 (m, 4H), 6.55 (m, 1H), 4.79 (s, 4H), 4.19 (m,



1,3-dihydro-2H-
2H), 3.86 (m, 2H), 3.70 (t, J = 5.7 Hz, 2H), 3.42 (td,



isoindole-2-
J = 11.4, 2.5 Hz, 2H), 2.92 (m, 1H), 2.60 (m, 2H),



carboxamide
1.73-1.60 (m, 2H), 1.56 (m, 2H)


713
N-[1′-(1,4-dioxan-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



ylcarbonyl)-1′,2′,3′,6′-
8.70 (d, J = 2.6 Hz, 1H), 8.35 (s, 1H), 7.96 (dd, J =
m/e 435



tetrahydro-2,4′-
8.6, 2.6 Hz, 1H), 7.43 (d, J = 8.6 Hz, 1H), 7.38-
(M + H)+



bipyridin-5-yl]-1,3-
7.26 (m, 4H), 6.54 (m, 1H), 4.79 (s, 4H), 4.37 (dd,



dihydro-2H-isoindole-
J = 9.1, 3.0 Hz, 1H), 4.20 (m, 2H), 3.83-3.61 (m,



2-carboxamide
7H), 3.52 (m, 1H), 2.61 (m, 2H)


714
N-{1′-[(1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



methylpyrrolidin-3-
8.69 (dd, J = 2.6, 0.7 Hz, 1H), 8.34 (s, 1H), 7.95 (dd,
m/e 432



yl)carbonyl]-1′,2′,3′,6′-
J = 8.6, 2.6 Hz, 1H), 7.43 (d, J = 8.6 Hz, 1H), 7.38-
(M + H)+



tetrahydro-2,4′-
7.26 (m, 4H), 6.54 (m, 1H), 4.79 (s, 4H), 4.16 (m,



bipyridin-5-yl}-1,3-
2H), 3.68 (t, J = 5.7 Hz, 2H), 3.28 (m, 1H), 2.78 (t,



dihydro-2H-isoindole-
J = 8.6 Hz, 1H), 2.58 (m, 2H), 2.52 (m, 2H), 2.38 (q,



2-carboxamide
J = 7.7 Hz, 1H), 2.24 (s, 3H), 2.98 (m, 2H)


715
N-{1′-[(1,1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



dioxidotetrahydrothio-
8.70 (d, J = 2.6 Hz, 1H), 8.35 (s, 1H), 7.96 (dd, J =
m/e 467



phen-3-yl)carbonyl]-
8.6, 2.6 Hz, 1H), 7.45 (d, J = 8.6 Hz, 1H), 7.38-
(M + H)+



1′,2′,3′,6′-tetrahydro-
7.27 (m, 4H), 6.55 (m, 1H), 4.79 (s, 4H), 4.21 (m,



2,4′-bipyridin-5-yl}-
2H), 3.79-3.65 (m, 3H), 3.36-3.13 (m, 3H), 3.08



1,3-dihydro-2H-
(m, 1H), 2.63 (m, 2H), 2.37 (m, 1H), 2.14 (m, 1H)



isoindole-2-



carboxamide


758
N-[1′-(2-hydroxy-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



methylpropanoyl)-
8.69 (d, J = 2.6 Hz, 1H), 8.34 (bs, 1H), 7.95 (dd, J =
m/e 407



1′,2′,3′,6′-tetrahydro-
8.6, 2.6 Hz, 1H), 7.43(d, J = 8.6 Hz, 1H), 7.38-
(M + H)+



2,4′-bipyridin-5-yl]-
7.26 (m, 4H), 6.55 (m, 1H), 5.09 (s, 1H), 4.79 (s,



1,3-dihydro-2H-
4H), 4.32 (m, 2H), 3.93 (t, J = 5.7 Hz, 2H), 2.60 (m,



isoindole-2-
2H), 1.37(s, 6H)



carboxamide


800
N-[1′-(morpholin-4-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



ylacetyl)-1′,2′,3′,6′-
8.70 (d, J = 2.6 Hz, 1H), 8.34 (s, 1H), 7.95 (dd, J =
m/e 448



tetrahydro-2,4′-
8.6, 2.6 Hz, 1H), 7.44 (d, J = 8.6 Hz, 1H), 7.38-
(M + H)+



bipyridin-5-yl]-1,3-
7.27 (m, 4H), 6.54 (m, 1H), 4.79 (s, 4H), 4.20 (m,



dihydro-2H-isoindole-
2H), 3.71 (t, J = 5.2 Hz, 2H), 3.58 (m, 4H), 3.21 (s,



2-carboxamide
2H), 2.48 (m, 2H), 2.45 (m, 4H)


1466
N-(4-{1-[(3R)-
- 1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ
(ESI(+))



tetrahydrofuran-3-
ppm 8.13 (s, 1H), 7.54 (m, 2H), 7.31 (m, 6H), 6.07
m/e 418



ylcarbonyl]-1,2,3,6-
(m, 1H), 4.77 (s, 4H), 4.14 (m, 2H), 3.91 (t, J = 8.1
(M + H)+



tetrahydropyridin-4-
Hz, 1H), 3.77-3.67 (m, 5H), 3.38 (m, 1H), 2.50 (m,



yl}phenyl)-1,3-
2H), 2.02 (m, 2H)



dihydro-2H-isoindole-



2-carboxamide


1467
N-(4-{1-[(3S)-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



tetrahydrofuran-3-
8.12 (s, 1H), 7.54 (m, 2H), 7.31 (m, 6H), 6.07 (m,
m/e 418



ylcarbonyl]-1,2,3,6-
1H), 4.77 (s, 4H), 4.14 (m, 2H), 3.91 (t, J = 8.1 Hz,
(M + H)+



tetrahydropyridin-4-
1H), 3.77-3.67 (m, 5H), 3.38 (m, 1H), 2.50 (m,



yl}phenyl)-1,3-
2H), 2.05 (m, 2H)



dihydro-2H-isoindole-



2-carboxamide


1468
N-(4-{1-[(1,1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm

(ESI(+))



dioxidotetrahydro-2H-
8.13 (s, 1H), 7.54 (m, 2H), 7.31 (m, 6H), 6.07 (m,
m/e 480



thiopyran-4-
1H), 4.77 (s, 4H), 4.15 (m, 2H), 3.71 (t, J = 5.7 Hz,
(M + H)+



yl)carbonyl]-1,2,3,6-
2H), 3.25-3.02 (m, 5H), 2.50 (m, 2H), 2.07 (m, 4H)



tetrahydropyridin-4-



yl}phenyl)-1,3-



dihydro-2H-isoindole-



2-carboxamide









Example 611
N-(6-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide
Example 611A
methyl 6-aminopyridazine-3-carboxylate

To a solution of 6-chloropyridazin-3-amine (32 g, 248 mmol), Et3N (75 mL, 744 mmol) in MeOH (500 mL), Pd(dppf)Cl2 (12 g, 16.4 mmol) was added and the mixture was heated at 60° C. overnight under CO atmosphere at 50 psi. After cooling to room temperature, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was washed with MeOH and the precipitate was dried by high vacuum to give the title compound as a solid.


Example 611B
methyl 6-isocyanatopyridazine-3-carboxylate

To the solution of methyl 6-aminopyridazine-3-carboxylate (14 g, 91.5 mmol) in anhydrous toluene (700 mL) was added Et3N (11.1, 109.8 mmol). A solution of triphosgene (27.2 g, 91.5 mmol) in anhydrous toluene was added slowly at 0° C. The reaction mixture was stirred for 2 hrs at room temperature and then heated at 90° C. for 5 hrs. After cooling to room temperature, toluene and water were added to the mixture, the mixture was separated and the organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure to give the title compound as a solid.


Example 611C
methyl 6-(isoindoline-2-carboxamido)pyridazine-3-carboxylate

To a solution of methyl 6-isocyanatopyridazine-3-carboxylate (5.26 g, 29.4 mmol) in THF (100 mL), a solution of isoindoline (5.24 g, 4.41 mmol) in THF (50 mL) was added at 0° C. The reaction mixture was stirred overnight at room temperature. The reaction mixture was filtered and the precipitate was washed with cold EtOAc and dried in high vacuum to give the title compound as a solid.


Example 611D
6-(isoindoline-2-carboxamido)pyridazine-3-carboxylic acid

To a solution of methyl 6-(isoindoline-2-carboxamido)pyridazine-3-carboxylate (3.7 g, 12.4 mmol) in MeOH (40 mL) and THF (40 mL), a solution of LiOH (0.7 g, 29.2 mmol) in water (10 mL) was added at room temperature. The reaction mixture was stirred overnight at room temperature. The reaction mixture was poured into water (100 mL), extracted with EtOAc (2×50 mL) and the aqueous layer was acidified by addition of 2 N HCl to pH 3 to give a precipitate. The precipitate was washed with water and dried in high vacuum to give the title compound.


Example 611E
N-(6-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting (S)-(tetrahydrofuran-3-yl)methamine for 3-phenylpropan-1-amine and 6-(isoindoline-2-carboxamido)pyridazine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 9.94 (s, 1H), 9.12 (t, J=6.1 Hz, 1H), 8.31 (d, J=9.3 Hz, 1H), 8.11 (d, J=9.3 Hz, 1H), 7.41-7.28 (m, 4H), 4.89 (s, 4H), 3.80-3.55 (m, 3H), 3.50 (dd, J=8.5, 5.2 Hz, 1H), 3.37-3.31 (m, 2H), 2.63-2.51 (m, 1H), 2.01-1.85 (m, 1H), 1.71-1.55 (m, 1H); MS (ESI(+)) m/e 368 (M+H)+.


Example 612
N-{6-[(cyclopentylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting cyclopentylmethamine for 3-phenylpropan-1-amine and 6-(isoindoline-2-carboxamido)pyridazine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 9.97 (s, 1H), 9.00 (t, J=6.1 Hz, 1H), 8.31 (d, J=9.3 Hz, 1H), 8.11 (d, J=9.3 Hz, 1H), 7.41-7.28 (m, 4H), 5.13-4.72 (m, 4H), 3.31-3.16 (m, 2H), 2.22 (p, J=7.3 Hz, 1H), 1.70-1.45 (m, 6H), 1.38-1.20 (m, 2H); MS (ESI(+)) m/e 366 (M+H)+.


Example 616
5-(hydroxymethyl)-N-(4-phenylbutyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1A, substituting (4-isocyanatobutyl)benzene for methyl 4-isocyanatobenzoate and isoindolin-5-ylmethanol hydrochloride for isoindoline. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.32-7.12 (m, 8H), 6.32-6.24 (m, 1H), 5.16 (t, J=5.6 Hz, 1H), 4.54 (bs, 4H), 4.49 (d, J=5.7 Hz, 2H), 3.14-3.05 (m, 2H), 2.64-2.54 (m, 2H), 1.63-1.39 (m, 4H); MS (ESI(+)) m/e 325 (M+H)+.


Example 617
5-(hydroxymethyl)-N-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 1-isopentyl-1H-pyrazol-4-amine dihydrochloride for 4-amino-N-propylbenzamide and isoindolin-5-ylmethanol hydrochloride for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.39 (s, 1H), 7.73 (s, 1H), 7.39 (s, 1H), 7.34-7.18 (m, 3H), 5.19 (t, J=5.6 Hz, 1H), 4.67 (bs, 4H), 4.51 (d, J=5.5 Hz, 2H), 4.04 (t, J=7.1 Hz, 2H), 1.71-1.55 (m, 2H), 1.55-1.33 (m, 1H), 0.89 (d, J=6.5 Hz, 6H); MS (ESI(+)) m/e 329 (M+H)+.


Example 618
N-{5-[(3-methylbutyl)carbamoyl]pyrazin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 618A
ethyl 5-(isoindoline-2-carboxamido)pyrazine-2-carboxylate

The title compound was prepared as described in Example 344A, substituting ethyl 5-aminopyrazine-2-carboxylate for tert-butyl 5-aminoisoindoline-2-carboxylate.


Example 618B
5-(isoindoline-2-carboxamido)pyrazine-2-carboxylic acid

The title compound was prepared as described in Example 1B, substituting ethyl 5-(isoindoline-2-carboxamido)pyrazine-2-carboxylate for methyl 4-(isoindoline-2-carboxamido)benzoate.


Example 618C
N-{5-[(3-methylbutyl)carbamoyl]pyrazin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 3-methylbutan-1-amine for 3-phenylpropan-1-amine and 5-(isoindoline-2-carboxamido)pyrazine-2-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6, Temp=90° C.) δ ppm 9.34 (bs, 1H), 9.17 (d, J=1.4 Hz, 1H), 8.82 (d, J=1.4 Hz, 1H), 8.30-8.23 (m, 1H), 7.36-7.26 (m, 4H), 4.86 (bs, 4H), 3.37-3.30 (m, 2H), 1.69-1.58 (m, 1H), 1.50-1.44 (m, 2H), 0.92 (d, J=6.5 Hz, 6H); MS (ESI(+)) m/e 354 (M+H)+.


Example 621
N-(4-{(1E)-3-[benzyl(methyl)amino]prop-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
Example 621A
(E)-N-benzyl-N-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-2-en-1-amine

In a 4 mL vial were mixed (E)-2-(3-chloroprop-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.195 ml, 0.988 mmol) and potassium carbonate (273 mg, 1.975 mmol) in anhydrous acetonitrile (2 ml). Benzylmethylamine (0.166 ml, 1.284 mmol) was added to this mixture, and the reaction was stirred vigorously overnight at room temperature. The reaction was diluted with ethyl acetate and washed with water and brine. The organic layer was dried with sodium sulfate, decanted, and concentrated to provide the title compound.


Example 621B
N-(4-{(1E)-3-[benzyl(methyl)amino]prop-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting (E)-N-benzyl-N-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-2-en-1-amine for 1H-pyrazol-3-ylboronic acid and N-(4-bromophenyl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, DMSO-d6, Temp=90° C.) δ ppm 8.12 (s, 1H), 7.52 (m, 2H), 7.37-7.18 (m, 11H), 6.48 (d, J=15.8 Hz, 1H), 6.18 (dt, J=15.8, 6.5 Hz, 1H), 4.77 (s, 4H), 3.53 (s, 2H), 3.15 (dd, J=6.5, 1.4 Hz, 2H), 2.18 (s, 3H); MS (ESI(+)) m/e 398 (M+H)+.


Example 622
N-[4-(4-phenoxypiperidin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
Example 622A
1-(4-nitrophenyl)-4-phenoxypiperidine

A solution of 1-fluoro-4-nitrobenzene (0.15 g, 1.063 mmol) and 4-phenoxypiperidine hydrochloride (0.250 g, 1.169 mmol) in dimethylformamide (2.126 ml) was treated with potassium carbonate (0.367 g, 2.66 mmol). The suspension was stirred at ambient temperature 2 hours, at 55° C. for 4 hours and at ambient temperature for 16 hours. The reaction was poured into water and the suspension was filtered and vacuum dried to provide the title compound.


Example 622B
4-(4-phenoxypiperidin-1-yl)aniline

The title compound was prepared as described in Example 272A, substituting 1-(4-nitrophenyl)-4-phenoxypiperidine for 4-nitro-N-propylbenzamide.


Example 622C
N-[4-(4-phenoxypiperidin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 4-(4-phenoxypiperidin-1-yl)aniline for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.11 (s, 1H), 7.42-7.24 (m, 8H), 7.02-6.86 (m, 5H), 4.74 (bs, 4H), 4.59-4.47 (m, 1H), 3.49-3.39 (m, 2H), 3.03-2.91 (m, 2H), 2.11-1.98 (m, 2H), 1.81-1.66 (m, 2H); MS (ESI(+)) m/e 414 (M+H)+.


Example 623
N-[4-(3-phenoxyazetidin-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 622, substituting 3-phenoxyazetidine for 4-phenoxypiperidine hydrochloride in Example 622A. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.06 (s, 1H), 7.44-7.25 (m, 8H), 7.03-6.93 (m, 1H), 6.92-6.85 (m, 2H), 6.47-6.40 (m, 2H), 5.19-5.08 (m, 1H), 4.73 (bs, 4H), 4.32-4.23 (m, 2H), 3.69 (dd, J=8.2, 4.2 Hz, 2H); MS (ESI(+)) m/e 386 (M+H)+.


Example 624
N-(4-{[benzyl(methyl)amino]methyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

A suspension of isoindoline (0.1 g, 0.839 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.219 ml, 1.259 mmol) in acetonitrile (2.80 ml) was treated with N-methylpyrrolidine (2.80 ml). The solution was cooled to 0° C. and 1-(chloromethyl)-4-isocyanatobenzene (0.155 g, 0.923 mmol) was added. After stirring for 2 hours at 0° C., the reaction was treated with a solution of N-methyl-1-phenylmethanamine (0.102 g, 0.839 mmol) in 0.5 mL acetonitrile. The reaction was stirred at 0° C. for 5 minutes and at ambient temperature for 30 minutes. The reaction was treated with water and the mixture was stirred for 4 hours. The suspension was filtered and the solid collected was washed with water and dried under vacuum to provide the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.31 (s, 1H), 7.56-7.49 (m, 2H), 7.40-7.28 (m, 8H), 7.27-7.19 (m, 3H), 4.76 (bs, 4H), 3.47 (s, 2H), 3.43 (s, 2H), 2.06 (s, 3H); MS (ESI(+)) m/e 372 (M+H)+.


Example 625
5-fluoro-N-(4-{[(3R)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 410, substituting 5-fluoro-N-(4-{[tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide for N-(4-{[tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.39 (t, J=5.7 Hz, 1H), 7.81-7.73 (m, 2H), 7.69-7.62 (m, 2H), 7.40 (dd, J=8.4, 5.2 Hz, 1H), 7.24 (dd, J=9.1, 2.5 Hz, 1H), 7.15 (td, J=8.9, 2.5 Hz, 1H), 4.80-4.72 (m, 4H), 3.80-3.68 (m, 1H), 3.68-3.56 (m, 2H), 3.47 (dd, J=8.5, 5.2 Hz, 2H), 3.21 (dt, J=13.3, 5.9 Hz, 2H), 2.01-1.86 (m, 1H), 1.67-1.53 (m, 1H); MS (ESI(+)) m/e 384 (M+H)+.


Example 626
5-fluoro-N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 411, substituting 5-fluoro-N-(4-{[tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide for N-(4-{[tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.39 (t, J=5.7 Hz, 1H), 7.80-7.73 (m, 2H), 7.69-7.62 (m, 2H), 7.40 (dd, J=8.4, 5.2 Hz, 1H), 7.24 (dd, J=9.1, 2.5 Hz, 1H), 7.15 (td, J=8.9, 2.5 Hz, 1H), 4.80-4.73 (m, 4H), 3.80-3.56 (m, 3H), 3.47 (dd, J=8.5, 5.2 Hz, 1H), 3.24-3.13 (m, 2H), 2.01-1.86 (m, 1H), 1.67-1.53 (m, 1H); MS (ESI(+)) m/e 384 (M+H)+.


Example 636
N-[4-(1-benzyl-1H-1,2,3-triazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
Example 636A
N-(4-ethynylphenyl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 1A, substituting 1-ethynyl-4-isocyanatobenzene for methyl 4-isocyanatobenzoate.


Example 636B
N-[4-(1-benzyl-1H-1,2,3-triazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

A mixture of N-(4-ethynylphenyl)isoindoline-2-carboxamide (100 mg, 0.381 mmol), benzylamine (33.2 mg, 0.381 mmol), and sodium ascorbate (15 mg, 0.076 mmol) in methanol (1.9 ml) was treated with 1H-imidazole-1-sulfonyl azide hydrochloride (66.0 mg, 0.381 mmol), copper(II) sulfate pentahydrate (9.52 mg, 0.038 mmol) and triethylamine (63.8 μl, 0.457 mmol). Additional methanol (2 mL) was added and the vial was flushed with nitrogen and stirred for 2 days. The mixture was diluted with water and the resulting suspension was filtered with water washes to provide the title compound as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 8.51 (s, 1H), 8.45 (s, 1H), 7.73 (d, J=8.7 Hz, 2H), 7.65 (d, J=8.9 Hz, 2H), 7.49-7.24 (m, 9H), 5.63 (s, 2H), 4.78 (s, 4H), 1.11-1.00 (m, 1H); MS (ESI(+)) m/e 396 (M+H)+.









TABLE 12







The following Examples were essentially prepared as described in


Example 636B, substituting the appropriate amine for benzylamine.










Ex
Name

1H NMR

MS













637
N-{4-[1-(3-methylbutyl)-

1H NMR (300 MHz, DMSO-d6) δ 8.47 (s, 1H), 8.44

(ESI(+))



1H-1,2,3-triazol-4-
(s, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.65 (d, J = 8.8
m/e 376



yl]phenyl}-1,3-dihydro-
Hz, 2H), 7.41-7.27 (m, 6H), 4.79 (s, 5H), 4.40 (t,
(M + H)+



2H-isoindole-2-
J = 7.3 Hz, 2H), 1.77 (dd, J = 14.5, 7.0 Hz, 2H),



carboxamide
1.52(dt, J = 13.4, 6.7 Hz, 1H), 0.93 (d, J = 6.6 Hz,




7H)


638
N-{4-[1-

1H NMR (300 MHz, DMSO-d6) δ 8.50 (s, 1H), 8.45

(ESI(+))



(tetrahydrofuran-3-
(s, 1H), 7.73 (d, J = 8.9 Hz, 2H), 7.66 (d, J = 8.8
m/e 390



ylmethyl)-1H-1,2,3-
Hz, 2H), 7.34 (ddd, J = 8.9, 4.2, 2.5 Hz, 4H), 4.79
(M + H)+



triazol-4-yl]phenyl}-1,3-
(s, 4H), 4.39 (d, J = 7.5 Hz, 2H), 3.84-3.59 (m,



dihydro-2H-isoindole-2-
3H), 3.51 (dd, J = 8.8, 5.4 Hz, 1H), 2.88-2.69 (m,



carboxamide
1H), 2.04-1.86 (m, 1H), 1.73-1.55 (m, 1H)


639
N-(4-{1-[2-(2-

1H NMR (400 MHz, DMSO-d6) δ 8.46 (s, 2H), 7.72

(ESI(+))



oxopyrrolidin-1-
(d, J = 8.8 Hz, 2H), 7.66 (d, J = 8.9 Hz, 2H), 7.37
m/e 417



yl)ethyl]-1H-1,2,3-
(d, J = 5.5 Hz, 2H), 7.32 (dd, J = 5.6, 3.1 Hz, 2H),
(M + H)+



triazol-4-yl}phenyl)-1,3-
4.79 (s, 4H), 4.53 (t, J = 5.9 Hz, 2H), 3.66 (t, J =



dihydro-2H-isoindole-2-
5.9 Hz, 2H), 3.23 (t, J = 7.0 Hz, 2H), 2.15 (t, J =



carboxamide
8.0 Hz, 2H), 1.94-1.76 (m, 2H)


640
N-{4-[1-(1-

1H NMR (300 MHz, DMSO-d6) δ 8.57 (s, 1H), 8.43

(ESI(+))



benzylpiperidin-4-yl)-
(s, 1H), 7.73 (d, J = 8.7 Hz, 1H), 7.65 (d, J = 8.8
m/e 479



1H-1,2,3-triazol-4-
Hz, 1H), 7.41-7.24 (m, 9H), 4.79 (s, 3H), 4.53 (td,
(M + H)+



yl]phenyl}-1,3-dihydro-
J = 10.6, 5.1 Hz, 1H), 3.54 (s, 2H), 2.98-2.88 (m,



2H-isoindole-2-
2H), 2.33-1.93 (m, 6H)



carboxamide


641
N-{4-[1-(3-

1H NMR (300 MHz, DMSO-d6) δ 8.50 (s, 1H), 8.45

(ESI(+))



phenylpropyl)-1H-1,2,3-
(s, 1H), 7.74 (d, J = 8.7 Hz, 1H), 7.66 (d, J = 8.8
m/e 424



triazol-4-yl]phenyl}-1,3-
Hz, 1H), 7.50-7.26 (m, 6H), 7.27-7.16 (m, 3H),
(M + H)+



dihydro-2H-isoindole-2-
4.79 (s, 2H), 4.40 (t, J = 7.0 Hz, 2H), 2.62 (t, J =



carboxamide
7.7 Hz, 2H), 2.29-2.07 (m, 1H)


642
N-(4-{1-[4-(morpholin-

1H NMR (300 MHz, DMSO-d6) δ 8.44 (s, 2H), 7.72

(ESI(+))



4-yl)benzyl]-1H-1,2,3-
(d, J = 8.7 Hz, 2H), 7.64 (d, J = 8.8 Hz, 2H), 7.42-
m/e 481



triazol-4-yl}phenyl)-1,3-
7.19 (m, 6H), 6.94 (d, J = 8.7 Hz, 2H), 5.49 (s, 2H),
(M + H)+



dihydro-2H-isoindole-2-
4.78 (s, 4H), 3.79-3.65 (m, 4H), 3.23-2.97 (m,



carboxamide
4H)


643
N-[4-(1-isobutyl-1H-

1H NMR (300 MHz, DMSO-d6) δ 8.44 (s, 2H), 7.74

(ESI(+))



1,2,3-triazol-4-
(d, J = 8.7 Hz, 2H), 7.66 (d, J = 8.8 Hz, 2H), 7.41-
m/e 362



yl)phenyl]-1,3-dihydro-
7.27 (m, 5H), 4.79 (s, 4H), 4.21 (d, J = 7.2 Hz, 2H),
(M + H)+



2H-isoindole-2-
2.29-2.06 (m, 1H), 0.90 (d, J = 6.7 Hz, 3H)



carboxamide


644
N-{4-[1-

1H NMR (300 MHz, DMSO-d6) δ 8.46 (s, 1H), 8.44

(ESI(+))



(cyclopentylmethyl)-1H-
(s, 1H), 7.73 (d, J = 8.7 Hz, 1H), 7.66 (d, J = 8.8
m/e 388



1,2,3-triazol-4-
Hz, 1H), 7.41-7.28 (m, 4H), 4.79 (s, 2H), 4.31 (d,
(M + H)+



yl]phenyl}-1,3-dihydro-
J = 7.5 Hz, 1H), 3.31 (s, 2H), 2.40 (dt, J = 15.1, 7.4



2H-isoindole-2-
Hz, 1H), 1.73-1.47 (m, 6H), 1.36-1.21 (m, 2H)



carboxamide


645
N-{4-[1-(3-

1H NMR (300 MHz, DMSO-d6) δ 8.46 (s, 1H), 8.45

(ESI(+))



methoxypropyl)-1H-
(s, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.66 (d, J = 8.8
m/e 378



1,2,3-triazol-4-
Hz, 2H), 7.42-7.26 (m, 4H), 4.79 (s, 4H), 4.43 (t,
(M + H)+



yl]phenyl}-1,3-dihydro-
J = 7.1 Hz, 2H), 3.38-3.32 (m, 1H), 3.25 (s, 3H),



2H-isoindole-2-
2.10 (p, J = 6.4 Hz, 2H)



carboxamide









Example 646
N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide (50 mg, 0.128 mmol) and methanol (10 ml) were added to 5% Pd—C, wet (10.00 mg, 0.094 mmol) in a 50 ml pressure bottle and stirred for 16 hours at 30 psi and room temperature. The mixture was filtered through a nylon membrane and concentrated. Chromatography provided the title compound. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.60 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.35 (s, 1H), 7.49-7.40 (m, 3H), 7.13 (m, 2H), 4.79 (m, 4H), 4.56 (m, 1H), 4.05 (m, 1H), 3.12 (m, 1H), 2.90 (m, 1H), 2.71 (m, 1H), 2.57 (m, 1H), 1.79 (m, 2H), 1.55-1.30 (m, 2H), 1.02 (m, 6H); MS (ESI(+)) m/e 393 (M+H)+.


Example 647
N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 646, substituting N-(4-{1-[(2-methoxyethoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide for N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.27 (s, 1H), 7.47 (m, 2H), 7.39-7.28 (m, 4H), 7.12 (m, 2H), 4.75 (bs, 4H), 4.47 (m, 1H), 4.24-4.09 (m, 2H), 3.90 (m, 1H), 3.57 (m, 2H), 3.47 (t, J=4.7 Hz, 2H), 3.26 (s, 3H), 3.06 (m, 1H), 2.70 (m, 1H), 2.62 (m, 1H), 1.77 (m, 2H), 1.57 (m, 1H), 1.42 (m, 1H); MS (ESI(+)) m/e 438 (M+H)+.


Example 648
N-{5-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]pyridin-2-yl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 646, substituting N-[1′-(tetrahydrofuran-3-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-3,4′-bipyridin-6-yl]-1,3-dihydro-2H-isoindole-2-carboxamide for N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.81 (s, 1H), 8.16 (d, J=2.4 Hz, 1H), 7.85 (d, J=8.6 Hz, 1H), 7.63 (dd, J=8.7, 2.4 Hz, 1H), 7.39-7.25 (m, 4H), 4.80 (s, 4H), 4.56 (d, J=13.1 Hz, 1H), 4.08 (d, J=12.3 Hz, 1H), 3.88 (m, 1H), 3.72 (m, 3H), 3.38 (m, 1H), 3.11 (m, 1H), 2.78 (dd, J=11.9, 9.2 Hz, 1H), 2.63 (m, 1H), 2.03 (m, 2H), 1.80 (t, J=15.4 Hz, 2H), 1.51 (m, 2H); MS (ESI(+)) m/e 421 (M+H)+.


Example 651
N-(1′-isobutyryl-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
Example 651A
N-(6-chloropyridin-3-yl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide

The title compound was prepared as described in Example 1A, substituting 2-chloro-5-isocyanatopyridine for methyl 4-isocyanatobenzoate and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine for isoindoline.


Example 651B
tert-butyl 4-(5-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)pyridin-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate

The title compound was prepared as described in Example 280, substituting tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate for 1H-pyrazol-3-ylboronic acid and N-(6-chloropyridin-3-yl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide.


Example 651C
N-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(5-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)pyridin-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate for tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 651D
N-(1′-isobutyryl-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridin-3-yl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and isobutanoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (501 MHz, DMSO-d6, Temp=90° C.) δ ppm 8.73 (d, J=2.6 Hz, 1H), 8.64 (s, 1H), 8.52 (m, 2H), 7.99 (dd, J=8.6, 2.6 Hz, 1H), 7.49 (d, J=8.7 Hz, 1H), 7.44 (d, J=5.0 Hz, 1H), 6.60 (m, 1H), 4.88 (bs, 2H), 4.85 (d, J=2.3 Hz, 2H), 4.22 (m, 2H), 3.73 (t, J=5.7 Hz, 2H), 2.96 (m, 1H), 2.63 (m, 2H), 1.08 (d, J=6.7 Hz, 6H); MS (ESI(+)) m/e 392 (M+H)+.









TABLE 13







The following Examples were essentially prepared as described in Example 1C,


substituting N-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridin-3-yl)-1H-pyrrolo


[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and the corresponding


carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid.










Ex
Name

1H NMR

MS













652
N-(1′-benzoyl-1′,2′,3′,6′-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+)) m/e



tetrahydro-2,4′-bipyridin-
ppm 8.70 (d, J = 2.6 Hz, 1H), 8.60 (s, 1H),
426 (M + H)+



5-yl)-1,3-dihydro-2H-
8.49 (d, J = 5.0 Hz, 1H), 8.44 (s, 1H), 7.96



pyrrolo[3,4-c]pyridine-2-
(dd, J = 8.6, 2.6 Hz, 1H), 7.49-7.37 (m, 7H),



carboxamide
6.56 (bs, 1H), 4.83 (m, 4H), 4.22 (m, 2H), 3.64




(m, 2H), 2.64 (m, 2H)


653
N-[1′-(tetrahydrofuran-3-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+)) m/e



ylcarbonyl)-1′,2′,3′,6′-
ppm 8.70 (s, 1H), 8.60 (bs, 1H), 8.49 (dd, J =
420 (M + H)+



tetrahydro-2,4′-bipyridin-
8.6, 2.7 Hz , 1H), 8.43 (s, 1H), 7.95 (d, J = 2.7



5-yl]-1,3-dihydro-2H-
Hz, 1H), 7.45 (d, J = 8.6, 1H), 7.40 (d, J = 2.7



pyrrolo[3,4-c]pyridine-2-
Hz, 1H) 6.56 (bs, 1H), 4.78 (m, 4H), 4.20 (m,



carboxamide
2H), 3.92 (m, 1H), 3.72 (m, 4H), 3.40 (m, 1H),




2.60 (m, 2H), 2.05 (m, 3H)


654
N-{1′-[(2-

1H NMR (501 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+)) m/e



methoxyethoxy)acetyl]-
ppm 8.69 (d, J = 2.6 Hz, 1H), 8.59 (s, 1H),
438 (M + H)+



1′,2′,3′,6′-tetrahydro-2,4′-
8.49 (d, J = 5.0 Hz, 1H), 8.47 (m, 1H), 7.95



bipyridin-5-yl}-1,3-
(dd, J = 8.6, 2.6 Hz, 1H), 7.45 (d, J = 8.7 Hz,



dihydro-2H-pyrrolo[3,4-
1H), 7.40 (d, J = 5.1 Hz, 1H), 6.55 (bs, 1H),



c]pyridine-2-
4.84 (bs, 2H), 4.81 (bs, 2H), 4.19 (s, 2H), 4.14



carboxamide
(m, 2H), 3.65 (m, 2H), 3.60 (m, 2H), 3.48 (m,




2H), 3.26 (s, 3H), 2.60 (m, 2H)


700
N-[1′-(tetrahydrofuran-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+)) m/e



ylcarbonyl)-1′,2′,3′,6′-
ppm 8.69 (dd, J = 8.7, 2.6 Hz, in), 8.59 (s,
420 (M + H)+



tetrahydro-2,4′-bipyridin-
1H), 8.48 (d, J = 8.7, 1H), 8.42 (bs, 1H), 7.94



5-yl]-1,3-dihydro-2H-
(dd, J = 8.7, 2.6 Hz, 1H), 7.44 (m, 1H), 7.39



pyrrolo[3,4-c]pyridine-2-
(d, J = 5.1, 1H) 6.55 (m, 1H), 4.82 (m, 4H),



carboxamide
4.68 (dd, J = 7.5, 5.8 Hz, 1H), 4.19 (bs, 2H),




3.88-3.62 (m, 4H), 2.60 (m, 2H), 2.10 (m,




1H), 2.01 (m, 1H), 1.87 (m, 2H)


701
N-[1′-(tetrahydro-2H-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+)) m/e



pyran-4-ylcarbonyl)-
ppm 8.69 (d, J = 2.5 Hz, 1H), 8.59 (s, 1H),
434 (M + H)+



1′,2′,3′,6′-tetrahydro-2,4′-
8.48 (d, J = 5.0 Hz, 1H), 8.42 (s, 1H), 7.94



bipyridin-5-yl]-1,3-
(dd, J = 8.7, 2.6 Hz, 1H), 7.44 (d, J = 8.6 Hz,



dihydro-2H-pyrrolo[3,4-
1H), 7.39 (d, J = 4.9 Hz, 1H), 6.55 (m, 1H),



c]pyridine-2-
4.82 (m, 4H), 4.18 (bs, 2H), 3.85 (m, 2H), 3.70



carboxamide
(t, J = 5.8 Hz, 2H), 3.42 (td, J = 11.4, 2.5 Hz,




2H), 2.92 (m, 1H), 2.60 (bs, 2H), 1.66 (m,




2H), 1.57 (m, 2H)


702
N-[1′-(1,4-dioxan-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+)) m/e



ylcarbonyl)-1′,2′,3′,6′-
ppm 8.69 (dd, J = 2.7, 0.5 Hz, 1H), 8.59 (s,
436 (M + H)+



tetrahydro-2,4′-bipyridin-
1H), 8.48 (d, J = 5.0 Hz, 1H), 8.43 (bs, 1H),



5-yl]-1,3-dihydro-2H-
7.94 (dd, J = 8.7, 2.6 Hz, 1H), 7.43 (m, 1H),



pyrrolo[3,4-c]pyridine-2-
7.39 (m, 1H), 6.54 (m, 1H), 4.82 (m, 4H), 4.37



carboxamide
(dd, J = 9.2, 2.9 Hz, 1H), 4.18 (bs, 2H), 3.82-




3.61 (m, 7H), 3.52 (m, 1H), 2.61 (s, 2H)


703
N-{1′-[(1,1-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+)) m/e



dioxidotetrahydrothiophen-
ppm 8.69 (d, J = 2.4 Hz, 1H), 8.59 (s, 1H),
468 (M + H)+



3-yl)carbonyl]-
8.48 (d, J = 5.0 Hz, 1H), 8.43 (s, 1H), 7.95



1′,2′,3′,6′-tetrahydro-2,4′-
(dd, J = 8.7, 2.6 Hz, 1H), 7.45 (d, J = 8.7 Hz,



bipyridin-5-yl}-1,3-
1H), 7.39 (d, J = 4.9 Hz, 1H), 6.55 (m, 1H),



dihydro-2H-pyrrolo[3,4-
4.82 (m, 4H), 4.21 (s, 2H), 3.85-3.65 (m,



c]pyridine-2-
3H), 3.35-3.13 (m, 3H), 3.06 (m, 1H), 2.63



carboxamide
(bs, 2H), 2.37 (m, 1H), 2.13 (m, 1H)


704
N-[1′-(2-hydroxy-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+)) m/e



methylpropanoyl)-
ppm 8.68 (s, 1H), 8.59 (s, 1H), 8.48 (d, J = 4.8
408 (M + H)+



1′,2′,3′,6′-tetrahydro-2,4′-
Hz, 1H), 8.41 (s, 1H), 7.94 (m, 1H), 7.43 (d,



bipyridin-5-yl]-1,3-
J = 8.6 Hz, 1H), 7.39 (d, J = 4.7 Hz, 1H), 6.55



dihydro-2H-pyrrolo[3,4-
(m, 1H), 5.09 (s, 1H), 4.82 (m, 4H), 4.32 (bs,



c]pyridine-2-
2H), 3.92 (bs, 2H), 2.59 (bs, 2H), 1.37 (s, 6H)



carboxamide









Example 699
N-{4-[1-(pyridin-2-ylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting picolinoyl chloride for acetyl chloride and N-[4-(piperidin-4-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.56 (d, J=4.76 Hz, 1H) 7.83-7.97 (m, 1H) 7.38-7.57 (m, 2H) 7.18-7.40 (m, 4H) 6.27 (t, J=5.55 Hz, 1H) 4.56 (s, 4H) 4.47 (d, J=13.09 Hz, 1H) 3.59 (d, J=13.88 Hz, 1H) 3.00-3.16 (m, 3H) 2.92-3.01 (m, 1H) 2.68-2.81 (m, 1H) 1.77 (d, J=12.69 Hz, 1H) 0.97-1.64 (m, 11H); MS (ESI(+)) m/e 407 (M+H)+.


Example 718
N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
Example 718A
benzyl(tetrahydrofuran-3-yl)methylcarbamate

Racemic (tetrahydrofuran-3-yl)methanamine (3.84 g, 38.0 mmol) and diisopropylethylamine (13.26 ml, 76 mmol), were dissolved in dichloromethane (100 ml) and cooled to 0° C. The mixture was treated dropwise via an addition funnel with benzyl carbonochloridate (6.19 ml, 41.8 mmol) dissolved in 30 ml dichlormethane. After the addition the cooling bath was removed and the homogeneous solution was stirred at ambient temperature overnight. The reaction mixture was partitioned between water and ethyl acetate and the separated aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated. Chromatography provided the title compound.


Example 718B
(S)-benzyl(tetrahydrofuran-3-yl)methylcarbamate

A racemic mixture of benzyl(tetrahydrofuran-3-yl)methylcarbamate was dissolved in tetrahydrofuran and separated by liquid chromatography with a Chiralpak IC 2.5 cm ID×25 cm, 20 micron column, eluting with hexane/tetrahydrofuran/isopropanol (85/10/5), to provide (R)-benzyl(tetrahydrofuran-3-yl)methylcarbamate and (S)-benzyl(tetrahydrofuran-3-yl)methylcarbamate.


Example 718C
(S)-(tetrahydrofuran-3-yl)methanamine

(R)-Benzyl(tetrahydrofuran-3-yl)methylcarbamate (8.9 g, 37.8 mmol) and ethanol (160 ml) were added to 20% wet palladium (II) hydroxide (0.890 g, 6.34 mmol) in a 250 mL stainless steel pressure bottle and stirred for 40 minutes at 30 psi and room temperature. The mixture was filtered through a nylon filter and acidified with 4N HCl in dioxane (5 eq). Concentration and drying provided the title compound.


Example 718D
N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting (S)-(tetrahydrofuran-3-yl)methanamine for 3-phenylpropan-1-amine and 4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)benzoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 8.64 (s, 2H), 8.61 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.38 (t, J=5.7 Hz, 1H), 7.81-7.74 (m, 2H), 7.69-7.62 (m, 2H), 7.44 (d, J=5.1 Hz, 1H), 4.86-4.79 (m, 4H), 3.80-3.66 (m, 2H), 3.67-3.56 (m, 1H), 3.47 (dd, J=8.5, 5.3 Hz, 1H), 3.21 (dt, J=13.2, 5.8 Hz, 1H), 2.01-1.86 (m, 1H), 1.67-1.53 (m, 1H); MS (ESI(+)) m/e 367 (M+H)+.


Example 720
N-(7-oxo-7-{[(3R)-tetrahydrofuran-3-ylmethyl]amino}heptyl)-1,3-dihydro-2H-isoindole-2-carboxamide
Example 720A
methyl 7-(isoindoline-2-carboxamido)heptanoate

The title compound was prepared as described in Example 344A, substituting methyl 7-aminoheptanoate for tert-butyl 5-aminoisoindoline-2-carboxylate.


Example 720B
7-(isoindoline-2-carboxamido)heptanoic acid

The title compound was prepared as described in Example 1B, substituting methyl 7-(isoindoline-2-carboxamido)heptanoate for methyl 4-(isoindoline-2-carboxamido)benzoate.


Example 720C
N-(7-oxo-7-{[(3R)-tetrahydrofuran-3-ylmethyl]amino}heptyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting (R)-(tetrahydrofuran-3-yl)methanamine for 3-phenylpropan-1-amine and 7-(isoindoline-2-carboxamido)heptanoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.85 (t, J=5.76 Hz, 1H) 7.20-7.37 (m, 4H) 6.26 (t, J=5.59 Hz, 1H) 4.57 (s, 4H) 3.49-3.79 (m, 3H) 3.35 (dd, J=8.48, 5.43 Hz, 1H) 2.94-3.15 (m, 4H) 2.18-2.38 (m, 1H) 2.05 (t, J=7.29 Hz, 2H) 1.79-1.98 (m, 1H) 1.35-1.60 (m, 7H) 1.17-1.35 (m, 2H); MS (ESI(+)) m/e 374 (M+H)+.


Example 721
N-{7-oxo-7-[(tetrahydro-2H-pyran-4-ylmethyl)amino]heptyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting (tetrahydro-2H-pyran-4-yl)methanamine for 3-phenylpropan-1-amine and 7-(isoindoline-2-carboxamido)heptanoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.76 (t, J=5.75 Hz, 1H) 7.20-7.40 (m, 4H) 6.26 (t, J=5.55 Hz, 1H) 4.57 (s, 4H) 3.82 (dd, J=11.10, 2.78 Hz, 2H) 3.14-3.29 (m, 2H) 3.05 (q, J=6.74 Hz, 2H) 2.92 (t, J=6.15 Hz, 2H) 2.06 (t, J=7.54 Hz, 2H) 1.33-1.65 (m, 9H) 1.19-1.34 (m, 2H) 0.98-1.22 (m, 2H); MS (ESI(+)) m/e 388 (M+H)+.


Example 722
N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
Example 722A
tert-butyl 4-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)butyl)piperidine-1-carboxylate

The title compound was prepared as described in Example 344, substituting tert-butyl 4-(4-aminobutyl)piperidine-1-carboxylate for tert-butyl 5-aminoisoindoline-2-carboxylate and substituting 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine for isoindoline in Example 344A.


Example 722B
N-(4-(piperidin-4-yl)butyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)butyl)piperidine-1-carboxylate for tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 722C
N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(4-(piperidin-4-yl)butyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and benzoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (500 MHz, DMSO-d6, Temp=90° C.) δ ppm 8.54 (s, 1H) 8.45 (d, J=5.04 Hz, 1H) 7.38-7.46 (m, 3H) 7.28-7.37 (m, 3H) 6.09 (s, 1H) 4.62 (dd, J=9.08, 1.60 Hz, 4H) 3.07-3.15 (m, 2H) 2.79-2.94 (m, 2H) 1.61-1.75 (m, 2H) 1.41-1.58 (m, 3H) 1.20-1.40 (m, 4H) 0.99-1.17 (m, 2H); MS (ESI(+)) m/e 407 (M+H)+.









TABLE 14







The following Examples were essentially prepared as described in Example


722C, substituting an appropriate carboxylic acid for benzoic acid.










Ex
Name

1H NMR

MS













757
N-{4-[1-(2-

1H NMR (300 MHz, DMSO-d6) δ 8.55 (s, 1 H) 8.46

(ESI(+))



chlorobenzoyl)piperidin-
(d, J = 5.16 Hz, 1 H) 7.25-7.57 (m, 5 H) 6.36 (t,
m/e 441



4-yl]butyl}-1,3-
J = 5.55 Hz, 1 H) 4.60 (s, 2 H) 4.60 (s, 2 H) 4.43-4.54
(M + H)+



dihydro-2H-
(m, 1 H) 3.13-3.28 (m, 1 H) 2.85-3.12 (m, 3 H) 2.74



pyrrolo[3,4-c]pyridine-
(t, J = 12.10 Hz, 1 H) 1.76 (d, J = 13.09 Hz, 1 H) 0.86-



2-carboxamide
1.67 (m, 10 H)


1350
N-{4-[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.63 (s,

(ESI(+))



(tetrahydrofuran-2-
1H), 8.53 (d, J = 5.3 Hz, 1H), 7.52 (d, J = 5.3 Hz, 1H),
m/e 415



ylacetyl)piperidin-4-
6.13-5.96 (m, 1H), 4.67 (s, 1H), 4.09 (p, J = 6.6 Hz,
(M + H)+



yl]butyl}-1,3-dihydro-
2H), 3.73 (q, J = 7.2 Hz, 5H), 3.10 (t, J = 7.0 Hz, 2H),



2H-pyrrolo[3,4-
2.82-2.55 (m, 3H), 2.35 (dd, J = 14.8, 6.5 Hz, 2H),



c]pyridine-2-
2.04-1.92 (m, 2H), 1.79 (tt, J = 12.8, 6.3 Hz, 2H),



carboxamide
1.66 (d, J = 12.9 Hz, 2H), 1.54-1.42 (m, 3H), 1.39-




1.29 (m, 2H), 1.24 (dd, J = 14.3, 5.9 Hz, 2H), 1.06-




0.90 (m, 2H)


1351
N-(4-{1-[(1,1-
1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.64 (s,
(ESI(+))



dioxidotetrahydrothiophen-3-
1H), 8.55 (d, J = 5.2 Hz, 1H), 7.55 (d, J = 5.3 Hz, 1H),
m/e 449



yl)carbonyl]piperidin-
6.08 (s, 1H), 4.68 (s, 5H), 3.70-3.58 (m, 2H), 3.22-
(M + H)+



4-yl}butyl)-1,3-
3.15 (m, 3H), 3.15-3.00 (m, 3H), 2.29 (td, J = 12.8,



dihydro-2H-
7.0 Hz, 2H), 2.08 (ddd, J = 17.0, 13.4, 8.8 Hz, 2H),



pyrrolo[3,4-c]pyridine-
1.69 (d, J = 12.9 Hz, 2H), 1.50 (ddt, J = 21.4, 14.3, 7.3



2-carboxamide
Hz, 3H), 1.40-1.21 (m, 4H), 1.03 (d, J = 11.6 Hz,




2H)


1352
N-{4-[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.62 (s,

(ESI(+))



(tetrahydrofuran-3-
1H), 8.52 (d, J = 5.3 Hz, 1H), 7.51 (d, J = 5.1 Hz, 1H),
m/e 415



ylacetyl)piperidin-4-
6.13-5.95 (m, 1H), 4.65 (d, J = 7.1 Hz, 4H), 3.83-
(M + H)+



yl]butyl}-1,3-dihydro-
3.75 (m, 1H), 3.70 (td, J = 8.0, 5.3 Hz, 1H), 3.57 (dd,



2H-pyrrolo[3,4-
J = 24.8, 17.4 Hz, 2H), 3.28-3.14 (m, 3H), 3.10 (t, J =



c]pyridine-2-
7.0 Hz, 2H), 2.40-2.26 (m, 3H), 1.99 (dt, J = 12.8,



carboxamide
7.6 Hz, 2H), 1.66 (d, J = 10.4 Hz, 3H), 1.55-1.40 (m,




3H), 1.36-1.16 (m, 3H), 0.99 (d, J = 9.4 Hz, 3H)


1353
N-{4-[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.64 (s,

(ESI(+))



(cyclohexylcarbonyl)pi-
1H), 8.54 (d, J = 5.2 Hz, 1H), 7.54 (d, J = 5.3 Hz, 1H),
m/e 413



peridin-4-yl]butyl}-
6.08 (s, 1H), 4.68 (s, 4H), 4.17-3.95 (m, 4H), 3.10 (t,
(M + H)+



1,3-dihydro-2H-
J = 7.0 Hz, 2H), 2.78-2.53 (m, 3H), 1.72-1.62 (m,



pyrrolo[3,4-c]pyridine-
5H), 1.57 (d, J = 14.8 Hz, 3H), 1.46 (dd, J = 14.3, 7.3



2-carboxamide
Hz, 3H), 1.39-1.13 (m, 6H), 1.03-0.91 (m, 2H)


1354
N-(4-{1-[(4,4-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.61 (s,

(ESI(+))



difluorocyclohexyl)car-
1H), 8.52 (d, J = 5.2 Hz, 1H), 7.49 (d, J = 5.2 Hz, 1H),
m/e 449



bonyl]piperidin-4-
6.17-5.91 (m, 1H), 4.66 (s, 4H), 4.17-3.95 (m, 3H),
(M + H)+



yl}butyl)-1,3-dihydro-
3.10 (t, J = 7.0 Hz, 2H), 2.84-2.68 (m, 3H), 2.09-



2H-pyrrolo[3,4-
1.96 (m, 2H), 1.93-1.77 (m, 2H), 1.65 (dd, J = 27.2,



c]pyridine-2-
12.8 Hz, 6H), 1.56-1.40 (m, 2H), 1.41-1.20 (m,



carboxamide
4H), 1.06-0.92 (m, 2H)


1355
N-{4-[1-(2-hydroxy-2-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.62 (s,

(ESI(+))



methylpropanoyl)pi-
1H), 8.53 (d, J = 5.2 Hz, 1H), 7.51 (d, J = 5.2 Hz, 1H),
m/e 389



peridin-4-yl]butyl}-1,3-
6.18-5.92 (m, 1H), 4.67 (s, 4H), 4.52-4.43 (m, 2H),
(M + H)+



dihydro-2H-
3.10 (t, J = 7.0 Hz, 2H), 2.82-2.70 (m, 2H), 1.70-



pyrrolo[3,4-c]pyridine-
1.62 (m, 2H), 1.56-1.42 (m, 4H), 1.32 (s, 8H), 1.28



2-carboxamide
(d, J = 13.3 Hz, 2H), 1.08-1.02 (m, 2H)


1356
N-(4-{1-[(2R)-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.63 (s,

(ESI(+))



tetrahydrofuran-2-
1H), 8.53 (d, J = 5.2 Hz, 1H), 7.53 (d, J = 5.2 Hz, 1H),
m/e 401



ylcarbonyl]piperidin-
6.08 (s, 1H), 4.67 (s, 4H), 4.58 (dd, J = 7.5, 5.6 Hz,
(M + H)+



4-yl}butyl)-1,3-
2H), 4.20-4.05 (m, 3H), 3.83-3.62 (m, 3H), 3.10 (t,



dihydro-2H-
J = 7.0 Hz, 2H), 2.76 (bs, 2H), 2.11-1.99 (m, 1H),



pyrrolo[3,4-c]pyridine-
2.00-1.75 (m, 3H), 1.71-1.63 (m, 2H), 1.46 (dd, J =



2-carboxamide
14.2, 7.2 Hz, 2H), 1.37-1.19 (m, 2H), 1.10-0.92




(m, 2H)


1357
N-(4-{1-[(2S)-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.62 (s,

(ESI(+))



tetrahydrofuran-2-
1H), 8.53 (d, J = 5.2 Hz, 1H), 7.51 (d, J = 5.2 Hz, 1H),
m/e 401



ylcarbonyl]piperidin-
6.07 (s, 1H), 4.67 (s, 4H), 4.58 (dd, J = 7.5, 5.6 Hz,
(M + H)+



4-yl}butyl)-1,3-
1H), 3.77 (q, J = 7.2 Hz, 2H), 3.82-3.67 (m, 3H),



dihydro-2H-
3.10 (t, J = 7.0 Hz, 2H), 2.75 (bs, 1H), 2.11-1.99 (m,



pyrrolo[3,4-c]pyridine-
1H), 2.00-1.75 (m, 3H), 1.71-1.62 (m, 2H), 1.53-



2-carboxamide
1.21 (m, 7H), 1.08-0.92 (m, 2H)


1358
N-(4-{1-[(2-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.62 (s,

(ESI(+))



methoxyethoxy)acetyl]
1H), 8.53 (d, J = 5.2 Hz, 1H), 7.51 (d, J = 5.2 Hz, 1H),
m/e 419



piperidin-4-yl}butyl)-
6.15-5.99 (m, 1H), 4.67 (s, 4H), 4.58 (dd, J = 7.5,
(M + H)+



1,3-dihydro-2H-
5.6 Hz, 2H), 3.77 (q, J = 7.2 Hz, 2H), 3.82-3.67 (m,



pyrrolo[3,4-c]pyridine-
3H), 3.10 (t, J = 7.0 Hz, 2H), 2.75 (bs, 1H), 2.11-



2-carboxamide
1.99 (m, 1H), 1.95 (ddd, J = 17.4, 9.9, 6.6 Hz, 1H),




1.88-1.77 (m, 1H), 1.71-1.62 (m, 2H), 1.46 (dd, J =




14.4, 7.4 Hz, 3H), 1.37-1.19 (m, 4H), 1.08-0.92




(m, 2H)


1359
N-{4-[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.64 (s,

(ESI(+))



(tetrahydrofuran-3-
4H), 8.54 (d, J = 5.3 Hz, 1H), 7.55 (d, J = 5.3 Hz, 1H),
m/e 401



ylcarbonyl)piperidin-
6.08 (s, 1H), 4.68 (s, 4H), 3.85 (t, J = 8.1 Hz, 1H),
(M + H)+



4-yl]butyl}-1,3-
3.73-3.58 (m, 2H), 3.33-3.22 (m, 2H), 3.10 (t, J =



dihydro-2H-
7.0 Hz, 2H), 1.99 (dd, J = 14.3, 7.1 Hz, 3H), 1.68 (d,



pyrrolo[3,4-c]pyridine-
J = 12.7 Hz, 2H), 1.55-1.41 (m, 3H), 1.33 (dt, J =



2-carboxamide
13.8, 6.4 Hz, 2H), 1.24 (dd, J = 13.4, 6.3 Hz, 2H),




0.99 (dd, J = 24.0, 12.4 Hz, 2H)


1360
N-(4-{1-[(propan-2-

1H NMR (400 MHz, DMSO; Temp = 90° C.) δ 8.63 (s,

(ESI(+))



yloxy)acetyl]piperidin-
4H), 8.53 (d, J = 5.3 Hz, 1H), 7.53 (d, J = 5.2 Hz, 1H),
m/e 403



4-yl}butyl)-1,3-
6.09 (s, 1H), 4.66 (d, J = 7.5 Hz, 5H), 3.60 (dt, J =
(M + H)+



dihydro-2H-
12.2, 6.1 Hz, 2H), 3.10 (t, J = 7.0 Hz, 2H), 1.67 (d, J =



pyrrolo[3,4-c]pyridine-
13.1 Hz, 2H), 1.54-1.41 (m, 3H), 1.33 (dd, J = 15.9,



2-carboxamide
7.1 Hz, 2H), 1.24 (dd, J = 14.3, 5.7 Hz, 3H), 1.10 (d, J =




6.1 Hz, 6H), 1.02 (d, J = 11.2 Hz, 2H)


1361
N-{4-[1-

1H NMR (400 MHz, DMSO, Temp = 90° ) δ 8.63 (s,

(ESI(+))



(cyclopropylacetyl)pi-
4H), 8.54 (d, J = 5.3 Hz, 1H), 7.54 (d, J = 5.3 Hz, 1H),
m/e 385



peridin-4-yl]butyl}-1,3-
6.13-6.00 (m, 1H), 4.67 (s, 4H), 3.10 (t, J = 7.0 Hz,
(M + H)+



dihydro-2H-
2H), 2.22 (d, J = 6.6 Hz, 2H), 1.63 (t, J = 21.9 Hz,



pyrrolo[3,4-c]pyridine-
2H), 1.47 (dt, J = 14.1, 7.0 Hz, 3H), 1.38-1.28 (m,



2-carboxamide
2H), 1.24 (dd, J = 14.3, 5.8 Hz, 2H), 1.07-0.85 (m,




4H), 0.47-0.39 (m, 2H), 0.15-0.05 (m, 2H)


1362
N-{4-[1-(4,4,4-

1H NMR (400 MHz, DMSO Temp = 90° ) δ 8.63 (s,

(ESI(+))



trifluorobutanoyl)pi-
4H), 8.53 (d, J = 5.3 Hz, 1H), 7.52 (d, J = 5.3 Hz, 1H),
m/e 427



peridin-4-yl]butyl}-1,3-
6.07 (s, 1H), 4.67 (s, 4H), 3.10 (t, J = 7.0 Hz, 2H),
(M + H)+



dihydro-2H-
1.67 (d, J = 13.3 Hz, 2H), 1.47 (dt, J = 14.3, 7.1 Hz,



pyrrolo[3,4-c]pyridine-
3H), 1.38-1.29 (m, 4H), 1.25 (dt, J = 13.6, 6.8 Hz,



2-carboxamide
3H), 1.03 (s, 3H)









Example 753
N-{4-[5-(morpholin-4-ylmethyl)-1,2,4-oxadiazol-3-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 753A
N-(4-(5-(chloromethyl)-1,2,4-oxadiazol-3-yl)phenyl)isoindoline-2-carboxamide

To a 25 mL round-bottomed flask containing (Z)—N-(4-(N′-hydroxycarbamimidoyl)phenyl)isoindoline-2-carboxamide (1.5 g, 5.06 mmol) in acetone (5 ml) was added potassium carbonate (7.00 g, 50.6 mmol) in a single portion. The reaction mixture was cooled to 0° C. and 2-chloroacetyl chloride (3.22 ml, 40.5 mmol) was added slowly. The resulting mixture was warmed to room temperature and stirred for two hours. The solvent was removed and the solid was triturated with water and then filtered with water washes. The dried solid was dissolved in DMF, heated to 100° C. and stirred for two hours. Work-up with water and dichlormethane followed by chromatography provided the title compound.


Example 753B
N-{4-[5-(morpholin-4-ylmethyl)-1,2,4-oxadiazol-3-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

To a 20 mL vial was added N-(4-(5-(chloromethyl)-1,2,4-oxadiazol-3-yl)phenyl)isoindoline-2-carboxamide (50 mg, 0.141 mmol) and morpholine (36.8 mg, 0.423 mmol) in DMF (470 μl). The mixture was heated to 50° C. for 30 minutes, cooled, and diluted with 2 mL methanol. Chromatography provided the title compound. 1H NMR (300 MHz, DMSO-d6) δ 8.69 (s, 1H), 7.92 (d, J=8.8 Hz, 2H), 7.80 (d, J=8.9 Hz, 2H), 7.35 (ddd, J=8.8, 3.9, 2.4 Hz, 4H), 4.80 (s, 4H), 3.95 (s, 2H), 3.68-3.48 (m, 4H), 2.62-2.51 (m, 5H); MS (ESI(+)) m/e 406 (M+H)+.


Example 754
N-(4-{5-[(4-methylpiperazin-1-yl)methyl]-1,2,4-oxadiazol-3-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 753B, substituting 1-methylpiperazine for morpholine. 1H NMR (300 MHz, DMSO-d6) δ 8.69 (s, 1H), 7.91 (d, J=8.8 Hz, 3H), 7.80 (d, J=8.8 Hz, 3H), 7.45-7.23 (m, 5H), 4.80 (s, 5H), 3.93 (s, 2H), 2.65-2.51 (m, 75H), 2.34 (s, 5H), 2.15 (s, 4H); MS (ESI(+)) m/e 419 (M+H)+.


Example 755
N-[4-(5-[(3-methylbutyl)amino]methyl}-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 753B, substituting 3-methylbutan-1-amine for morpholine. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.68 (s, 1H), 7.91 (d, J=8.8 Hz, 2H), 7.79 (d, J=8.8 Hz, 2H), 7.35 (tdd, J=8.9, 5.4, 3.4 Hz, 4H), 4.80 (s, 4H), 4.02 (s, 2H), 2.66-2.53 (m, 1H), 2.43-2.30 (m, 1H), 1.63 (dt, J=13.4, 6.7 Hz, 1H), 1.32 (dd, J=14.4, 7.0 Hz, 2H), 0.86 (d, J=6.5 Hz, 6H); MS (ESI(+)) m/e 406 (M+H)+.


Example 756
N-(4-{5-[(4-hydroxypiperidin-1-yl)methyl]-1,2,4-oxadiazol-3-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 753B, substituting piperidin-4-ol for morpholine. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.68 (s, 1H), 7.91 (d, J=8.8 Hz, 2H), 7.79 (d, J=8.8 Hz, 2H), 7.45-7.25 (m, 4H), 4.80 (s, 4H), 4.56 (d, J=4.2 Hz, 1H), 3.91 (s, 2H), 3.45 (dd, J=8.7, 4.3 Hz, 1H), 3.17 (d, J=5.2 Hz, 1H), 2.76 (dd, J=10.6, 5.0 Hz, 2H), 2.42-2.18 (m, 3H), 1.72 (d, J=8.9 Hz, 2H), 1.43 (dt, J=18.5, 6.4 Hz, 2H); MS (ESI(+)) m/e 420 (M+H)+.


Example 787
N-[4-(2-{benzyl[3-(morpholin-4-yl)propyl]amino}-2-oxoethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
Example 787A
N-benzyl-N-(3-morpholinopropyl)-2-(4-nitrophenyl)acetamide

The title compound was prepared as described in Example 1C, substituting N-benzyl-3-morpholinopropan-1-amine for 3-phenylpropan-1-amine and 2-(4-nitrophenyl)acetic acid for 4-(isoindoline-2-carboxamido)benzoic acid.


Example 787B
2-(4-aminophenyl)-N-benzyl-N-(3-morpholinopropyl)acetamide

The title compound was prepared as described in Example 272A, substituting N-benzyl-N-(3-morpholinopropyl)-2-(4-nitrophenyl)acetamide for 4-nitro-N-propylbenzamide.


Example 787C
N-[4-(2-{benzyl[3-(morpholin-4-yl)propyl]amino}-2-oxoethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 2-(4-aminophenyl)-N-benzyl-N-(3-morpholinopropyl)acetamide for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (400 MHz, DMSO-d6, Temp=90° C.) δ ppm 8.05 (bs, 1H), 7.47 (d, J=8.5 Hz, 2H), 7.37-7.17 (m, 9H), 7.15-7.08 (m, 2H), 4.76 (s, 4H), 4.56 (bs, 2H), 3.77-3.55 (m, 2H), 3.56-3.50 (m, 4H), 3.30 (t, J=7.3 Hz, 2H), 2.33-2.24 (m, 4H), 2.21 (t, J=6.8 Hz, 2H), 1.60 (p, J=7.1 Hz, 2H); MS (ESI(+)) m/e 513 (M+H)+.


Example 788
N-[4-(3-{benzyl[3-(morpholin-4-yl)propyl]amino}-3-oxopropyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 787, substituting 3-(4-nitrophenyl)propanoic acid for 2-(4-nitrophenyl)acetic acid in Example 787A. 1H NMR (400 MHz, DMSO-d6, Temp=90° C.) δ ppm 7.99 (bs, 1H), 7.48-7.39 (m, 2H), 7.37-7.19 (m, 7H), 7.19-7.13 (m, 2H), 7.13-7.00 (m, 2H), 4.76 (s, 4H), 4.53 (s, 2H), 3.56-3.45 (m, 4H), 3.31-3.23 (m, 2H), 2.87-2.78 (m, 2H), 2.72-2.57 (m, 2H), 2.29-2.22 (m, 4H), 2.20 (t, J=6.8 Hz, 2H), 1.63-1.54 (m, 2H); MS (ESI(+)) m/e 527 (M+H)+.


Example 795
N-{6-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting tetrahydro-2H-pyran-4-ylmethamine for 3-phenylpropan-1-amine and 6-(isoindoline-2-carboxamido)pyridazine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 9.98 (s, 1H), 9.03 (t, J=6.2 Hz, 1H), 8.31 (d, J=9.3 Hz, 1H), 8.10 (d, J=9.3 Hz, 1H), 7.41-7.28 (m, 4H), 5.03-4.67 (m, 4H), 3.89-3.79 (m, 2H), 3.29-3.11 (m, 4H), 2.01-1.78 (m, 1H), 1.63-1.53 (m, 2H), 1.30-1.12 (m, 2H); MS (ESI(+)) m/e 382 (M+H)+.


Example 797
N-[4-(6-bromo-2-oxoquinolin-1(2H)-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide
Example 797A
tert-butyl 4-(6-bromo-2-oxoquinolin-1(2H)-yl)butylcarbamate

To a solution of 6-bromoquinolin-2(1H)-one (430 mg, 1.91 mmol) in tetrahydrofuran (8 ml) was added sodium bis(trimethylsilyl)amide (2.1 ml, 2.08 mmol). After 15 minutes, 4-(boc-amino)butyl bromide (403 mg, 1.6 mmol) was added. The solution was stirred for 15 hours, concentrated and purified by flash chromatography to provide the title compound.


Example 797B
1-(4-aminobutyl)-6-bromoquinolin-2(1H)-one

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(6-bromo-2-oxoquinolin-1(2H)-yl)butylcarbamate for tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 797C
N-[4-(6-bromo-2-oxoquinolin-1(2H)-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 1-(4-aminobutyl)-6-bromoquinolin-2(1H)-one for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (400 MHz, CDCl3) δ ppm 7.67 (d, J=2.2 Hz, 2H), 7.61 (d, J=2.3 Hz, 1H), 7.60 (d, J=2.3 Hz, 1H), 7.57 (d, J=9.6 Hz, 2H), 7.28 (s, 1H), 7.24 (s, 1H), 6.70 (d, J=9.5 Hz, 2H), 4.76 (t, J=5.7 Hz, 2H), 4.70 (s, 4H), 4.29 (m, 2H), 3.42 (m, 2H), 1.79 (m, 2H), 1.69 (m, 2H); MS (ESI(+)) m/e 440.1 (M+H).


Example 798
N-{4-[6-(3-acetylphenyl)-2-oxoquinolin-1(2H)-yl]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting 3-acetylphenyl boronic acid for 1H-pyrazol-3-ylboronic acid and N-[4-(6-bromo-2-oxoquinolin-1(2H)-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, CDCl3) δ ppm 8.20 (t, J=1.5 Hz, 1H), 7.94 (d, J=7.7 Hz, 1H), 7.80 (m, 3H), 7.75 (d, J=9.5 Hz, 2H), 7.56 (t, J=7.7 Hz, 1H), 7.49 (d, J=9.4 Hz, 2H), 7.24 (s, 1H), 6.75 (t, J=9.4 Hz, 2H), 4.82 (t, J=5.4 Hz, 1H), 4.72 (s, 4H), 4.37 (m, 2H), 3.45 (m, 2H), 2.66 (s, 3H), 1.88 (m, 2H), 1.74 (m, 2H); MS (ESI(+)) m/e 480.3 (M+H).


Example 804
5-(hydroxymethyl)-N-(3-phenylpropyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 3-phenylpropan-1-amine for 4-amino-N-propylbenzamide and isoindolin-5-ylmethanol hydrochloride for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.30-7.14 (m, 8H), 6.30 (t, J=5.5 Hz, 1H), 5.16 (t, J=5.5 Hz, 1H), 4.55 (bs, 4H), 4.49 (d, J=4.9 Hz, 2H), 3.16-3.05 (m, 2H), 2.64-2.56 (m, 2H), 1.76 (p, J=7.4 Hz, 2H); MS (ESI(+)) m/e 311 (M+H)+.


Example 805
N-(2-{(4-fluorobenzyl)[4-(pyridin-3-yl)benzyl]amino}-1,3-thiazol-5-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
Example 805A
methyl 2-(4-(pyridin-3-yl)benzylamino)thiazole-5-carboxylate

In a 250 mL round-bottomed flask was added 4-(pyridin-3-yl)benzaldehyde (4 g, 21.83 mmol), methyl 2-aminothiazole-5-carboxylate (3.45 g, 21.83 mmol), and acetic acid (0.375 ml, 6.55 mmol) in toluene (109 ml). The mixture was heated at reflux under Dean-Stark conditions for 3 hours, cooled, concentrated and redissolved in methanol. The mixture was cooled to 0° C. and sodium borohydride (1.322 g, 34.9 mmol) was carefully added. The mixture was warmed to room temperature and the resulting suspension was filtered with water washes to provide the title compound after drying.


Example 805B
2-(4-fluorobenzyl)(4-(pyridin-3-yl)benzyl)amino)thiazole-5-carboxylic acid

In a 250 mL round-bottomed flask was added methyl 2-(4-(pyridin-3-yl)benzylamino)thiazole-5-carboxylate (3 g, 9.22 mmol) and 1-(bromomethyl)-4-fluorobenzene (1.264 ml, 10.14 mmol) in dimethylformamide (46.1 ml). The mixture was cooled to 0° C., sodium hydride (0.738 g, 18.44 mmol) was added carefully; and the mixture was warmed to room temperature. After the mixture was stirred for about 30 minutes, it was found to be predominantly carboxylic acid. 1 N NaOH was added to complete the conversion; and a water work up followed by chromatography provided the title compound.


Example 805C
N-(4-fluorobenzyl)-5-isocyanato-N-(4-(pyridin-3-yl)benzyl)thiazol-2-amine

To a 50 mL round-bottomed flask was added 2-((4-fluorobenzyl)(4-(pyridin-3-yl)benzyl)amino)thiazole-5-carboxylic acid (850 mg, 2.026 mmol) in dichloromethane (10.100 ml) and the solution was cooled to 0° C. Oxalyl chloride (0.266 ml, 3.04 mmol) and dimethylformamide (0.016 ml, 0.203 mmol) were added and some bubbling occurred. The solution was warmed to room temperature and stirred for 1 hour. The mixture was cooled to 0° C., and trimethylsilyl azide (0.538 ml, 4.05 mmol) was added. The mixture was warmed to room temperature, stirred for 30 minutes and concentrated under vacuum. Toluene (5 ml) was added and the mixture was heated to 95° C. for 2.5 hours. The toluene was removed and the resulting solid was triturated/sonicated with ether and filtered with ether washes to provide the title compound.


Example 805D
N-(2-{(4-fluorobenzyl)[4-(pyridin-3-yl)benzyl]amino}-1,3-thiazol-5-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1A, substituting N-(4-fluorobenzyl)-5-isocyanato-N-(4-(pyridin-3-yl)benzyl)thiazol-2-amine for methyl 4-isocyanatobenzoate and 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine for isoindoline. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.27 (s, 1H), 8.99 (d, J=2.1 Hz, 1H), 8.76 (s, 1H), 8.71-8.56 (m, 2H), 8.29 (d, J=7.8 Hz, 1H), 7.81-7.56 (m, 5H), 7.51-7.27 (m, 5H), 7.27-7.06 (m, 2H), 6.86 (s, 1H), 4.80 (d, J=3.6 Hz, 4H), 4.72 (d, J=7.7 Hz, 4H); MS (ESI(+)) m/e 537 (M+H)+.


Example 806
N-[4-(2-benzyl-1,3-thiazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
Example 806A
4-(2-benzylthiazol-4-yl)aniline

2-Bromo-1-(4-nitrophenyl)ethanone (0.5 g, 2.049 mmol) and 2-phenylethanethioamide (0.310 g, 2.049 mmol) were combined in ethanol (10 ml) in a 20 mL microwave reaction vessel and heated at 140° C. for 15 minutes. The solution was transferred to a 250 mL round bottom flask where it immediately solidified. The material was diluted with an additional ethanol (10 ml) and was heated at reflux with stirring until the solids were dissolved. Water (5.0 ml, 278 mmol), and hydrochloric acid (1 ml, 12.00 mmol) were added. Iron (0.625 g, 11.19 mmol) was added and the mixture was heated at reflux for 2 hours. The mixture was allowed to cool and 5 mL NH4OH was added. The material was filtered through a pad of diatomaceous earth and the pad was washed with 50 mL of ethyl acetate. The filtrate was washed with 100 mL of water and the aqueous phase was extracted with an additional 50 mL of ethyl acetate. The combined organic fractions were dried over sodium sulfate, filtered, and the solvent was removed under reduced pressure. The material was re-dissolved in 50 mL of ethyl acetate and filtered through a ¼-inch pad of silica gel. The pad was washed with an additional 50 mL of ethyl acetate and the combined filtrate was concentrated to provide the title compound.


Example 806B
N-[4-(2-benzyl-1,3-thiazol-4-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 4-(2-benzylthiazol-4-yl)aniline for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (400 MHz, CDCl3) δ ppm 7.79 (d, J=8.7 Hz, 2H), 7.48 (d, J=8.7 Hz, 2H), 7.30 (s, 1H), 7.29 (d, J=3.8 Hz, 2H), 7.26 (m, 5H), 7.20 (d, J=3.7 Hz, 2H), 6.29 (s, 1H), 4.80 (s, 4H), 4.32 (s, 2H); MS (ESI(+)) m/e 412 (M+H).


Example 807
N-(7-{benzyl[3-(morpholin-4-yl)propyl]amino}-7-oxoheptyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-benzyl-3-morpholinopropan-1-amine for 3-phenylpropan-1-amine and 7-(isoindoline-2-carboxamido)heptanoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.41-7.13 (m, 9H), 6.32-6.22 (m, 1H), 4.59-4.48 (m, 6H), 3.58-3.47 (m, 4H), 3.27-3.20 (m, 2H), 3.11-2.98 (m, 2H), 2.44-2.36 (m, 1H), 2.31-2.23 (m, 5H), 2.23-2.12 (m, 2H), 1.70-1.17 (m, 10H); MS (ESI(+)) m/e 507 (M+H)+.


Example 808
N-{4-[(3-methylbutyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 808A
N-isopentyl-4-nitrobenzenesulfonamide

4-Nitrobenzene-1-sulfonyl chloride (1.5 g, 6.57 mmol) was dissolved in dichloromethane (30 ml) and cooled to 0° C. followed by addition of diisopropylethylamine (2.293 ml, 13.13 mmol). 3-Methylbutan-1-amine (0.926 ml, 7.88 mmol) was dissolved in 5 ml dichloromethane and added via syringe. After the addition, the mixture was allowed to warm to room temperature for 3 hours. The solution was diluted with aqueous sodium bicarbonate and extracted twice with dichloromethane. The organics were combined, dried over magnesium sulfate, filtered and concentrated. Chromatography provided the title compound.


Example 808B
4-amino-N-isopentylbenzenesulfonamide

The title compound was prepared as described in Example 272A, substituting N-isopentyl-4-nitrobenzenesulfonamide for 4-nitro-N-propylbenzamide.


Example 808C
N-{4-[(3-methylbutyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 4-amino-N-isopentylbenzenesulfonamide for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.75 (s, 1H), 7.82-7.74 (m, 2H), 7.70-7.64 (m, 2H), 7.41-7.27 (m, 5H), 4.80 (s, 4H), 2.77-2.67 (m, 2H), 1.64-1.47 (m, 1H), 1.30-1.19 (m, 2H), 0.79 (d, J=6.6 Hz, 6H); MS (ESI(+)) m/e 388 (M+H)+.


Example 839
N-(5-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}pyridin-2-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting (S)-benzyl(tetrahydrofuran-3-yl)methylcarbamate for 3-phenylpropan-1-amine and 6-(isoindoline-2-carboxamido)nicotinic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (500 MHz, DMSO-d6) δ ppm 9.27 (s, 1H), 8.74 (d, J=2.1 Hz, 1H), 8.60 (t, J=5.7 Hz, 1H), 8.14 (dd, J=8.8, 2.4 Hz, 1H), 8.00 (d, J=8.7 Hz, 1H), 7.41-7.27 (m, 4H), 4.89 (m, 4H), 3.75 (m, 1H), 3.69 (m, 1H), 3.62 (m, 1H), 3.48 (dd, J=8.5, 5.3 Hz, 1H), 3.25 (m, 2H), 2.48 (m, 1H), 1.95 (m, 1H), 1.61 (m, 1H); MS (ESI(+)) m/e 367 (M+H).


Example 871
N-[4-(4-{benzyl[3-(morpholin-4-yl)propyl]amino}-4-oxobutyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 787, substituting 3-(4-nitrophenyl)butanoic acid for 2-(4-nitrophenyl)acetic acid in Example 787A. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.29-8.21 (m, 1H), 7.51-7.41 (m, 2H), 7.40-7.13 (m, 9H), 7.11-6.98 (m, 2H), 4.75 (s, 4H), 4.57-4.47 (m, 2H), 3.60-3.44 (m, 4H), 3.27-3.13 (m, 2H), 2.60-2.53 (m, 1H), 2.48-2.34 (m, 2H), 2.33-2.11 (m, 7H), 1.90-1.71 (m, 2H), 1.66-1.51 (m, 2H); MS (ESI(+)) m/e 541 (M+H)+.


Example 872
N-(4-phenylbutyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1A, substituting (4-isocyanatobutyl)benzene for methyl 4-isocyanatobenzoate and 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine for isoindoline. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.55 (s, 1H), 8.46 (d, J=5.0 Hz, 1H), 7.38 (d, J=5.1 Hz, 1H), 7.32-7.22 (m, 2H), 7.23-7.11 (m, 3H), 6.38 (t, J=5.6 Hz, 1H), 4.63-4.57 (m, 4H), 3.10-3.07 (m, 2H), 2.59 (t, J=7.5 Hz, 2H), 1.66-1.39 (m, 4H); MS (ESI(+)) m/e 296 (M+H)+.


Example 873
N-[4-(2-{benzyl[3-(morpholin-4-yl)propyl]amino}ethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide
Example 873A
N-benzyl-3-morpholino-N-(4-nitrophenethyl)propan-1-amine

A suspension of 1-(2-bromoethyl)-4-nitrobenzene (0.314 g, 1.366 mmol), N-benzyl-3-morpholinopropan-1-amine (0.128 g, 0.546 mmol), and potassium carbonate (0.189 g, 1.366 mmol) in dimethylformamide (1.821 ml) was heated at 65° C. for 20 hours. The reaction was partitioned in ethyl acetate and water. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The concentrate was purified by flash chromatography to provide the title compound.


Example 873B
4-(2-(benzyl(3-morpholinopropyl)amino)ethyl)aniline

The title compound was prepared as described in Example 272A, substituting N-benzyl-3-morpholino-N-(4-nitrophenethyl)propan-1-amine for 4-nitro-N-propylbenzamide.


Example 873C
N-[4-(2-{benzyl[3-(morpholin-4-yl)propyl]amino}ethyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 4-(2-(benzyl(3-morpholinopropyl)amino)ethyl)aniline for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.24 (s, 1H), 7.43 (d, J=8.5 Hz, 2H), 7.38-7.18 (m, 9H), 7.04 (d, J=8.5 Hz, 2H), 4.75 (s, 4H), 3.60 (s, 2H), 3.54-3.47 (m, 4H), 2.70-2.54 (m, 4H), 2.48-2.41 (m, 2H), 2.29-2.16 (m, 6H), 1.62-1.46 (m, 2H); MS (ESI(+)) m/e 499 (M+H)+.


Example 876
5-cyano-N-{4-[(3-methylbutyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 4-amino-N-isopentylbenzenesulfonamide for 4-amino-N-propylbenzamide and isoindoline-5-carbonitrile for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.82 (s, 1H), 7.89 (s, 1H), 7.83-7.74 (m, 3H), 7.71-7.64 (m, 2H), 7.59 (d, J=7.9 Hz, 1H), 7.31 (t, J=5.8 Hz, 1H), 4.89-4.81 (m, 4H), 2.78-2.67 (m, 2H), 1.56 (dp, J=13.3, 6.7 Hz, 1H), 1.30-1.19 (m, 2H), 0.78 (d, J=6.6 Hz, 6H); MS (ESI(+)) m/e 413 (M+H)+.


Example 877
N-{4-[(3-methylbutyl)sulfamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 4-amino-N-isopentylbenzenesulfonamide for 4-amino-N-propylbenzamide and 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.82 (s, 1H), 8.62 (s, 1H), 8.51 (d, J=5.0 Hz, 1H), 7.81-7.74 (m, 2H), 7.71-7.64 (m, 2H), 7.44 (d, J=5.1 Hz, 1H), 7.32 (t, J=5.8 Hz, 1H), 4.87-4.80 (m, 4H), 2.78-2.67 (m, 2H), 1.56 (dp, J=13.3, 6.7 Hz, 1H), 1.30-1.13 (m, 2H), 0.78 (d, J=6.6 Hz, 6H); MS (ESI(+)) m/e 389 (M+H)+.


Example 883
N-(4-{[(3-methoxybenzyl)sulfonyl]amino}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

N-(4-aminophenyl)isoindoline-2-carboxamide (0.0585 g, 0.231 mmol) was suspended in dichloromethane (2 ml) followed by addition of triisopropylethylamine (0.081 ml, 0.462 mmol). (3-Methoxyphenyl)methanesulfonyl chloride (0.061 g, 0.277 mmol) was dissolved in 1 ml dichloromethane and added to the mixture via syringe slowly. The mixture was quenched with water and the separated aqueous layer was extracted with dichloromethane. The combined organic layers were dried over magnesium sulfate, filtered and concentrated. Reverse-phase HPLC provided the title compound. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.65 (s, 1H), 8.61 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.34 (t, J=5.6 Hz, 1H), 7.80-7.73 (m, 2H), 7.69-7.61 (m, 2H), 7.44 (d, J=5.0 Hz, 1H), 4.86-4.79 (m, 4H), 3.20 (t, J=6.2 Hz, 2H), 2.46-2.25 (m, 3H), 2.20 (d, J=7.9 Hz, 3H), 2.06-1.78 (m, 1H), 1.52-1.37 (m, 1H); MS (ESI(+)) m/e 438 (M+H)+.


Example 909
N-{4-[6-(3-acetylphenyl)-4-(3-hydroxypropyl)-2-oxoquinolin-1(2H)-yl]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 909A
6-bromo-4-(3-(tert-butyldiphenylsilyloxy)propyl)quinolin-2(1H)-one

6-Bromo-4-(3-hydroxypropyl)quinolin-2(1H)-one (4.7 g, 16.67 mmoles), imidazole (2.84 g, 41.7 mmoles) and tert-butyldiphenylsilyl chloride (5.14 mL, 20 mmoles) were stirred in dimethylformamide (60 mL) overnight at room temperature. The reaction mixture was poured into water and extracted with ethyl acetate twice. The organic layers were combined, dried over magnesium sulfate, filtered and concentrated. The crude product was purified by normal phase chromatography to provide the title compound.


Example 909B
tert-butyl 4-(6-bromo-4-(3-(tert-butyldiphenylsilyloxy)propyl)-2-oxoquinolin-1(2H)-yl)butylcarbamate

The title compound was prepared as described in Example 797A, substituting 6-bromo-4-(3-(tert-butyldiphenylsilyloxy)propyl)quinolin-2(1H)-one for 6-bromoquinolin-2(1H)-one.


Example 909C
1-(4-aminobutyl)-6-bromo-4-(3-(tert-butyldiphenylsilyloxy)propyl)quinolin-2(1H)-one

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(6-bromo-4-(3-(tert-butyldiphenylsilyloxy)propyl)-2-oxoquinolin-1(2H)-yl)butylcarbamate for tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 909D
N-(4-(6-bromo-4-(3-hydroxypropyl)-2-oxoquinolin-1(2H)-yl)butyl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 1-(4-aminobutyl)-6-bromo-4-(3-(tert-butyldiphenylsilyloxy)propyl)quinolin-2(1H)-one for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride followed by TBAF deprotection and work up.


Example 909E
N-{4-[6-(3-acetylphenyl)-4-(3-hydroxypropyl)-2-oxoquinolin-1(2H)-yl]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 280, substituting 3-acetylphenylboronic acid for 1H-pyrazol-3-ylboronic acid and N-(4-(6-bromo-4-(3-hydroxypropyl)-2-oxoquinolin-1(2H)-yl)butyl)isoindoline-2-carboxamide for 5-bromo-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, CDCl3) δ ppm 8.24 (s, 1H), 8.08 (d, J=2.0 Hz, 1H), 7.96 (d, J=7.9 Hz, 1H), 7.87-7.79 (m, 2H), 7.58 (t, J=7.7 Hz, 1H), 7.54 (d, J=8.8 Hz, 1H), 7.28 (s, 4H), 6.71 (s, 1H), 4.74 (s, 4H), 4.41 (t, J=7.4 Hz, 2H), 3.82 (t, J=6.0 Hz, 2H), 3.46 (t, J=6.7 Hz, 2H), 3.12-2.99 (m, 2H), 2.68 (s, 3H), 2.10-1.96 (m, 2H), 1.96-1.83 (m, 2H), 1.79-1.72 (m, 2H); MS (APCI(+)) m/e 538 (M+H).


Example 910
N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
Example 910A
N-(4-(piperidin-4-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide

N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide (2.0 g, 6.24 mmol) in 80 mL of 1:1 THF:methanol was added to 5% Pd on carbon (wet) (0.500 g) in a 250 mL SS pressure bottle and the mixture was stirred for 38 hours at 30 atm and 25° C. The mixture was filtered through a nylon membrane, concentrated and suspended in ether. Filtration with ether washes provided the title compound.


Example 910B
N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(4-(piperidin-4-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and tetrahydrofuran-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.35 (s, 1H), 7.46 (m, 2H), 7.43 (d, J=5.0 Hz, 1H), 7.14 (m, 2H), 4.79 (m, 4H), 4.54 (m, 1H), 4.07 (m, 1H), 3.88 (dt, J=10.4, 8.1 Hz, 1H), 3.71 (m, 3H), 3.37 (m, 1H), 3.13 (m, 1H), 2.64-2.59 (m, 2H), 2.01 (m, 2H), 1.79 (m, 2H), 1.46 (m, 2H); MS (ESI(+)) m/e 421 (M+H).









TABLE 15







The following Examples were essentially prepared as described in Example 1C, substituting N-


(4-(piperidin-4-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-


1-amine and the appropriate carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid.










Ex
Name

1H NMR

MS













911
N-(4-{1-[(2-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.62 (m, 1H),

(ESI(+))



methoxyethoxy)acetyl]pi-
8.51 (d, J = 7.4 Hz, 1H), 8.37 (s, 1H), 7.45 (m, 3H),
m/e 439



peridin-4-yl}phenyl)-1,3-
7.13 (d, J = 8.6 Hz, 2H), 4.83 (m, 4H), 4.48 (m, 1H),
(M + H)+



dihydro-2H-pyrrolo[3,4-
4.17 (m, 2H), 3.89 (m, 1H), 3.60 (m, 2H), 3.46 (m,



c]pyridine-2-
2H), 3.26 (s, 3H), 3.07 (m, 1H), 2.78-2.56 (m, 2H),



carboxamide
1.74 (m, 2H), 1.57 (m, 1H), 1.42 (m, 1H)


912
N-{4-[1-(tetrahydrofuran-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H),

(ESI(+))



2-ylcarbonyl)piperidin-4-
8.50 (d, J = 5.0 Hz, 1H), 8.35 (s, 1H), 7.48 (s, 2H),
m/e 421



yl]phenyl}-1,3-dihydro-
7.43 (d, J = 5.0 Hz, 1H), 7.13 (m, 2H), 4.79 (m, 4H),
(M + H)+



2H-pyrrolo[3,4-
4.68 (dd, J = 7.6, 5.7 Hz, 1H), 4.49 (m, 1H), 4.11 (m,



c]pyridine-2-
1H), 3.78 (m, 2H), 3.10 (m, 1H), 2.79-2.57 (m,



carboxamide
2H), 2.03 (m, 2H), 1.84 (m, 4H), 1.61-1.36 (m, 2H)


913
N-{4-[1-(tetrahydro-2H-

1H NMR (500 MHz, DMSO-d6) δ ppm 8.60 (s, 1H),

(ESI(+))



pyran-4-
8.50 (d, J = 5.0 Hz, 1H), 8.35 (s, 1H), 7.46 (m, 2H),
m/e 435



ylcarbonyl)piperidin-4-
7.43 (d, J = 5.0 Hz, 1H), 7.13 (m, 2H), 4.79 (m, 4H),
(M + H)+



yl]phenyl}-1,3-dihydro-
4.55 (m, 1H), 4.09 (m, 1H), 3.85 (m, 2H), 3.41 (m,



2H-pyrrolo[3,4-
2H), 3.10 (m, 1H), 2.91 (m, 1H), 2.71 (m, 1H), 2.58



c]pyridine-2-
(m, 1H), 1.79 (m, 2H), 1.68-1.33 (m, 6H)



carboxamide


914
N-{4-[1-(1,4-dioxan-2-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H),

(ESI(+))



ylcarbonyl)piperidin-4-
8.50 (d, J = 4.9 Hz, 1H), 8.35 (s, 1H), 7.45 (m, 3H),
m/e 437



yl]phenyl}-1,3-dihydro-
7.13 (s, 2H), 4.79 (d, J = 7.1 Hz, 4H), 4.45 (m, 1H),
(M + H)+



2H-pyrrolo[3,4-
4.34 (m, 1H), 4.07 (m, 1H), 3.80-3.55 (m, 5H),



c]pyridine-2-
3.50 (m, 1H), 3.09 (m, 1H), 2.65 (m, 2H), 1.79 (m,



carboxamide
2H), 1.67-1.29 (m, 2H)


915
N-(4-{1-[(1-

1H NMR (500 MHz, DMSO-d6) δ ppm 8.60 (s, 1H),

(ESI(+))



methylpyrrolidin-3-
8.50 (d, J = 5.0 Hz, 1H), 8.35 (s, 1H), 7.47 (m, 2H),
m/e 434



yl)carbonyl]piperidin-4-
7.43 (d, J = 5.0 Hz, 1H), 7.12 (m, 2H), 4.79 (m, 4H),
(M + H)+



yl}phenyl)-1,3-dihydro-
4.49 (m, 1H), 4.16 (m, 1H), 3.58 (m, 4H), 3.26 (m,



2H-pyrrolo[3,4-
1H), 3.06 (m, 2H), 2.71 (m, 1H), 2.61 (m, 1H), 2.39



c]pyridine-2-
(m, 4H), 1.78 (m, 2H), 1.57 (m, 1H), 1.40 (m, 1H)



carboxamide


916
N-(4-{1-[(1,1-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.61 (s, 1H),

(ESI(+))



dioxidotetrahydrothiophen-
8.50 (d, J = 5.0 Hz, 1H), 8.35 (s, 1H), 7.47 (m, 2H),
m/e 469



3-yl)carbonyl]piperidin-4-
7.43 (d, J = 5.0 Hz, 1H), 7.14 (m, 2H), 4.79 (m, 4H),
(M + H)+



yl}phenyl)-1,3-dihydro-
4.53 (m, 1H), 4.08 (m, 1H), 3.73 (m, 1H), 3.26-



2H-pyrrolo[3,4-
3.04 (m, 5H), 2.69 (m, 2H), 2.35 (m, 1H), 2.07 (m,



c]pyridine-2-
1H), 1.81 (m, 2H), 1.51 (m, 2H)



carboxamide


917
N-{4-[1-(2-hydroxy-2-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H),

(ESI(+))



methylpropanoyl)piperidin-
8.50 (d, J = 5.0 Hz, 1H), 8.35 (s, 1H), 7.45 (m, 3H),
m/e 409



4-yl]phenyl}-1,3-
7.13 (m, 2H), 5.38 (s, 1H), 4.75 (m, 4H), 4.60 (m,
(M + H)+



dihydro-2H-pyrrolo[3,4-
2H), 2.95 (m, 1H), 2.80 (m, 2H), 1.77 (m, 2H), 1.48



c]pyridine-2-
(m, 2H), 1.34 (s, 6H)



carboxamide


918
N-{4-[1-(morpholin-4-

1H NMR (500 MHz, DMSO-d6) δ ppm 8.60 (s, 1H),

(ESI(+))



ylacetyl)piperidin-4-
8.50 (d, J = 5.0 Hz, 1H), 8.35 (s, 1H), 7.47 (m, 2H),
m/e 450



yl]phenyl}-1,3-dihydro-
7.43 (d, J = 5.0 Hz, 1H), 7.12 (m, 2H), 4.79 (m, 4H),
(M + H)+



2H-pyrrolo[3,4-
4.49 (m, 1H), 4.16 (m, 1H), 3.58 (m, 4H), 3.26 (m,



c]pyridine-2-
1H), 3.06 (m, 2H), 2.71 (m, 1H), 2.61 (m, 1H), 2.39



carboxamide
(m, 4H), 1.78 (m, 2H), 1.57 (m, 1H), 1.40 (m, 1H)


1279
N-(4-{1-[(2S)-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H),

(ESI(+))



tetrahydrofuran-2-
8.50 (d, J = 5.0 Hz, 1H), 8.35 (s, 1H), 7.46 (m, 2H),
m/e 421



ylcarbonyl]piperidin-4-
7.43 (d, J = 5.1 Hz, 1H), 7.13 (m, 2H), 4.79 (m, 4H),
(M + H)+



yl}phenyl)-1,3-dihydro-
4.68 (dd, J = 7.4, 5.8 Hz, 1H), 4.49 (d, J = 12.8 Hz,



2H-pyrrolo[3,4-
1H), 4.10 (m, 1H), 3.78 (m, 2H), 3.08 (m, 1H), 2.78-



c]pyridine-2-
2.57 (m, 2H), 2.04 (m, 2H), 1.90-1.71 (m, 4H),



carboxamide
1.61-1.32 (m, 2H)


1280
N-(4-{1-[(3S)-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H),

(ESI(+))



tetrahydrofuran-3-
8.50 (d, J = 5.0 Hz, 1H), 8.35 (s, 1H), 7.49-7.40
m/e 421



ylcarbonyl]piperidin-4-
(m, 3H), 7.14 (m, 2H), 4.79 (m, 4H), 4.54 (m, 1H),
(M + H)+



yl}phenyl)-1,3-dihydro-
4.06 (m, 1H), 3.88 (dt, J = 10.4, 8.1 Hz, 1H), 3.78-



2H-pyrrolo[3,4-
3.54 (m, 3H), 3.38 (m, 1H), 3.15 (m, 1H), 2.77-



c]pyridine-2-
2.56 (m, 2H), 2.04 (m, 2H), 1.79 (m, 2H), 1.59-



carboxamide
1.29 (m, 2H)


1384
N-(4-{1-[(2R)-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H),

(ESI(+))



tetrahydrofuran-2-
8.50 (d, J = 5.0 Hz, 1H), 8.35 (s, 1H), 7.45 (m, 3H),
m/e 421



ylcarbonyl]piperidin-4-
7.13 (m, 2H), 4.79 (m, 4H), 4.68 (dd, J = 7.4, 5.8 Hz,
(M + H)+



yl}phenyl)-1,3-dihydro-
1H), 4.48 (d, J = 12.7 Hz, 1H), 4.10 (d, J = 12.8 Hz,



2H-pyrrolo[3,4-
1H), 3.78 (m, 2H), 3.08 (dd, J = 26.0, 12.3 Hz, 1H),



c]pyridine-2-
2.77-2.55 (m, 2H), 2.04 (m, 2H), 1.83 (m, 4H),



carboxamide
1.62-1.32 (m, 2H)


1385
N-(4-{1-[(3R)-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H),

(ESI(+))



tetrahydrofuran-3-
8.50 (d, J = 5.0 Hz, 1H), 8.35 (s, 1H), 7.45 (m, 3H),
m/e 421



ylcarbonyl]piperidin-4-
7.14 (m, 2H), 4.79 (m, 4H), 4.54 (m, 1H), 4.07 (m,
(M + H)+



yl}phenyl)-1,3-dihydro-
1H), 3.88 (dt, J = 10.4, 8.1 Hz, 1H), 3.71 (m, 3H),



2H-pyrrolo[3,4-
3.37 (m, 1H), 3.10 (m, 1H), 2.80-2.55 (m, 2H),



c]pyridine-2-
2.00 (m, 2H), 1.79 (m, 2H), 1.59-1.33 (m, 2H)



carboxamide









Example 920
N-{5-[2-(2-chlorobenzyl)-1,3-thiazol-4-yl]-2-thienyl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 920A
5-(2-(2-chlorobenzyl)thiazol-4-yl)thiophen-2-amine

The title compound was prepared as described in Example 806A, substituting 2-bromo-1-(5-nitrothiophen-2-yl)ethanone for 2-bromo-1-(4-nitrophenyl)ethanone and 2-(2-chlorophenyl)ethanethioamide for 2-phenylethanethioamide.


Example 920B
N-{5-[2-(2-chlorobenzyl)-1,3-thiazol-4-yl]-2-thienyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 5-(2-(2-chlorobenzyl)thiazol-4-yl)thiophen-2-amine for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (400 MHz, DMSO-d6,) δ ppm 9.73 (s, 1H), 7.46-7.55 (m, 3H), 7.34-7.40 (m, 4H), 7.28-7.34 (m, 2H), 7.20 (d, J=3.9 Hz, 1H), 6.62 (d, J=3.9 Hz, 1H), 4.76 (s, 4H), 4.45 (s, 2H); MS (ESI(+)) m/e 452.0 (M+H).


Example 921
N-[4-(4-fluorophenyl)butyl]-5-(hydroxymethyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 4-(4-fluorophenyl)butylamine for 4-amino-N-propylbenzamide and isoindolin-5-ylmethanol hydrochloride for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.28-7.17 (m, 5H), 7.13-7.03 (m, 2H), 6.29 (t, J=5.6 Hz, 1H), 5.16 (t, J=5.6 Hz, 1H), 4.54 (bs, 4H), 4.49 (d, J=5.5 Hz, 2H), 3.15-3.04 (m, 2H), 2.58 (t, J=7.4 Hz, 2H), 1.63-1.37 (m, 4H); MS (ESI(+)) m/e 343 (M+H)+.


Example 926
N-[4-(1-isobutyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

In a 20 mL scintillation vial were mixed N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide (100 mg, 0.312 mmol), isobutyraldehyde (0.343 mmol), and sodium triacetoxyborohydride (0.43 mmol) in anhydrous dichloroethane (4 ml). The reaction mixture was stirred overnight at room temperature. This mixture was diluted with water and the resulting suspension was stirred again overnight at room temperature. The solid was filtered through a 30 mL plastic disposable Buchner funnel, and the collected solid was washed with water, dried for 2 hours, washed with ether, and dried again to provide the title compound. 1H NMR (400 MHz, DMSO-d6, Temp=90° C.) δ ppm 8.58 (s, 1H), 8.47 (d, J=5.0 Hz, 1H), 8.18 (m, 1H), 7.50 (m, 2H), 7.38 (d, J=5.1 Hz, 1H), 7.30 (m, 2H), 6.03 (m, 1H), 4.80 (m, 4H), 3.06 (m, 2H), 2.61 (t, J=5.6 Hz, 2H), 2.44 (m, 2H), 2.17 (d, J=7.2 Hz, 2H), 1.82 (m, 1H), 0.89 (d, J=6.6 Hz, 6H); MS (ESI(+)) m/e 377 (M+H).


Example 927
N-{4-[1-(tetrahydrofuran-3-ylmethyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 926, substituting tetrahydrofuran-3-carbaldehyde for isobutraldehyde. 1H NMR (400 MHz, DMSO-d6, Temp=90° C.) δ ppm 8.58 (s, 1H), 8.48 (d, J=5.0 Hz, 1H), 8.17 (bs, 1H), 7.60 (m, 2H), 7.38 (d, J=5.0 Hz, 1H), 7.30 (m, 2H), 6.05 (m, 1H), 4.83 (m, 4H), 3.77 (m, 2H), 3.62 (q, J=7.6 Hz, 1H), 3.39 (m, 1H), 3.10 (t, J=3.1 Hz, 2H), 2.95 (m, 1H), 2.65 (m, 2H), 2.43 (m, 2H), 2.38 (m, 2H), 1.95 (m, 1H), 1.54 (m, 1H); MS (ESI(+)) m/e 405 (M+H).


Example 928
N-{4-[1-(tetrahydro-2H-pyran-4-ylmethyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 926, substituting tetrahydro-2H-pyran-4-carbaldehyde for isobutraldehyde. 1H NMR (400 MHz, DMSO-d6, Temp=90° C.) δ ppm 8.58 (s, 1H), 8.48 (d, J=5.0 Hz, 1H), 8.17 (bs, 1H), 7.50 (m, 2H), 7.38 (d, J=5.1 Hz, 1H), 7.30 (m, 2H), 6.03 (m, 1H), 4.79 (m, 4H), 3.83 (m, 2H), 3.31 (td, J=11.5, 2.2 Hz, 2H), 3.07 (m, 2H), 2.63 (t, J=5.6 Hz, 2H), 2.43 (m, 2H), 2.27 (d, J=7.1 Hz, 2H), 1.80 (m, 1H), 1.64 (m, 2H), 1.17 (m, 2H); MS (ESI(+)) m/e 419 (M+H).


Example 929
N-[4-(1-isobutylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 926, substituting N-(4-(piperidin-4-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.33 (s, 1H), 7.43 (m, 3H), 7.13 (m, 2H), 4.79 (m, 4H), 2.41 (m, 1H), 2.92 (m, 2H), 2.15-1.85 (m, 4H), 1.85-1.50 (m, 5H), 0.87 (d, J=6.5 Hz, 6H); MS (ESI(+)) m/e 379 (M+H).


Example 930
N-{4-[1-(tetrahydrofuran-3-ylmethyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 926, substituting N-(4-(piperidin-4-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide and tetrahydrofuran-3-carbaldehyde for isobutraldehyde. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.33 (s, 1H), 7.44 (m, 3H), 7.13 (m, 2H), 4.78 (m, 4H), 3.71 (m, 2H), 3.61 (q, J=7.6 Hz, 1H), 3.36 (m, 2H), 2.96 (m, 2H), 2.40 (m, 1H), 2.27 (m, 2H), 96 (m, 3H), 1.72 (m, 2H), 1.66-1.46 (m, 3H); MS (ESI(+)) m/e 407 (M+H).


Example 931
N-{4-[1-(tetrahydro-2H-pyran-4-ylmethyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 926, substituting N-(4-(piperidin-4-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide and tetrahydro-2H-pyran-4-carbaldehyde for isobutraldehyde. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H), 8.49 (d, J=5.0 Hz, 1H), 8.33 (s, 1H), 7.44 (m, 3H), 7.12 (m, 2H), 4.79 (m, 4H), 3.83 (m, 2H), 3.27 (m, 2H), 2.92 (m, 2H), 2.40 (m, 1H), 2.14 (d, J=7.2 Hz, 2H), 1.95 (m, 2H), 1.74 (m, 3H), 1.61 (m, 4H), 1.12 (m, 2H); MS (ESI(+)) m/e 421 (M+H).


Example 933
tert-butyl {4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]benzyl}carbamate

The title compound was prepared as described in Example 272B, substituting tert-butyl 4-aminobenzylcarbamate for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.29 (s, 1H), 7.52-7.45 (m, 2H), 7.40-7.24 (m, 5H), 7.15-7.08 (m, 2H), 4.76 (bs, 4H), 4.09-3.99 (m, 2H), 1.39 (s, 9H); MS (ESI(+)) m/e 368 (M+H)+.


Example 934
N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
Example 934A
N-(4-nitrophenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide

The title compound was prepared as described in Example 1A, substituting 1-isocyanato-4-nitrobenzene for methyl 4-isocyanatobenzoate and 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine for isoindoline.


Example 934B
N-(4-aminophenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide

The title compound was prepared as described in Example 272A, substituting N-(4-nitrophenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 4-nitro-N-propylbenzamide.


Example 934C
N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(4-aminophenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and cyclopentylacetic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 9.70 (s, 1H), 8.60 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.34 (s, 1H), 7.51 -7.40 (m, 5H), 4.82-4.75 (m, 4H), 2.33-2.17 (m, 3H), 1.81-1.68 (m, 2H), 1.68-1.43 (m, 4H), 1.27-1.13 (m, 2H); (ESI(+)) m/e 365 (M+H)+.


Example 936
N-[4-(5-{[(tetrahydrofuran-2-ylmethyl)amino]methyl}-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 753B, substituting (tetrahydrofuran-2-yl)methanamine for morpholine. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.68 (s, 1H), 7.91 (d, J=8.7 Hz, 2H), 7.79 (d, J=8.8 Hz, 2H), 7.45-7.20 (m, 4H), 4.80 (s, 4H), 4.08 (s, 2H), 3.95-3.78 (m, 1H), 3.79-3.66 (m, 1H), 3.66-3.49 (m, 1H), 2.66 (d, J=5.6 Hz, 2H), 2.00-1.67 (m, 4H), 1.67-1.41 (m, 2H), 1.40-1.16 (m, 2H), 0.87 (dd, J=9.3, 5.4 Hz, 1H); MS (ESI(+)) m/e 420 (M+H)+.


Example 937
N-(4-{5-[(4-methoxypiperidin-1-yl)methyl]-1,2,4-oxadiazol-3-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 753B, substituting 4-methoxypiperidine for morpholine. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.69 (s, 1H), 7.92 (d, J=8.8 Hz, 2H), 7.80 (d, J=8.8 Hz, 2H), 7.45-7.20 (m, 4H), 4.80 (s, 4H), 3.93 (s, 2H), 3.21 (s, 3H), 3.20-3.10 (m, 1H), 2.82-2.68 (m, 2H), 2.50 (dt, J=3.6, 1.8 Hz, 2H), 2.41-2.24 (m, 2H), 1.92-1.75 (m, 2H), 1.56-1.37 (m, 2H); MS (ESI(+)) m/e 434 (M+H)+.


Example 938
N-[4-(5-{[4-(2-methoxyethyl)piperazin-1-yl]methyl}-1,2,4-oxadiazol-3-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 753B, substituting N-(2-methoxyethyl)piperazine for morpholine. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.69 (s, 1H), 7.92 (d, J=8.8 Hz, 2H), 7.86-7.70 (m, 2H), 7.46-7.23 (m, 4H), 4.80 (s, 4H), 3.93 (s, 2H), 3.40 (t, J=5.8 Hz, 3H), 3.21 (s, 3H), 2.55 (s, 4H), 2.45 (t, J=5.8 Hz, 6H); MS (ESI(+)) m/e 463 (M+H)+.


Example 940
N-{4-[(1-pentanoylpiperidin-4-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
Example 940A
tert-butyl 4-(4-nitrophenoxy)piperidine-1-carboxylate

4-Hydroxy-1-piperidine-1-carboxylic acid tert-butyl ester (6.04 g, 30 mmol) was dissolved in 1-fluoro-4-nitrobenzene (7.83 g, 55.5 mmol). Aqueous potassium hydroxide solution (25 percent wt, 44 mL) was added, followed by addition of tetrabutylammonium bromide (1.26 g). The reaction mixture was stirred at 35° C. for 17 hours. The solid was collected by filtration and washed with water (4×50 mL) to provide the title compound after vacuum drying.


Example 940B
tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate

The title compound was prepared as described in Example 274, substituting tert-butyl 4-(4-nitrophenoxy)piperidine-1-carboxylate for 5-nitro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide.


Example 940C
tert-butyl 4-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenoxy)piperidine-1-carboxylate

The title compound was prepared as described in Example 272B, substituting tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate for 4-amino-N-propylbenzamide and 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine for methyl isoindoline-5-carboxylate hydrochloride.


Example 940D
N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenoxy)piperidine-1-carboxylate for tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 940E
N-{4-[(1-pentanoylpiperidin-4-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and pentanoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.80 (s, 1H), 8.68 (d, J=5.5 Hz, 1H), 8.36 (s, 1H), 7.77 (d, J=5.5 Hz, 1H), 7.42 (d, J=9.0 Hz, 1H), 6.95-6.87 (m, 2H), 4.87 (d, J=6.4 Hz, 4H), 4.64-4.45 (m, 1H), 3.92-3.79 (m, 1H), 3.76-3.63 (m, 1H), 3.38-3.15 (m, 2H), 2.31 (t, J=7.4 Hz, 2H), 1.96-1.81 (m, 2H), 1.61-1.41 (m, 4H), 1.38-1.22 (m, 2H), 0.88 (t, J=7.2 Hz, 3H); MS (ESI(+)) m/e 423 (M+H)+.









TABLE 16







The following Examples were essentially prepared as described in Example 940, substituting


the appropriate alcohol, in place of 4-hydroxy-1-piperidine-1-carboxylic acid tert-butyl


ester in Example 940A, and the appropriate carboxylic acid in Example 940E.










Ex
Name

1H NMR

MS













941
N-{4-[(1-
1H NMR (300 MHz, DMSO-d6) δ 8.83 (s, 1H), 8.71
(ESI(+))



acetylpiperidin-4-
(d, J = 5.6 Hz, 1H), 8.38 (s, 1H), 7.83 (d, J = 5.6 Hz,
m/e 381



yl)oxy]phenyl}-1,3-
1H), 7.42 (d, J = 8.9 Hz, 2H), 6.91 (d, J = 9.0 Hz,
(M + H)+



dihydro-2H-
2H), 4.89 (d, J = 9.8 Hz, 4H), 4.57-4.44 (m, 1H),



pyrrolo[3,4-
3.91-3.76 (m, 1H), 3.76-3.57 (m, 1H), 3.43-3.12



c]pyridine-2-
(m, 2H), 2.02 (s, 3H), 1.97-1.77 (m, 2H), 1.68-1.33



carboxamide
(m, 2H)


942
N-{4-[(1-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50

(ESI(+))



butyrylpiperidin-4-
(d, J = 5.0 Hz, 1H), 8.28 (s, 1H), 7.43 (dd, J = 7.0, 1.8
m/e 409



yl)oxy]phenyl}-1,3-
Hz, 3H), 6.90 (d, J = 9.0 Hz, 2H), 4.78 (d, J = 4.0 Hz,
(M + H)+



dihydro-2H-
4H), 4.57-4.39 (m, 1H), 3.95-3.76 (m, 1H), 3.70



pyrrolo[3,4-
(d, J = 14.0 Hz, 1H), 3.23 (dd, J = 15.9, 6.4 Hz, 1H),



c]pyridine-2-
2.30 (t, J = 7.4 Hz, 2H), 1.90 (s, 2H), 1.51 (dq, J =



carboxamide
14.6, 7.3 Hz, 4H), 0.89 (t, J = 7.4 Hz, 3H)


943
N-(4-{[1-(2-

1H NMR (300 MHz, DMSO-d6) δ 8.79 (s, 1H), 8.67

(ESI(+))



methylbutanoyl)pi-
(d, J = 5.5 Hz, 1H), 8.36 (s, 1H), 7.76 (d, J = 5.5 Hz,
m/e 423



peridin-4-
1H), 7.42 (d, J = 9.0 Hz, 1H), 6.91 (d, J = 9.0 Hz,
(M + H)+



yl]oxy}phenyl)-1,3-
1H), 4.87 (d, J = 5.8 Hz, 2H), 4.66-4.47 (m, 1H),



dihydro-2H-
3.98-3.74 (m, 2H), 3.43-3.14 (m, 2H), 2.81-2.63



pyrrolo[3,4-
(m, 1H), 1.99-1.82 (m, 2H), 1.55 (dt, J = 20.8, 7.2



c]pyridine-2-
Hz, 1H), 1.31 (td, J = 13.9, 7.1 Hz, 1H), 0.98 (d, J =



carboxamide
6.7 Hz, 3H), 0.81 (t, J = 7.4 Hz, 1H)


944
N-(4-{[1-(3,3,3-

1H NMR (300 MHz, DMSO-d6) δ 8.80 (s, 1H), 8.68

(ESI(+))



trifluoropropanoyl)pi-
(d, J = 5.5 Hz, 1H), 8.37 (s, 1H), 7.78 (d, J = 5.5 Hz,
m/e 449



peridin-4-
1H), 7.42 (d, J = 8.9 Hz, 2H), 6.91 (d, J = 8.9 Hz,
(M + H)+



yl]oxy}phenyl)-1,3-
2H), 4.88 (d, J = 7.3 Hz, 5H), 4.60-4.44 (m, 1H),



dihydro-2H-
3.85 (dd, J = 14.1, 5.4 Hz, 1H), 3.67 (q, J = 11.0 Hz,



pyrrolo[3,4-
3H), 3.41-3.21 (m, 2H), 1.92 (dd, J = 16.5, 13.5 Hz,



c]pyridine-2-
2H), 1.73-1.35 (m, 2H)



carboxamide


945
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50

(ESI(+))



(methoxyacetyl)pi-
(d, J = 5.0 Hz, 1H), 8.28 (s, 1H), 7.43 (dd, J = 6.9, 1.9
m/e 411



peridin-4-
Hz, 3H), 6.90 (d, J = 9.0 Hz, 2H), 4.78 (d, J = 3.9 Hz,
(M + H)+



yl]oxy}phenyl)-1,3-
5H), 4.51 (dd, J = 7.8, 3.9 Hz, 1H), 4.09 (s, 2H), 3.89-



dihydro-2H-
3.74 (m, 1H), 3.62 (ddd, J = 8.2, 4.1, 1.1 Hz, 1H),



pyrrolo[3,4-
3.29 (s, 3H), 1.91 (d, J = 1.3 Hz, 2H), 1.69-1.39 (m,



c]pyridine-2-
2H)



carboxamide


946
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.80 (s, 1H), 8.69

(ESI(+))



(tetrahydrofuran-2-
(d, J = 5.5 Hz, 1H), 8.36 (s, 1H), 7.78 (d, J = 5.5 Hz,
m/e 437



ylcarbonyl)piperidin-
1H), 7.42 (d, J = 9.0 Hz, 2H), 6.91 (d, J = 9.0 Hz,
(M + H)+



4-yl]oxy }phenyl)-
2H), 4.88 (d, J = 8.2 Hz, 4H), 4.76-4.62 (m, 1H),



1,3-dihydro-2H-
4.52 (s, 1H), 3.75 (dd, J = 12.0, 6.6 Hz, 5H), 3.48-



pyrrolo[3,4-
3.14 (m, 2H), 1.91 (dddd, J = 19.4, 15.1, 7.6, 5.2 Hz,



c]pyridine-2-
6H), 1.51 (dd, J = 20.6, 12.0 Hz, 2H)



carboxamide


947
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50

(ESI(+))



(cyclopropylcarbon-
(d, J = 5.0 Hz, 1H), 8.27 (s, 1H), 7.43 (d, J = 8.9 Hz,
m/e 407



yl)piperidin-4-
3H), 6.91 (d, J = 9.0 Hz, 2H), 4.78 (d, J = 4.0 Hz,
(M + H)+



yl]oxy}phenyl)-1,3-
4H), 4.53 (dt, J = 7.9, 4.0 Hz, 1H), 4.06-3.66 (m,



dihydro-2H-
2H), 3.64-3.39 (m, 1H), 2.08-1.73 (m, 3H), 1.73-



pyrrolo[3,4-
1.37 (m, 2H), 0.84-0.52 (m, 4H)



c]pyridine-2-



carboxamide


948
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50

(ESI(+))



(cyclopropylacetyl)
(d, J = 5.0 Hz, 1H), 8.27 (s, 1H), 7.42 (dd, J = 7.0, 1.8
m/e 421



piperidin-4-
Hz, 2H), 6.90 (d, J = 9.0 Hz, 1H), 4.81-4.74 (m,
(M + H)+



yl]oxy}phenyl)-1,3-
4H), 4.57-4.45 (m, 1H), 3.93-3.81 (m, 1H), 3.73-



dihydro-2H-
3.62 (m, 1H), 2.27 (d, J = 6.7 Hz, 2H), 1.99-1.82 (m,



pyrrolo[3,4-
2H), 1.68-1.35 (m, 2H), 1.04-0.87 (m, 1H), 0.50-



c]pyridine-2-
0.40 (m, 2H), 0.16-0.07 (m, 2H)



carboxamide


949
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.83 (s, 1H), 8.71

(ESI(+))



(cyclobutylcarbonyl)
(d, J = 5.6 Hz, 1H), 8.37 (s, 1H), 7.82 (d, J = 5.6 Hz,
m/e 421



piperidin-4-
1H), 7.41 (d, J = 9.0 Hz, 2H), 6.90 (d, J = 9.0 Hz,
(M + H)+



yl]oxy}phenyl)-1,3-
2H), 4.89 (d, J = 9.7 Hz, 4H), 4.61-4.38 (m, 1H),



dihydro-2H-
3.90-3.75 (m, 1H), 3.64-3.46 (m, 1H), 3.27-3.06



pyrrolo[3,4-
(m, 2H), 2.12 (ddd, J = 13.8, 12.3, 7.5 Hz, 4H), 2.00-



c]pyridine-2-
1.77 (m, 3H), 1.74 (dd, J = 9.1, 4.8 Hz, 1H), 1.59-



carboxamide
1.28 (m, 2H)


950
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.78 (s, 1H), 8.66

(ESI(+))



(cyclopentylcarbon-
(d, J = 5.5 Hz, 1H), 8.35 (s, 1H), 7.74 (d, J = 5.4 Hz,
m/e 435



yl)piperidin-4-
1H), 7.42 (d, J = 9.0 Hz, 2H), 6.91 (d, J = 9.0 Hz,
(M + H)+



yl]oxy}phenyl)-1,3-
2H), 4.87 (d, J = 4.5 Hz, 4H), 4.51 (dd, J = 7.7, 3.9



dihydro-2H-
Hz, 1H), 3.92-3.70 (m, 2H), 3.45-3.30 (m, 1H),



pyrrolo[3,4-
3.21 (dd, J = 18.3, 8.9 Hz, 1H), 2.98 (dd, J = 15.4, 7.5



c]pyridine-2-
Hz, 1H), 2.01-1.38 (m, 12H)



carboxamide


951
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.78 (s, 1H), 8.67

(ESI(+))



(cyclopentylacetyl)pi-
(d, J = 5.4 Hz, 1H), 8.35 (s, 1H), 7.75 (d, J = 5.5 Hz,
m/e 449



peridin-4-
1H), 7.42 (d, J = 9.0 Hz, 2H), 6.91 (d, J = 9.0 Hz,
(M + H)+



yl]oxy}phenyl)-1,3-
2H), 4.87 (d, J = 5.1 Hz, 5H), 4.55-4.45 (m, 1H),



dihydro-2H-
3.86 (d, J = 12.3 Hz, 1H), 3.71 (d, J = 14.1 Hz, 1H),



pyrrolo[3,4-
3.39-3.08 (m, 2H), 2.34 (d, J = 7.1 Hz, 2H), 2.13 (dt,



c]pyridine-2-
J = 15.3, 7.6 Hz, 1H), 1.90 (s, 2H), 1.74 (dt, J = 11.2,



carboxamide
6.5 Hz, 2H), 1.65-1.36 (m, 6H), 1.23-1.02 (m, 2H)


952
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.78 (s, 1H), 8.66

(ESI(+))



(cyclohexylcarbon-
(d, J = 5.4 Hz, 1H), 8.35 (s, 1H), 7.74 (d, J = 5.3 Hz,
m/e 449



yl)piperidin-4-
1H), 7.42 (d, J = 9.0 Hz, 2H), 6.91 (d, J = 9.0 Hz,
(M + H)+



yl]oxy}phenyl)-1,3-
2H), 4.87 (d, J = 4.5 Hz, 4H), 4.54-4.44 (m, 1H),



dihydro-2H-
3.83 (s, 2H), 3.17 (d, J = 0.9 Hz, 2H), 2.63-2.52 (m,



pyrrolo[3,4-
1H), 1.91 (s, 3H), 1.61 (dd, J = 38.7, 30.1 Hz, 7H),



c]pyridine-2-
1.43-1.02 (m, 7H)



carboxamide


987
N-(4-{[1-(3,3,3-

1H NMR (300 MHz, DMSO-d6) δ 8.77 (s, 1H), 8.65

(ESI(+))



trifluoropropanoyl)azetidin-
(d, J = 5.4 Hz, 1H), 8.38 (s, 1H), 7.72 (d, J = 5.5 Hz,
m/e 421



3-yl]oxy}phenyl)-1,3-
2H), 7.45 (d, J = 9.1 Hz, 2H), 6.78 (d, J = 9.1 Hz,
(M + H)+



dihydro-2H-
2H), 5.06-4.93 (m, 1H), 4.87 (d, J = 3.6 Hz, 4H),



pyrrolo[3,4-
4.60 (dd, J = 8.6, 6.5 Hz, 1H), 4.34 (dd, J = 11.0, 6.1



c]pyridine-2-
Hz, 1H), 4.15 (dd, J = 9.6, 2.9 Hz, 1H), 3.81 (dd, J =



carboxamide
10.7, 3.8 Hz, 1H), 3.40 (q, J = 11.2 Hz, 2H)


988
N-(4-{[1-(4,4,4-

1H NMR (300 MHz, DMSO-d6) δ 8.69 (s, 1H), 8.58

(ESI(+))



trifluorobutanoyl)azetidin-
(d, J = 5.3 Hz, 1H), 8.34 (s, 1H), 7.58 (d, J = 5.2 Hz,
m/e 435



3-yl]oxy}phenyl)-1,3-
1H), 7.45 (d, J = 9.1 Hz, 2H), 6.78 (d, J = 9.0 Hz,
(M + H)+



dihydro-2H-
2H), 4.98 (dd, J = 8.4, 4.4 Hz, 1H), 4.82 (s, 4H), 4.66-



pyrrolo[3,4-
4.49 (m, 1H), 4.31 (dd, J = 10.6, 6.5 Hz, 1H), 4.13



c]pyridine-2-
(dd, J = 9.4, 3.5 Hz, 1H), 3.78 (dd, J = 10.5, 3.7 Hz,



carboxamide
2H), 2.40-2.29 (m, 4H)


989
N-(4-{[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.57 (s,

(ESI(+))



(tetrahydrofuran-2-
1H), 8.47 (d, J = 5.0 Hz, 1H), 8.06 (s, 1H), 7.50-7.39
m/e 409



ylcarbonyl)azetidin-
(m, 2H), 7.37 (d, J = 4.9 Hz, 1H), 6.82-6.70 (m, 2H),
(M + H)+



3-yl]oxy}phenyl)-
4.98 (tt, J = 6.5, 4.1 Hz, 1H), 4.83-4.73 (m, 5H),



1,3-dihydro-2H-
4.34 (dd, J = 7.6, 6.2 Hz, 2H), 3.85-3.61 (m, 4H),



pyrrolo[3,4-
2.10-1.90 (m, 2H), 1.90-1.70 (m, 2H)



c]pyridine-2-



carboxamide


990
N-(4-{[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.57 (s,

(ESI(+))



(tetrahydrofuran-3-
1H), 8.47 (d, J = 5.0 Hz, 1H), 8.06 (s, 1H), 7.50-7.41
m/e 423



ylacetyl)azetidin-3-
(m, 2H), 7.37 (d, J = 5.0 Hz, 1H), 6.92-6.66 (m, 2H),
(M + H)+



yl]oxy}phenyl)-1,3-
5.03-4.91 (m, 1H), 4.83-4.73 (m, 5H), 3.78 (dd, J =



dihydro-2H-
8.3, 7.1 Hz, 1H), 3.71 (td, J = 8.1, 5.4 Hz, 1H), 3.62



pyrrolo[3,4-
(dd, J = 15.4, 7.4 Hz, 1H), 3.27 (dd, J = 8.4, 6.5 Hz,



c]pyridine-2-
1H), 2.24-2.09 (m, 3H), 2.05-1.89 (m, 1H), 1.50



carboxamide
(dt, J = 14.7, 7.0 Hz, 1H)


991
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.76 (s, 1H), 8.64

(ESI(+))



(cyclobutylcarbonyl)
(d, J = 5.4 Hz, 1H), 8.38 (s, 1H), 7.70 (d, J = 5.4 Hz,
m/e 393



azetidin-3-
1H), 7.44 (d, J = 9.0 Hz, 2H), 6.77 (d, J = 9.0 Hz,
(M + H)+



yl]oxy}phenyl)-1,3-
2H), 5.05-4.90 (m, 1H), 4.86 (s, 4H), 4.52-4.40 (m,



dihydro-2H-
1H), 4.30-4.20 (m, 1H), 3.97 (dd, J = 9.5, 3.8 Hz,



pyrrolo[3,4-
1H), 3.74 (dd, J = 10.4, 3.8 Hz, 1H), 3.12 (p, J = 8.4



c]pyridine-2-
Hz, 1H), 2.19-1.96 (m, 4H), 1.96-1.79 (m, 1H),



carboxamide
1.79-1.62 (m, 1H)


992
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.77 (s, 1H), 8.66

(ESI(+))



(cyclopentylcarbon-
(d, J = 5.4 Hz, 1H), 8.38 (s, 1H), 7.73 (d, J = 5.3 Hz,
m/e 407



yl)azetidin-3-
1H), 7.45 (d, J = 9.0 Hz, 2H), 6.78 (d, J = 9.0 Hz,
(M + H)+



yl]oxy}phenyl)-1,3-
2H), 4.97 (t, J = 5.1 Hz, 1H), 4.87 (d, J = 3.9 Hz, 4H),



dihydro-2H-
4.64-4.47 (m, 1H), 4.27 (dd, J = 10.3, 6.6 Hz, 1H),



pyrrolo[3,4-
4.14-4.02 (m, 1H), 3.82-3.65 (m, 1H), 2.76-2.55



c]pyridine-2-
(m, 1H), 1.89-1.39 (m, 8H)



carboxamide


993
N-(4-{[1-(3-

1H NMR (300 MHz, DMSO-d6) δ 8.80 (s, 1H), 8.68

(ESI(+))



phenylpropanoyl)pyrrolidin-
(d, J = 5.4 Hz, 1H), 8.37 (s, 1H), 7.77 (d, J = 5.3 Hz,
m/e 457



3-yl]oxy}phenyl)-1,3-
1H), 7.49-7.37 (m, 2H), 7.33-7.11 (m, 5H), 6.87
(M + H)+



dihydro-2H-
(dd, J = 9.1, 2.3 Hz, 2H), 4.91 (dd, J = 22.6, 11.0 Hz,



pyrrolo[3,4-
5H), 3.51 (d, J = 9.0 Hz, 4H), 2.81 (dd, J = 13.6, 7.3



c]pyridine-2-
Hz, 2H), 2.63-2.51 (m, 2H), 2.07 (dd, J = 17.7, 8.2



carboxamide
Hz, 2H)


994
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.49

(ESI(+))



(phenylacetyl)pyrrolidin-3-
(d, J = 5.0 Hz, 1H), 8.29 (s, 1H), 7.43 (dd, J = 6.8, 4.6
m/e 443



yl]oxy}phenyl)-1,3-
Hz, 3H), 7.38-7.10 (m, 5H), 6.86 (dd, J = 8.9, 1.9
(M + H)+



dihydro-2H-
Hz, 2H), 4.98 (d, J = 21.6 Hz, 1H), 4.78 (d, J = 4.4



pyrrolo[3,4-
Hz, 4H), 3.59 (dd, J = 29.8, 8.4 Hz, 6H), 2.24-1.94



c]pyridine-2-
(m, 2H)



carboxamide


995
N-[4-({1-[(4-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.49

(ESI(+))



methoxyphenyl)ace-
(d, J = 5.0 Hz, 1H), 8.29 (s, 1H), 7.52-7.34 (m, 3H),
m/e 473



tyl]pyrrolidin-3-
7.14 (t, J = 8.1 Hz, 2H), 6.95-6.73 (m, 4H), 4.97 (d,
(M + H)+



yl}oxy)phenyl]-1,3-
J = 21.7 Hz, 1H), 4.78 (d, J = 4.4 Hz, 4H), 3.70 (t, J =



dihydro-2H-
10.2 Hz, 5H), 3.63-3.47 (m, 4H), 2.31-1.91 (m,



pyrrolo[3,4-
2H)



c]pyridine-2-



carboxamide


996
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.82 (s, 1H), 8.70

(ESI(+))



(methoxyacetyl)pyr-
(d, J = 5.5 Hz, 1H), 8.39 (s, 1H), 7.81 (d, J = 5.3 Hz,
m/e 397



rolidin-3-
1H), 7.44 (d, J = 9.0 Hz, 2H), 6.96-6.81 (m, 2H),
(M + H)+



yl]oxy}phenyl)-1,3-
4.91 (t, J = 9.8 Hz, 5H), 4.05 (s, 1H), 3.99 (s, 1H),



dihydro-2H-
3.76-3.32 (m, 4H), 3.30 (s, 1.5H), 3.28 (s, 1.5H),



pyrrolo[3,4-
2.13 (dd, J = 7.4, 3.7 Hz, 1H), 2.07-1.96 (m, 1H)



c]pyridine-2-



carboxamide


997
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50

(ESI(+))



(cyclopropylcarbon-
(d, J = 5.0 Hz, 1H), 8.29 (s, 1H), 7.53-7.32 (m, 3H),
m/e 393



yl)pyrrolidin-3-
6.89 (dd, J = 9.0, 7.4 Hz, 2H), 5.03 (dd, J = 18.0, 16.5
(M + H)+



yl]oxy}phenyl)-1,3-
Hz, 1H), 4.78 (d, J = 3.8 Hz, 4H), 3.98-3.61 (m,



dihydro-2H-
2H), 3.51 (m, 2H), 2.31-1.91 (m, 2H), 1.76 (d, J =



pyrrolo[3,4-
20.7 Hz, 1H), 0.83-0.59 (m, 4H)



c]pyridine-2-



carboxamide


998
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.80 (s, 1H), 8.68

(ESI(+))



(cyclohexylcarbon-
(d, J = 5.5 Hz, 1H), 8.37 (s, 1H), 7.77 (d, J = 5.0 Hz,
m/e 435



yl)pyrrolidin-3-
1H), 7.43 (dd, J = 9.0, 1.8 Hz, 2H), 6.88 (dd, J = 9.0,
(M + H)+



yl]oxy}phenyl)-1,3-
7.5 Hz, 2H), 5.01 (s, 1H), 4.89 (t, J = 8.6 Hz, 4H),



dihydro-2H-
3.82-3.25 (m, 4H), 2.43-1.93 (m, 3H), 1.67 (d, J =



pyrrolo[3,4-
10.0 Hz, 5H), 1.47-1.03 (m, 5H)



c]pyridine-2-



carboxamide


999
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.76 (s, 1H), 8.65

(ESI(+))



(cyclopentylace-
(d, J = 5.4 Hz, 1H), 8.35 (s, 1H), 7.71 (d, J = 5.2 Hz,
m/e 435



tyl)pyrrolidin-3-
1H), 7.44 (d, J = 8.6 Hz, 2H), 7.02-6.78 (m, 2H),
(M + H)+



yl]oxy}phenyl)-1,3-
4.96 (d, J = 21.3 Hz, 1H), 4.86 (d, J = 2.2 Hz, 4H),



dihydro-2H-
3.67-3.44 (m, 4H), 2.31-2.01 (m, 5H), 1.75 (s, 2H),



pyrrolo[3,4-
1.62-1.38 (m, 4H), 1.10 (dd, J = 13.0, 5.9 Hz, 2H)



c]pyridine-2-



carboxamide


1000
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.76 (s, 1H), 8.64

(ESI(+))



(cyclopentylcarbon-
(d, J = 5.4 Hz, 1H), 8.35 (s, 1H), 7.70 (d, J = 5.0 Hz,
m/e 421



yl)pyrrolidin-3-
1H), 7.54-7.34 (m, 2H), 6.97-6.77 (m, 2H), 4.97
(M + H)+



yl]oxy}phenyl)-1,3-
(m, 1H), 4.86 (s, 4H), 3.69-3.36 (m, 4H), 2.95-2.68



dihydro-2H-
(m, 1H), 2.11 (ddd, J = 17.8, 8.5, 4.2 Hz, 2H), 1.86-



pyrrolo[3,4-
1.41 (m, 8H)



c]pyridine-2-



carboxamide


1001
N-{4-[(1-

1H NMR (300 MHz, DMSO-d6) δ 8.78 (d, J = 2.9 Hz,

(ESI(+))



benzoylpyrrolidin-3-
1H), 8.67 (d, J = 4.0 Hz, 1H), 8.36 (d, J = 14.5 Hz,
m/e 429



yl)oxy]phenyl}-1,3-
1H), 7.75 (d, J = 4.4 Hz, 1H), 7.61-7.33 (m, 7H),
(M + H)+



dihydro-2H-
6.88 (dd, J = 27.8, 8.9 Hz, 2H), 4.98 (m, 1H), 4.87 (m,



pyrrolo[3,4-
4H), 3.90-3.75 (m, 1H), 3.71-3.57 (m, 2H), 3.46



c]pyridine-2-
(d, J = 24.5 Hz, 1H), 2.11 (d, J = 13.7 Hz, 2H)



carboxamide


1002
N-(4-{[1-(3-

1H NMR (300 MHz, DMSO-d6) δ 8.73 (s, 1H), 8.61

(ESI(+))



ethoxypropanoyl)pyr-
(d, J = 5.3 Hz, 1H), 8.34 (s, 1H), 7.65 (d, J = 5.1 Hz,
m/e 425



rolidin-3-
1H), 7.44 (dd, J = 9.0, 1.1 Hz, 2H), 6.88 (dd, J = 9.0,
(M + H)+



yl]oxy}phenyl)-1,3-
5.3 Hz, 2H), 4.97 (d, J = 19.1 Hz, 1H), 4.84 (s, 4H),



dihydro-2H-
3.62-3.47 (m, 6H), 3.47-3.32 (m, 4H), 2.19-2.09



pyrrolo[3,4-
(m, 1H), 2.09-2.00 (m, 1H), 1.07 (dt, J = 9.8, 7.0 Hz,



c]pyridine-2-
3H)



carboxamide


1003
N-[4-({1-[(2-

1H NMR (300 MHz, DMSO-d6) δ 8.78 (s, 1H), 8.66

(ESI(+))



methylcyclopropyl)car-
(d, J = 5.4 Hz, 1H), 8.36 (s, 1H), 7.74 (d, J = 5.3 Hz,
m/e 407



bonyl]pyrrolidin-
1H), 7.54-7.35 (m, 2H), 6.88 (td, J = 9.9, 5.3 Hz,
(M + H)+



3-yl}oxy)phenyl]-
2H), 4.99 (d, J = 30.6 Hz, 1H), 4.87 (d, J = 4.1 Hz,



1,3-dihydro-2H-
4H), 3.94-3.58 (m, 2H), 3.52 (t, J = 5.2 Hz, 2H),



pyrrolo[3,4-
2.29-2.01 (m, 2H), 1.57-1.42 (m, 1H), 1.12-1.01



c]pyridine-2-
(m, 4H), 0.94 (ddd, J = 9.5, 7.6, 4.7 Hz, 1H), 0.62-



carboxamide
0.50 (m, 1H)


1004
N-[4-({1-[(1-

1H NMR (300 MHz, DMSO-d6) δ 8.77 (s, 1H), 8.65

(ESI(+))



methylcyclopropyl)car-
(d, J = 5.4 Hz, 1H), 8.36 (s, 1H), 7.72 (d, J = 5.4 Hz,
m/e 407



bonyl]pyrrolidin-
1H), 7.57-7.37 (m, 2H), 6.88 (d, J = 9.0 Hz, 2H),
(M + H)+



3-yl}oxy)phenyl]-
4.97 (s, 1H), 4.87 (d, J = 3.5 Hz, 4H), 4.26 (s, 2H),



1,3-dihydro-2H-
3.77 (s, 2H), 2.10 (s, 2H), 1.26-1.17 (m, 3H), 0.92-



pyrrolo[3,4-
0.80 (m, 1H), 0.66 (s, 1H), 0.48 (s, 2H)



c]pyridine-2-



carboxamide


1005
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.75 (s, 1H), 8.63

(ESI(+))



(cyclobutylcarbonyl)
(d, J = 5.3 Hz, 1H), 8.34 (s, 1H), 7.68 (d, J = 5.1 Hz,
m/e 407



pyrrolidin-3-
1H), 7.49-7.34 (m, 2H), 6.94-6.76 (m, 2H), 4.95
(M + H)+



yl]oxy}phenyl)-1,3-
(d, J = 17.9 Hz, 1H), 4.85 (s, 4H), 3.67-3.10 (m,



dihydro-2H-
5H), 2.10 (dtd, J = 19.7, 15.3, 8.2 Hz, 6H), 1.96-1.64



pyrrolo[3,4-
(m, 2H)



c]pyridine-2-



carboxamide


1006
N-(4-{[1-(3-

1H NMR (300 MHz, DMSO-d6) δ 8.79 (s, 1H), 8.67

(ESI(+))



methylbutanoyl)pyr-
(d, J = 5.4 Hz, 1H), 8.37 (s, 1H), 7.75 (d, J = 5.4 Hz,
m/e 409



rolidin-3-
1H), 7.44 (d, J = 9.0 Hz, 2H), 6.96-6.76 (m, 2H),
(M + H)+



yl]oxy}phenyl)-1,3-
4.97 (d, J = 21.3 Hz, 1H), 4.87 (d, J = 5.4 Hz, 4H),



dihydro-2H-
3.83-3.24 (m, 4H), 2.25-1.98 (m, 5H), 0.98-0.81



pyrrolo[3,4-
(m, 6H)



c]pyridine-2-



carboxamide


1007
N-(4-{[1-(2-

1H NMR (300 MHz, DMSO-d6) δ 8.76 (s, 1H), 8.65

(ESI(+))



methylpropanoyl)pyr-
(d, J = 5.4 Hz, 1H), 8.36 (s, 1H), 7.71 (d, J = 5.0 Hz,
m/e 395



rolidin-3-
1H), 7.44 (d, J = 8.8 Hz, 2H), 6.88 (dd, J = 9.0, 6.9
(M + H)+



yl]oxy}phenyl)-1,3-
Hz, 2H), 4.97 (d, J = 25.9 Hz, 1H), 4.86 (d, J = 2.6



dihydro-2H-
Hz, 4H), 3.80-3.26 (m, 4H), 2.64 (ddt, J = 21 A,



pyrrolo[3,4-
13.9, 7.1 Hz, 1H), 2.31-2.00 (m, 2H), 0.99 (ddd, J =



c]pyridine-2-
16.0, 9.0, 4.2 Hz, 6H)



carboxamide


1008
N-{4-[(1-

1H NMR (300 MHz, DMSO-d6) δ 8.79 (s, 1H), 8.67

(ESI(+))



acetylpyrrolidin-3-
(d, J = 5.5 Hz, 1H), 8.37 (s, 1H), 7.75 (d, J = 5.4 Hz,
m/e 367



yl)oxy]phenyl}-1,3-
1H), 7.44 (d, J = 8.9 Hz, 2H), 6.95-6.79 (m, 2H),
(M + H)+



dihydro-2H-
5.07-4.90 (m, 1H), 4.87 (d, J = 5.3 Hz, 4H), 3.83-



pyrrolo[3,4-
3.22 (m, 4H), 2.26-2.00 (m, 2H), 1.97 (s, 1.5H), 1.93



c]pyridine-2-
(s, 1.5H)



carboxamide


1009
N-(4-{[1-(4,4,4-

1H NMR (300 MHz, DMSO-d6) δ 8.76 (s, 1H), 8.64

(ESI(+))



trifluorobutanoyl)pyr-
(d, J = 5.4 Hz, 1H), 8.36 (s, 1H), 7.71 (d, J = 5.4 Hz,
m/e 449



rolidin-3-
1H), 7.44 (dd, J = 9.0, 1.7 Hz, 2H), 6.88 (dd, J = 8.9,
(M + H)+



yl]oxy}phenyl)-1,3-
6.4 Hz, 2H), 4.99 (d, J = 21.2 Hz, 1H), 4.86 (d, J = 2.1



dihydro-2H-
Hz, 4H), 3.85-3.29 (m, 4H), 2.56 (d, J = 5.1 Hz,



pyrrolo[3,4-
4H), 2.11 (dd, J = 24.1, 8.1 Hz, 2H)



c]pyridine-2-



carboxamide


1010
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.77 (s, 1H), 8.66

(ESI(+))



(tetrahydrofuran-3-
(d, J = 5.4 Hz, 1H), 8.37 (s, 1H), 7.73 (d, J = 5.1 Hz,
m/e 423



ylcarbonyl)pyrrolidin-
1H), 7.44 (dd, J = 8.9, 1.6 Hz, 2H), 6.89 (dd, J = 8.8,
(M + H)+



3-yl]oxy}phenyl)-
6.9 Hz, 2H), 4.98 (d, J = 21.7 Hz, 1H), 4.86 (d, J = 3.8



1,3-dihydro-2H-
Hz, 4H), 3.95-3.46 (m, 8H), 3.20 (dd, J = 14.8, 7.8



pyrrolo[3,4-
Hz, 1H), 1.97 (d, J = 7.5 Hz, 4H)



c]pyridine-2-



carboxamide


1011
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.80 (s, 1H), 8.68

(ESI(+))



(tetrahydrofuran-2-
(d, J = 5.5 Hz, 1H), 8.38 (s, 1H), 7.78 (d, J = 5.4 Hz,
m/e 423



ylcarbonyl)pyrrolidin-
1H), 7.44 (d, J = 9.0 Hz, 2H), 6.88 (dd, J = 8.2, 4.6
(M + H)+



3-yl]oxy}phenyl)-
Hz, 2H), 4.98 (d, J = 23.0 Hz, 1H), 4.88 (d, J = 7.4



1,3-dihydro-2H-
Hz, 4H), 4.51 (dt, J = 13.2, 6.2 Hz, 2H), 3.89-3.46



pyrrolo[3,4-
(m, 5H), 2.33-1.67 (m, 6H)



c]pyridine-2-



carboxamide


1012
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.79 (s, 1H), 8.67

(ESI(+))



(ethoxyacetyl)pyrrolidin-
(d, J = 5.5 Hz, 1H), 8.38 (s, 1H), 7.76 (d, J = 5.1 Hz,
m/e 411



3-yl]oxy}phenyl)-1,3-
1H), 7.44 (d, J = 9.0 Hz, 2H), 6.94-6.76 (m, 2H),
(M + H)+



dihydro-2H-
4.98 (d, J = 22.7 Hz, 2H), 4.87 (d, J = 5.8 Hz, 5H),



pyrrolo[3,4-
4.07 (s, 1H), 4.01 (s, 1H), 3.75-3.27 (m, 7H), 2.24-



c]pyridine-2-
1.98 (m, 2H), 1.11 (dt, J = 10.8, 6.9 Hz, 3H)



carboxamide


1026
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.77 (s, 1H), 8.65

(ESI(+))



(cyclohexylacetyl)pi-
(d, J = 5.4 Hz, 1H), 8.34 (s, 1H), 7.72 (d, J = 5.4 Hz,
m/e 463



peridin-4-
1H), 7.50-7.34 (m, 2H), 6.99-6.82 (m, 2H), 4.86
(M + H)+



yl]oxy}phenyl)-1,3-
(d, J = 3.5 Hz, 4H), 4.56-4.45 (m, 1H), 3.60-3.89 (m,



dihydro-2H-
2H), 3.39-3.14 (m, 2H), 2.20 (d, J = 6.7 Hz, 2H),



pyrrolo[3,4-
1.90 (s, 2H), 1.72-1.39 (m, 8H), 1.29-1.06 (m, 3H),



c]pyridine-2-
0.94 (t, J = 11.6 Hz, 2H)



carboxamide


1027
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.79 (s, 1H), 8.67

(ESI(+))



(tetrahydro-2H-
(d, J = 5.5 Hz, 1H), 8.36 (s, 1H), 7.76 (d, J = 5.5 Hz,
m/e 465



pyran-4-
1H), 7.42 (d, J = 9.0 Hz, 2H), 6.91 (d, J = 9.0 Hz,
(M + H)+



ylacetyl)piperidin-4-
2H), 4.87 (d, J = 6.1 Hz, 5H), 4.50 (dd, J = 7.7, 3.9



yl]oxy}phenyl)-1,3-
Hz, 2H), 3.81 (ddd, J = 27.5, 21.4, 10.7 Hz, 4H), 3.39-



dihydro-2H-
3.14 (m, 4H), 2.27 (d, J = 6.5 Hz, 2H), 2.01-1.77



pyrrolo[3,4-
(m, 3H), 1.65-1.35 (m, 4H), 1.19 (tdd, J = 13.5, 9.2,



c]pyridine-2-
4.4 Hz, 2H)



carboxamide


1037
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.75 (s, 1H), 8.63

(ESI(+))



(tetrahydrofuran-2-
(d, J = 5.4 Hz, 1H), 8.37 (s, 1H), 7.68 (d, J = 5.2 Hz,
m/e 423



ylacetyl)azetidin-3-
1H), 7.45 (d, J = 9.0 Hz, 2H), 6.78 (d, J = 9.0 Hz,
(M + H)+



yl]oxy}phenyl)-1,3-
2H), 4.97 (dd, J = 10.3, 6.6 Hz, 1H), 4.85 (s, 4H), 4.63-



dihydro-2H-
4.48 (m, 1H), 4.27 (s, 2H), 4.05 (dd, J = 13.5, 6.8



pyrrolo[3,4-
Hz, 2H), 3.62-3.45 (m, 2H), 2.28 (dddd, J = 20.3,



c]pyridine-2-
14.5, 10.4, 7.5 Hz, 3H), 2.06-1.90 (m, 1H), 1.81 (dd,



carboxamide
J = 13.8, 6.4 Hz, 2H), 1.47 (ddd, J = 15.7, 11.8, 7.2




Hz, 1H)


1038
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.77 (s, 1H), 8.65

(ESI(+))



(tetrahydro-2H-
(d, J = 5.4 Hz, 1H), 8.38 (s, 1H), 7.71 (d, J = 5.5 Hz,
m/e 437



pyran-4-
1H), 7.45 (d, J = 9.1 Hz, 2H), 6.78 (d, J = 9.0 Hz,
(M + H)+



ylacetyl)azetidin-3-
2H), 4.96 (s, 1H), 4.86 (d, J = 3.0 Hz, 4H), 4.62-4.47



yl]oxy}phenyl)-1,3-
(m, 1H), 4.27 (dd, J = 10.7, 6.3 Hz, 1H), 4.03 (dd, J =



dihydro-2H-
14.3, 7.2 Hz, 1H), 3.76 (dd, J = 18.7, 8.0 Hz, 3H),



pyrrolo[3,4-
3.25 (dd, J = 27.4, 15.8 Hz, 2H), 2.01 (t, J = 7.5 Hz,



c]pyridine-2-
2H), 1.89 (s, 1H), 1.56 (d, J = 11.3 Hz, 2H), 1.34-



carboxamide
1.03 (m, 2H)


1039
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.70 (s, 1H), 8.59

(ESI(+))



(morpholin-4-
(d, J = 5.3 Hz, 1H), 8.37 (s, 1H), 7.59 (d, J = 5.1 Hz,
m/e 438



ylacetyl)azetidin-3-
1H), 7.47 (d, J = 9.0 Hz, 2H), 6.80 (d, J = 9.0 Hz,
(M + H)+



yl]oxy}phenyl)-1,3-
2H), 5.06 (s, 1H), 4.83 (s, 4H), 4.65-4.53 (m, 1H),



dihydro-2H-
4.44 (dd, J = 10.8, 6.2 Hz, 1H), 4.21-4.12 (m, 2H),



pyrrolo[3,4-
4.07 (s, 5H), 3.23 (s, 4H)



c]pyridine-2-



carboxamide


1040
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.77 (s, 1H), 8.66

(ESI(+))



(cyclohexylacetyl)azetidin-
(d, J = 5.4 Hz, 1H), 8.38 (s, 1H), 7.73 (d, J = 5.4 Hz,
m/e 435



3-yl]oxy}phenyl)-1,3-
1H), 7.45 (d, J = 9.0 Hz, 2H), 6.78 (d, J = 9.0 Hz,
(M + H)+



dihydro-2H-pyrrolo[3,4-
2H), 5.05-4.91 (m, 1H), 4.87 (d, J = 3.9 Hz, 4H),



c]pyridine-2-carboxamide
4.62-4.45 (m, 1H), 4.27 (dd, J = 10.4, 6.5 Hz, 1H),




4.04 (dd, J = 9.1, 3.5 Hz, 1H), 3.74 (dd, J = 10.6, 3.7




Hz, 1H), 2.05-1.88 (m, 2H), 1.64 (d, J = 12.0 Hz,




6H), 1.16 (m, 3H), 0.94 (t, J = 11.8 Hz, 2H)


1041
N-(4-{[1-(2-

1H NMR (300 MHz, DMSO-d6) δ 8.76 (s, 1H), 8.65

(ESI(+))



methylbutanoyl)azetidin-
(d, J = 5.4 Hz, 1H), 8.38 (s, 1H), 7.71 (d, J = 5.4 Hz,
m/e 395



3-yl]oxy}phenyl)-1,3-
1H), 7.51-7.37 (m, 2H), 6.79 (d, J = 9.0 Hz, 2H),
(M + H)+



dihydro-2H-pyrrolo[3,4-
4.98 (d, J = 2.5 Hz, 1H), 4.86 (d, J = 2.9 Hz, 4H), 4.64-



c]pyridine-2-carboxamide
4.48 (m, 1H), 4.33-4.21 (m, 1H), 4.12-4.02 (m,




1H), 3.76 (dd, J = 10.5, 3.8 Hz, 1H), 2.29 (dd, J =




13.8, 6.9 Hz, 1H), 1.58-1.39 (m, 1H), 1.39-1.20




(m, 1H), 0.97 (dd, J = 6.8, 4.1 Hz, 3H), 0.82 (q, J =




7.3 Hz, 3H)


1042
N-(4-{[1-(2, 2-

1H NMR (300 MHz, DMSO-d6) δ 8.78 (s, 1H), 8.67

(ESI(+))



dimethylpropanoyl)azetidin-
(d, J = 5.5 Hz, 1H), 8.39 (s, 1H), 7.74 (d, J = 5.4 Hz,
m/e 395



3-yl]oxy}phenyl)-1,3-
1H), 7.54-7.33 (m, 2H), 6.82-6.64 (m, 2H), 4.94
(M + H)+



dihydro-2H-pyrrolo[3,4-
(td, J = 6.3, 3.2 Hz, 1H), 4.87 (d, J = 4.8 Hz, 4H), 4.55-



c]pyridine-2-carboxamide
4.12 (m, 4H), 1.12 (s, 9H)


1043
N-(4-{[1-(3, 3-

1H NMR (300 MHz, DMSO-d6) δ 8.80 (s, 1H), 8.68

(ESI(+))



dimethylbutanoyl)azetidin-
(d, J = 5.5 Hz, 1H), 8.39 (s, 1H), 7.77 (d, J = 5.5 Hz,
m/e 409



3-yl]oxy}phenyl)-1,3-
1H), 7.44 (d, J = 9.0 Hz, 2H), 6.78 (d, J = 9.0 Hz,
(M + H)+



dihydro-2H-pyrrolo[3,4-
2H), 5.01-4.90 (m, 1H), 4.88 (d, J = 6.5 Hz, 4H),



c]pyridine-2-carboxamide
4.60-4.45 (m, 1H), 4.27 (dd, J = 10.4, 6.5 Hz, 1H),




4.04 (dd, J = 8.9, 5.2 Hz, 1H), 3.74 (dd, J = 10.6, 3.8




Hz, 1H), 1.96 (s, 2H), 0.98 (s, 9H)


1044
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.76 (s, 1H), 8.64

(ESI(+))



(tricyclo[3.3.1.1~3,7~]dec-
(d, J = 5.4 Hz, 1H), 8.38 (s, 1H), 7.70 (d, J = 5.4 Hz,
m/e 487



1-ylacetyl)azetidin-3-
1H), 7.52-7.36 (m, 2H), 6.82-6.69 (m, 2H), 4.97-
(M + H)+



yl]oxy}phenyl)-1,3-
4.90 (m, 1H), 4.86 (s, 4H), 4.61-4.47 (m, 1H), 4.26



dihydro-2H-
(dd, J = 10.3, 6.4 Hz, 1H), 4.08-3.99 (m, 1H), 3.74



pyrrolo[3,4-
(dd, J = 10.6, 3.9 Hz, 1H), 1.92 (s, 2H), 1.83 (s, 2H),



c]pyridine-2-
1.70-1.52 (m, 13H)



carboxamide


1045
N-[4-({1-[(4-

1H NMR (300 MHz, DMSO-d6) δ 8.76 (s, 1H), 8.65

(ESI(+))



methoxycyclohexyl)
(d, J = 5.4 Hz, 1H), 8.38 (s, 1H), 7.71 (d, J = 5.4 Hz,
m/e 451



carbonyl]azetidin-3-
1H), 7.45 (d, J = 9.0 Hz, 2H), 6.78 (d, J = 9.0 Hz,
(M + H)+



yl}oxy)phenyl]-1,3-
2H), 4.96 (s, 1H), 4.86 (d, J = 2.7 Hz, 4H), 4.58 (s,



dihydro-2H-
1H), 4.31-4.19 (m, 1H), 4.05 (dd, J = 14.5, 7.4 Hz,



pyrrolo[3,4-
1H), 3.74 (d, J = 10.3 Hz, 1H), 3.36 (s, 1H), 3.19 (s,



c]pyridine-2-
3H), 2.27(s, 1H), 1.81 (s, 2H), 1.57 (t, J = 12.2 Hz,



carboxamide
2H), 1.38 (s, 4H)


1288
N-(4-{[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.57 (s,

(ESI(+))



(tetrahydro-2H-
1H), 8.47 (d, J = 5.0 Hz, 1H), 8.06 (s, 1H), 7.50-7.40
m/e 423



pyran-2-
(m, 2H), 7.37 (d, J = 5.0 Hz, 1H), 6.82-6.70 (m, 2H),
(M + H)+



ylcarbonyl)azetidin-
4.97 (tt, J = 6.4, 4.0 Hz, 1H), 4.83-4.73 (m, 4H),



3-yl]oxy}phenyl)-
4.69-4.44 (m, 1H), 4.44-4.19 (m, 1H), 4.21-3.98



1,3-dihydro-2H-
(m, 1H), 3.89 (ddd, J = 14.6, 10.3, 2.3 Hz, 3H), 3.48-



pyrrolo[3,4-
3.33 (m, 1H), 1.79 (dt, J = 6.0, 4.3 Hz, 1H), 1.70 (dt,



c]pyridine-2-
J = 6.7, 2.5 Hz, 1H), 1.61-1.39 (m, 4H)



carboxamide


1289
N-(4-{[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.57 (s,

(ESI(+))



(tetrahydro-2H-
1H), 8.47 (d, J = 5.0 Hz, 1H), 8.08-7.96 (m, 1H),
m/e 437



pyran-2-
7.46-7.39 (m, 2H), 7.37 (d, J = 5.2 Hz, 1H), 6.84 (t,
(M + H)+



ylcarbonyl)pyrrolidin-
J = 5.9 Hz, 2H), 5.00-4.86 (m, 1H), 4.86-4.72 (m,



3-yl]oxy}phenyl)-
4H), 4.08-3.92 (m, 1H), 3.92-3.36 (m, 6H), 2.21-



1,3-dihydro-2H-
1.95 (m, 2H), 1.69-1.40 (m, 6H)



pyrrolo[3,4-



c]pyridine-2-



carboxamide


1292
N-{4-[(1-

1H NMR (300 MHz, DMSO-d6) δ 8.83 (s, 1H), 8.71

(ESI(+))



acetylpiperidin-3-
(d, J = 5.4 Hz, 1H), 8.38 (s, 1H), 7.83 (dd, J = 5.2, 3.0
m/e 381



yl)oxy]phenyl}-1,3-
Hz, 1H), 7.42 (dd, J = 8.9, 6.6 Hz, 2H), 6.89 (t, J = 8.5
(M + H)+



dihydro-2H-
Hz, 2H), 4.89 (d, J = 9.6 Hz, 4H), 4.43 (s, 1H), 4.22-



pyrrolo[3,4-
3.94 (m, 1H), 3.67-3.47 (m, 2H), 3.36-3.02 (m,



c]pyridine-2-
1H), 2.02 (s, 1.5H), 1.87 (s, 1.5H), 1.83-1.32 (m,



carboxamide
3H)


1293
N-{4-[(1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.66 (s,

(ESI(+))



butanoylpiperidin-3-
1H), 8.55 (d, J = 5.3 Hz, 1H), 8.07 (s, 1H), 7.54 (d,
m/e 409



yl)oxy]phenyl}-1,3-
J = 5.1 Hz, 1H), 7.41 (d, J = 8.9 Hz, 2H), 6.95-6.70
(M + H)+



dihydro-2H-
(m, 2H), 4.83 (s, 4H), 4.23 (bs, 2H), 3.45 (bs, 2H),



pyrrolo[3,4-
2.24 (bs, 2H), 1.96 (bs, 1H), 1.73 (bs, 2H), 1.51 (dt,



c]pyridine-2-
J = 14.8, 7.4 Hz, 3H), 0.87 (t, J = 7.4 Hz, 3H)



carboxamide


1294
N-(4-{[1-(3-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.65 (s,

(ESI(+))



methylbutanoyl)pi-
1H), 8.54 (d, J = 5.2 Hz, 1H), 8.07 (s, 1H), 7.52 (d,
m/e 423



peridin-3-
J = 5.2 Hz, 1H), 7.41 (d, J = 8.9 Hz, 2H), 6.92-6.79
(M + H)+



yl]oxy}phenyl)-1,3-
(m, 2H), 4.82 (s, 4H), 4.25 (bs, 2H), 3.46 (bs, 2H),



dihydro-2H-
2.14 (s, 2H), 2.05-1.90 (m, 2H), 1.73 (bs, 2H), 1.45



pyrrolo[3,4-
(bs, 1H), 0.90 (dd, J = 9.3, 6.5 Hz, 6H)



c]pyridine-2-



carboxamide


1295
N-(4-{[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.64

(ESI(+))



(methoxyacetyl)pi-
(s, 1H), 8.54 (d, J = 5.2 Hz, 1H), 8.07 (s, 1H), 7.51 (d,
m/e 411



peridin-3-
J = 5.1 Hz, 1H), 7.42 (d, J = 9.0 Hz, 2H), 6.86 (d, J =
(M + H)+



yl]oxy}phenyl)-1,3-
9.0 Hz, 2H), 4.82 (s, 4H), 4.26 (bs, 1H), 4.05 (d, J =



dihydro-2H-
13.6 Hz, 1H), 3.96 (s, 1H), 3.42 (m, 4H), 3.27 (bs,



pyrrolo[3,4-
3H), 1.93 (d, J = 28.0 Hz, 1H), 1.74 (bs, 2H), 1.49 (bs,



c]pyridine-2-
1H)



carboxamide


1296
N-(4-{[1-(2-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.64

(ESI(+))



methylbutanoyl)pi-
(s, 1H), 8.53 (d, J = 5.1 Hz, 1H), 8.06 (d, J = 2.1 Hz,
m/e 423



peridin-3-
1H), 7.51 (d, J = 5.2 Hz, 1H), 7.44-7.38 (m, 2H),
(M + H)+



yl]oxy}phenyl)-1,3-
6.85 (dd, J = 8.7, 1.2 Hz, 2H), 4.82 (s, 4H), 4.28-



dihydro-2H-
4.17 (m, 1H), 3.67 (s, 2H), 3.51-3.37 (m, 2H), 2.65



pyrrolo[3,4-
(s, 1H), 2.02-1.88 (m, 1H), 1.79-1.65 (m, 2H), 1.63-



c]pyridine-2-
1.39 (m, 2H), 1.38-1.22 (m, 1H), 0.98 (dd, J = 6.7,



carboxamide
4.4 Hz, 3H), 0.90-0.76 (m, 3H)


1297
N-(4-{[1-(3,3,3-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.64 (s,

(ESI(+))



trifluoropropanoyl)pi-
1H), 8.54 (d, J = 5.2 Hz, 1H), 8.08 (m, 1H), 7.52 (d,
m/e 449



peridin-3-
J = 5.1 Hz, 1H), 7.42 (d, J = 8.9 Hz, 2H), 6.86 (d, J =
(M + H)+



yl]oxy}phenyl)-1,3-
9.0 Hz, 2H), 4.82 (m, 4H), 4.26 (s, 1H), 3.63-3.41



dihydro-2H-
(m, 6H), 1.93 (d, J = 26.2 Hz, 1H), 1.75 (m, 2H), 1.49



pyrrolo[3,4-
(m, 1H)



c]pyridine-2-



carboxamide


1298
N-(4-{[l-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.64 (s,

(ESI(+))



(cyclopropylacetyl)pi-
1H), 8.53 (d, J = 5.2 Hz, 1H), 8.06 (s, 1H), 7.51 (d,
m/e 421



peridin-3-
J = 5.3 Hz, 1H), 7.48-7.35 (m, 2H), 6.92-6.79 (m,
(M + H)+



yl]oxy}phenyl)-1,3-
2H), 4.82 (s, 4H), 4.23 (m, 1H), 3.42-3.13 (m, 4H),



dihydro-2H-
2.27 (d, J = 33.4 Hz, 3H), 1.93 (d, J = 26.2 Hz, 1H),



pyrrolo[3,4-
1.72 (m, 2H), 1.46 (m, 1H), 0.95 (m, 1H), 0.43 (d, J =



c]pyridine-2-
8.0 Hz, 2H), 0.09 (m, 2H)



carboxamide


1299
N-(4-{[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.64 (s,

(ESI(+))



(cyclobutylcarbonyl)
1H), 8.53 (d, J = 5.1 Hz, 1H), 8.07 (bs, 1H), 7.50 (d,
m/e 421



piperidin-3-
J = 5.2 Hz, 1H), 7.45-7.39 (m, 2H), 6.88-6.82 (m,
(M + H)+



yl]oxy}phenyl)-1,3-
2H), 4.82 (s, 4H), 4.27-4.15 (m, 1H), 3.48-3.38 (m,



dihydro-2H-
2H), 2.24-1.65 (m, 9H), 1.50-1.38 (m, 1H)



pyrrolo[3,4-



c]pyridine-2-



carboxamide


1300
N-(4-{[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.64 (s,

(ESI(+))



(cyclobutylacetyl)pi-
1H), 8.53 (d, J = 5.1 Hz, 1H), 8.10-8.05 (m, 1H),
m/e 435



peridin-3-
7.51 (d, J = 5.2 Hz, 1H), 7.42 (d, J = 7.7 Hz, 1H), 6.89-
(M + H)+



yl]oxy}phenyl)-1,3-
6.82 (m, 2H), 4.82 (s, 4H), 4.51-3.84 (m, 1H), 2.67-



dihydro-2H-
2.53 (m, 1H), 2.30 (d, J = 7.4 Hz, 1H), 2.11-1.91



pyrrolo[3,4-
(m, 3H), 1.88-1.58 (m, 7H)



c]pyridine-2-



carboxamide


1301
N-(4-{[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.64 (s,

(ESI(+))



(cyclopentylcarbon-
1H), 8.53 (d, J = 5.2 Hz, 1H), 8.07 (s, 1H), 7.51 (d,
m/e 435



yl)piperidin-3-
J = 5.2 Hz, 1H), 7.42 (dd, J = 9.0, 3.7 Hz, 2H), 6.86 (d,
(M + H)+



yl]oxy}phenyl)-1,3-
J = 9.0 Hz, 2H), 4.82 (s, 4H), 4.45-3.57 (m, 5H),



dihydro-2H-
2.92 (s, 2H), 1.97 (s, 1H), 1.67 (m, 12H)



pyrrolo[3,4-



c]pyridine-2-



carboxamide


1302
N-(4-{[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.65 (s,

(ESI(+))



(cyclopentylacetyl)pi-
1H), 8.54 (d, J = 5.2 Hz, 1H), 8.07 (s, 1H), 7.52 (d, J =
m/e 449



peridin-3-
5.2 Hz, 1H), 7.49-7.35 (m, 2H), 6.92-6.79 (m,
(M + H)+



yl]oxy}phenyl)-1,3-
2H), 4.82 (s, 4H), 4.24 (s, 1H), 3.46 (s, 4H), 2.36-



dihydro-2H-
2.07 (m, 3H), 1.93 (m, 1H), 1.73 (m, 4H), 1.51 (dd, J =



pyrrolo[3,4-
22.2, 13.1 Hz, 5H), 1.13 (m, 2H)



c]pyridine-2-



carboxamide


1303
N-[4-({1-[(2S)-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.64

(ESI(+))



tetrahy drofuran-2-
(bs, 1H), 8.53 (m, 1H), 8.07 (bs, 1H), 7.51 (d, J = 5.2
m/e 437



ylcarbonyl]piperidin-
Hz, 1H), 7.44-7.38 (m, 3H), 6.87 (dd, J = 9.0, 3.3
(M + H)+



3-yl}oxy)phenyl]-
Hz, 3H), 4.82 (s, 4H), 4.64-4.50 (m, 1H), 4.30-4.17



1,3-dihydro-2H-
(m, 1H), 3.99-3.87 (m, 1H), 3.83-3.55 (m, 4H),



pyrrolo[3,4-
2.03-1.68 (m, 7H), 1.48 (m, 1H)



c]pyridine-2-



carboxamide


1304
N-[4-({1-[(2R)-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.64

(ESI(+))



tetrahydrofuran-2-
(bs, 1H), 8.54 (m, 1H), 8.07 (bs, 1H), 7.52 (d, J = 4.8
m/e 437



ylcarbonyl]piperidin-
Hz, 1H), 7.44-7.38 (m, 3H), 6.91-6.83 (m, 3H),
(M + H)+



3-yl}oxy)phenyl]-
4.82 (bs, 4H), 4.64-4.49 (m, 1H), 4.30-4.16 (m,



1,3-dihydro-2H-
1H), 3.93 (s, 1H), 3.43-3.20 (m, 3H), 2.05-1.75 (m,



pyrrolo[3,4-
7H), 1.48 (s, 1H)



c]pyridine-2-



carboxamide


1305
N-(4-{[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.62 (s,

(ESI(+))



(tetrahydro-2H-
1H), 8.52 (d, J = 5.1 Hz, 1H), 8.06 (s, 1H), 7.53-7.42
m/e 451



pyran-4-
(m, 2H), 7.41 (s, 1H), 6.91-6.79 (m, 2H), 4.81 (s,
(M + H)+



ylcarbonyl)piperidin-
4H), 4.26 (s, 1H), 3.81 (m, 3H), 3.45 (s, 2H), 2.76 (s,



3-yl]oxy}phenyl)-
2H), 2.14 (m, 2H), 1.88-1.42 (m, 7H)



1,3-dihydro-2H-



pyrrolo[3,4-



c]pyridine-2-



carboxamide


1306
N-(4-{[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.62 (s,

(ESI(+))



(tetrahydro-2H-
1H), 8.52 (d, J = 5.1 Hz, 1H), 8.06 (s, 1H), 7.47 (d, J =
m/e 451



pyran-2-
5.2 Hz, 1H), 7.42 (dd, J = 9.1, 2.6 Hz, 2H), 6.86
(M + H)+



ylcarbonyl)piperidin-
(dd, J = 9.0, 2.1 Hz, 2H), 4.81 (s, 4H), 4.08 (m, 3H),



3-yl]oxy}phenyl)-
3.93-3.54 (m, 3H), 3.28-3.13 (m, 2H), 2.00 (s, 1H),



1,3-dihydro-2H-
1.85-1.36 (m, 9H)



pyrrolo[3,4-



c]pyridine-2-



carboxamide


1307
N-(4-{[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.64 (s,

(ESI(+))



(tetrahydro-2H-
1H), 8.54 (d, J = 5.2 Hz, 1H), 8.07 (s, 1H), 7.51 (d, J =
m/e 465



pyran-4-
5.1 Hz, 1H), 7.42 (d, J = 8.9 Hz, 2H), 6.85 (d, J =
(M + H)+



ylacetyl)piperidin-3-
9.0 Hz, 2H), 4.24 (s, 2H), 3.32 (dd, J = 50.2, 38.3 Hz,



yl]oxy}phenyl)-1,3-
6H), 2.20 (m, 2H), 1.92 (m, 2H), 1.73 (m, 2H), 1.56



dihydro-2H-
(m, 2H), 1.46 (m, 1H), 1.20 (m, 2H)



pyrrolo[3,4-



c]pyridine-2-



carboxamide


1308
N-(4-{[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.63 (s,

(ESI(+))



(tetrahydrofuran-2-
1H), 8.52 (d, J = 5.2 Hz, 1H), 8.06 (s, 1H), 7.49 (d,
m/e 451



ylacetyl)piperidin-3-
J = 5.2 Hz, 1H), 7.42 (d, J = 8.8 Hz, 2H), 6.86 (d, J =
(M + H)+



yl]oxy}phenyl)-1,3-
9.0 Hz, 2H), 4.81 (s, 5H), 4.37-4.03 (m, 2H), 3.71 (s,



dihydro-2H-
2H), 3.63-3.50 (m, 3H), 2.61 (m, 2H), 2.44-2.25



pyrrolo[3,4-
(m, 1H), 1.96 (m, 2H), 1.87-1.63 (m, 4H), 1.47 (m,



c]pyridine-2-
2H)



carboxamide


1309
N-(4-{[1-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.64 (s,

(ESI(+))



(tetrahydrofuran-3-
1H), 8.54 (d, J = 5.2 Hz, 1H), 8.07 (s, 1H), 7.51 (d, J =
m/e 451



ylacetyl)piperidin-3-
5.2 Hz, 1H), 7.42 (d, J = 8.9 Hz, 2H), 6.89-6.76
(M + H)+



yl]oxy}phenyl)-1,3-
(m, 2H), 4.82 (s, 5H), 4.27 (s, 1H), 3.67-3.17 (m,



dihydro-2H-
11H), 2.34 (d, J = 26.3 Hz, 3H), 1.93 (d, J = 29.4 Hz,



pyrrolo[3,4-
3H), 1.73 (s, 3H), 1.47 (s, 3H)



c]pyridine-2-



carboxamide


1347
N-(4-{[1-(5-oxo-L-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



prolyl)piperidin-4-
ppm 8.57 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H) 7.40 (d,
m/e 450



yl]oxy}phenyl)-1,3-
J = 8.54 Hz, 3 H) 6.90 (d, J = 8.85 Hz, 2 H) 4.79 (d,
(M + H)+



dihydro-2H-
J = 7.63 Hz, 4 H) 4.45-4.58 (m, 2 H) 3.75 (s, 2 H)



pyrrolo[3,4-
3.34-3.42 (m, 4 H) 2.30-2.43 (m, 1 H) 2.10-2.21



c]pyridine-2-
(m, 2 H) 1.94 (d, J = 5.80 Hz, 1 H) 1.54-1.69 (m, 2 H)



carboxamide


1386
N-(4-{[1-(5-oxo-L-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



prolyl)azetidin-3-
ppm 8.57 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H) 7.38-7.48
m/e 421



yl]oxy}phenyl)-1,3-
(m, 3 H) 6.75-6.83 (m, 2 H) 4.98-5.06 (m, 1 H) 4.79
(M + H)+



dihydro-2H-
(d, J = 7.93 Hz, 4 H) 4.29-4.72 (m, 2 H) 4.18 (dd,



pyrrolo[3,4-
J = 8.39, 4.73 Hz, 1 H) 3.64-4.12 (m, 2 H) 2.06-2.41



c]pyridine-2-
(m, 3 H) 1.90-2.06 (m, 1 H)



carboxamide


1387
N-{4-[(1-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



propanoylazetidin-3-
ppm 8.57 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H) 7.38-7.46
m/e 367



yl)oxy]phenyl}-1,3-
(m, 3 H) 6.74-6.82 (m, 2 H) 4.94-5.03 (m, 1 H) 4.79
(M + H)+



dihydro-2H-
(d, J = 7.02 Hz, 4 H) 4.35 (s, 2 H) 3.90 (s, 2 H) 2.10 (q,



pyrrolo[3,4-
J = 7.43 Hz, 2 H) 1.00 (t, J = 7.48 Hz, 3 H)



c]pyridine-2-



carboxamide


1388
N-(4-{[1-(2, 2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



dimethylbutanoyl)azetidin-
ppm 8.57 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H) 7.39-7.46
m/e 409



3-yl]oxy}phenyl)-1,3-
(m, 3 H) 6.78 (d, J = 8.85 Hz, 2 H) 4.90-5.02 (m, 1 H)
(M + H)+



dihydro-2H-pyrrolo[3,4-
4.79 (d, J = 7.93 Hz, 4 H) 4.51 (s, 2 H) 4.01 (d, J = 8.54



c]pyridine-2-carboxamide
Hz, 2 H) 1.49 (q, J = 7.32 Hz, 2 H) 1.09 (s, 6 H) 0.81 (t,




J = 7.48 Hz, 3 H)


1389
N-(4-{[1-(2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



ethylbutanoyl)azetidin-
ppm 8.57 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H) 7.37-7.47
m/e 409



3-yl]oxy}phenyl)-
(m, 3 H) 6.79 (d, J = 8.85 Hz, 2 H) 4.95-5.03 (m, 1 H)
(M + H)+



1,3-dihydro-2H-
4.79 (d, J = 7.93 Hz, 4 H) 4.44 (s, 2 H) 3.95 (s, 2 H)



pyrrolo[3,4-
2.08-2.22 (m, 1 H) 1.32-1.55 (m, 4 H) 0.83 (t,



c]pyridine-2-
J = 7.32 Hz, 6 H)



carboxamide


1390
N-(4-{[1-(pent-4-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



ynoyl)azetidin-3-
ppm 8.57 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H) 7.34-7.49
m/e 391



yl]oxy}phenyl)-1,3-
(m, 3 H) 6.78 (d, J = 8.85 Hz, 2 H) 4.92-5.06 (m, 1 H)
(M + H)+



dihydro-2H-
4.79 (d, J = 7.93 Hz, 4 H) 4.42 (d, J = 78.13 Hz, 2 H)



pyrrolo[3,4-
3.66-4.19 (m, 2 H) 2.54 (t, J = 2.44 Hz, 1 H) 2.27-



c]pyridine-2-
2.43 (m, 4 H)



carboxamide


1391
N-(4-{[1-(furan-2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



ylcarbonyl)azetidin-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H) 7.77 (s, 1
m/e 405



3-yl]oxy}phenyl)-
H) 7.37-7.48 (m, 3 H) 7.04 (d, J = 3.66 Hz, 1 H) 6.81
(M + H)+



1,3-dihydro-2H-
(d, J = 8.85 Hz, 2 H) 6.57-6.63 (m, 1 H) 5.01-5.14



pyrrolo[3,4-
(m, 1 H) 4.79 (d, J = 8.24 Hz, 4 H) 4.67 (s, 2 H) 4.17



c]pyridine-2-
(s, 2 H)



carboxamide


1392
N-(4-{[1-(furan-3-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



ylcarbonyl)azetidin-
ppm 8.57 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H) 8.07 (s, 1
m/e 405



3-yl]oxy}phenyl)-
H) 7.67 (s, 1 H) 7.38-7.47 (m, 3 H) 6.80 (d, J = 8.85
(M + H)+



1,3-dihydro-2H-
Hz, 2 H) 6.72 (s, 1 H) 5.03-5.11 (m, 1 H) 4.79 (d,



pyrrolo[3,4-
J = 7.63 Hz, 4 H) 4.60 (s, 2 H) 4.12 (s, 2 H)



c]pyridine-2-



carboxamide


1393
N-(4-{[1-(thiophen-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



3-
ppm 8.57 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H) 7.97 (d,
m/e 421



ylcarbonyl)azetidin-
J = 1.83 Hz, 1 H) 7.55 (dd, J = 5.04, 2.90 Hz, 1 H) 7.35-
(M + H)+



3-yl]oxy}phenyl)-
7.46 (m, 4 H) 6.80 (d, J = 8.85 Hz, 2 H) 5.01-5.11 (m,



1,3-dihydro-2H-
1 H) 4.79 (d, J = 7.93 Hz, 4 H) 4.62 (s, 2 H) 4.16 (s, 2



pyrrolo[3,4-
H)



c]pyridine-2-



carboxamide


1394
N-(4-{[1-(1H-pyrrol-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



2-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H) 7.37-7.48
m/e 404



ylcarbonyl)azetidin-
(m, 3 H) 6.93 (s, 1 H) 6.81 (d, J = 8.85 Hz, 2 H) 6.51
(M + H)+



3-yl]oxy}phenyl)-
(d, J = 3.36 Hz, 1 H) 6.14-6.18 (m, 1 H) 5.02-5.14



1,3-dihydro-2H-
(m, 1 H) 4.79 (d, J = 7.93 Hz, 4 H) 4.57-4.66 (m, 2 H)



pyrrolo[3,4-
4.13 (d, J = 7.93 Hz, 2 H)



c]pyridine-2-



carboxamide


1395
N-(4-{[1-(pyrimidin-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



4-
ppm 9.09 (s, 1 H) 8.75 (d, J = 2.14 Hz, 1 H) 8.66 (s, 1
m/e 417



ylcarbonyl)azetidin-
H) 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H) 7.37-7.47
(M + H)+



3-yl]oxy}phenyl)-
(m, 3 H) 6.81 (d, J = 8.85 Hz, 2 H) 5.06-5.13 (m, 1 H)



1,3-dihydro-2H-
4.92-5.04 (m, 1 H) 4.79 (d, J = 7.63 Hz, 4 H) 4.50 (s,



pyrrolo[3,4-
2 H) 4.09 (s, 1 H)



c]pyridine-2-



carboxamide


1396
N-[4-({1-[(5-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



methylpyrazin-2-
ppm 8.96 (s, 1 H) 8.58 (s, 1 H) 8.54 (s, 1 H) 8.48 (d,
m/e 431



yl)carbonyl]azetidin-
J = 4.88 Hz, 1 H) 7.38-7.47 (m, 3 H) 6.80 (d, J = 8.85
(M + H)+



3-yl}oxy)phenyl]-
Hz, 2 H) 5.04-5.13 (m, 1 H) 4.89-5.02 (m, 1 H)



1,3-dihydro-2H-
4.79 (d, J = 7.63 Hz, 4 H) 4.48 (s, 2 H) 4.06 (s, 1 H)



pyrrolo[3,4-
2.57 (s, 3 H)



c]pyridine-2-



carboxamide


1397
N-(4-{[1-(N,N-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(APCI(+))



dimethylglycyl)azetidin-
Temp = 90° C.) δ ppm 8.57-8.59 (bs, 1H), 8.48 (dd, J =
m/e 396



3-yl]oxy}phenyl)-1,3-
4.9, 1.8 Hz, 1H), 7.43-7.47 (m, 2H), 7.41 (d, J = 6.7
(M + H)+



dihydro-2H-
Hz, 1H), 6.80-6.83 (m, 2H), 5.08-5.16 (m, 1H), 4.82



pyrrolo[3,4-
(s, 2H), 4.79 (s, 2H), 4.67-4.74 (m, 2H), 4.30 (dd, J =



c]pyridine-2-
10.1, 4.1 Hz, 2H), 2.91 (s, 8H)



carboxamide


1398
N-(4-{[1-(N, N-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(APCI(+))



dimethyl-beta-
Temp = 90° C.) δ ppm 8.57 (s, 1H), 8.48 (d, J = 5.2 Hz,
m/e 410



alanyl)azetidin-3-
1H), 7.44-7.48 (m, 2H), 7.40 (d, J = 4.6 Hz, 1H),
(M + H)+



yl]oxy}phenyl)-1,3-
6.80-6.84 (m, 2H), 5.09-5.16 (m, 1H), 4.83 (s, 2H),



dihydro-2H-
4.79 (s, 2H), 4.70 (ddd, J = 10.4, 6.6, 1.2 Hz, 2H),



pyrrolo[3,4-
4.30 (ddd, J = 10.4, 4.1, 1.2 Hz, 2H), 2.91 (s, 6H),



c]pyridine-2-
2.50 (t, J = 7.3 Hz, 2H), 2.23 (t, J = 7.2 Hz, 2H)



carboxamide


1399
N-(4-{[1-(pyrrolidin-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(APCI(+))



1-ylacetyl)azetidin-
Temp = 90° C.) δ ppm 8.58 (s, 1H), 8.48 (dd, J = 5.2, 1.8
m/e 422



3-yl]oxy}phenyl)-
Hz, 1H), 7.43-7.47 (m, 2H), 7.40 (d, J = 5.2 Hz, 1H),
(M + H)+



1,3-dihydro-2H-
6.80-6.84 (m, 2H), 5.09-5.16 (m, 1H), 4.82 (s, 2H),



pyrrolo[3,4-
4.79 (s, 2H), 4.70 (ddd, J = 10.2, 6.4, 1.1 Hz, 2H),



c]pyridine-2-
4.30 (ddd, J = 10.3, 4.2, 1.1 Hz, 2H), 3.18 (s, 2H),



carboxamide
2.55-2.62 (m, 4H), 1.68-1.75 (m, 4H)


1400
N-[4-({-[3-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(APCI(+))



(pyrrolidin-1-
Temp = 90° C.) δ ppm 8.57-8.58 (bs, 1H), 8.48 (dd, J =
m/e 436



yl)propanoyl]azetidin-
5.0, 2.0 Hz, 1H), 7.41-7.45 (m, 2H), 7.40 (d, J = 4.9
(M + H)+



3-yl}oxy)phenyl]-
Hz, 1H), 6.76-6.80 (m, 2H), 4.94-5.01 (m, 1H), 4.82



1,3-dihydro-2H-
(s, 2H), 4.79 (s, 2H), 4.19-4.64 (m, 2H), 3.70-4.17 (m,



pyrrolo[3,4-
2H), 2.66 (t, J = 7.3 Hz, 2H), 2.44-2.50 (m, 4H), 2.27



c]pyridine-2-
(t, J = 7.3 Hz, 2H), 1.65-1.71 (m, 4H)



carboxamide


1401
N-[4-({1-[3-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



(piperidin-1-
ppm 8.57 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H) 7.35-7.48
m/e 450



yl)propanoyl]azetidin-
(m, 3 H) 6.74-6.83 (m, 2 H) 4.92-5.02 (m, 1 H) 4.79
(M + H)+



3-yl}oxy)phenyl]-
(d, J = 7.93 Hz, 4 H) 4.18-4.71 (m, 2 H) 3.94 (d,



1,3-dihydro-2H-
J = 92.77 Hz, 2 H) 2.53-2.58 (m, 2 H) 2.32-2.40 (m,



pyrrolo[3,4-
4 H) 2.24 (t, J = 7. 17 Hz, 2 H) 1.44-1.54 (m, 4 H) 1.33-



c]pyridine-2-
1.41 (m, 2H)



carboxamide


1402
N-[4-({1-[(4-

1H NMR (400 MHz, DMSO-d6/Deuterium Oxide,

(APCI(+))



methylpiperazin-1-
Temp = 90° C.) δ ppm 8.58 (s, 1H), 8.48 (dd, J = 5.0,
m/e 451



yl)acetyl]azetidin-3-
2.0 Hz, 1H), 7.41-7.45 (m, 2H), 7.40 (d, J = 5.2 Hz, 1H),
(M + H)+



yl}oxy)phenyl]-1,3-
6.75-6.80 (m, 2H), 5.08-5.17 (m, 1H), 4.82 (s, 2H),



dihydro-2H-
4.79 (s, 2H), 4.70 (ddd, J = 10.0, 6.3, 1.3 Hz, 2H),



pyrrolo[3,4-
4.30 (ddd, J = 10.0, 4.0, 1.0 Hz, 2H), 3.00 (s, 2H),



c]pyridine-2-
2.41-2.48 (m, 4H), 2.30-2.37 (m, 4H), 2.15 (s, 3H)



carboxamide


1403
N-[4-({1-[3-(4-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



methylpiperazin-1-
ppm 8.57 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H) 7.38-7.48
m/e 456



yl)propanoyl]azetidin-
(m, 3 H) 6.78 (d, J = 9.16 Hz, 2 H) 4.93-5.01 (m, 1 H)
(M + H)+



3-yl}oxy)phenyl]-
4.79 (d, J = 7.93 Hz, 4 H) 4.19-4.64 (m, 2 H) 3.94 (d,



1,3-dihydro-2H-
J = 87.28 Hz, 2 H) 2.53-2.58 (m, 2 H) 2.36-2.43 (m,



pyrrolo[3,4-
4 H) 2.29-2.35 (m, 4 H) 2.24 (t, J = 7.17 Hz, 2 H) 2.15



c]pyridine-2-
(s, 3 H)



carboxamide


1423
N-[4-({1-[(2S)-2-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50

(ESI(+))



methylbutanoyl]pi-
(d, J = 5.0 Hz, 1H), 8.27 (s, 1H), 7.51-7.34 (m, 3H),
m/e 423



peridin-4-
6.90 (d, J = 9.0 Hz, 2H), 4.78 (d, J = 4.0 Hz, 4H),
(M + H)+



yl}oxy)phenyl]-1,3-
4.60-4.44 (m, 1H), 3.84 (d, J = 39.0 Hz, 2H), 3.46-3.12



dihydro-2H-
(m, 2H), 2.73 (dd, J = 13.4, 6.8 Hz, 1H), 1.99 (s, 2H),



pyrrolo[3,4-
1.55 (dt, J = 21.7, 7.3 Hz, 3H), 1.42-1.21 (m, 1H),



c]pyridine-2-
0.97 (t, J = 5.7 Hz, 3H), 0.81 (t, J = 7.4 Hz, 3H)



carboxamide


1424
N-[4-({1-[(2S)-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50

(ESI(+))



tetrahydrofuran-2-
(d, J = 5.0 Hz, 1H), 8.28 (s, 1H), 7.46-7.39 (m, 3H),
m/e 437



ylcarbonyl]piperidin-
6.94-6.87 (m, 2H), 4.86-4.74 (m, 4H), 4.67 (t, J =
(M + H)+



4-yl}oxy)phenyl]-
6.6 Hz, 1H), 4.57-4.46 (m, 1H), 3.93-3.67 (m, 4H),



1,3-dihydro-2H-
3.31 (s, 2H), 2.12-1.77 (m, 6H), 1.65-1.39 (m, 2H)



pyrrolo[3,4-



c]pyridine-2-



carboxamide


1425
N-[4-({1-[(2R)-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50

(ESI(+))



tetrahy drofuran-2-
(d, J = 5.0 Hz, 1H), 8.27 (s, 1H), 7.53-7.33 (m, 3H),
m/e 437



ylcarbonyl]piperidin-
6.90 (d, J = 9.0 Hz, 2H), 4.78 (d, J = 4.0 Hz, 4H), 4.73-
(M + H)+



4-yl}oxy)phenyl]-
4.60 (m, 1H), 4.52 (s, 1H), 3.93-3.63 (m, 4H), 3.49-



1,3-dihydro-2H-
3.07 (m, 2H), 2.11-1.72 (m, 6H), 1.66-1.40 (m,



pyrrolo[3,4-
2H)



c]pyridine-2-



carboxamide


1426
N-[4-({1-[(4,4-

1H NMR (400 MHz, DMSO, Temp = 90° C.) δ 8.57 (s,

(ESI(+))



difluorocyclohexyl)carbon-
1H), 8.47 (d, J = 5.0 Hz, 1H), 8.05 (d, J = 8.0 Hz,
m/e 457



yl]azetidin-3-
1H), 7.48-7.39 (m, 2H), 7.37 (d, J = 4.8 Hz, 1H),
(M + H)+



yl}oxy)phenyl]-1,3-
6.86-6.60 (m, 2H), 4.96 (m, 1H), 4.78 (d, J = 8.8 Hz,



dihydro-2H-
5H), 4.19 (m, 2H), 3.74 (m, 2H), 3.22 (d, J = 6.2 Hz,



pyrrolo[3,4-
1H), 2.42 (t, J = 10.6 Hz, 1H), 2.26 (t, J = 6.9 Hz,



c]pyridine-2-
1H), 2.04 (d, J = 10.0 Hz, 2H), 1.81 (ddd, J = 26.3,



carboxamide
15.5, 8.4 Hz, 3H), 1.68-1.49 (m, 2H)


1427
N-(4-{[1-(5-oxo-D-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



prolyl)piperidin-4-
ppm 8.57 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H) 7.40 (d,
m/e 450



yl]oxy}phenyl)-1,3-
J = 8.54 Hz, 3 H) 6.90 (d, J = 8.85 Hz, 2 H) 4.79 (d,
(M + H)+



dihydro-2H-
J = 7.63 Hz, 4 H) 4.46-4.60 (m, 2 H) 3.75 (s, 2 H)



pyrrolo[3,4-
3.34-3.41 (m, 2 H) 2.30-2.41 (m, 1 H) 2.10-2.23



c]pyridine-2-
(m, 2 H) 1.92-2.05 (m, 3 H) 1.56-1.74 (m, 2 H)



carboxamide


1428
N-(4-{[1-(2,2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



dimethylpropanoyl)pi-
ppm 8.58 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H) 7.36-7.44
m/e 423



peridin-4-
(m, 3 H) 6.89 (d, J = 8.85 Hz, 2 H) 4.79 (d, J = 7.32 Hz,
(M + H)+



yl]oxy}phenyl)-1,3-
4 H) 4.43-4.53 (m, 1 H) 3.80-3.93 (m, 2 H) 3.34-



dihydro-2H-
3.42 (m, 2 H) 1.94-1.99 (m, J = 3.36 Hz, 2 H) 1.50-



pyrrolo[3,4-
1.68 (m, 2 H) 1.22 (s, 9 H)



c]pyridine-2-



carboxamide


1429
N-(4-{[1-(2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



methylpentanoyl)pi-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H) 7.40 (d,
m/e 437



peridin-4-
J = 8.85 Hz, 3 H) 6.89 (d, J = 8.85 Hz, 2 H) 4.79 (d,
(M + H)+



yl]oxy}phenyl)-1,3-
J = 7.32 Hz, 4 H) 4.45-4.54 (m, 1 H) 3.81 (dd,



dihydro-2H-
J = 11.14, 5.34 Hz, 2 H) 3.35 (s, 2 H) 2.75-2.84 (m, 1



pyrrolo[3,4-
H) 1.93-1.98 (m, 2 H) 1.49-1.64 (m, 3 H) 1.19-



c]pyridine-2-
1.35 (m, 3 H) 1.01 (d, J = 6.71 Hz, 3 H) 0.86 (t, J = 7.02



carboxamide
Hz, 3 H)


1430
N-(4-{[1-(2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



ethylbutanoyl)pi-
ppm 8.58 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H) 7.40 (d,
m/e 437



peridin-4-
J = 9.16 Hz, 3 H) 6.90 (d, J = 8.85 Hz, 2 H) 4.79 (d,
(M + H)+



yl]oxy}phenyl)-1,3-
J = 7.63 Hz, 4 H) 4.46-4.56 (m, J = 11.22, 7.40, 3.66



dihydro-2H-
Hz, 1 H) 3.80-3.92 (m, 2 H) 3.35-3.43 (m, 2 H)



pyrrolo[3,4-
2.58-2.68 (m, 1 H) 1.87-1.95 (m, 2 H) 1.47-1.64



c]pyridine-2-
(m, 4 H) 1.34-1.46 (m, 2 H) 0.82 (t, J = 7.48 Hz, 6 H)



carboxamide


1431
N-(4-{[1-(1H-pyrrol-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



2-
ppm 8.57 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H) 7.37-7.46
m/e 432



ylcarbonyl)piperidin-
(m, 3 H) 6.85-6.95 (m, 3 H) 6.49 (d, J = 3.05 Hz, 1 H)
(M + H)+



4-yl]oxy}phenyl)-
6.13 (t, J = 2.90 Hz, 1 H) 4.79 (d, J = 7.93 Hz, 4 H) 4.47-



1,3-dihydro-2H-
4.60 (m, 1 H) 3.93-4.09 (m, 2 H) 3.49-3.59 (m, 2



pyrrolo[3,4-
H) 1.95-2.03 (m, 2 H) 1.56-1.74 (m, 2 H)



c]pyridine-2-



carboxamide


1432
N-(4-{[1-(1,2-

1H NMR (400 MHz, Solvent) δ ppm 8.57 (s, 1 H) 8.47

(APCI(+))



oxazol-5-
(d, J = 4.88 Hz, 1 H) 7.36-7.44 (m, 3 H) 6.89 (d,
m/e 434



ylcarbonyl)piperidin-
J = 8.54 Hz, 2 H) 4.79 (d, J = 7.93 Hz, 4 H) 3.44-4.62
(M + H)+



4-yl]oxy}phenyl)-
(m, 4 H) 1.79-1.89 (m, 2 H) 1.40-1.80 (m, 3 H)



1,3-dihydro-2H-



pyrrolo[3,4-



c]pyridine-2-



carboxamide


1433
N-(4-{[1-(pyridin-3-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



ylcarbonyl)piperidin-
ppm 8.62 (d, J = 4.58 Hz, 1 H) 8.58 (d, J = 7.32 Hz, 2 H)
m/e 444



4-yl]oxy}phenyl)-
8.47 (d, J = 5.19 Hz, 1 H) 7.82 (d, J = 7.93 Hz, 1 H) 7.47
(M + H)+



1,3-dihydro-2H-
(dd, J = 7.63,4.88 Hz, 1 H) 7.40 (d, J = 8.54 Hz, 3 H)



pyrrolo[3,4-
6.91 (d, J = 8.85 Hz, 2 H) 4.79 (d, J = 7.63 Hz, 4 H) 4.50-



c]pyridine-2-
4.58 (m, 1 H) 3.75 (s, 2 H) 3.38-3.50 (m, J = 8.85



carboxamide
Hz, 2 H) 1.93-2.05 (m, 2 H) 1.62-1.76 (m, 2 H)


1434
N-(4-{[1-(pyridazin-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



3-ylcarbonyl)piperidin-
ppm 9.26 (dd, J = 4.58, 2.14 Hz, 1 H) 8.58 (s, 1 H) 8.49
m/e 445



4-yl]oxy}phenyl)-
(d, J = 4.88 Hz, 1 H) 7.76-7.85 (m, 2 H) 7.37-7.45
(M + H)+



1,3-dihydro-2H-
(m, 3 H) 6.91 (t, J = 9.16 Hz, 2 H) 4.80 (d, J = 6.10 Hz,



pyrrolo[3,4-
4 H) 4.48-4.63 (m, 1 H) 3.99 (s, 2 H) 3.60 (s, 2 H)



c]pyridine-2-
1.95-2.14 (m, 2 H) 1.72 (s, 2 H)



carboxamide


1435
N-(4-{[1-(pyrazin-2-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



ylcarbonyl)piperidin-
ppm 9.20 (s, 1 H) 8.93 (d, J = 5.19 Hz, 1 H) 8.57 (s, 1
m/e 445



4-yl]oxy}phenyl)-
H) 8.47 (d, J = 4.88 Hz, 1 H) 7.60-7.65 (m, 1 H) 7.36-
(M + H)+



1,3-dihydro-2H-
7.44 (m, 3 H) 6.87-6.94 (m, 2 H) 4.79 (d, J = 7.63



pyrrolo[3,4-
Hz, 4 H) 4.47-4.62 (m, 1 H) 3.94 (s, 2 H) 3.55 (s, 2



c]pyridine-2-
H) 1.93-2.11 (m, 2 H) 1.61-1.78 (m, J = 15.87 Hz, 2



carboxamide
H)


1436
N-(4-{[1-(pyrimidin-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



4-
ppm 8.40-8.87 (m, 5 H) 7.33-7.47 (m, 3 H) 6.91 (d,
m/e 445



ylcarbonyl)piperidin-
J = 8.85 Hz, 2 H) 4.79 (d, J = 7.93 Hz, 4 H) 4.48-4.63
(M + H)+



4-yl]oxy}phenyl)-
(m, 1 H) 3.45-4.22 (m, 4 H) 1.94-2.12 (m, 2 H) 1.56-



1,3-dihydro-2H-
1.79 (m, 2 H)



pyrrolo[3,4-



c]pyridine-2-



carboxamide


1437
N-[4-({1-[(5-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



methylpyrazin-2-
ppm 8.66 (s, 1 H) 8.57 (s, 1 H) 8.52 (s, 1 H) 8.48 (d,
m/e 459



yl)carbonyl]piperidin-
J = 4.88 Hz, 1 H) 7.40 (d, J = 8.54 Hz, 3 H) 6.91 (d,
(M + H)+



4-yl}oxy)phenyl]-
J = 9.16 Hz, 2 H) 4.79 (d, J = 7.63 Hz, 4 H) 4.51-4.60



1,3-dihydro-2H-
(m, 1 H) 3.63-4.07 (m, 2 H) 3.39-3.62 (m, 2 H) 2.55



pyrrolo[3,4-
(s, 3 H) 1.93-2.06 (m, 2 H) 1.62-1.78 (m, J = 10.38



c]pyridine-2-
Hz, 2 H)



carboxamide


1438
N-[4-({1-[3-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



(piperidin-1-
ppm 8.57 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H) 7.33-7.45
m/e 478



yl)propanoyl]piperidin-
(m, 3 H) 6.89 (d, J = 8.85 Hz, 2 H) 4.79 (d, J = 7.93 Hz,
(M + H)+



4-yl}oxy)phenyl]-
4 H) 4.43-4.52 (m, 1 H) 3.66-3.92 (m, 2 H) 3.34-



1,3-dihydro-2H-
3.40 (m, 2 H) 2.55-2.62 (m, J = 7.02, 7.02 Hz, 2 H)



pyrrolo[3,4-
2.46-2.50 (m, 2 H) 2.37-2.43 (m, 4 H) 1.91-2.00



c]pyridine-2-
(m, 2 H) 1.55-1.68 (m, 2 H) 1.45-1.55 (m, 4 H) 1.33-



carboxamide
1.42 (m, 2 H)


1439
N-(4-{[1-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



(morpholin-4-
ppm 8.57 (s, 1 H) 8.48 (d, J = 5.19 Hz, 1 H) 7.34-7.48
m/e 466



ylacetyl)piperidin-4-
(m, 3 H) 6.90 (d, J = 8.85 Hz, 2 H) 4.79 (d, J = 7.63 Hz,
(M + H)+



yl]oxy}phenyl)-1,3-
4 H) 4.40-4.59 (m, 1 H) 3.72-3.91 (m, 2 H) 3.53-



dihydro-2H-
3.64 (m, 4 H) 3.35-3.45 (m, 2 H) 3.16 (s, 2 H) 2.39-



pyrrolo[3,4-
2.47 (m, 4 H) 1.90-2.01 (m, 2 H) 1.50-1.68 (m, 2 H)



c]pyridine-2-



carboxamide


1440
N-[4-({1-[3-(4-

1H NMR (400 MHz, DMSO-D2O, Temp = 90° C.) δ

(APCI(+))



methylpiperazin-1-
ppm 8.57 (s, 1 H) 8.48 (d, J = 4.88 Hz, 1 H) 7.36-7.44
m/e 493



yl)propanoyl]piperidin-
(m, 3 H) 6.89 (d, J = 8.85 Hz, 2 H) 4.79 (d, J = 7.93 Hz,
(M + H)+



4-yl}oxy)phenyl]-
4 H) 4.40-4.60 (m, 1 H) 3.69-3.85 (m, 2 H) 3.36-



1,3-dihydro-2H-
3.50 (m, 2 H) 2.55-2.63 (m, 2 H) 2.46-2.50 (m, 2 H)



pyrrolo[3,4-
2.40-2.45 (m, 4 H) 2.30-2.36 (m, 4 H) 2.16 (s, 3 H)



c]pyridine-2-
1.91-2.00 (m, 2 H) 1.52-1.67 (m, 2 H)



carboxamide


1532
N-(4-{[(3R)-1-(3-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.49

(ESI(+))



methylbutanoyl)pyr-
(d, J = 5.0 Hz, 1H), 8.28 (s, 1H), 7.49-7.36 (m, 3H),
m/e 409



rolidin-3-
6.95-6.79 (m, 2H), 4.96 (d, J = 21.2 Hz, 1H), 4.78
(M + H)+



yl]oxy}phenyl)-1,3-
(d, J = 4.0 Hz, 5H), 3.81-3.44 (m, 4H), 2.21-1.84



dihydro-2H-
(m, 6H), 0.99-0.79 (m, 6H)



pyrrolo[3,4-



c]pyridine-2-



carboxamide


1533
N-(4-{[(3R)-1-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.49

(ESI(+))



(cyclobutylcarbonyl)
(d, J = 5.0 Hz, 1H), 8.28 (s, 1H), 7.53-7.38 (m, 3H),
m/e 407



pyrrolidin-3-
6.96-6.81 (m, 2H), 5.04-4.85 (m, 1H), 4.78 (d, J =
(M + H)+



yl]oxy}phenyl)-1,3-
3.9 Hz, 4H), 3.72-3.07 (m, 5H), 2.24-1.56 (m, 8H)



dihydro-2H-



pyrrolo[3,4-



c]pyridine-2-



carboxamide


1534
N-[4-({(3R)-1-[(2R)-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50

(ESI(+))



tetrahydrofuran-2-
(d, J = 5.0 Hz, 1H), 8.29 (s, 1H), 7.48-7.43 (m, 2H),
m/e 423



ylcarbonyl]pyrrolidin-
7.45-7.39 (m, 2H), 6.92-6.83 (m, 2H), 5.05-4.90
(M + H)+



3-yl}oxy)phenyl]-
(m, 1H), 4.82-4.75 (m, 4H), 4.59-4.42 (m, 1H),



1,3-dihydro-2H-
3.89-3.42 (m, 5H), 2.25-1.68 (m, 6H)



pyrrolo[3,4-



c]pyridine-2-



carboxamide


1535
N-[4-({(3R)-1-[(2S)-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50

(ESI(+))



tetrahydrofuran-2-
(d, J = 5.0 Hz, 1H), 8.29 (s, 1H), 7.45-7.39 (m, 2H),
m/e 423



ylcarbonyl]pyrrolidin-
6.93-6.83 (m, 2H), 5.06-4.90 (m, 1H), 4.82-4.75
(M + H)+



3-yl}oxy)phenyl]-
(m, 4H), 4.60-4.42 (m, 1H), 3.85-3.63 (m, 3H),



1,3-dihydro-2H-
3.63-3.41 (m, 2H), 2.30-1.71 (m, 6H)



pyrrolo[3,4-



c]pyridine-2-



carboxamide


1536
N-(4-{[(3R)-1-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50

(ESI(+))



(cyclopropylacetyl)pyr-
(d, J = 5.0 Hz, 1H), 8.29 (s, 1H), 7.48-7.40 (m, 3H),
m/e 407



rolidin-3-
6.92-6.82 (m, 2H), 5.03-4.90 (m, 1H), 4.81-4.75
(M + H)+



yl]oxy}phenyl)-1,3-
(m, 4H), 3.79-3.43 (m, 2H), 2.32-1.95 (m, 5H),



dihydro-2H-
1.05-0.88 (m, 1H), 0.49-0.36 (m, 2H), 0.20-0.07



pyrrolo[3,4-
(m, 2H)



c]pyridine-2-



carboxamide


1537
N-(4-{[(3S)-1-(3-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50

(ESI(+))



methylbutanoyl)pyr-
(d, J = 5.0 Hz, 1H), 8.29 (s, 1H), 7.49-7.39 (m, 3H),
m/e 409



rolidin-3-
6.92-6.81 (m, 2H), 5.04-4.89 (m, 1H), 4.81-4.75
(M + H)+



yl]oxy}phenyl)-1,3-
(m, 4H), 3.66-3.42 (m, 4H), 2.25-1.90 (m, 5H),



dihydro-2H-
0.96-0.82 (m, 6H)



pyrrolo[3,4-



c]pyridine-2-



carboxamide


1538
N-(4-{[(3S)-1-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50

(ESI(+))



(cyclobutylcarbonyl)
(d, J = 5.0 Hz, 1H), 8.29 (s, 1H), 7.48-7.40 (m, 3H),
m/e 407



pyrrolidin-3-
6.91-6.81 (m, 2H), 5.02-4.89 (m, 1H), 4.81-4.75
(M + H)+



yl]oxy}phenyl)-1,3-
(m, 4H), 3.32 (s, 5H), 2.27-1.65 (m, 8H)



dihydro-2H-



pyrrolo[3,4-



c]pyridine-2-



carboxamide


1539
N-[4-({(3S)-1-[(2R)-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50

(ESI(+))



tetrahydrofuran-2-
(d, J = 5.0 Hz, 1H), 8.29 (s, 1H), 7.48-7.41 (m, 3H),
m/e 423



ylcarbonyl]pyrrolidin-
7.43 (d, J = 5 .4 Hz, 2H), 6.93-6.82 (m, 2H), 5.05-
(M + H)+



3-yl}oxy)phenyl]-
4.91 (m, 1H), 4.81-4.75 (m, 4H), 4.60-4.42 (m,



1,3-dihydro-2H-
1H), 3.89-3.64 (m, 4H), 3.65-3.43 (m, 2H), 2.26-



pyrrolo[3,4-
1.73 (m, 6H)



c]pyridine-2-



carboxamide


1540
N-[4-({(3S)-1-[(2S)-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50

(ESI(+))



tetrahydrofuran-2-
(d, J = 5.0 Hz, 1H), 8.29 (s, 1H), 7.48-7.40 (m, 3H),
m/e 423



ylcarbonyl]pyrrolidin-
6.93-6.83 (m, 2H), 5.05-4.91 (m, 1H), 4.81-4.75
(M + H)+



3-yl}oxy)phenyl]-
(m, 3H), 4.59-4.42 (m, 1H), 3.89-3.42 (m, 6H),



1,3-dihydro-2H-
2.25-1.70 (m, 6H)



pyrrolo[3,4-



c]pyridine-2-



carboxamide


1541
N-(4-{[(3S)-1-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50

(ESI(+))



(cyclopropylacetyl)pyr-
(d, J = 5.0 Hz, 1H), 8.29 (s, 1H), 7.48-7.40 (m, 3H),
m/e 407



rolidin-3-
6.93-6.82 (m, 2H), 5.03-4.90 (m, 1H), 4.81-4.75
(M + H)+



yl]oxy}phenyl)-1,3-
(m, 4H), 3.80-3.33 (m, 2H), 2.30-1.95 (m, 5H),



dihydro-2H-
1.07-0.88 (m, 1H), 0.49-0.35 (m, 2H), 0.19-0.07



pyrrolo[3,4-
(m, 2H)



c]pyridine-2-



carboxamide









Example 953
N-{6-[(1-acetylpiperidin-4-yl)oxy]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 953A
tert-butyl 4-(5-nitropyridin-2-yloxy)piperidine-1-carboxylate

A suspension of pre-washed NaH (0.1 g, 2.48 mmol, 60% percent dispersion in mineral oil) in THF (2 mL) was added to an ice cold solution of 4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester (0.5 g, 2.48 mmol) in dry THF (3 mL). The mixture was stirred for 20 minutes, and added to 2-chloro-5-nitro-pyridine (0.36 g, 2.26 mmol) in portions. After the addition was completed, the cooling bath was removed and the reaction mixture was stirred at 22° C. overnight. The reaction mixture was cooled in an ice bath and treated with a saturated aqueous sodium bicarbonate solution (5 mL). The reaction mixture was diluted with ethyl acetate (25 mL) and distilled water (25 mL). The separated aqueous phase was extracted with ethyl acetate (3×35 mL), and the combined organic phases were dried over sodium sulfate, filtered and concentrated under reduced pressure. Chromatography provided the title compound.


Example 953B
tert-butyl 4-(5-aminopyridin-2-yloxy)piperidine-1-carboxylate

The title compound was prepared as described in Example 274, substituting tert-butyl 4-(5-nitropyridin-2-yloxy)piperidine-1-carboxylate for 5-nitro-N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide.


Example 953C
tert-butyl 4-(5-(isoindoline-2-carboxamido)pyridin-2-yloxy)piperidine-1-carboxylate

The title compound was prepared as described in Example 272B, substituting tert-butyl 4-(5-aminopyridin-2-yloxy)piperidine-1-carboxylate for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride.


Example 953D
N-(6-(piperidin-4-yloxy)pyridin-3-yl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(5-(isoindoline-2-carboxamido)pyridin-2-yloxy)piperidine-1-carboxylate for tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 953E
N-{6-[(1-acetylpiperidin-4-yl)oxy]pyridin-3-yl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(6-(piperidin-4-yloxy)pyridin-3-yl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and acetic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.37 (s, 1H), 8.26 (d, J=2.7 Hz, 1H), 7.86 (dd, J=8.9, 2.7 Hz, 1H), 7.44-7.24 (m, 4H), 6.75 (d, J=8.8 Hz, 1H), 5.21-5.07 (m, 1H), 4.75 (s, 4H), 3.72-3.63 (m, 1H), 3.40-3.11 (m, 2H), 1.97-1.85 (m, 1H), 1.73-1.38 (m, 2H); MS (ESI(+)) m/e 495 (M+H)+.









TABLE 17







The following Examples were essentially prepared as described in Example 1C, substituting


N-(6-(piperidin-4-yloxy)pyridin-3-yl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine


and the appropriate carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid.










Ex
Name

1H NMR

MS





954
N-{6-[(1-
1H NMR (300 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.26
(ESI(+))



isobutyrylpiperidin-4-
(dd, J = 2.7, 0.7 Hz, 1H), 7.86 (dd, J = 8.8, 2.7 Hz,
m/e 409



yl)oxy]pyridin-3-yl}-
1H), 7.41-7.26 (m, 4H), 6.74 (d, J = 8.5 Hz, 1H),
(M + H)+



1,3-dihydro-2H-
5.21-5.09 (m, 1H), 4.75 (s, 4H), 3.99-3.72 (m, 2H),



isoindole-2-
3.44-3.14 (m, 2H), 2.98-2.80 (m, 1H), 2.07-1.87



carboxamide
(m, 2H), 1.67-1.42 (m, 2H), 1.00 (d, J = 6.7 Hz, 6H)


955
N-(6-{[1-(3-

1H NMR (300 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.26

(ESI(+))



methylbutanoyl)piperidin-
(d, J = 2.9 Hz, 1H), 7.85 (dd, J = 8.8, 2.7 Hz, 1H),
m/e 423



4-yl]oxy}pyridin-3-
7.41-7.26 (m, 4H), 6.74 (d, J = 8.8 Hz, 1H), 5.21-
(M + H)+



yl)-1,3-dihydro-2H-
5.09 (m, 1H), 4.75 (s, 4H), 3.99-3.88 (m, 1H), 3.80-



isoindole-2-
3.67 (m, 1H), 3.45-3.13 (m, 3H), 2.22 (d, J = 1.4 Hz,



carboxamide
1H), 2.05-1.87 (m, 3H), 1.65-1.41 (m, 2H), 0.91




(d, J = 6.6 Hz, 6H)


956
N-(6-{[1-(4,4,4-

1H NMR (300 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.26

(ESI(+))



trifluorobutanoyl)piperidin-
(d, J = 2.7 Hz, 1H), 7.86 (dd, J = 8.8, 2.7 Hz, 1H),
m/e 463



4-yl]oxy}pyridin-3-
7.42-7.26 (m, 4H), 6.75 (d, J = 8.8 Hz, 1H), 5.21-
(M + H)+



yl)-1,3-dihydro-2H-
5.09 (m, 1H), 4.75 (s, 4H), 3.98-3.85 (m, 1H), 3.77-



isoindole-2-
3.66 (m, 1H), 3.42-3.15 (m, 2H), 2.68-2.56 (m,



carboxamide
2H), 2.03-1.88 (m, 2H), 1.71-1.41 (m, 2H)


957
N-(6-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.26

(ESI(+))



(methoxyacetyl)piperidin-
(d, J = 2.6 Hz, 1H), 7.86 (dd, J = 8.9, 2.7 Hz, 1H),
m/e 411



4-yl]oxy}pyridin-3-
7.34 (tdd, J = 9.0, 5.6, 3.5 Hz, 4H), 6.75 (d, J = 8.8
(M + H)+



yl)-1,3-dihydro-2H-
Hz, 1H), 5.25-5.06 (m, 1H), 4.75 (s, 4H), 4.08 (t, J =



isoindole-2-
6.0 Hz, 3H), 3.63 (s, 1H), 3.42-3.11 (m, 5H), 1.96 (s,



carboxamide
2H), 1.59 (d, J = 25.8 Hz, 2H)


958
N-(6-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.26

(ESI(+))



(tetrahydrofuran-2-
(d, J = 2.7 Hz, 1H), 7.86 (dd, J = 8.8, 2.7 Hz, 1H),
m/e 437



ylcarbonyl)piperidin-4-
7.40-7.28 (m, 4H), 6.75 (d, J = 8.8 Hz, 1H), 5.15 (d,
(M + H)+



yl]oxy}pyridin-3-yl)-
J = 4.1 Hz, 1H), 4.75 (s, 3H), 4.73-4.63 (m, 1H),



1,3-dihydro-2H-
3.92-3.63 (m, 5H), 3.62-3.12 (m, 2H), 2.09-1.89



isoindole-2-
(m, 2H), 1.89-1.69 (m, 1H), 1.70-1.32 (m, 1H)



carboxamide


959
N-(6-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.26

(ESI(+))



(tetrahydrofuran-3-
(d, J = 2.7 Hz, 1H), 7.86 (dd, J = 8.8, 2.8 Hz, 1H),
m/e 437



ylcarbonyl)piperidin-4-
7.40-7.22 (m, 4H), 6.75 (d, J = 8.8 Hz, 1H), 5.16
(M + H)+



yl]oxy}pyridin-3-yl)-
(dq, J = 8.2, 4.1 Hz, 1H), 4.75 (bs, 4H), 3.98-3.70



1,3-dihydro-2H-
(m, 4H), 3.74-3.63 (m, 2H), 3.45-3.14 (m, 3H),



isoindole-2-
2.08-1.88 (m, 4H), 1.68-1.43 (m, 2H)



carboxamide


960
N-(6-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.39 (d, J = 8.2 Hz,

(ESI(+))



(cyclopropylcarbonyl)piperidin-
1H), 8.31-8.20 (m, 1H), 7.91-7.78 (m, 1H), 7.44-
m/e 407



4-yl]oxy}pyridin-3-yl)-
7.24 (m, 4H), 6.82-6.68 (m, 1H), 5.27-5.07 (m,
(M + H)+



1,3-dihydro-2H-
1H), 4.75 (s, 4H), 4.07-3.86 (m, 2H), 3.61-3.46 (m,



isoindole-2-
1H), 3.26-3.13 (m, 1H), 2.10-1.86 (m, 3H), 1.70-



carboxamide
1.42 (m, 2H), 0.79-0.62 (m, 4H)


961
N-(6-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.26

(ESI(+))



(cyclopropylacetyl)piperidin-
(d, J = 3.1 Hz, 1H), 7.86 (dd, J = 8.9, 2.9 Hz, 1H),
m/e 421



4-yl]oxy}pyridin-3-
7.43-7.22 (m, 4H), 6.74 (d, J = 8.4 Hz, 1H), 5.21-
(M + H)+



yl)-1,3-dihydro-2H-
5.09 (m, 1H), 4.75 (bs, 4H), 3.98-3.87 (m, 1H), 3.76-



isoindole-2-
3.64 (m, 1H), 3.38-3.14 (m, 2H), 2.28 (d, J = 6.7



carboxamide
Hz, 2H), 2.21-1.89 (m, 2H), 1.67-1.43 (m, 2H),




1.05-0.87 (m, 1H), 0.51-0.35 (m, 2H), 0.22-0.08




(m, 2H)


962
N-(6-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.24

(ESI(+))



(cyclobutylcarbonyl)piperidin-
(t, J = 4.4 Hz, 1H), 7.93-7.77 (m, 1H), 7.44-7.24
m/e 421



4-yl]oxy}pyridin-
(m, 4H), 6.74 (t, J = 6.5 Hz, 1H), 5.23-5.03 (m, 1H),
(M + H)+



3-yl)-1,3-dihydro-2H-
4.75 (s, 4H), 3.98-3.81 (m, 1H), 3.66-3.50 (m, 1H),



isoindole-2-
3.27-3.10 (m, 2H), 2.26-1.99 (m, 4H), 1.99-1.80



carboxamide
(m, 3H), 1.80-1.42 (m, 3H)


963
N-(6-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.26

(ESI(+))



(cyclopentylcarbonyl)piperidin-
(d, J = 2.7 Hz, 1H), 7.85 (dd, J = 8.8, 2.7 Hz, 1H),
m/e 435



4-yl]oxy}pyridin-3-yl)-
7.40-7.28 (m, 4H), 6.74 (d, J = 8.8 Hz, 1H), 5.21-
(M + H)+



1,3-dihydro-2H-
5.09 (m, 1H), 4.75 (s, 4H), 3.98-3.75 (m, 3H), 3.45-



isoindole-2-
3.31 (m, 1H), 3.26-3.14 (m, 1H), 3.00 (p, J = 7.6 Hz,



carboxamide
1H), 2.03-1.87 (m, 2H), 1.81-1.44 (m, 10H)


964
N-(6-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.26

(ESI(+))



(cyclopentylacetyl)piperidin-
(dd, J = 2.7, 0.7 Hz, 1H), 7.85 (dd, J = 8.8, 2.7 Hz,
m/e 449



4-yl]oxy}pyridin-3-
1H), 7.41-7.26 (m, 4H), 6.74 (d, J = 8.5 Hz, 1H),
(M + H)+



yl)-1,3-dihydro-2H-
5.20-5.08 (m, 1H), 4.75 (s, 3H), 3.99-3.86 (m, 1H),



isoindole-2-
3.79-3.68 (m, 1H), 3.25-3.05 (m, 1H), 2.36 (d, J =



carboxamide
0.8 Hz, 1H), 2.35-2.06 (m, 3H), 2.04-1.85 (m, 2H),




1.82-1.68 (m, 2H), 1.65-1.40 (m, 6H), 1.23-0.99




(m, 2H)


965
N-(6-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.37 (s, 1H), 8.26

(ESI(+))



(cyclohexylcarbonyl)piperidin-
(d, J = 2.3 Hz, 1H), 7.85 (dd, J = 8.8, 2.7 Hz, 1H),
m/e 449



4-yl]oxy}pyridin-
7.33 (s, 2H), 6.74 (d, J = 8.8 Hz, 1H), 5.21-5.09 (m,
(M + H)+



3-yl)-1,3-dihydro-2H-
1H), 4.75 (s, 4H), 3.99-3.72 (m, 2H), 3.25-3.11 (m,



isoindole-2-
1H), 2.56 (d, J = 19.6 Hz, 1H), 2.06-1.85 (m, 2H),



carboxamide
1.74-1.08 (m, 13H)









Example 966
tert-butyl (2-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}ethyl)carbamate

The title compound was prepared as described in Example 272B, substituting tert-butyl 4-aminophenethylcarbamate for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.26 (s, 1H), 7.50-7.43 (m, 2H), 7.40-7.26 (m, 4H), 7.11-7.03 (m, 2H), 6.87-6.79 (m, 1H), 4.75 (s, 4H), 3.18-3.02 (m, 2H), 2.66-2.58 (m, 2H), 1.37 (s, 9H); MS (ESI(+)) m/e 382 (M+H)+.


Example 973
N-{4-[(tetrahydrofuran-3-ylmethyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 808, substituting (tetrahydrofuran-3-yl)methanamine for 3-methylbutan-1-amine in Example 808A. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.76 (s, 1H), 7.82-7.75 (m, 2H), 7.71-7.64 (m, 2H), 7.54 (t, J=6.1 Hz, 1H), 7.41-7.25 (m, 4H), 4.80 (bs, 4H), 3.70-3.49 (m, 3H), 2.69 (t, J=6.7 Hz, 2H), 2.34-2.16 (m, 1H), 1.94-1.79 (m, 1H), 1.54-1.39 (m, 1H); MS (ESI(+)) m/e 402 (M+H)+.


Example 974
N-{4-[(tetrahydrofuran-3-ylmethyl)sulfamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 4-amino-N-((tetrahydrofuran-3-yl)methyl)benzenesulfonamide for 4-amino-N-propylbenzamide and 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.83 (s, 1H), 8.62 (s, 1H), 8.51 (d, J=5.0 Hz, 1H), 7.82-7.75 (m, 2H), 7.72-7.65 (m, 2H), 7.55 (t, J=6.0 Hz, 1H), 7.44 (d, J=5.1 Hz, 1H), 4.87-4.75 (m, 4H), 3.76-3.49 (m, 3H), 2.69 (t, J=6.7 Hz, 2H), 2.34-2.16 (m, 1H), 1.94-1.79 (m, 1H), 1.54-1.39 (m, 1H); MS (ESI(+)) m/e 403 (M+H)+.


Example 975
5-cyano-N-{4-[(tetrahydrofuran-3-ylmethyl)sulfamoyl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 4-amino-N-((tetrahydrofuran-3-yl)methyl)benzenesulfonamide for 4-amino-N-propylbenzamide and isoindoline-5-carbonitrile for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.83 (s, 1H), 7.89 (s, 1H), 7.83-7.74 (m, 3H), 7.72-7.64 (m, 2H), 7.59 (d, J=7.9 Hz, 1H), 7.54 (t, J=6.1 Hz, 1H), 4.93-4.76 (m, 4H), 3.70-3.49 (m, 3H), 2.69 (t, J=6.7 Hz, 2H), 2.31-2.05 (m, 1H), 1.94-1.78 (m, 1H), 1.54-1.39 (m, 1H); MS (ESI(+)) m/e 427 (M+H)+.


Example 979
N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 979A
N-(4-(piperidin-4-yl)phenyl)isoindoline-2-carboxamide

tert-Butyl 4-(4-(isoindoline-2-carboxamido)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate (1.00 g, 2.38 mmol) in 20 ml of 1:1 methanol/tetrahydrofuran was added to 5% Pd on carbon (wet) (0.200 g) in a 50 ml pressure bottle and stirred for 16 hours at 30 atm and room temperature. The mixture was filtered through a nylon membrane and concentrated. The residue was suspended in dichloromethane, stirred 1 hour and filtered with dichloromethane washes to provide the title compound.


Example 979B
N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(4-(piperidin-4-yl)phenyl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and tetrahydrofuran-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.26 (s, 1H), 7.46 (m, 2H), 7.31 (m, 4H), 7.12 (m, 2H), 4.74 (bs, 4H), 4.53 (m, 1H), 4.05 (m, 1H), 3.87 (m, 1H), 3.70 (m, 3H), 3.36 (m, 2H), 3.12 (m, 1H), 2.75-2.58 (m, 1H), 2.01 (m, 2H), 1.76 (m, 2H), 1.45 (m, 2H); MS (ESI(+)) m/e 420 (M+H).









TABLE 18







The following Examples were essentially prepared as described in Example


1C, substituting the apropriate amine for 3-phenylpropan-1-amine and the


appropriate carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid.










Ex
Name

1H NMR

MS













980
N-{4-[1-(tetrahydrofuran-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.26 (d, J =

(ESI(+))



2-ylcarbonyl)piperidin-4-
8.7 Hz, 1H), 7.47 (m, 2H), 7.33 (m, 4H), 7.14 (m,
m/e 420



yl]phenyl}-1,3-dihydro-
2H), 4.75 (s, 4H), 4.68 (m, 1H), 4.45 (m, 1H), 4.09
(M + H)+



2H-isoindole-2-
(m, 1H), 3.75 (m, 2H), 3.10 (m, 1H), 2.76-2.56 (m,



carboxamide
2H), 2.04 (m, 2H), 1.80 (m, 4H), 1.61-1.33 (m, 2H)


981
N-{4-[1-(tetrahydro-2H-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.26 (s, 1H),

(ESI(+))



pyran-4-
7.47 (m, 2H), 7.33 (m, 4H), 7.12 (m, 2H), 4.75 (bs,
m/e 434



ylcarbonyl)piperidin-4-
4H), 4.55 (m, 1H), 4.09 (m, 1H), 3.85 (m, 2H), 3.40
(M + H)+



yl]phenyl}-1,3-dihydro-
(m, 2H), 3.09 (m, 1H), 2.91 (m, 1H), 2.70 (m, 1H),



2H-isoindole-2-
2.56 (m, 1H), 1.79 (m, 2H), 1.68-1.35 (m, 6H)



carboxamide


982
N-{4-[1-(1,4-dioxan-2-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.26 (s, 1H),

(ESI(+))



ylcarbonyl)piperidin-4-
7.48 (t, J = 1 0.0 Hz, 2H), 7.32 (m, 4H), 7.10 (d, J =
m/e 436



yl]phenyl}-1,3-dihydro-
7.5 Hz, 2H), 4.74 (s, 4H), 4.44 (d, J = 12.2 Hz, 1H),
(M + H)+



2H-isoindole-2-
4.34 (t, J = 9.2 Hz, 1H), 4.07 (d, J = 11.4 Hz, 1H),



carboxamide
3.83-3.56 (m, 4H), 3.50 (m, 2H), 3.08 (m, 1H),




2.66 (m, 2H), 1.78 (m, 2H), 1.67-1.30 (m, 2H)


983
N-(4-{1-[(1-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.26 (s, 1H),

(ESI(+))



methylpyrrolidin-3-
7.46 (d, J = 8.3 Hz, 2H), 7.31 (m, 4H), 7.11 (d, J =
m/e 433



yl)carbonyl]piperidin-4-
8.3 Hz, 2H), 4.74 (s, 4H), 4.52 (d, J = 12.0 Hz, 1H),
(M + H)+



yl}phenyl)-1,3-dihydro-
4.01 (d, J = 13.0 Hz, 1H), 3.25 (m, 1H), 3.06 (m,



2H-isoindole-2-
1H), 2.71 (m, 2H), 2.63-2.43 (m, 3H), 2.32 (m,



carboxamide
1H), 2.21 (s, 3H), 1.94 (m, 2H), 1.75 (m, 2H), 1.59-




1.30(m, 2H)


984
N-(4-{1-[(1,1-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.27 (s, 1H),

(ESI(+))



dioxidotetrahydrothiophen-3-
7.48 (m, 2H), 7.31 (m, 4H), 7.14 (m, 2H), 4.75 (s,
m/e 468



yl)carbonyl]piperidin-4-
4H), 4.53 (m, 1H), 4.08 (m, 1H), 3.75 (m, 1H), 3.30-
(M + H)+



yl}phenyl)-1,3-dihydro-
3.04 (m, 5H), 2.71 (m, 2H), 2.33 (m, 1H), 2.08 (m,



2H-isoindole-2-
1H), 1.79 (m, 2H), 1.66-1.36 (m, 2H)



carboxamide


985
N-{4-[1-(2-hydroxy-2-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.26 (s, 1H),

(ESI(+))



methylpropanoyl)piperidin-
7.48 (m, 2H), 7.31 (m, 4H), 7.11 (d, J = 8.5 Hz, 2H),
m/e 408



4-yl]phenyl}-1,3-
5.37 (s, 1H), 4.74 (s, 4H), 4.53 (m, 2H), 3.30 (m,
(M + H)+



dihydro-2H-isoindole-2-
1H), 2.71 (m, 2H), 1.76 (d, J = 11.8 Hz, 2H), 1.50



carboxamide
(m, 2H), 1.32 (s, 6H)


986
N-{4-[1-(morpholin-4-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.26 (s, 1H),

(ESI(+))



ylacetyl)piperidin-4-
7.46 (m, 2H), 7.33 (m, 4H), 7.10 (m, 2H), 4.74 (bs,
m/e 449



yl]phenyl}-1,3-dihydro-
4H), 4.46 (m, 1H), 4.13 (m, 1H), 3.57 (m, 4H), 3.06
(M + H)+



2H-isoindole-2-
(m, 3H), 2.71-2.50 (m, 2H), 2.40 (m, 4H), 1.77 (m,



carboxamide
2H), 1.56 (m, 1H), 1.40 (m, 1H)


1469
N-(4-{1-[(2R)-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.28 (s, 1H),

(ESI(+))



tetrahydrofuran-2-
7.47 (m, 2H), 7.32 (m, 4H), 7.13 (m, 2H), 4.75 (s,
m/e 420



ylcarbonyl]piperidin-4-
4H), 4.70 (m, 1H), 4.48 (m, 1H), 4.10 (m, 1H), 3.76
(M + H)+



yl}phenyl)-1,3-dihydro-
(m, 2H), 3.08 (m, 1H), 2.69 (m, 2H), 2.03 (m, 2H),



2H-isoindole-2-
1.81 (m, 4H), 1.54 (m, 1H), 1.42 (m, 1H)



carboxamide


1470
N-(4-{1-[(2S)-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.28 (s, 1H),

(ESI(+))



tetrahydrofuran-2-
7.47 (m, 2H), 7.33 (m, 4H), 7.12 (dd, J = 8.3, 2.5 Hz,
m/e 420



ylcarbonyl]piperidin-4-
2H), 4.75 (s, 4H), 4.68 (dd, J = 7.5, 5.7 Hz, 1H), 4.49
(M + H)+



yl}phenyl)-1,3-dihydro-
(m, 1H), 4.10 (m, 1H), 3.76 (m, 2H), 3.13 (m, 1H),



2H-isoindole-2-
268 (m, 2H), 2.01 (m, 2H), 1.80 (m, 4H), 1.50 (m, 2H)



carboxamide


1471
N-(4-{1-[(3R)-
A-1361467.0 - 1H NMR (400 MHz, DMSO-d6) δ
(ESI(+))



tetrahydrofuran-3-
8.28 (s, 1H), 7.47 (m, 2H), 7.34 (m, 4H), 7.13 (m,
m/e 420



ylcarbonyl]piperidin-4-
2H), 4.75 (s, 4H), 4.54 (m, 1H), 4.08 (m, 1H), 3.88
(M + H)+



yl}phenyl)-1,3-dihydro-
(m, 1H), 3.71 (m, 3H), 3.39 (m, 1H), 3.14 (m, 1H),



2H-isoindole-2-
2.66 (m, 2H), 2.01 (m, 2H), 1.79 (m, 2H), 1.46 (m, 2H)



carboxamide









Example 1013
N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
Example 1013A
tert-butyl 4-(4-(isoindoline-2-carboxamido)phenoxy)piperidine-1-carboxylate

The title compound was prepared as described in Example 272B, substituting tert-butyl 4-(4-aminophenoxy)piperidine-1-carboxylate for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride.


Example 1013B
N-(4-(piperidin-4-yloxy)phenyl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(4-(isoindoline-2-carboxamido)phenoxy)piperidine-1-carboxylate for tert-butyl 44(4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 1013C
N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(4-(piperidin-4-yloxy)phenyl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and tetrahydrofuran-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.20 (s, 1H), 7.47-7.27 (m, 6H), 6.93-6.86 (m, 2H), 4.74 (s, 4H), 4.58-4.47 (m, 1H), 3.93-3.56 (m, 6H), 3.44-3.32 (m, 3H), 2.06-1.83 (m, 4H), 1.69-1.40 (m, 2H); MS (ESI(+)) m/e 436 (M+H)+.









TABLE 19







The following Examples were essentially prepared as described in Example 1C, substituting an appropriate


amine for 3-phenylpropan-1-amine and appropriate acid for 4-(isoindoline-2-carboxamido)benzoic acid.










Ex
Name

1H NMR

MS





1028
N-(4-{[1-(2-

1H NMR (300 MHz, DMSO-d6) δ 8.20 (s, 1H), 7.42

(ESI(+))



methylbutanoyl)piperidin-
(dd, J = 12.5, 10.6 Hz, 2H), 7.37-7.23 (m, 4H), 6.90
m/e 422



4-yl]oxy}phenyl)-1,3-
(d, J = 9.0 Hz, 2H), 4.74 (s, 4H), 4.66-4.42 (m, 1H),
(M + H)+



dihydro-2H-isoindole-2-
3.90 (s, 2H), 3.45-3.11 (m, 2H), 2.73 (dd, J = 13.4,



carboxamide
6.8 Hz, 1H), 1.92 (s, 2H), 1.68-1.12 (m, 4H), 0.98




(d, J = 6.7 Hz, 3H), 0.81 (t, J = 7.4 Hz, 3H)


1029
N-(4-{[1-(3-

1H NMR (300 MHz, DMSO-d6) δ 8.19 (s, 1H), 7.48-

(ESI(+))



methylbutanoyl)piperidin-
7.38 (m, 2H), 7.33 (tdd, J = 8.9, 5.6, 3.5 Hz, 4H), 6.98-
m/e 422



4-yl]oxy}phenyl)-1,3-
6.81 (m, 2H), 4.74 (s, 4H), 4.50 (dt, J = 8.0, 4.1 Hz,
(M + H)+



dihydro-2H-isoindole-2-
1H), 3.85 (s, 1H), 3.69 (s, 1H), 3.21 (d, J = 9.3 Hz,



carboxamide
1H), 2.34-2.14 (m, 2H), 2.13-1.80 (m, 3H), 1.53




(d, J = 21.1 Hz, 2H), 0.90 (d, J = 6.6 Hz, 6H)


1030
N-(4-{[1-(2,3-

1H NMR (300 MHz, DMSO-d6) δ 8.20 (s, 1H), 7.47-

(ESI(+))



dimethylbutanoyl)piperidin-
7.27 (m, 6H), 6.94-6.86 (m, 2H), 4.74 (s, 4H), 4.72-
m/e 436



4-yl]oxy}phenyl)-
4.47 (m, 1H), 4.02-3.76 (m, 2H), 3.50-3.12 (m,
(M + H)+



1,3-dihydro-2H-
2H), 2.00-1.63 (m, 3H), 1.63-1.39 (m, 2H), 0.95



isoindole-2-
(d, J = 6.7 Hz, 3H), 0.85 (t, J = 6.6 Hz, 6H)



carboxamide


1031
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.20 (s, 1H), 7.44

(ESI(+))



(tetrahydrofuran-2-
(d, J = 9.0 Hz, 2H), 7.34 (tdd, J = 8.9, 5.5, 3.5 Hz,
m/e 436



ylcarbonyl)piperidin-4-
4H), 6.90 (d, J = 9.0 Hz, 2H), 4.74 (s, 4H), 4.70-4.63
(M + H)+



yl]oxy}phenyl)-1,3-
(m, 1H), 4.51 (s, 1H), 3.80-3.68 (m, 4H), 3.47-3.08



dihydro-2H-isoindole-2-
(m, 2H), 2.13-1.68 (m, 6H), 1.66-1.33 (m, 2H)



carboxamide


1032
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.18 (d, J = 6.7 Hz,

(ESI(+))



(cyclohexylcarbonyl)piperidin-
1H), 7.48-7.39 (m, 2H), 7.39-7.22 (m, 4H), 6.96-
m/e 448



4-yl]oxy}phenyl)-1,3-
6.81 (m, 2H), 4.74 (s, 4H), 4.56-4.41 (m, 1H), 3.97-
(M + H)+



dihydro-2H-isoindole-2-
3.64 (m, 2H), 3.28-3.10 (m, 2H), 2.67-2.54 (m,



carboxamide
1H), 2.02-1.78 (m, 2H), 1.74-1.39 (m, 7H), 1.39-




1.04 (m, 5H)


1033
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.20 (s, 1H), 7.41

(ESI(+))



(cyclohexylacetyl)piperidin-
(t, J = 11.1 Hz, 2H), 7.37-7.20 (m, 4H), 6.89 (d, J =
m/e 462



4-yl]oxy}phenyl)-
9.0 Hz, 2H), 4.74 (s, 4H), 4.57-4.38 (m, 1H), 3.77
(M + H)+



1,3-dihydro-2H-
(d, J = 47.0 Hz, 2H), 3.21 (t, J = 9.7 Hz, 2H), 2.20 (d,



isoindole-2-
J = 6.6 Hz, 2H), 1.89 (s, 2H), 1.60 (t, J = 30.4 Hz,



carboxamide
8H), 1.17 (dd, J = 28.3, 16.2 Hz, 3H), 0.94 (t, J = 11.4




Hz, 2H)


1034
N-(4-{[1-(tetrahydro-

1H NMR (300 MHz, DMSO-d6) δ 8.20 (s, 1H), 7.40

(ESI(+))



2H-pyran-4-
(dd, J = 19.8, 6.3 Hz, 3H), 7.36-7.23 (m, 3H), 6.89
m/e 464



ylacetyl)piperidin-4-
(d, J = 9.0 Hz, 2H), 4.74 (s, 4H), 4.50 (s, 1H), 3.95-
(M + H)+



yl]oxy}phenyl)-1,3-
3.64 (m, 4H), 3.28-3.14 (m, 4H), 2.27 (d, J = 6.4 Hz,



dihydro-2H-isoindole-2-
2H), 1.91 (d, J = 3.7 Hz, 3H), 1.55 (t, J = 18.1 Hz,



carboxamide
4H), 1.32-1.07 (m, 2H)


1035
N-(4-{[1-(morpholin-4-

1H NMR (300 MHz, DMSO-d6) δ 10.01 (s, 1H), 8.21

(ESI(+))



ylacetyl)piperidin-4-
(s, 1H), 7.43 (t, J = 13.2 Hz, 2H), 7.37-7.24 (m, 3H),
m/e 465



yl]oxy}phenyl)-1,3-
6.91 (d, J = 9.1 Hz, 2H), 4.74 (s, 4H), 4.71-4.45 (m,
(M + H)+



dihydro-2H-isoindole-2-
1H), 4.37 (s, 2H), 4.04-3.71 (m, 6H), 3.56 (d, J =



carboxamide
15.9 Hz, 2H), 3.47-3.20 (m, 4H), 3.13 (s, 2H), 1.97




(s, 2H), 1.62 (dd, J = 33.2, 8.7 Hz, 2H)


1036
N-(4-{[1-

1H NMR (300 MHz, DMSO-d6) δ 8.20 (s, 1H), 7.51-

(ESI(+))



(tetrahydrofuran-3-
7.35 (m, 3H), 7.35-7.23 (m, 3H), 6.89 (d, J = 9.0 Hz,
m/e 450



ylacetyl)piperidin-4-
2H), 4.74 (s, 4H), 4.50 (dd, J = 7.7, 3.9 Hz, 1H), 3.92-
(M + H)+



yl]oxy}phenyl)-1,3-
3.71 (m, 3H), 3.71-3.52 (m, 2H), 3.22 (dd, J = 9.8,



dihydro-2H-isoindole-2-
4.3 Hz, 3H), 2.45 (s, 3H), 2.13-1.80 (m, 3H), 1.67-



carboxamide
1.37 (m, 3ff)









Example 1018
N-(4-{4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
Example 1018A
N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide

2,3-Dihydro-1H-pyrrolo[3,4-c]pyridine 2.HCl (1.55 g, 8.03 mmol) was suspended in dimethylformamide (30 ml) and treated with triisopropylethylamine (4.21 ml, 24.08 mmol). After stirring for 20 minutes, the mixture was cooled to −15° C. 2-(4-Isocyanatophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.028 g, 8.03 mmol) was dissolved in 10 ml tetrahydrofuran and added via syringe over 10 minutes. The mixture was allowed to warm to room temperature, and it was stirred for 3 hours and concentrated under a stream of nitrogen to minimal volume. The residue was diluted with cold water to give a turbid mixture which was filtered with water washes to provide the title compound after drying.


Example 1018B
tert-butyl 4-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenyl)cyclohex-3-enylcarbamate

N-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide (1.692 g, 4.63 mmol), 4-(tert-butoxycarbonylamino)cyclohex-1-enyl trifluoromethanesulfonate (1.6 g, 4.63 mmol) and cesium carbonate (3.77 g, 11.58 mmol) were suspended in terahydrofuran (30 ml), methanol (5.00 ml) and water (15.00 ml). Nitrogen was bubbled through the solution for 10 min when PdCl2(dppf)-dichloromethane adduct (0.189 g, 0.232 mmol) was added and the mixture was heated to 80° C. for 7 h. After dilution with ethyl acetate and brine, the separated aqueous layer was extracted several times with ethyl acetate and the combined organic layers were dried over magnesium sulfate, filtered and concentrated. Flash chromatography provided the title compound.


Example 1018C
N-(4-(4-aminocyclohex-1-enyl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenyl)cyclohex-3-enylcarbamate for tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 1018D
N-(4-{4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(4-(4-aminocyclohex-1-enyl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and isobutyric acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.61 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.41 (s, 1H), 7.66 (d, J=7.6 Hz, 1H), 7.56-7.48 (m, 2H), 7.43 (d, J=5.1 Hz, 1H), 7.37-7.29 (m, 2H), 6.06-5.99 (m, 1H), 4.83-4.77 (m, 4H), 3.87-3.73 (m, 1H), 2.37 (t, J=6.7 Hz, 2H), 2.11-1.97 (m, 1H), 1.95-1.82 (m, 1H), 1.80-1.50 (m, 1H), 1.38-1.20 (m, 2H), 1.00 (dd, J=6.8, 2.5 Hz, 6H); MS (ESI(+)) m/e 405 (M+H)+.









TABLE 20







The title compound was prepared as described in Example 1C, substituting N-(4-(4-aminocyclohex-


1-enyl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine


and the appropriate carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid.










Ex
Name

1H NMR

MS





1022
N-(4-{4-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d,

(ESI(+))



[(tetrahydrofuran-3-
J = 5.0 Hz, 1H), 8.42 (s, 1H), 7.91 (d, J = 7.5 Hz, 1H),
m/e 433



ylcarbonyl)amino]cyclohex-
7.52 (d, J = 8.6 Hz, 2H), 7.43 (d, J = 5.0 Hz, 1H), 7.33
(M + H)+



1-en-1-yl}phenyl)-
(d, J = 8.6 Hz, 2H), 6.02 (s, 1H), 4.80 (d, J = 4.1 Hz,



1,3-dihydro-2H-
4H), 3.84 (td, J = 8.1, 3.7 Hz, 2H), 3.76-3.52 (m,



pyrrolo[3,4-c]pyridine-
3H), 2.93 (p, J = 7.7 Hz, 1H), 2.11-1.79 (m, 5H),



2-carboxamide
1.60 (s, 1H)


1023
N-(4-{4-[(tetrahydro-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d,

(ESI(+))



2H-pyran-4-
J = 5.0 Hz, 1H), 8.42 (s, 1H), 7.77-7.69 (m, 1H), 7.56-
m/e 447



ylcarbonyl)amino]cyclohex-
7.48 (m, 2H), 7.43 (d, J = 5.1 Hz, 1H), 7.37-7.29
(M + H)+



1-en-1-yl}phenyl)-
(m, 2H), 6.02 (bs, 1H), 4.84-4.72 (m, 4H), 3.90-



1,3-dihydro-2H-
3.78 (m, 4H), 2.48-2.41 (m, 2H), 2.36 (s, 2H), 2.11-



pyrrolo[3,4-c]pyridine-
1.98 (m, 1H), 1.93-1.81 (m, 1H), 1.69-1.52 (m, 6H)



2-carboxamide


1024
N-(4-{4-[(morpholin-4-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d,

(ESI(+))



ylacetyl)amino]cyclohex-
J = 4.9 Hz, 1H), 8.42 (s, 1H), 7.62 (d, J = 8.1 Hz, 1H),
m/e 462



1-en-1-yl}phenyl)-
7.53 (d, J = 8.7 Hz, 2H), 7.43 (d, J = 5.0 Hz, 1H), 7.33
(M + H)+



1,3-dihydro-2H-
(d, J = 8.7 Hz, 2H), 6.02 (s, 1H), 4.80 (d, J = 4.2 Hz,



pyrrolo[3,4-c]pyridine-
4H), 3.91 (s, 1H), 3.64-3.49 (m, 5H), 2.92 (s, 2H),



2-carboxamide
2.41 (dd, J = 12.8, 8.2 Hz, 5H), 2.18 (s, 1H), 1.86 (s,




1H), 1.77-1.59 (m, 1H)


1025
N-[4-(4-{[(2-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d,

(ESI(+))



methoxyethoxy)acetyl]
J = 4.9 Hz, 1H), 8.42 (s, 1H), 7.59-7.49 (m, 3H), 7.43
m/e 451



amino}cyclohex-1-en-
(d, J = 5.1 Hz, 1H), 7.37-7.30 (m, 2H), 6.03 (bs, 1H),
(M + H)+



1-yl)phenyl]-1,3-
4.83-4.77 (m, 4H), 3.88 (s, 4H), 3.60 (d, J = 3.8 Hz,



dihydro-2H-
2H), 3.48 (d, J = 2.8 Hz, 2H), 3.25 (s, 3H), 2.36-1.97



pyrrolo[3,4-c]pyridine-
(m, 3H), 1.93-1.82 (m, 1H), 1.77-1.57 (m, 1H)



2-carboxamide


1081
N-(4-{4-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d,

(ESI(+))



[(tetrahydrofuran-2-
J = 5.0 Hz, 1H), 8.42 (s, 1H), 7.79 (d, J = 7.4 Hz, 1H),
m/e 447



ylacetyl)amino]cyclohex-
7.52 (d, J = 8.7 Hz, 2H), 7.43 (d, J = 5.1 Hz, 1H), 7.33
(M + H)+



1-en-1-yl}phenyl)-
(d, J = 8.7 Hz, 2H), 6.02 (s, 1H), 4.80 (d, J = 4.0 Hz,



1,3-dihydro-2H-
4H), 4.07 (p, J = 6.7 Hz, 1H), 3.83 (s, 1H), 3.73 (dd, J =



pyrrolo[3,4-c]pyridine-
14.2, 7.3 Hz, 1H), 3.58 (dd, J = 14.5, 7.6 Hz, 1H),



2-carboxamide
2.45 (s, 2H), 2.34 (dd, J = 13.8, 6.9 Hz, 2H), 2.28-




2.16 (m, 1H), 2.11-1.96 (m, 1H), 1.96-1.71 (m,




4H), 1.68-1.39 (m, 2H)


1082
N-(4-{4-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d,

(ESI(+))



[(tetrahydrofuran-3-
J = 5.0 Hz, 1H), 8.42 (s, 1H), 7.84 (d, J = 7.6 Hz, 1H),
m/e 447



ylacetyl)amino]cyclohex-
7.52 (d, J = 8.8 Hz, 2H), 7.43 (d, J = 5.1 Hz, 1H), 7.36-
(M + H)+



1-en-1-yl}phenyl)-
7.29 (m, 2H), 6.02 (bs, 1H), 4.83-4.77 (m, 4H),



1,3-dihydro-2H-
3.91-3.79 (m, 1H), 3.78-3.67 (m, 1H), 3.66-3.55



pyrrolo[3,4-c]pyridine-
(m, 1H), 3.26 (q, J = 3.7 Hz, 1H), 2.44 (dd, J = 10.1,



2-carboxamide
4.1 Hz, 2H), 2.41-2.33 (m, 1H), 2.21-2.12 (m, 1H),




2.11-1.82 (m, 4H), 1.67-1.41 (m, 3H)


1083
N-(4-{4-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d,

(ESI(+))



[(cyclohexylcarbonyl)ami-
J = 5.0 Hz, 1H), 8.42 (s, 1H), 7.62 (d, J = 7.6 Hz, 1H),
m/e 445



no]cyclohex-1-en-1-
7.56-7.48 (m, 2H), 7.43 (d, J = 5.1 Hz, 1H), 7.36-
(M + H)+



yl}phenyl)-1,3-
7.29 (m, 2H), 6.01 (bs, 1H), 4.83-4.77 (m, 4H), 3.84-



dihydro-2H-
3.74 (m, 1H), 2.43-2.29 (m, 2H), 2.29-1.97 (m,



pyrrolo[3,4-c]pyridine-
2H), 1.91-1.80 (m, 1H), 1.74-1.48 (m, 6H), 1.43-



2-carboxamide
1.03 (m, 5H)


1084
N-[4-(4-{[(1,1-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d,

(ESI(+))



dioxidotetrahydrothiophen-3-
J = 5.0 Hz, 1H), 8.42 (s, 1H), 8.12 (d, J = 7.4 Hz, 1H),
m/e 481



yl)carbonyl]amino}cyclohex-
8.10-8.05 (m, 1H), 7.53 (d, J = 8.8 Hz, 2H), 7.43 (d,
(M + H)+



1-en-1-
J = 5.1 Hz, 1H), 7.34 (d, J = 8.7 Hz, 2H), 6.02 (s, 1H),



yl)phenyl]-1,3-dihydro-
4.80 (d, J = 4.1 Hz, 4H), 3.85 (s, 1H), 3.21 (ddd, J =



2H-pyrrolo[3,4-
16.3, 11.0, 6.6 Hz, 3H), 3.14-2.96 (m, 2H), 2.31 (dd,



c]pyridine-2-
J = 12.3, 6.1 Hz, 2H), 2.19-1.97 (m, 2H), 1.88 (s,



carboxamide
1H), 1.62 (s, 1H)


1085
N-[4-(4-{[(4,4-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d,

(ESI(+))



difluorocyclohexyl)carbonyl]ami-
J = 5.0 Hz, 1H), 8.42 (s, 1H), 7.80 (d, J = 7.5 Hz, 1H),
m/e 481



no}cyclohex-
7.56-7.48 (m, 2H), 7.43 (d, J = 5.1 Hz, 1H), 7.37-
(M + H)+



1-en-1-yl)phenyl]-1,3-
7.29 (m, 2H), 6.02 (bs, 1H), 4.83-4.77 (m, 4H), 3.89-



dihydro-2H-
3.77 (m, 1H), 2.41 (d, J = 23.9 Hz, 1H), 2.24-2.14



pyrrolo[3,4-c]pyridine-
(m, 1H), 2.12-1.96 (m, 4H), 1.80 (d, J = 22.0 Hz,



2-carboxamide
4H), 1.70-1.50 (m, 4H)


1086
N-(4-{4-[(2-hydroxy-2-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d,

(ESI(+))



methylpropanoyl)ami-
J = 5.0 Hz, 1H), 8.42 (s, 1H), 7.56-7.49 (m, 2H), 7.42
m/e 421



no]cyclohex-1-en-1-
(d, J = 3.1 Hz, 2H), 7.37-7.30 (m, 2H), 6.03 (bs, 1H),
(M + H)+



yl}phenyl)-1,3-
5.38 (s, 1H), 4.84-4.72 (m, 4H), 3.89-3.79 (m, 1H),



dihydro-2H-
2.35 (s, 1H), 2.39-2.05 (m, 2H), 1.80 (d, J = 19.6 Hz,



pyrrolo[3,4-c]pyridine-
1H), 1.77-1.61 (m, 1H), 1.25 (s, 6H)



2-carboxamide


1087
N-(4-{4-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d,

(ESI(+))



[(tetrahydrofuran-2-
J = 5.0 Hz, 1H), 8.42 (s, 1H), 7.65-7.54 (m, 1H), 7.52
m/e 433



ylcarbonyl)amino]cyclohex-
(d, J = 8.7 Hz, 2H), 7.43 (d, J = 5.0 Hz, 1H), 7.33 (d, J =
(M + H)+



1-en-1-yl}phenyl)-
8.7 Hz, 2H), 6.02 (s, 1H), 4.80 (d, J = 4.0 Hz, 4H),



1,3-dihydro-2H-
4.20 (dd, J = 8.1, 5.1 Hz, 1H), 3.89 (dd, J = 13.8, 7.1



pyrrolo[3,4-c]pyridine-
Hz, 2H), 3.76 (dd, J = 14.4, 6.7 Hz, 1H), 2.30 (dd, J =



2-carboxamide
28.6, 11.2 Hz, 1H), 2.26-2.01 (m, 3H), 1.93-1.60




(m, 6H)


1291
N-(4-{4-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d,

(ESI(+))



[(cyclopropylacetyl)ami-
J = 5.0 Hz, 1H), 8.42 (s, 1H), 7.67 (d, J = 7.6 Hz, 1H),
m/e 417



no]cyclohex-1-en-1-
7.56-7.49 (m, 2H), 7.43 (d, J = 5.1 Hz, 1H), 7.37-
(M + H)+



yl}phenyl)-1,3-
7.29 (m, 2H), 6.02 (bs, 1H), 4.84-4.77 (m, 4H), 3.92-



dihydro-2H-
3.75 (m, 1H), 2.42 (d, J = 23.1 Hz, 2H), 2.10-2.03



pyrrolo[3,4-c]pyridine-
(m, 1H), 1.99 (d, J = 7.0 Hz, 2H), 1.94-1.84 (m, 1H),



2-carboxamide
1.83-1.51 (m, 1H), 1.05-0.88 (m, 1H), 0.43(dd, J =




9.8, 4.2 Hz, 2H), 0.21-0.07 (m, 2H)


1442
N-[4-(4-{[(4-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d,

(ESI(+))



methylpiperazin-1-
J = 5.0 Hz, 1H), 8.42 (s, 1H), 7.59-7.49 (m, 3H), 7.43
m/e 475



yl)acetyl]amino}cyclohex-
(d, J = 4.6 Hz, 1H), 7.37-7.30 (m, 2H), 6.06-5.98
(M + H)+



1-en-1-yl)phenyl]-
(m, 1H), 5.75 (s, 1H), 4.84-4.77 (m, 4H), 4.00-3.85



1,3-dihydro-2H-
(m, 1H), 3.05-2.90 (m, 2H), 2.90 (s, 3H), 2.32-2.13



pyrrolo[3,4-c]pyridine-
(m, 5H), 2.12 (s, 3H), 2.12 (s, 3H), 1.91-1.80 (m,



2-carboxamide
1H), 1.75-1.61 (m, 1H)


1443
N-(4-{4-[(tetrahydro-

1H NMR (300 MHz, DMSO-d6) δ 8.65-8.57 (m, 1H),

(ESI(+))



2H-pyran-4-
8.55-8.45 (m, 1H), 8.44-8.36 (m, 2H), 7.88-7.75
m/e 461



ylacetyl)amino]cyclohex-
(m, 1H), 7.60-7.47 (m, 2H), 7.47-7.37 (m, 1H),
(M + H)+



1-en-1-yl}phenyl)-
7.36-7.24 (m, 2H), 6.07-5.86 (m, 1H), 4.87-4.62



1,3-dihydro-2H-
(m, 4H), 3.90-3.68 (m, 2H), 3.29-3.17 (m, 2H),



pyrrolo[3,4-c]pyridine-
2.45-2.28 (m, 2H), 2.09-1.91 (m, 4H), 1.93-1.79



2-carboxamide
(m, 2H), 1.64-1.42 (m, 3H), 1.28-1.07 (m, 2H)


1444
N-{4-[4-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.49 (t,

(ESI(+))



(benzoylamino)cyclohex-
J = 4.7 Hz, 1H), 8.43 (s, 1H), 8.32 (d, J = 7.7 Hz, 1H),
m/e 439



1-en-1-yl]phenyl}-
7.91-7.83 (m, 2H), 7.57-7.41 (m, 6H), 7.38-7.28
(M + H)+



1,3-dihydro-2H-
(m, 2H), 6.07 (d, J = 1.8 Hz, 1H), 4.87-4.71 (m, 4H),



pyrrolo[3,4-c]pyridine-
4.16-3.95 (m, 1H), 2.35-2.19 (m, 2H), 2.08-1.93



2-carboxamide
(m, 2H), 1.8 1-1.65 (m, 2H)


1445
N-[4-(4-{[(2S)-

1H NMR (300 MHz, DMSO-d6) δ 8.62 (d, J = 5.8 Hz,

(ESI(+))



tetrahydrofuran-2-
1H), 8.54-8.45 (m, 1H), 8.44-8.35 (m, 1H), 7.63-
m/e 433



ylcarbonyl]amino}cyclohex-
7.54 (m, 1H), 7.56-7.46 (m, 2H), 7.46-7.38 (m,
(M + H)+



1-en-1-
1H), 7.33 (d, J = 8.7 Hz, 2H), 6.06-5.90 (m, 1H),



yl)phenyl]-1,3-dihydro-
4.86-4.65 (m, 4H), 4.26-4.11 (m, 1H), 3.94-3.80



2H-pyrrolo[3,4-
(m, 2H), 3.80-3.62 (m, 1H), 2.40-2.25 (m, 2H),



c]pyridine-2-
2.27-2.02 (m, 2H), 1.92-1.77 (m, 4H), 1.75-1.60



carboxamide
(m, 1H)


1446
N-[4-(4-{[(2R)-

1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.53-

(ESI(+))



tetrahydrofuran-2-
8.44 (m, 1H), 8.41 (d, J = 6.7 Hz, 1H), 7.65-7.56 (m,
m/e 433



ylcarbonyl]amino}cyclohex-
1H), 7.56-7.47 (m, 2H), 7.46-7.39 (m, 1H), 7.33 (d,
(M + H)+



1-en-1-
J = 8.7 Hz, 2H), 6.01 (t, J = 4.3 Hz, 1H), 4.80 (d, J =



yl)phenyl]-1,3-dihydro-
4.0 Hz, 4H), 4.24-4.16 (m, 1H), 3.93-3.82 (m, 3H),



2H-pyrrolo[3,4-
3.80-3.70 (m, 1H), 2.33 (dd, J = 5.3, 3.1 Hz, 1H),



c]pyridine-2-
2.24-2.01 (m, 3H), 2.01-1.63 (m, 5H)



carboxamide


1447
N-[4-(4-{[(1-

1H NMR (300 MHz, DMSO-d6) δ 8.68-8.56 (m, 1H),

(ESI(+))



methylpiperidin-4-
8.50 (d, J = 5.0 Hz, 1H), 8.42 (s, 1H), 7.70 (d, J = 7.6
m/e 460



yl)carbonyl]amino}cyclohex-
Hz, 1H), 7.56-7.48 (m, 2H), 7.43 (d, J = 5.2 Hz, 1H),
(M + H)+



1-en-1-yl)phenyl]-1,3-dihydro-
7.37-7.29 (m, 2H), 6.02 (bs, 1H), 4.83-4.77 (m,



2H-pyrrolo[3,4-
4H), 3.86-3.76 (m, 1H), 2.81-2.70 (m, 3H), 2.38-



c]pyridine-2-
2.25 (m, 1H), 2.13 (s, 3H), 2.10-1.97 (m, 2H), 1.90-



carboxamide
1.74 (m, 3H), 1.68-1.49 (m, 5H)


1448
N-[4-(4-{[(1,1-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d,

(ESI(+))



dioxidotetrahydro-2H-
J = 5.0 Hz, 1H), 8.42 (s, 1H), 7.92 (d, J = 7.5 Hz, 1H),
m/e 495



thiopyran-4-
7.56-7.49 (m, 2H), 7.43 (d, J = 5.1 Hz, 1H), 7.37-
(M + H)+



yl)carbonyl]amino}cyclohex-
7.29 (m, 2H), 6.02 (bs, 1H), 4.87-4.77 (m, 4H), 3.83



1-en-1-
(d, J = 3.0 Hz, 1H), 3.16-3.01 (m, 4H), 2.42 (d, J =



yl)phenyl]-1,3-dihydro-
24.4 Hz, 4H), 2.11-1.91 (m, 5H), 1.93-1.78 (m,



2H-pyrrolo[3,4-
1H), 1.72-1.52 (m, 1H)



c]pyridine-2-



carboxamide


1449
N-[4-(4-{[(3R)-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d,

(ESI(+))



tetrahydrofuran-3-
J = 5.0 Hz, 1H), 8.42 (s, 1H), 7.92 (d, J = 7.5 Hz, 1H),
m/e 433



ylcarbonyl]amino}cyclohex-
7.56-7.49 (m, 2H), 7.43 (d, J = 5.1 Hz, 1H), 7.37-
(M + H)+



1-en-1-
7.29 (m, 2H), 6.02 (bs, 1H), 4.88-4.72 (m, 4H), 3.84



yl)phenyl]-1,3-dihydro-
(td, J = 8.1, 3.8 Hz, 2H), 3.76-3.55 (m, 3H), 2.93 (p,



2H-pyrrolo[3,4-
J = 7.6 Hz, 1H), 2.42 (d, J = 19.4 Hz, 3H), 2.12-1.84



c]pyridine-2-
(m, 4H), 1.69-1.51 (m, 1H)



carboxamide


1450
N-[4-(4-{[(3S)-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d,

(ESI(+))



tetrahydrofuran-3-
J = 5.0 Hz, 1H), 8.41 (s, 1H), 7.91 (d, J = 7.6 Hz, 1H),
m/e 433



ylcarbonyl]amino}cyclohex-
7.54 (s, 2H), 7.43 (d, J = 5.1 Hz, 1H), 7.37-7.29 (m,
(M + H)+



1-en-1-
2H), 6.02 (bs, 1H), 4.85-4.72 (m, 4H), 3.84 (td, J =



yl)phenyl]-1,3-dihydro-
8.1, 3.8 Hz, 2H), 3.78-3.55 (m, 3H), 2.93 (p, J = 7.7



2H-pyrrolo[3,4-
Hz, 1H), 2.43 (d, J = 18.2 Hz, 2H), 2.11-1.79 (m,



c]pyridine-2-
4H), 1.60 (s, 1H)



carboxamide


1451
N-[4-(4-{[(2S)-2-

1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.53-

(ESI(+))



methylbutanoyl]amino}
8.43 (m, 1H), 8.42 (d, J = 6.6 Hz, 1H), 7.76-7.62 (m,
m/e 41 9



cyclohex-1-en-1-
1H), 7.56-7.46 (m, 2H), 7.49-7.36 (m, 1H), 7.35-
(M + H)+



yl)phenyl]-1,3-dihydro-
7.28 (m, 2H), 6.05-5.94 (m, 1H), 4.91-4.65 (m,



2H-pyrrolo[3,4-
4H), 4.06-3.70 (m, 1H), 2.48-2.31 (m, 2H), 2.24-



c]pyridine-2-
1.98 (m, 2H), 1.94-1.77 (m, 1H), 1.70-1.40 (m,



carboxamide
2H), 1.39-1.14 (m, 2H), 1.04-0.86 (m, 3H), 0.82




(td, J = 7.4, 3.3 Hz, 3H)









Example 1020
tert-butyl 3-{[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]methyl}azetidine-1-carboxylate

The title compound was prepared as described in Example 272B, substituting tert-butyl 3-(aminomethyl)azetidine-1-carboxylate for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 7.37-7.23 (m, 4H), 6.58-6.48 (m, 1H), 4.58 (s, 4H), 3.91-3.75 (m, 2H), 3.65-3.51 (m, 2H), 3.30-3.20 (m, 2H), 2.68-2.55 (m, 1H), 1.35 (s, 9H); MS (ESI(+)) m/e 332 (M+H)+.


Example 1021
tert-butyl[(1-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}azetidin-3-yl)methyl]carbamate
Example 1021A
tert-butyl (1-(4-nitrophenyl)azetidin-3-yl)methylcarbamate

A solution of 1-fluoro-4-nitrobenzene (0.61 g, 4.32 mmol) and tert-butyl azetidin-3-ylmethylcarbamate (0.886 g, 4.76 mmol) in dimethylformamide (8.65 ml) was treated with potassium carbonate (0.896 g, 6.48 mmol) and the suspension was heated at 55° C. (12 pm) for 3 hours and at ambient temperature for 16 hours. The reaction was poured into water and the suspension was filtered. The solid was washed with water and dried to provide the title compound.


Example 1021B
tert-butyl (1-(4-aminophenyl)azetidin-3-yl)methylcarbamate

The title compound was prepared as described in Example 272A, substituting tert-butyl (1-(4-nitrophenyl)azetidin-3-yl)methylcarbamate for 4-nitro-N-propylbenzamide.


Example 1021C
tert-butyl[(1-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}azetidin-3-yl)methyl]carbamate

The title compound was prepared as described in Example 272B, substituting tert-butyl (1-(4-aminophenyl)azetidin-3-yl)methylcarbamate for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.03 (s, 1H), 7.39-7.25 (m, 6H), 7.07-6.94 (m, 1H), 6.33 (d, J=8.8 Hz, 2H), 4.72 (s, 4H), 3.75 (t, J=7.4 Hz, 2H), 3.48-3.40 (m, 2H), 3.22-3.14 (m, 2H), 2.76-2.65 (m, 1H), 1.38 (s, 9H); MS (ESI(+)) m/e 423 (M+H)+.


Example 1046
N-[4-({[4-(acetylamino)phenyl]sulfonyl}amino)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-aminophenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and 4-(acetylamino)phenyl]sulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (400 MHz, DMSO-D2O, Temp=90° C.) 3 ppm 8.72 (s, 1H) 8.62 (d, J=4.88 Hz, 1H) 7.73 (d, J=5.49 Hz, 1H) 7.61-7.69 (m, 4H) 7.36 (d, J=8.54 Hz, 2H) 6.98 (d, J=8.85 Hz, 2H) 4.88 (d, J=7.02 Hz, 4H) 2.00-2.10 (m, 3H); MS (APCI(+)) m/e 452 (M+H)+.


Example 1047
N-{4-[(propylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-aminophenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and propylsulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (400 MHz, DMSO-D2O, Temp=90° C.) 3 ppm 8.72 (s, 1H) 8.62 (d, J=5.49 Hz, 1H) 7.73 (d, J=5.49 Hz, 1H) 7.46 (d, J=8.54 Hz, 2H) 7.14 (d, J=8.85 Hz, 2H) 4.91 (d, J=6.10 Hz, 4H) 2.98-3.06 (m, 2H) 1.66-1.78 (m, 2H) 0.96 (t, J=7.48 Hz, 3H); MS (APCI(+)) m/e 361 (M+H)+.


Example 1048
N-(4-{[(4-propylphenyl)sulfonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-aminophenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and (4-propylphenyl)sulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (300 MHz, DMSO-d6) δ 9.90 (s, 1H), 8.59 (s, 1H), 8.49 (d, J=5.0 Hz, 1H), 8.33 (s, 1H), 7.64-7.58 (m, 2H), 7.45-7.33 (m, 4H), 7.33 (s, 1H), 6.99-6.92 (m, 2H), 4.79-4.72 (m, 4H), 2.57 (dd, J=17.1, 9.3 Hz, 1H), 1.65-1.49 (m, 2H), 0.86 (t, J=7.3 Hz, 3H); MS (ESI(+)) m/e 437 (M+H)+.


Example 1049
N-{4-[(butylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-aminophenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and butylsulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (400 MHz, DMSO-D2O, Temp=90° C.) 3 ppm 8.71 (s, 1H) 8.61 (d, J=5.19 Hz, 1H) 7.70 (d, J=5.49 Hz, 1H) 7.47 (d, J=8.85 Hz, 2H) 7.14 (d, J=8.85 Hz, 2H) 4.90 (d, J=3.66 Hz, 4H) 2.97-3.08 (m, 2H) 1.61-1.72 (m, 2H) 1.30-1.44 (m, 2H) 0.85 (t, J=7.32 Hz, 3H); MS (APCI(+)) m/e 375 (M+H)+.


Example 1050
N-{4-[({[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl}sulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-aminophenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and (1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl}sulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (400 MHz, DMSO-D2O, Temp=90° C.) δ ppm 8.72 (s, 1H) 8.61 (d, J=5.19 Hz, 1H) 7.71 (d, J=5.49 Hz, 1H) 7.49 (d, J=8.85 Hz, 2H) 7.18 (d, J=8.85 Hz, 2H) 4.90 (d, J=3.97 Hz, 4H) 2.81 (s, 2H) 2.27-2.41 (m, 2H) 2.07 (t, J=4.43 Hz, 1H) 1.94-2.03 (m, 2H) 1.34-1.66 (m, 2H) 1.02 (s, 3H) 0.79 (s, 3H); MS (APCI(+)) m/e 469 (M+H)+.


Example 1051
N-{4-[(ethylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-aminophenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and ethylsulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (400 MHz, DMSO-D2O, Temp=90° C.) 3 ppm 8.70-8.75 (m, 1H) 8.60-8.64 (m, J=5.65, 5.65 Hz, 1H) 7.74 (d, J=5.19 Hz, 1H) 7.46 (d, J=8.85 Hz, 2H) 7.15 (d, J=8.54 Hz, 2H) 4.91 (d, J=7.02 Hz, 4H) 3.04 (q, J=7.32 Hz, 2H) 1.23 (t, J=7.32 Hz, 3H); MS (APCI(+)) m/e 347 (M+H)+.


Example 1052
N-{4-[(benzylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-aminophenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and benzylsulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (400 MHz, DMSO-D2O, Temp=90° C.) 3 ppm 8.72 (s, 1H) 8.61 (d, J=4.88 Hz, 1H) 7.70 (d, J=5.19 Hz, 1H) 7.46 (d, J=8.85 Hz, 2H) 7.28-7.37 (m, 5H) 7.11 (d, J=8.85 Hz, 2H) 4.90 (d, J=3.05 Hz, 4H) 4.37 (s, 2H); MS (APCI(+)) m/e 409 (M+H)+.


Example 1053
N-(4-{[(4-fluorophenyl)sulfonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-aminophenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and (4-fluorophenyl)sulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (400 MHz, DMSO-D2O, Temp=90° C.) 3 ppm 8.71 (s, 1H) 8.61 (d, J=5.19 Hz, 1H) 7.78 (dd, J=8.85, 5.19 Hz, 2H) 7.67-7.73 (m, 1H) 7.28-7.43 (m, 4H) 6.98 (d, J=8.85 Hz, 2H) 4.87 (d, J=4.27 Hz, 4H); MS (APCI(+)) m/e 412 (M+H)+.


Example 1054
N-{4-[(thiophen-2-ylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-aminophenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and thiophen-2-ylsulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (400 MHz, DMSO-D2O, Temp=90° C.) 3 ppm 8.70 (s, 1H) 8.61 (d, J=4.88 Hz, 1H) 7.81 (d, J=4.88 Hz, 1H) 7.69 (d, J=5.19 Hz, 1H) 7.49 (d, J=2.75 Hz, 1H) 7.42 (d, J=8.85 Hz, 2H) 7.09-7.13 (m, 1H) 7.04 (d, J=8.85 Hz, 2H) 4.88 (d, J=3.36 Hz, 4H); MS (APCI(+)) m/e 401 (M+H)+.


Example 1088
N-[4-(piperidin-1-ylsulfonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 4-(piperidin-1-ylsulfonyl)aniline for 4-amino-N-propylbenzamide and 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.89 (s, 1H), 8.62 (s, 1H), 8.51 (d, J=5.0 Hz, 1H), 7.86-7.79 (m, 2H), 7.66-7.59 (m, 2H), 7.44 (d, J=5.0 Hz, 1H), 4.89-4.76 (m, 4H), 3.25-3.00 (m, 1H), 2.95-2.82 (m, 4H), 1.57-1.44 (m, 4H), 1.41-1.31 (m, 1H); MS (ESI(+)) m/e 387 (M+H)+.


Example 1246
methyl 1-{4-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]phenyl}azetidine-3-carboxylate
Example 1246A
methyl 1-(4-nitrophenyl)azetidine-3-carboxylate

A solution of methyl azetidine-3-carboxylate hydrochloride (1.236 g, 8.15 mmol) and N-methylmorpholine (2.338 ml, 21.26 mmol) in dimethylformamide (10 mL) was treated with a solution of 1-fluoro-4-nitrobenzene (1 g, 7.09 mmol) in dimethylformamide (7 mL) and the reaction was allowed to stir at room temperature for 60 hours. Water (50 mL) was added and the resulting suspension was stirred 10 minutes and filtered. The collected solid was washed with water and dried under vacuum. Flash chromatography of the collected solid provided the title compound.


Example 1246B
methyl 1-(4-aminophenyl)azetidine-3-carboxylate

The title compound was prepared as described in Example 272A, substituting methyl 1-(4-nitrophenyl)azetidine-3-carboxylate for 4-nitro-N-propylbenzamide.


Example 1246C
methyl 1-{4-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]phenyl}azetidine-3-carboxylate

The title compound was prepared as described in Example 272B, substituting methyl 1-(4-aminophenyl)azetidine-3-carboxylate for 4-amino-N-propylbenzamide and 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.60 (s, 1H), 8.49 (d, J=5.0 Hz, 1H), 8.15 (s, 1H), 7.42 (d, J=5.1 Hz, 1H), 7.36-7.29 (m, 2H), 6.44-6.37 (m, 2H), 4.80-4.72 (m, 4H), 4.02-3.93 (m, 2H), 3.86-3.77 (m, 2H), 3.68 (s, 3H), 3.66-3.56 (m, 1H); MS (ESI(+)) m/e 353 (M+H)+.


Example 1247
N-(4-{3-[(3-methylbutyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
Example 1247A
1-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenyl)azetidine-3-carboxylic acid

The title compound was prepared as described in Example 1B, substituting methyl 1-{4-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]phenyl}azetidine-3-carboxylate for methyl 4-(isoindoline-2-carboxamido)benzoate.


Example 1247B
N-(4-{3-[(3-methylbutyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 3-methylbutan-1-amine for 3-phenylpropan-1-amine and 1-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenyl)azetidine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.59 (s, 1H), 8.49 (d, J=5.0 Hz, 1H), 8.13 (s, 1H), 7.90 (t, J=5.5 Hz, 1H), 7.42 (d, J=4.8 Hz, 1H), 7.34-7.27 (m, 2H), 6.41-6.34 (m, 2H), 4.79-4.73 (m, 4H), 3.94-3.85 (m, 2H), 3.76-3.69 (m, 2H), 3.47-3.36 (m, 1H), 3.13-3.04 (m, 2H), 1.65-1.48 (m, 1H), 1.35-1.24 (m, 2H), 0.87 (d, J=6.6 Hz, 6H); MS (ESI(+)) m/e 408 (M+H)+.


Example 1248
N-(4-{3-[(tetrahydrofuran-2-ylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting (tetrahydrofuran-2-yl)methanamine for 3-phenylpropan-1-amine and 1-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenyl)azetidine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.59 (s, 1H), 8.49 (d, J=5.0 Hz, 1H), 8.13 (s, 1H), 8.05 (t, J=5.8 Hz, 1H), 7.42 (d, J=5.1 Hz, 1H), 7.35-7.27 (m, 2H), 6.41-6.34 (m, 2H), 4.79-4.73 (m, 4H), 3.94-3.68 (m, 6H), 3.68-3.55 (m, 1H), 3.54-3.39 (m, 1H), 3.20-3.07 (m, 2H), 1.93-1.71 (m, 3H), 1.55-1.41 (m, 1H); MS (ESI(+)) m/e 422 (M+H)+.


Example 1249
N-(4-{3-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting (tetrahydro-2H-pyran-4-yl)methanamine for 3-phenylpropan-1-amine and 1-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenyl)azetidine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.59 (s, 1H), 8.49 (d, J=5.0 Hz, 1H), 8.13 (s, 1H), 7.97 (t, J=5.8 Hz, 1H), 7.42 (d, J=5.1 Hz, 1H), 7.34-7.27 (m, 2H), 6.41-6.34 (m, 2H), 4.79-4.73 (m, 4H), 3.95-3.86 (m, 2H), 3.86 -3.78 (m, 2H), 3.77-3.69 (m, 2H), 3.51-3.40 (m, 1H), 3.31-3.19 (m, 2H), 3.02-2.94 (m, 2H), 1.69-1.48 (m, 3H), 1.22-1.04 (m, 2H); MS (ESI(+)) m/e 436 (M+H)+.


Example 1250
N-{4-[3-(benzylcarbamoyl)azetidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting benzylamine for 3-phenylpropan-1-amine and 1-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenyl)azetidine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.59 (s, 1H), 8.53-8.45 (m, 2H), 8.13 (s, 1H), 7.42 (d, J=5.0 Hz, 1H), 7.37-7.22 (m, 7H), 6.43-6.35 (m, 2H), 4.76 (m, 4H), 4.30 (d, J=5.9 Hz, 2H), 3.99-3.88 (m, 2H), 3.83-3.72 (m, 2H), 3.57-3.46 (m, 1H); MS (ESI(+)) m/e 428 (M+H)+.


Example 1251
N-{4-[3-(cyclopentylcarbamoyl)azetidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting cyclopentylamine for 3-phenylpropan-1-amine and 1-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenyl)azetidine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.59 (s, 1H), 8.49 (d, J=5.0 Hz, 1H), 8.13 (s, 1H), 7.91 (d, J=7.2 Hz, 1H), 7.42 (d, J=5.1 Hz, 1H), 7.34-7.27 (m, 2H), 6.41-6.33 (m, 2H), 4.79-4.73 (m, 4H), 4.06-3.94 (m, 1H), 3.92-3.84 (m, 2H), 3.76-3.66 (m, 2H), 3.46-3.33 (m, 1H), 1.86-1.72 (m, 2H), 1.67-1.30 (m, 6H); MS (ESI(+)) m/e 406 (M+H)+.


Example 1252
N-(4-{3-[(cyclopentylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting cyclopentylmethamine for 3-phenylpropan-1-amine and 1-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenyl)azetidine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.59 (s, 1H), 8.49 (d, J=5.0 Hz, 1H), 8.13 (s, 1H), 7.96 (t, J=5.7 Hz, 1H), 7.42 (d, J=4.7 Hz, 1H), 7.34-7.27 (m, 2H), 6.41-6.33 (m, 2H), 4.81-4.72 (m, 4H), 3.94-3.85 (m, 2H), 3.77-3.68 (m, 2H), 3.50-3.37 (m, 1H), 3.04-2.97 (m, 2H), 2.04-1.89 (m, 1H), 1.71-1.39 (m, 6H), 1.25-1.08 (m, 2H); MS (ESI(+)) m/e 420 (M+H)+.


Example 1253
N-(4-{3-[(2-methoxyethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 2-methoxyeth-1-ylamine for 3-phenylpropan-1-amine and 1-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenyl)azetidine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.59 (s, 1H), 8.49 (d, J=5.0 Hz, 1H), 8.13 (s, 1H), 8.05 (t, J=5.5 Hz, 1H), 7.42 (d, J=5.1 Hz, 1H), 7.35-7.27 (m, 2H), 6.42-6.34 (m, 2H), 4.79-4.73 (m, 4H), 3.93-3.86 (m, 2H), 3.73 (t, J=6.6 Hz, 2H), 3.52-3.41 (m, 1H), 3.38-3.30 (m, 2H), 3.27-3.21 (m, 5H); MS (ESI(+)) m/e 396 (M+H)+.


Example 1268
N-(6-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting (5)-(tetrahydrofuran-2-yl)methamine for 3-phenylpropan-1-amine and 6-(isoindoline-2-carboxamido)pyridazine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 10.03 (s, 1H), 8.85 (t, J=6.1 Hz, 1H), 8.32 (d, J=9.3 Hz, 1H), 8.12 (d, J=9.3 Hz, 1H), 7.41-7.28 (m, 4H), 5.04-4.72 (m, 4H), 4.04 (p, J=6.2 Hz, 1H), 3.85-3.74 (m, 1H), 3.69-3.58 (m, 1H), 3.38 (dd, J=11.2, 5.0 Hz, 2H), 2.01-1.74 (m, 3H), 1.71-1.54 (m, 1H); MS (ESI(+)) m/e 368 (M+H)+.


Example 1285
N-{4-[(4-fluorobenzyl)(3-methylbutanoyl)amino]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide
Example 1285A
tert-butyl 4-(4-fluorobenzylamino)butylcarbamate

Tert-butyl 4-bromobutylcarbamate (0.735 g, 2.91 mmoles), (4-fluorophenyl)methanamine (0.333 g, 2.91 mmoles) and potassium carbonate (0.806 g, 5.83 mmoles) were stirred in acetonitrile (15 mL) at 100° C. for 1 hour. The reaction mixture was cooled, the solvent wags concentrated and the residue was taken into dichloromethane and washed with water twice. The organic layers were combined, dried over magnesium sulfate, filtered and concentrated to provide the title compound which was used without further purification in the next step.


Example 1285B
tert-butyl 4-(N-(4-fluorobenzyl)-3-methylbutanamido)butylcarbamate

The title compound was prepared as described in Example 278, substituting 3-methylbutanoyl chloride for acetyl chloride and tert-butyl 4-(4-fluorobenzylamino)butylcarbamate for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide.


Example 1285C
N-(4-aminobutyl)-N-(4-fluorobenzyl)-3-methylbutanamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(N-(4-fluorobenzyl)-3-methylbutanamido)butylcarbamate for tert-butyl 44(4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 1285D
N-{4-[(4-fluorobenzyl)(3-methylbutanoyl)amino]butyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 272B, substituting N-(4-aminobutyl)-N-(4-fluorobenzyl)-3-methylbutanamide for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (400 MHz, CDCl3) δ ppm 7.34-7.27 (m, 4H), 7.23 (dd, J=8.5, 5.5 Hz, 1H), 7.13 (dd, J=8.5, 5.5 Hz, 1H), 7.06 (t, J=8.6 Hz, 1H), 6.99 (t, J=8.6 Hz, 1H), 5.49-5.17 (m, 1H), 4.72 (m, 4H), 4.56 (d, J=17.7 Hz, 2H), 3.34 (m, 4H), 2.29 (m, 2H), 2.23-2.12 (m, 1H), 1.68-1.50 (m, 4H), 1.01-0.93 (d, J=6.9 Hz, 6H); MS (APCI(+)) m/e 426 (M+H)+.


Example 1286
N-[4-(9-chloro-5-oxo-2,3,3a,4,4a,5-hexahydro-6H-furo[2′,3′:2,3]cyclobuta[1,2-c]quinolin-6-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
Example 1286A
4-(but-3-enyloxy)-6-chloroquinolin-2(1H)-one

To a solution of 6-chloro-4-hydroxyquinolin-2(1H)-one (800 mg, 4.09 mmol) and N,N-diisopropylethylamine (1415 μl, 8.18 mmol) in dimethylformamide (13.6 ml) was added 4-bromo-1-butene (415 μl, 4.09 mmol). The solution was heated to 60° C. and stirred for 18 hours. The reaction mixture was purified by column chromatography to provide the title compound.


Example 1286B
9-chloro-3,3a,4,4a-tetrahydro-2H-furo[2′,3′:2,3]cyclobuta[1,2-c]quinolin-5(6H)-one

A solution of 4-(but-3-enyloxy)-6-chloroquinolin-2(1H)-one (600 mg, 2.403 mmol) in benzene (240 mL) was placed under a 450 W Hg UV lamp (fitted with a condenser for cooling) and stirred for 4 days (96 hours). The mixture was then cooled, concentrated in vacuo, and taken up in 75 mL of methylene chloride (with mild heating to dissolve as much as possible). The sample, which was a mixture of regioisomers, was purified by column chromatography. Concentration of the compound that eluted second provided the title compound.


Example 1286C
tert-butyl[4-(9-chloro-5-oxo-2,3,3a,4,4a,5-hexahydro-6H-furo[2′,3′:2,3]cyclobuta[1,2-c]quinolin-6-yl)butyl]carbamate

To a solution of 9-chloro-3,3a,4,4a-tetrahydro-2H-furo[2′,3′:2,3]cyclobuta[1,2-c]quinolin-5(6H)-one (200 mg, 0.801 mmol) in dimethylformamide (4 ml) at 0° C. was slowly added sodium hydride (19 mg, 0.801 mmol) over 15 minutes. The suspension was allowed to warm to room temperature. The mixture stirred for 45 minutes and 4-(Boc-amino)butyl bromide (202 mg, 0.801 mmol) was added. The solution was stirred for 15 hours, followed by addition of 0.25 mL methanol. Column chromatography provided the title compound.


Example 1286D
6-(4-aminobutyl)-9-chloro-3,3a,4,4a-tetrahydro-2H-furo[2′,3′:2,3]cyclobuta[1,2-c]quinolin-5(6H)-one

The title compound was prepared as described in Example 2D, substituting tert-butyl[4-(9-chloro-5-oxo-2,3,3a,4,4a,5-hexahydro-6H-furo[2′,3′:2,3]cyclobuta[1,2-c]quinolin-6-yl)butyl]carbamate for tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 1286E
N-[4-(9-chloro-5-oxo-2,3,3a,4,4a,5-hexahydro-6H-furo[2′,3′:2,3]cyclobuta[1,2-c]quinolin-6-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 272B, substituting 6-(4-aminobutyl)-9-chloro-3,3a,4,4a-tetrahydro-2H-furo[2′,3′:2,3]cyclobuta[1,2-c]quinolin-5(6H)-one for 4-amino-N-propylbenzamide and 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (400 MHz, CDCl3) δ ppm 8.58 (s, 1H), 8.54 (d, J=4.9 Hz, 1H), 7.29 (d, J=4.9 Hz, 1H), 7.25 (m, 1H), 7.23 (d, J=2.6 Hz, 1H), 6.92 (d, J=8.9 Hz, 1H), 4.84 (t, J=5.6 Hz, 1H), 4.74 (bs, 4H), 4.46 (t, J=8.1 Hz, 1H), 4.22 (m, 1H), 4.05 (m, 1H), 3.91 (m, 1H), 3.39 (m, 3H), 2.93 (m, 1H), 2.31 (m, 1H), 2.22 (m, 1H), 1.84 (m, 1H), 1.69 (m, 5H); MS (ESI(+)) m/e 467 (M+H)+.


Example 1287
N-{4-[7-chloro-1-(2-hydroxyethyl)-3-oxo-1,3-dihydrocyclobuta[c]quinolin-4(2H)-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

To a solution of N-[4-(9-chloro-5-oxo-2,3,3a,4,4a,5-hexahydro-6H-furo[2′,3′:2,3]cyclobuta[1,2-c]quinolin-6-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide (30 mg, 0.064 mmol) in dimethylformamide (292 uL) and water (292 uL) was added sodium hydroxide (1.679μl, 0.064 mmol). The solution was stirred for 18 hours and then brought to pH ˜7 by dropwise addition of 1M HCl. Column chromatography of the wet, crude mixture provided the title compound. 1H NMR (400 MHz, CDCl3) δ ppm 8.58 (s, 1H), 8.54 (d, J=5.1 Hz, 1H), 7.54 (d, J=2.4 Hz, 1H), 7.46 (dd, J=9.1, 2.4 Hz, 1H), 7.37 (d, J=9.1 Hz, 1H), 7.25 (m, 1H), 5.06 (t, J=5.7 Hz, 1H) 4.77 (bs, 2H), 4.75 (bs, 2H), 4.33 (t, J=7.4 Hz, 2H), 3.87 (m, 2H), 3.74 (m, 2H), 3.46 (m, 2H), 3.37 (dd, J=14.0, 4.5 Hz, 1H), 2.86 (dd, J=14.0, 1.3 Hz, 1H), 2.27 (m, 1H), 1.97 (m, 1H), 1.82 (m, 2H), 1.71 (m, 2H); MS (ESI(+)) m/e 467 (M+H)+.


Example 1290
N-(6-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting (R)-(tetrahydrofuran-2-yl)methamine for 3-phenylpropan-1-amine and 6-(isoindoline-2-carboxamido)pyridazine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 10.02 (s, 1H), 8.85 (t, J=6.1 Hz, 1H), 8.32 (d, J=9.3 Hz, 1H), 8.12 (d, J=9.3 Hz, 1H), 7.41-7.28 (m, 4H), 5.00-4.71 (m, 4H), 4.04 (p, J=6.2 Hz, 1H), 3.85-3.74 (m, 1H), 3.70-3.58 (m, 1H), 3.44-3.33 (m, 3H), 1.99-1.71 (m, 2H), 1.69-1.54 (m, 1H); MS (ESI(+)) m/e 368 (M+H)+.









TABLE 21







The following Examples were essentially prepared as described in Example 1C, substituting


N-(4-aminophenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-


amine and the appropriate carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid.










Ex
Name

1H NMR

MS





1363
N-{4-[(3-

1H NMR (400 MHz, DMSO/D2O, 90° C.) δ 8.71

(APCI(+))



ethoxypropanoyl)amino]phenyl}-
(s, 1H), 8.61 (d, J = 5.4 Hz, 1H), 7.70 (d, J = 5.5
m/e 355



1,3-dihydro-2H-
Hz, 1H), 7.44 (m, 4H), 4.89 (m, 4H), 3.68 (t, J =
(M + H)+



pyrrolo[3,4-c]pyridine-2-
4.7 Hz, 2H), 3.47 (q, J = 7.0 Hz, 2H), 2.52 (m,



carboxamide
2H), 1.11 (t, J = 7.0 Hz, 3H)


1364
N-(4-{[(1-acetylpiperidin-4-

1H NMR (400 MHz, DMSO/D2O, 90° C.) δ 8.73

(APCI (+))



yl)carbonyl]amino}phenyl)-
(s, 1H), 8.62 (d, J = 5.46, 1H), 7.75 (m, 1H), 7.41
m/e 408



1,3-dihydro-2H-
(m, 4H), 4.91 (m, 4H), 4.13 (m, 2H), 2.95 (m,
(M + H)+



pyrrolo[3,4-c]pyridine-2-
2H), 2.60 (m, 1H), 1.99 (m, 3H), 1.84 (m, 2H),



carboxamide
1.52 (m, 2H)


1365
N-{4-

1H NMR (400 MHz, DMSO/D2O, 90° C.) δ 8.69

(APCI (+))



[(ethoxyacetyl)amino]phenyl}-
(s, 1H), 8.59(d, J = 5.4 Hz, 1H), 7.66 (d, J = 5.5
m/e 341



1,3-dihydro-2H-
Hz, 1H), 7.48 (m, 4H), 4.89 (bs, 4H), 4.00 (s,
(M + H)+



pyrrolo[3,4-c]pyridine-2-
2H), 3.60(q, J = 7.0 Hz, 2H), 1.21 (t, J = 6.9 Hz,



carboxamide
3H)


1366
N-{4-[(tetrahydrofuran-2-

1H NMR (400 MHz, DMSO/D2O, 90° C.) δ 8.70

(APCI (+))



ylcarbonyl)amino]phenyl}-
(s, 1H), 8.60 (d, J = 5.4 Hz, 1H), 7.69 (d, J = 5.5
m/e 353



1,3-dihydro-2H-
Hz, 1H), 7.48 (m, 4H), 4.89 (m, 4H), 4.35 (dd, J =
(M + H)+



pyrrolo[3,4-c]pyridine-2-
8.1, 5.6 Hz, 1H), 4.00 (m, 1H), 3.83 (dt, J =



carboxamide
8.1, 6.7 Hz, 1H), 2.92 (m, 1H), 2.71 (s, 1H), 2.23




(m, 1H), 2.00 (m, 1H), 1.92 (m, 2H)


1367
N-{4-[(tetrahydrofuran-3-

1H NMR (400 MHz, DMSO/D2O, 90° C.) δ 8.73

(APCI (+))



ylcarbonyl)amino]phenyl}-
(m, 1H), 8.61 (m, 1H), 7.70 (m, 1H), 7.43 (m,
m/e 353



1,3-dihydro-2H-
4H), 4.90 (d, J = 8.2 Hz, 4H), 3.93 (m, 1H), 3.76
(M + H)+



pyrrolo[3,4-c]pyridine-2-
(m, 3H), 3.13 (m, 1H), 2.10 (q, J = 7.2 Hz, 2H)



carboxamide


1368
N-{4-

1H NMR (400 MHz, DMSO/D2O, 90° C.) δ 8.67

(APCI (+))



[(cyclopentylcarbonyl)ami-
(s, 1H), 8.57 (d, J = 5.3 Hz, 1H), 7.62 (d, J = 5.4
m/e 351



no]phenyl}-1,3-dihydro-2H-
Hz, 1H), 7.44 (m, 4H), 4.87 (s, 4H), 2.77 (m,
(M + H)+



pyrrolo[3,4-c]pyridine-2-
1H), 1.70 (m, 8H)



carboxamide


1370
N-{4-[(bicyclo[2.2.1]hept-

1H NMR (400 MHz, DMSO/D2O, 90° C.) δ 8.66

(APCI (+))



2-ylacetyl)amino]phenyl}-
(s, 1H), 8.56 (d, J = 5.3 Hz, 1H), 7.60 (d, J = 5.2
m/e 391



1,3-dihydro-2H-
Hz, 1H), 7.43 (m, 4H), 4.86 (s, 4H), 2.25 (dd, J =
(M + H)+



pyrrolo[3,4-c]pyridine-2-
14.1, 7.8 Hz, 1H), 2.20 (s, 1H), 2.12 (dd, J =



carboxamide
14.0, 7.6 Hz, 1H), 1.98 (d, J = 17.2 Hz, 1H), 1.90




(s, 1H), 1.41 (m, 4H), 1.14 (m, 4H)


1371
N-{4-[(1,3-thiazol-5-

1H NMR (400 MHz, DMSO/D2O, 90° C.) δ 9.20

(APCI (+))



ylcarbonyl)amino]phenyl}-
(s, 1H), 8.67 (s, 1H), 8.60 (s, 1H), 8.57 (d, J = 5.3
m/e 366



1,3-dihydro-2H-
Hz, 1H), 7.61 (d, J = 5.3 Hz, 4H), 7.55 (m, 4H)
(M + H)+



pyrrolo[3,4-c]pyridine-2-



carboxamide


1372
N-(4-{[(4-oxo-4,5,6,7-

1H NMR (400 MHz, DMSO/D2O, 90° C.) δ 8.65

(APCI (+))



tetrahydro-1-benzofuran-3-
(s, 1H), 8.55 (d, J = 5.2 Hz, 1H), 8.26 (d, J = 14.4
m/e 417



yl)carbonyl]amino}phenyl)-
Hz, 1H), 7.55 (m, 5H), 4.86 (s, 4H), 2.96 (m,
(M + H)+



1,3-dihydro-2H-
2H), 2.64 (m, 2H), 2.18 (m, 2H)



pyrrolo[3,4-c]pyridine-2-



carboxamide









Example 1369
N-{7-oxo-7-[(3-phenylpropyl)amino]heptyl}-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 7-(isoindoline-2-carboxamido)heptanoic acid for 4-(isoindoline-2-carboxamido)benzoic acid.


Example 1373
N-(4-{2-[(3-methylbutanoyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
Example 1373A
N-(4-(2-aminoethyl)phenyl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl (2-{4-[(1,3-dihydro-2H-isoindol-2-ylcarbonyl)amino]phenyl}ethyl)carbamate for tert-butyl 4-44-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 1373B
N-(4-{2-[(3-methylbutanoyl)amino]ethyl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(4-(2-aminoethyl)phenyl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and 3-methylbutanoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (400 MHz, DMSO-d6, Temp=90° C.) δ 7.50-7.40 (m, 2H), 7.40-7.24 (m, 4H), 7.13-7.02 (m, 2H), 4.76 (s, 4H), 2.68 (t, J=7.3 Hz, 2H), 2.07-1.84 (m, 3H), 0.95-0.76 (m, 6H). MS (ESI (+)) m/e 366 (M+H)+.









TABLE 22







The following Examples were essentially prepared as described in Example 1C, substituting


N-(4-(2-aminoethyl)phenyl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and


the appropriate carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid.










Ex
Name

1H NMR

MS





1374
N-(4-{2-[(4-

1H NMR (400 MHz, DMSO-6, Temp = 90° C.) δ

(ESI(+))



methylpentanoyl)amino]eth-
7.44 (t, J = 8.2 Hz, 2H), 7.38-7.18 (m, 4H), 7.18-
m/e 380



yl}phenyl)-1,3-dihydro-
6.99 (m, 2H), 4.76 (s, 4H), 2.78-2.60 (m, 2H),
(M + H)+



2H-isoindole-2-
2.13-1.99 (m, 2H), 1.58-1.33 (m, 3H), 0.90-



carboxamide
0.79 (m, 6H)


1375
N-(4-{2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



[(ethoxyacetyl)amino]eth-
8.07-7.98 (m, 1H), 7.50-7.25 (m, 7H), 7.11 (t,
m/e 368



yl]phenyl)-1,3-dihydro-2H-
J = 6.6 Hz, 2H), 4.76 (s, 4H), 3.80 (s, 2H), 3.55-
(M + H)+



isoindole-2-carboxamide
3.41 (m, 2H), 3.41-3.33 (m, 2H), 2.78-2.64 (m,




2H), 1.19-1.07 (m, 3H)


1376
N-[4-(2-{[(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



methoxyethoxy)acetyl]ami-
7.45 (d, J = 8.4 Hz, 2H), 7.40-7.25 (m, 4H), 7.20-
m/e 398



no}ethyl)phenyl]-1,3-
6.98 (m, 2H), 4.76 (s, 4H), 3.85 (s, 2H), 3.67-
(M + H)+



dihydro-2H-isoindole-2-
3.51 (m, 2H), 3.51-3.42 (m, 2H), 3.41-3.33 (m,



carboxamide
2H), 3.28 (s, 5H), 2.76-2.64 (m, 2H)


1377
N-(4-{2-[(tetrahydrofuran-2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



ylcarbonyl)amino]ethyl}phenyl)-
7.52-7.37 (m, 2H), 7.37-7.21 (m, 4H), 7.10 (t,
m/e 380



1,3-dihydro-2H-
J = 7.3 Hz, 2H), 4.76 (s, 4H), 4.28-4.03 (m, 1H),
(M + H)+



isoindole-2-carboxamide
3.89-3.78 (m, 1H), 3.80-3.65 (m, 1H), 3.53-




3.31 (m, 2H), 2.75-2.60 (m, 2H), 2.20-2.02 (m,




1H), 1.94-1.64 (m, 3H)


1378
N-(4-{2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



[(cyclopentylcarbonyl)ami-
7.43 (d, J = 8.5 Hz, 2H), 7.37-7.21 (m, 4H), 7.09
m/e 378



no]ethyl}phenyl)-1,3-
(d, J = 8.4 Hz, 2H), 4.76 (s, 4H), 2.68 (t, J = 7.3
(M + H)+



dihydro-2H-isoindole-2-
Hz, 2H), 1.61 (t, J = 44.5 Hz, 8H)



carboxamide


1379
N-(4-{2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



[(cyclopentylacetyl)amino]
7.43 (dd, J = 6.3, 4.5 Hz, 2H), 7.37-7.24 (m,
m/e 392



ethyl}phenyl)-1,3-dihydro-
4H), 7.09 (d, J = 8.4 Hz, 2H), 4.76 (s, 4H), 2.67
(M + H)+



2H-isoindole-2-
(dd, J = 9.4, 5.3 Hz, 2H), 2.23-1.94 (m, 4H),



carboxamide
1.76-1.42 (m, 6H), 1.22-1.05 (m, 2H)


1380
N-{4-[2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



(benzoylamino)ethyl]phenyl}-
7.82-7.73 (m, 2H), 7.56-7.40 (m, 5H), 7.37-
m/e 386



1,3-dihydro-2H-
7.25 (m, 4H), 7.20-7.07 (m, 2H), 4.76 (s, 4H),
(M + H)+



isoindole-2-carboxamide
3.51 (t, J = 7.4 Hz, 2H), 2.93-2.67 (m, 2H)


1381
N-(4-{2-[(tetrahydro-2H-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



pyran-4-
7.49-7.38 (m, 2H), 7.37-7.24 (m, 4H), 7.09 (d,
m/e 394



ylcarbonyl)amino]ethyl}phenyl)-
J = 8.4 Hz, 2H), 4.76 (s, 4H), 3.90-3.74 (m, 2H),
(M + H)+



1,3-dihydro-2H-
3.37-3.30 (m, 2H), 2.68 (t, J = 7.3 Hz, 2H), 2.39-



isoindole-2-carboxamide
2.23 (m, 1H), 1.66-1.48 (m, 4H)


1382
N-(4-{2-[(tetrahydro-2H-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



pyran-4-
7.43 (t, J = 5.4 Hz, 2H), 7.40-7.24 (m, 4H), 7.09
m/e 408



ylacetyl)amino]ethyl}phenyl)-
(d, J = 8.4 Hz, 2H), 4.76 (s, 4H), 3.85-3.68 (m,
(M + H)+



1,3-dihydro-2H-
2H), 3.28-3.24 (m, 4H), 2.68 (t, J = 7.3 Hz, 2H),



isoindole-2-carboxamide
2.01 (d, J = 7.1 Hz, 2H), 1.94-1.76 (m, 1H), 1.59-




1.42 (m, 2H), 1.29-1.03 (m, 2H)


1383
N-(4-{2-[(tetrahydrofuran-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ

(ESI(+))



3-ylacetyl)amino]ethyl}phenyl)-
7.53-7.35 (m, 3H), 7.42-7.22 (m, 4H), 7.09 (d,
m/e 394



1,3-dihydro-2H-
J = 8.4 Hz, 2H), 4.76 (s, 4H), 3.82-3.55 (m, 3H),
(M + H)+



isoindole-2-carboxamide
3.35-3.30 (m, 1H), 3.26 (dd, J = 7.1, 5.3 Hz,




2H), 2.68 (t, J = 7.3 Hz, 2H), 2.48-2.36 (m, 1H),




2.22-2.07 (m, 2H), 2.04-1.81 (m, 1H), 1.62-




1.29 (m, 1H)









Example 1404
N-(4-{[1-(2-cyclopropylethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 429, substituting 2-cyclopropylacetaldehyde for isobutyraldehyde and N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, Pyridine-d5. Temp=90° C.) δ ppm 8.54-8.58 (m, 2H) 8.08 (s, 1H) 7.72-7.77 (m, 2H) 7.10 (d, J=4.88 Hz, 1H) 7.01 (d, J=9.16 Hz, 2H) 4.82-4.88 (m, 4H) 3.71 (s, 1H) 2.74-2.82 (m, 2H) 2.43-2.50 (m, 2H) 2.22-2.31 (m, 2H) 1.97 (s, 2H) 1.79-1.90 (m, 2H) 1.35-1.47 (m, 2H) 0.70 (s, 1H) 0.36-0.45 (m, 2H) 0.05 (q, J=4.78 Hz, 2H); MS (APCI(+)) m/e 407 (M+H)+.


Example 1405
N-(4-{[1-(2-cyclopentylethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 429, substituting 2-cyclopentylacetaldehyde for isobutyraldehyde and N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, Pyridine-d5. Temp=90° C.) δ ppm 8.54-8.58 (m, 2H) 8.08 (s, 1H) 7.72-7.78 (m, 2H) 7.10 (d, J=4.88 Hz, 1H) 7.00-7.04 (m, 2H) 4.82-4.90 (m, 4H) 4.21-4.31 (m, 1H) 2.73-2.83 (m, 2H) 2.34-2.40 (m, 2H) 2.20-2.29 (m, 2H) 1.96-2.03 (m, 2H) 1.67-1.93 (m, 5H) 1.40-1.62 (m, 6H) 1.04-1.17 (m, 2H); MS (APCI(+)) m/e 435 (M+H)+.


Example 1406
N-(4-{[1-(2-methylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 429, substituting 2-methylbutanal for isobutyraldehyde and N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, Pyridine-d5. Temp=90° C.) δ ppm 8.52-8.58 (m, 2H) 8.08 (s, 1H) 7.74 (d, J=8.85 Hz, 2H) 7.10 (d, J=4.58 Hz, 1H) 6.97-7.05 (m, 2H) 4.84 (d, J=6.71 Hz, 4H) 2.72 (d, J=10.68 Hz, 2H) 2.13-2.26 (m, 3H) 2.01-2.07 (m, 2H) 1.91-2.00 (m, 2H) 1.83 (s, 2H) 1.54 (s, 2H) 1.14 (s, 1H) 0.81-0.95 (m, 6H); MS (APCI(+)) m/e 409 (M+H)+.


Example 1407
N-(4-{[1-(tetrahydrofuran-3-ylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 429, substituting tetrahydrofuran-3-carbaldehyde for isobutyraldehyde and N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, Pyridine-d5. Temp=90° C.) δ ppm 8.53-8.58 (m, 1H) 8.08 (s, 1H) 7.70-7.77 (m, 2H) 7.10 (d, J=5.19 Hz, 1H) 7.01 (d, J=8.85 Hz, 2H) 4.84 (d, J=7.63 Hz, 4H) 4.19-4.27 (m, 1H) 3.75-3.90 (m, 2H) 3.67-3.72 (m, 1H) 3.56 (dd, J=8.55, 5.80 Hz, 1H) 2.65-2.82 (m, 2H) 2.31-2.45 (m, 1H) 2.15-2.31 (m, 4H) 1.71-2.00 (m, 5H) 1.48-1.59 (m, 1H); MS (APCI(+)) m/e 423 (M+H)+.


Example 1408
N-(4-{[1-(3,3-dimethylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 429, substituting 3,3-dimethylbutanal for isobutyraldehyde and N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, Pyridine-d5. Temp=90° C.) δ ppm 8.52-8.58 (m, 2H) 8.09 (s, 1H) 7.71-7.78 (m, 2H) 7.10 (d, J=4.88 Hz, 1H) 6.99-7.04 (m, 2H) 4.84 (dd, J=8.39, 1.68 Hz, 4H) 3.85 (d, J=13.43 Hz, 1H) 2.75-2.85 (m, 2H) 2.38-2.47 (m, 2H) 2.21-2.34 (m, 2H) 1.98 (d, J=2.14 Hz, 2H) 1.78-1.91 (m, 2H) 1.39-1.49 (m, 2H) 0.84-0.92 (m, 9H); MS (APCI(+)) m/e 423 (M+H)+.


Example 1409
N-(4-{[1-(cyclohexylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 429, substituting cyclohexanecarbaldehyde for isobutyraldehyde and N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, Pyridine-d5. Temp=90° C.) δ ppm 8.53-8.57 (m, 2H) 8.08 (s, 1H) 7.69-7.77 (m, 2H) 7.10 (s, 1H) 6.97-7.04 (m, 2H) 4.82-4.87 (m, 4H) 4.20-4.27 (m, 1H) 2.73 (t, J=10.68 Hz, 2H) 2.17-2.26 (m, 2H) 2.13 (d, J=7.02 Hz, 2H) 1.93-2.01 (m, 2H) 1.76-1.87 (m, 4H) 1.55-1.72 (m, 3H) 1.44-1.54 (m, 1H) 1.09-1.29 (m, 3H) 0.89 (d, J=12.51 Hz, 2H); MS (APCI(+)) m/e 435 (M+H)+.


Example 1410
N-(4-{[1-(3-methylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 429, substituting 3-methylbutanal for isobutyraldehyde and N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, Pyridine-d5. Temp=90° C.) δ ppm 8.53-8.57 (m, 2H) 8.09 (s, 1H) 7.70-7.78 (m, 2H) 7.10 (d, J=5.19 Hz, 1H) 6.98-7.04 (m, 2H) 4.79-4.89 (m, 4H) 4.26 (d, J=3.66 Hz, 1H) 2.72-2.83 (m, 2H) 2.34-2.41 (m, 2H) 2.21-2.30 (m, 2H) 1.96-2.03 (m, 2H) 1.79-1.91 (m, 2H) 1.54-1.68 (m, 1H) 1.35-1.44 (m, 2H) 0.86-0.90 (m, 6H); MS (APCI(+)) m/e 408 (M+H)+.


Example 1411
N-(4-{[1-(cyclopentylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 429, substituting cyclopentanecarbaldehyde for isobutyraldehyde and N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, Pyridine-d5. Temp=90° C.) δ ppm 8.53-8.57 (m, 2H) 8.08 (s, 1H) 7.70-7.77 (m, 2H) 7.10 (d, J=4.88 Hz, 1H) 6.97-7.05 (m, 2H) 4.84 (dd, J=8.54, 1.53 Hz, 4H) 4.23-4.27 (m, 1H) 2.75 (d, J=10.99 Hz, 2H) 2.18-2.29 (m, 4H) 2.04 (s, 1H) 1.94-2.02 (m, 2H) 1.77-1.90 (m, 2H) 1.65-1.76 (m, 2H) 1.42-1.59 (m, 4H) 1.17-1.32 (m, 2H); MS (APCI(+)) m/e 420 (M+H)+.


Example 1412
N-(4-{[1-(tetrahydrofuran-2-ylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 429, substituting tetrahydrofuran-2-carbaldehyde for isobutyraldehyde and N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, Pyridine-d5. Temp=90° C.) δ ppm 8.53-8.59 (m, 2H) 8.07 (s, 1H) 7.73 (d, J=9.16 Hz, 2H) 7.10 (d, J=5.49 Hz, 1H) 6.97-7.02 (m, 2H) 4.80-4.87 (m, 4H) 4.03 (d, J=11.60 Hz, 1H) 3.77-3.84 (m, 1H) 3.61-3.69 (m, 1H) 2.88 (d, J=41.81 Hz, 2H) 2.25-2.63 (m, 4H) 1.97 (s, 2H) 1.77-1.91 (m, 4H) 1.64-1.76 (m, 2H) 1.44-1.58 (m, 1H); MS (APCI(+)) m/e 423 (M+H)+.


Example 1413
N-(4-{[1-(2-methylpropyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 429, substituting isobutyraldehyde for isobutyraldehyde and N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)isoindoline-2-carboxamide. 1H NMR (400 MHz, Pyridine-d5. Temp=90° C.) δ ppm 8.49-8.60 (m, 2H) 8.09 (s, 1H) 7.68-7.80 (m, 2H) 7.10 (d, J=5.19 Hz, 1H) 6.96-7.04 (m, 2H) 4.85 (s, 4H) 4.21-4.28 (m, 1H) 2.65-2.79 (m, 2H) 2.13-2.24 (m, 2H) 2.06 (m, 2H) 1.98 (s, 2H) 1.77-1.88 (m, 2H) 1.67-1.77 (m, 1H) 0.89 (d, J=6.71 Hz, 6H); MS (APCI(+)) m/e 395 (M+H)+.


Example 1414
N-(4-{[1-(butylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and 1-butylsulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (400 MHz, DMSO-D2O, Temp=90° C.) 3 ppm 8.59 (s, 1H) 8.49 (d, J=4.88 Hz, 1H) 7.36-7.48 (m, 3H) 6.90 (d, J=8.85 Hz, 2H) 4.80 (d, J=6.10 Hz, 4H) 4.39-4.50 (m, 1H) 3.41-3.49 (m, 2H) 3.13-3.20 (m, 2H) 2.99-3.06 (m, 2H) 1.94-2.01 (m, 2H) 1.63-1.76 (m, 4H) 1.37-1.49 (m, 2H) 0.91 (t, J=7.48 Hz, 3H); MS (APCI(+)) m/e 459 (M+H)+.


Example 1415
N-(4-{[1-(cyclopropylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and cyclopropylsulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (400 MHz, DMSO-D2O, Temp=90° C.) 3 ppm 8.57 (s, 1H) 8.48 (d, J=4.88 Hz, 1H) 7.40 (d, J=8.54 Hz, 3H) 6.90 (d, J=8.85 Hz, 2H) 4.79 (d, J=8.24 Hz, 4H) 4.39-4.49 (m, 1H) 3.44-3.51 (m, 2H) 3.17-3.23 (m, 2H) 2.54-2.58 (m, 1H) 1.95-2.03 (m, 2H) 1.68-1.78 (m, 2H) 0.91-1.07 (m, 4H); MS (APCI(+)) m/e 442 (M+H)+.


Example 1416
N-(4-{[1-(phenylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and phenylsulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (400 MHz, DMSO-D2O, Temp=90° C.) 3 ppm 8.59 (s, 1H) 8.49 (d, J=4.88 Hz, 1H) 7.77 (d, J=7.32 Hz, 2H) 7.71 (t, J=7.32 Hz, 1H) 7.65 (t, J=7.32 Hz, 2H) 7.44 (d, J=4.88 Hz, 1H) 7.35 (d, J=8.85 Hz, 2H) 6.79 (d, J=9.16 Hz, 2H) 4.79 (d, J=4.27 Hz, 4H) 4.29-4.37 (m, 1H) 3.22-3.25 (m, 2H) 2.92-3.06 (m, 2H) 1.87-2.04 (m, 2H) 1.61-1.79 (m, 2H); MS (APCI(+)) m/e 479 (M+H)+.


Example 1417
N-[4-({1-[(4-fluorophenyl)sulfonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and (4-fluorophenyl)sulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (400 MHz, DMSO-D2O, Temp=90° C.) 3 ppm 8.58 (s, 1H) 8.49 (d, J=4.88 Hz, 1H) 7.84 (dd, J=8.85, 5.19 Hz, 2H) 7.40-7.49 (m, 3H) 7.36 (d, J=8.85 Hz, 2H) 6.80 (d, J=8.85 Hz, 2H) 4.79 (d, J=4.88 Hz, 4H) 4.28-4.41 (m, 1H) 3.21-3.26 (m, 2H) 2.94-3.05 (m, 2H) 1.89-2.02 (m, 2H) 1.62-1.76 (m, 2H); MS (APCI(+)) m/e 497 (M+H)+.


Example 1418
N-(4-{[1-(ethylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and ethylsulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (400 MHz, DMSO-D2O, Temp=90° C.) 3 ppm 8.58 (s, 1H) 8.48 (d, J=5.19 Hz, 1H) 7.40 (d, J=8.85 Hz, 3H) 6.90 (d, J=8.85 Hz, 2H) 4.79 (d, J=7.32 Hz, 4H) 4.39-4.48 (m, 1H) 3.41-3.49 (m, 2H) 3.14-3.22 (m, 2H) 3.05 (q, J=7.43 Hz, 2H) 1.94-2.03 (m, 2H) 1.64-1.78 (m, 2H) 1.24 (t, J=7.32 Hz, 3H); MS (APCI(+)) m/e 431 (M+H)+.


Example 1419
N-(4-{[1-(propan-2-ylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and isopropylsulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (400 MHz, DMSO-D2O, Temp=90° C.) 3 ppm 8.59 (s, 1H) 8.49 (d, J=5.19 Hz, 1H) 7.36-7.47 (m, 3H) 6.89 (d, J=8.85 Hz, 2H) 4.80 (d, J=5.49 Hz, 4H) 4.40-4.49 (m, 1H) 3.46-3.55 (m, 2H) 3.33-3.36 (m, 1H) 3.15-3.24 (m, 2H) 1.93-2.01 (m, 2H) 1.62-1.74 (m, 2H) 1.25 (d, J=6.71 Hz, 6H); MS (APCI(+)) m/e 445 (M+H)+.


Example 1420
N-(4-{[1-(benzylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and benzylsulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (400 MHz, DMSO-D2O, Temp=90° C.) 3 ppm 8.58 (s, 1H) 8.48 (d, J=4.88 Hz, 1H) 7.31-7.46 (m, 8H) 6.87 (d, J=9.16 Hz, 2H) 4.79 (d, J=7.02 Hz, 4H) 4.38-4.44 (m, 1H) 4.36 (s, 2H) 3.34-3.38 (m, 2H) 3.07-3.16 (m, 2H) 1.82-1.90 (m, 2H) 1.57-1.71 (m, 2H); MS (APCI(+)) m/e 493 (M+H)+.


Example 1421
N-(4-{[1-(propylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and 1-propylsulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (400 MHz, DMSO-D2O, Temp=90° C.) 3 ppm 8.59 (s, 1H) 8.49 (d, J=4.88 Hz, 1H) 7.35-7.46 (m, 3H) 6.90 (d, J=8.85 Hz, 2H) 4.80 (d, J=5.80 Hz, 4H) 4.39-4.48 (m, 1H) 3.39-3.49 (m, 2H) 3.12-3.22 (m, 2H) 2.96-3.06 (m, 2H) 1.93-2.03 (m, 2H) 1.62-1.79 (m, 4H) 1.01 (t, J=7.48 Hz, 3H); MS (APCI(+)) m/e 445 (M+H)+.


Example 1422
N-(4-{[1-(thiophen-2-ylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 883, substituting N-(4-(piperidin-4-yloxy)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for N-(4-aminophenyl)isoindoline-2-carboxamide and thiophene-2-sulfonyl chloride for (3-methoxyphenyl)methanesulfonyl chloride. 1H NMR (400 MHz, DMSO-D2O, Temp=90° C.) 6 ppm 8.58 (s, 1H) 8.49 (d, J=5.19 Hz, 1H) 7.96 (d, J=4.27 Hz, 1H) 7.63 (d, J=3.05 Hz, 1H) 7.44 (d, J=4.88 Hz, 1H) 7.37 (d, J=8.85 Hz, 2H) 7.23-7.30 (m, 1H) 6.81 (d, J=8.85 Hz, 2H) 4.79 (d, J=4.88 Hz, 4H) 4.29-4.43 (m, 1H) 3.31-3.38 (m, 2H) 2.97-3.09 (m, 2H) 1.93-2.06 (m, 2H) 1.65-1.81 (m, 2H); MS (APCI(+)) m/e 485 (M+H)+.


Example 1441
benzyl trans-3-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]cyclobutanecarboxylate
Example 1441A
benzyl trans-3-(tert-butoxycarbonylamino)cyclobutanecarboxylate

A suspension of trans-3-(tert-butoxycarbonylamino)cyclobutanecarboxylic acid (0.5 g, 2.323 mmol) and potassium carbonate (0.321 g, 2.323 mmol) in dimethylformamide (2.323 ml) was treated with (bromomethyl)benzene (0.401 g, 2.346 mmol) added from a syringe over 3 minutes. The reaction mixture was stirred at room temperature for 17 hours and water was added. The suspension was filtered and the solid collected was washed with water and dried under vacuum to give the title compound.


Example 1441B
trans-benzyl 3-aminocyclobutanecarboxylate

The title compound was prepared as described in Example 2D, substituting benzyl trans-3-(tert-butoxycarbonylamino)cyclobutanecarboxylate for tert-butyl 4-((4-(5-fluoroisoindoline-2 carboxamido)benzamido)methyl)benzylcarbamate.


Example 1441C
benzyl trans-3-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]cyclobutanecarboxylate

The title compound was prepared as described in Example 272B, substituting trans-benzyl 3-aminocyclobutanecarboxylate for 4-amino-N-propylbenzamide and 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine for methyl isoindoline-5-carboxylate hydrochloride. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.56 (s, 1H), 8.47 (d, J=5.0 Hz, 1H), 7.43-7.31 (m, 6H), 6.68 (d, J=7.6 Hz, 1H), 5.14 (s, 2H), 4.65-4.58 (m, 4H), 4.41-4.29 (m, 1H), 3.11-2.99 (m, 1H), 2.46-2.25 (m, 4H); MS (ESI(+)) m/e 352 (M+H)+.


Example 1452
N-(4-{3-[(3-methylbutanoyl)amino]oxetan-3-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
Example 1452A
2-methyl-N-(oxetan-3-ylidene)propane-2-sulfinamide

To a 250 mL round-bottomed flask was added 2-methylpropane-2-sulfinamide (3.36 g, 27.8 mmol) followed by tetraethoxytitanium (11.64 ml, 55.5 mmol) to a tetrahydrofuran (69.4 ml) solution of oxetan-3-one (2 g, 27.8 mmol) at room temperature. The mixture was stirred at 50° C. for 5 hours, cooled and poured into brine. The suspension was filtered through a pad of diatomaceous earth eluting with ethyl acetate. The organics were combined, dried with sodium sulfate, filtered and concentrated under vacuum. The residue was purified by regular phase flash column chromatography to give the title compound.


Example 1452B
N-(3-(4-bromophenyl)oxetan-3-yl)-2-methylpropane-2-sulfinamide

To a 50 mL round-bottomed flask was added 1,4-dibromobenzene (2.85 g, 12.07 mmol) in tetrahydrofuran (40.2 ml). The solution was cooled to −78° C. and n-butyl lithium (4.51 ml, 11.26 mmol) was added dropwise. The mixture was stirred for 1 hour at −78° C. 2-methyl-N-(oxetan-3-ylidene)propane-2-sulfinamide (1.41 g, 8.05 mmol) was added as a tetrahydrofuran solution (ca 1 ml) and the reaction was stirred for 10 minutes and warmed to room temperature. Saturated ammonium chloride was added followed by water and dichloromethane. The aqueous layer was extracted twice with dichloromethane and the combined organics were dried with magnesium sulfate, filtered and concentrated under vacuum. The residue was purified by regular phase, flash column chromatography to give the title compound.


Example 1452C
N-(4-(3-(1,1-dimethylethylsulfinamido)oxetan-3-yl)phenyl)acetamide

To a 5 mL microwave tube was added N-(3-(4-bromophenyl)oxetan-3-yl)-2-methylpropane-2-sulfinamide (436 mg, 1.312 mmol), cesium carbonate (1283 mg, 3.94 mmol), and acetamide (116 mg, 1.968 mmol) in dioxane (6.5 ml). Xantphos (76 mg, 0.131 mmol) and tris(dibenzylideneacetone)dipalladium(0) (60.1 mg, 0.066 mmol) were added; the tube was flushed with nitrogen and capped. The mixture was heated at 100° C. for 45 minutes. Aqueous work up with dichloromethane extraction gave an organic layer that was dried with sodium sulfate, filtered and concentrated under vacuum. Regular phase chromatography provided the title compound.


Example 1452D
N-(3-(4-aminophenyl)oxetan-3-yl)-2-methylpropane-2-sulfinamide

Claisen's alkali (potassium hydroxide, 12.7 g in 9 ml water and 33 ml methanol) was added to N-(4-(3-(1,1-dimethylethylsulfinamido)oxetan-3-yl)phenyl)acetamide (300 mg, 0.966 mmol) and the reaction was stirred at 90° C. for 2 hours. The mixture was cooled to room temperature when water and ethyl acetate were added. The aqueous layer was extracted twice with ethyl acetate and the combined organics were dried with magnesium sulfate, filtered and concentrated under vacuum. The residue was purified by regular phase flash column chromatography to give the title compound.


Example 1452E
N-(4-(3-(1,1-dimethylethylsulfinamido)oxetan-3-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide

The title compound was prepared as described in Example 272B, substituting N-(3-(4-aminophenyl)oxetan-3-yl)-2-methylpropane-2-sulfinamide for 4-amino-N-propylbenzamide and 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine for methyl isoindoline-5-carboxylate hydrochloride.


Example 1452F
N-(4-(3-aminooxetan-3-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide

In a 20 mL vial was added N-(4-(3-(1,1-dimethylethylsulfinamido)oxetan-3-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide (253 mg, 0.610 mmol) and methanol (6.1 ml). 4N HCl in dioxane (229 μl, 0.916 mmol) was added and the reaction was stirred for 2 hours. The mixture was concentrated under vacuum to give the title compound which was used without further purification.


Example 1452G
N-(4-{3-[(3-methylbutanoyl)amino]oxetan-3-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(4-(3-aminooxetan-3-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and 3-methylbutanoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 8.84 (s, 1H), 8.61 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.44 (s, 1H), 7.54 (d, J=8.7 Hz, 2H), 7.43 (d, J=4.8 Hz, 1H), 7.36 (d, J=8.8 Hz, 2H), 4.81 (d, J=6.5 Hz, 6H), 4.69 (d, J=6.5 Hz, 2H), 2.10-1.87 (m, 3H), 0.90 (d, J=6.4 Hz, 6H); MS (ESI(+)) m/e 395 (M+H)+.


Example 1453
tert-butyl 4-({4-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]phenyl}sulfonyl)piperidine-1-carboxylate
Example 1453A
tert-butyl 4-(4-aminophenylthio)piperidine-1-carboxylate

To a 100 mL round-bottomed flask was added 4-aminobenzenethiol (4.9 g, 39.1 mmol) and potassium carbonate (9.72 g, 70.3 mmol) in dimethylformamide (20 ml). tert-Butyl 4-(tosyloxy)piperidine-1-carboxylate (5 g, 14.07 mmol) was added and the reaction was stirred in a sealed flask at 70° C. for 20 hours. The mixture was cooled and filtered through a plug of silica gel with dichloromethane. The filtrate was concentrated under vacuum and chromatographed to give the title compound.


Example 1453B
tert-butyl 4-(4-acetamidophenylthio)piperidine-1-carboxylate

To a 10 mL round-bottomed flask was added tert-butyl 4-(4-aminophenylthio)piperidine-1-carboxylate (100 mg, 0.324 mmol) and triethylamine (249 μl, 1.783 mmol) in dichloromethane (3242 μl). The mixture was cooled to −78° C. and acetyl chloride (115 μl, 1.621 mmol) was added. The solution was warmed to room temperature, stirred for 1 h and then diluted with water and additional dichloromethane. The aqueous phase was extracted twice with dichloromethane and the combined organics were dried with sodium sulfate, filtered and concentrated to give the title compound.


Example 1453C
tert-butyl 4-(4-acetamidophenylsulfonyl)piperidine-1-carboxylate

In a 10 mL round-bottomed flask was added tert-butyl 4-(4-acetamidophenylthio)piperidine-1-carboxylate (100 mg, 0.285 mmol) in dichloromethane (2.9 ml). The solution was cooled to −20° C. and mCPBA (192 mg, 0.856 mmol) was added. The reaction mixture was allowed to warm to room temperature and treated with 1N aqueous NaOH. The aqueous layer was extracted with dichloromethane and the combined organics were dried with sodium sulfate, filtered and concentrated to give the title compound.


Example 1453D
tert-butyl 4-(4-aminophenylsulfonyl)piperidine-1-carboxylate

The title compound was prepared as described in Example 1452D, substituting tert-butyl 4-(4-acetamidophenylsulfonyl)piperidine-1-carboxylate for N-(4-(3-(1,1-dimethylethylsulfinamido)oxetan-3-yl)phenyl)acetamide.


Example 1453E
tert-butyl 4-({4-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]phenyl}sulfonyl)piperidine-1-carboxylate

The title compound was prepared as described in Example 272B, substituting tert-butyl 4-(4-aminophenylsulfonyl)piperidine-1-carboxylate for 4-amino-N-propylbenzamide and 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine for methyl isoindoline-5-carboxylate. 1H NMR (300 MHz, DMSO-d6) δ 8.95 (s, 1H), 8.62 (s, 1H), 8.51 (d, J=5.0 Hz, 1H), 7.90-7.83 (m, 2H), 7.76-7.69 (m, 2H), 7.44 (d, J=5.1 Hz, 1H), 4.93-4.76 (m, 4H), 4.09-3.93 (m, 2H), 2.84-2.56 (m, 1H), 1.83 (d, J=10.8 Hz, 1H), 1.48-1.16 (m, 6H); MS (ESI(+)) m/e 431 (M+H)+.


Example 1454
N-{4-[4-(propylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
Example 1454A
1-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenyl)piperidine-4-carboxylic acid

The title compound was prepared as described in Example 1246, substituting methyl piperidine-4-carboxylate for methyl azetidine-3-carboxylate hydrochloride in Example 1246A.


Example 1454B
N-{4-[4-(propylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting propan-1-amine for 3-phenylpropan-1-amine and 1-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenyl)piperidine-4-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ ppm 8.60 (s, 1H), 8.49 (d, J=5.0 Hz, 1H), 8.19 (s, 1H), 7.77 (t, J=5.6 Hz, 1H), 7.42 (d, J=5.1 Hz, 1H), 7.39-7.33 (m, 2H), 6.89-6.83 (m, 2H), 4.77 (d, J=6.2 Hz, 4H), 3.64-3.56 (m, 2H), 3.05-2.94 (m, 2H), 2.63-2.52 (m, 2H), 2.28-2.14 (m, 1H), 1.79-1.59 (m, 4H), 1.47-1.33 (m, 2H), 0.84 (t, J=7.4 Hz, 3H); MS (ESI(+)) m/e 408 (M+H)+.









TABLE 23







The following examples were essentially prepared as described in Example 1C, substituting the


appropriate amine for 3-phenylpropan-1-amine and 1-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-


2-carboxamido)phenyl)piperidine-4-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid.










Ex
Name

1H NMR

MS





1455
N-(4-{4-[(2-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm 8.57 (s,

(ESI(+))



methoxyethyl)carbamoyl]pi-
1H), 8.47 (d, J = 5.0 Hz, 1H), 7.91 (s, 1H), 7.47-7.41 (m,
m/e 424



peridin-1-yl}phenyl)-
1H), 7.40-7.30 (m, 3H), 6.86-6.80 (m, 2H), 4.80-4.74
(M + H)+



1,3-dihydro-2H-
(m, 4H), 3.61-3.52 (m, 2H), 3.36 (t, J = 5.9 Hz, 2H), 3.28-



pyrrolo[3,4-c]pyridine-2-
3.17 (m, 5H), 2.64 (td, J = 11.7, 3.2 Hz, 2H), 2.32-2.20 (m,



carboxamide
1H), 1.82-1.63 (m, 4H)


1456
N-(4-{4-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H), 8.49 (d, J =

(ESI(+))



[(cyclopentylmethyl)carbamoyl]pi-
5.0 Hz, 1H), 8.19 (s, 1H), 7.79 (t, J = 5.7 Hz, 1H), 7.42 (d, J =
m/e 448



peridin-1-
5.0 Hz, 1H), 7.39-7.33 (m, 2H), 6.89-6.83 (m, 2H), 4.80-
(M + H)+



yl}phenyl)-1,3-dihydro-
4.74 (m, 4H), 3.64-3.56 (m, 2H), 3.01-2.94 (m, 2H),



2H-pyrrolo[3,4-
2.64-2.53 (m, 2H), 2.30-2.16 (m, 1H), 2.04-1.91 (m,



c]pyridine-2-
1H), 1.74-1.43 (m, 10H), 1.29-1.06 (m, 2H)



carboxamide


1457
N-(4-{4-[(1,4-dioxan-2-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H), 8.49 (d, J =

(ESI(+))



ylmethyl)carbamoyl]piperidin-
5.0 Hz, 1H), 8.19 (s, 1H), 7.90 (t, J = 5.8 Hz, 1H), 7.42 (d, J =
m/e 466



1-yl}pheny1)-1,3-
5.1 Hz, 1H), 7.39-7.33 (m, 2H), 6.89-6.83 (m, 2H), 4.78-
(M + H)+



dihydro-2H-pyrrolo[3,4-
4.74 (m, 4H), 3.75-3.41 (m, 8H), 3.21-3.13 (m, 1H),



c]pyridine-2-
3.13-3.02 (m, 2H), 2.63-2.53 (m, 2H), 2.30-2.20 (m,



carboxamide
1H), 1.77-1.59 (m, 4H)


1458
N-{4-[4-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H), 8.49 (d, J =

(ESI(+))



(cyclopentylcarbamoyl)piperidin-
5.0 Hz, 1H), 8.19 (s, 1H), 7.73 (d, J = 7.2 Hz, 1H), 7.42 (d,
m/e 434



1-yl]phenyl}-
J = 5.1 Hz, 1H), 7.39-7.33 (m, 2H), 6.89-6.83 (m, 2H),
(M + H)+



1,3-dihydro-2H-
4.82-4.71 (m, 4H), 4.04-3.92 (m, 1H), 3.64-3.56 (m,



pyrrolo[3,4-c]pyridine-2-
2H), 2.61-2.51 (m, 2H), 2.24-2.13 (m, 1H), 1.84-1.56



carboxamide
(m, 8H), 1.55-1.42 (m, 2H), 1.40-1.29 (m, 2H)


1459
N-{4-[4-(tetrahydro-2H-

1H NMR (400 MHz, DMSO-d6, Temp = 90° C.) δ ppm 8.57 (s,

(ESI(+))



pyran-4-
1H), 8.47 (d, J = 5.0 Hz, 1H), 7.91 (s, 1H), 7.41-7.31 (m,
m/e 450



ylcarbamoyl)piperidin-1-
4H), 6.86-6.80 (m, 2H), 4.80-4.74 (m, 4H), 3.85-3.71
(M + H)+



yl]phenyl}-1,3-dihydro-
(m, 3H), 3.62-3.53 (m, 2H), 3.41-3.29 (m, 2H), 2.70-



2H-pyrrolo[3,4-
2.58 (m, 2H), 2.28-2.18 (m, 1H), 1.81-1.64 (m, 6H), 1.49-



c]pyridine-2-
1.36 (m, 2H)



carboxamide


1460
N-{4-[4-(morpholin-4-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H), 8.49 (d, J =

(ESI(+))



ylcarbonyl)piperidin-1-
5.0 Hz, 1H), 8.19 (s, 1H), 7.42 (d, J = 5.1 Hz, 1H), 7.39-
m/e 436



yl]phenyl}-1,3-dihydro-
7.33 (m, 2H), 6.89-6.83 (m, 2H), 4.81-4.72 (m, 4H), 3.65-
(M + H)+



2H-pyrrolo[3,4-
3.42 (m, 10H), 2.79-2.59 (m, 3H), 1.73-1.64 (m, 4H)



c]pyridine-2-



carboxamide


1461
N-(4-{4-[(tetrahydro-2H-

1H NMR (400 MHz, DMSO-dg) δ ppm 8.60 (s, 1H), 8.49 (d, J =

(ESI(+))



pyran-4-
5.0 Hz, 1H), 8.19 (s, 1H), 7.81 (t, J = 5.8 Hz, 1H), 7.42 (d, J =
m/e 464



ylmethyl)carbamoyl]piperidin-
5.1 Hz, 1H), 7.39-7.33 (m, 2H), 6.89-6.83 (m, 2H), 4.80-
(M + H)+



1-yl}pheny1)-1,3-
4.74 (m, 4H), 3.87-3.79 (m, 2H), 3.64-3.56 (m, 2H),



dihydro-2H-pyrrolo[3,4-
3.28-3.18 (m, 2H), 2.95 (t, J = 6.2 Hz, 2H), 2.64-2.52 (m,



c]pyridine-2-
2H), 2.29-2.18 (m, 1H), 1.78-1.56 (m, 5H), 1.57-1.47



carboxamide
(m, 2H), 1.20-1.06 (m, 2H)


1462
N-{4-[4-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H), 8.49 (d, J =

(ESI(+))



(cyclopropylcarbamoyl)piperidin-
5.0 Hz, 1H), 8.19 (s, 1H), 7.84 (d, J = 4.3 Hz, 1H), 7.42 (d,
m/e 406



1-yl]phenyl}-
J = 5.1 Hz, 1H), 7.39-7.33 (m, 2H), 6.89-6.83 (m, 2H),
(M + H)+



1,3-dihydro-2H-
4.80-4.74 (m, 4H), 3.63-3.55 (m, 2H), 2.66-2.48 (m,



pyrrolo[3,4-c]pyridine-2-
3H), 2.20-2.08 (m, 1H), 1.76-1.58 (m, 4H), 0.63-0.55



carboxamide
(m, 2H), 0.41-0.33 (m, 2H)


1463
N-(4-{4-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.59 (s, 1H), 8.49 (d, J =

(ESI(+))



[(tetrahydrofuran-3-
5.0 Hz, 1H), 8.19 (s, 1H), 7.91 (t, J = 5.7 Hz, 1H), 7.42 (d, J =
m/e 450



ylmethyl)carbamoyl]piperidin-
4.5 Hz, 1H), 7.39-7.33 (m, 2H), 6.89-6.83 (m, 2H), 4.80-
(M + H)+



1-yl}pheny1)-1,3-
4.74 (m, 4H), 3.73-3.54 (m, 5H), 3.40-3.34 (m, 1H),



dihydro-2H-pyrrolo[3,4-
3.09-2.98 (m, 2H), 2.64-2.53 (m, 2H), 2.37-2.27 (m,



c]pyridine-2-
1H), 2.27-2.17 (m, 1H), 1.94-1.83 (m, 1H), 1.79-1.61



carboxamide
(m, 4H), 1.57-1.46 (m, 1H)


1464
N-(4-{4-[(2-hydroxy-2-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H), 8.49 (d, J =

(ESI(+))



methylpropyl)carbamoyl]piperidin-
5.0 Hz, 1H), 8.19 (s, 1H), 7.66 (t, J = 6.0 Hz, 1H), 7.42 (d, J =
m/e 438



1-yl}phenyl)-
4.6 Hz, 1H), 7.39-7.33 (m, 2H), 6.90-6.83 (m, 2H), 4.83-
(M + H)+



1,3-dihydro-2H-
4.71 (m, 4H), 4.44 (s, 1H), 3.65-3.57 (m, 2H), 3.03 (d, J =



pyrrolo[3,4-c]pyridine-2-
6.0 Hz, 2H), 2.64-2.53 (m, 2H), 2.39-2.27 (m, 1H), 1.79-



carboxamide
1.61 (m, 4H), 1.04 (s, 6H)


1465
N-{4-[4-(butan-2-

1H NMR (400 MHz, DMSO-d6) δ ppm 8.60 (s, 1H), 8.49 (d, J =

(ESI(+))



ylcarbamoyl)piperidin-1-
5.0 Hz, 1H), 8.19 (s, 1H), 7.56 (d, J = 8.2 Hz, 1H), 7.42 (d,
m/e 422



yl]phenyl}-1,3-dihydro-
J = 4.5 Hz, 1H), 7.39-7.33 (m, 2H), 6.89-6.83 (m, 2H),
(M + H)+



2H-pyrrolo[3,4-
4.81-4.70 (m, 4H), 3.72-3.54 (m, 3H), 2.62-2.50 (m,



c]pyridine-2-
2H), 2.27-2.14 (m, 1H), 1.78-1.58 (m, 4H), 1.44-1.28



carboxamide
(m, 2H), 1.01 (d, J = 6.6 Hz, 3H), 0.81 (t, J = 7.4 Hz, 3H)









Example 1472
N-(4-{(4R)-4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

A racemic mixture of N-(4-{4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide (250 mg) was dissolved in methanol and separated using SCF-LC with a ChiralPak AD-H 21×250 mm column to provide N-(4-{(4R)-4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.41 (s, 1H), 7.66 (d, J=7.6 Hz, 1H), 7.56-7.48 (m, 2H), 7.43 (d, J=5.1 Hz, 1H), 7.37-7.29 (m, 2H), 6.02 (bs, 1H), 4.84-4.77 (m, 4H), 3.89-3.73 (m, 1H), 2.44 (ddd, J=12.7, 8.7, 4.6 Hz, 2H), 2.41-2.26 (m, 2H), 2.14-1.97 (m, 1H), 1.93-1.81 (m, 1H), 1.67-1.49 (m, 1H), 1.00 (dd, J=6.8, 2.4 Hz, 6H); MS (ESI(+)) m/e 405 (M+H)+.


Example 1473
N-(4-{(45)-4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

A racemic mixture of N-(4-{4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide (250 mg) was dissolved in methanol and separated using SCF-LC with a ChiralPak AD-H 21×250 mm column to provide N-(4-{(4S)-4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.41 (s, 1H), 7.66 (d, J=7.6 Hz, 1H), 7.56-7.49 (m, 2H), 7.43 (d, J=5.1 Hz, 1H), 7.37-7.29 (m, 2H), 6.05-5.99 (m, 1H), 4.84-4.77 (m, 4H), 3.89-3.73 (m, 1H), 2.47-2.39 (m, 1H), 2.41-2.30 (m, 2H), 2.11-1.97 (m, 1H), 1.93-1.82 (m, 1H), 1.67-1.50 (m, 1H), 1.00 (dd, J=6.8, 2.4 Hz, 6H); MS (ESI(+)) m/e 405 (M+H)+.


Example 1474
N-[4-(1-benzoylazetidin-3-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide
Example 1474A
tert-butyl 3-(2-hydroxyethyl)azetidine-1-carboxylate

A solution of 2-(1-(tert-butoxycarbonyl)azetidin-3-yl)acetic acid (1 g, 4.65 mmol) in tetrahydrofuran (5 ml) was cooled to 0° C. and treated with borane tetrahydrofuran complex (7.00 ml, 7 mmol) dropwise by syringe. After 1 hour at 0° C. the solution was allowed to warm to room temperature and stirred overnight and then it was quenched with 20 ml of 1M aqueous NaOH. The separated aqueous layer was extracted with ether (2×15 ml), dried with magnesium sulfate, filtered and concentrated to give the title compound which was used without purification.


Example 1474B
tert-butyl 3-(2-oxoethyl)azetidine-1-carboxylate

To a solution of oxalyl chloride (488 μl, 5.58 mmol) in 40 ml dichloromethane at −78° C. was added dimethyl sulfoxide (792 μl, 11.16 mmol) dropwise by syringe. The mixture was stirred for 15 minutes at −78° C. when a solution of tert-butyl 3-(2-hydroxyethyl)azetidine-1-carboxylate (936 mg, 4.65 mmol) in 10 ml dichloromethane was added dropwise by syringe. After 1 hour at −78° C., triethylamine (3241 μl, 23.25 mmol) was added and the suspension was warmed to room temperature and stirred for an additional hour. The mixture was quenched with water (25 ml) and saturated aqueous potassium carbonate (10 ml), stirred vigorously and separated. The aqueous layer was extracted with dichloromethane (2×20 ml) and the combined organic layers were dried with magnesium sulfate, filtered and concentrated. The crude material was flash chromatographed to give the title compound.


Example 1474C
tert-butyl 3-(3-cyanoallyl)azetidine-1-carboxylate

To a solution of potassium tert-butoxide, 1M in tetrahydrofuran (3694 μl, 3.69 mmol) at 0° C. was added dropwise by syringe a solution of diethyl cyanomethylphosphonate (570 μl, 3.52 mmol) in 5 ml tetrahydrofuran. The reaction mixture was warmed to room temperature and then cooled to 0° C. again. This solution was treated with tert-butyl 3-(2-oxoethyl)azetidine-1-carboxylate (701 mg, 3.52 mmol) in 2 ml tetrahydrofuran dropwise by syringe and then allowed to warm to room temperature. After stirring overnight the gelatinous mixture was quenched with water (20 ml) and extracted with ethyl acetate (2×20 ml); the organic layers were washed with brine (20 ml), dried with magnesium sulfate, filtered and concentrated. The liquid residue was flash chromatographed to give the title compound as a 1:1 mixture of E/Z isomers.


Example 1474D
tert-butyl 3-(4-aminobutyl)azetidine-1-carboxylate

7M NH3—CH3OH (10 mL) was added to tert-butyl 3-(3-cyanoallyl)azetidine-1-carboxylate (640 mg, 2.88 mmol) and Ra—Ni 2800, water slurry (881 mg, 6.75 mmol) in a 20 mL pressure bottle. The mixture was stirred under 30 psi of hydrogen at room temperature for 16 hours. The mixture was filtered through a polypropylene membrane, concentrated by rotovap and dried under vacuum to provide the title compound which was used without purification.


Example 1474E
tert-butyl 3-(4-(isoindoline-2-carboxamido)butyl)azetidine-1-carboxylate

The title compound was prepared as described in Example 344A, substituting tert-butyl 3-(4-aminobutyl)azetidine-1-carboxylate for tert-butyl 5-aminoisoindoline-2-carboxylate.


Example 1474F
N-(4-(azetidin-3-yl)butyl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 3-(4-(isoindoline-2-carboxamido)butyl)azetidine-1-carboxylate for tert-butyl 44(4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 1474G
N-[4-(1-benzoylazetidin-3-yl)butyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 278, substituting benzoyl chloride for acetyl chloride and N-(4-(azetidin-3-yl)butyl)isoindoline-2-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ 7.67-7.57 (m, 2H), 7.57-7.39 (m, 3H), 7.39-7.23 (m, 4H), 6.28 (s, 1H), 4.56 (s, 4H), 4.34 (t, J=8.3 Hz, 1H), 4.11 (t, J=9.0 Hz, 1H), 4.01-3.82 (m, 1H), 3.65 (dd, J=9.8, 5.8 Hz, 1H), 3.07 (dd, J=12.7, 6.8 Hz, 2H), 2.66-2.53 (m, 1H), 1.59 (dd, J=15.3, 7.7 Hz, 2H), 1.51-1.36 (m, 2H), 1.25 (dd, J=13.5, 6.4 Hz, 2H); MS (ESI(+)) m/e 378 (M+H)+.


Example 1475
N-[4-(1-benzoylazetidin-3-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
Example 1475A
tert-butyl 3-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)butyl)azetidine-1-carboxylate

The title compound was prepared as described in Example 344A, substituting ten-butyl 3-(4-aminobutyl)azetidine-1-carboxylate for tert-butyl 5-aminoisoindoline-2-carboxylate and 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine for isoindoline.


Example 1475B
N-(4-(azetidin-3-yl)butyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 3-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)butyl)azetidine-1-carboxylate for tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 1475C
N-[4-(1-benzoylazetidin-3-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 278, substituting benzoyl chloride for acetyl chloride and N-(4-(azetidin-3-yl)butyl)-1H-pyrrolo[3,4-c]pyridine-2 (3H)-carboxamide for 5-amino-N-(4-(propylcarbamoyl)phenyl)isoindoline-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ 8.55 (s, 1H), 8.46 (d, J=5.0 Hz, 1H), 7.67-7.55 (m, 2H), 7.55-7.34 (m, 4H), 6.37 (t, J=5.5 Hz, 1H), 4.60 (d, J=2.3 Hz, 4H), 4.35 (t, J=8.3 Hz, 1H), 4.11 (t, J=9.1 Hz, 1H), 3.96-3.83 (m, 1H), 3.65 (dd, J=9.7, 5.7 Hz, 1H), 3.07 (dd, J=12.8, 6.7 Hz, 2H), 2.65-2.53 (m, 1H), 1.59 (dd, J=15.2, 7.6 Hz, 2H), 1.43 (dd, J=14.4, 7.2 Hz, 2H), 1.34-1.09 (m, 2H); MS (ESI(+)) m/e 379 (M+H)+.


Example 1476
N-[trans-3-(benzylcarbamoyl)cyclobutyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
Example 1476A
trans-3-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)cyclobutanecarboxylic acid

The title compound was prepared as described in Example 272A, substituting benzyl trans-3-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]cyclobutanecarboxylate for 4-nitro-N-propylbenzamide.


Example 1476B
N-[trans-3-(benzylcarbamoyl)cyclobutyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting benzylamine for 3-phenylpropan-1-amine and trans-3-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)cyclobutanecarboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.56 (s, 1H), 8.47 (d, J=5.0 Hz, 1H), 8.26 (t, J=5.9 Hz, 1H), 7.39 (d, J=5.1 Hz, 1H), 7.36-7.28 (m, 2H), 7.27-7.20 (m, 3H), 6.60 (d, J=7.6 Hz, 1H), 4.65-4.59 (m, 4H), 4.45-4.29 (m, 1H), 4.28 (d, J=5.9 Hz, 2H), 2.96-2.84 (m, 1H), 2.41-2.29 (m, 2H), 2.30-2.15 (m, 2H); MS (ESI(+)) m/e 351 (M+H)+.


Example 1477
N-{trans-3-[(2-phenylethyl)carbamoyl]cyclobutyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 2-phenylethylamine for 3-phenylpropan-1-amine and trans-3-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)cyclobutanecarboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.56 (s, 1H), 8.47 (d, J=5.0 Hz, 1H), 7.80 (t, J=5.6 Hz, 1H), 7.39 (d, J=5.1 Hz, 1H), 7.33-7.24 (m, 2H), 7.23-7.16 (m, 3H), 6.57 (d, J=7.6 Hz, 1H), 4.65-4.58 (m, 4H), 4.38-4.24 (m, 1H), 3.33-3.23 (m, 2H), 2.84-2.74 (m, 1H), 2.72 (t, J=7.3 Hz, 2H), 2.32-2.22 (m, 2H), 2.24-2.09 (m, 2H); MS (ESI(+)) m/e 365 (M+H)+.


Example 1478
N-{trans-3-[(3-phenylpropyl)carbamoyl]cyclobutyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting 3-phenylpropylamine for 3-phenylpropan-1-amine and trans-3-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)cyclobutanecarboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.56 (s, 1H), 8.47 (d, J=5.0 Hz, 1H), 7.75 (t, J=5.5 Hz, 1H), 7.38 (d, J=5.1 Hz, 1H), 7.32-7.24 (m, 2H), 7.24-7.13 (m, 3H), 6.58 (d, J=7.6 Hz, 1H), 4.66-4.55 (m, 4H), 4.41-4.27 (m, 1H), 3.11-3.03 (m, 2H), 2.89-2.75 (m, 1H), 2.62-2.52 (m, 2H), 2.39-2.25 (m, 2H), 2.26-2.11 (m, 2H), 1.76-1.63 (m, 2H); MS (ESI(+)) m/e 379 (M+H)+.


Example 1525
N-[4-(cis-4-{[(2-methoxyethoxy)acetyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
Example 1525A
tert-butyl 4-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenyl)cyclohexylcarbamate

The title compound was prepared as described in Example 979A, substituting tert-butyl 4-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenyl)cyclohex-3-enylcarbamate for tert-Butyl 4-(4-(isoindoline-2-carboxamido)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate.


Example 1525B
N-(4-(4-aminocyclohexyl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(4-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)phenyl)cyclohexylcarbamate for tert-butyl 4-((4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 1525C
N-[4-(cis-4-{[(2-methoxyethoxy)acetyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C as a 1:1 cis/trans mixture, substituting N-(4-(4-aminocyclohexyl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and 2-(2-methoxyethoxy)acetic acid for 4-(isoindoline-2-carboxamido)benzoic acid. HPLC separation of the cis/trans isomers provided N-[4-(cis-4-{[(2-methoxyethoxy)acetyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide. 1H NMR (501 MHz, DMSO-d6) δ 8.59 (bs, 1H), 8.51-8.45 (m, 1H), 8.32 (bs, 1H), 7.44 (dd, J=11.5, 5.2 Hz, 3H), 7.40 (t, J=7.6 Hz, 1H), 7.17-7.11 (m, 2H), 4.81-4.74 (m, 4H), 4.03-3.96 (m, 1H), 3.90 (d, J=2.2 Hz, 2H), 3.63-3.58 (m, 2H), 3.52-3.46 (m, 2H), 3.27-3.23 (m, 3H), 1.80-1.30 (m, 8H); MS (ESI(+)) m/e 453 (M+H)+.


Example 1526
N-[4-(trans-4-{[(2-methoxyethoxy)acetyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C as a 1:1 cis/trans mixture, substituting N-(4-(4-aminocyclohexyl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and 2-(2-methoxyethoxy)acetic acid for 4-(isoindoline-2-carboxamido)benzoic acid. HPLC separation of the cis/trans isomers provided N-[4-(trans-4-{[(2-methoxyethoxy)acetyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide. 1H NMR (501 MHz, DMSO-d6) δ 8.58 (s, 1H), 8.48 (d, J=5.0 Hz, 1H), 8.31 (s, 1H), 7.50-7.39 (m, 4H), 7.15-7.09 (m, 2H), 4.81-4.74 (m, 4H), 3.85 (s, 2H), 3.74-3.58 (m, 1H), 3.58-3.55 (m, 2H), 3.49-3.46 (m, 2H), 3.28 (s, 3H), 2.45-2.37 (m, 1H), 1.89-1.82 (m, 2H), 1.83-1.75 (m, 2H), 1.58-1.42 (m, 2H), 1.44-1.29 (m, 2H); MS (ESI(+)) m/e 453 (M+H)+.


Example 1527
N-[4-(cis-4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C as a 1:1 cis/trans mixture, substituting N-(4-(4-aminocyclohexyl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and (S)-tetrahydrofuran-2-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. HPLC separation of the cis/trans isomers provided N-[4-(cis-4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide. 1H NMR (501 MHz, DMSO-d6) δ 8.59 (s, 1H), 8.48 (d, J=5.0 Hz, 1H), 8.32 (s, 1H), 7.47-7.38 (m, 4H), 7.17-7.12 (m, 2H), 4.81-4.75 (m, 4H), 4.29-4.22 (m, 1H), 3.94-3.86 (m, 2H), 3.77 (t, J=7.1 Hz, 1H), 2.14-2.02 (m, 1H), 1.88-1.78 (m, 3H), 1.70 (dd, J=22.1, 8.6 Hz, 3H), 1.63 (t, J=17.3 Hz, 6H); MS (ESI(+)) m/e 435 (M+H)+.


Example 1528
N-[4-(trans-4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C as a 1:1 cis/trans mixture, substituting N-(4-(4-aminocyclohexyl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and (S)-tetrahydrofuran-2-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. HPLC separation of the cis/trans isomers provided N-[4-(trans-4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide. 1H NMR (501 MHz, DMSO-d6) δ 8.58 (bs, 1H), 8.51-8.45 (m, 1H), 8.30 (bs, 1H), 7.53-7.45 (m, 1H), 7.42 (d, J=8.3 Hz, 2H), 7.14-7.08 (m, 2H), 4.81-4.74 (m, 4H), 4.20-4.13 (m, 1H), 3.92-3.85 (m, 1H), 3.78-3.71 (m, 1H), 3.66-3.58 (m, 1H), 2.39 (s, 1H), 2.09 (dd, J=10.8, 6.4 Hz, 1H), 1.79 (s, 7H), 1.62 (s, 1H), 1.45 (dd, J=26.5, 15.7 Hz, 4H); MS (ESI(+)) m/e 435 (M+H)+.


Example 1529
N-[4-(cis-4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C as a 1:1 cis/trans mixture, substituting N-(4-(4-aminocyclohexyl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and (R)-tetrahydrofuran-2-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. HPLC separation of the cis/trans isomers provided N-[4-(cis-4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide. 1H NMR (501 MHz, DMSO-d6) δ 8.55 (t, J=21.5 Hz, 1H), 8.46 (s, 1H), 8.32 (d, J=9.4 Hz, 1H), 7.47-7.37 (m, 4H), 7.14 (bs, 2H), 4.77 (bs, 4H), 4.29-4.20 (m, 1H), 3.96-3.84 (m, 2H), 3.80-3.71 (m, 1H), 2.12-2.01 (m, 1H), 1.76 (d, J=48.5 Hz, 4H), 1.60 (s, 7H); MS (ESI(+)) m/e 435 (M+H)+.


Example 1530
N-[4-(trans-4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C as a 1:1 cis/trans mixture, substituting N-(4-(4-aminocyclohexyl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and (R)-tetrahydrofuran-2-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. HPLC separation of the cis/trans isomers provided N-[4-(trans-4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide. 1H NMR (501 MHz, DMSO-d6) δ 8.58 (bs, 1H), 8.50-8.45 (m, 1H), 8.31 (bs, 1H), 7.52-7.46 (m, 1H), 7.45-7.39 (m, 3H), 7.14-7.08 (m, 2H), 4.81-4.74 (m, 4H), 4.20-4.13 (m, 1H), 3.92-3.84 (m, 1H), 3.78-3.70 (m, 1H), 3.66-3.57 (m, 1H), 2.43-2.34 (m, 1H), 2.14-2.02 (m, 1H), 2.04-1.52 (m, 7H), 1.54-1.24 (m, 4H); MS (ESI(+)) m/e 435 (M+H)+.


Example 1531
N-(6-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide
Example 1531A
methyl 6-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)pyridazine-3-carboxylate

Methyl 6-aminopyridazine-3-carboxylate (2 g, 13.06 mmol) was suspended in dichloromethane (50 ml) followed by addition of dry pyridine (1.265 ml, 15.67 mmol) under nitrogen. To this suspension was added a dichloromethane solution of 4-nitrophenyl carbonochloridate (2.99 g, 14.37 mmol) via syringe at ambient temperature. The mixture was stirred overnight to give a suspension that was concentrated to half volume under a stream of nitrogen. 2,3-Dihydro-1H-pyrrolo[3,4-c]pyridine, dihydrochloride (2.52 g, 13.06 mmol) was dissolved in 30 ml dimethylformamide with triisopropylethylamine (6.84 ml, 39.2 mmol) and added to the carbamate mixture via syringe. After stirring the mixture overnight and removing most of the solvent under vacuum, water was added; and the resulting suspension was stirred for 30 minutes and filtered to give a solid which was washed with water. Flash chromatography of the dried solid gave the title compound.


Example 1531B
6-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)pyridazine-3-carboxylic acid

The title compound was prepared as described in Example 1B, substituting methyl 6-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)pyridazine-3-carboxylate for methyl 4-(isoindoline-2-carboxamido)benzoate.


Example 1531C
N-(6-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting (25)-tetrahydrofuran-2-ylmethamine for 3-phenylpropan-1-amine and 6-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)pyridazine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 10.09 (s, 1H), 8.81 (t, J=6.1 Hz, 1H), 8.62 (s, 1H), 8.51 (d, J=5.0 Hz, 1H), 8.31 (d, J=9.3 Hz, 1H), 8.12 (d, J=9.3 Hz, 1H), 7.44 (d, J=5.1 Hz, 1H), 5.05-4.76 (m, 4H), 4.04 (p, J=6.2 Hz, 1H), 3.85-3.74 (m, 1H), 3.70-3.59 (m, 1H), 3.45-3.31 (m, 2H), 1.99-1.72 (m, 3H), 1.69-1.54 (m, 1H); MS (ESI(+)) m/e 369 (M+H)+.


Example 1542
N-(6-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting (2R)-tetrahydrofuran-2-ylmethamine for 3-phenylpropan-1-amine and 6-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)pyridazine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 10.09 (bs, 1H), 8.81 (t, J=6.1 Hz, 1H), 8.61 (s, 1H), 8.51 (d, J=5.0 Hz, 1H), 8.31 (d, J=9.3 Hz, 1H), 8.12 (d, J=9.3 Hz, 1H), 7.44 (d, J=5.1 Hz, 1H), 5.05-4.76 (m, 4H), 4.04 (p, J=6.2 Hz, 1H), 3.85-3.74 (m, 1H), 3.70-3.59 (m, 1H), 3.35 (d, J=25.7 Hz, 2H), 1.99-1.72 (m, 3H), 1.69-1.54 (m, 1H); MS (ESI(+)) m/e 369 (M+H)+.


Example 1543
N-{6-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting tetrahydro-2H-pyran-4-ylmethamine for 3-phenylpropan-1-amine and 6-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)pyridazine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 10.06 (s, 1H), 9.00 (t, J=6.2 Hz, 1H), 8.62 (s, 1H), 8.51 (d, J=5.0 Hz, 1H), 8.29 (d, J=9.3 Hz, 1H), 8.11 (d, J=9.3 Hz, 1H), 7.44 (d, J=5.1 Hz, 1H), 4.96-4.89 (m, 4H), 3.89-3.79 (m, 2H), 3.22 (d, J=2.6 Hz, 3H), 1.96-1.75 (m, 1H), 1.64-1.53 (m, 2H), 1.31-1.10 (m, 2H); MS (ESI(+)) m/e 383 (M+H)+.


Example 1544
N-{6-[(cyclopentylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting cyclopentylmethamine for 3-phenylpropan-1-amine and 6-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)pyridazine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 10.03 (bs, 1H), 8.95 (t, J=6.1 Hz, 1H), 8.62 (s, 1H), 8.51 (d, J=5.0 Hz, 1H), 8.29 (d, J=9.3 Hz, 1H), 8.11 (d, J=9.3 Hz, 1H), 7.44 (d, J=5.1 Hz, 1H), 4.99-4.75 (m, 4H), 3.28-3.20 (m, 2H), 2.31-2.13 (m, 1H), 1.75-1.38 (m, 6H), 1.39-1.18 (m, 2H); MS (ESI(+)) m/e 367 (M+H)+.


Example 1545
N-{6-[(tetrahydrofuran-3-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting tetrahydrofuran-3-ylmethamine for 3-phenylpropan-1-amine and 6-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)pyridazine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 10.05 (s, 1H), 9.13 (t, J=6.1 Hz, 1H), 8.62 (s, 1H), 8.51 (d, J=5.0 Hz, 1H), 8.30 (d, J=9.3 Hz, 1H), 8.12 (d, J=9.3 Hz, 1H), 7.44 (d, J=5.1 Hz, 1H), 5.05-4.76 (m, 4H), 3.80-3.57 (m, 4H), 3.48 (dd, J=12.1, 6.8 Hz, 1H), 3.37-3.31 (m, 1H), 2.62-2.52 (m, 1H), 2.01-1.80 (m, 1H), 1.71-1.56 (m, 1H); MS (ESI(+)) m/e 369 (M+H)+.


Example 1546
N-{6-[(bicyclo[2.2.1]hept-2-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C, substituting bicyclo[2.2.1]hept-2-ylmethamine for 3-phenylpropan-1-amine and 6-(2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-2-carboxamido)pyridazine-3-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 10.05 (bs, 1H), 8.92 (d, J=42.7 Hz, 1H), 8.61 (s, 1H), 8.51 (d, J=5.0 Hz, 1H), 8.29 (d, J=9.3 Hz, 1H), 8.10 (d, J=9.3 Hz, 1H), 7.47-7.41 (m, 1H), 5.07-4.74 (m, 4H), 3.23-2.84 (m, 2H), 2.30-2.02 (m, 3H), 1.86-1.57 (m, 2H), 1.58-0.99 (m, 6H); MS (ESI(+)) m/e 393 (M+H)+.


Example 1547
N-(4-{trans-4-[(2-methylpropanoyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C as a 1:1 cis/trans mixture, substituting N-(4-(4-aminocyclohexyl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and isobutyric acid for 4-(isoindoline-2-carboxamido)benzoic acid. HPLC separation of the cis/trans isomers provided N-(4-{trans-4-[(2-methylpropanoyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.32 (s, 1H), 7.58 (d, J=7.8 Hz, 1H), 7.48-7.40 (m, 3H), 7.17-7.09 (m, 2H), 4.82-4.76 (m, 4H), 3.65-3.47 (m, 1H), 2.41-2.23 (m, 2H), 1.93-1.69 (m, 4H), 1.62-1.38 (m, 2H), 1.39-1.12 (m, 2H), 0.99 (d, J=6.8 Hz, 6H); MS (ESI(+)) m/e 407 (M+H)+.


Example 1548
N-(4-{cis-4-[(2-methylpropanoyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C as a 1:1 cis/trans mixture, substituting N-(4-(4-aminocyclohexyl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and isobutyric acid for 4-(isoindoline-2-carboxamido)benzoic acid. HPLC separation of the cis/trans isomers provided N-(4-{cis-4-[(2-methylpropanoyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.33 (s, 1H), 7.68-7.61 (m, 1H), 7.49-7.40 (m, 3H), 7.21-7.14 (m, 2H), 4.83-4.76 (m, 4H), 3.98-3.90 (m, 1H), 1.97-1.49 (m, 9H), 1.04-0.97 (m, 6H); MS (ESI(+)) m/e 407 (M+H)+.


Example 1549
N-(4-{cis-4-[(cyclohexylcarbonyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C as a 1:1 cis/trans mixture, substituting N-(4-(4-aminocyclohexyl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and cyclohexanecarboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. HPLC separation of the cis/trans isomers provided N-(4-{cis-4-[(cyclohexylcarbonyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.33 (s, 1H), 7.66-7.59 (m, 1H), 7.47 (s, 1H), 7.47-7.40 (m, 2H), 7.21-7.14 (m, 2H), 4.83-4.76 (m, 4H), 3.98-3.90 (m, 1H), 2.45 (s, 1H), 2.31-2.19 (m, 1H), 1.89-1.46 (m, 12H), 1.46-1.05 (m, 6H); MS (ESI(+)) m/e 447 (M+H)+.


Example 1550
N-(4-{trans-4-[(cyclohexylcarbonyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C as a 1:1 cis/trans mixture, substituting N-(4-(4-aminocyclohexyl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and cyclohexanecarboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. HPLC separation of the cis/trans isomers provided N-(4-{trans-4-[(cyclohexylcarbonyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.49 (d, J=5.0 Hz, 1H), 8.32 (s, 1H), 7.54 (d, J=7.9 Hz, 1H), 7.47-7.40 (m, 3H), 7.16-7.09 (m, 2H), 4.82-4.75 (m, 4H), 3.62-3.42 (m, 1H), 2.42-2.33 (m, 1H), 2.12-1.99 (m, 1H), 1.87-1.61 (m, 8H), 1.55-1.37 (m, 3H), 1.38-1.08 (m, 7H); MS (ESI(+)) m/e 447 (M+H)+.


Example 1551
N-(4-{trans-4-[(cyclopropylacetyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C as a 1:1 cis/trans mixture, substituting N-(4-(4-aminocyclohexyl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and 2-cyclopropylacetic acid for 4-(isoindoline-2-carboxamido)benzoic acid. HPLC separation of the cis/trans isomers provided N-(4-{trans-4-[(cyclopropylacetyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.32 (s, 1H), 7.59 (d, J=7.8 Hz, 1H), 7.48-7.40 (m, 3H), 7.11 (s, 2H), 4.82-4.76 (m, 4H), 3.66-3.50 (m, 1H), 2.40 (t, J=10.1 Hz, 1H), 1.94 (t, J=11.8 Hz, 1H), 1.83 (dd, J=23.4, 12.2 Hz, 4H), 1.61-1.39 (m, 2H), 1.40-1.18 (m, 3H), 1.04-0.83 (m, 1H), 0.46-0.33 (m, 2H), 0.18-0.07 (m, 2H); MS (ESI(+)) m/e 419 (M+H)+.


Example 1552
N-(4-{cis-4-[(cyclopropylacetyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide

The title compound was prepared as described in Example 1C as a 1:1 cis/trans mixture, substituting N-(4-(4-aminocyclohexyl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide for 3-phenylpropan-1-amine and 2-cyclopropylacetic acid for 4-(isoindoline-2-carboxamido)benzoic acid. HPLC separation of the cis/trans isomers provided N-(4-{cis-4-[(cyclopropylacetyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide. 1H NMR (300 MHz, DMSO-d6) δ 8.61 (s, 1H), 8.50 (d, J=5.0 Hz, 1H), 8.33 (s, 1H), 7.67-7.60 (m, 1H), 7.49-7.40 (m, 3H), 7.21-7.13 (m, 2H), 4.83-4.76 (m, 4H), 4.02-3.92 (m, 1H), 2.06 (d, J=7.0 Hz, 2H), 1.84-1.65 (m, 4H), 1.65-1.47 (m, 4H), 1.25-0.90 (m, 1H), 0.47-0.34 (m, 2H), 0.23-0.11 (m, 2H); MS (ESI(+)) m/e 419 (M+H)+.


Example 1553
N-(4-{4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide
Example 1553A
tert-butyl 4-(4-nitrophenyl)cyclohex-3-enylcarbamate

The title was prepared as in Example 1018B, substituting 4,4,5,5-tetramethyl-2-(4-nitrophenyl)-1,3,2-dioxaborolane for N-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxamide.


Example 1553B
tert-butyl 4-(4-aminophenyl)cyclohex-3-enylcarbamate

tert-Butyl 4-(4-nitrophenyl)cyclohex-3-enylcarbamate (2.55 g, 8.01 mmol) was suspended in ethanol (30 ml) followed by addition of sodium sulfide, nonahydrate (10.37 ml, 80 mmol) dissolved in water (30 ml). The mixture was heated to 80° C. for 1.5 h and extracted with dichloromethane; the organic layers were combined, dried over magnesium sulfate, filtered and concentrated to give the title compound.


Example 1553C
tert-butyl 4-(4-(isoindoline-2-carboxamido)phenyl)cyclohex-3-enylcarbamate

The title compound was prepared as described in Example 272B, substituting tert-butyl 4-(4-aminophenyl)cyclohex-3-enylcarbamate for 4-amino-N-propylbenzamide and isoindoline for methyl isoindoline-5-carboxylate hydrochloride.


Example 1553D
N-(4-(4-aminocyclohex-1-enyl)phenyl)isoindoline-2-carboxamide

The title compound was prepared as described in Example 2D, substituting tert-butyl 4-(4-(isoindoline-2-carboxamido)phenyl)cyclohex-3-enylcarbamate for tert-butyl 44(4-(5-fluoroisoindoline-2-carboxamido)benzamido)methyl)benzylcarbamate.


Example 1553E
N-(4-{4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(4-(4-aminocyclohex-1-enyl)phenyl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and isobutyric acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 8.36 (s, 1H), 7.70 (d, J=7.6 Hz, 1H), 7.54 (d, J=2.1 Hz, 2H), 7.46-7.23 (m, 6H), 6.06-5.96 (m, 1H), 4.76 (s, 4H), 3.85-3.75 (m, 1H), 2.43-2.26 (m, 3H), 2.11-1.96 (m, 1H), 1.95-1.75 (m, 1H), 1.69-1.48 (m, 1H), 1.10-0.82 (m, 6H); MS (ESI(+)) m/e 404 (M+H)+.


Example 1554
N-[4-(4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(4-(4-aminocyclohex-1-enyl)phenyl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and -(2R)-tetrahydrofuran-2-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 8.36 (s, 1H), 7.61 (dt, J=9.2, 4.6 Hz, 1H), 7.58-7.45 (m, 2H), 7.49-7.23 (m, 6H), 6.02 (bs, 1H), 4.77 (s, 4H), 4.25-4.16 (m, 1H), 3.97-3.66 (m, 3H), 2.42-2.24 (m, 1H), 2.26-1.98 (m, 3H), 1.98-1.53 (m, 6H); MS (ESI(+)) m/e 432 (M+H)+.


Example 1555
N-[4-(4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(4-(4-aminocyclohex-1-enyl)phenyl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and -(25)-tetrahydrofuran-2-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 8.37 (s, 1H), 7.63 (dd, J=8.2, 3.5 Hz, 1H), 7.57-7.50 (m, 2H), 7.49-7.23 (m, 6H), 6.04-5.96 (m, 1H), 4.76 (s, 4H), 4.25-4.16 (m, 1H), 3.96-3.67 (m, 4H), 2.38-2.29 (m, 1H), 2.27-1.99 (m, 3H), 1.97-1.56 (m, 5H); MS (ESI(+)) m/e 432 (M+H)+.


Example 1556
N-(4-{4-[(cyclopentylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(4-(4-aminocyclohex-1-enyl)phenyl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and cyclopentylacetic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 8.34 (s, 1H), 7.72 (d, J=7.6 Hz, 1H), 7.57-7.49 (m, 2H), 7.49-7.23 (m, 6H), 6.01 (bs, 1H), 4.76 (s, 4H), 3.90-3.74 (m, 1H), 2.49-2.25 (m, 2H), 2.20-1.99 (m, 3H), 1.94-1.82 (m, 1H), 1.68 (tdd, J=9.4, 8.9, 4.4 Hz, 2H), 1.64-1.42 (m, 7H), 1.31-1.01 (m, 2H); MS (ESI(+)) m/e 444 (M+H)+.


Example 1557
N-(4-{4-[(cyclopropylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(4-(4-aminocyclohex-1-enyl)phenyl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and cyclopropylacetic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 8.36 (s, 1H), 7.70 (d, J=7.6 Hz, 1H), 7.66-7.47 (m, 2H), 7.47-7.24 (m, 6H), 6.02 (bs, 1H), 4.76 (s, 4H), 3.88-3.78 (m, 1H), 2.49-2.26 (m, 3H), 2.12-1.82 (m, 4H), 1.72-1.50 (m, 1H), 1.13-0.88 (m, 1H), 0.52-0.33 (m, 2H), 0.18-0.01 (m, 2H); MS (ESI(+)) m/e 416 (M+H)+.


Example 1558
N-(4-{4-[(2-hydroxy-2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(4-(4-aminocyclohex-1-enyl)phenyl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and 2-hydroxy-2-methylpropanoic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 8.36 (s, 1H), 7.52 (t, J=8.6 Hz, 2H), 7.46-7.39 (m, 1H), 7.35 (tdd, J=8.8, 7.1, 3.7 Hz, 6H), 6.07-5.96 (m, 1H), 5.40 (s, 1H), 4.77 (s, 4H), 3.92-3.76 (m, 1H), 2.46 (s, 1H), 2.39-2.25 (m, 1H), 2.24-2.09 (m, 2H), 1.93-1.78 (m, 1H), 1.70 (dt, J=12.4, 7.7 Hz, 1H), 1.25 (s, 6H); MS (ESI(+)) m/e 420 (M+H)+.


Example 1559
N-(4-{4-[(tetrahydro-2H-pyran-4-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-isoindole-2-carboxamide

The title compound was prepared as described in Example 1C, substituting N-(4-(4-aminocyclohex-1-enyl)phenyl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and tetrahydro-2H-pyran-4-carboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 8.36 (s, 1H), 7.76 (d, J=7.6 Hz, 1H), 7.57-7.49 (m, 2H), 7.46-7.23 (m, 6H), 6.02 (bs, 1H), 4.76 (s, 4H), 3.91-3.75 (m, 4H), 3.31-3.17 (m, 2H), 2.43-2.26 (m, 2H), 2.12-1.97 (m, 1H), 1.93-1.81 (m, 1H), 1.71-1.48 (m, 6H); MS (ESI(+)) m/e 446 (M+H)+.


The title compound was prepared as described in Example 1C, substituting N-(4-(4-aminocyclohex-1-enyl)phenyl)isoindoline-2-carboxamide for 3-phenylpropan-1-amine and cyclohexanecarboxylic acid for 4-(isoindoline-2-carboxamido)benzoic acid. 1H NMR (300 MHz, DMSO-d6) δ 8.35 (s, 1H), 7.64 (d, J=7.6 Hz, 1H), 7.57-7.49 (m, 2H), 7.47-7.23 (m, 6H), 6.01 (bs, 1H), 4.76 (s, 4H), 3.84-3.54 (m, 1H), 2.49-2.24 (m, 2H), 2.20-1.93 (m, 2H), 1.91-1.77 (m, 1H), 1.78-1.48 (m, 6H), 1.47-1.06 (m, 6H); MS (ESI(+)) m/e 444 (M+H)+.

Claims
  • 1. A compound of Formula (Ic), and pharmaceutically acceptable salts thereof
  • 2. A compound having Formula (Vc), or pharmaceutically acceptable salts thereof
  • 3. A compound having Formula (VIIc), or pharmaceutically acceptable salts thereof
  • 4. A compound having Formula (VIIIc), or pharmaceutically acceptable salts thereof
  • 5. (canceled)
  • 6. (canceled)
  • 7. The compound of claim 1, claim 2, claim 3, or claim 4, or pharmaceutically acceptable salts thereof; wherein X1 and X3 are CH; and X2 is N.
  • 8. The compound of claim 1, or pharmaceutically acceptable salts thereof; wherein R2 is phenyl which is substituted at the para position with R5; andR5 is phthalazin-1(2H)-onyl, isoquinolinyl, isoquinolin-1(2H)-onyl, 5,6,7,8-tetrahydrophthalazin-1(2H)-onyl, 5-fluorophthalazin-1(2H)-onyl, (Z)-3H-benzo[d][1,2]diazepin-4 (5H)-onyl, 5-(trifluoromethyl)phthalazin-1 (2H)-onyl, pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one, or isoindolin-1-onyl.
  • 9. The compound of claim 1, selected from the group consisting of: N-{4-[(3,5-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(4-chlorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[4-(pyridin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({[(1S)-2-hydroxy-1-phenylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({[(1S)-2-hydroxy-1-pyridin-2-ylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(3-methylbutyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(tetrahydrofuran-3-ylmethyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(4-pyridin-2-ylpiperazin-1-yl)carbonyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-[4-(1-butyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-benzoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(4-oxo-3,4-dihydrophthalazin-1-yl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(1S)-2-hydroxy-1-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{1-[(2-methoxyethoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(4-hydroxypiperidin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(2S)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(1-hydroxy-2-methylpropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(1′-isobutyryl-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(1′-benzoyl-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[1′-(tetrahydrofuran-3-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{1′-[(2-methoxyethoxy)acetyl]-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(morpholin-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[6-(benzoylamino)hexyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[1′-(tetrahydrofuran-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[1′-(tetrahydro-2H-pyran-4-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[1′-(1,4-dioxan-2-ylcarbonyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{1′-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[1′-(2-hydroxy-2-methylpropanoyl)-1′,2′,3′,6′-tetrahydro-2,4′-bipyridin-5-yl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(1,4-dioxan-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2-hydroxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(2-isopropoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(azetidin-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(2,6-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1,7-diazaspiro[4.4]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[methyl(propyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(isobutylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(butylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(cyclopentylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(2-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3-isopropoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[benzyl(methyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(6-methoxypyridin-3-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3-isobutoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[4-(trifluoromethyl)piperidin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[4-(2-aminoethyl)-1H-imidazol-1-yl]carbonyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(pyrimidin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[2-(pyridin-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(morpholin-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(2-{(4-fluorobenzyl)[4-(pyridin-3-yl)benzyl]amino}-1,3-thiazol-5-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-phenylbutyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3-methylbutyl)sulfamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(pyrrolidin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(3S)-pyrrolidin-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(1,4-dioxan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({[(3R)-1-isobutyrylpyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({[(3R)-1-benzoylpyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({[1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({[1-(methylsulfonyl)pyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-isobutyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-3-ylmethyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydro-2H-pyran-4-ylmethyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-isobutylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-3-ylmethyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydro-2H-pyran-4-ylmethyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(cyclopentylacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({[1-(morpholin-4-yl)cyclopentyl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(1-pentanoylpiperidin-4-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(1-acetylpiperidin-4-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(1-butyrylpiperidin-4-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(2-methylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(methoxyacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclopropylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclopropylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclobutylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclopentylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclopentylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclohexylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(1S)-1-(4-fluorophenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(1S)-2-hydroxy-1-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({[3-(hydroxymethyl)oxetan-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(1S)-1-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(tetrahydrofuran-3-ylmethyl)sulfamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(3,3,3-trifluoropropanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(4,4,4-trifluorobutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tetrahydrofuran-3-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclobutylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclopentylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(3-phenylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(phenylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[(4-methoxyphenyl)acetyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(methoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclopropylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclohexylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclopentylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclopentylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(1-benzoylpyrrolidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(3-ethoxypropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[(2-methylcyclopropyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[(1-methylcyclopropyl)carbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclobutylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(2-methylpropanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(1-acetylpyrrolidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(4,4,4-trifluorobutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tetrahydrofuran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(ethoxyacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1-methylpiperidin-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{4-[(tetrahydrofuran-3-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{4-[(tetrahydro-2H-pyran-4-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{4-[(morpholin-4-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(4-{[(2-methoxyethoxy)acetyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclohexylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tetrahydrofuran-2-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(morpholin-4-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclohexylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(2-methylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(2,2-dimethylpropanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(3,3-dimethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tricyclo[3 0.3 0.1.1˜3,7˜]dec-1-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[(4-methoxycyclohexyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({[4-(acetylamino)phenyl]sulfonyl}amino)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(propylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(4-propylphenyl)sulfonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(butylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[({[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl}sulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(ethylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(benzylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(4-fluorophenyl)sulfonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(thiophen-2-ylsulfonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1,7-diazaspiro[4.4]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(2,7-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(2,6-diazaspiro[4.5]dec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(2,7-diazaspiro[4.5]dec-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(2,9-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(2,8-diazaspiro[5.5]undec-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1,8-diazaspiro[5.5]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1,8-diazaspiro[4.6]undec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(2-oxa-9-azaspiro[5.5]undec-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-oxa-4,8-diazaspiro[5.5]undec-4-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1,8-diazaspiro[4.5]dec-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1,8-diazaspiro[4.5]dec-8-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1,7-diazaspiro[3.5]non-7-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1,6-diazaspiro[3.5]non-1-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(2,5-diazaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(5-oxa-2-azaspiro[3.4]oct-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(6-oxa-2-azaspiro[3.5]non-2-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(hexahydro-5H-furo[2,3-c]pyrrol-5-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(hexahydrofuro[3,4-c]pyridin-5(3H)-ylcarbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-3-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(N,N-dimethylglycyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{4-[(tetrahydrofuran-2-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{4-[(tetrahydrofuran-3-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{4-[(cyclohexylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(4-{[(4,4-difluorocyclohexyl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{4-[(2-hydroxy-2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{4-[(tetrahydrofuran-2-ylcarbonyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(piperidin-1-ylsulfonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[3-(5-methyl-1H-pyrazol-1-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-(4-chloro-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-methyl-2-(morpholin-4-yl)butyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-[4-({4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}carbonyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(2-carbamoylbenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[bis(2-methoxyethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(1-amino-1-oxohexan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;Nalpha-{4-[(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-ylcarbonyl)amino]benzoyl}-L-phenylalaninamide;N-(4-{[(2R)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(4-cyclohexylpiperazin-1-yl)carbonyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3-tert-butoxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-methyl-2-(morpholin-4-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(3S)-1-methyl-2-oxoazepan-3-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-[4-(4,5,6,7-tetrahydro-1H-indazol-5-ylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3,3-dimethylbutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[1-(furan-2-yl)propan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(3-methyl-1,2-oxazol-5-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(2R)-1-cyanobutan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[methyl(3-methylbutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(2-methoxybutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[1(1,3-thiazol-2-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[1-(1-methyl-1H-pyrazol-4-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(1-methoxybutan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(4-aminobenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(2-ethoxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(6-methoxypyridin-3-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(1-cyanocyclopropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-(5-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(4-methyl-1,3-thiazol-2-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[1-(1-methylcyclopropyl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(thiophen-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(4-methoxybutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-(tetrahydro-2H-pyran-3-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(2S)-1-methoxypropan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3,3-dimethyl-2-oxobutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(1-methyl-1H-pyrrol-2-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-(propan-2-yloxy)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-[4-(tetrahydro-2H-pyran-3-ylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-(1H-pyrrol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(2R)-3-methylbutan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-[4-(butylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[methyl(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(2-methoxyethyl)(methyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(1-cyanoethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(2-methoxy-2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[methyl(propyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;methyl 1-{4-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]phenyl}azetidine-3-carboxylate;N-(4-{3-[(3-methylbutyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{3-[(tetrahydrofuran-2-ylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{3-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[3-(benzylcarbamoyl)azetidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[3-(cyclopentylcarbamoyl)azetidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{3-[(cyclopentylmethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{3-[(2-methoxyethyl)carbamoyl]azetidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(3-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclopentylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-2-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydro-2H-pyran-2-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(pyrrolidin-1-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(pyrazin-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(9-chloro-5-oxo-2,3,3a,4,4a,5-hexahydro-6H-furo[2′,3′:2,3]cyclobuta[1,2-c]quinolin-6-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[7-chloro-1-(2-hydroxyethyl)-3-oxo-1,3-dihydrocyclobuta[c]quinolin-4(2H)-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tetrahydro-2H-pyran-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tetrahydro-2H-pyran-2-ylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{4-[(cyclopropylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(1-acetylpiperidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(1-butanoylpiperidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(3-methylbutanoyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(methoxyacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(2-methylbutanoyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(3,3,3-trifluoropropanoyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclopropylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclobutylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclobutylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclopentylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclopentylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tetrahydro-2H-pyran-2-ylcarbonyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tetrahydro-2H-pyran-4-ylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tetrahydrofuran-2-ylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tetrahydrofuran-3-ylacetyl)piperidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(5-oxo-L-prolyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-2-ylacetyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-3-ylacetyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(4,4-difluorocyclohexyl)carbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(propan-2-yloxy)acetyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3-ethoxypropanoyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(1-acetylpiperidin-4-yl)carbonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(ethoxyacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(tetrahydrofuran-2-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(tetrahydrofuran-3-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(cyclopentylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(bicyclo[2.2.1]hept-2-ylacetyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(1,3-thiazol-5-ylcarbonyl)amino]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(4-oxo-4,5,6,7-tetrahydro-1-benzofuran-3-yl)carbonyl]amino}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(5-oxo-L-prolyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(1-propanoylazetidin-3-yl)oxy]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(2,2-dimethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(2-ethylbutanoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(pent-4-ynoyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(furan-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(furan-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(thiophen-3-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(1H-pyrrol-2-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(pyrimidin-4-ylcarbonyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[(5-methylpyrazin-2-yl)carbonyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(N,N-dimethylglycyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(N,N-dimethyl-beta-alanyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(pyrrolidin-1-ylacetyl)azetidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[3-(pyrrolidin-1-yl)propanoyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[3-(piperidin-1-yl)propanoyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[(4-methylpiperazin-1-yl)acetyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[3-(4-methylpiperazin-1-yl)propanoyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(2-cyclopropylethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(2-cyclopentylethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(2-methylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tetrahydrofuran-3-ylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(3,3-dimethylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclohexylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(3-methylbutyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclopentylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(tetrahydrofuran-2-ylmethyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(2-methylpropyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(butylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(cyclopropylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(phenylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[(4-fluorophenyl)sulfonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(ethylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(propan-2-ylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(benzylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(propylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(thiophen-2-ylsulfonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[(2S)-2-methylbutanoyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[(4,4-difluoro cyclohexyl)carbonyl]azetidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(5-oxo-D-prolyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(2,2-dimethylpropanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(2-methylpentanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(2-ethylbutanoyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(1H-pyrrol-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(1,2-oxazol-5-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(pyridin-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(pyridazin-3-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(pyrazin-2-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(pyrimidin-4-ylcarbonyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[(5-methylpyrazin-2-yl)carbonyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[3-(piperidin-1-yl)propanoyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[1-(morpholin-4-ylacetyl)piperidin-4-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({1-[3-(4-methylpiperazin-1-yl)propanoyl]piperidin-4-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;benzyl trans-3-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]cyclobutanecarboxylate;N-[4-(4-{[(4-methylpiperazin-1-yl)acetyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{4-[(tetrahydro-2H-pyran-4-ylacetyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[4-(benzoylamino)cyclohex-1-en-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(4-{[(1-methylpiperidin-4-yl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(4-{[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(4-{[(3R)-tetrahydrofuran-3-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(4-{[(3S)-tetrahydrofuran-3-ylcarbonyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(4-{[(2S)-2-methylbutanoyl]amino}cyclohex-1-en-1-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{3-[(3-methylbutanoyl)amino]oxetan-3-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;tert-butyl 4-({4-[(1,3-dihydro-2H-pyrrolo[3,4-c]pyridin-2-ylcarbonyl)amino]phenyl}sulfonyl)piperidine-1-carboxylate;N-{4-[4-(propylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{4-[(2-methoxyethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{4-[(cyclopentylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{4-[(1,4-dioxan-2-ylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[4-(cyclopentylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[4-(tetrahydro-2H-pyran-4-ylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[4-(morpholin-4-ylcarbonyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[4-(cyclopropylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]piperidin-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[4-(butan-2-ylcarbamoyl)piperidin-1-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{(4R)-4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{(4 S)-4-[(2-methylpropanoyl)amino]cyclohex-1-en-1-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-benzoylazetidin-3-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[trans-3-(benzylcarbamoyl)cyclobutyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{trans-3-[(2-phenylethyl)carbamoyl]cyclobutyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{trans-3-[(3-phenylpropyl)carbamoyl]cyclobutyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2-methyl-1,3-oxazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(furan-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2E)-3-(furan-2-yl)prop-2-enoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(1,3-oxazol-5-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(3,3,3-trifluoropropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1,5-dimethyl-1H-pyrazol-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(4-methoxycyclohexyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2,3-dimethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2,2-difluorocyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(1H-pyrazol-5-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tert-butoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[3-(1H-1,2,4-triazol-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(3-ethoxypropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(3-hydroxy-3-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[3-(1H-pyrrol-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1-methylcyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2-methylpropoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(1-methylprolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2-hydroxy-2-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1-hydroxycyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclopropylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclopentylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-{[1-(methoxymethyl)cyclopropyl]carbonyl}-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(methylsulfonyl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1-methyl-1H-pyrazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclopropylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2-ethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(5-oxo-L-prolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2E)-4-methylpent-2-enoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2-methoxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclopent-1-en-1-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(thiophen-3-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclohexylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-propanoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2,2-dimethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(methoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2,2-dimethylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(4-methylhexanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2,2-dimethylcyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclobutylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(piperidin-1-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[2-(pyrrolidin-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1,3-dimethyl-1H-pyrazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(cis-4-{[(2-methoxyethoxy)acetyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(trans-4-{[(2-methoxyethoxy)acetyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(cis-4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(trans-4-{[(2S)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(cis-4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(trans-4-{[(2R)-tetrahydrofuran-2-ylcarbonyl]amino}cyclohexyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(6-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(3R)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(3R)-1-(cyclobutylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({(3R)-1-[(2R)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({(3R)-1-[(2S)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(3R)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(3S)-1-(3-methylbutanoyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(3S)-1-(cyclobutylcarbonyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({(3 S)-1-[(2R)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({(3 S)-1-[(2S)-tetrahydrofuran-2-ylcarbonyl]pyrrolidin-3-yl}oxy)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(3S)-1-(cyclopropylacetyl)pyrrolidin-3-yl]oxy}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(6-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}pyridazin-3-yl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{6-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{6-[(cyclopentylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{6-[(tetrahydrofuran-3-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{6-[(bicyclo[2.2.1]hept-2-ylmethyl)carbamoyl]pyridazin-3-yl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{trans-4-[(2-methylpropanoyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{cis-4-[(2-methylpropanoyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{cis-4-[(cyclohexylcarbonyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{trans-4-[(cyclohexylcarbonyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{trans-4-[(cyclopropylacetyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{cis-4-[(cyclopropylacetyl)amino]cyclohexyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;and pharmaceutically acceptable salts thereof.
  • 10. The compound of claim 1, selected from the group consisting of: N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide; and pharmaceutically acceptable salts thereof.
  • 11. The compound of claim 1, selected from the group consisting of: N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide; and pharmaceutically acceptable salts thereof.
  • 12. The compound of claim 2, selected from the group consisting of: N-{4-[(3,5-dimethoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(4-chlorobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3-phenylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(tetrahydrofuran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3-methylbutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({[(1S)-2-hydroxy-1-phenylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({[(1S)-2-hydroxy-1-pyridin-2-ylethyl]amino}carbonyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(3-methylbutyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(tetrahydrofuran-3-ylmethyl)amino]carbonyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(tetrahydro-2H-pyran-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(propylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(2S)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(2R)-tetrahydrofuran-2-ylmethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(2S)-1-hydroxy-4-methylpentan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(1S)-2-hydroxy-1-phenylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(tetrahydro-2H-pyran-4-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(1S)-2-hydroxy-1-(pyridin-2-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(4-hydroxybutyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(2S)-1-hydroxy-3-methylbutan-2-yl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(1-hydroxy-2-methylpropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(2R)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(2S)-2-hydroxypropyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(3S)-tetrahydrofuran-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(2-isopropoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(isobutylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(butylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(2-methoxyethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(cyclopentylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(2-thienylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3-isopropoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(6-methoxypyridin-3-yl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3-isobutoxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(pyridin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(pyrimidin-4-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[2-(pyridin-3-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(3-methyloxetan-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(1,1-dioxidotetrahydrothiophen-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(pyrrolidin-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(3S)-pyrrolidin-3-ylmethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(1-methylpyrrolidin-3-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(1-methylpiperidin-4-yl)methyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({[(3R)-1-isobutyrylpyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({[(3R)-1-benzoylpyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({[1-(tetrahydrofuran-3-ylcarbonyl)pyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({[1-(methylsulfonyl)pyrrolidin-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({[1-(morpholin-4-yl)cyclopentyl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(1S)-1-(4-fluorophenyl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(1S)-2-hydroxy-1-(4-methoxyphenyl)ethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-({[3-(hydroxymethyl)oxetan-3-yl]methyl}carbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[(1S)-1-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]carbamoyl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(1-oxa-8-azaspiro[4.5]dec-2-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-oxa-8-azaspiro[4.5]dec-3-ylcarbamoyl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[(2-oxa-9-azaspiro[5.5]undec-3-ylmethyl)carbamoyl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{[3-(5-methyl-1H-pyrazol-1-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-(4-chloro-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-methyl-2-(morpholin-4-yl)butyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(4-methoxybenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(2-carbamoylbenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(1-amino-1-oxohexan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;Nalpha-{4-[(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-ylcarbonyl)amino]benzoyl}-L-phenylalaninamide;N-(4-{[(2R)-1-amino-4-methyl-1-oxopentan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3-tert-butoxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3-methoxybenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-methyl-2-(morpholin-4-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(3S)-1-methyl-2-oxoazepan-3-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-(4-methylpiperazin-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[4-(morpholin-4-yl)benzyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[3-(piperidin-1-yl)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-[4-(4,5,6,7-tetrahydro-1H-indazol-5-ylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3-methoxy-2,2-dimethylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3,3-dimethylbutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[1-(furan-2-yl)propan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(3-methyl-1,2-oxazol-5-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(2R)-1-cyanobutan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(1-methyl-1H-pyrazol-3-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(2-methoxybutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[4-(dimethylamino)butyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[1-(1,3-thiazol-2-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[1-(1-methyl-1H-pyrazol-4-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3S)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(1-methoxybutan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(4-aminobenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(2-ethoxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(6-methoxypyridin-3-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(2S)-butan-2-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(1-cyanocyclopropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-(5-methyl-1H-pyrazol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(4-methyl-1,3-thiazol-2-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3-hydroxypropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(1R)-1-cyclopropylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[1-(1-methylcyclopropyl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(thiophen-2-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(1S)-1-cyclopropylethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(4-methoxybutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-(tetrahydro-2H-pyran-3-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(2S)-1-methoxypropan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3,3-dimethyl-2-oxobutyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(1-methyl-1H-pyrrol-2-yl)methyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-(propan-2-yloxy)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[3-(dimethylamino)propyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-[4-(tetrahydro-2H-pyran-3-ylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[2-(1H-pyrrol-1-yl)ethyl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(1-methoxypropan-2-yl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3-aminobenzyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-(4-{[(2R)-3-methylbutan-2-yl]carbamoyl}phenyl)-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(tetrahydro-2H-pyran-3-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(2-hydroxy-2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-[4-(butylcarbamoyl)phenyl]-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(1-cyanoethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(3R)-tetrahydrofuran-3-ylcarbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(cyclopentylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(2-methoxy-2-methylpropyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;N-{4-[(pyridin-4-ylmethyl)carbamoyl]phenyl}-5,7-dihydro-6H-pyrrolo[3,4-b]pyridine-6-carboxamide;and pharmaceutically acceptable salts thereof.
  • 13. The compound of claim 3, selected from the group consisting of: N-[4-(1-butyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-benzoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2-methoxyethoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-isobutyrylpiperidin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(1,4-dioxan-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2-hydroxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(morpholin-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydro-2H-pyran-4-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(1,4-dioxan-2-ylcarbonyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1-methylpyrrolidin-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(morpholin-4-ylacetyl)piperidin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1-methylpiperidin-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-3-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydro-2H-pyran-4-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(N,N-dimethylglycyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(4-methylpiperazin-1-yl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(3-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclopentylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-2-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydro-2H-pyran-2-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(pyrrolidin-1-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(pyrazin-2-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(3S)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(3R)-tetrahydrofuran-3-ylcarbonyl]piperidin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2-methyl-1,3-oxazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(furan-3-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2E)-3-(furan-2-yl)prop-2-enoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(1,3-oxazol-5-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(3,3,3-trifluoropropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1,5-dimethyl-1H-pyrazol-3-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(4-methoxycyclohexyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2,3-dimethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2,2-difluoro cyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(1H-pyrazol-5-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tert-butoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[3-(1H-1,2,4-triazol-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(3-ethoxypropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(3-hydroxy-3-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[3-(1H-pyrrol-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1-methylcyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2-methylpropoxy)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(1-methylprolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2-hydroxy-2-methylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1-hydroxycyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclopropylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclopentylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-{[1-(methoxymethyl)cyclopropyl]carbonyl}-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(methylsulfonyl)acetyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1-methyl-1H-pyrazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclopropylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2-ethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(5-oxo-L-prolyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2E)-4-methylpent-2-enoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2-methoxy-2-methylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclopent-1-en-1-ylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(thiophen-3-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclohexylcarbonyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-[4-(1-propanoyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2,2-dimethylbutanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(methoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2,2-dimethylpropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(4-methylhexanoyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2,2-dimethylcyclopropyl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1,3-dimethyl-1H-pyrazol-5-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclobutylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(piperidin-1-ylacetyl)-1,2,3,6-tetrahydropyridin-4-yl]phenyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[2-(pyrrolidin-1-yl)propanoyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1,3-dimethyl-1H-pyrazol-4-yl)carbonyl]-1,2,3,6-tetrahydropyridin-4-yl}phenyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide; and pharmaceutically acceptable salts thereof.
  • 14. The compound of claim 4, selected from the group consisting of: N-[4-(1-benzoylpiperidin-4-yl)butyl]-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2-chlorobenzoyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-2-ylacetyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(1,1-dioxidotetrahydrothiophen-3-yl)carbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-3-ylacetyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclohexylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(4,4-difluorocyclohexyl)carbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(2-hydroxy-2-methylpropanoyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2R)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2S)-tetrahydrofuran-2-ylcarbonyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(2-methoxyethoxy)acetyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(tetrahydrofuran-3-ylcarbonyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-(4-{1-[(propan-2-yloxy)acetyl]piperidin-4-yl}butyl)-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(cyclopropylacetyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide;N-{4-[1-(4,4,4-trifluorobutanoyl)piperidin-4-yl]butyl}-1,3-dihydro-2H-pyrrolo[3,4-c]pyridine-2-carboxamide; and pharmaceutically acceptable salts thereof.
  • 15. A composition comprising an excipient and a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salts thereof.
  • 16. (canceled)
  • 17. A method of treating hypertension, chronic and congestive heart failure, cardiac hypertrophy, restenosis, chronic renal failure, cerebral vasospasm after subarachnoid bleeding, pulmonary hypertension, atherosclerosis, asthma, male erectile dysfunctions, female sexual dysfunction, over-active bladder syndrome, spinal-cord injury, traumatic brain injury, stroke, inflammatory and demyelinating diseases, Alzheimer's disease, pain, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, inflammatory pain, rheumatoid arthritis, osteoarthritis, irritable bowel syndrome, Crohn's disease, psoriasis, ulcerative colitis, lupus, inflammatory bowel disease, cancer, tumor metastasis, viral infections, bacterial infections, insulin resistance, diabetes, ocular hypertension, preterm labor, atherosclerosis, spinal muscular atrophy, encephalomyelitis, osteoporosis, HIV-1, encephalitis, ischemic CNS disorders, vascular or AD type dementia, glaucoma, retinopathy, benign prostatic hypertrophy, psychiatric disorders including depression, schizophrenia, obsessive compulsive disorder and bipolar disorder, epilepsy and seizure disorders, for decreasing ischemia-reperfusion injury, myocardial infarct size and myocardial fibrosis, for the prevention of graft failure, and cystic fibrosis, in a patient, said method comprising administering to the patient a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salts thereof.
  • 18. A method of treating inflammatory and tissue repair disorders including rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, including breast cancer, prostate cancer, lung cancer, colon cancer, cervix cancer, ovarian cancer, skin cancer, CNS cancer, bladder cancer, pancreatic cancer, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia in a patient, said method comprising administering to the patient a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salts thereof.
  • 19. A method of treating hypertension, chronic and congestive heart failure, cardiac hypertrophy, restenosis, chronic renal failure, cerebral vasospasm after subarachnoid bleeding, pulmonary hypertension, atherosclerosis, asthma, male erectile dysfunctions, female sexual dysfunction, over-active bladder syndrome, spinal-cord injury, traumatic brain injury, stroke, inflammatory and demyelinating diseases, Alzheimer's disease, pain, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, inflammatory pain, rheumatoid arthritis, osteoarthritis, irritable bowel syndrome, Crohn's disease, psoriasis, ulcerative colitis, lupus, inflammatory bowel disease, cancer, tumor metastasis, viral infections, bacterial infections, insulin resistance, diabetes, ocular hypertension, preterm labor, atherosclerosis, spinal muscular atrophy, encephalomyelitis, osteoporosis, HIV-1, encephalitis, ischemic CNS disorders, vascular or AD type dementia, glaucoma, retinopathy, benign prostatic hypertrophy, psychiatric disorders, including depression, schizophrenia, obsessive compulsive disorder and bipolar disorder, epilepsy and seizure disorders, for decreasing ischemia-reperfusion injury, myocardial infarct size and myocardial fibrosis, for the prevention of graft failure, and cystic fibrosis in a patient, said method comprising administering to the patient therapeutically effective amount of the compound of claim 1, or pharmaceutically acceptable salts thereof; and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
  • 20. A method of treating inflammatory and tissue repair disorders including rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease), osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultra-violet induced skin damage; autoimmune diseases including systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, including breast cancer, prostate cancer, lung cancer, colon cancer, cervix cancer, ovarian cancer, skin cancer, CNS cancer, bladder cancer, pancreatic cancer, leukemia, lymphoma or Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, and ataxia telengiectasia or spleen cancer in a patient, said method comprising administering to the patient therapeutically effective amount of the compound of claim 1, or pharmaceutically acceptable salts thereof; and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
  • 21. A compound having Formula (IIc), or pharmaceutically acceptable salts thereof
  • 22. The compound of claim 21, or pharmaceutically acceptable salts thereof; wherein X1 and X3 are CH; and X2 is N; orX1 is CH; X2 is N; and X3 is CR1; orX1 is CR1; X2 is N; and X3 is CH.
  • 23. A compound having Formula (Inc), or pharmaceutically acceptable salts thereof
  • 24. The compound of claim 23, or pharmaceutically acceptable salts thereof; wherein X1 and X3 are CH; and X2 is N; orX1 is CH; X2 is N; and X3 is CR1; orX1 is CR1; X2 is N; and X3 is CH.
  • 25. The compound of claim 24, or pharmaceutically acceptable salts thereof; wherein Rx is R5; andR5 is heterocyclyl.
RELATED APPLICATION INFORMATION

This application claims the benefit of U.S. Provisional Patent Application Ser. No. 61/413,722, filed on Nov. 15, 2010, U.S. Provisional Patent Application Ser. No. 61/474,015, filed on Apr. 11, 2011, and U.S. Provisional Patent Application Ser. No. 61/525,405, filed on Aug. 19, 2011, the contents of each of which are herein incorporated by reference.

Continuations (1)
Number Date Country
Parent 13294303 Nov 2011 US
Child 14880834 US